<SEC-DOCUMENT>0000200406-21-000070.txt : 20211029
<SEC-HEADER>0000200406-21-000070.hdr.sgml : 20211029
<ACCEPTANCE-DATETIME>20211029160520
ACCESSION NUMBER:		0000200406-21-000070
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		87
CONFORMED PERIOD OF REPORT:	20211003
FILED AS OF DATE:		20211029
DATE AS OF CHANGE:		20211029

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			0102

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03215
		FILM NUMBER:		211363274

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>jnj-20211003.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:90dc118c-6428-4338-8b4d-8015054a0548,g:65f17fdb-8375-41f4-bf95-c047d59b03b3,d:f410ee6e03c8456f86a9fee997f08e65--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:jnj="http://www.jnj.com/20211003" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>jnj-20211003</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83L2ZyYWc6OTA4NzliZDJkYWVkNGZhNWE0NjQ1MTkwZTVmM2E5MzgvdGFibGU6MzIyMTJhNWQ2MGFmNDM2MWE0OTllOTc0ZTg2NzFhZGMvdGFibGVyYW5nZTozMjIxMmE1ZDYwYWY0MzYxYTQ5OWU5NzRlODY3MWFkY180LTEtMS0xLTA_d5a78295-3427-4652-be0f-01b19f896eac">0000200406</ix:nonNumeric><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" format="ixt:date-month-day" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83L2ZyYWc6OTA4NzliZDJkYWVkNGZhNWE0NjQ1MTkwZTVmM2E5MzgvdGFibGU6MzIyMTJhNWQ2MGFmNDM2MWE0OTllOTc0ZTg2NzFhZGMvdGFibGVyYW5nZTozMjIxMmE1ZDYwYWY0MzYxYTQ5OWU5NzRlODY3MWFkY181LTEtMS0xLTA_e53aa148-1b6f-408f-a5a0-d6ac5d9e98c2">1/2</ix:nonNumeric><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83L2ZyYWc6OTA4NzliZDJkYWVkNGZhNWE0NjQ1MTkwZTVmM2E5MzgvdGFibGU6MzIyMTJhNWQ2MGFmNDM2MWE0OTllOTc0ZTg2NzFhZGMvdGFibGVyYW5nZTozMjIxMmE1ZDYwYWY0MzYxYTQ5OWU5NzRlODY3MWFkY185LTEtMS0xLTA_b62da1b9-d5a2-4185-a4ae-76c72d2dbae1">2021</ix:nonNumeric><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83L2ZyYWc6OTA4NzliZDJkYWVkNGZhNWE0NjQ1MTkwZTVmM2E5MzgvdGFibGU6MzIyMTJhNWQ2MGFmNDM2MWE0OTllOTc0ZTg2NzFhZGMvdGFibGVyYW5nZTozMjIxMmE1ZDYwYWY0MzYxYTQ5OWU5NzRlODY3MWFkY18xMC0xLTEtMS0w_cb2e3e74-fd1d-43b6-9201-48db32632981">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" format="ixt:fixed-false" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83L2ZyYWc6OTA4NzliZDJkYWVkNGZhNWE0NjQ1MTkwZTVmM2E5MzgvdGFibGU6MzIyMTJhNWQ2MGFmNDM2MWE0OTllOTc0ZTg2NzFhZGMvdGFibGVyYW5nZTozMjIxMmE1ZDYwYWY0MzYxYTQ5OWU5NzRlODY3MWFkY18xMS0xLTEtMS0w_1e2f98ce-fa5e-42d3-a0c6-e7d69438de1d">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="jnj-20211003.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a8050abbb6b4fa087129310f939d84d_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b6adc1e7fc54138970a1ffce6545ea4_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.250NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d7f3f3cd9e848f386315ec977895ad1_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0d2f13d6fae4fea9e15a651e3245c28_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i579388adbc0145f5a9221b1e7204d902_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia256641b62ca4d77ac7b64775619302f_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i5cd455ee122743e7b308fecfa89422cf_I20211022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i524495c8e7d941efbc4c7057a7d882bf_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6223e38b49924566951c6ee22df12ea8_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f560bf19097496e9d3b17c570ba5487_I20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia36f1ef4e53741a698ce4eb8a63cfcc8_I20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d39696cd8124bebbcee13521011bc43_I20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fc21784cc544993916b76a2883b5fa7_I20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b91cb0100d34fc688b5e3ed019ce080_I20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia21d27ed7dc047cc83042ea5ddaf0820_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85720d7d2890498ca2589aaaa3d3c267_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c3f7de455fa4be484a940d40bf7d252_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic67ffcf2eac440a4a3acf47e9df62981_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd88e9907aaf4e8cbca11111329e2073_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdbe49f46d3548e69bcf28fa1c70f4a0_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib15db8a9bfc141e3b662784fb2f12036_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97cf81456e3d4ee78c0eb5ef14d6adfd_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib616b434ad574d54a671235ee0e19c40_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37e41918fcfb4a96aae4c8ddf736f81f_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6567971b97b8486f9c4ca8fcaa0bc916_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0f5194139614002a34759c09867b19b_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6f044a57fb04694b9504b1cc6b855fc_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i280f2f10a11c4c988142fed0ab0a55c4_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4c978ae9bd844bb8485b20fee0394d2_I20200628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i789e8630040645df9671180079be56c4_I20200628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c1cb280df774543988ac3e60b3700ff_I20200628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b1b5e269d61463c9d13dc7f3431be66_I20200628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc043974a53d45c09c9c4916e8c5d997_I20200628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i151bc89c89104e6fad68b01743dd13fc_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14461e2d7ae84af4b6b45899f46e8cdc_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94a2d6ba6c254c6b92dfd2a37f7901ed_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4de10452fa98443a826d732ac5ecfcd4_I20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21919a743da04e9ebb238e98bd59fa74_I20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i514541208cb44a09bd41a6c7b123cbb4_I20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i701c9aa0c90c443fa3b9239555242704_I20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4593a0dc4364211ae7edf29da4866d3_I20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if49e94e75cf04169b3ef119b2c588a4c_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6004d7a658874bffb0b05f268a6fc6e9_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e06dbf4f1b44f998d04005f6056c3d5_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ba2e82215dc4171a568af3512fd9d8f_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a829e70799a4429b48066d6c98beb81_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd97456bd71e47888787febf8fb403c0_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25e2937f00db4ffab2f056e05c4b797e_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76d47fefae324430be757b4f9833ed5f_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4743699b0eac46a588c10333167e9fae_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i137acfc8e8824efc95e1265512dd13d9_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7121dbd0cc754e319650cfe1e9a6d091_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i364bae74581b41469b167f1d57b47bec_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba2272c30bea4b1482458fce855c3373_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i306786a4d54f459696c4fb7907f30ea4_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc12ecbfad9b4436a408325ad670fee4_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6550a842150844a782974595356be4c8_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9431acda5084235a9355798c8cc8b2e_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58d78224ae6d43cf95b5735d5bb3dabb_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a29aa136e144ef7a4209eb7a9897d36_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fbb196ddcb14beaa7a23bd9de26d3d9_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i185910f7181845c8aed38c39fd4b6cab_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18c6f67375de464e98be9b5c858a0996_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7fc25fc53e54e21948d2ce281e9424a_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64662abe386b4a3b9044b4dbcffe47d5_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia53808fcfd3f400c939324049330ed77_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97512951ea1746ff957df24ca33bf674_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69229a2a50d442b795aa18fa30c26be4_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2f30918b36c48df9f73661bf07e071b_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i386cee1639274652826fd3eed1982a70_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e0add53586f4fb29f2838afbf423ad7_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9852777165f4b609444e7127f04f202_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c4d270b6af043e9be04d479dec5dd5c_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib219ae64b99744eaa1b7b8cc1067daf8_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dd7f04c9cf442d09d8944a1200e4e9e_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2446fd6831b74f84a1fbc08826466b5a_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5373c09ac6424f71abea9a4af34fad8d_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia29eda1bae054029be22f80a32d9bed0_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1176d5e87c548cf8e03d248b438c1fd_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46ddf01a2ed04decb15a346373711b4b_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf5522e302034e189c307e49dc73197d_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58a7e978302f42b1aa90a38f29c5a34b_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77a7f12df0b140499e72c6c5292e080d_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i513a49e58ab74680ba8b509c23674bf0_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48e5c25b196b4581a673892969bb5051_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93e401f2dd5c4ea586defab03d5e9b30_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c72adb013a948e8a95c6b4603152001_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82e5fff9c6bd45ca997965825f96a0d3_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99216cc8b79445dd8a6169989e70f809_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfc2d51c1b3943179426ac0f6638ea2b_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b598c35682943d4aa693d58ad7185a7_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0ccfa0f2f3043db8ffb4dd5132378b0_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77bd06875cea40cbacd7c9e2c6e60de2_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia171152160c9457eaf8a8198b50831df_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c22296c638b499dacba432243aabb21_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief08f28671bd449f85c45b2524dc11fd_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0490b39cdf9e468d851a818d788fa90a_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i767f5c4625154f0a8f7d74c8b8c3a35e_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c775ffd78004ecbaf03812778b4fb63_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15408f87a30b40a48076e15baf08bf94_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b90f9340101469daec861ce7a7fc255_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19054c05c6034f23a0b61aa630e73505_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i469f78b5da314cda95613d4aba1df12c_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3d4899630c6450886e61d01be554303_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0786ff8f130406bb2514f5c91f8a2a8_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d4a0150b247424e98fb6ecbe5b9c39d_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i078ef827e4f344eab96812a9740e1239_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie49f82a46b424edcab630d17792da6b8_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i204468adffd143848aaaba487ce0a656_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id01b13e20bd947928cfc3ced046acd64_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3753d069b34e42ffa037aa3a221eec25_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a8c3429d9ff41b7b0f85c7d87dad8f8_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafc5d51a497748cc9ad72884ab239bfb_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffc2ba0506404c9d92c54405efa208bf_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id97c9bcc0a104ab4bf86bb77681a798a_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36e6f6c2b8274124a6cd37dfbbe9c6fb_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if264742b6d944aba8d0e08c08df83a8e_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c801cb847184a7894fc5ff4b0c3f468_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i515bd1a2d43148349fd6ab9f0a2255e3_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8a28c76f65e4001af98e0f096fb76b2_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ade907d675d4c8c99740caca6ebd135_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e9d30cc4cfc488a862a5885738d2f05_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb60c19364b242d6917f7472855f3905_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c2b9f86e3934a9b831632fa60e4ba21_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0141e2177d24be384d24197d458ffe0_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6256db6dc0054ac18b141ae33e5ad29f_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8631e8b6ef484669be037922391c299d_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief5d0c9bb17948d6a1b2d29d6f8c062d_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8470a3d16a94257810c1ec46751fcbd_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91a4caee55e84fdb8343347b7638a55e_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e79014ed177468abd91b03922e18af0_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b8df8e17a0f46c78ae91bd6ad3784ba_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b9ff999f4544965b285cfeb8d1a0cb1_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bf2c274ee034f6688bb999de3bbb518_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8602046a27c64bd4926512027a77764a_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18cce9dd23084ad68d56d277f4166138_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25b25621104941d6a59c689bab906bf4_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f27a2322ca147eab04beab15bad4715_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3020bbfcfb1340499dec1be0f710b954_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99def0c623bf49c58f2cce64717f9eae_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafca8a975c524aedb162430401cc1a92_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id40428336fe54fb0b1d61580ad3f301d_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i855c33350d7746598cba6771e22ebcc2_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61b00628ead94443b3f921a3a6d612de_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94250734c05f4e5ab67af91d5851ea23_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib79aa24edb5c4b0589f5ba2b11f35226_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia495e7b3f52a4352880c86434b292e22_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a3574762e24474f8b845e390fc8124e_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74ad3f15a27f44939475bb5617afa269_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aec662a2dab41b5ab3eec8dd912eb2c_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie697d1e6b84a4b06b358ed0548d7499d_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1e60dc0c01d47d1955296c160459cb5_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a1ff01920b54a71b8bdeb95dd658754_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id36f5e85786140ebaab64dfb8e6e1c3a_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba61370bc5134de1ba733b99d4caa214_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i547a7a9339204ab39e0413979ed1a2ab_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2835247bbd164156ac697a316626d4b8_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief9761af24a4460ea012090015fb22ae_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6e0ead4649b4a7a87dc1937b5e8d0ce_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d4896777472483c91059e670b9b3b89_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i086fb509c2da43bdbf100b4f08fd1272_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a83ab881bc04e018d1d2f066bc40669_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib65942949a8b4ab2858ac418b39805b8_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12239b7d99e147329855a8ae0ec87490_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib42b4b45f7a24a98ab6f6f966bf2ff2f_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f3dc535bc03400d84053d66430136d1_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i342e3f1749ef42f4a46139b2cb020f4f_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba821c9267974930aa7f53fa5bcdb8c5_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id49fbada050b40ec920b3e2ec7d1b351_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i864a93092b7f471e9b3af685acca4202_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52e8eabf585e41898fda5db69bd674df_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i380144a9a9fa42fd8158904a1c5d0700_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c668ea680234cec82c45cb5e0c7a70c_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie922169de489430ca26a82b6556fdcbc_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4eb1c56e86814746bc74797880579d47_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9a3a355d8f84cf5bf2f61990c01ad9a_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied95fcc9c6ec43e28079e110635c1c3e_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e894ed981be4116a2355b4062397ba2_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3dd051494d44e5a963f074248d0e103_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia541a8d551c4468c8f6e756afd118e10_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia929718f7d4b44af9534961189e19b18_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c61c290cdfa47aa90f28583b201ca61_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia918a096df5248d794e6e608f618f2d3_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdd29fe7311d4c0f9fccaf4d085f95c5_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8bf2953dcaf482eabe10bcdb5890292_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cc97e40d3d4405d9a96f873abcd8d6e_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31ec175a56664fa0bd90af394bda5a04_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cf8d2cf87a94bf7a55afbbff98f5daf_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6cb46a97d3b4230ae9dcca4c2069fb6_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b78f843aa1346368fb728d955f6da33_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9e29ba46f0d4a8bb33c9e8eb07ffda5_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if00b7b3746e54851b72fa7817a56cc7e_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibeca5e8660d14e0e95ab595851e5a044_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib78fc1819e4c481fb01505843db10e28_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5820db2145564d76a142f0b76e3fbff3_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaed609fd41ee4cf9a82d74bf5e73e604_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i831bedde345c419192edc69c0e317205_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b704f7750e54b2c8511c93e87192817_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i771e5eadfd734fc987bf5ecca1178170_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b7dc91718ce4ea0a9b05b4625568ef0_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if293da93cdf44458a788e386d073f1ee_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dcb1b245fd240b0b488db669a604f22_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f73056213bc43fc94fc5c10e89df326_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9385ca799d84dce96c2206ee78ac799_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic741579d386241e4bbf75342917d529a_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i009c78145cf74486a461497129412728_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fb649af90814478b37ac417cea6456b_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9178d762f0634d6a894dd86815cf64ec_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id829f858995a40ed8f879e67456295cc_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a81061eccb043c396dcd8d5162f888d_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18389b6ef2374d3c823b640e24fe8d12_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4204d24c6ab4dfa89a1c5d5867933ce_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ac4e3b179864a468bfaa6bba91852e4_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65df3ffe517245619ee40a22674cf249_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fa344c3c3a14482aa8f313597fd1bed_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07e445fc6ca14fef87c4fea6ac866c95_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7415834b451d40a98618e973debc442e_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c8213533087409db4d429fd040785cc_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b6ee0ef21ad4005b66cfbd8d7bd5087_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.05Notesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31b2046662244e3b9cbb92c5aed58fb6_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.05Notesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6b4ff6b5de74a15b368ea59a0de5057_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.05Notesdue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf70d477076242eeb2b9271915ba71b3_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0bd340801084b60adf4d9a44c9274d5_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia29178df168d49e381facf07098989fb_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e3d2dc107be43c5bd3e61ccb2b7faf4_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54f00a29b7c94893ba5de79c98a063b2_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica369f9fff05494a954f5c22e4edab8c_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie72e7ef5001e45cfa85cdf6654be4b80_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44489d6df8a8422c984028d2e3e54b5b_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81fc862d12094763922068d4e9c8537d_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4147275174c24eac885cc4fb0886ac54_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a6f8d9f883946d6b9af6c9d0a9be721_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if20ce7e060e548869eb894260b6fc64b_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie83d54bb9a4f4816bf50aec027245c33_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d23525d3b284b7d9852bad7add00e33_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1546f14269e447faa59f6da1aca49e8_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia478ea6acea24aff8eff14df6fecc891_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5640ee1ce1d47ad801b0d6eef582304_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d971262bcb64b6b893eb6fedc3a0beb_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedc4b4fd0b1b4ad390f5f63e58c47e8d_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e50b1400f70460a988afbc0dafd4823_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6cfc552441e4a8e8b91f3deb98f4c44_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia99340613822456eb8c3641db778ecd7_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa8046c340764588878db0a7b77c401f_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fd60cb1106c4c1499568e9a6eebfb28_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72bdc25703924ba3b6b0ce4527d18d88_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b28e0d7e40047fabff6dba54a753c51_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id23573442cd349c181d05b7186a88a8f_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99f7ce7c3c0a4e47bc46cb5013b85204_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fce897c159a440fa82606e78f5a8890_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9442a0f459844bc8b34a3edfbad734f2_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9abf297178741228613c2f1cc8f19d2_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34ef244a220d41cd93a8040056b208e7_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25ff7c6833044a3ebd91c3ef1f1367c4_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3fec2057e8c4da08b74b29f4fd4267c_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f58130f89ed4256a62ba7c75eb638c4_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefeb4b2784e6435384a917a1944c658e_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i860c18e3721d4d939bd33a8ea77e4421_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9daefad50e444c3b846ecb91f83159bc_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c801cc1caeb4c179693dba2260b0563_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dbba3a61c5540838ca8c89692469565_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4aecaa1385574720ad3d887864eeb207_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3125d97f80b94d60b77182ad35bb48fc_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7aeccd4baaf4417b5ffcdc8852c71d4_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib143b536bc9b45b4826b98a0ac180c8b_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide702a860cec442280c57a5771658c81_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2ca463645bb4a5b9739b8bc175da1db_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16f1d7b4085841078f18b613f1fe0a77_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib92d6482e7ea404eae4e1c4468904413_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2a6e34f48ee4c7d80d33f78478eb3f2_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdc7fc7a723e450cb48944879c0781e7_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1a7c9dbc6df42aeb77011ac535edea5_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57d6a4f83449492094bb6b200701e064_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2f2afd2bbca40be9ed9eff967565efe_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7d62d21ca6949dcbc76d7ab670920b7_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied109c22c97143bf9e2d8950f06aa9cd_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia107789c130e40adb3ad38987e6fbf7c_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d2f5ac2df314410bab3062026857504_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3b49374b2a540819767fb1780941cbf_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26dfa36f335f442fb41f8059c4cfe77f_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25547702bd0f47088ae87a4e661a13e2_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic31cdd75b29340eb9d44466d5ec7ffd8_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50afa95426c645b18294c42ab68e0a75_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a8f75d047704b5aa0d3db1bc03ed292_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3890ce020cce483fa079c7f7418ac44c_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f17e1a230b249b09dc6346803945e09_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6188505bd2214769b12b8c2e7a1c0463_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fa9c5baa5cc4e97becb950d913da01f_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie788a463953d40fc97d8f8e0d65f542d_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0244efd886bd4bd289f13fdfc63a76b3_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d3f77d18cb74144b8514b9fd3021780_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab5c42e4384e4963a7ae278858dc9a3b_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c7ebdcd26aa43d5be5ef11db34b14e8_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bb0296c854c4acf871e0335393ec672_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25548ce1ad154cad9b4737a0931325b0_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e73ad17867f4918ae13cdb77b42664d_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ea1027adfa8409fa2240d2e0d15da0b_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd27580aa37f4a75b8b17887161c3adc_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if98b3204979e45fb982f58b3cbb646c0_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida0748410a8c4eab9d417837ec838a91_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i483018bed3724cac829e9c16115d7f55_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i193c04c9acbf4263b63c3eda25c9c4c8_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15cf4b9be03f47eba85d4614348d2034_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i427dbcfc1b924d82bfa86831fd546f1c_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0be6f6c2cd547e687ae5108ce9ac42a_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ba0ab6b51254970ba452db5939f0a54_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:NotesDuePeriodFifteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idedd08cef78740fc9f67f0cf86fb8ba7_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:NotesDuePeriodFifteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e38f2e44f714a3d8fd4adc7b4276d3d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1e15dae48b34058996995a2834d63fe_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ac5b17e0fad468a80e8667a23da5ace_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6211b8d8ccd49788ecbb637deed070a_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice0924be1a6f4deb9320312504bf1648_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="rate"><xbrli:measure>utr:Rate</xbrli:measure></xbrli:unit><xbrli:context id="i0b4d8090e5a94aa6a43b8958bfdeabf1_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:RisperdalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9861446e76324a08b1c77c4fa0b1b5a3_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6bf26a76e934a0abbe42eb60a86e6f4_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a7e0b9b6e694546bcf63ba4da67114c_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d181abffa774cef94773798ffcbc773_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae538c397d5b4172843ae849a0fa8309_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0db0747f8e0e4cf9ad8b2c2022602317_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f89fe3ec42c4ee6b74d0ae62c74a640_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8ad9c18d6ef430fa4f2b3d36ff46598_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb909ef9c68340daae79d3dce5aa8dc4_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf1dec1c43ca4835b67df10da682c97a_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieeff0339058f4ac9808b5eba4dc8ff41_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87dfc4ba292d4afcaa274be4bf5a6019_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c9b670acb814f2e8e8cae1d3b139677_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49a74fa2fdfe4f89beaadf820f5ac713_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40bb249c8086466faca49b2fa9bc2a92_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90665923dd1c4a2fa6d99222fb60dc98_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfb362df49f946cc91574b4a35909613_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32fd6f9a0ed9441682053b3f396c5491_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd186072d3fc4864a3c6f62ea4a983ec_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1585241dd83540d68d0d4bb0179b4c35_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae5d5570b0974f90b2b495ca2a503dae_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d619304e810451eaf68e4fe20b97b9e_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc89c7db9aca490ebbcb9ac5ff66d285_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1ed865a3a524e718fe97e4283367b0d_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5932fe6bc8874865bd9bae6cd5c4e149_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9863b76d1752421eab7f10a27e21c3a6_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8648858c71084557978cd6faeca2cacd_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38fb4207f4f44740a27e0c6df6aeb726_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1c9f29f75fe43e4847364d3f7c39cab_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7a63d17adab4e81bbe6f8151842a30c_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib646ba6c37f94afe9e3d21b88039c182_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f7b6f883fcb4fa4a9afe5cf3bdb0815_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d28ecdc380c4101b6135c161dfad020_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d474e7ed1044d528c7b1ffac5e15cea_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie547a8c88fa940efb218427e0eabd0c6_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ddac223612a4d06a37f3fd6878493ca_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5975dabe875348b9b232e9e29d323eed_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40ce11cf1c234e67b7e6b1a8988ba942_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0847920abf9d4769baf2ea560468bf0d_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaf4498d8f5049aa8af464f01fcd4088_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37f5a592ff13494aada072e3bba0cea0_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd69d35e5a314c3f80c3949f37cc664f_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04f3d42910f54dbdbe61282d28955d56_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddf4ba62d5ce4571a62ee75dcd2a8e3c_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2674760a7034ccdac2446519a5166a9_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7da3b551671f44d192917a4c6f2efa57_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9f77528e7ac40108b66c8931a2c701e_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff3b6e1b8fdd425390328188812a6eb0_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic833af6372324ca3b5bfa4fcad54732c_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i525fc27ed821404fb38182e25fa87eb5_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55f1d4591fc84cfc8c2e037ca49db283_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibee17d8505bb4fe98b2e9fa97001fe0a_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8085b27842a47b581f106618510e63b_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i050772dc13db458dae8ef05843e7c1e4_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie892e3f1014a404389b2b3050897a15c_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03fd89880da847f0a48e5cd794cb0e76_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice21827a874a4c00b01f16ab3cf18368_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddf1dd064873494095b906942f5d38ed_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29ed38871138472c98810a5cd7f1dd95_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf97184ab0f344fa943bfc3649c4080c_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba082d308e2e40fab4c4792324108b13_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62d3c4191ff94bc2b0b06fd86e9ebbc2_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e4744bfcdba4605b67ce9cf20e5ed37_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a9371cd71e74f32b3d3425e7fa3120f_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c26ef7358064431907c0c0b8e35ca05_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9015829b0dd4cc083d55eb4725146ad_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i046a4a03db32475eb292807b6b65dc2a_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i987662a6928046d9a653a39c7642a99a_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf3567b227cf43b7b727c573098b1019_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fe2032b4fab44759101707824a42b5f_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if08e07c77ca240b6ac145790e6d91e27_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7237727cb89c4b3ca79fd4c8ab24fae8_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i776cc9f3f12444e19c75d71e9f1306ab_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42c653266dbc4cbfb3ad7de36334d59d_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf9f5672587c42ef82b704011560ab84_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cc4e2c56fe94f0ebb2696dfb6777df9_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1864c3f454d54b6099348e1437264d1e_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0001607d8afa4b969777538d3b0090ac_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe9e6fb867164bcab52ce074dbf7118b_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f00d71bd5644d7386d54e5e7ba6f9aa_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f6ca30128844134ad0de910cf66a408_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f8cb7b296594fc5add46b54007f21d3_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i988a335b32c84bc3982666bf61d8fd38_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0f9db2930c7434cb55c268ec21f1fe3_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic97d6e50fa564ecfa01edcf954ca9b30_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ccb194a8c094e919fdb8681e73ce223_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf724d7bf6384a4d99527cb12064aaf7_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id60c33805d624a1e863dd18b29ce66d8_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa415248ab90441fa1cc6656b8dcf614_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib69f132a3f0b40c581d2942e7d57a5b9_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic01e2ce9f12a469dba08795b5a902ed6_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie95cdb275193469989a402b370c02342_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98adf17c3209468a982a0f7200c745a1_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idca691679ad64cf583644d8594234216_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb215856dcc24e3f9d3079bf180a51ff_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3add39942c4242daa496b88f14058185_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a5b1e45c95842418dbd6dcbe4bce0b6_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91bd273779f6455f9fb27bde5dca4f93_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e2b0381a81c41c495cc13d352d5aeae_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i932f9d2df6c34e58b2f54f1f4929c220_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38d436a7587f45a1ab95abb5b18a129f_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9a74be9ea184900b90a441048493bc4_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0250c72ff9ac405c928f736053a9f5ff_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c4878d8e6ac4393a3e73e04f398611b_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27ba7c90a4c1434586cbf514f3e51927_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aa1fb345ea8443c9e0bc1aa8418aaec_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa93431137654cfa8d08a279d01cc337_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2860d64b06e045eb890021c7710f0aad_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59be6ed5442a4a678a48fc617f1eb13e_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c17375fbded4a6ba40cab9f3d8326d7_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45b42eb8b685491a806080af8dc02aac_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieab9cec340d34cec86ad2425fd1846fd_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cca5cafe25a4fe0a525fbc02d000afb_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic00d19a36bdf402ea98bd292be45894b_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87a41a88262640b3b2d8b6e97dba1464_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia281107d882e4be6a4d88169207e2a36_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd6a9a9e55274bffada72f2726569f6e_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77effd52b2654ae686fe2393749c515d_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia37c81e1cad0453994f3e00b01af754d_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41ab0a4211f24f9391eae4b6c0bce606_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c1c64eccdd14e999154f3c36cce6b77_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i909f193a74e24bfd8a95144ed8637f1a_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id049e506122f4113a401765a69fb9f08_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dab22a716c64564ba838f1dd48d7f2d_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacbd09691dfd48849fa8a06109049218_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0bef40f936c45448366cedf462d82d6_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifda8dae70c484419b819b08a661b39d5_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c3e9d721cf949aba7bed39328685faf_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic218b0d17bf9480fb2a4af23655e9de2_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i742b390271ec444ebf304d883a7aaf85_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0637885c2824f0e9c6471d6d38dc762_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i020a9535952b4c63a401a40815ddf115_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85aea8ddbc744caa8e21718122998c19_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49c1d50e36104bbd9d2fff5426a37ba7_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide16825e0c5042f89d58332d23f6ae0a_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65144a7d9e2a4b1db67b59d28e3d74cc_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6d3a01a24804bc9af0ecb6a9b2c67fb_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50211f0c1289483e8e0e6d1eed3c67e3_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i655717f0369640c4b9a157a17bb82e9d_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf386660945d4d5d9e6b8634ef6532a1_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb6d6e4976ac495b99e5329deaf58bfc_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7c46e72eb484be486c63c78eb02e206_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40bfe120527540219fcb38f6a07a75c7_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3510e548888f4e1fa6f52d81f4ab6cf3_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56965738078b457fae12de6ffa955475_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72a6f6ec594242669dac6cfa2e2c7076_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90f1a8b28bba41749b15a878c6c18fad_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91266aa05dd2425d985bfd9033fb1fb3_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15626b644ab14a8fb91a1555191c8648_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibae5bbcea9f94ad5b94969117f4e506e_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadc37e4e06744f8fb3399608c7e6ab66_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibad7ff907c4d46428f779f4bdb8db2ce_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if38f3c37921e44cda1b5db6443989c29_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73f09c17c23a42ac9ebe11023c84580f_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc3bf48554b44e80be08a060489581ca_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i744f7d39a15a411bbf361d82d82dfe4e_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7d413bd46d24d6abe8b625214ada14c_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcfdef25565c4ba58a2615e2ab0fc2ab_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadc0a4943c0e4c70a773401d645f1312_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i784ee54441974c4eb54e9257b0e31430_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3480e995cfa436c961a9a4d13e49bd9_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie13682ac60d24dee80fa0761d2ecfc64_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f1311d4010d4f319357cbf0e5b86b3d_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf40956a9c1347769a071ff6bfafc142_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4658279dda2e4f0fa81448f27d0b4f77_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i199ccf31df6140dcb89e1686bb513228_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d8b2515e72b4a779aaf43dfbe387804_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa84aee89c7944bf90b3125200ecd80e_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie349729608994bf887fda0639a138ad3_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2f2c2e83225451d902cf2623ede1f1c_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29cff2e6865142d9a4661c3fcb511df1_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b35562d3e004031ba416de20b26cf73_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba4873f02ec94b1199e6f56536d6dfe1_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i319fc8a3857049aa8eee5c1b14cce0dc_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56710d10c9af4516b82e08bcd605ff90_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b95a95d0ab74b0593bd0223e4b8ad13_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8c876f733014aa39f0d8214e223f585_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaa2dae0ae2f4573be92b240376298b0_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b04f604d38f430783a61651065a0a13_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide71f27d89ff4ecba07e81f6917e063e_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5df2445aa9db4bcba1f2c495dfcf06c7_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c2ea56b89e848afb39b9ca75576f81a_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7d0cd308a8142d6a92cd40abc7d9327_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id029b233fbaa480b812c80c34fbb60f5_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c03fd29ef754d63b27fc58525b944c6_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ad4fad0fa5b4730bebb0dfc08f8b7f8_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b2360aa64bf40069c6622e4971e8616_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb258923b1f94a218e7cf9e72e1a4e29_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc0f0b78e2774313ad18d0495403fcce_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie38211ff6f4549ca99cf9a47fdc50a68_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc3c076d95ff48c485eb3d0187e68b87_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e8c4072e9244960b877a66a60def445_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24d94e00bd754768a1c1b598eb47950d_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48712a124534471ea2804e884605a06f_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3ded785627e4686af72f0b8d2f046fe_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0cd8c26245b493ea80fd420a16b98d9_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic49e6c0c298b45d384afc6010a6b7762_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96b42a988d6c44c5ab94f2e2bc145a16_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d2c74c6b3434964b75d4a41dae81179_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0693b3d163314be799135d4bc4076c22_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief37e3faf17c4c568270eae6b145b3cd_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cbad562537b416c87c3c047d42d646a_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5edcc1f3bb72432eb95672f9fe6b9d10_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06145f78f1d34def882f37c971b1b1d9_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7ec43159f654583ba1e536a80658f9f_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f8c3daec6804be1859d4f0afafc33f0_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i867a837018b24f99a9a411f45c919e92_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb6e3d84fcc04f4ca22b4170593731ed_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0de05d9759a54853ac7066c47b8847e0_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic83f61d0cfea4373978c400de01b8b78_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if43c23fa8a1c41859b4371ea5c634e3d_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1bd97635393475dad752c246c239a5d_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc468b2507d144f2a14b7c6ac31458ab_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica34b4218d3541b09c3da6d94f2cb5e6_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i992584c4bfc6471d9deb7b1eb40513be_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d7969d1f8aa4dda8ea8586ae9c4137b_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eb3f22e2a6640ce84be77248010d037_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1aea64ee5d24421ab72f13729dedbd07_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id867ff6ff03b414389070eb180dfb49b_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6506a7038e6c4b3fa851ccb2c53be423_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide35fefcff44453d8d65564e21d05eb2_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id44eb4835c3848728a14a8c3f6cdc458_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81052cefe0fd4a0b8c431e3080dd0f2e_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94d8014e61a64d64883ac98c61c9fc14_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3c431fe980745c0b7193b78927935bd_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8525a44d8d614f5cb1fbc085ac7ad72a_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a2a1d85a1814d26a7c59cb5406c544e_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia499ee071d3a4a3d9c98fc4f9f4361e1_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i540e20523e4d4912bdc772d9ad3994cb_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73c1c368ad7148d183d9d0514e949c26_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24eecfd1ba81496297deca71fae20acc_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie28012ef976642138e574f32ea5efcf8_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic76c81a4858d4b609fe0712808499995_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b9be986d0744a89a11e10191af92b0e_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f066a7522d44e21adceaa01bcb1f033_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i882e0bdc376e4cedb6907617bd05c7c5_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e2cfa64c77f4036aad98fade9ef0701_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1fdc084f5464520a7448be49c5db0ac_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0244f8cf8aa940419de1c1d28d1e142b_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98f0dbf3d46c438aa1e111583f3997d4_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ef97d90cd6c439db72bf9c70f28da42_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61f0183768bc4e7b9bc935793c8ef1ba_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10eb1b72e5a84ad7ac1da3701bb76c90_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0374102facf24dc5823fc308260ee163_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23ec342a5f954896b84f92b9d5abcbf9_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b66ffdc877e4f1e89900a1d433731ee_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i562f5f706f934d47812f786fbf3d7b58_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if306bf45e84e4e3892e099cf48267fe1_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d13ded3c3b947ca960fe5a1e8612116_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ebeaa1f49bf4e0baa2712e4c5bf91de_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bdc076fc45d46928fdee43fba7031c4_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea17f40f7b2248da9dcf9bbeb1298aae_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaf3b58ecba448c98c4fbea9e5a1bebb_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5884a5e7ed954d8aa9eddb0b6e4da9da_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50df7cd55cd6495a81565d60de245388_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic189fd1fc7df4bdcb5e752b731b041bb_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia84578dea56b42ee89fdffe82f1f0218_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d9afbd7f944468489ecd62be054ea29_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c352bec2ed24d399d4198a694dc76c6_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4827a6e9fcb14cf5a2e458c318845354_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c05ffbc94dd44c8877b9c05314ad378_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c1d26f41ed64110ba7168ddec63bb54_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1967287f9578497e995a11c707bf2f53_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide1e53eb0492409cb4653d655cefdab7_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddca17b69fda4b1cb462915c216a46d8_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib42c8f3666d34ae7aa8627db6a446790_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3d0a4693f564cb8bc9e73e16b7952c1_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5284a31246ef4a8c838a1e4123f9f505_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5e9cffd91ca411a853422a72582bb93_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice59f9c85be54b839acb8e82d6d4f087_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5854490403eb4af9a2d3b60108890558_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbeee4aeea57426e992c6d70c15e7c2b_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd2c49b4b2204484a5dc99464f909943_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic558f7b084d04003a7b5d749f85db400_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i622659a4109b4f55941ea9eab234897d_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd9e4baa754142e2874a7b15ef2af88e_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76cf0ef8cb30429197a1518d631d35d8_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie84450c6d85a401fbd2cf8cf38737ead_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1bea109b1b7492ea05f6750a7a1228f_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i600831f07e1a4339b1e94d5e21d66372_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2af09556bc84fd1ba481c7e0406146e_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1af77281c754257a1fa2e2fc2ed937c_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06dfeb7913f3474fb76e8bafad008be1_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1290f60dba7e446e8d8b08ad7c42874c_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d862660b5a04a089a8bdc443ee48fbd_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia53773f630fc465eb5108bfbd89f5f47_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45ee541218b04971b53ff4e5d19ad204_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8360a75d208433d90de437993ea4a59_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6d0af4fc35f41b78b153cac7769eca7_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1242a55b9a0485193c8b3dfc6ebdc75_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i951a06fcbe4640689f8e364e8afdbcd2_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98c68fd3171e4813b03d948e6c1538d5_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fed2345a1ee4c23bd04c0f52f574fb5_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i024835e205554573a9c3504cb27a8c5a_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c485d85051e4317842b009e214d3fe0_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2039f6815f94c8eb39335bdd8780f31_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f82ffb3600448bdb45ded460d8052af_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bdfd9d747b14c3fb94da3568d458766_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b106a80587443fa9b0d89c8d306ddd9_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fad4ca7557147fe95699ddfe8a3615d_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8c8e0238b104ea08be4e264097dc22e_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4a4e436169b42529a9d0389c604a63f_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cddbb6a917e47509f085811d392a493_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49e72c9dd590489aa2ee17a974f38a86_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id58b0cb1491f4c01a2650b1b46fbefa7_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b81c853b79c40f5a5e333ea61fb2b15_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i053a5c0a067448d38267b4d4d0371d39_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7230aa1f363542928871b474a14f1f8e_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic09e7e58a12a4405a99ed854054ef46f_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic88a9f1b52334567a7c5d218c774bdf4_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ea1dce9275644229c0975d44045301f_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia50d35187ab3428390ef63a28a7e6961_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25bc2d1842ab4478b3d89958785ab19e_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8d3a81114da408489e4e01d642c9082_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eaf6ce2f8af425790cb397e4499b14a_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf0f6411562d444f9e80f8a62cc71594_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i969af2be04a041288cd2cfddbec62364_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i411f812e4d114ffb8b1267fa1cb56c6d_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c6952baf25542b68c9499c21641991f_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12599e668dbc41358348e5544d2dba07_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eb10a316fe84f059ae619a1305077dc_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7368a505f53e4badbb0e085fcb131b8a_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78842fece6ba4955bf4a23337f9c5f22_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16e861eec4c443828199789a528253cf_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i629b6a7bc81546dca94d639d376629f9_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idafd1bf909ca4919aaaabc6674fb242c_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if665cac9f7d94d4594494bff63142705_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88009127c2544c78b9aed9223b7b8337_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fea18f4d9d94ba2b90cc4f81dafacaa_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07b9844b50d54100a2982651b8823c9a_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i232ddf875322462bbd406ee0ae4f9c85_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b3d697a4fad4697830a9e243e1e0747_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3d70f93807b47b3aff1d8a1e73cb8f5_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idef7b076ea1546a89cde23fde1560ab0_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i496a22b78b1d457ca678ca6d564331b5_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9ccb9aa1cc34b1e9f6f123765de70e6_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4798987e78844d73831f5474a76abebe_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5e5e1acad6f430bad7029515d202b51_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b00b20de7c94aa1933c4f6eb44fb6f6_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i207b52ef8f4b48de8416ca244f8b522d_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55ce0b393cce45109fb4fabeeeaa64fd_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8278bbfd6e74d48a7d676153d80e78e_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib26f9da69a6044e4a8bd640d1dbfd732_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5457dfbd70624cab91476a355fa5115b_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i553115651d944c87988eb5dd696715f6_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a584f32c5b84a33b71234d8cc85f779_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8ec118f64784127b948ce57a03251d3_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2041012c7fe94696ab6a160eae5a0d28_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fea7ff2b8d04558ad6fc2362b74bf38_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60a807f1dd544cac8e57c11caf619604_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01ec1719a93544dd847dd8eabc9f9027_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06b7e00e28414ef1af6c648b94de249d_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife8d592b718e4648b32dd579c98199c1_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice26ad0a6ed346fb8cd1cbe7031efb8c_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d26596d2402468f925f727a0ba02ff8_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fec763a254e49a38e7ad0d9a0f09012_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8302f031c56743a1a3a21fb700613bdb_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff9d00b4dac646eb8e2d975cfd2be240_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6a7f6a3730144bca2ea36f15ea20490_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6096f7b9393042f5b2b82bc8fb59bd2e_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b3780cbf7d543e7b543bfaa92165ed4_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91e2cc727626439296018d3621df8996_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcd8a72bb32b468fa5b37fc14195304f_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9112184634e44b0cbfd9d823f1219aa3_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i920ec4d1d57649248aa990c4b93fe684_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i453a034a54da477f8370e78e927a3539_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a991002f04c401e97d727678badafbf_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aee8dd846874e159438cc4a03f7bab0_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00b9571f2a6b4a2bbc14ea2f3077c57b_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0518e784a66b49d68047ddf7ee9cc00b_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31e66b96468f420288f19c564089d8a2_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47183644d19945a8bb49dd3a27546be6_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c83e880c458472b8c50b6cf24267d08_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56502c183aac4db6ac72f64b0b31c8c8_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib67fc9ee208641588e1c086557319199_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i916f3760699b40dd9d58b5336d356442_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedaf2bda66294ffba5d53d0ef7f61370_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4c445f8624f40d6824d709a9744cae5_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37ccb6eef64a4045a8c29d06c8cf02d8_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dbe05ea1dac40b0b66f0aac32a160b5_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb72505c1d974357bf35c6715df00b92_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fc5d639ff1a4b4e921cb3c51ac5125c_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fa923eeef864e7aa46c2f7515d33025_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6bf4f3e987046c38170406d258eb94a_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8db06e2cc04c458d912a58a028760c4b_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f4582f93ea64baf9c7628c58576a173_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41e8da5f36f54d4bbdfc91d37ee03c6c_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5424c438f2644ed794b321513eaa316d_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5deab209e23645b498b422f99964df0d_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib84b38a234fb454083a8048492807925_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3b2572faea149698d267bcb7cf881f7_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i605343b19cc64b1482f6408c0434084c_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5c97cf898604cf4ad7406f9531426d4_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ac76396403e46669ddb9bb2a99e7626_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1c93d444f7d4ab4a13e6d1f8efea458_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fa54f45363a4ac999c0b20e1c5f28a7_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i178889716f424850af73d18091ac8fb3_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19889197e7014b5abe659ff2ab7a326e_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc84e135342246ada537c96c79411c73_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie334cb54a91c4aa489e4470d9dd267d2_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieff90fbe65b14dccbcde52e76abe2491_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28c4b7c2d0fe47d6a4a59c5126dfe022_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f1a31cc19a448fbbbc2285717ad1b08_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f62cbc379cc47b1b559838e47e5e9b9_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6eed07d82dd4b42871be86888306c52_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f839300e00c4a4d859e26c2fa5c6e37_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1873788fac6a46e8be4e456fa927ff6a_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12ba7c96d6b34b73b2dc889a40179104_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e0ccc4ef75a4c3cac7174f2de54a9cc_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8becabeadf84e98b9d419b68203265b_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68239219992142d2aa3702fc95b596b7_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife0ab2f3b60049508c2fc1e1d78d4cb9_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a330731470745e48d563c9c6d517be1_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e7548bbd31e49bab7d5fec3a6b41671_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ac34ad4788d43b3a301f9c1c62308c9_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i106f48ae57ab4181ac0362aa6cfc6106_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bb172db98c34f69a96a8e61c2990f49_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac83ab04fd454d808f7a0f2ba77b1fb3_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebe8c5ef936a40769b7f7a23f0b8f324_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29b333eb2dd34c4e84797c94386443a5_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i894f559ee892432bb4a292bbcc61acdc_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i796f5d7d4c4840a8992ef9c2f85752ff_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89c02fa080d343cc9ff82372eac2f123_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80392036102c45ecbc3621717d0b2c74_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b0d1c1d0a014d889948f7983d615275_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7ad75c915974e13baa608e010a4dbfe_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42ff1e292f27485f8ff84644532adc72_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i144c6515230549dc9ae750420daa70c0_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12c283c3ebdc43f685bfcfb86adbaec3_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66f80a64500142458617dbf774e7f46a_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifce0de714d9b45428f3968fc9988e0c7_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3367c13477ea4799ac8e90b9e213d261_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fb626460b96415bb179ccaa4c0ed5b5_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id11e5789ebb948679c1a5ad0d35ae54c_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffea672a5b3c47eea9012fe82778494b_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie993d24b54904ea888b1293ce96956fc_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c1b37038bc7487ea392d8a7578b3110_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c5d285afcf84094bbff26299ad4e109_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a8c160f547f4d6ca4252136e13831b0_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic72c4574496a4c4fb83a4560784b72a4_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d908ad9d290413a98b31cf4d5ea0d87_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8298a87ec6094a83a8f67eaeaaed0f98_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i246d9eeb9fc948d0a353e9a5e7db555a_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic58138fbb27f46fa9ceb6e76659f1262_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i583b1aa9afbf4206bfc48b54ba5bc3fd_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fa5dc18ef454b7099777b9a2e9edf1b_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i450c72826782487189f185be011ada8c_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87186edc0be942c3a224af0c83083a2e_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if86e5be3d1d0462981071e831b1b1941_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i118eb58e43a74473be63948e7e8b110d_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14fb81ce0da94fd782c69b4cf8735fb2_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4595e7a6d7c0489b8e9bd4072d2f0958_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb6afd2ee42744da955bfb4de57ea068_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52e5864ae7034aacb7d9ee6a4b6ccc99_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5224eaa3aeab4bb6b58685ece2af0a80_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e6e8316702148888c8f276675d24468_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8fabe771e534cf0acd946d6aff01f6e_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic749d8f0affe4953bf8a83f1ad6aa6b6_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f0243ceaf5947389c637d5ed6092fe9_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i184a57e2be914b2593d8414dcd7ebd91_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60cfac9b2a974827a630d010512f5c77_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14031fe7bc3f40a795242b575acf51dd_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eb67a9b82764e84a6203e5424624500_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if278a32c9dce4fefa94c62fe1b00772f_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7780cd75cc6246779ff11406eb223052_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i691d2c928a4a4a60bc0a0d1ef168d8c9_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66aa28c488584714acd26eb645da8e89_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9360b52072034cfdae74e58d3dea3f33_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7e3e8b15ac3457193a8e87969a76f91_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic31063913c464d9f982eb66bf1ed7177_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia42b914656c14beba7b1d52f061668e2_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia376c7c58c6643b982dd021a28407a4e_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d6cc5a8d92c432cb5364a4922a91d91_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81cccc8066a04b4e8587f7022fcef5bb_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id91713fd7da44504bbad7b781cd667f1_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39b68889f48547fbb59d17264b094ef6_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdeb350dde814f6da9360e6b2898ed8b_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i939e8441406e477a9fc9fd99aec89197_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff6994e434614d1a876eb0d4c2bc823f_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a65b49f54754536b37dd908a689ce2f_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie60d62e420664954b1fcb37f6569c27f_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a75d9e9a4ab4545b4d6d05ead21ec93_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic37a66f35b5c4a6d99c2c3e0d691685f_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f78539697c141f2a5eac40f4a433cd2_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5912aea718a849be9bf7b9153fd78d98_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia241c89cf4794e2bbee7d74dce0875de_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b6e382369c74f9ea1f6e2762ea30c35_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieba41c75d5da400e9fb64a10752e1807_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad2d34311e684aa1a6203f5714c84491_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c2dbbb07733475cb4da59ccd3196294_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08295db3a10c439ca068a77285361be5_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia15056130be2407b92273859fdb8febf_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ee43394ce814ec8b0f42fe52e12760b_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90d459ed7f3b48f1b2b9174f1965fbd3_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i664cbb9c037f4d99a4376475a351858b_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id97af143662643b3842da08b330a6f6a_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7759e2ab5024d0fa40501ce6cc6e6b5_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd8d56e959874c8cbac753320da2c5e0_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68c3a86a25ea429f97b80b17ca08e649_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cd56ef47b4f4058acf28c65ff513a42_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fa4a52ab3bc45caa61ce84e01cf51df_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i485a9a2a0c8f4d779f31ad655745be2f_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66ee637b96ac4b0cb5d60d3c4d7ff8e9_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1b1017d106d47a89606d3c777ad71f0_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bfe547121e24789b19f5f8208fa6fd4_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d7f9514d7a44d1ca6005181785ac3ba_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d1f8a03726c4067a2929437ae2fe5f3_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25f9cfc65bb24864b3563c647160d27a_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7aaf4b905834c92835e38cca37238c7_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86237042c73a4330be6316b8b9dd8739_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i368def26f6ea4bfaa9177cfd9b260470_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63a357e6381c4197a2f2034714a76f9c_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd7333903aa847658f94ecffe462a28d_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38fa03f6ded84c66aa2bd6d34a67b4cc_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2a3d236dbe3452793a752eded62785d_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b2a6b8d156a4c78be2c856e9636bc48_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03f2bbdd3f2943d8b8a157f236abbaa4_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc2283c62b61497f9e264c1563dc631b_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd21677efb134c17a84394025e299a84_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb78ecc3071f4f89a308782d6a88edfb_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i777e00866382412a98d3a01a40a39f9d_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idebbda9d775f4719aa69f47ce5be05a3_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50813470f09748ba803e03a49ac76836_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19eab095e76442c7a15bf5f8be178453_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63c6e6e9b6ae4771aea32259886b1dbd_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad15e1fa199a4cbb875175ac153591d6_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i690c132eaf514ca895f63e12fbbb455b_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59d819aa14d94e3a8762d8ec158426d0_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i015af99c4a2e448e9c7144c5eb3975aa_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if160394e7e1d40f2b37c20e7236b7b62_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77a21754634a4942a38523ea36f795bd_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a08b9538fa74a208fbf96aec8a31dcb_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d390e81e3db43408b91740c66c31b04_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f4babed7b4d42b5a5c2d40a153c2633_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafe600a9ab7a44c68df5d9ad63069018_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66818b9b3aff45fa9b5309ab5d6ebdae_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb44530d18d642e683cefa298f2e197a_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3db704224024476bb17f015b1c0abc3c_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65804c36217740f0b729d452073739ca_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8af97229f0b54fb9a42e82e133be93e3_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e62e22d053f4be19970487099e52b46_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67cc2a6d5c864c8aa19c1d21575a1fda_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib53589fb1d174c0883c5a99ce3b7df76_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fe69a5c4f3340bfac6f40428dfe05f1_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib89bd6041e30431ea64fca96eaf48c0e_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1283c6dd19e48b2ab1219dcf3751cff_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i346c10c16c374bf6970c356a17deb3f0_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e475b85e02746e4b631284e2dfad017_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a1ad64f1a3644558ba0bd78d14887f5_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib837c1b7b81c46c79b81103985f70413_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2b39b6e0ce043d59ef4f7c826aee38e_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4004c5d0ca6d43168b2cc99025ba0344_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69dfc54530ab4ceebe84a4e443cc7206_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7879c0d85bbc427bb4a31690ab8da4b8_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f7f8554621548c9a359d347cbbbac3f_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46c22958c0c549558f53ab422062f508_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03538a98c9f84546a0878f97b68fb052_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9758b02c72df4754b31600d639492fd4_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16af716d82004476883437376d33e296_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b848b4c72814939a4ee849afee353c0_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdfe043a81224cd7aa4b84062546d3e2_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ec97248e6e44f398ee8bbac82b179bb_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6cbc53d626149a08db3eeb2b61e356a_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d0754c7fbfc40ebb8439cae628ac5f2_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0fd94b5ecb742a2acf56d48a30e9baa_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e2b16d94b1e4ef99fe58558a8b6b7ec_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d422a20e0ae4335846ca1405c432d7b_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib99c3f2e02614e95bd95c334578642f6_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i941f7b5cb0944651ad943556245e42af_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e245c440a8b4af9833fa1a0c53fb2f1_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6dfa6170bb04384890d25bf750f7285_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52d965366a5743539f8a0c66e807ebf6_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i957af76e03cf41b2b4137b9fb5b797b5_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fac8e5af73743b892d0ff019286d402_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic713079734e24fb0aded04ea2f5ef4f1_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17cb3783cf374d5589ec58a0de356fe9_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75c76e0dab5d49728cf41af893706809_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i251fe35eeedb4dfda33118b3264a40b0_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11aebf9815c5450b8eb28d8737503b25_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie503be36392943c2aa1fc032e197cffe_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7962ec68b8054973bda571c916266fbc_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77a23c165c324817adfa8ff05e524d4d_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96dfc5cff1454f418137861a7c0bd661_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52be8cd00a544fb9837055c28c31a0bc_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a091c8ec3e4450b9c534d593ee3f48f_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f051d97946b48f98a750ba79b71b129_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22ea02a9de494a629f2a4d89b43a24fb_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i212cc5dc91cd478984ad00fae62e7737_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00191b17ba9d4f05a61536365cba8dad_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb99fb7943bf4d77bb82160d491f0b87_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18be951542f44ecb96828af068093472_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4adae2c06c9b4940ac03d2eac7f0f1e1_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1997e6c1765e4a75b9bad7033aac8b26_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecc5a7943edf4572be993acdc0b1bd83_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bb2fb97435a4fc68bf0fac1ebcf132c_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i122148b592b24cdabf78d0a482cdb38a_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6234adc69a847759f0dc2168c7a7ed8_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dff7af12b264ddc884a1eb374f6b51e_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i494fe80075ac40acbe0318a3db1a774d_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i490240ac5d354958bca7ade168be4ddd_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26fb731c7d16411daeea4aeb1d065918_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a3313d8d5cc43f5a89429b00db0f9ff_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18341461a0b64ada9ce1d9bf3032cbd6_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i106ec6964b614734a6df2f1c7aec49b6_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42418c9e338b42f1a79e47c3637bb792_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87bfc75fd15049b0ad902fc45bddb23e_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e89c3ffa20849288d5655da93e8d070_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3359d80da2904900a689911b61bec8e9_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93a48db34f67401b89ec28786da34bb4_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ca482bac6f143ad8311c2f32ac8745a_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77d5cba624204db7a4fdf3c92b03712c_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bd7def248f4471292b3bc6fe506f3c2_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a49b832a4ce4356beec3af3897dd8ca_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica4dc3e811fa45c38117526d37a372e4_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id39f1cfaa5034f7d8963544179ed45f7_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09830464a4ac485fb8800a57861ec07a_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd336d1de1d7402e86a487789816638f_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i868e4a3228b745b69f76acf1ef47fa4e_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied76a8d7c3a849859381acdd5b40e26b_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib963c3361a9e429ea23e9be78632d5f7_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c87a451aba6470f8513849722c6f687_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5574bb64c5442568419329c1ddf953b_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i890b0d4ac71f441eba6bf1198c410a5b_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98ce489b2b83414fafb7d08826ccae52_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84a3df8795414451a2635599c9f326f4_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic40e1fc715504106941039635c311b42_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cc28cefdee24db587c2c44627a5d4a3_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id90e5b6cac784a01a3ec9b835573dd8b_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14af6f66309945bbb345d1e5080fc3ab_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5adee58e8c554a2fa51b9dd0dff78319_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8954550cb9744329c0944ee64bf182d_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dc24dbfe93c42a5bedd17d3f4602b07_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20171878a2664b1396a4e8dfab867c63_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib792371a81394b76adb8d9160ed815f4_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1c483984fa940d4a2263fdde35ae2b6_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40b2a961cef64c3f81dd66d2cc8d30cc_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5e248410521459d8d4e90e3229028f7_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07d6c5cc14f04a4aaecd3ac4c2a56626_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic77ca9253fc245e696f14b2344a21c4a_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f766b8bc30a495cabb27a63cdfa21dc_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74aa9c650ce94f7f8b6a94ad4ec01ce9_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50d4546f23234e4a95f876fa114ea771_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78f6125d4e1f4642a4d765a351286c3c_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93a0aa8ef0ed416c9429b2b5b88cafd0_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2f9faa3f7c645ed95dad829fbe0f3f7_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadc95fab6c004ee8a52836e72d8e51fb_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34f633e2629c400f81fb20c99145e112_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4fd30965b31465e953a69a10b46ae75_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d5d0922cabe4f6fa55f3ac6507c79fa_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fb264a5db024fa1895bcd3a4069036e_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37b312259598430096ff868f08b6757a_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51a85394d9a14ff08bfeb689185d9ee0_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie63bc91b9c82473fa1e0ce9ddfc407bc_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e2feb214c2c4da99c1a6b518a224dff_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2f54909f5e146f3bd1d3b4357419206_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dc0ed7f6bc641189e3c6e00c91f73c2_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43e3289369584ba8afd76314fc686eaa_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2f69aa2c55f4826a2d6918db36d8504_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if044c23d97b94f7e9198830e79b71e75_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice42e5369e6b45f0adf19543436ac0b0_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d701fb1987245ca88cf01f3640777be_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic16d2db94474459387159b0687052bee_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6ef5074333a4f0d83205f62d497b7b9_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id87ab88275fe48e88b999c9d8843e970_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia28c90140a094ef6b236aa35a8e77056_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b2df3c4074c46f3829a9f1fe6d1b3d6_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab8b7c86635743468dc8ac2476edee79_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0d190ecec914687861142e006d00019_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fcf37770f4b482490a1deeb32ca5fb3_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a08d0a4fd414fb0a743ba8926a6de8f_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa95b6bbe9ce43f59b2c55eccaef0947_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9a33a98d27c46748aef00c3c783085e_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b79863c6ede4c88a5b5a6aae528d65b_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0c8f9eac7f34ffeb651669100cadca2_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86880b7c7c2c429080f9c83aaaf12cfe_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6353fe8fafb84e8b9c268c65fd303086_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6337b707147a48869ac16b7992cb215b_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1e1fcd02b464ee2a9ec2881679e5e2b_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cf5b5276af745aaae4d731df390a2e3_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a407e33714d43e5b6f57eceb1da3644_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i774d073624f5479f99c44707399d81a2_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie104a5f4ba5646e5ac756ddb0f8fe1e9_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa7453bcb1f1499cb56bf4c488b9f6ff_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i548df4a2b991433e95457098102bdc1b_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12056b6b1c854b9b986a9a3fbc149483_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i543547499d5747568f983b53ce0eb701_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic400b23cafa440aca0f838eec065bd9b_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i237bc393dc5541fe92d8e43c47a8e02f_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53dd9cb72725412faea6075a5b94f5f7_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie745b9ff518641abb53ef1f33093480c_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76eb46ab7e594c6e955830b051a4634d_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3925875d2d8b49ed84c2f94483fbddc9_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:EvraAndDoxilMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aa76dc85f4d47988a65dc0767f87e60_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17afbc0e69e34400b507b3fa36f4cca9_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8abbc5ec72a249a68e86c66cec320d05_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:VerbSurgicalInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claimant"><xbrli:measure>jnj:claimant</xbrli:measure></xbrli:unit><xbrli:context id="idd91294a39994bf7a5d46ad21d5ce73f_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AsrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e112538e52040febbef4f9ec3d08be6_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PinnacleAcetabularCupSystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38e0af4dfc454327a9035d9ecf2f71de_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PelvicMeshesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6fd89964b9b478c98b0b7b32284ace4_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RisperdalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd11e0e4967746c686c30187b7771685_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b95b40b62fa4991958c542357558bc5_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f2f6f0d91a04e85af9ca78c9af911bc_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:InvokanaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f85d89b6d8146aaa779ff9a82bd22b8_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="patient"><xbrli:measure>jnj:patient</xbrli:measure></xbrli:unit><xbrli:context id="ieb622359a78248788392bf4fc7788239_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:DePuyASRU.S.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i432d9a09731c43af8b981697f2d30a00_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia06bd5801ebb4de3847b03a9ebbf31df_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i888336974542449dbfef3a3a1d8c4d58_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0511c88e69e54af3b80ae9e01a00203b_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93cea90b33244c4f8bd342dd3f008b23_D20200601-20200628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2961f0a11b248a9b0915353245c62bb_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief20b90c9cc3400e9758007a2c93489a_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>jnj:vote</xbrli:measure></xbrli:unit><xbrli:context id="i43837e43114841208382ec8e806920e4_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if23041d120f4417a80290be9a7d86354_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="jnj:LegalJurisdictionAxis">jnj:StateLevelJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8c468efba6f4c8eb730082ee4eedf85_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="jnj:LegalJurisdictionAxis">jnj:FederalLevelJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5c767d6b7254013824d1430cea6166d_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib02d3415bfe94365991511ce5fb09ebf_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27171efe2b3941548d265f05e276162e_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i653b6f4b1cbf484b8781c02b3402e666_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i945c4e1bacda4ec68c3b7c94557f3765_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fc8a90a726a4462b931044e9118c5df_D20200120-20200120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:SurgicalMeshProductsMarketingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-20</xbrli:startDate><xbrli:endDate>2020-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>jnj:claim</xbrli:measure></xbrli:unit><xbrli:context id="i57db9f0a21bd4a538b012b2e386a50fa_I20150430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ContactLensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c79c8166fea4d28acc6e2a5c55371e3_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41e6c3af78c84e7a96704669c8534fbd_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bf46255c4954869ba02f4fcf0890318_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id03bd483db33402eafee3a37392a50dd_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i395c16cff1fd472887230111aec654c7_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b2139d6e4794867beaf8b64054355a3_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9335dfec33444d1fa82036d4e0556288_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddfd422a68bd4c3fb53443eddc899e5d_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a40709bfe644a94ba4984bd52754e41_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30de6283641a414eb591a7e379e8ca06_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if65f698d763e4aa69ebb37089739db4d_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i155df99154524c01b1d1bc1cda9bd334_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7b66f9b903d4029a697b4d5bbd09f00_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86e59d6adba6473da76a65735fc95b35_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f1238f4cde44b00a401b4e14983e6af_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c74256bce09412bb1c7eb851708c6bb_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68831153f9a14ae1b239033a0c1a9104_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i965b447464ee4a389bab1a83195f092c_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6d484844090412aa63423ed27e77165_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7a5f799f220481ba0964cbf04e6d485_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69a08f7d7ee644f69fa747b7bb19e88c_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6911c9fe2fc4680883030bd35fb4405_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecd272aa6bf84db3985f9de3d1a4af33_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b5a49c0f5b94001a4430dceb7eab418_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7cacd129fca46088c70b938e656f2d7_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="if410ee6e03c8456f86a9fee997f08e65_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8yMDY2_8388def3-1bf5-439e-9025-b9f33bc0988e">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.406%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6Y2YwNjBjYmEyMTZhNGFjMjk2YzBlNTllMWExMjg1ZTMvdGFibGVyYW5nZTpjZjA2MGNiYTIxNmE0YWMyOTZjMGU1OWUxYTEyODVlM18xLTAtMS0xLTA_b4436604-cf1d-4d30-9905-2358d8f20591">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quarterly Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">for the quarterly period ended <ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8xMjI_6e6d15b5-dd88-469d-b2d8-cc8f4b8c6bed">October 3, 2021</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6NDNkY2RjZWI3YjFkNDNkN2E1YmM5ODk4MzYxNGU3ZjQvdGFibGVyYW5nZTo0M2RjZGNlYjdiMWQ0M2Q3YTViYzk4OTgzNjE0ZTdmNF8xLTAtMS0xLTA_c1269977-d38e-49db-ae88-90ec19f2f042">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transition Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934<br/>for the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8yMDYw_2cab69be-df58-42fb-91a5-4307742b7fc4">1-3215</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8yMDY3_82bd2c98-188d-4412-be20-72f809efd3c4">Johnson &amp; Johnson</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6NjQ3OGZkMWQxZjk1NDQyMjlhZWI0NTY1MWNjYTRjYmIvdGFibGVyYW5nZTo2NDc4ZmQxZDFmOTU0NDIyOWFlYjQ1NjUxY2NhNGNiYl8wLTAtMS0xLTA_f8a3b532-1549-448b-b760-2b8f4432323b">New Jersey</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6NjQ3OGZkMWQxZjk1NDQyMjlhZWI0NTY1MWNjYTRjYmIvdGFibGVyYW5nZTo2NDc4ZmQxZDFmOTU0NDIyOWFlYjQ1NjUxY2NhNGNiYl8wLTItMS0xLTA_d31053ac-e140-4c6c-bdda-1cb554b3864f">22-1024240</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8yMDYx_0b6386c9-7530-4a65-a13a-8daedf225dcb">One Johnson &amp; Johnson Plaza</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8yMDYy_d92622a6-0bdd-4c9e-b9c0-8f8207b3fe2f">New Brunswick</ix:nonNumeric>, <ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8yMDY4_b6ba88f8-c86e-4792-9dd1-58da88b497ef">New Jersey</ix:nonNumeric> <ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8yMDYz_17cf1f80-39fd-4a9f-b122-b084cb04d2d8">08933</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code (<ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8yMDU3_7c2c7b96-70cd-4d7e-beba-28eabb048771">732</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8yMDU4_bfd4b35e-7ada-4eb3-a04b-b11849c08e10">524-0400</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8yMDY0_7552a630-e4b5-4b0c-a1e5-ba79941c1bae">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8yMDY1_480cbf76-192e-4bf1-9413-2f641f3faff5">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:12.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6MzNjNjQ4OTk3Yzc1NDU3NTkzZTgyZjY4YTFlM2ViNTAvdGFibGVyYW5nZTozM2M2NDg5OTdjNzU0NTc1OTNlODJmNjhhMWUzZWI1MF8wLTEtMS0xLTA_ee3a1b17-1865-4c93-8fe2-5ddd46e8397b">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6MzNjNjQ4OTk3Yzc1NDU3NTkzZTgyZjY4YTFlM2ViNTAvdGFibGVyYW5nZTozM2M2NDg5OTdjNzU0NTc1OTNlODJmNjhhMWUzZWI1MF8xLTQtMS0xLTA_40d49ef2-a1ce-4f6b-8240-d7e1be3f16cc">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6MzNjNjQ4OTk3Yzc1NDU3NTkzZTgyZjY4YTFlM2ViNTAvdGFibGVyYW5nZTozM2M2NDg5OTdjNzU0NTc1OTNlODJmNjhhMWUzZWI1MF8yLTItMS0xLTA_e4c68b08-f1fa-4fca-ab4e-5e3681362f8d">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If&#160;an&#160;emerging&#160;growth&#160;company,&#160;indicated&#160;by&#160;check&#160;mark&#160;if&#160;the&#160;registrant&#160;has&#160;elected&#160;not&#160;to&#160;use&#160;the&#160;extended&#160;transition period&#160;for&#160;complying with&#160;any&#160;new&#160;or&#160;revised&#160;financial&#160;accounting&#160;standards&#160;provided pursuant&#160;to&#160;Section&#160;13(a)&#160;of&#160;the&#160;Exchange&#160;Act. &#9744;</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8yMDU5_f35f4804-8ab7-414f-bbe6-7be2014ed954">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:15.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:15.75pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES REGISTERED PURSUANT TO SECTION&#160;12(b) OF THE ACT</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:41.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.093%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9a8050abbb6b4fa087129310f939d84d_D20210104-20211003" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV8xLTAtMS0xLTA_a8f6b2c0-9497-40c7-8fae-3c97a2377bee">Common Stock, Par Value $1.00</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9a8050abbb6b4fa087129310f939d84d_D20210104-20211003" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV8xLTEtMS0xLTA_09ba26c6-584e-477c-95b5-50edac66e83b">JNJ</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9a8050abbb6b4fa087129310f939d84d_D20210104-20211003" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV8xLTItMS0xLTA_0e2c7378-c5b0-4241-a4b5-3c0b979feaa2">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5b6adc1e7fc54138970a1ffce6545ea4_D20210104-20211003" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV8yLTAtMS0xLTA_f7b6158c-8000-4048-be89-661d48a43786">0.250% Notes Due January 2022</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5b6adc1e7fc54138970a1ffce6545ea4_D20210104-20211003" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV8yLTEtMS0xLTA_69a558a5-68ad-458a-9e1f-0ea074f0bd47">JNJ22</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5b6adc1e7fc54138970a1ffce6545ea4_D20210104-20211003" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV8yLTItMS0xLTA_b48087ae-cfcf-4984-ac11-389bf3393943">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6d7f3f3cd9e848f386315ec977895ad1_D20210104-20211003" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV8zLTAtMS0xLTA_7268f75b-9179-4feb-b24e-65d554787d8d">0.650% Notes Due May 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6d7f3f3cd9e848f386315ec977895ad1_D20210104-20211003" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV8zLTEtMS0xLTA_bba7a23f-157a-44b0-af22-e6d381604563">JNJ24C</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6d7f3f3cd9e848f386315ec977895ad1_D20210104-20211003" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV8zLTItMS0xLTA_bdb5e8db-fad7-4851-9ee4-1141cebdffd7">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie0d2f13d6fae4fea9e15a651e3245c28_D20210104-20211003" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV80LTAtMS0xLTA_5531e7af-fccc-4965-9c66-d63f9671b803">5.50% Notes Due November 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie0d2f13d6fae4fea9e15a651e3245c28_D20210104-20211003" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV80LTEtMS0xLTA_4e4a8fda-fe7f-445c-bb0d-93631413f27d">JNJ24BP</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie0d2f13d6fae4fea9e15a651e3245c28_D20210104-20211003" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV80LTItMS0xLTA_9ac4b12b-7946-40aa-992d-7316f59f8e74">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i579388adbc0145f5a9221b1e7204d902_D20210104-20211003" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV81LTAtMS0xLTA_9f23e25c-5579-42d5-988e-d6d103cf0622">1.150% Notes Due November 2028</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i579388adbc0145f5a9221b1e7204d902_D20210104-20211003" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV81LTEtMS0xLTA_69e2f4bc-a92c-4f0d-946c-b5b55509c13c">JNJ28</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i579388adbc0145f5a9221b1e7204d902_D20210104-20211003" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV81LTItMS0xLTA_e6a154ff-3317-44b8-86aa-2f4dee447125">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia256641b62ca4d77ac7b64775619302f_D20210104-20211003" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV82LTAtMS0xLTA_755f0840-2149-4d0e-b7fc-84d3e4a96d19">1.650% Notes Due May 2035</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia256641b62ca4d77ac7b64775619302f_D20210104-20211003" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV82LTEtMS0xLTA_b6520cb3-ff29-42f6-a3ae-a1b27ffd56f5">JNJ35</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia256641b62ca4d77ac7b64775619302f_D20210104-20211003" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV82LTItMS0xLTA_e44ae50d-dc59-4b86-8690-aebd9a099662">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date.</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 22, 2021, <ix:nonFraction unitRef="shares" contextRef="i5cd455ee122743e7b308fecfa89422cf_I20211022" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8xOTk2_81705644-13e6-499a-b53e-225abaf603e4">2,632,596,969</ix:nonFraction> shares of Common Stock, $1.00 par value, were outstanding.</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if410ee6e03c8456f86a9fee997f08e65_4"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="if410ee6e03c8456f86a9fee997f08e65_10"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">No.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_16">Part I &#8212; Financial Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_19">Item&#160;1. Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_19">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_22">Consolidated Balance Sheets &#8212; </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_22">October</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_22"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_22">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_22">, 2021 and January 3, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_22">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_28">Consolidated Statements of Earnings for the Fiscal </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_28">Third</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_28"> Quarter Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_28">October </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_28">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_28">, 2021 and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_28">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_28"> 2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_28">7</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_28">, 2020</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_28">2</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_31">Consolidated Statements of Earnings for the Fiscal </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_31">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_31"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_31">Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_31">October </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_31">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_31">, 2021 and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_31">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_31"> 2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_31">7</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_31">, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_31">3</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_34">Consolidated Statements of Comprehensive Income for the Fiscal </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_34">Thir</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_34">d Quarter and Fiscal </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_34">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_34"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_34">October</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_34"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_34">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_34">, 2021 and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_34">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_34"> 2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_34">7</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_34">, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_34">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_40">Consolidated Statements of Equity for the Fiscal </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_40">Third</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_40"> Quarter and Fiscal </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_40">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_40"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_40">October</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_40"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_40">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_40">, 2021 and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_40">Septem</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_40">ber</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_40"> 2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_40">7</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_40">, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_40">5</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_46">Consolidated Statements of Cash Flows for the Fiscal </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_46">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_46"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_46">October</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_46"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_46">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_46">, 2021 and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_46">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_46"> 2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_46">7</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_46">, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_46">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_49">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_49">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_106">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_106">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_109">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_109">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_112">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_112">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_115">Part II &#8212; Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_115">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_118">Item&#160;1 - Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_118">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_121">Item&#160;2 - Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_121">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_124">Item&#160;6 - Exhibits</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_124">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_127">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if410ee6e03c8456f86a9fee997f08e65_127">66</a></span></div></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if410ee6e03c8456f86a9fee997f08e65_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q </span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Johnson &amp; Johnson's other publicly available documents contain </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forward-looking statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.&#160;Management and representatives of Johnson &amp; Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements do not relate strictly to historical or current facts and reflect management&#8217;s assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;will,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Company's strategy for growth; product development activities; regulatory approvals; market position and expenditures.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Company's control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Company&#8217;s actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but are not limited to:</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Product Development, Market Success and Competition</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company&#8217;s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success;  </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Challenges to the Company&#8217;s ability to obtain and protect adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of patent expirations, typically followed by the introduction of competing biosimilars and generics and resulting revenue and market share losses;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increasingly aggressive and frequent challenges to the Company&#8217;s patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Allegations that the Company&#8217;s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company&#8217;s ability to sell the products in question and require the payment of money damages and future royalties.</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Product Liability, Litigation and Regulatory Activity</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product efficacy or safety concerns, whether or not based on scientific evidence, potentially resulting in product withdrawals, recalls, regulatory action on the part of the United States Food and Drug Administration (or international counterparts), declining sales, reputational damage, increased litigation expense and share price impact;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Impact, including declining sales and reputational damage, of significant litigation or government action adverse to the Company, including product liability claims and allegations related to pharmaceutical marketing practices and contracting strategies;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Impact of an adverse judgment or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, product liability, personal injury claims, securities class actions, government investigations, employment and other legal proceedings;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased scrutiny of the health care industry by government agencies and state attorneys general resulting in investigations and prosecutions, which carry the risk of significant civil and criminal penalties, including, but not limited to, debarment from government business; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to meet compliance obligations in compliance agreements with governments or government agencies, which could result in significant sanctions;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Potential changes to applicable laws and regulations affecting United States&#160;and international operations, including relating to: approval of new products; licensing and patent rights; sales and promotion of health care products; access to, and reimbursement and pricing for, health care products and services; environmental protection and sourcing of raw materials;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compliance with local regulations and laws that may restrict the Company&#8217;s ability to manufacture or sell its products in relevant markets, including requirements to comply with medical device reporting regulations and other requirements such as the European Union's Medical Devices Regulation;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in domestic and international tax laws and regulations, including changes related to the Tax Cuts and Jobs Act in the United States, increasing audit scrutiny by tax authorities around the world and exposures to additional tax liabilities potentially in excess of existing reserves; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Issuance of new or revised accounting standards by the Financial Accounting Standards Board and regulations by the Securities and Exchange Commission.</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to the Company&#8217;s Strategic Initiatives and Healthcare Market Trends</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pricing pressures resulting from trends toward health care cost containment, including the continued consolidation among health care providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payers of health care expenses, significant new entrants to the health care markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restricted spending patterns of individual, institutional and governmental purchasers of health care products and services due to economic hardship and budgetary constraints; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Challenges to the Company&#8217;s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected.</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Economic Conditions, Financial Markets and Operating Internationally</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal systems; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of global public health crises and pandemics, including the outbreak of the novel coronavirus (COVID-19) pandemic;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes to global climate, extreme weather and natural disasters that could affect demand for the Company's products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company's products and operations; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of armed conflicts and terrorist attacks in the United States and other parts of the world including social and economic disruptions and instability of financial and other markets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Supply Chain and Operations </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Difficulties and delays in manufacturing, internally, through third party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interruptions and breaches of the Company's information technology systems or those of the Company's vendors, which could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Company&#8217;s products; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The potential that the expected benefits and opportunities related to restructuring actions contemplated for the global supply chain may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities. Disruptions associated with the announced global supply chain actions may adversely affect supply and sourcing of materials used in the Company's products.</span></div><div style="margin-bottom:2pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors also should carefully read the Risk Factors described in Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021, for a description of certain risks that could, among other things, cause the Company&#8217;s actual results to differ materially from those expressed in its forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if410ee6e03c8456f86a9fee997f08e65_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part&#160;I &#8212; FINANCIAL INFORMATION</span></div><div><span><br/></span></div><div id="if410ee6e03c8456f86a9fee997f08e65_19"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;1 &#8212; FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div id="if410ee6e03c8456f86a9fee997f08e65_22"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars in Millions Except Share and Per Share Data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:69.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMy0yLTEtMS0w_b65f02b9-6f96-4648-a184-a2977f8c01ab">17,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMy00LTEtMS0w_0644412c-e912-4a8d-ae1e-de65c2e9a999">13,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfNC0yLTEtMS0w_def080e2-0b34-4f5e-a308-c86922e54eec">13,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfNC00LTEtMS0w_ef67b585-3a62-4d26-9453-14cbff438d97">11,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, trade, less allowances for doubtful accounts and credit losses $<ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfNS0wLTEtMS0wL3RleHRyZWdpb246ZmU0OTZhNDE2NmQ5NDUxNDg5MjJjNDZlMGUwNzQ2ZmZfODg_7d1291a3-d0dc-4c83-8be4-8a15d796067a">223</ix:nonFraction> (2020, $<ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfNS0wLTEtMS0wL3RleHRyZWdpb246ZmU0OTZhNDE2NmQ5NDUxNDg5MjJjNDZlMGUwNzQ2ZmZfOTg_84eeb180-07b2-4628-8f34-0d6f4c036eab">293</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfNS0yLTEtMS0w_ad950547-1e58-4e1c-8b7b-4aaf1bc9a8fb">14,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfNS00LTEtMS0w_aeb735c8-3a1f-4e46-b12c-da84a6dea415">13,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories (Note 2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfNi0yLTEtMS0w_a881ce8c-16b8-4eae-8731-ee79bd919e4a">10,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfNi00LTEtMS0w_c34abce2-5615-4390-9b67-db3fc18c6ec5">9,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfNy0yLTEtMS0w_2e80a9ba-d064-48d8-8612-181c2d6babdb">3,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfNy00LTEtMS0w_443629d4-4649-4fc3-a931-7f1aafbcf6dd">3,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfOS0yLTEtMS0w_03aad98f-b87c-46b1-8b0e-7805f92405d7">59,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfOS00LTEtMS0w_50a01945-ba12-4b4d-a50b-815d726c5fb0">51,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment at cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTAtMi0xLTEtMA_79c1aeea-8302-40c0-848f-7cb2a783b8c7">47,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTAtNC0xLTEtMA_e78c9a9e-8e6b-4f17-9967-33767a4fa796">46,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTEtMi0xLTEtMA_00ddddb5-1202-4d56-8d7d-0a601bc2e865">28,869</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTEtNC0xLTEtMA_7ea41c07-28c8-47c8-b715-891c87310602">28,038</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTItMi0xLTEtMA_8c9f16bb-3289-4534-aaae-b4f6dcf2ce4b">18,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTItNC0xLTEtMA_c0435183-dd50-4085-aad7-845f7e10d4a7">18,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net (Note 3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTMtMi0xLTEtMA_4a4e99f1-40a2-4050-8c01-814d9b1f76ca">47,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTMtNC0xLTEtMA_e850845c-89f1-4016-8b55-da73d4de16d0">53,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill (Note 3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTQtMi0xLTEtMA_18fdaa41-e221-418b-9859-8ef3a75e6744">35,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTQtNC0xLTEtMA_fe5e5991-debe-4f46-91f7-eeb1a6ebe0d4">36,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes on income (Note 5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTUtMi0xLTEtMA_2903e311-d4b4-437f-b624-27758f7d2946">10,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTUtNC0xLTEtMA_3a84667f-85b6-468f-8cde-d7d8d7024564">8,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTYtMi0xLTEtMA_963e9ce1-893b-467b-9d75-93ada5902e77">6,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTYtNC0xLTEtMA_c02144b1-dc12-440a-85ab-b161ca5a9fca">6,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTctMi0xLTEtMA_6d48525c-afc7-404f-9aef-b36528bdaa2d">179,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTctNC0xLTEtMA_f5b795f1-a895-4842-984a-aa9bcbb9ffdb">174,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans and notes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjAtMi0xLTEtMA_429f800b-de3a-40ac-965c-d82ed230c449">3,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjAtNC0xLTEtMA_f210a9a3-8b47-4aa8-8fb4-5159a7f88101">2,631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjEtMi0xLTEtMA_8607b6a6-81a2-4038-b917-dd8216af0a38">8,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjEtNC0xLTEtMA_28178036-1ff7-452d-ac02-291c4a9b1d03">9,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjItMi0xLTEtMA_b7ba5b35-ccbe-4056-9b57-be93d17c43b1">13,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjItNC0xLTEtMA_f78cf197-8964-42ff-81fc-1043691f3523">13,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates, returns and promotions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="jnj:AccruedRebatesReturnsAndPromotions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjMtMi0xLTEtMA_6119e46b-fa0e-4921-9ed2-6304da90b9c3">12,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="jnj:AccruedRebatesReturnsAndPromotions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjMtNC0xLTEtMA_c42baf8d-fcef-4c57-b071-cd12f8ade733">11,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee related obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjQtMi0xLTEtMA_e5be1624-806b-4879-9295-e85d306e3c72">3,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjQtNC0xLTEtMA_d6421287-5624-432d-88ac-a58c691eee3d">3,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes on income (Note 5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjUtMi0xLTEtMA_d96afb0e-e297-45fc-a5aa-535ec781fedd">2,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjUtNC0xLTEtMA_d84c1b28-a0f8-46ca-b37d-a94f2e910a82">1,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjYtMi0xLTEtMA_58fbfe85-005f-4663-92fb-001a46d3e819">44,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjYtNC0xLTEtMA_dd048c85-1330-40c6-89c5-9f183d4f9422">42,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt (Note 4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjctMi0xLTEtMA_b6b3c7e4-f8b8-4f5e-9b0d-4deafb8b6dd8">30,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjctNC0xLTEtMA_5d2a9f09-38a5-464b-84ad-a80c3950958b">32,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes on income (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjgtMi0xLTEtMA_674a8bd9-a44f-471d-b123-3127930db99a">7,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjgtNC0xLTEtMA_093044ab-cb8e-48ef-b309-855542f6f6c1">7,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations (Note 6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjktMi0xLTEtMA_8e44805b-1e21-4e03-8c55-1ec5a4b98fbe">10,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjktNC0xLTEtMA_bb4a09df-a39b-410b-8bbc-9ecd25a22d46">10,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term taxes payable (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzAtMi0xLTEtMA_3787fe0b-eeb9-4736-827d-471186088a50">5,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzAtNC0xLTEtMA_e48d77e4-d0be-4526-9fdd-b068f725bebd">6,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzEtMi0xLTEtMA_7075de69-3706-4207-a5e8-5ef502dd867d">11,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzEtNC0xLTEtMA_0a754dc0-2894-45d1-89ec-49e0374f687e">11,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzItMi0xLTEtMA_8782625d-fae7-49db-a494-6328cb02194a">108,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzItNC0xLTEtMA_440d2439-e917-4351-86b1-836277f10924">111,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and Contingencies (Note 11)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzMtMi0xLTEtMA_79be4af8-56d8-4862-b747-710ad73373fc"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzMtNC0xLTEtMA_dfca3dd8-9f06-4ea1-bbc5-ce688c3887b2"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock &#8212; par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjcxMzYzMTY5MWQyNzRiZTRhOGU4ZTMwMTFiZTg1MTU0XzI5_5f369d27-6e20-4328-9760-da43845373ab"><ix:nonFraction unitRef="usdPerShare" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjcxMzYzMTY5MWQyNzRiZTRhOGU4ZTMwMTFiZTg1MTU0XzI5_a4f0fa70-35f7-471c-9e41-5ba2de995023">1.00</ix:nonFraction></ix:nonFraction> per share (authorized <ix:nonFraction unitRef="shares" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjcxMzYzMTY5MWQyNzRiZTRhOGU4ZTMwMTFiZTg1MTU0XzU0_350f1595-5860-4c0a-b2b9-220f7c5910a9"><ix:nonFraction unitRef="shares" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjcxMzYzMTY5MWQyNzRiZTRhOGU4ZTMwMTFiZTg1MTU0XzU0_eccce558-1241-4fbd-b36c-889f30ba7dd6">4,320,000,000</ix:nonFraction></ix:nonFraction> shares; issued <ix:nonFraction unitRef="shares" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjcxMzYzMTY5MWQyNzRiZTRhOGU4ZTMwMTFiZTg1MTU0Xzcy_b83f0045-4c7c-4174-99af-c54016274421"><ix:nonFraction unitRef="shares" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjcxMzYzMTY5MWQyNzRiZTRhOGU4ZTMwMTFiZTg1MTU0Xzcy_b8763806-09a0-4c51-9eab-8ca253074d64">3,119,843,000</ix:nonFraction></ix:nonFraction> shares)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzUtMi0xLTEtMA_a443c35e-8c51-4a40-a929-c23e43d7404b">3,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzUtNC0xLTEtMA_be2a621d-f630-4471-9fdb-91e6d4be9e9e">3,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss) (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzYtMi0xLTEtMA_70883d7b-5c7a-4ef7-924e-9e994acaa550">15,415</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzYtNC0xLTEtMA_f001d1dc-5520-4239-90f2-4dae612b06a6">15,242</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzctMi0xLTEtMA_1cb2f3e1-0e34-42d8-baeb-3f9bd9366975">121,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzctNC0xLTEtMA_340a6eed-81eb-491e-9b2b-346fd15c84a9">113,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: common stock held in treasury, at cost (<ix:nonFraction unitRef="shares" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjhjNzA2OTYzMjM4YjQxODg5MGYzNmI5MjVlYTFmYTJjXzUw_c4ce138f-61d3-4fe4-95e3-3ac8ea1f9136">487,358,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjhjNzA2OTYzMjM4YjQxODg5MGYzNmI5MjVlYTFmYTJjXzU3_b4c500fe-1fc7-4667-9622-900d41b69665">487,331,000</ix:nonFraction> shares)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzgtMi0xLTEtMA_a54597bc-7e7e-40c9-9308-c3b6cbc8ffac">38,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzgtNC0xLTEtMA_1f146901-19cc-468e-bb67-adeef6cdd48d">38,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzktMi0xLTEtMA_40a32ab3-032d-4809-bfc9-77dcf488db43">70,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzktNC0xLTEtMA_93956990-4a03-42bd-a93a-135fb92a22b8">63,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfNDAtMi0xLTEtMA_45a621c3-bd90-494e-a715-d9131a06b915">179,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfNDAtNC0xLTEtMA_ddfc71cb-f87b-4514-b6fb-d14d980a3381">174,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="if410ee6e03c8456f86a9fee997f08e65_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF EARNINGS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars &amp; Shares in Millions Except Per Share Amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:54.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.756%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>to Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>to Sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales to customers (Note 9)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMi0yLTEtMS0w_8b0f6d02-d462-44e0-ae9a-2f4f54dff6ec">23,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="3" name="jnj:SalesRevenueGoodsNetPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMi00LTEtMS0w_3f982dd8-2675-4258-88cf-6034e4abae6a">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMi02LTEtMS0w_b4fe5c0c-16db-4db4-ade5-78b793384205">21,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="3" name="jnj:SalesRevenueGoodsNetPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMi04LTEtMS0w_4dadb1bb-e99d-4828-b566-08f83b0efc34">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMy0yLTEtMS0w_aeab66e7-b1af-4b6d-be09-ff4b76aee8af">7,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="3" name="jnj:CostOfGoodsSoldPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMy00LTEtMS0w_42d0e64a-ae9c-472d-af7e-8a9c102422e4">31.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMy02LTEtMS0w_662f324c-d5c3-423f-bf2b-dd2db13fa9f0">6,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="3" name="jnj:CostOfGoodsSoldPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMy04LTEtMS0w_b770aaa6-fc46-4628-8be3-66363b765bcb">33.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNC0yLTEtMS0w_5f1bc2c3-de0e-4adb-abe9-645064ab70bf">16,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="3" name="jnj:GrossProfitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNC00LTEtMS0w_f667fdb6-9538-4eff-9706-87e45d0a2b07">68.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNC02LTEtMS0w_212a1f8f-8b9b-49c9-97c0-1cd6a7601249">14,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="3" name="jnj:GrossProfitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNC04LTEtMS0w_55ed9be7-2f00-4055-a799-48469e453ca1">66.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, marketing and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNS0yLTEtMS0w_2bbbf028-2b09-4e5c-ad3e-e666388a9dd3">6,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="3" name="jnj:SellingGeneralAndAdministrativeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNS00LTEtMS0w_8d9687fb-b35a-46e5-8097-042c86cf68d7">25.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNS02LTEtMS0w_293b7290-24a5-42b4-95f5-fae4d1b44925">5,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="3" name="jnj:SellingGeneralAndAdministrativeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNS04LTEtMS0w_b29eba2f-d7a4-4a0f-9afa-1d6f3b93902d">25.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNi0yLTEtMS0w_a5a49e78-ef71-4416-8ac7-c144e6fdf8ef">3,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="3" name="jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNi00LTEtMS0w_7c2eb117-633e-41ae-a683-8d26d2abe79c">14.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNi02LTEtMS0w_eb042bb1-a9fa-4e40-a26c-ff4cc69ed08d">2,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="3" name="jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNi04LTEtMS0w_0e208ea5-407d-41b8-83e6-f159eb0210b3">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNy0yLTEtMS0w_c93010e1-5afe-4a10-ba2d-150a1122fb29">900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="3" name="jnj:ResearchAndDevelopmentInProcessPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNy00LTEtMS0w_c5256d6a-78e0-48bc-8e79-9f51f6c04c23">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNy02LTEtMS0w_fb42eedc-dee8-4326-a4ec-8182a5b8d6e8">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="3" name="jnj:ResearchAndDevelopmentInProcessPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNy04LTEtMS0w_ee650c32-f697-45be-a5d0-67f2aedd9798">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfOC0yLTEtMS0w_60159bf6-fb2e-4dcf-8430-57c7086f1596">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="3" sign="-" name="jnj:InvestmentIncomeInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfOC00LTEtMS0w_b5cf12be-a6a2-4985-8ccc-3598c123d54e">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfOC02LTEtMS0w_eea9a30c-6bd2-48ac-9226-4d99bf6367c9">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="3" sign="-" name="jnj:InvestmentIncomeInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfOC04LTEtMS0w_a869adb2-df80-4443-888a-a942edfd5923">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net of portion capitalized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfOS0yLTEtMS0w_030c26e1-811d-4669-9e4b-d73c45b052d0">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="3" name="jnj:InterestExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfOS00LTEtMS0w_4b1babef-60a5-46e1-9529-d708fb9fb85f">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfOS02LTEtMS0w_118bd29c-2149-4885-a92f-835015e9c2c9">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="3" name="jnj:InterestExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfOS04LTEtMS0w_8fafd881-d3b8-4f90-a593-53ee9978f0c0">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTAtMi0xLTEtMA_b59f549a-a844-4306-ab36-6bbedc8ceb0d">1,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="3" name="jnj:OtherNonOperatingIncomeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTAtNC0xLTEtMA_029111fc-a017-4065-ae08-6acccde5ed5e">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTAtNi0xLTEtMA_125b75dc-5fde-4692-8115-edc12c4dd12d">1,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="3" name="jnj:OtherNonOperatingIncomeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTAtOC0xLTEtMA_f9377020-1fc1-4f97-ac97-87c69cf4aa2b">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring (Note 12)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTEtMi0xLTEtMA_3f1abba1-ddf6-467e-8246-ff4fde864f5f">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="3" name="jnj:Restructuringchargepercenttosales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTEtNC0xLTEtMA_fb938392-0d51-4871-b35c-623ad76be0a4">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTEtNi0xLTEtMA_04c2fe22-46d9-4aa2-ba0b-4c33f197942d">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="3" name="jnj:Restructuringchargepercenttosales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTEtOC0xLTEtMA_a00bcd5c-d11e-4d35-a628-1d42966a2fe3">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before provision for taxes on income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTItMi0xLTEtMA_493bea1d-14ed-47f4-9abb-806cabbfcf6e">3,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="3" name="jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTItNC0xLTEtMA_160bfe95-e1c4-4f99-9aea-16d3930a1cbc">16.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTItNi0xLTEtMA_c2b61552-cb66-42f9-aa55-14e95085a333">4,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="3" name="jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTItOC0xLTEtMA_c057f9c8-961b-4fee-b13a-3f1c94dc0ccc">20.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for taxes on income (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTMtMi0xLTEtMA_33c1062c-cd5a-45b9-a1e0-5a4d61b6a4f0">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="3" name="jnj:IncomeTaxExpenseBenefitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTMtNC0xLTEtMA_8674d52b-bcfb-4f51-9389-41cf2608f6a0">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTMtNi0xLTEtMA_b95d6729-8ad2-4757-b168-e8360b74c6d4">847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="3" name="jnj:IncomeTaxExpenseBenefitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTMtOC0xLTEtMA_e5f8628b-2f3c-40e0-b578-67c6f2f96b3f">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET EARNINGS </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTQtMi0xLTEtMA_0441068f-63f4-4f22-98b8-feeb6ea1647e">3,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="3" name="jnj:NetIncomeAttributableToParentPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTQtNC0xLTEtMA_4e8e3009-9bdd-4348-8dea-fb38bf273ff8">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTQtNi0xLTEtMA_88c415a1-ffc8-4942-9564-20311587b452">3,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="3" name="jnj:NetIncomeAttributableToParentPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTQtOC0xLTEtMA_1f3a71db-7e68-4ba8-955a-51464bb00407">16.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET EARNINGS PER SHARE (Note 8)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTctMi0xLTEtMA_d1d99b7c-9efe-4f2f-89ed-e89061a98ada">1.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTctNi0xLTEtMA_6e268f60-3d14-4848-973e-2f6292e4a0db">1.35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTgtMi0xLTEtMA_72613bfc-0853-46e9-92b4-fe62b0b4771a">1.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTgtNi0xLTEtMA_bcd3ec92-29c6-4e46-b3ca-924bc92e6346">1.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AVG. SHARES OUTSTANDING</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMjEtMi0xLTEtMA_c48752e5-8681-4c51-8de1-02700fd8ee10">2,632.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMjEtNi0xLTEtMA_8e2e5de2-0fd8-42b6-b03a-d973496d926d">2,632.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMjItMi0xLTEtMA_23a11692-97fc-49a4-be7d-9d8ffb97a049">2,674.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMjItNi0xLTEtMA_bbbce720-4523-4d46-9e86-e15a2a1c2dd1">2,669.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div id="if410ee6e03c8456f86a9fee997f08e65_31"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF EARNINGS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars &amp; Shares in Millions Except Per Share Amounts)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.00pt"><tr><td style="width:1.0pt"></td><td style="width:283.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>to Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>to Sales</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales to customers (Note 9)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMi0yLTEtMS0w_4ca524dd-9e6e-4617-8870-6e726750358f">68,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="3" name="jnj:SalesRevenueGoodsNetPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMi00LTEtMS0w_6c623414-f3f4-411a-9e22-acacee0b0306">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMi02LTEtMS0w_aa982844-25fb-43ff-b777-5d40ad0eeb39">60,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="3" name="jnj:SalesRevenueGoodsNetPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMi04LTEtMS0w_b771205d-0f3a-4b12-85dd-0d4f0b84d915">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMy0yLTEtMS0w_1d3ffecc-790f-4816-b947-0a018fea105c">21,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="3" name="jnj:CostOfGoodsSoldPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMy00LTEtMS0w_c1677b87-3ffa-4d03-a742-0a3d9f4ed5ce">31.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMy02LTEtMS0w_66c09688-9b53-4fab-8bb0-6b7c2a4446cf">20,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="3" name="jnj:CostOfGoodsSoldPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMy04LTEtMS0w_b62efdef-f9e9-47d5-a768-e38acbc15ffc">34.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNC0yLTEtMS0w_e1149281-705f-4c31-813d-532f0d36137e">47,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="3" name="jnj:GrossProfitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNC00LTEtMS0w_63178a67-323d-4d7a-8e7c-fd7be6ea201b">68.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNC02LTEtMS0w_688f88a6-2a44-4b65-9e45-9ee37bf769cd">39,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="3" name="jnj:GrossProfitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNC04LTEtMS0w_c289f9a1-6756-4672-ae76-9d594aab302b">65.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, marketing and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNS0yLTEtMS0w_ce3b49bd-d5f8-450d-9777-e1a45bdfaf07">17,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="3" name="jnj:SellingGeneralAndAdministrativeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNS00LTEtMS0w_cf946b07-fad5-474c-949b-d274f598b68e">25.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNS02LTEtMS0w_4a011b9a-9c69-4bad-9490-f3d9110f4266">15,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="3" name="jnj:SellingGeneralAndAdministrativeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNS04LTEtMS0w_bf9e2702-faeb-4ef0-82b9-8ddc07c35680">26.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNi0yLTEtMS0w_28332cff-310a-4700-9f4f-b50ce843c560">9,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="3" name="jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNi00LTEtMS0w_4d87540e-f111-475f-a229-9614468a10a6">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNi02LTEtMS0w_122b2af7-ecbc-40ea-a2db-3b732b87eb81">8,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="3" name="jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNi04LTEtMS0w_6f7777a0-a121-4d2f-a1d8-a9740c4e60fa">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNy0yLTEtMS0w_8cf6ce2a-05dc-4a5c-91ef-c028fd61b80a">900</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="3" name="jnj:ResearchAndDevelopmentInProcessPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNy00LTEtMS0w_410446c4-b4b8-438d-9a71-05e68a658554">1.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNy02LTEtMS0w_a570f2ec-ba11-4823-a1d9-62f803262fad">144</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="3" name="jnj:ResearchAndDevelopmentInProcessPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNy04LTEtMS0w_043bd764-d52d-485f-ada3-4895138e951a">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfOC0yLTEtMS0w_b0a912fb-12d3-4e63-a908-abceb7cae19f">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="3" sign="-" name="jnj:InvestmentIncomeInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfOC00LTEtMS0w_de82a135-f20e-42bc-8255-00451c029731">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfOC02LTEtMS0w_23525f20-da9a-4219-955c-6a3400e39c1c">98</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="3" sign="-" name="jnj:InvestmentIncomeInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfOC04LTEtMS0w_2af5c606-608f-43ea-b8ad-597c337aebae">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net of portion capitalized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfOS0yLTEtMS0w_61b366e7-0f4f-4541-a1bf-8601e1ce1e9a">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="3" name="jnj:InterestExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfOS00LTEtMS0w_f61c7add-3f5d-4985-af88-6c3ccfd97683">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfOS02LTEtMS0w_6005836c-584b-4db4-9a04-c5323678f037">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="3" name="jnj:InterestExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfOS04LTEtMS0w_7cf39c1e-4026-4bb7-839f-f8f4207e397a">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTAtMi0xLTEtMA_b7795b75-c2f0-4cc2-9ea9-0ef4952e293f">480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="3" name="jnj:OtherNonOperatingIncomeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTAtNC0xLTEtMA_f192435a-b94e-41b7-aa20-9f2eb8e2735c">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTAtNi0xLTEtMA_18f04dab-1c58-4831-8129-66259fe6fa41">545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="3" name="jnj:OtherNonOperatingIncomeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTAtOC0xLTEtMA_2de1adaa-8799-46a9-973b-a3027da0cee0">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring (Note 12)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTEtMi0xLTEtMA_1ba7fd63-1d38-4390-a843-f3fbd6fb2377">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="3" name="jnj:Restructuringchargepercenttosales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTEtNC0xLTEtMA_5da3bd35-ff34-4185-96d2-f87214f93c35">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTEtNi0xLTEtMA_52e01f7a-3af6-4d01-9268-da6f9d451511">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="3" name="jnj:Restructuringchargepercenttosales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTEtOC0xLTEtMA_6b7e2428-9ed3-4790-a6c3-b2432a6b69e6">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before provision for taxes on income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTItMi0xLTEtMA_e537f297-15f2-444f-a16d-5f8f456a13dd">17,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="3" name="jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTItNC0xLTEtMA_3cb30b72-486f-4e83-a005-7bbaca16d0fa">26.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTItNi0xLTEtMA_3d35efc9-970f-4009-9aed-f2ff4a49ba90">14,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="3" name="jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTItOC0xLTEtMA_e7fcc175-42c5-4d31-9687-293072f776b2">24.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for taxes on income (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTMtMi0xLTEtMA_c5d9e91d-7dc7-4291-8201-62d080cd65ed">1,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="3" name="jnj:IncomeTaxExpenseBenefitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTMtNC0xLTEtMA_f150d9d2-3385-4888-bfd9-d02823e3afe7">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTMtNi0xLTEtMA_6d6a551d-5bab-47b8-b442-41408d2e2a34">1,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="3" name="jnj:IncomeTaxExpenseBenefitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTMtOC0xLTEtMA_67ba8fee-a0cd-4609-a883-a4a3cb925853">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET EARNINGS </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTQtMi0xLTEtMA_55ec364f-11d3-42b2-a28e-0e271cffe4eb">16,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="3" name="jnj:NetIncomeAttributableToParentPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTQtNC0xLTEtMA_7f89d9dd-f271-4f61-88ce-173581466e76">23.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTQtNi0xLTEtMA_e36764a5-8074-41c8-9810-c03e6c79307c">12,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="3" name="jnj:NetIncomeAttributableToParentPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTQtOC0xLTEtMA_3786fb7f-832b-445c-b5e4-89e65377a475">21.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET EARNINGS PER SHARE (Note 8)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTctMi0xLTEtMA_216657d1-53a6-4bc9-9445-31155ac1ea80">6.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTctNi0xLTEtMA_b37bd908-aebb-4ee9-a427-c0aed7cdc460">4.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTgtMi0xLTEtMA_a22639a7-8d44-47c4-8be4-ef9eca5d210b">6.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTgtNi0xLTEtMA_2f892aa7-0da6-44e3-a386-128ff19f6af2">4.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AVG. SHARES OUTSTANDING</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMjEtMi0xLTEtMA_cc610af1-5f20-4d64-ac3e-a9f171782afe">2,632.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMjEtNi0xLTEtMA_08086eb0-80f4-4575-b357-8259ab23daea">2,633.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMjItMi0xLTEtMA_7b80a22c-fd5b-47f1-b886-d25cfc8df8c8">2,674.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMjItNi0xLTEtMA_d27ad6cd-3628-426b-9e4f-c0131f1957d7">2,670.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">See Notes to Consolidated Financial Statements</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="if410ee6e03c8456f86a9fee997f08e65_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars in Millions)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 27, 2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMy0xLTEtMS0w_a869423d-563e-4fce-a12d-c1a26a3af5e6">3,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMy0zLTEtMS0w_6a5528b1-0f39-4eec-ba3d-7a1e9183427b">3,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMy01LTEtMS0w_23ba5ad9-145f-49d1-9cab-73fce239eaf8">16,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMy03LTEtMS0w_943cba37-eaf8-482c-aab5-255c6c289663">12,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfNi0xLTEtMS0w_c963402f-8ebf-4917-a193-aa4a8c217e09">382</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfNi0zLTEtMS0w_5b94ec24-5c4b-4f8b-bbb6-0451818db4ad">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfNi01LTEtMS0w_2e1917b4-36da-4a72-aa50-3006fb81af57">241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfNi03LTEtMS0w_ef5907ac-7b03-45b2-a505-add00892a2b3">741</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Unrealized holding gain (loss) arising during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfOS0xLTEtMS0w_e33a3f09-e4ca-4503-936e-f67a33a02905">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfOS0zLTEtMS0w_a4d818d6-3541-4a4a-8519-d2f640d0ba2d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfOS01LTEtMS0w_5f0864dd-efa7-4a44-8b1c-85baf545a5a3">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfOS03LTEtMS0w_e3553299-686f-40a5-8283-cac26e3ba199">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Reclassifications to earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTAtMS0xLTEtMA_8ba87608-9a58-4e0a-9d51-5b6c8438832c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTAtMy0xLTEtMA_5ab2f8d2-9f7b-45f3-b35a-c5dce4b8807f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTAtNS0xLTEtMA_eb5188ea-090c-4c8d-b1e5-3f664b684f16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTAtNy0xLTEtMA_8d6af8ff-2bb1-4209-bcbc-9e4bb4196ca1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Net change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTItMS0xLTEtMA_799e3568-2099-4e26-b9ec-e88ebdf3db92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTItMy0xLTEtMA_58fc92b8-3cb7-4de8-8101-d0cd28f9c457">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTItNS0xLTEtMA_e2058dd7-2795-49cb-b79a-928bed3a93bc">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTItNy0xLTEtMA_5a9fd80f-4656-4a12-ae1e-3586a3294572">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Prior service cost amortization during period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTUtMS0xLTEtMA_80cf36ea-4574-4527-b0c9-f96097e5dace">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTUtMy0xLTEtMA_b7627018-1d46-44e3-9a81-37135f5ddfe7">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTUtNS0xLTEtMA_78484387-a235-4e6f-93a5-4bc8bc6ec0f7">122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTUtNy0xLTEtMA_7c5187d2-b872-4056-8219-c9983066a92f">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Gain (loss) amortization during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTYtMS0xLTEtMA_d7b4fddf-f7df-4e8d-a817-7f220da2b2dd">273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTYtMy0xLTEtMA_bc0a94de-e6eb-43d1-9d71-190dc22f0d80">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTYtNS0xLTEtMA_ca8549fe-8fae-481e-92a3-2ed1687c37a3">822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTYtNy0xLTEtMA_01564439-d967-4761-b5bf-7c4691c794ae">604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Net change</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTgtMS0xLTEtMA_cc1d7da6-7276-4286-89f2-f954f177b4b1">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTgtMy0xLTEtMA_855226b7-85d2-4994-b257-03a4f9f4dbc8">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTgtNS0xLTEtMA_fdb78aa3-bc71-4cf2-a1cc-0f90cfdff517">700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTgtNy0xLTEtMA_2371a1f7-2dd2-40a7-987e-f2feffdbc2b9">587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives &amp; hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Unrealized gain (loss) arising during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjEtMS0xLTEtMA_e5177b56-ac32-4956-86ca-77ae5a22ad9d">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjEtMy0xLTEtMA_548d244c-bf00-401e-ba19-8ade076895a3">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjEtNS0xLTEtMA_ae4a0369-ec5a-4a23-9360-bc9b97e133cd">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjEtNy0xLTEtMA_6d57a55a-e40d-4d87-92db-389d87b094c5">1,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Reclassifications to earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjItMS0xLTEtMA_e2f5883a-de9c-4b16-a0e0-654aba8c0140">233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjItMy0xLTEtMA_08a2daea-6b16-49e0-9ece-72fd9d32ff27">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjItNS0xLTEtMA_b4d2a99d-d5cb-4e74-b14d-21c5838e0274">576</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjItNy0xLTEtMA_c6f2516d-1361-4e43-98c8-4fa65e12f36c">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Net change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjMtMS0xLTEtMA_b2569bfd-b1ea-41ca-bcf4-c1641db50d2d">166</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjMtMy0xLTEtMA_10bfa48c-4eaa-43cd-b6f8-b2e119813d1f">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjMtNS0xLTEtMA_77df5d86-8a46-46d0-bb5a-82049a792301">631</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjMtNy0xLTEtMA_4ca12eb6-2f54-4e55-99f1-451d4f1fa33f">1,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjUtMS0xLTEtMA_870017da-2157-4bb7-b581-cea3245d5049">315</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjUtMy0xLTEtMA_29544c2a-8441-4fb4-898c-77eb2d6abf89">595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjUtNS0xLTEtMA_11ab1aec-f8a9-4e79-aa37-77e03f05a746">173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjUtNy0xLTEtMA_a210c0c8-7e73-47e7-ab15-290d66957337">953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjctMS0xLTEtMA_c8933df5-6dcb-4910-a908-74391a09aad2">3,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjctMy0xLTEtMA_f3ec0366-3cdc-40ee-8ff2-4317a6b042a0">4,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjctNS0xLTEtMA_33739a8d-ec52-4f99-8e4d-310f4221b2e0">15,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjctNy0xLTEtMA_a5588fe9-7581-4919-915f-cd25c8e0eb36">13,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The tax effects in other comprehensive income for the fiscal third quarter were as follows for 2021 and 2020, respectively: Foreign Currency Translation: $<ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOjY5MzhmNGVhZjNlMDRhMGU4YTY0Y2U3Mjg5MDYzYjA1L3RhYmxlcmFuZ2U6NjkzOGY0ZWFmM2UwNGEwZThhNjRjZTcyODkwNjNiMDVfMC0wLTEtMS0wL3RleHRyZWdpb246MWU1ZGY3ZTcwMDJkNDljYWFkNjg4ODJhY2NhZDk5YWJfMTYw_76d8cab1-ee84-4188-adcb-76b96e28b47e">86</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOjY5MzhmNGVhZjNlMDRhMGU4YTY0Y2U3Mjg5MDYzYjA1L3RhYmxlcmFuZ2U6NjkzOGY0ZWFmM2UwNGEwZThhNjRjZTcyODkwNjNiMDVfMC0wLTEtMS0wL3RleHRyZWdpb246MWU1ZGY3ZTcwMDJkNDljYWFkNjg4ODJhY2NhZDk5YWJfMTc2_f97cd5ee-50b6-44e9-a750-f75c9380bd38">139</ix:nonFraction> million; Employee Benefit Plans: $<ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOjY5MzhmNGVhZjNlMDRhMGU4YTY0Y2U3Mjg5MDYzYjA1L3RhYmxlcmFuZ2U6NjkzOGY0ZWFmM2UwNGEwZThhNjRjZTcyODkwNjNiMDVfMC0wLTEtMS0wL3RleHRyZWdpb246MWU1ZGY3ZTcwMDJkNDljYWFkNjg4ODJhY2NhZDk5YWJfMjEz_bb149deb-8c56-414e-9535-799d7b8f0092">65</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOjY5MzhmNGVhZjNlMDRhMGU4YTY0Y2U3Mjg5MDYzYjA1L3RhYmxlcmFuZ2U6NjkzOGY0ZWFmM2UwNGEwZThhNjRjZTcyODkwNjNiMDVfMC0wLTEtMS0wL3RleHRyZWdpb246MWU1ZGY3ZTcwMDJkNDljYWFkNjg4ODJhY2NhZDk5YWJfMjI5_0ac568f8-b562-4812-9d0e-0c161be98933">56</ix:nonFraction> million; Derivatives &amp; Hedges: $<ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOjY5MzhmNGVhZjNlMDRhMGU4YTY0Y2U3Mjg5MDYzYjA1L3RhYmxlcmFuZ2U6NjkzOGY0ZWFmM2UwNGEwZThhNjRjZTcyODkwNjNiMDVfMC0wLTEtMS0wL3RleHRyZWdpb246MWU1ZGY3ZTcwMDJkNDljYWFkNjg4ODJhY2NhZDk5YWJfMjY0_1c64bcb7-62a9-4654-9c9f-06399159af09">43</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOjY5MzhmNGVhZjNlMDRhMGU4YTY0Y2U3Mjg5MDYzYjA1L3RhYmxlcmFuZ2U6NjkzOGY0ZWFmM2UwNGEwZThhNjRjZTcyODkwNjNiMDVfMC0wLTEtMS0wL3RleHRyZWdpb246MWU1ZGY3ZTcwMDJkNDljYWFkNjg4ODJhY2NhZDk5YWJfMjgw_1ae7f63e-aaa7-4f8f-83e0-d5ebd6df49c6">47</ix:nonFraction> million.</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The tax effects in other comprehensive income for the fiscal nine months were as follows for 2021 and 2020, respectively: Foreign Currency Translation: $<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOjY5MzhmNGVhZjNlMDRhMGU4YTY0Y2U3Mjg5MDYzYjA1L3RhYmxlcmFuZ2U6NjkzOGY0ZWFmM2UwNGEwZThhNjRjZTcyODkwNjNiMDVfMi0wLTEtMS0wL3RleHRyZWdpb246YmQzNjVmYWRhYTNiNGI2NDg4NTg5NjRjNTUzOTgzNjZfMTU2_aed7ce57-b8d4-405d-a0b2-43531c27fdf5">315</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOjY5MzhmNGVhZjNlMDRhMGU4YTY0Y2U3Mjg5MDYzYjA1L3RhYmxlcmFuZ2U6NjkzOGY0ZWFmM2UwNGEwZThhNjRjZTcyODkwNjNiMDVfMi0wLTEtMS0wL3RleHRyZWdpb246YmQzNjVmYWRhYTNiNGI2NDg4NTg5NjRjNTUzOTgzNjZfMTcy_dd1c2a0c-c995-4cc1-8e34-dbc1a8f9021c">207</ix:nonFraction> million; Employee Benefit Plans: $<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOjY5MzhmNGVhZjNlMDRhMGU4YTY0Y2U3Mjg5MDYzYjA1L3RhYmxlcmFuZ2U6NjkzOGY0ZWFmM2UwNGEwZThhNjRjZTcyODkwNjNiMDVfMi0wLTEtMS0wL3RleHRyZWdpb246YmQzNjVmYWRhYTNiNGI2NDg4NTg5NjRjNTUzOTgzNjZfMjA5_e8c66743-a994-488d-af52-461ba6868ab6">197</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOjY5MzhmNGVhZjNlMDRhMGU4YTY0Y2U3Mjg5MDYzYjA1L3RhYmxlcmFuZ2U6NjkzOGY0ZWFmM2UwNGEwZThhNjRjZTcyODkwNjNiMDVfMi0wLTEtMS0wL3RleHRyZWdpb246YmQzNjVmYWRhYTNiNGI2NDg4NTg5NjRjNTUzOTgzNjZfMjI1_e54b3842-815a-4dda-9362-66eb75681c63">167</ix:nonFraction> million; Derivatives &amp; Hedges: $<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOjY5MzhmNGVhZjNlMDRhMGU4YTY0Y2U3Mjg5MDYzYjA1L3RhYmxlcmFuZ2U6NjkzOGY0ZWFmM2UwNGEwZThhNjRjZTcyODkwNjNiMDVfMi0wLTEtMS0wL3RleHRyZWdpb246YmQzNjVmYWRhYTNiNGI2NDg4NTg5NjRjNTUzOTgzNjZfMjYw_2e242797-44d2-4497-85db-099e89134f84">167</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOjY5MzhmNGVhZjNlMDRhMGU4YTY0Y2U3Mjg5MDYzYjA1L3RhYmxlcmFuZ2U6NjkzOGY0ZWFmM2UwNGEwZThhNjRjZTcyODkwNjNiMDVfMi0wLTEtMS0wL3RleHRyZWdpb246YmQzNjVmYWRhYTNiNGI2NDg4NTg5NjRjNTUzOTgzNjZfMjc2_f47a591a-df87-47cc-9314-684dd01fd2a2">293</ix:nonFraction> million.</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="if410ee6e03c8456f86a9fee997f08e65_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON&#160;&amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars in Millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fiscal Third Quarter Ended October&#160;3, 2021 </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:38.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.037%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock<br/>Issued Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury<br/>Stock<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, July 4, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f560bf19097496e9d3b17c570ba5487_I20210704" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfMS0xLTEtMS0w_64facb3f-bb67-4161-88ac-53c0a63eb1b9">69,580</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia36f1ef4e53741a698ce4eb8a63cfcc8_I20210704" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfMS0zLTEtMS0w_a837f20f-cc12-4092-afc5-e4922bd9aba2">120,154</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d39696cd8124bebbcee13521011bc43_I20210704" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfMS01LTEtMS0w_e229901d-89b0-4132-9a6a-d5b8a5a5866e">15,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fc21784cc544993916b76a2883b5fa7_I20210704" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfMS03LTEtMS0w_f3d734f1-c8c1-43ea-bb34-6e83677b4379">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b91cb0100d34fc688b5e3ed019ce080_I20210704" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfMS05LTEtMS0w_dce0649f-9073-4959-a77d-9b5102f5a678">38,594</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfMi0xLTEtMS0w_e7bb39d5-510b-4fbf-a457-dc29a315dc98">3,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia21d27ed7dc047cc83042ea5ddaf0820_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfMi0zLTEtMS0w_f98bd438-32b7-443b-ba9f-3a4ea9ffd2f5">3,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfMy0wLTEtMS0wL3RleHRyZWdpb246MTQ5OWY3NWVkYjg4NDM0ODhlOTIwYWY0YTgwZGExMzlfMjY_216fa420-5898-41db-87a6-ecf9455a15bc">1.06</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfMy0xLTEtMS0w_07999132-649c-4066-9b97-73bbfcdbc9b3">2,791</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia21d27ed7dc047cc83042ea5ddaf0820_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfMy0zLTEtMS0w_97e52dbe-30f6-4cf6-9a63-ca6bd3d4307d">2,791</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfNC0xLTEtMS0w_6cbf556c-928e-4571-8dbd-e1928861aab8">522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia21d27ed7dc047cc83042ea5ddaf0820_D20210705-20211003" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfNC0zLTEtMS0w_4ee8a0e3-9dc4-4473-80e3-e9f0d2a07d86">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85720d7d2890498ca2589aaaa3d3c267_D20210705-20211003" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfNC05LTEtMS0w_8c707d9e-0ae8-4f35-9fd8-f9b907e60de4">460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfNS0xLTEtMS0w_435a1802-c453-41b2-bced-a6ca872f69b0">391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85720d7d2890498ca2589aaaa3d3c267_D20210705-20211003" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfNS05LTEtMS0w_c7f60112-a431-46a8-b367-0ee691bb2693">391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfNy0xLTEtMS0w_c93cf6bf-a296-4627-a2ac-f37dd6048e74">315</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c3f7de455fa4be484a940d40bf7d252_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfNy01LTEtMS0w_c4f8a9d3-f8b8-4dce-a02f-6bc686c97b8c">315</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, October 3, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfOC0xLTEtMS0w_bbf2a537-00a2-4013-b019-47681db5f6c3">70,272</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic67ffcf2eac440a4a3acf47e9df62981_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfOC0zLTEtMS0w_2beae7f4-e3a6-437b-85ea-d0ecb344676f">121,092</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd88e9907aaf4e8cbca11111329e2073_I20211003" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfOC01LTEtMS0w_093d25d8-1f1d-441b-aaaf-7fcb38ad5f18">15,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdbe49f46d3548e69bcf28fa1c70f4a0_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfOC03LTEtMS0w_00ceea33-891b-4b31-81fd-876047e589c7">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib15db8a9bfc141e3b662784fb2f12036_I20211003" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfOC05LTEtMS0w_13a67fd5-9527-4daa-9adb-7f53d18bd3d5">38,525</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fiscal Nine Months Ended October&#160;3, 2021</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:38.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.037%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock<br/>Issued Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury<br/>Stock<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, January 3, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfMy0xLTEtMS0w_6edfe319-cfba-4c23-a4f8-94ef44352cb0">63,278</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97cf81456e3d4ee78c0eb5ef14d6adfd_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfMy0zLTEtMS0w_c6ee0172-8697-43b5-82e5-cd8706560389">113,890</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib616b434ad574d54a671235ee0e19c40_I20210103" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfMy01LTEtMS0w_1a458b75-b52b-4767-9aa7-ca5aea5883ab">15,242</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37e41918fcfb4a96aae4c8ddf736f81f_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfMy03LTEtMS0w_f541587a-10cf-4964-8a0a-95d68889397f">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6567971b97b8486f9c4ca8fcaa0bc916_I20210103" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfMy05LTEtMS0w_96a6189c-2062-4dda-a80f-017f0166fa91">38,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfNC0xLTEtMS0w_b156afe0-2d20-41dd-a2ae-45488fdd38db">16,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0f5194139614002a34759c09867b19b_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfNC0zLTEtMS0w_c65b870e-4b49-4363-a105-1c42aaf2e0bb">16,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfNS0wLTEtMS0wL3RleHRyZWdpb246ODljOGFiMDhiM2Q5NGRlYWJjNDhjODBhMzlmZDNiZGRfMjY_69bcc7fa-5a57-488c-8611-2561fc4d79e4">3.13</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfNS0xLTEtMS0w_a4f6afe9-b81a-4fe2-b057-f6e66bc21005">8,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0f5194139614002a34759c09867b19b_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfNS0zLTEtMS0w_50e675bf-cd03-4682-8d46-eefc09efb67f">8,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfNi0xLTEtMS0w_8791d791-4df7-4daf-9b12-b7d3cfdb8aab">1,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0f5194139614002a34759c09867b19b_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfNi0zLTEtMS0w_b9e72e4c-972f-4722-a5eb-ec5289a63e9c">699</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6f044a57fb04694b9504b1cc6b855fc_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfNi05LTEtMS0w_7925f759-932d-4744-ad66-b85c9501be1d">2,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfNy0xLTEtMS0w_0c7f882f-1a99-46ba-80c7-af8192caa2b1">2,460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic6f044a57fb04694b9504b1cc6b855fc_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfNy05LTEtMS0w_c3d9993a-8202-4cb7-bffd-88fb97125a67">2,460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfOS0xLTEtMS0w_00d52817-860e-4460-b26f-b5945f62211c">173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i280f2f10a11c4c988142fed0ab0a55c4_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfOS01LTEtMS0w_93f416e2-0201-4b63-9b87-1a45b0da63a1">173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, October 3, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfMTAtMS0xLTEtMA_22999106-24fa-46a1-a9cf-7ebd8e7e8631">70,272</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic67ffcf2eac440a4a3acf47e9df62981_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfMTAtMy0xLTEtMA_2e25623a-bfd2-4e80-9c70-9e0902ff81b8">121,092</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd88e9907aaf4e8cbca11111329e2073_I20211003" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfMTAtNS0xLTEtMA_a3995078-310d-46e7-9bcc-bfd76e1b0d8d">15,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdbe49f46d3548e69bcf28fa1c70f4a0_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfMTAtNy0xLTEtMA_f017b967-6ec4-4ad9-829a-86670c5f8413">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib15db8a9bfc141e3b662784fb2f12036_I20211003" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfMTAtOS0xLTEtMA_6187ce6f-8f97-458f-87c5-33bf99d85952">38,525</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fiscal Third Quarter Ended September&#160;27, 2020 </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:37.985%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.081%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock<br/>Issued Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury<br/>Stock<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June 28, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4c978ae9bd844bb8485b20fee0394d2_I20200628" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfMS0xLTEtMS0w_902244cc-2826-4214-b0a1-d0fc97293e00">62,978</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i789e8630040645df9671180079be56c4_I20200628" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfMS0zLTEtMS0w_68b76a00-346d-422e-99bd-b7195504a3ec">113,898</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c1cb280df774543988ac3e60b3700ff_I20200628" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfMS01LTEtMS0w_cd585c4d-a753-413e-94f2-83ea1f8b630d">15,533</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1b5e269d61463c9d13dc7f3431be66_I20200628" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfMS03LTEtMS0w_fa5ed7f8-4bec-4e10-bf23-d62f26addf8e">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc043974a53d45c09c9c4916e8c5d997_I20200628" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfMS05LTEtMS0w_5e50a5dd-fa26-40be-a37b-ce70a1765704">38,507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfMy0xLTEtMS0w_541d1da8-e385-411c-bb2b-4b66075ba55d">3,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151bc89c89104e6fad68b01743dd13fc_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfMy0zLTEtMS0w_d5508aea-5702-46ca-a155-73f9807dc3b7">3,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfNC0wLTEtMS0wL3RleHRyZWdpb246NGI0NjVkOTYyOWYzNGNmNTljOTU2OWEwZTc1OGM3MWJfMjY_4a7019a7-c9b5-4ca9-b42a-f04db24bd118">1.01</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfNC0xLTEtMS0w_3c0e7e82-e6c3-41a1-babe-6178a5233bdb">2,659</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i151bc89c89104e6fad68b01743dd13fc_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfNC0zLTEtMS0w_a94c7276-f02d-481f-9965-ec454ba13e27">2,659</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfNS0xLTEtMS0w_798332af-8bfa-4650-b956-9e8ab6bfcab1">559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151bc89c89104e6fad68b01743dd13fc_D20200629-20200927" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfNS0zLTEtMS0w_f9151178-df31-4007-8cc8-e197bf57af60">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14461e2d7ae84af4b6b45899f46e8cdc_D20200629-20200927" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfNS05LTEtMS0w_097adb3e-14a6-4284-92b2-981a3a1d0a72">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfNi0xLTEtMS0w_e9f5fec7-59b4-4a59-b92d-442226422d82">483</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14461e2d7ae84af4b6b45899f46e8cdc_D20200629-20200927" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfNi05LTEtMS0w_6d9f24a0-727f-47af-9fc6-84e3e81f8eda">483</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfNy0xLTEtMS0w_8df06292-4327-497b-ab7d-b226265e3d9a">71</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i151bc89c89104e6fad68b01743dd13fc_D20200629-20200927" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfNy0zLTEtMS0w_a3ae382d-64de-45da-9fa0-19bc0647e60f">71</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfOC0xLTEtMS0w_6c342df7-e48a-4226-9f83-b399222867c0">595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94a2d6ba6c254c6b92dfd2a37f7901ed_D20200629-20200927" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfOC01LTEtMS0w_c0493513-8cce-43f5-8d0e-34ce0290c279">595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, September 27, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de10452fa98443a826d732ac5ecfcd4_I20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfOS0xLTEtMS0w_68f807df-fe1b-43cd-8a9e-316aacb045c6">64,473</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21919a743da04e9ebb238e98bd59fa74_I20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfOS0zLTEtMS0w_190ce185-aec8-4f40-8067-6fc27e95bf5a">114,831</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i514541208cb44a09bd41a6c7b123cbb4_I20200927" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfOS01LTEtMS0w_0161b62a-5c85-4b4e-a361-e754cae3ef88">14,938</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i701c9aa0c90c443fa3b9239555242704_I20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfOS03LTEtMS0w_b2fdeb6e-5369-468e-97a6-6e82efa84bd4">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4593a0dc4364211ae7edf29da4866d3_I20200927" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfOS05LTEtMS0w_be2df13d-e677-4a40-99f3-4cfc33f73139">38,540</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fiscal Nine Months Ended September&#160;27, 2020</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.993%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock<br/>Issued Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury<br/>Stock<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 29, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if49e94e75cf04169b3ef119b2c588a4c_I20191229" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfMy0xLTEtMS0w_42f952f0-c2f2-4b28-a507-d1ca207e9cb3">59,471</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6004d7a658874bffb0b05f268a6fc6e9_I20191229" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfMy0zLTEtMS0w_2c8bfbfd-1092-48ee-a26d-d7a3928c1efd">110,659</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e06dbf4f1b44f998d04005f6056c3d5_I20191229" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfMy01LTEtMS0w_54029c0d-4af4-4b04-897c-a2e827278b61">15,891</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ba2e82215dc4171a568af3512fd9d8f_I20191229" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfMy03LTEtMS0w_82a78fa1-01cf-4f9f-9c8c-e1c4100b6788">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a829e70799a4429b48066d6c98beb81_I20191229" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfMy05LTEtMS0w_f43c7a56-07df-4eb3-8363-544f6a907a8c">38,417</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfNS0xLTEtMS0w_e2c0d9fa-9700-42fd-a855-d693185bc4a5">12,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd97456bd71e47888787febf8fb403c0_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfNS0zLTEtMS0w_b79d9505-919c-4e22-9043-7024ba1c82a2">12,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfNi0wLTEtMS0wL3RleHRyZWdpb246Nzg0NmE3MzBiMjY0NDYxYjg0OGI3OTNiYWQ3NjZkYTdfMjY_7be158d4-49e0-48b2-a771-5c7132d4f6aa">2.97</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfNi0xLTEtMS0w_5b818b1c-a446-4a96-82e5-1b9aae661f33">7,823</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd97456bd71e47888787febf8fb403c0_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfNi0zLTEtMS0w_09b9487b-3bbe-4c4d-b3de-1369a0a771d7">7,823</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfNy0xLTEtMS0w_19460ba2-a7f7-4b94-9602-00c305512350">1,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd97456bd71e47888787febf8fb403c0_D20191230-20200927" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfNy0zLTEtMS0w_67ec3584-9c25-4923-bd69-514b5f2a9adb">911</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25e2937f00db4ffab2f056e05c4b797e_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfNy05LTEtMS0w_eeacf1d0-65b1-45bc-8805-b46aeb38463c">2,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfOC0xLTEtMS0w_9f4de8f1-d0b6-4048-a17a-05bcc505905c">2,900</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25e2937f00db4ffab2f056e05c4b797e_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfOC05LTEtMS0w_45822c47-6177-4910-b91d-cc60d65ef7c2">2,900</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfOS0xLTEtMS0w_abcbf78b-604d-47a5-89ad-5349337e5be3">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd97456bd71e47888787febf8fb403c0_D20191230-20200927" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfOS0zLTEtMS0w_43669f1d-1f13-469c-b99d-be19e5f1b859">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfMTAtMS0xLTEtMA_13396be0-580e-4be6-af55-41643ff80c00">953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76d47fefae324430be757b4f9833ed5f_D20191230-20200927" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfMTAtNS0xLTEtMA_d9528744-8718-47f1-b1d2-44a3e8b0fbc4">953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, September 27, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de10452fa98443a826d732ac5ecfcd4_I20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfMTEtMS0xLTEtMA_2b0a6578-7d94-4297-a356-587bba8b8c39">64,473</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21919a743da04e9ebb238e98bd59fa74_I20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfMTEtMy0xLTEtMA_b69c2564-facc-44b6-836d-932c548988ec">114,831</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i514541208cb44a09bd41a6c7b123cbb4_I20200927" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfMTEtNS0xLTEtMA_d22d8025-7894-4d02-a02e-e0bde3864bff">14,938</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i701c9aa0c90c443fa3b9239555242704_I20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfMTEtNy0xLTEtMA_be5f4d2d-d1c0-4140-b6cb-4fbbae684f75">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4593a0dc4364211ae7edf29da4866d3_I20200927" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfMTEtOS0xLTEtMA_36b19684-5753-4090-8215-ab3c4956e4b6">38,540</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:13pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="if410ee6e03c8456f86a9fee997f08e65_46"></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars in Millions)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:76.319%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMy0yLTEtMS0w_eafa635c-e650-4c0b-971e-a003ec94aafc">16,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMy00LTEtMS0w_cf33be8b-bbc1-4de5-833c-ee54482d8532">12,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net earnings to cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization of property and intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNS0yLTEtMS0w_a557d3d9-18dd-487c-8a07-ac21ab80d470">5,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNS00LTEtMS0w_4dcbdb38-bb13-404e-99c3-7bd9e7a431f6">5,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNi0yLTEtMS0w_a12a409b-1c95-4c17-8d9d-453be2e2151c">920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNi00LTEtMS0w_35dac905-7aaa-40fc-ba4a-e5d83326e955">845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset write-downs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfOS0yLTEtMS0w_a67b68a5-632a-4826-ac4f-34c86855d7a3">964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfOS00LTEtMS0w_6c58532f-8103-46d1-8c86-89a1a5883dbe">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Contingent consideration reversal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTAtMi0xLTEtMA_de7393b6-0f73-4351-8d96-b8fe603be8f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTAtNC0xLTEtMA_6a3f240c-5700-48f5-80b7-f6cbd9a6dfc7">1,148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain on sale of assets/businesses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTEtMi0xLTEtMA_765d30ae-4b2c-427e-af56-2fe177199187">601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTEtNC0xLTEtMA_c183909b-adb4-4ca9-9f14-db64b9eff617">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTMtMi0xLTEtMA_a72c26d7-fdf2-4b26-880e-84d7e953d005">2,564</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTMtNC0xLTEtMA_ed60c0c2-af01-478e-b6cd-d3d7584f4028">238</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit losses and accounts receivable allowances </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTQtMi0xLTEtMA_f028efa3-678b-47f3-93b6-0bc77c59a925">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTQtNC0xLTEtMA_60700fc0-898c-477b-8e6e-70c387af3ef3">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities, net of effects from acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTYtMi0xLTEtMA_ed9bc0c5-e7e1-4471-8b26-be760dfdcdd3">1,818</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTYtNC0xLTEtMA_10e5c930-d1d5-4ca5-9ee4-95ca71804644">440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTctMi0xLTEtMA_d5073398-fc10-4e0d-ae18-7f1b87928cad">1,178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTctNC0xLTEtMA_e12a8d86-f16b-4e3a-8b57-ccb579033bf5">784</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase/(Decrease) in accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTgtMi0xLTEtMA_4e6dca32-74c4-44be-9154-346a6fe638b9">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTgtNC0xLTEtMA_44ae2ccd-eca7-49ea-932c-ee4a84466385">119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease/(Increase) in other current and non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTktMi0xLTEtMA_542ced2a-c1b7-40cc-818d-0b9aadc2371d">2,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTktNC0xLTEtMA_31e80d47-6609-42c4-b333-2e992c9edad9">1,983</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Decrease)/Increase in other current and non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjAtMi0xLTEtMA_1139b055-46f4-4edb-9ff7-3fe7608ddd11">1,938</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjAtNC0xLTEtMA_37bed96f-e4d1-44d0-bd1a-8c76123fccc9">581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET CASH FLOWS FROM OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjItMi0xLTEtMA_33fc4197-83d8-4f99-9c01-24d8da934f9d">17,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjItNC0xLTEtMA_f7e9085c-a78c-4fe6-9df4-deca1a9e2305">15,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjUtMi0xLTEtMA_8db59ce1-d0a5-4e39-b946-9f10fcde422b">2,237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjUtNC0xLTEtMA_058bdff1-5500-45a8-bfed-ff9e449adaf0">2,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the disposal of assets/businesses, net (Note 10)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjYtMi0xLTEtMA_d2f95f5b-3381-4471-8c3e-ecf6891b219c">666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjYtNC0xLTEtMA_69c9fea2-37fc-4997-8355-f8b722040bd9">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions, net of cash acquired (Note 10)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjctMi0xLTEtMA_d83f77ce-d3ee-4cee-8e1e-4db78a225cd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjctNC0xLTEtMA_8d521824-a336-428f-a8b8-af53841e3d86">949</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjgtMi0xLTEtMA_932b854d-364e-4ab8-87b5-6f97070efc99">18,843</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjgtNC0xLTEtMA_48914a65-3583-4a8f-9ddb-3c2dd0ef350c">16,243</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjktMi0xLTEtMA_b33088fc-5de3-47d0-aac9-8e3962e9fd16">16,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjktNC0xLTEtMA_fafd54a1-6951-4d37-960f-71ac32814ed5">6,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit support agreements activity, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzAtMi0xLTEtMA_9519c278-1d71-49b3-9aa8-23e4ac475ac6">696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzAtNC0xLTEtMA_c251ce6b-6a50-4702-a8f7-fd87efd526a6">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (primarily licenses and milestones)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzEtMi0xLTEtMA_be521f81-9f09-4785-855e-7faad351c6f1">414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzEtNC0xLTEtMA_bb675a9d-e6a0-451d-b037-29bb1a698dd8">516</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET CASH USED BY INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzMtMi0xLTEtMA_dc4eb4de-ec1e-4abc-a040-fd805ca21f94">3,323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzMtNC0xLTEtMA_8c73f928-0340-4caf-8967-7e0fa9b626d7">12,922</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends to shareholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfOrdinaryDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzYtMi0xLTEtMA_d6a9163c-f14e-4cc5-8b51-74fa6816b1f5">8,241</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfOrdinaryDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzYtNC0xLTEtMA_f0cb2356-7b5b-408b-ba23-dee9acee3367">7,823</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzctMi0xLTEtMA_f50c4cca-07dc-46fb-9555-351160d4b224">2,460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzctNC0xLTEtMA_28852c71-e378-4989-afb3-5839a82a41f4">2,900</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from short-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzgtMi0xLTEtMA_dc7a6b9f-271c-4f74-9fbb-a0143a88f9a4">1,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzgtNC0xLTEtMA_7c311bde-de09-4ed1-aede-357320469400">3,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of short-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzktMi0xLTEtMA_e375e742-37aa-4087-9c57-f1e4cc76e828">821</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzktNC0xLTEtMA_46f13d03-65a9-46ef-a179-70c43bcedd66">310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from long-term debt, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDAtMi0xLTEtMA_087f82e8-eff0-486d-94da-a07d47734097">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDAtNC0xLTEtMA_d647a5e3-dd7f-4960-9907-28233d6fe061">7,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDEtMi0xLTEtMA_dc9f0b0e-58d1-4edc-89c2-45f8ae07375f">1,452</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDEtNC0xLTEtMA_6de7ff73-bee0-46ac-b96a-282395746a88">562</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" name="jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDItMi0xLTEtMA_cb06c068-50c3-4fde-9b9d-7f0a398087ed">808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDItNC0xLTEtMA_98d978a0-f18a-4285-8119-0c8644cbd50b">922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit support agreements activity, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDMtMi0xLTEtMA_5043c4a3-9090-440f-b197-6a9328499572">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDMtNC0xLTEtMA_0328922a-f94d-4f5d-a75d-4883c1940ef4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDQtMi0xLTEtMA_198cd066-2ab3-4391-a6a5-b2fdc5caeee0">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDQtNC0xLTEtMA_5430a358-71b5-4ce0-8cb7-ee9c22688ac9">569</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET CASH USED BY FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDYtMi0xLTEtMA_2e353d52-38f6-432a-b607-71e7794eb673">10,611</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDYtNC0xLTEtMA_f6e58d89-357c-44f2-a931-2d85114762cb">476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDgtMi0xLTEtMA_78022442-d799-42eb-a71b-ec8c0b33066e">125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDgtNC0xLTEtMA_50ab4c59-dea3-4b1d-bcdd-16e2a6386a7c">135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDktMi0xLTEtMA_7433195e-efc5-4536-9e29-fa1cbe1f8080">3,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDktNC0xLTEtMA_d73c3f22-c5f3-43a9-8316-d9baf3d188e7">1,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash equivalents, beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNTAtMi0xLTEtMA_17bcc36c-fc02-43d6-908b-69a9219141a9">13,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if49e94e75cf04169b3ef119b2c588a4c_I20191229" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNTAtNC0xLTEtMA_974a6b8f-e8bd-40c2-88d0-3ec8056c073b">17,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH AND CASH EQUIVALENTS, END OF PERIOD</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNTEtMi0xLTEtMA_9f511098-8b7d-4018-9001-1edab96f903e">17,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de10452fa98443a826d732ac5ecfcd4_I20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNTEtNC0xLTEtMA_9a0859c7-980a-4ce5-88f4-f228e3c394df">18,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNTgtMi0xLTEtMA_c93fffc0-c990-464a-b46c-afeccb77df1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNTgtNC0xLTEtMA_1f297408-2181-4c8b-99cf-430a49dc29da">1,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed and noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNTktMi0xLTEtMA_478aa46a-1812-4c7b-97c4-d6e55cd724cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNTktNC0xLTEtMA_fa5dc12c-19ff-4feb-bbd5-120b728dc24a">224</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNjAtMi0xLTEtMA_eb3ec641-9849-488b-8218-d379202fa9e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNjAtNC0xLTEtMA_4aa9fe54-7dd1-4e75-9667-19a5a9130d60">949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="if410ee6e03c8456f86a9fee997f08e65_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="if410ee6e03c8456f86a9fee997f08e65_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NOTE 1 &#8212; <ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81Mi9mcmFnOjhhZDQ5NGE3MzUwNDRiN2Y5MWJkMGJhYjBjMTczMzI4L3RleHRyZWdpb246OGFkNDk0YTczNTA0NGI3ZjkxYmQwYmFiMGMxNzMzMjhfMjgyMQ_2b4d35d9-8d26-4bb8-90f6-14fbae1f476e" continuedAt="i2f49865874f94287b17c401429a67d5e" escape="true">The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson &amp; Johnson and its subsidiaries (the Company) and related notes as contained in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i2f49865874f94287b17c401429a67d5e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81Mi9mcmFnOjhhZDQ5NGE3MzUwNDRiN2Y5MWJkMGJhYjBjMTczMzI4L3RleHRyZWdpb246OGFkNDk0YTczNTA0NGI3ZjkxYmQwYmFiMGMxNzMzMjhfMjgyOA_cfd2f705-90c5-40f0-ac25-e679e293b435" escape="true"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of October&#160;3, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets along with the Company&#8217;s on-going vaccine development and distribution efforts. While there was not a material impact to the Company&#8217;s consolidated financial statements as of and for the quarter ended October&#160;3, 2021, the Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div></ix:nonNumeric><div style="margin-top:3pt"><span><br/></span></div><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81Mi9mcmFnOjhhZDQ5NGE3MzUwNDRiN2Y5MWJkMGJhYjBjMTczMzI4L3RleHRyZWdpb246OGFkNDk0YTczNTA0NGI3ZjkxYmQwYmFiMGMxNzMzMjhfMjgyOQ_75643b3a-89e4-4335-b6f9-17f3528f4a5c" escape="true"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021. There were no new material accounting standards issued in the fiscal nine months of 2021 that impacted the Company.</span></div><div style="margin-top:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the fiscal nine months of 2021.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81Mi9mcmFnOjhhZDQ5NGE3MzUwNDRiN2Y5MWJkMGJhYjBjMTczMzI4L3RleHRyZWdpb246OGFkNDk0YTczNTA0NGI3ZjkxYmQwYmFiMGMxNzMzMjhfMjgzMA_a01ecbb8-5482-4558-8aae-580f96e5c0a5" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current year presentation.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="if410ee6e03c8456f86a9fee997f08e65_55"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 2 &#8212; <ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81NS9mcmFnOmJlYzgwOWIzNmRkYzQzMjM4M2NjNTQwM2ZjZTAwYjRlL3RleHRyZWdpb246YmVjODA5YjM2ZGRjNDMyMzgzY2M1NDAzZmNlMDBiNGVfMzI_5534e2ea-e5ef-4e23-b780-c4455879aee6" continuedAt="ibf1847af88774210beab534d631c1f4e" escape="true">INVENTORIES </ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="ibf1847af88774210beab534d631c1f4e"><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81NS9mcmFnOmJlYzgwOWIzNmRkYzQzMjM4M2NjNTQwM2ZjZTAwYjRlL3RleHRyZWdpb246YmVjODA5YjM2ZGRjNDMyMzgzY2M1NDAzZmNlMDBiNGVfNDE_d0e02885-76df-47bb-8c93-f15f0b3822b1" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"><tr><td style="width:1.0%"></td><td style="width:51.896%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.310%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81NS9mcmFnOmJlYzgwOWIzNmRkYzQzMjM4M2NjNTQwM2ZjZTAwYjRlL3RhYmxlOjVlZWYxNGUxMWU2OTQ4MzI5Mjk2ZDk0YTU0OGRkMGU0L3RhYmxlcmFuZ2U6NWVlZjE0ZTExZTY5NDgzMjkyOTZkOTRhNTQ4ZGQwZTRfMS0yLTEtMS0w_b09a2c15-7c0d-40ca-84c2-be683d3c586e">1,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81NS9mcmFnOmJlYzgwOWIzNmRkYzQzMjM4M2NjNTQwM2ZjZTAwYjRlL3RhYmxlOjVlZWYxNGUxMWU2OTQ4MzI5Mjk2ZDk0YTU0OGRkMGU0L3RhYmxlcmFuZ2U6NWVlZjE0ZTExZTY5NDgzMjkyOTZkOTRhNTQ4ZGQwZTRfMS00LTEtMS0w_f2b14104-8a3a-4856-a8d6-96e1551714bd">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goods in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81NS9mcmFnOmJlYzgwOWIzNmRkYzQzMjM4M2NjNTQwM2ZjZTAwYjRlL3RhYmxlOjVlZWYxNGUxMWU2OTQ4MzI5Mjk2ZDk0YTU0OGRkMGU0L3RhYmxlcmFuZ2U6NWVlZjE0ZTExZTY5NDgzMjkyOTZkOTRhNTQ4ZGQwZTRfMi0yLTEtMS0w_92292c74-8461-4372-a30a-6df41efea8d7">2,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81NS9mcmFnOmJlYzgwOWIzNmRkYzQzMjM4M2NjNTQwM2ZjZTAwYjRlL3RhYmxlOjVlZWYxNGUxMWU2OTQ4MzI5Mjk2ZDk0YTU0OGRkMGU0L3RhYmxlcmFuZ2U6NWVlZjE0ZTExZTY5NDgzMjkyOTZkOTRhNTQ4ZGQwZTRfMi00LTEtMS0w_2a870afd-4b56-402b-b3c2-67d5dd6c5400">2,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81NS9mcmFnOmJlYzgwOWIzNmRkYzQzMjM4M2NjNTQwM2ZjZTAwYjRlL3RhYmxlOjVlZWYxNGUxMWU2OTQ4MzI5Mjk2ZDk0YTU0OGRkMGU0L3RhYmxlcmFuZ2U6NWVlZjE0ZTExZTY5NDgzMjkyOTZkOTRhNTQ4ZGQwZTRfMy0yLTEtMS0w_b95d9356-6d11-4d52-bcae-9db3a56efbfa">6,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81NS9mcmFnOmJlYzgwOWIzNmRkYzQzMjM4M2NjNTQwM2ZjZTAwYjRlL3RhYmxlOjVlZWYxNGUxMWU2OTQ4MzI5Mjk2ZDk0YTU0OGRkMGU0L3RhYmxlcmFuZ2U6NWVlZjE0ZTExZTY5NDgzMjkyOTZkOTRhNTQ4ZGQwZTRfMy00LTEtMS0w_b9700c6d-d70e-496b-9786-efee215c36bc">5,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81NS9mcmFnOmJlYzgwOWIzNmRkYzQzMjM4M2NjNTQwM2ZjZTAwYjRlL3RhYmxlOjVlZWYxNGUxMWU2OTQ4MzI5Mjk2ZDk0YTU0OGRkMGU0L3RhYmxlcmFuZ2U6NWVlZjE0ZTExZTY5NDgzMjkyOTZkOTRhNTQ4ZGQwZTRfNC0yLTEtMS0w_901b0067-af4d-450f-9647-f6a3c8d569a0">10,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81NS9mcmFnOmJlYzgwOWIzNmRkYzQzMjM4M2NjNTQwM2ZjZTAwYjRlL3RhYmxlOjVlZWYxNGUxMWU2OTQ4MzI5Mjk2ZDk0YTU0OGRkMGU0L3RhYmxlcmFuZ2U6NWVlZjE0ZTExZTY5NDgzMjkyOTZkOTRhNTQ4ZGQwZTRfNC00LTEtMS0w_99966b39-c616-4d61-8668-4f6a59d8cb43">9,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="if410ee6e03c8456f86a9fee997f08e65_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 3 &#8212; <ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RleHRyZWdpb246NGNiMTdhN2IzYjhhNGJkZWIwNGNhN2ViZTNhYjcyODBfMTM2MA_badba801-7ea0-4edc-b899-2a2dcbe42553" continuedAt="i91f8d468ea5c45cda2c03491fd6ebd4c" escape="true">INTANGIBLE ASSETS AND GOODWILL</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i91f8d468ea5c45cda2c03491fd6ebd4c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2020. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.</span></div><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RleHRyZWdpb246NGNiMTdhN2IzYjhhNGJkZWIwNGNhN2ViZTNhYjcyODBfMTM3Mg_9abc5fbc-deaf-4ee8-ad08-f9be33d4ad44" escape="true"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:61.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with definite lives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; gross</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4743699b0eac46a588c10333167e9fae_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfMi0yLTEtMS0w_883dba75-6e36-4816-8ab4-9cf1ee7d4f56">39,176</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137acfc8e8824efc95e1265512dd13d9_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfMi00LTEtMS0w_abd363b7-8126-40c8-ad3b-be1e98fe618c">39,990</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4743699b0eac46a588c10333167e9fae_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfMy0yLTEtMS0w_1ff4abf7-7402-401f-acb3-e3e4922526d3">19,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i137acfc8e8824efc95e1265512dd13d9_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfMy00LTEtMS0w_da3c3af1-932d-4636-b10d-acf3974b6eaa">17,618</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4743699b0eac46a588c10333167e9fae_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfNC0yLTEtMS0w_22120f7b-02d6-40de-9c51-575cfaf5b10d">19,607</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137acfc8e8824efc95e1265512dd13d9_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfNC00LTEtMS0w_e37bb6db-cf81-4c1a-8b33-6f5e37a91073">22,372</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles &#8212; gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7121dbd0cc754e319650cfe1e9a6d091_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfNS0yLTEtMS0w_a590b91a-c7d0-48ce-a613-f956d58c0a95">22,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i364bae74581b41469b167f1d57b47bec_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfNS00LTEtMS0w_0f3f21d3-a1ea-4125-be9b-f431a0febff0">22,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7121dbd0cc754e319650cfe1e9a6d091_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfNi0yLTEtMS0w_ecbc5ffd-4cf8-4061-b500-94dacc84fdb7">11,637</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i364bae74581b41469b167f1d57b47bec_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfNi00LTEtMS0w_cf806e46-4a42-46e0-9fbe-30d5432bc950">10,912</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; net*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7121dbd0cc754e319650cfe1e9a6d091_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfNy0yLTEtMS0w_ad20cfc2-1c0e-4f36-9d0e-e1753e5df025">11,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i364bae74581b41469b167f1d57b47bec_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfNy00LTEtMS0w_50523b2a-61ae-4a1f-9bc4-877227c78293">11,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2272c30bea4b1482458fce855c3373_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfOS0yLTEtMS0w_8265ea09-611c-4423-ab4c-3937004c9f50">7,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306786a4d54f459696c4fb7907f30ea4_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfOS00LTEtMS0w_3982111a-00d8-4d09-ac30-47498df895c5">7,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased in-process research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc12ecbfad9b4436a408325ad670fee4_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfMTAtMi0xLTEtMA_dfbeb821-67c4-4bdc-b77c-7245dfe75103">9,843</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6550a842150844a782974595356be4c8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfMTAtNC0xLTEtMA_91b867f6-208f-455a-abb7-94b37a9b0654">11,849</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfMTEtMi0xLTEtMA_56997be2-7b83-48f3-96d4-db3ea7063417">16,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfMTEtNC0xLTEtMA_87f26ba6-49d6-4ebd-b05f-bb901749a21b">19,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets &#8212; net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfMTItMi0xLTEtMA_802ff4c6-259c-415f-8673-3995ff2baeaf">47,776</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfMTItNC0xLTEtMA_7e3b59e2-2ef3-4b99-9f02-051149d9ab2d">53,402</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*The majority is comprised of customer relationships</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In the fiscal third quarter of 2021, the Company recorded a partial IPR&amp;D impairment charge of $<ix:nonFraction unitRef="usd" contextRef="ie9431acda5084235a9355798c8cc8b2e_D20210705-20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RleHRyZWdpb246NGNiMTdhN2IzYjhhNGJkZWIwNGNhN2ViZTNhYjcyODBfMTA5OTUxMTYyODEwNDE_66bcb73a-d579-4fbf-815f-7c264c81ab40">0.9</ix:nonFraction>&#160;billion primarily related to expected development delays in the general surgery digital robotics platform (Ottava) acquired with the Auris Health acquisition in 2019. The impairment charge was calculated based on revisions to the discounted cash flow valuation model reflecting a delay of first in human procedures of approximately two years from the initial acquisition model assumption of the second half of 2022. The remaining reduction was driven by assets that reached commercialization and are now classified as having definite lives.</span></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RleHRyZWdpb246NGNiMTdhN2IzYjhhNGJkZWIwNGNhN2ViZTNhYjcyODBfMTM2OA_489fbdde-26ac-4a46-8418-dea4d62906a5" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill as of October&#160;3, 2021 was allocated by segment of business as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:39.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58d78224ae6d43cf95b5735d5bb3dabb_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfMS0yLTEtMS0w_57b9b761-0f4c-4272-b343-81d18c05b928">10,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a29aa136e144ef7a4209eb7a9897d36_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfMS00LTEtMS0w_6d0f79a0-a447-4cf3-ad5c-d20cdfff55a3">11,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fbb196ddcb14beaa7a23bd9de26d3d9_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfMS02LTEtMS0w_35e2fa39-d5c1-4642-a7aa-7885f268dd9f">15,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfMS04LTEtMS0w_ba69f65d-28ec-4dfb-a7ed-f3b6dfc6d779">36,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i185910f7181845c8aed38c39fd4b6cab_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfMi0yLTEtMS0w_c681827e-cd2f-4c29-a1ae-db92e42c082a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c6f67375de464e98be9b5c858a0996_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfMi00LTEtMS0w_a4db8fac-887c-4c32-96fe-822f922f6e03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7fc25fc53e54e21948d2ce281e9424a_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfMi02LTEtMS0w_b384113e-508f-4a04-a5dc-745881250630">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfMi04LTEtMS0w_55a16563-b4f3-4d54-a34f-778608387f25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to divestitures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i185910f7181845c8aed38c39fd4b6cab_D20210104-20211003" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfMy0yLTEtMS0w_2d6f850e-50aa-42c2-b2fb-2ea59e47575e">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c6f67375de464e98be9b5c858a0996_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfMy00LTEtMS0w_0fd22655-cd87-40a8-8f92-59b58d34fbb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7fc25fc53e54e21948d2ce281e9424a_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfMy02LTEtMS0w_806da089-b73d-4e08-a94f-6094eb674596">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfMy04LTEtMS0w_f5461482-6196-491c-b186-e3c3fb18d574">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i185910f7181845c8aed38c39fd4b6cab_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfNC0yLTEtMS0w_6ded8070-3fba-4cee-ac7e-4b3af74da0be">347</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18c6f67375de464e98be9b5c858a0996_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfNC00LTEtMS0w_36920655-659c-4068-8e52-e3c4838c3a10">283</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7fc25fc53e54e21948d2ce281e9424a_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfNC02LTEtMS0w_0b8a5db3-ff97-4a18-9a2f-1970b612fbf4">187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfNC04LTEtMS0w_1c3f8c24-889d-4816-9b5b-7868aa363c8d">817</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at October 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64662abe386b4a3b9044b4dbcffe47d5_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfNS0yLTEtMS0w_9e323bc4-eaf1-4168-b6e4-7431f574387c">9,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia53808fcfd3f400c939324049330ed77_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfNS00LTEtMS0w_23210948-d572-4713-b264-cf36be1140fd">10,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97512951ea1746ff957df24ca33bf674_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfNS02LTEtMS0w_015a5460-3473-4535-b071-7d9fa47d252c">14,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfNS04LTEtMS0w_45739ec8-3431-491e-a83a-ed9c1b7acbff">35,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average amortization period for patents and trademarks is <ix:nonNumeric contextRef="i69229a2a50d442b795aa18fa30c26be4_D20210104-20211003" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RleHRyZWdpb246NGNiMTdhN2IzYjhhNGJkZWIwNGNhN2ViZTNhYjcyODBfNjQx_7505ebb3-4816-4c05-aedb-cf29a884ca54">12</ix:nonNumeric> years. The weighted average amortization period for customer relationships and other intangible assets is <ix:nonNumeric contextRef="if2f30918b36c48df9f73661bf07e071b_D20210104-20211003" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RleHRyZWdpb246NGNiMTdhN2IzYjhhNGJkZWIwNGNhN2ViZTNhYjcyODBfNzUw_e0cbce91-a617-41ab-b9bf-ff23fe467bfb">21</ix:nonNumeric> years. The amortization expense of amortizable intangible assets included in cost of products sold was $<ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RleHRyZWdpb246NGNiMTdhN2IzYjhhNGJkZWIwNGNhN2ViZTNhYjcyODBfODU2_1e9776ea-6cf0-4d5c-864c-bad97249c960">1.1</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RleHRyZWdpb246NGNiMTdhN2IzYjhhNGJkZWIwNGNhN2ViZTNhYjcyODBfODYz_71bca403-294e-46ca-be33-16bd94a1a901">1.2</ix:nonFraction>&#160;billion for the fiscal third quarters ended October&#160;3, 2021 and September&#160;27, 2020, respectively. The amortization expense of amortizable intangible assets included in cost of products sold was $<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RleHRyZWdpb246NGNiMTdhN2IzYjhhNGJkZWIwNGNhN2ViZTNhYjcyODBfOTk4_36a10177-4e2a-4119-8e71-fc5ca3547672">3.6</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RleHRyZWdpb246NGNiMTdhN2IzYjhhNGJkZWIwNGNhN2ViZTNhYjcyODBfMTAwNQ_de4d0089-1963-41d5-93c9-9353b447ef35">3.4</ix:nonFraction>&#160;billion for the fiscal nine months ended October&#160;3, 2021 and September&#160;27, 2020, respectively. Intangible asset write-downs are included in Other (income) expense, net. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RleHRyZWdpb246NGNiMTdhN2IzYjhhNGJkZWIwNGNhN2ViZTNhYjcyODBfMTM2OQ_ebe7ebb5-fdca-4ebd-bc09-238a44597de2" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"><tr><td style="width:1.0%"></td><td style="width:18.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOmYxZjhmMDIyOTIxYjQ5ODA5ODQ3M2NiOWY4YTUzMDU1L3RhYmxlcmFuZ2U6ZjFmOGYwMjI5MjFiNDk4MDk4NDczY2I5ZjhhNTMwNTVfMi0wLTEtMS0w_70f03c3c-ba33-4c9a-b9f2-a9baa1566493">4,700</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOmYxZjhmMDIyOTIxYjQ5ODA5ODQ3M2NiOWY4YTUzMDU1L3RhYmxlcmFuZ2U6ZjFmOGYwMjI5MjFiNDk4MDk4NDczY2I5ZjhhNTMwNTVfMi0yLTEtMS0w_522aa1aa-af24-4d4e-b1c3-c226897fd00f">4,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOmYxZjhmMDIyOTIxYjQ5ODA5ODQ3M2NiOWY4YTUzMDU1L3RhYmxlcmFuZ2U6ZjFmOGYwMjI5MjFiNDk4MDk4NDczY2I5ZjhhNTMwNTVfMi00LTEtMS0w_f79de7b7-d246-4e1b-9c38-836734e4c589">4,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOmYxZjhmMDIyOTIxYjQ5ODA5ODQ3M2NiOWY4YTUzMDU1L3RhYmxlcmFuZ2U6ZjFmOGYwMjI5MjFiNDk4MDk4NDczY2I5ZjhhNTMwNTVfMi02LTEtMS0w_b9171d47-38b1-47e5-8c87-62a43a7e8246">4,300</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOmYxZjhmMDIyOTIxYjQ5ODA5ODQ3M2NiOWY4YTUzMDU1L3RhYmxlcmFuZ2U6ZjFmOGYwMjI5MjFiNDk4MDk4NDczY2I5ZjhhNTMwNTVfMi04LTEtMS0w_978415ed-f28b-4af5-8328-c3ec5913a8bf">3,600</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div id="if410ee6e03c8456f86a9fee997f08e65_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 4 &#8212; <ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTIwMDM_81c4997e-f023-4e17-bba2-90499d5b690b" continuedAt="i6f0bac52b47140b6b40147fb559fd542" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i6f0bac52b47140b6b40147fb559fd542" continuedAt="ie0620214e4b747f4a2c2b7c67dc55503"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings.  These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of October&#160;3, 2021, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $<ix:nonFraction unitRef="usd" contextRef="i386cee1639274652826fd3eed1982a70_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CollateralAlreadyPostedAggregateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTY0Nw_70980c3d-c3da-41bb-b7fc-a2a21a69b669">202</ix:nonFraction> million net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating.  Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of October&#160;3, 2021, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $<ix:nonFraction unitRef="usd" contextRef="i386cee1639274652826fd3eed1982a70_I20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMjMyMg_0ebe033a-a471-406f-b119-ae918b3c642a">45.8</ix:nonFraction>&#160;billion, $<ix:nonFraction unitRef="usd" contextRef="i0e0add53586f4fb29f2838afbf423ad7_I20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMjMyNg_f7ddfadb-bc57-4ceb-87f7-1846c07cd5e3">35.1</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="ic9852777165f4b609444e7127f04f202_I20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMjMzMw_3c420163-6be4-4149-a3de-768653822363">10.0</ix:nonFraction>&#160;billion, respectively. As of January&#160;3, 2021, the Company had notional amounts outstanding for forward foreign exchange contracts and cross currency interest rate swaps of $<ix:nonFraction unitRef="usd" contextRef="i7c4d270b6af043e9be04d479dec5dd5c_I20210103" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMjQ4Ng_d33c1d6f-480a-42f9-a888-0c69dcbb3db5">37.8</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ib219ae64b99744eaa1b7b8cc1067daf8_I20210103" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMjQ5Mw_47d5c8f2-9888-467c-93ac-024582f8baa8">30.6</ix:nonFraction> billion, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur.  Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October&#160;3, 2021, the balance of deferred net gain on derivatives included in accumulated other comprehensive income was $<ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfNDYyNA_f5985c67-4fd8-4867-aaeb-e0f3d52ad043">21</ix:nonFraction>&#160;million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the <ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:DescriptionOfReclassificationOfCashFlowHedgeGainLoss" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfNDg4Mg_d3f8a00d-1eb3-434a-8f2b-06c3c438d922">next 12 months</ix:nonNumeric> as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is <ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" format="ixt-sec:durmonth" name="us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfNTA0Mw_f1faa43c-bedb-4ffb-8fe4-a3e0f05aca86">18</ix:nonNumeric> months, excluding interest rate contracts and </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net investment hedge</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span><br/></span></div><ix:continuation id="ie0620214e4b747f4a2c2b7c67dc55503" continuedAt="ib526a982a2fc456fb929fdefff9e42da"><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTE5NzI_5b45fce2-09c1-402f-bd3c-d0bf22bd769c" continuedAt="ia50cc54002c74368b5f1a32b6b2c6b32" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal third quarters ended in 2021 and 2020, net of tax:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.102%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.836%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.836%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.836%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 27, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd7f04c9cf442d09d8944a1200e4e9e_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOC0xLTEtMS0w_4a8084a8-256a-4957-8539-8017cdd0ea7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2446fd6831b74f84a1fbc08826466b5a_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOC0yLTEtMS0w_1d12d80e-63d1-4a62-b884-7c7066190835">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5373c09ac6424f71abea9a4af34fad8d_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOC0zLTEtMS0w_075c034e-515b-4ed4-99a7-253c91801567">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia29eda1bae054029be22f80a32d9bed0_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOC00LTEtMS0w_328644f6-c823-443a-b8db-cc99acc8c95c">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1176d5e87c548cf8e03d248b438c1fd_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOC01LTEtMS0w_0ec60514-8ca6-4714-a883-40f7670280f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ddf01a2ed04decb15a346373711b4b_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOC02LTEtMS0w_b51c54f9-af66-478e-be91-0946e2437d9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf5522e302034e189c307e49dc73197d_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOC03LTEtMS0w_61c84224-87c4-4725-aa10-2f76e1360865">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58a7e978302f42b1aa90a38f29c5a34b_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOC04LTEtMS0w_255d4723-e581-4c49-afd4-6a3e9c275371">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i77a7f12df0b140499e72c6c5292e080d_D20200629-20200927" xsi:nil="true" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOC05LTEtMS0w_cd2011bf-1573-45bd-93c5-962564e76ccb"></ix:nonFraction></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i513a49e58ab74680ba8b509c23674bf0_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOC0xMC0xLTEtMA_c797444e-67d9-4352-9dfb-3d17624eed31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd7f04c9cf442d09d8944a1200e4e9e_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOS0xLTEtMS0w_a3b8fc1f-5d15-4d3d-ab14-9d93888d0437">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2446fd6831b74f84a1fbc08826466b5a_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOS0yLTEtMS0w_7d8d3b74-2e6e-45b0-adb6-618b4a6f90e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5373c09ac6424f71abea9a4af34fad8d_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOS0zLTEtMS0w_7d041443-0f5a-49f7-a88a-f50d4511a7df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia29eda1bae054029be22f80a32d9bed0_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOS00LTEtMS0w_84cf890b-c185-4745-8579-7780ef4b4e71">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1176d5e87c548cf8e03d248b438c1fd_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOS01LTEtMS0w_7bab8f44-2468-4cb6-9bc5-20b519d1bc9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ddf01a2ed04decb15a346373711b4b_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOS02LTEtMS0w_6573a2ef-4e85-4e4b-beb7-868763133176">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf5522e302034e189c307e49dc73197d_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOS03LTEtMS0w_df8e3b11-117f-4cc8-8f0a-0f3de4eaabf3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58a7e978302f42b1aa90a38f29c5a34b_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOS04LTEtMS0w_f1e74876-7390-422d-91a7-c030da2d75aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i77a7f12df0b140499e72c6c5292e080d_D20200629-20200927" xsi:nil="true" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOS05LTEtMS0w_be31544e-5b5b-42cd-bd8d-0f94c6eb2da8"></ix:nonFraction></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i513a49e58ab74680ba8b509c23674bf0_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOS0xMC0xLTEtMA_1237809d-872b-49d9-b716-78d72f17ae4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e5c25b196b4581a673892969bb5051_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTMtMS0xLTEtMA_b52fb450-d113-4ecd-b08e-5f3b04e45f77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93e401f2dd5c4ea586defab03d5e9b30_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTMtMi0xLTEtMA_6ccfe44a-e971-4d05-b17c-1c2147b7ad6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c72adb013a948e8a95c6b4603152001_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTMtMy0xLTEtMA_30eec87b-4a1f-4f9d-ad2d-15c7e62a001d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82e5fff9c6bd45ca997965825f96a0d3_D20210705-20211003" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTMtNC0xLTEtMA_45b3740e-14ee-44a9-aa84-5b1d8aaa3208">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99216cc8b79445dd8a6169989e70f809_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTMtNS0xLTEtMA_60287edd-a2f0-4294-8144-57a3ca4cd1c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfc2d51c1b3943179426ac0f6638ea2b_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTMtNi0xLTEtMA_8987bae5-569f-4ab4-90b1-4f3d5ce5ff68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b598c35682943d4aa693d58ad7185a7_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTMtNy0xLTEtMA_26a2196e-105d-43a1-8636-32df2a2ce6a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0ccfa0f2f3043db8ffb4dd5132378b0_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTMtOC0xLTEtMA_495c5288-c5ce-4eca-9d56-fee0ec351024">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77bd06875cea40cbacd7c9e2c6e60de2_D20200629-20200927" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTMtOS0xLTEtMA_38405ccd-5e3d-42fa-93e3-2bd8e62bdbb4">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia171152160c9457eaf8a8198b50831df_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTMtMTAtMS0xLTA_2431ee5d-630f-436b-994e-ea92c31dc4ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e5c25b196b4581a673892969bb5051_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTQtMS0xLTEtMA_9ba11c8d-c6a7-45c8-af13-688a31aae279">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93e401f2dd5c4ea586defab03d5e9b30_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTQtMi0xLTEtMA_aa1878d8-0a7f-472c-87f7-3b821cba4945">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c72adb013a948e8a95c6b4603152001_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTQtMy0xLTEtMA_7b898e52-0dbd-43d1-b7e1-fd64afda6beb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82e5fff9c6bd45ca997965825f96a0d3_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTQtNC0xLTEtMA_9f49bff0-72ba-4fed-aa8d-f0ab2cab2947">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99216cc8b79445dd8a6169989e70f809_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTQtNS0xLTEtMA_283e61b1-555d-43fc-aba4-c764b929d97b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfc2d51c1b3943179426ac0f6638ea2b_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTQtNi0xLTEtMA_3f1faf95-d28c-47c5-84cd-261cbc9c5478">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b598c35682943d4aa693d58ad7185a7_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTQtNy0xLTEtMA_062a8334-178e-402a-8754-03b500d2cae5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0ccfa0f2f3043db8ffb4dd5132378b0_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTQtOC0xLTEtMA_df790f4a-92ff-4425-baa9-9ba2d9e27737">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77bd06875cea40cbacd7c9e2c6e60de2_D20200629-20200927" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTQtOS0xLTEtMA_a562552e-8ae5-4056-9e6e-9257ca4c2d9a">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia171152160c9457eaf8a8198b50831df_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTQtMTAtMS0xLTA_2c6e4da1-0d7d-44e3-8192-ac5e864948a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c22296c638b499dacba432243aabb21_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTgtMS0xLTEtMA_9de2667d-6073-4f4d-833e-1ecfdab8bf8f">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief08f28671bd449f85c45b2524dc11fd_D20210705-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTgtMi0xLTEtMA_3e02083d-481d-475c-873f-d13da4d95b45">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0490b39cdf9e468d851a818d788fa90a_D20210705-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTgtMy0xLTEtMA_b7a0c252-e902-4fd3-a5da-3987147e799f">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767f5c4625154f0a8f7d74c8b8c3a35e_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTgtNC0xLTEtMA_9c69421f-adeb-4c61-ad7e-a445c7bf7e29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c775ffd78004ecbaf03812778b4fb63_D20210705-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTgtNS0xLTEtMA_b9975819-18c2-4076-8b7c-d4ba5c1fd42e">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15408f87a30b40a48076e15baf08bf94_D20200629-20200927" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTgtNi0xLTEtMA_b5762c6a-42cd-4513-82e7-d0150aef417b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b90f9340101469daec861ce7a7fc255_D20200629-20200927" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTgtNy0xLTEtMA_aacd016c-cf3c-4d4a-906b-dead025f93dd">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19054c05c6034f23a0b61aa630e73505_D20200629-20200927" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTgtOC0xLTEtMA_97ed75f6-3182-4f77-889a-e773f3316b70">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i469f78b5da314cda95613d4aba1df12c_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTgtOS0xLTEtMA_6024be83-7d63-4053-bf5e-021d54640870">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3d4899630c6450886e61d01be554303_D20200629-20200927" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTgtMTAtMS0xLTA_ef2212b8-9fd6-4dd8-a6c1-b44aaa732273">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c22296c638b499dacba432243aabb21_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjItMS0xLTEtMA_5219b3d0-94b6-4365-93e0-3df134ba30b7">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief08f28671bd449f85c45b2524dc11fd_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjItMi0xLTEtMA_56f84661-d15e-4cc2-9698-1326dcf2d33d">155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0490b39cdf9e468d851a818d788fa90a_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjItMy0xLTEtMA_ef0f9130-5985-4c36-a56e-86c356f795e5">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767f5c4625154f0a8f7d74c8b8c3a35e_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjItNC0xLTEtMA_2cd36abb-cdfb-45d3-abee-8ef9ee3b9e3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c775ffd78004ecbaf03812778b4fb63_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjItNS0xLTEtMA_4776691f-3545-49f8-977a-498a44488bf9">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15408f87a30b40a48076e15baf08bf94_D20200629-20200927" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjItNi0xLTEtMA_789cde46-58f5-41e8-8de6-a79ab2501993">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b90f9340101469daec861ce7a7fc255_D20200629-20200927" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjItNy0xLTEtMA_360cf74a-a81f-4905-9681-e2baf2446dab">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19054c05c6034f23a0b61aa630e73505_D20200629-20200927" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjItOC0xLTEtMA_0c1ccd3d-80a4-4d94-a873-5dd1b99afb9b">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i469f78b5da314cda95613d4aba1df12c_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjItOS0xLTEtMA_56c929db-3d56-4e5c-afbe-65607fbe31f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3d4899630c6450886e61d01be554303_D20200629-20200927" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjItMTAtMS0xLTA_40159af1-b91f-4bcf-975d-3ac5ed711596">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0786ff8f130406bb2514f5c91f8a2a8_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjUtMS0xLTEtMA_6cb3e5d7-313c-49b6-b563-3ebb0ab4cdd9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d4a0150b247424e98fb6ecbe5b9c39d_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjUtMi0xLTEtMA_f8ec77e6-5d44-4272-9e08-7ce520eb56ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i078ef827e4f344eab96812a9740e1239_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjUtMy0xLTEtMA_bea723d2-8e7e-431f-b17d-1618b4000c68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie49f82a46b424edcab630d17792da6b8_D20210705-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjUtNC0xLTEtMA_3acb7194-d5dd-4720-a79c-ec8e681068e7">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i204468adffd143848aaaba487ce0a656_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjUtNS0xLTEtMA_f58e24bc-d196-46b5-ba4f-e587b3ca6266">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id01b13e20bd947928cfc3ced046acd64_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjUtNi0xLTEtMA_bfa72aca-f13e-441a-9f7b-fc9fe38a840b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i3753d069b34e42ffa037aa3a221eec25_D20200629-20200927" xsi:nil="true" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjUtNy0xLTEtMA_c4e533fb-36d0-4de1-a733-b6d85e41aeaa"></ix:nonFraction></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a8c3429d9ff41b7b0f85c7d87dad8f8_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjUtOC0xLTEtMA_4f61d884-2a53-4da1-b61f-0057fd052e2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafc5d51a497748cc9ad72884ab239bfb_D20200629-20200927" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjUtOS0xLTEtMA_d8891fd7-264c-4d66-8a22-305482dc86c9">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc2ba0506404c9d92c54405efa208bf_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjUtMTAtMS0xLTA_fc5528e4-4633-416f-ac19-f0eac2d15952">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0786ff8f130406bb2514f5c91f8a2a8_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjctMS0xLTEtMA_7c574b72-613c-40db-a2ae-74c319b70c1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d4a0150b247424e98fb6ecbe5b9c39d_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjctMi0xLTEtMA_09e4fd9d-191c-4e1e-905d-74a872d7f190">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i078ef827e4f344eab96812a9740e1239_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjctMy0xLTEtMA_e60fd4ff-f223-4c93-af20-285d073da639">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie49f82a46b424edcab630d17792da6b8_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjctNC0xLTEtMA_0e11c815-c525-4198-ae5b-347eeebb9cd8">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i204468adffd143848aaaba487ce0a656_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjctNS0xLTEtMA_60b5f9ff-2a40-41c4-9f38-716aa924e5e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id01b13e20bd947928cfc3ced046acd64_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjctNi0xLTEtMA_976233df-d018-4da4-acef-e4bc5169311a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3753d069b34e42ffa037aa3a221eec25_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjctNy0xLTEtMA_a2733944-c950-48a6-ad13-c763a6b9f739">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a8c3429d9ff41b7b0f85c7d87dad8f8_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjctOC0xLTEtMA_63a48950-9ebf-48ac-83d2-1391145bf17d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafc5d51a497748cc9ad72884ab239bfb_D20200629-20200927" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjctOS0xLTEtMA_33112ee8-9764-4bcb-b91c-3be520e9ab6d">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc2ba0506404c9d92c54405efa208bf_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjctMTAtMS0xLTA_9d48aca6-05d5-4f3d-bafd-170353f3be58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><ix:continuation id="ib526a982a2fc456fb929fdefff9e42da" continuedAt="iaa98ba5f4ad34e61a2e7b6fecae390f2"><ix:continuation id="ia50cc54002c74368b5f1a32b6b2c6b32" continuedAt="i6e026f55a67c4f7aa4784063006a5c70"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal nine months ended in 2021 and 2020, net of tax:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.493%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.760%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 27, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id97c9bcc0a104ab4bf86bb77681a798a_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOC0xLTEtMS0w_8516b669-2865-4b54-9919-aed6a4674a85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36e6f6c2b8274124a6cd37dfbbe9c6fb_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOC0yLTEtMS0w_c6c29bc8-f127-4ff3-a74b-4ac31fccad51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if264742b6d944aba8d0e08c08df83a8e_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOC0zLTEtMS0w_9a146e82-42a5-4e89-b8c7-6a8612270f15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c801cb847184a7894fc5ff4b0c3f468_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOC00LTEtMS0w_5ca81942-e620-4353-91d3-0c97427eaebb">56</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i515bd1a2d43148349fd6ab9f0a2255e3_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOC01LTEtMS0w_7eb56207-7db8-4130-b87a-262daf803641">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8a28c76f65e4001af98e0f096fb76b2_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOC02LTEtMS0w_dac6241a-0442-4c4b-8a07-64516065fc8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ade907d675d4c8c99740caca6ebd135_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOC03LTEtMS0w_49c1c8f9-0d1f-4cbf-899c-274669bbd3a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e9d30cc4cfc488a862a5885738d2f05_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOC04LTEtMS0w_08f058a5-e396-4d92-9b0d-6c39370bb989">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="icb60c19364b242d6917f7472855f3905_D20191230-20200927" xsi:nil="true" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOC05LTEtMS0w_745a7b70-c267-428b-aef4-dd3249c29500"></ix:nonFraction></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c2b9f86e3934a9b831632fa60e4ba21_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOC0xMC0xLTEtMA_fc15b3d7-f04f-4fe1-8c2b-f9f6310e1e49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id97c9bcc0a104ab4bf86bb77681a798a_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOS0xLTEtMS0w_073ca979-f210-4b24-90c7-dc31ba1dd821">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36e6f6c2b8274124a6cd37dfbbe9c6fb_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOS0yLTEtMS0w_70eeda2d-ce61-48d9-a359-58b3779fe444">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if264742b6d944aba8d0e08c08df83a8e_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOS0zLTEtMS0w_ad59d84f-6b03-4f0b-91ea-ac98687d4488">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c801cb847184a7894fc5ff4b0c3f468_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOS00LTEtMS0w_7a37ce50-5714-42ac-9a1a-b923515b6e98">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i515bd1a2d43148349fd6ab9f0a2255e3_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOS01LTEtMS0w_9fa9c6d9-e393-4ef1-8f49-ddcd53b8bacc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8a28c76f65e4001af98e0f096fb76b2_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOS02LTEtMS0w_94be00f8-620a-4209-94e7-07aab3a5c943">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ade907d675d4c8c99740caca6ebd135_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOS03LTEtMS0w_93f95d70-29fb-4757-8ea6-6b6ba98681cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e9d30cc4cfc488a862a5885738d2f05_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOS04LTEtMS0w_b284e6ac-2a67-4d44-a7f3-e538b62487a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="icb60c19364b242d6917f7472855f3905_D20191230-20200927" xsi:nil="true" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOS05LTEtMS0w_12e1a0b4-1f35-4ac3-abb2-62efa8c34874"></ix:nonFraction></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c2b9f86e3934a9b831632fa60e4ba21_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOS0xMC0xLTEtMA_230bfebd-c571-43ec-a4a1-84a3f30e2229">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0141e2177d24be384d24197d458ffe0_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTMtMS0xLTEtMA_3f365533-f1ac-4289-9619-6c7e5c34dc17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6256db6dc0054ac18b141ae33e5ad29f_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTMtMi0xLTEtMA_d3c7dbf5-9ddb-4766-b706-0e1bcee9b069">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8631e8b6ef484669be037922391c299d_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTMtMy0xLTEtMA_2a53b440-bec3-4552-b469-fc1a1dcb5174">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief5d0c9bb17948d6a1b2d29d6f8c062d_D20210104-20211003" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTMtNC0xLTEtMA_aa8d0950-9e3f-421a-9c19-2ded3ab6f4f9">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8470a3d16a94257810c1ec46751fcbd_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTMtNS0xLTEtMA_3feb889b-df4a-42c2-a940-827422c862c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4caee55e84fdb8343347b7638a55e_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTMtNi0xLTEtMA_94088f67-e966-4494-ba73-b821dfb6f4bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e79014ed177468abd91b03922e18af0_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTMtNy0xLTEtMA_58bb2287-6566-4f73-9ecf-09ebf9cf8e1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8df8e17a0f46c78ae91bd6ad3784ba_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTMtOC0xLTEtMA_90c7b878-cb34-4245-9328-58f9709e9f9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b9ff999f4544965b285cfeb8d1a0cb1_D20191230-20200927" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTMtOS0xLTEtMA_e742c30d-985c-4e82-8dc7-167f0c220077">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bf2c274ee034f6688bb999de3bbb518_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTMtMTAtMS0xLTA_dc6d25db-c1f2-4ced-a30c-ffd1b9d6173b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0141e2177d24be384d24197d458ffe0_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTQtMS0xLTEtMA_7527370e-a51e-41c6-b2a3-d78fdb7f7a32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6256db6dc0054ac18b141ae33e5ad29f_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTQtMi0xLTEtMA_8fe53f45-a9e9-489c-96bf-aca5e89d71b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8631e8b6ef484669be037922391c299d_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTQtMy0xLTEtMA_c745511c-aaaf-4f15-8a1e-a134c1294fb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief5d0c9bb17948d6a1b2d29d6f8c062d_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTQtNC0xLTEtMA_6fc8747c-5f84-444a-9c51-8dbbaace6c9c">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8470a3d16a94257810c1ec46751fcbd_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTQtNS0xLTEtMA_71bd4a28-7bb9-4112-9dcc-414cb534f2b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4caee55e84fdb8343347b7638a55e_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTQtNi0xLTEtMA_4c86d36f-a8ae-4064-bb93-01ee7b821a03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e79014ed177468abd91b03922e18af0_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTQtNy0xLTEtMA_64179806-be19-44a4-be12-eb2cdc9daab4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8df8e17a0f46c78ae91bd6ad3784ba_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTQtOC0xLTEtMA_4242054a-cf22-456f-bb08-7a9f111215f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b9ff999f4544965b285cfeb8d1a0cb1_D20191230-20200927" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTQtOS0xLTEtMA_b6a83967-9c61-4a00-9aff-03e619f1c50d">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bf2c274ee034f6688bb999de3bbb518_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTQtMTAtMS0xLTA_b5fb8f8a-bd92-4286-9dfd-2f997907b934">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8602046a27c64bd4926512027a77764a_D20210104-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTgtMS0xLTEtMA_5251c55c-e861-4cfd-b5e7-5704584b1396">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18cce9dd23084ad68d56d277f4166138_D20210104-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTgtMi0xLTEtMA_e2037964-ba40-4983-99bf-e3b1d628400b">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25b25621104941d6a59c689bab906bf4_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTgtMy0xLTEtMA_d1189ab4-9fdb-4e83-97b0-84b7d0f21b23">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f27a2322ca147eab04beab15bad4715_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTgtNC0xLTEtMA_212cc9b3-a8a9-4905-9f5a-73bc83ad8af6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3020bbfcfb1340499dec1be0f710b954_D20210104-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTgtNS0xLTEtMA_5cf6c21e-75de-49ea-a4a7-3299ba3e8896">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99def0c623bf49c58f2cce64717f9eae_D20191230-20200927" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTgtNi0xLTEtMA_fa8893e9-dfbe-4a98-9104-d65fb6f9673d">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iafca8a975c524aedb162430401cc1a92_D20191230-20200927" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTgtNy0xLTEtMA_ce7a49d4-5df2-4110-8e83-602171b13d04">316</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id40428336fe54fb0b1d61580ad3f301d_D20191230-20200927" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTgtOC0xLTEtMA_4a7bd98c-8cb8-4474-8fb4-9bff65121c67">121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855c33350d7746598cba6771e22ebcc2_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTgtOS0xLTEtMA_d77d395e-1b73-41c0-81ea-1b65d4b3d0da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b00628ead94443b3f921a3a6d612de_D20191230-20200927" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTgtMTAtMS0xLTA_116adcdf-de9e-4569-9f69-11b78a71f344">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8602046a27c64bd4926512027a77764a_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjItMS0xLTEtMA_d27b5a72-1bd5-477a-ac41-01a47f361538">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18cce9dd23084ad68d56d277f4166138_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjItMi0xLTEtMA_5d804c91-f26f-47dd-8e43-cecc77e56710">398</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25b25621104941d6a59c689bab906bf4_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjItMy0xLTEtMA_db4b82aa-7ae0-4682-b94e-38c9bd769c9e">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f27a2322ca147eab04beab15bad4715_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjItNC0xLTEtMA_6cafb1af-15df-442b-af2c-6b1686d31fbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3020bbfcfb1340499dec1be0f710b954_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjItNS0xLTEtMA_f7e3b155-33d4-481e-a9bb-f04d40f9d88e">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99def0c623bf49c58f2cce64717f9eae_D20191230-20200927" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjItNi0xLTEtMA_a52ec858-bd89-4bfb-aec9-06607ea8e553">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafca8a975c524aedb162430401cc1a92_D20191230-20200927" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjItNy0xLTEtMA_20ae629d-b185-4568-b731-dc1a23cbe5be">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id40428336fe54fb0b1d61580ad3f301d_D20191230-20200927" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjItOC0xLTEtMA_e4e0911a-d88e-4398-808f-5e21d15f10f9">156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855c33350d7746598cba6771e22ebcc2_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjItOS0xLTEtMA_ddb79b6f-1276-4292-9ae5-c559b29cbd9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b00628ead94443b3f921a3a6d612de_D20191230-20200927" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjItMTAtMS0xLTA_d04da86c-2df2-4c09-8622-98621f387d53">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94250734c05f4e5ab67af91d5851ea23_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjUtMS0xLTEtMA_d1a46a2a-cc20-4352-aad4-f69377fe83c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib79aa24edb5c4b0589f5ba2b11f35226_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjUtMi0xLTEtMA_35c5b191-3104-4070-b66b-c396319e97ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia495e7b3f52a4352880c86434b292e22_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjUtMy0xLTEtMA_4d83752d-46d3-40a9-b53d-603188c41886">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a3574762e24474f8b845e390fc8124e_D20210104-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjUtNC0xLTEtMA_89fb34b2-9ae2-4466-9fca-36309fa85b69">307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ad3f15a27f44939475bb5617afa269_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjUtNS0xLTEtMA_38765d70-aea0-4496-8222-8d3caeaaa90d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aec662a2dab41b5ab3eec8dd912eb2c_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjUtNi0xLTEtMA_a80a8b7d-0fb4-42e5-9438-69f076d20895">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie697d1e6b84a4b06b358ed0548d7499d_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjUtNy0xLTEtMA_0e81a670-9448-4992-83de-4529f875e38d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1e60dc0c01d47d1955296c160459cb5_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjUtOC0xLTEtMA_f9125486-3f1f-49b2-b766-6f3c29fe0219">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a1ff01920b54a71b8bdeb95dd658754_D20191230-20200927" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjUtOS0xLTEtMA_a2fd1c22-d496-48c7-b540-85a03ce7930a">265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id36f5e85786140ebaab64dfb8e6e1c3a_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjUtMTAtMS0xLTA_f2ea970b-7950-4b72-8f05-8c54ca33b333">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94250734c05f4e5ab67af91d5851ea23_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjctMS0xLTEtMA_2df4426f-7ed1-446e-968a-4cca3e54c350">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib79aa24edb5c4b0589f5ba2b11f35226_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjctMi0xLTEtMA_9110f826-aa04-4684-ab44-2b0c10d4339d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia495e7b3f52a4352880c86434b292e22_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjctMy0xLTEtMA_80485153-890a-4bb5-97d5-6ab0886cee4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a3574762e24474f8b845e390fc8124e_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjctNC0xLTEtMA_976065ff-e74e-4f46-bda1-08bd5fd282be">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ad3f15a27f44939475bb5617afa269_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjctNS0xLTEtMA_be8c9189-4a6a-4b3d-bfd0-396729d09499">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aec662a2dab41b5ab3eec8dd912eb2c_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjctNi0xLTEtMA_92294dfa-eb89-408c-93da-53f98cdef8a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie697d1e6b84a4b06b358ed0548d7499d_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjctNy0xLTEtMA_292c0ac6-9164-44af-b7fb-f1c43cf0a6af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1e60dc0c01d47d1955296c160459cb5_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjctOC0xLTEtMA_d8cc8880-987c-4198-a8e1-60666393ec5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a1ff01920b54a71b8bdeb95dd658754_D20191230-20200927" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjctOS0xLTEtMA_0ad2e3d5-ca97-4433-87cf-8c88a6a737e7">790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id36f5e85786140ebaab64dfb8e6e1c3a_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjctMTAtMS0xLTA_9f31fc29-65d7-46a5-bc64-41d977e07ffc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-bottom:7pt"><span><br/></span></div><ix:continuation id="iaa98ba5f4ad34e61a2e7b6fecae390f2" continuedAt="if52114a8e37c4446aff8cd964bf5ef7a"><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTE5ODA_2bb66144-ae52-4028-900c-d29c4bb0d55c" escape="true"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of  October&#160;3, 2021, and January&#160;3, 2021, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges </span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Line item in the Consolidated Balance Sheet in which the hedged item is included</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount of the Hedged Liability<br/></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba61370bc5134de1ba733b99d4caa214_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjgxNWZkY2UyMWJhMjRiN2Y5YjdhZjY3MDkxNDJjMGNiL3RhYmxlcmFuZ2U6ODE1ZmRjZTIxYmEyNGI3ZjliN2FmNjcwOTE0MmMwY2JfNC0yLTEtMS0w_b32b3c82-a6bb-4fe1-b296-ae99e2983738">9,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i547a7a9339204ab39e0413979ed1a2ab_I20210103" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjgxNWZkY2UyMWJhMjRiN2Y5YjdhZjY3MDkxNDJjMGNiL3RhYmxlcmFuZ2U6ODE1ZmRjZTIxYmEyNGI3ZjliN2FmNjcwOTE0MmMwY2JfNC00LTEtMS0w_48862646-b87a-4d7b-bc27-fede8beb2087">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba61370bc5134de1ba733b99d4caa214_I20211003" decimals="-6" sign="-" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjgxNWZkY2UyMWJhMjRiN2Y5YjdhZjY3MDkxNDJjMGNiL3RhYmxlcmFuZ2U6ODE1ZmRjZTIxYmEyNGI3ZjliN2FmNjcwOTE0MmMwY2JfNC02LTEtMS0w_8ffd8a66-e5db-445f-9703-f8eb05031dd2">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i547a7a9339204ab39e0413979ed1a2ab_I20210103" decimals="-6" format="ixt:fixed-zero" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjgxNWZkY2UyMWJhMjRiN2Y5YjdhZjY3MDkxNDJjMGNiL3RhYmxlcmFuZ2U6ODE1ZmRjZTIxYmEyNGI3ZjliN2FmNjcwOTE0MmMwY2JfNC04LTEtMS0w_f5222432-bbf0-41e0-8de0-f8b6942207c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTE5OTY_083b9f5d-262b-40ca-8dfb-9bd8a97a9462" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of derivatives not designated as hedging instruments for the fiscal third quarters and fiscal nine months in 2021 and 2020: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.010%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.277%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain /(Loss) Recognized in Income on Derivative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2835247bbd164156ac697a316626d4b8_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjNlYTY1YzkxZGQ1NDQ1Yzg5NWU5Zjk0Y2U4ZjkyZjVhL3RhYmxlcmFuZ2U6M2VhNjVjOTFkZDU0NDVjODk1ZTlmOTRjZThmOTJmNWFfNC00LTEtMS0w_07f7d0be-222e-4a7a-8f48-8026addc2266">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief9761af24a4460ea012090015fb22ae_D20200629-20200927" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjNlYTY1YzkxZGQ1NDQ1Yzg5NWU5Zjk0Y2U4ZjkyZjVhL3RhYmxlcmFuZ2U6M2VhNjVjOTFkZDU0NDVjODk1ZTlmOTRjZThmOTJmNWFfNC02LTEtMS0w_3a1b3832-a94c-4c90-a590-b205d33a6d5c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e0ead4649b4a7a87dc1937b5e8d0ce_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjNlYTY1YzkxZGQ1NDQ1Yzg5NWU5Zjk0Y2U4ZjkyZjVhL3RhYmxlcmFuZ2U6M2VhNjVjOTFkZDU0NDVjODk1ZTlmOTRjZThmOTJmNWFfNC03LTEtMS0w_3981c8d9-d34c-4978-8239-4dd2db14835b">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d4896777472483c91059e670b9b3b89_D20191230-20200927" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjNlYTY1YzkxZGQ1NDQ1Yzg5NWU5Zjk0Y2U4ZjkyZjVhL3RhYmxlcmFuZ2U6M2VhNjVjOTFkZDU0NDVjODk1ZTlmOTRjZThmOTJmNWFfNC05LTEtMS0w_48ff9dd2-54be-42d0-a5b0-b3e70af2717c">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><ix:continuation id="i6e026f55a67c4f7aa4784063006a5c70"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of net investment hedges for the fiscal third quarters ended in 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.610%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.959%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated<br/>OCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 27, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjQ5N2NmYzBiOWI2ZDRjZDJiODBkMjM4YTViZTZiNGUzL3RhYmxlcmFuZ2U6NDk3Y2ZjMGI5YjZkNGNkMmI4MGQyMzhhNWJlNmI0ZTNfMy0yLTEtMS0w_1291393e-1efa-45a9-8af4-37c5278a726a">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjQ5N2NmYzBiOWI2ZDRjZDJiODBkMjM4YTViZTZiNGUzL3RhYmxlcmFuZ2U6NDk3Y2ZjMGI5YjZkNGNkMmI4MGQyMzhhNWJlNmI0ZTNfMy00LTEtMS0w_8d69938c-343a-4c36-80d0-cb479d5c9ed0">169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i086fb509c2da43bdbf100b4f08fd1272_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjQ5N2NmYzBiOWI2ZDRjZDJiODBkMjM4YTViZTZiNGUzL3RhYmxlcmFuZ2U6NDk3Y2ZjMGI5YjZkNGNkMmI4MGQyMzhhNWJlNmI0ZTNfMy04LTEtMS0w_487a23a4-e609-4c2a-8e9d-109417011c07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a83ab881bc04e018d1d2f066bc40669_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjQ5N2NmYzBiOWI2ZDRjZDJiODBkMjM4YTViZTZiNGUzL3RhYmxlcmFuZ2U6NDk3Y2ZjMGI5YjZkNGNkMmI4MGQyMzhhNWJlNmI0ZTNfMy0xMC0xLTEtMA_b1c4b2fc-c11a-441f-8ec1-01b8e81ec1c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib65942949a8b4ab2858ac418b39805b8_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjQ5N2NmYzBiOWI2ZDRjZDJiODBkMjM4YTViZTZiNGUzL3RhYmxlcmFuZ2U6NDk3Y2ZjMGI5YjZkNGNkMmI4MGQyMzhhNWJlNmI0ZTNfNC0yLTEtMS0w_736524dc-bb09-413a-b8bc-651a64f25fad">141</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12239b7d99e147329855a8ae0ec87490_D20200629-20200927" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjQ5N2NmYzBiOWI2ZDRjZDJiODBkMjM4YTViZTZiNGUzL3RhYmxlcmFuZ2U6NDk3Y2ZjMGI5YjZkNGNkMmI4MGQyMzhhNWJlNmI0ZTNfNC00LTEtMS0w_8b24d7b1-d683-43d2-8f1d-ecdcd88781a4">234</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib42b4b45f7a24a98ab6f6f966bf2ff2f_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjQ5N2NmYzBiOWI2ZDRjZDJiODBkMjM4YTViZTZiNGUzL3RhYmxlcmFuZ2U6NDk3Y2ZjMGI5YjZkNGNkMmI4MGQyMzhhNWJlNmI0ZTNfNC04LTEtMS0w_7a79c287-574b-465d-97f6-8ece46c22d35">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3dc535bc03400d84053d66430136d1_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjQ5N2NmYzBiOWI2ZDRjZDJiODBkMjM4YTViZTZiNGUzL3RhYmxlcmFuZ2U6NDk3Y2ZjMGI5YjZkNGNkMmI4MGQyMzhhNWJlNmI0ZTNfNC0xMC0xLTEtMA_2b49839f-e280-4f1b-a2f6-feb34621bf77">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of net investment hedges for the fiscal nine months ended in 2021 and 2020:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:24.725%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.265%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="33" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated OCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 27, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmQ3NjY4YmVkNmVkODRmOTVhN2Y0MDc1YThjODRhYjk1L3RhYmxlcmFuZ2U6ZDc2NjhiZWQ2ZWQ4NGY5NWE3ZjQwNzVhOGM4NGFiOTVfMy0yLTEtMS0w_7bb6c557-20f0-48a1-ba50-50c4354017a3">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmQ3NjY4YmVkNmVkODRmOTVhN2Y0MDc1YThjODRhYjk1L3RhYmxlcmFuZ2U6ZDc2NjhiZWQ2ZWQ4NGY5NWE3ZjQwNzVhOGM4NGFiOTVfMy00LTEtMS0w_fec84799-3a8f-452b-aa53-21fde59fb795">217</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342e3f1749ef42f4a46139b2cb020f4f_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmQ3NjY4YmVkNmVkODRmOTVhN2Y0MDc1YThjODRhYjk1L3RhYmxlcmFuZ2U6ZDc2NjhiZWQ2ZWQ4NGY5NWE3ZjQwNzVhOGM4NGFiOTVfMy04LTEtMS0w_8e383e3e-1b6d-496c-99a1-c341f1ec7f19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba821c9267974930aa7f53fa5bcdb8c5_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmQ3NjY4YmVkNmVkODRmOTVhN2Y0MDc1YThjODRhYjk1L3RhYmxlcmFuZ2U6ZDc2NjhiZWQ2ZWQ4NGY5NWE3ZjQwNzVhOGM4NGFiOTVfMy0xMC0xLTEtMA_940e950b-bfb2-4636-9efc-fe3a86f459d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id49fbada050b40ec920b3e2ec7d1b351_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmQ3NjY4YmVkNmVkODRmOTVhN2Y0MDc1YThjODRhYjk1L3RhYmxlcmFuZ2U6ZDc2NjhiZWQ2ZWQ4NGY5NWE3ZjQwNzVhOGM4NGFiOTVfNC0yLTEtMS0w_376684ac-51eb-4ebb-abb5-4c1b9a917db8">432</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i864a93092b7f471e9b3af685acca4202_D20191230-20200927" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmQ3NjY4YmVkNmVkODRmOTVhN2Y0MDc1YThjODRhYjk1L3RhYmxlcmFuZ2U6ZDc2NjhiZWQ2ZWQ4NGY5NWE3ZjQwNzVhOGM4NGFiOTVfNC00LTEtMS0w_8efef742-cb73-4b29-88ba-bf54f8ba5ffa">407</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52e8eabf585e41898fda5db69bd674df_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmQ3NjY4YmVkNmVkODRmOTVhN2Y0MDc1YThjODRhYjk1L3RhYmxlcmFuZ2U6ZDc2NjhiZWQ2ZWQ4NGY5NWE3ZjQwNzVhOGM4NGFiOTVfNC04LTEtMS0w_760e851d-248d-4ba9-b99b-631e32ed74dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i380144a9a9fa42fd8158904a1c5d0700_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmQ3NjY4YmVkNmVkODRmOTVhN2Y0MDc1YThjODRhYjk1L3RhYmxlcmFuZ2U6ZDc2NjhiZWQ2ZWQ4NGY5NWE3ZjQwNzVhOGM4NGFiOTVfNC0xMC0xLTEtMA_a1a10200-3b62-4a9c-a2fd-d5ba193b507a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values.  The Company has elected to measure equity investments that do not have readily determinable fair </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="if52114a8e37c4446aff8cd964bf5ef7a" continuedAt="ic3789dc30c6b425b82ce852bff9d1abc"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTE5NTc_9d48c088-df39-41d9-b23d-c3e31d453523" escape="true"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:25.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.464%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales/ Purchases/Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c668ea680234cec82c45cb5e0c7a70c_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmUxZWYxNGI3Y2ZmZDQwZTM5YTQ2Y2EyYWU3M2M1YTg3L3RhYmxlcmFuZ2U6ZTFlZjE0YjdjZmZkNDBlMzlhNDZjYTJhZTczYzVhODdfMi0yLTEtMS0w_e6dcf1bb-c190-41ab-9835-fcd6a81382b5">1,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie922169de489430ca26a82b6556fdcbc_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:EquityFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmUxZWYxNGI3Y2ZmZDQwZTM5YTQ2Y2EyYWU3M2M1YTg3L3RhYmxlcmFuZ2U6ZTFlZjE0YjdjZmZkNDBlMzlhNDZjYTJhZTczYzVhODdfMi00LTEtMS0w_5d4b6bbd-662c-4cc5-8147-b7bc676c45f7">83</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie922169de489430ca26a82b6556fdcbc_D20210104-20211003" decimals="-6" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmUxZWYxNGI3Y2ZmZDQwZTM5YTQ2Y2EyYWU3M2M1YTg3L3RhYmxlcmFuZ2U6ZTFlZjE0YjdjZmZkNDBlMzlhNDZjYTJhZTczYzVhODdfMi02LTEtMS0w_45c827e4-d2ab-4d57-976f-2818a4a034f7">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eb1c56e86814746bc74797880579d47_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmUxZWYxNGI3Y2ZmZDQwZTM5YTQ2Y2EyYWU3M2M1YTg3L3RhYmxlcmFuZ2U6ZTFlZjE0YjdjZmZkNDBlMzlhNDZjYTJhZTczYzVhODdfMi04LTEtMS0w_980f7d4a-3fc2-4239-8da8-46d53f96c0f4">1,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eb1c56e86814746bc74797880579d47_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmUxZWYxNGI3Y2ZmZDQwZTM5YTQ2Y2EyYWU3M2M1YTg3L3RhYmxlcmFuZ2U6ZTFlZjE0YjdjZmZkNDBlMzlhNDZjYTJhZTczYzVhODdfMi0xMC0xLTEtMA_de978946-56f5-4564-822b-5ea6e448d445">1,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9a3a355d8f84cf5bf2f61990c01ad9a_I20210103" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmUxZWYxNGI3Y2ZmZDQwZTM5YTQ2Y2EyYWU3M2M1YTg3L3RhYmxlcmFuZ2U6ZTFlZjE0YjdjZmZkNDBlMzlhNDZjYTJhZTczYzVhODdfNC0yLTEtMS0w_fdd7bd95-6a94-4b2e-92e3-250e57a32cb9">738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95fcc9c6ec43e28079e110635c1c3e_D20210104-20211003" decimals="-6" name="us-gaap:EquityFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmUxZWYxNGI3Y2ZmZDQwZTM5YTQ2Y2EyYWU3M2M1YTg3L3RhYmxlcmFuZ2U6ZTFlZjE0YjdjZmZkNDBlMzlhNDZjYTJhZTczYzVhODdfNC00LTEtMS0w_51ee633b-0d85-43fd-94f1-964389a2840f">392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied95fcc9c6ec43e28079e110635c1c3e_D20210104-20211003" decimals="-6" sign="-" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmUxZWYxNGI3Y2ZmZDQwZTM5YTQ2Y2EyYWU3M2M1YTg3L3RhYmxlcmFuZ2U6ZTFlZjE0YjdjZmZkNDBlMzlhNDZjYTJhZTczYzVhODdfNC02LTEtMS0w_b83d4150-25c2-48d8-8521-13a0500993c1">545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e894ed981be4116a2355b4062397ba2_I20211003" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmUxZWYxNGI3Y2ZmZDQwZTM5YTQ2Y2EyYWU3M2M1YTg3L3RhYmxlcmFuZ2U6ZTFlZjE0YjdjZmZkNDBlMzlhNDZjYTJhZTczYzVhODdfNC04LTEtMS0w_c445b77b-7d83-4bf3-82e4-bafc877ddeaa">585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e894ed981be4116a2355b4062397ba2_I20211003" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmUxZWYxNGI3Y2ZmZDQwZTM5YTQ2Y2EyYWU3M2M1YTg3L3RhYmxlcmFuZ2U6ZTFlZjE0YjdjZmZkNDBlMzlhNDZjYTJhZTczYzVhODdfNC0xMC0xLTEtMA_1057e139-e932-41ba-9eab-148c01f49a9b">585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded in Other Income/Expense</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other includes impact of currency</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity investments without readily determinable market values, there was a decrease of $<ix:nonFraction unitRef="usd" contextRef="ied95fcc9c6ec43e28079e110635c1c3e_D20210104-20211003" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="jnj:EquityFairValueAdjustmentImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfNjcwNg_564aed71-c387-4c9b-af45-6710d5ad3753">25</ix:nonFraction> million in the fair value reflected in net income as a result of impairments. There was an offsetting increase of  $<ix:nonFraction unitRef="usd" contextRef="if3dd051494d44e5a963f074248d0e103_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquityFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfNjgxMA_0b0145bf-6c7a-47cb-a5f0-200e55643b2b">417</ix:nonFraction> million in the fair value reflected in net income due to changes in observable prices and gains on the disposal of the Grail investment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#8217;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following three levels of inputs are used to measure fair value:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8212; Quoted prices in active markets for identical assets and liabilities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8212; Significant other observable inputs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8212; Significant unobservable inputs.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="ic3789dc30c6b425b82ce852bff9d1abc" continuedAt="i1683b918b3f34e748a5b5e810d2a5200"><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTE5NjI_5e4c9c3a-3184-4a0b-a7d7-cb2722f0af50" continuedAt="i81e53d9078fb43fb84b31db95f60aa19" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of October&#160;3, 2021 and January&#160;3, 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:48.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia541a8d551c4468c8f6e756afd118e10_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNC0yLTEtMS0w_c498ee71-4eb6-4486-8cde-bfac7a29a5ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia929718f7d4b44af9534961189e19b18_I20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNC00LTEtMS0w_7cd2a826-d69e-4ae9-935d-d684f8151c1b">459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c61c290cdfa47aa90f28583b201ca61_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNC02LTEtMS0w_efe413ec-22cc-4545-9be8-7f0086adfea0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i386cee1639274652826fd3eed1982a70_I20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNC04LTEtMS0w_5b64a571-f03f-4522-9c22-302f3a7a7a38">459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia918a096df5248d794e6e608f618f2d3_I20210103" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNC0xMC0xLTEtMA_c637db46-5f62-4832-bf3f-b4a13ba82055">849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd29fe7311d4c0f9fccaf4d085f95c5_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNS0yLTEtMS0w_c761f7ba-152f-426c-930d-e779a594b246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8bf2953dcaf482eabe10bcdb5890292_I20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNS00LTEtMS0w_a9f375ae-cc1b-4384-84dc-744cd041b6b6">707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cc97e40d3d4405d9a96f873abcd8d6e_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNS02LTEtMS0w_9ac91514-4576-4c94-81e0-43bf157c6aeb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31ec175a56664fa0bd90af394bda5a04_I20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNS04LTEtMS0w_45c7a232-e068-41e3-a552-3765a28d8f71">707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cf8d2cf87a94bf7a55afbbff98f5daf_I20210103" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNS0xMC0xLTEtMA_73c8df2a-9c9a-4b4b-8429-3ac2e546017b">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cb46a97d3b4230ae9dcca4c2069fb6_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNy0yLTEtMS0w_2cee88cb-a0a8-46af-8815-8dde7e0931bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b78f843aa1346368fb728d955f6da33_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNy00LTEtMS0w_c12aec86-e5f5-4bba-9562-26b77fc2ae0f">1,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9e29ba46f0d4a8bb33c9e8eb07ffda5_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNy02LTEtMS0w_7700403e-e978-4619-9d2f-a7c0ff250ac0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNy04LTEtMS0w_b147a9b5-be51-45c4-a62a-6a6c9214e371">1,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if00b7b3746e54851b72fa7817a56cc7e_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNy0xMC0xLTEtMA_c6af76dc-415e-46be-8a28-adb01d372ddd">1,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia541a8d551c4468c8f6e756afd118e10_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfOS0yLTEtMS0w_5762332d-a355-4929-923e-4415b53ce9bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia929718f7d4b44af9534961189e19b18_I20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfOS00LTEtMS0w_595f4115-dbc1-45cd-9371-275aa9d0cb4a">768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c61c290cdfa47aa90f28583b201ca61_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfOS02LTEtMS0w_2b33f432-7f1d-488d-92a9-ec71d66bb40c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i386cee1639274652826fd3eed1982a70_I20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfOS04LTEtMS0w_c8340f8b-cf57-4075-b6c7-9cb2a07ddd9d">768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia918a096df5248d794e6e608f618f2d3_I20210103" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfOS0xMC0xLTEtMA_2292573f-e9e5-4e67-bfb2-2879e970ab6c">702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd29fe7311d4c0f9fccaf4d085f95c5_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTAtMi0xLTEtMA_416fe610-91f7-4d6b-9c72-d9ab8eb896ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8bf2953dcaf482eabe10bcdb5890292_I20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTAtNC0xLTEtMA_91b5622a-195f-4492-b3f4-e2092a9cb9f0">468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cc97e40d3d4405d9a96f873abcd8d6e_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTAtNi0xLTEtMA_583fdc69-ba29-4b91-9b7f-90c67965a4c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31ec175a56664fa0bd90af394bda5a04_I20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTAtOC0xLTEtMA_584bd24c-c551-40e5-8fa5-bbe78798f3b4">468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cf8d2cf87a94bf7a55afbbff98f5daf_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTAtMTAtMS0xLTA_9ce1979d-7dbe-4ba9-86a6-2a2f524f7477">1,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cb46a97d3b4230ae9dcca4c2069fb6_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTItMi0xLTEtMA_db1673d5-5bc0-4a43-ab8d-a72d968a582d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b78f843aa1346368fb728d955f6da33_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTItNC0xLTEtMA_31cb1686-4bc1-46c5-a43e-e68cc97ed07b">1,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9e29ba46f0d4a8bb33c9e8eb07ffda5_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTItNi0xLTEtMA_224e3e35-4ba8-4bb0-9d25-30eb27620e15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTItOC0xLTEtMA_07126f6b-57b0-4764-8039-38b3fe4c298c">1,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if00b7b3746e54851b72fa7817a56cc7e_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTItMTAtMS0xLTA_c6cc2dd8-0f3e-400c-acbd-8cb5bcab0cc0">2,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia541a8d551c4468c8f6e756afd118e10_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTUtMi0xLTEtMA_39b3c0fb-577f-482b-82fd-9fec887c3d0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia929718f7d4b44af9534961189e19b18_I20211003" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTUtNC0xLTEtMA_9ca57968-4450-46cc-ab09-1f8321fe5007">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c61c290cdfa47aa90f28583b201ca61_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTUtNi0xLTEtMA_c19dabf3-433a-4a97-8bd7-859406d6b5df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i386cee1639274652826fd3eed1982a70_I20211003" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTUtOC0xLTEtMA_ac8e2452-9955-42ad-bdcd-8290a6af2fc4">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia918a096df5248d794e6e608f618f2d3_I20210103" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTUtMTAtMS0xLTA_f9c5a8d3-45eb-4e92-b01b-1fceb8ca15a1">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia541a8d551c4468c8f6e756afd118e10_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTctMi0xLTEtMA_b7d387fb-dc68-4dbf-b2cd-5a85eb268ba8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia929718f7d4b44af9534961189e19b18_I20211003" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTctNC0xLTEtMA_f8303819-df0a-4ef6-82df-e91c1ce330c8">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c61c290cdfa47aa90f28583b201ca61_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTctNi0xLTEtMA_59909c96-25b0-410f-867b-8a06d433c4a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i386cee1639274652826fd3eed1982a70_I20211003" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTctOC0xLTEtMA_03ac9072-3210-4d6a-ba63-81bef9b5783f">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia918a096df5248d794e6e608f618f2d3_I20210103" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTctMTAtMS0xLTA_5e882cdf-7737-4fd6-ae49-8afd3be395b6">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cb46a97d3b4230ae9dcca4c2069fb6_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTktMi0xLTEtMA_42f18d14-6178-4751-bbd0-1b6a110ae84f">1,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b78f843aa1346368fb728d955f6da33_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTktNC0xLTEtMA_25560207-8b64-49ce-af5d-ebb578e16bd3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9e29ba46f0d4a8bb33c9e8eb07ffda5_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTktNi0xLTEtMA_be9a67ca-211f-488e-806c-ba0df95bcc21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTktOC0xLTEtMA_573185ef-7669-4a33-ad07-d35559d4548d">1,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTktMTAtMS0xLTA_a8e18dee-0065-47af-83d1-57ef37994a04">1,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cb46a97d3b4230ae9dcca4c2069fb6_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMjAtMi0xLTEtMA_5511efb8-f641-42f3-81c8-65891ace8db5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b78f843aa1346368fb728d955f6da33_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMjAtNC0xLTEtMA_e2f971ec-4c9a-480e-96c6-6bd43360649c">18,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9e29ba46f0d4a8bb33c9e8eb07ffda5_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMjAtNi0xLTEtMA_11956ab8-2ab2-4a64-94d8-71a504ab0aed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMjAtOC0xLTEtMA_d5f87f91-2a59-4f18-9fd7-e1cbeac64843">18,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMjAtMTAtMS0xLTA_2e53e11a-086b-4844-8791-2c52ebc9c8e5">14,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cb46a97d3b4230ae9dcca4c2069fb6_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMjItMi0xLTEtMA_c8e0caad-e99c-443a-9228-79e0713fa8ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b78f843aa1346368fb728d955f6da33_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMjItNC0xLTEtMA_6678ed36-d109-4d1e-a6ee-d01be66e2901">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9e29ba46f0d4a8bb33c9e8eb07ffda5_I20211003" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMjItNi0xLTEtMA_3969ad91-ecbf-4f82-b26d-0772a787e00d">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMjItOC0xLTEtMA_60eedf27-834b-4407-9b99-3edb6c7df9ad">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMjItMTAtMS0xLTA_ead9e491-e7af-4d6f-81e6-fcd27d3a4992">633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.318%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2Y2ODcxMWRiOTQ1MzBiMzg0NzdlYThmZDJiMTYxL3RhYmxlcmFuZ2U6MjdjZjY4NzExZGI5NDUzMGIzODQ3N2VhOGZkMmIxNjFfMi0yLTEtMS0w_b3da472c-72b0-4305-aafa-38c6ea843915">1,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2Y2ODcxMWRiOTQ1MzBiMzg0NzdlYThmZDJiMTYxL3RhYmxlcmFuZ2U6MjdjZjY4NzExZGI5NDUzMGIzODQ3N2VhOGZkMmIxNjFfMi00LTEtMS0w_ba850650-4780-4535-b783-c8dbcef73b71">1,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DerivativeAssetFairValueGrossLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2Y2ODcxMWRiOTQ1MzBiMzg0NzdlYThmZDJiMTYxL3RhYmxlcmFuZ2U6MjdjZjY4NzExZGI5NDUzMGIzODQ3N2VhOGZkMmIxNjFfMy0yLTEtMS0w_eb4bfd2c-4c6d-46e2-80c1-6eec402d6242">1,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DerivativeAssetFairValueGrossLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2Y2ODcxMWRiOTQ1MzBiMzg0NzdlYThmZDJiMTYxL3RhYmxlcmFuZ2U6MjdjZjY4NzExZGI5NDUzMGIzODQ3N2VhOGZkMmIxNjFfMy00LTEtMS0w_41840343-7733-47c2-a1ba-c86345ad272c">1,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2Y2ODcxMWRiOTQ1MzBiMzg0NzdlYThmZDJiMTYxL3RhYmxlcmFuZ2U6MjdjZjY4NzExZGI5NDUzMGIzODQ3N2VhOGZkMmIxNjFfNC0yLTEtMS0w_d6fb07b4-6e3c-4bcf-a102-66c7bc932828">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2Y2ODcxMWRiOTQ1MzBiMzg0NzdlYThmZDJiMTYxL3RhYmxlcmFuZ2U6MjdjZjY4NzExZGI5NDUzMGIzODQ3N2VhOGZkMmIxNjFfNC00LTEtMS0w_3ffb0f36-b0f9-4e33-bff2-0ef9628bc590">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2Y2ODcxMWRiOTQ1MzBiMzg0NzdlYThmZDJiMTYxL3RhYmxlcmFuZ2U6MjdjZjY4NzExZGI5NDUzMGIzODQ3N2VhOGZkMmIxNjFfNi0yLTEtMS0w_53003557-ae37-46d6-9da5-f16c57f4eb1e">1,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2Y2ODcxMWRiOTQ1MzBiMzg0NzdlYThmZDJiMTYxL3RhYmxlcmFuZ2U6MjdjZjY4NzExZGI5NDUzMGIzODQ3N2VhOGZkMmIxNjFfNi00LTEtMS0w_ab5fe651-235b-4dbe-b17d-62b5be0cb12f">2,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2Y2ODcxMWRiOTQ1MzBiMzg0NzdlYThmZDJiMTYxL3RhYmxlcmFuZ2U6MjdjZjY4NzExZGI5NDUzMGIzODQ3N2VhOGZkMmIxNjFfNy0yLTEtMS0w_4264d4ab-0212-4d56-b0c7-cfd224b4c271">1,260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2Y2ODcxMWRiOTQ1MzBiMzg0NzdlYThmZDJiMTYxL3RhYmxlcmFuZ2U6MjdjZjY4NzExZGI5NDUzMGIzODQ3N2VhOGZkMmIxNjFfNy00LTEtMS0w_ab6921e5-8f29-4388-b967-5012da07c2ce">2,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2Y2ODcxMWRiOTQ1MzBiMzg0NzdlYThmZDJiMTYxL3RhYmxlcmFuZ2U6MjdjZjY4NzExZGI5NDUzMGIzODQ3N2VhOGZkMmIxNjFfOC0yLTEtMS0w_c9ab5edf-72e9-415e-8d27-a8e22fdf6634">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2Y2ODcxMWRiOTQ1MzBiMzg0NzdlYThmZDJiMTYxL3RhYmxlcmFuZ2U6MjdjZjY4NzExZGI5NDUzMGIzODQ3N2VhOGZkMmIxNjFfOC00LTEtMS0w_20019dea-e8fa-4d44-bc43-d4c29ccdc2fa">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><ix:continuation id="i1683b918b3f34e748a5b5e810d2a5200" continuedAt="iefd191d690244bd5b6c8d5e398eb2667"><ix:continuation id="i81e53d9078fb43fb84b31db95f60aa19" continuedAt="ib9ef7c3613c94586b520fbaf60ab63fd"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in liabilities for contingent consideration is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.807%"><tr><td style="width:1.0%"></td><td style="width:41.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.606%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.609%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 27, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmU3YzBlMzVmNDM4MTQ5M2U5Yzk1OTEzMjkzOGMxM2U1L3RhYmxlcmFuZ2U6ZTdjMGUzNWY0MzgxNDkzZTljOTU5MTMyOTM4YzEzZTVfMy0yLTEtMS0w_01b0cfa3-5ff3-4601-90fd-ee486829c1e3">633</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if49e94e75cf04169b3ef119b2c588a4c_I20191229" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmU3YzBlMzVmNDM4MTQ5M2U5Yzk1OTEzMjkzOGMxM2U1L3RhYmxlcmFuZ2U6ZTdjMGUzNWY0MzgxNDkzZTljOTU5MTMyOTM4YzEzZTVfMy00LTEtMS0w_11a52485-3286-4fdf-aeed-b7bddfa1452d">1,715</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" name="jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmU3YzBlMzVmNDM4MTQ5M2U5Yzk1OTEzMjkzOGMxM2U1L3RhYmxlcmFuZ2U6ZTdjMGUzNWY0MzgxNDkzZTljOTU5MTMyOTM4YzEzZTVfNC0yLTEtMS0w_858b3f3a-aa71-4be7-b5a8-9d2be351a275">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmU3YzBlMzVmNDM4MTQ5M2U5Yzk1OTEzMjkzOGMxM2U1L3RhYmxlcmFuZ2U6ZTdjMGUzNWY0MzgxNDkzZTljOTU5MTMyOTM4YzEzZTVfNC00LTEtMS0w_f8a08316-133f-449c-b991-32991b286634">1,088</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmU3YzBlMzVmNDM4MTQ5M2U5Yzk1OTEzMjkzOGMxM2U1L3RhYmxlcmFuZ2U6ZTdjMGUzNWY0MzgxNDkzZTljOTU5MTMyOTM4YzEzZTVfNS0yLTEtMS0w_b71c7685-af69-413a-9371-5100e90c3526">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmU3YzBlMzVmNDM4MTQ5M2U5Yzk1OTEzMjkzOGMxM2U1L3RhYmxlcmFuZ2U6ZTdjMGUzNWY0MzgxNDkzZTljOTU5MTMyOTM4YzEzZTVfNS00LTEtMS0w_13319de5-ad10-48de-a892-76b71067fd59">107</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmU3YzBlMzVmNDM4MTQ5M2U5Yzk1OTEzMjkzOGMxM2U1L3RhYmxlcmFuZ2U6ZTdjMGUzNWY0MzgxNDkzZTljOTU5MTMyOTM4YzEzZTVfNi0yLTEtMS0w_51617d4f-88df-46e4-b54e-80dd54b7eb5f">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmU3YzBlMzVmNDM4MTQ5M2U5Yzk1OTEzMjkzOGMxM2U1L3RhYmxlcmFuZ2U6ZTdjMGUzNWY0MzgxNDkzZTljOTU5MTMyOTM4YzEzZTVfNi00LTEtMS0w_c430c348-d325-454c-8fde-ca63aea6eed5">98</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmU3YzBlMzVmNDM4MTQ5M2U5Yzk1OTEzMjkzOGMxM2U1L3RhYmxlcmFuZ2U6ZTdjMGUzNWY0MzgxNDkzZTljOTU5MTMyOTM4YzEzZTVfNy0yLTEtMS0w_3503bfe2-320f-4000-80a4-8ae20f87b2db">613</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de10452fa98443a826d732ac5ecfcd4_I20200927" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmU3YzBlMzVmNDM4MTQ5M2U5Yzk1OTEzMjkzOGMxM2U1L3RhYmxlcmFuZ2U6ZTdjMGUzNWY0MzgxNDkzZTljOTU5MTMyOTM4YzEzZTVfNy00LTEtMS0w_83e9b8c2-96ba-4e62-87f2-1996c8aa2e85">636</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">2020 assets and liabilities are all classified as Level 2 with the exception of equity investments of $<ix:nonFraction unitRef="usd" contextRef="ibeca5e8660d14e0e95ab595851e5a044_I20210103" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfOTA2Mg_7c1b29fa-2120-4e0f-a811-6d78603efc47">1,481</ix:nonFraction> million, which are classified as Level 1 and contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="ib78fc1819e4c481fb01505843db10e28_I20210103" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfOTEzMA_45bbffeb-8812-4618-a43c-f6c8ad9b4b3b">633</ix:nonFraction> million, classified as Level 3.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes cross currency interest rate swaps and interest rate swaps as of October&#160;3, 2021. Includes cross currency interest rate swaps as of January&#160;3, 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classified as non-current other assets. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes $<ix:nonFraction unitRef="usd" contextRef="i5820db2145564d76a142f0b76e3fbff3_I20211003" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfOTQ0OQ_2242db00-8338-44d8-aeac-a05927e10be3">595</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iaed609fd41ee4cf9a82d74bf5e73e604_I20210103" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfOTQ2NA_59beabb0-3a8a-4970-84cc-a1464bf11f02">594</ix:nonFraction> million, classified as non-current other liabilities as of October&#160;3, 2021 and January&#160;3, 2021, respectively.  Includes $<ix:nonFraction unitRef="usd" contextRef="i831bedde345c419192edc69c0e317205_I20211003" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfOTU2MQ_5ae8d680-8d7a-4f79-9b7c-23c5d1da92ad">18</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2b704f7750e54b2c8511c93e87192817_I20210103" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfOTU3Ng_2ba7b8b1-1fe4-4055-8ec4-f7dfd0f65810">39</ix:nonFraction> million classified as current liabilities as of October&#160;3, 2021 and January&#160;3, 2021, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. </span></div></ix:continuation><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib9ef7c3613c94586b520fbaf60ab63fd">The Company recorded a contingent consideration reversal of $<ix:nonFraction unitRef="usd" contextRef="i771e5eadfd734fc987bf5ecca1178170_D20191230-20210103" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfOTgyOQ_aa50f694-e6e1-4683-af5d-43567fba2f67">1,148</ix:nonFraction> million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense, net.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTIwMTI_ce807754-e985-447f-b56a-fc99705fbe24" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cash, cash equivalents and current marketable securities as of October&#160;3, 2021 comprised:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:22.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.727%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.531%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.727%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.454%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.182%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Gain</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b7dc91718ce4ea0a9b05b4625568ef0_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMS0xLTEtMS0w_25481151-7d4c-4ee2-a235-e15a6c3f8e84">2,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b7dc91718ce4ea0a9b05b4625568ef0_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMS0zLTEtMS0w_3b475006-9da4-441c-a0af-1216088e6b0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b7dc91718ce4ea0a9b05b4625568ef0_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMS01LTEtMS0w_a6fbd57d-41b7-433d-9357-7b5537afceef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b7dc91718ce4ea0a9b05b4625568ef0_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMS03LTEtMS0w_aa7c2fce-d074-4102-87ab-0e20400e73ea">2,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b7dc91718ce4ea0a9b05b4625568ef0_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMS05LTEtMS0w_f44a4252-4741-48cc-a9ae-e6b9a0d2ab5c">2,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b7dc91718ce4ea0a9b05b4625568ef0_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMS0xMS0xLTEtMA_61de31f9-5170-472c-acb4-bda3d7287be0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. sovereign securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if293da93cdf44458a788e386d073f1ee_I20211003" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMy0xLTEtMS0w_172e8f87-2e3e-478b-81f5-493bd0861828">870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if293da93cdf44458a788e386d073f1ee_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMy0zLTEtMS0w_9eb6fa08-f668-4957-8f0d-06a3c16b8bc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if293da93cdf44458a788e386d073f1ee_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMy01LTEtMS0w_1c2445b1-b7d5-4c6e-a2dd-cf2d2e4c799f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if293da93cdf44458a788e386d073f1ee_I20211003" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMy03LTEtMS0w_b382a1c0-21ba-4feb-a0d9-edbe082c6002">870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if293da93cdf44458a788e386d073f1ee_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMy05LTEtMS0w_70208ffb-246f-4ed9-860e-8344f4265792">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if293da93cdf44458a788e386d073f1ee_I20211003" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMy0xMS0xLTEtMA_4b5f9a10-5f20-4007-8b36-0df165819ef9">870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. reverse repurchase agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dcb1b245fd240b0b488db669a604f22_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNC0xLTEtMS0w_d19aac48-d9f7-42f5-8734-c56d3784496f">1,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dcb1b245fd240b0b488db669a604f22_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNC0zLTEtMS0w_16ead62c-b0c1-4083-9ae6-5999ffba8d03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dcb1b245fd240b0b488db669a604f22_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNC01LTEtMS0w_489511fb-453c-4344-9263-0af71e68a3eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dcb1b245fd240b0b488db669a604f22_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNC03LTEtMS0w_9a8dd031-e524-4650-9483-92d4d1ae486f">1,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dcb1b245fd240b0b488db669a604f22_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNC05LTEtMS0w_2478fc64-453a-45cf-9200-d8861e83b85e">1,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dcb1b245fd240b0b488db669a604f22_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNC0xMS0xLTEtMA_9b2fad63-30e7-4d1b-9c60-6e90fa166d1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f73056213bc43fc94fc5c10e89df326_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNi0xLTEtMS0w_3ead6dbc-20bc-4e0f-9fba-c8810e47a11c">3,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f73056213bc43fc94fc5c10e89df326_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNi0zLTEtMS0w_fd8d32b4-36d4-46b7-bc20-62508a0485fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f73056213bc43fc94fc5c10e89df326_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNi01LTEtMS0w_d42e2a91-149e-4b7b-a352-dd46b3a3891e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f73056213bc43fc94fc5c10e89df326_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNi03LTEtMS0w_cf2e2a9d-6b4c-4eee-ba6c-c4017aae8f40">3,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f73056213bc43fc94fc5c10e89df326_I20211003" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNi05LTEtMS0w_a275d348-5520-4e26-98c4-b5c716d3a6b2">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f73056213bc43fc94fc5c10e89df326_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNi0xMS0xLTEtMA_3e8bf813-3bee-44c4-b89f-15adf0bf4fcf">3,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9385ca799d84dce96c2206ee78ac799_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNy0xLTEtMS0w_c1f4603f-765c-40e0-a64e-bfe5ab394d80">2,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9385ca799d84dce96c2206ee78ac799_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNy0zLTEtMS0w_fc006675-e1cb-48a3-934d-4ecb78ba6943">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9385ca799d84dce96c2206ee78ac799_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNy01LTEtMS0w_03d14b8c-79bc-4b87-83ed-94072a284d71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9385ca799d84dce96c2206ee78ac799_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNy03LTEtMS0w_0fcddb00-8664-4eed-b91c-b8bbcfa211b7">2,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9385ca799d84dce96c2206ee78ac799_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNy05LTEtMS0w_4f5ed5bc-bfe0-49db-a765-8e2efb0fb412">2,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9385ca799d84dce96c2206ee78ac799_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNy0xMS0xLTEtMA_af1cf1ec-6ffd-49b8-9c18-7fbb12577928">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic741579d386241e4bbf75342917d529a_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfOC0xLTEtMS0w_0cc6758d-6b96-4e7e-b339-a7d4fb4db419">1,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic741579d386241e4bbf75342917d529a_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfOC0zLTEtMS0w_9a98bfe1-6349-4393-a866-c4ce294f8975">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic741579d386241e4bbf75342917d529a_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfOC01LTEtMS0w_ac7b39aa-255d-492f-b43a-bca508fdee9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic741579d386241e4bbf75342917d529a_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfOC03LTEtMS0w_d7b883ff-1bed-48b0-80f2-4f69b58f518f">1,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic741579d386241e4bbf75342917d529a_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfOC05LTEtMS0w_5f9e48b7-1f4c-402b-9be7-2a4dc4629277">1,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic741579d386241e4bbf75342917d529a_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfOC0xMS0xLTEtMA_ca12bbf9-63c1-44fe-90f9-15bda0ea7752">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i009c78145cf74486a461497129412728_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfOS0xLTEtMS0w_f9b1fd3a-02a9-47c8-86a3-2d5499119d18">12,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i009c78145cf74486a461497129412728_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfOS0zLTEtMS0w_6cd74cb3-e667-4ee2-bd7e-b66c997bdc51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i009c78145cf74486a461497129412728_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfOS01LTEtMS0w_4d85c592-367a-4c2a-9a47-c0244b34ec55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i009c78145cf74486a461497129412728_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfOS03LTEtMS0w_06ae1467-59ca-4b7e-acca-b01e2f507746">12,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i009c78145cf74486a461497129412728_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfOS05LTEtMS0w_16d76ac5-33ad-4725-a26d-41440458a91d">7,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i009c78145cf74486a461497129412728_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfOS0xMS0xLTEtMA_84903d79-2acc-426a-a1e4-d15935a852b4">4,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fb649af90814478b37ac417cea6456b_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTItMS0xLTEtMA_a8dc87a1-50fa-44aa-9ccb-6d8ee8f71474">18,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fb649af90814478b37ac417cea6456b_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTItMy0xLTEtMA_e2649686-d2d9-4c17-8091-0c18add6e027">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fb649af90814478b37ac417cea6456b_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTItNS0xLTEtMA_c61c5f77-14eb-4fe9-a6b3-9179980fd109">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fb649af90814478b37ac417cea6456b_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTItNy0xLTEtMA_4a97af1b-016c-4602-ba07-225c7d64aa03">18,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fb649af90814478b37ac417cea6456b_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTItOS0xLTEtMA_22284493-4317-45c5-ad7c-76186feb8844">9,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fb649af90814478b37ac417cea6456b_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTItMTEtMS0xLTA_4367d0c8-08a0-4731-88c0-7a209ec04647">8,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other sovereign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9178d762f0634d6a894dd86815cf64ec_I20211003" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTMtMS0xLTEtMA_7c8156f0-0b4c-4173-a7f7-9a05e4bdfaa4">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9178d762f0634d6a894dd86815cf64ec_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTMtMy0xLTEtMA_1de5b3df-b966-4cbc-adda-4d6e4de7c8bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9178d762f0634d6a894dd86815cf64ec_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTMtNS0xLTEtMA_57bfcc42-5bbf-4146-86a0-f462fe473dba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9178d762f0634d6a894dd86815cf64ec_I20211003" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTMtNy0xLTEtMA_3fe50475-2c2d-4c0d-b30a-247b332f0591">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9178d762f0634d6a894dd86815cf64ec_I20211003" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTMtOS0xLTEtMA_90e684ed-b60f-448e-af1e-744affe822ae">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9178d762f0634d6a894dd86815cf64ec_I20211003" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTMtMTEtMS0xLTA_73ad1551-4c2e-4cb4-bc68-6749a451ffb4"><ix:nonFraction unitRef="usd" contextRef="i9178d762f0634d6a894dd86815cf64ec_I20211003" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTMtMTEtMS0xLTA_a8465f57-846c-4266-9be6-c241b94fc5e8">1</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id829f858995a40ed8f879e67456295cc_I20211003" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTQtMS0xLTEtMA_04594201-c0c6-4295-a7c3-f5eb95fdf65a">251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id829f858995a40ed8f879e67456295cc_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTQtMy0xLTEtMA_00c6fa3e-8f50-4312-b3cb-91149ae8babc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id829f858995a40ed8f879e67456295cc_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTQtNS0xLTEtMA_f450138d-fc9a-4573-ac70-6b72a0a14dd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id829f858995a40ed8f879e67456295cc_I20211003" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTQtNy0xLTEtMA_617ac279-f485-484a-a7bd-f3221ba0137b">251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id829f858995a40ed8f879e67456295cc_I20211003" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTQtOS0xLTEtMA_40625ad2-b7d8-4cf9-a70d-3e6a83ef6106">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id829f858995a40ed8f879e67456295cc_I20211003" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTQtMTEtMS0xLTA_4c227f9f-65ac-4f81-a9bc-0ad563624fa2">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal available for sale debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a81061eccb043c396dcd8d5162f888d_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTUtMS0xLTEtMA_7bb3fff3-1d0a-406c-8791-60ee4f6405d6">18,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a81061eccb043c396dcd8d5162f888d_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTUtMy0xLTEtMA_896511e1-dfb0-46a9-8c08-d2a2e7facb00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a81061eccb043c396dcd8d5162f888d_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTUtNS0xLTEtMA_a384813d-0400-4240-9c9d-b776257d4902">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a81061eccb043c396dcd8d5162f888d_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTUtNy0xLTEtMA_89acd65b-93f8-4b2b-bd24-5ac213d70a0c">18,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a81061eccb043c396dcd8d5162f888d_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTUtOS0xLTEtMA_41a26ebe-3771-43da-9b70-55f65a77243c">9,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a81061eccb043c396dcd8d5162f888d_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTUtMTEtMS0xLTA_d0560459-a950-4195-b3c0-e103f84b48a1">9,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTYtMS0xLTEtMA_5520b84e-e345-4a2e-90fb-0ea83e288879">31,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:fixed-zero" name="jnj:CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTYtMy0xLTEtMA_30c994a1-97f7-476d-92d7-8b7d1d72a3e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:fixed-zero" name="jnj:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTYtNS0xLTEtMA_8ee94b6d-3385-44c3-ad4f-38c825ed0efd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="jnj:CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTYtNy0xLTEtMA_923ef579-0ea0-4773-9b3b-ad948b0269e3">31,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTYtOS0xLTEtMA_4150bc6a-22dd-49b8-b926-77d2b881f2b3">17,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTYtMTEtMS0xLTA_709fc213-1258-49d4-963d-e6242626a4f2">13,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="iefd191d690244bd5b6c8d5e398eb2667" continuedAt="iaa370d695d9e4e6d96ef8bbc9db3719b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the fiscal year ended January&#160;3, 2021 the carrying amount was approximately the same as the estimated fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTE5OTM_a7848b96-e8b8-4616-9caf-993961691cc7" escape="true">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.</ix:nonNumeric></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTE5NDM_235e0567-b915-4ebb-9afb-9b745b66fbec" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the available for sale securities as of October&#160;3, 2021 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.415%"><tr><td style="width:1.0%"></td><td style="width:43.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.031%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjYxOGIyOWE2MDdiODQyYjQ4NGY2MjU3NzRmZjU0OWY0L3RhYmxlcmFuZ2U6NjE4YjI5YTYwN2I4NDJiNDg0ZjYyNTc3NGZmNTQ5ZjRfMS0yLTEtMS0w_8d85f2c5-eb6e-4ee3-bfc4-d7ede98c837b">18,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjYxOGIyOWE2MDdiODQyYjQ4NGY2MjU3NzRmZjU0OWY0L3RhYmxlcmFuZ2U6NjE4YjI5YTYwN2I4NDJiNDg0ZjYyNTc3NGZmNTQ5ZjRfMS00LTEtMS0w_eb26c8e5-00ad-4b89-81bd-3d0e8f1986c3">18,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjYxOGIyOWE2MDdiODQyYjQ4NGY2MjU3NzRmZjU0OWY0L3RhYmxlcmFuZ2U6NjE4YjI5YTYwN2I4NDJiNDg0ZjYyNTc3NGZmNTQ5ZjRfMi0yLTEtMS0w_690526f4-b983-4257-8a95-c605bfa0bb90">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjYxOGIyOWE2MDdiODQyYjQ4NGY2MjU3NzRmZjU0OWY0L3RhYmxlcmFuZ2U6NjE4YjI5YTYwN2I4NDJiNDg0ZjYyNTc3NGZmNTQ5ZjRfMi00LTEtMS0w_ef464c2f-1bf4-4832-940d-010bfa282b83">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjYxOGIyOWE2MDdiODQyYjQ4NGY2MjU3NzRmZjU0OWY0L3RhYmxlcmFuZ2U6NjE4YjI5YTYwN2I4NDJiNDg0ZjYyNTc3NGZmNTQ5ZjRfMy0yLTEtMS0w_9d4af0ec-55ed-4442-940c-5abec7442d88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjYxOGIyOWE2MDdiODQyYjQ4NGY2MjU3NzRmZjU0OWY0L3RhYmxlcmFuZ2U6NjE4YjI5YTYwN2I4NDJiNDg0ZjYyNTc3NGZmNTQ5ZjRfMy00LTEtMS0w_fc24cf6a-0ee7-4058-87a9-9c43729ece8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjYxOGIyOWE2MDdiODQyYjQ4NGY2MjU3NzRmZjU0OWY0L3RhYmxlcmFuZ2U6NjE4YjI5YTYwN2I4NDJiNDg0ZjYyNTc3NGZmNTQ5ZjRfNC0yLTEtMS0w_2c7bd39e-c7c7-4c6b-9461-74b7209089eb">18,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjYxOGIyOWE2MDdiODQyYjQ4NGY2MjU3NzRmZjU0OWY0L3RhYmxlcmFuZ2U6NjE4YjI5YTYwN2I4NDJiNDg0ZjYyNTc3NGZmNTQ5ZjRfNC00LTEtMS0w_2958e0cd-43df-4e00-8aaa-c00a000be686">18,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="iaa370d695d9e4e6d96ef8bbc9db3719b" continuedAt="i4ad69c7d58784621beb795de7d3c54c4"><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTE5ODE_712d4689-bad8-4d78-b4d4-1320eb4623d1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Instruments not measured at Fair Value:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial liabilities are held at carrying amount on the consolidated balance sheet as of October&#160;3, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.838%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.259%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18389b6ef2374d3c823b640e24fe8d12_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNC0yLTEtMS0w_d3d52174-d099-4d96-8f5c-09705532147d">3,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4204d24c6ab4dfa89a1c5d5867933ce_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNC00LTEtMS0w_d05b934f-80bc-49cb-a5c8-f8f839c0cd30">3,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ac4e3b179864a468bfaa6bba91852e4_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNy0wLTEtMS0wL3RleHRyZWdpb246NzVkN2JlYmE3MGI3NDNhZDk4MGMwZmEzYWQ5MzU2M2RfNA_e8a5adbf-8108-486c-b501-757d258744f7">6.73</ix:nonFraction>% Debentures due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65df3ffe517245619ee40a22674cf249_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNy0yLTEtMS0w_98b8d301-f532-423f-b52a-a3fe6973c50a">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa344c3c3a14482aa8f313597fd1bed_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNy00LTEtMS0w_2ea36064-55f8-4131-9c71-2ec57a30b190">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07e445fc6ca14fef87c4fea6ac866c95_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfOC0wLTEtMS0wL3RleHRyZWdpb246ZWMyNWZjODg4OGE4NDlhMDg2ZDAxNDAxMmFhYmRhOTZfNA_c11121d0-ca5f-403e-b0ae-e238776ac8db">3.375</ix:nonFraction>% Notes due 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7415834b451d40a98618e973debc442e_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfOC0yLTEtMS0w_8f27bea6-6e3e-46c0-a43b-506b4bceb273">802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c8213533087409db4d429fd040785cc_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfOC00LTEtMS0w_f3aa2a13-5291-405f-ad74-323f6a250f98">857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b6ee0ef21ad4005b66cfbd8d7bd5087_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfOS0wLTEtMS0wL3RleHRyZWdpb246N2Y3NTExYzc2ZGQ1NGIzMTkyNTZmMWRiYTM5MTk0MjNfNA_ea1e265f-54dd-4993-baed-ccd21ad90835">2.05</ix:nonFraction>% Notes due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31b2046662244e3b9cbb92c5aed58fb6_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfOS0yLTEtMS0w_81e28a3e-c32e-481b-baa5-2d571ba84900">499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6b4ff6b5de74a15b368ea59a0de5057_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfOS00LTEtMS0w_a831d801-5a2c-42ce-8e2f-1db296d9a461">511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibf70d477076242eeb2b9271915ba71b3_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTAtMC0xLTEtMC90ZXh0cmVnaW9uOmFhOTI1MjYzZjFiMjRhMGRhNWI3ZmJmNzJkMGQ2ODBkXzQ_5b6abab0-30a5-4835-aafe-4b748c7540c3">0.650</ix:nonFraction>% Notes due 2024 (750MM Euro 1.1581)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0bd340801084b60adf4d9a44c9274d5_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTAtMi0xLTEtMA_994d7ca8-6a5a-442c-998b-0e5ed812f85e">867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia29178df168d49e381facf07098989fb_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTAtNC0xLTEtMA_03a1b7c6-ef4a-4843-98d2-17f83d12f076">889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1e3d2dc107be43c5bd3e61ccb2b7faf4_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjRkMTNkMzU4ZTNkMjQxNmI4Mjc4NGFmYzNiZTExNzZhXzQ_41c48f0c-00fe-45d0-a933-a37b6639fc36">5.50</ix:nonFraction>% Notes due 2024 (500 MM GBP 1.3465)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54f00a29b7c94893ba5de79c98a063b2_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTEtMi0xLTEtMA_577b46bd-0311-46dd-8081-8a1d32b2109f">671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica369f9fff05494a954f5c22e4edab8c_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTEtNC0xLTEtMA_9bc87605-02d8-46c4-ab3a-b30b457abc21">769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie72e7ef5001e45cfa85cdf6654be4b80_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTItMC0xLTEtMC90ZXh0cmVnaW9uOjg1MGJjNzA0MWI0NzRhZTBhMGNjYjdlMTE3NzNmNGNmXzQ_ee10d818-43e4-4a11-9fe0-7d95ba8f382e">2.625</ix:nonFraction>% Notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44489d6df8a8422c984028d2e3e54b5b_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTItMi0xLTEtMA_91a54844-8b5c-4310-9be1-79c875a97ccb">749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81fc862d12094763922068d4e9c8537d_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTItNC0xLTEtMA_fc90b5c3-cd30-4384-bffe-cc4a55893377">794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4147275174c24eac885cc4fb0886ac54_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTQtMC0xLTEtMC90ZXh0cmVnaW9uOjViODM0N2M4MmZhNjQ5MjQ4YWY5YTNlZDJkMzYyN2JiXzQ_816d0e48-c754-4fdb-9049-803aa8be1bb2">0.55</ix:nonFraction>% Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6f8d9f883946d6b9af6c9d0a9be721_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTQtMi0xLTEtMA_ae735e27-3d45-4222-8c40-e719404a6323">993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if20ce7e060e548869eb894260b6fc64b_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTQtNC0xLTEtMA_ff27be22-94fd-49ba-997c-e767302d3960">982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie83d54bb9a4f4816bf50aec027245c33_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTUtMC0xLTEtMC90ZXh0cmVnaW9uOjc5YjIwM2Q5NGZjNzQ2YzlhMmZmZjFhNDZkYTE5M2MyXzQ_031dac21-ee05-489d-9161-345b678014a9">2.45</ix:nonFraction>% Notes due 2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d23525d3b284b7d9852bad7add00e33_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTUtMi0xLTEtMA_b1cdf70c-31a2-4f57-941b-66c93f28e7b9">1,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1546f14269e447faa59f6da1aca49e8_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTUtNC0xLTEtMA_e503b943-f7e5-4734-999d-92631ec71fd9">2,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia478ea6acea24aff8eff14df6fecc891_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTYtMC0xLTEtMC90ZXh0cmVnaW9uOjIzNThhZDdiNWE5MzQ0M2U5ODQ1YTAzMDIxYTE5NDEyXzQ_35faedee-d62a-44d9-98d6-edd4bb85a389">2.95</ix:nonFraction>% Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5640ee1ce1d47ad801b0d6eef582304_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTYtMi0xLTEtMA_0211e064-047f-47cc-84bb-f061e972b39f">989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d971262bcb64b6b893eb6fedc3a0beb_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTYtNC0xLTEtMA_559d162a-3363-4716-9a06-e649b7ad7bd2">1,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iedc4b4fd0b1b4ad390f5f63e58c47e8d_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTgtMC0xLTEtMC90ZXh0cmVnaW9uOjM0OTkwMTc2M2YzMTRlNTc4NTQ2Y2ZkYTE3MmZmMWE1XzQ_6a602c10-898d-4767-9e41-bea1c487a722">0.95</ix:nonFraction>% Notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e50b1400f70460a988afbc0dafd4823_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTgtMi0xLTEtMA_c064ef52-d44f-46b0-92c5-d08bf492f1ee">1,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6cfc552441e4a8e8b91f3deb98f4c44_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTgtNC0xLTEtMA_4478990e-da0d-4ac5-9e74-f9dac10c9960">1,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia99340613822456eb8c3641db778ecd7_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTktMC0xLTEtMC90ZXh0cmVnaW9uOjYwNmQzMDdlYTRlZjRiYzFhZGE2ZDllODM0ZjhjNThiXzQ_cab0b76a-a28a-4823-8ae2-a48fe4878fa9">2.90</ix:nonFraction>%&#160;Notes due 2028</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa8046c340764588878db0a7b77c401f_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTktMi0xLTEtMA_b26917db-b6aa-427e-bf6e-5776e70a72e8">1,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fd60cb1106c4c1499568e9a6eebfb28_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTktNC0xLTEtMA_13928cba-b58c-4a93-9c19-32118c10ebf2">1,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72bdc25703924ba3b6b0ce4527d18d88_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmQxYmEyYzM0YzY2MzRlYmY5NGM3MWZhNzY3OGEyZTgxXzQ_13c8eb39-a557-407e-88c7-ae0a6373c49a">1.150</ix:nonFraction>% Notes due 2028 (750MM Euro 1.1581)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b28e0d7e40047fabff6dba54a753c51_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjAtMi0xLTEtMA_63de2a0a-33f7-4ffb-92f1-b6e977612de4">863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23573442cd349c181d05b7186a88a8f_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjAtNC0xLTEtMA_c4693e92-90ad-45ae-97bb-8e4d3f4ad384">932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i99f7ce7c3c0a4e47bc46cb5013b85204_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOjhmYjBjOGIwMGM5YjQ4MDJhYTRhYmRmM2YyNDFkZmE2XzQ_b4de3976-cee7-44f3-b367-c259e2d1690f">6.95</ix:nonFraction>% Notes due 2029</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fce897c159a440fa82606e78f5a8890_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjEtMi0xLTEtMA_c81c15c6-ac89-40b3-b58b-f20d0ede9403">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9442a0f459844bc8b34a3edfbad734f2_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjEtNC0xLTEtMA_0946e807-82f7-4b89-8807-0833eda654d1">414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if9abf297178741228613c2f1cc8f19d2_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOmM0ZmYxOTgxMzE4ZTQyNzA5NGE2NTkxN2E5NThlNzdkXzQ_daa8d0ad-2cfe-4e7b-971c-0a8608f14d14">1.30</ix:nonFraction>% Notes due 2030</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34ef244a220d41cd93a8040056b208e7_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjMtMi0xLTEtMA_c57d8698-d35a-4568-8856-e74dbb47f6f8">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ff7c6833044a3ebd91c3ef1f1367c4_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjMtNC0xLTEtMA_90000706-9dec-4772-9bc0-d46ab49bb98a">1,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3fec2057e8c4da08b74b29f4fd4267c_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmJlYzFjNmRmY2IzMjQ1NzJhOWE3NWYyYmY0MTY1ZTI0XzQ_721f413e-75a9-4ff1-92a1-1650d182c5c3">4.95</ix:nonFraction>% Debentures due 2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f58130f89ed4256a62ba7c75eb638c4_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjQtMi0xLTEtMA_fd8220b3-4d4c-4a39-9a60-582ce3341d4f">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefeb4b2784e6435384a917a1944c658e_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjQtNC0xLTEtMA_bbe79ae4-3aad-4aa4-b6cd-1e14bf73f10c">647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i860c18e3721d4d939bd33a8ea77e4421_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjEwNjgyMmI1OTUzNDQ4YWFiZGM2YjdiYWY0YmNlMDc4XzQ_badc7509-56b8-4e67-9ec3-fc540a29cb2c">4.375</ix:nonFraction>% Notes due 2033</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9daefad50e444c3b846ecb91f83159bc_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjUtMi0xLTEtMA_31b2165a-ab61-4f59-9283-0b605c0c8a02">855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c801cc1caeb4c179693dba2260b0563_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjUtNC0xLTEtMA_51811d70-deb5-4a63-8cfc-4fcead3a6fd7">1,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0dbba3a61c5540838ca8c89692469565_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjJkZGE3YmQ4MjM5MzRlY2I4ZjE5ZGZlODgyNGMwNTAxXzQ_ac1032f1-c4ac-4659-84d5-00f196ff5dfb">1.650</ix:nonFraction>% Notes due 2035 (1.5B Euro 1.1581)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aecaa1385574720ad3d887864eeb207_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjYtMi0xLTEtMA_7cdc8e80-3e76-44e6-b83e-b6fd86fce9a1">1,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3125d97f80b94d60b77182ad35bb48fc_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjYtNC0xLTEtMA_b1207fbb-bc84-4d36-98ab-ef59cd0f0928">1,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic7aeccd4baaf4417b5ffcdc8852c71d4_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjU2ZmU5OTJiMDZlYzQzY2E5YzU1ZTNmZDAwODllMGMxXzQ_33829150-a683-4824-ba72-9a1e906a12e2">3.55</ix:nonFraction>% Notes due 2036</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib143b536bc9b45b4826b98a0ac180c8b_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjctMi0xLTEtMA_fa9d8edc-23da-44c0-8d06-02f455a2a101">980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide702a860cec442280c57a5771658c81_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjctNC0xLTEtMA_ad9f8ffc-b192-42a3-acf5-3c3c153b550b">1,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic2ca463645bb4a5b9739b8bc175da1db_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmQ0NGFiNGNhM2VkNDQ0NjA5ODA4ODhiNTYyZWU1NDdkXzQ_77b00c77-94ed-4be8-b7e7-35984450c894">5.95</ix:nonFraction>% Notes due 2037</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f1d7b4085841078f18b613f1fe0a77_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjgtMi0xLTEtMA_2f8e4676-77c7-4694-a398-f9f356ef39f6">993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib92d6482e7ea404eae4e1c4468904413_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjgtNC0xLTEtMA_d58cd1cf-c3d4-46ce-87c4-8805fe801639">1,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2a6e34f48ee4c7d80d33f78478eb3f2_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmM1ZDY5YmI1OTVkODQxOWM4NDQ4NWNjNzYwYWVjYjA1XzQ_fb4b95b7-270d-4917-9d94-a3f88261a322">3.625</ix:nonFraction>% Notes due 2037</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdc7fc7a723e450cb48944879c0781e7_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjktMi0xLTEtMA_af8d6856-6139-4c95-996b-58c9cf8f4217">1,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1a7c9dbc6df42aeb77011ac535edea5_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjktNC0xLTEtMA_d4d98ffc-af26-4d6c-84d8-17e1b35d3b43">1,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i57d6a4f83449492094bb6b200701e064_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjdmN2IxNmRmM2YwYjQxZDhiNDhkZTY5ZGE1ZWFmYTM2XzQ_e1540b0f-e9c1-49b4-96d1-ea462bac2875">3.40</ix:nonFraction>%&#160;Notes due 2038</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2f2afd2bbca40be9ed9eff967565efe_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzAtMi0xLTEtMA_4e2cf73c-ca21-406f-a0a6-0219ca29e1aa">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7d62d21ca6949dcbc76d7ab670920b7_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzAtNC0xLTEtMA_b6180b90-36f1-472c-b529-1ff10ceff437">1,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ied109c22c97143bf9e2d8950f06aa9cd_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmY4ZGMwMDY3MTU0YTQ4MGU4YjBmMGJlNDk1NThjMzEyXzQ_d0180a1f-0cef-47dd-9b99-a6f423464d48">5.85</ix:nonFraction>% Debentures due 2038</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia107789c130e40adb3ad38987e6fbf7c_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzEtMi0xLTEtMA_0fb9afb8-f3ea-45e1-bfdd-6655a01cbdc7">696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d2f5ac2df314410bab3062026857504_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzEtNC0xLTEtMA_8e1922fb-6c64-4e67-bb02-cb4767244d9f">1,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3b49374b2a540819767fb1780941cbf_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjI0NmM3ODY3MTk0ZDQ5ZTc5ODgzYzA1MzQyMDA0MDI0XzQ_af89d61a-eae2-4dc3-939d-d1c83c08c7ad">4.50</ix:nonFraction>% Debentures due 2040</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26dfa36f335f442fb41f8059c4cfe77f_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzItMi0xLTEtMA_e51178e6-a9f5-423e-bee7-a49b4022252d">540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25547702bd0f47088ae87a4e661a13e2_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzItNC0xLTEtMA_5ff03c8c-ac6a-4045-865e-e8b919619e69">693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic31cdd75b29340eb9d44466d5ec7ffd8_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmJjZWNjOWFjY2EzZTRlMTM5YjdjNTAyNWE4NTEwODRkXzQ_d1898930-d4ed-4d15-ab14-c90cdafa5129">2.10</ix:nonFraction>% Notes due 2040</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50afa95426c645b18294c42ab68e0a75_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzQtMi0xLTEtMA_88c8a206-6470-4d6e-ac10-2aa5368ad7f8">979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a8f75d047704b5aa0d3db1bc03ed292_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzQtNC0xLTEtMA_0e89db23-c471-42a7-a2a7-e1512b0f8292">933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3890ce020cce483fa079c7f7418ac44c_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjE2ODA4MmE2NGYzYjQwMzk4ZjQzOTlkNjVkNTRlMzJjXzQ_cfd41061-607d-49ac-9f6f-38a21ffa5b31">4.85</ix:nonFraction>% Notes due 2041</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f17e1a230b249b09dc6346803945e09_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzUtMi0xLTEtMA_d6a5f646-0640-4174-8e21-2957a2d9ba79">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6188505bd2214769b12b8c2e7a1c0463_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzUtNC0xLTEtMA_7aa75d9d-5c99-41a1-9610-ca86b6ade23a">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7fa9c5baa5cc4e97becb950d913da01f_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOmZlZmIxNDNmMGM0ZjQwM2ViMzZhNWQ5YjJjNWJiNzA0XzQ_2cd6da85-32a9-4eea-abeb-01ac938999c4">4.50</ix:nonFraction>% Notes due 2043</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie788a463953d40fc97d8f8e0d65f542d_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzYtMi0xLTEtMA_0faaf13c-570d-4338-a920-aadb9cd1ebbe">496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0244efd886bd4bd289f13fdfc63a76b3_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzYtNC0xLTEtMA_1d9562af-49a0-44fe-be85-dac2953c0b4d">640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d3f77d18cb74144b8514b9fd3021780_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmRjZDdmODFmYjBiNzRmOGY5YWQxNDgzYzQzMGZlYzY0XzQ_9e190d82-4af5-49eb-9f5c-a9223c9c750f">3.70</ix:nonFraction>% Notes due 2046</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab5c42e4384e4963a7ae278858dc9a3b_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzctMi0xLTEtMA_436452df-d1e3-4c61-bcc9-ae68d78e8b7b">1,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c7ebdcd26aa43d5be5ef11db34b14e8_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzctNC0xLTEtMA_72293323-5986-44a3-88a5-e15bcb1522ed">2,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7bb0296c854c4acf871e0335393ec672_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjk5ZDA4MzJmNTI5YzQ4YWE5YTI3NTI4ODVlNTNjNzQ5XzQ_3438fd50-b068-498e-bfbd-bf98d5a3242a">3.75</ix:nonFraction>% Notes due 2047</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25548ce1ad154cad9b4737a0931325b0_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzgtMi0xLTEtMA_cf8e431e-c00c-45c3-b181-145f397bdc7b">974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e73ad17867f4918ae13cdb77b42664d_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzgtNC0xLTEtMA_f33a717e-2899-4d58-b5d4-92853c4c236c">1,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ea1027adfa8409fa2240d2e0d15da0b_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjE1MTQ3ODUzMzBhNzQ4ZTViODI5NzQ4YzY4ODliYTc0XzQ_a7dfd161-9aec-4d52-9bc2-f3c6af7289da">3.50</ix:nonFraction>% Notes due 2048</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd27580aa37f4a75b8b17887161c3adc_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzktMi0xLTEtMA_f6ff9a47-0f88-42b9-89ec-13d4c4477994">743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if98b3204979e45fb982f58b3cbb646c0_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzktNC0xLTEtMA_33157e99-d675-497e-8ede-aedb522fc1c3">860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ida0748410a8c4eab9d417837ec838a91_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjBkZmQ2MmNlOTk4NjQ0ZDk5YjA3YTQ5Y2Y2OWRhM2ZlXzQ_d8949ef7-e234-482c-90ae-880fcd7382fe">2.25</ix:nonFraction>% Notes due 2050</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i483018bed3724cac829e9c16115d7f55_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNDAtMi0xLTEtMA_2e057b2c-2d7a-4cfc-91a1-52ee0a732c4a">986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i193c04c9acbf4263b63c3eda25c9c4c8_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNDAtNC0xLTEtMA_ad76af18-2b67-47ba-a595-40a2da92eb06">928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i15cf4b9be03f47eba85d4614348d2034_I20211003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNDEtMC0xLTEtMC90ZXh0cmVnaW9uOjA1ZWI0OWYyYzJmYjRmYzM4MjMzZmE1YzNhZTJiNjBlXzQ_aa36c813-5ec6-47ce-b63b-3862f2206769">2.45</ix:nonFraction>% Notes due 2060</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i427dbcfc1b924d82bfa86831fd546f1c_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNDEtMi0xLTEtMA_37213dfb-8667-4f02-a2a2-c0a4181336e1">1,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0be6f6c2cd547e687ae5108ce9ac42a_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNDEtNC0xLTEtMA_93fd5c84-a44b-4477-b5f2-2bbe0ccb15ba">1,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ba0ab6b51254970ba452db5939f0a54_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNDItMi0xLTEtMA_071de91a-8afe-4d1a-82a1-d8355d064410">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedd08cef78740fc9f67f0cf86fb8ba7_I20211003" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNDItNC0xLTEtMA_950fe79e-53f1-4b4e-aec4-33957caf6852">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-Current Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18389b6ef2374d3c823b640e24fe8d12_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNDMtMi0xLTEtMA_268446ec-ed35-4db8-a663-cc64a30612a3">30,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4204d24c6ab4dfa89a1c5d5867933ce_I20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNDMtNC0xLTEtMA_54d529e8-7c36-4448-9c25-f1f218b0d685">33,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average effective interest rate on non-current debt is <ix:nonFraction unitRef="number" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="4" name="us-gaap:LongtermDebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTE0OTg_150ee395-16d1-4335-adcf-8e10f2871287">2.98</ix:nonFraction>%.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the estimated fair value over the carrying value of debt was $<ix:nonFraction unitRef="usd" contextRef="i6e38f2e44f714a3d8fd4adc7b4276d3d_D20191230-20210103" decimals="-8" format="ixt:num-dot-decimal" name="jnj:ExcessOfFairValueOverCarryingValueOfDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTE1Nzg_8c79059e-6110-4500-be26-900db18b690c">5.4</ix:nonFraction> billion at January 3, 2021.</span></div></ix:continuation><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i4ad69c7d58784621beb795de7d3c54c4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The current debt balance as of October&#160;3, 2021 includes $<ix:nonFraction unitRef="usd" contextRef="ia1e15dae48b34058996995a2834d63fe_I20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTE2NDU_7b1ef5f0-01a1-41b8-82c9-34291d5123b7">1.3</ix:nonFraction>&#160;billion of commercial paper which has a weighted average interest rate of <ix:nonFraction unitRef="number" contextRef="ia1e15dae48b34058996995a2834d63fe_I20211003" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTE3MTQ_f112bc26-0ec9-4ab3-abcc-d2ce9a69a2eb">0.08</ix:nonFraction>% and a weighted average maturity of approximately <ix:nonNumeric contextRef="i0ac5b17e0fad468a80e8667a23da5ace_D20210104-20211003" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTE3NjY_bbd3914a-27c8-4908-900e-0be63d1335cd">three months</ix:nonNumeric>.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.</span></div></ix:continuation><div id="if410ee6e03c8456f86a9fee997f08e65_70"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 5 &#8212; <ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfNDEzNQ_dfc927df-4dd9-4c06-ba10-ea4476e3d935" continuedAt="ief0ae907ce46452a83fee6c9a0285f7f" escape="true">INCOME TAXES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ief0ae907ce46452a83fee6c9a0285f7f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The worldwide effective income tax rates for the fiscal nine months of 2021 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2020 were <ix:nonFraction unitRef="number" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfMTE0_7afa043e-1392-4f8e-9fb6-ee9b339a0204">10.0</ix:nonFraction>% an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">d <ix:nonFraction unitRef="number" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfMTIx_3929c349-98ed-451b-8929-d725794e14dc">12.6</ix:nonFraction>%, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In the second fiscal quarter of 2021, the Company reorganized the ownership structure of certain wholly-owned international subsidiaries. As part of this reorganization, the Company increased the tax basis of certain assets to fair value in accordance with applicable local regulations.  Accordingly, the Company recorded a local deferred tax benefit of approximately $<ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-8" format="ixt:num-dot-decimal" name="jnj:DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfNTA3_cb60f183-a45d-40c9-bb6c-e74dd760dbf1">2.3</ix:nonFraction>&#160;billion, which was partially offset by a related increase in the U.S. GILTI deferred tax liability of approximately $<ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-8" format="ixt:num-dot-decimal" name="jnj:IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfNjE4_058447bc-ef4d-4d9a-b2e4-36c642139ad6">1.7</ix:nonFraction>&#160;billion. The net impact of this restructuring was approximately $<ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfNjc3_5405c713-f0e3-4f53-be53-549d8ab4b658">0.6</ix:nonFraction>&#160;billion net benefit or <ix:nonFraction unitRef="number" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="3" sign="-" name="jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfNjk1_afdd6e53-71d0-4e89-a0a3-9e51537db1c0">3.4</ix:nonFraction>% decrease to the 2021 year-to-date effective tax rate.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In 2019, Switzerland enacted the Federal Act on Tax Reform and AHV Financing (TRAF), which became effective on January 1, 2020. More information on the provisions of TRAF can be found in the Company&#8217;s Annual Report on Form 10-K for the year ended January 3, 2021. During the first fiscal quarter of 2020, the final canton where the Company maintains significant operations enacted TRAF legislation and, accordingly, the Company recorded a deferred tax benefit of approximately $<ix:nonFraction unitRef="usd" contextRef="ic6211b8d8ccd49788ecbb637deed070a_D20191230-20200329" decimals="-8" format="ixt:num-dot-decimal" name="jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfMTIzMg_68db4da8-9947-4898-bc07-f3a3a1c9ad97">0.3</ix:nonFraction>&#160;billion for the remeasurement of existing deferred tax liabilities offset by a related $<ix:nonFraction unitRef="usd" contextRef="ic6211b8d8ccd49788ecbb637deed070a_D20191230-20200329" decimals="-8" format="ixt:num-dot-decimal" name="jnj:IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfMTMxNA_04eef3fa-a94b-4610-8d96-d4cccf939440">0.2</ix:nonFraction>&#160;billion increase in U.S. GILTI deferred taxes. During the second fiscal quarter of 2020, the Company received rulings from the Swiss Federal and cantonal tax authorities in the remaining jurisdictions where it has significant operations. These rulings resulted in the Company increasing the tax basis of certain assets to fair value. As a result, the Company recorded additional deferred tax benefits in the second fiscal quarter of 2020 to recognize this step-up.  The total benefit recorded related to Swiss Tax reform in the fiscal nine months of 2020 was approximately $<ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-8" format="ixt:num-dot-decimal" name="jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfMTg4MQ_e288d848-957f-4e98-830b-6b9dd0ed9913">0.4</ix:nonFraction>&#160;billion, or <ix:nonFraction unitRef="number" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="3" name="jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfMTg4OA_f19ed240-bcd1-4e8f-b5b9-1dcd86d3ea8a">2.7</ix:nonFraction>% net benefit to the Company&#8217;s year-to-date  effective tax rate, inclusive of the impact of U.S. GILTI deferred taxes. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Additionally the following items impacted the Company&#8217;s effective tax rate as compared to the same period in the prior fiscal year:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">as a result of the recent filing of the 2020 U.S. tax return, as well as the impact of non-recurring favorable tax items, the Company recorded a <ix:nonFraction unitRef="number" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfNDk0NzgwMjMzMTgzMQ_19f8128e-4380-4bb1-a6c9-8c9cfcfe43b7">1.0</ix:nonFraction>% net benefit to the effective tax rate for the fiscal nine months of 2021.   </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">in the third quarter of 2021 the Company accrued additional legal expenses, $<ix:nonFraction unitRef="usd" contextRef="ice0924be1a6f4deb9320312504bf1648_D20210705-20211003" decimals="-8" format="ixt:num-dot-decimal" name="jnj:EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfNDk0NzgwMjMzMTgzNw_7b4d866f-f999-4f4d-b192-2cc89600a3dd">1.4</ix:nonFraction>&#160;billion for the Talc related litigation at an effective tax rate of <ix:nonFraction unitRef="rate" contextRef="ice0924be1a6f4deb9320312504bf1648_D20210705-20211003" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfNDk0NzgwMjMzMTg1MQ_ee888547-03c1-48da-a852-4265fb4d46a5">23.5</ix:nonFraction>% and $<ix:nonFraction unitRef="usd" contextRef="i0b4d8090e5a94aa6a43b8958bfdeabf1_D20210705-20211003" decimals="-8" format="ixt:num-dot-decimal" name="jnj:EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfNDk0NzgwMjMzMTg1OA_26d3af91-d458-449f-8a12-feadf1d026d9">0.8</ix:nonFraction>&#160;billion for the Risperdal settlement at an effective tax rate of <ix:nonFraction unitRef="rate" contextRef="i0b4d8090e5a94aa6a43b8958bfdeabf1_D20210705-20211003" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfNDk0NzgwMjMzMTg3Mg_1f195ddf-d5fb-40c7-925a-3816590e970a">16.4</ix:nonFraction>% (See note 11 to the Consolidated Financial Statements for more details).</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">in the third quarter of 2021 the Company recorded a partial IPR&amp;D charge of $<ix:nonFraction unitRef="usd" contextRef="i9861446e76324a08b1c77c4fa0b1b5a3_D20210705-20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfNDk0NzgwMjMzMTg3OQ_c61165a8-14fd-4331-a62b-eb989326819d">0.9</ix:nonFraction>&#160;billion for the Ottava intangible asset (acquired with the Auris Health acquisition in 2019) at an effective rate of <ix:nonFraction unitRef="number" contextRef="i9861446e76324a08b1c77c4fa0b1b5a3_D20210705-20211003" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfNDk0NzgwMjMzMTg5Mw_c8f44334-cd3c-4dc9-ad6c-4adb69a5a425">22.4</ix:nonFraction>% (See Notes 3 and 9 to the Consolidated Financial Statements for more details). </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">in the fiscal nine months of 2020, the Company reduced a contingent consideration liability related to the 2019 Auris Health acquisition that benefited the fiscal nine months of 2020 tax rate by approximately <ix:nonFraction unitRef="number" contextRef="ie6bf26a76e934a0abbe42eb60a86e6f4_D20191230-20200927" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfNDk0NzgwMjMzMTkxNw_9407eb64-1670-408c-bc91-4e63c0c50117">1.0</ix:nonFraction>% (see Note 4 to the Consolidated Financial Statements for more details). </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">the Company had lower income in higher tax jurisdictions relative to lower tax jurisdictions as compared to the same period in the prior year. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company also generated additional tax benefits from stock-based compensation that were either exercised or vested during the first three fiscal quarters of 2021 and 2020.  Additionally the company has reversed unrecognized tax benefit liabilities in 2021 as a result of the completion of tax examinations in certain international jurisdictions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of October&#160;3, 2021, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefits" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfMzI4OQ_f8ac4238-1111-4b61-aaf5-eb9e9ee02d00">3.3</ix:nonFraction> billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. In other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">major jurisdictions where the Company conducts business, the years that remain open to tax audit or are under appeal go back to the year 2008. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="if410ee6e03c8456f86a9fee997f08e65_73"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 6 &#8212; <ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RleHRyZWdpb246MmFiZDM4NWI2NzAxNGE5MGI5NDlhNTA1NjZkZjMxOTNfODkw_46b8584b-802f-49f5-93c2-cfcbed5a2362" continuedAt="i1372c227cdca43f19293b8ccf9468755" escape="true">PENSIONS AND OTHER BENEFIT PLANS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i1372c227cdca43f19293b8ccf9468755" continuedAt="if46f4f4ea1e64b05bd18bbac16f7f6ac"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of Net Periodic Benefit Cost</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RleHRyZWdpb246MmFiZDM4NWI2NzAxNGE5MGI5NDlhNTA1NjZkZjMxOTNfODg3_c4b7600c-30db-4e85-9617-32587a03070e" continuedAt="ib6ef463ec0064337a41fa6d89165326b" escape="true">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans include the following components:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="if46f4f4ea1e64b05bd18bbac16f7f6ac"><div style="margin-top:5pt"><ix:continuation id="ib6ef463ec0064337a41fa6d89165326b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.338%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a7e0b9b6e694546bcf63ba4da67114c_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMy0yLTEtMS0w_ed55ef0f-aeca-434a-a8c7-a2c155d0be67">339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d181abffa774cef94773798ffcbc773_D20200629-20200927" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMy00LTEtMS0w_e32133a2-ad57-4d77-98cc-e0978f55fc1d">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae538c397d5b4172843ae849a0fa8309_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMy02LTEtMS0w_2f509452-fe43-4452-98ac-d667476d49f3">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db0747f8e0e4cf9ad8b2c2022602317_D20200629-20200927" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMy04LTEtMS0w_92a6b74f-a5eb-4988-b15f-e10a00b15460">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f89fe3ec42c4ee6b74d0ae62c74a640_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMy0xMC0xLTEtMA_25df1661-3318-46cc-837c-3f8ef6e95b71">1,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8ad9c18d6ef430fa4f2b3d36ff46598_D20191230-20200927" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMy0xMi0xLTEtMA_91ab5520-3397-48bb-aabf-8dd64c7c9e4e">979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb909ef9c68340daae79d3dce5aa8dc4_D20210104-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMy0xNC0xLTEtMA_5df48f68-6d48-46e5-bddb-a452d67a7b60">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1dec1c43ca4835b67df10da682c97a_D20191230-20200927" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMy0xNi0xLTEtMA_63ec0edc-cfd2-41e1-b5d4-30a4f58de642">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a7e0b9b6e694546bcf63ba4da67114c_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNC0yLTEtMS0w_40076091-46cc-429d-a272-aa0dbfbbae0f">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d181abffa774cef94773798ffcbc773_D20200629-20200927" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNC00LTEtMS0w_56056fa2-4583-4133-a0c5-7a1cc8883f82">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae538c397d5b4172843ae849a0fa8309_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNC02LTEtMS0w_750d27d6-4292-4775-8a60-a328a89cc1f1">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db0747f8e0e4cf9ad8b2c2022602317_D20200629-20200927" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNC04LTEtMS0w_cfbd8840-867c-4fde-9206-2da5e7c0afd5">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f89fe3ec42c4ee6b74d0ae62c74a640_D20210104-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNC0xMC0xLTEtMA_bc623b8d-292f-4903-af62-d8be43af0d0c">578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8ad9c18d6ef430fa4f2b3d36ff46598_D20191230-20200927" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNC0xMi0xLTEtMA_4f2263e3-4919-4c1c-9308-0205bfbeea44">715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb909ef9c68340daae79d3dce5aa8dc4_D20210104-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNC0xNC0xLTEtMA_a48fb0f9-baff-4c86-b53d-0c69fe1adb11">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1dec1c43ca4835b67df10da682c97a_D20191230-20200927" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNC0xNi0xLTEtMA_12ccdda3-cdd5-42cc-b1d8-baf69bfd0f48">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a7e0b9b6e694546bcf63ba4da67114c_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNS0yLTEtMS0w_921d233c-a00a-4fb6-9d5e-6aed1c80e7a3">661</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d181abffa774cef94773798ffcbc773_D20200629-20200927" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNS00LTEtMS0w_f3475b35-f5bb-4ac4-bc87-515a03e46bfa">617</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae538c397d5b4172843ae849a0fa8309_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNS02LTEtMS0w_aff2bce0-afb3-49ad-9019-3cba2b7bab0a">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0db0747f8e0e4cf9ad8b2c2022602317_D20200629-20200927" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNS04LTEtMS0w_64322ca5-ef98-4096-895e-30c65f762fe5">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f89fe3ec42c4ee6b74d0ae62c74a640_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNS0xMC0xLTEtMA_0cf74e07-a56d-4120-9597-fe6e5c251ad3">1,988</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8ad9c18d6ef430fa4f2b3d36ff46598_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNS0xMi0xLTEtMA_6cfdadb9-4d44-4f96-b2f2-d6e849fa3d12">1,839</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb909ef9c68340daae79d3dce5aa8dc4_D20210104-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNS0xNC0xLTEtMA_451dc268-9c99-418e-baf5-2975c370b4a2">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf1dec1c43ca4835b67df10da682c97a_D20191230-20200927" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNS0xNi0xLTEtMA_b4a32a29-40d0-405d-a5ca-c2c5b27f1d67">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost/(credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a7e0b9b6e694546bcf63ba4da67114c_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNi0yLTEtMS0w_7acce750-2772-4026-8204-b47390edae2c">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d181abffa774cef94773798ffcbc773_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNi00LTEtMS0w_fb853693-7bcb-4aac-a827-4f9d74c14dab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae538c397d5b4172843ae849a0fa8309_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNi02LTEtMS0w_01c7c513-95aa-49be-a1ed-52f5b1823668">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0db0747f8e0e4cf9ad8b2c2022602317_D20200629-20200927" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNi04LTEtMS0w_5f564800-b185-46bb-9600-3216feb5b27b">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f89fe3ec42c4ee6b74d0ae62c74a640_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNi0xMC0xLTEtMA_42665e3a-b946-4ab5-bec2-0526d7fe28ba">136</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8ad9c18d6ef430fa4f2b3d36ff46598_D20191230-20200927" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNi0xMi0xLTEtMA_a2ff0b3d-8756-47e1-a551-93a2b809edf9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb909ef9c68340daae79d3dce5aa8dc4_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNi0xNC0xLTEtMA_4b147291-b6e7-436a-b34a-86967cda4e4b">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf1dec1c43ca4835b67df10da682c97a_D20191230-20200927" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNi0xNi0xLTEtMA_e9e6dc20-b32d-4058-a5cc-db0030a9b1bf">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a7e0b9b6e694546bcf63ba4da67114c_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOC0yLTEtMS0w_bb3898a2-a7f8-450c-89d4-fbd21d65b61c">314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d181abffa774cef94773798ffcbc773_D20200629-20200927" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOC00LTEtMS0w_2efd301b-30d5-45e1-8f5d-49f6b3f6d6bb">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae538c397d5b4172843ae849a0fa8309_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOC02LTEtMS0w_dc501326-e3ef-495f-b4f6-48420d38151b">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db0747f8e0e4cf9ad8b2c2022602317_D20200629-20200927" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOC04LTEtMS0w_10a2dbd1-fb04-4eb0-901f-df608257696a">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f89fe3ec42c4ee6b74d0ae62c74a640_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOC0xMC0xLTEtMA_ed74d85f-ea20-407f-ae09-8cc91cdeca72">944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8ad9c18d6ef430fa4f2b3d36ff46598_D20191230-20200927" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOC0xMi0xLTEtMA_974bf7b8-8a71-47f5-8a65-c5841907df9e">669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb909ef9c68340daae79d3dce5aa8dc4_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOC0xNC0xLTEtMA_c1f9fb54-573e-4a75-a902-b5238a92064d">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1dec1c43ca4835b67df10da682c97a_D20191230-20200927" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOC0xNi0xLTEtMA_6eb15ef7-fd6c-4c1f-ad2f-7e8d36241674">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments and settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a7e0b9b6e694546bcf63ba4da67114c_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOS0yLTEtMS0w_f32275fe-97a5-44e1-899b-ba9387622d15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d181abffa774cef94773798ffcbc773_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOS00LTEtMS0w_d0708f19-dfb6-497f-bd1a-1b876d6720e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae538c397d5b4172843ae849a0fa8309_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOS02LTEtMS0w_6f90a824-d633-4f52-88aa-10aacd5f98dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db0747f8e0e4cf9ad8b2c2022602317_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOS04LTEtMS0w_d23a7e49-f400-445f-8de2-f1c6a7590255">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f89fe3ec42c4ee6b74d0ae62c74a640_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOS0xMC0xLTEtMA_1a519542-5bd5-4018-b66f-88bdc1a85180">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8ad9c18d6ef430fa4f2b3d36ff46598_D20191230-20200927" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOS0xMi0xLTEtMA_91077076-3041-4e68-954a-bfbefbfbca2b">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb909ef9c68340daae79d3dce5aa8dc4_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOS0xNC0xLTEtMA_856e81e8-4131-44d4-a473-cc1bf96010b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1dec1c43ca4835b67df10da682c97a_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOS0xNi0xLTEtMA_ae21c848-159a-449c-b42c-9cc9be623b27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a7e0b9b6e694546bcf63ba4da67114c_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMTAtMi0xLTEtMA_fbd6f015-e035-4c04-838e-4455cc467345">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d181abffa774cef94773798ffcbc773_D20200629-20200927" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMTAtNC0xLTEtMA_42218c88-0623-4883-a9d7-381cad7c1517">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae538c397d5b4172843ae849a0fa8309_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMTAtNi0xLTEtMA_bf2293c1-189a-4a73-ab04-c5ae4dca3935">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db0747f8e0e4cf9ad8b2c2022602317_D20200629-20200927" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMTAtOC0xLTEtMA_b31a0130-ee1b-424e-8a1d-f582baf6499e">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f89fe3ec42c4ee6b74d0ae62c74a640_D20210104-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMTAtMTAtMS0xLTA_81a51b17-2643-4556-ab74-ec922e67a401">418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8ad9c18d6ef430fa4f2b3d36ff46598_D20191230-20200927" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMTAtMTItMS0xLTA_f635229e-8382-46da-86ec-4ab6279f4f7a">544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb909ef9c68340daae79d3dce5aa8dc4_D20210104-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMTAtMTQtMS0xLTA_bd505ad8-2e2a-4ccb-a852-ea744d6ae370">378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1dec1c43ca4835b67df10da682c97a_D20191230-20200927" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMTAtMTYtMS0xLTA_c2aab837-11fa-4618-af58-2c1b69d03731">394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company Contributions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal nine months ended October&#160;3, 2021, the Company contributed $<ix:nonFraction unitRef="usd" contextRef="ieeff0339058f4ac9808b5eba4dc8ff41_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PensionContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RleHRyZWdpb246MmFiZDM4NWI2NzAxNGE5MGI5NDlhNTA1NjZkZjMxOTNfNjIz_4c33e0c2-1ae7-4ab2-a2e9-77894f49e401">71</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i87dfc4ba292d4afcaa274be4bf5a6019_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PensionContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RleHRyZWdpb246MmFiZDM4NWI2NzAxNGE5MGI5NDlhNTA1NjZkZjMxOTNfNjMw_acfdd0fc-5384-4be9-b28a-e1ffd5f62cbf">232</ix:nonFraction> million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.</span></div></ix:continuation><div><span><br/></span></div><div id="if410ee6e03c8456f86a9fee997f08e65_76"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 7 &#8212; <ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RleHRyZWdpb246YTQxOGZlYzY2M2M4NDc1Yjk5OWRmZmM3MWU1NzQ1MTFfOTI3_5462b371-97da-4522-a757-38f88526995d" continuedAt="i95294ccbf6b049ccb777c7e73aef68d0" escape="true">ACCUMULATED OTHER COMPREHENSIVE INCOME</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i95294ccbf6b049ccb777c7e73aef68d0"><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RleHRyZWdpb246YTQxOGZlYzY2M2M4NDc1Yjk5OWRmZmM3MWU1NzQ1MTFfOTI5_de98f8c2-511c-4d83-b838-a0f556c2ca2a" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) consist of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:34.774%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.719%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.306%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.991%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Accumulated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Comprehensive</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c9b670acb814f2e8e8cae1d3b139677_I20210103" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNC0yLTEtMS0w_12078408-f937-4d89-8765-013d7ae4b660">8,938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49a74fa2fdfe4f89beaadf820f5ac713_I20210103" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNC00LTEtMS0w_735a18a3-412a-483d-a25d-a170f9382ad1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40bb249c8086466faca49b2fa9bc2a92_I20210103" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNC02LTEtMS0w_b12c13c2-0444-400c-8ffa-fc42b9272d38">6,957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90665923dd1c4a2fa6d99222fb60dc98_I20210103" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNC04LTEtMS0w_e25a9d07-c662-4148-a87d-aedc6c9f9db8">652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib616b434ad574d54a671235ee0e19c40_I20210103" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNC0xMC0xLTEtMA_e6bff0f0-a773-4b00-b93e-68f1f88be8c9">15,242</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfb362df49f946cc91574b4a35909613_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNS0yLTEtMS0w_2006916f-75cd-4849-9701-31cb858bb7d6">241</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32fd6f9a0ed9441682053b3f396c5491_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNS00LTEtMS0w_614f4ceb-362d-4412-9a7b-fca31a8cf922">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd186072d3fc4864a3c6f62ea4a983ec_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNS02LTEtMS0w_ad583850-0e38-4bdf-a1c6-cf10faeced32">700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1585241dd83540d68d0d4bb0179b4c35_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNS04LTEtMS0w_f07cd0fb-329c-44ac-bba7-ba0e2d333d8a">631</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i280f2f10a11c4c988142fed0ab0a55c4_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNS0xMC0xLTEtMA_f4cb785a-4d62-4129-8876-08a6df35e47c">173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae5d5570b0974f90b2b495ca2a503dae_I20211003" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNy0yLTEtMS0w_973271a0-7adb-48d0-95a2-635d4df9db01">9,179</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d619304e810451eaf68e4fe20b97b9e_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNy00LTEtMS0w_3552de3b-9e8f-40f5-9f8c-4ec5b464f4dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc89c7db9aca490ebbcb9ac5ff66d285_I20211003" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNy02LTEtMS0w_bc823686-d9b3-42f9-aabb-9468cc952bc8">6,257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ed865a3a524e718fe97e4283367b0d_I20211003" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNy04LTEtMS0w_fac21684-14ec-4e71-a995-5a91c3dd89d1">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd88e9907aaf4e8cbca11111329e2073_I20211003" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNy0xMC0xLTEtMA_4fd5ab69-5ee6-498d-94a9-b923e1bb6fa6">15,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in accumulated other comprehensive income are presented net of the related tax impact.  Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries.  For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details on reclassifications out of Accumulated Other Comprehensive Income:</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Derivatives &amp; Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="if410ee6e03c8456f86a9fee997f08e65_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 8 &#8212; <ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RleHRyZWdpb246ZmUzOGYyNDM5YjIxNDgyNzljNjcxNjJlODAwYzZmMmVfMTQ5MQ_1caeaad4-ee29-4244-a49d-5a8d8d32fb5a" continuedAt="ic0f6a2904fa54515a09080ce862726ae" escape="true">EARNINGS PER SHARE</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ic0f6a2904fa54515a09080ce862726ae"><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RleHRyZWdpb246ZmUzOGYyNDM5YjIxNDgyNzljNjcxNjJlODAwYzZmMmVfMTQ5NA_212a9b99-fc31-476c-bd15-e9d9100579a2" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"></td><td style="width:53.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.304%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Shares in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings per share </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfMi0yLTEtMS0w_69d94152-4963-4ba3-a140-3d10a66e1147">1.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfMi00LTEtMS0w_7a56abdb-a583-4ca5-8a0a-6c7fbb391d85">1.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfMi02LTEtMS0w_5d955522-b950-48ff-a8cb-d95e8c173f06">6.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfMi04LTEtMS0w_9c4b7207-ce9c-4fb7-8fff-14664ed2fe5a">4.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfMy0yLTEtMS0w_88d79de9-2b00-418d-be5f-aa2833596334">2,632.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfMy00LTEtMS0w_1d0d2994-1648-4192-bac4-fc51152c30ee">2,632.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfMy02LTEtMS0w_2eb64105-3e4c-4f32-9ca0-cce55a808c53">2,632.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfMy04LTEtMS0w_b7a65e19-2b86-4b6c-9fc0-fca22aea9850">2,633.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfNC0yLTEtMS0w_bdaf8586-3db7-4c16-b919-ece11b52e4f0">138.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfNC00LTEtMS0w_a460b375-8e92-4345-8eed-639b0d745224">115.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfNC02LTEtMS0w_45431f98-fce2-425f-be31-06296d177269">139.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfNC04LTEtMS0w_3ea612fa-077c-4a28-a531-80a8bc4edfd8">120.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: shares which could be repurchased under treasury stock method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfNS0yLTEtMS0w_07b33048-3eb5-49b3-8df6-15e50e5d1b23">96.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfNS00LTEtMS0w_41cb7a10-51c1-4c74-8c6a-93f6b40aa5ed">78.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfNS02LTEtMS0w_1b7cd632-8011-4c4a-9bdc-cc9b5c2ee57c">96.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfNS04LTEtMS0w_6bb9c60f-ee61-4867-9485-cf1f881798f3">82.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfNy0yLTEtMS0w_d8cf4b5c-f360-4947-b215-8e1dfd7a0397">2,674.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfNy00LTEtMS0w_2c9465ca-9f27-44bb-9a96-ca99005ccdcf">2,669.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfNy02LTEtMS0w_f1950867-7f69-4f83-bd4c-3c21f0bbb86d">2,674.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfNy04LTEtMS0w_7a462450-ba9c-44c9-a681-7d0e4d595851">2,670.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfOC0yLTEtMS0w_62b6259e-03cb-4fe1-981b-80a2e640e257">1.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfOC00LTEtMS0w_c3a8f62a-9253-470b-91a9-cbda1a6724a1">1.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfOC02LTEtMS0w_2373aabb-03e5-44d0-ad65-e0fb46626a79">6.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfOC04LTEtMS0w_4101123a-9eec-42e1-abff-3e5091e8c82c">4.86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The diluted net earnings per share calculation for the fiscal third quarter ended October&#160;3, 2021 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company&#8217;s stock. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The diluted net earnings per share calculation for the fiscal third quarter ended September&#160;27, 2020 excluded <ix:nonFraction unitRef="shares" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RleHRyZWdpb246ZmUzOGYyNDM5YjIxNDgyNzljNjcxNjJlODAwYzZmMmVfNTM3_ee8ddb68-cbfa-4fb5-8567-fa87a3fc4fc6">20</ix:nonFraction>&#160;million shares related to stock options, as the exercise price of these options was greater than their average market value. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The diluted net earnings per share calculation for the fiscal nine months ended October&#160;3, 2021 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company's stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The diluted net earnings per share calculation for the fiscal nine months ended September&#160;27, 2020 excluded <ix:nonFraction unitRef="shares" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RleHRyZWdpb246ZmUzOGYyNDM5YjIxNDgyNzljNjcxNjJlODAwYzZmMmVfMTE4OA_fab25cd1-a16b-43a1-8b8b-14ecebcc167c">17</ix:nonFraction>&#160;million shares related to stock options, as the exercise price of these options was greater than their average market value.</span></div></ix:continuation><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.327%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="if410ee6e03c8456f86a9fee997f08e65_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 9 &#8212; <ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMjU5MQ_2b026b53-941e-41a5-b68e-b1a4d72db870" continuedAt="ifd6555c28ace46929b13a34599172ae2" escape="true">SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ifd6555c28ace46929b13a34599172ae2" continuedAt="i188ae22de97e4d959498996d20e076de"><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="jnj:SalesBySegmentOfBusinessTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMjU4MA_7493cca7-b8ae-47ec-8a50-b6d6d33b5dc6" continuedAt="icb2ba7837a34406e901b03d13a54c016" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY SEGMENT OF BUSINESS </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent Change</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5932fe6bc8874865bd9bae6cd5c4e149_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNS0yLTEtMS0w_7ff5a007-42fb-4ed0-98f3-d2737fe48bf4">686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9863b76d1752421eab7f10a27e21c3a6_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNS00LTEtMS0w_f9b245f6-fba0-476b-894c-205da08a06aa">601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5932fe6bc8874865bd9bae6cd5c4e149_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNS02LTEtMS0w_d3deaad5-99a3-4fa0-a159-3bf9b9138853">14.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8648858c71084557978cd6faeca2cacd_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNS04LTEtMS0w_6fe72279-3c8e-472f-9a30-491268678f7d">1,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38fb4207f4f44740a27e0c6df6aeb726_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNS0xMC0xLTEtMA_1e7a607f-1150-432d-b2c3-ee87a1c75f72">1,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8648858c71084557978cd6faeca2cacd_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNS0xMi0xLTEtMA_b8293154-260d-4875-a257-3a3be26b906b">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1c9f29f75fe43e4847364d3f7c39cab_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNi0yLTEtMS0w_673dcf62-f6d4-4e55-b218-b15dab3f3008">686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7a63d17adab4e81bbe6f8151842a30c_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNi00LTEtMS0w_3ebe878d-5a5a-4167-b128-34bc4d82cf94">541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib1c9f29f75fe43e4847364d3f7c39cab_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNi02LTEtMS0w_7f982590-8cd8-4970-82f8-878db6092aae">26.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib646ba6c37f94afe9e3d21b88039c182_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNi04LTEtMS0w_08506df7-590f-41d0-a46f-3340a1900d12">1,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f7b6f883fcb4fa4a9afe5cf3bdb0815_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNi0xMC0xLTEtMA_e45e0c76-a277-4024-b7da-9b8a4ce64709">1,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib646ba6c37f94afe9e3d21b88039c182_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNi0xMi0xLTEtMA_7f455a7c-51b3-4403-9d51-cd2a910668cc">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d28ecdc380c4101b6135c161dfad020_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNy0yLTEtMS0w_db9cf39f-492d-42e1-8f67-e78a166cd4a0">1,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d474e7ed1044d528c7b1ffac5e15cea_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNy00LTEtMS0w_e6be5c79-1146-4afe-ab83-46b25c8bbb3f">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6d28ecdc380c4101b6135c161dfad020_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNy02LTEtMS0w_58f489f1-2bec-4059-96ef-859b24300b87">20.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie547a8c88fa940efb218427e0eabd0c6_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNy04LTEtMS0w_0bc7e374-586a-4dc4-b01e-0a130ac7d5d6">3,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddac223612a4d06a37f3fd6878493ca_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNy0xMC0xLTEtMA_34294058-cabc-4c07-a0bf-3ded0accf57c">3,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie547a8c88fa940efb218427e0eabd0c6_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNy0xMi0xLTEtMA_93df5949-1846-49f0-b645-c98cb14d8c91">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5975dabe875348b9b232e9e29d323eed_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOS0yLTEtMS0w_9cfa9a23-eb5f-494b-a30e-953492bead64">569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40ce11cf1c234e67b7e6b1a8988ba942_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOS00LTEtMS0w_e2992824-0fab-4794-b2e0-447805124e9f">572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5975dabe875348b9b232e9e29d323eed_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOS02LTEtMS0w_06640b79-0364-44b7-8fa7-7f5526440d95">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0847920abf9d4769baf2ea560468bf0d_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOS04LTEtMS0w_a271b6da-78c8-40a4-81d3-b4609b5d41b2">1,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaf4498d8f5049aa8af464f01fcd4088_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOS0xMC0xLTEtMA_2a9cbc13-9702-45d4-b768-fff31d9c3f1c">1,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0847920abf9d4769baf2ea560468bf0d_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOS0xMi0xLTEtMA_cc9cf64d-25f0-404e-b120-ecdbcc948d8b">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37f5a592ff13494aada072e3bba0cea0_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAtMi0xLTEtMA_1fc44e50-cb14-4544-af7f-7f8396c91842">555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd69d35e5a314c3f80c3949f37cc664f_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAtNC0xLTEtMA_dea74251-208f-41dc-aade-08ad65dbea87">577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i37f5a592ff13494aada072e3bba0cea0_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAtNi0xLTEtMA_1a00d5dd-f326-4d1d-884c-dc93652620e5">3.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04f3d42910f54dbdbe61282d28955d56_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAtOC0xLTEtMA_b93a09a8-a6dd-4c8d-8f66-4e16cbb17f55">1,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddf4ba62d5ce4571a62ee75dcd2a8e3c_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAtMTAtMS0xLTA_796d33e3-7ddc-4737-b925-16053aa87daf">1,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i04f3d42910f54dbdbe61282d28955d56_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAtMTItMS0xLTA_d885b162-3bab-4fa8-b7a6-2c0e00024716">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2674760a7034ccdac2446519a5166a9_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEtMi0xLTEtMA_6ce49ed4-087b-4b19-8ca4-0153caecc87a">1,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7da3b551671f44d192917a4c6f2efa57_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEtNC0xLTEtMA_371780e4-c77f-41a5-b2f3-f3832c6782ab">1,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie2674760a7034ccdac2446519a5166a9_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEtNi0xLTEtMA_96c7fa10-c5b4-49d9-bf3b-1ab9fe6f55bb">2.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9f77528e7ac40108b66c8931a2c701e_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEtOC0xLTEtMA_9b8db0f7-f3b7-4e8d-9329-2bf71cc886d2">3,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3b6e1b8fdd425390328188812a6eb0_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEtMTAtMS0xLTA_e2403b8c-775d-48eb-83c9-40018599ad0f">3,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9f77528e7ac40108b66c8931a2c701e_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEtMTItMS0xLTA_e288000f-9a15-494f-abdd-98ecb679800d">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic833af6372324ca3b5bfa4fcad54732c_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMtMi0xLTEtMA_6a4e6b1c-f57d-4ec9-99ed-4a14ace79c25">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i525fc27ed821404fb38182e25fa87eb5_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMtNC0xLTEtMA_6de390c4-dd42-478e-a06f-d0978af73996">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic833af6372324ca3b5bfa4fcad54732c_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMtNi0xLTEtMA_297250ab-0f90-41c1-b5a6-267372b1bf8e">8.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55f1d4591fc84cfc8c2e037ca49db283_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMtOC0xLTEtMA_ce98aa63-1208-490a-98a6-51a7f9a44cdb">478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibee17d8505bb4fe98b2e9fa97001fe0a_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMtMTAtMS0xLTA_ec2ad1cf-01d3-41e3-88c3-f55c068d3ef8">510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i55f1d4591fc84cfc8c2e037ca49db283_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMtMTItMS0xLTA_40c2cff8-6ca2-4e38-9875-a9b3ff55e513">6.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8085b27842a47b581f106618510e63b_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQtMi0xLTEtMA_59993a86-ce74-40d4-9e92-7b020346c41d">248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i050772dc13db458dae8ef05843e7c1e4_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQtNC0xLTEtMA_a86331b9-28de-41f5-b047-6099cedfc628">248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic8085b27842a47b581f106618510e63b_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQtNi0xLTEtMA_b7639d4c-0276-4eb7-a7c4-fe1751aeffe7">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie892e3f1014a404389b2b3050897a15c_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQtOC0xLTEtMA_1cc77646-5df4-4e11-847a-d43d72d1d634">762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03fd89880da847f0a48e5cd794cb0e76_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQtMTAtMS0xLTA_7b853a9a-afd6-4f07-a95e-e57a24205827">694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie892e3f1014a404389b2b3050897a15c_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQtMTItMS0xLTA_cfdd7fc1-8e2f-4dd7-af19-399573c61287">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice21827a874a4c00b01f16ab3cf18368_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUtMi0xLTEtMA_e39dcbe2-a558-4acb-b266-2b5a9ff491c0">398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddf1dd064873494095b906942f5d38ed_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUtNC0xLTEtMA_eafcfbd0-98ce-4123-a7e9-e3be17b4356f">412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ice21827a874a4c00b01f16ab3cf18368_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUtNi0xLTEtMA_ad9587d0-62f3-476a-b177-ec772f116bb6">3.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29ed38871138472c98810a5cd7f1dd95_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUtOC0xLTEtMA_38421dcf-9db7-4c47-a2fc-d9c21e5d58c7">1,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf97184ab0f344fa943bfc3649c4080c_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUtMTAtMS0xLTA_1c732af2-1433-4edf-aedd-ea0c582337e9">1,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i29ed38871138472c98810a5cd7f1dd95_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUtMTItMS0xLTA_486eb18a-905d-4753-8aae-31bf7329804a">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba082d308e2e40fab4c4792324108b13_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTctMi0xLTEtMA_f2acd523-7f49-4fb6-91ac-3210047c2201">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d3c4191ff94bc2b0b06fd86e9ebbc2_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTctNC0xLTEtMA_9f1e7210-1a1b-4d92-926c-d453f3614249">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iba082d308e2e40fab4c4792324108b13_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTctNi0xLTEtMA_8e2e0618-657f-4f0d-9510-6e586392b50d">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4744bfcdba4605b67ce9cf20e5ed37_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTctOC0xLTEtMA_0266849c-e0f9-4c88-ab8c-a007e18e48a7">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a9371cd71e74f32b3d3425e7fa3120f_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTctMTAtMS0xLTA_0a9e5e29-d105-4ed9-a8e2-387ab5be19d2">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2e4744bfcdba4605b67ce9cf20e5ed37_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTctMTItMS0xLTA_a439968f-472c-47ea-94c5-53144eda17d5">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c26ef7358064431907c0c0b8e35ca05_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTgtMi0xLTEtMA_ddf72218-8c69-4160-a7c9-be0a4094692d">296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9015829b0dd4cc083d55eb4725146ad_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTgtNC0xLTEtMA_4b86c444-f90e-4cb8-a3bc-8276e5828fab">302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9c26ef7358064431907c0c0b8e35ca05_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTgtNi0xLTEtMA_06fe83d8-2bf2-46d1-9796-4e575c013970">2.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i046a4a03db32475eb292807b6b65dc2a_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTgtOC0xLTEtMA_92f60a6d-5a63-4611-9f43-4cbe54b1065a">879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i987662a6928046d9a653a39c7642a99a_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTgtMTAtMS0xLTA_f11e48e7-2a74-416b-90ff-46a3234c45df">831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i046a4a03db32475eb292807b6b65dc2a_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTgtMTItMS0xLTA_6dee8d95-27e8-4a37-b2e7-aade2991a24a">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf3567b227cf43b7b727c573098b1019_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTktMi0xLTEtMA_6be083f7-fb0c-4173-b6ca-b6734d3b4c55">391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fe2032b4fab44759101707824a42b5f_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTktNC0xLTEtMA_0c1cd166-4870-4570-af77-019e1d9613b0">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idf3567b227cf43b7b727c573098b1019_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTktNi0xLTEtMA_a7a725d3-f199-435d-b4c8-20a6334544c6">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08e07c77ca240b6ac145790e6d91e27_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTktOC0xLTEtMA_436b23fc-f34a-4805-90a5-ba91de8a5d71">1,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7237727cb89c4b3ca79fd4c8ab24fae8_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTktMTAtMS0xLTA_5434078c-746d-47ca-bd9b-e4ccde411fc1">1,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if08e07c77ca240b6ac145790e6d91e27_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTktMTItMS0xLTA_18213182-4b2f-485b-9db8-39dc32c8c49f">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776cc9f3f12444e19c75d71e9f1306ab_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEtMi0xLTEtMA_9e08ebc8-97fb-458a-bcdb-cdb32eb904ac">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42c653266dbc4cbfb3ad7de36334d59d_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEtNC0xLTEtMA_5cf53178-ae7f-4bee-a9e6-0fc75ff69cf8">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i776cc9f3f12444e19c75d71e9f1306ab_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEtNi0xLTEtMA_391b987f-fa3d-45ce-890f-905ce3aeef6b">20.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf9f5672587c42ef82b704011560ab84_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEtOC0xLTEtMA_dccb320c-73ca-46b6-8535-620c9ff9ce04">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc4e2c56fe94f0ebb2696dfb6777df9_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEtMTAtMS0xLTA_8c49d092-3380-4ec0-b52d-ccc8ac9e4ec5">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icf9f5672587c42ef82b704011560ab84_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEtMTItMS0xLTA_0660395b-cebe-493e-84e9-44fc4250275f">5.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1864c3f454d54b6099348e1437264d1e_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjItMi0xLTEtMA_e08e094b-9cc6-444e-bb9b-82eac690e864">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0001607d8afa4b969777538d3b0090ac_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjItNC0xLTEtMA_aa0057fc-a6aa-414c-9d25-cf82783a7160">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1864c3f454d54b6099348e1437264d1e_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjItNi0xLTEtMA_f7a310bc-e045-4158-8925-0b9ffd7cb861">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe9e6fb867164bcab52ce074dbf7118b_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjItOC0xLTEtMA_b0948981-8f5c-4662-a6ba-3c6054a225b5">675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f00d71bd5644d7386d54e5e7ba6f9aa_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjItMTAtMS0xLTA_d24b937f-e794-4c12-9111-cd28d565f5b2">654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe9e6fb867164bcab52ce074dbf7118b_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjItMTItMS0xLTA_8ffc0ae4-9879-43a0-b152-584f0813517c">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6ca30128844134ad0de910cf66a408_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMtMi0xLTEtMA_d0940cfe-af75-4937-abbf-e7059b0f92a7">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f8cb7b296594fc5add46b54007f21d3_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMtNC0xLTEtMA_8436edbf-655d-47a6-8165-05f40e110c62">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f6ca30128844134ad0de910cf66a408_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMtNi0xLTEtMA_c87e85da-ccf9-4f7a-bee0-2e3fc0f80563">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i988a335b32c84bc3982666bf61d8fd38_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMtOC0xLTEtMA_da334a04-92aa-4f23-8925-2e3556525140">684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0f9db2930c7434cb55c268ec21f1fe3_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMtMTAtMS0xLTA_673e313f-200b-4350-a8b4-88d1b11a9588">664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i988a335b32c84bc3982666bf61d8fd38_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMtMTItMS0xLTA_ae6b34f6-3261-4e3d-8b09-e5ace3f2c2c3">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97d6e50fa564ecfa01edcf954ca9b30_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjUtMi0xLTEtMA_6e72d6ed-0ec1-45c0-a2b3-0f2c5f6ef331">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ccb194a8c094e919fdb8681e73ce223_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjUtNC0xLTEtMA_84dfacdc-404a-4820-9582-5eddb03c7d6d">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic97d6e50fa564ecfa01edcf954ca9b30_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjUtNi0xLTEtMA_0d0041dc-6f31-4ffb-a6a3-66f26ef26bb2">2.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf724d7bf6384a4d99527cb12064aaf7_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjUtOC0xLTEtMA_ffd61357-f392-431b-86b4-34e766f4106e">390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id60c33805d624a1e863dd18b29ce66d8_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjUtMTAtMS0xLTA_4ca038ee-ceb0-44fd-9bf6-69b301e31c9a">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icf724d7bf6384a4d99527cb12064aaf7_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjUtMTItMS0xLTA_9b9a22b4-5f9d-40d7-8fcc-992674f734e2">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa415248ab90441fa1cc6656b8dcf614_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjYtMi0xLTEtMA_0e7ada08-e165-4c58-825a-8721a7804a68">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib69f132a3f0b40c581d2942e7d57a5b9_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjYtNC0xLTEtMA_3463a8af-d549-40a4-9811-e063a7c33c6d">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifa415248ab90441fa1cc6656b8dcf614_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjYtNi0xLTEtMA_cc47d7a3-84cc-4a02-a59a-a53898d7e41c">5.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic01e2ce9f12a469dba08795b5a902ed6_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjYtOC0xLTEtMA_88290da3-0591-437a-8a94-a067174f2604">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie95cdb275193469989a402b370c02342_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjYtMTAtMS0xLTA_fea54be5-5a9d-4af3-8792-3acbc04dcd22">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic01e2ce9f12a469dba08795b5a902ed6_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjYtMTItMS0xLTA_4c676dd7-34f6-4770-ba81-045eb63d2862">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98adf17c3209468a982a0f7200c745a1_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjctMi0xLTEtMA_b1a020c6-5fe5-49bb-a40a-f671c7cdf4d7">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idca691679ad64cf583644d8594234216_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjctNC0xLTEtMA_c22f7174-9b6e-4200-a586-ada7f740bb2f">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i98adf17c3209468a982a0f7200c745a1_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjctNi0xLTEtMA_584c6e87-51b1-4637-9f2a-9b6a059c062e">3.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb215856dcc24e3f9d3079bf180a51ff_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjctOC0xLTEtMA_9d2453f8-e649-4418-bdda-8d319ce90c70">575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3add39942c4242daa496b88f14058185_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjctMTAtMS0xLTA_1bfc3e3a-25d0-4ced-b87a-00801a5a942b">545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifb215856dcc24e3f9d3079bf180a51ff_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjctMTItMS0xLTA_ec20072b-e720-4422-afb1-cf29ed6a655c">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consumer Health</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a5b1e45c95842418dbd6dcbe4bce0b6_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjktMi0xLTEtMA_2fe0905e-b3dc-4780-a868-b2c5e6f188f7">1,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91bd273779f6455f9fb27bde5dca4f93_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjktNC0xLTEtMA_5aeea039-4a6d-49cb-9c52-ebca9f9a9b90">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8a5b1e45c95842418dbd6dcbe4bce0b6_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjktNi0xLTEtMA_33bc6cd5-1c91-4d69-bbe8-9e49bc228647">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2b0381a81c41c495cc13d352d5aeae_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjktOC0xLTEtMA_0e423c45-fc65-43a6-a86d-3d6b929e6839">4,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i932f9d2df6c34e58b2f54f1f4929c220_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjktMTAtMS0xLTA_5385fefc-846f-493c-90a7-e84c8a827fb9">4,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2e2b0381a81c41c495cc13d352d5aeae_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjktMTItMS0xLTA_57758fdf-1e7c-414a-8b33-dadac13029f0">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d436a7587f45a1ab95abb5b18a129f_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzAtMi0xLTEtMA_ed64bd25-1308-4d85-9892-d40305bc59ff">2,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9a74be9ea184900b90a441048493bc4_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzAtNC0xLTEtMA_7e5a2baa-d8a7-4abb-9e7c-4ad56638ba11">1,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38d436a7587f45a1ab95abb5b18a129f_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzAtNi0xLTEtMA_aff8132c-6123-40a8-9ed5-242a7ab2981a">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0250c72ff9ac405c928f736053a9f5ff_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzAtOC0xLTEtMA_c3c7ef82-82e1-4e90-a6fd-d78e05a8d838">5,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c4878d8e6ac4393a3e73e04f398611b_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzAtMTAtMS0xLTA_32ebf200-ce54-4066-9391-4c1596776737">5,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0250c72ff9ac405c928f736053a9f5ff_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzAtMTItMS0xLTA_55340bed-d32b-47c1-ac8a-0ce09cfc8646">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27ba7c90a4c1434586cbf514f3e51927_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzEtMi0xLTEtMA_fcc2b2e0-4db6-4242-ae07-69a05b750a76">3,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aa1fb345ea8443c9e0bc1aa8418aaec_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzEtNC0xLTEtMA_bde06e30-1acc-4f8f-86a6-a0c3da6b6b75">3,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i27ba7c90a4c1434586cbf514f3e51927_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzEtNi0xLTEtMA_418d18c7-3dbe-42f4-b069-223961cfeeae">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i185910f7181845c8aed38c39fd4b6cab_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzEtOC0xLTEtMA_27d4d38e-519e-4ce4-a633-993c2787cf4f">10,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa93431137654cfa8d08a279d01cc337_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzEtMTAtMS0xLTA_54143d48-fb85-468f-b0c5-67e51f51f52e">10,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i185910f7181845c8aed38c39fd4b6cab_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzEtMTItMS0xLTA_bb7936ae-6bdd-4ab3-99f3-966a94ce681b">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:168pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-top:5pt"><ix:continuation id="i188ae22de97e4d959498996d20e076de" continuedAt="i4217e19313eb46ff8610a930580b58be"><ix:continuation id="icb2ba7837a34406e901b03d13a54c016" continuedAt="ie2f985be1e3143a5b240d772446b17bd"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2860d64b06e045eb890021c7710f0aad_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzYtMi0xLTEtMA_f7002cd7-20f3-4491-85c1-a34ff1d95f3b">2,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59be6ed5442a4a678a48fc617f1eb13e_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzYtNC0xLTEtMA_ec0aa9da-8920-41a5-aa69-bd208810135e">2,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2860d64b06e045eb890021c7710f0aad_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzYtNi0xLTEtMA_626eb13a-fc07-483f-a079-05216c9986fe">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c17375fbded4a6ba40cab9f3d8326d7_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzYtOC0xLTEtMA_87c21356-d3ac-410a-bce6-c10224dabd84">7,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45b42eb8b685491a806080af8dc02aac_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzYtMTAtMS0xLTA_d39ecda7-69c7-469c-946f-23b8c5091e1f">7,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8c17375fbded4a6ba40cab9f3d8326d7_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzYtMTItMS0xLTA_6625d976-2b1e-4b32-ba5b-9d7616a6869d">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieab9cec340d34cec86ad2425fd1846fd_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzctMi0xLTEtMA_24b2fbb1-fbc5-404f-a998-b9daf7ab82f6">1,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cca5cafe25a4fe0a525fbc02d000afb_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzctNC0xLTEtMA_cc0ad683-a6cc-4bf1-9352-f1a241644b12">1,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieab9cec340d34cec86ad2425fd1846fd_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzctNi0xLTEtMA_1ad66855-fcb2-4987-8a3e-2214689a6fb5">20.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic00d19a36bdf402ea98bd292be45894b_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzctOC0xLTEtMA_a0344658-1162-4476-b466-6608f5d22a81">4,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a41a88262640b3b2d8b6e97dba1464_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzctMTAtMS0xLTA_aa5b3b70-ec38-47e3-8782-2c911b29b2db">3,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic00d19a36bdf402ea98bd292be45894b_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzctMTItMS0xLTA_1f4e5f9a-4635-43e8-a0d3-05364b521bc7">23.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia281107d882e4be6a4d88169207e2a36_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzgtMi0xLTEtMA_3c1c7fce-6050-4a0e-800b-faf13e289533">4,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd6a9a9e55274bffada72f2726569f6e_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzgtNC0xLTEtMA_e7d28df0-71b5-47ec-82a2-be29ae9acc0f">3,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia281107d882e4be6a4d88169207e2a36_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzgtNi0xLTEtMA_0de0598f-b9d6-4ec0-bdac-2719ad33ad5b">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77effd52b2654ae686fe2393749c515d_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzgtOC0xLTEtMA_2fa5af8e-02f5-4612-87cf-da41d3c05c8c">12,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia37c81e1cad0453994f3e00b01af754d_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzgtMTAtMS0xLTA_0de3ba95-d84c-4942-bbbe-d4079708a11e">10,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i77effd52b2654ae686fe2393749c515d_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzgtMTItMS0xLTA_d1183ca2-0553-411a-b8dc-fa88f4a61678">13.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ab0a4211f24f9391eae4b6c0bce606_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDAtMi0xLTEtMA_ecc7d3d0-3534-4665-b4e3-2e2860efc34d">480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1c64eccdd14e999154f3c36cce6b77_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDAtNC0xLTEtMA_fb1e3046-4f18-4fd1-acfd-03bf0e072920">634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i41ab0a4211f24f9391eae4b6c0bce606_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDAtNi0xLTEtMA_21ee8329-2674-4cad-9005-1cdd8f99106c">24.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i909f193a74e24bfd8a95144ed8637f1a_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDAtOC0xLTEtMA_61fe636a-2445-46ae-878b-2802da900475">1,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id049e506122f4113a401765a69fb9f08_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDAtMTAtMS0xLTA_acb825cd-ec29-4934-8244-96f6074c3316">1,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i909f193a74e24bfd8a95144ed8637f1a_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDAtMTItMS0xLTA_0cef0fbc-a467-4dfd-8307-490055fdb14e">18.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Exports</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dab22a716c64564ba838f1dd48d7f2d_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDEtMi0xLTEtMA_0f73dcbc-74bd-410c-bb6f-458d0ebc6200">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacbd09691dfd48849fa8a06109049218_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDEtNC0xLTEtMA_82b7b2fd-24fb-4628-8514-f694405e0a75">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0dab22a716c64564ba838f1dd48d7f2d_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDEtNi0xLTEtMA_1d90ca31-8142-40b5-b3c1-52801b600fba">40.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0bef40f936c45448366cedf462d82d6_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDEtOC0xLTEtMA_4aa96fd0-0b57-4173-8d6d-d67702895220">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifda8dae70c484419b819b08a661b39d5_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDEtMTAtMS0xLTA_67c3082e-e593-44cd-8472-d4fd108720e0">321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib0bef40f936c45448366cedf462d82d6_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDEtMTItMS0xLTA_9c61bd7e-6551-4124-8af6-442985c119cf">38.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3e9d721cf949aba7bed39328685faf_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDItMi0xLTEtMA_cab5af70-d38f-4d66-949e-de2edaa67c4a">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic218b0d17bf9480fb2a4af23655e9de2_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDItNC0xLTEtMA_d73aa5b3-ee0f-4d6e-9839-df3fb0699c0c">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7c3e9d721cf949aba7bed39328685faf_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDItNi0xLTEtMA_f25afeca-ab40-43bb-b96a-2a11064b66e4">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742b390271ec444ebf304d883a7aaf85_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDItOC0xLTEtMA_2cd7ecec-01c6-4b15-a8f7-50c9bbad9c01">721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0637885c2824f0e9c6471d6d38dc762_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDItMTAtMS0xLTA_ae5cc4e4-1366-4381-be02-890754fa62c4">673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i742b390271ec444ebf304d883a7aaf85_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDItMTItMS0xLTA_51238462-f661-4e69-a43e-7ddf58316d88">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i020a9535952b4c63a401a40815ddf115_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDMtMi0xLTEtMA_05bade86-80fd-4a65-8d51-7c3b25e25a8f">761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85aea8ddbc744caa8e21718122998c19_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDMtNC0xLTEtMA_649338ab-1467-4688-ba54-a31aefced8a4">921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i020a9535952b4c63a401a40815ddf115_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDMtNi0xLTEtMA_141109d5-0660-4d13-a8e3-87c6dddd8d5d">17.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c1d50e36104bbd9d2fff5426a37ba7_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDMtOC0xLTEtMA_4f573bac-803f-4758-8ea2-ed81763d2876">2,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide16825e0c5042f89d58332d23f6ae0a_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDMtMTAtMS0xLTA_1a478a3a-6cf9-4606-b937-1677c473ab39">2,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i49c1d50e36104bbd9d2fff5426a37ba7_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDMtMTItMS0xLTA_b95d386a-fd4a-417c-afa8-2bf3078583c9">14.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65144a7d9e2a4b1db67b59d28e3d74cc_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDUtMi0xLTEtMA_d9a527ac-ba4d-429d-b384-c70a67b203be">295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6d3a01a24804bc9af0ecb6a9b2c67fb_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDUtNC0xLTEtMA_2329b3c6-1fb9-4abd-b868-fa66d8870483">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i65144a7d9e2a4b1db67b59d28e3d74cc_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDUtNi0xLTEtMA_49f24549-d24b-4db9-bf1e-15f47a29c345">5.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50211f0c1289483e8e0e6d1eed3c67e3_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDUtOC0xLTEtMA_c2de9304-56b3-4eb6-9ee6-1c64254846fa">840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i655717f0369640c4b9a157a17bb82e9d_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDUtMTAtMS0xLTA_369880c2-6cc7-4c6b-a165-fb3f2034c710">840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i50211f0c1289483e8e0e6d1eed3c67e3_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDUtMTItMS0xLTA_e96c8d21-2635-4b7e-b3b3-8b2c9bf8136d">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf386660945d4d5d9e6b8634ef6532a1_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDYtMi0xLTEtMA_51a743e2-c0ef-4e0f-b7f7-a42b1095719c">276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb6d6e4976ac495b99e5329deaf58bfc_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDYtNC0xLTEtMA_89ee4db3-da9b-4d0a-8cec-663980ec123f">280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibf386660945d4d5d9e6b8634ef6532a1_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDYtNi0xLTEtMA_8aa313c4-6677-442c-97dd-6ba16a3a420c">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7c46e72eb484be486c63c78eb02e206_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDYtOC0xLTEtMA_3622c6b7-b06f-4c0f-b433-c137908642e2">877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40bfe120527540219fcb38f6a07a75c7_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDYtMTAtMS0xLTA_9b573304-3bea-4e97-9139-a74d4d6255f2">827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib7c46e72eb484be486c63c78eb02e206_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDYtMTItMS0xLTA_0cd753c0-c2c8-4e8f-bd22-092568ad29cc">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3510e548888f4e1fa6f52d81f4ab6cf3_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDctMi0xLTEtMA_ea3f3899-85f7-41e6-aa02-7cfe2e6a2708">571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56965738078b457fae12de6ffa955475_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDctNC0xLTEtMA_a4b8f3c4-446b-4e5a-bdb2-be05c5e12e94">592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3510e548888f4e1fa6f52d81f4ab6cf3_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDctNi0xLTEtMA_79a33435-f093-470f-8983-50c304dc9e76">3.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a6f6ec594242669dac6cfa2e2c7076_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDctOC0xLTEtMA_b4075aa7-775f-4b2b-98ff-1a79b5ea8154">1,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90f1a8b28bba41749b15a878c6c18fad_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDctMTAtMS0xLTA_6d4614b9-3e38-4b2d-b585-4b431e8f3068">1,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72a6f6ec594242669dac6cfa2e2c7076_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDctMTItMS0xLTA_16e69256-befd-400a-b6b0-9411946ac2fc">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91266aa05dd2425d985bfd9033fb1fb3_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDktMi0xLTEtMA_fb6598b5-72f1-47cf-9527-cfa62d2de53f">1,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15626b644ab14a8fb91a1555191c8648_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDktNC0xLTEtMA_b54f3753-e8b8-472e-a15c-9e1eeb860f24">1,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i91266aa05dd2425d985bfd9033fb1fb3_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDktNi0xLTEtMA_372dd3b6-306e-4e19-bfb6-9c637837d0b5">19.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibae5bbcea9f94ad5b94969117f4e506e_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDktOC0xLTEtMA_aaf85462-0441-4952-9a8e-fd3680de76a2">4,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadc37e4e06744f8fb3399608c7e6ab66_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDktMTAtMS0xLTA_fa8b9b2f-3ea7-47fb-86a1-1a6346b9430d">3,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibae5bbcea9f94ad5b94969117f4e506e_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDktMTItMS0xLTA_5ddef944-b170-472a-9dd0-5eec01c2020a">19.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibad7ff907c4d46428f779f4bdb8db2ce_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTAtMi0xLTEtMA_bc4ceab1-399d-44ab-81e1-e68a21343330">809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if38f3c37921e44cda1b5db6443989c29_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTAtNC0xLTEtMA_a4d59305-6dad-4eda-b633-6083f421dccf">634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibad7ff907c4d46428f779f4bdb8db2ce_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTAtNi0xLTEtMA_43e6122a-3173-4d9e-9b73-bc0201c7d412">27.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f09c17c23a42ac9ebe11023c84580f_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTAtOC0xLTEtMA_ae169f9d-1f30-4d6d-bd36-f04b2220b6bc">2,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc3bf48554b44e80be08a060489581ca_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTAtMTAtMS0xLTA_aebca971-3fb6-4a7e-bdca-5dd657c28ade">1,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i73f09c17c23a42ac9ebe11023c84580f_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTAtMTItMS0xLTA_1d85d522-8fd1-460e-9543-ba0b6a0d4691">33.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744f7d39a15a411bbf361d82d82dfe4e_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTEtMi0xLTEtMA_8fe4f2b7-9829-497b-bee4-071bd110421a">2,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7d413bd46d24d6abe8b625214ada14c_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTEtNC0xLTEtMA_f3b2c99b-28bc-4b9e-99b3-27d5bcec5cfe">1,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i744f7d39a15a411bbf361d82d82dfe4e_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTEtNi0xLTEtMA_77b6c9f3-1243-4774-b8a3-243615570e3c">22.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcfdef25565c4ba58a2615e2ab0fc2ab_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTEtOC0xLTEtMA_54cbb2ab-86f8-4a3c-8c28-c58c3cf60175">6,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadc0a4943c0e4c70a773401d645f1312_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTEtMTAtMS0xLTA_b7b07f7a-0000-4627-b2e1-73eb9403c1d9">5,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifcfdef25565c4ba58a2615e2ab0fc2ab_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTEtMTItMS0xLTA_3ce67ed7-79e2-4387-b478-a39920ba3214">24.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784ee54441974c4eb54e9257b0e31430_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTMtMi0xLTEtMA_95f8ec32-846a-4c8c-b0f1-92d924d453c3">376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3480e995cfa436c961a9a4d13e49bd9_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTMtNC0xLTEtMA_92d3d5d7-bbeb-4ad3-8b68-8056a1169180">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i784ee54441974c4eb54e9257b0e31430_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTMtNi0xLTEtMA_2dcb739f-818f-4af8-a9be-3891b4bc0fb9">69.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie13682ac60d24dee80fa0761d2ecfc64_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTMtOC0xLTEtMA_1ff12cac-1cd2-421c-b80f-64e9a9c2167b">975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f1311d4010d4f319357cbf0e5b86b3d_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTMtMTAtMS0xLTA_3f8bb297-5194-4b62-a3d6-10693ff4e7e9">650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie13682ac60d24dee80fa0761d2ecfc64_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTMtMTItMS0xLTA_6ff320b3-2713-44a2-b077-cfbd422ba0cb">50.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf40956a9c1347769a071ff6bfafc142_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTQtMi0xLTEtMA_fbe964b7-0a32-4dbe-85c1-a05dc58e4102">161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4658279dda2e4f0fa81448f27d0b4f77_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTQtNC0xLTEtMA_e65f82f9-75c9-499d-b180-c74983e2b225">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icf40956a9c1347769a071ff6bfafc142_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTQtNi0xLTEtMA_a261c713-faf7-4225-b697-4db3e92fc618">52.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i199ccf31df6140dcb89e1686bb513228_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTQtOC0xLTEtMA_af523b1f-6f82-489e-b95e-806d89fc68d1">459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d8b2515e72b4a779aaf43dfbe387804_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTQtMTAtMS0xLTA_0137847b-f69b-44ac-8a19-40efec31aab1">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i199ccf31df6140dcb89e1686bb513228_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTQtMTItMS0xLTA_35add58c-bc9b-41f2-956a-cb8da3fa4b17">45.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa84aee89c7944bf90b3125200ecd80e_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTUtMi0xLTEtMA_9a13e59d-28d2-474a-a542-6ff0a25fb580">537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie349729608994bf887fda0639a138ad3_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTUtNC0xLTEtMA_316dcdff-f566-4459-8c06-2757c96e6b5c">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaa84aee89c7944bf90b3125200ecd80e_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTUtNi0xLTEtMA_8d686e09-24e3-4a49-8eef-ab29c0327bb5">64.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2f2c2e83225451d902cf2623ede1f1c_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTUtOC0xLTEtMA_a45476bc-fde5-401c-a838-e9157a97c196">1,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29cff2e6865142d9a4661c3fcb511df1_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTUtMTAtMS0xLTA_e8e3ae42-2535-4f11-a6a8-5c435d2e71c1">965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie2f2c2e83225451d902cf2623ede1f1c_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTUtMTItMS0xLTA_11e2453d-3ca1-4031-94d2-1618ff333a7b">48.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER IMMUNOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b35562d3e004031ba416de20b26cf73_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTctMi0xLTEtMA_e7bf01e7-3dc1-4503-9ef6-b0c3c90efd16">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba4873f02ec94b1199e6f56536d6dfe1_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTctNC0xLTEtMA_605fe772-9f9e-48d2-8f86-bb03940d341b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i319fc8a3857049aa8eee5c1b14cce0dc_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTctOC0xLTEtMA_ac5ff573-cd1b-4e68-92c0-f62f7dae4ad6">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56710d10c9af4516b82e08bcd605ff90_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTctMTAtMS0xLTA_45bc4177-116a-49cb-8f5e-26609caa17c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b95a95d0ab74b0593bd0223e4b8ad13_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTgtMi0xLTEtMA_3632d12c-9c49-4b53-b2ee-9bef2c5f3b5c">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8c876f733014aa39f0d8214e223f585_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTgtNC0xLTEtMA_de4a0c4d-4cbd-44d6-9b05-5b3d2ef00606">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaa2dae0ae2f4573be92b240376298b0_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTgtOC0xLTEtMA_32ead7a2-0339-4bbc-adf9-4b9ac19dab6f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b04f604d38f430783a61651065a0a13_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTgtMTAtMS0xLTA_82bec315-8f30-41dc-9425-1cc03779a4ee">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifaa2dae0ae2f4573be92b240376298b0_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTgtMTItMS0xLTA_a7e581b8-4472-4271-aa97-9954a8b8f5f6">68.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide71f27d89ff4ecba07e81f6917e063e_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTktMi0xLTEtMA_75bdad11-df91-45c3-9a73-88a23d375ea6">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5df2445aa9db4bcba1f2c495dfcf06c7_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTktNC0xLTEtMA_f7c9bc55-f48e-4237-8b00-cbef01a63646">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ide71f27d89ff4ecba07e81f6917e063e_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTktNi0xLTEtMA_ec06e01e-592a-4236-9ae0-8e41e7c647a4">26.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c2ea56b89e848afb39b9ca75576f81a_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTktOC0xLTEtMA_1fb5037c-dbd4-461e-97a5-99698997e8fb">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7d0cd308a8142d6a92cd40abc7d9327_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTktMTAtMS0xLTA_a50f5174-f204-4f65-bed1-961fbc8d4b42">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3c2ea56b89e848afb39b9ca75576f81a_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTktMTItMS0xLTA_de931f48-e85a-439b-9eb3-1ba456ac13fc">91.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id029b233fbaa480b812c80c34fbb60f5_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjItMi0xLTEtMA_b4786c11-c4c2-478f-9dd7-0d8c513d26b5">679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c03fd29ef754d63b27fc58525b944c6_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjItNC0xLTEtMA_9663e83e-1ae4-40c6-9ebf-46331c31458f">413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id029b233fbaa480b812c80c34fbb60f5_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjItNi0xLTEtMA_4af3a79e-b275-4d65-a482-a624ea03a058">64.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ad4fad0fa5b4730bebb0dfc08f8b7f8_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjItOC0xLTEtMA_380cb61e-dd2d-4a6a-8a3e-83adcf03138f">1,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b2360aa64bf40069c6622e4971e8616_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjItMTAtMS0xLTA_bf0da281-17f4-42b0-8817-5b41b126325b">1,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9ad4fad0fa5b4730bebb0dfc08f8b7f8_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjItMTItMS0xLTA_403c006b-ba62-4032-8b6f-387a87070115">29.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb258923b1f94a218e7cf9e72e1a4e29_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjMtMi0xLTEtMA_817a2412-7acb-4234-9d01-a5747c7dae5c">709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0f0b78e2774313ad18d0495403fcce_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjMtNC0xLTEtMA_f5cae74d-085e-46e8-9e4f-6f1977df32e4">451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb258923b1f94a218e7cf9e72e1a4e29_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjMtNi0xLTEtMA_e419660a-c80c-47fa-9fa7-9fdbb23ecfef">57.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38211ff6f4549ca99cf9a47fdc50a68_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjMtOC0xLTEtMA_cb320dce-a7b3-47d6-948d-ce205d5e4057">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc3c076d95ff48c485eb3d0187e68b87_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjMtMTAtMS0xLTA_2fa7fd01-4d42-4e0f-b309-77b95aa16a76">1,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie38211ff6f4549ca99cf9a47fdc50a68_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjMtMTItMS0xLTA_13a79502-2099-4f01-af86-c86c527e086a">28.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e8c4072e9244960b877a66a60def445_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjQtMi0xLTEtMA_68d84b6c-a4c0-476b-81a6-4fe61175bd4f">1,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24d94e00bd754768a1c1b598eb47950d_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjQtNC0xLTEtMA_fd5dbb9a-b074-4997-a3d7-6825b8ddfb2a">864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9e8c4072e9244960b877a66a60def445_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjQtNi0xLTEtMA_f93d6b76-a5f3-4d9f-a6bc-1f6abd431631">60.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48712a124534471ea2804e884605a06f_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjQtOC0xLTEtMA_dd9cbfc1-e2b7-4691-a7e0-1d32ab0a1f32">3,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ded785627e4686af72f0b8d2f046fe_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjQtMTAtMS0xLTA_f9ca5a67-f1b6-4462-9aa2-ac208e886c79">2,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i48712a124534471ea2804e884605a06f_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjQtMTItMS0xLTA_edbaed02-d432-4696-8811-d58afc8eae4f">28.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">COVID-19 VACCINE</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0cd8c26245b493ea80fd420a16b98d9_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjYtMi0xLTEtMA_be83d511-9d06-4ec2-8745-d74046a860ba">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic49e6c0c298b45d384afc6010a6b7762_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjYtNC0xLTEtMA_6851954d-a4b4-4f7c-acc4-ab560716a1e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b42a988d6c44c5ab94f2e2bc145a16_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjYtOC0xLTEtMA_22a0b9e4-be62-40d5-b8e8-201abdd2444e">421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d2c74c6b3434964b75d4a41dae81179_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjYtMTAtMS0xLTA_a57ec3bf-3781-4ed3-9081-37a80d443dd1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0693b3d163314be799135d4bc4076c22_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjctMi0xLTEtMA_d60d6b8d-5d7c-4ae6-945c-2b8569dc309a">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief37e3faf17c4c568270eae6b145b3cd_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjctNC0xLTEtMA_3594f52d-58a9-4bff-a397-396623c3f698">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cbad562537b416c87c3c047d42d646a_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjctOC0xLTEtMA_b6e25172-c876-4f2d-b5c3-d43f6d30873b">346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5edcc1f3bb72432eb95672f9fe6b9d10_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjctMTAtMS0xLTA_da49d1f4-5079-4052-b3da-e572e83923ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06145f78f1d34def882f37c971b1b1d9_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjgtMi0xLTEtMA_582d2dd1-7ea3-492d-92e0-d43036c49bbf">502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ec43159f654583ba1e536a80658f9f_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjgtNC0xLTEtMA_7ffe2e3a-da96-4f86-81a8-33caa3b51d21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f8c3daec6804be1859d4f0afafc33f0_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjgtOC0xLTEtMA_6268e30d-7e96-4480-8408-74b749142a24">766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867a837018b24f99a9a411f45c919e92_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjgtMTAtMS0xLTA_43344555-da05-483f-800e-fd5d6e6095f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">EDURANT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / rilpivirine</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb6e3d84fcc04f4ca22b4170593731ed_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzAtMi0xLTEtMA_95a708e4-4517-4bee-854f-0212d8590fe1">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de05d9759a54853ac7066c47b8847e0_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzAtNC0xLTEtMA_72a5c425-d600-4a8b-af42-ca7def9ad1ca">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb6e3d84fcc04f4ca22b4170593731ed_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzAtNi0xLTEtMA_3ce0d976-3e1e-4717-b5f5-bc6431846659">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic83f61d0cfea4373978c400de01b8b78_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzAtOC0xLTEtMA_5cab1d0b-7d99-4d17-955a-4ba5bff027a3">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43c23fa8a1c41859b4371ea5c634e3d_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzAtMTAtMS0xLTA_512e6e40-e777-411b-9d84-d9a910186b06">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic83f61d0cfea4373978c400de01b8b78_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzAtMTItMS0xLTA_ed41bd57-e107-4873-ad25-4d0ad36772d9">4.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1bd97635393475dad752c246c239a5d_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzEtMi0xLTEtMA_d21e1622-b8a4-4e7a-b7c3-1ebeda74b285">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc468b2507d144f2a14b7c6ac31458ab_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzEtNC0xLTEtMA_c2e58dc5-64a7-4ac4-873b-60864c4ee24e">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib1bd97635393475dad752c246c239a5d_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzEtNi0xLTEtMA_7007d810-c347-46df-aea4-aea5bd67cb9a">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica34b4218d3541b09c3da6d94f2cb5e6_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzEtOC0xLTEtMA_831af114-84b1-495a-acd8-2c7b1228fc7d">733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i992584c4bfc6471d9deb7b1eb40513be_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzEtMTAtMS0xLTA_38645ab2-e699-4ed0-947d-7c15a7c9e6ee">684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ica34b4218d3541b09c3da6d94f2cb5e6_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzEtMTItMS0xLTA_6cc4fc19-abec-4de0-86fb-c1732d0ddfcb">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d7969d1f8aa4dda8ea8586ae9c4137b_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzItMi0xLTEtMA_1d523dd9-8e56-4fa9-8b08-bfb7193c82a5">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eb3f22e2a6640ce84be77248010d037_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzItNC0xLTEtMA_240a508e-66ad-4e5b-822c-d84220b73bda">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0d7969d1f8aa4dda8ea8586ae9c4137b_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzItNi0xLTEtMA_fb7a35b1-c976-4ce0-96bb-d1b30b4e14df">9.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1aea64ee5d24421ab72f13729dedbd07_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzItOC0xLTEtMA_f1125ad1-71d2-480a-9b87-fd624e2de294">764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id867ff6ff03b414389070eb180dfb49b_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzItMTAtMS0xLTA_e5de7ce0-a60e-4cfa-b06c-1c87fc113ffe">716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1aea64ee5d24421ab72f13729dedbd07_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzItMTItMS0xLTA_1060ec33-9d29-4913-8388-24b302a14eec">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / PREZCOBIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> /</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">                                    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">            REZOLSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / SYMTUZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6506a7038e6c4b3fa851ccb2c53be423_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzQtMi0xLTEtMA_cb4741a0-7e32-414e-a76e-81ae67a67be8">380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide35fefcff44453d8d65564e21d05eb2_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzQtNC0xLTEtMA_8c353290-515c-4920-8d34-df5b00c1458d">379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6506a7038e6c4b3fa851ccb2c53be423_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzQtNi0xLTEtMA_5f7b9cc6-f5f8-4653-9e3c-df3d0b2231af">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id44eb4835c3848728a14a8c3f6cdc458_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzQtOC0xLTEtMA_f2b5f16e-fb80-4f77-981f-7193c93d4586">1,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81052cefe0fd4a0b8c431e3080dd0f2e_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzQtMTAtMS0xLTA_925dc45d-2333-4396-ba24-c9b0cc9f1cc3">1,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id44eb4835c3848728a14a8c3f6cdc458_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzQtMTItMS0xLTA_7d12130e-2838-4542-8601-194973ed5e74">2.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94d8014e61a64d64883ac98c61c9fc14_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzUtMi0xLTEtMA_a2511edd-fdec-4739-9c09-12f8acf558bf">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3c431fe980745c0b7193b78927935bd_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzUtNC0xLTEtMA_50a1d236-c113-4b76-aabe-9adff2bdac3b">147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i94d8014e61a64d64883ac98c61c9fc14_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzUtNi0xLTEtMA_b51135fc-08c5-43c6-90c2-1dbc685c3f10">7.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8525a44d8d614f5cb1fbc085ac7ad72a_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzUtOC0xLTEtMA_c53fa218-ff68-4539-93ab-6bad5eed9a5c">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a2a1d85a1814d26a7c59cb5406c544e_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzUtMTAtMS0xLTA_bbca902f-5497-443a-a464-e43d11f3a85c">461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8525a44d8d614f5cb1fbc085ac7ad72a_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzUtMTItMS0xLTA_ad2bb687-01ca-4a44-ad42-30e351291754">4.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia499ee071d3a4a3d9c98fc4f9f4361e1_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzYtMi0xLTEtMA_59a9b0a0-7997-4a66-a7dd-612e5845fdd4">517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i540e20523e4d4912bdc772d9ad3994cb_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzYtNC0xLTEtMA_8685ce80-5c36-44bd-86c4-1e52aff2310a">526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia499ee071d3a4a3d9c98fc4f9f4361e1_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzYtNi0xLTEtMA_e936f8ac-2b4f-4425-9412-1d96124bd6d8">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c1c368ad7148d183d9d0514e949c26_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzYtOC0xLTEtMA_be4ca1f4-8c36-49b8-a2b9-c9e153370e68">1,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24eecfd1ba81496297deca71fae20acc_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzYtMTAtMS0xLTA_63f20671-e1b3-4c40-83b9-8ca14edbb64b">1,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i73c1c368ad7148d183d9d0514e949c26_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzYtMTItMS0xLTA_cfe0dcfd-a9f2-4a86-ab2e-4a1ea9602e87">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-top:5pt"><ix:continuation id="i4217e19313eb46ff8610a930580b58be" continuedAt="i44910920d1f44d53b8494e798002102f"><ix:continuation id="ie2f985be1e3143a5b240d772446b17bd" continuedAt="ia02612af7a20492ba347b1ec1ebaf946"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER INFECTIOUS DISEASES</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie28012ef976642138e574f32ea5efcf8_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODAtMi0xLTEtMA_98257513-5d8c-42e3-b0af-b4f955990453">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic76c81a4858d4b609fe0712808499995_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODAtNC0xLTEtMA_275ea0a4-4573-47dd-95e1-85a40b75b598">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie28012ef976642138e574f32ea5efcf8_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODAtNi0xLTEtMA_55f0139e-54b6-4e9b-ac52-58a8f9931070">26.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b9be986d0744a89a11e10191af92b0e_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODAtOC0xLTEtMA_80c181ca-292b-46f3-ab88-cf32d8733d92">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f066a7522d44e21adceaa01bcb1f033_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODAtMTAtMS0xLTA_0f201c15-cf96-4651-a729-077bf954ba2d">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5b9be986d0744a89a11e10191af92b0e_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODAtMTItMS0xLTA_8e74933c-7830-481d-a310-08d34aa32b03">29.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i882e0bdc376e4cedb6907617bd05c7c5_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODEtMi0xLTEtMA_00c628b2-e8c8-4517-a075-3003bd37e776">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e2cfa64c77f4036aad98fade9ef0701_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODEtNC0xLTEtMA_0c101f5b-1612-43fa-a137-dc7777676d69">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i882e0bdc376e4cedb6907617bd05c7c5_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODEtNi0xLTEtMA_749a9d05-438a-41cf-9878-4366ba756dfb">18.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1fdc084f5464520a7448be49c5db0ac_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODEtOC0xLTEtMA_9ecbb8d5-9ea2-4301-adb6-2138b80213f6">270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0244f8cf8aa940419de1c1d28d1e142b_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODEtMTAtMS0xLTA_0f71a3f6-966f-4c6e-b2d5-1b4a29edef74">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1fdc084f5464520a7448be49c5db0ac_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODEtMTItMS0xLTA_4b083ab5-0534-4e54-a2bf-91dcdddc24d2">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f0dbf3d46c438aa1e111583f3997d4_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODItMi0xLTEtMA_980f7970-7e2c-4fdc-b698-6c741260a027">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef97d90cd6c439db72bf9c70f28da42_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODItNC0xLTEtMA_749b32dc-4fa4-439d-8a2c-ef817959732d">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i98f0dbf3d46c438aa1e111583f3997d4_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODItNi0xLTEtMA_61a90730-d366-4a56-aed0-2d78dbb403b5">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61f0183768bc4e7b9bc935793c8ef1ba_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODItOC0xLTEtMA_a9b641c0-50d6-4730-8766-91bb8955fbaa">325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10eb1b72e5a84ad7ac1da3701bb76c90_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODItMTAtMS0xLTA_2a6d23d0-83e3-4b59-9eac-eb2cfc5a205d">331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i61f0183768bc4e7b9bc935793c8ef1ba_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODItMTItMS0xLTA_785cb477-9743-4f19-9116-0b743ed4c648">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0374102facf24dc5823fc308260ee163_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODUtMi0xLTEtMA_b05850ed-2a11-427f-9725-0fb61c985233">835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23ec342a5f954896b84f92b9d5abcbf9_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODUtNC0xLTEtMA_e9976ba2-153e-4874-85fc-388f55d7c6ae">759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0374102facf24dc5823fc308260ee163_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODUtNi0xLTEtMA_a2829052-100c-428e-902b-f690d80f70b7">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b66ffdc877e4f1e89900a1d433731ee_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODUtOC0xLTEtMA_183b7227-1355-4066-bbae-791f00f07e39">2,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i562f5f706f934d47812f786fbf3d7b58_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODUtMTAtMS0xLTA_d14358b8-0c3c-4ca0-bd29-f2edc294a493">2,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b66ffdc877e4f1e89900a1d433731ee_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODUtMTItMS0xLTA_6fc8ad47-6f17-40e6-bc11-d55ea18016a5">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if306bf45e84e4e3892e099cf48267fe1_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODYtMi0xLTEtMA_a077c27f-f675-444a-a232-57c8b6508efb">854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d13ded3c3b947ca960fe5a1e8612116_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODYtNC0xLTEtMA_9c47c6a9-e61b-4c21-bcf4-ea0e3dac2909">846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if306bf45e84e4e3892e099cf48267fe1_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODYtNi0xLTEtMA_294e5d4a-359f-4529-8d11-82062926099b">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebeaa1f49bf4e0baa2712e4c5bf91de_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODYtOC0xLTEtMA_0eda0912-049d-42b3-bd13-c71f24d7e5d4">2,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdc076fc45d46928fdee43fba7031c4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODYtMTAtMS0xLTA_1fbdd423-f6e8-48b2-adac-8c845c6f7b53">2,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ebeaa1f49bf4e0baa2712e4c5bf91de_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODYtMTItMS0xLTA_2e8fd715-0565-4bcb-b4bd-3128c847ae07">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea17f40f7b2248da9dcf9bbeb1298aae_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODctMi0xLTEtMA_5718de35-580e-4eb6-bd51-b4cf9df47aa9">1,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaf3b58ecba448c98c4fbea9e5a1bebb_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODctNC0xLTEtMA_5b1ed83a-4a1e-49c3-8501-61fb4403a92d">1,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iea17f40f7b2248da9dcf9bbeb1298aae_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODctNi0xLTEtMA_95932337-4d0b-42bc-8b14-00fbe6d9302c">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5884a5e7ed954d8aa9eddb0b6e4da9da_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODctOC0xLTEtMA_53313fb7-9e87-4fe0-b086-c43f14d3dbf8">5,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50df7cd55cd6495a81565d60de245388_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODctMTAtMS0xLTA_1de8e3b0-efa3-4fa7-ad36-c00257a1ea3e">4,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5884a5e7ed954d8aa9eddb0b6e4da9da_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODctMTItMS0xLTA_aa810cc1-8d93-4158-9b20-ee04cef54798">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONCERTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / methylphenidate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic189fd1fc7df4bdcb5e752b731b041bb_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODktMi0xLTEtMA_d88bc998-36d1-4037-8873-4b7232f043e1">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia84578dea56b42ee89fdffe82f1f0218_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODktNC0xLTEtMA_a2c14447-88bb-4570-b99b-2052f1aac1b0">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic189fd1fc7df4bdcb5e752b731b041bb_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODktNi0xLTEtMA_c8bb4adb-39df-4102-aeee-ff9508592e60">19.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d9afbd7f944468489ecd62be054ea29_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODktOC0xLTEtMA_c13c1ee0-d7ae-4a57-8196-cca3c8b2c858">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c352bec2ed24d399d4198a694dc76c6_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODktMTAtMS0xLTA_084ecc8c-344c-4aad-84dc-ca09ad755827">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6d9afbd7f944468489ecd62be054ea29_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODktMTItMS0xLTA_ec0666b8-6bd2-4737-ae42-83f064f7e023">22.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4827a6e9fcb14cf5a2e458c318845354_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTAtMi0xLTEtMA_a45613c1-bb28-43cd-900e-05407e63037b">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c05ffbc94dd44c8877b9c05314ad378_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTAtNC0xLTEtMA_81ec815a-e155-41cf-b1a2-83ed1f0cc3cb">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4827a6e9fcb14cf5a2e458c318845354_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTAtNi0xLTEtMA_7201ffc7-29ef-4294-b5f0-45ab3534bbad">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c1d26f41ed64110ba7168ddec63bb54_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTAtOC0xLTEtMA_5a34b9c5-4433-4db5-8637-d53b5ca79611">372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1967287f9578497e995a11c707bf2f53_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTAtMTAtMS0xLTA_9ab5342f-1595-4fc0-b8c9-fa54116adadd">319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8c1d26f41ed64110ba7168ddec63bb54_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTAtMTItMS0xLTA_3851d01c-caa0-43c0-b1c3-16007b912e2c">16.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide1e53eb0492409cb4653d655cefdab7_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTEtMi0xLTEtMA_5d422ac3-e4e2-45d9-a66e-dea63ae14454">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddca17b69fda4b1cb462915c216a46d8_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTEtNC0xLTEtMA_056ec031-538d-4b3b-ba86-bf0a9d012402">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide1e53eb0492409cb4653d655cefdab7_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTEtNi0xLTEtMA_bc8842c3-f0a0-482a-9db2-8800ed52c186">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib42c8f3666d34ae7aa8627db6a446790_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTEtOC0xLTEtMA_335b05c0-eaa1-4009-9aa7-78f316d390bd">489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3d0a4693f564cb8bc9e73e16b7952c1_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTEtMTAtMS0xLTA_b87eb771-30b4-4b83-9594-757ee34f249a">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib42c8f3666d34ae7aa8627db6a446790_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTEtMTItMS0xLTA_aefbffc1-73e9-4294-9ea8-317176cd9ee9">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / XEPLION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / INVEGA   TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / TREVICTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5284a31246ef4a8c838a1e4123f9f505_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTMtMi0xLTEtMA_e313c0b9-07aa-4f52-a5e2-713c34d426ef">648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5e9cffd91ca411a853422a72582bb93_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTMtNC0xLTEtMA_142979c0-0ce9-47ad-9805-8b43df3612d0">585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5284a31246ef4a8c838a1e4123f9f505_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTMtNi0xLTEtMA_20501cfd-46c9-4d68-9ec2-f15267aebd46">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice59f9c85be54b839acb8e82d6d4f087_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTMtOC0xLTEtMA_e4fcca02-2b9f-4d91-a12a-b2dec696520d">1,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5854490403eb4af9a2d3b60108890558_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTMtMTAtMS0xLTA_e33f9c25-39b2-48ec-81ae-1a2a9aced8b5">1,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice59f9c85be54b839acb8e82d6d4f087_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTMtMTItMS0xLTA_02cf334c-2c39-4df1-b19e-b50844fcbeb6">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbeee4aeea57426e992c6d70c15e7c2b_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTQtMi0xLTEtMA_8c7a34e5-7afe-4d44-8b8c-c83b3a84d71f">355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd2c49b4b2204484a5dc99464f909943_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTQtNC0xLTEtMA_0c922e80-133c-4628-bbc5-9888d1614650">341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idbeee4aeea57426e992c6d70c15e7c2b_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTQtNi0xLTEtMA_e2628839-c14d-4283-9826-1753910fee8e">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic558f7b084d04003a7b5d749f85db400_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTQtOC0xLTEtMA_689307a4-4549-47a0-8ce3-c8f5d54cd63d">1,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i622659a4109b4f55941ea9eab234897d_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTQtMTAtMS0xLTA_536f7c3c-5481-44ae-bf11-f6224ad54000">983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic558f7b084d04003a7b5d749f85db400_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTQtMTItMS0xLTA_c7893193-3df1-4341-a052-edc01a235be7">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd9e4baa754142e2874a7b15ef2af88e_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTUtMi0xLTEtMA_2f97215c-3cff-4003-ba28-32de9081225e">1,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76cf0ef8cb30429197a1518d631d35d8_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTUtNC0xLTEtMA_969af61d-6ba7-4f9b-8a91-79510355fd1b">926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifd9e4baa754142e2874a7b15ef2af88e_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTUtNi0xLTEtMA_31ed58ac-ecd6-47f7-8764-473535822b63">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie84450c6d85a401fbd2cf8cf38737ead_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTUtOC0xLTEtMA_874b2f76-ab2d-41ed-af89-ccbc06696e51">2,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1bea109b1b7492ea05f6750a7a1228f_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTUtMTAtMS0xLTA_bb3dbc1d-103c-4a2a-99eb-851d4d6b2a69">2,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie84450c6d85a401fbd2cf8cf38737ead_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTUtMTItMS0xLTA_c6677fc9-e911-470e-aef7-a12f3be0edc7">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;RISPERDAL CONSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i600831f07e1a4339b1e94d5e21d66372_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTctMi0xLTEtMA_de899b0d-d97c-4f62-8761-9b22501dec3f">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2af09556bc84fd1ba481c7e0406146e_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTctNC0xLTEtMA_ac45fe5e-4d54-4c07-a5fb-105b2e37fd1b">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i600831f07e1a4339b1e94d5e21d66372_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTctNi0xLTEtMA_71373980-0255-4748-8dbf-302862fee458">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1af77281c754257a1fa2e2fc2ed937c_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTctOC0xLTEtMA_93223348-099d-4043-a930-51ff1a3a2bd2">210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfeb7913f3474fb76e8bafad008be1_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTctMTAtMS0xLTA_a552172f-61ef-4cd0-8781-e6e8e4d3212d">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if1af77281c754257a1fa2e2fc2ed937c_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTctMTItMS0xLTA_4a76b9ca-533b-4aec-ab63-e307f1b039c9">4.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1290f60dba7e446e8d8b08ad7c42874c_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTgtMi0xLTEtMA_d7b4f086-9f41-4782-a296-d2d4a784d140">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d862660b5a04a089a8bdc443ee48fbd_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTgtNC0xLTEtMA_5486bdb2-450c-45c8-8798-13471c28335e">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1290f60dba7e446e8d8b08ad7c42874c_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTgtNi0xLTEtMA_0478d370-cc90-4e95-b8d5-5100305a362f">16.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia53773f630fc465eb5108bfbd89f5f47_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTgtOC0xLTEtMA_237411df-3db3-464e-b7f0-a8936c3608b9">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45ee541218b04971b53ff4e5d19ad204_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTgtMTAtMS0xLTA_89ce7b7d-1369-40f2-b042-32723f1ce72d">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia53773f630fc465eb5108bfbd89f5f47_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTgtMTItMS0xLTA_2a0d58f5-e2f6-4fdb-9c08-63e6a0ac34a2">5.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8360a75d208433d90de437993ea4a59_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTktMi0xLTEtMA_7f7746f6-31c5-4ed7-8afc-76242bfeede0">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d0af4fc35f41b78b153cac7769eca7_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTktNC0xLTEtMA_ff530ae0-35c0-4889-98ca-6235f993bee9">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if8360a75d208433d90de437993ea4a59_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTktNi0xLTEtMA_d3f19904-9d16-4e1b-94a1-66df984ed727">8.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1242a55b9a0485193c8b3dfc6ebdc75_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTktOC0xLTEtMA_c80ca9ea-21c0-4f7c-a3c9-a50114112351">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951a06fcbe4640689f8e364e8afdbcd2_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTktMTAtMS0xLTA_5f27baf2-dd37-4083-a36b-2d3803ed6545">475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic1242a55b9a0485193c8b3dfc6ebdc75_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTktMTItMS0xLTA_9b228754-4227-450c-a2bd-7efe78e07bc2">4.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER NEUROSCIENCE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98c68fd3171e4813b03d948e6c1538d5_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAxLTItMS0xLTA_9c612543-9f7b-48ac-81e1-619b59c31ec9">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fed2345a1ee4c23bd04c0f52f574fb5_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAxLTQtMS0xLTA_e535599c-89e1-470f-bfcd-d84577e51fd4">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i98c68fd3171e4813b03d948e6c1538d5_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAxLTYtMS0xLTA_10d06ad5-d3b7-48bb-9a2b-bbd350f61d80">34.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024835e205554573a9c3504cb27a8c5a_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAxLTgtMS0xLTA_97b9827e-ae73-4233-a84a-6b4c6b52f1c5">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c485d85051e4317842b009e214d3fe0_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAxLTEwLTEtMS0w_1e0d69d4-60e6-4b1f-9d4c-283f480426eb">210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i024835e205554573a9c3504cb27a8c5a_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAxLTEyLTEtMS0w_6789184d-af67-442d-8b2b-68fffc814526">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2039f6815f94c8eb39335bdd8780f31_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAyLTItMS0xLTA_3796ef33-58d4-4fb9-a0d6-55af97ea23e1">307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f82ffb3600448bdb45ded460d8052af_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAyLTQtMS0xLTA_137257d0-c337-4d56-a01c-7ac5dc5366cc">317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie2039f6815f94c8eb39335bdd8780f31_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAyLTYtMS0xLTA_a1b1c1ec-75f5-49dd-af79-4b292f99a5da">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bdfd9d747b14c3fb94da3568d458766_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAyLTgtMS0xLTA_33ca9c88-1f17-41b7-a15d-2b6e9f110767">1,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b106a80587443fa9b0d89c8d306ddd9_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAyLTEwLTEtMS0w_0b189d63-7568-4df4-8e34-a3c816be88fc">1,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0bdfd9d747b14c3fb94da3568d458766_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAyLTEyLTEtMS0w_da289306-ad58-4541-a26d-e75f06272cd7">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fad4ca7557147fe95699ddfe8a3615d_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAzLTItMS0xLTA_7be94a19-4341-47cd-9188-289fd09f420d">388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8e0238b104ea08be4e264097dc22e_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAzLTQtMS0xLTA_57be8a46-f5a5-472e-a27d-2e0e059db09b">377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1fad4ca7557147fe95699ddfe8a3615d_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAzLTYtMS0xLTA_fb5842bc-4d93-4832-9c81-30c06404e85e">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4a4e436169b42529a9d0389c604a63f_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAzLTgtMS0xLTA_3ca3927f-83f2-4329-9bea-a5646bf0bb42">1,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cddbb6a917e47509f085811d392a493_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAzLTEwLTEtMS0w_07363a90-0326-4319-9f49-08347f87e96b">1,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib4a4e436169b42529a9d0389c604a63f_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAzLTEyLTEtMS0w_a1322d64-7ccd-4110-929e-10029cd44b2b">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49e72c9dd590489aa2ee17a974f38a86_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA2LTItMS0xLTA_7a76b98e-7f4b-459e-98f1-b7074bf1fcfb">1,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id58b0cb1491f4c01a2650b1b46fbefa7_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA2LTQtMS0xLTA_e56d305e-7541-4c4c-bbbe-62d617bc6960">1,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i49e72c9dd590489aa2ee17a974f38a86_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA2LTYtMS0xLTA_76c2268d-1047-4a23-8432-e80f1bc0d6d8">20.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b81c853b79c40f5a5e333ea61fb2b15_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA2LTgtMS0xLTA_92c28a59-6104-4ba4-a553-2f39ac7a1659">4,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i053a5c0a067448d38267b4d4d0371d39_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA2LTEwLTEtMS0w_c1e29cc3-b304-4d7d-bdee-34183e4cc18b">3,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8b81c853b79c40f5a5e333ea61fb2b15_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA2LTEyLTEtMS0w_6a6f2008-ffe2-47bf-9589-41498d84cd5f">20.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7230aa1f363542928871b474a14f1f8e_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA3LTItMS0xLTA_696c3570-4b65-4630-a341-2343862506b1">2,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic09e7e58a12a4405a99ed854054ef46f_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA3LTQtMS0xLTA_8465ff14-76de-45ab-896a-75857e569858">1,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7230aa1f363542928871b474a14f1f8e_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA3LTYtMS0xLTA_1ac48f3f-479a-4584-bc5c-9d86ec4e391c">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic88a9f1b52334567a7c5d218c774bdf4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA3LTgtMS0xLTA_aa5c8006-3040-4305-ae8d-32a11f2bd2a7">6,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ea1dce9275644229c0975d44045301f_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA3LTEwLTEtMS0w_40eb69af-ebc0-452c-b732-91df9c941bee">5,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic88a9f1b52334567a7c5d218c774bdf4_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA3LTEyLTEtMS0w_1b6ad49c-03fd-4161-9c20-61d8f028293c">20.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia50d35187ab3428390ef63a28a7e6961_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA4LTItMS0xLTA_f7c6600b-1d0c-4fa3-be80-0ddd00b600f8">3,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25bc2d1842ab4478b3d89958785ab19e_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA4LTQtMS0xLTA_ab88dc35-4f70-40f6-a72d-60887b00be7a">3,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia50d35187ab3428390ef63a28a7e6961_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA4LTYtMS0xLTA_4ff5139c-9214-4599-8f77-94569e1997e0">17.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8d3a81114da408489e4e01d642c9082_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA4LTgtMS0xLTA_7ac6bfae-b3ed-4bbc-8dd3-475d0bfe64dd">10,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eaf6ce2f8af425790cb397e4499b14a_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA4LTEwLTEtMS0w_14e28a27-6fec-499a-8e6e-a3660694c48f">8,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id8d3a81114da408489e4e01d642c9082_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA4LTEyLTEtMS0w_9609f486-6755-4e63-9aa2-0855c47cd44a">20.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf0f6411562d444f9e80f8a62cc71594_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEwLTItMS0xLTA_c44f4558-5d6e-4b55-bf5f-f0c8387a1f3a">841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i969af2be04a041288cd2cfddbec62364_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEwLTQtMS0xLTA_ca8fe376-c04d-4162-988b-ec7e8573482a">585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaf0f6411562d444f9e80f8a62cc71594_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEwLTYtMS0xLTA_7b17c6c4-e918-4033-8c41-f28e3da2ff99">43.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411f812e4d114ffb8b1267fa1cb56c6d_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEwLTgtMS0xLTA_ae598ac8-0be7-4988-903c-d7af3d110d88">2,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6952baf25542b68c9499c21641991f_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEwLTEwLTEtMS0w_5396bc4c-3d37-4fe0-a91e-c55bac3297d8">1,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i411f812e4d114ffb8b1267fa1cb56c6d_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEwLTEyLTEtMS0w_79013339-7b37-4940-882c-2199999fedb8">49.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12599e668dbc41358348e5544d2dba07_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTExLTItMS0xLTA_a5c672f0-b437-4a61-896a-31ce7fa75a0b">739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eb10a316fe84f059ae619a1305077dc_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTExLTQtMS0xLTA_c6922b08-aec8-44d5-ae3c-da9f5ba3ff90">514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12599e668dbc41358348e5544d2dba07_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTExLTYtMS0xLTA_efd5e4f1-67f4-4208-a599-34d62f7f1928">43.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7368a505f53e4badbb0e085fcb131b8a_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTExLTgtMS0xLTA_ef68ee7f-4940-4ef1-8383-01f7ab54f149">2,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78842fece6ba4955bf4a23337f9c5f22_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTExLTEwLTEtMS0w_8f2886ab-bcb2-4132-af13-bf397cb76d48">1,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7368a505f53e4badbb0e085fcb131b8a_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTExLTEyLTEtMS0w_25f31129-e923-46fe-ba1e-c112ea69834c">48.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16e861eec4c443828199789a528253cf_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEyLTItMS0xLTA_3e2a5576-98de-47a2-ab4d-7c2333a4884a">1,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i629b6a7bc81546dca94d639d376629f9_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEyLTQtMS0xLTA_1e563e5b-30d5-4f6f-8ab9-c42ac2b528d4">1,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i16e861eec4c443828199789a528253cf_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEyLTYtMS0xLTA_c5d9668e-fb7c-462e-9638-33328fc62665">43.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafd1bf909ca4919aaaabc6674fb242c_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEyLTgtMS0xLTA_27c44467-0c0c-420a-98d1-c70540f7ec87">4,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if665cac9f7d94d4594494bff63142705_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEyLTEwLTEtMS0w_7a1c2a26-c215-41b6-b87f-b34c3d7a1c6a">2,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idafd1bf909ca4919aaaabc6674fb242c_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEyLTEyLTEtMS0w_d7b4e0de-ae40-4b21-a909-eb63f39f447f">49.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88009127c2544c78b9aed9223b7b8337_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE0LTItMS0xLTA_5d6a6283-0d3f-47bd-b72f-b63fe04151f5">214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fea18f4d9d94ba2b90cc4f81dafacaa_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE0LTQtMS0xLTA_add0c88f-deee-458f-b4f3-2a84ac9467fe">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88009127c2544c78b9aed9223b7b8337_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE0LTYtMS0xLTA_e565ad3f-f536-4854-bdd6-22a28056ab9a">40.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b9844b50d54100a2982651b8823c9a_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE0LTgtMS0xLTA_3db90aea-bf24-4191-86c2-bbc27f9c7346">578</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i232ddf875322462bbd406ee0ae4f9c85_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE0LTEwLTEtMS0w_5c2e8173-e5c9-4caf-96fd-d6103a3c5b91">407</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07b9844b50d54100a2982651b8823c9a_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE0LTEyLTEtMS0w_d6d5a083-cdcf-4274-94c7-db6b47a5e018">41.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b3d697a4fad4697830a9e243e1e0747_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE1LTItMS0xLTA_0f2eaaca-c701-448b-81f8-6c777b15e1eb">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3d70f93807b47b3aff1d8a1e73cb8f5_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE1LTQtMS0xLTA_ded8317b-3ead-4096-a91a-40330c228693">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idef7b076ea1546a89cde23fde1560ab0_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE1LTgtMS0xLTA_b206081a-5d8c-42e1-889b-6f251ebd5e5d">329</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i496a22b78b1d457ca678ca6d564331b5_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE1LTEwLTEtMS0w_3ea1b8de-005d-46f4-ab88-018394429b2e">112</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9ccb9aa1cc34b1e9f6f123765de70e6_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE2LTItMS0xLTA_bb532773-9d52-4f2f-ab4f-1260cb30b77c">344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4798987e78844d73831f5474a76abebe_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE2LTQtMS0xLTA_bdb9eb27-696c-495e-8c5e-f20749e39f03">206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie9ccb9aa1cc34b1e9f6f123765de70e6_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE2LTYtMS0xLTA_55b6d07b-1db2-4d64-907f-2ff06460d18e">66.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e5e1acad6f430bad7029515d202b51_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE2LTgtMS0xLTA_bc03aacd-ea44-4324-b746-55ffd951add3">907</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b00b20de7c94aa1933c4f6eb44fb6f6_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE2LTEwLTEtMS0w_524ca655-4f4a-4940-a35f-bd925ea34f1f">519</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5e5e1acad6f430bad7029515d202b51_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE2LTEyLTEtMS0w_173b0160-12af-484f-adbc-57bedc22beee">74.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207b52ef8f4b48de8416ca244f8b522d_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE4LTItMS0xLTA_66a780df-6b9a-4d53-8410-ef58318682a4">413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55ce0b393cce45109fb4fabeeeaa64fd_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE4LTQtMS0xLTA_3cef158a-290d-49bd-82ac-a27c3546ab50">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i207b52ef8f4b48de8416ca244f8b522d_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE4LTYtMS0xLTA_c71e557a-ce9a-471b-a195-af36bf43ac2d">8.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8278bbfd6e74d48a7d676153d80e78e_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE4LTgtMS0xLTA_5590b108-3020-45e7-8448-925154c5b26a">1,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib26f9da69a6044e4a8bd640d1dbfd732_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE4LTEwLTEtMS0w_f1ee9bcd-6f45-4dae-8bf7-3c1199604e07">1,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id8278bbfd6e74d48a7d676153d80e78e_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE4LTEyLTEtMS0w_6b21e89e-4284-454c-a613-ecbbc5f57bf7">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5457dfbd70624cab91476a355fa5115b_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE5LTItMS0xLTA_44c4b8e8-91c6-4f23-b4d5-de25d1ff0ebb">654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i553115651d944c87988eb5dd696715f6_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE5LTQtMS0xLTA_20aece40-204a-4a03-b92b-182508ad3793">581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5457dfbd70624cab91476a355fa5115b_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE5LTYtMS0xLTA_888f7851-8ad7-4630-a952-6cdfabfc68f6">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a584f32c5b84a33b71234d8cc85f779_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE5LTgtMS0xLTA_5bed2498-0c5d-4ce3-b07b-a15b7a2a6d29">1,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8ec118f64784127b948ce57a03251d3_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE5LTEwLTEtMS0w_166d748a-26e4-401c-aef3-649ad911d460">1,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2a584f32c5b84a33b71234d8cc85f779_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE5LTEyLTEtMS0w_e8f40cca-92da-462a-a87f-10c94e560b3b">18.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2041012c7fe94696ab6a160eae5a0d28_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIwLTItMS0xLTA_10b15d5b-b724-459b-bde5-22254a77ce8e">1,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fea7ff2b8d04558ad6fc2362b74bf38_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIwLTQtMS0xLTA_d1ed26da-9474-4df9-80b4-38ada280ecd8">1,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2041012c7fe94696ab6a160eae5a0d28_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIwLTYtMS0xLTA_4e084fa0-2a99-43c3-a4b0-675af0a51be3">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a807f1dd544cac8e57c11caf619604_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIwLTgtMS0xLTA_e80525c7-42c9-4f0b-90eb-8274095c2502">3,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01ec1719a93544dd847dd8eabc9f9027_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIwLTEwLTEtMS0w_d0969191-bac5-4045-99d8-6522423ad847">3,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i60a807f1dd544cac8e57c11caf619604_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIwLTEyLTEtMS0w_6c42e18e-4e30-45a8-b460-fd65efe1faed">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> / </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">abiraterone acetate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b7e00e28414ef1af6c648b94de249d_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIyLTItMS0xLTA_87c3c3fd-2f57-4fc8-b950-1b30e633d280">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife8d592b718e4648b32dd579c98199c1_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIyLTQtMS0xLTA_41cf3e63-4649-403e-a809-9a8f7863d552">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i06b7e00e28414ef1af6c648b94de249d_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIyLTYtMS0xLTA_3231bf12-f127-4f5d-8fe9-2fda984e3be7">57.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice26ad0a6ed346fb8cd1cbe7031efb8c_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIyLTgtMS0xLTA_ed840f34-a0f9-4ae5-afb5-bce7f0dff5ed">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d26596d2402468f925f727a0ba02ff8_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIyLTEwLTEtMS0w_00a30e0b-d6ee-417a-8798-10425300bc76">284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ice26ad0a6ed346fb8cd1cbe7031efb8c_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIyLTEyLTEtMS0w_caf7ddab-7729-4a84-a5f9-43de157bff42">66.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fec763a254e49a38e7ad0d9a0f09012_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIzLTItMS0xLTA_027ad494-12b8-4d98-835b-9d219f28f631">523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8302f031c56743a1a3a21fb700613bdb_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIzLTQtMS0xLTA_727bbb37-4fac-47ab-9f6b-83806ad2529f">532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5fec763a254e49a38e7ad0d9a0f09012_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIzLTYtMS0xLTA_1ad86790-8a62-4be4-bba2-52668638a5ad">1.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff9d00b4dac646eb8e2d975cfd2be240_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIzLTgtMS0xLTA_2c6cae64-eb11-4542-8a99-049a9c4ce042">1,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6a7f6a3730144bca2ea36f15ea20490_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIzLTEwLTEtMS0w_2336fe24-bca9-4f95-bfe7-c6f321233977">1,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff9d00b4dac646eb8e2d975cfd2be240_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIzLTEyLTEtMS0w_ecf5d1e9-dd42-4887-a3e7-3536b38edf83">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6096f7b9393042f5b2b82bc8fb59bd2e_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI0LTItMS0xLTA_d84e5658-aba6-4254-a223-81e44bd34b21">548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b3780cbf7d543e7b543bfaa92165ed4_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI0LTQtMS0xLTA_0fdfc95d-452e-423c-bbcd-51a0bfdf3f6e">590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6096f7b9393042f5b2b82bc8fb59bd2e_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI0LTYtMS0xLTA_fd176f3c-947a-43b7-8782-01256b0dd6e5">7.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e2cc727626439296018d3621df8996_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI0LTgtMS0xLTA_a8be63e9-f64b-485a-b228-fefbc4d484ca">1,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcd8a72bb32b468fa5b37fc14195304f_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI0LTEwLTEtMS0w_8d3e7fa4-0b02-43fe-866d-b4ac0068e844">1,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i91e2cc727626439296018d3621df8996_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI0LTEyLTEtMS0w_badc9722-7b45-4640-8363-fc3cb77d137a">5.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-top:5pt"><ix:continuation id="i44910920d1f44d53b8494e798002102f" continuedAt="i1b1edb6dd8d2470aaac550aefcb94d8d"><ix:continuation id="ia02612af7a20492ba347b1ec1ebaf946" continuedAt="ia2e91883243541589fba835941b7c99e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER ONCOLOGY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9112184634e44b0cbfd9d823f1219aa3_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI3LTItMS0xLTA_6f1ca681-8a7d-4a8e-be6d-d6eccdd742e5">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i920ec4d1d57649248aa990c4b93fe684_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI3LTQtMS0xLTA_d0882a6d-8826-4fc1-ac22-82b336ab3017">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9112184634e44b0cbfd9d823f1219aa3_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI3LTYtMS0xLTA_7f475e66-60ca-4c8a-ba5d-cca361c506dc">49.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i453a034a54da477f8370e78e927a3539_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI3LTgtMS0xLTA_180563f9-3f10-441e-9536-e462fa8874f1">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a991002f04c401e97d727678badafbf_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI3LTEwLTEtMS0w_8f6b8038-d538-4edc-9aca-d91da396c73f">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i453a034a54da477f8370e78e927a3539_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI3LTEyLTEtMS0w_16679dc1-5853-408c-9179-4fdce67f37f9">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7aee8dd846874e159438cc4a03f7bab0_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI4LTItMS0xLTA_d56c9166-e16d-42a2-b15d-5ecea4b3ebea">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b9571f2a6b4a2bbc14ea2f3077c57b_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI4LTQtMS0xLTA_9007a835-451e-4359-a881-37e909ac7e75">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7aee8dd846874e159438cc4a03f7bab0_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI4LTYtMS0xLTA_7b9ccd2a-f32e-48bd-b861-f2086d5f6f7b">48.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0518e784a66b49d68047ddf7ee9cc00b_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI4LTgtMS0xLTA_04b5b3fc-e7a2-4b6c-8336-b440af928dae">352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31e66b96468f420288f19c564089d8a2_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI4LTEwLTEtMS0w_af6019d6-1e1c-4c44-8e85-56a6de56faa4">556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0518e784a66b49d68047ddf7ee9cc00b_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI4LTEyLTEtMS0w_5aae8033-7e08-44b2-ade2-d51a59640519">36.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47183644d19945a8bb49dd3a27546be6_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI5LTItMS0xLTA_e1fb0e42-305b-4ae9-9033-98dfe276831f">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c83e880c458472b8c50b6cf24267d08_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI5LTQtMS0xLTA_c1b78f21-8097-4bd1-aac0-9c65968ee076">203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i47183644d19945a8bb49dd3a27546be6_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI5LTYtMS0xLTA_d3288c4b-3b35-4441-8bf5-c648d0c41dff">37.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56502c183aac4db6ac72f64b0b31c8c8_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI5LTgtMS0xLTA_70f789f5-c409-400b-bc1f-5127836dc9b8">428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67fc9ee208641588e1c086557319199_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI5LTEwLTEtMS0w_d37a1bf1-cde4-4ee9-bc4b-d1db5331bbbe">619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i56502c183aac4db6ac72f64b0b31c8c8_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI5LTEyLTEtMS0w_895030af-d840-440e-b4ad-0c8f62c0ce40">30.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i916f3760699b40dd9d58b5336d356442_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMyLTItMS0xLTA_d5e53a7e-d8c5-449c-89cf-637933933b87">610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedaf2bda66294ffba5d53d0ef7f61370_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMyLTQtMS0xLTA_2469d059-3e3e-4fce-9469-2561c9e2bb00">510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i916f3760699b40dd9d58b5336d356442_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMyLTYtMS0xLTA_f01b17ac-7607-484c-a76c-b9bc9a68dfb9">19.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c445f8624f40d6824d709a9744cae5_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMyLTgtMS0xLTA_9aa78ea3-82b5-4cb6-bac4-f9700794fc4b">1,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37ccb6eef64a4045a8c29d06c8cf02d8_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMyLTEwLTEtMS0w_3cc5bccc-f32e-4172-8c85-0d0d94c9c0f5">1,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if4c445f8624f40d6824d709a9744cae5_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMyLTEyLTEtMS0w_59b07ac1-4a2c-4bee-b1d8-2633f41546fe">15.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbe05ea1dac40b0b66f0aac32a160b5_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMzLTItMS0xLTA_36fecf4c-b34f-479e-9ab3-b528110d8bcc">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb72505c1d974357bf35c6715df00b92_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMzLTQtMS0xLTA_67ed9017-743c-48bc-a00a-cfe20d6f8d53">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3dbe05ea1dac40b0b66f0aac32a160b5_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMzLTYtMS0xLTA_24af325c-ec95-44fc-ab72-2f78b6f0a128">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fc5d639ff1a4b4e921cb3c51ac5125c_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMzLTgtMS0xLTA_4b213a32-1d25-4e58-a79b-c03ad8ec6056">821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa923eeef864e7aa46c2f7515d33025_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMzLTEwLTEtMS0w_3a2ff895-bce4-43bf-885a-06905af29f0d">742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2fc5d639ff1a4b4e921cb3c51ac5125c_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMzLTEyLTEtMS0w_e9dd1afc-ac23-4c01-bb22-80e68e803426">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6bf4f3e987046c38170406d258eb94a_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM0LTItMS0xLTA_5176d864-05e8-4a4f-9d99-7eed565a56ff">868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8db06e2cc04c458d912a58a028760c4b_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM0LTQtMS0xLTA_5c565432-5028-47ff-a0e2-4d47a68a48bb">749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id6bf4f3e987046c38170406d258eb94a_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM0LTYtMS0xLTA_6c8fe6a4-53bb-4244-a195-7f9079da38ab">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4582f93ea64baf9c7628c58576a173_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM0LTgtMS0xLTA_1d5daa07-d70e-4efb-9bf1-4f038c0007bf">2,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41e8da5f36f54d4bbdfc91d37ee03c6c_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM0LTEwLTEtMS0w_5edeed9b-de2d-4cf3-ad65-1a68153250ab">2,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f4582f93ea64baf9c7628c58576a173_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM0LTEyLTEtMS0w_e2153880-256a-44b6-99df-8df2cc36070f">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5424c438f2644ed794b321513eaa316d_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM2LTItMS0xLTA_c51fe7e8-d79a-4e21-964a-a95adbbbcb2d">299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5deab209e23645b498b422f99964df0d_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM2LTQtMS0xLTA_e65f1abb-3ba0-4e57-a117-2867d7b1ab34">244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5424c438f2644ed794b321513eaa316d_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM2LTYtMS0xLTA_d59d7015-8053-490c-9454-26c6dc718d4c">22.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib84b38a234fb454083a8048492807925_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM2LTgtMS0xLTA_9a368867-1a02-4929-b439-22fe3e879436">861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3b2572faea149698d267bcb7cf881f7_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM2LTEwLTEtMS0w_af7c1e4d-6dd6-4787-a6a2-eb9e7d187f1f">729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib84b38a234fb454083a8048492807925_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM2LTEyLTEtMS0w_4dcdf6a2-4356-4d2a-9bda-2feae183d8c8">18.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i605343b19cc64b1482f6408c0434084c_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM3LTItMS0xLTA_78ff2fd1-060e-4b43-b78b-b2fdc7025ab8">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5c97cf898604cf4ad7406f9531426d4_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM3LTQtMS0xLTA_3c79b684-5584-4fd4-a137-e22f98cd6013">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i605343b19cc64b1482f6408c0434084c_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM3LTYtMS0xLTA_e20d1106-553b-4504-9092-3ec196c22589">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ac76396403e46669ddb9bb2a99e7626_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM3LTgtMS0xLTA_0e111a2a-ca72-4be7-962a-07a471e56478">510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1c93d444f7d4ab4a13e6d1f8efea458_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM3LTEwLTEtMS0w_59d10c4e-3824-4507-9b14-5f42f522be1c">458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ac76396403e46669ddb9bb2a99e7626_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM3LTEyLTEtMS0w_e416f2ff-139d-4989-80ae-d9b3ca42168a">11.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fa54f45363a4ac999c0b20e1c5f28a7_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM4LTItMS0xLTA_54efebd1-6876-4d1d-a2be-226a8954b493">458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i178889716f424850af73d18091ac8fb3_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM4LTQtMS0xLTA_8b35acfb-1ced-4e64-becd-5aba198e9169">392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5fa54f45363a4ac999c0b20e1c5f28a7_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM4LTYtMS0xLTA_c10f0bf1-bfdd-4a47-8f3c-177140e72786">17.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19889197e7014b5abe659ff2ab7a326e_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM4LTgtMS0xLTA_fce8e8f5-0ff2-4028-b1f5-32eb94cfc2e6">1,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc84e135342246ada537c96c79411c73_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM4LTEwLTEtMS0w_b72af1b8-d808-44c1-b69c-a21b5615c80b">1,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i19889197e7014b5abe659ff2ab7a326e_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM4LTEyLTEtMS0w_07c3c7ed-f465-41ba-a903-2d46af68e242">15.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie334cb54a91c4aa489e4470d9dd267d2_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQwLTItMS0xLTA_523d5fc8-b35f-4e87-9ef6-a748bee8f53e">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieff90fbe65b14dccbcde52e76abe2491_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQwLTQtMS0xLTA_4c884fd8-b51c-4694-840d-7d06349434e2">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie334cb54a91c4aa489e4470d9dd267d2_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQwLTYtMS0xLTA_6693d807-43a5-4c3b-b6c2-dbbdac056b30">17.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28c4b7c2d0fe47d6a4a59c5126dfe022_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQwLTgtMS0xLTA_ffb265fd-b081-446e-96ee-146756102cf8">792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f1a31cc19a448fbbbc2285717ad1b08_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQwLTEwLTEtMS0w_35610cda-0e92-4567-be02-ca45d046c5e1">692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i28c4b7c2d0fe47d6a4a59c5126dfe022_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQwLTEyLTEtMS0w_92aa6c29-df07-4da1-9485-3b21483fc5d0">14.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f62cbc379cc47b1b559838e47e5e9b9_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQxLTItMS0xLTA_d9dd003a-f356-4af2-9b18-2e392bd39552">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6eed07d82dd4b42871be86888306c52_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQxLTQtMS0xLTA_1938d8ea-d853-403b-ac15-72e9c204ca73">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3f62cbc379cc47b1b559838e47e5e9b9_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQxLTYtMS0xLTA_a41c5c19-6df7-4676-9211-474b10b6971b">30.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f839300e00c4a4d859e26c2fa5c6e37_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQxLTgtMS0xLTA_03bef81f-6e7e-489e-83b7-88d93be731c9">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1873788fac6a46e8be4e456fa927ff6a_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQxLTEwLTEtMS0w_b8f903ca-8693-4da2-b425-404b7c6a5938">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f839300e00c4a4d859e26c2fa5c6e37_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQxLTEyLTEtMS0w_8c697849-9d9d-4c91-a81b-56eb6db841b2">34.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12ba7c96d6b34b73b2dc889a40179104_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQyLTItMS0xLTA_2b68b6dd-b3e5-4189-b7d2-6f768dde5dc8">309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0ccc4ef75a4c3cac7174f2de54a9cc_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQyLTQtMS0xLTA_6afd1200-9b3f-4ec6-a2de-64c5c8b36573">260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12ba7c96d6b34b73b2dc889a40179104_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQyLTYtMS0xLTA_a57de3bf-0552-43f6-9739-9b0aae593b10">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8becabeadf84e98b9d419b68203265b_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQyLTgtMS0xLTA_d7d9ee82-d5a7-4ba0-b32f-7d8c1333ae1c">927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68239219992142d2aa3702fc95b596b7_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQyLTEwLTEtMS0w_5690b66c-ca89-460b-b938-6cb72a17c640">792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie8becabeadf84e98b9d419b68203265b_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQyLTEyLTEtMS0w_2a74e4d3-4ed2-499f-aa2b-bc2918bc8702">17.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER PULMONARY HYPERTENSION</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife0ab2f3b60049508c2fc1e1d78d4cb9_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ0LTItMS0xLTA_816bf68d-aace-48b7-b685-2d3373da0e98">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a330731470745e48d563c9c6d517be1_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ0LTQtMS0xLTA_aba2d3f8-386c-47dd-aab8-d27071346552">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ife0ab2f3b60049508c2fc1e1d78d4cb9_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ0LTYtMS0xLTA_f566dc1e-2526-4c67-ae74-552e7363b2a6">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e7548bbd31e49bab7d5fec3a6b41671_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ0LTgtMS0xLTA_5b30bd88-7b45-4b48-91a9-4dce922d58f5">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ac34ad4788d43b3a301f9c1c62308c9_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ0LTEwLTEtMS0w_22ad4ee5-0a6a-481f-ae55-b853543d7e5f">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8e7548bbd31e49bab7d5fec3a6b41671_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ0LTEyLTEtMS0w_3ded6865-4498-4b77-9743-56c3b9160f2c">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i106f48ae57ab4181ac0362aa6cfc6106_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ1LTItMS0xLTA_8fc4c238-0a06-490e-a9e8-fe4fbfede981">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bb172db98c34f69a96a8e61c2990f49_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ1LTQtMS0xLTA_4947e5de-1683-4397-b6f8-8f46c37146a4">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i106f48ae57ab4181ac0362aa6cfc6106_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ1LTYtMS0xLTA_f09a6efc-aaa8-4b51-8fe0-0d423a686520">4.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac83ab04fd454d808f7a0f2ba77b1fb3_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ1LTgtMS0xLTA_c30896c4-bebb-4edc-8ad6-199430975eea">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebe8c5ef936a40769b7f7a23f0b8f324_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ1LTEwLTEtMS0w_bd6cfa0d-0adc-4ff7-baa7-3b42a0a3b9bd">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iac83ab04fd454d808f7a0f2ba77b1fb3_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ1LTEyLTEtMS0w_c6b97191-c3fb-4410-8239-6fa1c0b8b783">3.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29b333eb2dd34c4e84797c94386443a5_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ2LTItMS0xLTA_a57512be-b348-4457-be54-e4b406ba3eb7">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894f559ee892432bb4a292bbcc61acdc_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ2LTQtMS0xLTA_110a20f8-247d-467a-879d-b2ff60ab948c">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i29b333eb2dd34c4e84797c94386443a5_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ2LTYtMS0xLTA_25b04d3d-42c9-4a01-82a1-08bb61b389f0">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i796f5d7d4c4840a8992ef9c2f85752ff_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ2LTgtMS0xLTA_1a1e65d2-135e-48fa-b52c-9ec297ded4e1">301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89c02fa080d343cc9ff82372eac2f123_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ2LTEwLTEtMS0w_efdf162e-6428-40e6-a8e4-43ec36a6a6bd">304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i796f5d7d4c4840a8992ef9c2f85752ff_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ2LTEyLTEtMS0w_fabe36a4-82a4-4d6f-88e9-9f4ba86ceef4">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80392036102c45ecbc3621717d0b2c74_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ5LTItMS0xLTA_d6f4d38b-8647-47b7-a090-c34b21ab0138">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0d1c1d0a014d889948f7983d615275_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ5LTQtMS0xLTA_3acf9f2b-1263-4ee3-9631-7c7858911db9">931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i80392036102c45ecbc3621717d0b2c74_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ5LTYtMS0xLTA_d79d2ca4-4389-4998-b1d0-c6a83dd33fce">14.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7ad75c915974e13baa608e010a4dbfe_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ5LTgtMS0xLTA_9ae1a971-935b-41dc-abda-f8eea6793a77">2,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42ff1e292f27485f8ff84644532adc72_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ5LTEwLTEtMS0w_61fbc5c8-ea2b-46a3-be84-8e7ca6a5d6ef">2,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib7ad75c915974e13baa608e010a4dbfe_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ5LTEyLTEtMS0w_3b866884-19c3-4279-9559-a89887fb5d5f">7.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144c6515230549dc9ae750420daa70c0_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUwLTItMS0xLTA_a64fa6a5-c0a3-4259-958f-c56b60b1d2c0">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12c283c3ebdc43f685bfcfb86adbaec3_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUwLTQtMS0xLTA_1a1c159b-7305-49e1-a0ff-1fc53156a938">351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i144c6515230549dc9ae750420daa70c0_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUwLTYtMS0xLTA_b7d701b6-a6c4-41ed-a2f3-37028d8094e2">5.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66f80a64500142458617dbf774e7f46a_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUwLTgtMS0xLTA_bd2ac8a2-c68c-4c2d-85bb-1e27a4c91f81">1,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifce0de714d9b45428f3968fc9988e0c7_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUwLTEwLTEtMS0w_af2c11e3-4861-4660-830d-fc219fcfc304">1,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i66f80a64500142458617dbf774e7f46a_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUwLTEyLTEtMS0w_e5577df1-6b93-47c7-b495-74a8f19fa079">4.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3367c13477ea4799ac8e90b9e213d261_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUxLTItMS0xLTA_3a016432-dc8b-4c3c-82cf-5f5dde833506">1,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fb626460b96415bb179ccaa4c0ed5b5_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUxLTQtMS0xLTA_0ed83a38-bce0-4925-8371-d3dc39f89517">1,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3367c13477ea4799ac8e90b9e213d261_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUxLTYtMS0xLTA_220e89b5-f58e-49f8-b898-f45352ee9465">11.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id11e5789ebb948679c1a5ad0d35ae54c_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUxLTgtMS0xLTA_0dd8074d-d9b6-4f9d-b8c9-e70442e4f5f1">3,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffea672a5b3c47eea9012fe82778494b_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUxLTEwLTEtMS0w_63b4c78a-2ce1-40e6-88b1-638a9a7cc179">3,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id11e5789ebb948679c1a5ad0d35ae54c_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUxLTEyLTEtMS0w_bfdad2ea-24c5-4517-bb3b-e06147b8428b">6.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie993d24b54904ea888b1293ce96956fc_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUzLTItMS0xLTA_5e7dd8d6-f0eb-414a-8ee1-62f847e6a093">636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1b37038bc7487ea392d8a7578b3110_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUzLTQtMS0xLTA_d23be0b1-0899-46bb-a05c-295bc117bfde">630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie993d24b54904ea888b1293ce96956fc_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUzLTYtMS0xLTA_76b26533-2b1b-47c6-bc93-ac134fb8b54f">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5d285afcf84094bbff26299ad4e109_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUzLTgtMS0xLTA_a3655c6d-55c0-4d04-9418-6dd6ed07d207">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a8c160f547f4d6ca4252136e13831b0_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUzLTEwLTEtMS0w_2710cc67-b09f-44e8-a859-0997555edea6">1,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8c5d285afcf84094bbff26299ad4e109_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUzLTEyLTEtMS0w_0b294cb4-94ef-4085-8a4a-bcebb16d9925">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic72c4574496a4c4fb83a4560784b72a4_D20210705-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU0LTItMS0xLTA_47de444f-bffc-4344-ac09-ebf7a78dd8e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d908ad9d290413a98b31cf4d5ea0d87_D20200629-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU0LTQtMS0xLTA_b3477f33-322e-447e-b7d4-13eaba6682fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic72c4574496a4c4fb83a4560784b72a4_D20210705-20211003" decimals="3" format="ixt:fixed-zero" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU0LTYtMS0xLTA_d33de107-a260-464d-b989-0b0a85e0cd06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8298a87ec6094a83a8f67eaeaaed0f98_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU0LTgtMS0xLTA_6a74fbb7-098b-48ab-9677-8fe3034e3262">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i246d9eeb9fc948d0a353e9a5e7db555a_D20191230-20200927" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU0LTEwLTEtMS0w_91801474-2443-4764-a83e-b34473a25a59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8298a87ec6094a83a8f67eaeaaed0f98_D20210104-20211003" decimals="3" format="ixt:fixed-zero" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU0LTEyLTEtMS0w_7fc5350e-dc0b-4557-8460-258d836a2673">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic58138fbb27f46fa9ceb6e76659f1262_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU1LTItMS0xLTA_6c15dd1c-4944-43fe-a7cf-4411c6d44bcd">636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i583b1aa9afbf4206bfc48b54ba5bc3fd_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU1LTQtMS0xLTA_20034c9c-a8d8-4b56-819c-9a1b7c202da9">630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic58138fbb27f46fa9ceb6e76659f1262_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU1LTYtMS0xLTA_4c60f441-f104-4b27-bffb-9d3d0a34ab44">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fa5dc18ef454b7099777b9a2e9edf1b_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU1LTgtMS0xLTA_4a2c9491-7bbb-4907-b527-ab12dcd59206">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i450c72826782487189f185be011ada8c_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU1LTEwLTEtMS0w_fc29c14f-0052-44ba-93c0-a5cdf9317448">1,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2fa5dc18ef454b7099777b9a2e9edf1b_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU1LTEyLTEtMS0w_51ca6c46-cdd0-4832-a19d-e6006a802b16">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87186edc0be942c3a224af0c83083a2e_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU3LTItMS0xLTA_d5ddb654-69fd-4bfd-a533-a534c8a1b2b7">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if86e5be3d1d0462981071e831b1b1941_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU3LTQtMS0xLTA_d2cddcda-8a46-4bb6-8428-dd3de6f6d95f">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i87186edc0be942c3a224af0c83083a2e_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU3LTYtMS0xLTA_e7529cd3-a9f6-4d7a-8316-d2255dcc13ec">57.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i118eb58e43a74473be63948e7e8b110d_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU3LTgtMS0xLTA_37f57455-04c0-413c-affa-a2ffb3310668">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14fb81ce0da94fd782c69b4cf8735fb2_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU3LTEwLTEtMS0w_75ffc1d1-0bc9-4ab4-bc3e-dfae97ac664f">405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i118eb58e43a74473be63948e7e8b110d_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU3LTEyLTEtMS0w_fbce01bf-779b-4562-8348-186f824cef20">38.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4595e7a6d7c0489b8e9bd4072d2f0958_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU4LTItMS0xLTA_2efb1c23-ab42-4ed8-8111-2443dc02cbb3">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb6afd2ee42744da955bfb4de57ea068_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU4LTQtMS0xLTA_e98eeb6d-e4cd-4b08-9806-3964caeb9a25">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4595e7a6d7c0489b8e9bd4072d2f0958_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU4LTYtMS0xLTA_28207726-204b-4313-9840-5ef2fa32a466">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52e5864ae7034aacb7d9ee6a4b6ccc99_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU4LTgtMS0xLTA_de2b254a-04af-4fe9-a457-7f2488659d40">194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5224eaa3aeab4bb6b58685ece2af0a80_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU4LTEwLTEtMS0w_d62dfc1c-d89c-4dee-83e4-87484602328e">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i52e5864ae7034aacb7d9ee6a4b6ccc99_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU4LTEyLTEtMS0w_fed18271-3607-4fc5-bcae-1a9a74927d27">11.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e6e8316702148888c8f276675d24468_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU5LTItMS0xLTA_9e1c1ee7-ce5c-49c7-8e06-5bbcc4fe7545">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8fabe771e534cf0acd946d6aff01f6e_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU5LTQtMS0xLTA_9d106ab0-8b1a-4f03-9667-f3e313b318dc">224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7e6e8316702148888c8f276675d24468_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU5LTYtMS0xLTA_6505e8f7-7070-410c-8fea-5340bfafa124">40.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic749d8f0affe4953bf8a83f1ad6aa6b6_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU5LTgtMS0xLTA_be51082b-1a6c-476c-bc96-ed7ad4f54f6a">443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f0243ceaf5947389c637d5ed6092fe9_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU5LTEwLTEtMS0w_a98aa5fd-fa52-4c10-ab61-30f7be76cd27">578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic749d8f0affe4953bf8a83f1ad6aa6b6_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU5LTEyLTEtMS0w_610d7349-6741-457e-af18-ae64fcd5e318">23.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i184a57e2be914b2593d8414dcd7ebd91_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYxLTItMS0xLTA_ae6d753c-2a83-4313-bddd-9d86457b49e2">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60cfac9b2a974827a630d010512f5c77_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYxLTQtMS0xLTA_b0007534-b86a-45f2-9c6e-e3e124b9d135">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i184a57e2be914b2593d8414dcd7ebd91_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYxLTYtMS0xLTA_8b980028-a3d9-472e-89cc-f009b0e6a591">30.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14031fe7bc3f40a795242b575acf51dd_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYxLTgtMS0xLTA_097bc589-8f3d-46fd-8442-b2ea5823bc95">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eb67a9b82764e84a6203e5424624500_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYxLTEwLTEtMS0w_789e84b7-9528-4df3-befa-36b6126fbddc">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i14031fe7bc3f40a795242b575acf51dd_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYxLTEyLTEtMS0w_7fcb0226-682b-489c-87c1-5d85247764d8">21.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if278a32c9dce4fefa94c62fe1b00772f_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYyLTItMS0xLTA_3cabebac-bda0-496d-b782-a0ee6d682651">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7780cd75cc6246779ff11406eb223052_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYyLTQtMS0xLTA_9a6d56f2-2ee1-4296-b6a9-721ad425824e">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if278a32c9dce4fefa94c62fe1b00772f_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYyLTYtMS0xLTA_c3e24079-e40e-403a-b855-c426cb1e171d">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i691d2c928a4a4a60bc0a0d1ef168d8c9_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYyLTgtMS0xLTA_d674b6cd-c6a3-427f-8447-293bd80403ac">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aa28c488584714acd26eb645da8e89_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYyLTEwLTEtMS0w_629ce88e-06c8-4a71-afdc-d3ce273cd5ce">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i691d2c928a4a4a60bc0a0d1ef168d8c9_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYyLTEyLTEtMS0w_5bc979d5-74c0-456f-ae4e-9921a59a6633">4.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9360b52072034cfdae74e58d3dea3f33_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYzLTItMS0xLTA_89dc31da-d068-4be5-914f-e02ce816fc58">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7e3e8b15ac3457193a8e87969a76f91_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYzLTQtMS0xLTA_fa129810-e751-45a4-ad20-42319f2697e4">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9360b52072034cfdae74e58d3dea3f33_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYzLTYtMS0xLTA_42d7402e-4432-4f38-aa1d-0caa62304b28">14.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic31063913c464d9f982eb66bf1ed7177_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYzLTgtMS0xLTA_da1aaf60-94f8-448d-9bd4-dcd6eb112257">366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42b914656c14beba7b1d52f061668e2_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYzLTEwLTEtMS0w_4d23900a-c865-4690-9e85-a5239b2a5f99">423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic31063913c464d9f982eb66bf1ed7177_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYzLTEyLTEtMS0w_48054bb1-003e-46c9-a0fa-a12e3cc12f0f">13.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia376c7c58c6643b982dd021a28407a4e_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY1LTItMS0xLTA_59a914c7-7025-4a8b-974c-3f63039914e4">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d6cc5a8d92c432cb5364a4922a91d91_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY1LTQtMS0xLTA_f81324f3-5bf4-4a03-af2f-40878bd7b499">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia376c7c58c6643b982dd021a28407a4e_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY1LTYtMS0xLTA_2321fbc6-3e2f-45a4-8329-e11a97f799bf">32.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81cccc8066a04b4e8587f7022fcef5bb_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY1LTgtMS0xLTA_eec73753-cd24-4c32-af4c-0b7b5cc164c4">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id91713fd7da44504bbad7b781cd667f1_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY1LTEwLTEtMS0w_153d8faf-2dc7-4bf4-bee7-cc4630226c26">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i81cccc8066a04b4e8587f7022fcef5bb_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY1LTEyLTEtMS0w_dff31b73-1618-47d9-8e29-7bca7dc7c5ba">29.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39b68889f48547fbb59d17264b094ef6_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY2LTItMS0xLTA_c11a0af1-4a15-4115-bc58-d36ff0d54b9a">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdeb350dde814f6da9360e6b2898ed8b_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY2LTQtMS0xLTA_ecd22cca-0918-4ea5-91b7-4dbb8577c548">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i39b68889f48547fbb59d17264b094ef6_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY2LTYtMS0xLTA_2b7d0870-d125-486f-a8c5-b3abc5f9d2d4">8.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939e8441406e477a9fc9fd99aec89197_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY2LTgtMS0xLTA_2a01183b-9f2a-4aec-a6be-60cb30e8d95d">615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff6994e434614d1a876eb0d4c2bc823f_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY2LTEwLTEtMS0w_2a22ca48-6043-480e-97e5-b4db3e836a8c">670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i939e8441406e477a9fc9fd99aec89197_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY2LTEyLTEtMS0w_546d4c22-2774-45cc-8837-fadce0015370">8.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a65b49f54754536b37dd908a689ce2f_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY3LTItMS0xLTA_83ddb338-0618-4b85-8955-2e4495c90c0f">251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie60d62e420664954b1fcb37f6569c27f_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY3LTQtMS0xLTA_952ddca6-99a1-4b76-9087-dc0bbc27b28f">294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6a65b49f54754536b37dd908a689ce2f_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY3LTYtMS0xLTA_01802e31-1d75-48f3-aed5-05f85573f0fb">14.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a75d9e9a4ab4545b4d6d05ead21ec93_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY3LTgtMS0xLTA_ed66ebd1-caf5-4b63-9320-97a4db0ecdb0">783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37a66f35b5c4a6d99c2c3e0d691685f_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY3LTEwLTEtMS0w_e51374a9-c2ed-453d-a504-ab7068a0f2e8">908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4a75d9e9a4ab4545b4d6d05ead21ec93_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY3LTEyLTEtMS0w_720775ef-022e-4b4c-b55c-cf4b1a6e1864">13.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f78539697c141f2a5eac40f4a433cd2_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcwLTItMS0xLTA_8e321039-b8b7-475f-9b43-31da57ce7124">7,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5912aea718a849be9bf7b9153fd78d98_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcwLTQtMS0xLTA_436266da-3c14-4de8-afe9-6223d18316e0">6,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3f78539697c141f2a5eac40f4a433cd2_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcwLTYtMS0xLTA_00fe2f9c-4c59-4964-b0a9-3b972edebff7">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia241c89cf4794e2bbee7d74dce0875de_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcwLTgtMS0xLTA_f640dad5-3c69-4e48-a262-7b8463de97ce">20,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b6e382369c74f9ea1f6e2762ea30c35_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcwLTEwLTEtMS0w_c015b21f-c01b-48d7-8c3f-7c4a82f88ca2">18,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia241c89cf4794e2bbee7d74dce0875de_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcwLTEyLTEtMS0w_dd8d72be-c726-4cb3-ba16-f1c8123451a6">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieba41c75d5da400e9fb64a10752e1807_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcxLTItMS0xLTA_1469a5a3-5df9-4640-b41a-69e51a4db2fe">5,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad2d34311e684aa1a6203f5714c84491_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcxLTQtMS0xLTA_abe27a2b-0667-4df6-9cdb-ae131861e039">4,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieba41c75d5da400e9fb64a10752e1807_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcxLTYtMS0xLTA_cc14183c-869c-458d-bce2-f6833c7025d0">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c2dbbb07733475cb4da59ccd3196294_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcxLTgtMS0xLTA_85f52aa2-c134-4f77-801b-7b674b82cce1">17,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08295db3a10c439ca068a77285361be5_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcxLTEwLTEtMS0w_5b91b497-76be-4ac1-bb91-a8cd4b1a110a">14,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c2dbbb07733475cb4da59ccd3196294_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcxLTEyLTEtMS0w_f47dc6ae-7796-4289-beb1-fd69eea591b1">17.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia15056130be2407b92273859fdb8febf_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcyLTItMS0xLTA_e5616de6-0720-4931-b7bc-3111ba653622">12,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ee43394ce814ec8b0f42fe52e12760b_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcyLTQtMS0xLTA_e8f79fa2-5d6b-4a3b-b121-8895463490e4">11,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia15056130be2407b92273859fdb8febf_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcyLTYtMS0xLTA_df2ae2a9-c341-41f1-9b4a-8c2d8d5074eb">13.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c6f67375de464e98be9b5c858a0996_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcyLTgtMS0xLTA_a808b3f1-6fd0-4439-8406-a4bb3f7fc513">37,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90d459ed7f3b48f1b2b9174f1965fbd3_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcyLTEwLTEtMS0w_e374f548-45fa-491c-ba39-4c8d3500259a">33,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18c6f67375de464e98be9b5c858a0996_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcyLTEyLTEtMS0w_c10c43e8-2940-4b0d-91c7-e35745e1c99d">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-top:5pt"><ix:continuation id="i1b1edb6dd8d2470aaac550aefcb94d8d" continuedAt="i8aed0cf407054c8c8ec90ea7a2c0090d"><ix:continuation id="ia2e91883243541589fba835941b7c99e" continuedAt="ib7372bd84de745d4b532ebbc3b69b669"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MEDICAL DEVICES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i664cbb9c037f4d99a4376475a351858b_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTgzLTItMS0xLTA_7961f5d7-c8e4-4086-ae3f-1db84acbf7a0">444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id97af143662643b3842da08b330a6f6a_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTgzLTQtMS0xLTA_b5b02965-4041-49e7-a699-7b5e81545164">399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i664cbb9c037f4d99a4376475a351858b_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTgzLTYtMS0xLTA_89c9f661-a1d2-4ff1-96d4-f5c73e2336a2">11.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7759e2ab5024d0fa40501ce6cc6e6b5_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTgzLTgtMS0xLTA_b7bae1b2-15e3-4a9a-ad52-f89a4d585aa5">1,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd8d56e959874c8cbac753320da2c5e0_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTgzLTEwLTEtMS0w_b7f6ab5c-7e32-4d57-9b56-6f5147aad5e6">1,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic7759e2ab5024d0fa40501ce6cc6e6b5_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTgzLTEyLTEtMS0w_d9c76426-a28a-4163-b5a9-4286ad8c3cf1">32.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c3a86a25ea429f97b80b17ca08e649_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg0LTItMS0xLTA_bfb327fb-fb11-4a68-8a96-f6b668c200bc">513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cd56ef47b4f4058acf28c65ff513a42_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg0LTQtMS0xLTA_05efc0f6-5862-4a0f-bef2-1ff461ff1b32">437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i68c3a86a25ea429f97b80b17ca08e649_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg0LTYtMS0xLTA_1d6715a2-2141-4eb2-8d41-d3d8e73b9922">17.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa4a52ab3bc45caa61ce84e01cf51df_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg0LTgtMS0xLTA_5f641e36-3bcd-4ad6-8db6-ecf39f916b19">1,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485a9a2a0c8f4d779f31ad655745be2f_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg0LTEwLTEtMS0w_1fc8330f-d190-423d-ac02-ce80fb264ec2">1,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6fa4a52ab3bc45caa61ce84e01cf51df_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg0LTEyLTEtMS0w_ed1205bd-dc2f-461a-a00e-7fcaee92cb18">41.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66ee637b96ac4b0cb5d60d3c4d7ff8e9_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg1LTItMS0xLTA_8ce9e94a-8fa7-40dd-a5eb-31dde09e65e5">957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1b1017d106d47a89606d3c777ad71f0_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg1LTQtMS0xLTA_6fbda353-842b-4eaf-9514-2512affd7dec">836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i66ee637b96ac4b0cb5d60d3c4d7ff8e9_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg1LTYtMS0xLTA_1f3eb85f-9d84-4f59-ba41-df07e1965153">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bfe547121e24789b19f5f8208fa6fd4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg1LTgtMS0xLTA_c6924ce2-cc24-47af-a3eb-fd440c138d3a">2,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d7f9514d7a44d1ca6005181785ac3ba_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg1LTEwLTEtMS0w_21f6d13d-bc71-4c04-963a-79e3c40aaa47">2,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0bfe547121e24789b19f5f8208fa6fd4_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg1LTEyLTEtMS0w_fb091499-bafe-474a-97fb-39d91b3bbb2c">37.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d1f8a03726c4067a2929437ae2fe5f3_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg3LTItMS0xLTA_19cb30bb-50f4-4a39-a938-eea77d359e43">1,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25f9cfc65bb24864b3563c647160d27a_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg3LTQtMS0xLTA_96c7e913-89b9-4167-8bd0-28acd55c16dc">1,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7d1f8a03726c4067a2929437ae2fe5f3_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg3LTYtMS0xLTA_374d6bdb-524e-4650-a93d-a2f8aebd94a4">4.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7aaf4b905834c92835e38cca37238c7_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg3LTgtMS0xLTA_b3370273-6065-4402-9d86-8e5484fafaff">3,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86237042c73a4330be6316b8b9dd8739_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg3LTEwLTEtMS0w_60c1cfab-dd99-4d76-822c-cb8288c9b6c1">3,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia7aaf4b905834c92835e38cca37238c7_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg3LTEyLTEtMS0w_52114389-d0b5-4558-87b2-1196ec1f1a8c">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i368def26f6ea4bfaa9177cfd9b260470_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg4LTItMS0xLTA_4c7e44e2-e022-46ff-b858-25dfc2219517">843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a357e6381c4197a2f2034714a76f9c_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg4LTQtMS0xLTA_38f0d2cf-37d5-4c37-b141-a57027fc334a">774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i368def26f6ea4bfaa9177cfd9b260470_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg4LTYtMS0xLTA_bc2d613b-7c85-4bd6-b87d-3aac1e9868df">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd7333903aa847658f94ecffe462a28d_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg4LTgtMS0xLTA_4826de02-8f35-4621-ba5a-c50e427e461f">2,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38fa03f6ded84c66aa2bd6d34a67b4cc_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg4LTEwLTEtMS0w_0e2dd0d8-2907-4f9d-b059-22262adfe62c">2,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd7333903aa847658f94ecffe462a28d_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg4LTEyLTEtMS0w_8ba2954a-0488-458a-b951-d2567aa63952">21.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2a3d236dbe3452793a752eded62785d_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg5LTItMS0xLTA_63193ac6-b840-4e70-abc2-a06ae38e048f">2,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b2a6b8d156a4c78be2c856e9636bc48_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg5LTQtMS0xLTA_22e229d1-94af-4819-a9e6-6dcc9fe50c22">2,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic2a3d236dbe3452793a752eded62785d_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg5LTYtMS0xLTA_bbe41cad-2ef5-4e80-b5bf-0e314e685b1a">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03f2bbdd3f2943d8b8a157f236abbaa4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg5LTgtMS0xLTA_731cf98b-ca67-48ba-9a62-dd7bc880fb00">6,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc2283c62b61497f9e264c1563dc631b_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg5LTEwLTEtMS0w_efe1f5d6-1f0a-4967-b873-fd6931dbd6e3">5,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i03f2bbdd3f2943d8b8a157f236abbaa4_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg5LTEyLTEtMS0w_dab180f8-e245-4920-89d7-2df45e089325">15.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">HIPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd21677efb134c17a84394025e299a84_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkxLTItMS0xLTA_6bb09eec-b5b2-4c71-b1eb-b1b0ea8fa617">210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb78ecc3071f4f89a308782d6a88edfb_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkxLTQtMS0xLTA_9c12e381-4b40-4956-85a8-d65cfaf2de7b">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibd21677efb134c17a84394025e299a84_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkxLTYtMS0xLTA_2569d3c9-bb89-4722-9e05-b14f3e4a1428">5.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i777e00866382412a98d3a01a40a39f9d_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkxLTgtMS0xLTA_26892bc6-bb55-4c00-a66a-c3464cde5c8c">654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idebbda9d775f4719aa69f47ce5be05a3_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkxLTEwLTEtMS0w_bb392f78-0c91-4eb9-bb09-02f5a5872739">564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i777e00866382412a98d3a01a40a39f9d_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkxLTEyLTEtMS0w_3ac3a1b2-a89b-4d12-aa5f-68619ee72b73">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50813470f09748ba803e03a49ac76836_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkyLTItMS0xLTA_27c37586-5f03-4cda-b3e6-ac81e321f223">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19eab095e76442c7a15bf5f8be178453_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkyLTQtMS0xLTA_ebc393da-c55b-4c2a-8ca1-a10eaff75203">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i50813470f09748ba803e03a49ac76836_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkyLTYtMS0xLTA_efbb4ab0-5e63-4dc7-804e-24afc4d37589">18.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63c6e6e9b6ae4771aea32259886b1dbd_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkyLTgtMS0xLTA_96fb5015-8dd6-4d90-acc7-74e468eac8c8">451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad15e1fa199a4cbb875175ac153591d6_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkyLTEwLTEtMS0w_1f962f9a-fb34-4c7a-95b0-a6cfb2f81a90">344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i63c6e6e9b6ae4771aea32259886b1dbd_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkyLTEyLTEtMS0w_0f7f048f-9345-4406-a780-ac97fcf6f2e8">31.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i690c132eaf514ca895f63e12fbbb455b_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkzLTItMS0xLTA_36c887fa-31f8-42d3-b780-246f36b5f29c">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59d819aa14d94e3a8762d8ec158426d0_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkzLTQtMS0xLTA_a030efee-2db3-4251-802d-692b3860ebe9">345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i690c132eaf514ca895f63e12fbbb455b_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkzLTYtMS0xLTA_83925221-9770-4658-af38-946f7632e6de">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015af99c4a2e448e9c7144c5eb3975aa_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkzLTgtMS0xLTA_99b9ed07-e980-49fc-97c7-a498fec174fa">1,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if160394e7e1d40f2b37c20e7236b7b62_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkzLTEwLTEtMS0w_b5a28e1b-7053-4354-b959-fbd3f4db22d3">908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i015af99c4a2e448e9c7144c5eb3975aa_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkzLTEyLTEtMS0w_bfa2448f-d424-4db0-81a9-e16ebacf111b">21.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">KNEES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a21754634a4942a38523ea36f795bd_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk1LTItMS0xLTA_fc718506-5209-439d-9f0a-f4f5fcad7905">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a08b9538fa74a208fbf96aec8a31dcb_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk1LTQtMS0xLTA_1b198b1a-7aee-4ca7-8c6b-4e286c8d397a">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i77a21754634a4942a38523ea36f795bd_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk1LTYtMS0xLTA_602327fe-812c-43b7-969b-c171728ef986">9.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d390e81e3db43408b91740c66c31b04_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk1LTgtMS0xLTA_0173ae33-fd04-4921-aa25-00d6b34c68a8">579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f4babed7b4d42b5a5c2d40a153c2633_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk1LTEwLTEtMS0w_8ae6dc7f-41b4-4789-ac0c-87172708058e">527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d390e81e3db43408b91740c66c31b04_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk1LTEyLTEtMS0w_1fc9dcaf-6f60-4b55-9d7d-93a82920eaf8">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe600a9ab7a44c68df5d9ad63069018_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk2LTItMS0xLTA_37d4315f-2e21-4800-9484-0f1285994338">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66818b9b3aff45fa9b5309ab5d6ebdae_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk2LTQtMS0xLTA_7fd27d8c-1cb8-47f0-8044-f357390a0379">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iafe600a9ab7a44c68df5d9ad63069018_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk2LTYtMS0xLTA_20f98350-029f-4c99-b8f3-9d4b66240790">28.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb44530d18d642e683cefa298f2e197a_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk2LTgtMS0xLTA_49462df8-7e27-4171-9818-5e490c45dfcc">403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3db704224024476bb17f015b1c0abc3c_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk2LTEwLTEtMS0w_9f03d7bb-613e-4b52-a486-e5c07301c00d">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifb44530d18d642e683cefa298f2e197a_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk2LTEyLTEtMS0w_dcf5a716-a7ef-4a77-ae61-c426bd9300c5">35.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65804c36217740f0b729d452073739ca_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk3LTItMS0xLTA_4aa2c31a-cabe-4a75-b090-c8c32f43978e">316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8af97229f0b54fb9a42e82e133be93e3_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk3LTQtMS0xLTA_ab30b258-156d-44c4-85cc-2e9bbba97fbe">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i65804c36217740f0b729d452073739ca_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk3LTYtMS0xLTA_927eff0c-eb19-4098-8478-8591519be0a1">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e62e22d053f4be19970487099e52b46_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk3LTgtMS0xLTA_35c55aaf-d5e3-4fc0-8f24-00f38d2a4ea4">983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67cc2a6d5c864c8aa19c1d21575a1fda_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk3LTEwLTEtMS0w_dce4c8b1-ffdf-4eff-a58e-3c59179d36c8">825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e62e22d053f4be19970487099e52b46_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk3LTEyLTEtMS0w_18a790ce-81f6-4283-820d-6468e929ba28">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TRAUMA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib53589fb1d174c0883c5a99ce3b7df76_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk5LTItMS0xLTA_e6b30827-6af4-47ce-b79f-b7206e3dd4d9">455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fe69a5c4f3340bfac6f40428dfe05f1_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk5LTQtMS0xLTA_6813ca25-5f88-4b8a-8298-eb2fd717670f">433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib53589fb1d174c0883c5a99ce3b7df76_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk5LTYtMS0xLTA_0234c540-e865-4680-add7-4fd223197ec6">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib89bd6041e30431ea64fca96eaf48c0e_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk5LTgtMS0xLTA_e3d096ea-dbee-48bc-ac2f-9b2e35998d14">1,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1283c6dd19e48b2ab1219dcf3751cff_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk5LTEwLTEtMS0w_a27b729b-5e0b-4d3b-93f1-ea740f865c2a">1,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib89bd6041e30431ea64fca96eaf48c0e_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk5LTEyLTEtMS0w_8d4817d6-8dfd-49dc-b613-3e65a8195d9a">13.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i346c10c16c374bf6970c356a17deb3f0_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAwLTItMS0xLTA_82371058-166e-43d0-b851-5b27b3d65686">260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e475b85e02746e4b631284e2dfad017_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAwLTQtMS0xLTA_12a7775d-1d52-43b4-a551-cfa3ccfb81a5">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i346c10c16c374bf6970c356a17deb3f0_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAwLTYtMS0xLTA_ed359eb8-262d-404b-818e-2786f21231a7">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1ad64f1a3644558ba0bd78d14887f5_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAwLTgtMS0xLTA_fb6d4de0-3bd4-4de2-a775-af17a9966cac">805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib837c1b7b81c46c79b81103985f70413_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAwLTEwLTEtMS0w_afbc498f-eac5-4473-9bf1-42b36a5e289a">698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0a1ad64f1a3644558ba0bd78d14887f5_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAwLTEyLTEtMS0w_cf925332-4527-4e12-a44e-5c57dced7456">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b39b6e0ce043d59ef4f7c826aee38e_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAxLTItMS0xLTA_0a01f949-c286-41a0-9673-da58787ac013">715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4004c5d0ca6d43168b2cc99025ba0344_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAxLTQtMS0xLTA_7fd9f807-8cf6-429f-a806-992aeb9dae6b">685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if2b39b6e0ce043d59ef4f7c826aee38e_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAxLTYtMS0xLTA_f987d8dd-a3d9-4cfb-b09a-98b1fcf45b55">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69dfc54530ab4ceebe84a4e443cc7206_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAxLTgtMS0xLTA_594e5d80-469f-4da0-9127-c80098f66e0d">2,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7879c0d85bbc427bb4a31690ab8da4b8_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAxLTEwLTEtMS0w_216791b8-d105-42e9-b9ef-ef383a07ce7c">1,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69dfc54530ab4ceebe84a4e443cc7206_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAxLTEyLTEtMS0w_9a43efdb-a77c-4fa5-87d3-902f6206b57b">14.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f7f8554621548c9a359d347cbbbac3f_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAzLTItMS0xLTA_21cd5368-90cf-44cf-945f-3c84e6e9ef66">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46c22958c0c549558f53ab422062f508_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAzLTQtMS0xLTA_2bee8c3f-9bcd-4584-a7ca-51b8b0d4429b">449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6f7f8554621548c9a359d347cbbbac3f_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAzLTYtMS0xLTA_4ba1c2cb-ee49-4279-ac7f-1fbad5ec2780">11.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03538a98c9f84546a0878f97b68fb052_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAzLTgtMS0xLTA_3c251591-0c19-4a3d-9517-77d3a4e7177d">1,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9758b02c72df4754b31600d639492fd4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAzLTEwLTEtMS0w_13056172-356b-4fd4-be5c-b93de5963287">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i03538a98c9f84546a0878f97b68fb052_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAzLTEyLTEtMS0w_56d93176-a1d4-470e-b196-3a5f0cd0901c">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16af716d82004476883437376d33e296_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA0LTItMS0xLTA_589d1dcb-dbb5-4c40-bdfc-a5a35c7bdbc8">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b848b4c72814939a4ee849afee353c0_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA0LTQtMS0xLTA_9711d754-815e-44ce-8935-f79874431dce">295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i16af716d82004476883437376d33e296_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA0LTYtMS0xLTA_90c2b3b7-16ca-4883-b6d1-0db1fc09c931">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdfe043a81224cd7aa4b84062546d3e2_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA0LTgtMS0xLTA_841464bd-3e2b-4114-8279-7bfa8bdbbed3">952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ec97248e6e44f398ee8bbac82b179bb_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA0LTEwLTEtMS0w_d73a05a8-ace3-406e-a200-b15c5ad8da9a">805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icdfe043a81224cd7aa4b84062546d3e2_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA0LTEyLTEtMS0w_f55cc049-b73d-420b-82be-b4992d343eb4">18.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6cbc53d626149a08db3eeb2b61e356a_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA1LTItMS0xLTA_9b41affc-4f4b-4026-b3b1-493cede8cfa6">705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0754c7fbfc40ebb8439cae628ac5f2_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA1LTQtMS0xLTA_43252311-952f-4ee3-bf1f-923fd606f873">745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id6cbc53d626149a08db3eeb2b61e356a_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA1LTYtMS0xLTA_a8476fc1-ece3-47a1-9d26-7b0386bddd28">5.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0fd94b5ecb742a2acf56d48a30e9baa_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA1LTgtMS0xLTA_3cbfc987-dadf-40c9-a1ce-84f46c41e340">2,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2b16d94b1e4ef99fe58558a8b6b7ec_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA1LTEwLTEtMS0w_d2969cc1-affd-4ca7-b8e6-131c27e1b9ae">1,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic0fd94b5ecb742a2acf56d48a30e9baa_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA1LTEyLTEtMS0w_8071ab2b-f83b-40cd-90a4-499a82390005">12.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d422a20e0ae4335846ca1405c432d7b_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA3LTItMS0xLTA_e0c323f2-6636-47a6-bb4e-9c9b007c39cb">948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib99c3f2e02614e95bd95c334578642f6_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA3LTQtMS0xLTA_20a15c9e-9428-454c-bc3f-770b520d1096">913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d422a20e0ae4335846ca1405c432d7b_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA3LTYtMS0xLTA_31197b0b-5159-4702-bb63-5a1c66c9fd50">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i941f7b5cb0944651ad943556245e42af_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA3LTgtMS0xLTA_e9f13d5e-36d8-4a27-85ab-7d11a069b562">2,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e245c440a8b4af9833fa1a0c53fb2f1_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA3LTEwLTEtMS0w_9fa58d01-7037-4138-872c-bd0b1cf07f19">2,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i941f7b5cb0944651ad943556245e42af_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA3LTEyLTEtMS0w_b6aeda1a-5147-4cf6-8c3f-71f0c4b24420">28.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6dfa6170bb04384890d25bf750f7285_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA4LTItMS0xLTA_55776a2f-0f65-41c3-a397-b5ba92fd2900">1,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d965366a5743539f8a0c66e807ebf6_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA4LTQtMS0xLTA_7c9153f8-532b-42ce-971e-c027574c2830">1,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie6dfa6170bb04384890d25bf750f7285_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA4LTYtMS0xLTA_2e841b29-af4b-48dc-b75c-7cc625c234c7">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i957af76e03cf41b2b4137b9fb5b797b5_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA4LTgtMS0xLTA_ec05ea85-5a94-4e2d-a216-60d8cd08e94c">4,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fac8e5af73743b892d0ff019286d402_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA4LTEwLTEtMS0w_2f4a1e8c-b2f8-4929-9a8f-8f5392ad886c">3,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i957af76e03cf41b2b4137b9fb5b797b5_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA4LTEyLTEtMS0w_428e4df2-bd00-4eea-b53b-fefa0e96355c">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic713079734e24fb0aded04ea2f5ef4f1_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA5LTItMS0xLTA_125013f7-3cac-4127-8dad-d86ba27bbafb">2,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17cb3783cf374d5589ec58a0de356fe9_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA5LTQtMS0xLTA_c71689c5-2b2d-45a9-a762-afc9a1fe6d38">2,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic713079734e24fb0aded04ea2f5ef4f1_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA5LTYtMS0xLTA_22f42349-a6f2-4806-8fc0-a311a7fad9be">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75c76e0dab5d49728cf41af893706809_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA5LTgtMS0xLTA_1344e6cd-a7e2-4c4a-9995-3204ce799388">7,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i251fe35eeedb4dfda33118b3264a40b0_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA5LTEwLTEtMS0w_b701275b-0e2d-4516-a0d5-64c33947d473">5,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i75c76e0dab5d49728cf41af893706809_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA5LTEyLTEtMS0w_01accaca-aa0a-436a-af29-47bbca5be250">25.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ADVANCED</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11aebf9815c5450b8eb28d8737503b25_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjExLTItMS0xLTA_7a83494d-03aa-40c7-8521-6819f22ad593">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie503be36392943c2aa1fc032e197cffe_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjExLTQtMS0xLTA_c98b8b7b-f4b0-4036-b58e-371147f4fe0d">421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i11aebf9815c5450b8eb28d8737503b25_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjExLTYtMS0xLTA_7b78bc69-75f8-49b2-b5e2-ebf93878dc99">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7962ec68b8054973bda571c916266fbc_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjExLTgtMS0xLTA_29ddb666-f56a-473f-a747-26530af8cef9">1,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a23c165c324817adfa8ff05e524d4d_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjExLTEwLTEtMS0w_9d8da738-096d-4ad7-b0fc-097a8dc0ff46">1,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7962ec68b8054973bda571c916266fbc_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjExLTEyLTEtMS0w_0a26a477-ed42-41af-baee-6a535a4a67ee">20.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96dfc5cff1454f418137861a7c0bd661_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEyLTItMS0xLTA_ebff7189-9bcb-4736-9104-753aa1bd350a">705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52be8cd00a544fb9837055c28c31a0bc_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEyLTQtMS0xLTA_bb32e726-3721-4a72-9187-43e30d87cb98">579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i96dfc5cff1454f418137861a7c0bd661_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEyLTYtMS0xLTA_65e0dbcf-87cf-492d-8c0b-e4e3fbe46e6d">21.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a091c8ec3e4450b9c534d593ee3f48f_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEyLTgtMS0xLTA_d779c250-548f-467f-b986-3222ef81aaa1">2,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f051d97946b48f98a750ba79b71b129_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEyLTEwLTEtMS0w_63260545-0245-41b8-8282-4d4d41101f43">1,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9a091c8ec3e4450b9c534d593ee3f48f_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEyLTEyLTEtMS0w_c44b70fc-b825-42ac-b5c8-df7e8f9d0aa3">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22ea02a9de494a629f2a4d89b43a24fb_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEzLTItMS0xLTA_468e3338-74bb-471a-a912-f6a3778746f4">1,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212cc5dc91cd478984ad00fae62e7737_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEzLTQtMS0xLTA_816dcc67-1a60-4cf4-be1b-7c6a8beb50c7">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i22ea02a9de494a629f2a4d89b43a24fb_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEzLTYtMS0xLTA_0d533d0c-16d2-44b0-93f1-3503158bbe73">14.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00191b17ba9d4f05a61536365cba8dad_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEzLTgtMS0xLTA_45109f9e-4df6-430d-af96-4bda7b167ec6">3,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb99fb7943bf4d77bb82160d491f0b87_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEzLTEwLTEtMS0w_30e4919c-6f0d-442d-a99b-1f6b01f711b1">2,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00191b17ba9d4f05a61536365cba8dad_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEzLTEyLTEtMS0w_666ce9ff-ec62-4e33-bfac-fc54a5c76ea0">26.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18be951542f44ecb96828af068093472_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE1LTItMS0xLTA_d18a705b-08ec-4531-9f84-75640262ddcb">508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4adae2c06c9b4940ac03d2eac7f0f1e1_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE1LTQtMS0xLTA_0af6f9df-5a76-4c2d-9672-f71fa3061154">492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18be951542f44ecb96828af068093472_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE1LTYtMS0xLTA_0f0c8453-76c1-4e2f-b7b1-f0c4fc471faa">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1997e6c1765e4a75b9bad7033aac8b26_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE1LTgtMS0xLTA_16fc6003-86a2-4550-8c9a-f1a83f5c5ff0">1,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc5a7943edf4572be993acdc0b1bd83_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE1LTEwLTEtMS0w_642fcdcb-4c53-4d6f-adc5-12329ad402ef">1,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1997e6c1765e4a75b9bad7033aac8b26_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE1LTEyLTEtMS0w_8f8c6c6c-4f25-44bf-8b06-3b948d2a9b30">35.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bb2fb97435a4fc68bf0fac1ebcf132c_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE2LTItMS0xLTA_c375aaa1-d4ca-4582-98ee-0c617fd12d2a">752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i122148b592b24cdabf78d0a482cdb38a_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE2LTQtMS0xLTA_05d4d4c1-2277-4a6d-91f4-2845e29930ad">660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1bb2fb97435a4fc68bf0fac1ebcf132c_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE2LTYtMS0xLTA_553c2780-2352-461f-a2f8-791efc802b2e">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6234adc69a847759f0dc2168c7a7ed8_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE2LTgtMS0xLTA_70f295db-94f1-4432-933a-adcfb289a530">2,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dff7af12b264ddc884a1eb374f6b51e_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE2LTEwLTEtMS0w_db87bf7d-991e-4d03-a5a7-873e43032be8">1,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic6234adc69a847759f0dc2168c7a7ed8_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE2LTEyLTEtMS0w_75ba6a3e-5623-4d69-91b9-39ba788b5792">19.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i494fe80075ac40acbe0318a3db1a774d_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE3LTItMS0xLTA_e9b8d946-348b-4e6d-bfb7-b8061633b19b">1,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i490240ac5d354958bca7ade168be4ddd_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE3LTQtMS0xLTA_a6a01bef-d635-4c12-979b-a67c7d34dad8">1,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i494fe80075ac40acbe0318a3db1a774d_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE3LTYtMS0xLTA_c0caed3b-ad58-45d8-9b1d-b28fb9d2746a">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26fb731c7d16411daeea4aeb1d065918_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE3LTgtMS0xLTA_39bd5bc6-bebe-4da2-88a6-cc37842bb957">3,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a3313d8d5cc43f5a89429b00db0f9ff_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE3LTEwLTEtMS0w_d15eb728-176e-40fe-9573-a6ff07db826f">3,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i26fb731c7d16411daeea4aeb1d065918_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE3LTEyLTEtMS0w_fc119544-4bb6-4e5e-b980-5338ee67de71">25.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18341461a0b64ada9ce1d9bf3032cbd6_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE5LTItMS0xLTA_31035172-265b-4bfd-820a-d4134fccabdf">475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i106ec6964b614734a6df2f1c7aec49b6_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE5LTQtMS0xLTA_4195b15c-9280-4139-92b7-b69d45328938">473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18341461a0b64ada9ce1d9bf3032cbd6_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE5LTYtMS0xLTA_729baa2d-61a0-49c7-a2d7-15053e10e14a">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42418c9e338b42f1a79e47c3637bb792_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE5LTgtMS0xLTA_915932e1-df52-462a-8a44-daf1af452915">1,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87bfc75fd15049b0ad902fc45bddb23e_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE5LTEwLTEtMS0w_c8dd79d7-7da4-4af6-bd8b-b662bd8d93b8">1,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i42418c9e338b42f1a79e47c3637bb792_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE5LTEyLTEtMS0w_2de080d6-4812-425d-965c-846081af918b">21.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e89c3ffa20849288d5655da93e8d070_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIwLTItMS0xLTA_aac58cf2-8ccd-4ff1-8051-608178e30ffc">714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3359d80da2904900a689911b61bec8e9_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIwLTQtMS0xLTA_78bcffd7-ef1f-4f2f-a4bd-a96f7a67fab3">608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e89c3ffa20849288d5655da93e8d070_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIwLTYtMS0xLTA_3a6a73af-7cf2-4112-be16-87a9dab959d7">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93a48db34f67401b89ec28786da34bb4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIwLTgtMS0xLTA_72243b87-350f-49c7-933c-6517bad2f1e4">2,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca482bac6f143ad8311c2f32ac8745a_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIwLTEwLTEtMS0w_b54487d4-6c8e-4755-8d73-6b0f4503e27e">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i93a48db34f67401b89ec28786da34bb4_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIwLTEyLTEtMS0w_2ad45e92-29a6-4f0a-8718-a87c6fa97f1c">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77d5cba624204db7a4fdf3c92b03712c_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIxLTItMS0xLTA_0aaeab29-aed2-4d56-9114-66e7455afec9">1,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bd7def248f4471292b3bc6fe506f3c2_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIxLTQtMS0xLTA_eaaf5cfb-0ae2-4d66-af25-b9f997d9f9a4">1,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i77d5cba624204db7a4fdf3c92b03712c_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIxLTYtMS0xLTA_6d1b24be-5cba-49f5-bff4-22878fc11a69">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a49b832a4ce4356beec3af3897dd8ca_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIxLTgtMS0xLTA_2a8c7885-b7a7-4fe9-89d9-b556f2747728">3,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica4dc3e811fa45c38117526d37a372e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIxLTEwLTEtMS0w_26f43eb6-7ecc-4740-8604-2b5fa2a3d226">2,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8a49b832a4ce4356beec3af3897dd8ca_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIxLTEyLTEtMS0w_93eaa9d6-e158-4d8d-9081-9068ce280bdd">23.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONTACT LENSES / OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39f1cfaa5034f7d8963544179ed45f7_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIzLTItMS0xLTA_8665d40f-94f6-4a56-89b0-8d367a6366ff">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09830464a4ac485fb8800a57861ec07a_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIzLTQtMS0xLTA_8b3a65aa-9245-4413-a783-19cdbfedd083">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id39f1cfaa5034f7d8963544179ed45f7_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIzLTYtMS0xLTA_87efd90b-fec6-4f25-af74-d8f4c1667b54">4.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd336d1de1d7402e86a487789816638f_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIzLTgtMS0xLTA_b4a84481-73e6-4c34-83b8-8c23bb816b0e">1,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i868e4a3228b745b69f76acf1ef47fa4e_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIzLTEwLTEtMS0w_42e5f0e1-cb40-4be4-aeba-05814f2b0230">924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifd336d1de1d7402e86a487789816638f_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIzLTEyLTEtMS0w_90c3073f-dfe2-4f27-a76a-f6db969a2bba">17.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied76a8d7c3a849859381acdd5b40e26b_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI0LTItMS0xLTA_6f642c3a-6047-496f-9cf6-d6002b2626d5">522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib963c3361a9e429ea23e9be78632d5f7_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI0LTQtMS0xLTA_52c8256c-d223-4578-ae31-5340ad6c243b">455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ied76a8d7c3a849859381acdd5b40e26b_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI0LTYtMS0xLTA_2135de2c-51d5-490d-afa7-0998c9953061">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c87a451aba6470f8513849722c6f687_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI0LTgtMS0xLTA_3c5e7ab2-0882-4fac-a1fe-a5dd8c99def8">1,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5574bb64c5442568419329c1ddf953b_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI0LTEwLTEtMS0w_83333a8d-2b8a-4246-bbfd-d5767a48a375">1,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9c87a451aba6470f8513849722c6f687_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI0LTEyLTEtMS0w_52fc006e-90b0-42a6-8d4f-cb6873e3bb07">19.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i890b0d4ac71f441eba6bf1198c410a5b_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI1LTItMS0xLTA_a6a6b833-55d6-45b7-b4a3-fd1125334826">882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98ce489b2b83414fafb7d08826ccae52_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI1LTQtMS0xLTA_09d0c4cf-d569-471b-8112-16e754de450c">830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i890b0d4ac71f441eba6bf1198c410a5b_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI1LTYtMS0xLTA_eac355df-2d51-4094-ab45-33acfe7f80b0">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84a3df8795414451a2635599c9f326f4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI1LTgtMS0xLTA_dafe5ef5-805b-4249-b777-4368cb805b5f">2,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic40e1fc715504106941039635c311b42_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI1LTEwLTEtMS0w_44759593-c15f-498e-891a-308bc3f62a1c">2,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i84a3df8795414451a2635599c9f326f4_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI1LTEyLTEtMS0w_081de124-4764-4c70-947e-b17986f8c7c1">18.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i8aed0cf407054c8c8ec90ea7a2c0090d" continuedAt="i43e190b2cf7e4893a0160055bde6cfe8"><ix:continuation id="ib7372bd84de745d4b532ebbc3b69b669"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SURGICAL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc28cefdee24db587c2c44627a5d4a3_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI4LTItMS0xLTA_86fd987a-49a8-4c3b-93b2-dfad3009da68">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id90e5b6cac784a01a3ec9b835573dd8b_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI4LTQtMS0xLTA_16a67423-b030-4a54-8022-7b0880bce7a2">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4cc28cefdee24db587c2c44627a5d4a3_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI4LTYtMS0xLTA_b04d3e3e-c8d1-4829-b083-637224131765">19.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14af6f66309945bbb345d1e5080fc3ab_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI4LTgtMS0xLTA_e15e0518-c3e9-4576-8523-6740e38e1d29">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5adee58e8c554a2fa51b9dd0dff78319_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI4LTEwLTEtMS0w_3c4b9793-346d-4fd5-8f1a-849c87874449">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i14af6f66309945bbb345d1e5080fc3ab_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI4LTEyLTEtMS0w_a121650b-11a7-4463-88c4-fd458ffaf486">41.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8954550cb9744329c0944ee64bf182d_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI5LTItMS0xLTA_b3f60e7c-7bae-41c8-b588-19a6d2bd55fa">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dc24dbfe93c42a5bedd17d3f4602b07_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI5LTQtMS0xLTA_4256d693-ec14-4796-adbb-fe9c1f93f062">153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8954550cb9744329c0944ee64bf182d_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI5LTYtMS0xLTA_eb8a33de-3510-47eb-b3d4-d69cb9fa4035">24.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20171878a2664b1396a4e8dfab867c63_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI5LTgtMS0xLTA_7624b053-a48d-4753-89eb-ea99a9b90c3e">577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib792371a81394b76adb8d9160ed815f4_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI5LTEwLTEtMS0w_a5d04be0-7b17-4500-8f48-5b957010d317">409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20171878a2664b1396a4e8dfab867c63_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI5LTEyLTEtMS0w_5d1e35d9-ce76-4176-93d2-ea37a34bd090">41.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1c483984fa940d4a2263fdde35ae2b6_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMwLTItMS0xLTA_6d7d2bf5-73ed-44b2-ba16-c7aec8664cb5">308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40b2a961cef64c3f81dd66d2cc8d30cc_D20200629-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMwLTQtMS0xLTA_652530b4-4182-46df-9c19-c8a2f534b006">251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if1c483984fa940d4a2263fdde35ae2b6_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMwLTYtMS0xLTA_253e7827-0887-4654-90c8-e4f84346b54e">22.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5e248410521459d8d4e90e3229028f7_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMwLTgtMS0xLTA_f044d67e-d4e7-4865-9ccc-3f9996307680">910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d6c5cc14f04a4aaecd3ac4c2a56626_D20191230-20200927" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMwLTEwLTEtMS0w_be7fa04e-4748-447d-9ba7-3f8efebdef49">645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5e248410521459d8d4e90e3229028f7_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMwLTEyLTEtMS0w_8abe84de-77db-49b1-ae4e-bb17a139d4b0">41.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL MEDICAL DEVICES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic77ca9253fc245e696f14b2344a21c4a_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMzLTItMS0xLTA_16d371e5-6a6f-40f8-b014-73be50950bf9">3,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f766b8bc30a495cabb27a63cdfa21dc_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMzLTQtMS0xLTA_275e5351-a894-4619-a3c7-97070dc02b8c">3,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic77ca9253fc245e696f14b2344a21c4a_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMzLTYtMS0xLTA_991746c3-66a3-4c00-ab38-93ce5494b03a">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74aa9c650ce94f7f8b6a94ad4ec01ce9_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMzLTgtMS0xLTA_b5e6e25f-a9d5-4f11-961c-f844a30b31dc">9,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50d4546f23234e4a95f876fa114ea771_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMzLTEwLTEtMS0w_20e97382-04ad-4687-ae72-5c68dde94347">7,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i74aa9c650ce94f7f8b6a94ad4ec01ce9_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMzLTEyLTEtMS0w_2c72aabd-9fd8-4922-ab3f-7fa3eaa50a42">20.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78f6125d4e1f4642a4d765a351286c3c_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM0LTItMS0xLTA_b1c95978-16e1-4961-9466-b7f7a59d1301">3,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93a0aa8ef0ed416c9429b2b5b88cafd0_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM0LTQtMS0xLTA_35badb99-bda5-4e38-81a8-ec5d48aa0e1a">3,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i78f6125d4e1f4642a4d765a351286c3c_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM0LTYtMS0xLTA_a5f415ff-7973-4b83-a231-d322d44fcdea">15.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2f9faa3f7c645ed95dad829fbe0f3f7_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM0LTgtMS0xLTA_36f5cb88-b873-458e-a928-0866769c2f18">10,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadc95fab6c004ee8a52836e72d8e51fb_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM0LTEwLTEtMS0w_1b15d766-a30a-40f6-8f38-b7814d4d9828">8,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie2f9faa3f7c645ed95dad829fbe0f3f7_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM0LTEyLTEtMS0w_0160595d-9ac3-471f-9846-67d5b68c12c5">26.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34f633e2629c400f81fb20c99145e112_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM1LTItMS0xLTA_416ebb07-5d44-447d-84b0-e306acaa6c08">6,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4fd30965b31465e953a69a10b46ae75_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM1LTQtMS0xLTA_57afae84-d074-4626-b395-f2e244f28830">6,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34f633e2629c400f81fb20c99145e112_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM1LTYtMS0xLTA_dbd0f7e6-62f7-4a78-baed-af41fe06c5d2">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7fc25fc53e54e21948d2ce281e9424a_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM1LTgtMS0xLTA_ca4c53dd-aefc-497a-9e07-3b73560a96c2">20,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d5d0922cabe4f6fa55f3ac6507c79fa_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM1LTEwLTEtMS0w_a778cd3e-8f36-4ed6-90c2-1090a7077e79">16,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7fc25fc53e54e21948d2ce281e9424a_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM1LTEyLTEtMS0w_2e618a6e-2a51-490c-a88c-4830d0d9676f">23.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WORLDWIDE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb264a5db024fa1895bcd3a4069036e_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM4LTItMS0xLTA_563062ce-ae74-4d65-9541-32a6105e43c3">11,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b312259598430096ff868f08b6757a_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM4LTQtMS0xLTA_76f7902e-fd19-4ffe-aec0-d353ce1e71a3">11,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9fb264a5db024fa1895bcd3a4069036e_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM4LTYtMS0xLTA_fc3ef7bb-f459-4c39-93f5-e8a2bd88796d">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51a85394d9a14ff08bfeb689185d9ee0_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM4LTgtMS0xLTA_3cad3635-0320-4043-8292-b7f2c2d12926">34,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie63bc91b9c82473fa1e0ce9ddfc407bc_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM4LTEwLTEtMS0w_92c83f7d-14ac-44b6-9cae-a122d717d75b">31,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i51a85394d9a14ff08bfeb689185d9ee0_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM4LTEyLTEtMS0w_aacb872a-0732-4915-bb71-80b88135a547">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e2feb214c2c4da99c1a6b518a224dff_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM5LTItMS0xLTA_89309b00-6aaa-4a43-94a0-d53e4c197d21">11,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2f54909f5e146f3bd1d3b4357419206_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM5LTQtMS0xLTA_3225f9d5-834a-4576-bd52-d6232ff7be56">9,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e2feb214c2c4da99c1a6b518a224dff_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM5LTYtMS0xLTA_7ac1b276-dbcb-41b7-a550-daeace2f8ffc">13.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dc0ed7f6bc641189e3c6e00c91f73c2_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM5LTgtMS0xLTA_041df218-765b-4517-afa6-5f68a180a989">33,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43e3289369584ba8afd76314fc686eaa_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM5LTEwLTEtMS0w_d42567d7-ec4c-49a4-9b6f-0d2c901b2622">28,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1dc0ed7f6bc641189e3c6e00c91f73c2_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM5LTEyLTEtMS0w_89fea4b8-1c2d-4553-ada5-58f04c83b6dc">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjQwLTItMS0xLTA_9783ddab-ced5-4689-bc27-63758937a62b">23,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjQwLTQtMS0xLTA_0c90a699-8425-4812-9baf-72df90f4eb37">21,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjQwLTYtMS0xLTA_215cb318-bcc6-4f0d-aaac-f400b6cf3306">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjQwLTgtMS0xLTA_2418a1ff-aacf-469e-b42e-864301c0a6c9">68,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjQwLTEwLTEtMS0w_20da4197-4fd6-48b5-90c3-49d6bc836ec6">60,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjQwLTEyLTEtMS0w_37156fe8-34a3-4d90-b872-4f8af091b049">14.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inclusive of VELCADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMjYwNg_562a78e8-5e46-4949-9c71-babefac4f8a8" continuedAt="ia0217bba5fb44bbcabc8b6d2efe91914" escape="true"><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMjYwNg_d877e0b9-880a-4135-94f5-c556f4627b23" continuedAt="i02522e1b576a4334a06ee2cc6c03b429" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT  </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:36.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27,<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27,<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2f69aa2c55f4826a2d6918db36d8504_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfMi0yLTEtMS0w_5167df69-fc8d-403e-b4a4-9019181730fd">636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if044c23d97b94f7e9198830e79b71e75_D20200629-20200927" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfMi00LTEtMS0w_25e98338-57fa-40b2-a2a3-f8c9f65d1820">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice42e5369e6b45f0adf19543436ac0b0_D20210104-20211003" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfMi04LTEtMS0w_4aa5c3bb-6783-4997-8858-20485fcaab91">956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d701fb1987245ca88cf01f3640777be_D20191230-20200927" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfMi0xMC0xLTEtMA_c4ef35a8-6765-437a-8234-d6e442506c07">993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ice42e5369e6b45f0adf19543436ac0b0_D20210104-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfMi0xMi0xLTEtMA_fc0cd038-8867-48e2-838d-8e7024f6b832">3.7</ix:nonFraction>)%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic16d2db94474459387159b0687052bee_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfMy0yLTEtMS0w_399db545-d66a-4745-a643-3f12c0739573">4,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6ef5074333a4f0d83205f62d497b7b9_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfMy00LTEtMS0w_d4ab62eb-b706-45f3-b561-7fb4762ae308">3,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic16d2db94474459387159b0687052bee_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfMy02LTEtMS0w_b0d9fdbd-1e34-43f3-9c7f-590e44180e11">23.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id87ab88275fe48e88b999c9d8843e970_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfMy04LTEtMS0w_e5d75b8a-b72a-4843-9bca-689ffba2858d">13,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia28c90140a094ef6b236aa35a8e77056_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfMy0xMC0xLTEtMA_c4e03f35-8d8a-4a24-9a47-5b58eaad1af1">11,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id87ab88275fe48e88b999c9d8843e970_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfMy0xMi0xLTEtMA_ba2bcdb2-d020-40f6-89f3-251c4b4495ee">17.4</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b2df3c4074c46f3829a9f1fe6d1b3d6_D20210705-20211003" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNC0yLTEtMS0w_9dc6c8e4-ff9a-40a8-b0c9-b10c9a9fce43">423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab8b7c86635743468dc8ac2476edee79_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNC00LTEtMS0w_c332b43e-9797-4ded-b283-300d6571cf01">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9b2df3c4074c46f3829a9f1fe6d1b3d6_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNC02LTEtMS0w_20f5154f-ff62-413d-96af-0a1443e345ce">58.1</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0d190ecec914687861142e006d00019_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNC04LTEtMS0w_fa08462c-02c5-40fc-a2ba-e4f6c87a0db6">3,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fcf37770f4b482490a1deeb32ca5fb3_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNC0xMC0xLTEtMA_8e9d9465-0bee-4f41-bb50-807cfc300bf1">2,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia0d190ecec914687861142e006d00019_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNC0xMi0xLTEtMA_0156f062-382c-4309-8771-80085b6a5a6f">41.7</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before provision for taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a08d0a4fd414fb0a743ba8926a6de8f_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNS0yLTEtMS0w_e98a9f11-6462-48a1-8808-122540b1a0d0">4,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa95b6bbe9ce43f59b2c55eccaef0947_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNS00LTEtMS0w_28c1f0bb-be01-414b-955c-88b0ee1789fd">4,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9a08d0a4fd414fb0a743ba8926a6de8f_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNS02LTEtMS0w_81417c0a-637a-4951-9c67-849bfdf9b531">12.8</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9a33a98d27c46748aef00c3c783085e_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNS04LTEtMS0w_c5b3584d-5999-4785-90d4-a4c2ac7d66d0">18,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b79863c6ede4c88a5b5a6aae528d65b_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNS0xMC0xLTEtMA_b79fb667-28f5-4334-b444-864c0d92bab6">15,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if9a33a98d27c46748aef00c3c783085e_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNS0xMi0xLTEtMA_6306a1da-b47c-435a-b4af-face20c754af">20.3</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c8f9eac7f34ffeb651669100cadca2_D20210705-20211003" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNi0yLTEtMS0w_5211771e-b2b5-4d9c-b680-e82c15674ccd">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86880b7c7c2c429080f9c83aaaf12cfe_D20200629-20200927" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNi00LTEtMS0w_fc4129aa-df2f-4ae0-bc57-9b05fcbbce4e">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6353fe8fafb84e8b9c268c65fd303086_D20210104-20211003" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNi04LTEtMS0w_e58cf316-883d-46d0-a8cd-5763d065473e">652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6337b707147a48869ac16b7992cb215b_D20191230-20200927" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNi0xMC0xLTEtMA_0a65c73c-dc65-4d63-89f3-e76c321d2480">611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNy0yLTEtMS0w_ab0c487e-827b-4f48-8609-248406ce8b7f">3,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNy00LTEtMS0w_d5304ca6-ed21-4094-9c12-c9cfdf6e6ef9">4,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="3" sign="-" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNy02LTEtMS0w_2c7c70eb-face-4ed4-a51a-98c96ee177c4">12.5</ix:nonFraction>)%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNy04LTEtMS0w_3e284871-4a4c-459a-826a-776f16e2a012">17,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNy0xMC0xLTEtMA_33b44bfe-4629-4c1e-a788-85a67955ee8e">14,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNy0xMi0xLTEtMA_fdaf4ebc-1b1d-40c6-bc58-9aefbc551266">20.8</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consumer Health</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Includes intangible amortization expense of $<ix:nonFraction unitRef="usd" contextRef="if2f69aa2c55f4826a2d6918db36d8504_D20210705-20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentForAmortization" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMzcw_8aa97004-945c-433a-be08-95921542f084"><ix:nonFraction unitRef="usd" contextRef="if044c23d97b94f7e9198830e79b71e75_D20200629-20200927" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentForAmortization" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMzcw_e6202d57-8367-4e97-a5b1-2171384d8907">0.1</ix:nonFraction></ix:nonFraction> billion in both the fiscal third quarter of 2021 and 2020 and $<ix:nonFraction unitRef="usd" contextRef="ice42e5369e6b45f0adf19543436ac0b0_D20210104-20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentForAmortization" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDA5_8d54d0fc-cd79-44fa-bafc-2e7ffaee3316"><ix:nonFraction unitRef="usd" contextRef="i1d701fb1987245ca88cf01f3640777be_D20191230-20200927" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentForAmortization" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDA5_a58d69a6-d28f-4d8e-87d2-f3f73d1b8ba2">0.3</ix:nonFraction></ix:nonFraction>&#160;billion in both the fiscal nine months of 2021 and 2020. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Includes litigation expense of $<ix:nonFraction unitRef="usd" contextRef="i27ba7c90a4c1434586cbf514f3e51927_D20210705-20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDky_3b5ff64f-bef8-417f-8a47-3ef6cc2d152c">1.4</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i8aa1fb345ea8443c9e0bc1aa8418aaec_D20200629-20200927" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk5_18dcdf45-6d9c-4429-97b4-e5a4a9ba42da">0.5</ix:nonFraction>&#160;billion in the fiscal third quarter of 2021 and 2020, respectively. Includes litigation expense of  $<ix:nonFraction unitRef="usd" contextRef="i185910f7181845c8aed38c39fd4b6cab_D20210104-20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMyOTY1Mw_ecbc2314-8a4f-41b9-a2c0-1906c1046f6e">1.5</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="iaa93431137654cfa8d08a279d01cc337_D20191230-20200927" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMyOTY2OQ_822a1471-f8bd-45c3-8056-c60af5b44767">1.2</ix:nonFraction>&#160;billion in the fiscal nine months of 2021 and 2020, respectively. Litigation expense in both periods is primarily related to talc.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Includes a restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="i185910f7181845c8aed38c39fd4b6cab_D20210104-20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMyOTgzNg_885371c8-0343-4eb4-9062-579d4487a2c5"><ix:nonFraction unitRef="usd" contextRef="iaa93431137654cfa8d08a279d01cc337_D20191230-20200927" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMyOTgzNg_98f2fe6e-7f64-4698-9ee3-440113dfb9b6">0.1</ix:nonFraction></ix:nonFraction>&#160;billion in both the fiscal nine months of 2021 and 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pharmaceutical</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes divestiture gains of $<ix:nonFraction unitRef="usd" contextRef="id87ab88275fe48e88b999c9d8843e970_D20210104-20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNjcy_0f8c1073-2689-4f3d-b29d-6b37f83d32b2">0.6</ix:nonFraction>&#160;billion in the fiscal nine months of 2021 related to two brands outside the U.S.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes intangible amortization expense of $<ix:nonFraction unitRef="usd" contextRef="ic16d2db94474459387159b0687052bee_D20210705-20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentForAmortization" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfOTQ3_6cca26d1-e121-4291-8ef2-76916b080734"><ix:nonFraction unitRef="usd" contextRef="ib6ef5074333a4f0d83205f62d497b7b9_D20200629-20200927" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentForAmortization" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfOTQ3_f779657e-00c1-4d40-b18d-9851220ac58b">0.8</ix:nonFraction></ix:nonFraction>&#160;billion in both the fiscal third quarter of 2021 and 2020. Includes intangible amortization expense of $<ix:nonFraction unitRef="usd" contextRef="id87ab88275fe48e88b999c9d8843e970_D20210104-20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentForAmortization" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMTAyNw_3ff04262-5870-42fa-af9e-eac19629ccc0">2.5</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="ia28c90140a094ef6b236aa35a8e77056_D20191230-20200927" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentForAmortization" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMTAzNA_4d6118fe-442a-437f-a930-95de1f4ad945">2.4</ix:nonFraction>&#160;billion in the fiscal nine months of 2021 and 2020, respectively.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes net litigation expense of $<ix:nonFraction unitRef="usd" contextRef="ia15056130be2407b92273859fdb8febf_D20210705-20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMzMDM3MQ_3de3b240-bfb7-4315-adea-599934bebcbf">0.8</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i4ee43394ce814ec8b0f42fe52e12760b_D20200629-20200927" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMzMDM4NQ_795a8a09-8500-434d-8e0f-eb2faed7d409">1.0</ix:nonFraction>&#160;billion in the fiscal third quarter of 2021 and 2020, respectively. Includes net litigation expense of  $<ix:nonFraction unitRef="usd" contextRef="i18c6f67375de464e98be9b5c858a0996_D20210104-20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMzMDQwOQ_25443727-16f6-4ad3-8d78-f30ea1ed3c4c">0.7</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i90d459ed7f3b48f1b2b9174f1965fbd3_D20191230-20200927" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMzMDQyMw_a41e7c1a-667b-4ac6-b918-f658a734c9a0">1.0</ix:nonFraction>&#160;billion in the fiscal nine months of 2021 and 2020, respectively. Litigation expense in 2021 is primarily related to Risperdal. Litigation expense in 2020 is related to the opioid settlement.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes a gain on securities of $<ix:nonFraction unitRef="usd" contextRef="ic16d2db94474459387159b0687052bee_D20210705-20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesRealizedGainLoss" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMTA5OTUxMTYzNTk5NA_e8b53ce5-23a2-4b0c-8db3-e5d9cdda5c9e">0.1</ix:nonFraction>&#160;billion in the fiscal third quarter of 2021 and $<ix:nonFraction unitRef="usd" contextRef="id87ab88275fe48e88b999c9d8843e970_D20210104-20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesRealizedGainLoss" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMTA5OTUxMTYzNjAyMQ_797685df-f246-40ae-b41f-715ad562701b"><ix:nonFraction unitRef="usd" contextRef="ia28c90140a094ef6b236aa35a8e77056_D20191230-20200927" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesRealizedGainLoss" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMTA5OTUxMTYzNjAyMQ_b9e8c56b-4749-476f-ba63-4b8620d669f7">0.2</ix:nonFraction></ix:nonFraction>&#160;billion in both the fiscal nine months of 2021 and 2020, respectively. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes a restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="i18c6f67375de464e98be9b5c858a0996_D20210104-20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMzMDc4Mw_0eda3042-c918-457b-93dd-06816dbf896a"><ix:nonFraction unitRef="usd" contextRef="i90d459ed7f3b48f1b2b9174f1965fbd3_D20191230-20200927" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMzMDc4Mw_ecdf2d00-1484-44d8-ade0-7c5e26624148">0.1</ix:nonFraction></ix:nonFraction>&#160;billion in both the fiscal nine months of 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In fiscal 2020 and 2021, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $<ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-8" format="ixt:num-dot-decimal" name="jnj:AmountPrepaidAndDueToManufacturers" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMTU2Mw_cc4902a2-d527-43ff-9e79-03488689ddf3">1.2</ix:nonFraction>&#160;billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities </span></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i43e190b2cf7e4893a0160055bde6cfe8"><ix:continuation id="ia0217bba5fb44bbcabc8b6d2efe91914" continuedAt="ic429fe3e83754f0f8235a8abe8afe2f3"><ix:continuation id="i02522e1b576a4334a06ee2cc6c03b429" continuedAt="i8b9c457bf3dc412a99796b5c01f3f08e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Devices </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes a contingent consideration reversal of $<ix:nonFraction unitRef="usd" contextRef="id1e1fcd02b464ee2a9ec2881679e5e2b_D20200629-20200927" decimals="-8" sign="-" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMzMjYzOA_0b1f1953-5ee3-4d81-a725-bac30d18f6df">0.2</ix:nonFraction>&#160;billion in the fiscal third quarter of 2020 and $<ix:nonFraction unitRef="usd" contextRef="i9cf5b5276af745aaae4d731df390a2e3_D20191230-20200927" decimals="-8" sign="-" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMzMjY2NQ_2a72a9a4-489f-461b-b6fa-94ff81bb4ec8">1.1</ix:nonFraction>&#160;billion in the fiscal nine months of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes a restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="i34f633e2629c400f81fb20c99145e112_D20210705-20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMjEzMw_669a160e-4e97-4eaf-bf60-4ba5d7b28058"><ix:nonFraction unitRef="usd" contextRef="id4fd30965b31465e953a69a10b46ae75_D20200629-20200927" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMjEzMw_934b65c2-c506-48a4-a2ec-49e6ddc23c5e">0.1</ix:nonFraction></ix:nonFraction> billion in both the fiscal third quarter of 2021 and 2020, respectively. Includes a restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="if7fc25fc53e54e21948d2ce281e9424a_D20210104-20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMzMTc0NQ_8afb4474-a472-47cd-b79c-b94834834992"><ix:nonFraction unitRef="usd" contextRef="i9d5d0922cabe4f6fa55f3ac6507c79fa_D20191230-20200927" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMzMTc0NQ_9432e32b-c578-440c-86d5-4e725c286787">0.2</ix:nonFraction></ix:nonFraction>&#160;billion in both the fiscal nine months of 2021 and 2020, respectively.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes intangible amortization expense of $<ix:nonFraction unitRef="usd" contextRef="i9b2df3c4074c46f3829a9f1fe6d1b3d6_D20210705-20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentForAmortization" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMjIyOQ_9f3799f8-dfee-4668-a5f4-85895728a633">0.3</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="iab8b7c86635743468dc8ac2476edee79_D20200629-20200927" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentForAmortization" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMjIzNg_eef3d56d-8d8e-458f-80c1-8681a0ce854a">0.2</ix:nonFraction>&#160;billion in the fiscal third quarter of 2021 and 2020, respectively. Includes intangible amortization expense of $<ix:nonFraction unitRef="usd" contextRef="ia0d190ecec914687861142e006d00019_D20210104-20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentForAmortization" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMjI1NA_99f1f611-ae56-4e20-9b41-02324008c6e3">0.8</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i8fcf37770f4b482490a1deeb32ca5fb3_D20191230-20200927" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentForAmortization" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMzMTIyNw_919366c8-ebfe-43dd-98ba-26ecec07e2f5">0.7</ix:nonFraction>&#160;billion in the fiscal nine months of 2021 and 2020, respectively. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes a gain on securities of $<ix:nonFraction unitRef="usd" contextRef="ia0d190ecec914687861142e006d00019_D20210104-20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesRealizedGainLoss" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMjM2NQ_79169c2f-82f1-4b31-abd3-1bbb6df4ee50"><ix:nonFraction unitRef="usd" contextRef="i9b2df3c4074c46f3829a9f1fe6d1b3d6_D20210705-20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesRealizedGainLoss" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMjM2NQ_adb712a1-eb67-4812-b488-cf11cc361b3c">0.1</ix:nonFraction></ix:nonFraction>&#160;billion in the fiscal nine months of 2021.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Includes an in-process research and development expense of $<ix:nonFraction unitRef="usd" contextRef="i9b2df3c4074c46f3829a9f1fe6d1b3d6_D20210705-20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMzMTQ5OQ_1b1a08e9-8770-4ea3-a13b-d5097afd67ba"><ix:nonFraction unitRef="usd" contextRef="ia0d190ecec914687861142e006d00019_D20210104-20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMzMTQ5OQ_3e811849-9fa7-48b0-ba2b-555f501bec3b">0.9</ix:nonFraction></ix:nonFraction>&#160;billion related to the general surgery offering in digital robotics (Ottava) acquired with the Auris Health acquisition in 2019 in both the fiscal third quarter and fiscal nine months of 2021. See Note 3 to the Consolidated Financial Statements for more details.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="ic429fe3e83754f0f8235a8abe8afe2f3" continuedAt="ie6a1196b6df2499bb006570f0ea20a44"><ix:continuation id="i8b9c457bf3dc412a99796b5c01f3f08e" continuedAt="iad920f4854064073acfdfbe9b92f92c3">(4)</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie6a1196b6df2499bb006570f0ea20a44"><ix:continuation id="iad920f4854064073acfdfbe9b92f92c3"> Amounts not allocated to segments include interest income/expense and general corporate income/expense.</ix:continuation></ix:continuation> </span></div><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMjU5OQ_ffbc0475-8bda-441f-b695-61ea7e61948e" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY GEOGRAPHIC AREA</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.889%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.889%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.751%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.339%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb264a5db024fa1895bcd3a4069036e_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfMi0yLTEtMS0w_2a6b1cb1-7a59-4bba-a750-c08341907b8a">11,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b312259598430096ff868f08b6757a_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfMi00LTEtMS0w_d9830a00-3023-4608-8274-050a18978d28">11,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9fb264a5db024fa1895bcd3a4069036e_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfMi02LTEtMS0w_177753bd-f780-4bab-8f67-553ccb77a592">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51a85394d9a14ff08bfeb689185d9ee0_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfMi04LTEtMS0w_643620e5-b6b5-42c4-98c8-efd63b47b59b">34,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie63bc91b9c82473fa1e0ce9ddfc407bc_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfMi0xMC0xLTEtMA_055b90e9-8353-41e3-aa4f-9e53e3999611">31,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i51a85394d9a14ff08bfeb689185d9ee0_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfMi0xMi0xLTEtMA_df52b0ec-3d79-4ed7-9340-60d569879938">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a407e33714d43e5b6f57eceb1da3644_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfMy0yLTEtMS0w_afb5fa8f-150c-4cf4-b63b-e8f12876c25c">5,587</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i774d073624f5479f99c44707399d81a2_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfMy00LTEtMS0w_fbdec8e4-fc7b-4404-9dac-a3be6ce1e6cb">4,819</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9a407e33714d43e5b6f57eceb1da3644_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfMy02LTEtMS0w_4472e8ab-5016-491a-a03b-a954a236a8ee">15.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie104a5f4ba5646e5ac756ddb0f8fe1e9_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfMy04LTEtMS0w_4401b4f0-a815-4a08-a33b-aba98040b7b0">16,669</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7453bcb1f1499cb56bf4c488b9f6ff_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfMy0xMC0xLTEtMA_602c3c01-6d8f-4db1-82a3-a2ea6e048f50">13,709</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie104a5f4ba5646e5ac756ddb0f8fe1e9_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfMy0xMi0xLTEtMA_a328d646-030a-4b5d-83a6-054cf233a04a">21.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere, excluding U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i548df4a2b991433e95457098102bdc1b_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNC0yLTEtMS0w_2cfdaba2-d7a2-44ed-9a83-8b3d3773c62d">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12056b6b1c854b9b986a9a3fbc149483_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNC00LTEtMS0w_647cfd86-ca40-442c-89f7-38af5ee0773e">1,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i548df4a2b991433e95457098102bdc1b_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNC02LTEtMS0w_63caeadf-1088-4944-b7fb-58eabb2167ac">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i543547499d5747568f983b53ce0eb701_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNC04LTEtMS0w_097d1eca-d75c-46ce-8a77-304da4767f27">4,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic400b23cafa440aca0f838eec065bd9b_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNC0xMC0xLTEtMA_a955eaeb-0d76-4d13-8a88-da8aa2a01b8f">3,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i543547499d5747568f983b53ce0eb701_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNC0xMi0xLTEtMA_ad085dfb-f352-4cfa-b083-b00191991f08">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific, Africa</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i237bc393dc5541fe92d8e43c47a8e02f_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNS0yLTEtMS0w_026c49ef-61a5-452d-8ee0-f99153500e5e">4,288</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53dd9cb72725412faea6075a5b94f5f7_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNS00LTEtMS0w_555e501d-3dd5-463e-9ccc-3dcb8eb81d57">3,881</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i237bc393dc5541fe92d8e43c47a8e02f_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNS02LTEtMS0w_fa98b49e-4fd0-4813-8870-424ebb3081b3">10.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie745b9ff518641abb53ef1f33093480c_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNS04LTEtMS0w_bb2c5caf-d185-47e7-a7fc-f36c2744a7f0">13,018</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76eb46ab7e594c6e955830b051a4634d_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNS0xMC0xLTEtMA_602046e4-cf13-47a0-a041-fe11d5f5fe27">11,145</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie745b9ff518641abb53ef1f33093480c_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNS0xMi0xLTEtMA_8516ce8d-781a-4dd1-ad5f-c8e93104cdcc">16.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNi0yLTEtMS0w_1c4de039-b10c-476d-a434-4171310cc408">23,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNi00LTEtMS0w_87f494e7-572c-4ae1-8e06-7b93d9bf44b3">21,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNi02LTEtMS0w_d1438ed8-7b7a-4a38-8fa4-52a888ad442c">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNi04LTEtMS0w_d4606205-5b8b-463c-88ce-d8b39a82c209">68,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNi0xMC0xLTEtMA_df10bd64-8cc7-4254-aad4-640d34c94d82">60,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNi0xMi0xLTEtMA_02300e81-8b87-4cbf-8c80-e0eed2b28f2c">14.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="if410ee6e03c8456f86a9fee997f08e65_85"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 10&#8212; <ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84NS9mcmFnOjhlYjExMjRjMTFjNTQyY2M4Nzk4M2EzMTkwYWNmYmY4L3RleHRyZWdpb246OGViMTEyNGMxMWM1NDJjYzg3OTgzYTMxOTBhY2ZiZjhfMTUxMg_55d543df-2f70-4e15-a409-051c1d34828a" continuedAt="ife5980f6955e40e5bd09b9b43c660dd5" escape="true">ACQUISITIONS AND DIVESTITURES</ix:nonNumeric></span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="ife5980f6955e40e5bd09b9b43c660dd5" continuedAt="i5d8a4298e0da4c37b7441ed505171c38">During the first fiscal quarter of 2021, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $<ix:nonFraction unitRef="usd" contextRef="i3925875d2d8b49ed84c2f94483fbddc9_D20210104-20210404" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84NS9mcmFnOjhlYjExMjRjMTFjNTQyY2M4Nzk4M2EzMTkwYWNmYmY4L3RleHRyZWdpb246OGViMTEyNGMxMWM1NDJjYzg3OTgzYTMxOTBhY2ZiZjhfMjky_040a0d52-80d8-453e-b7d8-b8c8cd1ee036">0.6</ix:nonFraction>&#160;billion. </ix:continuation></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i5d8a4298e0da4c37b7441ed505171c38">During the fiscal first quarter of 2020, the Company completed the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc., for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i8aa76dc85f4d47988a65dc0767f87e60_D20191230-20200329" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84NS9mcmFnOjhlYjExMjRjMTFjNTQyY2M4Nzk4M2EzMTkwYWNmYmY4L3RleHRyZWdpb246OGViMTEyNGMxMWM1NDJjYzg3OTgzYTMxOTBhY2ZiZjhfNTU1_8a77291e-1568-4322-8c8f-c5586f0efbb0">0.8</ix:nonFraction> billion. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;D, for $<ix:nonFraction unitRef="usd" contextRef="i17afbc0e69e34400b507b3fa36f4cca9_I20200329" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84NS9mcmFnOjhlYjExMjRjMTFjNTQyY2M4Nzk4M2EzMTkwYWNmYmY4L3RleHRyZWdpb246OGViMTEyNGMxMWM1NDJjYzg3OTgzYTMxOTBhY2ZiZjhfNjc2_9b2e3f00-6519-4388-ab72-9d80bab9141e">0.8</ix:nonFraction> billion. XBiotech may be eligible to receive additional payments upon the receipt of certain commercialization authorizations. The transaction was accounted for as a business combination and included in the Pharmaceutical segment. Additionally, the Company completed the acquisition of all outstanding shares in Verb Surgical Inc., a company with world-class robotics and data science capabilities, including those shares previously held by Verily. The transaction was accounted for as a business combination and included in the Medical Devices segment. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;D, for $<ix:nonFraction unitRef="usd" contextRef="i8abbc5ec72a249a68e86c66cec320d05_I20200329" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84NS9mcmFnOjhlYjExMjRjMTFjNTQyY2M4Nzk4M2EzMTkwYWNmYmY4L3RleHRyZWdpb246OGViMTEyNGMxMWM1NDJjYzg3OTgzYTMxOTBhY2ZiZjhfMTM0Mg_d8d17753-ac81-412f-b85a-fdfd05528eb8">0.4</ix:nonFraction> billion, goodwill for $<ix:nonFraction unitRef="usd" contextRef="i8abbc5ec72a249a68e86c66cec320d05_I20200329" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84NS9mcmFnOjhlYjExMjRjMTFjNTQyY2M4Nzk4M2EzMTkwYWNmYmY4L3RleHRyZWdpb246OGViMTEyNGMxMWM1NDJjYzg3OTgzYTMxOTBhY2ZiZjhfMTM1OQ_f2cce31c-97f6-42dc-a195-aca6f2c13fda">0.2</ix:nonFraction> billion, other assets of $<ix:nonFraction unitRef="usd" contextRef="i8abbc5ec72a249a68e86c66cec320d05_I20200329" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84NS9mcmFnOjhlYjExMjRjMTFjNTQyY2M4Nzk4M2EzMTkwYWNmYmY4L3RleHRyZWdpb246OGViMTEyNGMxMWM1NDJjYzg3OTgzYTMxOTBhY2ZiZjhfMTM3OQ_d6bad0f3-4e08-4383-8000-38f4db3df7e4">0.2</ix:nonFraction> billion and liabilities assumed of $<ix:nonFraction unitRef="usd" contextRef="i8abbc5ec72a249a68e86c66cec320d05_I20200329" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84NS9mcmFnOjhlYjExMjRjMTFjNTQyY2M4Nzk4M2EzMTkwYWNmYmY4L3RleHRyZWdpb246OGViMTEyNGMxMWM1NDJjYzg3OTgzYTMxOTBhY2ZiZjhfMTQwOQ_e6245d40-cf39-4100-bb0e-799399ea9432">0.3</ix:nonFraction> billion. The fair value of the Company's previously held equity investment in Verb Surgical Inc. was $<ix:nonFraction unitRef="usd" contextRef="i8abbc5ec72a249a68e86c66cec320d05_I20200329" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84NS9mcmFnOjhlYjExMjRjMTFjNTQyY2M4Nzk4M2EzMTkwYWNmYmY4L3RleHRyZWdpb246OGViMTEyNGMxMWM1NDJjYzg3OTgzYTMxOTBhY2ZiZjhfMTUwNQ_214ac227-b26f-42c4-ae81-280cd137660e">0.4</ix:nonFraction> billion.</ix:continuation> </span></div><div><span><br/></span></div><div id="if410ee6e03c8456f86a9fee997f08e65_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 11 &#8212; <ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfOTEzMDM_7e82caf8-1906-4743-a065-ed2f7cc34b02" continuedAt="i52f10010e382473abde2081c88c023d2" escape="true">LEGAL PROCEEDINGS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i52f10010e382473abde2081c88c023d2" continuedAt="iaf8db55b123947eba3eeaee09825ebb7"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; supplier indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. Due to the ongoing impacts of the COVID-19 pandemic, certain trials have been rescheduled or delayed.  The Company continues to monitor its legal proceedings as the situation evolves and in person trials resume.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of October&#160;3, 2021, the Company has determined that </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="iaf8db55b123947eba3eeaee09825ebb7" continuedAt="iac2bd7a38cae40ce9a02c79704c4fe02"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">PRODUCT LIABILITY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant of these cases include: the DePuy ASR&#8482; XL Acetabular System and DePuy ASR&#8482; Hip Resurfacing System; the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acetabular Cup System; pelvic meshes; RISPERDAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; body powders containing talc, primarily JOHNSONS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Baby Powder; INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; and ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Flexible Composite Mesh. As of October&#160;3, 2021, in the United States there were approximately <ix:nonFraction unitRef="claimant" contextRef="idd91294a39994bf7a5d46ad21d5ce73f_I20211003" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNDYxNA_a9179e42-ff5e-493b-ae8c-beabb8491a67">300</ix:nonFraction> plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR&#8482; XL Acetabular System and DePuy ASR&#8482; Hip Resurfacing System; <ix:nonFraction unitRef="claimant" contextRef="i1e112538e52040febbef4f9ec3d08be6_I20211003" decimals="INF" format="ixt:num-dot-decimal" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNDc3OA_492ac407-fe45-4409-a8f0-8de3ec42f368">5,400</ix:nonFraction> with respect to the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acetabular Cup System; <ix:nonFraction unitRef="claimant" contextRef="i38e0af4dfc454327a9035d9ecf2f71de_I20211003" decimals="INF" format="ixt:num-dot-decimal" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNDgzNA_1846fc7e-8e26-4105-834b-c332189743f3">10,700</ix:nonFraction> with respect to pelvic meshes; <ix:nonFraction unitRef="claimant" contextRef="ib6fd89964b9b478c98b0b7b32284ace4_I20211003" decimals="INF" format="ixt:num-dot-decimal" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNDg2OA_8f760924-3ae6-4687-8c50-c50911ba5012">9,000</ix:nonFraction> with respect to RISPERDAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; <ix:nonFraction unitRef="claimant" contextRef="idd11e0e4967746c686c30187b7771685_I20211003" decimals="INF" format="ixt:num-dot-decimal" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNDg5OQ_3f72cee1-e469-4c99-b3ad-d9883ea5c73e">6,600</ix:nonFraction> with respect to XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; <ix:nonFraction unitRef="claimant" contextRef="i3b95b40b62fa4991958c542357558bc5_I20211003" decimals="INF" format="ixt:num-dot-decimal" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNDkyOA_43196601-aaa2-4299-8276-ece3e448f123">38,200</ix:nonFraction> with respect to body powders containing talc; <ix:nonFraction unitRef="claimant" contextRef="i9f2f6f0d91a04e85af9ca78c9af911bc_I20211003" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNDk3Nw_e7768e34-bf63-4a0d-99e9-043461e160f3">100</ix:nonFraction> with respect to INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and <ix:nonFraction unitRef="claimant" contextRef="i5f85d89b6d8146aaa779ff9a82bd22b8_I20211003" decimals="INF" format="ixt:num-dot-decimal" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNTAxMg_f16ac735-b7ec-4b5f-b903-eeb9221927b6">4,700</ix:nonFraction> with respect to ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Flexible Composite Mesh.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> XL Acetabular System and DePuy ASR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hip Resurfacing System used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson &amp; Johnson. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip System plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 31, 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 31, 2013 and prior to February 15, 2017. This settlement program has resolved more than <ix:nonFraction unitRef="patient" contextRef="ieb622359a78248788392bf4fc7788239_I20211003" decimals="0" format="ixt:num-dot-decimal" name="jnj:Numberofpatientsinsettlement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNjQwMg_6cb3d2e7-ec66-43e6-9cd8-e8cd841b3fd7">10,000</ix:nonFraction> claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle </span><span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the class actions filed in that country</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company continues to receive information with </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="iac2bd7a38cae40ce9a02c79704c4fe02" continuedAt="i9c3d24f1cb644c3882bcddb79effd62d"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and DePuy ASR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hip-related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson &amp; Johnson (collectively, DePuy) relating to the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation also has been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acetabular Cup System and the related settlement program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp; Johnson arising out of Ethicon's pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved a majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company's accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon's pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands and class actions in Israel, Australia and Canada. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court issued a decision and entered damages awards to the three Lead Applicants. The Company appealed the decision to the intermediate appellate court, the Full Court. The appeal was heard in February 2021 and, in March 2021, the Full Court entered a judgment dismissing the appeal. An application for special leave to the High Court of Australia was filed in April 2021, and in July 2021, the High Court agreed to hear oral argument on the application, which is scheduled to occur in November 2021. With respect to class members other than the Lead Applicants, the Federal Court will conduct an individual case assessment process that will require proof of use and causally related loss, although the form of that process has not yet been decided. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021, which is subject to court approval. The Company has established accruals with respect to product liability litigation associated with Ethicon's pelvic mesh products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Flexible Composite Mesh, claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp; Johnson alleging personal injury arising out of the use of this hernia mesh device.&#160;Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., one multi-plaintiff lawsuit pending in Oklahoma state court and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately <ix:nonFraction unitRef="claimant" contextRef="i432d9a09731c43af8b981697f2d30a00_I20210531" decimals="0" format="ixt:num-dot-decimal" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTIwOTA_14aa2093-c484-420e-83a3-8477bc93f524">3,600</ix:nonFraction> Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement was entered into in September 2021. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. The costs associated with this proposed settlement are reflected in the Company&#8217;s accruals. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Claims have also been filed against Ethicon and Johnson &amp; Johnson alleging personal injuries arising from the PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> Mesh and PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the US, and in jurisdictions outside the US. Discovery is underway in the MCL proceedings. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ethicon and Johnson &amp; Johnson also have been subject to claims for personal injuries arising from the PROLENE&#8482; Polypropylene Hernia System (PHS). In January 2020, New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. </span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i9c3d24f1cb644c3882bcddb79effd62d" continuedAt="ib03a84e656074b6cbbddda6622f29511"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Flexible Composite Mesh, PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Mesh and PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Ventral Patch, and PROLENE&#8482; Polypropylene Hernia System products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson arising out of the use of RISPERDAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $<ix:nonFraction unitRef="usd" contextRef="ia06bd5801ebb4de3847b03a9ebbf31df_D20191001-20191031" decimals="-9" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTQ1NTU_3a3a237f-f2d0-457c-83a1-bec5879e115b">8.0</ix:nonFraction>&#160;billion of punitive damages related to one plaintiff, which the trial judge reduced to $<ix:nonFraction unitRef="usd" contextRef="i888336974542449dbfef3a3a1d8c4d58_D20200101-20200131" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTQ2Mzc_f464269e-1751-4acd-bfb1-8fbce9db7d9e">6.8</ix:nonFraction>&#160;million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company's accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury arising out of the use of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson &amp; Johnson; and JPI&#8217;s collaboration partner for XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Bayer AG and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases have been filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and Johnson  &amp; Johnson announced an agreement in principle to settle the XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> related product liability litigation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A significant number of personal injury claims alleging that talc causes cancer were made against Johnson &amp; Johnson Consumer Inc. and Johnson &amp; Johnson arising out of the use of body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Baby Powder. The number of these personal injury lawsuits, filed in state and federal courts in the United States as well as outside of the United States, continued to increase through, and including, October 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $<ix:nonFraction unitRef="usd" contextRef="i0511c88e69e54af3b80ae9e01a00203b_D20180701-20180731" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyDamagesSoughtValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTA5OTUxMTY0NzY2MjM_fbeab3b0-f975-45a9-89b5-945361c27190">4.7</ix:nonFraction>&#160;billion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ingham v. Johnson &amp; Johnson, et al., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No. ED 207476 (Mo. App.), reducing the overall award to $<ix:nonFraction unitRef="usd" contextRef="i93cea90b33244c4f8bd342dd3f008b23_D20200601-20200628" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyDamagesSoughtValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTA5OTUxMTY0NzY2Mzc_b6c1e9a2-db3e-4dc6-8cff-bfcdef085be6">2.1</ix:nonFraction>&#160;billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ingham </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">decision by the United States Supreme Court was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $<ix:nonFraction unitRef="usd" contextRef="ib2961f0a11b248a9b0915353245c62bb_D20210601-20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForLegalSettlements" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTA5OTUxMTY0NzY2NTE_2b77f713-aa67-459a-92f0-0bb2c84b05ce">2.5</ix:nonFraction>&#160;billion. The facts and circumstances, including the terms of the award, were unique to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ingham</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> decision and not representative of other claims brought against the Company.  The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company&#8217;s confidence in the safety of its talc products, in certain circumstances the Company has and may settle cases. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, Johnson &amp; Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring).  As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor), (b) Royalty A&amp;M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor's direct parent, Johnson &amp; Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI's assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers&#8217; compensation statute or act (the Talc-Related Liabilities).  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, notwithstanding the Company&#8217;s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Filing). As a result of the LTL Bankruptcy Filing, the Court entered a temporary restraining order staying all litigation against LTL and Old JJCI.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further hearings on whether a permanent restraining order staying all litigation against those entities, as well other entities, such as Johnson &amp; Johnson, its affiliates, and certain other third parties, are scheduled in November 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The Company has agreed to provide funding to LTL for the payment of amounts the Bankruptcy Court determines are owed by LTL through the establishment of a $<ix:nonFraction unitRef="usd" contextRef="ief20b90c9cc3400e9758007a2c93489a_D20211001-20211031" decimals="-9" format="ixt:num-dot-decimal" name="jnj:LossContingencyReserveEstablishedWithinTrust" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTA5OTUxMTY0NzY2NjU_740b0225-2896-4734-906b-47b6b3119083">2</ix:nonFraction>&#160;billion trust in furtherance of this purpose. The Company has established a reserve for approximately $<ix:nonFraction unitRef="usd" contextRef="ief20b90c9cc3400e9758007a2c93489a_D20211001-20211031" decimals="-9" format="ixt:num-dot-decimal" name="jnj:LossContingencyReserveEstablishedWithinTrust" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTA5OTUxMTY0NzY2Nzc_3f2d81ce-e4cb-45ab-9e00-6f935b4ae0e9">2</ix:nonFraction>&#160;billion in connection with the aforementioned trust, resulting in an incremental $<ix:nonFraction unitRef="usd" contextRef="ief20b90c9cc3400e9758007a2c93489a_D20211001-20211031" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTA5OTUxMTY0NzY2ODk_44cb1d23-77fd-42db-b886-a5f4d3b857ed">1.4</ix:nonFraction>&#160;billion litigation charge. Subsequent to the fiscal third quarter, the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="ib03a84e656074b6cbbddda6622f29511" continuedAt="i00e265d12e48492687b64c38074f6bf2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Company has de-consolidated LTL as a result of the bankruptcy filing.  The impact of the de-consolidation is not material to the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2019, the Company&#8217;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary chapter 11 petition under chapter 11 of title 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#8217;s potential liability for personal injury from exposure to talcum powder sold by Imerys (Talc Claims). In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. During the bankruptcy, the Company proposed to resolve Imerys's (and the Company&#8217;s) obligations arising out of Talc Claims involving the Company&#8217;s products by agreeing to assume the defense of litigation of all such Talc Claims, waiving the Company&#8217;s indemnification claims against Imerys, and lifting the automatic stay to enable the Talc Claims to proceed outside the bankruptcy forum with the Company agreeing to settle or pay any judgment against Imerys. Imerys rejected that proposal. In May 2020, Imerys, its parent Imerys S.A., the Tort Claimants&#8217; Committee (TCC), and the Future Claimants&#8217; Representative (FCR) (collectively, the Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related thereto. The Plan Proponents have since filed numerous amendments to the Plan and Disclosure Statement. A hearing on the Plan Proponent&#8217;s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement, allowing Imerys to proceed with soliciting votes on the Plan. In March 2021, the Company voted to reject the Plan and opted out of the consensual releases in the Plan. In April 2021, the Plan Proponents announced the Plan had received the requisite number of accepting votes to confirm the Plan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, the Bankruptcy Court issued a ruling deeming almost <ix:nonFraction unitRef="vote" contextRef="ief20b90c9cc3400e9758007a2c93489a_D20211001-20211031" decimals="-3" format="ixt:num-dot-decimal" name="jnj:LossContingencyNumberOfVotesInFavor" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTA5OTUxMTY0NzY3MDM_a15ae4e6-fc38-4d22-a08a-bff0d973c639">16,000</ix:nonFraction> votes in favor of the Plan as withdrawn, based upon evidence that no due diligence had been done by the plaintiff&#8217;s counsel to ascertain whether the votes were cast on behalf of individuals who used the Company&#8217;s products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Bankruptcy Court also ruled that more than <ix:nonFraction unitRef="vote" contextRef="ief20b90c9cc3400e9758007a2c93489a_D20211001-20211031" decimals="-2" format="ixt:num-dot-decimal" name="jnj:LossContingencyNumberOfVotesRejected" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTA5OTUxMTY0NzY3MTE_1f98014b-0fe3-4790-9f8d-37a60b8cf8a7">1,500</ix:nonFraction> votes cast by another firm should count as rejecting instead of accepting. In October 2021, Imerys filed a notice on the docket cancelling the confirmation hearing on its Plan that was scheduled to begin in November 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In July 2021, Imerys commenced an adversary proceeding against the Company in the Imerys Bankruptcy (the Imerys adversary proceeding).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Imerys adversary proceeding sought, among other things, certain declarations with respect to the indemnification obligations allegedly owed by the Company to Imerys.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The TCC and FCR simultaneously filed a motion for temporary restraining order and preliminary injunction seeking to enjoin the Company from undergoing a corporate restructuring that would separate the Company&#8217;s talc liabilities from its other assets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The bankruptcy court denied the motion.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company thereafter filed a motion to dismiss the adversary proceeding.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Bankruptcy Court has not yet decided the motion to dismiss. In October 2021, the Company filed a Notice of  Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the LTL Bankruptcy Filing should apply to the Imerys adversary proceeding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2020, Cyprus Mines Corporation and its parent (together, Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company and Imerys in the Imerys Bankruptcy seeking a declaration of indemnity rights under certain contractual agreements (the Cyprus adversary proceeding). The Company denies such indemnification is owed, and filed a motion to dismiss the adversary complaint. In February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan. The Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against Talc Claims asserted against it. Cyprus has not yet sought approval of its Disclosure Statement and Plan. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the LTL Bankruptcy Filing should apply to the Cyprus adversary proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2021, several of the Company&#8217;s insurers involved in coverage litigation in New Jersey State Court (the Coverage Action) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action. In March 2021, the Company filed a limited response and reservation of rights with respect to the motion. The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. In October 2021, LTL filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the LTL Bankruptcy Filing should apply to the Coverage Action.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2018, a securities class action lawsuit was filed against Johnson &amp; Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson &amp; Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON'S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Baby Powder, and that purchasers of Johnson &amp; Johnson&#8217;s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, Defendants answered the complaint. In April 2021 briefing on Plaintiffs&#8217; motion for class certification was completed. Discovery is ongoing. </span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i00e265d12e48492687b64c38074f6bf2" continuedAt="i86afcd2f03f746d4aeaa430ce22f03ff"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2019, a shareholder filed a complaint initiating a summary proceeding in New Jersey state court for a books and records inspection. In August 2019, Johnson &amp; Johnson responded to the books and records complaint and filed a cross motion to dismiss. In September 2019, Plaintiff replied and the Court heard oral argument. The Court has not yet ruled in the books and records action. In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson &amp; Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Baby Powder, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">In re Johnson &amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2020, a report was delivered to the Company&#8217;s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues and demanding that suit be brought against certain Directors. Four of the shareholders who sent demands are plaintiffs in th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">In re Johnson &amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel&#8217;s report. In October 2020, the shareholders filed a consolidated complaint, and in January 2021, Johnson &amp; Johnson moved to dismiss the consolidated complaint. In March 2021, Plaintiffs filed a motion for discovery. The Court temporarily terminated Johnson &amp; Johnson&#8217;s motion to dismiss pending a decision on Plaintiff&#8217;s motion for discovery. In October 2021, the Court requested supplemental briefing on Plaintiff&#8217;s motion for discovery. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson &amp; Johnson Savings Plan against Johnson &amp; Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson &amp; Johnson stock as a Johnson &amp; Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants&#8217; motion but granted leave to amend. In June 2020, Plaintiffs filed an amended complaint, and in July 2020, Defendants moved to dismiss the amended complaint. As of October 2020, briefing on Defendants&#8217; motion was complete. In February 2021, the Court granted Defendants&#8217; motion, and granted Plaintiffs leave to amend. In April 2021, Plaintiffs informed the Court that they did not intend to file an amended complaint, and the Court dismissed the case with prejudice. In May 2021, Plaintiffs filed a notice of appeal with the Third Circuit. In July 2021, Plaintiffs filed their opening brief in the Third Circuit and in September 2021, Defendants filed their response brief. In October 2021, Plaintiffs filed their reply brief. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California&#8217;s Consumer Legal Remedies Act (CLRA) relating to JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Baby Powder. In that lawsuit, the plaintiffs allege that Johnson &amp; Johnson violated the CLRA by failing to provide required Proposition 65 warnings.  In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company&#8217;s favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. In October 2021, a Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the Company has received preliminary inquiries and subpoenas to produce documents regarding talc matters from Senator Murray, a member of the Senate Committee on Health, Education, Labor and Pensions, the Department of Justice and the U.S. Congressional Subcommittee on Economic and Consumer Policy. The Company produced documents as required in response and will continue to cooperate with government inquiries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. In December 2016, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company's accruals.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i86afcd2f03f746d4aeaa430ce22f03ff" continuedAt="i872b03ac7db241d68deee3eb8a5ef4c4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, a prescription medication  indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases also have been filed in various state courts. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> related product liability litigation.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">INTELLECTUAL PROPERTY</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain subsidiaries of Johnson &amp; Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company&#8217;s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. Significant matters are described below.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medical Devices</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2016, Dr. Ford Albritton sued Acclarent, Inc. (Acclarent) in United States District Court for the Northern District of Texas alleging that Acclarent&#8217;s RELIEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Spin and RELIEVEA SpinPlus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> products infringe U.S. Patent No. 9,011,412.  Dr. Albritton also alleges breach of contract, fraud and that he is the true owner of Acclarent&#8217;s U.S. Patent No. 8,414,473. Trial began in October 2021, and shortly thereafter, the parties reached an agreement to settle the case. Plaintiff's motion to dismiss with prejudice was filed in October 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2017, Board of Regents, The University of Texas System and TissueGen, Inc. (collectively, UT) filed a lawsuit in the United States District Court for the Western District of Texas against Ethicon, Inc. and Ethicon US, LLC (collectively, Ethicon) alleging the manufacture and sale of VICRYL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Plus Antibacterial Sutures, MONOCRYL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Plus Antibacterial Sutures, PDS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Plus Antibacterial Sutures, STRATAFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> PDS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Antibacterial Sutures and STRATAFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> MONOCRYL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Plus Antibacterial Sutures infringe plaintiffs&#8217; United States Patent Nos. 6,596,296 (&#8217;296) and 7,033,603 (&#8217;603) directed to implantable polymer drug releasing biodegradable fibers containing a therapeutic agent. UT is seeking damages and an injunction. In December 2018, Ethicon filed petitions with the United States Patent and Trademark Office (USPTO), seeking Inter Partes Review (IPR) of both asserted patents. In June 2020, the USPTO denied institution of the &#8217;296 patent IPR and granted institution of the &#8217;603 patent IPR. UT dismissed the &#8217;603 patent from the suit and no longer accuses PDS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Plus Antibacterial Sutures or STRATAFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> PDS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Plus Antibacterial Sutures of infringement. In August 2021, the parties entered into a settlement agreement, and the case was dismissed. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (collectively, Intuitive) filed a patent infringement suit against Auris Health, Inc. (Auris) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos. 6,246,200 (&#8217;200); 6,491,701 (&#8217;701); 6,522,906 (&#8217;906); 6,800,056 (&#8217;056); 8,142,447 (&#8217;447); 8,620,473 (&#8217;473); 8,801,601 (&#8217;601); and 9,452,276 (&#8217;276) based on Auris&#8217; Monarch&#8482; Platform. Auris filed IPR Petitions with the U.S. Patent and Trademark Office (USPTO) regarding the &#8217;200, &#8217;056, &#8217;601 &#8217;701, &#8217;447, &#8217;276 and &#8217;906 patents. Intuitive subsequently dropped the &#8217;200, &#8217;473 and &#8217;701 patents from the suit. In December 2019, the USPTO instituted review of the &#8217;601 patent and denied review of the &#8217;056 patent. In February and March 2020, the USPTO instituted review of the &#8217;200, &#8217;447, &#8217;701 and &#8217;906 patents and denied review of the &#8217;276 patent. In December 2020, the USPTO declared all of the challenged claims in the &#8217;601 patent to be invalid. Intuitive has appealed that decision. In March 2021, the USPTO ruled that the challenged claims of the &#8217;447 and &#8217;906 patents are not invalid. Auris has appealed that decision. Trial is scheduled to begin in January 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2019, RSB Spine LLC (RSB Spine) filed a patent infringement suit against DePuy Synthes, Inc. in United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of United States Patent Nos. 6,984,234 and 9,713,537 by one or more of the following products:  ZERO-P-VA&#8482; Spacer, ZERO-P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Spacer, ZERO-P NATURAL&#8482; Plate, SYNFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> LR Spacer and SYNFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Evolution System. RSB Spine seeks monetary damages and injunctive relief. In November 2019, the suit was consolidated for pre-trial purposes with other patent infringement suits brought by RSB Spine in the United States District Court for the District of Delaware against Life Spine, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i872b03ac7db241d68deee3eb8a5ef4c4" continuedAt="i0b7cce43a4674fb0876044ab68aa27d8"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inc., Medacta USA, Inc., and Precision Spine, Inc. A stay that had been entered pending Inter Partes Review at the U.S. Patent &amp; Trademark Office has been lifted, and trial is scheduled to begin in December 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2020, Osteoplastics, LLC filed a patent infringement suit against DePuy Synthes, Inc., DePuy Synthes Products, Inc., Medical Device Business Services, Inc., and Synthes, Inc. (collectively, DePuy Synthes) in the United States District Court for the District of Delaware. In the suit, Osteoplastics alleges willful infringement of U.S. Patent Nos. 8,781,557; 9,929,920; 9,330,206; 9,626,756; 9,672,617; 9,672,302; and 9,275,191 based on the PROPLAN CMF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Virtual Surgical Planning Services and the TruMatch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> CMF Personalize Solutions. In April 2020, Osteoplastics filed an amended complaint to substitute U.S. Patent No. 9,292,920 for U.S. Patent No. 9,929,920.  Osteoplastics seeks monetary damages and injunctive relief. In June 2020, DePuy Synthes filed a motion to dismiss the complaint. In October 2020, the Court dismissed Medical Device Business Services, Inc. from the case but otherwise denied the motion. In June 2021, Osteoplastics admitted that the PROPLAN CMF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Virtual Surgical Planning Services do not infringe any asserted patents. Trial is scheduled for October 2022.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pharmaceutical</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes lawsuits the Company's subsidiaries have brought against generic companies that have filed ANDAs with the FDA or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson &amp; Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement and invalidity of the applicable patents. In the event the Company's subsidiaries are not successful in an action, or the automatic statutory stay of the ANDAs expires before the United States District Court rulings are obtained, the generic companies involved would have the ability, upon approval of the FDA, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company's subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. The Inter Partes Review (IPR) process with the USPTO, created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits, to challenge the applicable patents.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in January 2019, Janssen Inc. and Janssen Oncology Inc. (collectively, Janssen) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations in Canada against Apotex Inc. (Apotex), Pharmascience Inc. (Pharmascience) and Dr. Reddy's Laboratories Ltd. and Dr. Reddy's Laboratories, Inc. (collectively, DRL) in response to those parties&#8217; filing of Abbreviated New Drug Submissions (ANDS) seeking approval to market generic versions of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before the expiration of the Canadian Patent No. 2,661,422 (&#8217;422). The trial in these actions concluded in November 2020, and the Court issued a decision holding the &#8217;422 patent invalid in January 2021. In February 2021, Janssen appealed the decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian actions, Janssen is seeking an order enjoining the defendants from marketing their generic versions of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the &#8217;422 patent.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2021, Janssen Pharmaceuticals, Inc. (JPI) and Bayer Pharma AG and Bayer AG (collectively, Bayer) filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Lupin Limited and Lupin Pharmaceuticals, Inc. which filed an ANDA seeking approval to market a generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of U.S. Patent No. 10,828,310 (&#8217;310). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Accord Healthcare Inc., Accord Healthcare Limited, and Intas Pharmaceuticals Limited which filed an ANDA seeking approval to market a generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before expiration of the &#8217;310 patent. In July 2021, the parties entered into a confidential settlement agreement, and the action was dismissed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Dr. Reddy&#8217;s Laboratories, Inc. and Dr. Reddy&#8217;s Laboratories, Ltd. which filed an ANDA seeking approval to market a generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;310 patent.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i0b7cce43a4674fb0876044ab68aa27d8" continuedAt="i192ff7e041574659a2560cd4eaa44e67"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals U.S.A., Inc. (collectively, Taro) which filed an ANDA seeking approval to market a generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;310 patent. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. which filed an ANDA seeking approval to market a generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;310 patent. In August 2021, the court entered a joint stipulation dismissing Teva Pharmaceutical Industries Ltd.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the Northern District of West Virginia against Mylan Pharmaceuticals Inc. and Mylan Inc. which filed an ANDA seeking approval to market a generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;310 patent. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In each of these lawsuits, JPI and Bayer are seeking an order enjoining defendants from marketing their generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before the expiration of the &#8217;310 patent. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning in July 2017, Janssen Pharmaceuticals, Inc., Janssen Research &amp; Development, LLC, Cilag GmbH International and Janssen Pharmaceutica NV (collectively, Janssen) and Mitsubishi Tanabe Pharma Corporation (MTPC) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against a number of generic companies that filed ANDAs seeking approval to market generic versions of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and/or INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> XR before expiration of MTPC&#8217;s United States Patent Nos. 7,943,582 (&#8217;582) and/or 8,513,202 (&#8217;202) relating to INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and/or INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> XR. Janssen is the exclusive licensee of the asserted patents. Named defendants include MSN Laboratories Private Ltd. and MSN Pharmaceuticals, Inc. (MSN); Zydus Pharmaceuticals (USA) Inc. (Zydus). These cases were consolidated into one action (Polymorph Main Action).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2017, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Zydus which filed ANDAs seeking approval to market generic versions of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">before expiration of MTPC&#8217;s United States Patent No. 7,943,788 (&#8217;788), 8,222,219 (&#8217;219) and/or 8,785,403 (&#8217;403) relating to INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (Compounds Main Action). Janssen is the exclusive licensee of the asserted patents. Trial concluded in October 2020. The Court issued a decision holding that the patents are not invalid and would be infringed by Zydus&#8217; generic products. Zydus has appealed the decision. In July 2021, Janssen and Zydus entered into a confidential settlement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2019, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against MSN, which filed an ANDA seeking approval to market a generic version of INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;582 patent and &#8217;202 patent relating to INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. In October 2019, Janssen and MTPC initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against MSN, which filed ANDAs seeking approval to market generic versions of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;788 patent. In July 2021, Janssen and MSN entered into a confidential settlement and the lawsuits were dismissed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2019, Janssen and MTPC initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Dr. Reddy&#8217;s Laboratories, Inc. and Dr. Reddy&#8217;s Laboratories Ltd (DRL), who filed an ANDA seeking approval to market a generic version of INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before expiration of the &#8217;788 patent. In January 2021, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Macleods), which filed an ANDA seeking approval to market a generic version of INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before expiration of the &#8217;582 patent and &#8217;202 patent relating to INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. In February 2021, Janssen filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Macleods), which filed an ANDA seeking approval to market a generic version of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before expiration of United States Patent No. 10,617,668 (&#8217;668)  relating to INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. In September 2021, Janssen and MTPC dismissed the lawsuit against Macleods relating to the &#8217;668 patent. These lawsuits have not been consolidated with the Polymorph Main Action or Compound Main Action.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">In each of these U.S. lawsuits, Janssen and MTPC are seeking an order enjoining the defendant from marketing their generic versions of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:102%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">, INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:102%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"> and/or, INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:102%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, Janssen Inc., Janssen Pharmaceutica NV and MTPC initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the Canadian Patent Nos. 2,799,204, 2,534,024 and 2,671,357. Janssen Inc., Janssen Pharmaceutica NV and MTPC are seeking an </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i192ff7e041574659a2560cd4eaa44e67" continuedAt="i8016a6b608264a3eaa6e6ac95b129ccc"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">order enjoining Sandoz from marketing its generic version of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the relevant patents. The trial is scheduled to begin in August 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2020, Janssen Inc. (Janssen) and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before the expiration of Canadian Patent No. 2,659,770 (&#8217;770). Trial is scheduled to begin in January 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in Canada in response to Apotex&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of the &#8217;770 patent. Trial is scheduled to begin in February 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against JAMP Pharma Corporation (JAMP) in Canada in response to JAMP&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10 mg before the expiration of the &#8217;770 patent and Canadian Patent No. 2,621,273 (&#8217;273). Trial is scheduled to begin in April 2022.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian actions, Janssen and Actelion are seeking an order enjoining the defendants from marketing their generic versions of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. (Teva), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before the expiration of United States Patent No. 9,439,906 (&#8217;906).  Trial concluded in October 2020. In October 2021, the court issued a decision in Janssen's favor.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited (Mylan), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, Janssen initiated a patent infringement lawsuit in the United States District Courts for the Districts of New Jersey and Delaware against Pharmascience Inc., Mallinckrodt PLC and Specgx LLC (collectively, Pharmascience), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In each of these U.S. lawsuits, Janssen is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, Janssen Inc. and Janssen Pharmaceutica NV (collectively, Janssen Canada) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Teva Canada Limited (Teva Canada) in response to Teva's filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of Canadian Patent Nos. 2,309,629 (&#8217;629) and 2,655,335 (&#8217;335). Janssen subsequently discontinued the portion of the lawsuit relating to the &#8217;629 patent. In May 2020, the Canadian Federal Court issued a Public Judgment and Reasons declaring that Teva Canada&#8217;s generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if approved, would infringe certain claims of the &#8217;335 patent and that the claims of the &#8217;335 patent are not invalid for obviousness. Teva Canada appealed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience Inc. in response to Pharmascience Inc.'s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement is scheduled for November 2021. The trial is scheduled to begin in July 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in response to Apotex's filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement is scheduled for December 2021. The trial is scheduled to begin in September 2022.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i8016a6b608264a3eaa6e6ac95b129ccc" continuedAt="ic430b4089aac47039a9c1d39035fe6b4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian lawsuits, Janssen Canada is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp; Development, LCC (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., and Mylan Institutional LLC (collectively, Mylan). Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (546 mg) before expiration of United States Patent No. 10,143,693 (&#8217;693) relating to INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(546 mg). Janssen is seeking an order enjoining Mylan from marketing a generic version of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before the expiration of the &#8217;693 patent. Trial is scheduled to begin in October 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(819 mg) before expiration of the &#8217;693 patent. Janssen is seeking an order enjoining Mylan from marketing a generic version of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (819 mg) before the expiration of the &#8217;693 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (273 mg and 410 mg) before expiration of the &#8217;693 patent. Janssen is seeking an order enjoining Mylan from marketing a generic version of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (273 mg and 410 mg) before the expiration of the &#8217;693 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in January 2018, Pharmacyclics LLC (Pharmacyclics) and Janssen Biotech, Inc. (JBI) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies that filed ANDAs seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> 140 mg capsules before expiration of Pharmacyclics&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">United States Patent Nos. 8,008,309, 7,514,444, 8,697,711, 8,735,403, 8,957,079, 9,181,257, 8,754,091, 8,497,277, 8,925,015, 8,476,284, 8,754,090, 8,999,999, 9,125,889, 9,801,881, 9,801,883, 9,814,721, 9,795,604, 9,296,753, 9,540,382, 9,713,617 and/or 9,725,455 relating to IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. JBI is the exclusive licensee of the asserted patents. The named defendants include the following generic companies: Sandoz Inc. and Lek Pharmaceuticals d.d. (collectively, Sandoz).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2019 and February 2019, Pharmacyclics and JBI amended their complaint against Sandoz to allege infringement of United States Patent Nos. 10,125,140 and 10,106,548. In August 2019, Pharmacyclics and JBI amended their complaint against Sandoz to further allege infringement of U.S. Patent Nos. 10,294,231 and 10,294,232.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen Pine Brook LLC and Natco Pharma Ltd. (collectively, Alvogen), which filed an ANDA seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, asserting infringement of United States Patent Nos. 7,514,444, 8,003,309, 8,476,284, 8,497,277, 8,697,711, 8,753,403, 8,754,090, 8,754,091, 8,952,015, 8,957,079, 9,181,257, 9,296,753,  9,655,857, 9,725,455, 10,010,507, 10,106,548, and 10,125,140. In June 2019, Pharmacyclics and JBI amended their complaint against Alvogen to further allege infringement of United States Patent No. 10,213,386. Pharmacyclics and JBI are seeking an order enjoining the defendants from marketing generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Trial in the foregoing actions against Sandoz and Alvogen took place in October 2020. In May 2021, JBI, Pharmacyclics and Sandoz entered into a confidential settlement agreement. In August 2021, the District Court issued a decision in favor of Pharmacyclics and Janssen finding the asserted claims against Alvogen to be infringed and not invalid. Alvogen has appealed that decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2021, Pharmacyclics and Janssen Inc. (Janssen Canada) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Natco Pharma (Canada) Inc. (Natco) in response to Natco&#8217;s filing of two ANDSs seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">capsules before the expiration of Canadian Patent Nos. 2,663,116; 2,928,721; 2,800,913; 3,007,787; 3,007,788, 2,875,986; and 3,022,256. The trial is scheduled to begin in July 2023. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pharmacyclics and Janssen are seeking an order enjoining Natco from marketing its generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2020, Actelion Pharmaceuticals Ltd (Actelion) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Zydus Pharmaceuticals (USA), </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="ic430b4089aac47039a9c1d39035fe6b4" continuedAt="ib52a9880ed27454a9f25e174583f5068"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inc. and Zydus Worldwide DMCC (collectively, Zydus),  who filed an ANDA seeking approval to market a generic version of UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">before expiration of Nippon Shinyaku&#8217;s United States Patent Nos. 7,205,302 (&#8217;302); 8,791,122 (&#8217;122); and 9,284,280 (&#8217;280) relating to UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. In January 2021, the court entered a joint stipulation dismissing the claims against Zydus related to the &#8217;122 and &#8217;280 patents.  Actelion is the exclusive licensee of the &#8217;302 patent. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Actelion and Nippon Shinyaku are seeking an order enjoining Zydus from marketing a generic version of UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before the expiration of the &#8217;302 patent.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GOVERNMENT PROCEEDINGS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like other companies in the pharmaceutical, consumer health and medical devices industries, Johnson &amp; Johnson and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Average Wholesale Price (AWP) Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and several of its pharmaceutical subsidiaries (the J&amp;J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&amp;J AWP Defendants were ultimately dismissed. The J&amp;J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. The case brought by Illinois was settled after trial. In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), Johnson &amp; Johnson and ALZA Corporation. All other cases have been resolved.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Opioid Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in 2014 and continuing to the present, Johnson &amp; Johnson and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in approximately <ix:nonFraction unitRef="claimant" contextRef="i43837e43114841208382ec8e806920e4_I20211003" decimals="0" format="ixt:num-dot-decimal" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNTc3MDQ_e48de382-174f-4dbe-b55e-6476b82488c9">3,300</ix:nonFraction> lawsuits related to the marketing of opioids, including DURAGESIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, NUCYNTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and NUCYNTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> ER. The suits also raise allegations related to previously owned active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children suffering from Neonatal Abstinence Syndrome; hospitals; and health insurers/payors. To date, complaints against pharmaceutical manufacturers, including Johnson &amp; Johnson and JPI, have been filed by the state Attorneys General in Arkansas, Florida, Idaho, Illinois, Kentucky, Louisiana, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, South Dakota, Texas, Washington and West Virginia. Complaints against the manufacturers also have been filed in state or federal court by city, county and local government agencies in the following states: Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, West Virginia and Wisconsin. The Government of Puerto Rico filed suit in Superior Court of San Juan. There are approximately <ix:nonFraction unitRef="claimant" contextRef="if23041d120f4417a80290be9a7d86354_I20211003" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTA5OTUxMTY0NzY3MTg_51b4d854-2370-4afe-adc2-785ffc28400b">390</ix:nonFraction> cases pending in various state&#160;courts. There are over <ix:nonFraction unitRef="claimant" contextRef="ic8c468efba6f4c8eb730082ee4eedf85_I20211003" decimals="0" format="ixt:num-dot-decimal" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTA5OTUxMTY0NzY3MjM_cc2cafee-c06c-49fc-83a5-dcd272c9178f">2,900</ix:nonFraction> federal cases coordinated in a federal Multi-District Litigation (MDL) pending in the U.S. District Court for the Northern District of Ohio.&#160;In addition, the Province of British Columbia filed suit against Johnson &amp; Johnson and its Canadian affiliate Janssen Inc., and many other industry members, in Canada, and is seeking to have that action certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada. Additional proposed class actions have been filed in Canada against Johnson &amp; Johnson and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. In October 2019, an anti-trust complaint was filed by private plaintiffs in federal court in Tennessee and is pending transfer to the MDL. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="ib52a9880ed27454a9f25e174583f5068" continuedAt="id7f624f30af84708be6ab8feec40554f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The trial in the matter filed by the Oklahoma Attorney General resulted in a judgment against Johnson &amp; Johnson and JPI in the amount of $<ix:nonFraction unitRef="usd" contextRef="ib5c767d6b7254013824d1430cea6166d_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNjA1MTk_ac16ca4e-dec6-4764-8656-ce8d5a5783e5">465</ix:nonFraction>&#160;million. Johnson &amp; Johnson and JPI have appealed the judgment. The Company believes that it has strong grounds to overturn this judgment. In October 2019 Johnson &amp; Johnson and JPI announced a settlement of the first case set for trial in the MDL with two counties in Ohio. In April 2021, three California counties and the City of Oakland commenced a trial in California state court against Johnson &amp; Johnson and JPI, and other affiliates, as well as three other pharmaceutical manufacturers. The trial concluded in October 2021 and the parties are awaiting a ruling.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Johnson &amp; Johnson received a grand jury subpoena from the United States Attorney&#8217;s Office for the Eastern District of New York for documents related to the Company&#8217;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#8217; and distributors&#8217; monitoring programs and reporting under the Controlled Substances Act. In September 2019, Johnson &amp; Johnson received subpoenas from the New York State Department of Financial Services (NYDFS) as part of an industry-wide inquiry into the effect of opioid prescriptions on New York health insurance premiums.&#160;In September 2020, the Company learned that NYDFS filed a statement of charges related to this investigation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2021, the Company and JPI announced a settlement agreement with the State of New York and its participating subdivisions, including Nassau County and Suffolk County, resolving their opioid-related claims against the Company on terms consistent with the Company&#8217;s previously announced agreement in principle to contribute up to $<ix:nonFraction unitRef="usd" contextRef="ib02d3415bfe94365991511ce5fb09ebf_D20210601-20210630" decimals="-9" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNjIxOTE_37d639e9-d741-44e8-adf2-a17eaeba3bab">5</ix:nonFraction>&#160;billion to all-in settlement of opioid-related claims by states, cities, counties, and tribal governments. The settlement provides New York and its participating subdivisions with up to $<ix:nonFraction unitRef="usd" contextRef="ib02d3415bfe94365991511ce5fb09ebf_D20210601-20210630" decimals="-6" format="ixt:num-dot-decimal" name="jnj:LossContingencyDamagesAwardedAdditionalReimbursementValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNjIzNzI_2f8a6f44-bb3a-42df-8278-c0092cdbaa29">263</ix:nonFraction>&#160;million to address opioid-related issues, reimburses attorney fees and costs, and removes the Company and Janssen from a multi-defendant trial of opioid-related claims that commenced in Suffolk County in June 2021. In exchange, the Company and JPI receive releases from the claims asserted by New York and the participating parties, including   NYDFS.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, the Company and JPI announced a settlement agreement with the State of Texas and its participating subdivisions, including Dallas County, Bexar County, and Tarrant County, resolving their opioid-related claims against the Company on terms consistent with the Company&#8217;s previously announced agreement to contribute up to $<ix:nonFraction unitRef="usd" contextRef="i27171efe2b3941548d265f05e276162e_D20211001-20211031" decimals="-9" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTA5OTUxMTY0NzY3MzA_fbf70238-93e7-472c-95cc-9a429b45c0d4">5</ix:nonFraction>&#160;billion to all-in settlement of opioid-related claims by states, cities, counties, and tribal governments. The settlement provides Texas and its participating subdivisions with up to $<ix:nonFraction unitRef="usd" contextRef="i27171efe2b3941548d265f05e276162e_D20211001-20211031" decimals="-6" format="ixt:num-dot-decimal" name="jnj:LossContingencyDamagesAwardedAdditionalReimbursementValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTA5OTUxMTY0NzY3NDI_11441c9a-2d65-4f60-8f02-1156d1bf69e7">297</ix:nonFraction>&#160;million to address opioid-related issues and reimburse attorney fees and costs, and removes the Company and Janssen from multi-defendant bellwether trials of opioid-related claims scheduled to commence in Texas state courts in early 2022. In exchange, the Company and JPI will receive releases from the claims asserted by Texas and the participating subdivisions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Johnson &amp; Johnson, JPI and other pharmaceutical companies have also received subpoenas or requests for information related to opioids marketing practices from the following state Attorneys General: Alaska, Indiana, Montana, New Hampshire, South Carolina, Tennessee, Texas and Washington. In September 2017, Johnson &amp; Johnson and JPI were contacted by the Texas and Colorado Attorney General&#8217;s Offices on behalf of approximately 38 states regarding a multi-state Attorney General investigation. In October 2019, the Company announced a proposed agreement in principle that would include the Company paying $<ix:nonFraction unitRef="usd" contextRef="i653b6f4b1cbf484b8781c02b3402e666_I20191031" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNjMzMjU_c0594418-1c2f-4f58-afff-03fcce12786b">4</ix:nonFraction>&#160;billion as settlement of these matters. In October 2020, the Company agreed to contribute up to an additional $<ix:nonFraction unitRef="usd" contextRef="i945c4e1bacda4ec68c3b7c94557f3765_I20201031" decimals="-9" format="ixt:num-dot-decimal" name="jnj:LossContingencyEstimateOfAdditionalPossibleLoss" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNjM0MzA_e7060f67-2ce5-4c83-8437-ae69d945d753">1</ix:nonFraction>&#160;billion to an all-in settlement amount that would resolve opioid lawsuits filed and future claims by states, cities, counties and tribal governments, for a total of $<ix:nonFraction unitRef="usd" contextRef="i945c4e1bacda4ec68c3b7c94557f3765_I20201031" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNjM1OTA_cc0a2b42-beda-4f49-b2cd-c3462428b18b">5</ix:nonFraction>&#160;billion which has been accrued, subject to various conditions and an agreement being finalized. This agreement in principle is not an admission of liability or wrong-doing. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims have been finalized and up to 25% of the all-in settlement is expected to be paid within the next 12 months, depending upon the level of participation by the states and their subdivisions. The terms provide a period of time for states to elect to participate in the agreement and, thereafter, a period for the subdivisions of the participating states to opt-in. The opt-in period expires in January 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company retains the right to opt-out of the agreement if, in its sole discretion, there is insufficient participation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From June 2017 through December 2019, the Company&#8217;s Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Board unanimously adopted the recommendations of the independent counsel&#8217;s report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2019, one of the shareholders who sent a demand filed a derivative complaint against Johnson &amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. In May 2020, the shareholder filed an amended complaint challenging the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="id7f624f30af84708be6ab8feec40554f" continuedAt="i734bf2d0d47a49b0bd5f66f4f9838d72"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Board&#8217;s rejection of his demand. In August 2020, Johnson &amp; Johnson moved to dismiss the amended complaint. In February 2021, the Court held oral argument on Johnson &amp; Johnson's motion. In August 2020, another shareholder who sent a demand filed a separate derivative complaint in the same court making similar allegations. In October 2020, the Court granted defendants&#8217; request to reassign the second-filed case to the division where the first-filed case is pending. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2019, two additional shareholders who sent demands filed two separate derivative complaints making similar allegations against Johnson &amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the United States District for the District of New Jersey. In April 2020, the two federal cases were consolidated into a single action captioned</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> In re Johnson &amp; Johnson Opioid Stockholder Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. In July 2020, the shareholders filed a consolidated complaint. In September 2020, Johnson &amp; Johnson moved to dismiss the consolidated complaint, and in December 2020, the shareholders opposed Johnson &amp; Johnson&#8217;s motion. Johnson &amp; Johnson filed its reply in February 2021. In July 2020, an additional shareholder who sent a demand filed a derivative complaint in the same federal court making similar allegations against the same defendants named in the consolidated action. In January 2021, pursuant to an order in the consolidated action, the third case was consolidated into the consolidated action. In February 2021, the Court granted the shareholders motion to voluntarily dismiss the consolidated action without prejudice, and the shareholders&#8217; counsel then filed a notice of association in the first-filed derivative action pending in the Superior Court of New Jersey. </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson &amp; Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney's Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ASR&#8482; XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> case filed pursuant to the False Claims Act against the companies concerning the hip devices. In February 2016, the District Court granted the companies&#8217; motion to dismiss with prejudice, unsealed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint, and denied the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> relators&#8217; request for leave to file a further amended complaint. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the District Court&#8217;s dismissal in part, reversed in part, and affirmed the decision to deny the relators&#8217; request to file a third amended complaint. The relators&#8217; remaining claims are now pending before the District Court, and the District Court has not yet closed the fact discovery time period. In March 2021, DePuy filed its motion to strike and dismiss the relators&#8217; second amended complaint; the District Court denied DePuy&#8217;s motion to strike and dismiss on July 6, 2021.  DePuy filed a motion for reconsideration of the District Court&#8217;s July 6, 2021 ruling.  On August 18, 2021, the District Court stated that it was reviewing DePuy&#8217;s motion for reconsideration, and on September 16, 2021, in connection with the District Court&#8217;s review of the motion for reconsideration, the District Court ordered the parties to file additional submissions by September 30, 2021, which are now under review by the District Court.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2012, Johnson &amp; Johnson was contacted by the California Attorney General's office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by Johnson &amp; Johnson's subsidiary, Ethicon, Inc. (Ethicon). In May 2016, California and Washington filed civil complaints against Johnson &amp; Johnson, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states:  Kentucky, Mississippi, West Virginia and Oregon. In April 2019, Johnson &amp; Johnson and Ethicon settled the Washington case. The California case started trial in July 2019 and concluded in September 2019. The trial date for the Kentucky case was scheduled for September 2019 but has been adjourned and no new trial date has been scheduled. In October 2019, Johnson &amp; Johnson and Ethicon settled the multi-state investigation with 41 other states and the District of Columbia. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $<ix:nonFraction unitRef="usd" contextRef="i5fc8a90a726a4462b931044e9118c5df_D20200120-20200120" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNzA1Njc_cb339ae6-46ed-4b07-b5dd-2140a8063fc8">344</ix:nonFraction>&#160;million. In April 2020, the Court in California denied the Company's motion for a new trial. In August 2020, the Court entered judgment with respect to the penalties of $<ix:nonFraction unitRef="usd" contextRef="i5fc8a90a726a4462b931044e9118c5df_D20200120-20200120" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNzA3MzE_0f1a7436-657a-4076-a550-f0683b7d639b">344</ix:nonFraction>&#160;million, but denied the Attorney General&#8217;s request for injunctive relief. The Company is appealing the penalty judgment. In April 2020, the Company settled the West Virginia case. In October 2020, the Company settled with the Attorney General of Oregon.  In November 2020, the Company settled with the Attorney General of Mississippi. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Companies, Inc. (now known as Johnson &amp; Johnson Consumer Inc.) (JJCI).&#160;The complaint alleges that defendants violated the Mississippi Consumer Protection Act by </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">failing to disclose alleged health risks associated with female consumers' use of talc contained in JOHNSON'S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Baby Powder and JOHNSON'S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. The Mississippi Supreme Court granted Johnson &amp; Johnson and JJCI's request to file an interlocutory appeal of the denial of the motion for summary judgment in late 2019. Johnson &amp; Johnson and JJCI moved for summary judgment on the grounds that the State's claim was barred by preemption. In April 2021, the Mississippi Supreme Court dismissed the Company&#8217;s interlocutory appeal and remanded the case back to the Hinds County Chancery Court. Discovery is now proceeding in that court. In August 2021, Johnson &amp; Johnson and JJCI filed a Petition for Writ of Certiorari in the US Supreme Court. </span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i734bf2d0d47a49b0bd5f66f4f9838d72" continuedAt="i1bba31a452a549d2acded26b09853852"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The State of New Mexico filed an Amended Complaint in March 2020. The Company moved to dismiss certain of the claims in the Amended Complaint, which was granted. The Company then filed a motion for partial judgment on the pleadings in December 2020, which was denied. The Company made its first document production in February 2021 and discovery is ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Forty-two states have commenced a joint investigation into the Company&#8217;s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington. The Company has entered into a tolling agreement with thirty-three States, which is set to expire in November 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, Janssen Pharmaceuticals, Inc. (JPI) received a Civil Investigative Demand from the United States Attorney&#8217;s Office for the Southern District of New York related to JPI&#8217;s contractual relationships with pharmacy benefit managers over the period from January 1, 2006 to the present with regard to certain of JPI's pharmaceutical products. The demand was issued in connection with an investigation under the False Claims Act. The Company has provided documents in response to the demand. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2016, Johnson &amp; Johnson and Janssen Products LP were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and INTELENCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, and anti-kickback violations in connection with the promotion of these products.&#160;The complaint was filed under seal in December 2012.&#160;The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators.&#160;Summary judgment and Daubert motions are currently pending with the Court. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April and September 2017, Johnson &amp; Johnson received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, OLYSIO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, SIMPONI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.&#160;The subpoenas also seek documents relating to&#160;Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies. The Company has provided documents in response to the subpoenas. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, Johnson &amp; Johnson received a subpoena from the United States Attorney's Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc.(DePuy) spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these hospitals. Johnson &amp; Johnson and DePuy have produced documents in response to the subpoena and are fully cooperating with the government&#8217;s investigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2018 the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp; Johnson do Brasil Ind&#250;stria e Com&#233;rcio de Produtos para Sa&#250;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson &amp; Johnson to cooperate with these inquiries by producing the requested information.</span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GENERAL LITIGATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2018, a purported class action was filed in the Circuit Court Third Judicial District Madison County, Illinois against Johnson &amp; Johnson Consumer, Inc. (JJCI), alleging violations of state consumer fraud statutes based on nondisclosure of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i1bba31a452a549d2acded26b09853852" continuedAt="ia408a1424c7a40ff9e2f436226e2ce39"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">alleged health risks associated with talc contained in JOHNSON'S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Baby Powder. The complaint seeks damages but does not allege personal injury. In August 2021, the Court granted JJCI&#8217;s motion to dismiss the complaint.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March and April 2015, over <ix:nonFraction unitRef="claim" contextRef="i57db9f0a21bd4a538b012b2e386a50fa_I20150430" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMjE5OTAyMzQ1NDU0OA_7ee1c3d4-7082-4a64-a419-57984ee47511">30</ix:nonFraction> putative class action complaints were filed by contact lens patients in a number of courts around the United States against Johnson &amp; Johnson Vision Care, Inc. (JJVCI) and other contact lens manufacturers, distributors, and retailers, alleging vertical and horizontal conspiracies to fix the retail prices of contact lenses. The complaints allege that the manufacturers reached agreements with each other and certain distributors and retailers concerning the prices at which some contact lenses could be sold to consumers. The plaintiffs are seeking damages and injunctive relief. All of the class action cases were transferred to the United States District Court for the Middle District of Florida in June 2015. The plaintiffs filed a consolidated class action complaint in November 2015. Discovery and pre-trial motion practice are complete. Trial is scheduled to begin in March 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in September 2017, multiple purported class actions were filed on behalf of indirect purchasers of REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) alleging that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The cases were consolidated for pre-trial purposes as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Antitrust Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in United States District Court for the Eastern District of Pennsylvania. The consolidated complaint seeks damages and injunctive relief.  Discovery is ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, Walgreen Co. and Kroger Co., filed an antitrust complaint against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in the United States District Court for the Eastern District of Pennsylvania.  The complaint alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The complaint seeks damages and injunctive relief. In March 2019, summary judgment was granted in favor of Janssen. In February 2020, the United States Court of Appeals for the Third Circuit reversed the District Court&#8217;s decision. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to Johnson &amp; Johnson in connection with its investigation of whether Janssen&#8217;s REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act.  The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2021, plaintiffs appealed the District Court&#8217;s decision to the United States Court of Appeals for the District of Columbia Circuit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia.&#160;The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.&#160; TRACLEER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> is subject to a Risk Evaluation and Mitigation Strategy required by the Food and Drug Administration, which imposes restrictions on distribution of the product.&#160; In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland.&#160; In October 2019, the Court granted Actelion&#8217;s motion to dismiss the amended complaint. In April 2021, the United States Court of Appeals for the Fourth Circuit reversed and remanded. Discovery is ongoing.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research &amp; Development, LLC, and Johnson &amp; Johnson (collectively, Janssen) were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint filed on behalf of the United States, 28 states, and the District of Columbia.&#160;The complaint, which was filed in December 2017 in United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> to the government in connection with direct government sales and government-funded drug reimbursement programs.&#160;At this time, the federal and state governments have declined to intervene. The case has been transferred to United States District Court for the District of New Jersey. In September 2019, Janssen moved to dismiss the complaint. In February 2021, the judge has set a renewed schedule for the Company's motion to dismiss, with briefs to be fully submitted by early July 2021. In April 2021, Janssen renewed its motion to dismiss pursuant to Court order.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2019, Blue Cross &amp; Blue Shield of Louisiana and HMO Louisiana, Inc. filed a class action complaint against Janssen Biotech, Inc, Janssen Oncology, Inc, Janssen Research &amp; Development, LLC (collectively, Janssen) and BTG International Limited in the United States District Court for the Eastern District of Virginia on behalf of indirect purchasers of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Several additional complaints were filed thereafter in Virginia and New Jersey. The indirect purchaser complaints generally allege that the defendants violated the antitrust and consumer protections laws of several states and the Sherman Act by </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="ia408a1424c7a40ff9e2f436226e2ce39"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">pursuing patent litigation relating to ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in order to delay generic entry and seek damages. The Virginia cases have been transferred to the United States District Court for the District of New Jersey and consolidated with the New Jersey case. A consolidated amended complaint was filed in February 2021. In April 2021, Janssen moved to dismiss the Indirect Purchaser Action. Discovery in the Indirect Purchaser Action is ongoing. In May 2020, a class action complaint was filed against Janssen Biotech Inc., Janssen Oncology, Inc., Janssen Research &amp; Development LLC and BTG International Limited in the United States District Court for the District of New Jersey, on behalf of direct purchasers of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The direct purchaser complaint alleges that defendants violated the Sherman Act by pursuing patent litigation relating to ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in order to delay generic entry, and seek damages and injunctive relief. In April 2021, Janssen moved to compel arbitration of the Direct Purchaser Action. In October 2021, the Court granted Janssen&#8217;s motion and compelled arbitration of the Direct Purchaser Action.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2019, a class action antitrust complaint was filed against Janssen R&amp;D Ireland (Janssen) and Johnson &amp; Johnson in the United States District Court for the Northern District of California. The complaint alleges that Janssen violated federal and state antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the development and marketing of combination antiretroviral therapies (cART) to treat HIV. The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers Squibb and Japan Tobacco. In March 2020, the Court granted in part and denied in part defendants&#8217; motions to dismiss.  Plaintiffs filed an amended complaint in April 2020. Defendants moved to dismiss the amended complaint.  In July 2020, the Court granted in part and denied in part the renewed motion to dismiss. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California. The complaint alleges that certain of BWI&#8217;s&#160;business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In January 2020, BWI filed a motion to dismiss the complaint. In August 2020, the Court granted in part and denied in part BWI&#8217;s motion to dismiss. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, Johnson &amp; Johnson received a demand for indemnification from Pfizer Inc., pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson &amp; Johnson, Inc. received a demand for indemnification from Sanofi Consumer Health, Inc., pursuant to the 2016 Asset Purchase Agreement between J&amp;J, Inc. and Sanofi. In January 2020, Johnson &amp; Johnson received a demand for indemnification from Boehringer Ingelheim Pharmaceuticals, Inc., pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim.  The notices seek indemnification for legal claims related to over-the-counter ZANTAC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ranitidine) products. Plaintiffs in the underlying actions allege that ZANTAC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against Johnson &amp; Johnson, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#8217;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2020, Ethicon moved to dismiss certain causes of action in the complaint. Discovery is ongoing.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning in May 2021, multiple </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">putative </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">class actions were filed in state and federal courts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(California, Florida, New York, and New Jersey)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> against various Johnson &amp; Johnson entities alleging violations of state consumer fraud statutes based on nondisclosure of alleged benzene contamination of certain Neutrogena and Aveeno sunscreen products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and the affirmative promotion of those products as &#8220;safe&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">; and, in at least one case, alleging a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strict liability manufacturing defect and failure to warn </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">claims, asserting that the named plaintiffs</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> suffered unspecified injuries as a result of alleged exposure to benzene.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Judicial Panel on Multi-District Litigation has consolidated all pending actions, except one product liability matter, in the United States District Court-Southern District of Florida-Fort Lauderdale Division. In October 2021, the Company reached an agreement in principle for the settlement of a nationwide class, encompassing the claims of the consolidated actions, subject to approval by the Florida federal Court.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson or its subsidiaries are also parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div id="if410ee6e03c8456f86a9fee997f08e65_91"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 12&#8212; <ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfMjU2Ng_b6bc33a3-bdba-4079-8fb6-f1ca1f39025d" continuedAt="i69a3b67bbf7f41b6b31cc6034bf0a557" escape="true">RESTRUCTURING</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i69a3b67bbf7f41b6b31cc6034bf0a557"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal second quarter of 2018 the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions will include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. In the fiscal third quarter of 2021, the Company recorded a pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="i5c79c8166fea4d28acc6e2a5c55371e3_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfNjYw_b2d03409-ebf8-482b-ae2f-5564aaa9091f">121</ix:nonFraction> million, which is included on the following lines of the Consolidated Statement of Earnings, $<ix:nonFraction unitRef="usd" contextRef="i41e6c3af78c84e7a96704669c8534fbd_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfNzQ4_67f3b9e9-1baa-4298-9e2f-724574993bf1">60</ix:nonFraction> million in restructuring, $<ix:nonFraction unitRef="usd" contextRef="i0bf46255c4954869ba02f4fcf0890318_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfNzY5_6e11038c-bb7a-44e3-8e2e-08c0e7992ca9">18</ix:nonFraction> million in cost of products sold and $<ix:nonFraction unitRef="usd" contextRef="id03bd483db33402eafee3a37392a50dd_D20210705-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfODAx_9880bf7e-1d77-488e-88fe-48a44a36cafb">43</ix:nonFraction> million in other (income) expense, net. In the fiscal nine months of 2021, the Company recorded a pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="i395c16cff1fd472887230111aec654c7_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfODk2_7c73f290-a2a6-43e5-870f-991693d989fe">333</ix:nonFraction>&#160;million, which is included on the following lines of the Consolidated Statement of Earnings, $<ix:nonFraction unitRef="usd" contextRef="i8b2139d6e4794867beaf8b64054355a3_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfOTg0_cc3cbde9-6742-4638-bc36-8b7c6f56e0a1">169</ix:nonFraction>&#160;million in restructuring, $<ix:nonFraction unitRef="usd" contextRef="i9335dfec33444d1fa82036d4e0556288_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfMTAwNQ_7d7e4c21-b0d1-427e-af64-dbf4c73285cc">65</ix:nonFraction>&#160;million in cost of products sold and $<ix:nonFraction unitRef="usd" contextRef="iddfd422a68bd4c3fb53443eddc899e5d_D20210104-20211003" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfMTAzNw_791b70ff-88a7-42e8-83d2-4d0176456d8c">99</ix:nonFraction>&#160;million in other (income) expense, net. Total project costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i1a40709bfe644a94ba4984bd52754e41_I20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfMTExMA_0eeafee8-efac-4e3f-a410-9f7249607459">1.6</ix:nonFraction> billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company expects the Global Supply Chain actions to generate approximately $<ix:nonFraction unitRef="usd" contextRef="i30de6283641a414eb591a7e379e8ca06_I20211003" decimals="-8" format="ixt:num-dot-decimal" name="jnj:RestructuringandRelatedCostExpectedFutureSavings" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfMTMzOA_8b7d8b2b-d848-460f-ad93-1516b61a9159">0.6</ix:nonFraction> billion to $<ix:nonFraction unitRef="usd" contextRef="if65f698d763e4aa69ebb37089739db4d_I20211003" decimals="-8" format="ixt:num-dot-decimal" name="jnj:RestructuringandRelatedCostExpectedFutureSavings" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfMTM0NA_723c0036-6747-4381-8bdc-35bb5bdb01c5">0.8</ix:nonFraction> billion in annual pre-tax cost savings that will be substantially delivered by 2022. The Company expects to record pre-tax restructuring charges of approximately $<ix:nonFraction unitRef="usd" contextRef="i30de6283641a414eb591a7e379e8ca06_I20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfMTUwMQ_4e9c11ca-5e77-4da0-b1a6-34023de22ca9">1.9</ix:nonFraction> billion to $<ix:nonFraction unitRef="usd" contextRef="if65f698d763e4aa69ebb37089739db4d_I20211003" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfMTUwNw_fb4cf7cb-73ed-4db6-b201-e4aed46fe7f2">2.3</ix:nonFraction> billion, over the <ix:nonNumeric contextRef="i155df99154524c01b1d1bc1cda9bd334_D20210104-20211003" format="ixt-sec:duryear" name="jnj:RestructuringandRelatedCostDurationofRestructuringPlan" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfMTUyMA_b799468b-b982-4eaf-8ff7-11290b29df4e">4</ix:nonNumeric> to <ix:nonNumeric contextRef="ia7b66f9b903d4029a697b4d5bbd09f00_D20210104-20211003" format="ixt-sec:duryear" name="jnj:RestructuringandRelatedCostDurationofRestructuringPlan" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfMTUyNg_eda58e3e-0a3d-4e6b-888e-89c57fd1e9b7">5</ix:nonNumeric> year period of this activity. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization.&#160; &#160;</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfMjU2NQ_60a367c0-6255-4fdc-b011-fa6ed92af8ff" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal third quarter of 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:33.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.272%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.881%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.272%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Write-offs</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January 3, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86e59d6adba6473da76a65735fc95b35_I20210103" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfMS0xLTEtMS0w_fe06398c-5786-4123-b82e-c7c85081121e">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f1238f4cde44b00a401b4e14983e6af_I20210103" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfMS0yLTEtMS0w_4eee205d-2aba-4673-af76-6dcdd7c501c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c74256bce09412bb1c7eb851708c6bb_I20210103" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfMS0zLTEtMS0w_f905c8a8-b5fd-4476-b9ec-083c9c251ef7">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68831153f9a14ae1b239033a0c1a9104_I20210103" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfMS01LTEtMS0w_2b99304e-195f-461c-9a0b-62ff2694187a">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Charges  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i965b447464ee4a389bab1a83195f092c_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfNC0xLTEtMS0w_3ec4194f-5c61-4814-a8bd-fbc076d910aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d484844090412aa63423ed27e77165_D20210104-20211003" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfNC0yLTEtMS0w_2555bb05-af60-412a-8d1e-f4053baa2517">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a5f799f220481ba0964cbf04e6d485_D20210104-20211003" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfNC0zLTEtMS0w_0b66dfe3-626e-46ec-8908-09ea383d47bc">295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a08f7d7ee644f69fa747b7bb19e88c_D20210104-20211003" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfNC01LTEtMS0w_d6d7883a-2ea4-4866-9c67-24190610dabe">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i965b447464ee4a389bab1a83195f092c_D20210104-20211003" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfNS0xLTEtMS0w_1bd4f87e-f3ee-4924-9df8-2a62185fe322">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d484844090412aa63423ed27e77165_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfNS0yLTEtMS0w_5af0a468-bdb5-44d7-a033-8d886f5bf1dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a5f799f220481ba0964cbf04e6d485_D20210104-20211003" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfNS0zLTEtMS0w_6aee315a-f92c-403f-9c1f-e18302989057">270</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a08f7d7ee644f69fa747b7bb19e88c_D20210104-20211003" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfNS01LTEtMS0w_a5c9b44e-afcc-4ced-bcad-968e0f1d060b">287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Settled non cash </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i965b447464ee4a389bab1a83195f092c_D20210104-20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfNi0xLTEtMS0w_97f22e06-7f98-4394-860d-7169afdb6560">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6d484844090412aa63423ed27e77165_D20210104-20211003" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfNi0yLTEtMS0w_467dddf1-ecd3-48a3-857e-9c4d681ab6b2">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie7a5f799f220481ba0964cbf04e6d485_D20210104-20211003" sign="-" xsi:nil="true" name="us-gaap:RestructuringReserveSettledWithoutCash2" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfNi0zLTEtMS0w_624e8637-8ae2-48b3-80c9-b3d932c3c56c"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a08f7d7ee644f69fa747b7bb19e88c_D20210104-20211003" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfNi01LTEtMS0w_029a3c0a-adcf-48c9-884e-421c52c2aaba">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, October 3, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6911c9fe2fc4680883030bd35fb4405_I20211003" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfOS0xLTEtMS0w_b5d27858-1084-4e9a-b947-d2ff8aaa9149">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecd272aa6bf84db3985f9de3d1a4af33_I20211003" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfOS0yLTEtMS0w_6fa63665-8326-4ddc-a2bb-327d87171568">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5a49c0f5b94001a4430dceb7eab418_I20211003" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfOS0zLTEtMS0w_058d7752-086f-4d65-bec9-0cb46d4bca73">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7cacd129fca46088c70b938e656f2d7_I20211003" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfOS01LTEtMS0w_6395c3ca-4b01-4bec-9259-bf4fedb9fa1c">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash outlays for severance are expected to be substantially paid out over the next <ix:nonNumeric contextRef="i69a08f7d7ee644f69fa747b7bb19e88c_D20210104-20211003" format="ixt-sec:durmonth" name="jnj:RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid" id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfMTg5Mw_314c90a7-c14c-4393-bbd1-0f44d77e7c97">18</ix:nonNumeric> months in accordance with the Company's plans and local laws. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div id="if410ee6e03c8456f86a9fee997f08e65_106"></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><span><br/></span></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;2 &#8212; MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales to Customers</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Analysis of Consolidated Sales</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal nine months of 2021, worldwide sales were $69.0 billion, a total increase of 14.7%, including an operational increase of 12.4% as compared to 2020 fiscal nine months sales of $60.1 billion. Currency fluctuations had a positive impact of 2.3% for the fiscal nine months of 2021. In the fiscal nine months of 2021, the net impact of acquisitions and divestitures on worldwide operational sales growth was a negative 0.7%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales by U.S. companies were $35.0 billion in the fiscal nine months of 2021, which represented an increase of 11.7% as compared to the prior year. In the fiscal nine months of 2021, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a negative 0.1%.  Sales by international companies were $34.0 billion, an increase of 18.0%, including an operational increase of 13.1%, and a positive currency impact of 4.9% as compared to the fiscal nine months sales of 2020. In the fiscal nine months of 2021, the net impact of acquisitions and divestitures on the international operational sales growth was a negative 1.3%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal nine months of 2021, sales by companies in Europe achieved growth of 21.6%, which included an operational increase of 15.3% and a positive currency impact of 6.3%. Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 9.2%, which included an operational increase of 8.1%, and a positive currency impact of 1.1%. Sales by companies in the Asia-Pacific, Africa region achieved growth of 16.8%, including an operational increase of 12.3% and a positive currency impact of 4.5%.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="text-align:center"><img src="jnj-20211003_g1.jpg" alt="jnj-20211003_g1.jpg" style="height:264px;margin-bottom:5pt;vertical-align:text-bottom;width:350px"/><img src="jnj-20211003_g2.jpg" alt="jnj-20211003_g2.jpg" style="height:264px;margin-bottom:5pt;vertical-align:text-bottom;width:310px"/></div><div style="padding-left:180pt"><span><br/></span></div><div style="padding-left:180pt"><span><br/></span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note: values may have been rounded</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:180pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="padding-left:180pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal third quarter of 2021, worldwide sales were $23.3 billion, a total increase of 10.7%, which included operational growth of 9.9%  and a positive currency impact of 0.8% as compared to 2020 fiscal third quarter sales of $21.1 billion. In the fiscal third quarter of 2021, the net impact of acquisitions and divestitures on worldwide operational sales growth was a negative 0.7%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales by U.S. companies were $12.0 billion in the fiscal third quarter of 2021, which represented an increase of 7.9% as compared to the prior year. In the fiscal third quarter of 2021, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a negative 0.1%.  Sales by international companies were $11.4 billion, a total increase of 13.8%, which included operational growth of 12.1% and a positive currency impact of 1.7%. In the fiscal third quarter of 2021, the net impact of acquisitions and divestitures on the international operational sales growth was a negative 1.4%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal third quarter of 2021, sales by companies in Europe achieved growth of 15.9%, which included operational growth of 14.6% and a positive currency impact of 1.3%. Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 15.7%, including operational growth of 13.4% and a positive currency impact of 2.3%. Sales by companies in the Asia-Pacific, Africa region achieved growth 10.5%, including operational growth of 8.5% and a positive currency impact of 2.0%.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="text-align:center"><img src="jnj-20211003_g3.jpg" alt="jnj-20211003_g3.jpg" style="height:264px;margin-bottom:5pt;vertical-align:text-bottom;width:350px"/><img src="jnj-20211003_g4.jpg" alt="jnj-20211003_g4.jpg" style="height:264px;margin-bottom:5pt;vertical-align:text-bottom;width:310px"/></div><div style="padding-left:180pt"><span><br/></span></div><div style="padding-left:180pt"><span><br/></span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note: values may have been rounded</span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span><br/></span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span><br/></span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Analysis of Sales by Business Segments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consumer Health </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consumer Health segment sales in the fiscal nine months of 2021 were $11.0 billion, an increase of 5.2% as compared to the same period a year ago, including operational growth of 3.1% and a positive currency impact of 2.1%. U.S. Consumer Health segment sales increased by 2.8%.  International Consumer Health segment sales increased by 7.3%, including operational growth of 3.5% and a positive currency impact of 3.8%.  In the fiscal nine months of 2021, the net impact of acquisitions and divestitures on the Consumer Health segment operational sales growth was a negative 1.0%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major Consumer Health Franchise Sales &#8212; Fiscal Nine Months Ended</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:42.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency<br/>Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Women&#8217;s Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Consumer Health Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,978</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,435</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Consumer Health segment sales in the fiscal third quarter of 2021 were $3.7 billion, an increase of 5.3% as compared to the same period a year ago, including operational growth of 4.1% and a positive currency impact of 1.2%. U.S. Consumer Health segment sales increased by 4.5%. International Consumer Health segment sales increased by 5.9% including operational growth of 3.7% and a positive currency impact of 2.2%. In the fiscal third quarter of 2021, the net impact of acquisitions and divestitures on the Consumer Health segment operational sales growth was a negative 1.6% primarily due to the DR. CI:LABO - Sedona divestiture in Asia Pacific. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Major Consumer Health Franchise Sales &#8212; Fiscal Third Quarter Ended</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:43.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.380%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.380%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.567%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency<br/>Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Women&#8217;s Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Consumer Health Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,514</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OTC franchise achieved operational growth of 18.2% as compared to the prior year fiscal third quarter. Growth was driven by Analgesics, TYLENOL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MOTRIN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, digestive health and the hydration benefit offering (ORSL).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Skin Health/Beauty franchise experienced an operational decline of 3.0% as compared to the prior year fiscal third quarter. The decline was driven by the DR. CI:LABO - Sedona divestiture in Asia Pacific, U.S. external supply constraints and the aerosol sunscreen voluntary recall partially offset by worldwide COVID-19 recovery and e-commerce growth as well as strong growth outside the U.S. of AVEENO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NEUTROGENA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Oral Care franchise experienced an operational decline of 4.5% as compared to the prior year fiscal third quarter. The decline was primarily driven by divestitures and U.S. external supply constraints partially offset by market growth in the U.S. along with strong performance in Asia Pacific due to successful brand building and promotional campaigns. </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Baby Care franchise experienced an operational decline of 1.2% as compared to the prior year fiscal third quarter. The decline was driven by COVID-19 related lockdowns in parts of Asia Pacific coupled with competitive pressures in that region partially offset by worldwide AVEENO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Baby strength. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Women&#8217;s Health franchise achieved operational growth of 0.8% as compared to the prior year fiscal third quarter primarily driven by COVID-19 market recovery and favorable price in Latin America partially offset by disruptions in Europe due to flooding.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Wound Care/Other franchise experienced an operational decline of 4.8% as compared to the prior year fiscal third quarter primarily driven by competitive pressures outside the U.S. and impacts from prior year stocking partially offset by U.S. category growth. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment sales in the fiscal nine months of 2021 were $37.8 billion, an increase of 13.5% as compared to the same period a year ago, with an operational increase of 11.3% and a positive currency impact of 2.2%. U.S. Pharmaceutical sales increased 10.3% as compared to the same period a year ago. International Pharmaceutical sales increased by 17.5%, including operational growth of 12.5% and a positive currency impact of 5.0%.  In the fiscal nine months of 2021, the net impact of acquisitions and divestitures on the Pharmaceutical segment operational sales growth was a negative 0.5%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major Pharmaceutical Therapeutic Area Sales** &#8212; Fiscal Nine Months Ended</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:48.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.017%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency<br/>Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,395</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,950</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;SIMPONI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,424</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,662</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;COVID-19 VACCINE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;EDURANT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/rilpivirine</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/ PREZCOBIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/ REZOLSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/ SYMTUZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,218</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,850</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;CONCERTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/methylphenidate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/ XEPLION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/ INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/ TREVICTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;RISPERDAL CONSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,770</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,933</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ abiraterone acetate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,599</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,283</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,386</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,625</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Pharmaceutical Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,792</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33,304</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inclusive of VELCADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment sales in the fiscal third quarter of 2021 were $13.0 billion, an increase of 13.8% as compared to the same period a year ago, including an operational increase of 13.2% and a positive currency impact of 0.6%. U.S. Pharmaceutical sales increased 12.2% as compared to the same period a year ago. International Pharmaceutical sales increased by 15.9%, including operational growth of 14.6% and a positive currency impact of 1.3%. In the fiscal third quarter of 2021, the net impact of acquisitions and divestitures on the Pharmaceutical segment operational sales growth was a negative 0.6%. Adjustments to previous sales reserve estimates were approximately $0.2 billion in both fiscal third quarters of 2021 and 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major Pharmaceutical Therapeutic Area Sales** &#8212; Fiscal Third Quarter Ended</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:47.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency<br/>Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,789</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;SIMPONI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,389</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">864</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">59.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;COVID-19 VACCINE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;EDURANT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/rilpivirine</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/ PREZCOBIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/ REZOLSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SYMTUZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,689</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,605</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;CONCERTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ methylphenidate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/ XEPLION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/ INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TREVICTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;RISPERDAL CONSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,665</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,129</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ abiraterone acetate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">868</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">749</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,133</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Pharmaceutical Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,418</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inclusive of VELCADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunology products achieved operational growth of 11.7% as compared to the same period a year ago driven by continued strong uptake of STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ustekinumab) in Crohn's disease and Ulcerative Colitis, strength of TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(guselkumab) in Psoriasis and uptake in Psoriatic Arthritis and market and share gains in SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This was partially offset by lower sales of REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(infliximab) due to biosimilar competition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biosimilar versions of REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been introduced in the United States and certain markets outside the United States and additional competitors continue to enter the market. Continued infliximab biosimilar competition will result in a further reduction in sales of REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Infectious disease products achieved operational growth of 59.8% as compared to the same period a year ago. Growth was primarily driven by the contribution of the COVID-19 vaccine.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This was partially offset by lower sales of PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and PREZCOBIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/REZOLSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (darunavir/cobicistat) due to increased competition and loss of exclusivity of PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in certain countries outside the U.S. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neuroscience products achieved operational sales growth of 4.6% as compared to the same period a year ago. Growth of Paliperidone long-acting injectables INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/XEPLION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (paliperidone palmitate) and INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/TREVICTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was due to increased new patient starts and persistence of treatment. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncology products achieved operational sales growth of 16.5% as compared to the same period a year ago. Contributors to the growth were strong sales of DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (daratumumab) driven by continued strong market growth, share gains in all regions and solid uptake of the subcutaneous formulation launched in 2020; the continued global launch uptake of ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (apalutamide) and IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ibrutinib) growth primarily driven by market and continued share leadership. The growth of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ibrutinib) was partially offset by COVID-19 related market dynamics including delays in new patient starts as well as competitive pressures from novel oral agents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pulmonary Hypertension achieved operational sales growth of 16.1% as compared to the same period a year ago. Sales growth of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (macitentan) and UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (selexipag) were due to continued share gains and market growth.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiovascular / Metabolism / Other products experienced an operational decline of 12.4% as compared to the same period a year ago. The decline was primarily attributable to lower sales of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (canagliflozin) due to competitive pressures and PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/ EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(epoetin alfa) due to biosimilar competition.  </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medical Devices</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medical Devices segment sales in the fiscal nine months of 2021 were $20.2 billion, an increase of 23.4% as compared to the same period a year ago, with an operational increase of 20.5% and a positive currency impact of 2.9%. U.S. Medical Devices sales increased 20.6%. International Medical Devices sales increased by 26.0%, including an operational increase of 20.5% and a positive currency impact of 5.5%. In the fiscal nine months of 2021, the net impact of acquisitions and divestitures on the Medical Devices segment operational sales growth was a negative 0.9% primarily due to the divestiture of the Advanced Sterilization Products (ASP) business. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major Medical Devices Franchise Sales &#8212; Fiscal Nine Months Ended</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"></td><td style="width:228.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency<br/>Change</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,299</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,803</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Advanced</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;General</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,433</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,572</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Hips</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Knees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Trauma</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Spine, Sports &amp; Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,517</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,843</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contact Lenses/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Surgical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,952</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,153</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Medical Devices Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,201</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,370</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medical Devices segment sales in the fiscal third quarter of 2021 were $6.6 billion, an increase of 8.0% as compared to the same period a year ago, which included operational growth of 7.0% and a positive currency impact of 1.0%. U.S. Medical Devices sales increased 0.8%. International Medical Devices sales increased by 15.4%, including operational growth of 13.3% and a positive currency impact of 2.1%. In the fiscal third quarter of 2021, the net impact of acquisitions and divestitures on the Medical Devices segment operational sales growth was a negative 0.6% primarily due to the divestiture of the ASP business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has seen a general recovery in global procedural volumes in the Medical Devices segment as compared to the prior year which had significant negative impacts from COVID-19.  This procedural volume recovery is the primary driver of sales and earnings growth in the current quarter as compared to the prior year. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major Medical Devices Franchise Sales &#8212; Fiscal Third Quarter Ended</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"></td><td style="width:235.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:45.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency<br/>Change</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,405</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,152</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Advanced</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;General</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,093</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,083</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Hips</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Knees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Trauma</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Spine, Sports &amp; Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,189</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,081</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contact Lenses/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Surgical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">957</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">836</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Medical Devices Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,644</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,150</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Surgery franchise achieved operational sales growth of 10.2% as compared to the prior year fiscal third quarter. The operational growth in Advanced Surgery was primarily driven Endocutter, Biosurgery and Energy products attributable to  market recovery, market expansion and the success of new products offsetting competitive pressures in the U.S. The operational growth in General Surgery was primarily driven by market recovery and the continued strength of the suture portfolio partially offset by the impact of the ASP divestiture in the prior year. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Orthopaedics franchise experienced an operational decline of 0.3% as compared to the prior year fiscal third quarter. The operational growth in hips reflects the market recovery combined with continued strength of the portfolio including the ACTIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> stem and enabling technologies &#8211; KINCISE&#8482; and VELYS&#8482; Hip Navigation. The operational growth in knees was primarily driven by procedure recovery and timing of a tender outside the U.S. The operational growth in Trauma was driven by global market recovery and uptake of new products. The operational decline in Spine, Sports &amp; Other was driven by COVID-19 related impacts on the market partially offset by new products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Vision franchise achieved operational sales growth of 10.0% as compared to the prior year fiscal third quarter. The Contact Lenses/Other operational growth was due to market recovery and new products partially offset by prior year higher level of stocking in the U.S. The Surgical operational growth was primarily due to market recovery and uptake of recently launched products.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Interventional Solutions franchise achieved operational sales growth of 13.2% as compared to the prior year fiscal third quarter driven by the market recovery and success of new products and commercial strategies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANALYSIS OF CONSOLIDATED EARNINGS BEFORE PROVISION FOR TAXES ON INCOME </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated earnings before provision for taxes on income for the fiscal nine months of 2021 was $17.9 billion representing 26.0% of sales as compared to $14.9 billion in the fiscal nine months of 2020, representing 24.7% of sales.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated earnings before provision for taxes on income for the fiscal third quarter of 2021 was $3.8 billion representing 16.5% of sales as compared to $4.4 billion in the fiscal third quarter of 2020, representing 20.9% of sales. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Products Sold </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><img src="jnj-20211003_g5.jpg" alt="jnj-20211003_g5.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/><img src="jnj-20211003_g6.jpg" alt="jnj-20211003_g6.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in billions. Percentages in chart are as a percent to total sales)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fiscal Nine months Q3 2021 versus Fiscal Nine months Q3 2020</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold decreased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.15pt">Non-recurring prior year COVID-19 production related slow downs and related inventory impacts</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Fixed cost deleveraging in the Medical Devices business in the fiscal 2020</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset amortization expense included in cost of products sold for the fiscal nine months of 2021 and 2020 was $3.6 billion and $3.4 billion, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Q3 2021 versus Q3 2020</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products decreased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Non-recurring prior year COVID-19 production related slow-downs and related inventory impacts</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Fixed cost deleveraging in the Medical Devices business in the fiscal 2020</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:13.8pt">Favorable mix within the Pharmaceutical business as well as at the enterprise level</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">with a higher percentage of sales coming from the Pharmaceutical business</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The intangible asset amortization expense included in cost of products sold for the fiscal third quarters of 2021 and 2020 was $1.1 billion and $1.2 billion, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, Marketing and Administrative Expenses</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><img src="jnj-20211003_g7.jpg" alt="jnj-20211003_g7.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/><img src="jnj-20211003_g8.jpg" alt="jnj-20211003_g8.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in billions. Percentages in chart are as a percent to total sales)</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fiscal Nine months Q3 2021 versus Fiscal Nine months Q3 2020</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, Marketing and Administrative Expenses decreased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Leveraging in the Medical Devices business resulting from the recovery of sales from the prior years impact of COVID-19</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Segment mix with a higher percentage of sales coming from the Medical Devices business in the current year</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Q3 2021 versus Q3 2020</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, Marketing and Administrative Expenses slightly decreased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Leveraging in the Medical Devices business resulting from the recovery of sales from the prior years impact of COVID-19</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Segment mix with a higher percentage of sales coming from the Pharmaceutical business</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="text-align:center"><img src="jnj-20211003_g9.jpg" alt="jnj-20211003_g9.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/><img src="jnj-20211003_g10.jpg" alt="jnj-20211003_g10.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in billions. Percentages in chart are as a percent to total sales)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fiscal Nine months Q3 2021 versus Fiscal Nine months Q3 2020</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development increased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">COVID-19 vaccine expenses, net of governmental reimbursements</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Portfolio progression in the Pharmaceutical business</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partially offset by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Recovery of Medical Devices sales from the prior year&#8217;s negative COVID-19 impact</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Q3 2021 versus Q3 2020</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development increased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Portfolio progression in the Pharmaceutical business</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">In-Process Research and Development (IPR&amp;D)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the fiscal third quarter and fiscal nine months of 2021, the Company recorded a partial IPR&amp;D charge of $0.9 billion primarily related to expected development delays in the general surgery digital robotics platform (Ottava) acquired with the Auris Health acquisition in 2019. The impairment charge was calculated based on revisions to the discounted cash flow valuation model reflecting a delay of first in human procedures of approximately two years from the initial acquisition model assumption of the second half of 2022. The Company will continue to monitor the remaining $1.5 billion Ottava platform intangible asset as development program activities continue.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest (Income) Expense</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest (Income) Expense in the fiscal nine months of 2021 was a net interest expense of $83 million as compared to net interest expense of $16 million in the same period a year ago primarily due to reduced interest income. Interest (Income) Expense in the fiscal third quarter of 2021 was a net interest expense of $7 million as compared to $32 million in the same period a year ago primarily due to the benefit from net investment hedging. The balance of cash, cash equivalents and current marketable securities was $31.0&#160;billion at the end of the fiscal third quarter of 2021 as compared to $30.8 billion at the end of the fiscal third quarter of 2020. The Company&#8217;s debt position was $33.9 billion as of October&#160;3, 2021 as compared to $37.8 billion the same period a year ago. </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other (Income) Expense, Net*</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fiscal Nine months Q3 2021 versus Fiscal Nine months Q3 2020</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income)&#160;expense, net for the fiscal nine months of 2021 was flat as compared to the prior year primarily due to the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:49.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.146%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal Nine Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in Billions)(Income)/Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition, Integration and Divestiture Related</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation related</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring related</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit plan related</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other (Income) Expense, Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Q3 2021 versus Q3 2020</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income)&#160;expense, net for the fiscal third quarter of 2021 was unfavorable by $0.7 billion as compared to the prior year primarily due to the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:49.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.146%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal Third Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in Billions)(Income)/Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation related</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit plan related</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other (Income) Expense, Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Primarily related to divestiture gains of two pharmaceutical brands outside the U.S. in the fiscal nine months of 2021. Primarily related to a contingent consideration reversal related to the timing of certain developmental milestones associated with the Auris Health acquisition in the fiscal nine months of 2020.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Primarily related to talc and Risperdal in the fiscal third quarter and fiscal nine months of 2021. Primarily related to talc and the opioid litigation settlement in the fiscal third quarter and fiscal nine months of 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">*Other (income) expense, net is the account where the Company records gains and losses related to the sale and write-down of certain investments in equity securities held by Johnson &amp; Johnson Innovation - JJDC, Inc. (JJDC), unrealized gains and losses on investments, gains and losses on divestitures, certain transactional currency gains and losses, acquisition-related costs, litigation accruals and settlements, investment (income)/loss related to employee benefit plans, as well as royalty income.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before tax by segment of business for the fiscal nine months ended were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.970%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.334%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Before Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percent of Segment Sales</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 27, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,592&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,461&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,971&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expenses not allocated to segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,940&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,971&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,109&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amounts not allocated to segments include interest (income) expense and general corporate (income) expense</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consumer Health segment income before tax as a percent of sales in the fiscal nine months of 2021 was 8.7% versus 9.5% for the same period a year ago. The decline in the income before tax as a percent of sales in the fiscal nine months of 2021 as compared to the prior year was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Higher litigation expense, primarily talc ($1.5 billion in 2021 vs. $1.2 billion in 2020)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased brand marketing expense</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      &#160;&#160;&#160;&#160;partially offset by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Supply chain efficiencies</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment income before tax as a percent of sales in the fiscal nine months of 2021 was 36.6% versus 35.4% for the same period a year ago. The increase in the income before tax as a percent of sales for the fiscal nine months of 2021 as compared to the prior year was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Divestiture gains of $0.6 billion related to two pharmaceutical brands outside the U.S. in the fiscal nine months of 2021</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Lower litigation expense ($0.7 billion in 2021 primarily related to Risperdal vs. $1.0 billion in 2020 primarily related to opioid litigation settlement)</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partially offset by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Research &amp; Development investment in the COVID-19 vaccine net of governmental reimbursements and general portfolio progression </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medical Devices segment income before tax as a percent of sales in the fiscal nine months of 2021 was 18.8% versus 16.4% for the same period a year ago. The increase in the income before tax as a percent of sales for the fiscal nine months of 2021 was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Recovery of prior year COVID-19 production related slow downs and related inventory impacts</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Overall expense leveraging resulting from the Medical Devices sales recovery</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partially offset by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">A contingent consideration reversal of approximately $1.1 billion in the fiscal nine months of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">A higher IPR&amp;D charge of $0.8 billion ($0.9 billion in 2021 related to the general surgery offering in digital robotics (Ottava) acquired with the Auris Health acquisition in 2019) </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before tax by segment of business for the fiscal third quarters were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Before Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percent of Segment Sales</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 27, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,046&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,640&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,338&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,082&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expenses not allocated to segments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,849&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,401&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,338&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,082&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consumer Health Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consumer Health segment income/(loss) before tax as a percent of sales in the fiscal third quarter of 2021 was a negative  17.2% versus 5.4% for the same period a year ago. The decrease in the income before tax as a percent of sales in the fiscal third quarter of 2021 as compared to the prior year was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Higher litigation expense, primarily associated with talc ($1.4 billion in 2021 vs. $0.5 billion in 2020)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased brand marketing expense</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      &#160;&#160;&#160;&#160;partially offset by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Supply chain efficiencies </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment income before tax as a percent of sales in the fiscal third quarter of 2021 was 32.8% versus 30.1% for the same period a year ago. The increase in the income before tax as a percent of sales for the fiscal third quarter of 2021 as compared to the prior year was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lower litigation expense ($0.8 billion in 2021 primarily related to Risperdal vs. $1.0 billion in 2020 primarily related to opioid litigation settlement)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Higher gains on securities ($0.1 billion in 2021 vs. $0.0 billion in 2020)</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research &amp; Development investment for general portfolio progression </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medical Devices Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medical Devices segment income before tax as a percent of sales in the fiscal third quarter of 2021 was 6.4% versus 16.4% for the same period a year ago. The decrease in the income before tax as a percent of sales for the fiscal third quarter was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">A higher IPR&amp;D charge of $0.8 billion ($0.9 billion in 2021 related to the general surgery offering in digital robotics (Ottava) acquired with the Auris Health acquisition in 2019) </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">A contingent consideration reversal of approximately $0.2 billion in the fiscal third quarter of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partially offset by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Recovery of prior year COVID-19 production related slow downs and related inventory impacts</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Overall expense leveraging resulting from the Medical Devices sales recovery</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">                                                          </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal second quarter of 2018, the Company announced plans to implement actions across its Global Supply Chain that are intended to enable the Company to focus resources and increase investments in critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio of the future, enhance agility and drive growth. The Company expects these supply chain actions will include expanding its use of strategic collaborations, and bolstering its initiatives to reduce complexity, improving cost-competitiveness, enhancing capabilities and optimizing its network.&#160;Discussions regarding specific future actions are ongoing and are subject to all relevant consultation requirements before they are finalized. In total, the Company expects these actions to generate approximately $0.6 to $0.8 billion in annual </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pre-tax cost savings that will be substantially delivered by 2022. The Company expects to record pre-tax restructuring charges of approximately $1.9 to $2.3 billion. In the fiscal third quarter of 2021, the Company recorded a pre-tax charge of $121 million, which is included on the following lines of the Consolidated Statement of Earnings, $60 million in restructuring, $18 million in cost of products sold and $43 million in other (income) expense, net. In the fiscal third quarter of 2020, the Company recorded a pre-tax charge of $130 million, which is included on the following lines of the Consolidated Statement of Earnings, $68 million in restructuring, $32 million in cost of products sold and $30 million in other (income) expense, net. In the fiscal nine months of 2021, the Company recorded a pre-tax charge of $333 million, which is included on the following lines of the Consolidated Statement of Earnings, $169 million in restructuring, $65 million in cost of products sold and $99 million in other (income) expense, net. In the fiscal nine months of 2020, the Company recorded a pre-tax charge of $363 million, which is included on the following lines of the Consolidated Statement of Earnings, $187 million in restructuring, $69 million in cost of products sold and $107 million in other (income) expense, net. Restructuring charges of approximately $1.6 billion have been recorded since the restructuring was announced.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;12 to the Consolidated Financial Statements for additional details related to the restructuring.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provision for Taxes on Income</span></div><div><span><br/></span></div><div style="margin-top:2.7pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For discussion related to the fiscal nine months of 2021 provision for taxes refer to Note&#160;5 to the Consolidated Financial Statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In the fiscal second quarter of 2021, the Company reorganized the ownership structure of certain wholly-owned international subsidiaries. As part of this reorganization, the Company increased the tax basis of certain assets to fair value in accordance with applicable local regulations.  Accordingly, the Company recorded a local deferred tax benefit of approximately $2.3 billion, which was partially offset by a related increase in the U.S. GILTI deferred tax liability of approximately $1.7 billion. The net impact of this restructuring was approximately $0.6 billion net benefit or a 3.4% decrease to the 2021 year-to-date effective tax rate. This restructuring is not expected to have material impact to the Company&#8217;s future effective tax rate. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LIQUIDITY AND CAPITAL RESOURCES </span></div><div><span><br/></span></div><div style="text-align:center"><img src="jnj-20211003_g11.jpg" alt="jnj-20211003_g11.jpg" style="height:184px;margin-bottom:5pt;vertical-align:text-bottom;width:193px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><img src="jnj-20211003_g12.jpg" alt="jnj-20211003_g12.jpg" style="height:184px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><img src="jnj-20211003_g13.jpg" alt="jnj-20211003_g13.jpg" style="height:184px;margin-bottom:5pt;vertical-align:text-bottom;width:193px"/></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash Flows</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents were $17.6 billion at the end of the fiscal third quarter of 2021 as compared with $14.0&#160;billion at the end of fiscal year 2020. The primary sources and uses of cash that contributed to the $3.6&#160;billion increase were:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:21.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.436%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q4 2020 Cash and cash equivalents balance</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">cash generated from operating activities</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net cash used by investing activities</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net cash used by financing activities</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">effect of exchange rate and rounding</span></td></tr><tr><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3 2021 Cash and cash equivalents balance</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company had $13.4 billion in marketable securities at the end of the fiscal third quarter of 2021 and $11.2 billion at the end of fiscal year 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow from operations of $17.7&#160;billion was the result of:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Earnings</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation, asset write-downs partially offset by the deferred tax provision, net gain on sale of assets/businesses and credit losses and accounts receivable allowances</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a decrease in other current and non-current liabilities</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">an increase in accounts receivable and inventories </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">an increase accounts payable and accrued liabilities</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a decrease in other current and non-current assets</span></td></tr><tr><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Flow from operations</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing activities use of $3.3 billion of cash was primarily used for:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">additions to property, plant and equipment</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">proceeds from the disposal of assets/businesses, net</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net purchases of investments</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">credit support agreements activity, net</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (primarily licenses and milestones) and rounding</span></td></tr><tr><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used for investing activities</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities use of $10.6 billion of cash was primarily used for: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">dividends to shareholders </span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">repurchase of common stock</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net repayment of short and long term debt</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">proceeds from stock options exercised/employee withholding tax on stock awards, net</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">credit support agreements activity, net</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">other and rounding</span></td></tr><tr><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used for financing activities</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has access to substantial sources of funds at numerous banks worldwide. In September 2021, the Company secured a new 364-day Credit Facility. Total credit available to the Company approximates $10&#160;billion, which expires on September&#160;8, 2022.  Interest charged on borrowings under the credit line agreement is based on either Term Secured Overnight Financing Rate (SOFR) Reference Rate or other applicable market rates as allowed under the terms of the agreement, plus applicable margins. Commitment fees under the agreement are not material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the fiscal third quarter of 2021, the Company's notes payable and long-term debt was in excess of cash, cash equivalents and marketable securities. As of October&#160;3, 2021, the net debt position was $2.9 billion as compared to the prior year of $7.0 billion. Considering recent market conditions and the on-going COVID-19 crisis, the Company has re-evaluated its operating cash flows and liquidity profile and does not foresee any significant incremental risk. The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the Company's </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">approximate $1.2 billion in contractual supply commitments associated with its development of the COVID-19 vaccine, the agreement to settle opioid litigation for $5 billion and the establishment of the $2 billion trust for talc related liabilities (See Note 11 to the Consolidated Financial Statements for additional details). In addition, the Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable. Additionally, as a result of the Tax Cuts and Jobs Act (TCJA), the Company has access to its cash outside the U.S. at a significantly reduced cost. During the fiscal third quarter of 2021, in accordance with the terms of the agreement associated with the acquisition of Actelion, the Company's undrawn credit facility with Idorsia was terminated. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the fiscal nine months of 2021, the Company paid approximately $1.7 billion to the U.S. Treasury which included $0.8 billion related to the current installment due on foreign undistributed earnings as part of the TCJA (see Note 1 to the Consolidated Financial Statements in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January 3, 2021) and $0.9 billion primarily related to the normal estimated payment for the fiscal first, second and third quarters of 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2021, the Board of Directors declared a regular cash dividend of $1.06 per share, payable on September 7, 2021 to shareholders of record as of August 24, 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 21, 2021, the Board of Directors declared a regular cash dividend of $1.06 per share, payable on December 7, 2021 to shareholders of record as of November 23, 2021. The Company expects to continue the practice of paying regular quarterly cash dividends.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OTHER INFORMATION</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New Accounting Pronouncements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 1 to the Consolidated Financial Statements for new accounting pronouncements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Economic and Market Factors</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 considerations and business continuity</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has considered various internal and external factors in assessing the potential impact of COVID-19 on its business and financial results based upon information available at this time, as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Operating Model: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a diversified business model across the healthcare industry with flexibility designed into its manufacturing, research and development clinical operations and commercial capabilities. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Supply Chain: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to leverage its global manufacturing footprint and dual-source capabilities while closely monitoring and maintaining critical inventory at major distribution centers away from high-risk areas to ensure adequate and effective distribution. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Business Continuity: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The robust, active business continuity plans across the Company's network have been instrumental in preparing the Company for events like COVID-19 and the ability to meet the majority of patient and consumer needs remains uninterrupted.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Workforce: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has put procedures in place to protect its essential workforce in manufacturing, distribution, commercial and research operations while ensuring appropriate remote working protocols have been established for other employees. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Liquidity:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's high-quality credit rating allows the Company superior access to the financial capital markets for the foreseeable future. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Domestic and Foreign Legislation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will continue to assess and evaluate the on-going global legislative efforts to combat the COVID-19 impact on economies and the sectors in which it participates. Currently, the recent legislative acts put in place are not expected to have a material impact on the Company&#8217;s operations. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In fiscal 2020 and 2021, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid for services to be delivered</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">and contractually obligated to be paid to these contract manufacturing organizations of approximately $1.2 billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to evaluate and monitor both its internal and external supply arrangements, including its contract with Emergent BioSolutions and related production activities at its Bayview, Maryland facility. The Company  has established a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">global vaccine supply network, where, in addition to its internal manufacturing site in Leiden, the Netherlands, ten other manufacturing sites will be involved in the production of vaccine across different countries and continents. The Company does not believe that a disruption at a vaccine manufacturing site, or the resulting delay would have a material financial impact on the Company&#8217;s consolidated financial statements or results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in certain countries where the economic conditions continue to present significant challenges. The Company continues to monitor these situations and take appropriate actions. Inflation rates and currency exchange rates continue to have an effect on worldwide economies and, consequently, on the way the Company operates. The Company has accounted for operations in Venezuela and Argentina as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. This did not have a material impact on the Company's results in the period. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In June 2016, the United Kingdom (U.K.) held a referendum in which voters approved an exit from the European Union (E.U.), commonly referred to as &#8220;Brexit&#8221;. The U.K. officially exited the E.U. on January 31, 2020, however, there was a transition period  to allow time to agree the terms of a new trade deal. On December 30, 2020, the U.K., E.U. and the European Atomic Energy Community (Euratom) signed the EU&#8211;UK Trade and Cooperation Agreement (TCA). Over the last few years, Brexit has created global political and economic uncertainty and has led to volatility in exchange rates and interest rates, additional cost containment by third-party payors and changes in regulations. While the UK and EU have now agreed on a future trade and cooperation agreement, it is still unclear what the ultimate financial, trade, regulatory and legal implications the withdrawal of the U.K. from the E.U. will have. However, the Company currently does not believe that these and other related effects will have a material impact on the Company&#8217;s consolidated financial position or operating results. As of October&#160;3, 2021, and for the fiscal nine months, the business of the Company&#8217;s U.K. subsidiaries represented less than 6% of the Company&#8217;s consolidated assets and less than 3% of the fiscal nine months revenues. </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Governments around the world consider various proposals to make changes to tax laws and regulations, which may include increasing or decreasing existing statutory tax rates. A change in statutory tax rate in any country would result in the revaluation of the Company&#8217;s deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted.&#160; This change would result in an expense or benefit recorded to the Company&#8217;s Consolidated Statement of Earnings.&#160; The Company closely monitors these proposals as they arise in the countries where it operates. Changes to the statutory tax rate may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company faces various worldwide health care changes that may continue to result in pricing pressures that include health care cost containment and government legislation relating to sales, promotions and reimbursement of health care products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the behavior and spending patterns of purchasers of health care products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and foregoing health care insurance coverage, may continue to impact the Company&#8217;s businesses.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also operates in an environment increasingly hostile to intellectual property rights. Firms have filed Abbreviated New Drug Applications or Biosimilar Biological Product Applications with the FDA or otherwise challenged the coverage and/or validity of the Company's patents, seeking to market generic or biosimilar forms of many of the Company&#8217;s key pharmaceutical products prior to expiration of the applicable patents covering those products. In the event the Company is not successful in defending the patent claims challenged in the resulting lawsuits, generic or biosimilar versions of the products at issue will be introduced to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset. There is also a risk that one or more competitors could launch a generic or biosimilar version of the product at issue following regulatory approval even though one or more valid patents are in place. </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="if410ee6e03c8456f86a9fee997f08e65_109"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;3 &#8212; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no material change in the Company&#8217;s assessment of its sensitivity to market risk since its presentation set forth in Item&#160;7A, &#8220;Quantitative and Qualitative Disclosures About Market Risk,&#8221; in its Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div id="if410ee6e03c8456f86a9fee997f08e65_112"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;4 &#8212; CONTROLS AND PROCEDURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure controls and procedures. At the end of the period covered by this report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Company&#8217;s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is accumulated and communicated to the Company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Alex Gorsky, Chairman and Chief Executive Officer, and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs.&#160;Gorsky and Wolk concluded that, as of the end of the period covered by this report, the Company&#8217;s disclosure controls and procedures were effective.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Internal control. During the period covered by this report, there were no changes in the Company&#8217;s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. The Company has not experienced any material impact to its internal controls over financial reporting despite the fact that most of its employees are working remotely due to the COVID-19 pandemic. The Company proactively took actions to re-evaluate and refine its financial reporting process through additional monitoring controls to provide reasonable assurance that the financial results are reported accurately and timely. The Company continues to monitor and assess the effectiveness of the design and operation of its disclosure controls and procedures. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="if410ee6e03c8456f86a9fee997f08e65_115"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part II &#8212; OTHER INFORMATION</span></div><div><span><br/></span></div><div id="if410ee6e03c8456f86a9fee997f08e65_118"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;1 &#8212; LEGAL PROCEEDINGS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this item is incorporated herein by reference to Note 11 included in Part&#160;I, Item&#160;1, Financial Statements (unaudited) &#8212; Notes to Consolidated Financial Statements.</span></div><div><span><br/></span></div><div id="if410ee6e03c8456f86a9fee997f08e65_121"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;2 &#8212; UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;Purchases of Equity Securities by the Issuer and Affiliated Purchasers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information with respect to Common Stock purchases by the Company during the fiscal third quarter of 2021. Common stock purchases on the open market are made as part of a systematic plan to meet the needs of the Company's compensation programs. The repurchases below also include the stock-for-stock option exercises that settled in the fiscal third quarter.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:497.25pt"><tr><td style="width:1.0pt"></td><td style="width:210.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:84.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:57pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal Month Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Shares Purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Avg. Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs</span></td></tr><tr style="height:18pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 5, 2021 through August 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2, 2021 through August 29, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,220,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 30, 2021 through October 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,220,897&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;During the fiscal third quarter of 2021, the Company repurchased an aggregate of 2,220,897 shares of Johnson &amp; Johnson Common Stock in open-market transactions, all of which were purchased as part of a systematic plan to meet the needs of the Company&#8217;s compensation programs.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="if410ee6e03c8456f86a9fee997f08e65_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;6 &#8212; EXHIBITS</span></div><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20213qex311ceocertificati.htm">Exhibit&#160;31.1  </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certification of Chief Executive Officer under Rule&#160;13a-14(a) of the Securities Exchange Act pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 &#8212; Filed with this document.</span></div><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20213qex312cfocertificati.htm">Exhibit&#160;31.2 </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certification of Chief Financial Officer under Rule&#160;13a-14(a) of the Securities Exchange Act pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 &#8212; Filed with this document.</span></div><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20213qex321ceocertificati.htm">Exhibit&#160;32.1 </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certification of Chief Executive Officer pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 &#8212; Furnished with this document.</span></div><div style="text-indent:11.25pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20213q2021ex322cfocertifi.htm">Exhibit&#160;32.2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certification of Chief Financial Officer pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 &#8212; Furnished with this document.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 101: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instance Document - the instance document does not appear in the Interactive Data File because its                XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Document</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 104:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File&#8211;&#8211;the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="if410ee6e03c8456f86a9fee997f08e65_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURES</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:51.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.340%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JOHNSON &amp; JOHNSON<br/>(Registrant)&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: October 29, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By /s/ J. J. WOLK</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. J. WOLK</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer (Principal Financial Officer)&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: October 29, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By /s/&#160;R. J. DECKER Jr.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. J. DECKER Jr.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controller (Principal Accounting Officer)&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a20213qex311ceocertificati.htm
<DESCRIPTION>EX-31.1 CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib1d47803882444ec86ee194bf6ad1352_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT </font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Alex Gorsky, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended October&#160;3, 2021 (the &#8220;report&#8221;) of Johnson &#38; Johnson (the &#34;Company&#34;)&#59; </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The Company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the Company and have&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)  Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)  Disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;5.  The Company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.</font></div><div style="padding-left:288pt"><font><br></font></div><div style="padding-left:288pt"><font><br></font></div><div style="padding-left:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Alex Gorsky</font></div><div style="padding-left:288pt"><font style="color:#7d7d7d;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">__________________________</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alex Gorsky</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;   October&#160;29, 2021</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a20213qex312cfocertificati.htm
<DESCRIPTION>EX-31.2 CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ie83b6ab5cdf04ce4bf1d6f1dfb6474de_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joseph J. Wolk, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended October&#160;3, 2021 (the &#8220;report&#8221;) of Johnson &#38; Johnson (the &#34;Company&#34;)&#59; </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The Company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the Company and have&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)  Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)  Disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;5.  The Company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Joseph J. Wolk</font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">______________________________</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Joseph J. Wolk</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; October&#160;29, 2021</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a20213qex321ceocertificati.htm
<DESCRIPTION>EX-32.1 CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i376a5f83d49148b6b2147eb1305ba670_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;padding-right:38.25pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 32.1</font></div><div style="margin-top:18pt;padding-left:19.12pt;padding-right:19.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="margin-top:18pt;padding-left:19.12pt;padding-right:19.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:18pt;padding-left:19.12pt;padding-right:19.12pt;text-align:center"><font><br></font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The undersigned, Alex Gorsky, the Chief Executive Officer of Johnson &#38; Johnson, a New Jersey corporation (the &#8220;Company&#8221;), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge&#58;</font></div><div style="margin-top:11pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Company's Quarterly Report on Form 10-Q for the quarterly period ended October 3, 2021 (the&#8220;Report&#8221;) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934&#59; and</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="21" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Alex Gorsky</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alex Gorsky&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:1pt;padding-left:22.5pt;padding-right:38.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58;  October&#160;29, 2021</font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt"><font><br></font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This certification is being furnished to the SEC with this Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section.</font></div><div style="margin-top:11.25pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160; </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>a20213q2021ex322cfocertifi.htm
<DESCRIPTION>EX-32.2 CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id29a998032654676bfb698d239cefc5a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;padding-right:38.25pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 32.2</font></div><div style="margin-top:18pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="margin-top:18pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:18pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font><br></font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The undersigned, Joseph J. Wolk, the Chief Financial Officer of Johnson &#38; Johnson, a New Jersey corporation (the &#8220;Company&#8221;), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge&#58;</font></div><div style="padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Company's Quarterly Report on Form 10-Q for the quarterly period ended October 3, 2021 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934&#59; and</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="21" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph J. Wolk</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph J. Wolk&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:1pt;padding-left:22.5pt;padding-right:38.25pt;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Dated&#58;  October&#160;29, 2021</font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-indent:-20.25pt"><font><br></font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This certification is being furnished to the SEC with this Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section.</font></div><div style="margin-top:11.25pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160; </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>jnj-20211003.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:90dc118c-6428-4338-8b4d-8015054a0548,g:65f17fdb-8375-41f4-bf95-c047d59b03b3-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:jnj="http://www.jnj.com/20211003" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.jnj.com/20211003">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20211003_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20211003_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20211003_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20211003_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.jnj.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEarnings" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings">
        <link:definition>1003004 - Statement - Consolidated Statements of Earnings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>1004005 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncomeParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical">
        <link:definition>1005006 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquity" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity">
        <link:definition>1006007 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquityParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical">
        <link:definition>1007008 - Statement - Consolidated Statements of Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1008009 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.jnj.com/role/Inventories">
        <link:definition>2103102 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.jnj.com/role/InventoriesTables">
        <link:definition>2304301 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.jnj.com/role/InventoriesDetails">
        <link:definition>2405401 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwill" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwill">
        <link:definition>2106103 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillTables" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables">
        <link:definition>2307302 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails">
        <link:definition>2408402 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillGoodwillBySegmentDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails">
        <link:definition>2409403 - Disclosure - Intangible Assets and Goodwill - Goodwill By Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillNarrativeDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails">
        <link:definition>2410404 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails">
        <link:definition>2411405 - Disclosure - Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.jnj.com/role/FairValueMeasurements">
        <link:definition>2112104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.jnj.com/role/FairValueMeasurementsTables">
        <link:definition>2313303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2414406 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofDerivativeActivityDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails">
        <link:definition>2415407 - Disclosure - Fair Value Measurements - Summary of Derivative Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDerivativesBalanceSheetLocationDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails">
        <link:definition>2416408 - Disclosure - Fair Value Measurements - Derivatives, Balance Sheet Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails">
        <link:definition>2417409 - Disclosure - Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails">
        <link:definition>2418410 - Disclosure - Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails">
        <link:definition>2419411 - Disclosure - Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails">
        <link:definition>2420412 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails">
        <link:definition>2421413 - Disclosure - Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails">
        <link:definition>2422414 - Disclosure - Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails">
        <link:definition>2423415 - Disclosure - Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.jnj.com/role/IncomeTaxes">
        <link:definition>2124105 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.jnj.com/role/IncomeTaxesDetails">
        <link:definition>2425416 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlans" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlans">
        <link:definition>2126106 - Disclosure - Pensions and Other Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansTables" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables">
        <link:definition>2327304 - Disclosure - Pensions and Other Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails">
        <link:definition>2428417 - Disclosure - Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails">
        <link:definition>2429418 - Disclosure - Pensions and Other Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncome" roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome">
        <link:definition>2130107 - Disclosure - Accumulated Other Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeTables" roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables">
        <link:definition>2331305 - Disclosure - Accumulated Other Comprehensive Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeDetails" roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails">
        <link:definition>2432419 - Disclosure - Accumulated Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.jnj.com/role/EarningsPerShare">
        <link:definition>2133108 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.jnj.com/role/EarningsPerShareTables">
        <link:definition>2334306 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.jnj.com/role/EarningsPerShareDetails">
        <link:definition>2435420 - Disclosure - Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreas" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas">
        <link:definition>2136109 - Disclosure - Segments of Business and Geographic Areas</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasTables" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables">
        <link:definition>2337307 - Disclosure - Segments of Business and Geographic Areas (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails">
        <link:definition>2438421 - Disclosure - Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails">
        <link:definition>2439422 - Disclosure - Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails">
        <link:definition>2440423 - Disclosure - Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestitures" roleURI="http://www.jnj.com/role/AcquisitionsandDivestitures">
        <link:definition>2141110 - Disclosure - Acquisitions and Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresNarrativeDetails" roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails">
        <link:definition>2442424 - Disclosure - Acquisitions and Divestitures - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails" roleURI="http://www.jnj.com/role/BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails">
        <link:definition>2443425 - Disclosure - Business Combinations and Divestitures - Schedule of Pro Forma Results (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedings" roleURI="http://www.jnj.com/role/LegalProceedings">
        <link:definition>2144111 - Disclosure - Legal Proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsDetails" roleURI="http://www.jnj.com/role/LegalProceedingsDetails">
        <link:definition>2445426 - Disclosure - Legal Proceedings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://www.jnj.com/role/Restructuring">
        <link:definition>2146112 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringTables" roleURI="http://www.jnj.com/role/RestructuringTables">
        <link:definition>2347308 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringNarrativeDetails" roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails">
        <link:definition>2448427 - Disclosure - Restructuring - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringScheduleofRestructuringReserveDetails" roleURI="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails">
        <link:definition>2449428 - Disclosure - Restructuring - Schedule of Restructuring Reserve (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="jnj_RestructuringandRelatedCostDurationofRestructuringPlan" abstract="false" name="RestructuringandRelatedCostDurationofRestructuringPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jnj_VerbSurgicalInc.Member" abstract="true" name="VerbSurgicalInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_RISPERDALCONSTAMember" abstract="true" name="RISPERDALCONSTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_PercentageChangeInSalesByGeographicArea" abstract="false" name="PercentageChangeInSalesByGeographicArea" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_RestructuringandRelatedCostExpectedFutureSavings" abstract="false" name="RestructuringandRelatedCostExpectedFutureSavings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_GENERALMember" abstract="true" name="GENERALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_NotesDuePeriodFifteenMember" abstract="true" name="NotesDuePeriodFifteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A2.625Notesdue2025Member" abstract="true" name="A2.625Notesdue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_StelaraMember" abstract="true" name="StelaraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_EquityInvestmentRollForward" abstract="true" name="EquityInvestmentRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_LossContingencyEstimateOfAdditionalPossibleLoss" abstract="false" name="LossContingencyEstimateOfAdditionalPossibleLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" abstract="true" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_SURGICALMember" abstract="true" name="SURGICALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A4.85Notesdue2041Member" abstract="true" name="A4.85Notesdue2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_RisperdalMember" abstract="true" name="RisperdalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_SupplyChainMember" abstract="true" name="SupplyChainMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid" abstract="false" name="RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jnj_StateLevelJurisdictionMember" abstract="true" name="StateLevelJurisdictionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" abstract="true" name="ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="jnj_COVID19Member" abstract="true" name="COVID19Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_LegalProceedingTextualsAbstract" abstract="true" name="LegalProceedingTextualsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_ZYTIGAMember" abstract="true" name="ZYTIGAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" abstract="false" name="ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_LitigationSettlementByCompaniesAxis" abstract="true" name="LitigationSettlementByCompaniesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="jnj_A4.50Debenturesdue2040Member" abstract="true" name="A4.50Debenturesdue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OtherInfectiousDiseasesMember" abstract="true" name="OtherInfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_Numberofpatientsinsettlement" abstract="false" name="Numberofpatientsinsettlement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_A3.500Notesdue2048Member" abstract="true" name="A3.500Notesdue2048Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_SalesRevenueGoodsNetPercentToSales" abstract="false" name="SalesRevenueGoodsNetPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_OTCMember" abstract="true" name="OTCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OrthopaedicsMember" abstract="true" name="OrthopaedicsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" abstract="false" name="ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_OtherNonOperatingIncomeExpensePercentToSales" abstract="false" name="OtherNonOperatingIncomeExpensePercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_A2.95Notesdue2027Member" abstract="true" name="A2.95Notesdue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_SellingGeneralAndAdministrativeExpensePercentToSales" abstract="false" name="SellingGeneralAndAdministrativeExpensePercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_PatentsAndTrademarksMember" abstract="true" name="PatentsAndTrademarksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A0.250NotesDue2022Member" abstract="true" name="A0.250NotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" abstract="false" name="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain" abstract="false" name="CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_BabyCareMember" abstract="true" name="BabyCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_PinnacleAcetabularCupSystemMember" abstract="false" name="PinnacleAcetabularCupSystemMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_NetIncomeAttributableToParentPercentToSales" abstract="false" name="NetIncomeAttributableToParentPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" abstract="false" name="SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_A1.150NotesDue2028Member" abstract="true" name="A1.150NotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_SalesBySegmentOfBusinessTableTextBlock" abstract="false" name="SalesBySegmentOfBusinessTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="jnj_IncomeTaxTextualsAbstract" abstract="true" name="IncomeTaxTextualsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_PercentageChangeInSalesBySegmentOfBusiness" abstract="false" name="PercentageChangeInSalesBySegmentOfBusiness" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue" abstract="false" name="LossContingencyDamagesAwardedAdditionalReimbursementValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_A3.70Notesdue2046Member" abstract="true" name="A3.70Notesdue2046Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_InterestExpensePercentToSales" abstract="false" name="InterestExpensePercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_CostOfGoodsSoldPercentToSales" abstract="false" name="CostOfGoodsSoldPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_PercentageChangeInOperatingIncomeLoss" abstract="false" name="PercentageChangeInOperatingIncomeLoss" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_AurisHealthMember" abstract="true" name="AurisHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_KNEESMember" abstract="true" name="KNEESMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A210NotesDue2040Member" abstract="true" name="A210NotesDue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OTHERNEUROSCIENCEMember" abstract="true" name="OTHERNEUROSCIENCEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_AmountPrepaidAndDueToManufacturers" abstract="false" name="AmountPrepaidAndDueToManufacturers" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_PROCRITEPREXMember" abstract="true" name="PROCRITEPREXMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_AssetWriteoffMember" abstract="true" name="AssetWriteoffMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A4.375Notesdue2033Member" abstract="true" name="A4.375Notesdue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_PurchasedInProcessResearchAndDevelopmentMember" abstract="true" name="PurchasedInProcessResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" abstract="false" name="ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" abstract="false" name="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_MedicalDevicesMember" abstract="true" name="MedicalDevicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_CardiovascularMetabolismOtherMember" abstract="true" name="CardiovascularMetabolismOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A0550NotesDue2025Member" abstract="true" name="A0550NotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A2.05Notesdue2023Member" abstract="true" name="A2.05Notesdue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_TremfyaMember" abstract="true" name="TremfyaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ImmunologyMember" abstract="true" name="ImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A095NotesDue2027Member" abstract="true" name="A095NotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A2.900Notesdue2028Member" abstract="true" name="A2.900Notesdue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_UPTRAVIMember" abstract="true" name="UPTRAVIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ConsumerMember" abstract="true" name="ConsumerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ADVANCEDMember" abstract="true" name="ADVANCEDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A2.45Notesdue2026Member" abstract="true" name="A2.45Notesdue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ProductLiabilityContingencyNumberOfClaimant" abstract="false" name="ProductLiabilityContingencyNumberOfClaimant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_GrossProfitPercentToSales" abstract="false" name="GrossProfitPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" abstract="true" name="OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_LegalJurisdictionDomain" abstract="true" name="LegalJurisdictionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_BeautyMember" abstract="true" name="BeautyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_LossContingencyNumberOfVotesInFavor" abstract="false" name="LossContingencyNumberOfVotesInFavor" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_A5.85Debenturesdue2038Member" abstract="true" name="A5.85Debenturesdue2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OPSUMITMember" abstract="true" name="OPSUMITMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" abstract="false" name="DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_A3.75Notesdue2047Member" abstract="true" name="A3.75Notesdue2047Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" abstract="true" name="PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_TRAUMAMember" abstract="true" name="TRAUMAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_UNITEDSTATESExportsMember" abstract="true" name="UNITEDSTATESExportsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" abstract="false" name="FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_NeuroscienceMember" abstract="true" name="NeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A2250NotesDue2050Member" abstract="true" name="A2250NotesDue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A4.95Debenturesdue2033Member" abstract="true" name="A4.95Debenturesdue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_FederalLevelJurisdictionMember" abstract="true" name="FederalLevelJurisdictionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" abstract="false" name="EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_EvraAndDoxilMember" abstract="true" name="EvraAndDoxilMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" abstract="false" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_LossContingencyReserveEstablishedWithinTrust" abstract="false" name="LossContingencyReserveEstablishedWithinTrust" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" abstract="false" name="OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ERLEADAMember" abstract="true" name="ERLEADAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OtherIncomeExpenseNetMember" abstract="true" name="OtherIncomeExpenseNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A2450NotesDue2060Member" abstract="true" name="A2450NotesDue2060Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ExcessOfFairValueOverCarryingValueOfDebt" abstract="false" name="ExcessOfFairValueOverCarryingValueOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_InfectiousDiseasesMember" abstract="true" name="InfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_InterestIncomeExpenseNetMember" abstract="true" name="InterestIncomeExpenseNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OtherMember" abstract="true" name="OtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_HIPSMember" abstract="true" name="HIPSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A1300NotesDue2030Member" abstract="true" name="A1300NotesDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="jnj_LossContingencyNumberOfVotesRejected" abstract="false" name="LossContingencyNumberOfVotesRejected" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_A3.400Notesdue2038Member" abstract="true" name="A3.400Notesdue2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" abstract="false" name="IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_InterventionalSolutionsMember" abstract="true" name="InterventionalSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A5.50NotesDue2024Member" abstract="true" name="A5.50NotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_A6.73Debenturesdue2023Member" abstract="true" name="A6.73Debenturesdue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" abstract="false" name="CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_OralCareMember" abstract="true" name="OralCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_TalcMember" abstract="true" name="TalcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_WesternHemisphereExcludingUSMember" abstract="true" name="WesternHemisphereExcludingUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_VisionMember" abstract="true" name="VisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_EquityInvestmentswithReadilyDeterminableValueMember" abstract="true" name="EquityInvestmentswithReadilyDeterminableValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_BabyPowderMember" abstract="true" name="BabyPowderMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OtherImmunologyMember" abstract="true" name="OtherImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_AsrMember" abstract="false" name="AsrMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_XareltoMember" abstract="true" name="XareltoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_EquityFairValueAdjustmentImpairmentLoss" abstract="false" name="EquityFairValueAdjustmentImpairmentLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_PharmaceuticalMember" abstract="true" name="PharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" abstract="false" name="ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_WoundCareandOtherMember" abstract="true" name="WoundCareandOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_CONTACTLENSESOTHERMember" abstract="true" name="CONTACTLENSESOTHERMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_SurgicalMeshProductsMarketingMember" abstract="true" name="SurgicalMeshProductsMarketingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent" abstract="false" name="FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_A1.650NotesDue2035Member" abstract="true" name="A1.650NotesDue2035Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_CONCERTAMethylphenidateMember" abstract="true" name="CONCERTAMethylphenidateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_DARZALEXMember" abstract="true" name="DARZALEXMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" abstract="true" name="EquityInvestmentswithoutReadilyDeterminableValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_InvokanaMember" abstract="true" name="InvokanaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" abstract="false" name="CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DePuyASRU.S.Member" abstract="true" name="DePuyASRU.S.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_PhysiomeshMember" abstract="true" name="PhysiomeshMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A3.55Notesdue2036Member" abstract="true" name="A3.55Notesdue2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_WomensHealthMember" abstract="true" name="WomensHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A3.625Notesdue2037Member" abstract="true" name="A3.625Notesdue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ContactLensesMember" abstract="true" name="ContactLensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OncologyMember" abstract="true" name="OncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ResearchAndDevelopmentInProcessPercentToSales" abstract="false" name="ResearchAndDevelopmentInProcessPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_A3.375Notesdue2023Member" abstract="true" name="A3.375Notesdue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_SimponiSimponiAriaMember" abstract="true" name="SimponiSimponiAriaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_EDURANTrilpivirineMember" abstract="true" name="EDURANTrilpivirineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" abstract="true" name="INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A4.50Notesdue2043Member" abstract="true" name="A4.50Notesdue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_PulmonaryHypertensionMember" abstract="true" name="PulmonaryHypertensionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_INVOKANAINVOKAMETMember" abstract="true" name="INVOKANAINVOKAMETMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_SurgeryMember" abstract="true" name="SurgeryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_Restructuringchargepercenttosales" abstract="false" name="Restructuringchargepercenttosales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_PelvicMeshesMember" abstract="false" name="PelvicMeshesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_LegalJurisdictionAxis" abstract="true" name="LegalJurisdictionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="jnj_LitigationSettlementByCompaniesDomain" abstract="true" name="LitigationSettlementByCompaniesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_RemicadeMember" abstract="true" name="RemicadeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_AsiaPacificAfricaMember" abstract="true" name="AsiaPacificAfricaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A0.650NotesDue2024Member" abstract="true" name="A0.650NotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A6.95Notesdue2029Member" abstract="true" name="A6.95Notesdue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_IMBRUVICAMember" abstract="true" name="IMBRUVICAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" abstract="false" name="IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_IncomeTaxExpenseBenefitPercentToSales" abstract="false" name="IncomeTaxExpenseBenefitPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_AccruedRebatesReturnsAndPromotions" abstract="false" name="AccruedRebatesReturnsAndPromotions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_OpioidMember" abstract="true" name="OpioidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A5.95Notesdue2037Member" abstract="true" name="A5.95Notesdue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OtherOncologyMember" abstract="true" name="OtherOncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_BermekimabMember" abstract="true" name="BermekimabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_SPINEOTHERMember" abstract="true" name="SPINEOTHERMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_InvestmentIncomeInterestPercentToSales" abstract="false" name="InvestmentIncomeInterestPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>jnj-20211003_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:90dc118c-6428-4338-8b4d-8015054a0548,g:65f17fdb-8375-41f4-bf95-c047d59b03b3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="jnj-20211003.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2735d4d4-1913-4f29-b1e7-5bcf999caa8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_611b93e1-34c4-430f-bb2f-6e34c067bbb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2735d4d4-1913-4f29-b1e7-5bcf999caa8d" xlink:to="loc_us-gaap_Liabilities_611b93e1-34c4-430f-bb2f-6e34c067bbb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fc83d216-4041-4f4e-a4da-4ea0d0cc2c76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2735d4d4-1913-4f29-b1e7-5bcf999caa8d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fc83d216-4041-4f4e-a4da-4ea0d0cc2c76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e9864712-cbb4-4bab-9fec-f0b0ea7a8a33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2735d4d4-1913-4f29-b1e7-5bcf999caa8d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e9864712-cbb4-4bab-9fec-f0b0ea7a8a33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0cfa4bd3-adc3-4ab4-a13c-7f8c8756669e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_66f88866-c104-418c-8c5e-b8c64dbdc43a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0cfa4bd3-adc3-4ab4-a13c-7f8c8756669e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_66f88866-c104-418c-8c5e-b8c64dbdc43a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_da42a386-db76-443c-b4d9-2052ea0b0310" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0cfa4bd3-adc3-4ab4-a13c-7f8c8756669e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_da42a386-db76-443c-b4d9-2052ea0b0310" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b567ece6-c664-4b12-a6da-bb5269af1e93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0cfa4bd3-adc3-4ab4-a13c-7f8c8756669e" xlink:to="loc_us-gaap_CommonStockValue_b567ece6-c664-4b12-a6da-bb5269af1e93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_802339e0-a80b-45b2-8b0d-ef6a196db3f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0cfa4bd3-adc3-4ab4-a13c-7f8c8756669e" xlink:to="loc_us-gaap_TreasuryStockValue_802339e0-a80b-45b2-8b0d-ef6a196db3f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_48bfdaca-1fb6-4c75-8f53-e58e05b8d1bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a0a55728-5363-4425-92a2-ed29c32cc18e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_48bfdaca-1fb6-4c75-8f53-e58e05b8d1bd" xlink:to="loc_us-gaap_LiabilitiesCurrent_a0a55728-5363-4425-92a2-ed29c32cc18e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_31f74532-f609-4c02-a1c1-cb3263d6dcaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_48bfdaca-1fb6-4c75-8f53-e58e05b8d1bd" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_31f74532-f609-4c02-a1c1-cb3263d6dcaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_4b73b6fa-e893-4bf0-91b3-691fd756d1e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_48bfdaca-1fb6-4c75-8f53-e58e05b8d1bd" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_4b73b6fa-e893-4bf0-91b3-691fd756d1e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_2c0a30ef-0bfe-4751-999b-5a9902f3e0db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_48bfdaca-1fb6-4c75-8f53-e58e05b8d1bd" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_2c0a30ef-0bfe-4751-999b-5a9902f3e0db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_a2ed5686-e917-461b-bf6c-51bee78baa18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_48bfdaca-1fb6-4c75-8f53-e58e05b8d1bd" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_a2ed5686-e917-461b-bf6c-51bee78baa18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7217c6d7-174e-41c5-b82b-2bf49a90cbf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_48bfdaca-1fb6-4c75-8f53-e58e05b8d1bd" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7217c6d7-174e-41c5-b82b-2bf49a90cbf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_864faf4f-f6fe-4e51-a0dd-c5d64fbcb17e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5e9ae0b7-7058-4f72-a391-35a43ae03efd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_864faf4f-f6fe-4e51-a0dd-c5d64fbcb17e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5e9ae0b7-7058-4f72-a391-35a43ae03efd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_89521701-9b2e-4b78-bd9f-4f0f3fb5f220" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_864faf4f-f6fe-4e51-a0dd-c5d64fbcb17e" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_89521701-9b2e-4b78-bd9f-4f0f3fb5f220" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_146005dd-4bdd-4413-b572-7d0bf49f0f90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_864faf4f-f6fe-4e51-a0dd-c5d64fbcb17e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_146005dd-4bdd-4413-b572-7d0bf49f0f90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_723561b1-bc05-4054-8309-5fc194dfc101" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_864faf4f-f6fe-4e51-a0dd-c5d64fbcb17e" xlink:to="loc_us-gaap_InventoryNet_723561b1-bc05-4054-8309-5fc194dfc101" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_06b75387-771c-4276-a454-60a743e4174d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_864faf4f-f6fe-4e51-a0dd-c5d64fbcb17e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_06b75387-771c-4276-a454-60a743e4174d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_25c5e67b-2cf0-4420-80ae-be87986e3937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_721165b7-05f8-42ae-b9c2-25e3c64acada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_25c5e67b-2cf0-4420-80ae-be87986e3937" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_721165b7-05f8-42ae-b9c2-25e3c64acada" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3b7c53c6-2865-4c43-b97b-324aeae9ee47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_25c5e67b-2cf0-4420-80ae-be87986e3937" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3b7c53c6-2865-4c43-b97b-324aeae9ee47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f0e807bb-636c-4f11-b553-3064a969d594" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_d7c3eab0-88b1-4c64-b36b-0eb507cb8d01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f0e807bb-636c-4f11-b553-3064a969d594" xlink:to="loc_us-gaap_ShortTermBorrowings_d7c3eab0-88b1-4c64-b36b-0eb507cb8d01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_24aa76c5-dacd-42e0-a2ac-66122606357d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f0e807bb-636c-4f11-b553-3064a969d594" xlink:to="loc_us-gaap_AccountsPayableCurrent_24aa76c5-dacd-42e0-a2ac-66122606357d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_bbeffdbf-7e75-44bc-ab46-353827416c2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f0e807bb-636c-4f11-b553-3064a969d594" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_bbeffdbf-7e75-44bc-ab46-353827416c2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_36859a06-a6a3-44b9-ba75-be9f18f4d270" xlink:href="jnj-20211003.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f0e807bb-636c-4f11-b553-3064a969d594" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_36859a06-a6a3-44b9-ba75-be9f18f4d270" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0000b61d-d629-4d04-bd4c-0df8cbed3888" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f0e807bb-636c-4f11-b553-3064a969d594" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0000b61d-d629-4d04-bd4c-0df8cbed3888" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_1c67ce08-9594-4b30-ad1d-7d9883ac764a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f0e807bb-636c-4f11-b553-3064a969d594" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_1c67ce08-9594-4b30-ad1d-7d9883ac764a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b713a327-0e10-4e31-a9c2-d19c43a28734" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b00237d2-a9ac-4645-8780-12de7ae0bee8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b713a327-0e10-4e31-a9c2-d19c43a28734" xlink:to="loc_us-gaap_AssetsCurrent_b00237d2-a9ac-4645-8780-12de7ae0bee8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_421c4926-7893-4241-811b-52dc68e5a554" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b713a327-0e10-4e31-a9c2-d19c43a28734" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_421c4926-7893-4241-811b-52dc68e5a554" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8a8aed17-b7c4-4227-9af4-eeac99270563" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b713a327-0e10-4e31-a9c2-d19c43a28734" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8a8aed17-b7c4-4227-9af4-eeac99270563" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_48fc44f5-ba40-42c6-8ef8-95bd3c59f8d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b713a327-0e10-4e31-a9c2-d19c43a28734" xlink:to="loc_us-gaap_Goodwill_48fc44f5-ba40-42c6-8ef8-95bd3c59f8d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_52a299d9-c5f0-482c-b16b-4f5b98d89b20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b713a327-0e10-4e31-a9c2-d19c43a28734" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_52a299d9-c5f0-482c-b16b-4f5b98d89b20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8bc50e7c-6dcb-462e-a5b1-7b78b5155e21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b713a327-0e10-4e31-a9c2-d19c43a28734" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8bc50e7c-6dcb-462e-a5b1-7b78b5155e21" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="jnj-20211003.xsd#ConsolidatedStatementsofEarnings"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_14d8403f-2227-44ee-bc74-ad1daac1878f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_89609fed-e421-405d-9e3d-348afd9f745d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_14d8403f-2227-44ee-bc74-ad1daac1878f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_89609fed-e421-405d-9e3d-348afd9f745d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3020d0b7-2c2a-4d15-a3ba-b03cb333b21b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_14d8403f-2227-44ee-bc74-ad1daac1878f" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3020d0b7-2c2a-4d15-a3ba-b03cb333b21b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_047e85f9-cc35-4a5f-8073-5df17517600f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_229e062d-9323-4576-8a7b-a63797748207" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_047e85f9-cc35-4a5f-8073-5df17517600f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_229e062d-9323-4576-8a7b-a63797748207" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7205822b-118b-45f1-a117-d249e51edcf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_047e85f9-cc35-4a5f-8073-5df17517600f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7205822b-118b-45f1-a117-d249e51edcf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_61e67b99-4515-45c8-b504-ca4a724ed988" xlink:href="jnj-20211003.xsd#jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_b053e87a-1965-4373-8bf6-d0cbcbaf5ee3" xlink:href="jnj-20211003.xsd#jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_61e67b99-4515-45c8-b504-ca4a724ed988" xlink:to="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_b053e87a-1965-4373-8bf6-d0cbcbaf5ee3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales_777ae068-bf6e-4246-b1d9-602efae1c02b" xlink:href="jnj-20211003.xsd#jnj_OtherNonOperatingIncomeExpensePercentToSales"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_61e67b99-4515-45c8-b504-ca4a724ed988" xlink:to="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales_777ae068-bf6e-4246-b1d9-602efae1c02b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvestmentIncomeInterestPercentToSales_1c81acee-57f2-461d-bf16-de2114c4fc68" xlink:href="jnj-20211003.xsd#jnj_InvestmentIncomeInterestPercentToSales"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_61e67b99-4515-45c8-b504-ca4a724ed988" xlink:to="loc_jnj_InvestmentIncomeInterestPercentToSales_1c81acee-57f2-461d-bf16-de2114c4fc68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales_b0af17b3-0ff0-426c-af26-9dde1cf99a69" xlink:href="jnj-20211003.xsd#jnj_ResearchAndDevelopmentInProcessPercentToSales"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_61e67b99-4515-45c8-b504-ca4a724ed988" xlink:to="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales_b0af17b3-0ff0-426c-af26-9dde1cf99a69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Restructuringchargepercenttosales_f5735bfc-f8fa-4629-ab5c-edb99b13bf3b" xlink:href="jnj-20211003.xsd#jnj_Restructuringchargepercenttosales"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_61e67b99-4515-45c8-b504-ca4a724ed988" xlink:to="loc_jnj_Restructuringchargepercenttosales_f5735bfc-f8fa-4629-ab5c-edb99b13bf3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestExpensePercentToSales_f2df00a2-8153-4289-88d0-be2efee7b3d7" xlink:href="jnj-20211003.xsd#jnj_InterestExpensePercentToSales"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_61e67b99-4515-45c8-b504-ca4a724ed988" xlink:to="loc_jnj_InterestExpensePercentToSales_f2df00a2-8153-4289-88d0-be2efee7b3d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_6946f98b-1ff5-4656-a260-a087bcd54807" xlink:href="jnj-20211003.xsd#jnj_SellingGeneralAndAdministrativeExpensePercentToSales"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_61e67b99-4515-45c8-b504-ca4a724ed988" xlink:to="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_6946f98b-1ff5-4656-a260-a087bcd54807" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GrossProfitPercentToSales_9f9b1905-3f58-4e97-8627-ab868d752fbd" xlink:href="jnj-20211003.xsd#jnj_GrossProfitPercentToSales"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_61e67b99-4515-45c8-b504-ca4a724ed988" xlink:to="loc_jnj_GrossProfitPercentToSales_9f9b1905-3f58-4e97-8627-ab868d752fbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GrossProfitPercentToSales_6dafc8c2-a75b-40bc-8d3b-0e5aa2e71406" xlink:href="jnj-20211003.xsd#jnj_GrossProfitPercentToSales"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CostOfGoodsSoldPercentToSales_7fd5207a-33c9-4d3c-8c45-7dfcd9914416" xlink:href="jnj-20211003.xsd#jnj_CostOfGoodsSoldPercentToSales"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_GrossProfitPercentToSales_6dafc8c2-a75b-40bc-8d3b-0e5aa2e71406" xlink:to="loc_jnj_CostOfGoodsSoldPercentToSales_7fd5207a-33c9-4d3c-8c45-7dfcd9914416" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesRevenueGoodsNetPercentToSales_77a2d9f4-341e-49cd-a21c-a512da74935b" xlink:href="jnj-20211003.xsd#jnj_SalesRevenueGoodsNetPercentToSales"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_GrossProfitPercentToSales_6dafc8c2-a75b-40bc-8d3b-0e5aa2e71406" xlink:to="loc_jnj_SalesRevenueGoodsNetPercentToSales_77a2d9f4-341e-49cd-a21c-a512da74935b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NetIncomeAttributableToParentPercentToSales_92696842-3d7a-4199-8e33-df0819ae4785" xlink:href="jnj-20211003.xsd#jnj_NetIncomeAttributableToParentPercentToSales"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeTaxExpenseBenefitPercentToSales_6ffe5343-8c2f-48c5-8c44-1555bf7faa76" xlink:href="jnj-20211003.xsd#jnj_IncomeTaxExpenseBenefitPercentToSales"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_NetIncomeAttributableToParentPercentToSales_92696842-3d7a-4199-8e33-df0819ae4785" xlink:to="loc_jnj_IncomeTaxExpenseBenefitPercentToSales_6ffe5343-8c2f-48c5-8c44-1555bf7faa76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_cc41bcd6-6e4b-4b40-b41c-6805782f4d05" xlink:href="jnj-20211003.xsd#jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_NetIncomeAttributableToParentPercentToSales_92696842-3d7a-4199-8e33-df0819ae4785" xlink:to="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_cc41bcd6-6e4b-4b40-b41c-6805782f4d05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d6f6dc62-303f-45d0-b073-64df06e7038a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6070828d-12e5-4e8a-afb4-781f6277a2ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d6f6dc62-303f-45d0-b073-64df06e7038a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6070828d-12e5-4e8a-afb4-781f6277a2ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_726db226-2763-4a93-a185-a4805d1e2a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d6f6dc62-303f-45d0-b073-64df06e7038a" xlink:to="loc_us-gaap_GrossProfit_726db226-2763-4a93-a185-a4805d1e2a8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_716bdbd1-1a7b-441a-8483-463bce3fb552" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d6f6dc62-303f-45d0-b073-64df06e7038a" xlink:to="loc_us-gaap_InvestmentIncomeInterest_716bdbd1-1a7b-441a-8483-463bce3fb552" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_d3641fcc-d3e2-4935-a606-103d823cb827" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d6f6dc62-303f-45d0-b073-64df06e7038a" xlink:to="loc_us-gaap_RestructuringCharges_d3641fcc-d3e2-4935-a606-103d823cb827" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b4d36416-19ec-4950-a37d-ff64c0710e22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d6f6dc62-303f-45d0-b073-64df06e7038a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b4d36416-19ec-4950-a37d-ff64c0710e22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_b8c021b7-28c3-4dd7-902f-4accfe92e853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d6f6dc62-303f-45d0-b073-64df06e7038a" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_b8c021b7-28c3-4dd7-902f-4accfe92e853" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_6131c607-9d0d-4f69-8258-4210297aafc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d6f6dc62-303f-45d0-b073-64df06e7038a" xlink:to="loc_us-gaap_InterestExpense_6131c607-9d0d-4f69-8258-4210297aafc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d7073b7b-c83c-4444-b74d-fa01b32b0fda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d6f6dc62-303f-45d0-b073-64df06e7038a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d7073b7b-c83c-4444-b74d-fa01b32b0fda" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20211003.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_71228b0e-9f3f-4003-ba1e-f859470d0555" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_bb68d4a4-782e-4bd4-a0ae-65daf29a2d32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_71228b0e-9f3f-4003-ba1e-f859470d0555" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_bb68d4a4-782e-4bd4-a0ae-65daf29a2d32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_9dd45ff6-ddfa-4489-8428-d74f4b72394a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_71228b0e-9f3f-4003-ba1e-f859470d0555" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_9dd45ff6-ddfa-4489-8428-d74f4b72394a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_c7fa2d9c-8bff-4892-b33a-3e55b6c00dac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_0c4260a0-c93e-4d71-8cc6-1316d286d6c0" xlink:href="jnj-20211003.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_c7fa2d9c-8bff-4892-b33a-3e55b6c00dac" xlink:to="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_0c4260a0-c93e-4d71-8cc6-1316d286d6c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_862718e4-927c-4bdd-b011-630ea66ea64b" xlink:href="jnj-20211003.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_c7fa2d9c-8bff-4892-b33a-3e55b6c00dac" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_862718e4-927c-4bdd-b011-630ea66ea64b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6ef6df2c-a386-4cb2-9514-e8181fd86b08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_4e546746-80d4-4c4a-8ea6-6e22f0043bc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6ef6df2c-a386-4cb2-9514-e8181fd86b08" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_4e546746-80d4-4c4a-8ea6-6e22f0043bc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_10b68d7a-0c61-443f-83ad-c35bc8efe133" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6ef6df2c-a386-4cb2-9514-e8181fd86b08" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_10b68d7a-0c61-443f-83ad-c35bc8efe133" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cfc16be6-7f18-4767-9386-6d104ca84e2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_0c821f15-a856-465c-ab99-25bc7c0899a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cfc16be6-7f18-4767-9386-6d104ca84e2e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_0c821f15-a856-465c-ab99-25bc7c0899a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5ec9f42c-15a7-4171-9a35-277b4cf2364f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cfc16be6-7f18-4767-9386-6d104ca84e2e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5ec9f42c-15a7-4171-9a35-277b4cf2364f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_9f0f7f93-630f-4dfb-b496-fb75ce110e68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cfc16be6-7f18-4767-9386-6d104ca84e2e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_9f0f7f93-630f-4dfb-b496-fb75ce110e68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_d3f4452c-74f6-4b7f-aa5c-7bf71d95c39b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cfc16be6-7f18-4767-9386-6d104ca84e2e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_d3f4452c-74f6-4b7f-aa5c-7bf71d95c39b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b04cdae9-ca60-4be2-a20f-03f806a28e29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_41a7564f-243e-4ee8-9e4f-75741e4a4f94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b04cdae9-ca60-4be2-a20f-03f806a28e29" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_41a7564f-243e-4ee8-9e4f-75741e4a4f94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2a8d6517-86f0-45f8-9d47-a20d82ac3e48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b04cdae9-ca60-4be2-a20f-03f806a28e29" xlink:to="loc_us-gaap_NetIncomeLoss_2a8d6517-86f0-45f8-9d47-a20d82ac3e48" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="jnj-20211003.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bdc7d908-c0df-469b-9788-f5ac28a1c5db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_3eff436d-0725-489e-b053-4e68724b0e10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bdc7d908-c0df-469b-9788-f5ac28a1c5db" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_3eff436d-0725-489e-b053-4e68724b0e10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_858f2830-d7d1-4194-99f4-5f0d7122a7db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bdc7d908-c0df-469b-9788-f5ac28a1c5db" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_858f2830-d7d1-4194-99f4-5f0d7122a7db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_1400d7a4-a8c4-43f0-a1f2-5d895bd3b525" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bdc7d908-c0df-469b-9788-f5ac28a1c5db" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_1400d7a4-a8c4-43f0-a1f2-5d895bd3b525" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_d6df2aaa-6aaa-415e-ac4a-9bafcdc56a14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bdc7d908-c0df-469b-9788-f5ac28a1c5db" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_d6df2aaa-6aaa-415e-ac4a-9bafcdc56a14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_8de16c3d-a357-4827-8b42-07f61d888f2a" xlink:href="jnj-20211003.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bdc7d908-c0df-469b-9788-f5ac28a1c5db" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_8de16c3d-a357-4827-8b42-07f61d888f2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_59d8d9ec-7e93-4f94-a2d9-11a46623c9fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bdc7d908-c0df-469b-9788-f5ac28a1c5db" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_59d8d9ec-7e93-4f94-a2d9-11a46623c9fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_74d94894-0b06-4e2a-89c5-58bd0b25462e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bdc7d908-c0df-469b-9788-f5ac28a1c5db" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_74d94894-0b06-4e2a-89c5-58bd0b25462e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_93f52836-f7b9-4084-9984-df6f18928915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d977b999-75a1-4709-b9e5-cbeb44d6a422" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_93f52836-f7b9-4084-9984-df6f18928915" xlink:to="loc_us-gaap_NetIncomeLoss_d977b999-75a1-4709-b9e5-cbeb44d6a422" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_605ade4d-1464-4dce-9ec1-7ed976691512" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_93f52836-f7b9-4084-9984-df6f18928915" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_605ade4d-1464-4dce-9ec1-7ed976691512" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a2de82e6-d514-433c-b879-25156876abfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_93f52836-f7b9-4084-9984-df6f18928915" xlink:to="loc_us-gaap_ShareBasedCompensation_a2de82e6-d514-433c-b879-25156876abfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_720ff108-5d45-4d8a-a177-27ebda7b06d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_93f52836-f7b9-4084-9984-df6f18928915" xlink:to="loc_us-gaap_AssetImpairmentCharges_720ff108-5d45-4d8a-a177-27ebda7b06d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3d949a2f-ede0-438c-96d3-f1984e6fcae7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_93f52836-f7b9-4084-9984-df6f18928915" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3d949a2f-ede0-438c-96d3-f1984e6fcae7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_1bb51f0d-36d9-49ae-a762-26146937cd8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_93f52836-f7b9-4084-9984-df6f18928915" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_1bb51f0d-36d9-49ae-a762-26146937cd8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_245d0c7d-c1d4-44c7-82c9-862408c65697" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_93f52836-f7b9-4084-9984-df6f18928915" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_245d0c7d-c1d4-44c7-82c9-862408c65697" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_dd422222-b6a8-451b-a6f0-b391610fc9ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_93f52836-f7b9-4084-9984-df6f18928915" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_dd422222-b6a8-451b-a6f0-b391610fc9ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_74f10ec5-ebd8-47f8-8757-066ad8b0995c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_93f52836-f7b9-4084-9984-df6f18928915" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_74f10ec5-ebd8-47f8-8757-066ad8b0995c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_04880d50-faf3-4e15-a51c-49f2673dc571" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_93f52836-f7b9-4084-9984-df6f18928915" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_04880d50-faf3-4e15-a51c-49f2673dc571" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ceefabb8-98e6-45e0-8407-c8a12c3a3abd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_93f52836-f7b9-4084-9984-df6f18928915" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ceefabb8-98e6-45e0-8407-c8a12c3a3abd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7f2cb5ce-ccf2-40dd-89b5-8a0e566badc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_93f52836-f7b9-4084-9984-df6f18928915" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7f2cb5ce-ccf2-40dd-89b5-8a0e566badc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8b38d4be-6f0c-49ad-9ed5-8082d2dcf714" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_93f52836-f7b9-4084-9984-df6f18928915" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8b38d4be-6f0c-49ad-9ed5-8082d2dcf714" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_48917ad2-07ad-4c03-9456-2a01381cea02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_1dce7c21-e255-4d8e-8e22-84ed75e9d496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_48917ad2-07ad-4c03-9456-2a01381cea02" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_1dce7c21-e255-4d8e-8e22-84ed75e9d496" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_c6afefe4-233e-4938-ab25-fbdfb4f637b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_48917ad2-07ad-4c03-9456-2a01381cea02" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_c6afefe4-233e-4938-ab25-fbdfb4f637b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bc4cf97d-c5c7-415f-80b0-d5b267380673" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_904afe33-31c4-420c-9049-9e665072451b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bc4cf97d-c5c7-415f-80b0-d5b267380673" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_904afe33-31c4-420c-9049-9e665072451b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_81a695f7-e75a-4814-bc2b-1eeb53b6fdb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bc4cf97d-c5c7-415f-80b0-d5b267380673" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_81a695f7-e75a-4814-bc2b-1eeb53b6fdb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_3ce1921e-3b90-49a5-a069-c7903fd66b68" xlink:href="jnj-20211003.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bc4cf97d-c5c7-415f-80b0-d5b267380673" xlink:to="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_3ce1921e-3b90-49a5-a069-c7903fd66b68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_75db5873-9b16-4be4-8707-00718920402d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bc4cf97d-c5c7-415f-80b0-d5b267380673" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_75db5873-9b16-4be4-8707-00718920402d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_5687682f-0cdd-4c5e-8954-6fd6eb4673aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bc4cf97d-c5c7-415f-80b0-d5b267380673" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_5687682f-0cdd-4c5e-8954-6fd6eb4673aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_fe2451e7-2126-480a-8f93-5091c3f05ca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bc4cf97d-c5c7-415f-80b0-d5b267380673" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_fe2451e7-2126-480a-8f93-5091c3f05ca6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_29a803d8-951d-4b1c-8342-5ee516c984c2" xlink:href="jnj-20211003.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bc4cf97d-c5c7-415f-80b0-d5b267380673" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_29a803d8-951d-4b1c-8342-5ee516c984c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_fe0eddc7-8666-4d63-a206-e62ae9f10298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bc4cf97d-c5c7-415f-80b0-d5b267380673" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_fe0eddc7-8666-4d63-a206-e62ae9f10298" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0adb5cca-5331-4405-918e-9b3d772c2cbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bc4cf97d-c5c7-415f-80b0-d5b267380673" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0adb5cca-5331-4405-918e-9b3d772c2cbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2a818968-0543-44a8-8476-cb1d9cbf3256" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0fc6940c-9754-4a6c-92cf-e6acfa3f03f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2a818968-0543-44a8-8476-cb1d9cbf3256" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0fc6940c-9754-4a6c-92cf-e6acfa3f03f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2809361a-af35-418f-8aae-e69580c89dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2a818968-0543-44a8-8476-cb1d9cbf3256" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2809361a-af35-418f-8aae-e69580c89dc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_950bae53-1bed-4597-a986-167f9e0a83e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2a818968-0543-44a8-8476-cb1d9cbf3256" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_950bae53-1bed-4597-a986-167f9e0a83e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_85953bf2-903b-46cf-9a64-3f3d4187c188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2a818968-0543-44a8-8476-cb1d9cbf3256" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_85953bf2-903b-46cf-9a64-3f3d4187c188" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_911ed37f-4131-4621-a8ca-0621dcfffe89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_de9667cf-94db-4713-b484-2e75dfdba52e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_911ed37f-4131-4621-a8ca-0621dcfffe89" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_de9667cf-94db-4713-b484-2e75dfdba52e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_36ddd841-79ea-46f2-a12f-2d3fcc0f5d27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_911ed37f-4131-4621-a8ca-0621dcfffe89" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_36ddd841-79ea-46f2-a12f-2d3fcc0f5d27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_9f2c4c8c-d800-4c4d-8d6f-d83b1e142f3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_911ed37f-4131-4621-a8ca-0621dcfffe89" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_9f2c4c8c-d800-4c4d-8d6f-d83b1e142f3c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_571ed2cf-e362-44a9-abdb-c2e993151d96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b88b88ea-97d3-434e-aa9b-b529758c905c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_571ed2cf-e362-44a9-abdb-c2e993151d96" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b88b88ea-97d3-434e-aa9b-b529758c905c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8f9d4224-e62c-48e3-85ab-f0415254088d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_571ed2cf-e362-44a9-abdb-c2e993151d96" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8f9d4224-e62c-48e3-85ab-f0415254088d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_4e1b07fe-e163-49b5-ab0c-0f0507c8cf6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_97dd42ed-ee7f-4935-a8e3-ec3292472a38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssets_4e1b07fe-e163-49b5-ab0c-0f0507c8cf6f" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_97dd42ed-ee7f-4935-a8e3-ec3292472a38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_03f689d7-e48b-4736-a008-cbb778c284a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssets_4e1b07fe-e163-49b5-ab0c-0f0507c8cf6f" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_03f689d7-e48b-4736-a008-cbb778c284a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_3142faab-5cdc-4a8a-8033-c844bf95cc89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_6f3e9fc8-0b49-43fb-b98b-962f1f66dc59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_3142faab-5cdc-4a8a-8033-c844bf95cc89" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_6f3e9fc8-0b49-43fb-b98b-962f1f66dc59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_8933463b-42e0-4659-a9d1-5793e4db8b4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_3142faab-5cdc-4a8a-8033-c844bf95cc89" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_8933463b-42e0-4659-a9d1-5793e4db8b4d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_23411fc9-daf8-4189-8aa5-b43308843134" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c755533f-fe45-4f84-844b-dbb1fecdbfdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_23411fc9-daf8-4189-8aa5-b43308843134" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c755533f-fe45-4f84-844b-dbb1fecdbfdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d9a8000f-a7ec-4432-9348-0401d3a5b418" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_23411fc9-daf8-4189-8aa5-b43308843134" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d9a8000f-a7ec-4432-9348-0401d3a5b418" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dc9cc564-a2ba-46d1-8291-d101a152c0f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_23411fc9-daf8-4189-8aa5-b43308843134" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dc9cc564-a2ba-46d1-8291-d101a152c0f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_69c2caf8-a706-47e7-88e1-194e0d6c7118" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_7d606a99-7f61-4df0-a335-b7b70cf6447d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_69c2caf8-a706-47e7-88e1-194e0d6c7118" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_7d606a99-7f61-4df0-a335-b7b70cf6447d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_083b61eb-6d61-4bd8-9063-4ac93f540532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_69c2caf8-a706-47e7-88e1-194e0d6c7118" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_083b61eb-6d61-4bd8-9063-4ac93f540532" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_ef76eb94-f761-4c03-b21f-789adfa49107" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_69c2caf8-a706-47e7-88e1-194e0d6c7118" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_ef76eb94-f761-4c03-b21f-789adfa49107" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_fe991030-56c1-450b-9dec-b0427811f76a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ebb0898f-af2a-4b9d-9391-7584f100c88f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_fe991030-56c1-450b-9dec-b0427811f76a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ebb0898f-af2a-4b9d-9391-7584f100c88f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_b2cfd4b7-ad92-4974-83c1-59174772e75b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_fe991030-56c1-450b-9dec-b0427811f76a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_b2cfd4b7-ad92-4974-83c1-59174772e75b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_8494b2d0-853b-42ba-a923-aa936ad696b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_fe991030-56c1-450b-9dec-b0427811f76a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_8494b2d0-853b-42ba-a923-aa936ad696b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_b078ca00-135d-4126-a9b9-018cec7433ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_a8ff0f5f-aeb5-4a93-a677-41073e916ae7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_b078ca00-135d-4126-a9b9-018cec7433ad" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_a8ff0f5f-aeb5-4a93-a677-41073e916ae7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ca28a617-50dd-47b9-9083-b9c9bcca9392" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_b078ca00-135d-4126-a9b9-018cec7433ad" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ca28a617-50dd-47b9-9083-b9c9bcca9392" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_d4280742-5070-4559-ad40-dd7f74e951b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_b078ca00-135d-4126-a9b9-018cec7433ad" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_d4280742-5070-4559-ad40-dd7f74e951b7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_5b103acd-b0a1-43d3-812f-74d4e818b146" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_5cf32242-97cb-490f-9a69-f0027c6909aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_5b103acd-b0a1-43d3-812f-74d4e818b146" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_5cf32242-97cb-490f-9a69-f0027c6909aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_cb461e2c-fc40-4b75-9a0b-84f829c8dcd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_5b103acd-b0a1-43d3-812f-74d4e818b146" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_cb461e2c-fc40-4b75-9a0b-84f829c8dcd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_49fb8513-b6cd-490e-a5de-dc6f4f56b596" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_5b103acd-b0a1-43d3-812f-74d4e818b146" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_49fb8513-b6cd-490e-a5de-dc6f4f56b596" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_f8a1ea17-3a9a-40f1-9b53-d9c8583b584e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_5b103acd-b0a1-43d3-812f-74d4e818b146" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_f8a1ea17-3a9a-40f1-9b53-d9c8583b584e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_a11acf9c-0e96-4894-a11d-3ddd19d4d59d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_5b103acd-b0a1-43d3-812f-74d4e818b146" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_a11acf9c-0e96-4894-a11d-3ddd19d4d59d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_141b3410-c518-4198-9b5f-cc6af8b02bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_5b103acd-b0a1-43d3-812f-74d4e818b146" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_141b3410-c518-4198-9b5f-cc6af8b02bb1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#EarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ed4953ec-009c-4589-9642-6ac321a26b2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_569289a9-1234-4154-81e1-054bf4b33a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ed4953ec-009c-4589-9642-6ac321a26b2c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_569289a9-1234-4154-81e1-054bf4b33a39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7f999c1b-053d-4d53-82cf-42304fd70f60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ed4953ec-009c-4589-9642-6ac321a26b2c" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7f999c1b-053d-4d53-82cf-42304fd70f60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_0dd873a4-c37b-4db0-b2cd-a8a3a4a1fc97" xlink:href="jnj-20211003.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ed4953ec-009c-4589-9642-6ac321a26b2c" xlink:to="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_0dd873a4-c37b-4db0-b2cd-a8a3a4a1fc97" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>jnj-20211003_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:90dc118c-6428-4338-8b4d-8015054a0548,g:65f17fdb-8375-41f4-bf95-c047d59b03b3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.jnj.com/role/Cover" xlink:type="simple" xlink:href="jnj-20211003.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/Cover" xlink:type="extended" id="i78d22ec219894cd488b4b24841914170_Cover">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d03c6dac-0926-44f0-b388-74faa697f8a6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_DocumentType_d03c6dac-0926-44f0-b388-74faa697f8a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_4e49625f-0e53-46bb-846d-dddd7f739d22" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_DocumentQuarterlyReport_4e49625f-0e53-46bb-846d-dddd7f739d22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a4744110-dd3d-4697-beb1-ec3c0217c6e5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_DocumentPeriodEndDate_a4744110-dd3d-4697-beb1-ec3c0217c6e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_063fef78-30ce-4dde-8ebe-e93db52a82d7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_DocumentTransitionReport_063fef78-30ce-4dde-8ebe-e93db52a82d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9976f4bf-1c21-454d-9ea3-384195af5dab" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityFileNumber_9976f4bf-1c21-454d-9ea3-384195af5dab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_37e8370f-04cc-4f53-9bb0-e697ea262097" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityRegistrantName_37e8370f-04cc-4f53-9bb0-e697ea262097" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2632647c-bf7a-4d7b-a556-9066f19ecd17" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2632647c-bf7a-4d7b-a556-9066f19ecd17" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f2b8e006-331e-41e3-bb1b-17a5953954bc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityTaxIdentificationNumber_f2b8e006-331e-41e3-bb1b-17a5953954bc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_731e5133-4cf4-4f4f-847b-cf08d140c03a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityAddressAddressLine1_731e5133-4cf4-4f4f-847b-cf08d140c03a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_36342b63-7d48-434b-b96d-0f88b2ea4884" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityAddressCityOrTown_36342b63-7d48-434b-b96d-0f88b2ea4884" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_9d69f1ae-a744-489f-bd0e-e926f8d446f3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityAddressStateOrProvince_9d69f1ae-a744-489f-bd0e-e926f8d446f3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e83917c4-4110-4518-a1b0-0df5c8c0572c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityAddressPostalZipCode_e83917c4-4110-4518-a1b0-0df5c8c0572c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_17ae9527-55c8-416b-b9c4-2d0d7da13b3c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_CityAreaCode_17ae9527-55c8-416b-b9c4-2d0d7da13b3c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_46117227-c6f6-4fe0-93df-5b9520dc5285" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_LocalPhoneNumber_46117227-c6f6-4fe0-93df-5b9520dc5285" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_bcd7533d-2640-49be-b919-0d3216a1b467" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityCurrentReportingStatus_bcd7533d-2640-49be-b919-0d3216a1b467" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_574483f7-f430-4d2f-bdf2-a57ae89997d1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityInteractiveDataCurrent_574483f7-f430-4d2f-bdf2-a57ae89997d1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_8f626e53-e4c4-4b26-9157-78a85e6da56d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityFilerCategory_8f626e53-e4c4-4b26-9157-78a85e6da56d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e7be4c5a-d7a3-45fc-b074-7e12cacb7900" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntitySmallBusiness_e7be4c5a-d7a3-45fc-b074-7e12cacb7900" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ca1cb058-37bc-44b5-8b83-83e0b02c66ce" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityEmergingGrowthCompany_ca1cb058-37bc-44b5-8b83-83e0b02c66ce" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_263a6f7d-cf1e-4788-a5eb-6677c496749d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityShellCompany_263a6f7d-cf1e-4788-a5eb-6677c496749d" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_79ccf960-f50f-4bae-bb62-67cb7738cdcd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_Security12bTitle_79ccf960-f50f-4bae-bb62-67cb7738cdcd" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_27126af8-fb24-481b-85e8-c178f872484d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_TradingSymbol_27126af8-fb24-481b-85e8-c178f872484d" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ce33e936-613d-4a3b-948b-f399ae9bf35a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_SecurityExchangeName_ce33e936-613d-4a3b-948b-f399ae9bf35a" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d404c240-2091-4aca-93d8-d7a7e9ec6422" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d404c240-2091-4aca-93d8-d7a7e9ec6422" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fa6212e5-de41-4a86-b71c-68aa39a597ed" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityCentralIndexKey_fa6212e5-de41-4a86-b71c-68aa39a597ed" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_ca7bac4b-50ac-4394-94bf-d2576da809b6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_CurrentFiscalYearEndDate_ca7bac4b-50ac-4394-94bf-d2576da809b6" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_90ccb21b-9c5d-43c3-ae4b-041e4a83e07c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_DocumentFiscalYearFocus_90ccb21b-9c5d-43c3-ae4b-041e4a83e07c" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_d55675fc-dcdb-4127-a214-f96766da50da" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_DocumentFiscalPeriodFocus_d55675fc-dcdb-4127-a214-f96766da50da" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e0957f75-02e4-49b7-8ad8-f6f1920e7af7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_AmendmentFlag_e0957f75-02e4-49b7-8ad8-f6f1920e7af7" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_011e9054-982c-4376-90ba-61b24e4e982a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntitiesTable_011e9054-982c-4376-90ba-61b24e4e982a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_32ffad90-4c03-4011-ba54-4b03e608ce30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_011e9054-982c-4376-90ba-61b24e4e982a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_32ffad90-4c03-4011-ba54-4b03e608ce30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_32ffad90-4c03-4011-ba54-4b03e608ce30_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_32ffad90-4c03-4011-ba54-4b03e608ce30" xlink:to="loc_us-gaap_ClassOfStockDomain_32ffad90-4c03-4011-ba54-4b03e608ce30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c7b50371-e8f9-4fed-87bb-1a92b1d05578" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_32ffad90-4c03-4011-ba54-4b03e608ce30" xlink:to="loc_us-gaap_ClassOfStockDomain_c7b50371-e8f9-4fed-87bb-1a92b1d05578" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cbae9ca6-43d0-4429-a14f-a01decd87f6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c7b50371-e8f9-4fed-87bb-1a92b1d05578" xlink:to="loc_us-gaap_CommonStockMember_cbae9ca6-43d0-4429-a14f-a01decd87f6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.250NotesDue2022Member_eb38fe45-2a2a-470f-b996-7322bafebf89" xlink:href="jnj-20211003.xsd#jnj_A0.250NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c7b50371-e8f9-4fed-87bb-1a92b1d05578" xlink:to="loc_jnj_A0.250NotesDue2022Member_eb38fe45-2a2a-470f-b996-7322bafebf89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_f3ce2507-2d84-454f-a220-8956e1f204b9" xlink:href="jnj-20211003.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c7b50371-e8f9-4fed-87bb-1a92b1d05578" xlink:to="loc_jnj_A0.650NotesDue2024Member_f3ce2507-2d84-454f-a220-8956e1f204b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_47e8a1b4-efeb-4e31-87d8-fcf34f4bde64" xlink:href="jnj-20211003.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c7b50371-e8f9-4fed-87bb-1a92b1d05578" xlink:to="loc_jnj_A5.50NotesDue2024Member_47e8a1b4-efeb-4e31-87d8-fcf34f4bde64" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_aa39b9cd-4702-417a-8340-5218ee544e6c" xlink:href="jnj-20211003.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c7b50371-e8f9-4fed-87bb-1a92b1d05578" xlink:to="loc_jnj_A1.150NotesDue2028Member_aa39b9cd-4702-417a-8340-5218ee544e6c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_2d30c2c4-1423-4328-adf4-13b5b8ca7eb2" xlink:href="jnj-20211003.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c7b50371-e8f9-4fed-87bb-1a92b1d05578" xlink:to="loc_jnj_A1.650NotesDue2035Member_2d30c2c4-1423-4328-adf4-13b5b8ca7eb2" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="jnj-20211003.xsd#ConsolidatedStatementsofEquity"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="extended" id="i462d4fdd22394459ab0bcf626f9003b7_ConsolidatedStatementsofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2d138d12-761c-451e-b7e4-acda17b23637" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_71dc6a43-5489-4ea5-b7ce-9c85bfaa6caf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d138d12-761c-451e-b7e4-acda17b23637" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_71dc6a43-5489-4ea5-b7ce-9c85bfaa6caf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7db5e42a-f201-4928-97b6-8dd4dc0bb27c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d138d12-761c-451e-b7e4-acda17b23637" xlink:to="loc_us-gaap_NetIncomeLoss_7db5e42a-f201-4928-97b6-8dd4dc0bb27c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_5a63fe22-8d9b-4156-a869-ca7706fd51dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d138d12-761c-451e-b7e4-acda17b23637" xlink:to="loc_us-gaap_DividendsCommonStockCash_5a63fe22-8d9b-4156-a869-ca7706fd51dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_69e184c7-cadc-489f-9617-58ca6a18bd39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d138d12-761c-451e-b7e4-acda17b23637" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_69e184c7-cadc-489f-9617-58ca6a18bd39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ea15fc0a-671a-4f0a-ab03-7eedc9019e83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d138d12-761c-451e-b7e4-acda17b23637" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ea15fc0a-671a-4f0a-ab03-7eedc9019e83" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_556f73b9-760b-40c2-a2a3-29cc7347043f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d138d12-761c-451e-b7e4-acda17b23637" xlink:to="loc_us-gaap_StockholdersEquityOther_556f73b9-760b-40c2-a2a3-29cc7347043f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a23622ad-00d9-4bd7-8f5d-990d7102d59f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d138d12-761c-451e-b7e4-acda17b23637" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a23622ad-00d9-4bd7-8f5d-990d7102d59f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d31f085d-78c6-46ab-b8cc-8915213e4839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9f527450-2d0f-4434-83fd-90e3fa3210b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2d138d12-761c-451e-b7e4-acda17b23637" xlink:to="loc_us-gaap_StatementTable_9f527450-2d0f-4434-83fd-90e3fa3210b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cb198d8b-2c95-4007-a0a0-0a20a9d626c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9f527450-2d0f-4434-83fd-90e3fa3210b1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cb198d8b-2c95-4007-a0a0-0a20a9d626c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cb198d8b-2c95-4007-a0a0-0a20a9d626c2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cb198d8b-2c95-4007-a0a0-0a20a9d626c2" xlink:to="loc_us-gaap_EquityComponentDomain_cb198d8b-2c95-4007-a0a0-0a20a9d626c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e285dc40-7ef1-477b-8dca-785aa55b60e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cb198d8b-2c95-4007-a0a0-0a20a9d626c2" xlink:to="loc_us-gaap_EquityComponentDomain_e285dc40-7ef1-477b-8dca-785aa55b60e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f351fdb2-f29a-49e7-be39-9b722785fa57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e285dc40-7ef1-477b-8dca-785aa55b60e1" xlink:to="loc_us-gaap_RetainedEarningsMember_f351fdb2-f29a-49e7-be39-9b722785fa57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_402ba2c6-24e4-4d25-a4d6-2513bea98da3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e285dc40-7ef1-477b-8dca-785aa55b60e1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_402ba2c6-24e4-4d25-a4d6-2513bea98da3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6a161cd3-392d-4e84-a00a-8c52fc4fd59a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e285dc40-7ef1-477b-8dca-785aa55b60e1" xlink:to="loc_us-gaap_CommonStockMember_6a161cd3-392d-4e84-a00a-8c52fc4fd59a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_bc161f54-b54c-40c5-b4c2-4661810cf9aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e285dc40-7ef1-477b-8dca-785aa55b60e1" xlink:to="loc_us-gaap_TreasuryStockMember_bc161f54-b54c-40c5-b4c2-4661810cf9aa" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended" id="i05f4b5656b984b6dbe65631516c83aa3_IntangibleAssetsandGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_6474976e-1fca-4f86-bc95-37d0fefb866b" xlink:href="jnj-20211003.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_850f0127-e8c2-44f0-9b2e-db7930888f9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_6474976e-1fca-4f86-bc95-37d0fefb866b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_850f0127-e8c2-44f0-9b2e-db7930888f9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1b121cdc-95be-495a-a64e-c521be0eb39a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_850f0127-e8c2-44f0-9b2e-db7930888f9d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1b121cdc-95be-495a-a64e-c521be0eb39a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c1d26d3d-012f-4817-b1b5-a55aa36f930d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1b121cdc-95be-495a-a64e-c521be0eb39a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c1d26d3d-012f-4817-b1b5-a55aa36f930d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7332935c-0d07-4066-a49e-be7dc0f78589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1b121cdc-95be-495a-a64e-c521be0eb39a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7332935c-0d07-4066-a49e-be7dc0f78589" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d16fb97e-8cc5-4318-b7ad-50562b4ab099" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1b121cdc-95be-495a-a64e-c521be0eb39a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d16fb97e-8cc5-4318-b7ad-50562b4ab099" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_248bd0b6-1ec7-41ff-9ed6-71a091c6b358" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_850f0127-e8c2-44f0-9b2e-db7930888f9d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_248bd0b6-1ec7-41ff-9ed6-71a091c6b358" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2bb126e5-e54f-490b-933e-19b910859377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_248bd0b6-1ec7-41ff-9ed6-71a091c6b358" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2bb126e5-e54f-490b-933e-19b910859377" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_69bc50d8-83f3-4e86-aedd-27758b88acb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_248bd0b6-1ec7-41ff-9ed6-71a091c6b358" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_69bc50d8-83f3-4e86-aedd-27758b88acb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_be450af1-1eb0-4adc-b9fb-5b4ad59bfd7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_6474976e-1fca-4f86-bc95-37d0fefb866b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_be450af1-1eb0-4adc-b9fb-5b4ad59bfd7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_3ecd90b2-03fa-4229-9e19-fb392431f0db" xlink:href="jnj-20211003.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_6474976e-1fca-4f86-bc95-37d0fefb866b" xlink:to="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_3ecd90b2-03fa-4229-9e19-fb392431f0db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8d7f1710-b773-4732-a790-fb545ee9d0c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_3ecd90b2-03fa-4229-9e19-fb392431f0db" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8d7f1710-b773-4732-a790-fb545ee9d0c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8d7f1710-b773-4732-a790-fb545ee9d0c1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8d7f1710-b773-4732-a790-fb545ee9d0c1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8d7f1710-b773-4732-a790-fb545ee9d0c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_971fb291-98a9-4e03-b786-69e4ab8ed645" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8d7f1710-b773-4732-a790-fb545ee9d0c1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_971fb291-98a9-4e03-b786-69e4ab8ed645" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_e2666e20-a8a6-441f-8ee6-d5f867ab60bf" xlink:href="jnj-20211003.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_971fb291-98a9-4e03-b786-69e4ab8ed645" xlink:to="loc_jnj_PatentsAndTrademarksMember_e2666e20-a8a6-441f-8ee6-d5f867ab60bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_65ba926d-5f06-48ce-8600-6ac2525809b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_971fb291-98a9-4e03-b786-69e4ab8ed645" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_65ba926d-5f06-48ce-8600-6ac2525809b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_57833af1-abda-4398-a11b-77fef206e134" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_971fb291-98a9-4e03-b786-69e4ab8ed645" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_57833af1-abda-4398-a11b-77fef206e134" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8bb5a8f9-8294-4662-becd-1a0fc34d3b3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_3ecd90b2-03fa-4229-9e19-fb392431f0db" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8bb5a8f9-8294-4662-becd-1a0fc34d3b3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8bb5a8f9-8294-4662-becd-1a0fc34d3b3a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8bb5a8f9-8294-4662-becd-1a0fc34d3b3a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8bb5a8f9-8294-4662-becd-1a0fc34d3b3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_096747a3-a1d7-4ad1-8012-d1d703f284e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8bb5a8f9-8294-4662-becd-1a0fc34d3b3a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_096747a3-a1d7-4ad1-8012-d1d703f284e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_0d9a4d88-f226-42f2-9f6d-b8a1fd1d7b84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_096747a3-a1d7-4ad1-8012-d1d703f284e6" xlink:to="loc_us-gaap_TrademarksMember_0d9a4d88-f226-42f2-9f6d-b8a1fd1d7b84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_cae21cab-3af4-4e30-b522-a209c11463bf" xlink:href="jnj-20211003.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_096747a3-a1d7-4ad1-8012-d1d703f284e6" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_cae21cab-3af4-4e30-b522-a209c11463bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0b87ce93-6d45-408f-8db3-dbbf19ac89a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_3ecd90b2-03fa-4229-9e19-fb392431f0db" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0b87ce93-6d45-408f-8db3-dbbf19ac89a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b87ce93-6d45-408f-8db3-dbbf19ac89a9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0b87ce93-6d45-408f-8db3-dbbf19ac89a9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b87ce93-6d45-408f-8db3-dbbf19ac89a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b440602-bac8-46ec-b2b0-cd6575017cdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0b87ce93-6d45-408f-8db3-dbbf19ac89a9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b440602-bac8-46ec-b2b0-cd6575017cdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_1b1f22e4-dd9e-4aae-b5aa-fbb9daa0353f" xlink:href="jnj-20211003.xsd#jnj_AurisHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b440602-bac8-46ec-b2b0-cd6575017cdd" xlink:to="loc_jnj_AurisHealthMember_1b1f22e4-dd9e-4aae-b5aa-fbb9daa0353f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#IntangibleAssetsandGoodwillGoodwillBySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails" xlink:type="extended" id="ieceb3034ea264e57a6a8f547586fdb50_IntangibleAssetsandGoodwillGoodwillBySegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_ca1afde1-3560-4a25-847e-9847af208bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_525a964d-77c9-4594-9531-e07885e6e34b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ca1afde1-3560-4a25-847e-9847af208bd2" xlink:to="loc_us-gaap_GoodwillRollForward_525a964d-77c9-4594-9531-e07885e6e34b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0c9a5b6e-cd82-4cd8-90db-f7e86e560cb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_525a964d-77c9-4594-9531-e07885e6e34b" xlink:to="loc_us-gaap_Goodwill_0c9a5b6e-cd82-4cd8-90db-f7e86e560cb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_331eaa2d-86e5-43b7-a551-90ad13832fb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_525a964d-77c9-4594-9531-e07885e6e34b" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_331eaa2d-86e5-43b7-a551-90ad13832fb1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_1a24d2c1-d6cd-430a-b56c-0347285b3be8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_525a964d-77c9-4594-9531-e07885e6e34b" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_1a24d2c1-d6cd-430a-b56c-0347285b3be8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_d4ed24ea-9201-4b9e-b9d9-38a330fb79f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_525a964d-77c9-4594-9531-e07885e6e34b" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_d4ed24ea-9201-4b9e-b9d9-38a330fb79f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_254b00af-1e7b-417d-bec4-368b8f8157eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_9a6310b8-853e-46c5-b896-f2c610a91c53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_ca1afde1-3560-4a25-847e-9847af208bd2" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_9a6310b8-853e-46c5-b896-f2c610a91c53" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_33c389db-3d53-4ed9-a38c-67af8784d8fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_9a6310b8-853e-46c5-b896-f2c610a91c53" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_33c389db-3d53-4ed9-a38c-67af8784d8fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_33c389db-3d53-4ed9-a38c-67af8784d8fa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_33c389db-3d53-4ed9-a38c-67af8784d8fa" xlink:to="loc_us-gaap_SegmentDomain_33c389db-3d53-4ed9-a38c-67af8784d8fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d26c9930-f152-4631-8358-ec5ee7fa4110" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_33c389db-3d53-4ed9-a38c-67af8784d8fa" xlink:to="loc_us-gaap_SegmentDomain_d26c9930-f152-4631-8358-ec5ee7fa4110" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_e73a2031-e017-4330-ad16-ece347ce05c0" xlink:href="jnj-20211003.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d26c9930-f152-4631-8358-ec5ee7fa4110" xlink:to="loc_jnj_ConsumerMember_e73a2031-e017-4330-ad16-ece347ce05c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_9237fdfb-a8de-4e44-a128-86b87f886b3d" xlink:href="jnj-20211003.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d26c9930-f152-4631-8358-ec5ee7fa4110" xlink:to="loc_jnj_PharmaceuticalMember_9237fdfb-a8de-4e44-a128-86b87f886b3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_ea54e2c8-7982-4450-8bdf-29a2c3a32e37" xlink:href="jnj-20211003.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d26c9930-f152-4631-8358-ec5ee7fa4110" xlink:to="loc_jnj_MedicalDevicesMember_ea54e2c8-7982-4450-8bdf-29a2c3a32e37" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended" id="i47ddfb690b2847ffb9659686045bda50_IntangibleAssetsandGoodwillNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2fac3ff4-bb7f-47fc-a220-5826e6c34777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_84b0525c-278a-4102-85d8-ff5b97beddd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2fac3ff4-bb7f-47fc-a220-5826e6c34777" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_84b0525c-278a-4102-85d8-ff5b97beddd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_704efcb1-5acb-4488-9d3a-59615f8b213b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2fac3ff4-bb7f-47fc-a220-5826e6c34777" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_704efcb1-5acb-4488-9d3a-59615f8b213b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1cdeaf34-fa34-43f4-b0ef-8a081c18ce26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2fac3ff4-bb7f-47fc-a220-5826e6c34777" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1cdeaf34-fa34-43f4-b0ef-8a081c18ce26" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d43e5e44-e8ad-408b-8a4b-5a7e07d7979e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1cdeaf34-fa34-43f4-b0ef-8a081c18ce26" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d43e5e44-e8ad-408b-8a4b-5a7e07d7979e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d43e5e44-e8ad-408b-8a4b-5a7e07d7979e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d43e5e44-e8ad-408b-8a4b-5a7e07d7979e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d43e5e44-e8ad-408b-8a4b-5a7e07d7979e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7e03dba9-dc72-435a-b2ec-27d31dceb379" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d43e5e44-e8ad-408b-8a4b-5a7e07d7979e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7e03dba9-dc72-435a-b2ec-27d31dceb379" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_ac69e194-9253-4e3d-a609-1e116644e86e" xlink:href="jnj-20211003.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7e03dba9-dc72-435a-b2ec-27d31dceb379" xlink:to="loc_jnj_PatentsAndTrademarksMember_ac69e194-9253-4e3d-a609-1e116644e86e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_98ca6407-291d-46e1-9e97-7c9557baea99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7e03dba9-dc72-435a-b2ec-27d31dceb379" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_98ca6407-291d-46e1-9e97-7c9557baea99" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i008f50c928a848bb811ac33005fcc92c_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_b6f11d49-d65a-4c2b-9777-58d7d9191667" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_b6f11d49-d65a-4c2b-9777-58d7d9191667" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_402b4624-c5fb-44bf-b5f5-ef1292d80ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:to="loc_us-gaap_DerivativeNotionalAmount_402b4624-c5fb-44bf-b5f5-ef1292d80ab4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_614dad94-3e7b-4b0b-b67b-559bf825e5fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_614dad94-3e7b-4b0b-b67b-559bf825e5fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_4da2ce42-dfbe-4719-ad14-5f2b32c9d16b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:to="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_4da2ce42-dfbe-4719-ad14-5f2b32c9d16b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_c13e6a54-f923-4f2f-8264-29f2d9f2f4a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:to="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_c13e6a54-f923-4f2f-8264-29f2d9f2f4a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_2f1d6015-e1e7-4e12-9146-e08ad66b5444" xlink:href="jnj-20211003.xsd#jnj_EquityFairValueAdjustmentImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:to="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_2f1d6015-e1e7-4e12-9146-e08ad66b5444" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_22608e12-3673-4744-a44f-0962cb8b7059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:to="loc_us-gaap_EquityFairValueAdjustment_22608e12-3673-4744-a44f-0962cb8b7059" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_65756e08-2706-40fd-8ffb-125bf01725c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:to="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_65756e08-2706-40fd-8ffb-125bf01725c0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_de88c9ac-427f-45ed-91c8-78feee4bc9ea" xlink:href="jnj-20211003.xsd#jnj_ExcessOfFairValueOverCarryingValueOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:to="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_de88c9ac-427f-45ed-91c8-78feee4bc9ea" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_feaffe3b-2276-4439-a5f9-288a3dcee234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:to="loc_us-gaap_ShortTermBorrowings_feaffe3b-2276-4439-a5f9-288a3dcee234" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_53cf6b8a-f138-4e16-9b6a-afeca45092e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_53cf6b8a-f138-4e16-9b6a-afeca45092e3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_6be81074-c91c-42f2-b8f5-b737263b9d57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:to="loc_us-gaap_DebtInstrumentTerm_6be81074-c91c-42f2-b8f5-b737263b9d57" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_1a58c633-ee19-4f1b-92a5-02bf65beaf06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:to="loc_us-gaap_DerivativeTable_1a58c633-ee19-4f1b-92a5-02bf65beaf06" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_4094d989-0f28-42ce-8244-5bad7f1cc69c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1a58c633-ee19-4f1b-92a5-02bf65beaf06" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_4094d989-0f28-42ce-8244-5bad7f1cc69c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_4094d989-0f28-42ce-8244-5bad7f1cc69c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_4094d989-0f28-42ce-8244-5bad7f1cc69c" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_4094d989-0f28-42ce-8244-5bad7f1cc69c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_d7dea776-b0b7-459b-a579-40896f0fa4c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_4094d989-0f28-42ce-8244-5bad7f1cc69c" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_d7dea776-b0b7-459b-a579-40896f0fa4c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_ebcd462d-155c-43db-bc22-d59a563d9ad6" xlink:href="jnj-20211003.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_d7dea776-b0b7-459b-a579-40896f0fa4c6" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_ebcd462d-155c-43db-bc22-d59a563d9ad6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_f5dc54d8-80cd-4039-95ca-5476676ed912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1a58c633-ee19-4f1b-92a5-02bf65beaf06" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_f5dc54d8-80cd-4039-95ca-5476676ed912" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f5dc54d8-80cd-4039-95ca-5476676ed912_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_f5dc54d8-80cd-4039-95ca-5476676ed912" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f5dc54d8-80cd-4039-95ca-5476676ed912_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2e530ea7-a5c4-4a95-9240-4de6d668e011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_f5dc54d8-80cd-4039-95ca-5476676ed912" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2e530ea7-a5c4-4a95-9240-4de6d668e011" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_32595d3e-789e-4877-8849-046035ac0f95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2e530ea7-a5c4-4a95-9240-4de6d668e011" xlink:to="loc_us-gaap_EquitySecuritiesMember_32595d3e-789e-4877-8849-046035ac0f95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_7bdd7d00-d06c-49e2-973d-1bf13d787507" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1a58c633-ee19-4f1b-92a5-02bf65beaf06" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_7bdd7d00-d06c-49e2-973d-1bf13d787507" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7bdd7d00-d06c-49e2-973d-1bf13d787507_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7bdd7d00-d06c-49e2-973d-1bf13d787507" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7bdd7d00-d06c-49e2-973d-1bf13d787507_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_95377d10-cd35-4df9-9bf0-f9d87aa9c860" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7bdd7d00-d06c-49e2-973d-1bf13d787507" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_95377d10-cd35-4df9-9bf0-f9d87aa9c860" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_72887246-7bea-48a1-a166-4391155c9372" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_95377d10-cd35-4df9-9bf0-f9d87aa9c860" xlink:to="loc_us-gaap_ForeignExchangeContractMember_72887246-7bea-48a1-a166-4391155c9372" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_bddf3b2c-38a6-41a7-9617-8403bf2c8fd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_95377d10-cd35-4df9-9bf0-f9d87aa9c860" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_bddf3b2c-38a6-41a7-9617-8403bf2c8fd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_b280da34-f91a-4419-b5ad-3115e27e5128" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_95377d10-cd35-4df9-9bf0-f9d87aa9c860" xlink:to="loc_us-gaap_InterestRateSwapMember_b280da34-f91a-4419-b5ad-3115e27e5128" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_8752fad0-1533-42b4-b264-ee0bc5b1d0fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1a58c633-ee19-4f1b-92a5-02bf65beaf06" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_8752fad0-1533-42b4-b264-ee0bc5b1d0fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_8752fad0-1533-42b4-b264-ee0bc5b1d0fe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_8752fad0-1533-42b4-b264-ee0bc5b1d0fe" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_8752fad0-1533-42b4-b264-ee0bc5b1d0fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_4ef048bb-3c33-4a7d-b355-0adee9b4874e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_8752fad0-1533-42b4-b264-ee0bc5b1d0fe" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_4ef048bb-3c33-4a7d-b355-0adee9b4874e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_159e7d56-1949-434f-b352-0980ec8e1851" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_4ef048bb-3c33-4a7d-b355-0adee9b4874e" xlink:to="loc_us-gaap_CommercialPaperMember_159e7d56-1949-434f-b352-0980ec8e1851" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#FairValueMeasurementsSummaryofDerivativeActivityDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="extended" id="i941de89df50f463a8dbfa1f3c3709e26_FairValueMeasurementsSummaryofDerivativeActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_777abd7c-ea5d-4eab-b0ed-35fa31a7cabe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_42a8d952-0de6-49e1-bdef-4dda054466c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_777abd7c-ea5d-4eab-b0ed-35fa31a7cabe" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_42a8d952-0de6-49e1-bdef-4dda054466c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_13b92a2e-5200-43ee-b463-78cbb72c1a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_777abd7c-ea5d-4eab-b0ed-35fa31a7cabe" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_13b92a2e-5200-43ee-b463-78cbb72c1a5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_aed16be9-121c-4d16-8e45-0592724133e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_777abd7c-ea5d-4eab-b0ed-35fa31a7cabe" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_aed16be9-121c-4d16-8e45-0592724133e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_04d56a0e-fdd5-42c9-8880-f624bc402e1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_777abd7c-ea5d-4eab-b0ed-35fa31a7cabe" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_04d56a0e-fdd5-42c9-8880-f624bc402e1c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_eb519ee7-b977-4126-8e41-e7733f966078" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_04d56a0e-fdd5-42c9-8880-f624bc402e1c" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_eb519ee7-b977-4126-8e41-e7733f966078" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_eb519ee7-b977-4126-8e41-e7733f966078_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_eb519ee7-b977-4126-8e41-e7733f966078" xlink:to="loc_us-gaap_HedgingRelationshipDomain_eb519ee7-b977-4126-8e41-e7733f966078_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_e920790f-78fc-4000-b5f7-e5fe3c0b4f58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_eb519ee7-b977-4126-8e41-e7733f966078" xlink:to="loc_us-gaap_HedgingRelationshipDomain_e920790f-78fc-4000-b5f7-e5fe3c0b4f58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_6ab3eea9-389a-474c-b8d5-0995fd0e299b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e920790f-78fc-4000-b5f7-e5fe3c0b4f58" xlink:to="loc_us-gaap_FairValueHedgingMember_6ab3eea9-389a-474c-b8d5-0995fd0e299b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_9f910468-511d-474b-a229-ad3b165c24a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e920790f-78fc-4000-b5f7-e5fe3c0b4f58" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_9f910468-511d-474b-a229-ad3b165c24a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_c5f5c239-cbe0-4528-ac54-bc0ba4bbc28e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e920790f-78fc-4000-b5f7-e5fe3c0b4f58" xlink:to="loc_us-gaap_CashFlowHedgingMember_c5f5c239-cbe0-4528-ac54-bc0ba4bbc28e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5346ffb6-50f0-4e58-8b90-1817b3feffd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_04d56a0e-fdd5-42c9-8880-f624bc402e1c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5346ffb6-50f0-4e58-8b90-1817b3feffd0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5346ffb6-50f0-4e58-8b90-1817b3feffd0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5346ffb6-50f0-4e58-8b90-1817b3feffd0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5346ffb6-50f0-4e58-8b90-1817b3feffd0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f7ef988d-1f45-4282-8fd3-43b086e141cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5346ffb6-50f0-4e58-8b90-1817b3feffd0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f7ef988d-1f45-4282-8fd3-43b086e141cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_05c59c5e-28f9-4c56-807e-1d1c31ad5ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f7ef988d-1f45-4282-8fd3-43b086e141cf" xlink:to="loc_us-gaap_InterestRateContractMember_05c59c5e-28f9-4c56-807e-1d1c31ad5ff7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_821ae202-0703-4167-827b-9f1b8bbe87df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f7ef988d-1f45-4282-8fd3-43b086e141cf" xlink:to="loc_us-gaap_ForeignExchangeContractMember_821ae202-0703-4167-827b-9f1b8bbe87df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_122d1312-43cb-48f4-ad09-83ecefe2a6ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f7ef988d-1f45-4282-8fd3-43b086e141cf" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_122d1312-43cb-48f4-ad09-83ecefe2a6ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_e1864b21-3cfb-4206-8d4a-74cf859bd352" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f7ef988d-1f45-4282-8fd3-43b086e141cf" xlink:to="loc_us-gaap_InterestRateSwapMember_e1864b21-3cfb-4206-8d4a-74cf859bd352" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_08b7948f-5d35-4100-9f8d-83b29aa7dbd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f7ef988d-1f45-4282-8fd3-43b086e141cf" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_08b7948f-5d35-4100-9f8d-83b29aa7dbd6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ac0870e2-e4a6-4acc-9559-aa16e3555242" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_04d56a0e-fdd5-42c9-8880-f624bc402e1c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ac0870e2-e4a6-4acc-9559-aa16e3555242" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ac0870e2-e4a6-4acc-9559-aa16e3555242_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ac0870e2-e4a6-4acc-9559-aa16e3555242" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ac0870e2-e4a6-4acc-9559-aa16e3555242_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_96b0154d-8243-4c7d-9ba6-2eb6fbf35ba0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ac0870e2-e4a6-4acc-9559-aa16e3555242" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_96b0154d-8243-4c7d-9ba6-2eb6fbf35ba0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_22fcf29d-0a83-4bc1-8eca-1a105185e9bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_96b0154d-8243-4c7d-9ba6-2eb6fbf35ba0" xlink:to="loc_us-gaap_SalesMember_22fcf29d-0a83-4bc1-8eca-1a105185e9bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_ef2a2400-a5db-4dd9-a9b8-ca8b8f9b2056" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_96b0154d-8243-4c7d-9ba6-2eb6fbf35ba0" xlink:to="loc_us-gaap_CostOfSalesMember_ef2a2400-a5db-4dd9-a9b8-ca8b8f9b2056" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_60c568a9-f685-40c3-839a-2b2244d5b9ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_96b0154d-8243-4c7d-9ba6-2eb6fbf35ba0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_60c568a9-f685-40c3-839a-2b2244d5b9ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_fc392fe0-331d-4429-82fc-b62d9bfdf69a" xlink:href="jnj-20211003.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_96b0154d-8243-4c7d-9ba6-2eb6fbf35ba0" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_fc392fe0-331d-4429-82fc-b62d9bfdf69a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember_71e0f866-b0bc-4386-9290-b9ead277b2a6" xlink:href="jnj-20211003.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_96b0154d-8243-4c7d-9ba6-2eb6fbf35ba0" xlink:to="loc_jnj_InterestIncomeExpenseNetMember_71e0f866-b0bc-4386-9290-b9ead277b2a6" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#FairValueMeasurementsDerivativesBalanceSheetLocationDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails" xlink:type="extended" id="i6a383d32600e4a7596c371094b8a8519_FairValueMeasurementsDerivativesBalanceSheetLocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_e97cde66-005e-4ead-aa1c-0c6aa4609097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_c3faa2d1-72bb-4e19-85f0-61768657d2e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e97cde66-005e-4ead-aa1c-0c6aa4609097" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_c3faa2d1-72bb-4e19-85f0-61768657d2e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_e1a6c5f2-7d6e-4146-ae7a-6cd96e1a5374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e97cde66-005e-4ead-aa1c-0c6aa4609097" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_e1a6c5f2-7d6e-4146-ae7a-6cd96e1a5374" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_f4ac8e40-e15b-4715-92b1-f89015e8792d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_e97cde66-005e-4ead-aa1c-0c6aa4609097" xlink:to="loc_us-gaap_DerivativeTable_f4ac8e40-e15b-4715-92b1-f89015e8792d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5d8e7952-eb8e-4aa4-8ab8-4de657f10053" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_f4ac8e40-e15b-4715-92b1-f89015e8792d" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5d8e7952-eb8e-4aa4-8ab8-4de657f10053" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5d8e7952-eb8e-4aa4-8ab8-4de657f10053_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5d8e7952-eb8e-4aa4-8ab8-4de657f10053" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5d8e7952-eb8e-4aa4-8ab8-4de657f10053_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_630850e2-d22e-4d72-a171-1dde4a4c4c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5d8e7952-eb8e-4aa4-8ab8-4de657f10053" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_630850e2-d22e-4d72-a171-1dde4a4c4c3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_8dbdf002-1887-4362-bf47-99d09929a0df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_630850e2-d22e-4d72-a171-1dde4a4c4c3d" xlink:to="loc_us-gaap_LongTermDebtMember_8dbdf002-1887-4362-bf47-99d09929a0df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_e41e268f-3d1a-4f03-8489-9e4b97edf81d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_f4ac8e40-e15b-4715-92b1-f89015e8792d" xlink:to="loc_us-gaap_HedgingDesignationAxis_e41e268f-3d1a-4f03-8489-9e4b97edf81d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e41e268f-3d1a-4f03-8489-9e4b97edf81d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_e41e268f-3d1a-4f03-8489-9e4b97edf81d" xlink:to="loc_us-gaap_HedgingDesignationDomain_e41e268f-3d1a-4f03-8489-9e4b97edf81d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_5e099449-c10c-4094-8dd6-e42f1285c4eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_e41e268f-3d1a-4f03-8489-9e4b97edf81d" xlink:to="loc_us-gaap_HedgingDesignationDomain_5e099449-c10c-4094-8dd6-e42f1285c4eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f49b14da-a45a-4fe1-909d-6602e7c95076" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_5e099449-c10c-4094-8dd6-e42f1285c4eb" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f49b14da-a45a-4fe1-909d-6602e7c95076" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="extended" id="i599beb30fae94b35aed44437055d037a_FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b0e96459-673a-456b-82ef-7649f24cc6a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_f7e73311-9de6-4a79-a904-0b53a6a5abb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b0e96459-673a-456b-82ef-7649f24cc6a0" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_f7e73311-9de6-4a79-a904-0b53a6a5abb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_22159a12-6ff5-4dcc-abcd-4ae33f5eb993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b0e96459-673a-456b-82ef-7649f24cc6a0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_22159a12-6ff5-4dcc-abcd-4ae33f5eb993" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_689d3e36-e79d-402c-98ad-8ef0f7f3ea88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_22159a12-6ff5-4dcc-abcd-4ae33f5eb993" xlink:to="loc_us-gaap_HedgingDesignationAxis_689d3e36-e79d-402c-98ad-8ef0f7f3ea88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_689d3e36-e79d-402c-98ad-8ef0f7f3ea88_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_689d3e36-e79d-402c-98ad-8ef0f7f3ea88" xlink:to="loc_us-gaap_HedgingDesignationDomain_689d3e36-e79d-402c-98ad-8ef0f7f3ea88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_9b6c3d77-2121-4585-8434-bb42ad08002e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_689d3e36-e79d-402c-98ad-8ef0f7f3ea88" xlink:to="loc_us-gaap_HedgingDesignationDomain_9b6c3d77-2121-4585-8434-bb42ad08002e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_96fea70a-ae13-4ce5-9393-cde2acca1a6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_9b6c3d77-2121-4585-8434-bb42ad08002e" xlink:to="loc_us-gaap_NondesignatedMember_96fea70a-ae13-4ce5-9393-cde2acca1a6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6338f688-3494-431e-b6a5-be6b7ab98840" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_22159a12-6ff5-4dcc-abcd-4ae33f5eb993" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6338f688-3494-431e-b6a5-be6b7ab98840" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6338f688-3494-431e-b6a5-be6b7ab98840_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6338f688-3494-431e-b6a5-be6b7ab98840" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6338f688-3494-431e-b6a5-be6b7ab98840_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d98cf140-1139-43bb-948b-7138e76eeffd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6338f688-3494-431e-b6a5-be6b7ab98840" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d98cf140-1139-43bb-948b-7138e76eeffd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_cadea375-427d-48e4-bc84-2cd994fd7ba3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d98cf140-1139-43bb-948b-7138e76eeffd" xlink:to="loc_us-gaap_ForeignExchangeContractMember_cadea375-427d-48e4-bc84-2cd994fd7ba3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_df28ad4e-9b52-4e85-97ec-7de11e79470e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_22159a12-6ff5-4dcc-abcd-4ae33f5eb993" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_df28ad4e-9b52-4e85-97ec-7de11e79470e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_df28ad4e-9b52-4e85-97ec-7de11e79470e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_df28ad4e-9b52-4e85-97ec-7de11e79470e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_df28ad4e-9b52-4e85-97ec-7de11e79470e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_18f10df3-1f1c-47a2-bef6-141eb24f98fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_df28ad4e-9b52-4e85-97ec-7de11e79470e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_18f10df3-1f1c-47a2-bef6-141eb24f98fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_4027ac4f-6602-4ea7-ab1c-b3e1e356d6c0" xlink:href="jnj-20211003.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_18f10df3-1f1c-47a2-bef6-141eb24f98fd" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_4027ac4f-6602-4ea7-ab1c-b3e1e356d6c0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="extended" id="ife42f261bde944e39a1304ed86c5e25c_FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_129e3f8e-e823-4646-9154-b9d5ff8bc4f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_e4d296aa-894e-4385-a786-50f4c66198e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_129e3f8e-e823-4646-9154-b9d5ff8bc4f8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_e4d296aa-894e-4385-a786-50f4c66198e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_90ea76bf-7ab5-401e-9810-a6c1c9c9bdd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_129e3f8e-e823-4646-9154-b9d5ff8bc4f8" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_90ea76bf-7ab5-401e-9810-a6c1c9c9bdd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_67340800-5731-48c2-bcd4-06d188431be0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_129e3f8e-e823-4646-9154-b9d5ff8bc4f8" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_67340800-5731-48c2-bcd4-06d188431be0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1223e313-db76-4a90-9a8d-c1bc0b514273" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_67340800-5731-48c2-bcd4-06d188431be0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1223e313-db76-4a90-9a8d-c1bc0b514273" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1223e313-db76-4a90-9a8d-c1bc0b514273_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1223e313-db76-4a90-9a8d-c1bc0b514273" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1223e313-db76-4a90-9a8d-c1bc0b514273_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ef2a0ca4-0390-4e06-a502-6cca1f355eaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1223e313-db76-4a90-9a8d-c1bc0b514273" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ef2a0ca4-0390-4e06-a502-6cca1f355eaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_dbfdda9a-eea9-4689-82d6-f8b02776dd09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ef2a0ca4-0390-4e06-a502-6cca1f355eaf" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_dbfdda9a-eea9-4689-82d6-f8b02776dd09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_758589ae-53ae-4858-8679-c0b8e4cbb783" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_67340800-5731-48c2-bcd4-06d188431be0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_758589ae-53ae-4858-8679-c0b8e4cbb783" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_758589ae-53ae-4858-8679-c0b8e4cbb783_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_758589ae-53ae-4858-8679-c0b8e4cbb783" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_758589ae-53ae-4858-8679-c0b8e4cbb783_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cc7d6bcf-9ec0-424f-901f-3972a3f12ee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_758589ae-53ae-4858-8679-c0b8e4cbb783" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cc7d6bcf-9ec0-424f-901f-3972a3f12ee9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_a9a588cb-1911-4710-b2ec-2c0ddcbfafcd" xlink:href="jnj-20211003.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cc7d6bcf-9ec0-424f-901f-3972a3f12ee9" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_a9a588cb-1911-4710-b2ec-2c0ddcbfafcd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="extended" id="i4410f2f6255d418d905c5e6b56ce96f9_FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_8bc7ed31-c9bf-4c11-a7f0-96b816b7c3df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward_89c29951-950a-46e6-af50-188d581f92cf" xlink:href="jnj-20211003.xsd#jnj_EquityInvestmentRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_8bc7ed31-c9bf-4c11-a7f0-96b816b7c3df" xlink:to="loc_jnj_EquityInvestmentRollForward_89c29951-950a-46e6-af50-188d581f92cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_53f60367-893e-4c60-88c2-bdf1cf03bf3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_89c29951-950a-46e6-af50-188d581f92cf" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_53f60367-893e-4c60-88c2-bdf1cf03bf3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_4370e693-feb8-4244-882c-e9dee892dfa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_89c29951-950a-46e6-af50-188d581f92cf" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_4370e693-feb8-4244-882c-e9dee892dfa8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_c7707315-e57e-49b2-98c4-35e63c176c76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_89c29951-950a-46e6-af50-188d581f92cf" xlink:to="loc_us-gaap_EquityFairValueAdjustment_c7707315-e57e-49b2-98c4-35e63c176c76" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_51aab142-ddab-4b34-8ff2-c97c77df0fa0" xlink:href="jnj-20211003.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_89c29951-950a-46e6-af50-188d581f92cf" xlink:to="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_51aab142-ddab-4b34-8ff2-c97c77df0fa0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_c1daacf4-9b6d-48ae-9ef5-546af2255ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_e6f22caf-52ed-490b-98d4-b00cf9c3d5f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_dd4a6bb2-c795-46b6-872e-6b00b8e9a661" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_89c29951-950a-46e6-af50-188d581f92cf" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_dd4a6bb2-c795-46b6-872e-6b00b8e9a661" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_773b03f7-9f6a-4309-9117-f2eff3fd0bc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_8bc7ed31-c9bf-4c11-a7f0-96b816b7c3df" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_773b03f7-9f6a-4309-9117-f2eff3fd0bc1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_7c547c3c-0e6f-488d-b9c3-75e1a3018fca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_773b03f7-9f6a-4309-9117-f2eff3fd0bc1" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_7c547c3c-0e6f-488d-b9c3-75e1a3018fca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7c547c3c-0e6f-488d-b9c3-75e1a3018fca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_7c547c3c-0e6f-488d-b9c3-75e1a3018fca" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7c547c3c-0e6f-488d-b9c3-75e1a3018fca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_56e292e5-f3b8-445e-a0cc-9311e6c47177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_7c547c3c-0e6f-488d-b9c3-75e1a3018fca" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_56e292e5-f3b8-445e-a0cc-9311e6c47177" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_55d47fa4-cfce-45d4-a738-7c5120ae3f0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_56e292e5-f3b8-445e-a0cc-9311e6c47177" xlink:to="loc_us-gaap_EquitySecuritiesMember_55d47fa4-cfce-45d4-a738-7c5120ae3f0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_687e9a93-81a3-4b8c-96fa-66f6efd0406a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_773b03f7-9f6a-4309-9117-f2eff3fd0bc1" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_687e9a93-81a3-4b8c-96fa-66f6efd0406a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_687e9a93-81a3-4b8c-96fa-66f6efd0406a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_687e9a93-81a3-4b8c-96fa-66f6efd0406a" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_687e9a93-81a3-4b8c-96fa-66f6efd0406a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_4c838519-fe95-4af3-9814-e19700fde211" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_687e9a93-81a3-4b8c-96fa-66f6efd0406a" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_4c838519-fe95-4af3-9814-e19700fde211" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_1dc57849-b08b-4dce-8de7-28aa372a741a" xlink:href="jnj-20211003.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_4c838519-fe95-4af3-9814-e19700fde211" xlink:to="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_1dc57849-b08b-4dce-8de7-28aa372a741a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_86914d3a-8ef0-4e6c-8317-994709cd6703" xlink:href="jnj-20211003.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_4c838519-fe95-4af3-9814-e19700fde211" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_86914d3a-8ef0-4e6c-8317-994709cd6703" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended" id="ied26821291ac449d87bad01521eecee9_FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_98a678b5-100e-4ef8-ae08-b46beefe1a28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:to="loc_us-gaap_DerivativeInstrumentDetailAbstract_98a678b5-100e-4ef8-ae08-b46beefe1a28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_bd85ce60-d459-4ce3-916f-997cc5763f13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_98a678b5-100e-4ef8-ae08-b46beefe1a28" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_bd85ce60-d459-4ce3-916f-997cc5763f13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_353f8f12-069d-44d3-9869-0c8dd0da76e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_98a678b5-100e-4ef8-ae08-b46beefe1a28" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_353f8f12-069d-44d3-9869-0c8dd0da76e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_10b92694-3b56-4464-980f-8edc53b70572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_98a678b5-100e-4ef8-ae08-b46beefe1a28" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_10b92694-3b56-4464-980f-8edc53b70572" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_7c414e90-636e-4d9d-91df-b3429f8ae474" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_98a678b5-100e-4ef8-ae08-b46beefe1a28" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_7c414e90-636e-4d9d-91df-b3429f8ae474" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_f58530cf-7749-4437-8e0c-453b44756f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_98a678b5-100e-4ef8-ae08-b46beefe1a28" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_f58530cf-7749-4437-8e0c-453b44756f5d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bf15d2d5-2536-4503-87a5-19f4c014ce8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_98a678b5-100e-4ef8-ae08-b46beefe1a28" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bf15d2d5-2536-4503-87a5-19f4c014ce8f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5ef4e6fd-bf12-404c-8db0-0e1b51212c97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_98a678b5-100e-4ef8-ae08-b46beefe1a28" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5ef4e6fd-bf12-404c-8db0-0e1b51212c97" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_8943c2db-2186-46dc-b863-4c3239133f17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_8943c2db-2186-46dc-b863-4c3239133f17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_569bfc80-d3b2-4093-82d2-24772f124023" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_569bfc80-d3b2-4093-82d2-24772f124023" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_3959f502-a485-462e-b824-7a82632ecc6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:to="loc_us-gaap_DerivativeAssets_3959f502-a485-462e-b824-7a82632ecc6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_9e35808e-367c-47ab-a817-33ede6ea7238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_9e35808e-367c-47ab-a817-33ede6ea7238" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_8fe62650-ade1-435b-a53c-dd28b576b66f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_8fe62650-ade1-435b-a53c-dd28b576b66f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_297d9c74-d0d7-4edc-87ac-7f2b5e182747" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:to="loc_us-gaap_DerivativeLiabilities_297d9c74-d0d7-4edc-87ac-7f2b5e182747" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5a58cedb-c4a8-448c-961e-ba8e3235a893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5a58cedb-c4a8-448c-961e-ba8e3235a893" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_bd7d224f-1f88-4ccf-ba41-39b47bfbd143" xlink:href="jnj-20211003.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:to="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_bd7d224f-1f88-4ccf-ba41-39b47bfbd143" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_7ab5fd3b-cabd-466f-beab-326d78630376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_7ab5fd3b-cabd-466f-beab-326d78630376" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_b72fd834-7b03-41ba-a686-ec73f65aa9ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_b72fd834-7b03-41ba-a686-ec73f65aa9ba" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2f601f11-bc18-47d5-b32c-415096000fea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e04e8846-2059-48a3-89f3-868472593b78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e04e8846-2059-48a3-89f3-868472593b78" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_bcaa02af-d4f4-4775-8d93-5b41bfe4f4c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_bcaa02af-d4f4-4775-8d93-5b41bfe4f4c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_0008f335-e12d-4cf1-b826-532bfe47c561" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_bcaa02af-d4f4-4775-8d93-5b41bfe4f4c3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_0008f335-e12d-4cf1-b826-532bfe47c561" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0008f335-e12d-4cf1-b826-532bfe47c561_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0008f335-e12d-4cf1-b826-532bfe47c561" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0008f335-e12d-4cf1-b826-532bfe47c561_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3821ad88-2904-4581-87bc-ad76d6d42006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0008f335-e12d-4cf1-b826-532bfe47c561" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3821ad88-2904-4581-87bc-ad76d6d42006" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_f2c731a8-e96f-4264-a07d-bab8eddcb64a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3821ad88-2904-4581-87bc-ad76d6d42006" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_f2c731a8-e96f-4264-a07d-bab8eddcb64a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_bf1fb724-bf3b-4903-875e-851527fea262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3821ad88-2904-4581-87bc-ad76d6d42006" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_bf1fb724-bf3b-4903-875e-851527fea262" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_ebeb3046-c1eb-46e3-bd24-817fb69fd9eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3821ad88-2904-4581-87bc-ad76d6d42006" xlink:to="loc_us-gaap_LongTermDebtMember_ebeb3046-c1eb-46e3-bd24-817fb69fd9eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_be96e1f1-63d2-43b3-abaa-dfcb41768201" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_bcaa02af-d4f4-4775-8d93-5b41bfe4f4c3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_be96e1f1-63d2-43b3-abaa-dfcb41768201" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_be96e1f1-63d2-43b3-abaa-dfcb41768201_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_be96e1f1-63d2-43b3-abaa-dfcb41768201" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_be96e1f1-63d2-43b3-abaa-dfcb41768201_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a7c4ce78-281c-4967-838b-92f305941654" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_be96e1f1-63d2-43b3-abaa-dfcb41768201" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a7c4ce78-281c-4967-838b-92f305941654" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_9919600d-bdf0-469b-aff2-90ed8e9653de" xlink:href="jnj-20211003.xsd#jnj_AurisHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a7c4ce78-281c-4967-838b-92f305941654" xlink:to="loc_jnj_AurisHealthMember_9919600d-bdf0-469b-aff2-90ed8e9653de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_4c9fc6a3-f492-450f-8eb2-2c5965895f3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_bcaa02af-d4f4-4775-8d93-5b41bfe4f4c3" xlink:to="loc_us-gaap_InvestmentTypeAxis_4c9fc6a3-f492-450f-8eb2-2c5965895f3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4c9fc6a3-f492-450f-8eb2-2c5965895f3f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_4c9fc6a3-f492-450f-8eb2-2c5965895f3f" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4c9fc6a3-f492-450f-8eb2-2c5965895f3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b6cd49d2-f6d6-42b2-a391-0240f7637368" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_4c9fc6a3-f492-450f-8eb2-2c5965895f3f" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b6cd49d2-f6d6-42b2-a391-0240f7637368" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_33915c06-e13c-4c3c-a86e-a1d798a81f11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b6cd49d2-f6d6-42b2-a391-0240f7637368" xlink:to="loc_us-gaap_EquitySecuritiesMember_33915c06-e13c-4c3c-a86e-a1d798a81f11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_09bd8608-acfc-4bfd-a79f-8e7246a56d72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_bcaa02af-d4f4-4775-8d93-5b41bfe4f4c3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_09bd8608-acfc-4bfd-a79f-8e7246a56d72" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_09bd8608-acfc-4bfd-a79f-8e7246a56d72_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_09bd8608-acfc-4bfd-a79f-8e7246a56d72" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_09bd8608-acfc-4bfd-a79f-8e7246a56d72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c3e1d986-e8bc-4cf7-b102-ddebb39141d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_09bd8608-acfc-4bfd-a79f-8e7246a56d72" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c3e1d986-e8bc-4cf7-b102-ddebb39141d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_f5cb46c3-0048-4a14-9d18-0f764a52434d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c3e1d986-e8bc-4cf7-b102-ddebb39141d9" xlink:to="loc_us-gaap_InterestRateContractMember_f5cb46c3-0048-4a14-9d18-0f764a52434d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_866743d6-618b-45d9-8113-830f57d3d63f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c3e1d986-e8bc-4cf7-b102-ddebb39141d9" xlink:to="loc_us-gaap_ForeignExchangeContractMember_866743d6-618b-45d9-8113-830f57d3d63f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_7d5b908b-f6fc-4a2d-aef5-1e4302b05818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c3e1d986-e8bc-4cf7-b102-ddebb39141d9" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_7d5b908b-f6fc-4a2d-aef5-1e4302b05818" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3688be16-66fc-431c-ac7a-bedee3b76e9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_bcaa02af-d4f4-4775-8d93-5b41bfe4f4c3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3688be16-66fc-431c-ac7a-bedee3b76e9a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3688be16-66fc-431c-ac7a-bedee3b76e9a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3688be16-66fc-431c-ac7a-bedee3b76e9a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3688be16-66fc-431c-ac7a-bedee3b76e9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49a4fdb9-9ddf-4766-af7b-1445a3c695de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3688be16-66fc-431c-ac7a-bedee3b76e9a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49a4fdb9-9ddf-4766-af7b-1445a3c695de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d8086fd9-9df2-4ae1-aac2-ca70793ecfa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49a4fdb9-9ddf-4766-af7b-1445a3c695de" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d8086fd9-9df2-4ae1-aac2-ca70793ecfa0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2a6d7f76-2cc2-498a-b04a-5950c4dcc262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49a4fdb9-9ddf-4766-af7b-1445a3c695de" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2a6d7f76-2cc2-498a-b04a-5950c4dcc262" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6a3ceeb3-3c92-4d19-871f-ff62c3feccbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49a4fdb9-9ddf-4766-af7b-1445a3c695de" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6a3ceeb3-3c92-4d19-871f-ff62c3feccbd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_36b2e3f9-da47-4247-a0f8-8409915ea08e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_bcaa02af-d4f4-4775-8d93-5b41bfe4f4c3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_36b2e3f9-da47-4247-a0f8-8409915ea08e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_36b2e3f9-da47-4247-a0f8-8409915ea08e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_36b2e3f9-da47-4247-a0f8-8409915ea08e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_36b2e3f9-da47-4247-a0f8-8409915ea08e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_593e3260-fa90-44e7-b7fd-dfe384f9fee2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_36b2e3f9-da47-4247-a0f8-8409915ea08e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_593e3260-fa90-44e7-b7fd-dfe384f9fee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_780cfe20-3e95-4b39-bb10-9336a30d91eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_593e3260-fa90-44e7-b7fd-dfe384f9fee2" xlink:to="loc_us-gaap_FairValueHedgingMember_780cfe20-3e95-4b39-bb10-9336a30d91eb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended" id="i1506031138104bc79a9934b7f2348c7d_FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_29ad7040-cd58-4493-8c3a-9900d43c2ceb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_774c55c3-8a36-4561-8bdd-1fa6b8a65811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_29ad7040-cd58-4493-8c3a-9900d43c2ceb" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_774c55c3-8a36-4561-8bdd-1fa6b8a65811" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_e03df6cf-0db9-438a-9c73-352ce872ef1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_774c55c3-8a36-4561-8bdd-1fa6b8a65811" xlink:to="loc_us-gaap_HeldToMaturitySecurities_e03df6cf-0db9-438a-9c73-352ce872ef1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_0a029f94-9d24-4e43-a38d-148618be0050" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_774c55c3-8a36-4561-8bdd-1fa6b8a65811" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_0a029f94-9d24-4e43-a38d-148618be0050" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_40905ed5-7a98-4af5-8e89-288fb717f40a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_774c55c3-8a36-4561-8bdd-1fa6b8a65811" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_40905ed5-7a98-4af5-8e89-288fb717f40a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_529ab353-1a0b-48a3-8ecb-770e576c5ffe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_774c55c3-8a36-4561-8bdd-1fa6b8a65811" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_529ab353-1a0b-48a3-8ecb-770e576c5ffe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_709a1cfd-ef99-4afc-9343-6a1d0e52501a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_29ad7040-cd58-4493-8c3a-9900d43c2ceb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_709a1cfd-ef99-4afc-9343-6a1d0e52501a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_67893e2b-c701-48da-88c2-245083bfb544" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_709a1cfd-ef99-4afc-9343-6a1d0e52501a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_67893e2b-c701-48da-88c2-245083bfb544" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_445d8124-d209-4914-8d31-cbf5451b4d7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_709a1cfd-ef99-4afc-9343-6a1d0e52501a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_445d8124-d209-4914-8d31-cbf5451b4d7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d7bf5265-ab5d-4d85-9fa5-a9f06b5c80a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_709a1cfd-ef99-4afc-9343-6a1d0e52501a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d7bf5265-ab5d-4d85-9fa5-a9f06b5c80a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e354b404-d4cc-4aba-b93d-dbc2cdef9a0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_709a1cfd-ef99-4afc-9343-6a1d0e52501a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e354b404-d4cc-4aba-b93d-dbc2cdef9a0c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a65eae78-d34a-415b-8def-7aa7f3872a36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_29ad7040-cd58-4493-8c3a-9900d43c2ceb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a65eae78-d34a-415b-8def-7aa7f3872a36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_67cb193f-bd09-42c7-ad0f-ce988004e288" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a65eae78-d34a-415b-8def-7aa7f3872a36" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_67cb193f-bd09-42c7-ad0f-ce988004e288" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_1f911040-b19a-4f8a-8e2e-60cb643ad925" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a65eae78-d34a-415b-8def-7aa7f3872a36" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_1f911040-b19a-4f8a-8e2e-60cb643ad925" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_548d67fc-bc1a-4e5d-a439-e5b4a4905c81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a65eae78-d34a-415b-8def-7aa7f3872a36" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_548d67fc-bc1a-4e5d-a439-e5b4a4905c81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain_b5c85b05-b893-4b71-9379-684951377573" xlink:href="jnj-20211003.xsd#jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a65eae78-d34a-415b-8def-7aa7f3872a36" xlink:to="loc_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain_b5c85b05-b893-4b71-9379-684951377573" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_6429de39-451d-4d3a-a2db-6043f31a3fa6" xlink:href="jnj-20211003.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a65eae78-d34a-415b-8def-7aa7f3872a36" xlink:to="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_6429de39-451d-4d3a-a2db-6043f31a3fa6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_2632928a-7d99-4a75-a416-d8d91265db0a" xlink:href="jnj-20211003.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a65eae78-d34a-415b-8def-7aa7f3872a36" xlink:to="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_2632928a-7d99-4a75-a416-d8d91265db0a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4a9db243-0f66-4566-b7b6-46b444a36f37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_29ad7040-cd58-4493-8c3a-9900d43c2ceb" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4a9db243-0f66-4566-b7b6-46b444a36f37" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_2fb6b942-b654-436d-a8ed-8ca5684dbce7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4a9db243-0f66-4566-b7b6-46b444a36f37" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_2fb6b942-b654-436d-a8ed-8ca5684dbce7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_2fb6b942-b654-436d-a8ed-8ca5684dbce7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_2fb6b942-b654-436d-a8ed-8ca5684dbce7" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_2fb6b942-b654-436d-a8ed-8ca5684dbce7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_cda19875-eda2-49cd-83ff-788f792a2bb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_2fb6b942-b654-436d-a8ed-8ca5684dbce7" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_cda19875-eda2-49cd-83ff-788f792a2bb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember_d860b5ea-3972-4990-9162-e9143abe46ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_cda19875-eda2-49cd-83ff-788f792a2bb6" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesMember_d860b5ea-3972-4990-9162-e9143abe46ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_7cb302aa-e15d-4aea-a310-144a2c6e9068" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_cda19875-eda2-49cd-83ff-788f792a2bb6" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_7cb302aa-e15d-4aea-a310-144a2c6e9068" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_3a551a1c-8c7f-4bf2-9801-86cde62012e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4a9db243-0f66-4566-b7b6-46b444a36f37" xlink:to="loc_us-gaap_InvestmentTypeAxis_3a551a1c-8c7f-4bf2-9801-86cde62012e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_3a551a1c-8c7f-4bf2-9801-86cde62012e1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_3a551a1c-8c7f-4bf2-9801-86cde62012e1" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_3a551a1c-8c7f-4bf2-9801-86cde62012e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_93546ba6-b98e-47be-acfc-fb942549a96a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_3a551a1c-8c7f-4bf2-9801-86cde62012e1" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_93546ba6-b98e-47be-acfc-fb942549a96a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_1fe27e86-8131-4fb7-86aa-421016d9568b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_93546ba6-b98e-47be-acfc-fb942549a96a" xlink:to="loc_us-gaap_CashMember_1fe27e86-8131-4fb7-86aa-421016d9568b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_ff1140d0-ff7f-4b3b-bfa3-3f4fa5047852" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_93546ba6-b98e-47be-acfc-fb942549a96a" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_ff1140d0-ff7f-4b3b-bfa3-3f4fa5047852" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_95d75016-dba2-49c4-afb0-eb8683c86dfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_93546ba6-b98e-47be-acfc-fb942549a96a" xlink:to="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_95d75016-dba2-49c4-afb0-eb8683c86dfb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_52c7fa5b-2896-41b9-84ad-cb890ed3d68b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_93546ba6-b98e-47be-acfc-fb942549a96a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_52c7fa5b-2896-41b9-84ad-cb890ed3d68b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_64945405-10fd-4e4b-a533-d3591fdecc1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_93546ba6-b98e-47be-acfc-fb942549a96a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_64945405-10fd-4e4b-a533-d3591fdecc1f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_aaac3c7d-4af5-4a13-a2a5-3ed0926a0b65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_93546ba6-b98e-47be-acfc-fb942549a96a" xlink:to="loc_us-gaap_BankTimeDepositsMember_aaac3c7d-4af5-4a13-a2a5-3ed0926a0b65" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_0766b693-51da-4a71-a3dd-359a4979fb0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_93546ba6-b98e-47be-acfc-fb942549a96a" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_0766b693-51da-4a71-a3dd-359a4979fb0f" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" xlink:type="extended" id="i0206abe45e63408382e6783b76053be9_FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5c40de7e-8545-46da-864d-5288b317a298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_c14db281-0b75-4d15-bd35-19eeaf2d9258" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5c40de7e-8545-46da-864d-5288b317a298" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_c14db281-0b75-4d15-bd35-19eeaf2d9258" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_7be06387-0451-410e-9ec9-5144244224fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_c14db281-0b75-4d15-bd35-19eeaf2d9258" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_7be06387-0451-410e-9ec9-5144244224fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_5959c4ae-1162-4ac3-9ca1-7a35f4a928e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_7be06387-0451-410e-9ec9-5144244224fd" xlink:to="loc_us-gaap_ShortTermBorrowings_5959c4ae-1162-4ac3-9ca1-7a35f4a928e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_1adb6a21-5f90-418d-977d-f001fc53f170" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_c14db281-0b75-4d15-bd35-19eeaf2d9258" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_1adb6a21-5f90-418d-977d-f001fc53f170" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_cd34224e-f8c0-45fc-8084-9129a417b6f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_1adb6a21-5f90-418d-977d-f001fc53f170" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_cd34224e-f8c0-45fc-8084-9129a417b6f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dd24427f-c35a-49fa-83b2-79504774d2d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_c14db281-0b75-4d15-bd35-19eeaf2d9258" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dd24427f-c35a-49fa-83b2-79504774d2d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6e0913fa-e6e3-4404-b1a0-6142c6937514" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5c40de7e-8545-46da-864d-5288b317a298" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6e0913fa-e6e3-4404-b1a0-6142c6937514" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_cf922e00-e4ad-431d-9116-55a6803e415e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6e0913fa-e6e3-4404-b1a0-6142c6937514" xlink:to="loc_us-gaap_DebtInstrumentAxis_cf922e00-e4ad-431d-9116-55a6803e415e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cf922e00-e4ad-431d-9116-55a6803e415e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_cf922e00-e4ad-431d-9116-55a6803e415e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cf922e00-e4ad-431d-9116-55a6803e415e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_cf922e00-e4ad-431d-9116-55a6803e415e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.73Debenturesdue2023Member_33df69a0-6436-4090-8d53-e1a847086e69" xlink:href="jnj-20211003.xsd#jnj_A6.73Debenturesdue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A6.73Debenturesdue2023Member_33df69a0-6436-4090-8d53-e1a847086e69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.375Notesdue2023Member_95916773-8a7f-46b4-ba8b-4f6e37738e94" xlink:href="jnj-20211003.xsd#jnj_A3.375Notesdue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A3.375Notesdue2023Member_95916773-8a7f-46b4-ba8b-4f6e37738e94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.05Notesdue2023Member_57d659a5-b788-4e20-974e-012ef4ac32d0" xlink:href="jnj-20211003.xsd#jnj_A2.05Notesdue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A2.05Notesdue2023Member_57d659a5-b788-4e20-974e-012ef4ac32d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_5b561c19-e110-4fd3-83c5-aa41ab0a4ae3" xlink:href="jnj-20211003.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A0.650NotesDue2024Member_5b561c19-e110-4fd3-83c5-aa41ab0a4ae3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_e0251ebf-5fc0-4365-8d8c-e94cdadb716c" xlink:href="jnj-20211003.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A5.50NotesDue2024Member_e0251ebf-5fc0-4365-8d8c-e94cdadb716c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member_f1ed3c00-2041-4feb-b133-7beb857f793c" xlink:href="jnj-20211003.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A2.625Notesdue2025Member_f1ed3c00-2041-4feb-b133-7beb857f793c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0550NotesDue2025Member_86eb1112-14e1-47f9-8c97-ffa99d4560c9" xlink:href="jnj-20211003.xsd#jnj_A0550NotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A0550NotesDue2025Member_86eb1112-14e1-47f9-8c97-ffa99d4560c9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member_89508d5f-d745-4a0a-9194-915ae4ee5677" xlink:href="jnj-20211003.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A2.45Notesdue2026Member_89508d5f-d745-4a0a-9194-915ae4ee5677" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member_02e3c641-50ba-4d24-a8e4-cfec0181e6ad" xlink:href="jnj-20211003.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A2.95Notesdue2027Member_02e3c641-50ba-4d24-a8e4-cfec0181e6ad" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member_f675bb74-cce4-4c0d-ab80-36ef982cbd76" xlink:href="jnj-20211003.xsd#jnj_A095NotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A095NotesDue2027Member_f675bb74-cce4-4c0d-ab80-36ef982cbd76" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member_54e8ca39-11ab-4680-af64-f2b76eda3549" xlink:href="jnj-20211003.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A2.900Notesdue2028Member_54e8ca39-11ab-4680-af64-f2b76eda3549" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_965d4b17-8fb8-4191-9c44-437c20cadd20" xlink:href="jnj-20211003.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A1.150NotesDue2028Member_965d4b17-8fb8-4191-9c44-437c20cadd20" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member_1cbe4ba2-503c-4dc3-856a-0f7dd5f01d95" xlink:href="jnj-20211003.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A6.95Notesdue2029Member_1cbe4ba2-503c-4dc3-856a-0f7dd5f01d95" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1300NotesDue2030Member_6f2700ed-1987-495e-8a13-932314fc1ec9" xlink:href="jnj-20211003.xsd#jnj_A1300NotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A1300NotesDue2030Member_6f2700ed-1987-495e-8a13-932314fc1ec9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member_a06a4fcf-1d11-4cf2-8da6-dde99212639b" xlink:href="jnj-20211003.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A4.95Debenturesdue2033Member_a06a4fcf-1d11-4cf2-8da6-dde99212639b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member_2e33e7bf-70e5-455c-9f3a-ef5f8bc1ac26" xlink:href="jnj-20211003.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A4.375Notesdue2033Member_2e33e7bf-70e5-455c-9f3a-ef5f8bc1ac26" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_e0cf2600-c9a3-4a91-bfae-09382f1ce0ef" xlink:href="jnj-20211003.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A1.650NotesDue2035Member_e0cf2600-c9a3-4a91-bfae-09382f1ce0ef" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member_405c7ffb-20cc-4f7d-8260-6892520e58d8" xlink:href="jnj-20211003.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A3.55Notesdue2036Member_405c7ffb-20cc-4f7d-8260-6892520e58d8" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member_c73c1a9a-2e02-49a8-be69-d16e2749ac8f" xlink:href="jnj-20211003.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A5.95Notesdue2037Member_c73c1a9a-2e02-49a8-be69-d16e2749ac8f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member_b9ddcf07-4c73-41f2-ac02-5fbf52dfe63e" xlink:href="jnj-20211003.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A3.625Notesdue2037Member_b9ddcf07-4c73-41f2-ac02-5fbf52dfe63e" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member_ed2ccd0a-458c-45a4-9214-0f0498f2d44d" xlink:href="jnj-20211003.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A3.400Notesdue2038Member_ed2ccd0a-458c-45a4-9214-0f0498f2d44d" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member_f028a8d7-cdde-47b3-90c6-14a02ab95b22" xlink:href="jnj-20211003.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A5.85Debenturesdue2038Member_f028a8d7-cdde-47b3-90c6-14a02ab95b22" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member_fa77787c-5413-4898-aeab-9cf33e0f89d7" xlink:href="jnj-20211003.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A4.50Debenturesdue2040Member_fa77787c-5413-4898-aeab-9cf33e0f89d7" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member_29ee055e-72ea-4115-886e-a51c0fe5535d" xlink:href="jnj-20211003.xsd#jnj_A210NotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A210NotesDue2040Member_29ee055e-72ea-4115-886e-a51c0fe5535d" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member_d4f8c799-2735-4bce-a245-aff4362d8d76" xlink:href="jnj-20211003.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A4.85Notesdue2041Member_d4f8c799-2735-4bce-a245-aff4362d8d76" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member_8bfa5db1-2884-4fb0-9b6f-7f333ff5c415" xlink:href="jnj-20211003.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A4.50Notesdue2043Member_8bfa5db1-2884-4fb0-9b6f-7f333ff5c415" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member_4928c7ba-785a-41c7-bbcd-edf9f3492561" xlink:href="jnj-20211003.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A3.70Notesdue2046Member_4928c7ba-785a-41c7-bbcd-edf9f3492561" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member_00a8bd07-83c5-4d14-8d56-48b089ce48ed" xlink:href="jnj-20211003.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A3.75Notesdue2047Member_00a8bd07-83c5-4d14-8d56-48b089ce48ed" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member_18d11fa4-b397-40be-a1c3-b8609ed55ecb" xlink:href="jnj-20211003.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A3.500Notesdue2048Member_18d11fa4-b397-40be-a1c3-b8609ed55ecb" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member_0e789407-224d-4008-b5cb-95c3ec85ebbb" xlink:href="jnj-20211003.xsd#jnj_A2250NotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A2250NotesDue2050Member_0e789407-224d-4008-b5cb-95c3ec85ebbb" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member_65736d29-0b11-43e3-abd0-577b09689d7e" xlink:href="jnj-20211003.xsd#jnj_A2450NotesDue2060Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A2450NotesDue2060Member_65736d29-0b11-43e3-abd0-577b09689d7e" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NotesDuePeriodFifteenMember_c69c5cab-ecfa-4735-a0c4-1259e883b555" xlink:href="jnj-20211003.xsd#jnj_NotesDuePeriodFifteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_NotesDuePeriodFifteenMember_c69c5cab-ecfa-4735-a0c4-1259e883b555" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_610afdf3-116c-436e-87ea-bb63c5476fa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6e0913fa-e6e3-4404-b1a0-6142c6937514" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_610afdf3-116c-436e-87ea-bb63c5476fa0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_610afdf3-116c-436e-87ea-bb63c5476fa0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_610afdf3-116c-436e-87ea-bb63c5476fa0" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_610afdf3-116c-436e-87ea-bb63c5476fa0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1ebed742-1b4a-4f08-804d-7a8f54e3009b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_610afdf3-116c-436e-87ea-bb63c5476fa0" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1ebed742-1b4a-4f08-804d-7a8f54e3009b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_27af0e5a-fe1b-4f89-b874-bfb5b2ef5b81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1ebed742-1b4a-4f08-804d-7a8f54e3009b" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_27af0e5a-fe1b-4f89-b874-bfb5b2ef5b81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_35cb9c08-45ad-4203-bb28-a728f509b74c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_27af0e5a-fe1b-4f89-b874-bfb5b2ef5b81" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_35cb9c08-45ad-4203-bb28-a728f509b74c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_611d3fd4-66d0-4e34-856d-e07e9539bc04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_27af0e5a-fe1b-4f89-b874-bfb5b2ef5b81" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_611d3fd4-66d0-4e34-856d-e07e9539bc04" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IncomeTaxesDetails" xlink:type="extended" id="i5583d71f76a54d27acd161beab2c1b6a_IncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_687bea72-ba6b-42a6-8e59-f8336f7e9227" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:href="jnj-20211003.xsd#jnj_IncomeTaxTextualsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_687bea72-ba6b-42a6-8e59-f8336f7e9227" xlink:to="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_63bafe58-ae23-4f7b-ab0e-123e335aa414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_63bafe58-ae23-4f7b-ab0e-123e335aa414" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_332edf6a-8e09-4db0-8a00-0b655c7bee0e" xlink:href="jnj-20211003.xsd#jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:to="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_332edf6a-8e09-4db0-8a00-0b655c7bee0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d583c6a8-5f4a-44e1-98ab-4a38e5b8b8c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d583c6a8-5f4a-44e1-98ab-4a38e5b8b8c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_2c283a32-8f69-4c4b-aa99-bd54f7734ce2" xlink:href="jnj-20211003.xsd#jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_2c283a32-8f69-4c4b-aa99-bd54f7734ce2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_88fe3000-fc41-470f-b52b-534ea7c1a084" xlink:href="jnj-20211003.xsd#jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:to="loc_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_88fe3000-fc41-470f-b52b-534ea7c1a084" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_11a11323-1ff2-4fd1-bf47-fb4a0805fe4c" xlink:href="jnj-20211003.xsd#jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_11a11323-1ff2-4fd1-bf47-fb4a0805fe4c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent_ccc212ed-859a-4ace-a791-916c10d0d1b4" xlink:href="jnj-20211003.xsd#jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent_ccc212ed-859a-4ace-a791-916c10d0d1b4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_7b42c43f-e50b-4ad2-8d28-29f22fcd22e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_7b42c43f-e50b-4ad2-8d28-29f22fcd22e7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount_fa276d2f-ba92-4c5d-966f-b171484acd1d" xlink:href="jnj-20211003.xsd#jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount_fa276d2f-ba92-4c5d-966f-b171484acd1d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent_afc7e33c-7680-4457-9ce9-91ab4111dea1" xlink:href="jnj-20211003.xsd#jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent_afc7e33c-7680-4457-9ce9-91ab4111dea1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_a5c1708c-08c5-41c9-ad4a-06b96246d33f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_a5c1708c-08c5-41c9-ad4a-06b96246d33f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_f5efb5ba-1a12-4d0c-8e11-df1aefe0b000" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_f5efb5ba-1a12-4d0c-8e11-df1aefe0b000" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_ff38d657-5aa2-4cdc-81fe-8bec3228e05a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_ff38d657-5aa2-4cdc-81fe-8bec3228e05a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_30d57b9e-afc0-4624-ab6e-52afe57f9316" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_687bea72-ba6b-42a6-8e59-f8336f7e9227" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_30d57b9e-afc0-4624-ab6e-52afe57f9316" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f3c12a9d-cfd0-4b1d-b4ca-0601581eeba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_30d57b9e-afc0-4624-ab6e-52afe57f9316" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f3c12a9d-cfd0-4b1d-b4ca-0601581eeba6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f3c12a9d-cfd0-4b1d-b4ca-0601581eeba6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f3c12a9d-cfd0-4b1d-b4ca-0601581eeba6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f3c12a9d-cfd0-4b1d-b4ca-0601581eeba6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_61aa120d-5f06-4a68-bf66-10309a645a52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f3c12a9d-cfd0-4b1d-b4ca-0601581eeba6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_61aa120d-5f06-4a68-bf66-10309a645a52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_8d175bab-458c-4bd5-9f7e-c732b52e01ce" xlink:href="jnj-20211003.xsd#jnj_AurisHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_61aa120d-5f06-4a68-bf66-10309a645a52" xlink:to="loc_jnj_AurisHealthMember_8d175bab-458c-4bd5-9f7e-c732b52e01ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_859dc4b3-c6a8-43f1-a961-7bb73ac79be7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_30d57b9e-afc0-4624-ab6e-52afe57f9316" xlink:to="loc_srt_LitigationCaseAxis_859dc4b3-c6a8-43f1-a961-7bb73ac79be7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_859dc4b3-c6a8-43f1-a961-7bb73ac79be7_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_859dc4b3-c6a8-43f1-a961-7bb73ac79be7" xlink:to="loc_srt_LitigationCaseTypeDomain_859dc4b3-c6a8-43f1-a961-7bb73ac79be7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_aff67556-adaf-4d09-99d6-a7ec9e6a36be" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_859dc4b3-c6a8-43f1-a961-7bb73ac79be7" xlink:to="loc_srt_LitigationCaseTypeDomain_aff67556-adaf-4d09-99d6-a7ec9e6a36be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_7e32c4a8-6dc6-4da8-9c73-c31144b2e63a" xlink:href="jnj-20211003.xsd#jnj_BabyPowderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_aff67556-adaf-4d09-99d6-a7ec9e6a36be" xlink:to="loc_jnj_BabyPowderMember_7e32c4a8-6dc6-4da8-9c73-c31144b2e63a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_029281e6-02a3-46ed-9371-4eb6e6b02f3c" xlink:href="jnj-20211003.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_aff67556-adaf-4d09-99d6-a7ec9e6a36be" xlink:to="loc_jnj_RisperdalMember_029281e6-02a3-46ed-9371-4eb6e6b02f3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_94e28128-beb5-4fc7-86c9-5edc69b77499" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_30d57b9e-afc0-4624-ab6e-52afe57f9316" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_94e28128-beb5-4fc7-86c9-5edc69b77499" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_94e28128-beb5-4fc7-86c9-5edc69b77499_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_94e28128-beb5-4fc7-86c9-5edc69b77499" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_94e28128-beb5-4fc7-86c9-5edc69b77499_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_30652530-7f5b-450c-ad14-e15ee58c788d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_94e28128-beb5-4fc7-86c9-5edc69b77499" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_30652530-7f5b-450c-ad14-e15ee58c788d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_bd6a6fca-6c4d-495c-8617-d84c24e7ff72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_30652530-7f5b-450c-ad14-e15ee58c788d" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_bd6a6fca-6c4d-495c-8617-d84c24e7ff72" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended" id="id9d786d4bfc3440bbce69d0f69bf8c5c_PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_86cefbdd-8d56-4486-8c72-80a95f9cb594" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_b6ff796b-ab95-410a-88a2-40ddbafd9bf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_86cefbdd-8d56-4486-8c72-80a95f9cb594" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_b6ff796b-ab95-410a-88a2-40ddbafd9bf2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_9baea0da-b9f3-4e9f-8839-cfe62a0d048a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_b6ff796b-ab95-410a-88a2-40ddbafd9bf2" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_9baea0da-b9f3-4e9f-8839-cfe62a0d048a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_a1b1624c-7904-4bea-9080-ec3c4656d815" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_b6ff796b-ab95-410a-88a2-40ddbafd9bf2" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_a1b1624c-7904-4bea-9080-ec3c4656d815" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_077a15ff-274a-4603-966f-49e4562ec73d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_b6ff796b-ab95-410a-88a2-40ddbafd9bf2" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_077a15ff-274a-4603-966f-49e4562ec73d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_d389a7a8-e305-4862-b4be-cf3e18b73da3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_b6ff796b-ab95-410a-88a2-40ddbafd9bf2" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_d389a7a8-e305-4862-b4be-cf3e18b73da3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_049822d7-981e-420f-91c8-fb4aa1dcd54e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_b6ff796b-ab95-410a-88a2-40ddbafd9bf2" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_049822d7-981e-420f-91c8-fb4aa1dcd54e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_70d70474-13a8-4cd4-9299-840d0bbccdb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_b6ff796b-ab95-410a-88a2-40ddbafd9bf2" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_70d70474-13a8-4cd4-9299-840d0bbccdb1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_2fd15476-d8f0-4806-8047-1093d3be021b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_b6ff796b-ab95-410a-88a2-40ddbafd9bf2" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_2fd15476-d8f0-4806-8047-1093d3be021b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8c23248e-eb05-4324-92f1-38bbe3d6653c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_86cefbdd-8d56-4486-8c72-80a95f9cb594" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8c23248e-eb05-4324-92f1-38bbe3d6653c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_bd907850-7f4d-4abe-878b-05154fcbf3c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8c23248e-eb05-4324-92f1-38bbe3d6653c" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_bd907850-7f4d-4abe-878b-05154fcbf3c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_bd907850-7f4d-4abe-878b-05154fcbf3c9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_bd907850-7f4d-4abe-878b-05154fcbf3c9" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_bd907850-7f4d-4abe-878b-05154fcbf3c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8094cf0b-9cd1-4619-b8f3-5f2fd5b988b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_bd907850-7f4d-4abe-878b-05154fcbf3c9" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8094cf0b-9cd1-4619-b8f3-5f2fd5b988b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_dc7490aa-8915-4fd8-b1b7-596b53a46c4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8094cf0b-9cd1-4619-b8f3-5f2fd5b988b6" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_dc7490aa-8915-4fd8-b1b7-596b53a46c4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_e7b57fa5-3137-48fb-96d9-62c749b2c217" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8094cf0b-9cd1-4619-b8f3-5f2fd5b988b6" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_e7b57fa5-3137-48fb-96d9-62c749b2c217" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#PensionsandOtherBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails" xlink:type="extended" id="ib748289e19904dd18e53beda9400ffc2_PensionsandOtherBenefitPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5b801e74-8cf6-4596-a1f2-bf02cb1e42dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions_ed9e5c1d-b806-4b2f-b6d0-dc4f217c1d37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5b801e74-8cf6-4596-a1f2-bf02cb1e42dc" xlink:to="loc_us-gaap_PensionContributions_ed9e5c1d-b806-4b2f-b6d0-dc4f217c1d37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_892299c4-193a-4999-a973-b4f2ba0ea574" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5b801e74-8cf6-4596-a1f2-bf02cb1e42dc" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_892299c4-193a-4999-a973-b4f2ba0ea574" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_2d2cd09f-b65c-40d7-934f-37d579839896" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_892299c4-193a-4999-a973-b4f2ba0ea574" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_2d2cd09f-b65c-40d7-934f-37d579839896" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_2d2cd09f-b65c-40d7-934f-37d579839896_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_2d2cd09f-b65c-40d7-934f-37d579839896" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_2d2cd09f-b65c-40d7-934f-37d579839896_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_585ba199-9afe-4391-9291-ab9b5c5120a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_2d2cd09f-b65c-40d7-934f-37d579839896" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_585ba199-9afe-4391-9291-ab9b5c5120a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f97469dd-d84e-411c-8584-356a85b37fc8" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_585ba199-9afe-4391-9291-ab9b5c5120a0" xlink:to="loc_country_US_f97469dd-d84e-411c-8584-356a85b37fc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_5768514e-82c6-4c74-9b9c-b56b4dbaee77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_585ba199-9afe-4391-9291-ab9b5c5120a0" xlink:to="loc_us-gaap_ForeignPlanMember_5768514e-82c6-4c74-9b9c-b56b4dbaee77" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#AccumulatedOtherComprehensiveIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended" id="i8c2e9f10bc0b4b529e83df0c0be512f9_AccumulatedOtherComprehensiveIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_337d807b-b532-4f7d-9def-06e889787d64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c15d8920-7f1e-4688-a231-9619698e07d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_337d807b-b532-4f7d-9def-06e889787d64" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c15d8920-7f1e-4688-a231-9619698e07d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_84782215-4997-44bb-86e4-b430cfcdca44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c15d8920-7f1e-4688-a231-9619698e07d4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_84782215-4997-44bb-86e4-b430cfcdca44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bc733ee5-0372-4a2c-b82a-4afb6b3928fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c15d8920-7f1e-4688-a231-9619698e07d4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bc733ee5-0372-4a2c-b82a-4afb6b3928fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a2bd8996-ee05-4138-a5b9-50aed745fb27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_16729344-5ea2-4a2c-b272-1bab9183f15a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_337d807b-b532-4f7d-9def-06e889787d64" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_16729344-5ea2-4a2c-b272-1bab9183f15a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_afb153bd-f1c4-424a-85fe-b1fdf8758ce6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_16729344-5ea2-4a2c-b272-1bab9183f15a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_afb153bd-f1c4-424a-85fe-b1fdf8758ce6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_afb153bd-f1c4-424a-85fe-b1fdf8758ce6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_afb153bd-f1c4-424a-85fe-b1fdf8758ce6" xlink:to="loc_us-gaap_EquityComponentDomain_afb153bd-f1c4-424a-85fe-b1fdf8758ce6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b8c8d5eb-5137-4ce1-886f-abaea76ddac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_afb153bd-f1c4-424a-85fe-b1fdf8758ce6" xlink:to="loc_us-gaap_EquityComponentDomain_b8c8d5eb-5137-4ce1-886f-abaea76ddac8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_ba11154a-3cbd-4c50-bc61-5fe146c0648f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8c8d5eb-5137-4ce1-886f-abaea76ddac8" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_ba11154a-3cbd-4c50-bc61-5fe146c0648f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_e129b8c4-c0a5-4f41-85c2-32c4b71f1e09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8c8d5eb-5137-4ce1-886f-abaea76ddac8" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_e129b8c4-c0a5-4f41-85c2-32c4b71f1e09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_cfc753fc-d705-4488-ae6e-b1605dc7f364" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8c8d5eb-5137-4ce1-886f-abaea76ddac8" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_cfc753fc-d705-4488-ae6e-b1605dc7f364" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_fe05b86a-6007-47d9-ae74-a93f9551ed0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8c8d5eb-5137-4ce1-886f-abaea76ddac8" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_fe05b86a-6007-47d9-ae74-a93f9551ed0d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c7bc85e4-be12-4b54-8ce4-04bc291ccc1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8c8d5eb-5137-4ce1-886f-abaea76ddac8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c7bc85e4-be12-4b54-8ce4-04bc291ccc1b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" xlink:type="extended" id="i743382711f214283a61837d29f696cf6_SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_9d1e1690-ec90-4bfc-8b1c-16c822a7345b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationRevenueAbstract_c456ba91-56d8-4cbb-acd7-77070422bdf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9d1e1690-ec90-4bfc-8b1c-16c822a7345b" xlink:to="loc_us-gaap_SegmentReportingInformationRevenueAbstract_c456ba91-56d8-4cbb-acd7-77070422bdf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2b231660-1534-47dd-b079-5319dead2797" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_c456ba91-56d8-4cbb-acd7-77070422bdf1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2b231660-1534-47dd-b079-5319dead2797" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_b59252d1-1506-41dd-9f62-7fc6d0c7af20" xlink:href="jnj-20211003.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_c456ba91-56d8-4cbb-acd7-77070422bdf1" xlink:to="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_b59252d1-1506-41dd-9f62-7fc6d0c7af20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3bee1677-4bca-42e6-9ef3-3180d92a8e28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9d1e1690-ec90-4bfc-8b1c-16c822a7345b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3bee1677-4bca-42e6-9ef3-3180d92a8e28" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6129aaff-3030-4a40-aa69-73efb3f077b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3bee1677-4bca-42e6-9ef3-3180d92a8e28" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6129aaff-3030-4a40-aa69-73efb3f077b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6129aaff-3030-4a40-aa69-73efb3f077b9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6129aaff-3030-4a40-aa69-73efb3f077b9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6129aaff-3030-4a40-aa69-73efb3f077b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_62d94a75-c0a5-4c31-acd8-ed0545791683" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6129aaff-3030-4a40-aa69-73efb3f077b9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_62d94a75-c0a5-4c31-acd8-ed0545791683" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_348b289e-9350-40cc-937e-eef11fb6172d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3bee1677-4bca-42e6-9ef3-3180d92a8e28" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_348b289e-9350-40cc-937e-eef11fb6172d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_348b289e-9350-40cc-937e-eef11fb6172d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_348b289e-9350-40cc-937e-eef11fb6172d" xlink:to="loc_us-gaap_SegmentDomain_348b289e-9350-40cc-937e-eef11fb6172d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e4c8eef0-6a7b-4b43-8f57-70de731320fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_348b289e-9350-40cc-937e-eef11fb6172d" xlink:to="loc_us-gaap_SegmentDomain_e4c8eef0-6a7b-4b43-8f57-70de731320fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_c3c8ce02-9f1d-49ff-bfae-655b754ae3f3" xlink:href="jnj-20211003.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e4c8eef0-6a7b-4b43-8f57-70de731320fd" xlink:to="loc_jnj_ConsumerMember_c3c8ce02-9f1d-49ff-bfae-655b754ae3f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_a4938e95-3101-4875-a973-59fbf860c7b1" xlink:href="jnj-20211003.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e4c8eef0-6a7b-4b43-8f57-70de731320fd" xlink:to="loc_jnj_PharmaceuticalMember_a4938e95-3101-4875-a973-59fbf860c7b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_a432ace6-7e5d-4bae-8d09-a7b7ccf3c083" xlink:href="jnj-20211003.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e4c8eef0-6a7b-4b43-8f57-70de731320fd" xlink:to="loc_jnj_MedicalDevicesMember_a432ace6-7e5d-4bae-8d09-a7b7ccf3c083" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_3d1020ab-9bd7-48fe-b475-4f51f388a535" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3bee1677-4bca-42e6-9ef3-3180d92a8e28" xlink:to="loc_us-gaap_SubsegmentsAxis_3d1020ab-9bd7-48fe-b475-4f51f388a535" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_3d1020ab-9bd7-48fe-b475-4f51f388a535_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_3d1020ab-9bd7-48fe-b475-4f51f388a535" xlink:to="loc_us-gaap_SubsegmentsDomain_3d1020ab-9bd7-48fe-b475-4f51f388a535_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_eba76446-0ba5-4e4f-aaf3-3c0018facb84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_3d1020ab-9bd7-48fe-b475-4f51f388a535" xlink:to="loc_us-gaap_SubsegmentsDomain_eba76446-0ba5-4e4f-aaf3-3c0018facb84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_afe41904-b8a1-4e26-9c48-29945eede02f" xlink:href="jnj-20211003.xsd#jnj_ImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_eba76446-0ba5-4e4f-aaf3-3c0018facb84" xlink:to="loc_jnj_ImmunologyMember_afe41904-b8a1-4e26-9c48-29945eede02f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember_f278af32-1069-42f6-8af3-f55df43ee700" xlink:href="jnj-20211003.xsd#jnj_InfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_eba76446-0ba5-4e4f-aaf3-3c0018facb84" xlink:to="loc_jnj_InfectiousDiseasesMember_f278af32-1069-42f6-8af3-f55df43ee700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember_b2dc7d0a-dd8a-42f7-a523-a7161786dd78" xlink:href="jnj-20211003.xsd#jnj_NeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_eba76446-0ba5-4e4f-aaf3-3c0018facb84" xlink:to="loc_jnj_NeuroscienceMember_b2dc7d0a-dd8a-42f7-a523-a7161786dd78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember_533aacd4-d0ce-4a13-99a9-e111ddf125dd" xlink:href="jnj-20211003.xsd#jnj_OncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_eba76446-0ba5-4e4f-aaf3-3c0018facb84" xlink:to="loc_jnj_OncologyMember_533aacd4-d0ce-4a13-99a9-e111ddf125dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember_7b3a5b87-e2a1-44f1-a75a-49bcc1bccf9e" xlink:href="jnj-20211003.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_eba76446-0ba5-4e4f-aaf3-3c0018facb84" xlink:to="loc_jnj_PulmonaryHypertensionMember_7b3a5b87-e2a1-44f1-a75a-49bcc1bccf9e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember_4888646a-23a6-42a8-9844-e5335ec5c8f2" xlink:href="jnj-20211003.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_eba76446-0ba5-4e4f-aaf3-3c0018facb84" xlink:to="loc_jnj_CardiovascularMetabolismOtherMember_4888646a-23a6-42a8-9844-e5335ec5c8f2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember_cdc9c2ca-96cf-4492-8106-1b997a393419" xlink:href="jnj-20211003.xsd#jnj_InterventionalSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_eba76446-0ba5-4e4f-aaf3-3c0018facb84" xlink:to="loc_jnj_InterventionalSolutionsMember_cdc9c2ca-96cf-4492-8106-1b997a393419" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember_2251bc30-d4e3-4f5c-8e21-c2490a44ab71" xlink:href="jnj-20211003.xsd#jnj_OrthopaedicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_eba76446-0ba5-4e4f-aaf3-3c0018facb84" xlink:to="loc_jnj_OrthopaedicsMember_2251bc30-d4e3-4f5c-8e21-c2490a44ab71" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember_ec8da28e-6eaa-4697-84de-032354a2a234" xlink:href="jnj-20211003.xsd#jnj_SurgeryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_eba76446-0ba5-4e4f-aaf3-3c0018facb84" xlink:to="loc_jnj_SurgeryMember_ec8da28e-6eaa-4697-84de-032354a2a234" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember_62e87186-492d-498e-a819-be5d16527a10" xlink:href="jnj-20211003.xsd#jnj_VisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_eba76446-0ba5-4e4f-aaf3-3c0018facb84" xlink:to="loc_jnj_VisionMember_62e87186-492d-498e-a819-be5d16527a10" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_849460a3-7c8c-4609-9ae8-9782ac03584a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3bee1677-4bca-42e6-9ef3-3180d92a8e28" xlink:to="loc_srt_ProductOrServiceAxis_849460a3-7c8c-4609-9ae8-9782ac03584a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_849460a3-7c8c-4609-9ae8-9782ac03584a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_849460a3-7c8c-4609-9ae8-9782ac03584a" xlink:to="loc_srt_ProductsAndServicesDomain_849460a3-7c8c-4609-9ae8-9782ac03584a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_849460a3-7c8c-4609-9ae8-9782ac03584a" xlink:to="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember_88ebd08f-2e77-4bd5-8fec-c142f3035af3" xlink:href="jnj-20211003.xsd#jnj_OTCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_OTCMember_88ebd08f-2e77-4bd5-8fec-c142f3035af3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BeautyMember_b64f0bd2-a9c0-4721-a9b2-a0ac06150f0e" xlink:href="jnj-20211003.xsd#jnj_BeautyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_BeautyMember_b64f0bd2-a9c0-4721-a9b2-a0ac06150f0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember_53ad5a83-0de5-4f17-bd61-14e9001e86b3" xlink:href="jnj-20211003.xsd#jnj_OralCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_OralCareMember_53ad5a83-0de5-4f17-bd61-14e9001e86b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember_f93d9596-17f2-412b-bead-cac29fb72822" xlink:href="jnj-20211003.xsd#jnj_BabyCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_BabyCareMember_f93d9596-17f2-412b-bead-cac29fb72822" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WomensHealthMember_63440377-ad56-418a-b042-e5fa33797e25" xlink:href="jnj-20211003.xsd#jnj_WomensHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_WomensHealthMember_63440377-ad56-418a-b042-e5fa33797e25" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WoundCareandOtherMember_04a9861f-f6e3-48b8-8adc-a2e8729e02c5" xlink:href="jnj-20211003.xsd#jnj_WoundCareandOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_WoundCareandOtherMember_04a9861f-f6e3-48b8-8adc-a2e8729e02c5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember_ffd6c294-01b7-4385-bbfa-695e06e9d2d4" xlink:href="jnj-20211003.xsd#jnj_RemicadeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_RemicadeMember_ffd6c294-01b7-4385-bbfa-695e06e9d2d4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember_ab076222-c395-4536-bf27-270319cb3c12" xlink:href="jnj-20211003.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_SimponiSimponiAriaMember_ab076222-c395-4536-bf27-270319cb3c12" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember_86d66e03-94bc-4189-84c8-2bfb1c5d6874" xlink:href="jnj-20211003.xsd#jnj_StelaraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_StelaraMember_86d66e03-94bc-4189-84c8-2bfb1c5d6874" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember_df911062-769e-4aba-ada4-9b0e2c44e03e" xlink:href="jnj-20211003.xsd#jnj_TremfyaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_TremfyaMember_df911062-769e-4aba-ada4-9b0e2c44e03e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember_561e33ef-b3bb-4680-b7c0-729750f3f5e3" xlink:href="jnj-20211003.xsd#jnj_OtherImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_OtherImmunologyMember_561e33ef-b3bb-4680-b7c0-729750f3f5e3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_COVID19Member_64f68ee7-13f4-4691-a9a0-f001c5318d07" xlink:href="jnj-20211003.xsd#jnj_COVID19Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_COVID19Member_64f68ee7-13f4-4691-a9a0-f001c5318d07" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember_5653a380-b196-44b2-ae08-f64e8328449c" xlink:href="jnj-20211003.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_EDURANTrilpivirineMember_5653a380-b196-44b2-ae08-f64e8328449c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_b818edca-afe6-4d05-a6ae-c70d6e500a53" xlink:href="jnj-20211003.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_b818edca-afe6-4d05-a6ae-c70d6e500a53" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember_0c2b35ca-ddcc-4f5b-83fa-538604d5e4ed" xlink:href="jnj-20211003.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_OtherInfectiousDiseasesMember_0c2b35ca-ddcc-4f5b-83fa-538604d5e4ed" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember_50e0deea-ecdb-461f-888e-fb62fed854ef" xlink:href="jnj-20211003.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_CONCERTAMethylphenidateMember_50e0deea-ecdb-461f-888e-fb62fed854ef" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_f842504c-d741-44c4-9905-0d666032067a" xlink:href="jnj-20211003.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_f842504c-d741-44c4-9905-0d666032067a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RISPERDALCONSTAMember_8c4a5f7d-6c0d-4d40-8ab8-03398a42c8ff" xlink:href="jnj-20211003.xsd#jnj_RISPERDALCONSTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_RISPERDALCONSTAMember_8c4a5f7d-6c0d-4d40-8ab8-03398a42c8ff" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember_6645dcaf-8500-4a56-b2bb-a44aa0343445" xlink:href="jnj-20211003.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_OTHERNEUROSCIENCEMember_6645dcaf-8500-4a56-b2bb-a44aa0343445" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember_e3553a77-6e9c-40f3-9813-128c3d3637f7" xlink:href="jnj-20211003.xsd#jnj_DARZALEXMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_DARZALEXMember_e3553a77-6e9c-40f3-9813-128c3d3637f7" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ERLEADAMember_b247b2bf-0b02-45b8-bb26-92715be10b4c" xlink:href="jnj-20211003.xsd#jnj_ERLEADAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_ERLEADAMember_b247b2bf-0b02-45b8-bb26-92715be10b4c" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember_06c8039f-5fdd-4f05-af71-4135545e810a" xlink:href="jnj-20211003.xsd#jnj_IMBRUVICAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_IMBRUVICAMember_06c8039f-5fdd-4f05-af71-4135545e810a" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember_78c70c32-a0aa-4c29-a1f1-b8529546bbcb" xlink:href="jnj-20211003.xsd#jnj_ZYTIGAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_ZYTIGAMember_78c70c32-a0aa-4c29-a1f1-b8529546bbcb" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember_4828be66-090b-4775-8d74-538582ce12e9" xlink:href="jnj-20211003.xsd#jnj_OtherOncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_OtherOncologyMember_4828be66-090b-4775-8d74-538582ce12e9" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember_7ed95580-0d49-43bb-b8c8-f050265bcf02" xlink:href="jnj-20211003.xsd#jnj_OPSUMITMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_OPSUMITMember_7ed95580-0d49-43bb-b8c8-f050265bcf02" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember_6e5e4f3a-1a54-4637-988d-0d08871ed70c" xlink:href="jnj-20211003.xsd#jnj_UPTRAVIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_UPTRAVIMember_6e5e4f3a-1a54-4637-988d-0d08871ed70c" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_c1cbff8c-9329-4e63-8777-bbd37c6c60cc" xlink:href="jnj-20211003.xsd#jnj_XareltoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_XareltoMember_c1cbff8c-9329-4e63-8777-bbd37c6c60cc" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVOKANAINVOKAMETMember_89c370b2-c402-4f6c-bcec-16ce408b75fe" xlink:href="jnj-20211003.xsd#jnj_INVOKANAINVOKAMETMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_INVOKANAINVOKAMETMember_89c370b2-c402-4f6c-bcec-16ce408b75fe" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PROCRITEPREXMember_38ef9183-b57f-4288-b1bc-d795ff2385e6" xlink:href="jnj-20211003.xsd#jnj_PROCRITEPREXMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_PROCRITEPREXMember_38ef9183-b57f-4288-b1bc-d795ff2385e6" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember_3ffc5821-cd59-4b5b-9f10-477cce629890" xlink:href="jnj-20211003.xsd#jnj_OtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_OtherMember_3ffc5821-cd59-4b5b-9f10-477cce629890" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember_dd614659-6891-4328-b631-5ba0e443a9c9" xlink:href="jnj-20211003.xsd#jnj_HIPSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_HIPSMember_dd614659-6891-4328-b631-5ba0e443a9c9" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember_4746bbeb-dd09-4837-b9c7-d75d1cdb1be4" xlink:href="jnj-20211003.xsd#jnj_KNEESMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_KNEESMember_4746bbeb-dd09-4837-b9c7-d75d1cdb1be4" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember_1e373744-ca2f-42d4-ba5c-69987dab2bb0" xlink:href="jnj-20211003.xsd#jnj_TRAUMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_TRAUMAMember_1e373744-ca2f-42d4-ba5c-69987dab2bb0" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINEOTHERMember_e76fd378-b6d7-445b-850e-fe84c6ea46ed" xlink:href="jnj-20211003.xsd#jnj_SPINEOTHERMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_SPINEOTHERMember_e76fd378-b6d7-445b-850e-fe84c6ea46ed" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember_00e7cad1-95ea-476b-8b48-c8ae75f56eba" xlink:href="jnj-20211003.xsd#jnj_ADVANCEDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_ADVANCEDMember_00e7cad1-95ea-476b-8b48-c8ae75f56eba" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember_bbf7ba20-58c5-46e8-8267-e7fff2c6aef6" xlink:href="jnj-20211003.xsd#jnj_GENERALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_GENERALMember_bbf7ba20-58c5-46e8-8267-e7fff2c6aef6" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember_bc896bf3-7df0-4689-b768-9160a8e0a0e2" xlink:href="jnj-20211003.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_CONTACTLENSESOTHERMember_bc896bf3-7df0-4689-b768-9160a8e0a0e2" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember_889e918a-86fa-4b38-b278-751840bef3e1" xlink:href="jnj-20211003.xsd#jnj_SURGICALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_SURGICALMember_889e918a-86fa-4b38-b278-751840bef3e1" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8e154a40-0310-4273-88ff-df3c940c02ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3bee1677-4bca-42e6-9ef3-3180d92a8e28" xlink:to="loc_srt_StatementGeographicalAxis_8e154a40-0310-4273-88ff-df3c940c02ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8e154a40-0310-4273-88ff-df3c940c02ae_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_8e154a40-0310-4273-88ff-df3c940c02ae" xlink:to="loc_srt_SegmentGeographicalDomain_8e154a40-0310-4273-88ff-df3c940c02ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1d9bbb30-a893-436a-b567-6c83e77363a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_8e154a40-0310-4273-88ff-df3c940c02ae" xlink:to="loc_srt_SegmentGeographicalDomain_1d9bbb30-a893-436a-b567-6c83e77363a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d315f9c1-37f3-40db-a5f8-57b3457a053b" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1d9bbb30-a893-436a-b567-6c83e77363a5" xlink:to="loc_country_US_d315f9c1-37f3-40db-a5f8-57b3457a053b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember_dcd4d4d1-54d2-444e-84ee-9af7ae624753" xlink:href="jnj-20211003.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1d9bbb30-a893-436a-b567-6c83e77363a5" xlink:to="loc_jnj_UNITEDSTATESExportsMember_dcd4d4d1-54d2-444e-84ee-9af7ae624753" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_4024cc40-950f-4b60-bfbf-fbdc571e6da4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1d9bbb30-a893-436a-b567-6c83e77363a5" xlink:to="loc_us-gaap_NonUsMember_4024cc40-950f-4b60-bfbf-fbdc571e6da4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" xlink:type="extended" id="id80feb88c6cb41949d1bc2f614aaea7c_SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_af66bdd1-bfb0-49eb-98b5-2844a68d1bcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_69dc04ef-1843-4008-9c96-911640c3fdfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_af66bdd1-bfb0-49eb-98b5-2844a68d1bcb" xlink:to="loc_us-gaap_OperatingIncomeLoss_69dc04ef-1843-4008-9c96-911640c3fdfc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInOperatingIncomeLoss_c1ccabca-3530-467d-ab94-a227bfe9eace" xlink:href="jnj-20211003.xsd#jnj_PercentageChangeInOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_af66bdd1-bfb0-49eb-98b5-2844a68d1bcb" xlink:to="loc_jnj_PercentageChangeInOperatingIncomeLoss_c1ccabca-3530-467d-ab94-a227bfe9eace" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d2986003-97b9-4108-9cb4-f2c261bdd148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_af66bdd1-bfb0-49eb-98b5-2844a68d1bcb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d2986003-97b9-4108-9cb4-f2c261bdd148" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_86ce03a0-1ce9-4679-96cb-025b3521c0ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_af66bdd1-bfb0-49eb-98b5-2844a68d1bcb" xlink:to="loc_us-gaap_AdjustmentForAmortization_86ce03a0-1ce9-4679-96cb-025b3521c0ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_b84d2c50-16f2-4142-ab9f-71804851f921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_af66bdd1-bfb0-49eb-98b5-2844a68d1bcb" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_b84d2c50-16f2-4142-ab9f-71804851f921" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_5036c421-74e6-4f57-a491-72647f4cfc07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_af66bdd1-bfb0-49eb-98b5-2844a68d1bcb" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_5036c421-74e6-4f57-a491-72647f4cfc07" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_afbc3217-60aa-4385-85fe-363e33c2f5b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_af66bdd1-bfb0-49eb-98b5-2844a68d1bcb" xlink:to="loc_us-gaap_LitigationSettlementExpense_afbc3217-60aa-4385-85fe-363e33c2f5b5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AmountPrepaidAndDueToManufacturers_b4bcd4de-ab25-4fd9-aff6-80269435141c" xlink:href="jnj-20211003.xsd#jnj_AmountPrepaidAndDueToManufacturers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_af66bdd1-bfb0-49eb-98b5-2844a68d1bcb" xlink:to="loc_jnj_AmountPrepaidAndDueToManufacturers_b4bcd4de-ab25-4fd9-aff6-80269435141c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_97969202-4719-4996-88fa-28888d85f359" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_af66bdd1-bfb0-49eb-98b5-2844a68d1bcb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_97969202-4719-4996-88fa-28888d85f359" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_15e92a7e-90c1-475b-be83-4c0bc9633872" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_af66bdd1-bfb0-49eb-98b5-2844a68d1bcb" xlink:to="loc_us-gaap_RestructuringCharges_15e92a7e-90c1-475b-be83-4c0bc9633872" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0d62f870-f1e8-454b-9e52-1719ee4865c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_af66bdd1-bfb0-49eb-98b5-2844a68d1bcb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0d62f870-f1e8-454b-9e52-1719ee4865c5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3927a5c8-98f9-4954-9930-c3ec487cf4e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_af66bdd1-bfb0-49eb-98b5-2844a68d1bcb" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3927a5c8-98f9-4954-9930-c3ec487cf4e5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_33830c86-bd9e-4fb5-95c0-edb8f4e71852" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3927a5c8-98f9-4954-9930-c3ec487cf4e5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_33830c86-bd9e-4fb5-95c0-edb8f4e71852" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_33830c86-bd9e-4fb5-95c0-edb8f4e71852_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_33830c86-bd9e-4fb5-95c0-edb8f4e71852" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_33830c86-bd9e-4fb5-95c0-edb8f4e71852_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7dcc02ed-1f47-443d-861a-4f18b18be5d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_33830c86-bd9e-4fb5-95c0-edb8f4e71852" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7dcc02ed-1f47-443d-861a-4f18b18be5d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeMember_daf7bcd9-6406-4f33-a743-94bb5746d0bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7dcc02ed-1f47-443d-861a-4f18b18be5d6" xlink:to="loc_us-gaap_OtherIncomeMember_daf7bcd9-6406-4f33-a743-94bb5746d0bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_14ae3bd4-0ccc-4e8d-ab9e-644593fe68e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3927a5c8-98f9-4954-9930-c3ec487cf4e5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_14ae3bd4-0ccc-4e8d-ab9e-644593fe68e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14ae3bd4-0ccc-4e8d-ab9e-644593fe68e1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_14ae3bd4-0ccc-4e8d-ab9e-644593fe68e1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14ae3bd4-0ccc-4e8d-ab9e-644593fe68e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b60e53e1-f7ac-44e7-8401-4910f4b7d8c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_14ae3bd4-0ccc-4e8d-ab9e-644593fe68e1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b60e53e1-f7ac-44e7-8401-4910f4b7d8c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_49004056-ac99-4d39-95cd-15ce034c5ed1" xlink:href="jnj-20211003.xsd#jnj_AurisHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b60e53e1-f7ac-44e7-8401-4910f4b7d8c6" xlink:to="loc_jnj_AurisHealthMember_49004056-ac99-4d39-95cd-15ce034c5ed1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_0e33d741-c0ef-40ab-9047-dd931f7b7b73" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3927a5c8-98f9-4954-9930-c3ec487cf4e5" xlink:to="loc_srt_ConsolidationItemsAxis_0e33d741-c0ef-40ab-9047-dd931f7b7b73" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_0e33d741-c0ef-40ab-9047-dd931f7b7b73_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_0e33d741-c0ef-40ab-9047-dd931f7b7b73" xlink:to="loc_srt_ConsolidationItemsDomain_0e33d741-c0ef-40ab-9047-dd931f7b7b73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_521bf906-f92e-420f-8ca7-6d5f942ac6ea" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_0e33d741-c0ef-40ab-9047-dd931f7b7b73" xlink:to="loc_srt_ConsolidationItemsDomain_521bf906-f92e-420f-8ca7-6d5f942ac6ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_f8a35ca1-1051-4a79-a9b5-092b89b42bed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_521bf906-f92e-420f-8ca7-6d5f942ac6ea" xlink:to="loc_us-gaap_OperatingSegmentsMember_f8a35ca1-1051-4a79-a9b5-092b89b42bed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_a43e879c-ebbe-4516-abcd-1622e5bf7b90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_521bf906-f92e-420f-8ca7-6d5f942ac6ea" xlink:to="loc_us-gaap_CorporateNonSegmentMember_a43e879c-ebbe-4516-abcd-1622e5bf7b90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9d87aceb-ac0e-4fb3-b8a1-bb84e92ae541" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3927a5c8-98f9-4954-9930-c3ec487cf4e5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9d87aceb-ac0e-4fb3-b8a1-bb84e92ae541" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9d87aceb-ac0e-4fb3-b8a1-bb84e92ae541_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9d87aceb-ac0e-4fb3-b8a1-bb84e92ae541" xlink:to="loc_us-gaap_SegmentDomain_9d87aceb-ac0e-4fb3-b8a1-bb84e92ae541_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b9db0aa7-dfe9-487c-8c53-944611221228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9d87aceb-ac0e-4fb3-b8a1-bb84e92ae541" xlink:to="loc_us-gaap_SegmentDomain_b9db0aa7-dfe9-487c-8c53-944611221228" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_0024423d-2f45-419a-bd11-b6140a957c13" xlink:href="jnj-20211003.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b9db0aa7-dfe9-487c-8c53-944611221228" xlink:to="loc_jnj_ConsumerMember_0024423d-2f45-419a-bd11-b6140a957c13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_6ef1aba5-3c65-4ecd-b6c4-a03ea6c52ffa" xlink:href="jnj-20211003.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b9db0aa7-dfe9-487c-8c53-944611221228" xlink:to="loc_jnj_PharmaceuticalMember_6ef1aba5-3c65-4ecd-b6c4-a03ea6c52ffa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_9b6583a0-485a-4236-ac4d-626ef356f549" xlink:href="jnj-20211003.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b9db0aa7-dfe9-487c-8c53-944611221228" xlink:to="loc_jnj_MedicalDevicesMember_9b6583a0-485a-4236-ac4d-626ef356f549" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="extended" id="i3971aee163894518b8361ec84f623c43_SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_8ec60565-ac6d-40da-8473-0581537f5bec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_db5f5a0b-073a-4fad-9824-0bdd080db5eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentsGeographicalAreasAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_8ec60565-ac6d-40da-8473-0581537f5bec" xlink:to="loc_us-gaap_SegmentsGeographicalAreasAbstract_db5f5a0b-073a-4fad-9824-0bdd080db5eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aa500a5f-d0e0-4132-8c6f-f50a2530807c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_db5f5a0b-073a-4fad-9824-0bdd080db5eb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aa500a5f-d0e0-4132-8c6f-f50a2530807c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesByGeographicArea_a56158a9-93bf-44a9-b783-4bc4c7eb997f" xlink:href="jnj-20211003.xsd#jnj_PercentageChangeInSalesByGeographicArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_db5f5a0b-073a-4fad-9824-0bdd080db5eb" xlink:to="loc_jnj_PercentageChangeInSalesByGeographicArea_a56158a9-93bf-44a9-b783-4bc4c7eb997f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_13fe914a-efe6-40cd-95ef-7139ce9019ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_8ec60565-ac6d-40da-8473-0581537f5bec" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_13fe914a-efe6-40cd-95ef-7139ce9019ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0920cf2b-9737-45c3-a139-544742e3069a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_13fe914a-efe6-40cd-95ef-7139ce9019ad" xlink:to="loc_srt_StatementGeographicalAxis_0920cf2b-9737-45c3-a139-544742e3069a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0920cf2b-9737-45c3-a139-544742e3069a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_0920cf2b-9737-45c3-a139-544742e3069a" xlink:to="loc_srt_SegmentGeographicalDomain_0920cf2b-9737-45c3-a139-544742e3069a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0204032a-1192-4be5-b2de-e7aaf76525f8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_0920cf2b-9737-45c3-a139-544742e3069a" xlink:to="loc_srt_SegmentGeographicalDomain_0204032a-1192-4be5-b2de-e7aaf76525f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_20f23b5d-bdfc-4156-ad79-7266a8b8d314" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0204032a-1192-4be5-b2de-e7aaf76525f8" xlink:to="loc_country_US_20f23b5d-bdfc-4156-ad79-7266a8b8d314" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_ef995810-da8b-46e9-b7a8-47282ad7bbe1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0204032a-1192-4be5-b2de-e7aaf76525f8" xlink:to="loc_srt_EuropeMember_ef995810-da8b-46e9-b7a8-47282ad7bbe1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember_9af51d37-e758-48e9-8862-18edc429e0c3" xlink:href="jnj-20211003.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0204032a-1192-4be5-b2de-e7aaf76525f8" xlink:to="loc_jnj_WesternHemisphereExcludingUSMember_9af51d37-e758-48e9-8862-18edc429e0c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember_ecefbb16-b4d0-47a7-8066-f8f284b042df" xlink:href="jnj-20211003.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0204032a-1192-4be5-b2de-e7aaf76525f8" xlink:to="loc_jnj_AsiaPacificAfricaMember_ecefbb16-b4d0-47a7-8066-f8f284b042df" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#AcquisitionsandDivestituresNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="extended" id="i9fea0a2324fc48f1bc1a25e2b7666ac0_AcquisitionsandDivestituresNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7b74d3f0-8070-4a22-8f0e-ea318c155bf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_fabdfbf2-18b9-44ad-a6f2-b2392361f63b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b74d3f0-8070-4a22-8f0e-ea318c155bf2" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_fabdfbf2-18b9-44ad-a6f2-b2392361f63b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_229b32ae-7230-4e9b-ab87-701e803a5412" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b74d3f0-8070-4a22-8f0e-ea318c155bf2" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_229b32ae-7230-4e9b-ab87-701e803a5412" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_218afe63-cb36-4651-a859-48f00e9c5947" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b74d3f0-8070-4a22-8f0e-ea318c155bf2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_218afe63-cb36-4651-a859-48f00e9c5947" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2c2fdfdc-8ddd-481e-9e5c-96719b065e6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b74d3f0-8070-4a22-8f0e-ea318c155bf2" xlink:to="loc_us-gaap_Goodwill_2c2fdfdc-8ddd-481e-9e5c-96719b065e6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_46529ccf-2106-4525-9d98-31f8e29164c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b74d3f0-8070-4a22-8f0e-ea318c155bf2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_46529ccf-2106-4525-9d98-31f8e29164c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_d43518e0-0675-480b-8a17-40942284915c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b74d3f0-8070-4a22-8f0e-ea318c155bf2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_d43518e0-0675-480b-8a17-40942284915c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_ea74c2db-8d4d-43c1-9db8-639094d4c411" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b74d3f0-8070-4a22-8f0e-ea318c155bf2" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_ea74c2db-8d4d-43c1-9db8-639094d4c411" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_00c67429-106b-4b41-8ff6-5b33f3590b75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b74d3f0-8070-4a22-8f0e-ea318c155bf2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_00c67429-106b-4b41-8ff6-5b33f3590b75" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_354e469e-d1f0-4851-983c-c6d12d268eb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_00c67429-106b-4b41-8ff6-5b33f3590b75" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_354e469e-d1f0-4851-983c-c6d12d268eb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_354e469e-d1f0-4851-983c-c6d12d268eb9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_354e469e-d1f0-4851-983c-c6d12d268eb9" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_354e469e-d1f0-4851-983c-c6d12d268eb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_67b37395-70ba-4b81-9224-89a79197efeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_354e469e-d1f0-4851-983c-c6d12d268eb9" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_67b37395-70ba-4b81-9224-89a79197efeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EvraAndDoxilMember_3b16898d-9bcc-4cdb-b4a9-705591174ce9" xlink:href="jnj-20211003.xsd#jnj_EvraAndDoxilMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_67b37395-70ba-4b81-9224-89a79197efeb" xlink:to="loc_jnj_EvraAndDoxilMember_3b16898d-9bcc-4cdb-b4a9-705591174ce9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a30f8f8c-5953-462f-9aad-ca245d5841df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_00c67429-106b-4b41-8ff6-5b33f3590b75" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a30f8f8c-5953-462f-9aad-ca245d5841df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a30f8f8c-5953-462f-9aad-ca245d5841df_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a30f8f8c-5953-462f-9aad-ca245d5841df" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a30f8f8c-5953-462f-9aad-ca245d5841df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_97237615-64ff-45c3-83e7-4ffa61724447" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a30f8f8c-5953-462f-9aad-ca245d5841df" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_97237615-64ff-45c3-83e7-4ffa61724447" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_c39e9bcc-2180-43db-ab7d-52973eade22c" xlink:href="jnj-20211003.xsd#jnj_BermekimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_97237615-64ff-45c3-83e7-4ffa61724447" xlink:to="loc_jnj_BermekimabMember_c39e9bcc-2180-43db-ab7d-52973eade22c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VerbSurgicalInc.Member_c2ea1998-353a-4804-bbdc-753185fb5ca9" xlink:href="jnj-20211003.xsd#jnj_VerbSurgicalInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_97237615-64ff-45c3-83e7-4ffa61724447" xlink:to="loc_jnj_VerbSurgicalInc.Member_c2ea1998-353a-4804-bbdc-753185fb5ca9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#LegalProceedingsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="extended" id="ib7055419e0b54517840f1d527c0edb68_LegalProceedingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_23112cf4-14a9-41ce-be55-eed1815ce3ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:href="jnj-20211003.xsd#jnj_LegalProceedingTextualsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_23112cf4-14a9-41ce-be55-eed1815ce3ca" xlink:to="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_5e0f0e1d-cf30-44f6-95c2-1c3ab8068daa" xlink:href="jnj-20211003.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:to="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_5e0f0e1d-cf30-44f6-95c2-1c3ab8068daa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement_1d55fcfb-777c-44e8-b3f1-56a1cec1fb94" xlink:href="jnj-20211003.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:to="loc_jnj_Numberofpatientsinsettlement_1d55fcfb-777c-44e8-b3f1-56a1cec1fb94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_48bedcb9-485d-47f2-a58b-028333164e8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_48bedcb9-485d-47f2-a58b-028333164e8c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue_8d6390ee-4647-47da-a92e-10944b55c094" xlink:href="jnj-20211003.xsd#jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:to="loc_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue_8d6390ee-4647-47da-a92e-10944b55c094" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_2f01e0ff-7f83-4f2a-8f81-b64dbb95e575" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_2f01e0ff-7f83-4f2a-8f81-b64dbb95e575" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_ffd9f931-2cdf-4be2-9421-110c605b04c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_ffd9f931-2cdf-4be2-9421-110c605b04c4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyReserveEstablishedWithinTrust_7d5593ed-054b-475c-90a8-382285ffc37f" xlink:href="jnj-20211003.xsd#jnj_LossContingencyReserveEstablishedWithinTrust"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:to="loc_jnj_LossContingencyReserveEstablishedWithinTrust_7d5593ed-054b-475c-90a8-382285ffc37f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_483d5bef-332c-456a-8c58-86e5468e0bd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:to="loc_us-gaap_LitigationSettlementExpense_483d5bef-332c-456a-8c58-86e5468e0bd7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyNumberOfVotesInFavor_aaa0dd62-5b36-4ad5-bfad-39a7ec37bc6e" xlink:href="jnj-20211003.xsd#jnj_LossContingencyNumberOfVotesInFavor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:to="loc_jnj_LossContingencyNumberOfVotesInFavor_aaa0dd62-5b36-4ad5-bfad-39a7ec37bc6e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyNumberOfVotesRejected_c8351aab-aa89-47f5-9965-111faf825c09" xlink:href="jnj-20211003.xsd#jnj_LossContingencyNumberOfVotesRejected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:to="loc_jnj_LossContingencyNumberOfVotesRejected_c8351aab-aa89-47f5-9965-111faf825c09" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_857851af-846d-4afb-a2fa-c2c8720c6775" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_857851af-846d-4afb-a2fa-c2c8720c6775" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_f3f9f60b-0c1c-4d75-8f2f-f814288be244" xlink:href="jnj-20211003.xsd#jnj_LossContingencyEstimateOfAdditionalPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:to="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_f3f9f60b-0c1c-4d75-8f2f-f814288be244" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_02630b2d-69d7-4c62-a3c3-5ccc3c867581" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_02630b2d-69d7-4c62-a3c3-5ccc3c867581" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_5956417c-36fd-4d37-b014-0a72d5792eb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_23112cf4-14a9-41ce-be55-eed1815ce3ca" xlink:to="loc_us-gaap_LossContingenciesTable_5956417c-36fd-4d37-b014-0a72d5792eb0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_be2e8ba7-a566-444e-9106-d7999a50ac2b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5956417c-36fd-4d37-b014-0a72d5792eb0" xlink:to="loc_srt_LitigationCaseAxis_be2e8ba7-a566-444e-9106-d7999a50ac2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_be2e8ba7-a566-444e-9106-d7999a50ac2b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_be2e8ba7-a566-444e-9106-d7999a50ac2b" xlink:to="loc_srt_LitigationCaseTypeDomain_be2e8ba7-a566-444e-9106-d7999a50ac2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d35786f7-1176-4de9-ba4a-9015ce6bfa91" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_be2e8ba7-a566-444e-9106-d7999a50ac2b" xlink:to="loc_srt_LitigationCaseTypeDomain_d35786f7-1176-4de9-ba4a-9015ce6bfa91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member_4a010dc7-5e5c-4293-9506-cfe0c106292e" xlink:href="jnj-20211003.xsd#jnj_DePuyASRU.S.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d35786f7-1176-4de9-ba4a-9015ce6bfa91" xlink:to="loc_jnj_DePuyASRU.S.Member_4a010dc7-5e5c-4293-9506-cfe0c106292e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_4b2de3cc-390c-438a-bc81-f7277b2d6d31" xlink:href="jnj-20211003.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d35786f7-1176-4de9-ba4a-9015ce6bfa91" xlink:to="loc_jnj_RisperdalMember_4b2de3cc-390c-438a-bc81-f7277b2d6d31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_5f47880f-0a9c-49c1-a712-818784c8d0ae" xlink:href="jnj-20211003.xsd#jnj_BabyPowderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d35786f7-1176-4de9-ba4a-9015ce6bfa91" xlink:to="loc_jnj_BabyPowderMember_5f47880f-0a9c-49c1-a712-818784c8d0ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_2917432b-61f0-4a8f-bc6e-d2f858fa39ec" xlink:href="jnj-20211003.xsd#jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d35786f7-1176-4de9-ba4a-9015ce6bfa91" xlink:to="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_2917432b-61f0-4a8f-bc6e-d2f858fa39ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgicalMeshProductsMarketingMember_6220ed2d-af34-4f9e-b690-712a7b1f623f" xlink:href="jnj-20211003.xsd#jnj_SurgicalMeshProductsMarketingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d35786f7-1176-4de9-ba4a-9015ce6bfa91" xlink:to="loc_jnj_SurgicalMeshProductsMarketingMember_6220ed2d-af34-4f9e-b690-712a7b1f623f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_f3376a6f-0bfe-4548-831a-c40760a1c4d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5956417c-36fd-4d37-b014-0a72d5792eb0" xlink:to="loc_us-gaap_LitigationStatusAxis_f3376a6f-0bfe-4548-831a-c40760a1c4d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_f3376a6f-0bfe-4548-831a-c40760a1c4d5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_f3376a6f-0bfe-4548-831a-c40760a1c4d5" xlink:to="loc_us-gaap_LitigationStatusDomain_f3376a6f-0bfe-4548-831a-c40760a1c4d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_94abc91c-10e3-480f-a015-2846f934f01b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_f3376a6f-0bfe-4548-831a-c40760a1c4d5" xlink:to="loc_us-gaap_LitigationStatusDomain_94abc91c-10e3-480f-a015-2846f934f01b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_ff500c2d-67a3-4852-9c74-db627a0a59f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_94abc91c-10e3-480f-a015-2846f934f01b" xlink:to="loc_us-gaap_SettledLitigationMember_ff500c2d-67a3-4852-9c74-db627a0a59f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember_bd5e5834-d336-471a-9699-8d5cceb0fa8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_JudicialRulingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_94abc91c-10e3-480f-a015-2846f934f01b" xlink:to="loc_us-gaap_JudicialRulingMember_bd5e5834-d336-471a-9699-8d5cceb0fa8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_02b814e1-7d51-4d36-8bef-4f1a6aa815af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_94abc91c-10e3-480f-a015-2846f934f01b" xlink:to="loc_us-gaap_PendingLitigationMember_02b814e1-7d51-4d36-8bef-4f1a6aa815af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3d070cf5-4daf-43e4-a65e-4cc06c05e042" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5956417c-36fd-4d37-b014-0a72d5792eb0" xlink:to="loc_srt_ProductOrServiceAxis_3d070cf5-4daf-43e4-a65e-4cc06c05e042" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3d070cf5-4daf-43e4-a65e-4cc06c05e042_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3d070cf5-4daf-43e4-a65e-4cc06c05e042" xlink:to="loc_srt_ProductsAndServicesDomain_3d070cf5-4daf-43e4-a65e-4cc06c05e042_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4fb529d4-eade-4408-854c-4fb025757d4c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3d070cf5-4daf-43e4-a65e-4cc06c05e042" xlink:to="loc_srt_ProductsAndServicesDomain_4fb529d4-eade-4408-854c-4fb025757d4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember_7426b230-150c-40bd-9e3d-0d5ef9fcd7db" xlink:href="jnj-20211003.xsd#jnj_AsrMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4fb529d4-eade-4408-854c-4fb025757d4c" xlink:to="loc_jnj_AsrMember_7426b230-150c-40bd-9e3d-0d5ef9fcd7db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember_642f2f33-4c12-43fe-899f-77c991e8e8a1" xlink:href="jnj-20211003.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4fb529d4-eade-4408-854c-4fb025757d4c" xlink:to="loc_jnj_PinnacleAcetabularCupSystemMember_642f2f33-4c12-43fe-899f-77c991e8e8a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember_5ea479cd-34b0-46da-bfe1-00ae2238f833" xlink:href="jnj-20211003.xsd#jnj_PelvicMeshesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4fb529d4-eade-4408-854c-4fb025757d4c" xlink:to="loc_jnj_PelvicMeshesMember_5ea479cd-34b0-46da-bfe1-00ae2238f833" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_5cb4d3f5-ad5b-4679-a306-47ea08e0eaf2" xlink:href="jnj-20211003.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4fb529d4-eade-4408-854c-4fb025757d4c" xlink:to="loc_jnj_RisperdalMember_5cb4d3f5-ad5b-4679-a306-47ea08e0eaf2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_2754ae54-4640-4aba-a4a7-8f37b18a1ca8" xlink:href="jnj-20211003.xsd#jnj_XareltoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4fb529d4-eade-4408-854c-4fb025757d4c" xlink:to="loc_jnj_XareltoMember_2754ae54-4640-4aba-a4a7-8f37b18a1ca8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_c9d0b481-35d7-4c49-9a7a-5bae7eafff53" xlink:href="jnj-20211003.xsd#jnj_TalcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4fb529d4-eade-4408-854c-4fb025757d4c" xlink:to="loc_jnj_TalcMember_c9d0b481-35d7-4c49-9a7a-5bae7eafff53" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvokanaMember_16358473-b747-4386-a4d0-691d6f966d3f" xlink:href="jnj-20211003.xsd#jnj_InvokanaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4fb529d4-eade-4408-854c-4fb025757d4c" xlink:to="loc_jnj_InvokanaMember_16358473-b747-4386-a4d0-691d6f966d3f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember_3153987f-436d-457e-8907-bae7798c67e4" xlink:href="jnj-20211003.xsd#jnj_PhysiomeshMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4fb529d4-eade-4408-854c-4fb025757d4c" xlink:to="loc_jnj_PhysiomeshMember_3153987f-436d-457e-8907-bae7798c67e4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpioidMember_7690773a-d4c6-4024-b648-4358681ef094" xlink:href="jnj-20211003.xsd#jnj_OpioidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4fb529d4-eade-4408-854c-4fb025757d4c" xlink:to="loc_jnj_OpioidMember_7690773a-d4c6-4024-b648-4358681ef094" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ContactLensesMember_fdaf1ac6-123c-454b-861c-5b52b5f61db7" xlink:href="jnj-20211003.xsd#jnj_ContactLensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4fb529d4-eade-4408-854c-4fb025757d4c" xlink:to="loc_jnj_ContactLensesMember_fdaf1ac6-123c-454b-861c-5b52b5f61db7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesAxis_f42b1407-9f4d-47d0-90cd-2abbfdce30d5" xlink:href="jnj-20211003.xsd#jnj_LitigationSettlementByCompaniesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5956417c-36fd-4d37-b014-0a72d5792eb0" xlink:to="loc_jnj_LitigationSettlementByCompaniesAxis_f42b1407-9f4d-47d0-90cd-2abbfdce30d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain_f42b1407-9f4d-47d0-90cd-2abbfdce30d5_default" xlink:href="jnj-20211003.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis_f42b1407-9f4d-47d0-90cd-2abbfdce30d5" xlink:to="loc_jnj_LitigationSettlementByCompaniesDomain_f42b1407-9f4d-47d0-90cd-2abbfdce30d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain_9b18b7f7-1709-4680-877b-a9dd163628e5" xlink:href="jnj-20211003.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis_f42b1407-9f4d-47d0-90cd-2abbfdce30d5" xlink:to="loc_jnj_LitigationSettlementByCompaniesDomain_9b18b7f7-1709-4680-877b-a9dd163628e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_8a8ab54c-36cc-4b11-9e25-eb01a058ba16" xlink:href="jnj-20211003.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LitigationSettlementByCompaniesDomain_9b18b7f7-1709-4680-877b-a9dd163628e5" xlink:to="loc_jnj_RisperdalMember_8a8ab54c-36cc-4b11-9e25-eb01a058ba16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6d43f9cf-dce4-476c-a616-1532ec0765ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5956417c-36fd-4d37-b014-0a72d5792eb0" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6d43f9cf-dce4-476c-a616-1532ec0765ee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_6d43f9cf-dce4-476c-a616-1532ec0765ee_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6d43f9cf-dce4-476c-a616-1532ec0765ee" xlink:to="loc_us-gaap_LossContingencyNatureDomain_6d43f9cf-dce4-476c-a616-1532ec0765ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_45858173-fa5d-47cd-afbf-33bbc04617ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6d43f9cf-dce4-476c-a616-1532ec0765ee" xlink:to="loc_us-gaap_LossContingencyNatureDomain_45858173-fa5d-47cd-afbf-33bbc04617ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember_4b21b601-491a-4a69-a46f-dceb03c40106" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DamagesFromProductDefectsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_45858173-fa5d-47cd-afbf-33bbc04617ac" xlink:to="loc_us-gaap_DamagesFromProductDefectsMember_4b21b601-491a-4a69-a46f-dceb03c40106" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_bf839bc9-4dd6-47c6-a8a2-d9a4de86a54e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5956417c-36fd-4d37-b014-0a72d5792eb0" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_bf839bc9-4dd6-47c6-a8a2-d9a4de86a54e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_bf839bc9-4dd6-47c6-a8a2-d9a4de86a54e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_bf839bc9-4dd6-47c6-a8a2-d9a4de86a54e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_bf839bc9-4dd6-47c6-a8a2-d9a4de86a54e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e8208577-9f7d-495b-9a29-997267f1b0c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_bf839bc9-4dd6-47c6-a8a2-d9a4de86a54e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e8208577-9f7d-495b-9a29-997267f1b0c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_12c1c7ec-dd9c-436a-9e98-11583725a182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e8208577-9f7d-495b-9a29-997267f1b0c8" xlink:to="loc_us-gaap_SubsequentEventMember_12c1c7ec-dd9c-436a-9e98-11583725a182" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalJurisdictionAxis_b76b142b-1b25-429a-9827-4957766a025e" xlink:href="jnj-20211003.xsd#jnj_LegalJurisdictionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5956417c-36fd-4d37-b014-0a72d5792eb0" xlink:to="loc_jnj_LegalJurisdictionAxis_b76b142b-1b25-429a-9827-4957766a025e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalJurisdictionDomain_b76b142b-1b25-429a-9827-4957766a025e_default" xlink:href="jnj-20211003.xsd#jnj_LegalJurisdictionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_jnj_LegalJurisdictionAxis_b76b142b-1b25-429a-9827-4957766a025e" xlink:to="loc_jnj_LegalJurisdictionDomain_b76b142b-1b25-429a-9827-4957766a025e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalJurisdictionDomain_f8c28a44-ba6d-4aa8-96c4-405ebde1fca6" xlink:href="jnj-20211003.xsd#jnj_LegalJurisdictionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_jnj_LegalJurisdictionAxis_b76b142b-1b25-429a-9827-4957766a025e" xlink:to="loc_jnj_LegalJurisdictionDomain_f8c28a44-ba6d-4aa8-96c4-405ebde1fca6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StateLevelJurisdictionMember_d298743c-6222-4740-bb1f-c683e86d95af" xlink:href="jnj-20211003.xsd#jnj_StateLevelJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalJurisdictionDomain_f8c28a44-ba6d-4aa8-96c4-405ebde1fca6" xlink:to="loc_jnj_StateLevelJurisdictionMember_d298743c-6222-4740-bb1f-c683e86d95af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalLevelJurisdictionMember_eef8fa45-6c5d-4b0b-9da4-97d62a85d0ce" xlink:href="jnj-20211003.xsd#jnj_FederalLevelJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalJurisdictionDomain_f8c28a44-ba6d-4aa8-96c4-405ebde1fca6" xlink:to="loc_jnj_FederalLevelJurisdictionMember_eef8fa45-6c5d-4b0b-9da4-97d62a85d0ce" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#RestructuringNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="extended" id="if70a0d54ec0340f38fedc17cdb411914_RestructuringNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_e6c2e46f-c1f2-4697-827e-6a4e1a45cc4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_ea7cc336-2c5c-4af6-a768-6445738c7825" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e6c2e46f-c1f2-4697-827e-6a4e1a45cc4f" xlink:to="loc_us-gaap_RestructuringCharges_ea7cc336-2c5c-4af6-a768-6445738c7825" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_af3119ae-d0cf-4af1-bb3f-4960edbdddff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e6c2e46f-c1f2-4697-827e-6a4e1a45cc4f" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_af3119ae-d0cf-4af1-bb3f-4960edbdddff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_41fc18a4-3175-4eca-8cab-69d7530d9147" xlink:href="jnj-20211003.xsd#jnj_RestructuringandRelatedCostExpectedFutureSavings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e6c2e46f-c1f2-4697-827e-6a4e1a45cc4f" xlink:to="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_41fc18a4-3175-4eca-8cab-69d7530d9147" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_8a6e2795-c8c0-4865-a2d3-82310b20e051" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e6c2e46f-c1f2-4697-827e-6a4e1a45cc4f" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_8a6e2795-c8c0-4865-a2d3-82310b20e051" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_3de1686a-9a81-4dfb-8044-d945838c4f13" xlink:href="jnj-20211003.xsd#jnj_RestructuringandRelatedCostDurationofRestructuringPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e6c2e46f-c1f2-4697-827e-6a4e1a45cc4f" xlink:to="loc_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_3de1686a-9a81-4dfb-8044-d945838c4f13" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e107365d-cc65-4d32-ba60-57f05317a524" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e6c2e46f-c1f2-4697-827e-6a4e1a45cc4f" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e107365d-cc65-4d32-ba60-57f05317a524" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d90c5e76-b05a-4b7c-956c-dde9e002c77d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e107365d-cc65-4d32-ba60-57f05317a524" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d90c5e76-b05a-4b7c-956c-dde9e002c77d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d90c5e76-b05a-4b7c-956c-dde9e002c77d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d90c5e76-b05a-4b7c-956c-dde9e002c77d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d90c5e76-b05a-4b7c-956c-dde9e002c77d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3dc67c9b-da8e-43c0-adf5-34c8a69e80e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d90c5e76-b05a-4b7c-956c-dde9e002c77d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3dc67c9b-da8e-43c0-adf5-34c8a69e80e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_f80f8a98-35a5-402b-b78b-fe069c0c4991" xlink:href="jnj-20211003.xsd#jnj_SupplyChainMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3dc67c9b-da8e-43c0-adf5-34c8a69e80e8" xlink:to="loc_jnj_SupplyChainMember_f80f8a98-35a5-402b-b78b-fe069c0c4991" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0e0f5bc0-a0cf-48ca-9724-a5ba4cd85b94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e107365d-cc65-4d32-ba60-57f05317a524" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0e0f5bc0-a0cf-48ca-9724-a5ba4cd85b94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0e0f5bc0-a0cf-48ca-9724-a5ba4cd85b94_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0e0f5bc0-a0cf-48ca-9724-a5ba4cd85b94" xlink:to="loc_us-gaap_SegmentDomain_0e0f5bc0-a0cf-48ca-9724-a5ba4cd85b94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bb2588a6-4fa1-4414-85d8-b6ea2d4b9bdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0e0f5bc0-a0cf-48ca-9724-a5ba4cd85b94" xlink:to="loc_us-gaap_SegmentDomain_bb2588a6-4fa1-4414-85d8-b6ea2d4b9bdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_b224ce3c-eeba-4f20-8197-10dc9aa01e3d" xlink:href="jnj-20211003.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bb2588a6-4fa1-4414-85d8-b6ea2d4b9bdf" xlink:to="loc_jnj_MedicalDevicesMember_b224ce3c-eeba-4f20-8197-10dc9aa01e3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_bc978a44-2171-425b-8573-6b613e8d9d0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e107365d-cc65-4d32-ba60-57f05317a524" xlink:to="loc_us-gaap_RestructuringPlanAxis_bc978a44-2171-425b-8573-6b613e8d9d0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_bc978a44-2171-425b-8573-6b613e8d9d0e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_bc978a44-2171-425b-8573-6b613e8d9d0e" xlink:to="loc_us-gaap_RestructuringPlanDomain_bc978a44-2171-425b-8573-6b613e8d9d0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_431cc6e0-879b-4049-99cc-f7ff9af11adf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_bc978a44-2171-425b-8573-6b613e8d9d0e" xlink:to="loc_us-gaap_RestructuringPlanDomain_431cc6e0-879b-4049-99cc-f7ff9af11adf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_655ba5a6-1fb0-416c-a38c-6baf494231e3" xlink:href="jnj-20211003.xsd#jnj_SupplyChainMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_431cc6e0-879b-4049-99cc-f7ff9af11adf" xlink:to="loc_jnj_SupplyChainMember_655ba5a6-1fb0-416c-a38c-6baf494231e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3d87f241-2f77-4dd5-bff3-429a184decab" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e107365d-cc65-4d32-ba60-57f05317a524" xlink:to="loc_srt_RangeAxis_3d87f241-2f77-4dd5-bff3-429a184decab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3d87f241-2f77-4dd5-bff3-429a184decab_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3d87f241-2f77-4dd5-bff3-429a184decab" xlink:to="loc_srt_RangeMember_3d87f241-2f77-4dd5-bff3-429a184decab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2d43532b-d090-4a10-8bc0-329a1a240019" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3d87f241-2f77-4dd5-bff3-429a184decab" xlink:to="loc_srt_RangeMember_2d43532b-d090-4a10-8bc0-329a1a240019" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6625c9c0-d09c-48ef-8d15-e0f4606df374" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2d43532b-d090-4a10-8bc0-329a1a240019" xlink:to="loc_srt_MinimumMember_6625c9c0-d09c-48ef-8d15-e0f4606df374" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0c781aaf-bd28-4432-bf27-a75a34d12fa4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2d43532b-d090-4a10-8bc0-329a1a240019" xlink:to="loc_srt_MaximumMember_0c781aaf-bd28-4432-bf27-a75a34d12fa4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7fb094ce-df39-4942-9b8c-9edf926177e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e107365d-cc65-4d32-ba60-57f05317a524" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7fb094ce-df39-4942-9b8c-9edf926177e3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7fb094ce-df39-4942-9b8c-9edf926177e3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7fb094ce-df39-4942-9b8c-9edf926177e3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7fb094ce-df39-4942-9b8c-9edf926177e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0b8ec2b2-5be6-4009-b08e-31ed83cf868d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7fb094ce-df39-4942-9b8c-9edf926177e3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0b8ec2b2-5be6-4009-b08e-31ed83cf868d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_0bd05f40-6a9c-4016-9381-666e291623ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0b8ec2b2-5be6-4009-b08e-31ed83cf868d" xlink:to="loc_us-gaap_RestructuringChargesMember_0bd05f40-6a9c-4016-9381-666e291623ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_07cf7fd6-d43b-4111-ab33-2a311e7db526" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0b8ec2b2-5be6-4009-b08e-31ed83cf868d" xlink:to="loc_us-gaap_CostOfSalesMember_07cf7fd6-d43b-4111-ab33-2a311e7db526" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_c64447c3-565c-4dcc-bd69-776d50df20c7" xlink:href="jnj-20211003.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0b8ec2b2-5be6-4009-b08e-31ed83cf868d" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_c64447c3-565c-4dcc-bd69-776d50df20c7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#RestructuringScheduleofRestructuringReserveDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" xlink:type="extended" id="i30959308f5224e25a3eac50ab8daa65f_RestructuringScheduleofRestructuringReserveDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_db30ff4c-3731-46f9-bcc8-598095f1fc98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_bef999c6-4ba6-4e09-b4cd-bcc49a31b140" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_db30ff4c-3731-46f9-bcc8-598095f1fc98" xlink:to="loc_us-gaap_RestructuringReserveRollForward_bef999c6-4ba6-4e09-b4cd-bcc49a31b140" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_7383f525-6c77-430d-8c62-4e2950bdab55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_bef999c6-4ba6-4e09-b4cd-bcc49a31b140" xlink:to="loc_us-gaap_RestructuringReserve_7383f525-6c77-430d-8c62-4e2950bdab55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_f8136906-b86b-4348-86cf-7f7ed978bfa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_bef999c6-4ba6-4e09-b4cd-bcc49a31b140" xlink:to="loc_us-gaap_RestructuringCharges_f8136906-b86b-4348-86cf-7f7ed978bfa2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_f818f108-e413-4840-82bb-73881c265d5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_bef999c6-4ba6-4e09-b4cd-bcc49a31b140" xlink:to="loc_us-gaap_PaymentsForRestructuring_f818f108-e413-4840-82bb-73881c265d5f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_9bc6b293-6629-4895-af9d-17f4531a2339" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_bef999c6-4ba6-4e09-b4cd-bcc49a31b140" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_9bc6b293-6629-4895-af9d-17f4531a2339" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_49a0a126-9f63-420e-9b4b-b1992711f3ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid_37dc1735-58d4-4137-a9a8-0124cd11442d" xlink:href="jnj-20211003.xsd#jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_db30ff4c-3731-46f9-bcc8-598095f1fc98" xlink:to="loc_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid_37dc1735-58d4-4137-a9a8-0124cd11442d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d6820137-fda4-438a-8914-698d9aa9ec3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_db30ff4c-3731-46f9-bcc8-598095f1fc98" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d6820137-fda4-438a-8914-698d9aa9ec3f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_e70d2d1d-3012-4970-9f42-b7ebd5b14e9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d6820137-fda4-438a-8914-698d9aa9ec3f" xlink:to="loc_us-gaap_RestructuringPlanAxis_e70d2d1d-3012-4970-9f42-b7ebd5b14e9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_e70d2d1d-3012-4970-9f42-b7ebd5b14e9c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_e70d2d1d-3012-4970-9f42-b7ebd5b14e9c" xlink:to="loc_us-gaap_RestructuringPlanDomain_e70d2d1d-3012-4970-9f42-b7ebd5b14e9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_37f38137-d26d-4096-a2bb-c326fcefdb4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_e70d2d1d-3012-4970-9f42-b7ebd5b14e9c" xlink:to="loc_us-gaap_RestructuringPlanDomain_37f38137-d26d-4096-a2bb-c326fcefdb4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_e5f9a6e4-2ad5-47db-a375-5f2ced46110f" xlink:href="jnj-20211003.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_37f38137-d26d-4096-a2bb-c326fcefdb4a" xlink:to="loc_jnj_MedicalDevicesMember_e5f9a6e4-2ad5-47db-a375-5f2ced46110f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_841aab4a-6401-4266-9ccd-a4ebf9f36d94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d6820137-fda4-438a-8914-698d9aa9ec3f" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_841aab4a-6401-4266-9ccd-a4ebf9f36d94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_841aab4a-6401-4266-9ccd-a4ebf9f36d94_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_841aab4a-6401-4266-9ccd-a4ebf9f36d94" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_841aab4a-6401-4266-9ccd-a4ebf9f36d94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_e85e884d-8519-4797-9c01-21191483b21f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_841aab4a-6401-4266-9ccd-a4ebf9f36d94" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_e85e884d-8519-4797-9c01-21191483b21f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_2805b422-17c1-4589-86cf-8d5b48f8d483" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e85e884d-8519-4797-9c01-21191483b21f" xlink:to="loc_us-gaap_EmployeeSeveranceMember_2805b422-17c1-4589-86cf-8d5b48f8d483" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetWriteoffMember_2466c802-c23a-4f2b-b3d5-392bb96e5328" xlink:href="jnj-20211003.xsd#jnj_AssetWriteoffMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e85e884d-8519-4797-9c01-21191483b21f" xlink:to="loc_jnj_AssetWriteoffMember_2466c802-c23a-4f2b-b3d5-392bb96e5328" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_4034ded4-63ab-4439-986e-4a53d9ec38b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e85e884d-8519-4797-9c01-21191483b21f" xlink:to="loc_us-gaap_OtherRestructuringMember_4034ded4-63ab-4439-986e-4a53d9ec38b6" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>jnj-20211003_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:90dc118c-6428-4338-8b4d-8015054a0548,g:65f17fdb-8375-41f4-bf95-c047d59b03b3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentType_38ac6dd8-da46-4ef4-b471-0435abe6ccb1_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentsGeographicalAreasAbstract_f3534c62-7caa-424d-82a2-2e6a73341511_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentsGeographicalAreasAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales by geographic area</link:label>
    <link:label id="lab_us-gaap_SegmentsGeographicalAreasAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentsGeographicalAreasAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments, Geographical Areas [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentsGeographicalAreasAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract" xlink:to="lab_us-gaap_SegmentsGeographicalAreasAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_ceaaffc7-de0f-4906-bda3-15124dbf6935_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_04bbabc6-ca44-4856-a8d2-68d791af2d37_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_59211f0e-969c-493e-8e2e-831ef0474e4c_terseLabel_en-US" xlink:label="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma Attorney General vs. Johnson &amp; Johnson and JPI</link:label>
    <link:label id="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_label_en-US" xlink:label="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]</link:label>
    <link:label id="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_documentation_en-US" xlink:label="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:href="jnj-20211003.xsd#jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:to="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BabyPowderMember_8fc152de-aaa2-486e-9f3b-6741cbbe846b_terseLabel_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Powder</link:label>
    <link:label id="lab_jnj_BabyPowderMember_label_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Powder [Member]</link:label>
    <link:label id="lab_jnj_BabyPowderMember_documentation_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Powder [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember" xlink:href="jnj-20211003.xsd#jnj_BabyPowderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BabyPowderMember" xlink:to="lab_jnj_BabyPowderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5031075f-06d9-4939-90dc-64aaa4768b82_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase/(Decrease) in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_226580df-2d25-4f9c-ae08-b45d7ff696f3_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Amount</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_e199f846-77c1-4634-8626-3a83732646f9_terseLabel_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in estimated fair value (6)</link:label>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_label_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</link:label>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_documentation_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:href="jnj-20211003.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:to="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_758ffc25-5c2b-4153-8614-f53aba09f6a5_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Business Segments</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_f96e40a0-ca84-46ea-8fc3-b932312572cb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_f0b9ba0d-e41e-498a-a7da-4fb53d004068_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pensions and Other Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_0b503cd2-b83b-4091-994c-92735c30e83c_terseLabel_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for activity</link:label>
    <link:label id="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_label_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Duration of Restructuring Plan</link:label>
    <link:label id="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_documentation_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Duration of Restructuring Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostDurationofRestructuringPlan" xlink:href="jnj-20211003.xsd#jnj_RestructuringandRelatedCostDurationofRestructuringPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RestructuringandRelatedCostDurationofRestructuringPlan" xlink:to="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_e20e2ef3-0ae7-4f4c-a149-e54618a90a8b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ConsumerMember_0b0ac8e6-d4e2-4ee0-906f-8f41655ea24d_terseLabel_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Health</link:label>
    <link:label id="lab_jnj_ConsumerMember_label_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer [Member]</link:label>
    <link:label id="lab_jnj_ConsumerMember_documentation_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember" xlink:href="jnj-20211003.xsd#jnj_ConsumerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ConsumerMember" xlink:to="lab_jnj_ConsumerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_0356dc90-c9d5-49e9-a78e-0909233be5f9_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DARZALEXMember_190acd0e-afb7-4d0b-a6ff-b7e467ffcce7_terseLabel_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARZALEX&#174;</link:label>
    <link:label id="lab_jnj_DARZALEXMember_label_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARZALEX [Member]</link:label>
    <link:label id="lab_jnj_DARZALEXMember_documentation_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARZALEX [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember" xlink:href="jnj-20211003.xsd#jnj_DARZALEXMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DARZALEXMember" xlink:to="lab_jnj_DARZALEXMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1ea82c8e-5e0b-435b-b397-6d140dbcbc8e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_d0a544a6-1c2c-4de7-a724-52d18eacc93b_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant unobservable inputs Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ADVANCEDMember_e65b917c-f6b8-4cd0-9e12-e62b5ffcfaab_terseLabel_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVANCED</link:label>
    <link:label id="lab_jnj_ADVANCEDMember_label_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVANCED [Member]</link:label>
    <link:label id="lab_jnj_ADVANCEDMember_documentation_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVANCED [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember" xlink:href="jnj-20211003.xsd#jnj_ADVANCEDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ADVANCEDMember" xlink:to="lab_jnj_ADVANCEDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_ef1cedc4-2572-493f-b8c8-694176d3e326_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Net Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_3ca84667-908e-4b90-b59f-6cebc2406d43_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_63c4b044-fe89-4759-a8cd-28063effe8b3_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets with indefinite lives:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_3512f78f-bc54-4df9-941a-e69af9a77184_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2ab1f3a8-4108-423f-8825-c01c9a44b770_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_c3d16141-c0d4-45f1-8b3f-fd5d275a6591_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageChangeInOperatingIncomeLoss_f4d51239-83e3-4a60-8104-53d7cc1fa1e2_terseLabel_en-US" xlink:label="lab_jnj_PercentageChangeInOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change in Operating Income Loss</link:label>
    <link:label id="lab_jnj_PercentageChangeInOperatingIncomeLoss_label_en-US" xlink:label="lab_jnj_PercentageChangeInOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change in Operating Income Loss</link:label>
    <link:label id="lab_jnj_PercentageChangeInOperatingIncomeLoss_documentation_en-US" xlink:label="lab_jnj_PercentageChangeInOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage change in operating income loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInOperatingIncomeLoss" xlink:href="jnj-20211003.xsd#jnj_PercentageChangeInOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageChangeInOperatingIncomeLoss" xlink:to="lab_jnj_PercentageChangeInOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_283ba910-75a5-425b-b406-f3d93a200b59_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes on income (Note 5)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_4f6f1bd8-db2d-4c7a-978a-4e280cdfc8b5_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_6263620c-b174-4b94-8a51-0ad234bba729_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net (Note 3)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_a51fbbb2-c58e-406d-a51e-8a264ced68d3_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets - net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_1c251978-7f9e-49ae-854b-f4f7f13a17b6_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Segment Operating Income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8dc676e2-6eb1-4d64-8b05-4be8e4808244_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from long-term debt, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_f658e501-62c3-46a0-8446-9c5ac66f469e_terseLabel_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Notes due 2047</link:label>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_label_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Notes due 2047 [Member]</link:label>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_documentation_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Notes due 2047 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member" xlink:href="jnj-20211003.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.75Notesdue2047Member" xlink:to="lab_jnj_A3.75Notesdue2047Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_735b5ba1-b011-4611-908c-f719d170eedf_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_1b104726-dd19-4055-b956-505f7e5b9bdf_terseLabel_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTACT LENSES / OTHER</link:label>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_label_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTACT LENSES/OTHER [Member]</link:label>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_documentation_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTACT LENSES/OTHER [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember" xlink:href="jnj-20211003.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CONTACTLENSESOTHERMember" xlink:to="lab_jnj_CONTACTLENSESOTHERMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LegalJurisdictionAxis_fc4ac08b-0f36-4669-9ed4-e3a134735b6a_terseLabel_en-US" xlink:label="lab_jnj_LegalJurisdictionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Jurisdiction [Axis]</link:label>
    <link:label id="lab_jnj_LegalJurisdictionAxis_label_en-US" xlink:label="lab_jnj_LegalJurisdictionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Jurisdiction [Axis]</link:label>
    <link:label id="lab_jnj_LegalJurisdictionAxis_documentation_en-US" xlink:label="lab_jnj_LegalJurisdictionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Jurisdiction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalJurisdictionAxis" xlink:href="jnj-20211003.xsd#jnj_LegalJurisdictionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LegalJurisdictionAxis" xlink:to="lab_jnj_LegalJurisdictionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_32ed73ed-c8b5-4335-bc7e-c8eee96f5e32_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_9e6d0f17-8cf8-47b5-9312-f4524d8d5f81_negatedTerseLabel_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and current marketable securities, Unrecognized Loss</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_label_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:href="jnj-20211003.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:to="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_b081e3ef-2785-4404-aca3-e229bae29274_negatedTerseLabel_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: shares which could be repurchased under treasury stock method</link:label>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_label_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Which Could Be Repurchased Under Treasury Stock Method</link:label>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_documentation_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:href="jnj-20211003.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:to="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d551d38a-164a-4cd4-ba7b-9183a632f339_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_df0e98f2-e61f-4671-9344-d1b01fc42aac_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_5c98edd2-44dc-46d8-be47-ceb238d45caf_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_db779e16-78e6-49a7-92d9-ca09871db97b_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_d0efecce-de09-4b2e-bf70-fac6196e32b6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_HIPSMember_55b376ec-a250-4066-9f95-96f60afc192e_terseLabel_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIPS</link:label>
    <link:label id="lab_jnj_HIPSMember_label_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIPS [Member]</link:label>
    <link:label id="lab_jnj_HIPSMember_documentation_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIPS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember" xlink:href="jnj-20211003.xsd#jnj_HIPSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_HIPSMember" xlink:to="lab_jnj_HIPSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b434679d-2586-443e-a69f-a0b8d6719fdb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_c7a12bdb-4b17-4f5a-8eaf-4c2813c68502_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_115b75c7-91ea-4ebd-bbfe-9fe6b655b9d8_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of basic net earnings per share to diluted net earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_b2e20c4f-23bd-4c5c-92e5-b75f4247ad01_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_ed320cd0-63c4-4cbf-a1a0-ee0dc8853e8e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_85fb817c-d173-4eb6-a2a0-92c6a2ed7e5b_verboseLabel_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes Due May 2035</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_444a1e7e-c516-4b25-98d7-1fe4653dbc06_terseLabel_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes due 2035 (1.5B Euro 1.1581)</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_label_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes Due 2035 [Member]</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_documentation_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes Due 2035 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member" xlink:href="jnj-20211003.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1.650NotesDue2035Member" xlink:to="lab_jnj_A1.650NotesDue2035Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3b4cb0a8-ecd0-490d-a180-2f1ee8e45fed_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4f481002-cd6c-45bd-8fad-323df164529c_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_027ba660-3a22-415e-9894-4c4f3aeb4e9e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) arising during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_92c6af6c-6472-4df2-bae9-0502df8bf3fa_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedging instruments : Liabilities</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:to="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_bb3177cb-369c-4a1e-812a-1ab99127e652_terseLabel_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit support agreements activity, net</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_label_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_documentation_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:href="jnj-20211003.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:to="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentRollForward_b044d009-b5d5-4113-8e11-e583aff1507c_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:label id="lab_jnj_EquityInvestmentRollForward_label_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:label id="lab_jnj_EquityInvestmentRollForward_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward" xlink:href="jnj-20211003.xsd#jnj_EquityInvestmentRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentRollForward" xlink:to="lab_jnj_EquityInvestmentRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_5ba9716d-489e-4054-8076-2240023d2488_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_d0bb417f-405b-4fe9-b4dc-d0fc8f25a275_terseLabel_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER NEUROSCIENCE</link:label>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_label_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER NEUROSCIENCE [Member]</link:label>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_documentation_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER NEUROSCIENCE [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember" xlink:href="jnj-20211003.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OTHERNEUROSCIENCEMember" xlink:to="lab_jnj_OTHERNEUROSCIENCEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_1bb2b9d0-30e1-430a-8904-091f88958f05_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceedings</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PhysiomeshMember_c86282bf-9fb6-4f03-9d62-be844b46b42e_terseLabel_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physiomesh</link:label>
    <link:label id="lab_jnj_PhysiomeshMember_label_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physiomesh [Member]</link:label>
    <link:label id="lab_jnj_PhysiomeshMember_documentation_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physiomesh [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember" xlink:href="jnj-20211003.xsd#jnj_PhysiomeshMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PhysiomeshMember" xlink:to="lab_jnj_PhysiomeshMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_1e0d2f96-a692-418e-820c-943052ac58f7_terseLabel_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_label_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_documentation_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement" xlink:href="jnj-20211003.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Numberofpatientsinsettlement" xlink:to="lab_jnj_Numberofpatientsinsettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_b86edb1b-72d1-4afe-8eea-697feac52e54_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_67b73cea-0e0f-40a4-8cd4-56c0eaf2bd87_terseLabel_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95% Notes due 2029</link:label>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_label_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95% Notes due 2029 [Member]</link:label>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_documentation_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95% Notes due 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member" xlink:href="jnj-20211003.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A6.95Notesdue2029Member" xlink:to="lab_jnj_A6.95Notesdue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_9dd6fc7e-9c97-4611-ae13-56d45636b42f_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Gov't securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9eefeff1-64c5-4904-a580-7958542eb835_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_390f51c8-853b-4fef-b8a5-da2246071a5b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Settled without Cash</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Settled without Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:to="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_f6a765f5-743a-49e0-a5c3-cf22f39d169f_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral already posted, aggregate fair value</link:label>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_label_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Already Posted, Aggregate Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:to="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_f79996e6-94b9-4dbe-9518-f3ac5708fadc_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_3bbe5adf-4e20-4cf3-b90a-253519b4de91_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value per share (per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyNumberOfVotesInFavor_0e334b48-3218-4f39-80b2-20a0754b195f_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyNumberOfVotesInFavor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes in favor</link:label>
    <link:label id="lab_jnj_LossContingencyNumberOfVotesInFavor_label_en-US" xlink:label="lab_jnj_LossContingencyNumberOfVotesInFavor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Votes in Favor</link:label>
    <link:label id="lab_jnj_LossContingencyNumberOfVotesInFavor_documentation_en-US" xlink:label="lab_jnj_LossContingencyNumberOfVotesInFavor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Votes in Favor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyNumberOfVotesInFavor" xlink:href="jnj-20211003.xsd#jnj_LossContingencyNumberOfVotesInFavor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyNumberOfVotesInFavor" xlink:to="lab_jnj_LossContingencyNumberOfVotesInFavor" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_2bd7538e-1bed-4dac-9ab1-12cb9e013373_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_be79ab0f-7a22-4ff7-af3a-63a428271ad1_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes on income (Note 5)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_ca6535c7-11f5-473d-9a8b-fce59bc80584_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (primarily licenses and milestones)</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_4883d141-95cb-43aa-99af-3c02cf9e6108_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InvokanaMember_7b694736-2772-4341-9783-93c10247510c_terseLabel_en-US" xlink:label="lab_jnj_InvokanaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invokana</link:label>
    <link:label id="lab_jnj_InvokanaMember_label_en-US" xlink:label="lab_jnj_InvokanaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invokana [Member]</link:label>
    <link:label id="lab_jnj_InvokanaMember_documentation_en-US" xlink:label="lab_jnj_InvokanaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invokana [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvokanaMember" xlink:href="jnj-20211003.xsd#jnj_InvokanaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InvokanaMember" xlink:to="lab_jnj_InvokanaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_c0e00348-7568-47c6-8b05-840a929bd6b7_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments with readily determinable value</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_label_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments with Readily Determinable Value [Member]</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments with Readily Determinable Value [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:href="jnj-20211003.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:to="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_a35cd1cf-6984-477a-92dd-903bfb501d3c_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_d4063bca-987c-495d-bc97-9f3882de32cf_terseLabel_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Western Hemisphere, excluding U.S.</link:label>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_label_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Western Hemisphere, excluding U.S. [Member]</link:label>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_documentation_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Western Hemisphere, excluding U.S. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember" xlink:href="jnj-20211003.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WesternHemisphereExcludingUSMember" xlink:to="lab_jnj_WesternHemisphereExcludingUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_11b49111-a4f9-4656-9420-2ebb17dc460b_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goods in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_cfd5032f-3e65-43ec-a4e0-a7d75c49ad1c_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories (Note 2)</link:label>
    <link:label id="lab_us-gaap_InventoryNet_58c4a4eb-af13-4f06-9bed-0c42e21e255b_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_11cf775f-0a9c-430f-a23c-e7b1812fb6cf_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_295cb2f0-1ad7-4160-b12f-e387117420b5_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6b19f7ae-e1d1-41a3-9b1d-f7ead139e6e9_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_StateLevelJurisdictionMember_8d0f883d-a4b8-407f-8ab0-37eb133de513_terseLabel_en-US" xlink:label="lab_jnj_StateLevelJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State Level Jurisdiction</link:label>
    <link:label id="lab_jnj_StateLevelJurisdictionMember_label_en-US" xlink:label="lab_jnj_StateLevelJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State Level Jurisdiction [Member]</link:label>
    <link:label id="lab_jnj_StateLevelJurisdictionMember_documentation_en-US" xlink:label="lab_jnj_StateLevelJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State Level Jurisdiction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StateLevelJurisdictionMember" xlink:href="jnj-20211003.xsd#jnj_StateLevelJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_StateLevelJurisdictionMember" xlink:to="lab_jnj_StateLevelJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_996fa5a3-7cd7-4385-b94c-8b061c435ccb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives &amp; hedges:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InvestmentIncomeInterestPercentToSales_f00334b3-0373-40aa-870a-aaa2f1f57aa1_terseLabel_en-US" xlink:label="lab_jnj_InvestmentIncomeInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income percent to sales</link:label>
    <link:label id="lab_jnj_InvestmentIncomeInterestPercentToSales_label_en-US" xlink:label="lab_jnj_InvestmentIncomeInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income Interest Percent To Sales</link:label>
    <link:label id="lab_jnj_InvestmentIncomeInterestPercentToSales_documentation_en-US" xlink:label="lab_jnj_InvestmentIncomeInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income interest percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvestmentIncomeInterestPercentToSales" xlink:href="jnj-20211003.xsd#jnj_InvestmentIncomeInterestPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InvestmentIncomeInterestPercentToSales" xlink:to="lab_jnj_InvestmentIncomeInterestPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_f4ed4f81-d4d7-4ee2-af90-8ca4dd30f8a9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_42586104-ee44-4e98-844e-cdfa94cfd830_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_16c6e013-a47e-4330-92ca-745c7ec024e7_negatedLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities, Unrecognized Loss</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_1f62e475-8dfc-4004-9b06-90d08630c784_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales_a088bc24-d730-4ec8-80cb-b027169fa7bc_terseLabel_en-US" xlink:label="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net percent to sales</link:label>
    <link:label id="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales_label_en-US" xlink:label="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non Operating Income Expense Percent To Sales</link:label>
    <link:label id="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales_documentation_en-US" xlink:label="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non operating income expense percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:href="jnj-20211003.xsd#jnj_OtherNonOperatingIncomeExpensePercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:to="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_84856647-b363-4823-b71d-474c5ba68924_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_f2d6727b-f014-4b55-9d13-04c538e9d381_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments : Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments in Hedges, Liabilities, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_76f6fe28-4e15-4d49-a98a-f34766599399_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_8f47a324-4734-4f58-853f-eb6d3f2b495a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of previously held equity investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_da70c124-32b2-4730-a32b-03f540cbf282_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_c32e58ec-6f4b-4f50-a463-475a0103e66e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) reclassified from AOCI into income</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtWeightedAverageInterestRate_f7fa2e33-f73f-426e-9708-e310bf056fda_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate on non-current debt</link:label>
    <link:label id="lab_us-gaap_LongtermDebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Weighted Average Interest Rate, at Point in Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_9d1eaa55-568d-4781-a106-32dda42c3dad_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BeautyMember_2dac43e3-9d3b-4fdd-afbb-4cec6dcad7b0_terseLabel_en-US" xlink:label="lab_jnj_BeautyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skin Health/Beauty</link:label>
    <link:label id="lab_jnj_BeautyMember_label_en-US" xlink:label="lab_jnj_BeautyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beauty [Member]</link:label>
    <link:label id="lab_jnj_BeautyMember_documentation_en-US" xlink:label="lab_jnj_BeautyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beauty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BeautyMember" xlink:href="jnj-20211003.xsd#jnj_BeautyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BeautyMember" xlink:to="lab_jnj_BeautyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_7748c871-8478-43d6-86bd-6fb6079fba92_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_2ec18950-d089-4e77-8f6a-25cc3a097638_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_80691af3-01f6-4fe4-8ae1-e18762c873c6_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_a317e4cb-4e39-4fca-a335-44bc94340963_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_COVID19Member_fb434973-a61b-4d19-821a-2bead46a44ef_terseLabel_en-US" xlink:label="lab_jnj_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:label id="lab_jnj_COVID19Member_label_en-US" xlink:label="lab_jnj_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 [Member]</link:label>
    <link:label id="lab_jnj_COVID19Member_documentation_en-US" xlink:label="lab_jnj_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_COVID19Member" xlink:href="jnj-20211003.xsd#jnj_COVID19Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_COVID19Member" xlink:to="lab_jnj_COVID19Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_61609817-88d1-4110-8f32-4c8de0ba72dc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_cc80771c-c6ce-441e-8146-7c6e8daa050f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Financial Instruments and Classification on Consolidated Balance Sheet</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_3f50c1e2-1ec6-4102-a829-b1dd12de9b86_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_118662f7-8a93-4610-b515-8adb95695e99_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.375Notesdue2023Member_ccbd8b61-d945-4965-b355-03e0fcc27cec_terseLabel_en-US" xlink:label="lab_jnj_A3.375Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes due 2023</link:label>
    <link:label id="lab_jnj_A3.375Notesdue2023Member_label_en-US" xlink:label="lab_jnj_A3.375Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes due 2023 [Member]</link:label>
    <link:label id="lab_jnj_A3.375Notesdue2023Member_documentation_en-US" xlink:label="lab_jnj_A3.375Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.375Notesdue2023Member" xlink:href="jnj-20211003.xsd#jnj_A3.375Notesdue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.375Notesdue2023Member" xlink:to="lab_jnj_A3.375Notesdue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_c043a602-84a4-4670-a2bb-e49a87d663dc_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DePuyASRU.S.Member_08f64ada-8ccd-4973-8565-b34023b4375e_terseLabel_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy ASR U.S.</link:label>
    <link:label id="lab_jnj_DePuyASRU.S.Member_label_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy ASR U.S. [Member]</link:label>
    <link:label id="lab_jnj_DePuyASRU.S.Member_documentation_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy ASR U.S. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member" xlink:href="jnj-20211003.xsd#jnj_DePuyASRU.S.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DePuyASRU.S.Member" xlink:to="lab_jnj_DePuyASRU.S.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A095NotesDue2027Member_50849219-3adb-465f-9017-2acdb9537738_terseLabel_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.95% Notes due 2027</link:label>
    <link:label id="lab_jnj_A095NotesDue2027Member_label_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.95% Notes due 2027 [Member]</link:label>
    <link:label id="lab_jnj_A095NotesDue2027Member_documentation_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.95% Notes due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member" xlink:href="jnj-20211003.xsd#jnj_A095NotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A095NotesDue2027Member" xlink:to="lab_jnj_A095NotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_afd2d954-c822-4be7-9b40-e99a626951bf_terseLabel_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREZISTA&#174; / PREZCOBIX&#174; / REZOLSTA&#174; / SYMTUZA&#174;</link:label>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_label_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]</link:label>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_documentation_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:href="jnj-20211003.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:to="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93f5a13d-31f4-4a4c-aade-ab3f3336b6fd_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales_e0776df7-a883-4d3f-90b6-e261608b999e_terseLabel_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development percent to sales</link:label>
    <link:label id="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales_label_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development in process percent to sales</link:label>
    <link:label id="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales_documentation_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">research and development in process percent to sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:href="jnj-20211003.xsd#jnj_ResearchAndDevelopmentInProcessPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:to="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SupplyChainMember_9f541109-36da-4ef8-8ff0-722c742cb98b_terseLabel_en-US" xlink:label="lab_jnj_SupplyChainMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Chain</link:label>
    <link:label id="lab_jnj_SupplyChainMember_label_en-US" xlink:label="lab_jnj_SupplyChainMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Chain [Member]</link:label>
    <link:label id="lab_jnj_SupplyChainMember_documentation_en-US" xlink:label="lab_jnj_SupplyChainMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Chain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember" xlink:href="jnj-20211003.xsd#jnj_SupplyChainMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SupplyChainMember" xlink:to="lab_jnj_SupplyChainMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_63053780-33c2-4932-9075-e99eaf1b46e2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d3775b40-063e-462e-a78b-5ee93bd219dc_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_792485b8-27c0-42d1-8786-faef1dd31ec8_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_ee711ffe-24d5-4056-90e4-45554a5e640f_terseLabel_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2033</link:label>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_label_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2033 [Member]</link:label>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_documentation_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2033 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member" xlink:href="jnj-20211003.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.375Notesdue2033Member" xlink:to="lab_jnj_A4.375Notesdue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0f7024b7-f865-4fef-bb5d-fdbf7637af76_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVG. SHARES OUTSTANDING</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f3b20ebe-d96d-4054-9c0e-da0057dcf382_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ab31351e-4b1a-47f8-967b-9d64455712fb_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2c3f1145-66e8-4d3b-8f20-16671bb7050e_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_d3448fdd-2afd-4be6-87ea-de673e51bbbb_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_a7daef52-52dd-41dd-b691-26eddf6650a7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_3d074746-2274-4356-9ad1-60309d0f84ee_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income on derivatives, after tax</link:label>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_label_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:to="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_f70b042b-53f3-4eb0-8e07-f41dd2b768d5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to earnings</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_d05dfaad-c54a-4b27-8fd4-03b425d61be5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SurgicalMeshProductsMarketingMember_c3b389e3-c6a8-4ec1-9dd4-e2235f9e1393_terseLabel_en-US" xlink:label="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Mesh Products Marketing</link:label>
    <link:label id="lab_jnj_SurgicalMeshProductsMarketingMember_label_en-US" xlink:label="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Mesh Products Marketing [Member]</link:label>
    <link:label id="lab_jnj_SurgicalMeshProductsMarketingMember_documentation_en-US" xlink:label="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Mesh Products Marketing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgicalMeshProductsMarketingMember" xlink:href="jnj-20211003.xsd#jnj_SurgicalMeshProductsMarketingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SurgicalMeshProductsMarketingMember" xlink:to="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f69deb90-8c00-4123-b559-d6d0264ae11f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_440f565e-f1d0-479d-936f-793d56851cd1_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_87acfc5c-576c-420a-9d94-681b06a6667b_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation expense</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_ebcec44b-94b0-4fd2-852b-f25ad913d237_verboseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation charge</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_b5e5532f-bdb8-47b4-9076-0c4afcc469f6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_ff27aea7-6988-4db3-8083-5693478a15f4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_987e2c79-9599-43b4-a440-137d57acbccc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_05634191-b622-4967-9ffa-2689a1b96008_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_32142861-58d6-4d25-b067-a6c198c74e4e_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities not Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_bbfd9a17-82ed-4111-b1a9-38809feada62_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_e66f9a58-76f2-4ac8-915d-dc384fa48ad5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) Recognized In Income on Derivative</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_edbab382-e5cb-4a3e-a066-3f0f5041f11d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_fa616da1-b831-4aac-903d-f04653a9d1ce_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from short-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_ac931f75-e64e-4b7d-8e3a-1c81c076bea9_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1300NotesDue2030Member_b7e1f8ee-a191-47db-8cd9-88077a5b6940_terseLabel_en-US" xlink:label="lab_jnj_A1300NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.30% Notes due 2030</link:label>
    <link:label id="lab_jnj_A1300NotesDue2030Member_label_en-US" xlink:label="lab_jnj_A1300NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.300% Notes due 2030 [Member]</link:label>
    <link:label id="lab_jnj_A1300NotesDue2030Member_documentation_en-US" xlink:label="lab_jnj_A1300NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.300% Notes due 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1300NotesDue2030Member" xlink:href="jnj-20211003.xsd#jnj_A1300NotesDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1300NotesDue2030Member" xlink:to="lab_jnj_A1300NotesDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_a65a821f-2fe0-41fd-bb62-82ffcdf33dbd_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_53f331e6-de7d-4660-8ec5-30c435d58be3_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c018e12b-c5bd-4ec6-a1f3-1ab71fc535b9_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities - Carrying Amount</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_66a5884e-a3c4-4a8c-91f0-dd9185e4cc47_totalLabel_en-US" xlink:label="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings before provision for taxes on income percent to sales</link:label>
    <link:label id="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_label_en-US" xlink:label="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Percent To Sales</link:label>
    <link:label id="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_documentation_en-US" xlink:label="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income loss from continuing operations before income taxes minority interest and income loss from equity method investments percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:href="jnj-20211003.xsd#jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:to="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6b52e5ce-3d00-494c-9dbd-25ee70dd927a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Unrecognized Gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_fc453fa6-feb9-41e4-838f-7301e2aaa6a3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_45047839-8da4-43aa-929d-9db06e326fb0_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term taxes payable (Note 5)</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_6f8091cc-862e-4d53-a192-71451bc765aa_terseLabel_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular / Metabolism / Other</link:label>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_label_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular/Metabolism/Other [Member]</link:label>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_documentation_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular/Metabolism/Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember" xlink:href="jnj-20211003.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CardiovascularMetabolismOtherMember" xlink:to="lab_jnj_CardiovascularMetabolismOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_66b2a9ac-277d-4423-9f44-d6191ede73bd_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_1c5935ab-25a8-4129-95bc-e7f7bf7f81e1_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_38f18b42-f66f-49c7-bfd1-d14bfd56e8de_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_c6cb8cd1-2fb3-4e9b-9ba7-0c3f06a52921_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_aee179bb-9fe9-49ab-80ea-cc10fb49a0f2_verboseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_ac612fd5-983b-433f-8819-57dda656f385_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_77c1a8d8-3fb2-486c-b692-b3a528d5416c_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_e56a9e79-39a8-4ce4-9be8-197b29a891f4_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_f5d0340c-626e-4ba8-a755-1d1b08d8bb89_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_0092565f-4eec-4496-8330-d08d8dfb1451_negatedTerseLabel_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service cost amortization during period</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_label_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_documentation_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:href="jnj-20211003.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:to="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LegalProceedingTextualsAbstract_26504cb0-2553-4548-ad42-48e3f3ae7f00_terseLabel_en-US" xlink:label="lab_jnj_LegalProceedingTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceeding (Textuals)</link:label>
    <link:label id="lab_jnj_LegalProceedingTextualsAbstract_label_en-US" xlink:label="lab_jnj_LegalProceedingTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceeding (Textuals) [Abstract]</link:label>
    <link:label id="lab_jnj_LegalProceedingTextualsAbstract_documentation_en-US" xlink:label="lab_jnj_LegalProceedingTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceeding Textuals Abstract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalProceedingTextualsAbstract" xlink:href="jnj-20211003.xsd#jnj_LegalProceedingTextualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LegalProceedingTextualsAbstract" xlink:to="lab_jnj_LegalProceedingTextualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_86fabc6b-79ba-4351-b33e-4b2b472d05ee_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate, impairment losses, amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28fc2c81-550e-439b-962e-cdb4ce7eb24b_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_1431d377-2498-4963-9d6d-b1cf1496f883_terseLabel_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVEGA SUSTENNA&#174; / XEPLION&#174; / INVEGA TRINZA&#174; / TREVICTA&#174;</link:label>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_label_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]</link:label>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_documentation_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:href="jnj-20211003.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:to="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldtomaturitySecuritiesMember_4033e4c5-06bb-4da0-acce-657eb4bf0155_terseLabel_en-US" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities</link:label>
    <link:label id="lab_us-gaap_HeldtomaturitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldtomaturitySecuritiesMember" xlink:to="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_f33e7e59-5b3f-4a6d-86a0-ecdfbc8c0929_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Equity Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_fa4f738e-10e6-4b30-8820-ad606395edc1_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, marketing and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis_d26d7ba3-f54a-4941-8e0c-768da2caafbd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_616b761d-ac12-4ebe-a947-bf84dcbbeb57_verboseLabel_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued rebates, returns and promotions</link:label>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_label_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates Returns And Promotions</link:label>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_documentation_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions" xlink:href="jnj-20211003.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AccruedRebatesReturnsAndPromotions" xlink:to="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_99eb0afe-dc88-4f9c-9812-7d5ad9f1432d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_18f00e8a-cf49-4187-80cf-802fbe957fe8_terseLabel_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased In-Process Research And Development</link:label>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased In-Process Research And Development [Member]</link:label>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased In-Process Research And Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:href="jnj-20211003.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:to="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BabyCareMember_7d3eb0e4-28f8-43e4-b48e-5543b60bcffa_terseLabel_en-US" xlink:label="lab_jnj_BabyCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Care</link:label>
    <link:label id="lab_jnj_BabyCareMember_label_en-US" xlink:label="lab_jnj_BabyCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Care [Member]</link:label>
    <link:label id="lab_jnj_BabyCareMember_documentation_en-US" xlink:label="lab_jnj_BabyCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember" xlink:href="jnj-20211003.xsd#jnj_BabyCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BabyCareMember" xlink:to="lab_jnj_BabyCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_0b466431-55f4-4c19-8844-a0a91e46bdef_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense of amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_8b74f6cf-a90f-4376-898c-018cd4947512_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward foreign exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_7ce4d53f-ce01-4fe3-8809-716cdf1352c7_terseLabel_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Acetabular Cup System</link:label>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_label_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Acetabular Cup System [Member]</link:label>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_documentation_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Acetabular cup system.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember" xlink:href="jnj-20211003.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PinnacleAcetabularCupSystemMember" xlink:to="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_eea8be82-03eb-465e-82bf-dace4cce75a3_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_5513ac5b-2ecd-480d-9333-ecc2daf10acb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Current Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_53fb5110-b4be-4288-83e3-aa0f5ad296bf_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments of Business and Geographic Areas</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_5a4fb06c-a105-4867-a08c-3f5700a714d9_periodStartLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, beginning of period</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_80d497b7-b9d5-4042-9edc-a4b57303aec4_periodEndLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, end of period</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_d61bdc6d-8d57-4cb0-a822-26fda1b5d2cd_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</link:label>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_label_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Excluded Component, Gain (Loss), Recognized in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:to="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_07f27dcb-86d2-4320-a3a0-5a128b7a7126_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_bfa6e276-b829-4b47-9f35-3457ee2e8647_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_b032d3e8-1079-47bf-ab98-e90d03e32fcf_terseLabel_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Debentures due 2040</link:label>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_label_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Debentures due 2040 [Member]</link:label>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_documentation_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Debentures due 2040 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member" xlink:href="jnj-20211003.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.50Debenturesdue2040Member" xlink:to="lab_jnj_A4.50Debenturesdue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_53373dc0-625a-4a27-a5a2-95b970cad833_terseLabel_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2036</link:label>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_label_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2036 [Member]</link:label>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_documentation_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member" xlink:href="jnj-20211003.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.55Notesdue2036Member" xlink:to="lab_jnj_A3.55Notesdue2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TalcMember_06fd319c-c600-4345-924e-ae8d76a7717b_terseLabel_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Talc</link:label>
    <link:label id="lab_jnj_TalcMember_label_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Talc [Member]</link:label>
    <link:label id="lab_jnj_TalcMember_documentation_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Talc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember" xlink:href="jnj-20211003.xsd#jnj_TalcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TalcMember" xlink:to="lab_jnj_TalcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_7088bb79-6290-4f83-94dd-6c3c587a9467_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_4a09e7af-99c6-4d42-98e0-045bba5bf63c_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_a57b751b-e296-4b2e-a04f-1e8aba88e46c_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service cost/(credit)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_0d8b7a61-28e8-4520-b89f-adf5726e0b59_terseLabel_en-US" xlink:label="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax benefits related to tax basis increase of certain assets due to reorganization</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_label_en-US" xlink:label="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Basis Increase of Certain Assets due to Reorganization</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_documentation_en-US" xlink:label="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Basis Increase of Certain Assets due to Reorganization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" xlink:href="jnj-20211003.xsd#jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" xlink:to="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_86fc4be1-0d22-4dd8-b1d1-db49d0aaf5b7_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_068a5f92-4cc4-4fb2-b72f-938cc04a8cfc_terseLabel_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85% Debentures due 2038</link:label>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_label_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85% Debentures due 2038 [Member]</link:label>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_documentation_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85% Debentures due 2038 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member" xlink:href="jnj-20211003.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.85Debenturesdue2038Member" xlink:to="lab_jnj_A5.85Debenturesdue2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_3c8a4292-82d9-43ce-9be2-f23e9e92099e_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued taxes on income (Note 5)</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_d523c3ab-33e2-4e77-aa5a-eff0c9331db3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e6ca45c2-6f99-4c3d-b99f-6126430df2b5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gain (loss) arising during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_17a9a93a-a189-4350-a8ff-f4563502387f_terseLabel_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SIMPONI / SIMPONI ARIA&#174;</link:label>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_label_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi/Simponi Aria [Member]</link:label>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_documentation_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi/Simponi Aria [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember" xlink:href="jnj-20211003.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SimponiSimponiAriaMember" xlink:to="lab_jnj_SimponiSimponiAriaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PelvicMeshesMember_597c0b56-985f-40a2-8be9-d1ebb4110576_terseLabel_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelvic Meshes</link:label>
    <link:label id="lab_jnj_PelvicMeshesMember_label_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelvic Meshes [Member]</link:label>
    <link:label id="lab_jnj_PelvicMeshesMember_documentation_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelvic meshes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember" xlink:href="jnj-20211003.xsd#jnj_PelvicMeshesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PelvicMeshesMember" xlink:to="lab_jnj_PelvicMeshesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_6c6f8de2-9625-43b3-b32c-0fc6f5430ee1_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_08b07039-1f90-417a-a3fa-ee653824e6bf_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net of portion capitalized</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_48b69fee-97f5-49f9-8e4c-3d89d121b54b_verboseLabel_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and Divestitures</link:label>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_1e5f42ef-e65b-4962-8c95-b315ea55bb73_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_2d83b05c-1bf2-4531-9e2d-4fa07e35c688_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization of property and intangibles</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_XareltoMember_faa12c68-019d-4c27-8c10-2aafc28b2806_terseLabel_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XARELTO&#174;</link:label>
    <link:label id="lab_jnj_XareltoMember_label_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xarelto [Member]</link:label>
    <link:label id="lab_jnj_XareltoMember_documentation_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xarelto [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember" xlink:href="jnj-20211003.xsd#jnj_XareltoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_XareltoMember" xlink:to="lab_jnj_XareltoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_d61e435a-e703-4c2f-aac4-d6e30874331d_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships and other intangible assets</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_e5b2ff99-e83a-42fa-a31e-dbec897814c1_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_091ef60d-34a6-4386-a713-c93f50b8cd41_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the disposal of assets/businesses, net (Note 10)</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_ff56497e-e279-4617-9316-6071f0dfdaca_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_c74e511e-ca91-4329-8a83-f92a7887cd4f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_b2cd1579-1f46-467a-a594-dcf817425319_verboseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross currency interest rate swaps</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_15bf86d9-923a-4386-816a-be9f371e07fc_terseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Interest Rate Contract</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:to="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_9363d812-ecbe-48a1-b135-1fd582ea77b8_terseLabel_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2026</link:label>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_label_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2026 [Member]</link:label>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_documentation_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member" xlink:href="jnj-20211003.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.45Notesdue2026Member" xlink:to="lab_jnj_A2.45Notesdue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_59e049a0-67ac-4ed3-97f8-91f4a83df5a7_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to customers</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_f9f46e29-dac3-4a91-b581-a280053a5e23_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_24f8eda1-ccff-4bcd-b943-bcce9493e5e2_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation contingency</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_5c440e6d-05a7-4d8c-a449-e14da3ff6a97_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_e3ab883e-ee31-4438-9bd6-4b15aa2abd45_verboseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_3a9b27ac-e5bd-4ae1-8490-477a13ccfc18_terseLabel_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Notes due 2043</link:label>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_label_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Notes due 2043 [Member]</link:label>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_documentation_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Notes due 2043 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member" xlink:href="jnj-20211003.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.50Notesdue2043Member" xlink:to="lab_jnj_A4.50Notesdue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IncomeTaxExpenseBenefitPercentToSales_04209d3d-9bca-49d9-a5cf-8a0a66df6853_terseLabel_en-US" xlink:label="lab_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for taxes on income percent to sales</link:label>
    <link:label id="lab_jnj_IncomeTaxExpenseBenefitPercentToSales_label_en-US" xlink:label="lab_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense Benefit Percent To Sales</link:label>
    <link:label id="lab_jnj_IncomeTaxExpenseBenefitPercentToSales_documentation_en-US" xlink:label="lab_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense benefit percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:href="jnj-20211003.xsd#jnj_IncomeTaxExpenseBenefitPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:to="lab_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c59cb9ac-f17d-4005-9d40-ff813b1b451c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount_8c6ae3d4-6d71-415c-8c49-37a7a13fd5d1_terseLabel_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate, accrued legal expenses, amount</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount_label_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Accrued Legal Expenses, Amount</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount_documentation_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Accrued Legal Expenses, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount" xlink:href="jnj-20211003.xsd#jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount" xlink:to="lab_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_356ff13f-7e20-494a-8da2-cb6330e32db5_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted prices in active markets for identical assets and liabilities Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SalesRevenueGoodsNetPercentToSales_327b2edb-6cb8-4f3b-9aba-d62a260421ba_terseLabel_en-US" xlink:label="lab_jnj_SalesRevenueGoodsNetPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to customers percent to sales</link:label>
    <link:label id="lab_jnj_SalesRevenueGoodsNetPercentToSales_label_en-US" xlink:label="lab_jnj_SalesRevenueGoodsNetPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue Goods Net Percent To Sales</link:label>
    <link:label id="lab_jnj_SalesRevenueGoodsNetPercentToSales_documentation_en-US" xlink:label="lab_jnj_SalesRevenueGoodsNetPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales revenue goods net percentage to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesRevenueGoodsNetPercentToSales" xlink:href="jnj-20211003.xsd#jnj_SalesRevenueGoodsNetPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SalesRevenueGoodsNetPercentToSales" xlink:to="lab_jnj_SalesRevenueGoodsNetPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_be1480ac-6887-4255-8448-d466734e342d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_009b38f1-002b-4f80-aadd-cf684ceb64f6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_2d8f2908-98fa-4324-ab42-39870d7bd95c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Support Agreement (CSA)</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_be1211d3-9bd3-4dee-87fa-7a13ceae7d97_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales/ Purchases/Other</link:label>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_label_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</link:label>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:href="jnj-20211003.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:to="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_e359a8a8-0eb1-424c-994a-b35e68bf61a5_verboseLabel_en-US" xlink:label="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of foreign exchange contracts into earnings, period</link:label>
    <link:label id="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_label_en-US" xlink:label="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Reclassification of Cash Flow Hedge Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:to="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_b9b3fa70-2f08-4cbf-8d79-59485ff102c4_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets acquired</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_626698d5-6c06-4269-a481-387de047b64b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends paid (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ZYTIGAMember_13988a1c-a747-4bef-ab1c-a58e5ca7acca_terseLabel_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYTIGA&#174; / abiraterone acetate</link:label>
    <link:label id="lab_jnj_ZYTIGAMember_label_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYTIGA [Member]</link:label>
    <link:label id="lab_jnj_ZYTIGAMember_documentation_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYTIGA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember" xlink:href="jnj-20211003.xsd#jnj_ZYTIGAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ZYTIGAMember" xlink:to="lab_jnj_ZYTIGAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_43c3c8aa-a464-4ebe-85c6-52a45ea37f90_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_2fa3cb0c-8141-473b-814b-d969a4d4fde3_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_565ec8db-78b1-4571-a6a2-397ceae178a4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_0b79cb36-311b-45ee-a3f7-36b6624e1505_verboseLabel_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_label_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_documentation_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:href="jnj-20211003.xsd#jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:to="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_d628ca90-54c6-46cc-b361-23100f7222c7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_ac20fb54-8a59-4954-9d4b-41cdd3bb002f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_8c1682a8-9994-4b23-a941-6d720d41d1f0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_7901d077-173b-4a30-adb6-bbe9bac3a37c_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Net Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28ba18b8-ec04-40fc-a03f-c7f780285e8a_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net earnings to cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_42d66c2e-922d-47dd-a72b-7b5de28c653f_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyNumberOfVotesRejected_90c3c8ee-07cf-4efa-bc80-e046cffc2c41_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyNumberOfVotesRejected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes rejected</link:label>
    <link:label id="lab_jnj_LossContingencyNumberOfVotesRejected_label_en-US" xlink:label="lab_jnj_LossContingencyNumberOfVotesRejected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Votes Rejected</link:label>
    <link:label id="lab_jnj_LossContingencyNumberOfVotesRejected_documentation_en-US" xlink:label="lab_jnj_LossContingencyNumberOfVotesRejected" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Votes Rejected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyNumberOfVotesRejected" xlink:href="jnj-20211003.xsd#jnj_LossContingencyNumberOfVotesRejected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyNumberOfVotesRejected" xlink:to="lab_jnj_LossContingencyNumberOfVotesRejected" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_2fc35202-8e7a-44a2-bdcc-8d43037e432b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_f5427105-de88-4efb-9e93-743f2c0dfee4_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments without readily determinable value</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_label_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments without Readily Determinable Value [Member]</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments without Readily Determinable Value [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:href="jnj-20211003.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:to="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_4fb94c3a-76f7-4025-9cef-34afc2aae3f0_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_0109130d-1732-47af-830d-866779ac7860_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesAxis_30725a51-6386-4ae8-bf57-01e2187862b7_terseLabel_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesAxis_label_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies [Axis]</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesAxis_documentation_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement by companies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesAxis" xlink:href="jnj-20211003.xsd#jnj_LitigationSettlementByCompaniesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis" xlink:to="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_96a48537-0116-46bf-ac47-2f9f3ae0f1d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PharmaceuticalMember_aa5aab9c-db8a-4f02-835f-5dc6e1812dcd_terseLabel_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PHARMACEUTICAL</link:label>
    <link:label id="lab_jnj_PharmaceuticalMember_label_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical [Member]</link:label>
    <link:label id="lab_jnj_PharmaceuticalMember_documentation_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember" xlink:href="jnj-20211003.xsd#jnj_PharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PharmaceuticalMember" xlink:to="lab_jnj_PharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_48bfabf5-15d5-48f0-9cb9-9fa663cab10f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefit plans:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f212167b-1ccd-4aef-b04d-75c0d394ab9a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings before provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_60bfdd32-9174-4144-9b2a-2b23a6771865_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Worldwide income before tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_084edfcb-7914-48dd-b6a5-6e9b7aa61973_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_780d26f5-08ab-4d81-ba02-9ccf3dedff73_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_754fb7e1-b903-4da5-92b1-ea69756bdcf6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_VerbSurgicalInc.Member_73c04329-67ab-47a2-9b17-96ebabfec84f_terseLabel_en-US" xlink:label="lab_jnj_VerbSurgicalInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verb Surgical Inc.</link:label>
    <link:label id="lab_jnj_VerbSurgicalInc.Member_label_en-US" xlink:label="lab_jnj_VerbSurgicalInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verb Surgical Inc. [Member]</link:label>
    <link:label id="lab_jnj_VerbSurgicalInc.Member_documentation_en-US" xlink:label="lab_jnj_VerbSurgicalInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verb Surgical Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VerbSurgicalInc.Member" xlink:href="jnj-20211003.xsd#jnj_VerbSurgicalInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_VerbSurgicalInc.Member" xlink:to="lab_jnj_VerbSurgicalInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_0237ca88-0a12-49ee-bac9-a2851a4abcc3_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f3f29f5c-d293-4487-8f6e-a0620d05c5dc_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, net of cash acquired (Note 10)</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_b558c018-70f2-4cd7-8e53-ccba4c9f718c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_fe1bf6d0-3cff-465d-bbf7-998aa972b585_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential shares exercisable under stock option plans</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_fd0244c1-83c0-4961-80e1-f51a3318c548_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_0a78edb0-d2df-4659-8be6-b34c850bd879_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageChangeInSalesByGeographicArea_ed0b53f3-bf39-477d-a3c2-99308d8e02dc_terseLabel_en-US" xlink:label="lab_jnj_PercentageChangeInSalesByGeographicArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Sales By Geographic Area</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesByGeographicArea_label_en-US" xlink:label="lab_jnj_PercentageChangeInSalesByGeographicArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Sales By Geographic Area</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesByGeographicArea_documentation_en-US" xlink:label="lab_jnj_PercentageChangeInSalesByGeographicArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage change in sales by geographic area.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesByGeographicArea" xlink:href="jnj-20211003.xsd#jnj_PercentageChangeInSalesByGeographicArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageChangeInSalesByGeographicArea" xlink:to="lab_jnj_PercentageChangeInSalesByGeographicArea" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SurgeryMember_2b30ed84-7610-4fb9-878b-34ae72674b0e_terseLabel_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery</link:label>
    <link:label id="lab_jnj_SurgeryMember_label_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery [Member]</link:label>
    <link:label id="lab_jnj_SurgeryMember_documentation_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember" xlink:href="jnj-20211003.xsd#jnj_SurgeryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SurgeryMember" xlink:to="lab_jnj_SurgeryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_23579143-e58f-48d8-8ee9-bd2b2dab8a4b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Profit by Segment of Business</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RemicadeMember_185070d8-8146-41d1-b54f-a33f486195e7_terseLabel_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REMICADE&#174;</link:label>
    <link:label id="lab_jnj_RemicadeMember_label_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member]</link:label>
    <link:label id="lab_jnj_RemicadeMember_documentation_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember" xlink:href="jnj-20211003.xsd#jnj_RemicadeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RemicadeMember" xlink:to="lab_jnj_RemicadeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_96abd818-0e19-4ced-91c7-fd6e32a55af7_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_740d07c8-46e6-4440-946e-3d6fb270289a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TremfyaMember_9ff2e6a5-a72b-4fbe-bc63-0f4e22e80fd5_terseLabel_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TREMFYA&#174;</link:label>
    <link:label id="lab_jnj_TremfyaMember_label_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfya [Member]</link:label>
    <link:label id="lab_jnj_TremfyaMember_documentation_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfaya</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember" xlink:href="jnj-20211003.xsd#jnj_TremfyaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TremfyaMember" xlink:to="lab_jnj_TremfyaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b5ed7451-f09f-4645-841b-db24929955a6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6c4a8d0e-57e4-4b5d-81f1-70cecb729fdd_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_cc06fb86-043a-42c0-82b4-555555b10198_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on disposition of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6194110c-c423-492f-a071-4810f9dd1e98_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_07fa00cb-61e7-48e9-821a-d188c03752d5_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NeuroscienceMember_276b9a78-96a4-4fc0-88b9-15d4bd85367e_terseLabel_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience</link:label>
    <link:label id="lab_jnj_NeuroscienceMember_label_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:label id="lab_jnj_NeuroscienceMember_documentation_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember" xlink:href="jnj-20211003.xsd#jnj_NeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NeuroscienceMember" xlink:to="lab_jnj_NeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_314c851f-ba48-468d-b127-e38e676ec4db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_61d19e16-9a31-4ebe-98a9-49b632d09996_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_cf02462f-8e2c-4af6-a45c-d8fe34fb3cee_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_bf6184b2-2c87-40c6-83b5-430a8028dadc_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_f41468f2-e9fe-47fe-b1ff-ea1ff28331f2_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_a058e465-c8b0-4afd-a917-12a27cda81a4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_d93ff66d-57dd-4b70-bde5-4e47aac36726_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_e455da76-00fe-47d2-aa9c-0a845b7c3ebd_terseLabel_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_label_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_d4313681-60dc-4c09-9103-de4bfad4f1f9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_ebab11a9-cf63-475d-b97e-76ab8cee8616_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate, impairment losses, percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_e8ef5547-be7a-4164-92f9-d30581a53dd2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_8ad04284-c36e-4a70-99c7-b156386728c1_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_2531e1d7-cad3-4f04-94b6-dece8a9d20f4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_14c0b567-f232-43bf-967f-60ea096d5e07_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) recognized in AOCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_6e1437d0-56c3-4915-9e6d-bd446c8bb681_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_VisionMember_ec59d548-7c85-4e0e-92f2-24ec09d71cfd_terseLabel_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision</link:label>
    <link:label id="lab_jnj_VisionMember_label_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision [Member]</link:label>
    <link:label id="lab_jnj_VisionMember_documentation_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision[Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember" xlink:href="jnj-20211003.xsd#jnj_VisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_VisionMember" xlink:to="lab_jnj_VisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1985f014-9edd-4668-b835-9364db9f05d1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9d5f3275-fa4c-474b-9b51-aa279d2d06ad_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_4e473815-c78a-431a-a1e8-0136d14b46e0_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_0c19868b-0651-48a7-8f8c-fd394ee5af9c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_dad82178-7586-457e-b2e9-f3b411a0262d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_53e13385-f958-41cb-bed3-b1d5a4ca2992_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_c92c80de-31a5-43d5-a6bd-82f5b96c2f50_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_610a35f5-6293-4086-983d-283c8146d21e_terseLabel_en-US" xlink:label="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in U.S. GILTI deferred tax liability</link:label>
    <link:label id="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_label_en-US" xlink:label="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Tax Liabilities, Global Intangible Low-Taxed Income (GILTI)</link:label>
    <link:label id="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_documentation_en-US" xlink:label="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Tax Liabilities, Global Intangible Low-Taxed Income (GILTI)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" xlink:href="jnj-20211003.xsd#jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" xlink:to="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_GENERALMember_207bf2df-fb65-4e79-8409-8941a3db5e89_terseLabel_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GENERAL</link:label>
    <link:label id="lab_jnj_GENERALMember_label_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GENERAL [Member]</link:label>
    <link:label id="lab_jnj_GENERALMember_documentation_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GENERAL [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember" xlink:href="jnj-20211003.xsd#jnj_GENERALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_GENERALMember" xlink:to="lab_jnj_GENERALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_59501148-e442-4716-9c6e-675c94bcb450_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_2bba485c-6721-4231-9598-76d5c6d5b5ff_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_a6840bb7-719f-434d-bcbe-a7454d65d63b_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee related obligations (Note 6)</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_ed3747c7-9f80-4089-9777-5ca9edc697f4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_6199ecd9-ed6b-4e4d-ac97-14df05065859_terseLabel_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.50% Notes due 2048</link:label>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_label_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.500% Notes due 2048 [Member]</link:label>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_documentation_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.500% Notes due 2048 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member" xlink:href="jnj-20211003.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.500Notesdue2048Member" xlink:to="lab_jnj_A3.500Notesdue2048Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5da86c8e-d77e-4006-b40a-fe469454b5e6_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A0550NotesDue2025Member_06428017-9a29-4bd1-b983-23eab8e1c014_terseLabel_en-US" xlink:label="lab_jnj_A0550NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.55% Notes due 2025</link:label>
    <link:label id="lab_jnj_A0550NotesDue2025Member_label_en-US" xlink:label="lab_jnj_A0550NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.550 Notes due 2025 [Member]</link:label>
    <link:label id="lab_jnj_A0550NotesDue2025Member_documentation_en-US" xlink:label="lab_jnj_A0550NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.550 Notes due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0550NotesDue2025Member" xlink:href="jnj-20211003.xsd#jnj_A0550NotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A0550NotesDue2025Member" xlink:to="lab_jnj_A0550NotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_5d429af8-c747-4e0c-a0a8-440c063c0b67_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeMember_fbccc615-99ca-4b52-8803-869c0982b960_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income</link:label>
    <link:label id="lab_us-gaap_OtherIncomeMember_label_en-US" xlink:label="lab_us-gaap_OtherIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeMember" xlink:to="lab_us-gaap_OtherIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_4abfc918-48c4-4bbd-ae63-a3cd9e6910d2_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityFairValueAdjustmentImpairmentLoss_46bc60b8-b1cc-4d26-aaa0-70c3d3cdb9da_terseLabel_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, fair value adjustment, impairment loss</link:label>
    <link:label id="lab_jnj_EquityFairValueAdjustmentImpairmentLoss_label_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment, Impairment Loss</link:label>
    <link:label id="lab_jnj_EquityFairValueAdjustmentImpairmentLoss_documentation_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:href="jnj-20211003.xsd#jnj_EquityFairValueAdjustmentImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:to="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_e72907ff-d533-4f69-ad5e-fd6f23916239_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_e573f45f-ea61-4c4c-89c4-3d93298b5488_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_40add153-3e4d-4aa1-aab4-2016fa880b59_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Restructuringchargepercenttosales_cbec843a-545e-4b1b-9acb-b2f94c1a26e6_terseLabel_en-US" xlink:label="lab_jnj_Restructuringchargepercenttosales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge percent to sales</link:label>
    <link:label id="lab_jnj_Restructuringchargepercenttosales_label_en-US" xlink:label="lab_jnj_Restructuringchargepercenttosales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge percent to sales</link:label>
    <link:label id="lab_jnj_Restructuringchargepercenttosales_documentation_en-US" xlink:label="lab_jnj_Restructuringchargepercenttosales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge percent to sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Restructuringchargepercenttosales" xlink:href="jnj-20211003.xsd#jnj_Restructuringchargepercenttosales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Restructuringchargepercenttosales" xlink:to="lab_jnj_Restructuringchargepercenttosales" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_f2281256-210b-4ed9-9f57-238ea02d8827_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_3b918af6-e6b5-43c0-9bef-4bd6cec83f4b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_0dfdcc81-b1fe-4a5f-8110-b02314ae49a8_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, related to acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_2fa0ef08-3a0a-4ee4-92d7-19ae2c231198_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available for Sale Securities Maturities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_27663ad6-f4d9-42a5-98e5-f915bdc59baa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effect of Derivatives not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_cedc6e0d-146c-4b37-ad4d-1700964b27e0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SPINEOTHERMember_fe51d107-a6c1-40e6-ad29-a3b32c78eeab_terseLabel_en-US" xlink:label="lab_jnj_SPINEOTHERMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINE, SPORTS &amp; OTHER</link:label>
    <link:label id="lab_jnj_SPINEOTHERMember_label_en-US" xlink:label="lab_jnj_SPINEOTHERMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINE &amp; OTHER [Member]</link:label>
    <link:label id="lab_jnj_SPINEOTHERMember_documentation_en-US" xlink:label="lab_jnj_SPINEOTHERMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINE &amp; OTHER [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINEOTHERMember" xlink:href="jnj-20211003.xsd#jnj_SPINEOTHERMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SPINEOTHERMember" xlink:to="lab_jnj_SPINEOTHERMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_7181feb9-6f6e-4774-bf1e-87503e5a99f2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_a653bd9e-9840-4d90-899e-adc51e1d8750_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_7d761432-ca72-4e91-8cd0-5ae06049e0b7_negatedTerseLabel_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) amortization during period</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_label_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_documentation_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:href="jnj-20211003.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:to="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CostOfGoodsSoldPercentToSales_50d9e410-c969-460e-b2e3-a7ee86cb2ce9_terseLabel_en-US" xlink:label="lab_jnj_CostOfGoodsSoldPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold percent to sales</link:label>
    <link:label id="lab_jnj_CostOfGoodsSoldPercentToSales_label_en-US" xlink:label="lab_jnj_CostOfGoodsSoldPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Goods Sold Percent To Sales</link:label>
    <link:label id="lab_jnj_CostOfGoodsSoldPercentToSales_documentation_en-US" xlink:label="lab_jnj_CostOfGoodsSoldPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CostOfGoodsSoldPercentToSales" xlink:href="jnj-20211003.xsd#jnj_CostOfGoodsSoldPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CostOfGoodsSoldPercentToSales" xlink:to="lab_jnj_CostOfGoodsSoldPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionContributions_acde6887-4cb7-4555-81de-c1508a7cff60_terseLabel_en-US" xlink:label="lab_us-gaap_PensionContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution to pension plans</link:label>
    <link:label id="lab_us-gaap_PensionContributions_label_en-US" xlink:label="lab_us-gaap_PensionContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Pension Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionContributions" xlink:to="lab_us-gaap_PensionContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_4bc56193-675e-4fb7-affb-847c79f0c459_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_273337c2-c3aa-4710-a5dd-29207c7b8177_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax benefit, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_8eab9903-c6e7-4780-98fc-735afcd47070_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_12db6598-3e55-442b-94c7-7e31777863e3_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_971e318e-1b6a-4e75-9a99-987dcca0cbad_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b1ba1504-42e0-45a0-b0fc-0472bb2feee4_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities - Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_75e7fffb-d943-4437-af85-915c8fd9f659_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to earnings</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_82c48fd7-f197-4120-a17f-e31e236ea240_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_69910cd9-0f8c-4194-86c2-16b24990a982_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_69bc6845-1df6-4750-abc3-18410854d93b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of pending claims</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ImmunologyMember_6bf43cfe-a926-4111-ac78-79e3fcaf709a_terseLabel_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology</link:label>
    <link:label id="lab_jnj_ImmunologyMember_label_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:label id="lab_jnj_ImmunologyMember_documentation_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember" xlink:href="jnj-20211003.xsd#jnj_ImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ImmunologyMember" xlink:to="lab_jnj_ImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_8d5d84ab-5f10-47f0-acc8-6fadb2747c03_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_f41cc392-d96e-4ebb-a44f-95335dba106c_negatedLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of liabilities assumed and noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_223104ec-4977-41a4-84e7-9ef0f6a4797c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_9864e4e2-9bfa-40e6-8989-69ebd0142375_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) Recognized In Accumulated OCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_13df116d-ed8a-4dc0-99e3-10aa8d0fa614_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_0eda2418-e941-4d66-b54c-582c65dc293a_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable_0cdd18b9-102b-4adb-b3e1-84f4c657dd5c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Table]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_0b2c3246-cd67-4bf5-bdbb-b21c5b1b51c9_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_a1f3f793-86bc-46b9-9fe0-31079984aa6c_terseLabel_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit support agreements activity, net</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_label_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_documentation_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:href="jnj-20211003.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:to="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_12610d78-3f62-43f8-90a8-f9af45b67c55_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Derivative Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_ed4b54a0-2ae2-40cc-b03e-92222754ad5d_terseLabel_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:href="jnj-20211003.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_1e80562b-d944-4abd-a3b2-c12969b88e59_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized actuarial losses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_a2e9f959-ed38-420e-a266-f36edf2dacdd_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_fcd639a2-9f16-4139-883b-7c2841cb124d_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_ddc81323-2f6b-47c9-935b-f964fc8f3a86_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_1517fe18-3260-4f1d-a55c-15a7ac1ea453_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_db7435e5-ea7c-4e56-a22a-182a6b4272fe_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_b45f62d2-e8ed-405b-b96a-82cf528b4f41_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets and Liabilities at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_af5fd118-25b7-4d65-bdef-4e25d3644263_verboseLabel_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes Due November 2028</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_428cd73f-3f4a-43cc-a538-21dc13a1695e_terseLabel_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes due 2028 (750MM Euro 1.1581)</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_label_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes Due 2028 [Member]</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_documentation_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes Due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member" xlink:href="jnj-20211003.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1.150NotesDue2028Member" xlink:to="lab_jnj_A1.150NotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_6e77622d-04f0-468f-b874-e290ab1d9444_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a2097879-ee5f-4b4e-9673-ac4d7fc2dd29_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_5aef86d2-1023-44cf-9754-98f2a77bf89a_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities - Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_55cb06ac-d2ff-443c-987d-67ca94622b55_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_501fbe1a-c004-4653-866b-2ccca4f4b180_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_d06e96ec-10e6-43e6-a9f5-f2db3cdc49fc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_JudicialRulingMember_d6a17d18-9b34-4ea3-aac8-d1ce578ee386_terseLabel_en-US" xlink:label="lab_us-gaap_JudicialRulingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judicial Ruling</link:label>
    <link:label id="lab_us-gaap_JudicialRulingMember_label_en-US" xlink:label="lab_us-gaap_JudicialRulingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judicial Ruling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_JudicialRulingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_JudicialRulingMember" xlink:to="lab_us-gaap_JudicialRulingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_ba967b71-0753-46dd-a391-22041535ef6b_terseLabel_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EDURANT&#174; / rilpivirine</link:label>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_label_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EDURANT/rilpivirine [Member]</link:label>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_documentation_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EDURANT/rilpivirine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember" xlink:href="jnj-20211003.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EDURANTrilpivirineMember" xlink:to="lab_jnj_EDURANTrilpivirineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent_c05ad353-53ef-46b0-97d8-c231facff210_terseLabel_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate, accrued legal expenses, percent</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent_label_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Accrued Legal Expenses, Percent</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent_documentation_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Accrued Legal Expenses, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent" xlink:href="jnj-20211003.xsd#jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent" xlink:to="lab_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_81f893a0-5392-4de8-8000-2f2a9795b422_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_67e84929-aee3-4334-a30d-7824904b9f38_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_6cd18307-a71b-4611-95af-2ca6bc9785c4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_e357a77f-907c-49ba-a825-39d83870adcf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_b7814f98-b9a7-4018-965b-b55da12bd151_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_2fad4813-dbcf-47af-878d-719d24883a3a_verboseLabel_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes Due May 2024</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_1cc75cc5-e658-400f-8881-cd4e645c2c2e_terseLabel_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes due 2024 (750MM Euro 1.1581)</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_label_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes Due 2024 [Member]</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_documentation_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member" xlink:href="jnj-20211003.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A0.650NotesDue2024Member" xlink:to="lab_jnj_A0.650NotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid_b7e3f11d-21bd-4535-94ff-8fcdbe8bf55b_terseLabel_en-US" xlink:label="lab_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of cash outlays for severance expected to be paid out</link:label>
    <link:label id="lab_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid_label_en-US" xlink:label="lab_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Cost, Expected Period Of Cash Outlays For Severance Paid</link:label>
    <link:label id="lab_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid_documentation_en-US" xlink:label="lab_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Cost, Expected Period Of Cash Outlays For Severance Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid" xlink:href="jnj-20211003.xsd#jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid" xlink:to="lab_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_2efc3c28-0139-4491-8b1d-e8d62a06a5a1_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, estimate of additional possible loss</link:label>
    <link:label id="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_label_en-US" xlink:label="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Additional Possible Loss</link:label>
    <link:label id="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_documentation_en-US" xlink:label="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Additional Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:href="jnj-20211003.xsd#jnj_LossContingencyEstimateOfAdditionalPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:to="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_ba892fc2-5ee5-4b3f-bda9-119d55666ba2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease)/Increase in other current and non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationRevenueAbstract_bcc8a491-4055-4c64-a879-9d6284beb0f7_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales by segment of business</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information, Revenue for Reportable Segment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:to="lab_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_7086f4c4-acb7-4989-95d1-c303c8a0b321_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset write-downs</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_28343b27-0b98-408f-ac99-e0744e1247ae_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and stock option plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_e1a8f3ef-af56-4956-8616-fb98a550e1eb_terseLabel_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in effective income tax rate, percent</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_label_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_documentation_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:href="jnj-20211003.xsd#jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:to="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AmountPrepaidAndDueToManufacturers_4d8a8784-e802-4941-bae1-bb85e85b4e0f_terseLabel_en-US" xlink:label="lab_jnj_AmountPrepaidAndDueToManufacturers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount prepaid and due to manufacturers</link:label>
    <link:label id="lab_jnj_AmountPrepaidAndDueToManufacturers_label_en-US" xlink:label="lab_jnj_AmountPrepaidAndDueToManufacturers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Prepaid and Due to Manufacturers</link:label>
    <link:label id="lab_jnj_AmountPrepaidAndDueToManufacturers_documentation_en-US" xlink:label="lab_jnj_AmountPrepaidAndDueToManufacturers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Prepaid and Due to Manufacturers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AmountPrepaidAndDueToManufacturers" xlink:href="jnj-20211003.xsd#jnj_AmountPrepaidAndDueToManufacturers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AmountPrepaidAndDueToManufacturers" xlink:to="lab_jnj_AmountPrepaidAndDueToManufacturers" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WomensHealthMember_699d49c9-b780-468e-a76d-c0da7719fe21_terseLabel_en-US" xlink:label="lab_jnj_WomensHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Women's Health</link:label>
    <link:label id="lab_jnj_WomensHealthMember_label_en-US" xlink:label="lab_jnj_WomensHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Women's Health [Member]</link:label>
    <link:label id="lab_jnj_WomensHealthMember_documentation_en-US" xlink:label="lab_jnj_WomensHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Women's Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WomensHealthMember" xlink:href="jnj-20211003.xsd#jnj_WomensHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WomensHealthMember" xlink:to="lab_jnj_WomensHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5fb782e6-8bdf-4482-b6ad-df0f7581d3e2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration reversal</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_790dbc71-31af-443a-a212-dd6415135443_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_76ec06a4-7103-4208-90bf-2bc4db9fe47d_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_13f92df6-6b05-4b08-a3b9-005740321d95_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IMBRUVICAMember_bc70066f-8091-4b05-9aa1-021d7e3d1f44_terseLabel_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMBRUVICA&#174;</link:label>
    <link:label id="lab_jnj_IMBRUVICAMember_label_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMBRUVICA [Member]</link:label>
    <link:label id="lab_jnj_IMBRUVICAMember_documentation_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMBRUVICA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember" xlink:href="jnj-20211003.xsd#jnj_IMBRUVICAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IMBRUVICAMember" xlink:to="lab_jnj_IMBRUVICAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_792df59a-0905-43ae-a5e6-24dbeb01c89f_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2250NotesDue2050Member_04f27dc1-d237-4ecc-9be7-7c70f03283a3_terseLabel_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Notes due 2050</link:label>
    <link:label id="lab_jnj_A2250NotesDue2050Member_label_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Notes due 2050 [Member]</link:label>
    <link:label id="lab_jnj_A2250NotesDue2050Member_documentation_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Notes due 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member" xlink:href="jnj-20211003.xsd#jnj_A2250NotesDue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2250NotesDue2050Member" xlink:to="lab_jnj_A2250NotesDue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_ab3d4bb5-c8a9-4a03-8d6c-f1581d0b2ae3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityFairValueAdjustment_9caf38ac-541a-4a62-9052-90d2574fa13c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Fair Value Reflected in Net Income</link:label>
    <link:label id="lab_us-gaap_EquityFairValueAdjustment_label_en-US" xlink:label="lab_us-gaap_EquityFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityFairValueAdjustment" xlink:to="lab_us-gaap_EquityFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_e217805a-54d9-4734-a342-5bfa37acb18c_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_0667cda0-0c52-4afb-9196-1fe426d7439b_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_aa12f98d-aa86-43ee-a747-15493e2e28f5_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_ab7e220e-5fb8-45c8-9f4d-a368b26ff5d8_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, trade, less allowances for doubtful accounts and credit losses $223 (2020, $293)</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_47dcc9c5-0790-4861-b83e-e6127f633574_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_64226a02-0a23-426c-849e-0b281f4ff7fd_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International retirement plans</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_34ce50bf-12c0-46f1-afc8-2a3b1a1a6d63_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_5a3e5129-5969-4ce3-a9b9-1ac75811d343_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve balance beginning</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_307bf638-744c-476f-a6b4-c14181702b37_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve balance ending</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesMember_b759507e-eaef-4dc3-aa04-89a3dacce5a8_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesMember_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesMember" xlink:to="lab_us-gaap_RestructuringChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OralCareMember_eb189b08-3140-4139-8e88-d6694fd64325_terseLabel_en-US" xlink:label="lab_jnj_OralCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Care</link:label>
    <link:label id="lab_jnj_OralCareMember_label_en-US" xlink:label="lab_jnj_OralCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Care [Member]</link:label>
    <link:label id="lab_jnj_OralCareMember_documentation_en-US" xlink:label="lab_jnj_OralCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember" xlink:href="jnj-20211003.xsd#jnj_OralCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OralCareMember" xlink:to="lab_jnj_OralCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2f8570ad-221a-4e62-8542-1a7ed34a45f3_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Unrecognized Loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OPSUMITMember_608288d7-7dc4-410e-befc-bd13e02a6e86_terseLabel_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPSUMIT&#174;</link:label>
    <link:label id="lab_jnj_OPSUMITMember_label_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPSUMIT [Member]</link:label>
    <link:label id="lab_jnj_OPSUMITMember_documentation_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPSUMIT [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember" xlink:href="jnj-20211003.xsd#jnj_OPSUMITMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OPSUMITMember" xlink:to="lab_jnj_OPSUMITMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_1696a71f-0fe7-4d52-9fdf-2a7e1ac93b32_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5c121542-084f-4754-ae91-a5eb8b2a66de_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_681eec2c-02f8-4f0e-b701-ade4c946b131_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_a3efbc12-ad3c-4606-ab53-c814ba072cbc_terseLabel_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_label_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_documentation_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:href="jnj-20211003.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:to="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_679e0573-9403-472b-8aed-31411cf424ad_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_8837f474-f30b-4543-9505-832bf07b7d71_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_a58eaa12-1345-4f8c-9c1b-f55ce8ae2568_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_a08d2c63-3357-4fe8-a0fd-8eb6fcb49401_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill (Note 3)</link:label>
    <link:label id="lab_us-gaap_Goodwill_c1d0c2d9-a6f4-43f0-af29-6f9b775b2ca5_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Beginning of Period</link:label>
    <link:label id="lab_us-gaap_Goodwill_c314bcae-bfd8-457e-a575-390ed1c869fc_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill End of Period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_89150e24-73f5-4706-98bd-9285aac25555_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A0.250NotesDue2022Member_7b5b9b88-56c1-45fa-a9b8-b8d0d779c78e_verboseLabel_en-US" xlink:label="lab_jnj_A0.250NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.250% Notes Due January 2022</link:label>
    <link:label id="lab_jnj_A0.250NotesDue2022Member_label_en-US" xlink:label="lab_jnj_A0.250NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.250% Notes Due 2022 [Member]</link:label>
    <link:label id="lab_jnj_A0.250NotesDue2022Member_documentation_en-US" xlink:label="lab_jnj_A0.250NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.250% Notes Due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.250NotesDue2022Member" xlink:href="jnj-20211003.xsd#jnj_A0.250NotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A0.250NotesDue2022Member" xlink:to="lab_jnj_A0.250NotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_7e0000e4-d6fb-4f11-9abb-e662030e4618_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_bba19d61-86af-4404-9a9c-2cd7b048f43b_terseLabel_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90%&#160;Notes due 2028</link:label>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_label_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.900% Notes due 2028 [Member]</link:label>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_documentation_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.900% Notes due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member" xlink:href="jnj-20211003.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.900Notesdue2028Member" xlink:to="lab_jnj_A2.900Notesdue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_3ffdf798-4d95-4ae1-898e-ecdc42c30629_terseLabel_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Exports</link:label>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_label_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES Exports [Member]</link:label>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_documentation_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES Exports [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember" xlink:href="jnj-20211003.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UNITEDSTATESExportsMember" xlink:to="lab_jnj_UNITEDSTATESExportsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FederalLevelJurisdictionMember_3696e7b9-1b29-4958-a860-62a51ae74c84_terseLabel_en-US" xlink:label="lab_jnj_FederalLevelJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Level Jurisdiction</link:label>
    <link:label id="lab_jnj_FederalLevelJurisdictionMember_label_en-US" xlink:label="lab_jnj_FederalLevelJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Level Jurisdiction [Member]</link:label>
    <link:label id="lab_jnj_FederalLevelJurisdictionMember_documentation_en-US" xlink:label="lab_jnj_FederalLevelJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Level Jurisdiction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalLevelJurisdictionMember" xlink:href="jnj-20211003.xsd#jnj_FederalLevelJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FederalLevelJurisdictionMember" xlink:to="lab_jnj_FederalLevelJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_e2fdd1cb-12b0-4677-9fa1-d8b75c5fc9f7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Gross Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AssetWriteoffMember_6e8fac03-671a-4f85-95e1-b9103e442f33_terseLabel_en-US" xlink:label="lab_jnj_AssetWriteoffMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-off</link:label>
    <link:label id="lab_jnj_AssetWriteoffMember_label_en-US" xlink:label="lab_jnj_AssetWriteoffMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-off [Member]</link:label>
    <link:label id="lab_jnj_AssetWriteoffMember_documentation_en-US" xlink:label="lab_jnj_AssetWriteoffMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-off [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetWriteoffMember" xlink:href="jnj-20211003.xsd#jnj_AssetWriteoffMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AssetWriteoffMember" xlink:to="lab_jnj_AssetWriteoffMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_b5df0d78-3d34-45f8-abdd-caae46068117_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_e4afffeb-e54b-4f8a-9a9e-7f5dbba097cf_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant other observable inputs Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_54e2c8f2-3fe5-465a-ab79-900647f48067_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_59bd6175-442c-4f2a-93b3-63c2665775c5_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_dd879e82-111e-4144-898d-2aa7fbfdd551_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_70fb5149-f6d1-4a2e-b923-48de044eea65_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_62119456-af34-4c49-9085-aabfafd9add9_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AsrMember_c31e556c-e531-404a-9e4d-21721a53d949_terseLabel_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR</link:label>
    <link:label id="lab_jnj_AsrMember_label_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR [Member]</link:label>
    <link:label id="lab_jnj_AsrMember_documentation_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember" xlink:href="jnj-20211003.xsd#jnj_AsrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AsrMember" xlink:to="lab_jnj_AsrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt_02271e9a-fab8-4111-a1b7-18e33d399853_terseLabel_en-US" xlink:label="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess of the estimated fair value over the carrying value of debt</link:label>
    <link:label id="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt_label_en-US" xlink:label="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Of Fair Value Over Carrying Value Of Debt</link:label>
    <link:label id="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt_documentation_en-US" xlink:label="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess of fair value over carrying value of debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:href="jnj-20211003.xsd#jnj_ExcessOfFairValueOverCarryingValueOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:to="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_GrossProfitPercentToSales_6bdb3ab3-ca78-40c7-9934-9ac18f04a42d_totalLabel_en-US" xlink:label="lab_jnj_GrossProfitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit Percent To Sales</link:label>
    <link:label id="lab_jnj_GrossProfitPercentToSales_label_en-US" xlink:label="lab_jnj_GrossProfitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit Percent To Sales</link:label>
    <link:label id="lab_jnj_GrossProfitPercentToSales_documentation_en-US" xlink:label="lab_jnj_GrossProfitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GrossProfitPercentToSales" xlink:href="jnj-20211003.xsd#jnj_GrossProfitPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_GrossProfitPercentToSales" xlink:to="lab_jnj_GrossProfitPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyReserveEstablishedWithinTrust_717629e2-139e-4250-aa5d-52499ebbfbb4_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve established</link:label>
    <link:label id="lab_jnj_LossContingencyReserveEstablishedWithinTrust_label_en-US" xlink:label="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Reserve Established within Trust</link:label>
    <link:label id="lab_jnj_LossContingencyReserveEstablishedWithinTrust_documentation_en-US" xlink:label="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Reserve Established within Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:href="jnj-20211003.xsd#jnj_LossContingencyReserveEstablishedWithinTrust"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:to="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_3c89fb68-cabc-40f0-a239-8c05be99a5d2_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate, prior year income taxes, percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_0e5c0625-afc6-45a9-93bc-89a803e6c6c2_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_f5a0b1ca-7d94-4610-96f5-ec145893b717_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of short-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_fa82c2f3-bcbd-40b3-8f9f-46ad6ea6f5c0_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_acda8df2-558e-48be-a98a-0102997d11f8_terseLabel_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% Debentures due 2033</link:label>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_label_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% Debentures due 2033 [Member]</link:label>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_documentation_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% Debentures due 2033 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member" xlink:href="jnj-20211003.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.95Debenturesdue2033Member" xlink:to="lab_jnj_A4.95Debenturesdue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_4bc54331-e646-4af7-8fe9-66db17e418d5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_68fe3fa9-d7b5-43bc-a01a-89112b49176c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fc16bffc-9b95-42cd-a8e5-a07aa9acb963_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average shares outstanding &#8212; diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_KNEESMember_e2eff209-fe2c-4c06-8c11-bc3c8c66a992_terseLabel_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KNEES</link:label>
    <link:label id="lab_jnj_KNEESMember_label_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KNEES [Member]</link:label>
    <link:label id="lab_jnj_KNEESMember_documentation_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KNEES [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember" xlink:href="jnj-20211003.xsd#jnj_KNEESMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_KNEESMember" xlink:to="lab_jnj_KNEESMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_c1c9f752-1445-47c5-9b9f-a885ba918864_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case Type</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_71892c40-ecce-4267-9f5d-4e62d47bdcf2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_bef4922e-e84d-4fed-ac3f-fe17acf04cd9_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_f996042d-c271-4867-aa05-4b46f9d739c7_terseLabel_en-US" xlink:label="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling marketing and administrative expenses percent to sales</link:label>
    <link:label id="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_label_en-US" xlink:label="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling General And Administrative Expense Percent To Sales</link:label>
    <link:label id="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_documentation_en-US" xlink:label="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling general and administrative expense percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:href="jnj-20211003.xsd#jnj_SellingGeneralAndAdministrativeExpensePercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:to="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3dea01b4-b0df-4496-bb83-4a24cc8298bd_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_16b12af4-6dfb-40ec-9f57-3aaa5c7572cf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_27584851-bf2b-4bd2-8411-8ee0d9f64cf6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IncomeTaxTextualsAbstract_0efa4209-65f1-4799-a6d6-7047a02b18af_verboseLabel_en-US" xlink:label="lab_jnj_IncomeTaxTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax (Textuals)</link:label>
    <link:label id="lab_jnj_IncomeTaxTextualsAbstract_label_en-US" xlink:label="lab_jnj_IncomeTaxTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax (Textuals) [Abstract]</link:label>
    <link:label id="lab_jnj_IncomeTaxTextualsAbstract_documentation_en-US" xlink:label="lab_jnj_IncomeTaxTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Textuals Abstract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeTaxTextualsAbstract" xlink:href="jnj-20211003.xsd#jnj_IncomeTaxTextualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IncomeTaxTextualsAbstract" xlink:to="lab_jnj_IncomeTaxTextualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_cbd2727f-bd05-4254-ab2a-7511de6cc3df_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CASH USED BY FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_d1ec2ac3-6344-4fc3-8a3d-73ed6508ce5c_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_8b282318-9bed-4e26-9b1e-2dc15116c0b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_15994a0a-513f-4793-9cc8-eb385eb9b684_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1412047f-0c14-4f97-a4ff-f73c05439010_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Investment Gain (Loss) Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_5c29af26-295e-496f-b278-5f28341f365b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_15962c2a-45d2-4cdb-91cd-c90236862710_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_5a874901-31dd-41a7-92b2-3618f5786de8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock &#8212; par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMember_0809e3a0-37c1-4397-b9f0-d286bdcad699_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMember_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMember" xlink:to="lab_us-gaap_LongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c5d9a031-b3e7-42a3-8cf7-da7b6d50b52d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_92d44582-9b22-4771-9d9c-ba7330522f81_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_3a4a693a-aab4-49e3-9594-1621beb7d2e7_terseLabel_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product liability contingency, number of claimants</link:label>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_label_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Contingency Number Of Claimant</link:label>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_documentation_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product liability contingency number of claimant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:href="jnj-20211003.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:to="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_e06df355-5cdc-44d0-8b91-1483113faad2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_1fbb9b81-fa9a-4840-8871-3bb7296042d4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_7b474706-2274-41d2-b934-64d90f641c27_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_30e768d2-82d7-4f1f-b150-74e80e89b2f9_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_c8bb16a0-2f7b-46ea-84d6-7c51f676cb36_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends to shareholders</link:label>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfOrdinaryDividends" xlink:to="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_5022ae5f-1a00-461b-82d1-19fe9cba68e2_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_05272170-ed69-43b3-8d4f-d4e5372dfd3e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_408403b8-f2e1-4b8e-9c64-2af42dfdd870_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring estimated cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_INVOKANAINVOKAMETMember_b39ac60d-7d34-4699-81ce-8211799d568e_terseLabel_en-US" xlink:label="lab_jnj_INVOKANAINVOKAMETMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVOKANA&#174; / INVOKAMET&#174;</link:label>
    <link:label id="lab_jnj_INVOKANAINVOKAMETMember_label_en-US" xlink:label="lab_jnj_INVOKANAINVOKAMETMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVOKANA/INVOKAMET [Member]</link:label>
    <link:label id="lab_jnj_INVOKANAINVOKAMETMember_documentation_en-US" xlink:label="lab_jnj_INVOKANAINVOKAMETMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVOKANA/INVOKAMET [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVOKANAINVOKAMETMember" xlink:href="jnj-20211003.xsd#jnj_INVOKANAINVOKAMETMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_INVOKANAINVOKAMETMember" xlink:to="lab_jnj_INVOKANAINVOKAMETMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_93ceb216-df6a-4957-a9bd-5bf56c36ac69_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_4e06003b-b3fd-4852-ba9d-a5ac06308af6_terseLabel_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.40%&#160;Notes due 2038</link:label>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_label_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.400% Notes due 2038 [Member]</link:label>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_documentation_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.400% Notes due 2038 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member" xlink:href="jnj-20211003.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.400Notesdue2038Member" xlink:to="lab_jnj_A3.400Notesdue2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.05Notesdue2023Member_b5083104-6b1e-4ac5-8509-31746bc36a4c_terseLabel_en-US" xlink:label="lab_jnj_A2.05Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.05% Notes due 2023</link:label>
    <link:label id="lab_jnj_A2.05Notesdue2023Member_label_en-US" xlink:label="lab_jnj_A2.05Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.05% Notes due 2023 [Member]</link:label>
    <link:label id="lab_jnj_A2.05Notesdue2023Member_documentation_en-US" xlink:label="lab_jnj_A2.05Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.05% Notes due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.05Notesdue2023Member" xlink:href="jnj-20211003.xsd#jnj_A2.05Notesdue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.05Notesdue2023Member" xlink:to="lab_jnj_A2.05Notesdue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_ef7983cc-1245-4251-8105-e8492679c38a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_e3ef80c3-24cf-48f9-b393-e19336fe8251_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans and notes payable</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_e1b70215-327f-4597-9e4f-95a721803c11_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Debt</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AurisHealthMember_9de0d04e-7005-4d15-9930-06e56595a7e3_terseLabel_en-US" xlink:label="lab_jnj_AurisHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auris Health</link:label>
    <link:label id="lab_jnj_AurisHealthMember_label_en-US" xlink:label="lab_jnj_AurisHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auris Health [Member]</link:label>
    <link:label id="lab_jnj_AurisHealthMember_documentation_en-US" xlink:label="lab_jnj_AurisHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auris Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember" xlink:href="jnj-20211003.xsd#jnj_AurisHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AurisHealthMember" xlink:to="lab_jnj_AurisHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_231b2270-e60c-400e-97c2-af262aacc9a5_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_bd4c2618-5f58-4dea-943a-983a51b17920_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d5a7ec88-2eef-4923-bfd1-21e808171d8e_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_35ef2f34-af10-4055-8653-aaacef81af72_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_50c34e3c-ea83-4e55-bb13-aab7f8a5ee9b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_2d02cea1-7adf-4984-985d-37fa716a6742_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_948f9f21-ba9b-4f63-81bd-46176abd9ec8_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt (Note 4)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_1f8776fc-d7bf-475c-a4e2-062f6dbe5d1d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_27f21a14-a76d-4893-ae02-7d09a2d35a5b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_48f78114-b7ff-4e00-a4ab-65a55ad536e3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Support Agreement (CSA)</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NotesDuePeriodFifteenMember_a984344b-9c4a-4153-a587-bfbe78790fdb_terseLabel_en-US" xlink:label="lab_jnj_NotesDuePeriodFifteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_jnj_NotesDuePeriodFifteenMember_label_en-US" xlink:label="lab_jnj_NotesDuePeriodFifteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due Period Fifteen Member</link:label>
    <link:label id="lab_jnj_NotesDuePeriodFifteenMember_documentation_en-US" xlink:label="lab_jnj_NotesDuePeriodFifteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes due period fifteen.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NotesDuePeriodFifteenMember" xlink:href="jnj-20211003.xsd#jnj_NotesDuePeriodFifteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NotesDuePeriodFifteenMember" xlink:to="lab_jnj_NotesDuePeriodFifteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_50e64ae7-379a-4916-ae47-7d6c4583cb72_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_833f4dc9-3b97-4495-80d5-c32650922ae2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_c2befb01-3970-487e-a16b-1c65d08be46c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition cost</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_e82f354f-dcf5-4548-9363-aaf9194537c8_terseLabel_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales By Segment Of Business</link:label>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_label_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales By Segment Of Business [Table Text Block]</link:label>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_documentation_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales by segment of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:href="jnj-20211003.xsd#jnj_SalesBySegmentOfBusinessTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:to="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_075004d5-4d7a-45a0-bebd-9d633279c18c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_c754d314-8e3b-48ad-bf2d-d1cf3228b1f2_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_54f3955f-b535-4f3b-934f-e975f8d060b6_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss) (Note 7)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_9f21aaac-e869-491c-b6cc-486611b697f9_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_1b3b45c1-98b8-4541-a0a4-ad7b15c6a9be_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives &amp; Hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_5e2e2eec-786c-4982-bb5b-64697bd01497_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_83cd098c-89a1-4bba-a8d4-55050e2957f7_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_5b809c6e-646e-4a3f-9bf9-c0ba6c85340a_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee related obligations</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_dfae9661-3ce5-4105-ba5a-87538781a7bd_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_6da63571-300a-445e-bdb2-4c836ba0cd94_verboseLabel_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes Due November 2024</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_99d7dd11-0aa7-446b-a421-104751257c1c_terseLabel_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes due 2024 (500 MM GBP 1.3465)</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_label_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes Due 2024 [Member]</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_documentation_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member" xlink:href="jnj-20211003.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.50NotesDue2024Member" xlink:to="lab_jnj_A5.50NotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_682dc2a9-82e4-4b3e-aef0-b0468423bc99_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages awarded</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_7cbc80cc-f292-4e6e-8f1b-85cb26de7679_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time deposits(1)</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent_b9474ea1-c820-448a-be85-37639d723255_terseLabel_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax benefit related to TRAF, percent</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent_label_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset, Percent</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent_documentation_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent" xlink:href="jnj-20211003.xsd#jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent" xlink:to="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_adefdb93-99f8-4bc6-a0d3-347545ca1f3d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RisperdalMember_f2e9ff66-ec2f-40c4-a3b3-44e44bc8da49_terseLabel_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risperdal</link:label>
    <link:label id="lab_jnj_RisperdalMember_label_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risperdal [Member]</link:label>
    <link:label id="lab_jnj_RisperdalMember_documentation_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risperdal.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember" xlink:href="jnj-20211003.xsd#jnj_RisperdalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RisperdalMember" xlink:to="lab_jnj_RisperdalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c31cf284-4844-43e8-821d-f4708f8d1bad_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_022f1ab3-de21-47fd-b925-0548708b4160_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_593cd616-2cad-4d81-aa83-578b9af80a14_terseLabel_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes due 2046</link:label>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_label_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes due 2046 [Member]</link:label>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_documentation_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes due 2046 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member" xlink:href="jnj-20211003.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.70Notesdue2046Member" xlink:to="lab_jnj_A3.70Notesdue2046Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6a89a038-06ea-4271-ae4b-be0b9b9fe817_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_79292bbe-4984-4149-8c32-0e5ef87aac35_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Weighted-Average Useful Life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_MedicalDevicesMember_ed3c248f-f8c4-425a-a949-7fa52a1c55e6_verboseLabel_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Devices</link:label>
    <link:label id="lab_jnj_MedicalDevicesMember_6e59065f-6cd2-43ec-aff6-270e0d1d1a3f_terseLabel_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MEDICAL DEVICES</link:label>
    <link:label id="lab_jnj_MedicalDevicesMember_label_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Devices [Member]</link:label>
    <link:label id="lab_jnj_MedicalDevicesMember_documentation_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Devices [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember" xlink:href="jnj-20211003.xsd#jnj_MedicalDevicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_MedicalDevicesMember" xlink:to="lab_jnj_MedicalDevicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_0b65b5de-f5ac-456e-bf30-a058efa671e6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_e6d12a6a-5afd-419e-b6a3-5c533ecb6002_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and current marketable securities, Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_b63899a6-fceb-4b44-aa67-bf45a825fecc_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_02a29224-87b6-4f80-b888-ba6570e64e94_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain_2a9b1e08-6500-4910-a127-94da59ddcb8e_terseLabel_en-US" xlink:label="lab_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and current marketable securities, Unrecognized Gain</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain_label_en-US" xlink:label="lab_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments, Accumulated Gross Unrealized Gain</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain_documentation_en-US" xlink:label="lab_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments, Accumulated Gross Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain" xlink:href="jnj-20211003.xsd#jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain" xlink:to="lab_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherOncologyMember_feacdf8e-f0c5-42a3-a22c-902e46031e1e_terseLabel_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER ONCOLOGY(1)</link:label>
    <link:label id="lab_jnj_OtherOncologyMember_label_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:label id="lab_jnj_OtherOncologyMember_documentation_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember" xlink:href="jnj-20211003.xsd#jnj_OtherOncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherOncologyMember" xlink:to="lab_jnj_OtherOncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_90568d18-2532-41c1-8703-051588e255b6_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0e7f2f49-ceb5-4a74-934e-1769b618b198_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f9ae8742-3513-4cdc-90c1-da35bfb7d243_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d76f505b-d72d-448e-965e-860351ec71a1_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A6.73Debenturesdue2023Member_f762085b-bd3c-4302-9293-03a075f281ea_terseLabel_en-US" xlink:label="lab_jnj_A6.73Debenturesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.73% Debentures due 2023</link:label>
    <link:label id="lab_jnj_A6.73Debenturesdue2023Member_label_en-US" xlink:label="lab_jnj_A6.73Debenturesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.73% Debentures due 2023 [Member]</link:label>
    <link:label id="lab_jnj_A6.73Debenturesdue2023Member_documentation_en-US" xlink:label="lab_jnj_A6.73Debenturesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.73% Debentures due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.73Debenturesdue2023Member" xlink:href="jnj-20211003.xsd#jnj_A6.73Debenturesdue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A6.73Debenturesdue2023Member" xlink:to="lab_jnj_A6.73Debenturesdue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateContractMember_0a282257-96d5-4a96-9139-af2904771b35_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember" xlink:to="lab_us-gaap_InterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_b21986c6-9466-4ce9-9ea3-b3097464c1a0_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_90bd04fe-8338-4520-9a4d-32898830253a_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_9de81ace-6e40-4aa0-a262-29a6c105494e_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_b98f0b34-9029-426a-b17f-36ba9dd15cd8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ERLEADAMember_72c49b30-bbd5-43eb-a198-1150ad24a2c7_terseLabel_en-US" xlink:label="lab_jnj_ERLEADAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ERLEADA</link:label>
    <link:label id="lab_jnj_ERLEADAMember_label_en-US" xlink:label="lab_jnj_ERLEADAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ERLEADA [Member]</link:label>
    <link:label id="lab_jnj_ERLEADAMember_documentation_en-US" xlink:label="lab_jnj_ERLEADAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ERLEADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ERLEADAMember" xlink:href="jnj-20211003.xsd#jnj_ERLEADAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ERLEADAMember" xlink:to="lab_jnj_ERLEADAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_108e0afc-b6ea-42f7-a046-5717101d6828_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities, net of effects from acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_804fb20e-8c83-4489-aee4-498ee1b2c0f8_terseLabel_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And Trademarks</link:label>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_label_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And Trademarks [Member]</link:label>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_documentation_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember" xlink:href="jnj-20211003.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PatentsAndTrademarksMember" xlink:to="lab_jnj_PatentsAndTrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_2bc1781b-96e0-4122-a45c-509fa498f60f_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_37e99cd3-7f24-4f27-bb8c-1141506150b6_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_39e0598c-8517-47cc-a908-dd632f3bb53f_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8b4a3845-ec2e-4519-b95d-b4e8b3c5cdd9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_27af0c24-f101-4d1a-91ae-7e141a29991c_terseLabel_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes due 2037</link:label>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_label_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes due 2037 [Member]</link:label>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_documentation_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes due 2037 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member" xlink:href="jnj-20211003.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.625Notesdue2037Member" xlink:to="lab_jnj_A3.625Notesdue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_a21a80ae-6a45-403d-ba97-bd315106e077_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum length of time for hedge exposure</link:label>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_label_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Length of Time, Foreign Currency Cash Flow Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:to="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_c8e70c9d-a0b3-4144-9cbb-a2e3a648a100_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_04c0ddec-8689-4d7e-b980-69a840133e19_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_22dc0855-7bcb-43a2-b875-1ddb9a08790f_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherImmunologyMember_443ed05e-00ce-4af3-998b-c5960715337a_terseLabel_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER IMMUNOLOGY</link:label>
    <link:label id="lab_jnj_OtherImmunologyMember_label_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:label id="lab_jnj_OtherImmunologyMember_documentation_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember" xlink:href="jnj-20211003.xsd#jnj_OtherImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherImmunologyMember" xlink:to="lab_jnj_OtherImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_55370e41-7b7e-4bf4-9c1f-f3a30754da06_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_a943fb05-349f-4ee6-9581-486e57b34578_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET EARNINGS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_b2946da4-e116-4e44-b8f6-b5e8f9956182_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BermekimabMember_fa5defde-bebb-41fe-b3a2-0748d69ad937_terseLabel_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bermekimab</link:label>
    <link:label id="lab_jnj_BermekimabMember_label_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bermekimab [Member]</link:label>
    <link:label id="lab_jnj_BermekimabMember_documentation_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bermekimab [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember" xlink:href="jnj-20211003.xsd#jnj_BermekimabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BermekimabMember" xlink:to="lab_jnj_BermekimabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RISPERDALCONSTAMember_d526939c-dc37-48f2-846a-d30975a263b9_terseLabel_en-US" xlink:label="lab_jnj_RISPERDALCONSTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RISPERDAL CONSTA&#174;</link:label>
    <link:label id="lab_jnj_RISPERDALCONSTAMember_label_en-US" xlink:label="lab_jnj_RISPERDALCONSTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RISPERDAL CONSTA [Member]</link:label>
    <link:label id="lab_jnj_RISPERDALCONSTAMember_documentation_en-US" xlink:label="lab_jnj_RISPERDALCONSTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RISPERDAL CONSTA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RISPERDALCONSTAMember" xlink:href="jnj-20211003.xsd#jnj_RISPERDALCONSTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RISPERDALCONSTAMember" xlink:to="lab_jnj_RISPERDALCONSTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_873394e6-00bd-4555-9932-476fdaf51cac_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities, Unrecognized Gain</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_9f89c4bc-856f-4125-b8fc-b3de374ad6e2_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring (Note 12)</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_b8c48e77-87ea-4f1c-9093-67e7bfb62a97_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_59e8e9b5-5721-42ea-8c32-270eaddff435_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract" xlink:to="lab_us-gaap_LongTermDebtNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_23939491-a22f-4ae1-b75a-bdad26050a8e_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities - Carrying Amount</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecurities" xlink:to="lab_us-gaap_HeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EvraAndDoxilMember_b9017f59-ad48-4ee5-8473-62139d80daf7_terseLabel_en-US" xlink:label="lab_jnj_EvraAndDoxilMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evra and Doxil</link:label>
    <link:label id="lab_jnj_EvraAndDoxilMember_label_en-US" xlink:label="lab_jnj_EvraAndDoxilMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evra and Doxil [Member]</link:label>
    <link:label id="lab_jnj_EvraAndDoxilMember_documentation_en-US" xlink:label="lab_jnj_EvraAndDoxilMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evra and Doxil</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EvraAndDoxilMember" xlink:href="jnj-20211003.xsd#jnj_EvraAndDoxilMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EvraAndDoxilMember" xlink:to="lab_jnj_EvraAndDoxilMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_57b78c1d-6115-4cab-895e-624d22da449d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2a5428e1-a5df-4881-89a8-e8f0965a6cd4_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_f89a337a-7994-4660-a4d5-d5c646ac343b_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_4b49a0e9-0871-4d58-8179-9df7996e8f3f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_84822e77-8493-49d6-829d-26a8c08f7bd9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5b2aadd3-7af8-47cc-9cfb-c812d1eee6b8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_da1d5401-f63a-41a8-9e66-2fe3b17d58cd_totalLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash paid for acquisitions</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_b48cb1c6-cf11-4bd3-a236-682a1352748e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_410746e6-ca18-443e-82a0-742c4d55b8b4_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments : Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments in Hedges, Assets, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_a5a440dc-04ae-466b-adf2-8fa7de92a91a_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InterventionalSolutionsMember_d5dca183-3215-451c-90ed-2e859de0d7d7_verboseLabel_en-US" xlink:label="lab_jnj_InterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Solutions</link:label>
    <link:label id="lab_jnj_InterventionalSolutionsMember_label_en-US" xlink:label="lab_jnj_InterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Solutions [Member]</link:label>
    <link:label id="lab_jnj_InterventionalSolutionsMember_documentation_en-US" xlink:label="lab_jnj_InterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Solutions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember" xlink:href="jnj-20211003.xsd#jnj_InterventionalSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InterventionalSolutionsMember" xlink:to="lab_jnj_InterventionalSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InterestExpensePercentToSales_ecefbbb1-be9b-440a-96bf-b60fff7a51af_terseLabel_en-US" xlink:label="lab_jnj_InterestExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net of portion capitalized percent to sales</link:label>
    <link:label id="lab_jnj_InterestExpensePercentToSales_label_en-US" xlink:label="lab_jnj_InterestExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense Percent To Sales</link:label>
    <link:label id="lab_jnj_InterestExpensePercentToSales_documentation_en-US" xlink:label="lab_jnj_InterestExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestExpensePercentToSales" xlink:href="jnj-20211003.xsd#jnj_InterestExpensePercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InterestExpensePercentToSales" xlink:to="lab_jnj_InterestExpensePercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_52e7e987-29d8-456f-b6a2-859402f77ada_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_32f29953-9161-4b44-85bb-77c9972a65d6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_b56fd72b-b45e-447c-9172-38d82a201834_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges recorded to date</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_1b27ca85-3b87-4fdc-bbfe-0d9a177ec535_verboseLabel_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</link:label>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_label_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</link:label>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_documentation_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:href="jnj-20211003.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:to="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_0554c8d2-7154-43df-a457-f90db1798ae0_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, estimate of possible loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_749acba4-4a1d-49da-b3e5-530c79dd66ee_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_19559aaf-9fc1-4e0d-bb05-28aa4a72d525_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_5c2ec3c9-550c-445f-a183-6781e7c83817_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par Value $1.00</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_61e5fa64-fac9-43d7-841c-9d96b347e9c4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Issued Amount</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_5d400185-a7b2-4e13-9738-da2c8890af62_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_130ca183-7210-4a66-8d28-c01153d55e29_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_15cf83f4-c1f9-4295-b33b-e0b5ffe15056_terseLabel_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Notes due 2027</link:label>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_label_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Notes due 2027 [Member]</link:label>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_documentation_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Notes due 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member" xlink:href="jnj-20211003.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.95Notesdue2027Member" xlink:to="lab_jnj_A2.95Notesdue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_91d25767-94b4-4e68-985d-84ea49b8c890_terseLabel_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. sovereign securities(1)</link:label>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sovereign Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SovereignDebtSecuritiesMember" xlink:to="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OpioidMember_22e414db-dbcd-4201-8067-04a52056cd5c_terseLabel_en-US" xlink:label="lab_jnj_OpioidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid</link:label>
    <link:label id="lab_jnj_OpioidMember_label_en-US" xlink:label="lab_jnj_OpioidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">opioid [Member]</link:label>
    <link:label id="lab_jnj_OpioidMember_documentation_en-US" xlink:label="lab_jnj_OpioidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpioidMember" xlink:href="jnj-20211003.xsd#jnj_OpioidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OpioidMember" xlink:to="lab_jnj_OpioidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2450NotesDue2060Member_5b96406f-4e5e-4e41-aca2-fa48bf08629b_terseLabel_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2060</link:label>
    <link:label id="lab_jnj_A2450NotesDue2060Member_label_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.450% Notes due 2060 [Member]</link:label>
    <link:label id="lab_jnj_A2450NotesDue2060Member_documentation_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.450% Notes due 2060</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member" xlink:href="jnj-20211003.xsd#jnj_A2450NotesDue2060Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2450NotesDue2060Member" xlink:to="lab_jnj_A2450NotesDue2060Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_8c4d800f-9e0d-4c55-9d63-771c8fe654f0_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_bc18b237-dde2-410f-93a5-f4d5ed01dba7_terseLabel_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.85% Notes due 2041</link:label>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_label_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.85% Notes due 2041 [Member]</link:label>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_documentation_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.85% Notes due 2041 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member" xlink:href="jnj-20211003.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.85Notesdue2041Member" xlink:to="lab_jnj_A4.85Notesdue2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3d102c05-cb5c-40d4-8696-d94a08d7390e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_21df327d-758a-4f00-b242-9abeea3455e2_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets with definite lives:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_806a67fb-a29e-48ad-912c-48f117fe6cfa_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_1c7babdc-ab89-4798-98b7-6435f714f574_verboseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit losses and accounts receivable allowances</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_a0a25f51-4647-40f6-8865-46d9fbbdc052_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6f5ea397-2857-4701-b281-67b9045b6a61_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherMember_b9049ab2-2610-42f7-9aa1-2ae4057c9399_terseLabel_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_jnj_OtherMember_label_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_jnj_OtherMember_documentation_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember" xlink:href="jnj-20211003.xsd#jnj_OtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherMember" xlink:to="lab_jnj_OtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DamagesFromProductDefectsMember_3933f510-68a3-4c86-8f9d-b469411ca43f_terseLabel_en-US" xlink:label="lab_us-gaap_DamagesFromProductDefectsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages from Product Defects</link:label>
    <link:label id="lab_us-gaap_DamagesFromProductDefectsMember_label_en-US" xlink:label="lab_us-gaap_DamagesFromProductDefectsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages from Product Defects [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DamagesFromProductDefectsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DamagesFromProductDefectsMember" xlink:to="lab_us-gaap_DamagesFromProductDefectsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5a836574-f34c-4b37-afe4-43b55f2bd90d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_9c334cfe-09c6-4eb1-a3c4-03f83f7ba209_verboseLabel_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (income)/Interest expense, net</link:label>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_label_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Expense Net Member</link:label>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_documentation_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Expense Net Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember" xlink:href="jnj-20211003.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InterestIncomeExpenseNetMember" xlink:to="lab_jnj_InterestIncomeExpenseNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LegalJurisdictionDomain_27c5c019-11c2-4c36-8939-f9e7494f4ec9_terseLabel_en-US" xlink:label="lab_jnj_LegalJurisdictionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Jurisdiction [Domain]</link:label>
    <link:label id="lab_jnj_LegalJurisdictionDomain_label_en-US" xlink:label="lab_jnj_LegalJurisdictionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Jurisdiction [Domain]</link:label>
    <link:label id="lab_jnj_LegalJurisdictionDomain_documentation_en-US" xlink:label="lab_jnj_LegalJurisdictionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalJurisdictionDomain" xlink:href="jnj-20211003.xsd#jnj_LegalJurisdictionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LegalJurisdictionDomain" xlink:to="lab_jnj_LegalJurisdictionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_5d00a118-55c8-4961-94ed-5e784fa7d2ea_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_08c1976d-5798-445b-be5c-7c86baf7b8f0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_0cbe1154-000e-4333-9685-f5f7e694e579_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TRAUMAMember_73d3585f-489a-4f6c-90fd-889114088da8_terseLabel_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAUMA</link:label>
    <link:label id="lab_jnj_TRAUMAMember_label_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAUMA [Member]</link:label>
    <link:label id="lab_jnj_TRAUMAMember_documentation_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAUMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember" xlink:href="jnj-20211003.xsd#jnj_TRAUMAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TRAUMAMember" xlink:to="lab_jnj_TRAUMAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9c1e4621-5991-4559-804d-52bc3f423dff_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e3d15ae7-2521-4c69-8395-39b3e1c6c77e_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average shares outstanding &#8212; basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_b47063c0-c6f6-41de-9f58-77aa84bbdf4a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_11b2b90c-2c56-4835-b311-cd120e93a17c_terseLabel_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_381f1c2a-30f2-4032-98e3-b0f18de310c7_verboseLabel_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expense Net</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_label_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expense Net [Member]</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_documentation_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expense Net [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember" xlink:href="jnj-20211003.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherIncomeExpenseNetMember" xlink:to="lab_jnj_OtherIncomeExpenseNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_e1b4f009-352e-4a1f-a412-d49f009381c5_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_ee3e99e1-167a-43d3-96cf-0e4434ffdfa6_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_b9a02978-8ddf-49d9-a836-5c7f8361accb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_4e75aa5e-d6d6-4312-bc4c-48a23f47e8ff_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OncologyMember_c1bb7f26-93fc-4bdc-aa6a-3731315ec9ab_terseLabel_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology</link:label>
    <link:label id="lab_jnj_OncologyMember_label_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_jnj_OncologyMember_documentation_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember" xlink:href="jnj-20211003.xsd#jnj_OncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OncologyMember" xlink:to="lab_jnj_OncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_227e71e1-c2aa-43ea-bb3c-7770eec403ee_verboseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_f725f783-e4c7-43dd-bf8c-e7938fd5624d_terseLabel_en-US" xlink:label="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_label_en-US" xlink:label="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Loaned or Sold under Agreements to Repurchase [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:to="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OTCMember_31a19e78-d329-432b-af33-10472ba86b83_terseLabel_en-US" xlink:label="lab_jnj_OTCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC</link:label>
    <link:label id="lab_jnj_OTCMember_label_en-US" xlink:label="lab_jnj_OTCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC [Member]</link:label>
    <link:label id="lab_jnj_OTCMember_documentation_en-US" xlink:label="lab_jnj_OTCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember" xlink:href="jnj-20211003.xsd#jnj_OTCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OTCMember" xlink:to="lab_jnj_OTCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_381642ce-6814-4b26-be21-838ae1274135_periodStartLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, beginning of period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_74b08b42-9ef5-4851-bf99-747081702ae3_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, end of period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_08e0a14c-0799-461a-9340-58f36dd5e351_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_76266c6b-2c8b-49d9-8a2b-8d5fdef6f957_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_656577f3-d883-445a-8a28-4ed6d956a69f_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_29bfcb0e-5eb8-4862-a149-015d3e530953_terseLabel_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense percent to sales</link:label>
    <link:label id="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_label_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense Excluding Acquired In Process Cost Percent To Sales</link:label>
    <link:label id="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_documentation_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense excluding acquired in process cost percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:href="jnj-20211003.xsd#jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:to="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2707557c-455c-41a4-9ca0-ae8a4a9f74fa_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3094058c-1fea-41be-8996-31edc3e26de7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_22c8b80d-313c-4fe6-a507-8e938983721c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_7569c191-e380-4b22-8f18-19cecf41fd90_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailments and settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_10514467-2ee2-4fc5-989e-ffd8eeb6d599_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for taxes on income (Note 5)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_4169c36a-0786-496a-88c2-f5dd95a12db8_terseLabel_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and current marketable securities, Estimated Fair Value</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_label_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, And Short-Term Investments, Estimated Fair Value</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_documentation_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments, Estimated Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:href="jnj-20211003.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:to="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_badca62c-9551-41ef-931d-df894491a855_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_76cec1d1-9121-43fa-9d4f-7c9988f5148e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2b9c5000-05b9-4a43-964b-a77ad1be64c2_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH AND CASH EQUIVALENTS, END OF PERIOD</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_0b5e5be1-2527-4776-9742-e974f6154d0c_terseLabel_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes due 2037</link:label>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_label_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes due 2037 [Member]</link:label>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_documentation_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes due 2037 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member" xlink:href="jnj-20211003.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.95Notesdue2037Member" xlink:to="lab_jnj_A5.95Notesdue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_4e9e2f87-c428-4431-92c1-7aecb8fee7dc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain on sale of assets/businesses</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2489ba2f-8313-4097-9b12-d56dc145b064_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3be28d62-5fe4-42f7-867e-70b7eb6c1920_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e7813fcd-ec27-4121-b403-d5bd01da7756_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_3c954f97-fc51-4437-8441-e4ed5ea038ca_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_b784dce4-0f0e-4c6b-9350-abfd127db740_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_65b7f9ee-3fd7-43ec-9e30-235682b8a424_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_dff68fd9-845b-414d-84ba-498cd3daa9d3_terseLabel_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax benefit related to TRAF</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_label_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_documentation_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:href="jnj-20211003.xsd#jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:to="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_2ec5c4af-9e62-4fc0-a504-aad930228e45_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset Amortization Expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_96c0b818-b69e-48cd-9042-dc5108d94778_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentDetailAbstract_5a7ee531-161e-493f-8b48-8447ff5f2670_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets and liabilities at fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentDetailAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument Detail [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_5c262a20-84da-4ba3-86d0-b8070ad5f57a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PROCRITEPREXMember_99bcd86c-ad1b-4776-86dd-1b6cf503e1ed_terseLabel_en-US" xlink:label="lab_jnj_PROCRITEPREXMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROCRIT&#174; / EPREX&#174;</link:label>
    <link:label id="lab_jnj_PROCRITEPREXMember_label_en-US" xlink:label="lab_jnj_PROCRITEPREXMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROCRIT/EPREX [Member]</link:label>
    <link:label id="lab_jnj_PROCRITEPREXMember_documentation_en-US" xlink:label="lab_jnj_PROCRITEPREXMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROCRIT/EPREX [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PROCRITEPREXMember" xlink:href="jnj-20211003.xsd#jnj_PROCRITEPREXMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PROCRITEPREXMember" xlink:to="lab_jnj_PROCRITEPREXMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A210NotesDue2040Member_32dece49-be86-40be-9c49-2729f3ac18df_terseLabel_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.10% Notes due 2040</link:label>
    <link:label id="lab_jnj_A210NotesDue2040Member_label_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.10% Notes due 2040 [Member]</link:label>
    <link:label id="lab_jnj_A210NotesDue2040Member_documentation_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.10% Notes due 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member" xlink:href="jnj-20211003.xsd#jnj_A210NotesDue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A210NotesDue2040Member" xlink:to="lab_jnj_A210NotesDue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_51b374c0-30a2-43d4-9ae1-f3ea2ab55aba_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesDomain_0fadc1eb-4f91-44b2-9a4a-bbbb18853926_terseLabel_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesDomain_label_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies [Domain]</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesDomain_documentation_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement by companies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain" xlink:href="jnj-20211003.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LitigationSettlementByCompaniesDomain" xlink:to="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_8f056c99-1e43-4d76-b3cb-f17f644d2d62_terseLabel_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONCERTA&#174; / methylphenidate</link:label>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_label_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONCERTA/Methylphenidate [Member]</link:label>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_documentation_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONCERTA/Methylphenidate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember" xlink:href="jnj-20211003.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CONCERTAMethylphenidateMember" xlink:to="lab_jnj_CONCERTAMethylphenidateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_StelaraMember_2689d278-88da-4ff6-b6b7-0276da749f8e_terseLabel_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STELARA&#174;</link:label>
    <link:label id="lab_jnj_StelaraMember_label_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stelara [Member]</link:label>
    <link:label id="lab_jnj_StelaraMember_documentation_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stelara [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember" xlink:href="jnj-20211003.xsd#jnj_StelaraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_StelaraMember" xlink:to="lab_jnj_StelaraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_51589854-797b-4a3f-9771-98704198b492_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease/(Increase) in other current and non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_76b1e1b5-b879-472b-9b3f-efba604ddb74_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SURGICALMember_a0e0e2e4-622c-48e1-91cd-cd800573147d_terseLabel_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SURGICAL</link:label>
    <link:label id="lab_jnj_SURGICALMember_label_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SURGICAL [Member]</link:label>
    <link:label id="lab_jnj_SURGICALMember_documentation_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SURGICAL [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember" xlink:href="jnj-20211003.xsd#jnj_SURGICALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SURGICALMember" xlink:to="lab_jnj_SURGICALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_bbfead74-0a8f-4cb2-a813-316b3fc188d6_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e07f08d1-8268-4fe6-94cc-c9926c9c2512_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_c3590a75-2e5c-4ea4-8d29-e406b6a4c6ae_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OrthopaedicsMember_255b8200-77ad-498d-a880-57755cfe1df1_terseLabel_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orthopaedics</link:label>
    <link:label id="lab_jnj_OrthopaedicsMember_label_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orthopaedics [Member]</link:label>
    <link:label id="lab_jnj_OrthopaedicsMember_documentation_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orthopaedics [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember" xlink:href="jnj-20211003.xsd#jnj_OrthopaedicsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OrthopaedicsMember" xlink:to="lab_jnj_OrthopaedicsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_dcf7e423-0866-4606-92c8-e3d4a89ac2cb_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of the Hedged Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_fb2f5b24-bb59-4593-9e1b-ac59f7e6d078_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Gross Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_40042c00-4c49-4e03-a6f1-678865267309_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedging instruments : Assets</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:to="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InfectiousDiseasesMember_9fa91175-eef0-41b4-8dee-9498d348db31_terseLabel_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infectious Diseases</link:label>
    <link:label id="lab_jnj_InfectiousDiseasesMember_label_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infectious Diseases [Member]</link:label>
    <link:label id="lab_jnj_InfectiousDiseasesMember_documentation_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infectious Diseases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember" xlink:href="jnj-20211003.xsd#jnj_InfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InfectiousDiseasesMember" xlink:to="lab_jnj_InfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_b4cedfc6-c054-4a80-8f82-3ac9e116c669_terseLabel_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonary Hypertension</link:label>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_label_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonary Hypertension [Member]</link:label>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_documentation_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonary Hypertension [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember" xlink:href="jnj-20211003.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PulmonaryHypertensionMember" xlink:to="lab_jnj_PulmonaryHypertensionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4583bd53-42bc-4469-be47-ab9d3cb5af37_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_11528113-ccc9-4fcc-b843-c9a0c1b3bd15_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_9df33ac6-89a9-42b3-b698-8564e07a1ea9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends paid</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_c19d8797-4f2f-4373-9cdb-bde9fcc70ec7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_0acef4b7-988a-4c3f-8938-6aa19fbe1161_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, related to divestitures</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_a334cca0-5cc1-4803-a6f1-5751d2ad909b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_f27a8101-71a2-4c5e-9b50-b8b9bcb14204_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NetIncomeAttributableToParentPercentToSales_cd40c511-54de-4197-a0d4-5e4ada6b1122_totalLabel_en-US" xlink:label="lab_jnj_NetIncomeAttributableToParentPercentToSales" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings percent to sales</link:label>
    <link:label id="lab_jnj_NetIncomeAttributableToParentPercentToSales_label_en-US" xlink:label="lab_jnj_NetIncomeAttributableToParentPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable to Parent Percent to Sales</link:label>
    <link:label id="lab_jnj_NetIncomeAttributableToParentPercentToSales_documentation_en-US" xlink:label="lab_jnj_NetIncomeAttributableToParentPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable to Parent Percent to Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NetIncomeAttributableToParentPercentToSales" xlink:href="jnj-20211003.xsd#jnj_NetIncomeAttributableToParentPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NetIncomeAttributableToParentPercentToSales" xlink:to="lab_jnj_NetIncomeAttributableToParentPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_e185679b-989e-4fba-906e-4da2409bbd36_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Net Periodic Benefit Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2b6fcaaa-3f4c-4bab-83d1-75f7bb77bba0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Worldwide effective income tax rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_35762949-b08c-4afd-95d0-928afe905b56_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CASH USED BY INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_3b3a02de-4329-4ce5-a522-6ac175bd99d4_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_1057382a-88b1-4281-94ab-5bcf5139346d_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_6f67d88f-133e-40c5-9d34-50bfef9ccc99_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue_597b107d-7cc3-4755-a925-842dc291aebd_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages awarded, including settlement for related issues, reimbursement for legal fees, and removal from related claims</link:label>
    <link:label id="lab_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue_label_en-US" xlink:label="lab_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Additional Reimbursement, Value</link:label>
    <link:label id="lab_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue_documentation_en-US" xlink:label="lab_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Additional Reimbursement, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue" xlink:href="jnj-20211003.xsd#jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue" xlink:to="lab_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_a474dfb7-a64e-4e39-a4a3-e7d4bf1cbe41_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_59d635d9-fec0-46be-b638-461226cb4a3e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_83218206-608f-4a25-89aa-c3c15ea15a51_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Benefit Plans</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_c25f683a-f667-4812-8430-93441861e2c5_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities(1)</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_55a041e3-7678-4680-8248-db2bb87b3388_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_1885ab61-fa7b-4d33-a4e0-338dd91f67f6_terseLabel_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent Change (as a percent)</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_label_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Sales By Segment Of Business</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_documentation_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage change in sales by segment of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:href="jnj-20211003.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:to="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_9420f0ad-7efb-4e21-85a0-f15f4bb19944_terseLabel_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625% Notes due 2025</link:label>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_label_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625 Notes due 2025 [Member]</link:label>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_documentation_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625 Notes due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member" xlink:href="jnj-20211003.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.625Notesdue2025Member" xlink:to="lab_jnj_A2.625Notesdue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_e3ab91a8-33b8-4a2e-85a1-7958612be161_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation/Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_d3883cc6-15a5-4ce3-81cd-108cdfee844c_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_57899afe-a5bb-4ebe-81f5-ff02c9f9df5b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_8d9d0102-bed7-4ea2-8ca3-a7233e1af9b8_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_d70073e4-8769-4499-919a-8a7663de14fa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_d9ff644c-efae-4287-a3ef-9d7b663ff7ae_terseLabel_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific, Africa</link:label>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_label_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific, Africa [Member]</link:label>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_documentation_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific, Africa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember" xlink:href="jnj-20211003.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AsiaPacificAfricaMember" xlink:to="lab_jnj_AsiaPacificAfricaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_e2f54f74-8cac-4a71-aa1c-1b73b915da50_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UPTRAVIMember_496b6b3b-8bdb-4ca2-bb8c-76391a9a20a5_terseLabel_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPTRAVI&#174;</link:label>
    <link:label id="lab_jnj_UPTRAVIMember_label_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPTRAVI [Member]</link:label>
    <link:label id="lab_jnj_UPTRAVIMember_documentation_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPTRAVI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember" xlink:href="jnj-20211003.xsd#jnj_UPTRAVIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UPTRAVIMember" xlink:to="lab_jnj_UPTRAVIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_4f3fe1ad-da6c-47bf-8d7c-ef93dc78b001_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: common stock held in treasury, at cost (487,358,000 and 487,331,000 shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_349c1213-0466-401e-bd0e-07761244bf66_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_b7220f94-e282-4a32-b265-b734621049fc_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WoundCareandOtherMember_671bb1ba-04ae-49bf-9fea-ada7602e9d9b_terseLabel_en-US" xlink:label="lab_jnj_WoundCareandOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care/Other</link:label>
    <link:label id="lab_jnj_WoundCareandOtherMember_label_en-US" xlink:label="lab_jnj_WoundCareandOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care and Other [Member]</link:label>
    <link:label id="lab_jnj_WoundCareandOtherMember_documentation_en-US" xlink:label="lab_jnj_WoundCareandOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care and Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WoundCareandOtherMember" xlink:href="jnj-20211003.xsd#jnj_WoundCareandOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WoundCareandOtherMember" xlink:to="lab_jnj_WoundCareandOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_0651fb3c-efea-4231-8800-8262453e86c4_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_7c80d67d-cd4e-49af-8e20-06970ed8b8eb_terseLabel_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER INFECTIOUS DISEASES</link:label>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_label_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Infectious Diseases [Member]</link:label>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_documentation_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Infectious Diseases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember" xlink:href="jnj-20211003.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherInfectiousDiseasesMember" xlink:to="lab_jnj_OtherInfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_74a3d5d8-bf10-42a1-8e48-539349cdfab4_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings_02fbadb3-bba4-41b9-9830-167ea4896acf_terseLabel_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost savings expected</link:label>
    <link:label id="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings_label_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Future Savings</link:label>
    <link:label id="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings_documentation_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Future Savings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:href="jnj-20211003.xsd#jnj_RestructuringandRelatedCostExpectedFutureSavings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:to="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_dcef99a8-912c-4ee5-a972-6dabb8d071be_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_c5a2c595-5d02-4e57-b6b7-be466a409ca9_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ContactLensesMember_8d812f99-5cd1-485f-8889-2f3144bc0abe_terseLabel_en-US" xlink:label="lab_jnj_ContactLensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Lenses</link:label>
    <link:label id="lab_jnj_ContactLensesMember_label_en-US" xlink:label="lab_jnj_ContactLensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Lenses [Member]</link:label>
    <link:label id="lab_jnj_ContactLensesMember_documentation_en-US" xlink:label="lab_jnj_ContactLensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Lenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ContactLensesMember" xlink:href="jnj-20211003.xsd#jnj_ContactLensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ContactLensesMember" xlink:to="lab_jnj_ContactLensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_79ce12db-9d8c-494c-aedc-eb0d81a7edaf_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New and Recently Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_811f76fa-7de1-4ea5-a1dc-6c5e45a07a32_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_0ea4982d-479a-4316-a220-e7eaac610c09_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>jnj-20211003_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:90dc118c-6428-4338-8b4d-8015054a0548,g:65f17fdb-8375-41f4-bf95-c047d59b03b3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.jnj.com/role/Cover" xlink:type="simple" xlink:href="jnj-20211003.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_2c291848-435a-48cb-badc-bef4b5d69705" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_011e9054-982c-4376-90ba-61b24e4e982a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2c291848-435a-48cb-badc-bef4b5d69705" xlink:to="loc_dei_EntitiesTable_011e9054-982c-4376-90ba-61b24e4e982a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_32ffad90-4c03-4011-ba54-4b03e608ce30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_011e9054-982c-4376-90ba-61b24e4e982a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_32ffad90-4c03-4011-ba54-4b03e608ce30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c7b50371-e8f9-4fed-87bb-1a92b1d05578" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_32ffad90-4c03-4011-ba54-4b03e608ce30" xlink:to="loc_us-gaap_ClassOfStockDomain_c7b50371-e8f9-4fed-87bb-1a92b1d05578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cbae9ca6-43d0-4429-a14f-a01decd87f6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c7b50371-e8f9-4fed-87bb-1a92b1d05578" xlink:to="loc_us-gaap_CommonStockMember_cbae9ca6-43d0-4429-a14f-a01decd87f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.250NotesDue2022Member_eb38fe45-2a2a-470f-b996-7322bafebf89" xlink:href="jnj-20211003.xsd#jnj_A0.250NotesDue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c7b50371-e8f9-4fed-87bb-1a92b1d05578" xlink:to="loc_jnj_A0.250NotesDue2022Member_eb38fe45-2a2a-470f-b996-7322bafebf89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_f3ce2507-2d84-454f-a220-8956e1f204b9" xlink:href="jnj-20211003.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c7b50371-e8f9-4fed-87bb-1a92b1d05578" xlink:to="loc_jnj_A0.650NotesDue2024Member_f3ce2507-2d84-454f-a220-8956e1f204b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_47e8a1b4-efeb-4e31-87d8-fcf34f4bde64" xlink:href="jnj-20211003.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c7b50371-e8f9-4fed-87bb-1a92b1d05578" xlink:to="loc_jnj_A5.50NotesDue2024Member_47e8a1b4-efeb-4e31-87d8-fcf34f4bde64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_aa39b9cd-4702-417a-8340-5218ee544e6c" xlink:href="jnj-20211003.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c7b50371-e8f9-4fed-87bb-1a92b1d05578" xlink:to="loc_jnj_A1.150NotesDue2028Member_aa39b9cd-4702-417a-8340-5218ee544e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_2d30c2c4-1423-4328-adf4-13b5b8ca7eb2" xlink:href="jnj-20211003.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c7b50371-e8f9-4fed-87bb-1a92b1d05578" xlink:to="loc_jnj_A1.650NotesDue2035Member_2d30c2c4-1423-4328-adf4-13b5b8ca7eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_011e9054-982c-4376-90ba-61b24e4e982a" xlink:to="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d03c6dac-0926-44f0-b388-74faa697f8a6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_DocumentType_d03c6dac-0926-44f0-b388-74faa697f8a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_4e49625f-0e53-46bb-846d-dddd7f739d22" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_DocumentQuarterlyReport_4e49625f-0e53-46bb-846d-dddd7f739d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a4744110-dd3d-4697-beb1-ec3c0217c6e5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_DocumentPeriodEndDate_a4744110-dd3d-4697-beb1-ec3c0217c6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_063fef78-30ce-4dde-8ebe-e93db52a82d7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_DocumentTransitionReport_063fef78-30ce-4dde-8ebe-e93db52a82d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9976f4bf-1c21-454d-9ea3-384195af5dab" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityFileNumber_9976f4bf-1c21-454d-9ea3-384195af5dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_37e8370f-04cc-4f53-9bb0-e697ea262097" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityRegistrantName_37e8370f-04cc-4f53-9bb0-e697ea262097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2632647c-bf7a-4d7b-a556-9066f19ecd17" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2632647c-bf7a-4d7b-a556-9066f19ecd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f2b8e006-331e-41e3-bb1b-17a5953954bc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityTaxIdentificationNumber_f2b8e006-331e-41e3-bb1b-17a5953954bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_731e5133-4cf4-4f4f-847b-cf08d140c03a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityAddressAddressLine1_731e5133-4cf4-4f4f-847b-cf08d140c03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_36342b63-7d48-434b-b96d-0f88b2ea4884" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityAddressCityOrTown_36342b63-7d48-434b-b96d-0f88b2ea4884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_9d69f1ae-a744-489f-bd0e-e926f8d446f3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityAddressStateOrProvince_9d69f1ae-a744-489f-bd0e-e926f8d446f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e83917c4-4110-4518-a1b0-0df5c8c0572c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityAddressPostalZipCode_e83917c4-4110-4518-a1b0-0df5c8c0572c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_17ae9527-55c8-416b-b9c4-2d0d7da13b3c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_CityAreaCode_17ae9527-55c8-416b-b9c4-2d0d7da13b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_46117227-c6f6-4fe0-93df-5b9520dc5285" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_LocalPhoneNumber_46117227-c6f6-4fe0-93df-5b9520dc5285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_bcd7533d-2640-49be-b919-0d3216a1b467" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityCurrentReportingStatus_bcd7533d-2640-49be-b919-0d3216a1b467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_574483f7-f430-4d2f-bdf2-a57ae89997d1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityInteractiveDataCurrent_574483f7-f430-4d2f-bdf2-a57ae89997d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_8f626e53-e4c4-4b26-9157-78a85e6da56d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityFilerCategory_8f626e53-e4c4-4b26-9157-78a85e6da56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e7be4c5a-d7a3-45fc-b074-7e12cacb7900" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntitySmallBusiness_e7be4c5a-d7a3-45fc-b074-7e12cacb7900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ca1cb058-37bc-44b5-8b83-83e0b02c66ce" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityEmergingGrowthCompany_ca1cb058-37bc-44b5-8b83-83e0b02c66ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_263a6f7d-cf1e-4788-a5eb-6677c496749d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityShellCompany_263a6f7d-cf1e-4788-a5eb-6677c496749d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_79ccf960-f50f-4bae-bb62-67cb7738cdcd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_Security12bTitle_79ccf960-f50f-4bae-bb62-67cb7738cdcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_27126af8-fb24-481b-85e8-c178f872484d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_TradingSymbol_27126af8-fb24-481b-85e8-c178f872484d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ce33e936-613d-4a3b-948b-f399ae9bf35a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_SecurityExchangeName_ce33e936-613d-4a3b-948b-f399ae9bf35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d404c240-2091-4aca-93d8-d7a7e9ec6422" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d404c240-2091-4aca-93d8-d7a7e9ec6422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fa6212e5-de41-4a86-b71c-68aa39a597ed" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_EntityCentralIndexKey_fa6212e5-de41-4a86-b71c-68aa39a597ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_ca7bac4b-50ac-4394-94bf-d2576da809b6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_CurrentFiscalYearEndDate_ca7bac4b-50ac-4394-94bf-d2576da809b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_90ccb21b-9c5d-43c3-ae4b-041e4a83e07c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_DocumentFiscalYearFocus_90ccb21b-9c5d-43c3-ae4b-041e4a83e07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_d55675fc-dcdb-4127-a214-f96766da50da" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_DocumentFiscalPeriodFocus_d55675fc-dcdb-4127-a214-f96766da50da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e0957f75-02e4-49b7-8ad8-f6f1920e7af7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_a4cbf65a-fab7-4c76-b5da-d61751e58c15" xlink:to="loc_dei_AmendmentFlag_e0957f75-02e4-49b7-8ad8-f6f1920e7af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="jnj-20211003.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9cf3efaa-9fef-4e62-a2a8-37c90135d0c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d46d763b-b20e-466a-bb23-fbe115b4d514" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9cf3efaa-9fef-4e62-a2a8-37c90135d0c0" xlink:to="loc_us-gaap_AssetsAbstract_d46d763b-b20e-466a-bb23-fbe115b4d514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1a6faab4-7118-40f6-a519-23e3c86d5a27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d46d763b-b20e-466a-bb23-fbe115b4d514" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1a6faab4-7118-40f6-a519-23e3c86d5a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bdc5c45d-be00-487f-82e2-de8915d40e48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1a6faab4-7118-40f6-a519-23e3c86d5a27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bdc5c45d-be00-487f-82e2-de8915d40e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_4b08a4b5-d865-4ec7-a78f-73f4fd619a13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1a6faab4-7118-40f6-a519-23e3c86d5a27" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_4b08a4b5-d865-4ec7-a78f-73f4fd619a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd19cadd-99de-4570-bed4-3344b8c72bce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1a6faab4-7118-40f6-a519-23e3c86d5a27" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dd19cadd-99de-4570-bed4-3344b8c72bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f6cfec41-7fe3-4d5a-a78a-f5b753f4947f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1a6faab4-7118-40f6-a519-23e3c86d5a27" xlink:to="loc_us-gaap_InventoryNet_f6cfec41-7fe3-4d5a-a78a-f5b753f4947f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_53daa472-59ed-4e22-b9d7-279c7d9303c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1a6faab4-7118-40f6-a519-23e3c86d5a27" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_53daa472-59ed-4e22-b9d7-279c7d9303c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2e837f9f-09ed-496f-ad34-a7bda7f961b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1a6faab4-7118-40f6-a519-23e3c86d5a27" xlink:to="loc_us-gaap_AssetsCurrent_2e837f9f-09ed-496f-ad34-a7bda7f961b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2f1ad4da-207d-4bcb-9c59-5cde6e619254" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d46d763b-b20e-466a-bb23-fbe115b4d514" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2f1ad4da-207d-4bcb-9c59-5cde6e619254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_21d2d36f-7315-40d6-b32d-773133590c69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d46d763b-b20e-466a-bb23-fbe115b4d514" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_21d2d36f-7315-40d6-b32d-773133590c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e58c1364-13f4-41a5-96e1-24a79f97aa40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d46d763b-b20e-466a-bb23-fbe115b4d514" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e58c1364-13f4-41a5-96e1-24a79f97aa40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7d612d75-7ff4-4a52-88e5-3bb1bb757f88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d46d763b-b20e-466a-bb23-fbe115b4d514" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7d612d75-7ff4-4a52-88e5-3bb1bb757f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_45d6494c-4144-4a60-87bf-b1db92f54cbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d46d763b-b20e-466a-bb23-fbe115b4d514" xlink:to="loc_us-gaap_Goodwill_45d6494c-4144-4a60-87bf-b1db92f54cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_259e7635-f5bf-444d-b8cc-8009209f9533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d46d763b-b20e-466a-bb23-fbe115b4d514" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_259e7635-f5bf-444d-b8cc-8009209f9533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_aa87ec37-13ab-44a6-8e0a-a807ef6768c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d46d763b-b20e-466a-bb23-fbe115b4d514" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_aa87ec37-13ab-44a6-8e0a-a807ef6768c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c57d9e05-f5f5-4009-a330-b414bdb31538" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d46d763b-b20e-466a-bb23-fbe115b4d514" xlink:to="loc_us-gaap_Assets_c57d9e05-f5f5-4009-a330-b414bdb31538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6774909a-d630-47df-a224-b97d652fea62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9cf3efaa-9fef-4e62-a2a8-37c90135d0c0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6774909a-d630-47df-a224-b97d652fea62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_142148fa-1d81-4276-8caa-04395827c413" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6774909a-d630-47df-a224-b97d652fea62" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_142148fa-1d81-4276-8caa-04395827c413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_40a7110c-b2c4-43ca-947e-959d85776030" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_142148fa-1d81-4276-8caa-04395827c413" xlink:to="loc_us-gaap_ShortTermBorrowings_40a7110c-b2c4-43ca-947e-959d85776030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_83b45cdc-cc19-4a53-9004-1af77e23c4af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_142148fa-1d81-4276-8caa-04395827c413" xlink:to="loc_us-gaap_AccountsPayableCurrent_83b45cdc-cc19-4a53-9004-1af77e23c4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8df0a736-3247-4c4d-880f-6c96e9c010bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_142148fa-1d81-4276-8caa-04395827c413" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8df0a736-3247-4c4d-880f-6c96e9c010bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_252dedfe-07bf-4204-bd65-f0ed89b398fa" xlink:href="jnj-20211003.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_142148fa-1d81-4276-8caa-04395827c413" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_252dedfe-07bf-4204-bd65-f0ed89b398fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_62015298-2967-4c4f-9631-8291b6352fac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_142148fa-1d81-4276-8caa-04395827c413" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_62015298-2967-4c4f-9631-8291b6352fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_690644e3-a15b-419b-8625-76f21cb30602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_142148fa-1d81-4276-8caa-04395827c413" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_690644e3-a15b-419b-8625-76f21cb30602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_88056ae0-3ab0-407f-ab69-918e82bb13c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_142148fa-1d81-4276-8caa-04395827c413" xlink:to="loc_us-gaap_LiabilitiesCurrent_88056ae0-3ab0-407f-ab69-918e82bb13c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0059c6ab-41d4-4efb-a79c-7b4cc5507999" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6774909a-d630-47df-a224-b97d652fea62" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_0059c6ab-41d4-4efb-a79c-7b4cc5507999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b651be33-7915-47c1-b392-8aebb3c31d8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6774909a-d630-47df-a224-b97d652fea62" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b651be33-7915-47c1-b392-8aebb3c31d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_65f12aa9-fe28-45b5-8ef4-52ff6aec8fb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6774909a-d630-47df-a224-b97d652fea62" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_65f12aa9-fe28-45b5-8ef4-52ff6aec8fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_68ed0d86-710e-45f4-a573-f143d9dfbc49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6774909a-d630-47df-a224-b97d652fea62" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_68ed0d86-710e-45f4-a573-f143d9dfbc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_0534f00f-fdc3-420f-b1c0-876100fd8dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6774909a-d630-47df-a224-b97d652fea62" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_0534f00f-fdc3-420f-b1c0-876100fd8dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3e36b8b9-8572-4166-bdd0-bcd66fd102b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6774909a-d630-47df-a224-b97d652fea62" xlink:to="loc_us-gaap_Liabilities_3e36b8b9-8572-4166-bdd0-bcd66fd102b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_353cbf75-0132-4fe8-8c28-1488b96b5ac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6774909a-d630-47df-a224-b97d652fea62" xlink:to="loc_us-gaap_CommitmentsAndContingencies_353cbf75-0132-4fe8-8c28-1488b96b5ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_b0146355-c03b-41fd-b6c6-536aace353b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6774909a-d630-47df-a224-b97d652fea62" xlink:to="loc_us-gaap_StockholdersEquityAbstract_b0146355-c03b-41fd-b6c6-536aace353b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_124c481c-9ad5-4171-861d-2b229ac79231" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b0146355-c03b-41fd-b6c6-536aace353b6" xlink:to="loc_us-gaap_CommonStockValue_124c481c-9ad5-4171-861d-2b229ac79231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_39eed1d8-4f78-4bd0-b4a9-c209bee50524" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b0146355-c03b-41fd-b6c6-536aace353b6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_39eed1d8-4f78-4bd0-b4a9-c209bee50524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e7adeb76-76c5-4c90-9d25-0a516febb28d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b0146355-c03b-41fd-b6c6-536aace353b6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e7adeb76-76c5-4c90-9d25-0a516febb28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_a53e4e02-21bb-46d3-97a0-fcf21850c580" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b0146355-c03b-41fd-b6c6-536aace353b6" xlink:to="loc_us-gaap_TreasuryStockValue_a53e4e02-21bb-46d3-97a0-fcf21850c580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_700c48ce-5084-412e-9499-f81069f541fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b0146355-c03b-41fd-b6c6-536aace353b6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_700c48ce-5084-412e-9499-f81069f541fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e0aa34c-f842-4b22-bc49-01d795bc7d0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6774909a-d630-47df-a224-b97d652fea62" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e0aa34c-f842-4b22-bc49-01d795bc7d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="jnj-20211003.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_73d9d232-63f8-4b38-a8d7-df62012b4328" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_62c51566-8815-4870-93e0-204f6ad26945" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_73d9d232-63f8-4b38-a8d7-df62012b4328" xlink:to="loc_us-gaap_AssetsCurrentAbstract_62c51566-8815-4870-93e0-204f6ad26945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_927bb4d6-66eb-4d46-94ef-a8eee6544c6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_62c51566-8815-4870-93e0-204f6ad26945" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_927bb4d6-66eb-4d46-94ef-a8eee6544c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_73c34127-12e0-49e8-9521-0212e703b731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_73d9d232-63f8-4b38-a8d7-df62012b4328" xlink:to="loc_us-gaap_StockholdersEquityAbstract_73c34127-12e0-49e8-9521-0212e703b731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_69f32963-c3e1-4e46-9a41-e74c3cfc5730" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_73c34127-12e0-49e8-9521-0212e703b731" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_69f32963-c3e1-4e46-9a41-e74c3cfc5730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a714b78d-aed4-4aeb-93fc-8458d308e5c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_73c34127-12e0-49e8-9521-0212e703b731" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a714b78d-aed4-4aeb-93fc-8458d308e5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_498aac50-147f-4cca-97d3-c2dd3d3d705b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_73c34127-12e0-49e8-9521-0212e703b731" xlink:to="loc_us-gaap_CommonStockSharesIssued_498aac50-147f-4cca-97d3-c2dd3d3d705b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_b02e980f-eb3f-4916-8ddc-5eaec722f0aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_73c34127-12e0-49e8-9521-0212e703b731" xlink:to="loc_us-gaap_TreasuryStockShares_b02e980f-eb3f-4916-8ddc-5eaec722f0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="jnj-20211003.xsd#ConsolidatedStatementsofEarnings"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3ccf74fd-9b25-4af6-ab90-ef2fdeeb7083" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3ccf74fd-9b25-4af6-ab90-ef2fdeeb7083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesRevenueGoodsNetPercentToSales_6c142f78-7090-4b46-ba06-3ec93929791d" xlink:href="jnj-20211003.xsd#jnj_SalesRevenueGoodsNetPercentToSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_jnj_SalesRevenueGoodsNetPercentToSales_6c142f78-7090-4b46-ba06-3ec93929791d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_4c097561-874b-4ec2-9e90-02a34aa6db03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_4c097561-874b-4ec2-9e90-02a34aa6db03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CostOfGoodsSoldPercentToSales_8ac33d2c-f510-403f-b1ac-b11a32879f77" xlink:href="jnj-20211003.xsd#jnj_CostOfGoodsSoldPercentToSales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_jnj_CostOfGoodsSoldPercentToSales_8ac33d2c-f510-403f-b1ac-b11a32879f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_9ba3e6d0-3491-4ce7-b827-3459d4a65dbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_us-gaap_GrossProfit_9ba3e6d0-3491-4ce7-b827-3459d4a65dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GrossProfitPercentToSales_30333cf7-789e-4527-811d-163dde5ef132" xlink:href="jnj-20211003.xsd#jnj_GrossProfitPercentToSales"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_jnj_GrossProfitPercentToSales_30333cf7-789e-4527-811d-163dde5ef132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_dd907d97-fa34-47dd-955f-b1b9a7e237f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_dd907d97-fa34-47dd-955f-b1b9a7e237f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_6c1d93e7-c994-412a-83c1-5cd4f2b31a96" xlink:href="jnj-20211003.xsd#jnj_SellingGeneralAndAdministrativeExpensePercentToSales"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_6c1d93e7-c994-412a-83c1-5cd4f2b31a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_942caaf9-c11c-4dc6-b0f3-9ffcf7d39e23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_942caaf9-c11c-4dc6-b0f3-9ffcf7d39e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_691407c1-d097-435e-9076-45214bc42f6e" xlink:href="jnj-20211003.xsd#jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_691407c1-d097-435e-9076-45214bc42f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_29d011b9-f72f-4bac-9352-aea0829acb01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_29d011b9-f72f-4bac-9352-aea0829acb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales_0a32704a-c925-4b3f-829e-b3dca8013034" xlink:href="jnj-20211003.xsd#jnj_ResearchAndDevelopmentInProcessPercentToSales"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales_0a32704a-c925-4b3f-829e-b3dca8013034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_7aa2b795-f01f-45bc-99b3-b08a76226308" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_us-gaap_InvestmentIncomeInterest_7aa2b795-f01f-45bc-99b3-b08a76226308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvestmentIncomeInterestPercentToSales_d545b594-3636-45de-a7e0-b5a02bda2a5c" xlink:href="jnj-20211003.xsd#jnj_InvestmentIncomeInterestPercentToSales"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_jnj_InvestmentIncomeInterestPercentToSales_d545b594-3636-45de-a7e0-b5a02bda2a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9b972b3b-9309-486e-9851-36787f782a52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_us-gaap_InterestExpense_9b972b3b-9309-486e-9851-36787f782a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestExpensePercentToSales_6946e73e-fcc8-46e8-8828-ca5020f4cb44" xlink:href="jnj-20211003.xsd#jnj_InterestExpensePercentToSales"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_jnj_InterestExpensePercentToSales_6946e73e-fcc8-46e8-8828-ca5020f4cb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_33ec06a1-4db2-4f8d-9373-d72a9cb98337" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_33ec06a1-4db2-4f8d-9373-d72a9cb98337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales_c021e549-f3b1-4890-96a3-9144d4d6c17f" xlink:href="jnj-20211003.xsd#jnj_OtherNonOperatingIncomeExpensePercentToSales"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales_c021e549-f3b1-4890-96a3-9144d4d6c17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_c6adfd89-6625-40ac-ad34-cedfeba464a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_us-gaap_RestructuringCharges_c6adfd89-6625-40ac-ad34-cedfeba464a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Restructuringchargepercenttosales_359e6067-135f-4db4-abb2-29248c197bcc" xlink:href="jnj-20211003.xsd#jnj_Restructuringchargepercenttosales"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_jnj_Restructuringchargepercenttosales_359e6067-135f-4db4-abb2-29248c197bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_86bd2a51-a549-47d0-9a0d-9e5b9c13bf31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_86bd2a51-a549-47d0-9a0d-9e5b9c13bf31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_b5f416c2-6eb6-4bdb-93d8-b738c59e7e42" xlink:href="jnj-20211003.xsd#jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_b5f416c2-6eb6-4bdb-93d8-b738c59e7e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c4634c0b-9a76-4346-a367-8c113212a620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c4634c0b-9a76-4346-a367-8c113212a620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeTaxExpenseBenefitPercentToSales_fb7f840b-4916-446a-972f-d1f1c8c54a6a" xlink:href="jnj-20211003.xsd#jnj_IncomeTaxExpenseBenefitPercentToSales"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_jnj_IncomeTaxExpenseBenefitPercentToSales_fb7f840b-4916-446a-972f-d1f1c8c54a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8ca59cd3-5bd0-4d61-b3a9-6bf93b5cefee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_us-gaap_NetIncomeLoss_8ca59cd3-5bd0-4d61-b3a9-6bf93b5cefee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NetIncomeAttributableToParentPercentToSales_01586afe-ff8f-4834-91e4-b442ef904276" xlink:href="jnj-20211003.xsd#jnj_NetIncomeAttributableToParentPercentToSales"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_jnj_NetIncomeAttributableToParentPercentToSales_01586afe-ff8f-4834-91e4-b442ef904276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5e81b074-ca11-415d-bd42-0b7ef26eb4a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_us-gaap_EarningsPerShareAbstract_5e81b074-ca11-415d-bd42-0b7ef26eb4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_cabb8bf4-41fb-4744-843a-42fb8449bd1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5e81b074-ca11-415d-bd42-0b7ef26eb4a0" xlink:to="loc_us-gaap_EarningsPerShareBasic_cabb8bf4-41fb-4744-843a-42fb8449bd1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d6c802d8-15f1-4b0b-9d38-dbd218c4e5de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5e81b074-ca11-415d-bd42-0b7ef26eb4a0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d6c802d8-15f1-4b0b-9d38-dbd218c4e5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_160111e5-9c2b-44a5-9019-08fe1a7cf999" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfed96eb-86bd-4b99-a577-32937e1d4ac6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_160111e5-9c2b-44a5-9019-08fe1a7cf999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_41031504-db87-4323-84a4-d5c18be9ee3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_160111e5-9c2b-44a5-9019-08fe1a7cf999" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_41031504-db87-4323-84a4-d5c18be9ee3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_59109623-a1ae-442a-908f-b66737457f64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_160111e5-9c2b-44a5-9019-08fe1a7cf999" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_59109623-a1ae-442a-908f-b66737457f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20211003.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ea6f0e78-9125-4932-a2bc-0f8713dc194b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4f01f907-3f01-4612-93aa-69ce2d98ce25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ea6f0e78-9125-4932-a2bc-0f8713dc194b" xlink:to="loc_us-gaap_NetIncomeLoss_4f01f907-3f01-4612-93aa-69ce2d98ce25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_c64918bb-b904-478a-ba78-f7a1d7adc3c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ea6f0e78-9125-4932-a2bc-0f8713dc194b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_c64918bb-b904-478a-ba78-f7a1d7adc3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_0fa90800-94b7-4fa7-a326-af953e32ed32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_c64918bb-b904-478a-ba78-f7a1d7adc3c1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_0fa90800-94b7-4fa7-a326-af953e32ed32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_9878f2b3-9e2c-43f4-bf22-bcd7ce4f0aa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_c64918bb-b904-478a-ba78-f7a1d7adc3c1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_9878f2b3-9e2c-43f4-bf22-bcd7ce4f0aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b5d4fb70-4db6-45ac-bae4-25df40c0ad26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_9878f2b3-9e2c-43f4-bf22-bcd7ce4f0aa5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b5d4fb70-4db6-45ac-bae4-25df40c0ad26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_64c1769d-361b-4239-8134-0725c782f3d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_9878f2b3-9e2c-43f4-bf22-bcd7ce4f0aa5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_64c1769d-361b-4239-8134-0725c782f3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b4b618ed-9392-41da-9946-ed6df3da067d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_9878f2b3-9e2c-43f4-bf22-bcd7ce4f0aa5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b4b618ed-9392-41da-9946-ed6df3da067d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_97def12c-19a3-41fd-a1e4-3420d469da9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_c64918bb-b904-478a-ba78-f7a1d7adc3c1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_97def12c-19a3-41fd-a1e4-3420d469da9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_bedbc836-225f-4cf1-bb59-0e5047bc088a" xlink:href="jnj-20211003.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_97def12c-19a3-41fd-a1e4-3420d469da9b" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_bedbc836-225f-4cf1-bb59-0e5047bc088a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_61968e7c-d9ef-408d-8d83-e3ddd2c3c8fe" xlink:href="jnj-20211003.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_97def12c-19a3-41fd-a1e4-3420d469da9b" xlink:to="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_61968e7c-d9ef-408d-8d83-e3ddd2c3c8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_b2bc62c1-ed6a-4658-85b6-57f12348f1ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_97def12c-19a3-41fd-a1e4-3420d469da9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_b2bc62c1-ed6a-4658-85b6-57f12348f1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_1e09996e-c677-4d4f-b2ee-31d00b315ff2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_c64918bb-b904-478a-ba78-f7a1d7adc3c1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_1e09996e-c677-4d4f-b2ee-31d00b315ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_178bfe39-ec0b-4365-adb7-0733f1bc162e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_1e09996e-c677-4d4f-b2ee-31d00b315ff2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_178bfe39-ec0b-4365-adb7-0733f1bc162e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_d4b6684e-1948-446a-ac10-58daff0c5d3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_1e09996e-c677-4d4f-b2ee-31d00b315ff2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_d4b6684e-1948-446a-ac10-58daff0c5d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_cddf6cc0-eccb-47e1-837e-87eec665c722" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_1e09996e-c677-4d4f-b2ee-31d00b315ff2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_cddf6cc0-eccb-47e1-837e-87eec665c722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_977d741e-5222-4c07-b016-4ca44c2c53f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ea6f0e78-9125-4932-a2bc-0f8713dc194b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_977d741e-5222-4c07-b016-4ca44c2c53f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c8549439-9823-43da-847d-08134aa92779" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ea6f0e78-9125-4932-a2bc-0f8713dc194b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_c8549439-9823-43da-847d-08134aa92779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="jnj-20211003.xsd#ConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_741ec031-59dc-4bdf-87d7-f662f4314270" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_b18ff58f-41f5-4849-ab87-5d2fc5033542" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_741ec031-59dc-4bdf-87d7-f662f4314270" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_b18ff58f-41f5-4849-ab87-5d2fc5033542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_3c305480-5b5a-4fc1-a815-4436f903fab9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_741ec031-59dc-4bdf-87d7-f662f4314270" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_3c305480-5b5a-4fc1-a815-4436f903fab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_eddf15ab-3078-4626-954d-8a2174448190" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_741ec031-59dc-4bdf-87d7-f662f4314270" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_eddf15ab-3078-4626-954d-8a2174448190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="jnj-20211003.xsd#ConsolidatedStatementsofEquity"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_11617313-fe47-47a8-92d2-51d3c38dbcfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9f527450-2d0f-4434-83fd-90e3fa3210b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_11617313-fe47-47a8-92d2-51d3c38dbcfc" xlink:to="loc_us-gaap_StatementTable_9f527450-2d0f-4434-83fd-90e3fa3210b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cb198d8b-2c95-4007-a0a0-0a20a9d626c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9f527450-2d0f-4434-83fd-90e3fa3210b1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cb198d8b-2c95-4007-a0a0-0a20a9d626c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e285dc40-7ef1-477b-8dca-785aa55b60e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cb198d8b-2c95-4007-a0a0-0a20a9d626c2" xlink:to="loc_us-gaap_EquityComponentDomain_e285dc40-7ef1-477b-8dca-785aa55b60e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f351fdb2-f29a-49e7-be39-9b722785fa57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e285dc40-7ef1-477b-8dca-785aa55b60e1" xlink:to="loc_us-gaap_RetainedEarningsMember_f351fdb2-f29a-49e7-be39-9b722785fa57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_402ba2c6-24e4-4d25-a4d6-2513bea98da3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e285dc40-7ef1-477b-8dca-785aa55b60e1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_402ba2c6-24e4-4d25-a4d6-2513bea98da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6a161cd3-392d-4e84-a00a-8c52fc4fd59a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e285dc40-7ef1-477b-8dca-785aa55b60e1" xlink:to="loc_us-gaap_CommonStockMember_6a161cd3-392d-4e84-a00a-8c52fc4fd59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_bc161f54-b54c-40c5-b4c2-4661810cf9aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e285dc40-7ef1-477b-8dca-785aa55b60e1" xlink:to="loc_us-gaap_TreasuryStockMember_bc161f54-b54c-40c5-b4c2-4661810cf9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2d138d12-761c-451e-b7e4-acda17b23637" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9f527450-2d0f-4434-83fd-90e3fa3210b1" xlink:to="loc_us-gaap_StatementLineItems_2d138d12-761c-451e-b7e4-acda17b23637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_71dc6a43-5489-4ea5-b7ce-9c85bfaa6caf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d138d12-761c-451e-b7e4-acda17b23637" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_71dc6a43-5489-4ea5-b7ce-9c85bfaa6caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7db5e42a-f201-4928-97b6-8dd4dc0bb27c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d138d12-761c-451e-b7e4-acda17b23637" xlink:to="loc_us-gaap_NetIncomeLoss_7db5e42a-f201-4928-97b6-8dd4dc0bb27c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_5a63fe22-8d9b-4156-a869-ca7706fd51dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d138d12-761c-451e-b7e4-acda17b23637" xlink:to="loc_us-gaap_DividendsCommonStockCash_5a63fe22-8d9b-4156-a869-ca7706fd51dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_69e184c7-cadc-489f-9617-58ca6a18bd39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d138d12-761c-451e-b7e4-acda17b23637" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_69e184c7-cadc-489f-9617-58ca6a18bd39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ea15fc0a-671a-4f0a-ab03-7eedc9019e83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d138d12-761c-451e-b7e4-acda17b23637" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ea15fc0a-671a-4f0a-ab03-7eedc9019e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_556f73b9-760b-40c2-a2a3-29cc7347043f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d138d12-761c-451e-b7e4-acda17b23637" xlink:to="loc_us-gaap_StockholdersEquityOther_556f73b9-760b-40c2-a2a3-29cc7347043f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a23622ad-00d9-4bd7-8f5d-990d7102d59f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d138d12-761c-451e-b7e4-acda17b23637" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a23622ad-00d9-4bd7-8f5d-990d7102d59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d31f085d-78c6-46ab-b8cc-8915213e4839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d138d12-761c-451e-b7e4-acda17b23637" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d31f085d-78c6-46ab-b8cc-8915213e4839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="simple" xlink:href="jnj-20211003.xsd#ConsolidatedStatementsofEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_800470d9-0ac0-4923-a672-2afbbad27800" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_a0e02880-f573-4128-850b-97d1610d3f24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_800470d9-0ac0-4923-a672-2afbbad27800" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_a0e02880-f573-4128-850b-97d1610d3f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="jnj-20211003.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f837fae3-815b-43ab-86e4-173298349b93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5cf9bb67-f5d0-4c4b-9610-b2193d2890b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f837fae3-815b-43ab-86e4-173298349b93" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5cf9bb67-f5d0-4c4b-9610-b2193d2890b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7b06f0a1-1cf7-48ee-bdd6-5138bb008053" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5cf9bb67-f5d0-4c4b-9610-b2193d2890b9" xlink:to="loc_us-gaap_NetIncomeLoss_7b06f0a1-1cf7-48ee-bdd6-5138bb008053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_77dd17f9-949a-4514-8a55-89eb5a448c65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5cf9bb67-f5d0-4c4b-9610-b2193d2890b9" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_77dd17f9-949a-4514-8a55-89eb5a448c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a0d9cdee-a132-4a79-93f1-6c8bc9bbd841" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_77dd17f9-949a-4514-8a55-89eb5a448c65" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a0d9cdee-a132-4a79-93f1-6c8bc9bbd841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2593cf84-cf90-4608-a41b-8c9e1319884d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_77dd17f9-949a-4514-8a55-89eb5a448c65" xlink:to="loc_us-gaap_ShareBasedCompensation_2593cf84-cf90-4608-a41b-8c9e1319884d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_b2abec24-e323-40a2-865f-fbd3fb14e78a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_77dd17f9-949a-4514-8a55-89eb5a448c65" xlink:to="loc_us-gaap_AssetImpairmentCharges_b2abec24-e323-40a2-865f-fbd3fb14e78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_93215a79-b702-4769-930a-e5c3634521f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_77dd17f9-949a-4514-8a55-89eb5a448c65" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_93215a79-b702-4769-930a-e5c3634521f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_be3b90f9-ccef-45ba-bd27-050ea3c2da13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_77dd17f9-949a-4514-8a55-89eb5a448c65" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_be3b90f9-ccef-45ba-bd27-050ea3c2da13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_28440184-2f5f-4639-8840-e12cb65d3fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_77dd17f9-949a-4514-8a55-89eb5a448c65" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_28440184-2f5f-4639-8840-e12cb65d3fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_66b3c1ab-5a6f-4939-a6b3-520c38fcdf89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_77dd17f9-949a-4514-8a55-89eb5a448c65" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_66b3c1ab-5a6f-4939-a6b3-520c38fcdf89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_41d12a90-2145-4cea-874d-37289846cc71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5cf9bb67-f5d0-4c4b-9610-b2193d2890b9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_41d12a90-2145-4cea-874d-37289846cc71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_14232254-421c-410a-a7d5-c5dd2bb4e5dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_41d12a90-2145-4cea-874d-37289846cc71" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_14232254-421c-410a-a7d5-c5dd2bb4e5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_8d9571f0-34bf-4d1f-9a2a-ac45ef1ec800" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_41d12a90-2145-4cea-874d-37289846cc71" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_8d9571f0-34bf-4d1f-9a2a-ac45ef1ec800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7b2af11d-ecb9-4979-835b-b3ffdc54aad5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_41d12a90-2145-4cea-874d-37289846cc71" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7b2af11d-ecb9-4979-835b-b3ffdc54aad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_42c4b101-3c07-4c52-b625-409627cd3076" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_41d12a90-2145-4cea-874d-37289846cc71" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_42c4b101-3c07-4c52-b625-409627cd3076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2059d6ad-a597-4b3f-af72-9106a6351842" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_41d12a90-2145-4cea-874d-37289846cc71" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2059d6ad-a597-4b3f-af72-9106a6351842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_73b61c2c-fdd1-4c68-9980-813e3ad55701" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5cf9bb67-f5d0-4c4b-9610-b2193d2890b9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_73b61c2c-fdd1-4c68-9980-813e3ad55701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_131938b6-e93e-49da-a850-43a6aa25db26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f837fae3-815b-43ab-86e4-173298349b93" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_131938b6-e93e-49da-a850-43a6aa25db26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9a1d5795-9750-42f3-9ce6-f93886023ac0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_131938b6-e93e-49da-a850-43a6aa25db26" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9a1d5795-9750-42f3-9ce6-f93886023ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_3fc8035b-ec17-463e-9019-a3a32726ace9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_131938b6-e93e-49da-a850-43a6aa25db26" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_3fc8035b-ec17-463e-9019-a3a32726ace9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ec057388-6496-4c38-b43a-81dd43849530" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_131938b6-e93e-49da-a850-43a6aa25db26" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ec057388-6496-4c38-b43a-81dd43849530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_7b59b936-e804-4b06-91d3-abfacc197e87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_131938b6-e93e-49da-a850-43a6aa25db26" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_7b59b936-e804-4b06-91d3-abfacc197e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_3e85d5cc-0d15-4c83-a901-f3f9caf7eb52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_131938b6-e93e-49da-a850-43a6aa25db26" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_3e85d5cc-0d15-4c83-a901-f3f9caf7eb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_26e803de-24b2-468a-a69a-1ab7bf9122ea" xlink:href="jnj-20211003.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_131938b6-e93e-49da-a850-43a6aa25db26" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_26e803de-24b2-468a-a69a-1ab7bf9122ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_3b389e3d-5855-4522-abb1-27ad618463ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_131938b6-e93e-49da-a850-43a6aa25db26" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_3b389e3d-5855-4522-abb1-27ad618463ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_41d94ac3-85f6-4b4c-9927-5688eecff9bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_131938b6-e93e-49da-a850-43a6aa25db26" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_41d94ac3-85f6-4b4c-9927-5688eecff9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47468c74-2dcf-466c-a251-4890e3c50da0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f837fae3-815b-43ab-86e4-173298349b93" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47468c74-2dcf-466c-a251-4890e3c50da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_2845bbae-801d-4424-b719-bab2d22aea9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47468c74-2dcf-466c-a251-4890e3c50da0" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_2845bbae-801d-4424-b719-bab2d22aea9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_bc7a937c-c5c5-485c-a9d8-0722f568661f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47468c74-2dcf-466c-a251-4890e3c50da0" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_bc7a937c-c5c5-485c-a9d8-0722f568661f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_cc566c7f-4782-4153-b218-9b96124f7f88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47468c74-2dcf-466c-a251-4890e3c50da0" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_cc566c7f-4782-4153-b218-9b96124f7f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_da415816-d059-45e8-ac97-58a6228ed28b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47468c74-2dcf-466c-a251-4890e3c50da0" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_da415816-d059-45e8-ac97-58a6228ed28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d2ec4853-482d-49e5-aa18-8d45efba1cff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47468c74-2dcf-466c-a251-4890e3c50da0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d2ec4853-482d-49e5-aa18-8d45efba1cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_d9c58ff6-1d4f-47cc-9483-add382361d8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47468c74-2dcf-466c-a251-4890e3c50da0" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_d9c58ff6-1d4f-47cc-9483-add382361d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_b03ea5eb-c922-4c88-b005-24f155e0d07c" xlink:href="jnj-20211003.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47468c74-2dcf-466c-a251-4890e3c50da0" xlink:to="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_b03ea5eb-c922-4c88-b005-24f155e0d07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_3fbdb558-3a8b-4878-a84a-1ea13b7058df" xlink:href="jnj-20211003.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47468c74-2dcf-466c-a251-4890e3c50da0" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_3fbdb558-3a8b-4878-a84a-1ea13b7058df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_7ffeef7b-848a-463a-87ac-3a59dedb4c83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47468c74-2dcf-466c-a251-4890e3c50da0" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_7ffeef7b-848a-463a-87ac-3a59dedb4c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_affa3684-1eb3-4fb8-9b33-5f26cdcd4733" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47468c74-2dcf-466c-a251-4890e3c50da0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_affa3684-1eb3-4fb8-9b33-5f26cdcd4733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_2d63ec9e-51e8-4b22-8188-91d6166ea5ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f837fae3-815b-43ab-86e4-173298349b93" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_2d63ec9e-51e8-4b22-8188-91d6166ea5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e4039726-4bb5-47b9-a8bb-2ac91fae26c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f837fae3-815b-43ab-86e4-173298349b93" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e4039726-4bb5-47b9-a8bb-2ac91fae26c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_34ec5fea-6d66-4ce1-b580-bfa6c5962d8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f837fae3-815b-43ab-86e4-173298349b93" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_34ec5fea-6d66-4ce1-b580-bfa6c5962d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a5599672-7f85-4d97-93a7-d51cda8b4779" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f837fae3-815b-43ab-86e4-173298349b93" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a5599672-7f85-4d97-93a7-d51cda8b4779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_8119c2f2-9ec1-448e-b57b-eec1cc9ef4f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f837fae3-815b-43ab-86e4-173298349b93" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_8119c2f2-9ec1-448e-b57b-eec1cc9ef4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_f1aa3cca-602f-45d6-a44b-97cfff237393" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_8119c2f2-9ec1-448e-b57b-eec1cc9ef4f9" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_f1aa3cca-602f-45d6-a44b-97cfff237393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_45797d2c-e970-41c1-a46e-8bbe020ef3c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_8119c2f2-9ec1-448e-b57b-eec1cc9ef4f9" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_45797d2c-e970-41c1-a46e-8bbe020ef3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_dcb02c31-58f2-4e2a-8dec-44f990bd205f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_8119c2f2-9ec1-448e-b57b-eec1cc9ef4f9" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_dcb02c31-58f2-4e2a-8dec-44f990bd205f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="jnj-20211003.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_de69e23b-62a5-4d9f-a2b9-05c5d59e69f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_beca3f2e-fb2d-4f86-add9-dde4c96d1677" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_de69e23b-62a5-4d9f-a2b9-05c5d59e69f4" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_beca3f2e-fb2d-4f86-add9-dde4c96d1677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="jnj-20211003.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9c32b483-cee0-4e83-8ea9-c978758d0108" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_3646973e-0c19-431e-a0e3-c4adb6f90862" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9c32b483-cee0-4e83-8ea9-c978758d0108" xlink:to="loc_us-gaap_UseOfEstimates_3646973e-0c19-431e-a0e3-c4adb6f90862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_859eb36c-21c0-449d-9de7-352df3b0b0e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9c32b483-cee0-4e83-8ea9-c978758d0108" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_859eb36c-21c0-449d-9de7-352df3b0b0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_32310e8b-f0e6-457a-b60f-304915d75b28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9c32b483-cee0-4e83-8ea9-c978758d0108" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_32310e8b-f0e6-457a-b60f-304915d75b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9125c492-520d-4029-99a6-d404a50e3b18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9c32b483-cee0-4e83-8ea9-c978758d0108" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9125c492-520d-4029-99a6-d404a50e3b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Inventories" xlink:type="simple" xlink:href="jnj-20211003.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_43497a5f-115c-4389-9781-aba1e2f3761d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_090eae7f-378c-4fd9-b33d-fd5449203e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_43497a5f-115c-4389-9781-aba1e2f3761d" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_090eae7f-378c-4fd9-b33d-fd5449203e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesTables" xlink:type="simple" xlink:href="jnj-20211003.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_af4c0c5e-006b-4940-bdf4-dc8b4991837f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_691a064b-4215-4205-aef4-b0a969540755" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_af4c0c5e-006b-4940-bdf4-dc8b4991837f" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_691a064b-4215-4205-aef4-b0a969540755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_2025ec2e-2087-4448-985a-284a6ce37f21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_c237425a-8567-47f1-bb49-9c6f1ca990c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2025ec2e-2087-4448-985a-284a6ce37f21" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_c237425a-8567-47f1-bb49-9c6f1ca990c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_7719c0ed-95e2-446c-9726-6d0fc5d18458" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2025ec2e-2087-4448-985a-284a6ce37f21" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_7719c0ed-95e2-446c-9726-6d0fc5d18458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_dc7a6db3-7a85-4d4a-a656-37db15f78bf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2025ec2e-2087-4448-985a-284a6ce37f21" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_dc7a6db3-7a85-4d4a-a656-37db15f78bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a3423c0a-6b9e-425e-8e26-2eb921f8615a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2025ec2e-2087-4448-985a-284a6ce37f21" xlink:to="loc_us-gaap_InventoryNet_a3423c0a-6b9e-425e-8e26-2eb921f8615a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="jnj-20211003.xsd#IntangibleAssetsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f0acb2ef-0535-4848-8621-0f513120ce66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_3363e5de-f1fc-483c-b606-dd2929aac046" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f0acb2ef-0535-4848-8621-0f513120ce66" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_3363e5de-f1fc-483c-b606-dd2929aac046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="jnj-20211003.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_26cd17ab-b04c-4d0d-b2b8-deeaa2bb137a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_692115af-036e-4fff-9417-ad3f4e09f466" xlink:href="jnj-20211003.xsd#jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_26cd17ab-b04c-4d0d-b2b8-deeaa2bb137a" xlink:to="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_692115af-036e-4fff-9417-ad3f4e09f466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_e56893db-27f5-45bf-8f3c-b63ee5194aaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_26cd17ab-b04c-4d0d-b2b8-deeaa2bb137a" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_e56893db-27f5-45bf-8f3c-b63ee5194aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_18375b55-f93b-4d35-89bf-c9f2b1d20456" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_26cd17ab-b04c-4d0d-b2b8-deeaa2bb137a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_18375b55-f93b-4d35-89bf-c9f2b1d20456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6240238e-5c15-48f4-a98a-561645751b0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_3ecd90b2-03fa-4229-9e19-fb392431f0db" xlink:href="jnj-20211003.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6240238e-5c15-48f4-a98a-561645751b0d" xlink:to="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_3ecd90b2-03fa-4229-9e19-fb392431f0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8d7f1710-b773-4732-a790-fb545ee9d0c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_3ecd90b2-03fa-4229-9e19-fb392431f0db" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8d7f1710-b773-4732-a790-fb545ee9d0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_971fb291-98a9-4e03-b786-69e4ab8ed645" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8d7f1710-b773-4732-a790-fb545ee9d0c1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_971fb291-98a9-4e03-b786-69e4ab8ed645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_e2666e20-a8a6-441f-8ee6-d5f867ab60bf" xlink:href="jnj-20211003.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_971fb291-98a9-4e03-b786-69e4ab8ed645" xlink:to="loc_jnj_PatentsAndTrademarksMember_e2666e20-a8a6-441f-8ee6-d5f867ab60bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_65ba926d-5f06-48ce-8600-6ac2525809b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_971fb291-98a9-4e03-b786-69e4ab8ed645" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_65ba926d-5f06-48ce-8600-6ac2525809b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_57833af1-abda-4398-a11b-77fef206e134" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_971fb291-98a9-4e03-b786-69e4ab8ed645" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_57833af1-abda-4398-a11b-77fef206e134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8bb5a8f9-8294-4662-becd-1a0fc34d3b3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_3ecd90b2-03fa-4229-9e19-fb392431f0db" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8bb5a8f9-8294-4662-becd-1a0fc34d3b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_096747a3-a1d7-4ad1-8012-d1d703f284e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8bb5a8f9-8294-4662-becd-1a0fc34d3b3a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_096747a3-a1d7-4ad1-8012-d1d703f284e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_0d9a4d88-f226-42f2-9f6d-b8a1fd1d7b84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_096747a3-a1d7-4ad1-8012-d1d703f284e6" xlink:to="loc_us-gaap_TrademarksMember_0d9a4d88-f226-42f2-9f6d-b8a1fd1d7b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_cae21cab-3af4-4e30-b522-a209c11463bf" xlink:href="jnj-20211003.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_096747a3-a1d7-4ad1-8012-d1d703f284e6" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_cae21cab-3af4-4e30-b522-a209c11463bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0b87ce93-6d45-408f-8db3-dbbf19ac89a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_3ecd90b2-03fa-4229-9e19-fb392431f0db" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0b87ce93-6d45-408f-8db3-dbbf19ac89a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b440602-bac8-46ec-b2b0-cd6575017cdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0b87ce93-6d45-408f-8db3-dbbf19ac89a9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b440602-bac8-46ec-b2b0-cd6575017cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_1b1f22e4-dd9e-4aae-b5aa-fbb9daa0353f" xlink:href="jnj-20211003.xsd#jnj_AurisHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b440602-bac8-46ec-b2b0-cd6575017cdd" xlink:to="loc_jnj_AurisHealthMember_1b1f22e4-dd9e-4aae-b5aa-fbb9daa0353f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_6474976e-1fca-4f86-bc95-37d0fefb866b" xlink:href="jnj-20211003.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_3ecd90b2-03fa-4229-9e19-fb392431f0db" xlink:to="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_6474976e-1fca-4f86-bc95-37d0fefb866b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_850f0127-e8c2-44f0-9b2e-db7930888f9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_6474976e-1fca-4f86-bc95-37d0fefb866b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_850f0127-e8c2-44f0-9b2e-db7930888f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1b121cdc-95be-495a-a64e-c521be0eb39a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_850f0127-e8c2-44f0-9b2e-db7930888f9d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1b121cdc-95be-495a-a64e-c521be0eb39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c1d26d3d-012f-4817-b1b5-a55aa36f930d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1b121cdc-95be-495a-a64e-c521be0eb39a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c1d26d3d-012f-4817-b1b5-a55aa36f930d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7332935c-0d07-4066-a49e-be7dc0f78589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1b121cdc-95be-495a-a64e-c521be0eb39a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7332935c-0d07-4066-a49e-be7dc0f78589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d16fb97e-8cc5-4318-b7ad-50562b4ab099" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1b121cdc-95be-495a-a64e-c521be0eb39a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d16fb97e-8cc5-4318-b7ad-50562b4ab099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_248bd0b6-1ec7-41ff-9ed6-71a091c6b358" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_850f0127-e8c2-44f0-9b2e-db7930888f9d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_248bd0b6-1ec7-41ff-9ed6-71a091c6b358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2bb126e5-e54f-490b-933e-19b910859377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_248bd0b6-1ec7-41ff-9ed6-71a091c6b358" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2bb126e5-e54f-490b-933e-19b910859377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_69bc50d8-83f3-4e86-aedd-27758b88acb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_248bd0b6-1ec7-41ff-9ed6-71a091c6b358" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_69bc50d8-83f3-4e86-aedd-27758b88acb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_be450af1-1eb0-4adc-b9fb-5b4ad59bfd7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_6474976e-1fca-4f86-bc95-37d0fefb866b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_be450af1-1eb0-4adc-b9fb-5b4ad59bfd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#IntangibleAssetsandGoodwillGoodwillBySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bf53afe0-9010-4751-98ae-e8645e262553" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_9a6310b8-853e-46c5-b896-f2c610a91c53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bf53afe0-9010-4751-98ae-e8645e262553" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_9a6310b8-853e-46c5-b896-f2c610a91c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_33c389db-3d53-4ed9-a38c-67af8784d8fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_9a6310b8-853e-46c5-b896-f2c610a91c53" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_33c389db-3d53-4ed9-a38c-67af8784d8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d26c9930-f152-4631-8358-ec5ee7fa4110" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_33c389db-3d53-4ed9-a38c-67af8784d8fa" xlink:to="loc_us-gaap_SegmentDomain_d26c9930-f152-4631-8358-ec5ee7fa4110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_e73a2031-e017-4330-ad16-ece347ce05c0" xlink:href="jnj-20211003.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d26c9930-f152-4631-8358-ec5ee7fa4110" xlink:to="loc_jnj_ConsumerMember_e73a2031-e017-4330-ad16-ece347ce05c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_9237fdfb-a8de-4e44-a128-86b87f886b3d" xlink:href="jnj-20211003.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d26c9930-f152-4631-8358-ec5ee7fa4110" xlink:to="loc_jnj_PharmaceuticalMember_9237fdfb-a8de-4e44-a128-86b87f886b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_ea54e2c8-7982-4450-8bdf-29a2c3a32e37" xlink:href="jnj-20211003.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d26c9930-f152-4631-8358-ec5ee7fa4110" xlink:to="loc_jnj_MedicalDevicesMember_ea54e2c8-7982-4450-8bdf-29a2c3a32e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_ca1afde1-3560-4a25-847e-9847af208bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_9a6310b8-853e-46c5-b896-f2c610a91c53" xlink:to="loc_us-gaap_GoodwillLineItems_ca1afde1-3560-4a25-847e-9847af208bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_525a964d-77c9-4594-9531-e07885e6e34b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ca1afde1-3560-4a25-847e-9847af208bd2" xlink:to="loc_us-gaap_GoodwillRollForward_525a964d-77c9-4594-9531-e07885e6e34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0c9a5b6e-cd82-4cd8-90db-f7e86e560cb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_525a964d-77c9-4594-9531-e07885e6e34b" xlink:to="loc_us-gaap_Goodwill_0c9a5b6e-cd82-4cd8-90db-f7e86e560cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_331eaa2d-86e5-43b7-a551-90ad13832fb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_525a964d-77c9-4594-9531-e07885e6e34b" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_331eaa2d-86e5-43b7-a551-90ad13832fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_1a24d2c1-d6cd-430a-b56c-0347285b3be8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_525a964d-77c9-4594-9531-e07885e6e34b" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_1a24d2c1-d6cd-430a-b56c-0347285b3be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_d4ed24ea-9201-4b9e-b9d9-38a330fb79f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_525a964d-77c9-4594-9531-e07885e6e34b" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_d4ed24ea-9201-4b9e-b9d9-38a330fb79f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_254b00af-1e7b-417d-bec4-368b8f8157eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_525a964d-77c9-4594-9531-e07885e6e34b" xlink:to="loc_us-gaap_Goodwill_254b00af-1e7b-417d-bec4-368b8f8157eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b979a06e-116a-4c56-86b5-292846192fe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1cdeaf34-fa34-43f4-b0ef-8a081c18ce26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b979a06e-116a-4c56-86b5-292846192fe4" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1cdeaf34-fa34-43f4-b0ef-8a081c18ce26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d43e5e44-e8ad-408b-8a4b-5a7e07d7979e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1cdeaf34-fa34-43f4-b0ef-8a081c18ce26" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d43e5e44-e8ad-408b-8a4b-5a7e07d7979e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7e03dba9-dc72-435a-b2ec-27d31dceb379" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d43e5e44-e8ad-408b-8a4b-5a7e07d7979e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7e03dba9-dc72-435a-b2ec-27d31dceb379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_ac69e194-9253-4e3d-a609-1e116644e86e" xlink:href="jnj-20211003.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7e03dba9-dc72-435a-b2ec-27d31dceb379" xlink:to="loc_jnj_PatentsAndTrademarksMember_ac69e194-9253-4e3d-a609-1e116644e86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_98ca6407-291d-46e1-9e97-7c9557baea99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7e03dba9-dc72-435a-b2ec-27d31dceb379" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_98ca6407-291d-46e1-9e97-7c9557baea99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2fac3ff4-bb7f-47fc-a220-5826e6c34777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1cdeaf34-fa34-43f4-b0ef-8a081c18ce26" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2fac3ff4-bb7f-47fc-a220-5826e6c34777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_84b0525c-278a-4102-85d8-ff5b97beddd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2fac3ff4-bb7f-47fc-a220-5826e6c34777" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_84b0525c-278a-4102-85d8-ff5b97beddd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_704efcb1-5acb-4488-9d3a-59615f8b213b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2fac3ff4-bb7f-47fc-a220-5826e6c34777" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_704efcb1-5acb-4488-9d3a-59615f8b213b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e919341a-4977-4dc1-ad15-ff72ff60ffc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_09fe4b0c-5207-4e36-9a24-51831a74161d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e919341a-4977-4dc1-ad15-ff72ff60ffc1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_09fe4b0c-5207-4e36-9a24-51831a74161d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_be7cf009-51c0-4d33-8f56-f0f4bbed97ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e919341a-4977-4dc1-ad15-ff72ff60ffc1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_be7cf009-51c0-4d33-8f56-f0f4bbed97ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_fb1a0918-0858-4215-a589-9c42c9467476" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e919341a-4977-4dc1-ad15-ff72ff60ffc1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_fb1a0918-0858-4215-a589-9c42c9467476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_fff3f2ce-d196-4155-b57a-9e2fb3c3343d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e919341a-4977-4dc1-ad15-ff72ff60ffc1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_fff3f2ce-d196-4155-b57a-9e2fb3c3343d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d034f9c2-a2a9-4520-aaf1-5c130988dea9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e919341a-4977-4dc1-ad15-ff72ff60ffc1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d034f9c2-a2a9-4520-aaf1-5c130988dea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="jnj-20211003.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9206600f-097d-4dbe-99d6-a87ab06b90e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_3551b305-b0e3-48fb-8d7a-6b4c30ab9bb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9206600f-097d-4dbe-99d6-a87ab06b90e0" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_3551b305-b0e3-48fb-8d7a-6b4c30ab9bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="jnj-20211003.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f41905cd-99ba-41af-8746-ad392e1d745b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_edaa3b78-92e0-4fe2-a20f-cd282c00b52e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f41905cd-99ba-41af-8746-ad392e1d745b" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_edaa3b78-92e0-4fe2-a20f-cd282c00b52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_c99c61ac-4902-45e0-aa8f-d5a6758a8279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f41905cd-99ba-41af-8746-ad392e1d745b" xlink:to="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_c99c61ac-4902-45e0-aa8f-d5a6758a8279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_a2376079-c82b-4122-99d1-649dd453d2a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f41905cd-99ba-41af-8746-ad392e1d745b" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_a2376079-c82b-4122-99d1-649dd453d2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_f1db3e72-12e9-4bab-9351-ff35bd622429" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f41905cd-99ba-41af-8746-ad392e1d745b" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_f1db3e72-12e9-4bab-9351-ff35bd622429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_97a0f822-4770-4f43-893d-5b8f2a66c22a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f41905cd-99ba-41af-8746-ad392e1d745b" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_97a0f822-4770-4f43-893d-5b8f2a66c22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_f42982f8-70a4-40d9-b6cc-9e5ab912557e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f41905cd-99ba-41af-8746-ad392e1d745b" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_f42982f8-70a4-40d9-b6cc-9e5ab912557e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_aeb51c5c-f5ec-4cc0-8cac-4229c87eda58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f41905cd-99ba-41af-8746-ad392e1d745b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_aeb51c5c-f5ec-4cc0-8cac-4229c87eda58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_6575cf06-de3e-4fc2-8f2f-7d238786778a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f41905cd-99ba-41af-8746-ad392e1d745b" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_6575cf06-de3e-4fc2-8f2f-7d238786778a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_631f8e1d-b422-4248-bf70-5327f253f9ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_1a58c633-ee19-4f1b-92a5-02bf65beaf06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_631f8e1d-b422-4248-bf70-5327f253f9ef" xlink:to="loc_us-gaap_DerivativeTable_1a58c633-ee19-4f1b-92a5-02bf65beaf06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_4094d989-0f28-42ce-8244-5bad7f1cc69c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1a58c633-ee19-4f1b-92a5-02bf65beaf06" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_4094d989-0f28-42ce-8244-5bad7f1cc69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_d7dea776-b0b7-459b-a579-40896f0fa4c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_4094d989-0f28-42ce-8244-5bad7f1cc69c" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_d7dea776-b0b7-459b-a579-40896f0fa4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_ebcd462d-155c-43db-bc22-d59a563d9ad6" xlink:href="jnj-20211003.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_d7dea776-b0b7-459b-a579-40896f0fa4c6" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_ebcd462d-155c-43db-bc22-d59a563d9ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_f5dc54d8-80cd-4039-95ca-5476676ed912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1a58c633-ee19-4f1b-92a5-02bf65beaf06" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_f5dc54d8-80cd-4039-95ca-5476676ed912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2e530ea7-a5c4-4a95-9240-4de6d668e011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_f5dc54d8-80cd-4039-95ca-5476676ed912" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2e530ea7-a5c4-4a95-9240-4de6d668e011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_32595d3e-789e-4877-8849-046035ac0f95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2e530ea7-a5c4-4a95-9240-4de6d668e011" xlink:to="loc_us-gaap_EquitySecuritiesMember_32595d3e-789e-4877-8849-046035ac0f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_7bdd7d00-d06c-49e2-973d-1bf13d787507" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1a58c633-ee19-4f1b-92a5-02bf65beaf06" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_7bdd7d00-d06c-49e2-973d-1bf13d787507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_95377d10-cd35-4df9-9bf0-f9d87aa9c860" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7bdd7d00-d06c-49e2-973d-1bf13d787507" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_95377d10-cd35-4df9-9bf0-f9d87aa9c860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_72887246-7bea-48a1-a166-4391155c9372" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_95377d10-cd35-4df9-9bf0-f9d87aa9c860" xlink:to="loc_us-gaap_ForeignExchangeContractMember_72887246-7bea-48a1-a166-4391155c9372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_bddf3b2c-38a6-41a7-9617-8403bf2c8fd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_95377d10-cd35-4df9-9bf0-f9d87aa9c860" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_bddf3b2c-38a6-41a7-9617-8403bf2c8fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_b280da34-f91a-4419-b5ad-3115e27e5128" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_95377d10-cd35-4df9-9bf0-f9d87aa9c860" xlink:to="loc_us-gaap_InterestRateSwapMember_b280da34-f91a-4419-b5ad-3115e27e5128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_8752fad0-1533-42b4-b264-ee0bc5b1d0fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1a58c633-ee19-4f1b-92a5-02bf65beaf06" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_8752fad0-1533-42b4-b264-ee0bc5b1d0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_4ef048bb-3c33-4a7d-b355-0adee9b4874e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_8752fad0-1533-42b4-b264-ee0bc5b1d0fe" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_4ef048bb-3c33-4a7d-b355-0adee9b4874e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_159e7d56-1949-434f-b352-0980ec8e1851" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_4ef048bb-3c33-4a7d-b355-0adee9b4874e" xlink:to="loc_us-gaap_CommercialPaperMember_159e7d56-1949-434f-b352-0980ec8e1851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1a58c633-ee19-4f1b-92a5-02bf65beaf06" xlink:to="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_b6f11d49-d65a-4c2b-9777-58d7d9191667" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_b6f11d49-d65a-4c2b-9777-58d7d9191667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_402b4624-c5fb-44bf-b5f5-ef1292d80ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:to="loc_us-gaap_DerivativeNotionalAmount_402b4624-c5fb-44bf-b5f5-ef1292d80ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_614dad94-3e7b-4b0b-b67b-559bf825e5fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_614dad94-3e7b-4b0b-b67b-559bf825e5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_4da2ce42-dfbe-4719-ad14-5f2b32c9d16b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:to="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_4da2ce42-dfbe-4719-ad14-5f2b32c9d16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_c13e6a54-f923-4f2f-8264-29f2d9f2f4a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:to="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_c13e6a54-f923-4f2f-8264-29f2d9f2f4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_2f1d6015-e1e7-4e12-9146-e08ad66b5444" xlink:href="jnj-20211003.xsd#jnj_EquityFairValueAdjustmentImpairmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:to="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_2f1d6015-e1e7-4e12-9146-e08ad66b5444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_22608e12-3673-4744-a44f-0962cb8b7059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:to="loc_us-gaap_EquityFairValueAdjustment_22608e12-3673-4744-a44f-0962cb8b7059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_65756e08-2706-40fd-8ffb-125bf01725c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:to="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_65756e08-2706-40fd-8ffb-125bf01725c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_de88c9ac-427f-45ed-91c8-78feee4bc9ea" xlink:href="jnj-20211003.xsd#jnj_ExcessOfFairValueOverCarryingValueOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:to="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_de88c9ac-427f-45ed-91c8-78feee4bc9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_feaffe3b-2276-4439-a5f9-288a3dcee234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:to="loc_us-gaap_ShortTermBorrowings_feaffe3b-2276-4439-a5f9-288a3dcee234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_53cf6b8a-f138-4e16-9b6a-afeca45092e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_53cf6b8a-f138-4e16-9b6a-afeca45092e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_6be81074-c91c-42f2-b8f5-b737263b9d57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8c081728-92c1-4d5a-acdd-1826d6d66552" xlink:to="loc_us-gaap_DebtInstrumentTerm_6be81074-c91c-42f2-b8f5-b737263b9d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#FairValueMeasurementsSummaryofDerivativeActivityDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7e230a4e-0c84-484c-ae8f-9299bc2bf2f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_04d56a0e-fdd5-42c9-8880-f624bc402e1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7e230a4e-0c84-484c-ae8f-9299bc2bf2f5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_04d56a0e-fdd5-42c9-8880-f624bc402e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_eb519ee7-b977-4126-8e41-e7733f966078" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_04d56a0e-fdd5-42c9-8880-f624bc402e1c" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_eb519ee7-b977-4126-8e41-e7733f966078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_e920790f-78fc-4000-b5f7-e5fe3c0b4f58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_eb519ee7-b977-4126-8e41-e7733f966078" xlink:to="loc_us-gaap_HedgingRelationshipDomain_e920790f-78fc-4000-b5f7-e5fe3c0b4f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_6ab3eea9-389a-474c-b8d5-0995fd0e299b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e920790f-78fc-4000-b5f7-e5fe3c0b4f58" xlink:to="loc_us-gaap_FairValueHedgingMember_6ab3eea9-389a-474c-b8d5-0995fd0e299b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_9f910468-511d-474b-a229-ad3b165c24a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e920790f-78fc-4000-b5f7-e5fe3c0b4f58" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_9f910468-511d-474b-a229-ad3b165c24a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_c5f5c239-cbe0-4528-ac54-bc0ba4bbc28e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e920790f-78fc-4000-b5f7-e5fe3c0b4f58" xlink:to="loc_us-gaap_CashFlowHedgingMember_c5f5c239-cbe0-4528-ac54-bc0ba4bbc28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5346ffb6-50f0-4e58-8b90-1817b3feffd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_04d56a0e-fdd5-42c9-8880-f624bc402e1c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5346ffb6-50f0-4e58-8b90-1817b3feffd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f7ef988d-1f45-4282-8fd3-43b086e141cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5346ffb6-50f0-4e58-8b90-1817b3feffd0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f7ef988d-1f45-4282-8fd3-43b086e141cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_05c59c5e-28f9-4c56-807e-1d1c31ad5ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f7ef988d-1f45-4282-8fd3-43b086e141cf" xlink:to="loc_us-gaap_InterestRateContractMember_05c59c5e-28f9-4c56-807e-1d1c31ad5ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_821ae202-0703-4167-827b-9f1b8bbe87df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f7ef988d-1f45-4282-8fd3-43b086e141cf" xlink:to="loc_us-gaap_ForeignExchangeContractMember_821ae202-0703-4167-827b-9f1b8bbe87df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_122d1312-43cb-48f4-ad09-83ecefe2a6ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f7ef988d-1f45-4282-8fd3-43b086e141cf" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_122d1312-43cb-48f4-ad09-83ecefe2a6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_e1864b21-3cfb-4206-8d4a-74cf859bd352" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f7ef988d-1f45-4282-8fd3-43b086e141cf" xlink:to="loc_us-gaap_InterestRateSwapMember_e1864b21-3cfb-4206-8d4a-74cf859bd352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_08b7948f-5d35-4100-9f8d-83b29aa7dbd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f7ef988d-1f45-4282-8fd3-43b086e141cf" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_08b7948f-5d35-4100-9f8d-83b29aa7dbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ac0870e2-e4a6-4acc-9559-aa16e3555242" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_04d56a0e-fdd5-42c9-8880-f624bc402e1c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ac0870e2-e4a6-4acc-9559-aa16e3555242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_96b0154d-8243-4c7d-9ba6-2eb6fbf35ba0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ac0870e2-e4a6-4acc-9559-aa16e3555242" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_96b0154d-8243-4c7d-9ba6-2eb6fbf35ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_22fcf29d-0a83-4bc1-8eca-1a105185e9bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_96b0154d-8243-4c7d-9ba6-2eb6fbf35ba0" xlink:to="loc_us-gaap_SalesMember_22fcf29d-0a83-4bc1-8eca-1a105185e9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_ef2a2400-a5db-4dd9-a9b8-ca8b8f9b2056" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_96b0154d-8243-4c7d-9ba6-2eb6fbf35ba0" xlink:to="loc_us-gaap_CostOfSalesMember_ef2a2400-a5db-4dd9-a9b8-ca8b8f9b2056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_60c568a9-f685-40c3-839a-2b2244d5b9ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_96b0154d-8243-4c7d-9ba6-2eb6fbf35ba0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_60c568a9-f685-40c3-839a-2b2244d5b9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_fc392fe0-331d-4429-82fc-b62d9bfdf69a" xlink:href="jnj-20211003.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_96b0154d-8243-4c7d-9ba6-2eb6fbf35ba0" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_fc392fe0-331d-4429-82fc-b62d9bfdf69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember_71e0f866-b0bc-4386-9290-b9ead277b2a6" xlink:href="jnj-20211003.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_96b0154d-8243-4c7d-9ba6-2eb6fbf35ba0" xlink:to="loc_jnj_InterestIncomeExpenseNetMember_71e0f866-b0bc-4386-9290-b9ead277b2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_777abd7c-ea5d-4eab-b0ed-35fa31a7cabe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_04d56a0e-fdd5-42c9-8880-f624bc402e1c" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_777abd7c-ea5d-4eab-b0ed-35fa31a7cabe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_42a8d952-0de6-49e1-bdef-4dda054466c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_777abd7c-ea5d-4eab-b0ed-35fa31a7cabe" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_42a8d952-0de6-49e1-bdef-4dda054466c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_13b92a2e-5200-43ee-b463-78cbb72c1a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_777abd7c-ea5d-4eab-b0ed-35fa31a7cabe" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_13b92a2e-5200-43ee-b463-78cbb72c1a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_aed16be9-121c-4d16-8e45-0592724133e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_777abd7c-ea5d-4eab-b0ed-35fa31a7cabe" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_aed16be9-121c-4d16-8e45-0592724133e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#FairValueMeasurementsDerivativesBalanceSheetLocationDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_033890dc-8193-469c-8ba1-09aa9e9d8e44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_f4ac8e40-e15b-4715-92b1-f89015e8792d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_033890dc-8193-469c-8ba1-09aa9e9d8e44" xlink:to="loc_us-gaap_DerivativeTable_f4ac8e40-e15b-4715-92b1-f89015e8792d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5d8e7952-eb8e-4aa4-8ab8-4de657f10053" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f4ac8e40-e15b-4715-92b1-f89015e8792d" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5d8e7952-eb8e-4aa4-8ab8-4de657f10053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_630850e2-d22e-4d72-a171-1dde4a4c4c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5d8e7952-eb8e-4aa4-8ab8-4de657f10053" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_630850e2-d22e-4d72-a171-1dde4a4c4c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_8dbdf002-1887-4362-bf47-99d09929a0df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_630850e2-d22e-4d72-a171-1dde4a4c4c3d" xlink:to="loc_us-gaap_LongTermDebtMember_8dbdf002-1887-4362-bf47-99d09929a0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_e41e268f-3d1a-4f03-8489-9e4b97edf81d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f4ac8e40-e15b-4715-92b1-f89015e8792d" xlink:to="loc_us-gaap_HedgingDesignationAxis_e41e268f-3d1a-4f03-8489-9e4b97edf81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_5e099449-c10c-4094-8dd6-e42f1285c4eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_e41e268f-3d1a-4f03-8489-9e4b97edf81d" xlink:to="loc_us-gaap_HedgingDesignationDomain_5e099449-c10c-4094-8dd6-e42f1285c4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f49b14da-a45a-4fe1-909d-6602e7c95076" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_5e099449-c10c-4094-8dd6-e42f1285c4eb" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f49b14da-a45a-4fe1-909d-6602e7c95076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_e97cde66-005e-4ead-aa1c-0c6aa4609097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f4ac8e40-e15b-4715-92b1-f89015e8792d" xlink:to="loc_us-gaap_DerivativeLineItems_e97cde66-005e-4ead-aa1c-0c6aa4609097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_c3faa2d1-72bb-4e19-85f0-61768657d2e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e97cde66-005e-4ead-aa1c-0c6aa4609097" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_c3faa2d1-72bb-4e19-85f0-61768657d2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_e1a6c5f2-7d6e-4146-ae7a-6cd96e1a5374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e97cde66-005e-4ead-aa1c-0c6aa4609097" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_e1a6c5f2-7d6e-4146-ae7a-6cd96e1a5374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_439e2a07-c9e9-4b8b-bfbc-8ef79cbd00ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_22159a12-6ff5-4dcc-abcd-4ae33f5eb993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_439e2a07-c9e9-4b8b-bfbc-8ef79cbd00ad" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_22159a12-6ff5-4dcc-abcd-4ae33f5eb993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_689d3e36-e79d-402c-98ad-8ef0f7f3ea88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_22159a12-6ff5-4dcc-abcd-4ae33f5eb993" xlink:to="loc_us-gaap_HedgingDesignationAxis_689d3e36-e79d-402c-98ad-8ef0f7f3ea88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_9b6c3d77-2121-4585-8434-bb42ad08002e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_689d3e36-e79d-402c-98ad-8ef0f7f3ea88" xlink:to="loc_us-gaap_HedgingDesignationDomain_9b6c3d77-2121-4585-8434-bb42ad08002e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_96fea70a-ae13-4ce5-9393-cde2acca1a6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_9b6c3d77-2121-4585-8434-bb42ad08002e" xlink:to="loc_us-gaap_NondesignatedMember_96fea70a-ae13-4ce5-9393-cde2acca1a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6338f688-3494-431e-b6a5-be6b7ab98840" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_22159a12-6ff5-4dcc-abcd-4ae33f5eb993" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6338f688-3494-431e-b6a5-be6b7ab98840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d98cf140-1139-43bb-948b-7138e76eeffd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6338f688-3494-431e-b6a5-be6b7ab98840" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d98cf140-1139-43bb-948b-7138e76eeffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_cadea375-427d-48e4-bc84-2cd994fd7ba3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d98cf140-1139-43bb-948b-7138e76eeffd" xlink:to="loc_us-gaap_ForeignExchangeContractMember_cadea375-427d-48e4-bc84-2cd994fd7ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_df28ad4e-9b52-4e85-97ec-7de11e79470e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_22159a12-6ff5-4dcc-abcd-4ae33f5eb993" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_df28ad4e-9b52-4e85-97ec-7de11e79470e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_18f10df3-1f1c-47a2-bef6-141eb24f98fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_df28ad4e-9b52-4e85-97ec-7de11e79470e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_18f10df3-1f1c-47a2-bef6-141eb24f98fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_4027ac4f-6602-4ea7-ab1c-b3e1e356d6c0" xlink:href="jnj-20211003.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_18f10df3-1f1c-47a2-bef6-141eb24f98fd" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_4027ac4f-6602-4ea7-ab1c-b3e1e356d6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b0e96459-673a-456b-82ef-7649f24cc6a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_22159a12-6ff5-4dcc-abcd-4ae33f5eb993" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b0e96459-673a-456b-82ef-7649f24cc6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_f7e73311-9de6-4a79-a904-0b53a6a5abb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b0e96459-673a-456b-82ef-7649f24cc6a0" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_f7e73311-9de6-4a79-a904-0b53a6a5abb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0bc92672-20ea-41ed-a3b9-ade3d5a7f406" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_67340800-5731-48c2-bcd4-06d188431be0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0bc92672-20ea-41ed-a3b9-ade3d5a7f406" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_67340800-5731-48c2-bcd4-06d188431be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1223e313-db76-4a90-9a8d-c1bc0b514273" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_67340800-5731-48c2-bcd4-06d188431be0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1223e313-db76-4a90-9a8d-c1bc0b514273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ef2a0ca4-0390-4e06-a502-6cca1f355eaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1223e313-db76-4a90-9a8d-c1bc0b514273" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ef2a0ca4-0390-4e06-a502-6cca1f355eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_dbfdda9a-eea9-4689-82d6-f8b02776dd09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ef2a0ca4-0390-4e06-a502-6cca1f355eaf" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_dbfdda9a-eea9-4689-82d6-f8b02776dd09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_758589ae-53ae-4858-8679-c0b8e4cbb783" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_67340800-5731-48c2-bcd4-06d188431be0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_758589ae-53ae-4858-8679-c0b8e4cbb783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cc7d6bcf-9ec0-424f-901f-3972a3f12ee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_758589ae-53ae-4858-8679-c0b8e4cbb783" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cc7d6bcf-9ec0-424f-901f-3972a3f12ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_a9a588cb-1911-4710-b2ec-2c0ddcbfafcd" xlink:href="jnj-20211003.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cc7d6bcf-9ec0-424f-901f-3972a3f12ee9" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_a9a588cb-1911-4710-b2ec-2c0ddcbfafcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_129e3f8e-e823-4646-9154-b9d5ff8bc4f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_67340800-5731-48c2-bcd4-06d188431be0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_129e3f8e-e823-4646-9154-b9d5ff8bc4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_e4d296aa-894e-4385-a786-50f4c66198e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_129e3f8e-e823-4646-9154-b9d5ff8bc4f8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_e4d296aa-894e-4385-a786-50f4c66198e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_90ea76bf-7ab5-401e-9810-a6c1c9c9bdd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_129e3f8e-e823-4646-9154-b9d5ff8bc4f8" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_90ea76bf-7ab5-401e-9810-a6c1c9c9bdd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_45608414-e193-495a-8e26-f23b0a41fe69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_773b03f7-9f6a-4309-9117-f2eff3fd0bc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_45608414-e193-495a-8e26-f23b0a41fe69" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_773b03f7-9f6a-4309-9117-f2eff3fd0bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_7c547c3c-0e6f-488d-b9c3-75e1a3018fca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_773b03f7-9f6a-4309-9117-f2eff3fd0bc1" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_7c547c3c-0e6f-488d-b9c3-75e1a3018fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_56e292e5-f3b8-445e-a0cc-9311e6c47177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_7c547c3c-0e6f-488d-b9c3-75e1a3018fca" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_56e292e5-f3b8-445e-a0cc-9311e6c47177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_55d47fa4-cfce-45d4-a738-7c5120ae3f0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_56e292e5-f3b8-445e-a0cc-9311e6c47177" xlink:to="loc_us-gaap_EquitySecuritiesMember_55d47fa4-cfce-45d4-a738-7c5120ae3f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_687e9a93-81a3-4b8c-96fa-66f6efd0406a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_773b03f7-9f6a-4309-9117-f2eff3fd0bc1" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_687e9a93-81a3-4b8c-96fa-66f6efd0406a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_4c838519-fe95-4af3-9814-e19700fde211" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_687e9a93-81a3-4b8c-96fa-66f6efd0406a" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_4c838519-fe95-4af3-9814-e19700fde211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_1dc57849-b08b-4dce-8de7-28aa372a741a" xlink:href="jnj-20211003.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_4c838519-fe95-4af3-9814-e19700fde211" xlink:to="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_1dc57849-b08b-4dce-8de7-28aa372a741a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_86914d3a-8ef0-4e6c-8317-994709cd6703" xlink:href="jnj-20211003.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_4c838519-fe95-4af3-9814-e19700fde211" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_86914d3a-8ef0-4e6c-8317-994709cd6703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_8bc7ed31-c9bf-4c11-a7f0-96b816b7c3df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_773b03f7-9f6a-4309-9117-f2eff3fd0bc1" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_8bc7ed31-c9bf-4c11-a7f0-96b816b7c3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward_89c29951-950a-46e6-af50-188d581f92cf" xlink:href="jnj-20211003.xsd#jnj_EquityInvestmentRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_8bc7ed31-c9bf-4c11-a7f0-96b816b7c3df" xlink:to="loc_jnj_EquityInvestmentRollForward_89c29951-950a-46e6-af50-188d581f92cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_53f60367-893e-4c60-88c2-bdf1cf03bf3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_89c29951-950a-46e6-af50-188d581f92cf" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_53f60367-893e-4c60-88c2-bdf1cf03bf3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_4370e693-feb8-4244-882c-e9dee892dfa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_89c29951-950a-46e6-af50-188d581f92cf" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_4370e693-feb8-4244-882c-e9dee892dfa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_c7707315-e57e-49b2-98c4-35e63c176c76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_89c29951-950a-46e6-af50-188d581f92cf" xlink:to="loc_us-gaap_EquityFairValueAdjustment_c7707315-e57e-49b2-98c4-35e63c176c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_51aab142-ddab-4b34-8ff2-c97c77df0fa0" xlink:href="jnj-20211003.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_89c29951-950a-46e6-af50-188d581f92cf" xlink:to="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_51aab142-ddab-4b34-8ff2-c97c77df0fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_c1daacf4-9b6d-48ae-9ef5-546af2255ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_89c29951-950a-46e6-af50-188d581f92cf" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_c1daacf4-9b6d-48ae-9ef5-546af2255ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_e6f22caf-52ed-490b-98d4-b00cf9c3d5f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_89c29951-950a-46e6-af50-188d581f92cf" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_e6f22caf-52ed-490b-98d4-b00cf9c3d5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_dd4a6bb2-c795-46b6-872e-6b00b8e9a661" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_89c29951-950a-46e6-af50-188d581f92cf" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_dd4a6bb2-c795-46b6-872e-6b00b8e9a661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d22124b5-06a7-4901-8459-1a6c2cd1f400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_bcaa02af-d4f4-4775-8d93-5b41bfe4f4c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d22124b5-06a7-4901-8459-1a6c2cd1f400" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_bcaa02af-d4f4-4775-8d93-5b41bfe4f4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_0008f335-e12d-4cf1-b826-532bfe47c561" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_bcaa02af-d4f4-4775-8d93-5b41bfe4f4c3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_0008f335-e12d-4cf1-b826-532bfe47c561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3821ad88-2904-4581-87bc-ad76d6d42006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0008f335-e12d-4cf1-b826-532bfe47c561" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3821ad88-2904-4581-87bc-ad76d6d42006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_f2c731a8-e96f-4264-a07d-bab8eddcb64a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3821ad88-2904-4581-87bc-ad76d6d42006" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_f2c731a8-e96f-4264-a07d-bab8eddcb64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_bf1fb724-bf3b-4903-875e-851527fea262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3821ad88-2904-4581-87bc-ad76d6d42006" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_bf1fb724-bf3b-4903-875e-851527fea262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_ebeb3046-c1eb-46e3-bd24-817fb69fd9eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3821ad88-2904-4581-87bc-ad76d6d42006" xlink:to="loc_us-gaap_LongTermDebtMember_ebeb3046-c1eb-46e3-bd24-817fb69fd9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_be96e1f1-63d2-43b3-abaa-dfcb41768201" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_bcaa02af-d4f4-4775-8d93-5b41bfe4f4c3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_be96e1f1-63d2-43b3-abaa-dfcb41768201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a7c4ce78-281c-4967-838b-92f305941654" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_be96e1f1-63d2-43b3-abaa-dfcb41768201" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a7c4ce78-281c-4967-838b-92f305941654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_9919600d-bdf0-469b-aff2-90ed8e9653de" xlink:href="jnj-20211003.xsd#jnj_AurisHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a7c4ce78-281c-4967-838b-92f305941654" xlink:to="loc_jnj_AurisHealthMember_9919600d-bdf0-469b-aff2-90ed8e9653de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_4c9fc6a3-f492-450f-8eb2-2c5965895f3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_bcaa02af-d4f4-4775-8d93-5b41bfe4f4c3" xlink:to="loc_us-gaap_InvestmentTypeAxis_4c9fc6a3-f492-450f-8eb2-2c5965895f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b6cd49d2-f6d6-42b2-a391-0240f7637368" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_4c9fc6a3-f492-450f-8eb2-2c5965895f3f" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b6cd49d2-f6d6-42b2-a391-0240f7637368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_33915c06-e13c-4c3c-a86e-a1d798a81f11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b6cd49d2-f6d6-42b2-a391-0240f7637368" xlink:to="loc_us-gaap_EquitySecuritiesMember_33915c06-e13c-4c3c-a86e-a1d798a81f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_09bd8608-acfc-4bfd-a79f-8e7246a56d72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_bcaa02af-d4f4-4775-8d93-5b41bfe4f4c3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_09bd8608-acfc-4bfd-a79f-8e7246a56d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c3e1d986-e8bc-4cf7-b102-ddebb39141d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_09bd8608-acfc-4bfd-a79f-8e7246a56d72" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c3e1d986-e8bc-4cf7-b102-ddebb39141d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_f5cb46c3-0048-4a14-9d18-0f764a52434d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c3e1d986-e8bc-4cf7-b102-ddebb39141d9" xlink:to="loc_us-gaap_InterestRateContractMember_f5cb46c3-0048-4a14-9d18-0f764a52434d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_866743d6-618b-45d9-8113-830f57d3d63f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c3e1d986-e8bc-4cf7-b102-ddebb39141d9" xlink:to="loc_us-gaap_ForeignExchangeContractMember_866743d6-618b-45d9-8113-830f57d3d63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_7d5b908b-f6fc-4a2d-aef5-1e4302b05818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c3e1d986-e8bc-4cf7-b102-ddebb39141d9" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_7d5b908b-f6fc-4a2d-aef5-1e4302b05818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3688be16-66fc-431c-ac7a-bedee3b76e9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_bcaa02af-d4f4-4775-8d93-5b41bfe4f4c3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3688be16-66fc-431c-ac7a-bedee3b76e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49a4fdb9-9ddf-4766-af7b-1445a3c695de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3688be16-66fc-431c-ac7a-bedee3b76e9a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49a4fdb9-9ddf-4766-af7b-1445a3c695de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d8086fd9-9df2-4ae1-aac2-ca70793ecfa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49a4fdb9-9ddf-4766-af7b-1445a3c695de" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d8086fd9-9df2-4ae1-aac2-ca70793ecfa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2a6d7f76-2cc2-498a-b04a-5950c4dcc262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49a4fdb9-9ddf-4766-af7b-1445a3c695de" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2a6d7f76-2cc2-498a-b04a-5950c4dcc262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6a3ceeb3-3c92-4d19-871f-ff62c3feccbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49a4fdb9-9ddf-4766-af7b-1445a3c695de" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6a3ceeb3-3c92-4d19-871f-ff62c3feccbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_36b2e3f9-da47-4247-a0f8-8409915ea08e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_bcaa02af-d4f4-4775-8d93-5b41bfe4f4c3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_36b2e3f9-da47-4247-a0f8-8409915ea08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_593e3260-fa90-44e7-b7fd-dfe384f9fee2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_36b2e3f9-da47-4247-a0f8-8409915ea08e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_593e3260-fa90-44e7-b7fd-dfe384f9fee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_780cfe20-3e95-4b39-bb10-9336a30d91eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_593e3260-fa90-44e7-b7fd-dfe384f9fee2" xlink:to="loc_us-gaap_FairValueHedgingMember_780cfe20-3e95-4b39-bb10-9336a30d91eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_bcaa02af-d4f4-4775-8d93-5b41bfe4f4c3" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_98a678b5-100e-4ef8-ae08-b46beefe1a28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:to="loc_us-gaap_DerivativeInstrumentDetailAbstract_98a678b5-100e-4ef8-ae08-b46beefe1a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_bd85ce60-d459-4ce3-916f-997cc5763f13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_98a678b5-100e-4ef8-ae08-b46beefe1a28" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_bd85ce60-d459-4ce3-916f-997cc5763f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_353f8f12-069d-44d3-9869-0c8dd0da76e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_98a678b5-100e-4ef8-ae08-b46beefe1a28" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_353f8f12-069d-44d3-9869-0c8dd0da76e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_10b92694-3b56-4464-980f-8edc53b70572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_98a678b5-100e-4ef8-ae08-b46beefe1a28" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_10b92694-3b56-4464-980f-8edc53b70572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_7c414e90-636e-4d9d-91df-b3429f8ae474" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_98a678b5-100e-4ef8-ae08-b46beefe1a28" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_7c414e90-636e-4d9d-91df-b3429f8ae474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_f58530cf-7749-4437-8e0c-453b44756f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_98a678b5-100e-4ef8-ae08-b46beefe1a28" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_f58530cf-7749-4437-8e0c-453b44756f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bf15d2d5-2536-4503-87a5-19f4c014ce8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_98a678b5-100e-4ef8-ae08-b46beefe1a28" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bf15d2d5-2536-4503-87a5-19f4c014ce8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5ef4e6fd-bf12-404c-8db0-0e1b51212c97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_98a678b5-100e-4ef8-ae08-b46beefe1a28" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5ef4e6fd-bf12-404c-8db0-0e1b51212c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_8943c2db-2186-46dc-b863-4c3239133f17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_8943c2db-2186-46dc-b863-4c3239133f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_569bfc80-d3b2-4093-82d2-24772f124023" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_569bfc80-d3b2-4093-82d2-24772f124023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_3959f502-a485-462e-b824-7a82632ecc6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:to="loc_us-gaap_DerivativeAssets_3959f502-a485-462e-b824-7a82632ecc6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_9e35808e-367c-47ab-a817-33ede6ea7238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_9e35808e-367c-47ab-a817-33ede6ea7238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_8fe62650-ade1-435b-a53c-dd28b576b66f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_8fe62650-ade1-435b-a53c-dd28b576b66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_297d9c74-d0d7-4edc-87ac-7f2b5e182747" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:to="loc_us-gaap_DerivativeLiabilities_297d9c74-d0d7-4edc-87ac-7f2b5e182747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5a58cedb-c4a8-448c-961e-ba8e3235a893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5a58cedb-c4a8-448c-961e-ba8e3235a893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_bd7d224f-1f88-4ccf-ba41-39b47bfbd143" xlink:href="jnj-20211003.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:to="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_bd7d224f-1f88-4ccf-ba41-39b47bfbd143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_7ab5fd3b-cabd-466f-beab-326d78630376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_7ab5fd3b-cabd-466f-beab-326d78630376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_b72fd834-7b03-41ba-a686-ec73f65aa9ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_b72fd834-7b03-41ba-a686-ec73f65aa9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2f601f11-bc18-47d5-b32c-415096000fea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2f601f11-bc18-47d5-b32c-415096000fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e04e8846-2059-48a3-89f3-868472593b78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec4aded3-91e2-4bae-9815-a522a2cda8e8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e04e8846-2059-48a3-89f3-868472593b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d997c51b-1131-4bc9-956b-828b8731284a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4a9db243-0f66-4566-b7b6-46b444a36f37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d997c51b-1131-4bc9-956b-828b8731284a" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4a9db243-0f66-4566-b7b6-46b444a36f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_2fb6b942-b654-436d-a8ed-8ca5684dbce7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4a9db243-0f66-4566-b7b6-46b444a36f37" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_2fb6b942-b654-436d-a8ed-8ca5684dbce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_cda19875-eda2-49cd-83ff-788f792a2bb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_2fb6b942-b654-436d-a8ed-8ca5684dbce7" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_cda19875-eda2-49cd-83ff-788f792a2bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember_d860b5ea-3972-4990-9162-e9143abe46ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_cda19875-eda2-49cd-83ff-788f792a2bb6" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesMember_d860b5ea-3972-4990-9162-e9143abe46ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_7cb302aa-e15d-4aea-a310-144a2c6e9068" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_cda19875-eda2-49cd-83ff-788f792a2bb6" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_7cb302aa-e15d-4aea-a310-144a2c6e9068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_3a551a1c-8c7f-4bf2-9801-86cde62012e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4a9db243-0f66-4566-b7b6-46b444a36f37" xlink:to="loc_us-gaap_InvestmentTypeAxis_3a551a1c-8c7f-4bf2-9801-86cde62012e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_93546ba6-b98e-47be-acfc-fb942549a96a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_3a551a1c-8c7f-4bf2-9801-86cde62012e1" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_93546ba6-b98e-47be-acfc-fb942549a96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_1fe27e86-8131-4fb7-86aa-421016d9568b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_93546ba6-b98e-47be-acfc-fb942549a96a" xlink:to="loc_us-gaap_CashMember_1fe27e86-8131-4fb7-86aa-421016d9568b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_ff1140d0-ff7f-4b3b-bfa3-3f4fa5047852" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_93546ba6-b98e-47be-acfc-fb942549a96a" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_ff1140d0-ff7f-4b3b-bfa3-3f4fa5047852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_95d75016-dba2-49c4-afb0-eb8683c86dfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_93546ba6-b98e-47be-acfc-fb942549a96a" xlink:to="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_95d75016-dba2-49c4-afb0-eb8683c86dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_52c7fa5b-2896-41b9-84ad-cb890ed3d68b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_93546ba6-b98e-47be-acfc-fb942549a96a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_52c7fa5b-2896-41b9-84ad-cb890ed3d68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_64945405-10fd-4e4b-a533-d3591fdecc1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_93546ba6-b98e-47be-acfc-fb942549a96a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_64945405-10fd-4e4b-a533-d3591fdecc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_aaac3c7d-4af5-4a13-a2a5-3ed0926a0b65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_93546ba6-b98e-47be-acfc-fb942549a96a" xlink:to="loc_us-gaap_BankTimeDepositsMember_aaac3c7d-4af5-4a13-a2a5-3ed0926a0b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_0766b693-51da-4a71-a3dd-359a4979fb0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_93546ba6-b98e-47be-acfc-fb942549a96a" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_0766b693-51da-4a71-a3dd-359a4979fb0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_29ad7040-cd58-4493-8c3a-9900d43c2ceb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4a9db243-0f66-4566-b7b6-46b444a36f37" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_29ad7040-cd58-4493-8c3a-9900d43c2ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_774c55c3-8a36-4561-8bdd-1fa6b8a65811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_29ad7040-cd58-4493-8c3a-9900d43c2ceb" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_774c55c3-8a36-4561-8bdd-1fa6b8a65811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_e03df6cf-0db9-438a-9c73-352ce872ef1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_774c55c3-8a36-4561-8bdd-1fa6b8a65811" xlink:to="loc_us-gaap_HeldToMaturitySecurities_e03df6cf-0db9-438a-9c73-352ce872ef1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_0a029f94-9d24-4e43-a38d-148618be0050" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_774c55c3-8a36-4561-8bdd-1fa6b8a65811" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_0a029f94-9d24-4e43-a38d-148618be0050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_40905ed5-7a98-4af5-8e89-288fb717f40a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_774c55c3-8a36-4561-8bdd-1fa6b8a65811" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_40905ed5-7a98-4af5-8e89-288fb717f40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_529ab353-1a0b-48a3-8ecb-770e576c5ffe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_774c55c3-8a36-4561-8bdd-1fa6b8a65811" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_529ab353-1a0b-48a3-8ecb-770e576c5ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_709a1cfd-ef99-4afc-9343-6a1d0e52501a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_29ad7040-cd58-4493-8c3a-9900d43c2ceb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_709a1cfd-ef99-4afc-9343-6a1d0e52501a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_67893e2b-c701-48da-88c2-245083bfb544" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_709a1cfd-ef99-4afc-9343-6a1d0e52501a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_67893e2b-c701-48da-88c2-245083bfb544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_445d8124-d209-4914-8d31-cbf5451b4d7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_709a1cfd-ef99-4afc-9343-6a1d0e52501a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_445d8124-d209-4914-8d31-cbf5451b4d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d7bf5265-ab5d-4d85-9fa5-a9f06b5c80a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_709a1cfd-ef99-4afc-9343-6a1d0e52501a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d7bf5265-ab5d-4d85-9fa5-a9f06b5c80a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e354b404-d4cc-4aba-b93d-dbc2cdef9a0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_709a1cfd-ef99-4afc-9343-6a1d0e52501a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e354b404-d4cc-4aba-b93d-dbc2cdef9a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a65eae78-d34a-415b-8def-7aa7f3872a36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_29ad7040-cd58-4493-8c3a-9900d43c2ceb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a65eae78-d34a-415b-8def-7aa7f3872a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_67cb193f-bd09-42c7-ad0f-ce988004e288" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a65eae78-d34a-415b-8def-7aa7f3872a36" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_67cb193f-bd09-42c7-ad0f-ce988004e288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_1f911040-b19a-4f8a-8e2e-60cb643ad925" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a65eae78-d34a-415b-8def-7aa7f3872a36" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_1f911040-b19a-4f8a-8e2e-60cb643ad925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_548d67fc-bc1a-4e5d-a439-e5b4a4905c81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a65eae78-d34a-415b-8def-7aa7f3872a36" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_548d67fc-bc1a-4e5d-a439-e5b4a4905c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain_b5c85b05-b893-4b71-9379-684951377573" xlink:href="jnj-20211003.xsd#jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a65eae78-d34a-415b-8def-7aa7f3872a36" xlink:to="loc_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain_b5c85b05-b893-4b71-9379-684951377573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_6429de39-451d-4d3a-a2db-6043f31a3fa6" xlink:href="jnj-20211003.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a65eae78-d34a-415b-8def-7aa7f3872a36" xlink:to="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_6429de39-451d-4d3a-a2db-6043f31a3fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_2632928a-7d99-4a75-a416-d8d91265db0a" xlink:href="jnj-20211003.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a65eae78-d34a-415b-8def-7aa7f3872a36" xlink:to="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_2632928a-7d99-4a75-a416-d8d91265db0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9bbb28d5-20a4-4ce3-8465-13a3aa948a71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_097348fd-f54b-4ecf-ade9-728b6793065f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9bbb28d5-20a4-4ce3-8465-13a3aa948a71" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_097348fd-f54b-4ecf-ade9-728b6793065f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_ceea3efd-1b05-4d70-8fec-470b07227bc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_097348fd-f54b-4ecf-ade9-728b6793065f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_ceea3efd-1b05-4d70-8fec-470b07227bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_e68e996d-1fea-4fd4-ad8e-e88ebed0e5bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_097348fd-f54b-4ecf-ade9-728b6793065f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_e68e996d-1fea-4fd4-ad8e-e88ebed0e5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_67230001-7a56-4dbc-b725-790aed53630b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_097348fd-f54b-4ecf-ade9-728b6793065f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_67230001-7a56-4dbc-b725-790aed53630b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_8616e13f-29be-4680-bdbd-83bf815a2918" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_097348fd-f54b-4ecf-ade9-728b6793065f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_8616e13f-29be-4680-bdbd-83bf815a2918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_8041e13f-aa01-4c45-906f-011e0423838e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9bbb28d5-20a4-4ce3-8465-13a3aa948a71" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_8041e13f-aa01-4c45-906f-011e0423838e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_f7195c7d-53f0-4d74-9f31-a3b0e8f4e6a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_8041e13f-aa01-4c45-906f-011e0423838e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_f7195c7d-53f0-4d74-9f31-a3b0e8f4e6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6f01bd2d-9f92-4d01-8dc4-8d69bc6bd623" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_8041e13f-aa01-4c45-906f-011e0423838e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6f01bd2d-9f92-4d01-8dc4-8d69bc6bd623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_92dd86cd-241e-4aaf-9009-b7860a52313f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_8041e13f-aa01-4c45-906f-011e0423838e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_92dd86cd-241e-4aaf-9009-b7860a52313f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_71dfaf0e-ef4d-4ce5-a002-2852b08431ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_8041e13f-aa01-4c45-906f-011e0423838e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_71dfaf0e-ef4d-4ce5-a002-2852b08431ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9914e64b-0bdc-4a5a-8422-6f011c496405" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6e0913fa-e6e3-4404-b1a0-6142c6937514" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9914e64b-0bdc-4a5a-8422-6f011c496405" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6e0913fa-e6e3-4404-b1a0-6142c6937514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_cf922e00-e4ad-431d-9116-55a6803e415e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6e0913fa-e6e3-4404-b1a0-6142c6937514" xlink:to="loc_us-gaap_DebtInstrumentAxis_cf922e00-e4ad-431d-9116-55a6803e415e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_cf922e00-e4ad-431d-9116-55a6803e415e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.73Debenturesdue2023Member_33df69a0-6436-4090-8d53-e1a847086e69" xlink:href="jnj-20211003.xsd#jnj_A6.73Debenturesdue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A6.73Debenturesdue2023Member_33df69a0-6436-4090-8d53-e1a847086e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.375Notesdue2023Member_95916773-8a7f-46b4-ba8b-4f6e37738e94" xlink:href="jnj-20211003.xsd#jnj_A3.375Notesdue2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A3.375Notesdue2023Member_95916773-8a7f-46b4-ba8b-4f6e37738e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.05Notesdue2023Member_57d659a5-b788-4e20-974e-012ef4ac32d0" xlink:href="jnj-20211003.xsd#jnj_A2.05Notesdue2023Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A2.05Notesdue2023Member_57d659a5-b788-4e20-974e-012ef4ac32d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_5b561c19-e110-4fd3-83c5-aa41ab0a4ae3" xlink:href="jnj-20211003.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A0.650NotesDue2024Member_5b561c19-e110-4fd3-83c5-aa41ab0a4ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_e0251ebf-5fc0-4365-8d8c-e94cdadb716c" xlink:href="jnj-20211003.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A5.50NotesDue2024Member_e0251ebf-5fc0-4365-8d8c-e94cdadb716c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member_f1ed3c00-2041-4feb-b133-7beb857f793c" xlink:href="jnj-20211003.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A2.625Notesdue2025Member_f1ed3c00-2041-4feb-b133-7beb857f793c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0550NotesDue2025Member_86eb1112-14e1-47f9-8c97-ffa99d4560c9" xlink:href="jnj-20211003.xsd#jnj_A0550NotesDue2025Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A0550NotesDue2025Member_86eb1112-14e1-47f9-8c97-ffa99d4560c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member_89508d5f-d745-4a0a-9194-915ae4ee5677" xlink:href="jnj-20211003.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A2.45Notesdue2026Member_89508d5f-d745-4a0a-9194-915ae4ee5677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member_02e3c641-50ba-4d24-a8e4-cfec0181e6ad" xlink:href="jnj-20211003.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A2.95Notesdue2027Member_02e3c641-50ba-4d24-a8e4-cfec0181e6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member_f675bb74-cce4-4c0d-ab80-36ef982cbd76" xlink:href="jnj-20211003.xsd#jnj_A095NotesDue2027Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A095NotesDue2027Member_f675bb74-cce4-4c0d-ab80-36ef982cbd76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member_54e8ca39-11ab-4680-af64-f2b76eda3549" xlink:href="jnj-20211003.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A2.900Notesdue2028Member_54e8ca39-11ab-4680-af64-f2b76eda3549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_965d4b17-8fb8-4191-9c44-437c20cadd20" xlink:href="jnj-20211003.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A1.150NotesDue2028Member_965d4b17-8fb8-4191-9c44-437c20cadd20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member_1cbe4ba2-503c-4dc3-856a-0f7dd5f01d95" xlink:href="jnj-20211003.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A6.95Notesdue2029Member_1cbe4ba2-503c-4dc3-856a-0f7dd5f01d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1300NotesDue2030Member_6f2700ed-1987-495e-8a13-932314fc1ec9" xlink:href="jnj-20211003.xsd#jnj_A1300NotesDue2030Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A1300NotesDue2030Member_6f2700ed-1987-495e-8a13-932314fc1ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member_a06a4fcf-1d11-4cf2-8da6-dde99212639b" xlink:href="jnj-20211003.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A4.95Debenturesdue2033Member_a06a4fcf-1d11-4cf2-8da6-dde99212639b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member_2e33e7bf-70e5-455c-9f3a-ef5f8bc1ac26" xlink:href="jnj-20211003.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A4.375Notesdue2033Member_2e33e7bf-70e5-455c-9f3a-ef5f8bc1ac26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_e0cf2600-c9a3-4a91-bfae-09382f1ce0ef" xlink:href="jnj-20211003.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A1.650NotesDue2035Member_e0cf2600-c9a3-4a91-bfae-09382f1ce0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member_405c7ffb-20cc-4f7d-8260-6892520e58d8" xlink:href="jnj-20211003.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A3.55Notesdue2036Member_405c7ffb-20cc-4f7d-8260-6892520e58d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member_c73c1a9a-2e02-49a8-be69-d16e2749ac8f" xlink:href="jnj-20211003.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A5.95Notesdue2037Member_c73c1a9a-2e02-49a8-be69-d16e2749ac8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member_b9ddcf07-4c73-41f2-ac02-5fbf52dfe63e" xlink:href="jnj-20211003.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A3.625Notesdue2037Member_b9ddcf07-4c73-41f2-ac02-5fbf52dfe63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member_ed2ccd0a-458c-45a4-9214-0f0498f2d44d" xlink:href="jnj-20211003.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A3.400Notesdue2038Member_ed2ccd0a-458c-45a4-9214-0f0498f2d44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member_f028a8d7-cdde-47b3-90c6-14a02ab95b22" xlink:href="jnj-20211003.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A5.85Debenturesdue2038Member_f028a8d7-cdde-47b3-90c6-14a02ab95b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member_fa77787c-5413-4898-aeab-9cf33e0f89d7" xlink:href="jnj-20211003.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A4.50Debenturesdue2040Member_fa77787c-5413-4898-aeab-9cf33e0f89d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member_29ee055e-72ea-4115-886e-a51c0fe5535d" xlink:href="jnj-20211003.xsd#jnj_A210NotesDue2040Member"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A210NotesDue2040Member_29ee055e-72ea-4115-886e-a51c0fe5535d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member_d4f8c799-2735-4bce-a245-aff4362d8d76" xlink:href="jnj-20211003.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A4.85Notesdue2041Member_d4f8c799-2735-4bce-a245-aff4362d8d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member_8bfa5db1-2884-4fb0-9b6f-7f333ff5c415" xlink:href="jnj-20211003.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A4.50Notesdue2043Member_8bfa5db1-2884-4fb0-9b6f-7f333ff5c415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member_4928c7ba-785a-41c7-bbcd-edf9f3492561" xlink:href="jnj-20211003.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A3.70Notesdue2046Member_4928c7ba-785a-41c7-bbcd-edf9f3492561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member_00a8bd07-83c5-4d14-8d56-48b089ce48ed" xlink:href="jnj-20211003.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A3.75Notesdue2047Member_00a8bd07-83c5-4d14-8d56-48b089ce48ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member_18d11fa4-b397-40be-a1c3-b8609ed55ecb" xlink:href="jnj-20211003.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A3.500Notesdue2048Member_18d11fa4-b397-40be-a1c3-b8609ed55ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member_0e789407-224d-4008-b5cb-95c3ec85ebbb" xlink:href="jnj-20211003.xsd#jnj_A2250NotesDue2050Member"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A2250NotesDue2050Member_0e789407-224d-4008-b5cb-95c3ec85ebbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member_65736d29-0b11-43e3-abd0-577b09689d7e" xlink:href="jnj-20211003.xsd#jnj_A2450NotesDue2060Member"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_A2450NotesDue2060Member_65736d29-0b11-43e3-abd0-577b09689d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NotesDuePeriodFifteenMember_c69c5cab-ecfa-4735-a0c4-1259e883b555" xlink:href="jnj-20211003.xsd#jnj_NotesDuePeriodFifteenMember"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06a72b47-95be-4399-986a-84bde238c615" xlink:to="loc_jnj_NotesDuePeriodFifteenMember_c69c5cab-ecfa-4735-a0c4-1259e883b555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_610afdf3-116c-436e-87ea-bb63c5476fa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6e0913fa-e6e3-4404-b1a0-6142c6937514" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_610afdf3-116c-436e-87ea-bb63c5476fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1ebed742-1b4a-4f08-804d-7a8f54e3009b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_610afdf3-116c-436e-87ea-bb63c5476fa0" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1ebed742-1b4a-4f08-804d-7a8f54e3009b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_27af0e5a-fe1b-4f89-b874-bfb5b2ef5b81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1ebed742-1b4a-4f08-804d-7a8f54e3009b" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_27af0e5a-fe1b-4f89-b874-bfb5b2ef5b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_35cb9c08-45ad-4203-bb28-a728f509b74c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_27af0e5a-fe1b-4f89-b874-bfb5b2ef5b81" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_35cb9c08-45ad-4203-bb28-a728f509b74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_611d3fd4-66d0-4e34-856d-e07e9539bc04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_27af0e5a-fe1b-4f89-b874-bfb5b2ef5b81" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_611d3fd4-66d0-4e34-856d-e07e9539bc04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5c40de7e-8545-46da-864d-5288b317a298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6e0913fa-e6e3-4404-b1a0-6142c6937514" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5c40de7e-8545-46da-864d-5288b317a298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_c14db281-0b75-4d15-bd35-19eeaf2d9258" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5c40de7e-8545-46da-864d-5288b317a298" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_c14db281-0b75-4d15-bd35-19eeaf2d9258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_7be06387-0451-410e-9ec9-5144244224fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_c14db281-0b75-4d15-bd35-19eeaf2d9258" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_7be06387-0451-410e-9ec9-5144244224fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_5959c4ae-1162-4ac3-9ca1-7a35f4a928e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_7be06387-0451-410e-9ec9-5144244224fd" xlink:to="loc_us-gaap_ShortTermBorrowings_5959c4ae-1162-4ac3-9ca1-7a35f4a928e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_1adb6a21-5f90-418d-977d-f001fc53f170" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_c14db281-0b75-4d15-bd35-19eeaf2d9258" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_1adb6a21-5f90-418d-977d-f001fc53f170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_cd34224e-f8c0-45fc-8084-9129a417b6f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_1adb6a21-5f90-418d-977d-f001fc53f170" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_cd34224e-f8c0-45fc-8084-9129a417b6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dd24427f-c35a-49fa-83b2-79504774d2d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_c14db281-0b75-4d15-bd35-19eeaf2d9258" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dd24427f-c35a-49fa-83b2-79504774d2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxes" xlink:type="simple" xlink:href="jnj-20211003.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_36ce8001-d1b5-4d7d-ad83-466647d6151d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_3ebb8d76-8705-4b47-b5fa-7d1a26bce906" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_36ce8001-d1b5-4d7d-ad83-466647d6151d" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_3ebb8d76-8705-4b47-b5fa-7d1a26bce906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f9b74882-571c-427f-866b-a54247906540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_30d57b9e-afc0-4624-ab6e-52afe57f9316" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f9b74882-571c-427f-866b-a54247906540" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_30d57b9e-afc0-4624-ab6e-52afe57f9316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f3c12a9d-cfd0-4b1d-b4ca-0601581eeba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_30d57b9e-afc0-4624-ab6e-52afe57f9316" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f3c12a9d-cfd0-4b1d-b4ca-0601581eeba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_61aa120d-5f06-4a68-bf66-10309a645a52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f3c12a9d-cfd0-4b1d-b4ca-0601581eeba6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_61aa120d-5f06-4a68-bf66-10309a645a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_8d175bab-458c-4bd5-9f7e-c732b52e01ce" xlink:href="jnj-20211003.xsd#jnj_AurisHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_61aa120d-5f06-4a68-bf66-10309a645a52" xlink:to="loc_jnj_AurisHealthMember_8d175bab-458c-4bd5-9f7e-c732b52e01ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_859dc4b3-c6a8-43f1-a961-7bb73ac79be7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_30d57b9e-afc0-4624-ab6e-52afe57f9316" xlink:to="loc_srt_LitigationCaseAxis_859dc4b3-c6a8-43f1-a961-7bb73ac79be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_aff67556-adaf-4d09-99d6-a7ec9e6a36be" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_859dc4b3-c6a8-43f1-a961-7bb73ac79be7" xlink:to="loc_srt_LitigationCaseTypeDomain_aff67556-adaf-4d09-99d6-a7ec9e6a36be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_7e32c4a8-6dc6-4da8-9c73-c31144b2e63a" xlink:href="jnj-20211003.xsd#jnj_BabyPowderMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_aff67556-adaf-4d09-99d6-a7ec9e6a36be" xlink:to="loc_jnj_BabyPowderMember_7e32c4a8-6dc6-4da8-9c73-c31144b2e63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_029281e6-02a3-46ed-9371-4eb6e6b02f3c" xlink:href="jnj-20211003.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_aff67556-adaf-4d09-99d6-a7ec9e6a36be" xlink:to="loc_jnj_RisperdalMember_029281e6-02a3-46ed-9371-4eb6e6b02f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_94e28128-beb5-4fc7-86c9-5edc69b77499" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_30d57b9e-afc0-4624-ab6e-52afe57f9316" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_94e28128-beb5-4fc7-86c9-5edc69b77499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_30652530-7f5b-450c-ad14-e15ee58c788d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_94e28128-beb5-4fc7-86c9-5edc69b77499" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_30652530-7f5b-450c-ad14-e15ee58c788d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_bd6a6fca-6c4d-495c-8617-d84c24e7ff72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_30652530-7f5b-450c-ad14-e15ee58c788d" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_bd6a6fca-6c4d-495c-8617-d84c24e7ff72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_687bea72-ba6b-42a6-8e59-f8336f7e9227" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_30d57b9e-afc0-4624-ab6e-52afe57f9316" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_687bea72-ba6b-42a6-8e59-f8336f7e9227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:href="jnj-20211003.xsd#jnj_IncomeTaxTextualsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_687bea72-ba6b-42a6-8e59-f8336f7e9227" xlink:to="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_63bafe58-ae23-4f7b-ab0e-123e335aa414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_63bafe58-ae23-4f7b-ab0e-123e335aa414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_332edf6a-8e09-4db0-8a00-0b655c7bee0e" xlink:href="jnj-20211003.xsd#jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:to="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_332edf6a-8e09-4db0-8a00-0b655c7bee0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d583c6a8-5f4a-44e1-98ab-4a38e5b8b8c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d583c6a8-5f4a-44e1-98ab-4a38e5b8b8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_2c283a32-8f69-4c4b-aa99-bd54f7734ce2" xlink:href="jnj-20211003.xsd#jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_2c283a32-8f69-4c4b-aa99-bd54f7734ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_88fe3000-fc41-470f-b52b-534ea7c1a084" xlink:href="jnj-20211003.xsd#jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:to="loc_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_88fe3000-fc41-470f-b52b-534ea7c1a084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_11a11323-1ff2-4fd1-bf47-fb4a0805fe4c" xlink:href="jnj-20211003.xsd#jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_11a11323-1ff2-4fd1-bf47-fb4a0805fe4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent_ccc212ed-859a-4ace-a791-916c10d0d1b4" xlink:href="jnj-20211003.xsd#jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent_ccc212ed-859a-4ace-a791-916c10d0d1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_7b42c43f-e50b-4ad2-8d28-29f22fcd22e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_7b42c43f-e50b-4ad2-8d28-29f22fcd22e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount_fa276d2f-ba92-4c5d-966f-b171484acd1d" xlink:href="jnj-20211003.xsd#jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount_fa276d2f-ba92-4c5d-966f-b171484acd1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent_afc7e33c-7680-4457-9ce9-91ab4111dea1" xlink:href="jnj-20211003.xsd#jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent_afc7e33c-7680-4457-9ce9-91ab4111dea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_a5c1708c-08c5-41c9-ad4a-06b96246d33f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_a5c1708c-08c5-41c9-ad4a-06b96246d33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_f5efb5ba-1a12-4d0c-8e11-df1aefe0b000" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_f5efb5ba-1a12-4d0c-8e11-df1aefe0b000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_ff38d657-5aa2-4cdc-81fe-8bec3228e05a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_6f272a7b-34d0-481e-84d4-0b3bf92dd22e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_ff38d657-5aa2-4cdc-81fe-8bec3228e05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlans" xlink:type="simple" xlink:href="jnj-20211003.xsd#PensionsandOtherBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3739b2b9-9db9-4170-8842-23f15e6d620f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_d79ca6c7-6fa9-41ca-b983-5541750750a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3739b2b9-9db9-4170-8842-23f15e6d620f" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_d79ca6c7-6fa9-41ca-b983-5541750750a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables" xlink:type="simple" xlink:href="jnj-20211003.xsd#PensionsandOtherBenefitPlansTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0afc8766-dcd6-479a-849c-bc4387d594e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_b6ae81c0-9128-46a6-be49-6054761b9472" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0afc8766-dcd6-479a-849c-bc4387d594e6" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_b6ae81c0-9128-46a6-be49-6054761b9472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9ef3a4c8-a961-4354-b882-64752552904f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8c23248e-eb05-4324-92f1-38bbe3d6653c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9ef3a4c8-a961-4354-b882-64752552904f" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8c23248e-eb05-4324-92f1-38bbe3d6653c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_bd907850-7f4d-4abe-878b-05154fcbf3c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8c23248e-eb05-4324-92f1-38bbe3d6653c" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_bd907850-7f4d-4abe-878b-05154fcbf3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8094cf0b-9cd1-4619-b8f3-5f2fd5b988b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_bd907850-7f4d-4abe-878b-05154fcbf3c9" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8094cf0b-9cd1-4619-b8f3-5f2fd5b988b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_dc7490aa-8915-4fd8-b1b7-596b53a46c4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8094cf0b-9cd1-4619-b8f3-5f2fd5b988b6" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_dc7490aa-8915-4fd8-b1b7-596b53a46c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_e7b57fa5-3137-48fb-96d9-62c749b2c217" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8094cf0b-9cd1-4619-b8f3-5f2fd5b988b6" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_e7b57fa5-3137-48fb-96d9-62c749b2c217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_86cefbdd-8d56-4486-8c72-80a95f9cb594" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8c23248e-eb05-4324-92f1-38bbe3d6653c" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_86cefbdd-8d56-4486-8c72-80a95f9cb594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_b6ff796b-ab95-410a-88a2-40ddbafd9bf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_86cefbdd-8d56-4486-8c72-80a95f9cb594" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_b6ff796b-ab95-410a-88a2-40ddbafd9bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_9baea0da-b9f3-4e9f-8839-cfe62a0d048a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_b6ff796b-ab95-410a-88a2-40ddbafd9bf2" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_9baea0da-b9f3-4e9f-8839-cfe62a0d048a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_a1b1624c-7904-4bea-9080-ec3c4656d815" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_b6ff796b-ab95-410a-88a2-40ddbafd9bf2" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_a1b1624c-7904-4bea-9080-ec3c4656d815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_077a15ff-274a-4603-966f-49e4562ec73d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_b6ff796b-ab95-410a-88a2-40ddbafd9bf2" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_077a15ff-274a-4603-966f-49e4562ec73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_d389a7a8-e305-4862-b4be-cf3e18b73da3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_b6ff796b-ab95-410a-88a2-40ddbafd9bf2" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_d389a7a8-e305-4862-b4be-cf3e18b73da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_049822d7-981e-420f-91c8-fb4aa1dcd54e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_b6ff796b-ab95-410a-88a2-40ddbafd9bf2" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_049822d7-981e-420f-91c8-fb4aa1dcd54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_70d70474-13a8-4cd4-9299-840d0bbccdb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_b6ff796b-ab95-410a-88a2-40ddbafd9bf2" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_70d70474-13a8-4cd4-9299-840d0bbccdb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_2fd15476-d8f0-4806-8047-1093d3be021b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_b6ff796b-ab95-410a-88a2-40ddbafd9bf2" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_2fd15476-d8f0-4806-8047-1093d3be021b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#PensionsandOtherBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3f64d744-8bd3-4586-878f-30f0faacf336" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_892299c4-193a-4999-a973-b4f2ba0ea574" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3f64d744-8bd3-4586-878f-30f0faacf336" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_892299c4-193a-4999-a973-b4f2ba0ea574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_2d2cd09f-b65c-40d7-934f-37d579839896" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_892299c4-193a-4999-a973-b4f2ba0ea574" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_2d2cd09f-b65c-40d7-934f-37d579839896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_585ba199-9afe-4391-9291-ab9b5c5120a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_2d2cd09f-b65c-40d7-934f-37d579839896" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_585ba199-9afe-4391-9291-ab9b5c5120a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f97469dd-d84e-411c-8584-356a85b37fc8" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_585ba199-9afe-4391-9291-ab9b5c5120a0" xlink:to="loc_country_US_f97469dd-d84e-411c-8584-356a85b37fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_5768514e-82c6-4c74-9b9c-b56b4dbaee77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_585ba199-9afe-4391-9291-ab9b5c5120a0" xlink:to="loc_us-gaap_ForeignPlanMember_5768514e-82c6-4c74-9b9c-b56b4dbaee77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5b801e74-8cf6-4596-a1f2-bf02cb1e42dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_892299c4-193a-4999-a973-b4f2ba0ea574" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5b801e74-8cf6-4596-a1f2-bf02cb1e42dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions_ed9e5c1d-b806-4b2f-b6d0-dc4f217c1d37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionContributions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5b801e74-8cf6-4596-a1f2-bf02cb1e42dc" xlink:to="loc_us-gaap_PensionContributions_ed9e5c1d-b806-4b2f-b6d0-dc4f217c1d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20211003.xsd#AccumulatedOtherComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f2e2c498-4b53-44f7-81a6-e41e768fd5cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_effe4026-e9a4-41be-9c99-a395f67e5ba1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f2e2c498-4b53-44f7-81a6-e41e768fd5cd" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_effe4026-e9a4-41be-9c99-a395f67e5ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="simple" xlink:href="jnj-20211003.xsd#AccumulatedOtherComprehensiveIncomeTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_bba584a6-14c0-4bc2-8c3b-68b4d57fd118" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_ed10a233-9d68-41a8-bbde-fc1d73e874e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bba584a6-14c0-4bc2-8c3b-68b4d57fd118" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_ed10a233-9d68-41a8-bbde-fc1d73e874e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#AccumulatedOtherComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7d4f1021-9317-4ebb-8c40-a2ece41ad4a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_16729344-5ea2-4a2c-b272-1bab9183f15a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7d4f1021-9317-4ebb-8c40-a2ece41ad4a4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_16729344-5ea2-4a2c-b272-1bab9183f15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_afb153bd-f1c4-424a-85fe-b1fdf8758ce6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_16729344-5ea2-4a2c-b272-1bab9183f15a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_afb153bd-f1c4-424a-85fe-b1fdf8758ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b8c8d5eb-5137-4ce1-886f-abaea76ddac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_afb153bd-f1c4-424a-85fe-b1fdf8758ce6" xlink:to="loc_us-gaap_EquityComponentDomain_b8c8d5eb-5137-4ce1-886f-abaea76ddac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_ba11154a-3cbd-4c50-bc61-5fe146c0648f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8c8d5eb-5137-4ce1-886f-abaea76ddac8" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_ba11154a-3cbd-4c50-bc61-5fe146c0648f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_e129b8c4-c0a5-4f41-85c2-32c4b71f1e09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8c8d5eb-5137-4ce1-886f-abaea76ddac8" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_e129b8c4-c0a5-4f41-85c2-32c4b71f1e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_cfc753fc-d705-4488-ae6e-b1605dc7f364" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8c8d5eb-5137-4ce1-886f-abaea76ddac8" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_cfc753fc-d705-4488-ae6e-b1605dc7f364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_fe05b86a-6007-47d9-ae74-a93f9551ed0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8c8d5eb-5137-4ce1-886f-abaea76ddac8" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_fe05b86a-6007-47d9-ae74-a93f9551ed0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c7bc85e4-be12-4b54-8ce4-04bc291ccc1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8c8d5eb-5137-4ce1-886f-abaea76ddac8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c7bc85e4-be12-4b54-8ce4-04bc291ccc1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_337d807b-b532-4f7d-9def-06e889787d64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_16729344-5ea2-4a2c-b272-1bab9183f15a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_337d807b-b532-4f7d-9def-06e889787d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c15d8920-7f1e-4688-a231-9619698e07d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_337d807b-b532-4f7d-9def-06e889787d64" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c15d8920-7f1e-4688-a231-9619698e07d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_84782215-4997-44bb-86e4-b430cfcdca44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c15d8920-7f1e-4688-a231-9619698e07d4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_84782215-4997-44bb-86e4-b430cfcdca44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bc733ee5-0372-4a2c-b82a-4afb6b3928fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c15d8920-7f1e-4688-a231-9619698e07d4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bc733ee5-0372-4a2c-b82a-4afb6b3928fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a2bd8996-ee05-4138-a5b9-50aed745fb27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c15d8920-7f1e-4688-a231-9619698e07d4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a2bd8996-ee05-4138-a5b9-50aed745fb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShare" xlink:type="simple" xlink:href="jnj-20211003.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_42ef33f6-44a1-4a17-80f2-30d844e2277d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_51045247-a36a-4cf0-9ca2-c3c316921799" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_42ef33f6-44a1-4a17-80f2-30d844e2277d" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_51045247-a36a-4cf0-9ca2-c3c316921799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="jnj-20211003.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_51ac7b90-7e09-44e4-8558-5f32f911a37f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_26ad11c9-67a6-44d2-8c55-8faf50def5f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_51ac7b90-7e09-44e4-8558-5f32f911a37f" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_26ad11c9-67a6-44d2-8c55-8faf50def5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#EarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1855ada5-7d22-44b3-ac68-3fae9cbc6fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_5b09adae-80cb-49b6-b445-35d263ec30cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1855ada5-7d22-44b3-ac68-3fae9cbc6fa3" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_5b09adae-80cb-49b6-b445-35d263ec30cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_61dd6859-96d2-486e-915a-fb715f1dfb60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_5b09adae-80cb-49b6-b445-35d263ec30cc" xlink:to="loc_us-gaap_EarningsPerShareBasic_61dd6859-96d2-486e-915a-fb715f1dfb60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_17e2939e-1a1f-4dcf-9662-dfcb03f184ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_5b09adae-80cb-49b6-b445-35d263ec30cc" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_17e2939e-1a1f-4dcf-9662-dfcb03f184ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4e627146-642a-4ded-8c5f-ea9c9d33d8e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_5b09adae-80cb-49b6-b445-35d263ec30cc" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4e627146-642a-4ded-8c5f-ea9c9d33d8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_d4fd07c6-c7b4-472a-8173-d96c301554f7" xlink:href="jnj-20211003.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_5b09adae-80cb-49b6-b445-35d263ec30cc" xlink:to="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_d4fd07c6-c7b4-472a-8173-d96c301554f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4897bbdc-53ad-4e31-8b30-2682234ab421" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_5b09adae-80cb-49b6-b445-35d263ec30cc" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4897bbdc-53ad-4e31-8b30-2682234ab421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_13eeec3d-7453-4eee-9e46-4c5448ed82f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_5b09adae-80cb-49b6-b445-35d263ec30cc" xlink:to="loc_us-gaap_EarningsPerShareDiluted_13eeec3d-7453-4eee-9e46-4c5448ed82f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c874d6fb-ffa3-4ad1-b183-a084390e06c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1855ada5-7d22-44b3-ac68-3fae9cbc6fa3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c874d6fb-ffa3-4ad1-b183-a084390e06c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas" xlink:type="simple" xlink:href="jnj-20211003.xsd#SegmentsofBusinessandGeographicAreas"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6c94a613-8c27-409d-b76d-c7224686207c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_f81fbc3b-1e31-4ab6-8626-81555f01d539" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6c94a613-8c27-409d-b76d-c7224686207c" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_f81fbc3b-1e31-4ab6-8626-81555f01d539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables" xlink:type="simple" xlink:href="jnj-20211003.xsd#SegmentsofBusinessandGeographicAreasTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_af6fa958-ac10-4f25-a67a-1612230de01c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesBySegmentOfBusinessTableTextBlock_88dc9fe7-c41c-47ed-a1fc-55eeae2deb2d" xlink:href="jnj-20211003.xsd#jnj_SalesBySegmentOfBusinessTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_af6fa958-ac10-4f25-a67a-1612230de01c" xlink:to="loc_jnj_SalesBySegmentOfBusinessTableTextBlock_88dc9fe7-c41c-47ed-a1fc-55eeae2deb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_9fdb1f40-c33a-4476-b974-ba29fbb8cb52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_af6fa958-ac10-4f25-a67a-1612230de01c" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_9fdb1f40-c33a-4476-b974-ba29fbb8cb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_4bdef41a-945d-44fa-9e35-c2c2fe0db35c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_af6fa958-ac10-4f25-a67a-1612230de01c" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_4bdef41a-945d-44fa-9e35-c2c2fe0db35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4c4a41cc-0c5f-4566-9df0-f2073f84222e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3bee1677-4bca-42e6-9ef3-3180d92a8e28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4c4a41cc-0c5f-4566-9df0-f2073f84222e" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3bee1677-4bca-42e6-9ef3-3180d92a8e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6129aaff-3030-4a40-aa69-73efb3f077b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3bee1677-4bca-42e6-9ef3-3180d92a8e28" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6129aaff-3030-4a40-aa69-73efb3f077b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_62d94a75-c0a5-4c31-acd8-ed0545791683" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6129aaff-3030-4a40-aa69-73efb3f077b9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_62d94a75-c0a5-4c31-acd8-ed0545791683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_348b289e-9350-40cc-937e-eef11fb6172d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3bee1677-4bca-42e6-9ef3-3180d92a8e28" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_348b289e-9350-40cc-937e-eef11fb6172d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e4c8eef0-6a7b-4b43-8f57-70de731320fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_348b289e-9350-40cc-937e-eef11fb6172d" xlink:to="loc_us-gaap_SegmentDomain_e4c8eef0-6a7b-4b43-8f57-70de731320fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_c3c8ce02-9f1d-49ff-bfae-655b754ae3f3" xlink:href="jnj-20211003.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e4c8eef0-6a7b-4b43-8f57-70de731320fd" xlink:to="loc_jnj_ConsumerMember_c3c8ce02-9f1d-49ff-bfae-655b754ae3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_a4938e95-3101-4875-a973-59fbf860c7b1" xlink:href="jnj-20211003.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e4c8eef0-6a7b-4b43-8f57-70de731320fd" xlink:to="loc_jnj_PharmaceuticalMember_a4938e95-3101-4875-a973-59fbf860c7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_a432ace6-7e5d-4bae-8d09-a7b7ccf3c083" xlink:href="jnj-20211003.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e4c8eef0-6a7b-4b43-8f57-70de731320fd" xlink:to="loc_jnj_MedicalDevicesMember_a432ace6-7e5d-4bae-8d09-a7b7ccf3c083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_3d1020ab-9bd7-48fe-b475-4f51f388a535" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3bee1677-4bca-42e6-9ef3-3180d92a8e28" xlink:to="loc_us-gaap_SubsegmentsAxis_3d1020ab-9bd7-48fe-b475-4f51f388a535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_eba76446-0ba5-4e4f-aaf3-3c0018facb84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_3d1020ab-9bd7-48fe-b475-4f51f388a535" xlink:to="loc_us-gaap_SubsegmentsDomain_eba76446-0ba5-4e4f-aaf3-3c0018facb84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_afe41904-b8a1-4e26-9c48-29945eede02f" xlink:href="jnj-20211003.xsd#jnj_ImmunologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_eba76446-0ba5-4e4f-aaf3-3c0018facb84" xlink:to="loc_jnj_ImmunologyMember_afe41904-b8a1-4e26-9c48-29945eede02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember_f278af32-1069-42f6-8af3-f55df43ee700" xlink:href="jnj-20211003.xsd#jnj_InfectiousDiseasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_eba76446-0ba5-4e4f-aaf3-3c0018facb84" xlink:to="loc_jnj_InfectiousDiseasesMember_f278af32-1069-42f6-8af3-f55df43ee700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember_b2dc7d0a-dd8a-42f7-a523-a7161786dd78" xlink:href="jnj-20211003.xsd#jnj_NeuroscienceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_eba76446-0ba5-4e4f-aaf3-3c0018facb84" xlink:to="loc_jnj_NeuroscienceMember_b2dc7d0a-dd8a-42f7-a523-a7161786dd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember_533aacd4-d0ce-4a13-99a9-e111ddf125dd" xlink:href="jnj-20211003.xsd#jnj_OncologyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_eba76446-0ba5-4e4f-aaf3-3c0018facb84" xlink:to="loc_jnj_OncologyMember_533aacd4-d0ce-4a13-99a9-e111ddf125dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember_7b3a5b87-e2a1-44f1-a75a-49bcc1bccf9e" xlink:href="jnj-20211003.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_eba76446-0ba5-4e4f-aaf3-3c0018facb84" xlink:to="loc_jnj_PulmonaryHypertensionMember_7b3a5b87-e2a1-44f1-a75a-49bcc1bccf9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember_4888646a-23a6-42a8-9844-e5335ec5c8f2" xlink:href="jnj-20211003.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_eba76446-0ba5-4e4f-aaf3-3c0018facb84" xlink:to="loc_jnj_CardiovascularMetabolismOtherMember_4888646a-23a6-42a8-9844-e5335ec5c8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember_cdc9c2ca-96cf-4492-8106-1b997a393419" xlink:href="jnj-20211003.xsd#jnj_InterventionalSolutionsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_eba76446-0ba5-4e4f-aaf3-3c0018facb84" xlink:to="loc_jnj_InterventionalSolutionsMember_cdc9c2ca-96cf-4492-8106-1b997a393419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember_2251bc30-d4e3-4f5c-8e21-c2490a44ab71" xlink:href="jnj-20211003.xsd#jnj_OrthopaedicsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_eba76446-0ba5-4e4f-aaf3-3c0018facb84" xlink:to="loc_jnj_OrthopaedicsMember_2251bc30-d4e3-4f5c-8e21-c2490a44ab71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember_ec8da28e-6eaa-4697-84de-032354a2a234" xlink:href="jnj-20211003.xsd#jnj_SurgeryMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_eba76446-0ba5-4e4f-aaf3-3c0018facb84" xlink:to="loc_jnj_SurgeryMember_ec8da28e-6eaa-4697-84de-032354a2a234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember_62e87186-492d-498e-a819-be5d16527a10" xlink:href="jnj-20211003.xsd#jnj_VisionMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_eba76446-0ba5-4e4f-aaf3-3c0018facb84" xlink:to="loc_jnj_VisionMember_62e87186-492d-498e-a819-be5d16527a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_849460a3-7c8c-4609-9ae8-9782ac03584a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3bee1677-4bca-42e6-9ef3-3180d92a8e28" xlink:to="loc_srt_ProductOrServiceAxis_849460a3-7c8c-4609-9ae8-9782ac03584a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_849460a3-7c8c-4609-9ae8-9782ac03584a" xlink:to="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember_88ebd08f-2e77-4bd5-8fec-c142f3035af3" xlink:href="jnj-20211003.xsd#jnj_OTCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_OTCMember_88ebd08f-2e77-4bd5-8fec-c142f3035af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BeautyMember_b64f0bd2-a9c0-4721-a9b2-a0ac06150f0e" xlink:href="jnj-20211003.xsd#jnj_BeautyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_BeautyMember_b64f0bd2-a9c0-4721-a9b2-a0ac06150f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember_53ad5a83-0de5-4f17-bd61-14e9001e86b3" xlink:href="jnj-20211003.xsd#jnj_OralCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_OralCareMember_53ad5a83-0de5-4f17-bd61-14e9001e86b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember_f93d9596-17f2-412b-bead-cac29fb72822" xlink:href="jnj-20211003.xsd#jnj_BabyCareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_BabyCareMember_f93d9596-17f2-412b-bead-cac29fb72822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WomensHealthMember_63440377-ad56-418a-b042-e5fa33797e25" xlink:href="jnj-20211003.xsd#jnj_WomensHealthMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_WomensHealthMember_63440377-ad56-418a-b042-e5fa33797e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WoundCareandOtherMember_04a9861f-f6e3-48b8-8adc-a2e8729e02c5" xlink:href="jnj-20211003.xsd#jnj_WoundCareandOtherMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_WoundCareandOtherMember_04a9861f-f6e3-48b8-8adc-a2e8729e02c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember_ffd6c294-01b7-4385-bbfa-695e06e9d2d4" xlink:href="jnj-20211003.xsd#jnj_RemicadeMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_RemicadeMember_ffd6c294-01b7-4385-bbfa-695e06e9d2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember_ab076222-c395-4536-bf27-270319cb3c12" xlink:href="jnj-20211003.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_SimponiSimponiAriaMember_ab076222-c395-4536-bf27-270319cb3c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember_86d66e03-94bc-4189-84c8-2bfb1c5d6874" xlink:href="jnj-20211003.xsd#jnj_StelaraMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_StelaraMember_86d66e03-94bc-4189-84c8-2bfb1c5d6874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember_df911062-769e-4aba-ada4-9b0e2c44e03e" xlink:href="jnj-20211003.xsd#jnj_TremfyaMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_TremfyaMember_df911062-769e-4aba-ada4-9b0e2c44e03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember_561e33ef-b3bb-4680-b7c0-729750f3f5e3" xlink:href="jnj-20211003.xsd#jnj_OtherImmunologyMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_OtherImmunologyMember_561e33ef-b3bb-4680-b7c0-729750f3f5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_COVID19Member_64f68ee7-13f4-4691-a9a0-f001c5318d07" xlink:href="jnj-20211003.xsd#jnj_COVID19Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_COVID19Member_64f68ee7-13f4-4691-a9a0-f001c5318d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember_5653a380-b196-44b2-ae08-f64e8328449c" xlink:href="jnj-20211003.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_EDURANTrilpivirineMember_5653a380-b196-44b2-ae08-f64e8328449c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_b818edca-afe6-4d05-a6ae-c70d6e500a53" xlink:href="jnj-20211003.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_b818edca-afe6-4d05-a6ae-c70d6e500a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember_0c2b35ca-ddcc-4f5b-83fa-538604d5e4ed" xlink:href="jnj-20211003.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_OtherInfectiousDiseasesMember_0c2b35ca-ddcc-4f5b-83fa-538604d5e4ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember_50e0deea-ecdb-461f-888e-fb62fed854ef" xlink:href="jnj-20211003.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_CONCERTAMethylphenidateMember_50e0deea-ecdb-461f-888e-fb62fed854ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_f842504c-d741-44c4-9905-0d666032067a" xlink:href="jnj-20211003.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_f842504c-d741-44c4-9905-0d666032067a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RISPERDALCONSTAMember_8c4a5f7d-6c0d-4d40-8ab8-03398a42c8ff" xlink:href="jnj-20211003.xsd#jnj_RISPERDALCONSTAMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_RISPERDALCONSTAMember_8c4a5f7d-6c0d-4d40-8ab8-03398a42c8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember_6645dcaf-8500-4a56-b2bb-a44aa0343445" xlink:href="jnj-20211003.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_OTHERNEUROSCIENCEMember_6645dcaf-8500-4a56-b2bb-a44aa0343445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember_e3553a77-6e9c-40f3-9813-128c3d3637f7" xlink:href="jnj-20211003.xsd#jnj_DARZALEXMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_DARZALEXMember_e3553a77-6e9c-40f3-9813-128c3d3637f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ERLEADAMember_b247b2bf-0b02-45b8-bb26-92715be10b4c" xlink:href="jnj-20211003.xsd#jnj_ERLEADAMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_ERLEADAMember_b247b2bf-0b02-45b8-bb26-92715be10b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember_06c8039f-5fdd-4f05-af71-4135545e810a" xlink:href="jnj-20211003.xsd#jnj_IMBRUVICAMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_IMBRUVICAMember_06c8039f-5fdd-4f05-af71-4135545e810a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember_78c70c32-a0aa-4c29-a1f1-b8529546bbcb" xlink:href="jnj-20211003.xsd#jnj_ZYTIGAMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_ZYTIGAMember_78c70c32-a0aa-4c29-a1f1-b8529546bbcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember_4828be66-090b-4775-8d74-538582ce12e9" xlink:href="jnj-20211003.xsd#jnj_OtherOncologyMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_OtherOncologyMember_4828be66-090b-4775-8d74-538582ce12e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember_7ed95580-0d49-43bb-b8c8-f050265bcf02" xlink:href="jnj-20211003.xsd#jnj_OPSUMITMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_OPSUMITMember_7ed95580-0d49-43bb-b8c8-f050265bcf02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember_6e5e4f3a-1a54-4637-988d-0d08871ed70c" xlink:href="jnj-20211003.xsd#jnj_UPTRAVIMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_UPTRAVIMember_6e5e4f3a-1a54-4637-988d-0d08871ed70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_c1cbff8c-9329-4e63-8777-bbd37c6c60cc" xlink:href="jnj-20211003.xsd#jnj_XareltoMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_XareltoMember_c1cbff8c-9329-4e63-8777-bbd37c6c60cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVOKANAINVOKAMETMember_89c370b2-c402-4f6c-bcec-16ce408b75fe" xlink:href="jnj-20211003.xsd#jnj_INVOKANAINVOKAMETMember"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_INVOKANAINVOKAMETMember_89c370b2-c402-4f6c-bcec-16ce408b75fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PROCRITEPREXMember_38ef9183-b57f-4288-b1bc-d795ff2385e6" xlink:href="jnj-20211003.xsd#jnj_PROCRITEPREXMember"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_PROCRITEPREXMember_38ef9183-b57f-4288-b1bc-d795ff2385e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember_3ffc5821-cd59-4b5b-9f10-477cce629890" xlink:href="jnj-20211003.xsd#jnj_OtherMember"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_OtherMember_3ffc5821-cd59-4b5b-9f10-477cce629890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember_dd614659-6891-4328-b631-5ba0e443a9c9" xlink:href="jnj-20211003.xsd#jnj_HIPSMember"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_HIPSMember_dd614659-6891-4328-b631-5ba0e443a9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember_4746bbeb-dd09-4837-b9c7-d75d1cdb1be4" xlink:href="jnj-20211003.xsd#jnj_KNEESMember"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_KNEESMember_4746bbeb-dd09-4837-b9c7-d75d1cdb1be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember_1e373744-ca2f-42d4-ba5c-69987dab2bb0" xlink:href="jnj-20211003.xsd#jnj_TRAUMAMember"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_TRAUMAMember_1e373744-ca2f-42d4-ba5c-69987dab2bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINEOTHERMember_e76fd378-b6d7-445b-850e-fe84c6ea46ed" xlink:href="jnj-20211003.xsd#jnj_SPINEOTHERMember"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_SPINEOTHERMember_e76fd378-b6d7-445b-850e-fe84c6ea46ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember_00e7cad1-95ea-476b-8b48-c8ae75f56eba" xlink:href="jnj-20211003.xsd#jnj_ADVANCEDMember"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_ADVANCEDMember_00e7cad1-95ea-476b-8b48-c8ae75f56eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember_bbf7ba20-58c5-46e8-8267-e7fff2c6aef6" xlink:href="jnj-20211003.xsd#jnj_GENERALMember"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_GENERALMember_bbf7ba20-58c5-46e8-8267-e7fff2c6aef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember_bc896bf3-7df0-4689-b768-9160a8e0a0e2" xlink:href="jnj-20211003.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_CONTACTLENSESOTHERMember_bc896bf3-7df0-4689-b768-9160a8e0a0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember_889e918a-86fa-4b38-b278-751840bef3e1" xlink:href="jnj-20211003.xsd#jnj_SURGICALMember"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3288774e-5a7e-4cc5-b7f5-ccb84ac54dbd" xlink:to="loc_jnj_SURGICALMember_889e918a-86fa-4b38-b278-751840bef3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8e154a40-0310-4273-88ff-df3c940c02ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3bee1677-4bca-42e6-9ef3-3180d92a8e28" xlink:to="loc_srt_StatementGeographicalAxis_8e154a40-0310-4273-88ff-df3c940c02ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1d9bbb30-a893-436a-b567-6c83e77363a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_8e154a40-0310-4273-88ff-df3c940c02ae" xlink:to="loc_srt_SegmentGeographicalDomain_1d9bbb30-a893-436a-b567-6c83e77363a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d315f9c1-37f3-40db-a5f8-57b3457a053b" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1d9bbb30-a893-436a-b567-6c83e77363a5" xlink:to="loc_country_US_d315f9c1-37f3-40db-a5f8-57b3457a053b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember_dcd4d4d1-54d2-444e-84ee-9af7ae624753" xlink:href="jnj-20211003.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1d9bbb30-a893-436a-b567-6c83e77363a5" xlink:to="loc_jnj_UNITEDSTATESExportsMember_dcd4d4d1-54d2-444e-84ee-9af7ae624753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_4024cc40-950f-4b60-bfbf-fbdc571e6da4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1d9bbb30-a893-436a-b567-6c83e77363a5" xlink:to="loc_us-gaap_NonUsMember_4024cc40-950f-4b60-bfbf-fbdc571e6da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_9d1e1690-ec90-4bfc-8b1c-16c822a7345b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3bee1677-4bca-42e6-9ef3-3180d92a8e28" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_9d1e1690-ec90-4bfc-8b1c-16c822a7345b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationRevenueAbstract_c456ba91-56d8-4cbb-acd7-77070422bdf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9d1e1690-ec90-4bfc-8b1c-16c822a7345b" xlink:to="loc_us-gaap_SegmentReportingInformationRevenueAbstract_c456ba91-56d8-4cbb-acd7-77070422bdf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2b231660-1534-47dd-b079-5319dead2797" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_c456ba91-56d8-4cbb-acd7-77070422bdf1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2b231660-1534-47dd-b079-5319dead2797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_b59252d1-1506-41dd-9f62-7fc6d0c7af20" xlink:href="jnj-20211003.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_c456ba91-56d8-4cbb-acd7-77070422bdf1" xlink:to="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_b59252d1-1506-41dd-9f62-7fc6d0c7af20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_96566f6a-8d39-4c0c-83aa-64554211b748" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3927a5c8-98f9-4954-9930-c3ec487cf4e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_96566f6a-8d39-4c0c-83aa-64554211b748" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3927a5c8-98f9-4954-9930-c3ec487cf4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_33830c86-bd9e-4fb5-95c0-edb8f4e71852" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3927a5c8-98f9-4954-9930-c3ec487cf4e5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_33830c86-bd9e-4fb5-95c0-edb8f4e71852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7dcc02ed-1f47-443d-861a-4f18b18be5d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_33830c86-bd9e-4fb5-95c0-edb8f4e71852" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7dcc02ed-1f47-443d-861a-4f18b18be5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeMember_daf7bcd9-6406-4f33-a743-94bb5746d0bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7dcc02ed-1f47-443d-861a-4f18b18be5d6" xlink:to="loc_us-gaap_OtherIncomeMember_daf7bcd9-6406-4f33-a743-94bb5746d0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_14ae3bd4-0ccc-4e8d-ab9e-644593fe68e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3927a5c8-98f9-4954-9930-c3ec487cf4e5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_14ae3bd4-0ccc-4e8d-ab9e-644593fe68e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b60e53e1-f7ac-44e7-8401-4910f4b7d8c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_14ae3bd4-0ccc-4e8d-ab9e-644593fe68e1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b60e53e1-f7ac-44e7-8401-4910f4b7d8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_49004056-ac99-4d39-95cd-15ce034c5ed1" xlink:href="jnj-20211003.xsd#jnj_AurisHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b60e53e1-f7ac-44e7-8401-4910f4b7d8c6" xlink:to="loc_jnj_AurisHealthMember_49004056-ac99-4d39-95cd-15ce034c5ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_0e33d741-c0ef-40ab-9047-dd931f7b7b73" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3927a5c8-98f9-4954-9930-c3ec487cf4e5" xlink:to="loc_srt_ConsolidationItemsAxis_0e33d741-c0ef-40ab-9047-dd931f7b7b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_521bf906-f92e-420f-8ca7-6d5f942ac6ea" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_0e33d741-c0ef-40ab-9047-dd931f7b7b73" xlink:to="loc_srt_ConsolidationItemsDomain_521bf906-f92e-420f-8ca7-6d5f942ac6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_f8a35ca1-1051-4a79-a9b5-092b89b42bed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_521bf906-f92e-420f-8ca7-6d5f942ac6ea" xlink:to="loc_us-gaap_OperatingSegmentsMember_f8a35ca1-1051-4a79-a9b5-092b89b42bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_a43e879c-ebbe-4516-abcd-1622e5bf7b90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_521bf906-f92e-420f-8ca7-6d5f942ac6ea" xlink:to="loc_us-gaap_CorporateNonSegmentMember_a43e879c-ebbe-4516-abcd-1622e5bf7b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9d87aceb-ac0e-4fb3-b8a1-bb84e92ae541" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3927a5c8-98f9-4954-9930-c3ec487cf4e5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9d87aceb-ac0e-4fb3-b8a1-bb84e92ae541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b9db0aa7-dfe9-487c-8c53-944611221228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9d87aceb-ac0e-4fb3-b8a1-bb84e92ae541" xlink:to="loc_us-gaap_SegmentDomain_b9db0aa7-dfe9-487c-8c53-944611221228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_0024423d-2f45-419a-bd11-b6140a957c13" xlink:href="jnj-20211003.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b9db0aa7-dfe9-487c-8c53-944611221228" xlink:to="loc_jnj_ConsumerMember_0024423d-2f45-419a-bd11-b6140a957c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_6ef1aba5-3c65-4ecd-b6c4-a03ea6c52ffa" xlink:href="jnj-20211003.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b9db0aa7-dfe9-487c-8c53-944611221228" xlink:to="loc_jnj_PharmaceuticalMember_6ef1aba5-3c65-4ecd-b6c4-a03ea6c52ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_9b6583a0-485a-4236-ac4d-626ef356f549" xlink:href="jnj-20211003.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b9db0aa7-dfe9-487c-8c53-944611221228" xlink:to="loc_jnj_MedicalDevicesMember_9b6583a0-485a-4236-ac4d-626ef356f549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_af66bdd1-bfb0-49eb-98b5-2844a68d1bcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3927a5c8-98f9-4954-9930-c3ec487cf4e5" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_af66bdd1-bfb0-49eb-98b5-2844a68d1bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_69dc04ef-1843-4008-9c96-911640c3fdfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_af66bdd1-bfb0-49eb-98b5-2844a68d1bcb" xlink:to="loc_us-gaap_OperatingIncomeLoss_69dc04ef-1843-4008-9c96-911640c3fdfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInOperatingIncomeLoss_c1ccabca-3530-467d-ab94-a227bfe9eace" xlink:href="jnj-20211003.xsd#jnj_PercentageChangeInOperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_af66bdd1-bfb0-49eb-98b5-2844a68d1bcb" xlink:to="loc_jnj_PercentageChangeInOperatingIncomeLoss_c1ccabca-3530-467d-ab94-a227bfe9eace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d2986003-97b9-4108-9cb4-f2c261bdd148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_af66bdd1-bfb0-49eb-98b5-2844a68d1bcb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d2986003-97b9-4108-9cb4-f2c261bdd148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_86ce03a0-1ce9-4679-96cb-025b3521c0ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_af66bdd1-bfb0-49eb-98b5-2844a68d1bcb" xlink:to="loc_us-gaap_AdjustmentForAmortization_86ce03a0-1ce9-4679-96cb-025b3521c0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_b84d2c50-16f2-4142-ab9f-71804851f921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_af66bdd1-bfb0-49eb-98b5-2844a68d1bcb" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_b84d2c50-16f2-4142-ab9f-71804851f921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_5036c421-74e6-4f57-a491-72647f4cfc07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_af66bdd1-bfb0-49eb-98b5-2844a68d1bcb" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_5036c421-74e6-4f57-a491-72647f4cfc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_afbc3217-60aa-4385-85fe-363e33c2f5b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_af66bdd1-bfb0-49eb-98b5-2844a68d1bcb" xlink:to="loc_us-gaap_LitigationSettlementExpense_afbc3217-60aa-4385-85fe-363e33c2f5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AmountPrepaidAndDueToManufacturers_b4bcd4de-ab25-4fd9-aff6-80269435141c" xlink:href="jnj-20211003.xsd#jnj_AmountPrepaidAndDueToManufacturers"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_af66bdd1-bfb0-49eb-98b5-2844a68d1bcb" xlink:to="loc_jnj_AmountPrepaidAndDueToManufacturers_b4bcd4de-ab25-4fd9-aff6-80269435141c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_97969202-4719-4996-88fa-28888d85f359" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_af66bdd1-bfb0-49eb-98b5-2844a68d1bcb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_97969202-4719-4996-88fa-28888d85f359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_15e92a7e-90c1-475b-be83-4c0bc9633872" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_af66bdd1-bfb0-49eb-98b5-2844a68d1bcb" xlink:to="loc_us-gaap_RestructuringCharges_15e92a7e-90c1-475b-be83-4c0bc9633872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0d62f870-f1e8-454b-9e52-1719ee4865c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_af66bdd1-bfb0-49eb-98b5-2844a68d1bcb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0d62f870-f1e8-454b-9e52-1719ee4865c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_5c0c2764-423c-4d5f-b4c9-85eb38a4f148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_13fe914a-efe6-40cd-95ef-7139ce9019ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5c0c2764-423c-4d5f-b4c9-85eb38a4f148" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_13fe914a-efe6-40cd-95ef-7139ce9019ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0920cf2b-9737-45c3-a139-544742e3069a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_13fe914a-efe6-40cd-95ef-7139ce9019ad" xlink:to="loc_srt_StatementGeographicalAxis_0920cf2b-9737-45c3-a139-544742e3069a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0204032a-1192-4be5-b2de-e7aaf76525f8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_0920cf2b-9737-45c3-a139-544742e3069a" xlink:to="loc_srt_SegmentGeographicalDomain_0204032a-1192-4be5-b2de-e7aaf76525f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_20f23b5d-bdfc-4156-ad79-7266a8b8d314" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0204032a-1192-4be5-b2de-e7aaf76525f8" xlink:to="loc_country_US_20f23b5d-bdfc-4156-ad79-7266a8b8d314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_ef995810-da8b-46e9-b7a8-47282ad7bbe1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0204032a-1192-4be5-b2de-e7aaf76525f8" xlink:to="loc_srt_EuropeMember_ef995810-da8b-46e9-b7a8-47282ad7bbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember_9af51d37-e758-48e9-8862-18edc429e0c3" xlink:href="jnj-20211003.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0204032a-1192-4be5-b2de-e7aaf76525f8" xlink:to="loc_jnj_WesternHemisphereExcludingUSMember_9af51d37-e758-48e9-8862-18edc429e0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember_ecefbb16-b4d0-47a7-8066-f8f284b042df" xlink:href="jnj-20211003.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0204032a-1192-4be5-b2de-e7aaf76525f8" xlink:to="loc_jnj_AsiaPacificAfricaMember_ecefbb16-b4d0-47a7-8066-f8f284b042df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_8ec60565-ac6d-40da-8473-0581537f5bec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_13fe914a-efe6-40cd-95ef-7139ce9019ad" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_8ec60565-ac6d-40da-8473-0581537f5bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_db5f5a0b-073a-4fad-9824-0bdd080db5eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentsGeographicalAreasAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_8ec60565-ac6d-40da-8473-0581537f5bec" xlink:to="loc_us-gaap_SegmentsGeographicalAreasAbstract_db5f5a0b-073a-4fad-9824-0bdd080db5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aa500a5f-d0e0-4132-8c6f-f50a2530807c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_db5f5a0b-073a-4fad-9824-0bdd080db5eb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aa500a5f-d0e0-4132-8c6f-f50a2530807c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesByGeographicArea_a56158a9-93bf-44a9-b783-4bc4c7eb997f" xlink:href="jnj-20211003.xsd#jnj_PercentageChangeInSalesByGeographicArea"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_db5f5a0b-073a-4fad-9824-0bdd080db5eb" xlink:to="loc_jnj_PercentageChangeInSalesByGeographicArea_a56158a9-93bf-44a9-b783-4bc4c7eb997f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestitures" xlink:type="simple" xlink:href="jnj-20211003.xsd#AcquisitionsandDivestitures"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_1aeb1cd0-f240-40bc-912c-e4e4de1ee45e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_5e949ef1-6143-47c6-84d4-bdf3637718af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_1aeb1cd0-f240-40bc-912c-e4e4de1ee45e" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_5e949ef1-6143-47c6-84d4-bdf3637718af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#AcquisitionsandDivestituresNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_8777685a-f168-44b6-826a-16c8cfce8964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_00c67429-106b-4b41-8ff6-5b33f3590b75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_8777685a-f168-44b6-826a-16c8cfce8964" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_00c67429-106b-4b41-8ff6-5b33f3590b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_354e469e-d1f0-4851-983c-c6d12d268eb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_00c67429-106b-4b41-8ff6-5b33f3590b75" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_354e469e-d1f0-4851-983c-c6d12d268eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_67b37395-70ba-4b81-9224-89a79197efeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_354e469e-d1f0-4851-983c-c6d12d268eb9" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_67b37395-70ba-4b81-9224-89a79197efeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EvraAndDoxilMember_3b16898d-9bcc-4cdb-b4a9-705591174ce9" xlink:href="jnj-20211003.xsd#jnj_EvraAndDoxilMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_67b37395-70ba-4b81-9224-89a79197efeb" xlink:to="loc_jnj_EvraAndDoxilMember_3b16898d-9bcc-4cdb-b4a9-705591174ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a30f8f8c-5953-462f-9aad-ca245d5841df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_00c67429-106b-4b41-8ff6-5b33f3590b75" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a30f8f8c-5953-462f-9aad-ca245d5841df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_97237615-64ff-45c3-83e7-4ffa61724447" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a30f8f8c-5953-462f-9aad-ca245d5841df" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_97237615-64ff-45c3-83e7-4ffa61724447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_c39e9bcc-2180-43db-ab7d-52973eade22c" xlink:href="jnj-20211003.xsd#jnj_BermekimabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_97237615-64ff-45c3-83e7-4ffa61724447" xlink:to="loc_jnj_BermekimabMember_c39e9bcc-2180-43db-ab7d-52973eade22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VerbSurgicalInc.Member_c2ea1998-353a-4804-bbdc-753185fb5ca9" xlink:href="jnj-20211003.xsd#jnj_VerbSurgicalInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_97237615-64ff-45c3-83e7-4ffa61724447" xlink:to="loc_jnj_VerbSurgicalInc.Member_c2ea1998-353a-4804-bbdc-753185fb5ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7b74d3f0-8070-4a22-8f0e-ea318c155bf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_00c67429-106b-4b41-8ff6-5b33f3590b75" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_7b74d3f0-8070-4a22-8f0e-ea318c155bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_fabdfbf2-18b9-44ad-a6f2-b2392361f63b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b74d3f0-8070-4a22-8f0e-ea318c155bf2" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_fabdfbf2-18b9-44ad-a6f2-b2392361f63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_229b32ae-7230-4e9b-ab87-701e803a5412" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b74d3f0-8070-4a22-8f0e-ea318c155bf2" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_229b32ae-7230-4e9b-ab87-701e803a5412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_218afe63-cb36-4651-a859-48f00e9c5947" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b74d3f0-8070-4a22-8f0e-ea318c155bf2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_218afe63-cb36-4651-a859-48f00e9c5947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2c2fdfdc-8ddd-481e-9e5c-96719b065e6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b74d3f0-8070-4a22-8f0e-ea318c155bf2" xlink:to="loc_us-gaap_Goodwill_2c2fdfdc-8ddd-481e-9e5c-96719b065e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_46529ccf-2106-4525-9d98-31f8e29164c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b74d3f0-8070-4a22-8f0e-ea318c155bf2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_46529ccf-2106-4525-9d98-31f8e29164c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_d43518e0-0675-480b-8a17-40942284915c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b74d3f0-8070-4a22-8f0e-ea318c155bf2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_d43518e0-0675-480b-8a17-40942284915c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_ea74c2db-8d4d-43c1-9db8-639094d4c411" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b74d3f0-8070-4a22-8f0e-ea318c155bf2" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_ea74c2db-8d4d-43c1-9db8-639094d4c411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedings" xlink:type="simple" xlink:href="jnj-20211003.xsd#LegalProceedings"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/LegalProceedings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f26e383c-50b3-407c-8da0-365ff04937e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_59e0e3eb-61ab-45f9-a4ea-edafe577352c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f26e383c-50b3-407c-8da0-365ff04937e9" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_59e0e3eb-61ab-45f9-a4ea-edafe577352c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#LegalProceedingsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bf9ee0e0-4173-4507-ba58-dcecf13abbbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_5956417c-36fd-4d37-b014-0a72d5792eb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bf9ee0e0-4173-4507-ba58-dcecf13abbbc" xlink:to="loc_us-gaap_LossContingenciesTable_5956417c-36fd-4d37-b014-0a72d5792eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_be2e8ba7-a566-444e-9106-d7999a50ac2b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5956417c-36fd-4d37-b014-0a72d5792eb0" xlink:to="loc_srt_LitigationCaseAxis_be2e8ba7-a566-444e-9106-d7999a50ac2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d35786f7-1176-4de9-ba4a-9015ce6bfa91" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_be2e8ba7-a566-444e-9106-d7999a50ac2b" xlink:to="loc_srt_LitigationCaseTypeDomain_d35786f7-1176-4de9-ba4a-9015ce6bfa91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member_4a010dc7-5e5c-4293-9506-cfe0c106292e" xlink:href="jnj-20211003.xsd#jnj_DePuyASRU.S.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d35786f7-1176-4de9-ba4a-9015ce6bfa91" xlink:to="loc_jnj_DePuyASRU.S.Member_4a010dc7-5e5c-4293-9506-cfe0c106292e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_4b2de3cc-390c-438a-bc81-f7277b2d6d31" xlink:href="jnj-20211003.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d35786f7-1176-4de9-ba4a-9015ce6bfa91" xlink:to="loc_jnj_RisperdalMember_4b2de3cc-390c-438a-bc81-f7277b2d6d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_5f47880f-0a9c-49c1-a712-818784c8d0ae" xlink:href="jnj-20211003.xsd#jnj_BabyPowderMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d35786f7-1176-4de9-ba4a-9015ce6bfa91" xlink:to="loc_jnj_BabyPowderMember_5f47880f-0a9c-49c1-a712-818784c8d0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_2917432b-61f0-4a8f-bc6e-d2f858fa39ec" xlink:href="jnj-20211003.xsd#jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d35786f7-1176-4de9-ba4a-9015ce6bfa91" xlink:to="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_2917432b-61f0-4a8f-bc6e-d2f858fa39ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgicalMeshProductsMarketingMember_6220ed2d-af34-4f9e-b690-712a7b1f623f" xlink:href="jnj-20211003.xsd#jnj_SurgicalMeshProductsMarketingMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d35786f7-1176-4de9-ba4a-9015ce6bfa91" xlink:to="loc_jnj_SurgicalMeshProductsMarketingMember_6220ed2d-af34-4f9e-b690-712a7b1f623f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_f3376a6f-0bfe-4548-831a-c40760a1c4d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5956417c-36fd-4d37-b014-0a72d5792eb0" xlink:to="loc_us-gaap_LitigationStatusAxis_f3376a6f-0bfe-4548-831a-c40760a1c4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_94abc91c-10e3-480f-a015-2846f934f01b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_f3376a6f-0bfe-4548-831a-c40760a1c4d5" xlink:to="loc_us-gaap_LitigationStatusDomain_94abc91c-10e3-480f-a015-2846f934f01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_ff500c2d-67a3-4852-9c74-db627a0a59f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_94abc91c-10e3-480f-a015-2846f934f01b" xlink:to="loc_us-gaap_SettledLitigationMember_ff500c2d-67a3-4852-9c74-db627a0a59f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember_bd5e5834-d336-471a-9699-8d5cceb0fa8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_JudicialRulingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_94abc91c-10e3-480f-a015-2846f934f01b" xlink:to="loc_us-gaap_JudicialRulingMember_bd5e5834-d336-471a-9699-8d5cceb0fa8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_02b814e1-7d51-4d36-8bef-4f1a6aa815af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_94abc91c-10e3-480f-a015-2846f934f01b" xlink:to="loc_us-gaap_PendingLitigationMember_02b814e1-7d51-4d36-8bef-4f1a6aa815af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3d070cf5-4daf-43e4-a65e-4cc06c05e042" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5956417c-36fd-4d37-b014-0a72d5792eb0" xlink:to="loc_srt_ProductOrServiceAxis_3d070cf5-4daf-43e4-a65e-4cc06c05e042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4fb529d4-eade-4408-854c-4fb025757d4c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3d070cf5-4daf-43e4-a65e-4cc06c05e042" xlink:to="loc_srt_ProductsAndServicesDomain_4fb529d4-eade-4408-854c-4fb025757d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember_7426b230-150c-40bd-9e3d-0d5ef9fcd7db" xlink:href="jnj-20211003.xsd#jnj_AsrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4fb529d4-eade-4408-854c-4fb025757d4c" xlink:to="loc_jnj_AsrMember_7426b230-150c-40bd-9e3d-0d5ef9fcd7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember_642f2f33-4c12-43fe-899f-77c991e8e8a1" xlink:href="jnj-20211003.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4fb529d4-eade-4408-854c-4fb025757d4c" xlink:to="loc_jnj_PinnacleAcetabularCupSystemMember_642f2f33-4c12-43fe-899f-77c991e8e8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember_5ea479cd-34b0-46da-bfe1-00ae2238f833" xlink:href="jnj-20211003.xsd#jnj_PelvicMeshesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4fb529d4-eade-4408-854c-4fb025757d4c" xlink:to="loc_jnj_PelvicMeshesMember_5ea479cd-34b0-46da-bfe1-00ae2238f833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_5cb4d3f5-ad5b-4679-a306-47ea08e0eaf2" xlink:href="jnj-20211003.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4fb529d4-eade-4408-854c-4fb025757d4c" xlink:to="loc_jnj_RisperdalMember_5cb4d3f5-ad5b-4679-a306-47ea08e0eaf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_2754ae54-4640-4aba-a4a7-8f37b18a1ca8" xlink:href="jnj-20211003.xsd#jnj_XareltoMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4fb529d4-eade-4408-854c-4fb025757d4c" xlink:to="loc_jnj_XareltoMember_2754ae54-4640-4aba-a4a7-8f37b18a1ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_c9d0b481-35d7-4c49-9a7a-5bae7eafff53" xlink:href="jnj-20211003.xsd#jnj_TalcMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4fb529d4-eade-4408-854c-4fb025757d4c" xlink:to="loc_jnj_TalcMember_c9d0b481-35d7-4c49-9a7a-5bae7eafff53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvokanaMember_16358473-b747-4386-a4d0-691d6f966d3f" xlink:href="jnj-20211003.xsd#jnj_InvokanaMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4fb529d4-eade-4408-854c-4fb025757d4c" xlink:to="loc_jnj_InvokanaMember_16358473-b747-4386-a4d0-691d6f966d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember_3153987f-436d-457e-8907-bae7798c67e4" xlink:href="jnj-20211003.xsd#jnj_PhysiomeshMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4fb529d4-eade-4408-854c-4fb025757d4c" xlink:to="loc_jnj_PhysiomeshMember_3153987f-436d-457e-8907-bae7798c67e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpioidMember_7690773a-d4c6-4024-b648-4358681ef094" xlink:href="jnj-20211003.xsd#jnj_OpioidMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4fb529d4-eade-4408-854c-4fb025757d4c" xlink:to="loc_jnj_OpioidMember_7690773a-d4c6-4024-b648-4358681ef094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ContactLensesMember_fdaf1ac6-123c-454b-861c-5b52b5f61db7" xlink:href="jnj-20211003.xsd#jnj_ContactLensesMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4fb529d4-eade-4408-854c-4fb025757d4c" xlink:to="loc_jnj_ContactLensesMember_fdaf1ac6-123c-454b-861c-5b52b5f61db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesAxis_f42b1407-9f4d-47d0-90cd-2abbfdce30d5" xlink:href="jnj-20211003.xsd#jnj_LitigationSettlementByCompaniesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5956417c-36fd-4d37-b014-0a72d5792eb0" xlink:to="loc_jnj_LitigationSettlementByCompaniesAxis_f42b1407-9f4d-47d0-90cd-2abbfdce30d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain_9b18b7f7-1709-4680-877b-a9dd163628e5" xlink:href="jnj-20211003.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis_f42b1407-9f4d-47d0-90cd-2abbfdce30d5" xlink:to="loc_jnj_LitigationSettlementByCompaniesDomain_9b18b7f7-1709-4680-877b-a9dd163628e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_8a8ab54c-36cc-4b11-9e25-eb01a058ba16" xlink:href="jnj-20211003.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LitigationSettlementByCompaniesDomain_9b18b7f7-1709-4680-877b-a9dd163628e5" xlink:to="loc_jnj_RisperdalMember_8a8ab54c-36cc-4b11-9e25-eb01a058ba16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6d43f9cf-dce4-476c-a616-1532ec0765ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5956417c-36fd-4d37-b014-0a72d5792eb0" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6d43f9cf-dce4-476c-a616-1532ec0765ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_45858173-fa5d-47cd-afbf-33bbc04617ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6d43f9cf-dce4-476c-a616-1532ec0765ee" xlink:to="loc_us-gaap_LossContingencyNatureDomain_45858173-fa5d-47cd-afbf-33bbc04617ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember_4b21b601-491a-4a69-a46f-dceb03c40106" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DamagesFromProductDefectsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_45858173-fa5d-47cd-afbf-33bbc04617ac" xlink:to="loc_us-gaap_DamagesFromProductDefectsMember_4b21b601-491a-4a69-a46f-dceb03c40106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_bf839bc9-4dd6-47c6-a8a2-d9a4de86a54e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5956417c-36fd-4d37-b014-0a72d5792eb0" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_bf839bc9-4dd6-47c6-a8a2-d9a4de86a54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e8208577-9f7d-495b-9a29-997267f1b0c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_bf839bc9-4dd6-47c6-a8a2-d9a4de86a54e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e8208577-9f7d-495b-9a29-997267f1b0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_12c1c7ec-dd9c-436a-9e98-11583725a182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e8208577-9f7d-495b-9a29-997267f1b0c8" xlink:to="loc_us-gaap_SubsequentEventMember_12c1c7ec-dd9c-436a-9e98-11583725a182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalJurisdictionAxis_b76b142b-1b25-429a-9827-4957766a025e" xlink:href="jnj-20211003.xsd#jnj_LegalJurisdictionAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5956417c-36fd-4d37-b014-0a72d5792eb0" xlink:to="loc_jnj_LegalJurisdictionAxis_b76b142b-1b25-429a-9827-4957766a025e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalJurisdictionDomain_f8c28a44-ba6d-4aa8-96c4-405ebde1fca6" xlink:href="jnj-20211003.xsd#jnj_LegalJurisdictionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalJurisdictionAxis_b76b142b-1b25-429a-9827-4957766a025e" xlink:to="loc_jnj_LegalJurisdictionDomain_f8c28a44-ba6d-4aa8-96c4-405ebde1fca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StateLevelJurisdictionMember_d298743c-6222-4740-bb1f-c683e86d95af" xlink:href="jnj-20211003.xsd#jnj_StateLevelJurisdictionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalJurisdictionDomain_f8c28a44-ba6d-4aa8-96c4-405ebde1fca6" xlink:to="loc_jnj_StateLevelJurisdictionMember_d298743c-6222-4740-bb1f-c683e86d95af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalLevelJurisdictionMember_eef8fa45-6c5d-4b0b-9da4-97d62a85d0ce" xlink:href="jnj-20211003.xsd#jnj_FederalLevelJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalJurisdictionDomain_f8c28a44-ba6d-4aa8-96c4-405ebde1fca6" xlink:to="loc_jnj_FederalLevelJurisdictionMember_eef8fa45-6c5d-4b0b-9da4-97d62a85d0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_23112cf4-14a9-41ce-be55-eed1815ce3ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5956417c-36fd-4d37-b014-0a72d5792eb0" xlink:to="loc_us-gaap_LossContingenciesLineItems_23112cf4-14a9-41ce-be55-eed1815ce3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:href="jnj-20211003.xsd#jnj_LegalProceedingTextualsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_23112cf4-14a9-41ce-be55-eed1815ce3ca" xlink:to="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_5e0f0e1d-cf30-44f6-95c2-1c3ab8068daa" xlink:href="jnj-20211003.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:to="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_5e0f0e1d-cf30-44f6-95c2-1c3ab8068daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement_1d55fcfb-777c-44e8-b3f1-56a1cec1fb94" xlink:href="jnj-20211003.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:to="loc_jnj_Numberofpatientsinsettlement_1d55fcfb-777c-44e8-b3f1-56a1cec1fb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_48bedcb9-485d-47f2-a58b-028333164e8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_48bedcb9-485d-47f2-a58b-028333164e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue_8d6390ee-4647-47da-a92e-10944b55c094" xlink:href="jnj-20211003.xsd#jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:to="loc_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue_8d6390ee-4647-47da-a92e-10944b55c094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_2f01e0ff-7f83-4f2a-8f81-b64dbb95e575" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_2f01e0ff-7f83-4f2a-8f81-b64dbb95e575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_ffd9f931-2cdf-4be2-9421-110c605b04c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_ffd9f931-2cdf-4be2-9421-110c605b04c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyReserveEstablishedWithinTrust_7d5593ed-054b-475c-90a8-382285ffc37f" xlink:href="jnj-20211003.xsd#jnj_LossContingencyReserveEstablishedWithinTrust"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:to="loc_jnj_LossContingencyReserveEstablishedWithinTrust_7d5593ed-054b-475c-90a8-382285ffc37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_483d5bef-332c-456a-8c58-86e5468e0bd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:to="loc_us-gaap_LitigationSettlementExpense_483d5bef-332c-456a-8c58-86e5468e0bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyNumberOfVotesInFavor_aaa0dd62-5b36-4ad5-bfad-39a7ec37bc6e" xlink:href="jnj-20211003.xsd#jnj_LossContingencyNumberOfVotesInFavor"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:to="loc_jnj_LossContingencyNumberOfVotesInFavor_aaa0dd62-5b36-4ad5-bfad-39a7ec37bc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyNumberOfVotesRejected_c8351aab-aa89-47f5-9965-111faf825c09" xlink:href="jnj-20211003.xsd#jnj_LossContingencyNumberOfVotesRejected"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:to="loc_jnj_LossContingencyNumberOfVotesRejected_c8351aab-aa89-47f5-9965-111faf825c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_857851af-846d-4afb-a2fa-c2c8720c6775" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_857851af-846d-4afb-a2fa-c2c8720c6775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_f3f9f60b-0c1c-4d75-8f2f-f814288be244" xlink:href="jnj-20211003.xsd#jnj_LossContingencyEstimateOfAdditionalPossibleLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:to="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_f3f9f60b-0c1c-4d75-8f2f-f814288be244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_02630b2d-69d7-4c62-a3c3-5ccc3c867581" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_c1074a0f-2804-4615-98d1-67aee82567c7" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_02630b2d-69d7-4c62-a3c3-5ccc3c867581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Restructuring" xlink:type="simple" xlink:href="jnj-20211003.xsd#Restructuring"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Restructuring" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e3253c41-17f0-484c-9863-ea433aee6de0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_b974988d-f146-4f6c-90ea-1a06d23f9667" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e3253c41-17f0-484c-9863-ea433aee6de0" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_b974988d-f146-4f6c-90ea-1a06d23f9667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringTables" xlink:type="simple" xlink:href="jnj-20211003.xsd#RestructuringTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/RestructuringTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b5ee558e-b7e2-4425-af13-7e8ca53abc6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_a4bd2fa5-ebd8-419c-af1f-73297f6ff5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b5ee558e-b7e2-4425-af13-7e8ca53abc6b" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_a4bd2fa5-ebd8-419c-af1f-73297f6ff5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#RestructuringNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ffd7ba38-8434-4266-b9c6-0a0f2f8b3060" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e107365d-cc65-4d32-ba60-57f05317a524" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ffd7ba38-8434-4266-b9c6-0a0f2f8b3060" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e107365d-cc65-4d32-ba60-57f05317a524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d90c5e76-b05a-4b7c-956c-dde9e002c77d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e107365d-cc65-4d32-ba60-57f05317a524" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d90c5e76-b05a-4b7c-956c-dde9e002c77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3dc67c9b-da8e-43c0-adf5-34c8a69e80e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d90c5e76-b05a-4b7c-956c-dde9e002c77d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3dc67c9b-da8e-43c0-adf5-34c8a69e80e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_f80f8a98-35a5-402b-b78b-fe069c0c4991" xlink:href="jnj-20211003.xsd#jnj_SupplyChainMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3dc67c9b-da8e-43c0-adf5-34c8a69e80e8" xlink:to="loc_jnj_SupplyChainMember_f80f8a98-35a5-402b-b78b-fe069c0c4991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0e0f5bc0-a0cf-48ca-9724-a5ba4cd85b94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e107365d-cc65-4d32-ba60-57f05317a524" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0e0f5bc0-a0cf-48ca-9724-a5ba4cd85b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bb2588a6-4fa1-4414-85d8-b6ea2d4b9bdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0e0f5bc0-a0cf-48ca-9724-a5ba4cd85b94" xlink:to="loc_us-gaap_SegmentDomain_bb2588a6-4fa1-4414-85d8-b6ea2d4b9bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_b224ce3c-eeba-4f20-8197-10dc9aa01e3d" xlink:href="jnj-20211003.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bb2588a6-4fa1-4414-85d8-b6ea2d4b9bdf" xlink:to="loc_jnj_MedicalDevicesMember_b224ce3c-eeba-4f20-8197-10dc9aa01e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_bc978a44-2171-425b-8573-6b613e8d9d0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e107365d-cc65-4d32-ba60-57f05317a524" xlink:to="loc_us-gaap_RestructuringPlanAxis_bc978a44-2171-425b-8573-6b613e8d9d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_431cc6e0-879b-4049-99cc-f7ff9af11adf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_bc978a44-2171-425b-8573-6b613e8d9d0e" xlink:to="loc_us-gaap_RestructuringPlanDomain_431cc6e0-879b-4049-99cc-f7ff9af11adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_655ba5a6-1fb0-416c-a38c-6baf494231e3" xlink:href="jnj-20211003.xsd#jnj_SupplyChainMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_431cc6e0-879b-4049-99cc-f7ff9af11adf" xlink:to="loc_jnj_SupplyChainMember_655ba5a6-1fb0-416c-a38c-6baf494231e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3d87f241-2f77-4dd5-bff3-429a184decab" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e107365d-cc65-4d32-ba60-57f05317a524" xlink:to="loc_srt_RangeAxis_3d87f241-2f77-4dd5-bff3-429a184decab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2d43532b-d090-4a10-8bc0-329a1a240019" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3d87f241-2f77-4dd5-bff3-429a184decab" xlink:to="loc_srt_RangeMember_2d43532b-d090-4a10-8bc0-329a1a240019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6625c9c0-d09c-48ef-8d15-e0f4606df374" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2d43532b-d090-4a10-8bc0-329a1a240019" xlink:to="loc_srt_MinimumMember_6625c9c0-d09c-48ef-8d15-e0f4606df374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0c781aaf-bd28-4432-bf27-a75a34d12fa4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2d43532b-d090-4a10-8bc0-329a1a240019" xlink:to="loc_srt_MaximumMember_0c781aaf-bd28-4432-bf27-a75a34d12fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7fb094ce-df39-4942-9b8c-9edf926177e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e107365d-cc65-4d32-ba60-57f05317a524" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7fb094ce-df39-4942-9b8c-9edf926177e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0b8ec2b2-5be6-4009-b08e-31ed83cf868d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7fb094ce-df39-4942-9b8c-9edf926177e3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0b8ec2b2-5be6-4009-b08e-31ed83cf868d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_0bd05f40-6a9c-4016-9381-666e291623ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0b8ec2b2-5be6-4009-b08e-31ed83cf868d" xlink:to="loc_us-gaap_RestructuringChargesMember_0bd05f40-6a9c-4016-9381-666e291623ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_07cf7fd6-d43b-4111-ab33-2a311e7db526" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0b8ec2b2-5be6-4009-b08e-31ed83cf868d" xlink:to="loc_us-gaap_CostOfSalesMember_07cf7fd6-d43b-4111-ab33-2a311e7db526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_c64447c3-565c-4dcc-bd69-776d50df20c7" xlink:href="jnj-20211003.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0b8ec2b2-5be6-4009-b08e-31ed83cf868d" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_c64447c3-565c-4dcc-bd69-776d50df20c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_e6c2e46f-c1f2-4697-827e-6a4e1a45cc4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e107365d-cc65-4d32-ba60-57f05317a524" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_e6c2e46f-c1f2-4697-827e-6a4e1a45cc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_ea7cc336-2c5c-4af6-a768-6445738c7825" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e6c2e46f-c1f2-4697-827e-6a4e1a45cc4f" xlink:to="loc_us-gaap_RestructuringCharges_ea7cc336-2c5c-4af6-a768-6445738c7825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_af3119ae-d0cf-4af1-bb3f-4960edbdddff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e6c2e46f-c1f2-4697-827e-6a4e1a45cc4f" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_af3119ae-d0cf-4af1-bb3f-4960edbdddff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_41fc18a4-3175-4eca-8cab-69d7530d9147" xlink:href="jnj-20211003.xsd#jnj_RestructuringandRelatedCostExpectedFutureSavings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e6c2e46f-c1f2-4697-827e-6a4e1a45cc4f" xlink:to="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_41fc18a4-3175-4eca-8cab-69d7530d9147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_8a6e2795-c8c0-4865-a2d3-82310b20e051" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e6c2e46f-c1f2-4697-827e-6a4e1a45cc4f" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_8a6e2795-c8c0-4865-a2d3-82310b20e051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_3de1686a-9a81-4dfb-8044-d945838c4f13" xlink:href="jnj-20211003.xsd#jnj_RestructuringandRelatedCostDurationofRestructuringPlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e6c2e46f-c1f2-4697-827e-6a4e1a45cc4f" xlink:to="loc_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_3de1686a-9a81-4dfb-8044-d945838c4f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" xlink:type="simple" xlink:href="jnj-20211003.xsd#RestructuringScheduleofRestructuringReserveDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_bbbe4906-399a-46ef-9b84-1a4b91da7942" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d6820137-fda4-438a-8914-698d9aa9ec3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_bbbe4906-399a-46ef-9b84-1a4b91da7942" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d6820137-fda4-438a-8914-698d9aa9ec3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_e70d2d1d-3012-4970-9f42-b7ebd5b14e9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d6820137-fda4-438a-8914-698d9aa9ec3f" xlink:to="loc_us-gaap_RestructuringPlanAxis_e70d2d1d-3012-4970-9f42-b7ebd5b14e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_37f38137-d26d-4096-a2bb-c326fcefdb4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_e70d2d1d-3012-4970-9f42-b7ebd5b14e9c" xlink:to="loc_us-gaap_RestructuringPlanDomain_37f38137-d26d-4096-a2bb-c326fcefdb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_e5f9a6e4-2ad5-47db-a375-5f2ced46110f" xlink:href="jnj-20211003.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_37f38137-d26d-4096-a2bb-c326fcefdb4a" xlink:to="loc_jnj_MedicalDevicesMember_e5f9a6e4-2ad5-47db-a375-5f2ced46110f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_841aab4a-6401-4266-9ccd-a4ebf9f36d94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d6820137-fda4-438a-8914-698d9aa9ec3f" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_841aab4a-6401-4266-9ccd-a4ebf9f36d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_e85e884d-8519-4797-9c01-21191483b21f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_841aab4a-6401-4266-9ccd-a4ebf9f36d94" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_e85e884d-8519-4797-9c01-21191483b21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_2805b422-17c1-4589-86cf-8d5b48f8d483" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e85e884d-8519-4797-9c01-21191483b21f" xlink:to="loc_us-gaap_EmployeeSeveranceMember_2805b422-17c1-4589-86cf-8d5b48f8d483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetWriteoffMember_2466c802-c23a-4f2b-b3d5-392bb96e5328" xlink:href="jnj-20211003.xsd#jnj_AssetWriteoffMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e85e884d-8519-4797-9c01-21191483b21f" xlink:to="loc_jnj_AssetWriteoffMember_2466c802-c23a-4f2b-b3d5-392bb96e5328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_4034ded4-63ab-4439-986e-4a53d9ec38b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e85e884d-8519-4797-9c01-21191483b21f" xlink:to="loc_us-gaap_OtherRestructuringMember_4034ded4-63ab-4439-986e-4a53d9ec38b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_db30ff4c-3731-46f9-bcc8-598095f1fc98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d6820137-fda4-438a-8914-698d9aa9ec3f" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_db30ff4c-3731-46f9-bcc8-598095f1fc98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_bef999c6-4ba6-4e09-b4cd-bcc49a31b140" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_db30ff4c-3731-46f9-bcc8-598095f1fc98" xlink:to="loc_us-gaap_RestructuringReserveRollForward_bef999c6-4ba6-4e09-b4cd-bcc49a31b140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_7383f525-6c77-430d-8c62-4e2950bdab55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_bef999c6-4ba6-4e09-b4cd-bcc49a31b140" xlink:to="loc_us-gaap_RestructuringReserve_7383f525-6c77-430d-8c62-4e2950bdab55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_f8136906-b86b-4348-86cf-7f7ed978bfa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_bef999c6-4ba6-4e09-b4cd-bcc49a31b140" xlink:to="loc_us-gaap_RestructuringCharges_f8136906-b86b-4348-86cf-7f7ed978bfa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_f818f108-e413-4840-82bb-73881c265d5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_bef999c6-4ba6-4e09-b4cd-bcc49a31b140" xlink:to="loc_us-gaap_PaymentsForRestructuring_f818f108-e413-4840-82bb-73881c265d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_9bc6b293-6629-4895-af9d-17f4531a2339" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_bef999c6-4ba6-4e09-b4cd-bcc49a31b140" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_9bc6b293-6629-4895-af9d-17f4531a2339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_49a0a126-9f63-420e-9b4b-b1992711f3ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_bef999c6-4ba6-4e09-b4cd-bcc49a31b140" xlink:to="loc_us-gaap_RestructuringReserve_49a0a126-9f63-420e-9b4b-b1992711f3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid_37dc1735-58d4-4137-a9a8-0124cd11442d" xlink:href="jnj-20211003.xsd#jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_db30ff4c-3731-46f9-bcc8-598095f1fc98" xlink:to="loc_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid_37dc1735-58d4-4137-a9a8-0124cd11442d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>jnj-20211003_g1.jpg
<TEXT>
begin 644 jnj-20211003_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXK?'CQ5^S!\-_COX;UKX@^"(%F\5^$M/U%9+S38RRJ6D0?W6=%?&=C.JOM+
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MX3G\2PQ:@]]*ZI';>0Y#B5F95"$9)8#'->\U_.U_P<L?L2:UKNN_&G_@I?\
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M;D';<LH#$B(N0%)Z FO<=7U?2?#^EW&N:]JEO965G"TUW>7<ZQQ01J,L[NQ
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MKR,3:Q2PX1EG6<E&/RAOW_T3P[X?\,VCV'AO0K/3X))FF>&QM4B1I&.6<A0
M6)ZGJ:2?PWX=NM;A\2W.@V4FI6T1BM]0DM4,\2'JJR$;E![@'% 'Y$?\%V/^
M"FFN_!W]J_\ 9=^!M[\*M4^''A[QU':ZQXB^+,W@.+4?%GAFQN;D6]UIND;8
M[@V5\L*_OVMQ+.HGA\L;AA_!/^"'/B;P!\'?^#D_]I;1-3TGQ7X:T_Q#X.U<
M^%[3QMI^I?VD]L^H:;>Q37C7@:XB+6J-.TMVRM@DR,')%?OY+;V\SI)- CM$
MVZ-F4$H<8R/0X)% MK9;@W:VZ"5D"M*$&XJ.0,]<<F@#\(/^#:7XG_#?6/\
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M)M;M?BNKV3:>T4$L=Y;1S:?%+,I2ZM"T0'F)YQ(#A":\9_X(E_M'_L6^.O\
M@I'^UQI?PV_8.L/@]\0/#>K7K_%3QDGQ+N-9L]3N(-4N(KHP)/;P)9P&XCEG
M)15#9&54*H4 _6*BOS.TK_@X.\3_ !3_ &:_BW^W_P#LX_LA6OBCX"?!WQ>-
M"U?7-2\=/I^O:ZB_9C<7MC8?89(5BBCNX)0D]PCR(Q_U; K7H7[=7_!<OP!^
MRW_P3B\!_P#!3WX&_!Q/BA\/O'%]:6Z6\OBDZ->V9N$EV I]DN%=XY8)H94+
M*4=."XR0 ?=]%?EI\0_^#C[QU\%_'?[-FM?''_@GOJWA/X7?M(Z?9S>'O%UY
MX\MI]0M6E6R\V8V,4!S;QM?0,K/)')-"XD$<; PU^I= !1110 4444 %%%%
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M<TD(BDD3"[7=AM7&![?J/A7POJ\\5SJWANPNI(+H7,,EQ9H[1SA0HE4L#AP
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MUCAAB4+%#$@544=  . *JZKX8\-:Y>VFI:WX>L;RXT^7S;">ZM$D>V?^]&S
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6.U*W%M(MQ8RA6D82>40RH!\_E/_  7651_P<J_L*N%&3?>&P3CDC_A)9O\
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MF9C0!^D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRZMIMSI>BW5G?B[MP=]H(+EDBD:8($W$L0JL1_0/<6EI=&-KJVCD,4@DB,B
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%<I\6?CK\&?@1H7_"2?&;XHZ%X8LF!,4VM:G' 9B.JQ
MJQ#2-_LJ"?:OC3XY?\'"G['_ ,/9YM+^$/A;Q'X]NH\A+JW@&G6+D=O-G'F_
MB(2/>O9ROAW/,Z?^Q8>4UW2]W_P)VBOO/$S7B/(LD7^W8B,'V;][_P !5Y/[
MC[VHK\6OBK_P<2?M?>+)Y8/A?X \(>$K1L^4[6LNH7:?625EB/\ WZ%> >.?
M^"J'_!0KXA323:Y^U;XIMO,ZKH5Q'IBJ/86B1XK[S!>$/$V(5Z\Z=/R;;?\
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MQJ1[Q:?Y;"T445QG:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 453\0^(M \):%=^)_%6MVFFZ;86[3WU_?7"Q
M0V\2C+.[L0%4#DDG%?EO^W]_P7VD<WOPJ_8<7:OS0W?Q!O[7D]C]B@D''_76
M4>NU!P]>_D'#6;\2XKV."A=+XI/2,?5_HKM]$?/\0\3Y/PQA?;8ZI9OX8K64
MO1?J[)=6??/[5'[<?[-'[&OAX:S\<OB+;V=W-&7L-!LAY^HWO7_5P*<[<C&]
MMJ \%A7Y=_M9_P#!P-^T-\49KCPU^S+H$/@#1&)1=5N%CN]5G7IG<P,5OD=D
M5F!Z25\&>+_&/BWX@>)+OQCXZ\37^LZM?S&6^U/4[MYYYW/\3NY+,?J:S:_H
M+AWPOR')XJIBU[>K_>7N+TCL_P#MZ_HC^=N)/%3/\YE*E@W]7I?W7[[]9[K_
M +=MVNS7\<>/_'7Q-\1S^,/B-XRU37M6NCFXU+6+^2YGD^KR$L?IFLBBBOTF
M$(4XJ,59+9(_,ISG4FY3=V]V]PHHHJB0HHHH **** "BBB@ KW+]E_\ X*._
MM?\ [(T\-M\)_BU>2:-$PW>&-<)O-.=?[HB<YASQDQ-&QQUKPVBN7&8'!YA0
M='%4XS@^DDFOQ.O!8[&Y=75;"U)0FNL6T_P/VH_8Z_X+Z?L]_&9[;P=^TEI2
M_#O7Y2$74VE:;1[ACW\TC?;9]) 4 ZR5]Z:3J^E:_I=OK>A:G;WME=PK+:W=
MI,LD4T;#*NCJ2&4CD$'!K^6.OH+]BS_@I9^TW^Q#JL=I\/O$_P#:OA=YM]]X
M-UIVDLI,GYFBYW6\AY^>,@$XW*X&*_'N)?"/"UXRKY/+DE_S[D[Q?^&6Z]'=
M>:1^R\,>,&*H2C0SJ//'_GY%6DO\45H_56?DV?T145X#^P__ ,%'?V>/VZ?#
M0E^'VM?V7XGMH ^K^#M4E47EM_>>/H+B+/\ RT3ID;@A.VO?J_"<=@,9EN*E
MA\53<)QW3W_X*[-:/H?OF!Q^"S/"QQ.$J*<);-.Z_P" ^Z>JZA1117(=@444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7$_M!_M$?"/]
MEWX8WWQ<^-/BV'2=(LEPI;YIKJ8@E8(8^LLK8.%'H2<*"17_ &E_VD_A5^R=
M\(-3^-'Q?UO[)I>GJ%B@B :>^N&!\NW@0D;Y'(.!P  68A58C\!?VY_VZ/BW
M^W7\6I/'_P 0+@V6D61>+PUX9MYBUOI=N3T'3?*V 7E(!8@ !5557[S@G@C%
M<58GVE2\,/%^]+JW_+'S[O:*WULG\!QSQUA.$\+[.G:>(FO=CT2_FEY=EO)[
M:7:[3_@H9_P5&^-/[=7B.;0%N)_#OP_M;G=I7A.VG_UVT_+/=LO^NE[A?N)T
M49R[?+]%%?U%EV6X'*<''"X2"A".R7YONWU;U9_*N99GC\XQDL5C*CG.6[?Y
M+HDNB6B"BBBNXX HHHH **** "BBB@ HHHH **** "BBB@ HHHH U/!?C7Q=
M\.?%5AXY\!>)+W1]8TNX6?3]2T^X:*:WD'1E93D>GN"0>#7[*?\ !+K_ (+,
M>'?VFIK#X#?M*7%GHWC]E6'2M94+%9^('Z!<<"&Y/]P?)(<[-I(CK\5Z=#-+
M;RK/!*R.C!D=&P5(Y!!'0U\QQ/PIEG%.#]EB%::^&:^*+_5=T]'Y.S/J>%N+
MLTX4QOM<,[P?Q0?PR7Z/M):KS5T?U145^;7_  1Z_P""NK_%D:?^RM^U)XG!
M\4*%@\)>*KZ7']L <+:7#G_EY'1'/^MZ']Y@R?I+7\J9]D.8<.YC+"8N-FMG
MTDNC3[?D]'J?UIP_G^7<29='&8.5T]&GO%]8M=_P:U6@5\<?MJ?\%.[WX-?M
M^_!__@F+\'9?"^F_$+XL:9<:O+XL\=QS3:7HNGQBY$*K:PS0/?75Q+:3Q1PB
M>  J,LQ8+7V/7Y_?\%N_^"(/PG_X*YZ1I?B;P?\ $Z+P3\;? 6F*?#'B)9"\
M<EI)+))#;7L:'S4A,T<QBG3YHW\TJ),,E>*>V:?_  3K_;,_X*&>.[?X"K^U
M-X2\$^+_  ?\;/AD-;L/B/X3L+C2;O1]4CL8[MK#4+-Y)X9FEC:0QSP/"K>3
M)^Y3 4^$?\%>OV]O^"]/[*/PPU?]NKX#_"7X3^&/@CX9U"!7\-^)$N+_ ,53
M64MPEO%?:C 1'%;Q2N\7^CP2F>%9@)<,K[/ O^#;O_@KG^U[\._C7\./^"1G
M[<G@.5M)\3>!8M1^"?BB:T6&XCTQ;"2\MHF9!LNK22W@E$<O^LCDC,3ECD1?
M7O\ P<O_ +'/[=7[5_["GB%OV7_CI8VWA;POIXUSQE\+9/#R--XHBL7-T2MX
M68DQ^6LBVAC"RM$,L3M4@'O?PO\ ^"D__":_\$BM,_X*9^)_APVCWVH?#,Z_
M'X3:4D3ZFRF*"SA9L%EN+KRXXF."RSQDXS7Q/\)/C]_P>%>,/B5X:T'XB_L9
M?!OPYX8U/6[.#7?$W]H:1<KIMA)*BS7?EP:Z\DHCC+/M169MN "2!72_LD^
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MQ^%AB*$N:$TFFNJ>Q^=/[ G_  1A\=>#-4^%?[4'[8_Q/B;XH?#3X#VWP^\
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MG2?"^.U<PRXLY+8PK-YX1+5VD%P\9A8F52006#)5^)?_  2$\6^%OVK?B_\
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M=.I%J2T:>C3"BBBK,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7I]S.MM;27+=(T+'\!FO'Y':61I'.68DD^]>UD\+SG/Y'SV?U+4X0[MO[O\
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M:S#IB2+97D]K)L-S;"1F98G!'REFVNLB[CMS5K_@LO\ \%--#_X)0_L0:O\
MM-R^&+?7?$-UJ<&A^"M"NYFC@O=5G61T\XK\WE1Q0S3.%P6$6P,I8,/FC_@U
M"_:X^+_[0G_!/G5_@E\9?!-AI-[\$O%K>$M/ET[1HK!9+58$E$4T,2JGVF)V
MD61PH+[D9]TA=W\4_P"#W#2?$D_[%WP<URU20Z1;?%">"^(^X+B33IF@S[[(
MKC'XT ?0,G_!5/\ :0_8R_;E_9P_9@_;1\8>'?&'AW]I3P=:26VO:3X=&ES^
M&?$DSI&MLBK*ZSV,DLT$*^9^^0R;VD<*5/Z6U_/W_P ''&F:]X@_;G_X)[Z!
MX*21]5NX-+BTH0_>,[ZGI:Q;<=]V,5_0)0 4444 9_BJ8P>&[V0=?LS#\QC^
MM>5UZ=XY<IX4O"/[BC\V KS&OH<G7[B3\_T/E,_E_M,5Y?JPHHHKUSP@HHHH
M **** "IM/M&O[^&R3K-*J#\3BH:UO \0F\5V:$='+?DI/\ 2LZLN2E*79,U
MH052M&#ZM+\3TV.-(8UBC4!54!0.P%+117Q9^A[!1110 4444 %%%% !1110
M 5^9G_!R-\&[?4/AG\/?C]9VH%QI6M3Z%?2J.7BN(C/%N]E:WEQ[RGUK],Z^
M/_\ @NMX?M]9_P""<'BS4IXP6TG5])NX21]UC?109'_ 9F'XU]9P-C)X+BW!
MSB]YJ/RG[OZGR/'F#ACN#\;"2V@Y?.'O_H?@W1117]@'\:A1110 4444 %%%
M% 'W3_P;U>)CH?[>-YI!DP-9\ ZA:A<]2L]K/^>(3^M?MW7X+_\ !#"\^S?\
M%)/!L.<?:-,U>/ZXT^=__9:_>BOYD\7::I\51DOM4XO\9+]#^H_!VJZG"4HO
M[-62_"+_ %"BBBORX_50HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ KF/C7\,K+XU?!KQ=\&]2U26QMO%OAB_T6XO8$#/;I=6\D#2*
M#P2HD) /!(KIZ* /S?\ B+_P3/\ ^"GOQ$UCP/\ !CQW^V3X&\0^%]*^#7C'
MP'JGQ6D^&TL>MKI^JG18BL]HVJ&*>]D@LI52Z0"-#&SRPNSJ#]1_"K]ANS_9
M5_86T3]A[]C#QEIWA+3O#^@3Z7I^M>*O#TFM,QG$SSW4D4-U9[YY+B9IV(<)
MEF4( 1M]]HH ^!/^")__  1:^)'_  1OTCQ;X&T[]K[1_B%X8\8:I!J.H65Q
M\,)=+O(+B*!X@8KA=5G0*=R$AH6/R$ C=D;'P%_82_X*P_LX?'3QWK/AO_@J
M=I?COX>^,]<NM3T[1/BY\/[O6;_PV9I&=8K.6+4[<!$!""/<L&$!6!"37W'1
M0!\BZS_P21^'_AS_ ()I>/\ _@GQ^S]\7->\&W_Q"COKS7_B6B+)J>H:S>3)
M-=7]RL1B5_.*"%XT,:B ^6NT 5Q?A3_@AK\/O$7_  1WT[_@D[^T]\<=;\=I
M81RW%GX]:W\JZTN_^U2W%M+:1R/(4C@\SRA&SG?$77Y5?:OW=10!\-?#;_@D
M'XL\6?M7_"#]K']MOXX:%X[U/X!^"HM!^&NC^&?"4NEVLETB[3K-]YUU<&6Y
M(",L4>R.-XU<%B !]RT44 %%%% &3XY7=X4O!_L*?_'A7F->J^*HO.\-WR8Z
M6SM^0S_2O*J^AR=_N)+S_0^4S]?[3%^7ZL****]<\(**** "BBB@ K6\#RB'
MQ79N3U<K^:D?UK)J;3[MK"_@O5ZPRJX_ YK.K'GI2CW3-:$U3K1F^C3_ !/7
MJ*;'(DT:RQME64%2.X-.KXL_0]PHHHH **** "BBB@ HHHH *^/_ /@NMX@M
M]&_X)P>+-.FD ;5M7TFTB!/WF%]%/C\H6/X5]@5^9G_!R-\9+?3_ (9?#WX
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M+_%-/%UX9-AI75-\U1K^;I'_ +=3;?FTMTPHHHK]J/Q **** "BBB@ HHHH
M_43_ (-J_A]Y_B3XJ?%6X@Q]EL=-TFTDQ][S7FFE'X>3#^8K]8*^*?\ @@A\
M(_\ A7/[!%EXPNK79<^-O$5]JS,RX;R486D8^F+9G'_73/>OM:OY$\0,<L?Q
M?BYQ>D9<B_[<2B_Q3/[$\/<"\OX.PE-K64>=_P#;[<E^#04445\<?:!1110
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M148JR1\W*4IR<I.[85Z'\"_VCM1^!MS*-8E,_AUSYNH6[MS!CK+'_M8Q\O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)7Y9D/G!F61 H!^FU%1W5S'9VLEW*DC+%&798HF=B ,X"J"6/H "3VK\??\
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MXG\^8O"8C XF5"O&THNS7]?AW"BBH[R\L]-LIM2U&X$-O;QEYY6Z*O\ 4DD
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *^K:3I>O:9/HNM
MZ;!>6=U$8[FUN8@\<J$8*LIX(/H:^,_VGO\ @F/,LEQXT_9R(9#F2?PO<S8(
M]?L\C'D?[#GUPQX6OM2BO?R#B;-^&L5[;!3LGO%ZQEZK]59KHSY[B'A?)^)\
M+[''4[M?#):2CZ/]'=/JC\9=;T/6O#6K3Z%XBTFYL;VUD*7-I=P-')$P[,K
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M!QO@YPQB&Y4)U*?DFI+_ ,F3?_DQ^.^J?##XE:&2-;^'FN6>W[WVK29H\?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@'POXE\9:SI6C>%[2STC5OB$RG6[RSCC"P2WF(XR)FB"$AHT<9 =5<,!Z/0
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MFD?&GX0_M4^#?VRM?_8YD_:)^".B^ KS0?%_P^TNPAU'5?"MW+=B9]?LM.N
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M&M26JVO]K?/B8>6LAE'R'E"W->L_$?\ 8M\=?%7]L+X=_M1^+_B_H$MAX+\
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M8?#_ %3PMX7^&AT>Q:&RO+BYMI;7-_.;9 ;A]\1\S<RC8T2?NA]3T4 %%%%
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%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>jnj-20211003_g10.jpg
<TEXT>
begin 644 jnj-20211003_g10.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#(!_Q$7._^?=/[I?\ R9]I?\-9_L_?]#__ .4J[_\ C5'_  UG^S]_T/\
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M_P"PH_\ 2OT#P\_Y&5;_  ?^W(_._$;_ )%E'_'_ .VLXVBBBOUP_'PHHHH
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MF6%Q$:?.XZ63Z7L]FUND^C>FJ[H]!HHHKH.<**** "OK[]BS_DB<?_84N/\
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MT+_L%O\ ^C#7@]?O?"G_ "3V']'^;/Y^XN_Y*/$>J_\ 24%%%%?0GS@4444
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M>?J_S/Z>P_\ N\/1?D%%%%8FP4444 %%%% !1110!\O_ +>?_(Z:%_V"W_\
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MX>B_(****Q-@HHHH **** "BBB@#Y?\ V\_^1TT+_L%O_P"C#7@]>\?MY_\
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M (D> I/B)H<&BQ>-M>T!H-1@N_MGAZ_^SS2>6V[R7;:<Q/T9>X[T?$CP1?\
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M_P#R/G_@E^:/6J***_%S]M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ44?]L:@ LUMHV&8;H4!CN+GLP,$)W+).J\?^PO\,?C_ /#K]J[X_>//BA\
M=:\/Z%\2/%]IJ?AK5+K6=)N%\F"WDB(FCMKR62-F.TJ K?>Y(P:[[X@_\$T_
MV#_BKXUU+XC?$3]F'PSJVN:Q=-<ZGJ5W YDN96ZNQ#CDU\_A:6,EERA3BOCF
MVI<T;ISDUT;L[KI9K3J?18NM@H9DYU)/X().'+*S4(I_:2NK/K=/7H>1?\$6
M_$GAV]^&'Q;TFRUZRENI/C_XJNH[:*Z1I&@,L $H4')0Y'S=.>M?9-WIVGW[
M0O?6,,QMYA-;F:(,8I " ZY^ZV"1D<\GUKX__P""57_!/O3?V2K;QYXX\:_
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M\.\_V\?^BZ_"S_PF-0_^2*]7_B(.2_\ /NI]T?\ Y,\G_B'6=_\ /RG]\O\
MY Y.BNL_X=Y_MX_]%U^%G_A,:A_\D4?\.\_V\?\ HNOPL_\ "8U#_P"2*/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /C;X@?M^_%S]H/]O37O^"<7[!C>'[34_A[H
MT&I?&;XJ^)=-DU"R\,_:,?9M,L[..6+[7J$H)8M)*L,*H^Y971HAB?MF_M3?
MMF_\$I/!EC^U-\;O'>F?&CX*6NL6EE\2/L_A!-)\1^%H+F98(]2MFMI3;WMN
MLLB(]NT22C>A$I&['SU_P;OQZCX9_P""D7_!13P/\0@T7B\_'.+4+E;GB2XL
M);[67MI4!Y,6R167L%F3IN%?6/\ P7HU#PSIO_!'3]H:Y\6O$MJWPXNXHC,>
M/M4C(EL/KY[1 >^* /4?CCXV_:.^+GPO\,3?L#>(O!T/_":Z>NI0?$WQ1:R:
MAI>EZ8\4<D4\-G#+%)>W$XF0Q*7CB"I*\CY5(I?!/^";'[7'[=VL?MF_&C_@
MGG^WK#X2\2Z]\,=(TC7M!^)7@729;&TU73M0#^7%<V[NPAG!0X"D9\N4?,$$
MC]3_ ,$7?!_Q;\/?\$:?@/X6UW4QI7B9OA99/97.J6+7(M(I5,EIOA\R,MMM
MWA&S<N, <8Q7@W["OB']M_\ 8P_X+'^.?V)OVM_B+H?Q5TGXX>$KGXB>&/BC
M8>%8=*U%)K)X;(Z=<QQ$@0PPA41"SJ@\HHP\V1% /TA\7^)+;P;X3U3Q?>Z?
M>W<.E:=/>2VNG6K3W$RQ1LY2*->9)"%PJCEB0!UK\U_VS?VC?^#@#]DCX,ZM
M_P %"=5T[X&7W@GPP@U?Q5\!K*PO)-1TW0]P,@.K%@L]Y#$=TKHJPJ4=D655
M"-^G-?+G_!1K1M8_:\\(WG_!-7X6:D\5]\0;&%?BCKUO@KX5\)22XNI&/(^U
MWJ1RVEK$>6+S3$%+9\@&+^UG_P %3=*^%'[&/P@^/7P.\'0ZOXS_ &C-2\,Z
M-\&O#.ONT<3ZAKD44L$M[Y1WK!!%(9)=A!)54#(7#B/Q)^UG\=/V*_VQOA!^
MSA^U=\2-)\;^%?CK]MTGPWXRLO#2Z3/HGB>VCCE6REB25TDM+M'*P=98Y8RK
MO*'#)\]_\%D_A[I/PX_;L_X)KZ%X:T9-.\#^&OC/)HEK9Q B"UF\K3H]-A&>
MA"P2*F>?E-:G_!PS;ZIK?QH_85\*>%%8ZY<_M>>'[JQ\K[Z10.K32<<[4#*S
M'L!0![+^TY>_\%F_C9XR\37G["7B7X3_  U\)>%KJ:Q\/_\ "R="N[[4_&-[
M!\L\K!,1Z?8^:'AB;;)+((VFXCDCKH/^".W_  4&\=?\%&/V3KWXE_&+X7P^
M#OB#X*\;ZEX*^(N@V3,UK!K5@(C,;?<S,(RL\1VEF*-O3<^W>?9_VF?CY%\
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MZ_,[_@V.M]4N?@O^TSXKC5ET/6OVO/%]UH']R2+99JTB=BI("Y'>-O2OTQH
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MU" P:_-X+M?#MIINGP1D0VD-A:2R0JWF2W#O."'D\Q%8'RE)]XHH ^2O!_\
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? 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>jnj-20211003_g11.jpg
<TEXT>
begin 644 jnj-20211003_g11.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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MRK'J%JJG&T1731R[>I-[*>BU^O7[;'[9OP+_ & ?V;/$?[4_[1.ORV7AOPY
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M+#&&C;B5G\K DY/_ (-=?V@_VN?B9^P-X)TKXE?L[W=[X1U/4?%.JW/QJO\
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MHHH _?[_ (--O^4IG[7?_;Q_Z?)Z_?ZOP!_X--O^4IG[7?\ V\?^GR>OW^H
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M  R_;E_9:\;?LG_&"!SH/C717L;BXA4&6SF#+);W48/'F0SI%,N>-T8SD9%
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M:[_[>/\ T^3U^_U?@#_P:;?\I3/VN_\ MX_]/D]?O]0 4444 %%%% !1110
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MEKK\&D:OJT$-[X7U>Z5C%9ZI:RK-;F3:"1$Y4Q.0"0DKD D 5^=W_!%[3O\
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MI31P688?\M5N;N=R/^G&0'MD _:2BBB@ HHHH **** "BBB@ HHHH *^0/\
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MM_RE,_:[_P"WC_T^3U^_U !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5\@?\%^/^4-G[0G_ &3^;_T=%7U_7R!_P7X_Y0V?
MM"?]D_F_]'14 ?QA4444 ?O]_P &FW_*4S]KO_MX_P#3Y/7[_5^ /_!IM_RE
M,_:[_P"WC_T^3U^_U !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]H3_ +)_-_Z.BH _C"HHHH _?[_@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\
ME*9^UW_V\?\ I\GK]_J "O&/VV]._;KU3P#H%G^P'XK\!Z/XFE\40IK][\0M
M'GO;*+23!-YDB)!-$YE6408 )RI88[CV>OG7_@HU\&OA#\?/!W@'X6_%C]L+
MQ5\'3JGQ&M(=#O?!?Q!D\.ZCXCO&M[E%TB*:.13*90Q<1 ,28%P,\T >5?\
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MM?\ !_AV_P!1EN4\.^)-,>9KN.S,S,T-I/9Q>8T .Q9D+H%WON /OFBO'/\
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M% '[_?\ !IM_RE,_:[_[>/\ T^3U^_U?@#_P:;?\I3/VN_\ MX_]/D]?O]0
M56O]&TK5+JRO=0L(IIM.N3<6,DBY,$IBDB+KZ'RY9%SZ.1WJS10 51M[3PZG
MB6[O[:.U&K26-O'>LC#SC;J\Y@#CKLWO<;<\9+XZ&ORK_;*\6?L+^)?^"C?Q
M=\%_\%$_^"N'CCX?1:*NAM\/? 'A+XPW/AO3M*L)-+A:=9X;;:S7K7)EG+N3
MN@N;?82 RQ^Z?\$?])_X)[V/QC^+][^P;^VGXN^,D<_ASPHOBFX\3>.[CQ%'
MI3+/KGV=(;NX8NID#3EX>B[$8<R$  ^[J*** "BBB@ HHHH **** "BBO"O^
M"DG[<W@[_@G/^QYXK_:G\6:#)K4^D1PVGAWP[;S>7+K.JW,JPVEHK8.T-(X+
ML 2L:NP#;<$ ]UHKXD^-/[6_[67_  3RN?@[\3_VT?B!X6\4^#?B9XRL?"'Q
M CT'PT=.7P1J]_$[6ES:2F>0W&GI-&UO-Y^Z7#1S*XPT1^VZ "BOC7X<_M;?
MM"?MY_M-?&KX6_LE_$O0O W@KX&:VGA6Y\4W_A@:O/XC\5",R7<!1YHUALK0
M[(I%7]],[L4EB51N]$_X)F_MSI^WK^SO=^/?$7A:W\/>-_!OBW4O!OQ-\-6E
MPTL.E^(-.E$=S'$S?,T+@QS1[OF"2A6)92: /H:BBB@ HHHH **** "BBB@
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M2_L<_##]A3]GS3/V?_A;=7U_#;W5SJ.MZ_JSJU]KFJ74K37=_<LH :661B<
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M_P 06Q7_ $&K_P  ?_R1\O\ \1NPO_0%+_P-?_(G]%/_  \__8!_Z.G\+_\
M?^3_ .(H_P"'G_[ /_1T_A?_ +_R?_$5_.MYTO\ SU;_ +ZH\Z7_ )ZM_P!]
M4?\ $%L5_P!!J_\  '_\D'_$;L+_ - 4O_ U_P#(G]%/_#S_ /8!_P"CI_"_
M_?\ D_\ B*/^'G_[ /\ T=/X7_[_ ,G_ ,17\ZWG2_\ /5O^^J/.E_YZM_WU
M1_Q!;%?]!J_\ ?\ \D'_ !&["_\ 0%+_ ,#7_P B?T4_\//_ -@'_HZ?PO\
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M)H_XC3A?^@)_^!K_ .1#_B".*_Z#8_\ @#_^2/PFIT/^M7_>%?NO_P .'O\
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M4 ?O]_P:;?\ *4S]KO\ [>/_ $^3U^_U?@#_ ,&FW_*4S]KO_MX_]/D]?O\
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M'/>AZ+X8_8Z_9S\-^&](M=/T[3_VL/!EM86%E L4-M"EGJ:I'&B@*B*H "@
M   4 ?:'PP_X*7?L _&SQ5<>!?@_^UYX$\3ZW:Z9+J,^CZ#KT5U=+:18\R;R
MHR7*+N&2!WK#M/\ @KW_ ,$N[[5[G0+?]O?X6&]L7=;ZV;QA;*]L4)#B4%AY
M>T@@[L8(YKV+Q7\%?AYXQ^)_A7XRZQH47_"2^#OMB:+JT4:"98+J!HI[9G*E
MC"_[N0H"/G@C;^$@_GC_ ,$ ((8/VQ/^"@ZPQ*@/[5FJDA5QUN;T_P R3^-
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M,U"Y-OIT_B'4TA:\E !9(8_OS%006"*=H.3@5\4?\%Y_AG9?LB_\$3=/\;?
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MB/XO>%?%=O?^&IK%[R'6+8,T4MNH),J\99< D$ Y'(SD5YAX8_X*7_\ !/\
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MH=_# ]N\6K3REV,HP00<8%?H)_Q&\_LL_P#1CWQ _P#"BL?\* /V^HK\0?\
MB-Y_99_Z,>^('_A16/\ A1_Q&\_LL_\ 1CWQ _\ "BL?\* /V^HK\0?^(WG]
MEG_HQ[X@?^%%8_X4?\1O/[+/_1CWQ _\**Q_PH _;ZBOQ!_XC>?V6?\ HQ[X
M@?\ A16/^%'_ !&\_LL_]&/?$#_PHK'_  H _;ZBOQ!_XC>?V6?^C'OB!_X4
M5C_A1_Q&\_LL_P#1CWQ _P#"BL?\* /V^HK\0?\ B-Y_99_Z,>^('_A16/\
MA1_Q&\_LL_\ 1CWQ _\ "BL?\* /V^HK\0?^(WG]EG_HQ[X@?^%%8_X4?\1O
M/[+/_1CWQ _\**Q_PH _;ZBOQ!_XC>?V6?\ HQ[X@?\ A16/^%'_ !&\_LL_
M]&/?$#_PHK'_  H _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_P#1CWQ
M_P#"BL?\* /V^HK\0?\ B-Y_99_Z,>^('_A16/\ A1_Q&\_LL_\ 1CWQ _\
M"BL?\* /V^HK\0?^(WG]EG_HQ[X@?^%%8_X4?\1O/[+/_1CWQ _\**Q_PH _
M;ZBOQ!_XC>?V6?\ HQ[X@?\ A16/^%'_ !&\_LL_]&/?$#_PHK'_  H _;ZB
MOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_P#1CWQ _P#"BL?\* /V^HK\0?\
MB-Y_99_Z,>^('_A16/\ A1_Q&\_LL_\ 1CWQ _\ "BL?\* /V^HK\0?^(WG]
MEG_HQ[X@?^%%8_X4?\1O/[+/_1CWQ _\**Q_PH _;ZBOQ!_XC>?V6?\ HQ[X
M@?\ A16/^%'_ !&\_LL_]&/?$#_PHK'_  H _;ZBOQ!_XC>?V6?^C'OB!_X4
M5C_A1_Q&\_LL_P#1CWQ _P#"BL?\* /V^HK\0?\ B-Y_99_Z,>^('_A16/\
MA1_Q&\_LL_\ 1CWQ _\ "BL?\* /V^HK\0?^(WG]EG_HQ[X@?^%%8_X4?\1O
M/[+/_1CWQ _\**Q_PH _;ZBOQ!_XC>?V6?\ HQ[X@?\ A16/^%'_ !&\_LL_
M]&/?$#_PHK'_  H _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_P#1CWQ
M_P#"BL?\* /V^HK\0?\ B-Y_99_Z,>^('_A16/\ A1_Q&\_LL_\ 1CWQ _\
M"BL?\* /V^HK\0?^(WG]EG_HQ[X@?^%%8_X4?\1O/[+/_1CWQ _\**Q_PH _
M;ZOD#_@OQ_RAL_:$_P"R?S?^CHJ^ /\ B-Y_99_Z,>^('_A16/\ A7B?_!1S
M_@[2_9X_;<_8=^)7[)_A;]DCQIH>H>.O#;Z;::MJ&N6DD-J[.C;W5!N(^7H/
*6@#\+:*** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>jnj-20211003_g12.jpg
<TEXT>
begin 644 jnj-20211003_g12.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M5^(/_![S_P FL_ __LH&H_\ I"* //\ _@TV_P"4IG[7?_;Q_P"GR>OW^K\
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MQ>%5F$4N#'"9EED2.0QBXCRIRHKZR_9Z_P"#K3P9\?;'XGZ)I'[ 7CNY\;>
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M&$&OZ9>PSQ:>&BCNXXH66YA9,2PM$ HDC9))0Q*_KM^V[_P5;\ ?\$VOA)\
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M/BSX6UWQ59M!X>TZ?Q/:_:IG:52NH+;,%C$4(5GP&3:%%?H?X[_X+E_L^?\
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M7]I_]F#XYWW@WQ;\/[*VO;;[-H^FW]O>B6\MH&BN8KVVF(7RY7*F,QL&()+
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MXS\4>++7PQX9N=4@\VWTV::WN;A[MX\@2E(K60*A.WS'0L&4,IX+_@G;X?\
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MWB/PW8G3(?&&I>-=,:WU?3O[62[AM[***=O,N<L8R[NEND,)D,A<K$P!J?\
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M\1FRNX?M8NWNYI))_M,%TJOO8X=!*NV3YZ]K_P""^O[8WQ"_:!_X+!?LV?\
M!(W3O$^H6/PH\0^)O"UW\3-+TZ\DM_\ A)DU'5!&UI<,A#/;I:)D)G:7N&9@
M3'&5U?\ @I+_ ,$]OV]_^"Z7_!1'X.67Q3_8TU[X-_!WX7V;)XUUKQEXCTNY
MDOGFNHY;V&Q%A<S>>)([>***3  )9Y!'PA]@_P""T_\ P21^/7Q6_;W^!/\
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M5\3?"'3OA_$MQ\9/&GC?4=+:UL;A;6WM7CTU+2[FDU D1W+(P5$.^'<R9?8
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M !1110 5^(/_  >\_P#)K/P/_P"R@:C_ .D(K]OJ_$'_ (/>?^36?@?_ -E
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M05[#'X;\;^"OBNNOVFC+-IMS?10:@IT^V:*Y80>4%B\V'=O!F#*$?I/VA?\
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M=(.IZMX;U'71I-_9PQ2F&[A)$-PAN8)1@QG:CJ&=)&&P2>3?#W_@X ?XI_\
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MLCWGB73/&MC:WVB>*= \8$RBWDN#;2^99?8F?SHY%<B.-Y/,79A@S%%^"_\
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MA\-^'U3Q5HD@2?2[6'6+U;^2W9T=?.A2<3$;6XDCXY% 'ZQ_LR?\%38/B/\
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MJ6K&437-QK^H:B;=)-GF);B\GE%N&\N,-Y84N(T#%@B@?2%% !1110 4444
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M0-1_](10!Y__ ,&FW_*4S]KO_MX_]/D]?O\ 5^ /_!IM_P I3/VN_P#MX_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "OQ!_P"#WG_DUGX'_P#90-1_](17[?5^(/\ P>\_\FL_ _\
M[*!J/_I"* //_P#@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\ E*9^UW_V\?\
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MIWQ3O[[6-'T'5[*TM-9MM6GU(6TD5I%!IY:U=C+;VS$2LNPBU;]YE2H^J/\
M@ASX4_X)'ZKX"\;?M!?\$G_!$WA;3O$T^G:-X]\+WIO(KO3K_3C=R1+<6]W+
M(T4A34'^9&,;JJX)*MCYF\;?\%=/^#=?6_\ @I5\,/VPK/X[>%5NO"GPT\36
M%SXCMOAUJ\9AU![K1UTW>HL [R);-K"QN%(19)067<@/U5_P3=_;*_8D_;@_
M;F^/OQB_8=\?6?B72)/A]X!C\5ZO8:+=6*7&K+=>)T)D2ZAB>246J6BF3:04
M2)=QV8 !]MT444 %%%% !1110 4444 %%%>,_P#!1OQUXI^&'_!/;X[?$KP/
M<RP:UX>^#?B?4M(G@)#Q7,&E7,L3J1SD.JGCGB@#R[5/^"M?@.7X>>,?VE?
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M>\_\FL_ _P#[*!J/_I"*_;ZOQ!_X/>?^36?@?_V4#4?_ $A% 'G_ /P:;?\
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M3P1X3LM)-V <W<T42K-<MGJ\LN^5CW:0FO1J* "BBB@ HHHH **** "BBB@
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M_P!_V^?^@WX9_P#";C_^*KXJ_L^]_P"?=J/[/O?^?=J/]3?"_P#Y^0_\'_\
MVX?ZZ^*?_/N?_@C_ .T/M7_A_O\ M\_]!OPS_P"$W'_\51_P_P!_V^?^@WX9
M_P#";C_^*KXJ_L^]_P"?=J/[/O?^?=J/]3?"_P#Y^0_\'_\ VX?ZZ^*?_/N?
M_@C_ .T/M7_A_O\ M\_]!OPS_P"$W'_\53X/^"^7[?4\RPC7/#(+'&3X:C_^
M*KXG_L^]_P"?=JELK*ZCND=X& #<DUPYGPCX;T<MK5*%2'/&$G']]?5)M:<V
MNO3J=^5\8>)E?,Z%.O3GR2G%2_<V]UR2>O+IIUZ']/WPSU[4/%/PW\/^)]69
M#=:CH=I=7)1=JF22%'; [#)/%;=<O\$/^2+>$/\ L5]/_P#2:.NHK^>3^C H
MHKY@_;V_X*>>!/V"O%V@>$?%WPOU?7Y-?TV6\AFTZ\BB6)4DV%2'ZDGGB@#Z
M?HK\Y?\ B(R^"W_1N/BC_P &MM_A1_Q$9?!;_HW'Q1_X-;;_  H _1JBOSE_
MXB,O@M_T;CXH_P#!K;?X4?\ $1E\%O\ HW'Q1_X-;;_"@#]&J*_.7_B(R^"W
M_1N/BC_P:VW^%'_$1E\%O^C<?%'_ (-;;_"@#]$K+2-)TV>XNM.TNWMY+N3S
M+J2&!4:9^FYR!\Q]S2MING-J*ZPVGP&[2%H4NC$/,6-B&*!L9"DJI(Z$@>E?
MG9_Q$9?!;_HW'Q1_X-;;_"C_ (B,O@M_T;CXH_\ !K;?X4 ?HU17YR_\1&7P
M6_Z-Q\4?^#6V_P */^(C+X+?]&X^*/\ P:VW^% 'Z-45^<O_ !$9?!;_ *-Q
M\4?^#6V_PH_XB,O@M_T;CXH_\&MM_A0!^C5%?G+_ ,1&7P6_Z-Q\4?\ @UMO
M\*/^(C+X+?\ 1N/BC_P:VW^% 'Z-45^<O_$1E\%O^C<?%'_@UMO\*[7]G/\
MX+D?"K]HOXW^&O@AHOP,\0Z;=>)-26S@OKK48'CA8J3N8*,D<=J /N6BBB@
MK\0?^#WG_DUGX'_]E U'_P!(17[?5^(/_![S_P FL_ __LH&H_\ I"* //\
M_@TV_P"4IG[7?_;Q_P"GR>OW^K\ ?^#3;_E*9^UW_P!O'_I\GK]_J "OG?\
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M"_\ X(+;_P"(H_X4A\%O^B0^%_\ P06W_P 17444 <O_ ,*0^"W_ $2'PO\
M^""V_P#B*/\ A2'P6_Z)#X7_ /!!;?\ Q%=110!R_P#PI#X+?]$A\+_^""V_
M^(H_X4A\%O\ HD/A?_P06W_Q%=110!R__"D/@M_T2'PO_P"""V_^(H_X4A\%
MO^B0^%__  06W_Q%=110!R__  I#X+?]$A\+_P#@@MO_ (BC_A2'P6_Z)#X7
M_P#!!;?_ !%=110!R_\ PI#X+?\ 1(?"_P#X(+;_ .(H_P"%(?!;_HD/A?\
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MY_Y-9^!__90-1_\ 2$5^WU?B#_P>\_\ )K/P/_[*!J/_ *0B@#S_ /X--O\
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MPR_X+,?!#XD?\$U-&_X*+'P)J6DQ:QKL'AO_ (0O5;^**>T\03:HNEK937+
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MZ='K<#7$FH0:OI[36JQA]QFC4%GC W*H+$ <U^WRJJJ%4  #  [4M 'Y4?\
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M3M4^$/@:_P!9OA%!,8;X#4-7:2;:FW[/#I>GPRYY2UN"&_?L*_4VB@#\7?\
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MQC!XQUR_TVVMM#OX8'MWBU:>4NQE&""#C K]!/\ B-Y_99_Z,>^('_A16/\
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M>?V6?^C'OB!_X45C_A0!^WU%?B#_ ,1O/[+/_1CWQ _\**Q_PH_XC>?V6?\
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/$EMQ$$41#(((SDT ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>jnj-20211003_g13.jpg
<TEXT>
begin 644 jnj-20211003_g13.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@!
M< &" P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ ^/?V'_V'_P!N3_@KK^W)\=_A1\*/V[O$'@C_ (0CQ!J%^[ZM
MX@U.6*6)]3FA6*-891MVX^F.*^P/^(3;_@J9_P!)=O\ RH:Y_P#'J/\ @TV_
MY2F?M=_]O'_I\GK]_J /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_T
MEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O
M_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH
M:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?
M_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZ
MOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_
MJ* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@
M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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MKBVM+6XMUT^1XIYKFUG"A6=?)ADEW%E\H@"_LX_\%2OV&/VL_P!ICQU^R%\
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MQ,^)'A#PQ+KOQ O_ !!XQ;0M"\/1+Y02U>ZBL[R2:[=IX5\I(=J>:-S@I($
M/L.BOB_]E?\ X+'>#_VR_P!A;XC?M5_!/X,S)XT^$HOH?'WPH\1>(EM+C3[R
MSC:6>!;R."59%>))3#+Y861T*-Y6'*?,GP(_X.@_&_[57[*WQ/\ VBOV;_\
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MW>XO;V[F6.*WB12SR.[$!%5026)  !)J6WGBNK=+JW<-'(@9&'<$9!K\/?\
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ME,_:[_[>/_3Y/7[_ %?@#_P:;?\ *4S]KO\ [>/_ $^3U^_U !1110 4444
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M%GQ/->7-Q,")C,9=299U<,RM'(&1E.TJ1Q0!^:7_  =O_LQ>._V>?C/\%_\
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M#^'_ ,5[6YM_$.D_"70K;4[.\!$UHZV46+=P>0\:[8R.Q0CM7T%110 4444
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M]AW74F^(/@JP7PFNC>./#-R+N\LUOU^R,1J@\II/MJ%7?$8$;[F4[0P!D_\
M!G_^U[XZ\(_L&?M(V?Q&\1ZCK'A3X._9O$6AZ7/=%_L<,EC?3W4$!;/EHQL5
M8(/E#N[8R[$X/_!"KP/X=_X+8>%/VM_VNO\ @HOX<L/B+XLOQ!I?A*ZUZ#[0
MG@R"2UO)RNCJ^?[/*,;?9)%MD7R%.[+.6]G_ .#8[_@EK^VY^PGX7^//P/\
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M';QF&V< DHXA:-]K'>5D5S]\$@'8T444 %%%% !1110 4444 %%%% !1110
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MASK/PB^+W@K3O$?AGQ#8/9:UHFK6PFM[N!Q@HZG\"".00""" :\E_P"'G_[
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M_HTEQ) FHV#$QF1#AEY Y!H Z:BBB@ HHHH **** "BBB@#G?B_\4?"/P/\
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MS7=HT.?MTEW=ZFI0PLI:17BD0 I%(G[+V>FZ=I[SRV&GP0-=3&:Y:&(*9I"
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MZ]I7B#Q9X6^#?AK5-7\+Z?KPLHGTZ[U.T%S%927Z6@M]C;6)C$:ON"[5]?\
M^":?QK\-?M!_M5?&[XCI\ _VB_!.OR^'?"O]I']H305TN2>V:XULV\&EVBDI
M%:PE9BQ0C?),=P+*6/'?M)VG_!4C]GW]L3XH?&+]GCXB?LD_#_X9^,?[$>WU
M'XT#6(+C6-0BL%MY)I7MKQ(C<*L*P9&S=!#; QDH7;VO]@M?^"D>I?$'QOXN
M_;T\2?!?5]'U+P[X?_X5]J'P3AU!+"7;+JC7AE^WR22-)B2S(97,94C&#NH
M^F**** "OS?_ .#D D? OX>$'!_X2:[Y'_7L*_2"OS?_ .#D'_DA7P\_[&:[
M_P#285ZV0I//<*G_ ,_(?^E(\G/VUD6*:_Y]U/\ TEGX^^=+_P ]6_[ZH\Z7
M_GJW_?5-HK^S_JN%_D7W(_B7ZWBO^?DOO8[SI?\ GJW_ 'U1YTO_ #U;_OJF
MT4?5<+_(ON0?6\5_S\E]['>=+_SU;_OJCSI?^>K?]]4VBCZKA?Y%]R#ZWBO^
M?DOO8[SI?^>K?]]4>=+_ ,]6_P"^J;11]5PO\B^Y!];Q7_/R7WL=YTO_ #U;
M_OJCSI?^>K?]]4VBCZKA?Y%]R#ZWBO\ GY+[V.\Z7_GJW_?5'G2_\]6_[ZIM
M%'U7"_R+[D'UO%?\_)?>QWG2_P#/5O\ OJCSI?\ GJW_ 'U3:*/JN%_D7W(/
MK>*_Y^2^]CO.E_YZM_WU7[K_ /!![G_@GYIA/_0S:E_Z&M?A-7[L_P#!![_E
M'WIG_8S:E_Z&M?B?C-2I4L-@^2*6L]E;I$_</!2M5JXK&\\F_=AN[]9'V711
M17X,?T ?+W[?7_!4'P!^P)XLT#PIXR^&6K:Z^OZ=)=PSZ=>11+$$DV;2'ZDG
MGBO /^(D'X%?]&\^)O\ P;6_^%>5_P#!R3_R5WX<_P#8L77_ *4BOS/K]<X(
M\/<LXHR9XS$59QESN-H\MK))]4^Y^/<=>(V:<*YVL%AZ,)1Y%*\N:]VVNC78
M_83_ (B0?@5_T;SXF_\ !M;_ .%'_$2#\"O^C>?$W_@VM_\ "OQ[HK[#_B#6
M1?\ 014_\E_^1/C?^(U9]_T#TO\ R?\ ^2/V$_XB0?@5_P!&\^)O_!M;_P"%
M'_$2#\"O^C>?$W_@VM_\*_'NBC_B#61?]!%3_P E_P#D0_XC5GW_ $#TO_)_
M_DC]A/\ B)!^!7_1O/B;_P &UO\ X4?\1(/P*_Z-Y\3?^#:W_P *_'NBC_B#
M61?]!%3_ ,E_^1#_ (C5GW_0/2_\G_\ DC]A/^(D'X%?]&\^)O\ P;6_^%'_
M !$@_ K_ *-Y\3?^#:W_ ,*_'NBC_B#61?\ 014_\E_^1#_B-6??] ]+_P G
M_P#DC]A/^(D'X%?]&\^)O_!M;_X4?\1(/P*_Z-Y\3?\ @VM_\*_'NBC_ (@U
MD7_014_\E_\ D0_XC5GW_0/2_P#)_P#Y(_83_B)!^!7_ $;SXF_\&UO_ (4?
M\1(/P*_Z-Y\3?^#:W_PK\>Z*/^(-9%_T$5/_ "7_ .1#_B-6??\ 0/2_\G_^
M2/V$_P"(D'X%?]&\^)O_  ;6_P#A0/\ @Y ^!9.!^SSXFR?^HM;?X5^/=.A_
MUJ_[PK.MX.Y'3HRFL14T3?V>G_;II0\9\^JUHP>'I:M+[75_XC^FW]G3XTZ7
M^T5\$/#7QOT71+C3;7Q)IJWD%C=2*\D*EB-K%>">.U=K7@__  3!_P"3 ?A7
M_P!BM'_Z,>O>*_G<_H\*^0/^"_'_ "AL_:$_[)_-_P"CHJ^OZ^0/^"_'_*&S
M]H3_ +)_-_Z.BH _C"HHHH _?[_@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\
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MD'_DA7P\_P"QFN__ $F%?I!7YO\ _!R#_P D*^'G_8S7?_I,*]?(/^1[A/\
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M&B:MXHMM9;4HH[_Q3*]RMS;1H@ ,ZIY6"R[=Q.' H ^T:*** "OS?_X.0?\
MDA7P\_[&:[_])A7Z05^;_P#P<@_\D*^'G_8S7?\ Z3"O7R#_ )'N$_Z^T_\
MTI'D<0?\B'%_]>JG_I#/Q[HHHK^U3^'@HHHH **** "BBB@ HHHH **** "B
MBB@ K]V?^"#W_*/O3/\ L9M2_P#0UK\)J_=G_@@]_P H^],_[&;4O_0UK\0\
M:?\ =L%ZS_*)^Z>"/^]XW_##\Y'V71117X$?T(?D7_P<D_\ )7?AS_V+%U_Z
M4BOS/K],/^#DG_DKOPY_[%BZ_P#2D5^9]?TWX1?\DI+_ *^2_*)_+GC%_P E
M;'_KU'\Y!1117ZB?E04444 %%%% !1110 4444 %%%% !3H?]:O^\*;3H?\
M6K_O"L,5_NM3_"_R.C"?[W3_ ,2_,_HJ_P""8/\ R8#\*_\ L5H__1CU[Q7@
M_P#P3!_Y,!^%?_8K1_\ HQZ]XK^&C^\ KY _X+\?\H;/VA/^R?S?^CHJ^OZ^
M0/\ @OQ_RAL_:$_[)_-_Z.BH _C"HHHH _?[_@TV_P"4IG[7?_;Q_P"GR>OW
M^K\ ?^#3;_E*9^UW_P!O'_I\GK]_J "FR0PRNDDL*LT;;HV902C8(R/0X)'T
M)IU% %'7/%'AKPQ''-XE\16.GI*Q6)[Z[2$.1U +D9K-\,_$GX9^,?%.I>&O
M!_C+2=3U;3+"TN=4@T^[2:2"WG>X6W9RA. S6]R%!/5'_'\GOVQ8/^"3$'_!
M4GXW'_@H3^S)\1?C'XBDM_#LN@SV_P .M=UNR\-69TJ%#IL"6H,"QNZM=B5!
MEI+J=&VM#E_HK_@C???\$SYOC'\8['_@G1^RYXF^&*0^'?";^,;;7_"=]HD=
M^[3:Y]E:*UO5#[D"S[Y1\KAT7JA) /O>BBB@ K\W_P#@Y!_Y(5\//^QFN_\
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M]H3_ +)_-_Z.BH _C"HHHH _?[_@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\
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M7_7R7Y1/Y<\8O^2MC_UZC^<@HHHK]1/RH**** "BBB@ HHHH **** "BBB@
MIT/^M7_>%-IT/^M7_>%88K_=:G^%_D=&$_WNG_B7YG]%7_!,'_DP'X5_]BM'
M_P"C'KWBO!_^"8/_ "8#\*_^Q6C_ /1CU[Q7\-']X!7R!_P7X_Y0V?M"?]D_
MF_\ 1T5?7]?('_!?C_E#9^T)_P!D_F_]'14 ?QA4444 ?O\ ?\&FW_*4S]KO
M_MX_]/D]?O\ 5^ /_!IM_P I3/VN_P#MX_\ 3Y/7[_4 %%%% !1110 4444
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M?SO[V'U3"_\ /N/W(^-/^'#W_!/S_H6/$W_A2/\ _$T?\.'O^"?G_0L>)O\
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MY\./#EMX@TWPQ<^-[;5++Q!IER"()X[Z"%5A/F>7'(I1MADX+E6  /J#Q_\
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M^&^A>.]=TBW8?9K'Q$%LK::54'$<MQ'<&64\&1E4MG:, 'W[\8_C=\)?V>_
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$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>jnj-20211003_g2.jpg
<TEXT>
begin 644 jnj-20211003_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[+_@:+XF_M$?&+0/!GAV>Y2WBUSQ!J*6UH97&43S6.T%L<9//:OSL_X. /\
M@J[\>?@G_P $C/!W[3W[%>B1V.A_''3M-MXO'-]?B+4=!M-5T][R$6]LH/\
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MNW>0<,MJ21N0E@#^@35]7TGP_I=QKFO:I;V5E9PM-=WEW.L<4$:C+.[L0%4
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M5"1K_1K10!\1?\%V?BWX2^'G_!'#XQ:%\:_B%X:T?Q-X@^%MQ9V^GOJ"6_\
M:.H2)'&T=I%*YDD'FN %!8@,,D]:\5_X-&?BE\-]>_X)'^&_AAHWCS1[GQ)H
M?B?77U?0(=1B:]LT>^,B/)"&WHA66,AB,'>.>:_4>B@ HHHH **** "BBB@
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MVM_J-@+588X)OLEP[+%<RM%'&&_>%M@ /T<HKXD^*'_!7ZZU3_@IXG_!)_\
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MX@_!5=66\%C\5X!I=XVGWAM9I'N;BQA:")B/W>(Y)79T4QHOF21]_P#L'?\
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M1_%_0]'^TZMJ&K7^N7EQ\.HS;3>>EU>7\S0JAEDD@CCC9S,9C(BE%ED3]-B
MP*L,@]0:HZ#X9\-^%;1[#PQX?L=-@DF:62"PM$A1I&^\Y"  L>YZF@#\ _\
M@C?\=O@IH_\ P72_;_\ '&K?%KPW;:+JUCXSOM*U>?6H$M;VVCUPRO-#*6VR
MH(OWFY21L&[IS6M_P:6RVOCC_@EU^U1\%O"VH6UYXKU*ZOFLO#\5RGVN5)]$
M\B%Q'G=L:4% V,;AC.:_?2B@#\6?^#-#XQ>"/"/['OQ _9*U^:_M_B':_&C5
M=4U3PQ)I4ZSZ99'2=+@$]T2@6W4SVLT(#D,9%VA>"1^TU,CM[>%WDA@1&E;=
M(RJ 7.,9/J< #\*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 >9-+(S.S8 RV%"J%4>H4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M73G:.PL1R =F?WLF#S*^6Y(&U<*/%:_HGA/PBP&!C'$9Q:K4WY%\$?7^9_\
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M:>*53YT[ 7*C[P_Z:#D?Q Y+#\#XM\*L1@8RQ647J06KIO62_P +^TO+XO\
M$?T%PAXLX;'RCA,X2IS>BJ+2#_Q+[+\_A_PGVS145A?V.J64.I:9>17%M<1K
M)!<02!TD0C(96'!!'((J6OQMIIV9^TIJ2N@HHHI#"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M**^3_P#@J3_P4BT3]B+X=IX4\#3VM]\1O$%LQT6QE =--@.5-[,OH""(T/WW
M!ZJC5Z.4Y5CL[S"&#PD>:<WIV7=M]$MVSS<WS; 9'E]3&XR?+3@KON^R2ZMO
M1(J?\%,_^"IG@O\ 8HT1_ASX!2UUSXD:A:[[73W;=;Z1&P^6XNL'))ZI",%A
MR2JD%OQ/^)7Q,\>_&'QQJ/Q)^)WBF[UK7-6N#-?ZC>R;GD;H!Z*H  55 55
M    JGXM\6^)_'OB>_\ &GC37KK5-6U2Z>YU#4+V8R2W$KG+.S'DDFLZOZZX
M/X,R[A+!<E-<U:2]^?5^2[171==W=G\>\9\:YEQ?CN>H^6C%^Y#HO-]Y/J^F
MRL@HHHK[$^+"BBB@ HHHH **** "BBB@ HHHH *.O2BO3?V6?A__ ,)9X_\
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M 4_\O3*?F;K&#L&#O+?=]?SUQYXIXAUYY?DL^6*TE56[?50?1?WMW]FRU?\
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MX=2U&\\2>)K/PWX,\+:''&]_K^L73%8+2 2O'&F<,S22.B(JDELE0?"O"/\
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M\$T-PJ)YT,H24*Q1&#0R K@!F /L.BBB@ HHHH **** "BBB@ HHHH ****
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MWTGQ?8:S/$KRV%M':0VDDV^%_M4*0Q3B2%-K.T@.'X,8!]??M,_'KX2?L=_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7[75YH=CZ]J]U?9(Y*@B!?P_<Y'USWK\XK.TN=0NXK"R@:6:>18X8T&2[$X
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MHMMVZM-+Y2MW/UMHKR^/X\ZT%Q+H5J6]5=@/ZU#=_'7Q-*-MIIME%[E68_S
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M94LS.OFM&#@N$SDKGC.,4 6:*** "BBB@ HHHH **** "BBB@ HHHH ****
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MS/Y?X+N;=O\ @^&\6!9T);PXB+ANK#P+9DCZC!_(UF:'Z?\ _!83PU\1K_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!5499B< "H[:^LKV-)K.\BE252T;12!@X!P2".H!(H EHHHH **** "BBB@
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M5C_M8?:?DTV'$A:/!>0E""H7K?CG_P $T;_]IG]H3Q9\5/C7\8M+O/"_C?\
M9\NOA7XB\)Z3X/EM;DP7%PUS)?P7KW\HBD$KDI&8'V@*"S$;B 9EW_P44_:4
M\-^*O$>@>)OV(=7DL[#X5:AXPTCQ%%%KEEI$=Y9#?-HE]>7NCQ+;SO&=\,R+
M(LI1U*)@%O2/V"_VD_VAOVKOA/H_QT^+/P!T'P3X9\7^!O#WB+P7)IOC-M3N
M[L7]E]HN8KF$VL2VWE,8MA5Y/,24%O+960<)\*/V)OVY=.^!OB#X(?M#?\%
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M$_\ ;<U/XY:+J6G?$KPUHVBS>#X/!$MO-80Z8+C[.ZWIU"02,QN9"^8%! 4
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M3TJ0JI-I/-)(VUAN243(Q)0F@#Z<HHHH **** "BBB@ HHHH **** "BBB@
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M+&APZ1:I9+&8ULUMU$00@@KLQC&"1C'>I[:VM[.W2TM+=(HHD"1Q1H%5% P
M . !Z4^B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>jnj-20211003_g3.jpg
<TEXT>
begin 644 jnj-20211003_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX[_L=U75K?0-526>S#9V-+"<2(C$$*Y4*Q4X)P:^/?\ @FE\'/A1_P %C_\
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M[3/@[6-4U'6/[*MM$M=:C_M 7WDR3?9I+1B)X9/*BDDVR(IVH6Z<UZW7S_\
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MIH_@WPM8310W.M:U<^7$)9&"QQKC+.[$\*H)."<8!KIO!WC#PK\0O"6E^/?
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MR_X=?4?BMKNN>,WTB*>]1;B232=-6.SN3/<*EG=JTDIBC66 IR&#USW[2O\
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MQI\/8;X697:0Y;[:Q?DXPO89!+=:Z_PWX*\&^#8YH?!_A+3-*2X??<+IMA'
M)6YY8(HW'D\GUH Y;]E?X0:A^SY^S#\./@'JVN#4[KP/X#T?P_<ZD"2+N2SL
MH;9IOFY^8QEN>>:_+O\ X.)_^"Y7[-W[/WBBT_X)N7.I^)-5M]>13\=)? 5S
M"FH66B2)N_L6&61U6&XO$(65^6AMI&PI>93'^P%% 'Y>?\$U/^"A/P5_X+=?
MLV_&+]B3]E[]F:X^%?PE\,?!X^#F756B+QS:M;75I;0V\=NQ1(8;>"9GR6=F
MDC^YM)D_/+X6Z?K'P#_X-N?VE/\ @F)\5;(Z9\?$^/EGHNE_"DL'UO5I9M0T
M&:*2SM5_>74,D=O<NDL:LCK"S*2,9_I0JG-X>T"XUJ'Q)/H=F^HV\+107[VR
M&>.,]45R-P4]P#B@#\K/'/[8?A7_ (-L?^"&/PD^"7C]K.[^,DWA.2V\->$
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MW]EM[>9TDF@1VB;=&S*"4.,9'H<$C\:!;6ZW!NUMT$K(%:4(-Q4<@9ZXY/%
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M'>Z?=+-$SQZ?#'(FY21N21'1AU5D93@@BO:J* "BBB@ HHHH **** "BBB@
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M?B^'_P $;&5MT.A:&F^>YEB7HL]YBSEFD'S$C9N**JC#_P""8G[0/[*7C_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFU?6=1GN[NXD,EQ=74S222N>K,S$EB?4U!117W*22LCX-MMW84444Q!1110
M4444 %%%% !7H7P*_:O_ &C_ -FC55U7X&?&77?#I$GF26=G>%K29O\ IK;/
MNAE_X&AKSVBL:^'P^*I.E6@I1>Z:33^3T-L/B,1A*JJT)N$ELTVFO1K4_4C]
MEO\ X.,-5MI+7PS^UY\*8[F(D(_BGP@-DBCINEM)&VMZEHW7VC/2OTC^ W[2
M_P "/VG/"@\:? GXGZ7XCL0%\\64V)[4GHLT+@20M_LNJFOYE*WOAK\4OB-\
M&_%]KX^^%7C;4_#^LV;9M]1TJ[:&11GE25/S*<<J<JPX((K\PX@\*,DS%.IE
M[]A4[;P?RW7_ &Z[+^5GZIP]XMYYEK5/,%[>GW>DU\]I?]O*[_F1_4-17Y=?
ML,_\' ]AJLMC\-_VW-'CM)G*PQ>/=&M<0L>@:[MD'R>\D(*\C]VH!:OTW\,^
M)_#?C3P_9^+/!^OV>JZ7J$"S6.HZ?<K-!<1MT='0E64^H-?@V?<-9QPYB/98
MZG:^TEK&7H_T=FNJ1^_Y!Q-DW$N&]K@:E[;Q>DH^J_573Z-EZBBBO!/?"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@Y)5)+C3X5F5?0?Z/&<>K$]S0!^U%%%% !1110 4444 %%%% !1110 4444
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M45^X'X4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<-C+0K;)_9EZ=GY=>G8_%N)N",3E?-B<'>=+=K[4?7NO/==>Y\B4445^@'P
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M(_#@$)A7)*?LEH.@:'X5T2T\->&='MM/TZPMDM[&QLH%BAMXD 58T10 J@
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M*E-6E%M/U6C/[DHUJ>(HQJP=XR2:]'J@HHHK,T"BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK[N\7>+_ !/X\\177BWQCK=QJ.I7LIDN;NY?<SG^@ X &     !7!?%GX/\
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M^I3.#*??((4>H)_AP?&69F8LS$DG))/6K.M:SJ'B#5)M9U6X,D\[[G8]!V
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MCP);9R,;T;MT&1T.!D<#'R/\6?A#XH^$6O\ ]EZY'YUI/N;3]2B0B.Y0=?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/ZQ/V%)^ZMWW?^2_%Z]@HHHKWSYX**** "BBB@ HHHH **** "BBB@ HHHH
MKZMI.EZ]I=QHFN:?%=V=U$8[FVG7*2+UP?3D @C!! (((!KY8^/G[..J_"^6
M3Q-X:$M[X?=QF0C=)9$G 67'522 ).A) ."1GZOILL4-Q"]M<P1RQ2QLDL4L
M8=)$88964\,I!((/!!(-1*+OS1W_ #_K^NQ<9*W++;\OZ[?\.? -%>T_M!_L
MPS^$5N/''PYM9)M(4&2]TX$O)8#J67/+Q#KGED'WL@%J\6IQDI"E%Q"BBOJW
M_@DQ^P%J7[;'Q^AU/Q;I;_\ "O\ PE/%=^*;AU(2\;.Z*P4]VD*_/C[L88Y!
M*9XLTS+"9/@*F,Q,K0@KO]$O-O1+N=V599B\YS"G@L+&\YNR_5OR2U;[(^]_
M^"#'[$%S\#_@M<_M._$'1_)\2>/K5!HL4R8DL]&!#H?8SL%E(_N)">"2*_0"
MF6UM;V=O'9V=ND442!(HHT"JB@8"@#@ #C%/K^.<]SC$Y]FM7'5]YO;LMDEZ
M+3SW/[0R#)L+P_E-+ 4-H+5]WNY/U>OEL%%%%>0>P%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XW^TA^W%\'_ -F[
MXC^#/@7J&EZYXK^(_P 0Y+D>#/AWX/MH)M4U**WC,EQ<DW$T-O;01H"6FN)H
MDX(!8@BO9*_*+_@X$_X)S_\ !0/Q9^T9\./^"M/_  3"\475Q\3_ (2>'&TF
M[\)6BH]U=V"S7,WF6L4@*719;NYBFMF^:6-E"!F&T@'U9^Q7_P %;?A9^UKK
M_@/X<^+?@=X^^&7B_P"(_@-?%O@W3?%6FQ7&GZ[IPBCDFDLM1LY)89/*66,M
M'-Y$RAUW1*6 KE_VX_\ @O?^PM^Q!\7_  [^SIK6I:YXO\?>)M<MM,LM"\,Z
M8QM[9I;H6QDGO9=D&U)-ZNL32R*R%60'I\J?\&X7_!7K]E#]M?P#\+?V(?B=
M\._^$:^-/P7\(M9^#+B[F,D.M6D-G]FN9K60;2DQ@!:6U<$83S$+^6?*\K_X
M.T54?M__ +$KA1N/B:Z!..2/[5TC_$T ?NQ7B7_!0[]N_P"$/_!-G]E#Q%^U
MO\;+'4;[1M EM($TG1Q&;S4+BXN$@CAA$KHI;+ESEAA(W;M7MM?GA_P7A^ O
M_!7GXZW_ ,(-5_X)7C1+*\^'FN7_ (DU'4]4U33TE;4FM&LK5(8+]'@<K!<W
MV6D& 9D((900 <Y_P3R_X.=_V9O^"DW[5OA[]DKX(?LM_%"SUG7HKJ>75M73
M3A9Z=;6\#S23SM'<LP7Y @PI)>1%_BK],J_'#_@D_P#\%QO^"AVF?MX:9_P2
MO_X+*_ H>'_'OB*"7_A$O%J:/'82W%PD4DJI.D!-K<PS"&18[FUP@D0(0^XM
M'^Q] !1110!\W?M?_ %K>6;XN>#[/,;G=KEK&OW&_P"?@#T/\7O\W=B/GBOT
M6FAAN(7M[B)9(W4JZ.N0P/!!!ZBODK]IO]G&Y^&^H2^-/!]FTF@7$F98D&38
M.3]T_P#3,G[I[?=/8G]5X-XFC5A'+\5+WEI!OJOY7YKIW6F^_P"3<:<+RHSE
MF&$C[KUFET?\R\GU[/7;;QZBBBOT<_- KA_C!X^&CVC^$M(F/VNXCQ>RJ<>3
M$P_U8_VF!Y]%..=QV[GC_P ;6W@C1OM*,CW]P"MC P#<]Y&!XVK[_>.!@@-C
MQ*YN;B]N9+R\G>665R\LLC%F=B<DDGJ2>]?09+EOMY^WJ+W5MYO_ "7Y^A\]
MGF9_5X?5Z3]Y[^2_S?Y>J&4445]@?&!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 *CO&P=&*L#D$'!%>!?M"?LMK,9_'7PITP!CF34-"MTXSU,E
MNH[=S$.G\'&%7WRM7P1X*\4_$7Q59>"_!>CS7VIW\PCM;:$<D]R3T50,DL<
M $DX%8UI4Z<'4E)145=M[)+>_D;4(U*M14H1<G)V26[;VMY]CXI_9D_9L^)_
M[67QDTGX)_"?2?M&I:E+F>YD!$%C;*1YES,P'RQH#DGJ20J@LR@_T.?LF?LO
M_#K]C[X&:-\#OAM;YMM.C\R_U"2,++J5XX'FW,F/XF(X&3M4*@X45SW[&_[%
M/PS_ &2]"U#5M&T2RD\7>)3'-XKUV"+!N9%'$:9^[&I))P 78EV^8\>U5_,'
MB!QM/B7%+#89VP]-Z?WY?S/R_E7;5ZNR_J?P[X&APQA'BL2KXFHM?[D=^5>?
M\S[Z+1791117YP?I84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5\U_'_XL?MH_ K]L+3?%W@7]F7Q'\3_ (,:
MWX#ALM?B\(:UIRZEX?UN"\N'2ZCL[VYM_M$4L$ZI*8F+_N8C@[,'Z4HH _%S
M_@DI_P $N/'WQ<_:[_9F_P""F6H? QOA?X7^&'[.^EZ5<S:A/:KJ/CW77TRY
ML_MOV>UDD,-O';72KYMP8YY/L\:^5L^8:O\ P<)?L'_\%%/V]/VQ_@'\2OV6
M?V)/$&O>'_@[J=Q=ZQJMYXT\-V*ZB6U"TF MHY]360@I:$YD2,_O5! (8#]C
MJ* /D_\ X*C^/O\ @IL/V$)_&'_!,?X4-8_%V;6;02:!XE.E3WUEIWF.)VB#
M7$ME)-Q$0#(X\MW('F  >=?M"?M*_P#!=;X"_"7X#>-OAG^PKX%^+.HW?A:!
MOVA?#FF>(4M-2LM5\J$NFGNUPL*IN,N65+H;A@ (%=OO6B@#XSD_9G\5?M\_
MMB_ O]N/XY?LS:U\*H/@=8:S<Z/H7C"_TZXUG5=4U&&&% XTVYN8HK.W6-Y5
M+R^;),ZYAB5&\S[,HHH **** "HKVRL]2LY=/U"UCG@GC*30RH&5U(P00>H(
MJ6BFFT[H32:LSY-_:,_9=O\ X?2S>,O EM+<Z&Q+SVZY:2Q^O=H_]KJ._J?#
M]<UK3O#>D3:YJTFV" ?=!PTCG[L:^K'!^@!)X!K](6574HZ@@C!!'!%?)_[:
M/[!.K>/K?_A./@A*J3VJN\_A8D)%,QY9X#T5S@#8?E('RE>A_6>$.+\/B*]/
M!YK4Y5LJCZ^4NSZ<VW5]W^0\9<&XC#T*F-RFGS/=TUT\XKJNO+OT79?#GB?Q
M)J7BS69=:U1QOD.$C082)!]U%'H!^)Y)))).?5C5M(U70=3GT77--GL[RUD,
M=S:W4)CDB<=596 ((]#5>OZ/I*G&FE3^&VEMK'\TU74E4;J?%?6^]PHHHJR
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MTC'T7ZN[?5G[_D'#&3<,X;V6!IV;WD]92]7^BLET2"BBBO!/H HHHH ****
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M_O<7-^BBOSYC\VO#'_!-']JC7V3^T_#^E:,K8^;4]8C;:/4B#S#^E>I>"?\
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MC?>$)U_9QT.ZD^'>C_$6&[GT6WOK:SA:6[E@M&21YOMUTLBLK(<6MODD1!2
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYIK>W7<;R2"=!YLD7F>44WLP5=U 'ZL7VJZ7IG.I:E;V^4+CSYE3Y054GD]
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MQ((BXW,"57/) QDX_$?F*@NM)TN^E\^]TVWF?R'AWRPJQ\M\;TR1]UL#(Z'
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M>%_%ND:%XD>./S!XJ&F:A>1R16"?:9+QVE\S<D1"SL=S%0K>U:;'\#?V<_\
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MU ) R,\X%>(?L7_L<:_^RQJOQ+UCQ=\2M'\6W'Q!^*.K>-()[/P@VFR:3+J
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M(8XR[;%,3>I?L2)^U!%\#(X/VMO'%EXF\41ZU?+;>(;3PD=";4-/\X_9Y9;
MR2&U?;D!"VXQB-G5)&=%]=HH \N_9S^!WQ'^$_B3X@^,_BK\4-&\6:MXZ\6C
M5DN]*\*2Z7]@M8[6&UM['$E[<^8D44"88&,%WE<KND8UX'\'/^"7GQH^#?[,
M7Q[_ &3M%_:L\-R>%?C!JWB:]\*VB_"Z>-/!":WYOVJU@3^UR+FW1II)(TS$
M5D=R25(0?9M% 'RGIW_!/3XP6?BO]E_Q/<?M)>')#^SAI=U8O"GPWG7_ (21
M)]&_LEFS_:I^QD1$N.)OGQU7Y2_XS?\ !,JV_:%^/'QH^('Q;^+%I=^#OC/\
M&;/X=ZGX3T_PP\%[IUM;27TL=Y'?M=NCS![^5L&V"@QQ^C;OJFB@#X_T7_@G
MY^V5XU_95\7_ +,/[3'_  4/N?$ U'X>7OA#PIXE\(^"/[%N[5)H1"-4U#_3
M)3?7@10N(VMX]KRY!>19(]G]G/\ 8)^-_P )OVL=(_:G^(7[1GA?5WMO@O8?
M#_5/"WA?X:'1[%H;*\N+FVEM<W\YMD!N'WQ'S-S*-C1)^Z'U/10 4444 %%%
M% !1110 4444 %%%% !1110 5\P_\%=_V>/C%^U!^QO>_"GX&>#_ .W-?F\0
M6%S'8?VA;VV8HW8NV^XDC3@$<;LGMFOIZBN[+<?6RK,*6,I).5.2DD[VNG?6
MS3M\T<&:9?1S;+JN"K-J-2+BVK7L]-+IJ_R9^ G_  Y._P""G'_1L_\ Y>>B
M_P#R970?";_@C3_P4E\,_%/PSXDUO]G#R++3_$%E<WDW_"8:.WEQ1SHSMA;P
MDX4$X )/:OW;HK](J>,'$M2FX.C1LU;X9_\ RP_-*?@WPQ2J*:K5KIW^*'3_
M +AA1117Y2?K04444 %?.GC']C/XG>%/VRM=_;7_ &7_ (KZ'HFL>-_"-AH'
MQ!\+^+O#LU_8:NM@\S6-[#)!<P26MQ$MQ+$V?-CDC8#8C#>?HNB@#QOPU^S]
M\:O#'@#XBZ_:_'#2V^+7CVT<P^-$\);=,T:>*U,%@D&G/<.SV\!S*4EG=I9)
M9F+JKK&E75O@E^UII?Q8M?B]X#_:,\,RR3> -+T'Q+X=\0>"9I++4[ZUGNYF
MU*!X+V-[)V-VP\O$R[0%;)".GMU% 'S5\"OV&_BA^S5\/-:L/@S\=M&TOQ9X
M^^.$GQ$^)^LGP0&L-3^U2PB_T^RLS<DV2R6UO%"DS2S2*RM*Q=G)'TK110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
)10 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>jnj-20211003_g4.jpg
<TEXT>
begin 644 jnj-20211003_g4.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR\)PR?$?2-/_ '<'B:*VO6ANH[E!A9#+:M F3RKP1R##J&K]0?\ @IC\(O\
M@D_X/^&7BO\ ;*_X*8_#OP_XKT:70DTNUU#Q;I!U.73K;RF9+/2(U0M:32OY
MDGFP[)6DDRTH1(Q& ?2?P%_:'^!?[4?PVM/C!^SK\6-!\:>&+Z1X[?6O#VHI
M<P&1#AXV*$[)%)&Y&PRYY KK;Z^LM,LIM2U*\BM[:WB:6XN)Y B1(HRS,QX4
M  DD\ "OQS_X,R?"?PKT/]C'XG>(_ WQTM-;U77O'D=QK'@.&27SO"D*1/':
M^>)$0/+<(K,98PT3+"JAR\<BI^J7[3?[.?@;]K'X/:C\!/BG>:D/"NO30+XF
MT_2[Y[9]5LDE622QDEC(D2";8(Y0A5GB9TW .30!Q'P+_P""GG_!/3]IKXJW
M'P/^ '[9'P_\6^++?S"-"T7Q%#+/<",$N8.<7(4 L3$7  R>.:]'^-?Q]^"_
M[.7A"/QY\<_B9I'A?2I[^&QM+K5KL1F[NY3MBMH$^_/.YR%BC#.V#A3BOPJ_
MX*B?\$J/@=\"O^"YG[(/P[_X)D?#P>!_%'B358->\5Z1X;GE%OI-CIVH0O\
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MWNKZULKL?N[J5H_)MD$9;]X)'/[M"U?I)K?_  6N_P"";\7[9'CO_@G!\?\
MQF? ?B3PU;I;7<OQ0L+?3M \0136ZNT=M<SR&.1=D@7;.L0ER?+\T<URG_!,
M;]AC_@J3_P $ZOA[H_[*&M?M+_";XD_";PW>F/PYJ>L>'=2L_$%AIS2EVME6
M.5H64;F\M7=C'NQO9%5!]OZUX'\%>)-3MM:\1>#]+O[RR_X\[N]T^.66#G/R
M,RDKSZ$4 ?E__P $"_\ @G9I?[.'[;/[4_[5OP7T:32/@GXV\2QZ5\';=49(
M-4L8II+B>[ME;&ZQ263R;:8966,,R$KAF^^_VWOVT/@;_P $_OV:?$G[4G[0
M?B'[#H'AZUS';1$&YU.[;(@LK9"1YDTK_*HX &68JBLP]9HH _G1_9)_X.:_
MV>O#_P 8O&/[06H?LC^,?&O[2OQ?N(](L-7O[ZTCTG1[8R>7IF@66':6&PB=
MHVE=5$MS*7F< E$C^HO^"L?[-7B']G__ (+]?LI?\%/_ !6(K7X;WT]EX6\=
M>*I!Y5CH>J+]KA@FNI&)6VAF2\B5'=MH-N^YN1G]C*AO]/L-5LI=-U2RAN;:
M="D]O<1!TD4]593P0?0T ?C7_P $Q_@$GQ>_X."OVJ_^"K2:I:'X/>%8KW1O
M#_CI[E5TW4M0\BTANI8+DGRY8+>&UN1)*I**98_FZUX-^TC_ ,'.'[!GQ+_X
M*)0_&#XL?!/QQ\0_ /P;U%T^"6CZ2+6'3[C5<;9_$MREQ(K2S\>7:(R@6\>Z
M7'FRXB_H-T_3M/TBQBTS2K&&UMH$"06]O$$2-1T55& !["IJ /GG]B3]O/P]
M^TG^PMX7_;H^-,>C?#70O&"WNH:?;Z_K$4$=AI@O+B.S-Q<2LL9EDMHHY6(P
MH,A"Y"Y/Y#_\&</QG^$VG_M'_M6^&M3^(VBV>I>,=:T"Z\*Z?>:E'%/JT4=S
MK?F-;QNP:7;]H@R%!(\U<]17[_44 %?FA\%/VE?^":G_  6'_9$B^#G_  4W
MT+P;'XS\.R7]CJ5C\13%HU[.L$\D UK2;J0POY4R1H[RVC!4<M&V  &_2^LG
M7/ ?@;Q/I=OH?B7P9I.H65H5-K9WVG1310D# V(ZD+@<# X% 'XA?\$2?@7X
MO_X)Q>#_ -N_]ISX"Z#K7Q,^ &BV%V/A';7D9>/Q\=-COI#+ 53;<P*CK;O=
M1(8YPS% VPJOP-^V]^THG[<'_!%;0_C7JEEXFD\7Z/\ 'H+K/AGPKX(NM'\!
M> -&:TU);:RT^*"-=/\ ,GDDBD>4M+=EB5D<+L\S^LJ***")8((U1$4*B(,!
M0.@ ["HSIVGFS.GFQA^SD$&#RAL.3D_+TZ\T ?SP?\'2OQH^%_Q+_P""7_['
MD/@WQ?;W-S>V"W]MI\R/;W;VB:9#;FY^SS*LHA,J,JRE=CXRI8$$]=_P7OO]
M+^ __!8#]F3_ (*O>,M*U/Q?^S[J/A#3]$U7Q/X.U2?RX$$U^MPL5U92*RDV
MU^)X@LB^<4E0$A7K]]ZKZKI.E:[I\ND:WIEO>6DZ[9[6ZA62.1?1E8$$?6@#
M\T-'O_\ @BGJ_P"R]\>/VL/V<?V;;KQY\.=<\$+9?%_QW"=8_P"*ALY9XUGM
M(9K\F>[NK>(&=FC ,;K"@D61CY?Q;_P3*_9Q\5?\$Z?^"WOPZ^$'_!,3]LVV
M^,?P!^+^A7^N>+M(TO5H[P:+I44,H5]52$F.&XBF\E8;@K%([;H2BY=&_H M
MM&T>STR+1;32;:*S@14AM(X%6*-5QM"J!@ 8& !QBF:;X=\/Z->7>HZ1H5G:
M7&H2B6_GMK5(WN7 P&D90"YQW.30!!XV_P"1,U?_ +!=Q_Z+:OYZ/^#=[]HC
MX1_LD_\ !'_]JO2OVB/&-CX0U75=%O->\-:+XEE%E<^(+&YT>2UMI;"*;:UX
MLMQ$T*F$."Y"]2,_T4NJNI1U!4C!!'!%9U[X.\(ZE)82ZCX6TVX?2F#:6TUC
M&YLR!@&(D?NS@ ?+CI0!^8__  :Z_P#!/OQ[\ O^"2VN>#_VJOA_/:+\9_$>
MHZO=>$=;MFCD71;FQM[%([B)L%#-'#))M.#Y<T>0#D5\^_\ ! C]CK]IS]F3
M_@HO\=?^":OCIY[GX.?!/XB6GCNRN+M&_P!.OY[:>#1N/N%9[9X;YL?<N-)A
M _BK]/O^"IOAK_@HYXF_98>#_@EMX]\/Z!\3[7Q'97)D\16]N\=[IJ%_/M8S
M<QR1)([&([G ^19%#*S CN?V6_AA\0?#%EXD^+GQOT?2K#Q[\0M8CU+Q#INC
M7[7EMI,$-O';6>G17#QQM,L4,0=WV*K3SW#J K@4 >JU^>O@;]L7]A7]ON[^
M,7[!_P#P4L\.^$GN_!WQ?\3Z-H-O\2K.*RLO$&F6^H3K;7&F74HC1KBVB/V9
MS _GQF#S"1OW5^A59VL^#_"7B+2'\/\ B#PMIU_823&62RO+&.6%I"Q<N48%
M2Q8ELXSDD]30!^&W_!*+_@E_9_#O_@IU^UII7_!/GXBWU_\ LY:A\(M1\'Z-
MXNDOS=:=/KU_%;.MC;W2_)??89/M(:="[1#$;L7D);PK_@AWX_\ ^"<_P:^%
M/Q._X)??\%B/AKXET?QWI7CV22Q\&ZH=?FAUU76W4:>FGZ>[1SW*7-N)(\QD
MS">(QE]F1_23I^G:?I%C#I>E6,-K;6\8C@M[>()'&@& JJ,  >@JO-X8\-W&
MO0^*;CP]8R:I;PM%!J3VB&>.,]460C<%/< XH _&'_@J9X5_8-_9F_;U_8K^
M(FA>,K+]G_XH^#?"-N^DVGCA&G\-:1X6L$F:+2]1>*1G%SYDMQ:Q/#(RC,F]
MR%AW>[_\$IOAO^P!XX_X*+_%W_@H3H/_  4,^&OQ=^.7Q*T]H9?#W@C48K>U
M\.Z+&MLAC@M99Y+BY(2TM0]TVT#;@(F\[NR_X*A_\$Q?&?[:G[9_@#XU?%CX
M >$/C;\&_"G@>]TQ_A?=Z\=!UBPUN>X$AU2&]1%^V0M"B0FTEN(8U8"4*S#(
MX3]F[_@@U\%_ '_!0'X5_MH?!3]D>P_9ZT;X9KJ=QJ.D6GQ!N=9U+Q5=7-J;
M:"*2$22VUE!"LDSL\<SO-O\ +9% WT ?)O\ P0C^.WP3TC_@X1_;B\:ZM\7/
M#5KHVKWWBJ_TG5[G6X([6]M8O$)GDGBE9PDD:P@REU)'E@OG:":\)_X((_%W
MX6>$?^"*_P#P4-\-^*_B-HFF:C>_#?4S9V&H:G%#-.+C0]0M(-B.P9]]Q+%"
MN <R2(O5@#_3-10!_-S^R%\$O''[7_\ P:,?$?X-_L^'_A(?&'A/XH2Z[J7A
M/2)!-?2VT%U;3O'Y*9?<8!),BXS(8,("V!7T5_P1\^,W_!';]N+]F;X$?"KQ
MU\&M;\:_M"?#Z#3--3P1?WVO7DNEWUB886UJ-I)C9V=H(X8[EW!14V^2J&3R
MXF_;RJ.E^&/#6B7UWJFB^'K&TN=0D$E_<6MHD<ERX_BD90"YY/)S0!^%$OQ7
M^&$?_!Z^=9D^(>B+9IH)T9[PZI%Y*ZB/"9A-H7W;1,)?W7EYW>9\F-W%2?\
M!ME\3?AUK?\ P7(_;>ET?QUI%TOBKQ5KE[X9:#48V&K6P\17<IEML-^^3RY$
M?<F1M8-TYK]X:* /P@_X-JO'FB?LO_\ !4/]LG]F_P"-EKJ6C>.O%?C^Q3P_
MX7DTF=KJ\CAU+5S-<*JH0((X[J"9IF(3RG#@D$9_=^F"WMUG-TL""5E"M(%&
MXJ,D#/IR?SI] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M@U*R74M.N-.>5D%Q \9=#@J&!&1[\U^//_!GEX1UOX*?!#]HW]F/QY:_9/%7
M@+XVO9^(+%QAX9%M5MN0>@,EG, >^TU^QM?-C_L+7WPA_;MU/]NO]E[4-+TZ
M[^(NG6>D_&KP;JCR0V7B"*W;%KJ\$L2.8=1MD:1-K(T5Q&Y1C"Y\^@#\J/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ7ERQ.&=I+2<'O%_JGT?7R::3J***^;/I0HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **EL+"^U6^ATO2[*:YN;F58K>WMXR\DKL<*JJ.6))
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU&5U_AGK^$D[^J/YB\:\E>%SNEF4%[M:/*_\4-/QBU;T9C4445^S'XH%%%%
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M50HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\?_\
M@OY^RK_PKWXUZ3^U!X8TW9I?C:(6>N-&F%BU2! %8]AYL"@@=V@D)ZU^P%>7
M?MF?LR>'/VN_V<_$7P/U\QQ3:C:^;HU_(N?L5_'\T$W'. _# <E&=>]?6\$<
M0OAKB*EBY/\ =OW9_P"&6[^3M+Y'Q_'7#BXGX;JX2*_>+WH?XX[+_MY7C\S^
M<BBM/QGX/\2?#WQ=JG@/QCI,MAJVC7\UEJ5E,,-!/$Y1T/T8$5F5_9L)QJ14
MHNZ>J9_%,X2IS<9*S6C044451(4444 %%%% !1110 4444  )!R#7WC_ ,$8
M?B[\?];^-.M:1>_&/Q3<>&]'\+.Z:/<Z[/+:)<//"D9$+L4!""7! [5\'5^A
M_P#P1 \(&W\)>/O'TB9%YJ-EI\+$?=\F.21P/KYZ?D*^2XW=!<-UG4BGLE=)
MZMI:7\KGU_ JQ#XFH*G)Q6K=FUHDWK;SL?H:GQ3\?1IL7Q"^/]J",G\RM17/
MQ'\<7:[9?$EP ?\ GD0G_H(%8E%?SNL'A$[JG'[D?T<\9C&K.I+[V2W=_?:A
M)YU_>RSO_>FD+'\S45%%="22LCG;;=V%%%%,04444 >!_M(?LI1:]Y_CWX7V
M"I?<R7^DQ+A;GN7B'9_5>C=1\W#?,LL4L$K03QLCHQ5T<8*D=01V-?HM7CW[
M17[,&G?$J*7Q?X+ABM=?5=TL7"QW^.S=ED]'Z'HW9E_1N%^,'A^7"8^5X[1D
M^GE+R\^G73;\VXJX,6)YL9E\;3WE!=?./GW77IKO\D45/J>F:AHVH3:5JUE+
M;7-O(8YX)D*O&PZ@@]#4%?JJ:DKK8_)6G%V>X4444Q!5C2=*U'7=5MM$TBT>
MXN[RX2"U@C&6DD=@JJ!ZDD#\:KU]4?\ !,+]G]_&7Q N/C;XAL-VF>'6,6E^
M8ORS7S+]X>OEH<^S.A'2O&X@SG#Y!E%7'5=H+1=Y/2*^;^Y:]#VN'LEQ'$.<
M4<!2^V]7VBM9/Y+[WIU/LOX!?"?3_@C\(=#^&M@$9]/LQ]MF0?ZZY;YY7^A<
MMC/08':NQHHK^,\3B:V,Q,Z]9WG-N3?=MW9_:^%PU'!X:&'HJT()12[)*R_
M****P-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH _+/_ (+S?L)/:WB?MM?#/2"8IS%9^/;:!/N/Q'!?8'8_+"Y]?*./F8U^
M8=?T[^,/"/AKQ_X4U+P/XRT:#4=)U>QEL]2L;E<I/!(I5T8>A!(K\"/^"B_[
M#/BG]AKXZ3^$&6XN_"FL%[OP?K,JY\^WS\T+D<>=$2%8<9!5\ . /Z4\)N,8
MX_!K)L7+][37[MO[4%]GUA_Z3_A9_,OB[P7++\:\ZPD?W51_O$OLS?VO2?\
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MGT!K]8OA#\+_  [\&?AQI7PV\+QXM=,MA&92N&GD/,DK?[3,2Q],X' KQ?\
MX)^_LH-\$?!A^(WC?3]GBC7K9?W,J_-I]J<,L/L[<,_IA5XVG/T97\S>)G%T
M<]S%8+"RO0I/=;2GLWZ+:/S>S1_4'AAP?+(,M>.Q4;5ZRV>\8;I>KWE\ENF%
M%%%?F!^J!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#_A./VOOA[H13<J>)(+UUQG*VV;D@^V(CFOVEK\A\2\1S8O#T.T7+_P)I?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 456UC4/[)TBZU7R?,^S6SR^7NQNVJ3C/;I7!?\+__ .I2_P#)_P#^
MUUUX; XK%Q;I1NEYI?FSCQ./PF#DE6E9OR;_ "1Z-17G/_"__P#J4O\ R?\
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MF5;V:G=1]V4KVM?X8RMNMS],**_+O_B)+_ZLQ_\ ,B__ 'NK[?\ V$/VN/\
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M!EXNZR\2:[>:F+.&:]A.4N[>U@5C'%("@GD\P@M&A'LWQ;^%'[)W[$>HZ_\
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M[.=E:1?&OXR2?#_4=+7QN\K:!,+W4[5;N.3[ HO5)TUV*$6Y'FJ,G!-=#/\
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M?M)ZO:ZM.GAGP9+I5[X9O[6VMH+2>WN'U"X$QB:TMY@&C7,B9R%.V@#?L?\
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MKQ26T$DL"N&FB?;O"1X56?Z6\-_\$X_BCX-UG]F;Q=X:_:4TB+6OV?OA]?\
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M"VFV6H^-;:PNYVUC3=*G57L4CA6-7E\F'S9PLBARF\?=W_!1#]B[QW^V_P"
M/!O@/P?\:]*\%)X3^)6A^,)+G4?!TFKF\FTNZ6ZAMP$OK7RD9U 9OF..!@\U
MV?[7?P \4?M2_L@_$#]F&U^(5AX?OOB#X%U#PU?>(W\/O>16J7MH]M/-':BY
MB)(61RBF;Y3MR6P<@'A'[+?[:7QB\-_$+P%^RG\5?V>;&SM=<_9[_P"$Q\ :
MAX=\5F_OK^/35L+>XL;NWDMX8K>Y?[; Z>7--']Y3(<!JN? S_@I%\3/B?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
$ '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>jnj-20211003_g5.jpg
<TEXT>
begin 644 jnj-20211003_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHQ17YST4?\0X_P"HK_R3_P"W#_B)7_4+_P"3_P#VA^C%%?G/7T9^P#_S-O\
MVX?^W%>9G/!7]D9;4Q?M^;EMIRVO=I;\S[]CU,EXX_MC,Z>$^K\O-?7GO:T6
M]N5=K;GT91117PA]\%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLY\QQ?U[&SKVLI/1=ELE\E8****[#B"OHS]@'_F;?^W#_P!N*^<Z^C/V ?\
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M</\ TE!1117EGJA1110 4444 %%%% !1110 4444 %%%% !1110!\6_M:?\
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M% !1110 5]&?L _\S;_VX?\ MQ7SG7T9^P#_ ,S;_P!N'_MQ7S'&7_)-U_\
MMW_TN)]3P5_R4U#_ +>_](D?1E%%%?A1^]A1110 4444 %%%% !1110 5^<]
M?HQ7YSU^G>''_,5_VY_[>?EOB5_S"_\ <3_VP****_3C\M"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#[2_9+_Y-^\/_ /;W_P"E<U>C5YS^R7_R;]X?
M_P"WO_TKFKT:OYWSO_D=8G_KY/\ ]*9_1^1_\B3"_P#7N'_I*"BBBO+/5"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#XM_:T_P"3@?$'_;I_Z20UYS7H
MW[6G_)P/B#_MT_\ 22&O.:_HG)/^1+AO^O</_24?S?GG_([Q7_7R?_I3"BBB
MO3/+"BBB@ HHHH **** "BBB@ HHHH **** "OHS]@'_ )FW_MP_]N*^<Z^C
M/V ?^9M_[</_ &XKYCC+_DFZ_P#V[_Z7$^IX*_Y*:A_V]_Z1(^C****_"C][
M"BBB@ HHHH **** "BBB@ K\YZ_1BOSGK].\./\ F*_[<_\ ;S\M\2O^87_N
M)_[8%%%%?IQ^6A1110 4444 %%%% !1110 4444 %%%% !1110!]I?LE_P#)
MOWA__M[_ /2N:O1J\Y_9+_Y-^\/_ /;W_P"E<U>C5_.^=_\ (ZQ/_7R?_I3/
MZ/R/_D287_KW#_TE!1117EGJA1110 4444 %%%% !1110 4444 %%%% !111
M0!\6_M:?\G ^(/\ MT_])(:\YKT;]K3_ ).!\0?]NG_I)#7G-?T3DG_(EPW_
M %[A_P"DH_F_//\ D=XK_KY/_P!*84445Z9Y84444 %%%% !1110 4444 %%
M%% !1110 5]&?L _\S;_ -N'_MQ7SG7T9^P#_P S;_VX?^W%?,<9?\DW7_[=
M_P#2XGU/!7_)34/^WO\ TB1]&4445^%'[V%%%% !1110 4444 %%%% !7YSU
M^C%?G/7Z=X<?\Q7_ &Y_[>?EOB5_S"_]Q/\ VP****_3C\M"BBDDDCAC:65P
MJJ"69C@ #J2: %HJ)K^Q6Q.IM>PBV6(R-<&0; @&2V[IC'.:A3Q!H,FAGQ-'
MK=HVFBV-P=0%RI@\D#<9/,SMV@#.[.,<T 6ZY_\ X6K\./\ A8__  J#_A--
M/_X2?^S_ +=_8GV@>?Y&<;]OZXZXYQCFO!?VW_\ @HGX"_9X\#0Z=\+M;TWQ
M!XLURR$VCBTN$GMK2!Q\MW(R$AE/5%!^?K]WK^7/_"U?B/\ \+'_ .%O_P#"
M::A_PD_]H?;O[;^T'S_/SG?N_3'3'&,<4 ?O!17S?^P-^WSX;_:K\-KX0\7R
MV^G>.M.M\WMDI"QZC&HYN(!_Z''U4\CY3Q](4 %%%% !1110 4444 ?:7[)?
M_)OWA_\ [>__ $KFKT:O.?V2_P#DW[P__P!O?_I7-7HU?SOG?_(ZQ/\ U\G_
M .E,_H_(_P#D287_ *]P_P#24%%%%>6>J%%%% !1110 4444 %%%% !1110
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MHK>1&W"%S.)!LVCDMNZ8]ZQ?"GPQ\%^"_AU;_"C0-)9-"M;!K**RFN9)3Y#
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MRE0?:OH?_@G7\5/#6N_"GQ9\8M'M-1N-*;2+348H%L'%U)$B73E5A;#>80I
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MG%\)E^UW.D1Z2VG.+R\>2:6!D*-OESN+%2?FSFET'X9>"O#GPWA^$FF:0?[
M@THZ<EC-<R2$VQ0H8R[,7/RDC).?>M^B@#%T3X=>"O#O@"'X6Z/X?BBT"#33
MI\6F%F=!;%"ABRQ)(VDCDYJ72O!'A#0_!T7P^TKPY:0Z'#8FSCTI808!;[=I
MBVG@KM)&.F*U:* /F3]MO_@G1\/_ -H+P%!>_"K0M-\/>*M!L1!HWV.W6"VN
MH$'RVDBH % Z(^/DZ?=/'Y=?\*J^(_\ PL?_ (5!_P (7J'_  D_]H?8?[$^
MSGS_ #\XV;?USTQSG'-?O!7/_P#"JOAQ_P +'_X6_P#\(7I__"3_ -G_ &'^
MV_LX\_R,YV;OTSUQQG'% 'A_[ W[ WAO]E3PVOB_Q?%;ZCXZU&WQ>WJ@-'IT
M;#FW@/\ Z')U8\#Y1S](444 %%%% !1110 4444 ?:7[)?\ R;]X?_[>_P#T
MKFKT:O.?V2_^3?O#_P#V]_\ I7-7HU?SOG?_ ".L3_U\G_Z4S^C\C_Y$F%_Z
M]P_])04445Y9ZH4444 %%%% !1110 4444 %%%% !1110 4444 ?%O[6G_)P
M/B#_ +=/_22&O.:]&_:T_P"3@?$'_;I_Z20UYS7]$Y)_R)<-_P!>X?\ I*/Y
MOSS_ )'>*_Z^3_\ 2F%%%%>F>6%%%% !1110!X?^U)^P-\%/VJ_$FC^+_%\5
MQIVIZ=<1B]O=,"K)J-HIYMY3_P"@R?>49 X/'L'A3PIX;\#>&[+PAX0T6WT[
M3-.MU@LK*UC"QPQJ. !_7J3DGDUH44 %%%% !1110 4444 %?1G[ /\ S-O_
M &X?^W%?.=?1G[ /_,V_]N'_ +<5\QQE_P DW7_[=_\ 2XGU/!7_ "4U#_M[
M_P!(D?1E%%%?A1^]A1110 4444 %%%% !1110 5^<]?HQ7YSU^G>''_,5_VY
M_P"WGY;XE?\ ,+_W$_\ ; HHHK]./RT***YSXK?$[0_A%X+N/&>MZ;J.H&-T
MALM)T6S-Q>ZC<N=L=O;Q C?(S>I"J 69E1683.481<I.R14(2J248J[9T=%?
M-WP5_P""B=OXZ_:4@_9.^-?[./C+X7>,=6TJ74O"]OXE>UN+?6;>(,T@BFMI
M'3S%168H"0 C98$ 'Z'US7-'\,Z+>>)/$6J06.GZ?:R7-]>W4H2*WAC4L\CL
M>%55!))X !K'#XK#XJ#G3E=)V>ZLUT:=FOF;XC"8C"U%"I&S:NMG=/9IJZ?R
M+5%>/?L6?MD>"OVW?AUKWQ1^'WAO4-.TK2/&5]H-L=3&V6[%N(B+C9@&(.)0
M?+;YEQ@\\5Z-\1O'_A_X7>"[[QUXF%T]I8HO^CV%JT]Q<RNZQQ00Q("TLLDC
M)&B*,L[J!UJJ6)H5J"K0E>#5[]+=R:N&KT<0Z$XVFG:W6_8VZ*^9OA__ ,%(
MH[_]I+0?V9OCS^S!XY^%^K>,H9Y/ ]_XF:TFM=7,*[WA,EK+(L4P7!\O+8)"
MD@LF[LOC/^V'8?#CXF:G\'? ?PWU#QAXB\/^"9?%GB.RL;Z*W6RTU7*(H>3B
M2YE*/Y<. "$)=XP5+81S'!SIN:EHG9Z.]][6M>]M=MM=C>66XV%10<=6KK56
MMM>][6OIOOIN>ST5S/PA^+O@7XX_"?0?C5\/M5^T:!XCTB+4=.N95V,(9$W8
M<$_(R\JRG[K*1VJ#X+_%>V^-7A&3X@Z)H4UKHEU?S)X<OIY 3JUDA"I?(N/D
MBE8.T622\7ER<"0*.F-:E+EY7?F5UYKOZ:K[SFE1JPYN96Y79^3[>NC^XZVB
MBBM#(**** /M+]DO_DW[P_\ ]O?_ *5S5Z-7G/[)?_)OWA__ +>__2N:O1J_
MG?._^1UB?^OD_P#TIG]'Y'_R),+_ ->X?^DH****\L]4**** "BBB@ HHHH
M**** "BBB@ HHHH **** /BW]K3_ ).!\0?]NG_I)#7G->C?M:?\G ^(/^W3
M_P!)(:\YK^B<D_Y$N&_Z]P_])1_-^>?\CO%?]?)_^E,****],\L*\I7]N?\
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MJ%>I1G.I#FDK/MV[7\[;_P!,\JO"%.?+%W7?OWMY7V_I!1116IB%?1G[ /\
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MF6,!Y N=H)ZD#)QGID^M,N=(TF\O8=2N]+MY;BW_ -1/) K/'_NL1D?A6=?
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MG-4+_P !^!]4\46GC?4_!FDW.M6$9CL=7GTZ)[JV0YRL<I7>@.3P".IK6K#
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M@ HHHH **** "BBB@ HHHH **** /BW]K3_DX'Q!_P!NG_I)#7G->C?M:?\
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M1.2?\B7#?]>X?^DH_F_//^1WBO\ KY/_ -*84445Z9Y84444 %%%% !1110
M4444 %%%% !1110 5]&?L _\S;_VX?\ MQ7SG7T9^P#_ ,S;_P!N'_MQ7S'&
M7_)-U_\ MW_TN)]3P5_R4U#_ +>_](D?1E%%%?A1^]A1110 4444 %%%% !1
M110 5^<]?HQ7YSU^G>''_,5_VY_[>?EOB5_S"_\ <3_VP****_3C\M"BBB@
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MFI7#06,^I.RK-(J[BJX!Y YKSG_AZ1_P3Y_Z.L\*_P#@1)_\17M7B3P9X/\
M&4$5MXO\*:;JL<+EH8]2L8YUC8C!*AP<''<5D?\ "C/@E_T1WPK_ .$];?\
MQ% 'EG_#TC_@GS_T=9X5_P# B3_XBC_AZ1_P3Y_Z.L\*_P#@1)_\17J?_"C/
M@E_T1WPK_P"$];?_ !%'_"C/@E_T1WPK_P"$];?_ !% 'EG_  ](_P""?/\
MT=9X5_\  B3_ .(H_P"'I'_!/G_HZSPK_P"!$G_Q%>I_\*,^"7_1'?"O_A/6
MW_Q%'_"C/@E_T1WPK_X3UM_\10!\'?M#_M@_LM>.OC#K'BGPK\??"MU877V?
MR)_[7C3=MMXT;Y7(8892.1VKB_\ AI7]GK_HMOA7_P 'L'_Q5?I+_P *,^"7
M_1'?"O\ X3UM_P#$4?\ "C/@E_T1WPK_ .$];?\ Q%?9X7CG-L)A84(0A:"4
M5=2O9*RO[Q\3B^ \HQF*J5YU*B<Y.3LXVNW=V]W8_-K_ (:5_9Z_Z+;X5_\
M![!_\51_PTK^SU_T6WPK_P"#V#_XJOTE_P"%&?!+_HCOA7_PGK;_ .(H_P"%
M&?!+_HCOA7_PGK;_ .(KH_XB#G7_ #[I_=+_ .3.?_B'62?\_*GWQ_\ D#\V
MO^&E?V>O^BV^%?\ P>P?_%4?\-*_L]?]%M\*_P#@]@_^*K])?^%&?!+_ *([
MX5_\)ZV_^(H_X49\$O\ HCOA7_PGK;_XBC_B(.=?\^Z?W2_^3#_B'62?\_*G
MWQ_^0/S:_P"&E?V>O^BV^%?_  >P?_%4?\-*_L]?]%M\*_\ @]@_^*K])?\
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M &C?"MC]N^R?9?\ B9++OV>=N_U>[&-Z]<=:^O/^%&?!+_HCOA7_ ,)ZV_\
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MX)\_]'6>%?\ P(D_^(H_X>D?\$^?^CK/"O\ X$2?_$5ZG_PHSX)?]$=\*_\
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M,/CT:C_9[>')/$T E6]W;?LA?/EB??\ )Y);S-WR[=W%>W>*_%GA;P)X9O\
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M(YKZPL_,CC\Z>)"6A!>5 -^TMNR 0"0 =G1110 4444 %%%% !1110 4444
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MX,_9-T7P4DG@SP3?Z;J%E872)(;Z]LKE+Q+JZ+*1-*]V@N9'(!>7+=Z^+O\
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MN"'$14JJOMV\;0<C _5C4=1T_2-/GU;5KZ&UM;6%IKFYN)0D<4:@EG9C@*H
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MG?&?Q!)JD_Q&^('AV'XQ227'FKXA30+?3I+RUG;D2Q3W,PD;/WC$IS5;3?\
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M%%% %?3-(TG18&M='TNWM(GD:1X[:!8U9VY+$*!DGN>]6*** "BBB@ HHHH
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M3J* "BBB@"OIFD:3HL#6NCZ7;VD3R-(\=M L:L[<EB% R3W/>K%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>jnj-20211003_g6.jpg
<TEXT>
begin 644 jnj-20211003_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#XM_:T_Y.!\0?]NG_ *20UYS7HW[6G_)P/B#_ +=/_22&O.:_HG)/
M^1+AO^O</_24?S?GG_([Q7_7R?\ Z4PHHHKTSRPHHHH **** "BBB@ HHHH
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M*^Z?!\?BB'PEI<7C>YM9]:73H!J\UC$4@DNA&OFM&I)*H7W$ DD#')KPK]J
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M^BNNK:+485\FG)1CS0E'96DDTTV]/>4G;J[/HDSZKHHHKV#Q@HHHH *^C/V
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M@ HHHH **** "BBB@ HHHH **** /BW]K3_DX'Q!_P!NG_I)#7G->C?M:?\
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MG_)P/B#_ +=/_22&O.:]&_:T_P"3@?$'_;I_Z20UYS7]$Y)_R)<-_P!>X?\
MI*/YOSS_ )'>*_Z^3_\ 2F%%%%>F>6%%%% !1110 4444 %%%% !1110 444
M4 %?1G[ /_,V_P#;A_[<5\YU]&?L _\ ,V_]N'_MQ7S'&7_)-U_^W?\ TN)]
M3P5_R4U#_M[_ -(D?1E%%%?A1^]A1110 4444 %%%% !1110 5^<]?HQ7YSU
M^G>''_,5_P!N?^WGY;XE?\PO_<3_ -L"BBBOTX_+0HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH ^TOV2_^3?O#_\ V]_^E<U>C5YS^R7_ ,F_>'_^WO\
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M\C_Y$F%_Z]P_])04445Y9ZH4444 %%%% !1110 4444 %%%% !1110 4444
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M7HW[6G_)P/B#_MT_])(:\YK^B<D_Y$N&_P"O</\ TE'\WYY_R.\5_P!?)_\
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M!965K&%CAC4< #^O4G)/)K0H **** "BBB@ HHHH ^TOV2_^3?O#_P#V]_\
MI7-7HU><_LE_\F_>'_\ M[_]*YJ]&K^=\[_Y'6)_Z^3_ /2F?T?D?_(DPO\
MU[A_Z2@HHHKRSU0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^+?VM/\
MDX'Q!_VZ?^DD-><UZ-^UI_R<#X@_[=/_ $DAKSFOZ)R3_D2X;_KW#_TE'\WY
MY_R.\5_U\G_Z4PHHHKTSRPHHHH **** /A_]L[_@D_\ \+0^(]I\0_V>9M/T
M?^V-05?$VF7)V06^XY>\A _$M$.I.5QDBOJ#]FW]FWX<?LO?#BW^'GP\L/23
M4]3F4>?J$^,&60C\@HX4<#N3Z!10 4444 %%%% !1110 5]&?L _\S;_ -N'
M_MQ7SG7T9^P#_P S;_VX?^W%?,<9?\DW7_[=_P#2XGU/!7_)34/^WO\ TB1]
M&4445^%'[V%%%% !1110 4444 %%%% !7YSU^C%?G/7Z=X<?\Q7_ &Y_[>?E
MOB5_S"_]Q/\ VP****_3C\M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#[2_9+_Y-^\/_P#;W_Z5S5Z-7G/[)?\ R;]X?_[>_P#TKFKT:OYWSO\ Y'6)
M_P"OD_\ TIG]'Y'_ ,B3"_\ 7N'_ *2@HHHKRSU0HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ^+?VM/^3@?$'_;I_P"DD-><UZ-^UI_R<#X@_P"W3_TD
MAKSFOZ)R3_D2X;_KW#_TE'\WYY_R.\5_U\G_ .E,****],\L**AU%;]]/G32
MIH8[HPL+:2XC+QK)@[2R@@LH.,@$$CN.M?!_[='[&7CSX4:+X8^.O[-GQ_\
MB->_'.Z\<Z9:Z=+J/BZXEMO$;S3#[1!+9;OL\-K' )IF2)$CCA@<,"HR.+'8
MJMA*+J0I\Z6KUL[>7=]EI?O>QW8#"4<965.=3D;T6EU?S?1=WK;M:Y][451\
M2:/<Z_H=SHUGX@OM*DN$VC4--,8GA&1DH94=02,C)4D9R,'!'RG_ ,$8M?\
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MBBM3(*^C/V ?^9M_[</_ &XKYSKZ,_8!_P"9M_[</_;BOF.,O^2;K_\ ;O\
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MDW7_ .W?_2XGU/!7_)34/^WO_2)'T91117X4?O84444 %%%% !1110 4444
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M_7R?_I3"BBBO3/+"BBB@ HHHH **** "BBB@ HHHH **** "OHS]@'_F;?\
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M_P!N'_MQ7S'&7_)-U_\ MW_TN)]3P5_R4U#_ +>_](D?1E%%%?A1^]A1110
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M:A_V]_Z1(^C****_"C]["BBB@ HHHH **** "BBB@ K\YZ_1BOSGK].\./\
MF*_[<_\ ;S\M\2O^87_N)_[8%%%%?IQ^6A1110 4444 %%%% !1110 4444
M%%%% !1110!]I?LE_P#)OWA__M[_ /2N:O1J\Y_9+_Y-^\/_ /;W_P"E<U>C
M5_.^=_\ (ZQ/_7R?_I3/Z/R/_D287_KW#_TE!1117EGJA1110 4444 %%%%
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M]?\ 1;?"O_@]@_\ BJ/^&E?V>O\ HMOA7_P>P?\ Q5?I+_PHSX)?]$=\*_\
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MK;_XBO>_XB#G7_/NG]TO_DSP/^(=9)_S\J??'_Y _-K_ (:5_9Z_Z+;X5_\
M![!_\51_PTK^SU_T6WPK_P"#V#_XJOTE_P"%&?!+_HCOA7_PGK;_ .(H_P"%
M&?!+_HCOA7_PGK;_ .(H_P"(@YU_S[I_=+_Y,/\ B'62?\_*GWQ_^0/S:_X:
M5_9Z_P"BV^%?_![!_P#%4?\ #2O[/7_1;?"O_@]@_P#BJ_27_A1GP2_Z([X5
M_P#">MO_ (BC_A1GP2_Z([X5_P#">MO_ (BC_B(.=?\ /NG]TO\ Y,/^(=9)
M_P _*GWQ_P#D#\VO^&E?V>O^BV^%?_![!_\ %4?\-*_L]?\ 1;?"O_@]@_\
MBJ_27_A1GP2_Z([X5_\ ">MO_B*/^%&?!+_HCOA7_P )ZV_^(H_XB#G7_/NG
M]TO_ ),/^(=9)_S\J??'_P"0/S:_X:5_9Z_Z+;X5_P#![!_\51_PTK^SU_T6
MWPK_ .#V#_XJOTE_X49\$O\ HCOA7_PGK;_XBC_A1GP2_P"B.^%?_">MO_B*
M/^(@YU_S[I_=+_Y,/^(=9)_S\J??'_Y _-K_ (:5_9Z_Z+;X5_\ ![!_\51_
MPTK^SU_T6WPK_P"#V#_XJOTE_P"%&?!+_HCOA7_PGK;_ .(H_P"%&?!+_HCO
MA7_PGK;_ .(H_P"(@YU_S[I_=+_Y,/\ B'62?\_*GWQ_^0/S:_X:5_9Z_P"B
MV^%?_![!_P#%4?\ #2O[/7_1;?"O_@]@_P#BJ_27_A1GP2_Z([X5_P#">MO_
M (BC_A1GP2_Z([X5_P#">MO_ (BC_B(.=?\ /NG]TO\ Y,/^(=9)_P _*GWQ
M_P#D#\VO^&E?V>O^BV^%?_![!_\ %4?\-*_L]?\ 1;?"O_@]@_\ BJ_27_A1
MGP2_Z([X5_\ ">MO_B*/^%&?!+_HCOA7_P )ZV_^(H_XB#G7_/NG]TO_ ),/
M^(=9)_S\J??'_P"0/G?]GC_@HW^PSX%^#VC^%O%7[3OA6UO[7[1Y\'VTOMW7
M$CK\R*5.58'@]Z[7_AZ1_P $^?\ HZSPK_X$2?\ Q%>I_P#"C/@E_P!$=\*_
M^$];?_$4?\*,^"7_ $1WPK_X3UM_\17Q>*Q$\7BIUY[S;D[;7;N['VV$PT,'
MA:="#;4(J*OO9*ROYGEG_#TC_@GS_P!'6>%?_ B3_P"(H_X>D?\ !/G_ *.L
M\*_^!$G_ ,17J?\ PHSX)?\ 1'?"O_A/6W_Q%'_"C/@E_P!$=\*_^$];?_$5
M@=!Y9_P](_X)\_\ 1UGA7_P(D_\ B*/^'I'_  3Y_P"CK/"O_@1)_P#$5ZG_
M ,*,^"7_ $1WPK_X3UM_\11_PHSX)?\ 1'?"O_A/6W_Q% '0Z3JNGZ[I=MK>
MD7:3VEY;I/:SQ_=DC=0RL/8@@_C5BF0006L"6MK"D<4:!8XXU 55 P  .@ [
M4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHJEXC\2>'?!^@WGBKQ=KUEI
M>EZ=;/<:AJ6HW206]M"@RTDDCD*B@ DL2  .: +M%>"Z#_P5!_X)^^(]9TW1
MM-_:M\)JNMW2VVA:I>7;VVG:K,QPD5K?3*MM<NW\*Q2,6R-N<BO=;Z^LM+LI
MM3U.\BM[:WB:6XN)Y B1(HRS,QX4  DD\ "@"6BO#?V?_P#@IA_P3_\ VJOB
M;>_!K]G/]KWP'XQ\4V$<DDVB:'K\4T\L<9Q))" <7"+U+Q%U ()."#7N5 !1
M7BW[3O\ P49_85_8P\0:;X2_:F_:I\&>"-6U>$3:?I6MZPB74D)8J)C$N76(
ML&'F, A*L,\''JG@CQSX+^)GA'3OB!\.?%VF:_H6L6B76DZUHU]'<VM[ XRL
ML4L9*2(1R&4D&@#5HKRW2/VVOV2M?^*@^"FB_M >&;GQ*^K2Z5#80Z@"DVI1
M*6EL(YO]5)=HH8O;*YF0*Q9!M.-?]HC]I_\ 9X_9)^'K_%?]ICXS>'? _AU+
MA;==4\1ZFEM'+,P)6&,,<RR$*Q"(&8A2<8!H [NBO//V;?VL_P!FC]L/P*_Q
M*_9=^./AOQUHD-R;>YOO#FII<"VF SY4R@[H7P0VUPIP0<8(-:'Q/_:*^!'P
M5\0^&O"'Q8^+OA_P_J_C+68-*\)Z1J>J1Q7>L7DLBQI#;0D[YF+, =H(4'+$
M#F@#LZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **Y#XU?
M'_X(_LX^$5\=_'GXKZ!X1TB2Y2V@O=?U..V6XN'^Y!$'(,TK'A8T#.QX -<O
M\'?VY?V2OCWXXD^%_P +OCIHM[XICM3=?\(M>-)8ZI);CK.EI=+'-)"/^>BH
M4]^: /5Z*Y+XW_'CX+_LU?#>_P#C!\?_ (HZ'X.\+Z8%^W:YXAU%+:WC+'")
MN<C<[' 5!EF)  )XK"_9C_;&_9:_;/\ !]UX]_95^/'AKQWI5A=?9M0N?#VI
M+,;.8C(CF3AXF(Y =1D<C(H ]*HHKP'4O^"J/_!.'1_CX?V7M4_;7^','CT:
MC_9[^')?$T E2]W;?LK/GRUGW?)Y)8/N^7;NXH ]^HJAXI\5>&/ WAN_\9>-
M?$=AH^CZ5:276IZKJEXEO;6D"*6>6660A8T50268@ #)-<7\$_VL?V<OVC+^
M]TCX*_%W2->OM/M(;N[T^WD:.Y2UFSY-T(9 KM;R;6V3J#&^T[6.#0!Z'17B
MW[3O_!1G]A7]C#Q!IOA+]J;]JGP9X(U;5X1-I^E:WK")=20EBHF,2Y=8BP8>
M8P"$JPSP<>J>"/'/@OXF>$=.^('PY\7:9K^A:Q:)=:3K6C7T=S:WL#C*RQ2Q
MDI(A'(920: -6BO+=(_;:_9*U_XJ#X*:+^T!X9N?$KZM+I4-A#J *3:E$I:6
MPCF_U4EVBAB]LKF9 K%D&TX]2H **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ K\LO\ @IU\1-2_:^_X+E?LU_\ !)/Q;.\G
MPI@T*?XC_$C00W[CQ)/;)?26%E=ITFMXY;!&:%OD?[02P8HFW]3:_-/_ (*L
M_LV_%#X _P#!3WX!?\%K?A;X#U;Q7X?^'NG7'A'XSZ'X?L'NKZS\/W"W:+JT
M5O$#)<+;_;[AY50%P(HB 5#E #[_ /C7\"OA1^T/\&M?^ 'Q>\%V6L^$O$ND
M2:;JNCW,"F-X'7;\HQ\C+PR,N"C*K*05!K\XO^#>+XI^)OVMOV*OBO\ \$__
M -KW4I_&_P#PHKXFW'@J:[U6=V.KZ+!,&MK:Z.<SQA[>>%XWRDEN%B<,I8'[
M&^)O_!4K]A;X??!@_&;0OVB_"WC%+VS+^%_#G@G6X-4U;Q)=%<Q6-A9V[/-<
M7$C80(JY4DE]JJQ'RQ_P2>^$6D?\$:/^">_C[]LC_@I/XE@\$>(?BG\0)?&G
MQ'(LY[Q?#QU"XCAL["06L<CLRO+N=@I"/<.I.V/=0!S_ .T]XS_X)N_';_@N
M-^S-\(OAO\6O!_A#XD?"2XU75-4N]-TYK*364>V$%GX>@N4B6&X=G,LAC+D)
M'')&F7F*C]2Z_-[_ (*0P?LJ?\%:6^ OAC]C/XE^$_B)X\\.?&?P_P")[3QC
MX%U*#4'\'Z);3?:+^YO+F M]C1XT5$MY61YKCR0J$QL4_2&@#QJ;]@[]D:\O
M/'?BSXH_!;POXNU+X@WL]SXTUWQCHEM>SWML5$<5H\DJ';:V]ND<,<0PJK'N
M(+N[M^8'[,OC/XG?\$V_^#:O]HCX[?"S7=3LM N_&OBB]^ %Q<W#F?2_#>I:
MC;Z7I=S$6^9<R22WL;'AO.63D/D^Y_MW?\%PO^"86M?'/7OV#?C!^V/IWA7P
MCH;&U^+6I:?INI7<VMMDK+X=M);&WE$:'!2]GW*RHQMXLR22R6W8_%/XG_LO
M_P#!>3_@F1\=OV:/V =7?5?#5MX:AT'PUXB;0)])TJ77+=$O;;3X([J**1$A
M:&Q#MY8C5+E-A;:< '#_ +4?[.OAOX=?\&NMMX,\+QG2]1\"? G0O%^CZM9,
M8KFTUZSCMM5;4(I!AHYWNUED+@AB97Y^8U],?LF>!?A1^WS\"?@7^WO^T!X$
MTSQ1XEU/X.Z1>:78:YIT-S9:)>WUM%<:A<VL+J5CGE?RXS+]X1VZJI4/('^0
M_CU^U):?M#_\$#])_8W^&X2]_:$\;> M)^&,_P (?.5-<L=>C^SV.J+=6A/F
MVL%O''<7#SRJL:PA'+8D0MZI^TO_ ,%%OV2/^"*7[-OP<_8 \4?M#>'M#\<V
MO@+2] TS5-4TVZOK?1+"TM$MGUN\MK2-YG4M"_DP *;B8A"T<:RS1 &3^P]^
MROX/^$O_  7W_:.^(7[+7ABU\.?#*'X3Z%IGC_1M$@6WTR3QK<SI>)Y42 1B
M6.P422!1\K:AN8 S<P_\%Q/AWX"M/VN/V&OB9:>"]*A\17/[66@V=UKL6GQK
M>3V_EL?*>8+O=,Q1X4D@;!Z5W?\ P39_X*=_\$M/BMXSTC]BW_@GY\7]7^)/
MB&[CU'Q%XRUL^&]0AF9C^]N]:U.ZO+:!)IKBZDBC(CR0]PBJD<2 +YK_ ,%\
MOC=\&_!G[2W[$F@^+?BKX=TR]TG]JC0]5U:TOM9@BDL;!4=6NIE9@8H09$!D
M;"C<.: /TSHJOI6JZ7KVEVVN:'J5O>V5[;I/9WEI,LD4\3J&21'4D,K*00P)
M!!!%6* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _*_P#X):^/
M;O\ X*-?\%F?VJ/VK_C(?[3LOV??$$?PZ^"^CW7SVVA1>?>0W]]!&>$N;@V2
M,9O]9LN'CR$55'M?_!PW\$+;QW_P33\9?'[PC>2Z)\1O@I''XW^'/C/36\J_
MT6\LY4DG,,H^8++;B5&3.UB4)!*+CQC]F?P))_P1D_X*U?'W5OCH1I'P(_:B
MUBW\3^$?B;>?)I.A>(Q/<RSZ3J$Y_=V+2O>SF%Y2L<BQ1*K;RRKZ9_P63_:5
M\/?M._LD^)/^">G[#?B71_B9\7OC':0Z#9Z-X4U2*]@T'2YYD^V:KJDT!=+&
MT2W$BK)*09)'58PY#8 /6OV+_C!\)?V[?V$?@E^W_P#M'>&M%;4(? ZZQ<3Z
MLJFPTO4WB6"]NXHG)C1P\,R1RD&2..:1%8"60-\X_P#!'WQ1^PK\?/\ @J)^
MU9^U1^QA\5]!AM-6CT70;KX?Z182Z=+<26:'[5KLMK)'&-DMPQBC= >4E>3#
M3@5]!?#WXR?L+?\ !&C]G_X%_L*?M ?M):)X1F_X15='\,ZKXE26TL]6GLHX
M1>7$ET5-O:[Y9Q)MFD3_ %N%W8./-/A1\%_A5^T'_P %O(O^"AG[*,VFWG@[
M1?@C=>'?'GCWPRR/I?BK6;B]C:VMHKB+]W?R06\3-/-&7$96UB9MR[4 /NSQ
M?H5SXH\)ZIX9LO$%[I,VHZ=/:Q:KIS*MQ9M)&R":(L"!(A.Y201D#(-?GY_P
M6?\ ^"?7[!_@C_@CM\0OASX<_9E\+:=-H6@0P?#4:+H,0U/_ (2.6:*WTY89
ME7SYKFXNI(HW)9GF\Y]Y;<V?O[Q[X\\%_"WP3JWQ(^(_BFQT/0-"T^:_UG6-
M3N5AM[*VB0O)+([$!55022?2ORSL/^#@[_@C7\>/C1:_'+]HK]L.STSP]X!U
M::3X8^ YO!FMW+_;%#PGQ!>B&R=&N"C2+:0*6^SQ2M*Y\^4):@$O_!3F]^+V
M@^ O^"=W_!,SXT^()=4N?B1\0/#%K\9));@RCQ!'H4&G/?6L[<B6*>YE61L_
M>,2G/6O1?^"U'Q"U+]F']MC]B/\ :I\%3FSU.Z^-P^'?B!X#M^WZ%K:Q1W%O
M,!_K4C:%9D5LA9%##!YK%_X*:R3?M7_!W]E'_@L'\"_ ^OWWA[X._%:S\8ZA
MITNEO_:%SX(O)XX[O4XK909#FV@MKQ8R-X@=F8*491H_MZV'@O\ X*B?MZ_L
MF_"/]FOQMI'C7PI\*_'O_"T_B;XG\,ZC'?:=I%O9I$^EVTMQ"S1^?>3%U2$-
MYGE*\A78-U 'UY-^P=^R->7GCOQ9\4?@MX7\7:E\0;V>Y\::[XQT2VO9[VV*
MB.*T>25#MM;>W2.&.(855CW$%W=V_,#]F7QG\3O^";?_  ;5_M$?';X6:[J=
MEH%WXU\47OP N+FX<SZ7X;U+4;?2]+N8BWS+F226]C8\-YRR<A\GW/\ ;N_X
M+A?\$PM:^.>O?L&_&#]L?3O"OA'0V-K\6M2T_3=2NYM;;)67P[:2V-O*(T."
ME[/N5E1C;Q9DDEDMNQ^*?Q/_ &7_ /@O)_P3(^.W[-'[ .KOJOAJV\-0Z#X:
M\1-H$^DZ5+KENB7MMI\$=U%%(B0M#8AV\L1JERFPMM. #A_VH_V=?#?PZ_X-
M=;;P9X7C.EZCX$^!.A>+]'U:R8Q7-IKUG';:JVH12##1SO=K+(7!#$ROS\QK
M[?\ V#/CIK'[3O[$?PB_:*\2(BZIXW^&VBZWJJQH%5;NYLHI9PH'11(SX]L5
M^?GQZ_:DM/VA_P#@@?I/[&_PW"7O[0GC;P%I/PQG^$/G*FN6.O1_9['5%NK0
MGS;6"WCCN+AYY56-80CEL2(6_1S]E#X%6/[+_P"R]\.?V;M-OENH? /@;2O#
MR7:J1]H^QVD5N9<'^^8RW_ J /0**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ^)OVD/^"*_P *O%7[7ND_\%&OV-/'
M9^#7QTTJ[>>_UK3])%YHGBE'4I/!JNGB2+S?.0E'FADBD^;>=[JC+]9^ '^)
MVN^&9++XW^#?#5E>N@CF@T#6IM0M;E2,,3]HM8&0'^X0^ <;CC-=-10!5TC1
M-%\/V0TW0=(M;&W5BRV]G;K$@)ZG:H R:M444 %%%% %>/2-)BU.36HM+MUO
M)8A'+=K HE=!T4MC) ],XJQ110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 4_$'A[0/%NA7OA;Q5HEGJ>F:E:R6VH:=J%LLT%U
MZE7BDC<%71E)!4@@@D&OB?\ 9R_X(_S?\$W/VA_$GQI_X)I_$"TT7P7XZ=)/
M&WP,\9R3/HTLZ%O+NM-OHQ)/ILB;F&UHKE&5RF%"Q^7]R44 9":)'XM\/6T'
MQ'\(:3)<@![BPWB]MXI.1\CRQ(7XZ,44\]!6K%%%!$L,,:HB*%1%& H'0 =A
M3J* "BBB@ JOIND:3HL#6VCZ7;VD;RM(\=M L:L[=6(4#)/<]35BB@ HHHH
MKQZ1I,6IR:U%I=NMY+$(Y;M8%$KH.BEL9('IG%6*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
' HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>jnj-20211003_g7.jpg
<TEXT>
begin 644 jnj-20211003_g7.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@!
M: 'T P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***R/&OCKPK\.]$/B+QCJOV.S$JQ&;R'D^9LX&$
M5CV/:KITZE:HH4TW)[):M^B(JU:=&FZE22C%;MNR7JS7HKSG_AK/]G[_ *'_
M /\ *5=__&J/^&L_V?O^A_\ _*5=_P#QJO1_L3.O^@:I_P" 2_R/-_MS)/\
MH*I_^!Q_S/1J*\Y_X:S_ &?O^A__ /*5=_\ QJC_ (:S_9^_Z'__ ,I5W_\
M&J/[$SK_ *!JG_@$O\@_MS)/^@JG_P"!Q_S/1J*\Y_X:S_9^_P"A_P#_ "E7
M?_QJC_AK/]G[_H?_ /RE7?\ \:H_L3.O^@:I_P" 2_R#^W,D_P"@JG_X''_,
M]&HKSG_AK/\ 9^_Z'_\ \I5W_P#&J/\ AK/]G[_H?_\ RE7?_P :H_L3.O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ) /^(BY)_S[J?='_P"3/M*BOBW_ (:S_:!_Z'__ ,I5I_\ &J/^&L_V@?\
MH?\ _P I5I_\:H_XA]G7_/RG]\O_ ) /^(BY)_S[J?='_P"3/M*BOBW_ (:S
M_:!_Z'__ ,I5I_\ &J/^&L_V@?\ H?\ _P I5I_\:H_XA]G7_/RG]\O_ ) /
M^(BY)_S[J?='_P"3/M*BOE+X._M*?&OQ5\4-#\.Z]XT\^SO-02*YA_LZV7>I
MZC*Q@C\#7U;7SF<Y)B\CKQI5Y1;DK^ZV^MNJ1]+DN>83/:$JN'C)*+M[R2Z7
MZ-A1117CGLA1110 4444 %%%% !1110 4444 %%%% !7DG[:O_)%&_["MO\
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M6YA7>%JXU5N6*BN1S2:M?3FY5?5>2NEK;2Q\E_LL:Q^V5^QA_P $S--_:O\
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M_P B'$_X'^1\A4445_09_.P4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'Z!^!?^1(T;_L%6_P#Z*6M6LKP+_P B1HW_ &"K?_T4M:M?S3B/X\_5
M_F?T[AO]VAZ+\@HHHK$W"BBB@ HHHH **** /E[]O+_D=]#_ .P4_P#Z-->$
M5[O^WE_R.^A_]@I__1IKPBOWOA3_ ))[#^C_ #9_/W%W_)1XCU7_ *2@HHHK
MZ$^<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#L?V??^2U^&O^PK'7W/
M7PQ^S[_R6OPU_P!A6.ON>OR3Q#_Y&5'_  ?JS]@\.?\ D65O\?\ [:@HHHK\
M^/T0**** "BBB@ HHHH **** "BBB@ HHHH *\D_;5_Y(HW_ &%;?_V:O6Z\
MD_;5_P"2*-_V%;?_ -FKV>'?^1[AO\<?S/$XD_Y$.)_P/\CY"HHHK^@S^=@H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /T#\"_\B1HW_8*M_P#T
M4M:M97@7_D2-&_[!5O\ ^BEK5K^:<1_'GZO\S^G<-_NT/1?D%%%%8FX4444
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M_P"PK'7W/7PQ^S[_ ,EK\-?]A6.ON>OR3Q#_ .1E1_P?JS]@\.?^196_Q_\
MMJ"BBBOSX_1 HHHH **** "BBB@ HHHH **** "BBB@ KR3]M7_DBC?]A6W_
M /9J];KR3]M7_DBC?]A6W_\ 9J]GAW_D>X;_ !Q_,\3B3_D0XG_ _P CY"HH
MHK^@S^=@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /T#\"_\B1H
MW_8*M_\ T4M:M97@7_D2-&_[!5O_ .BEK5K^:<1_'GZO\S^G<-_NT/1?D%%%
M%8FX4444 %%%% !1110!\O?MY?\ ([Z'_P!@I_\ T::\(KW?]O+_ )'?0_\
ML%/_ .C37A%?O?"G_)/8?T?YL_G[B[_DH\1ZK_TE!1117T)\X%%%% !1110
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M7B-Y;I8O/'822*01'/(GSJ"-ZQE#E68&?]A;XD7?@[XA_M(?#?Q%XD:+X?\
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M@ HHHH ^7OV\O^1WT/\ [!3_ /HTUX17N_[>7_([Z'_V"G_]&FO"*_>^%/\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?H'X%_Y$C1O^P5;_\
MHI:U:RO O_(D:-_V"K?_ -%+6K7\TXC^//U?YG].X;_=H>B_(****Q-PHHHH
M **** "BBB@#Y>_;R_Y'?0_^P4__ *-->$5[O^WE_P COH?_ &"G_P#1IKPB
MOWOA3_DGL/Z/\V?S]Q=_R4>(]5_Z2@HHHKZ$^<"BBB@ HHHH **** "BBB@
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M>O\ HMOA7_P>P?\ Q5'_  TK^SU_T6WPK_X/8/\ XJOTE_X49\$O^B.^%?\
MPGK;_P"(H_X49\$O^B.^%?\ PGK;_P"(H_XB#G7_ #[I_=+_ .3#_B'62?\
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MH_X49\$O^B.^%?\ PGK;_P"(H_XB#G7_ #[I_=+_ .3#_B'62?\ /RI]\?\
MY \<\)_\%.OV ],\+:9IM]^U1X52:WT^&*9/M+G:RH 1D+@\CM6A_P /2/\
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M_B(.=?\ /NG]TO\ Y,/^(=9)_P _*GWQ_P#D#\VO^&E?V>O^BV^%?_![!_\
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MSPK_ .!$G_Q%>I_\*,^"7_1'?"O_ (3UM_\ $4?\*,^"7_1'?"O_ (3UM_\
M$5\YG.=XO/*\:M>,4XJWNIKK?JV?2Y+D>$R*A*EAY2:D[^\T^ENB1Y9_P](_
MX)\_]'6>%?\ P(D_^(H_X>D?\$^?^CK/"O\ X$2?_$5ZG_PHSX)?]$=\*_\
MA/6W_P 11_PHSX)?]$=\*_\ A/6W_P 17CGLGEG_  ](_P""?/\ T=9X5_\
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M?#OQ9INO:%J]HEUI.LZ/?1W-K>0.,I+%+&2DB$<AE)!K T?]HKX$>(?C5?\
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M?";1?CUX@_:[\"6?@CQ&\B:#XOGUZ)=,OWCFE@=(KG/ELZRP3(5#9S&W'!H
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MXK>-K'P1IVN6<ICGTV&YAN)KB:)QRCF*V:$.OS)Y^Y2&4,/T/KXA_P"#@?\
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M"'@?7[SPY\'OBG:>+M2T^72W^WS>![Z:*.[U2.W4&0_Z-!;7@CQO$#LS!2C
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M#^SYJ'[1/[2OC&/3M,@D%KI.G1$-=ZQ?,I,=I;1_QR-M))^ZB*SN5521\/\
M[-O_  7-_P""347CVY^)E[^U/%\3/V@?B?/9:+8>'O"7@K6V$8:;;8>&]+EN
MK**.*W6:8EIIFB^T3R23R! 8X8@#K/AO\0-5_:,_X.;_ (A>$/%TAN=%_9U^
M 5K:>$=.E.8K/5=9>QN;F_0'[LSVLWV8L/\ EFH'K5/X1>)-;\ _\'"O[1W[
M&'A3Q1?Z'X<^,?P$T_QY(VDR*C:7KT)@TJ2^ME(*1SR0N)'?:=[P1ELXK8\3
M^![3]AG_ (+YZM^V%\3M1MM'^&7[1/PB@\/3>+]2G6"QTSQ7IDEN(+.YG<B.
M 7%C ?)9V7S94:-<L,'/_9=T_P (?$'_ (*V?M&_\%B_$OBS3].^#'A'X7V7
M@'P?X\O[E8]-UB"W\F^U?48)F.V2U@G@\@7"DQR-YNQFVF@"W_P6F_X)]?L)
M>#/^"/'C_P"&_A?]F3PMIMSH>B6]M\,4T/08EU,>(IKB*WT]8)E7SY;BXNI(
MHW)9GF$K[RVYC7G?_!3N_P#BYHWAG_@G=_P3.^,_B"35)_B-\0/#L/QBDDN/
M-7Q"F@6^G27EK.W(EBGN9A(V?O&)3FJVF_\ !P=_P1K^._QGM?CO^T7^V'9Z
M9H'@+59Y/AAX#F\&:W<NMVH>$^(+T0V3HURR-(MK"I;[/%*TCGSYMEMV/_!3
M-Y_VJ/A5^R;_ ,%AO@AX'U^\\.?![XIVGB[4M/ETM_M\W@>^FBCN]4CMU!D/
M^C06UX(\;Q [,P4HP !M_P#!:#XA:E^S%^W1^Q#^U)X*N#9ZGJ'QI/PY\0M"
M=O\ :&AZV(8YH)@/]:D;Q+.BMD+(H88/-?HO7YO?MWZ?X,_X*@_\% ?V3?A5
M^S9XUTGQIX3^$WCIOBE\3?%'AG48[[3M(AM%A?2K66XA9HS/>3;PD.[?Y2O*
M5V#)_2&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /EO\ X*6_
M\$A_V1O^"HOA.P@^-VAWNB^,?#WS^$/B1X6F6VUG1I V]0LN")8@_P WE2 @
M$ED*.=X],_9E\._M>_#[PKI_PX_:5\7>$?'+Z3:BW_X6+I!GTV^U@(N$EN=,
M:*2*&9@!YC1W11F)98T!V#UBB@"CIWACPWH]_<:II/AZQM;J[.;JYMK1$DF.
M<Y=E +<\\U>HHH **** "BBB@ HHHH **** "BBB@"OIFD:3HL#6NCZ7;VD3
MR-(\=M L:L[<EB% R3W/>K%%% !1110 4444 %%%% !1110 4444 %%%% !7
MQ/\ M*_\$5_A1XQ_:[TC_@HS^QQX[/P9^.VD7;3WNNZ=I(O-%\4(ZE)H-5T\
M21>:)D)1YHI(I/FWDNZHR_;%% ',?#]_BAKGAF2Q^.'@[PS9WK1B.:'P_K4V
MH6MRI&&)%Q:P,@/]PA\ XW-C)W=(T31?#UD--T#2+6QMPQ86]G;K$@)ZG:H
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C **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>jnj-20211003_g8.jpg
<TEXT>
begin 644 jnj-20211003_g8.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS_\ _)8?_(GT9_PW]_U2;_RO?_:*/^&_O^J3?^5[_P"T5\YT4?ZF\-_\^/\
MR:?_ ,D'^NO$W_/_ /\ )8?_ ")]&?\ #?W_ %2;_P KW_VBC_AO[_JDW_E>
M_P#M%?.=%'^IO#?_ #X_\FG_ /)!_KKQ-_S_ /\ R6'_ ,B?1G_#?W_5)O\
MRO?_ &BC_AO[_JDW_E>_^T5\YT4?ZF\-_P#/C_R:?_R0?ZZ\3?\ /_\ \EA_
M\B?1G_#?W_5)O_*]_P#:*/\ AO[_ *I-_P"5[_[17SG11_J;PW_SX_\ )I__
M "0?ZZ\3?\__ /R6'_R)]&?\-_?]4F_\KW_VBC_AO[_JDW_E>_\ M%?.=%'^
MIO#?_/C_ ,FG_P#)!_KKQ-_S_P#_ "6'_P B?1G_  W]_P!4F_\ *]_]HH_X
M;^_ZI-_Y7O\ [17SG11_J;PW_P ^/_)I_P#R0?ZZ\3?\_P#_ ,EA_P#(GZ':
M%J?]M:)9ZSY'E?:[2.;R]V[9O4-C.!G&>M6JRO O_(D:-_V"K?\ ]%+6K7X=
M6BHU916R;/W:A*4Z,9/=I?D%%%%9FH4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO^PK'7W/7PQ^S[_R6OPU_P!A6.ON>OR3Q#_Y&5'_  ?JS]@\.?\ D65O\?\
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M%%% !1110 5Y)^VK_P D4;_L*V__ +-7K=>2?MJ_\D4;_L*V_P#[-7L\._\
M(]PW^./YGB<2?\B'$_X'^1\A4445_09_.P4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'Z!^!?\ D2-&_P"P5;_^BEK5K*\"_P#(D:-_V"K?_P!%
M+6K7\TXC^//U?YG].X;_ ':'HOR"BBBL3<**** "BBB@ HHHH ^7OV\O^1WT
M/_L%/_Z-->$5[O\ MY?\COH?_8*?_P!&FO"*_>^%/^2>P_H_S9_/W%W_ "4>
M(]5_Z2@HHHKZ$^<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#L?V??\
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M10 4444 %%%% !1110 5Y)^VK_R11O\ L*V__LU>MUY)^VK_ ,D4;_L*V_\
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M% !1110 4444 %%%% !1110 4444 %>2?MJ_\D4;_L*V_P#[-7K=>2?MJ_\
M)%&_["MO_P"S5[/#O_(]PW^./YGB<2?\B'$_X'^1\A4445_09_.P4444 %%%
M% !6?XK\5^&_ WAN]\7^+]:M].TS3K=I[V]NI L<,:CDD_TZDX Y-:%>'_M\
M_LM^)/VJ_@HWA#PAXPN-.U/3KC[;9633E;349%7B&<?^@-T5N2,'@ ^#_P!L
M[_@I)\1_CE\1[3_A4&OZAX=\,>'=06XT3[-*8I[N=#\MU-C_ ,=C.0H/.237
MVA^P-^WSX;_:K\-KX0\7RV^G>.M.M\WMDI"QZC&HYN(!_P"AQ]5/(^4\?D_X
MK\*>)/ WB2]\(>+]%N-.U/3KAH+VRNHRLD,BGD$?UZ$8(X-?1?\ P3I_8E^(
M/[07CJV^)]SJNH^'?"FB7>Z36K*0Q7%Y,O6"V;Z'#OR%!(Y)Q0!^LM%<_P"%
MOAOH/A'X<0?"[3+S4)-.M]/:S2>ZOFDN3&P(),I^8M\Q^;KTH\+?#?0?"/PX
M@^%VF7FH2:=;Z>UFD]U?-)<F-@0293\Q;YC\W7I0!T%%<_X6^&^@^$?AQ!\+
MM,O-0DTZWT]K-)[J^:2Y,; @DRGYBWS'YNO2CPM\-]!\(_#B#X7:9>:A)IUO
MI[6:3W5\TER8V!!)E/S%OF/S=>E '045S_A;X;Z#X1^'$'PNTR\U"33K?3VL
MTGNKYI+DQL""3*?F+?,?FZ]*/"WPWT'PC\.(/A=IEYJ$FG6^GM9I/=7S27)C
M8$$F4_,6^8_-UZ4 =!17/^%OAOH/A'X<0?"[3+S4)-.M]/:S2>ZOFDN3&P()
M,I^8M\Q^;KTH\+?#?0?"/PX@^%VF7FH2:=;Z>UFD]U?-)<F-@0293\Q;YC\W
M7I0!^D?@7_D2-&_[!5O_ .BEK5KS[X*?!OPMX(_9HT+X):3J.K2Z3%X76P6Y
MO-3>6\,<D1W$SM\Q<;SANHP/2K_@#X'^$?AO\$+3X!:%J>LS:+9:-)ID5WJ&
MJR3WQA=6!9KAOG:3#'#]1QZ5_-N(C2]M/WOM/ITN]=_P_$_IG#2J^PI^[]E=
M>MEIM^/X'945QO@#X'^$?AO\$+3X!:%J>LS:+9:-)ID5WJ&JR3WQA=6!9KAO
MG:3#'#]1QZ4> /@?X1^&_P $+3X!:%J>LS:+9:-)ID5WJ&JR3WQA=6!9KAOG
M:3#'#]1QZ5DXT5>TGOIIT[[[^7XFT95G:\5MKKL^VVJWU_ [*BN-\ ? _P (
M_#?X(6GP"T+4]9FT6RT:33(KO4-5DGOC"ZL"S7#?.TF&.'ZCCTH\ ? _PC\-
M_@A:? +0M3UF;1;+1I-,BN]0U62>^,+JP+-<-\[288X?J./2AQHJ]I/?33IW
MWW\OQ",JSM>*VUUV?;;5;Z_@=E17&^ /@?X1^&_P0M/@%H6IZS-HMEHTFF17
M>H:K)/?&%U8%FN&^=I,,</U''I1X ^!_A'X;_!"T^ 6A:GK,VBV6C2:9%=ZA
MJLD]\875@6:X;YVDPQP_4<>E#C15[2>^FG3OOOY?B$95G:\5MKKL^VVJWU_
M[*BN-\ ? _PC\-_@A:? +0M3UF;1;+1I-,BN]0U62>^,+JP+-<-\[288X?J.
M/2CP!\#_  C\-_@A:? +0M3UF;1;+1I-,BN]0U62>^,+JP+-<-\[288X?J./
M2AQHJ]I/?33IWWW\OQ",JSM>*VUUV?;;5;Z_@>(?MY?\COH?_8*?_P!&FO"*
M]*_:G^#/A7X4^$_"?P/\.:CJ\^D:;X6EL+>YU/4WN+QHFD<%GG;YF?YC\QYZ
M5XKX6^&^@^$?AQ!\+M,O-0DTZWT]K-)[J^:2Y,; @DRGYBWS'YNO2OWCA=16
M0T%%W5G_ .E,_ >*W)\05W)6=U?K]E'045S_ (6^&^@^$?AQ!\+M,O-0DTZW
MT]K-)[J^:2Y,; @DRGYBWS'YNO2CPM\-]!\(_#B#X7:9>:A)IUOI[6:3W5\T
MER8V!!)E/S%OF/S=>E>^?/'045S_ (6^&^@^$?AQ!\+M,O-0DTZWT]K-)[J^
M:2Y,; @DRGYBWS'YNO2CPM\-]!\(_#B#X7:9>:A)IUOI[6:3W5\TER8V!!)E
M/S%OF/S=>E '045S_A;X;Z#X1^'$'PNTR\U"33K?3VLTGNKYI+DQL""3*?F+
M?,?FZ]*/"WPWT'PC\.(/A=IEYJ$FG6^GM9I/=7S27)C8$$F4_,6^8_-UZ4 <
M_P#M)?M)?#C]E[X<7'Q#^(=_ZQZ9ID+#S]0GQD11@_FS'A1R>P/Y?_\ #R3]
MH_\ X:/_ .&AO[?_ .G?_A&?-;[!]@W9^R[/U\S[V[YO:OHC_@I#_P $^O&-
MSX-TOXF_!_7]<UZS\*:.+.[\/:E?/=30VR$L;B GECR3(O+'&X9QBOSWH _<
M#]FW]I+X<?M0_#BW^(?P\O\ TCU/3)F'GZ?/C)BD _,,.&'([@>@5\/_ /!)
M_P#8Q^(_POW_ +0WQ#U;4-'_ +8T_P G3/#*.4^T0-R)[I#^<:'D9W'&0*^X
M* "BBB@ HHHH **** .Q_9]_Y+7X:_["L=?<]?#'[/O_ "6OPU_V%8Z^YZ_)
M/$/_ )&5'_!^K/V#PY_Y%E;_ !_^VH****_/C]$"BBB@ HHHH **** "BBB@
M HHHH **** "O)/VU?\ DBC?]A6W_P#9J];KR3]M7_DBC?\ 85M__9J]GAW_
M )'N&_QQ_,\3B3_D0XG_  /\CY"HHHK^@S^=@HHHH **** "BBB@#P_]J3]@
M;X*?M5^)-'\7^+XKC3M3TZXC%[>Z8%634;13S;RG_P!!D^\HR!P>/8/"GA3P
MWX&\-V7A#PAHMOIVF:=;K!965K&%CAC4< #^O4G)/)K0HH **** "BBB@ HH
MHH **** /T#\"_\ (D:-_P!@JW_]%+6K65X%_P"1(T;_ +!5O_Z*6M6OYIQ'
M\>?J_P S^G<-_NT/1?D%%%%8FX4444 %%%% !1110!\O?MY?\COH?_8*?_T:
M:\(KW?\ ;R_Y'?0_^P4__HTUX17[WPI_R3V']'^;/Y^XN_Y*/$>J_P#24%%%
M%?0GS@4444 %%%% !7S_ /\ #MO]G#_AH_\ X:&_L#_IX_X1GRE^P?;]V?M6
MS]?+^[N^;VKZ HH **** "BBB@ HHHH **** .Q_9]_Y+7X:_P"PK'7W/7PQ
M^S[_ ,EK\-?]A6.ON>OR3Q#_ .1E1_P?JS]@\.?^196_Q_\ MJ"BBBOSX_1
MHHHH **** "BBB@ HHHH **** "BBB@ KR3]M7_DBC?]A6W_ /9J];KR3]M7
M_DBC?]A6W_\ 9J]GAW_D>X;_ !Q_,\3B3_D0XG_ _P CY"HHHK^@S^=@HHHH
M *\D/[>G[&"_%O\ X42W[3G@P>+1>_8SHQUR+?\ :<[?L^[.SS=WR^7NW[OE
MQGBO3/%6B2>)O#&I>'(=8N].?4+":V74+!PL]L9$*B6,D$!USN4D'! KX_\
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M^]\*?\D]A_1_FS^?N+O^2CQ'JO\ TE!1117T)\X%%%% !1110 4444 %%%%
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M?_$4?\1!SK_GW3^Z7_R8?\0ZR3_GY4^^/_R!^;7_  TK^SU_T6WPK_X/8/\
MXJC_ (:5_9Z_Z+;X5_\ ![!_\57Z2_\ "C/@E_T1WPK_ .$];?\ Q%'_  HS
MX)?]$=\*_P#A/6W_ ,11_P 1!SK_ )]T_NE_\F'_ !#K)/\ GY4^^/\ \@?F
MU_PTK^SU_P!%M\*_^#V#_P"*H_X:5_9Z_P"BV^%?_![!_P#%5^DO_"C/@E_T
M1WPK_P"$];?_ !%'_"C/@E_T1WPK_P"$];?_ !%'_$0<Z_Y]T_NE_P#)A_Q#
MK)/^?E3[X_\ R!^;7_#2O[/7_1;?"O\ X/8/_BJ/^&E?V>O^BV^%?_![!_\
M%5^DO_"C/@E_T1WPK_X3UM_\11_PHSX)?]$=\*_^$];?_$4?\1!SK_GW3^Z7
M_P F'_$.LD_Y^5/OC_\ ('YM?\-*_L]?]%M\*_\ @]@_^*H_X:5_9Z_Z+;X5
M_P#![!_\57Z2_P#"C/@E_P!$=\*_^$];?_$4?\*,^"7_ $1WPK_X3UM_\11_
MQ$'.O^?=/[I?_)A_Q#K)/^?E3[X__('YM?\ #2O[/7_1;?"O_@]@_P#BJ/\
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M?!+_ *([X5_\)ZV_^(KQSV3RS_AZ1_P3Y_Z.L\*_^!$G_P 11_P](_X)\_\
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MTF62*>)U#)(CJ2&5E((8$@@@BK% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
6%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>jnj-20211003_g9.jpg
<TEXT>
begin 644 jnj-20211003_g9.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M44 %%%% !1110 4444 %%%% !1110 5\,_M"?\EL\2_]A1_Z5]S5\,_M"?\
M);/$O_84?^E?H'AY_P C*M_@_P#;D?G?B-_R+*/^/_VUG&T445^N'X^%%%%
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M7Z!X>?\ (RK?X/\ VY'YWXC?\BRC_C_]M9QM%%%?KA^/A1110 4444 %%%%
M!1110 4444 %%%% !1110!^@G@?_ )$O1_\ L%V__HM:U*R_ _\ R)>C_P#8
M+M__ $6M:E?S3B/X\_5_F?T]A_\ =X>B_(****Q-@HHHH **** "BBB@#Y?_
M &\_^1TT+_L%O_Z,->#U[Q^WG_R.FA?]@M__ $8:\'K][X4_Y)[#^C_-G\_<
M7?\ )1XCU7_I*"BBBOH3YP**** "BBB@ HHHH **** "BBB@ HHHH *^OOV+
M/^2)Q_\ 84N/_9:^0:^OOV+/^2)Q_P#84N/_ &6OB^/?^1%_V_'\F?;^'_\
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M#WB>UGT[2-7U;P7IVAK%93V=]-;QFTLK@2&<7""X 620R+(Z8,2;\)]=HV]
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M%G_)$X_^PI<?^RU\@U]??L6?\D3C_P"PI<?^RU\7Q[_R(O\ M^/Y,^W\/_\
MD?/_  2_-'K5%%%?BY^VA1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %?#/[0G_);/$O_84?^E?<U?#/[0G_ "6SQ+_V%'_I7Z!X>?\ (RK?X/\
MVY'YWXC?\BRC_C_]M9QM%%%?KA^/A1110 4444 %%%% !1110 4444 %%%%
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M"[@5"7A )8/E2<8/->I^ -'\5^'_  ?8:)XU\0V&JZC:VRQ7%_INE/90S;0
M&$+S3%.G_/1JV**TCAJ,<1*NE[S23=WLKM:7MI=].IE+$UI8:-!OW4VTK+=V
M3UM?6RZ] HHHK<P"BBB@ KZ^_8L_Y(G'_P!A2X_]EKY!KZ^_8L_Y(G'_ -A2
MX_\ 9:^+X]_Y$7_;\?R9]OX?_P#(^?\ @E^:/6J***_%S]M"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *^&?VA/^2V>)?^PH_]*^YJ^&?VA/\
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MM_\ T6M:E?S3B/X\_5_F?T]A_P#=X>B_(****Q-@HHHH **** "BBB@#Y?\
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M>B_(****Q-@HHHH **** "BBB@#Y?_;S_P"1TT+_ +!;_P#HPUX/7O'[>?\
MR.FA?]@M_P#T8:\'K][X4_Y)[#^C_-G\_<7?\E'B/5?^DH****^A/G HHHH
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M0!^P%%>?_LV_M)?#C]J'X<6_Q#^'E_Z1ZGIDS#S]/GQDQ2 ?F&'##D=P/0*
M"BBB@ HHHH **** /T$\#_\ (EZ/_P!@NW_]%K6I67X'_P"1+T?_ +!=O_Z+
M6M2OYIQ'\>?J_P S^GL/_N\/1?D%%%%8FP4444 %%%% !1110!\O_MY_\CIH
M7_8+?_T8:\'KWC]O/_D=-"_[!;_^C#7@]?O?"G_)/8?T?YL_G[B[_DH\1ZK_
M -)04445]"?.!1110 4444 %%>'_ +4G[?/P4_94\2:/X0\7RW&HZGJ-Q&;V
MRTPJTFG6C'FXE'_H,?WF&2.!S[!X4\5^&_'/ANR\7^$-:M]1TS4;=9[*]M9
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MX2^,/C+X/^'=,^"7Q;@\&:M#-IEQ=:G<Z!%J*W%F@5I[7RY" AE7Y?,'S)U
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MY(G'_P!A2X_]EKXOCW_D1?\ ;\?R9]OX?_\ (^?^"7YH]:HHHK\7/VT****
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MNK6ZA66VN;>4/'+&P!5U89#*0001P0:H>%_&_A3QJ^IIX5UJ*^&CZK+INHO
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M?_T6M:E?S3B/X\_5_F?T]A_]WAZ+\@HHHK$V"BBB@ HHHH **** /E_]O/\
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M /1:UJ5_-.(_CS]7^9_3V'_W>'HOR"BBBL38**** "BBB@ HHHH ^7_V\_\
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M\3?M!2ZGX*UW3+*#PMX'&B0QC09XXPLTPN,EI2[!GPPQ^\P<A%KSWP'^S/\
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MQ<_;0HHHH **** "BBB@ HHHH **** "BBB@ HKYCUWX6?\ !5NXUN\G\/\
M[5/PQM[![J1K&"?P/*[QPEB45FW<D+@$]R*J_P#"I_\ @KE_T=I\+/\ P@Y?
M_BZ /J:BOEG_ (5/_P %<O\ H[3X6?\ A!R__%T?\*G_ ."N7_1VGPL_\(.7
M_P"+H ^IJ^&?VA/^2V>)?^PH_P#2O0/^%3_\%<O^CM/A9_X0<O\ \77#>(?V
M$_\ @H1XJUNY\1Z_^T#\+)[R\E,ES-_PBE\F]CU.%G 'X"OJ.%<[PN1XN=6O
M&34HV]U)]4^K1\KQ9D>+SW!TZ6'E%.,K^\VNC71,X:BNL_X=Y_MX_P#1=?A9
M_P"$QJ'_ ,D4?\.\_P!O'_HNOPL_\)C4/_DBONO^(@Y+_P ^ZGW1_P#DSX+_
M (AUG?\ S\I_?+_Y Y.BNL_X=Y_MX_\ 1=?A9_X3&H?_ "11_P .\_V\?^BZ
M_"S_ ,)C4/\ Y(H_XB#DO_/NI]T?_DP_XAUG?_/RG]\O_D#DZ*ZS_AWG^WC_
M -%U^%G_ (3&H?\ R11_P[S_ &\?^BZ_"S_PF-0_^2*/^(@Y+_S[J?='_P"3
M#_B'6=_\_*?WR_\ D#DZ*ZS_ (=Y_MX_]%U^%G_A,:A_\D4?\.\_V\?^BZ_"
MS_PF-0_^2*/^(@Y+_P ^ZGW1_P#DP_XAUG?_ #\I_?+_ .0.3HKK/^'>?[>/
M_1=?A9_X3&H?_)%'_#O/]O'_ *+K\+/_  F-0_\ DBC_ (B#DO\ S[J?='_Y
M,/\ B'6=_P#/RG]\O_D#DZ*ZS_AWG^WC_P!%U^%G_A,:A_\ )%'_  [S_;Q_
MZ+K\+/\ PF-0_P#DBC_B(.2_\^ZGW1_^3#_B'6=_\_*?WR_^0.3HKK/^'>?[
M>/\ T77X6?\ A,:A_P#)%'_#O/\ ;Q_Z+K\+/_"8U#_Y(H_XB#DO_/NI]T?_
M ),/^(=9W_S\I_?+_P"0.3HKK/\ AWG^WC_T77X6?^$QJ'_R11_P[S_;Q_Z+
MK\+/_"8U#_Y(H_XB#DO_ #[J?='_ .3#_B'6=_\ /RG]\O\ Y ^V/ __ ")>
MC_\ 8+M__1:UJ5\J6/P:_P""M.FV4.G67[6'PL2&WB6.)/\ A!)CM51@#)?)
MX'>I?^%3_P#!7+_H[3X6?^$'+_\ %U^059*=24EU;/V.E!TZ48OHDCZFHKY9
M_P"%3_\ !7+_ *.T^%G_ (0<O_Q='_"I_P#@KE_T=I\+/_"#E_\ BZ@T/J:B
MOEG_ (5/_P %<O\ H[3X6?\ A!R__%T?\*G_ ."N7_1VGPL_\(.7_P"+H ^I
MJ*^6?^%3_P#!7+_H[3X6?^$'+_\ %T?\*G_X*Y?]':?"S_P@Y?\ XN@#ZFHK
MY9_X5/\ \%<O^CM/A9_X0<O_ ,71_P *G_X*Y?\ 1VGPL_\ "#E_^+H F_;S
M_P"1TT+_ +!;_P#HPUX/7I7CW]D#_@I1\3KV#4?''[2'PLOIK:(QP/\ \(?=
MQ;5)SC$<J@\^M8/_  [S_;Q_Z+K\+/\ PF-0_P#DBOTW).-,KRW*Z6&JPFY1
M5G91MNWUDOR/R[/."<US/-JN*I3@HR::NY7V2UM%_F<G176?\.\_V\?^BZ_"
MS_PF-0_^2*/^'>?[>/\ T77X6?\ A,:A_P#)%>K_ ,1!R7_GW4^Z/_R9Y/\
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M_;Q_Z+K\+/\ PF-0_P#DBC_AWG^WC_T77X6?^$QJ'_R11_Q$')?^?=3[H_\
MR8?\0ZSO_GY3^^7_ ,@<G7U]^Q9_R1./_L*7'_LM?-O_  [S_;Q_Z+K\+/\
MPF-0_P#DBNP\%?LV_P#!4GX=Z(/#G@[]J#X66=F)6D$/_"$W,GS-U.7D)[>M
M?/<3<5Y=G.6_5Z$)J7,G[R5M+]I,^CX7X2S+),S^L5YP<>5KW6V];=XKMW/K
MRBOEG_A4_P#P5R_Z.T^%G_A!R_\ Q='_  J?_@KE_P!':?"S_P (.7_XNOSX
M_1#ZFHKY9_X5/_P5R_Z.T^%G_A!R_P#Q='_"I_\ @KE_T=I\+/\ P@Y?_BZ
M/J:BO(OV;O!O[:'AG6]2G_:A^,WA#Q/82VJ+I<'AOPZ]D\$V[+,[,3N!7C'K
M7KM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD7.\=P16_P""3W_*=C_@HG_V%_ __I!>5K_\'8'_ "A*^(W_ &,'AW_T[6U
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MM4^(/P1TRV\06>J^%](>,^,?#=U;>?!=P68=V6[C;-M-$A*-+L:/:)-B?/\
M^R?I^H:5_P '1W[5+^)%99-4^!OA>[\."4<O8)%IT,Q3/\/VE&!QQNIWPVM]
M4UC_ (.P?B)J>@*WV'1_V1K.TU^5/N">75K.2&-O]LKAAGLAH K?MG?M'_\
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M._:/_P""_P#^R#\&M4_X*$ZYIWP+U'P1X9"ZMXL^ ]A87CZCIFB;E\P?VL6
MN+N&-MTKHBP@H[(DJJ$;W_\ :X_X*D:9\)OV//@_\;O@9X0@U?QI^T;JOAO1
M?@WX<\0,T<+7VMQQRPS7WE'>MO;Q2>9+L()*J@9-X<:W_!1K0]6_;!\*7?\
MP34^%^HO'=^/K. ?%37[;!7PMX3>7_268\C[7>K%):6T1Y.^><@I;/GY@_X+
M'^ -*^'G[?\ _P $U]&\.Z,FG>"/#?Q@NM%MK.)2+>UF\G38]-A&>A"P2*@/
M/RF@#Z$\0_M9_'+]B[]LOX1?LT_M6_$?2?&WA;XZI?:9X8\9V?AM=)GT;Q-:
MQQRBQFB25TDM;M'(@/\ K8Y8RCO*'#I1_::O?^"S_P ;/&/B?4/V$_$GPF^&
MWA+PO=S6/AY/B1H5W?:GXQO(#MGE?81'I]D9@\43!9))!&9N(Y(Z\<_X.$;?
M5-:^/?[!_A7PJK-K=Q^USH-W9^5]](()(VGDXYV*K*S>PK[K_:;^/J_ 3X?K
M?>'O#3^)/&6NW!TSP#X-MI0D^NZJZ,T< 8_ZJ%0K2SSGY8((Y96X3! /FC]@
M'_@KY:_'G_@FEXY_;<_:S^'R>!=<^#&I:[HOQ<T33B7AAU/28DEN%M [EF\Q
M98@D9=B)',>]\!VY#Q)^WU^W)\)?^">OA[_@KQ\4$\.W/A#4;72_$OB?X+:7
MH!$^E>$M0FB6*2VU!I?,FU*"WN(;F4R(L$F)8EBB(62O._\ @IO^Q!K7['/_
M  ;8?&SX*>'M:&N^,;^V3Q7\1?$5G 8QK&KW6O6=]J]TJ=5BV"5$!Y6&) V2
M"3Z5^WMK7A>U_P"#:+Q-JEI+$=,G_9@TU-/88V$2Z9;)!CZETQ^% 'WKX0\6
M>'/'OA/2_'7@_5HK_2-:TZ"_TN^@.4N;::-9(I%/=61E8>QK1KP'_@E+HWB7
MP[_P3#_9WT+QA'+'J=I\$O"\5Y%/G?$PTJV&QL\[E&%/N#7OU !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 >#_ +>'_!/SX1_MY^$O#<7B_6]5
M\+^,_ .OQZ_\-/B)X:>--4\,ZI&RLLT1D5DEB8H@E@D!2157.&5'7X?_ &T_
MVU/^"IOP)^+^B?L@?MIS^&OAS\%?',C:+J?[7OPT\,W,@MHYHRB"6*XN9(O#
MUS*Q$9N)O/BA,ADCW*A>/]6*CN[2TU"TEL+^UCG@GC:.:&9 R2(1@JP/!!!(
M(/6@#Y\TS]BUO@=^P/8?LE?\$R?BMI_P=?2--MAX,\7#P[;Z_'%^_2>:::&X
M(2Z:Z!E#RD[LSF1>0HJCHW['G[1'QJOO!-]^W[\=_!_C.S\ ^(;7Q!I/ASP#
MX#GT2SU#6+4'[)>W[7-_=O<>2Y\Z.&(01B8*["0(BK[OX"^%GPR^%6GS:3\+
M_AUH7ANTN)/,GM=!TF&SBD?GYF2)5!;D\XS6]0 5D^-[/QQJ'ABZM/AOXBTK
M2=9=,66H:WHTNH6L39ZO;Q7%N\@QV$J?7M6M10!\@_\ !('_ ()F_%'_ ()9
M?!;6O@'KW[3^C_$?0=5\57WB&*XC^'<FC7L%W=+")%,G]I7,;Q?N20OEJV9#
M\V !7UQJ*:A+I\\>DW,,%TT+"VFN(#+'')@[69 R%U!P2H921QN'6IJ* /C+
M]C;_ ()B?'G]E7]O'XU?MLZY^UOX8\3K\<[VPG\4>%H/A3/8"S%DLB6RVMR=
M8FVD1R,K%XWW'!PO2NA_X*\?\$Z/B-_P5(_9;O?V2M$_:,TCX>>'=7U"RN]9
MO9_ 4FLWDS6T_GHD3#4;5(E+K'G*.<*>1NX^K** /ESQ+^RO_P %(/'OPPC^
M#_B#_@HQX0\-::^GK8WVO_#'X&S:7KK0!-C>1=7^NW\-M(4_Y:K;EE;YD*D#
M'H?[#W["W[.G_!/+X$6G[/?[-/A2;3]'BNI+W4K_ %"Z-Q?ZQ?2 >;>W<Y ,
MTS[5!. H"JJJJJJCV"B@#Q;]O;]GS]H[]J+]GS4/@K^S5^UA'\&]3UF00ZMX
MPB\''6+L6)4B2"V'VRV^S2/P#-EF5-P0*Q#K\U>"_P#@F!_P5:TG3_#WPV\6
M_P#!;U)/ASI<EG:ZKX+\'_LT:)X?>[T>%D$FG6]Y:W1DL \*F)981NC#9 .,
M'[^HH ^?OVAOV);_ ,<_M0^#?VY/@)XYT_PG\4_"/A^[\-WEWJ^CO?:=XC\/
MW+B9]-O(HIH9!Y=PJSPRI(#')NW)*K;14^ W["_BGX(7OQ>^.UO\7=+U+XZ_
M&:6*?7_B'>>$V;3=.:UM?LVFVEMIHN@_V*U3!$37/F2LSL\N6 7Z,HH _.?X
M<_\ !*;_ (+$_";3-6T_P#_P7LM;*77M8N-5UK4IOV5=$N;N^O9B-\\TT]\[
MRL%5(T#$K'%%'$@6.-$7[3^!WP@^)?P8_9PT/X37WQKE\6^,=-TO&J>/O%&E
M-+_:VIR.TMS>26L<Z;$DF>1EMTF"Q(5C5MJ"O1:* /E?_@ES_P $]OBK_P $
M[?"'CKP)XO\ VC]#\?Z=XV^(>K>,Y&L?A[+HUQ9ZAJ#0M-&';4KI7@'E':NP
M."_+D#!^J*** "BBB@ HHHH **** "N._:!^ 7PD_:D^"_B/]GSX[^#+;Q!X
M2\5Z:]CK>DW60LT1((964AHW1@KI(I#(Z*RD%0:[&B@#\R?VI/%'_!77_@C?
M^S-I7A/]DCP'IG[1_P +?"]DMCI^K:WHMS<>+_"&F1X6)+JVM)XDUN&&(!5E
MB%O(%3$H"@S5]"?\$K/@;^S%8_"?7OVP/@3\<I/BIXN^-]TFL^.OB]?PQ+>:
MG=)'LCM#;(-NGPV@)B2PQF#:4?<P)KZRKG=,^$/PGT7QM=?$O1OACX>L_$=]
MG[=K]KHL$=[<Y&#YDZH)'X_O$T ?-/@[]DG_ (*:^*/ACK7P#_:F_P""AWA#
MQ5X:UR&XLM3\4>&?@]_8WBBZT^8%)((YX]0:RM',9*><MF[J&)7#A9%^G?AK
M\.?!/P?^'FA?"?X:^';?2/#OAG1[;2]"TJU!$=G:6\2Q0Q+DDX5%4<DGCFMN
MB@!)!(8V$3*KE3M9ER >V1D9_.OB[X+_ /!,']H;X5?\%1_'_P#P4QU7]K_P
MGJUQ\1O#-EX?UOP5#\([BVAM[&U%HL9M[DZU(RS8M>7='7,K'9@*!]I44 %?
M&'[4_P#P3#^/W[1?_!1;X0?M_:+^UUX6\/-\%TU&+PQX2G^$]Q>K=17T;PW
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MJVG^ ?\ @O9:V4NO:Q<:KK6I3?LJZ)<W=]>S$;YYII[YWE8*J1H&)6.**.)
ML<:(OOGQ2_X)KZ;\=?V(_"?[+_QF^.NO:YXW\&ZG8>)=%^,4EHBZE;>+K6X:
MZ76HX&9DC!N))?\ 10Q18)3"K* K#Z<HH ^;?#_[#WCSXC_M4^"_VOOVQOB?
MX?\ %FO_  OT:^LOAMH/A+PQ-I>EZ5=7R)'?:I*MQ=W,D]U)'&L2#>L<$98
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/ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>jnj-20211003_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:jnj="http://www.jnj.com/20211003"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="jnj-20211003.xsd" xlink:type="simple"/>
    <context id="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9a8050abbb6b4fa087129310f939d84d_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5b6adc1e7fc54138970a1ffce6545ea4_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.250NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i6d7f3f3cd9e848f386315ec977895ad1_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie0d2f13d6fae4fea9e15a651e3245c28_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i579388adbc0145f5a9221b1e7204d902_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia256641b62ca4d77ac7b64775619302f_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5cd455ee122743e7b308fecfa89422cf_I20211022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2021-10-22</instant>
        </period>
    </context>
    <context id="i524495c8e7d941efbc4c7057a7d882bf_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i6223e38b49924566951c6ee22df12ea8_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i4f560bf19097496e9d3b17c570ba5487_I20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2021-07-04</instant>
        </period>
    </context>
    <context id="ia36f1ef4e53741a698ce4eb8a63cfcc8_I20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-04</instant>
        </period>
    </context>
    <context id="i3d39696cd8124bebbcee13521011bc43_I20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-04</instant>
        </period>
    </context>
    <context id="i2fc21784cc544993916b76a2883b5fa7_I20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-04</instant>
        </period>
    </context>
    <context id="i2b91cb0100d34fc688b5e3ed019ce080_I20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-04</instant>
        </period>
    </context>
    <context id="ia21d27ed7dc047cc83042ea5ddaf0820_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i85720d7d2890498ca2589aaaa3d3c267_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7c3f7de455fa4be484a940d40bf7d252_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic67ffcf2eac440a4a3acf47e9df62981_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="idd88e9907aaf4e8cbca11111329e2073_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="icdbe49f46d3548e69bcf28fa1c70f4a0_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ib15db8a9bfc141e3b662784fb2f12036_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i97cf81456e3d4ee78c0eb5ef14d6adfd_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ib616b434ad574d54a671235ee0e19c40_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i37e41918fcfb4a96aae4c8ddf736f81f_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i6567971b97b8486f9c4ca8fcaa0bc916_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ie0f5194139614002a34759c09867b19b_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic6f044a57fb04694b9504b1cc6b855fc_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i280f2f10a11c4c988142fed0ab0a55c4_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie4c978ae9bd844bb8485b20fee0394d2_I20200628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="i789e8630040645df9671180079be56c4_I20200628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="i8c1cb280df774543988ac3e60b3700ff_I20200628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="i5b1b5e269d61463c9d13dc7f3431be66_I20200628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="icc043974a53d45c09c9c4916e8c5d997_I20200628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="i151bc89c89104e6fad68b01743dd13fc_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i14461e2d7ae84af4b6b45899f46e8cdc_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i94a2d6ba6c254c6b92dfd2a37f7901ed_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i4de10452fa98443a826d732ac5ecfcd4_I20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2020-09-27</instant>
        </period>
    </context>
    <context id="i21919a743da04e9ebb238e98bd59fa74_I20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-27</instant>
        </period>
    </context>
    <context id="i514541208cb44a09bd41a6c7b123cbb4_I20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-27</instant>
        </period>
    </context>
    <context id="i701c9aa0c90c443fa3b9239555242704_I20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-27</instant>
        </period>
    </context>
    <context id="ia4593a0dc4364211ae7edf29da4866d3_I20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-27</instant>
        </period>
    </context>
    <context id="if49e94e75cf04169b3ef119b2c588a4c_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i6004d7a658874bffb0b05f268a6fc6e9_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i5e06dbf4f1b44f998d04005f6056c3d5_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i0ba2e82215dc4171a568af3512fd9d8f_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i2a829e70799a4429b48066d6c98beb81_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ibd97456bd71e47888787febf8fb403c0_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i25e2937f00db4ffab2f056e05c4b797e_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i76d47fefae324430be757b4f9833ed5f_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i4743699b0eac46a588c10333167e9fae_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i137acfc8e8824efc95e1265512dd13d9_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i7121dbd0cc754e319650cfe1e9a6d091_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i364bae74581b41469b167f1d57b47bec_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="iba2272c30bea4b1482458fce855c3373_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i306786a4d54f459696c4fb7907f30ea4_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="idc12ecbfad9b4436a408325ad670fee4_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i6550a842150844a782974595356be4c8_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ie9431acda5084235a9355798c8cc8b2e_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i58d78224ae6d43cf95b5735d5bb3dabb_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i1a29aa136e144ef7a4209eb7a9897d36_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i0fbb196ddcb14beaa7a23bd9de26d3d9_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i185910f7181845c8aed38c39fd4b6cab_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i18c6f67375de464e98be9b5c858a0996_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if7fc25fc53e54e21948d2ce281e9424a_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i64662abe386b4a3b9044b4dbcffe47d5_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ia53808fcfd3f400c939324049330ed77_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i97512951ea1746ff957df24ca33bf674_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i69229a2a50d442b795aa18fa30c26be4_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if2f30918b36c48df9f73661bf07e071b_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i386cee1639274652826fd3eed1982a70_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i0e0add53586f4fb29f2838afbf423ad7_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ic9852777165f4b609444e7127f04f202_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i7c4d270b6af043e9be04d479dec5dd5c_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ib219ae64b99744eaa1b7b8cc1067daf8_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i9dd7f04c9cf442d09d8944a1200e4e9e_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i2446fd6831b74f84a1fbc08826466b5a_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5373c09ac6424f71abea9a4af34fad8d_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia29eda1bae054029be22f80a32d9bed0_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id1176d5e87c548cf8e03d248b438c1fd_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i46ddf01a2ed04decb15a346373711b4b_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="iaf5522e302034e189c307e49dc73197d_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i58a7e978302f42b1aa90a38f29c5a34b_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i77a7f12df0b140499e72c6c5292e080d_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i513a49e58ab74680ba8b509c23674bf0_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i48e5c25b196b4581a673892969bb5051_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i93e401f2dd5c4ea586defab03d5e9b30_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4c72adb013a948e8a95c6b4603152001_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i82e5fff9c6bd45ca997965825f96a0d3_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i99216cc8b79445dd8a6169989e70f809_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ibfc2d51c1b3943179426ac0f6638ea2b_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i3b598c35682943d4aa693d58ad7185a7_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="id0ccfa0f2f3043db8ffb4dd5132378b0_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i77bd06875cea40cbacd7c9e2c6e60de2_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ia171152160c9457eaf8a8198b50831df_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i5c22296c638b499dacba432243aabb21_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ief08f28671bd449f85c45b2524dc11fd_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0490b39cdf9e468d851a818d788fa90a_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i767f5c4625154f0a8f7d74c8b8c3a35e_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0c775ffd78004ecbaf03812778b4fb63_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i15408f87a30b40a48076e15baf08bf94_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i7b90f9340101469daec861ce7a7fc255_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i19054c05c6034f23a0b61aa630e73505_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i469f78b5da314cda95613d4aba1df12c_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ia3d4899630c6450886e61d01be554303_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ic0786ff8f130406bb2514f5c91f8a2a8_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9d4a0150b247424e98fb6ecbe5b9c39d_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i078ef827e4f344eab96812a9740e1239_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie49f82a46b424edcab630d17792da6b8_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i204468adffd143848aaaba487ce0a656_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id01b13e20bd947928cfc3ced046acd64_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i3753d069b34e42ffa037aa3a221eec25_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i0a8c3429d9ff41b7b0f85c7d87dad8f8_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="iafc5d51a497748cc9ad72884ab239bfb_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="iffc2ba0506404c9d92c54405efa208bf_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="id97c9bcc0a104ab4bf86bb77681a798a_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i36e6f6c2b8274124a6cd37dfbbe9c6fb_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if264742b6d944aba8d0e08c08df83a8e_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5c801cb847184a7894fc5ff4b0c3f468_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i515bd1a2d43148349fd6ab9f0a2255e3_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia8a28c76f65e4001af98e0f096fb76b2_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i3ade907d675d4c8c99740caca6ebd135_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i6e9d30cc4cfc488a862a5885738d2f05_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="icb60c19364b242d6917f7472855f3905_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i2c2b9f86e3934a9b831632fa60e4ba21_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="id0141e2177d24be384d24197d458ffe0_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i6256db6dc0054ac18b141ae33e5ad29f_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8631e8b6ef484669be037922391c299d_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ief5d0c9bb17948d6a1b2d29d6f8c062d_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic8470a3d16a94257810c1ec46751fcbd_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i91a4caee55e84fdb8343347b7638a55e_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i5e79014ed177468abd91b03922e18af0_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i7b8df8e17a0f46c78ae91bd6ad3784ba_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i7b9ff999f4544965b285cfeb8d1a0cb1_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i6bf2c274ee034f6688bb999de3bbb518_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i8602046a27c64bd4926512027a77764a_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i18cce9dd23084ad68d56d277f4166138_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i25b25621104941d6a59c689bab906bf4_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1f27a2322ca147eab04beab15bad4715_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i3020bbfcfb1340499dec1be0f710b954_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i99def0c623bf49c58f2cce64717f9eae_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="iafca8a975c524aedb162430401cc1a92_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="id40428336fe54fb0b1d61580ad3f301d_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i855c33350d7746598cba6771e22ebcc2_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i61b00628ead94443b3f921a3a6d612de_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i94250734c05f4e5ab67af91d5851ea23_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib79aa24edb5c4b0589f5ba2b11f35226_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia495e7b3f52a4352880c86434b292e22_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9a3574762e24474f8b845e390fc8124e_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i74ad3f15a27f44939475bb5617afa269_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8aec662a2dab41b5ab3eec8dd912eb2c_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ie697d1e6b84a4b06b358ed0548d7499d_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ib1e60dc0c01d47d1955296c160459cb5_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i4a1ff01920b54a71b8bdeb95dd658754_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="id36f5e85786140ebaab64dfb8e6e1c3a_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="iba61370bc5134de1ba733b99d4caa214_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i547a7a9339204ab39e0413979ed1a2ab_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i2835247bbd164156ac697a316626d4b8_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ief9761af24a4460ea012090015fb22ae_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ia6e0ead4649b4a7a87dc1937b5e8d0ce_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4d4896777472483c91059e670b9b3b89_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i086fb509c2da43bdbf100b4f08fd1272_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7a83ab881bc04e018d1d2f066bc40669_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ib65942949a8b4ab2858ac418b39805b8_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i12239b7d99e147329855a8ae0ec87490_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ib42b4b45f7a24a98ab6f6f966bf2ff2f_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i3f3dc535bc03400d84053d66430136d1_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i342e3f1749ef42f4a46139b2cb020f4f_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iba821c9267974930aa7f53fa5bcdb8c5_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="id49fbada050b40ec920b3e2ec7d1b351_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i864a93092b7f471e9b3af685acca4202_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i52e8eabf585e41898fda5db69bd674df_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i380144a9a9fa42fd8158904a1c5d0700_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i2c668ea680234cec82c45cb5e0c7a70c_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ie922169de489430ca26a82b6556fdcbc_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4eb1c56e86814746bc74797880579d47_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ic9a3a355d8f84cf5bf2f61990c01ad9a_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ied95fcc9c6ec43e28079e110635c1c3e_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5e894ed981be4116a2355b4062397ba2_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="if3dd051494d44e5a963f074248d0e103_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia541a8d551c4468c8f6e756afd118e10_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ia929718f7d4b44af9534961189e19b18_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i7c61c290cdfa47aa90f28583b201ca61_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ia918a096df5248d794e6e608f618f2d3_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ibdd29fe7311d4c0f9fccaf4d085f95c5_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ib8bf2953dcaf482eabe10bcdb5890292_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i7cc97e40d3d4405d9a96f873abcd8d6e_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i31ec175a56664fa0bd90af394bda5a04_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i0cf8d2cf87a94bf7a55afbbff98f5daf_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ib6cb46a97d3b4230ae9dcca4c2069fb6_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i7b78f843aa1346368fb728d955f6da33_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ie9e29ba46f0d4a8bb33c9e8eb07ffda5_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="if00b7b3746e54851b72fa7817a56cc7e_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ibeca5e8660d14e0e95ab595851e5a044_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ib78fc1819e4c481fb01505843db10e28_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i5820db2145564d76a142f0b76e3fbff3_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="iaed609fd41ee4cf9a82d74bf5e73e604_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i831bedde345c419192edc69c0e317205_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i2b704f7750e54b2c8511c93e87192817_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i771e5eadfd734fc987bf5ecca1178170_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5b7dc91718ce4ea0a9b05b4625568ef0_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="if293da93cdf44458a788e386d073f1ee_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i8dcb1b245fd240b0b488db669a604f22_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i9f73056213bc43fc94fc5c10e89df326_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ia9385ca799d84dce96c2206ee78ac799_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ic741579d386241e4bbf75342917d529a_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i009c78145cf74486a461497129412728_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i6fb649af90814478b37ac417cea6456b_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i9178d762f0634d6a894dd86815cf64ec_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="id829f858995a40ed8f879e67456295cc_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i6a81061eccb043c396dcd8d5162f888d_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i18389b6ef2374d3c823b640e24fe8d12_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ic4204d24c6ab4dfa89a1c5d5867933ce_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i7ac4e3b179864a468bfaa6bba91852e4_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i65df3ffe517245619ee40a22674cf249_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i6fa344c3c3a14482aa8f313597fd1bed_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i07e445fc6ca14fef87c4fea6ac866c95_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i7415834b451d40a98618e973debc442e_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i8c8213533087409db4d429fd040785cc_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i9b6ee0ef21ad4005b66cfbd8d7bd5087_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.05Notesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i31b2046662244e3b9cbb92c5aed58fb6_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.05Notesdue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ie6b4ff6b5de74a15b368ea59a0de5057_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.05Notesdue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ibf70d477076242eeb2b9271915ba71b3_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ib0bd340801084b60adf4d9a44c9274d5_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ia29178df168d49e381facf07098989fb_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i1e3d2dc107be43c5bd3e61ccb2b7faf4_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i54f00a29b7c94893ba5de79c98a063b2_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ica369f9fff05494a954f5c22e4edab8c_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ie72e7ef5001e45cfa85cdf6654be4b80_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i44489d6df8a8422c984028d2e3e54b5b_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i81fc862d12094763922068d4e9c8537d_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i4147275174c24eac885cc4fb0886ac54_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i4a6f8d9f883946d6b9af6c9d0a9be721_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="if20ce7e060e548869eb894260b6fc64b_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ie83d54bb9a4f4816bf50aec027245c33_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i2d23525d3b284b7d9852bad7add00e33_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="id1546f14269e447faa59f6da1aca49e8_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ia478ea6acea24aff8eff14df6fecc891_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ie5640ee1ce1d47ad801b0d6eef582304_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i6d971262bcb64b6b893eb6fedc3a0beb_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="iedc4b4fd0b1b4ad390f5f63e58c47e8d_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i4e50b1400f70460a988afbc0dafd4823_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ic6cfc552441e4a8e8b91f3deb98f4c44_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ia99340613822456eb8c3641db778ecd7_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="iaa8046c340764588878db0a7b77c401f_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i9fd60cb1106c4c1499568e9a6eebfb28_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i72bdc25703924ba3b6b0ce4527d18d88_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i8b28e0d7e40047fabff6dba54a753c51_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="id23573442cd349c181d05b7186a88a8f_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i99f7ce7c3c0a4e47bc46cb5013b85204_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i4fce897c159a440fa82606e78f5a8890_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i9442a0f459844bc8b34a3edfbad734f2_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="if9abf297178741228613c2f1cc8f19d2_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i34ef244a220d41cd93a8040056b208e7_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i25ff7c6833044a3ebd91c3ef1f1367c4_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="id3fec2057e8c4da08b74b29f4fd4267c_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i1f58130f89ed4256a62ba7c75eb638c4_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="iefeb4b2784e6435384a917a1944c658e_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i860c18e3721d4d939bd33a8ea77e4421_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i9daefad50e444c3b846ecb91f83159bc_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i3c801cc1caeb4c179693dba2260b0563_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i0dbba3a61c5540838ca8c89692469565_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i4aecaa1385574720ad3d887864eeb207_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i3125d97f80b94d60b77182ad35bb48fc_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ic7aeccd4baaf4417b5ffcdc8852c71d4_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ib143b536bc9b45b4826b98a0ac180c8b_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ide702a860cec442280c57a5771658c81_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ic2ca463645bb4a5b9739b8bc175da1db_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i16f1d7b4085841078f18b613f1fe0a77_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ib92d6482e7ea404eae4e1c4468904413_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="id2a6e34f48ee4c7d80d33f78478eb3f2_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ibdc7fc7a723e450cb48944879c0781e7_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ia1a7c9dbc6df42aeb77011ac535edea5_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i57d6a4f83449492094bb6b200701e064_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ic2f2afd2bbca40be9ed9eff967565efe_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ia7d62d21ca6949dcbc76d7ab670920b7_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ied109c22c97143bf9e2d8950f06aa9cd_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ia107789c130e40adb3ad38987e6fbf7c_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i6d2f5ac2df314410bab3062026857504_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="if3b49374b2a540819767fb1780941cbf_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i26dfa36f335f442fb41f8059c4cfe77f_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i25547702bd0f47088ae87a4e661a13e2_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ic31cdd75b29340eb9d44466d5ec7ffd8_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i50afa95426c645b18294c42ab68e0a75_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i0a8f75d047704b5aa0d3db1bc03ed292_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i3890ce020cce483fa079c7f7418ac44c_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i3f17e1a230b249b09dc6346803945e09_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i6188505bd2214769b12b8c2e7a1c0463_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i7fa9c5baa5cc4e97becb950d913da01f_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ie788a463953d40fc97d8f8e0d65f542d_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i0244efd886bd4bd289f13fdfc63a76b3_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i5d3f77d18cb74144b8514b9fd3021780_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="iab5c42e4384e4963a7ae278858dc9a3b_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i5c7ebdcd26aa43d5be5ef11db34b14e8_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i7bb0296c854c4acf871e0335393ec672_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i25548ce1ad154cad9b4737a0931325b0_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i4e73ad17867f4918ae13cdb77b42664d_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i0ea1027adfa8409fa2240d2e0d15da0b_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="idd27580aa37f4a75b8b17887161c3adc_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="if98b3204979e45fb982f58b3cbb646c0_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ida0748410a8c4eab9d417837ec838a91_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i483018bed3724cac829e9c16115d7f55_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i193c04c9acbf4263b63c3eda25c9c4c8_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i15cf4b9be03f47eba85d4614348d2034_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i427dbcfc1b924d82bfa86831fd546f1c_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ic0be6f6c2cd547e687ae5108ce9ac42a_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i7ba0ab6b51254970ba452db5939f0a54_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:NotesDuePeriodFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="idedd08cef78740fc9f67f0cf86fb8ba7_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:NotesDuePeriodFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i6e38f2e44f714a3d8fd4adc7b4276d3d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ia1e15dae48b34058996995a2834d63fe_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i0ac5b17e0fad468a80e8667a23da5ace_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic6211b8d8ccd49788ecbb637deed070a_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ice0924be1a6f4deb9320312504bf1648_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0b4d8090e5a94aa6a43b8958bfdeabf1_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:RisperdalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9861446e76324a08b1c77c4fa0b1b5a3_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie6bf26a76e934a0abbe42eb60a86e6f4_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i1a7e0b9b6e694546bcf63ba4da67114c_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i6d181abffa774cef94773798ffcbc773_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="iae538c397d5b4172843ae849a0fa8309_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0db0747f8e0e4cf9ad8b2c2022602317_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i8f89fe3ec42c4ee6b74d0ae62c74a640_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie8ad9c18d6ef430fa4f2b3d36ff46598_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="icb909ef9c68340daae79d3dce5aa8dc4_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iaf1dec1c43ca4835b67df10da682c97a_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ieeff0339058f4ac9808b5eba4dc8ff41_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i87dfc4ba292d4afcaa274be4bf5a6019_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i6c9b670acb814f2e8e8cae1d3b139677_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i49a74fa2fdfe4f89beaadf820f5ac713_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i40bb249c8086466faca49b2fa9bc2a92_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i90665923dd1c4a2fa6d99222fb60dc98_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="idfb362df49f946cc91574b4a35909613_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i32fd6f9a0ed9441682053b3f396c5491_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ifd186072d3fc4864a3c6f62ea4a983ec_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1585241dd83540d68d0d4bb0179b4c35_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iae5d5570b0974f90b2b495ca2a503dae_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i9d619304e810451eaf68e4fe20b97b9e_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="idc89c7db9aca490ebbcb9ac5ff66d285_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="id1ed865a3a524e718fe97e4283367b0d_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i5932fe6bc8874865bd9bae6cd5c4e149_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9863b76d1752421eab7f10a27e21c3a6_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i8648858c71084557978cd6faeca2cacd_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i38fb4207f4f44740a27e0c6df6aeb726_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ib1c9f29f75fe43e4847364d3f7c39cab_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if7a63d17adab4e81bbe6f8151842a30c_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ib646ba6c37f94afe9e3d21b88039c182_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i2f7b6f883fcb4fa4a9afe5cf3bdb0815_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i6d28ecdc380c4101b6135c161dfad020_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i2d474e7ed1044d528c7b1ffac5e15cea_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ie547a8c88fa940efb218427e0eabd0c6_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1ddac223612a4d06a37f3fd6878493ca_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i5975dabe875348b9b232e9e29d323eed_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i40ce11cf1c234e67b7e6b1a8988ba942_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i0847920abf9d4769baf2ea560468bf0d_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ifaf4498d8f5049aa8af464f01fcd4088_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i37f5a592ff13494aada072e3bba0cea0_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ifd69d35e5a314c3f80c3949f37cc664f_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i04f3d42910f54dbdbe61282d28955d56_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iddf4ba62d5ce4571a62ee75dcd2a8e3c_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ie2674760a7034ccdac2446519a5166a9_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7da3b551671f44d192917a4c6f2efa57_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="id9f77528e7ac40108b66c8931a2c701e_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iff3b6e1b8fdd425390328188812a6eb0_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ic833af6372324ca3b5bfa4fcad54732c_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i525fc27ed821404fb38182e25fa87eb5_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i55f1d4591fc84cfc8c2e037ca49db283_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ibee17d8505bb4fe98b2e9fa97001fe0a_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ic8085b27842a47b581f106618510e63b_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i050772dc13db458dae8ef05843e7c1e4_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ie892e3f1014a404389b2b3050897a15c_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i03fd89880da847f0a48e5cd794cb0e76_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ice21827a874a4c00b01f16ab3cf18368_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iddf1dd064873494095b906942f5d38ed_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i29ed38871138472c98810a5cd7f1dd95_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="icf97184ab0f344fa943bfc3649c4080c_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="iba082d308e2e40fab4c4792324108b13_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i62d3c4191ff94bc2b0b06fd86e9ebbc2_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i2e4744bfcdba4605b67ce9cf20e5ed37_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1a9371cd71e74f32b3d3425e7fa3120f_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i9c26ef7358064431907c0c0b8e35ca05_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic9015829b0dd4cc083d55eb4725146ad_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i046a4a03db32475eb292807b6b65dc2a_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i987662a6928046d9a653a39c7642a99a_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="idf3567b227cf43b7b727c573098b1019_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7fe2032b4fab44759101707824a42b5f_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="if08e07c77ca240b6ac145790e6d91e27_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7237727cb89c4b3ca79fd4c8ab24fae8_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i776cc9f3f12444e19c75d71e9f1306ab_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i42c653266dbc4cbfb3ad7de36334d59d_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="icf9f5672587c42ef82b704011560ab84_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4cc4e2c56fe94f0ebb2696dfb6777df9_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i1864c3f454d54b6099348e1437264d1e_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0001607d8afa4b969777538d3b0090ac_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ibe9e6fb867164bcab52ce074dbf7118b_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i6f00d71bd5644d7386d54e5e7ba6f9aa_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i0f6ca30128844134ad0de910cf66a408_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9f8cb7b296594fc5add46b54007f21d3_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i988a335b32c84bc3982666bf61d8fd38_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie0f9db2930c7434cb55c268ec21f1fe3_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ic97d6e50fa564ecfa01edcf954ca9b30_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0ccb194a8c094e919fdb8681e73ce223_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="icf724d7bf6384a4d99527cb12064aaf7_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id60c33805d624a1e863dd18b29ce66d8_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ifa415248ab90441fa1cc6656b8dcf614_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib69f132a3f0b40c581d2942e7d57a5b9_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ic01e2ce9f12a469dba08795b5a902ed6_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie95cdb275193469989a402b370c02342_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i98adf17c3209468a982a0f7200c745a1_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="idca691679ad64cf583644d8594234216_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ifb215856dcc24e3f9d3079bf180a51ff_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i3add39942c4242daa496b88f14058185_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i8a5b1e45c95842418dbd6dcbe4bce0b6_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i91bd273779f6455f9fb27bde5dca4f93_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i2e2b0381a81c41c495cc13d352d5aeae_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i932f9d2df6c34e58b2f54f1f4929c220_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i38d436a7587f45a1ab95abb5b18a129f_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie9a74be9ea184900b90a441048493bc4_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i0250c72ff9ac405c928f736053a9f5ff_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5c4878d8e6ac4393a3e73e04f398611b_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i27ba7c90a4c1434586cbf514f3e51927_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8aa1fb345ea8443c9e0bc1aa8418aaec_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="iaa93431137654cfa8d08a279d01cc337_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i2860d64b06e045eb890021c7710f0aad_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i59be6ed5442a4a678a48fc617f1eb13e_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i8c17375fbded4a6ba40cab9f3d8326d7_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i45b42eb8b685491a806080af8dc02aac_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ieab9cec340d34cec86ad2425fd1846fd_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0cca5cafe25a4fe0a525fbc02d000afb_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ic00d19a36bdf402ea98bd292be45894b_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i87a41a88262640b3b2d8b6e97dba1464_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ia281107d882e4be6a4d88169207e2a36_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="idd6a9a9e55274bffada72f2726569f6e_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i77effd52b2654ae686fe2393749c515d_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia37c81e1cad0453994f3e00b01af754d_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i41ab0a4211f24f9391eae4b6c0bce606_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i6c1c64eccdd14e999154f3c36cce6b77_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i909f193a74e24bfd8a95144ed8637f1a_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id049e506122f4113a401765a69fb9f08_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i0dab22a716c64564ba838f1dd48d7f2d_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iacbd09691dfd48849fa8a06109049218_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ib0bef40f936c45448366cedf462d82d6_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ifda8dae70c484419b819b08a661b39d5_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i7c3e9d721cf949aba7bed39328685faf_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic218b0d17bf9480fb2a4af23655e9de2_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i742b390271ec444ebf304d883a7aaf85_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib0637885c2824f0e9c6471d6d38dc762_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i020a9535952b4c63a401a40815ddf115_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i85aea8ddbc744caa8e21718122998c19_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i49c1d50e36104bbd9d2fff5426a37ba7_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ide16825e0c5042f89d58332d23f6ae0a_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i65144a7d9e2a4b1db67b59d28e3d74cc_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id6d3a01a24804bc9af0ecb6a9b2c67fb_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i50211f0c1289483e8e0e6d1eed3c67e3_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i655717f0369640c4b9a157a17bb82e9d_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ibf386660945d4d5d9e6b8634ef6532a1_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="icb6d6e4976ac495b99e5329deaf58bfc_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ib7c46e72eb484be486c63c78eb02e206_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i40bfe120527540219fcb38f6a07a75c7_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i3510e548888f4e1fa6f52d81f4ab6cf3_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i56965738078b457fae12de6ffa955475_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i72a6f6ec594242669dac6cfa2e2c7076_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i90f1a8b28bba41749b15a878c6c18fad_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i91266aa05dd2425d985bfd9033fb1fb3_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i15626b644ab14a8fb91a1555191c8648_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ibae5bbcea9f94ad5b94969117f4e506e_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iadc37e4e06744f8fb3399608c7e6ab66_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ibad7ff907c4d46428f779f4bdb8db2ce_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if38f3c37921e44cda1b5db6443989c29_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i73f09c17c23a42ac9ebe11023c84580f_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="idc3bf48554b44e80be08a060489581ca_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i744f7d39a15a411bbf361d82d82dfe4e_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia7d413bd46d24d6abe8b625214ada14c_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ifcfdef25565c4ba58a2615e2ab0fc2ab_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iadc0a4943c0e4c70a773401d645f1312_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i784ee54441974c4eb54e9257b0e31430_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib3480e995cfa436c961a9a4d13e49bd9_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ie13682ac60d24dee80fa0761d2ecfc64_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4f1311d4010d4f319357cbf0e5b86b3d_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="icf40956a9c1347769a071ff6bfafc142_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4658279dda2e4f0fa81448f27d0b4f77_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i199ccf31df6140dcb89e1686bb513228_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4d8b2515e72b4a779aaf43dfbe387804_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="iaa84aee89c7944bf90b3125200ecd80e_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie349729608994bf887fda0639a138ad3_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ie2f2c2e83225451d902cf2623ede1f1c_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i29cff2e6865142d9a4661c3fcb511df1_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i0b35562d3e004031ba416de20b26cf73_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iba4873f02ec94b1199e6f56536d6dfe1_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i319fc8a3857049aa8eee5c1b14cce0dc_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i56710d10c9af4516b82e08bcd605ff90_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i5b95a95d0ab74b0593bd0223e4b8ad13_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie8c876f733014aa39f0d8214e223f585_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ifaa2dae0ae2f4573be92b240376298b0_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7b04f604d38f430783a61651065a0a13_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ide71f27d89ff4ecba07e81f6917e063e_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5df2445aa9db4bcba1f2c495dfcf06c7_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i3c2ea56b89e848afb39b9ca75576f81a_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib7d0cd308a8142d6a92cd40abc7d9327_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="id029b233fbaa480b812c80c34fbb60f5_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8c03fd29ef754d63b27fc58525b944c6_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i9ad4fad0fa5b4730bebb0dfc08f8b7f8_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9b2360aa64bf40069c6622e4971e8616_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="idb258923b1f94a218e7cf9e72e1a4e29_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="idc0f0b78e2774313ad18d0495403fcce_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ie38211ff6f4549ca99cf9a47fdc50a68_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ifc3c076d95ff48c485eb3d0187e68b87_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i9e8c4072e9244960b877a66a60def445_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i24d94e00bd754768a1c1b598eb47950d_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i48712a124534471ea2804e884605a06f_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib3ded785627e4686af72f0b8d2f046fe_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ib0cd8c26245b493ea80fd420a16b98d9_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic49e6c0c298b45d384afc6010a6b7762_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i96b42a988d6c44c5ab94f2e2bc145a16_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8d2c74c6b3434964b75d4a41dae81179_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i0693b3d163314be799135d4bc4076c22_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ief37e3faf17c4c568270eae6b145b3cd_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i6cbad562537b416c87c3c047d42d646a_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5edcc1f3bb72432eb95672f9fe6b9d10_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i06145f78f1d34def882f37c971b1b1d9_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id7ec43159f654583ba1e536a80658f9f_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i2f8c3daec6804be1859d4f0afafc33f0_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i867a837018b24f99a9a411f45c919e92_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="idb6e3d84fcc04f4ca22b4170593731ed_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0de05d9759a54853ac7066c47b8847e0_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ic83f61d0cfea4373978c400de01b8b78_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if43c23fa8a1c41859b4371ea5c634e3d_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ib1bd97635393475dad752c246c239a5d_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ibc468b2507d144f2a14b7c6ac31458ab_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ica34b4218d3541b09c3da6d94f2cb5e6_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i992584c4bfc6471d9deb7b1eb40513be_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i0d7969d1f8aa4dda8ea8586ae9c4137b_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i3eb3f22e2a6640ce84be77248010d037_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i1aea64ee5d24421ab72f13729dedbd07_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id867ff6ff03b414389070eb180dfb49b_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i6506a7038e6c4b3fa851ccb2c53be423_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ide35fefcff44453d8d65564e21d05eb2_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="id44eb4835c3848728a14a8c3f6cdc458_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i81052cefe0fd4a0b8c431e3080dd0f2e_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i94d8014e61a64d64883ac98c61c9fc14_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib3c431fe980745c0b7193b78927935bd_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i8525a44d8d614f5cb1fbc085ac7ad72a_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7a2a1d85a1814d26a7c59cb5406c544e_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ia499ee071d3a4a3d9c98fc4f9f4361e1_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i540e20523e4d4912bdc772d9ad3994cb_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i73c1c368ad7148d183d9d0514e949c26_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i24eecfd1ba81496297deca71fae20acc_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ie28012ef976642138e574f32ea5efcf8_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic76c81a4858d4b609fe0712808499995_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i5b9be986d0744a89a11e10191af92b0e_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8f066a7522d44e21adceaa01bcb1f033_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i882e0bdc376e4cedb6907617bd05c7c5_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9e2cfa64c77f4036aad98fade9ef0701_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="id1fdc084f5464520a7448be49c5db0ac_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0244f8cf8aa940419de1c1d28d1e142b_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i98f0dbf3d46c438aa1e111583f3997d4_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0ef97d90cd6c439db72bf9c70f28da42_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i61f0183768bc4e7b9bc935793c8ef1ba_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i10eb1b72e5a84ad7ac1da3701bb76c90_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i0374102facf24dc5823fc308260ee163_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i23ec342a5f954896b84f92b9d5abcbf9_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i7b66ffdc877e4f1e89900a1d433731ee_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i562f5f706f934d47812f786fbf3d7b58_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="if306bf45e84e4e3892e099cf48267fe1_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1d13ded3c3b947ca960fe5a1e8612116_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i0ebeaa1f49bf4e0baa2712e4c5bf91de_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5bdc076fc45d46928fdee43fba7031c4_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="iea17f40f7b2248da9dcf9bbeb1298aae_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ibaf3b58ecba448c98c4fbea9e5a1bebb_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i5884a5e7ed954d8aa9eddb0b6e4da9da_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i50df7cd55cd6495a81565d60de245388_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ic189fd1fc7df4bdcb5e752b731b041bb_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia84578dea56b42ee89fdffe82f1f0218_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i6d9afbd7f944468489ecd62be054ea29_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i6c352bec2ed24d399d4198a694dc76c6_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i4827a6e9fcb14cf5a2e458c318845354_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9c05ffbc94dd44c8877b9c05314ad378_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i8c1d26f41ed64110ba7168ddec63bb54_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1967287f9578497e995a11c707bf2f53_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ide1e53eb0492409cb4653d655cefdab7_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iddca17b69fda4b1cb462915c216a46d8_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ib42c8f3666d34ae7aa8627db6a446790_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib3d0a4693f564cb8bc9e73e16b7952c1_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i5284a31246ef4a8c838a1e4123f9f505_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib5e9cffd91ca411a853422a72582bb93_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ice59f9c85be54b839acb8e82d6d4f087_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5854490403eb4af9a2d3b60108890558_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="idbeee4aeea57426e992c6d70c15e7c2b_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ifd2c49b4b2204484a5dc99464f909943_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ic558f7b084d04003a7b5d749f85db400_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i622659a4109b4f55941ea9eab234897d_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ifd9e4baa754142e2874a7b15ef2af88e_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i76cf0ef8cb30429197a1518d631d35d8_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ie84450c6d85a401fbd2cf8cf38737ead_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie1bea109b1b7492ea05f6750a7a1228f_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i600831f07e1a4339b1e94d5e21d66372_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if2af09556bc84fd1ba481c7e0406146e_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="if1af77281c754257a1fa2e2fc2ed937c_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i06dfeb7913f3474fb76e8bafad008be1_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i1290f60dba7e446e8d8b08ad7c42874c_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4d862660b5a04a089a8bdc443ee48fbd_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ia53773f630fc465eb5108bfbd89f5f47_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i45ee541218b04971b53ff4e5d19ad204_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="if8360a75d208433d90de437993ea4a59_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie6d0af4fc35f41b78b153cac7769eca7_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ic1242a55b9a0485193c8b3dfc6ebdc75_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i951a06fcbe4640689f8e364e8afdbcd2_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i98c68fd3171e4813b03d948e6c1538d5_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5fed2345a1ee4c23bd04c0f52f574fb5_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i024835e205554573a9c3504cb27a8c5a_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4c485d85051e4317842b009e214d3fe0_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ie2039f6815f94c8eb39335bdd8780f31_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7f82ffb3600448bdb45ded460d8052af_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i0bdfd9d747b14c3fb94da3568d458766_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0b106a80587443fa9b0d89c8d306ddd9_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i1fad4ca7557147fe95699ddfe8a3615d_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if8c8e0238b104ea08be4e264097dc22e_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ib4a4e436169b42529a9d0389c604a63f_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i6cddbb6a917e47509f085811d392a493_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i49e72c9dd590489aa2ee17a974f38a86_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id58b0cb1491f4c01a2650b1b46fbefa7_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i8b81c853b79c40f5a5e333ea61fb2b15_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i053a5c0a067448d38267b4d4d0371d39_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i7230aa1f363542928871b474a14f1f8e_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic09e7e58a12a4405a99ed854054ef46f_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ic88a9f1b52334567a7c5d218c774bdf4_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7ea1dce9275644229c0975d44045301f_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ia50d35187ab3428390ef63a28a7e6961_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i25bc2d1842ab4478b3d89958785ab19e_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="id8d3a81114da408489e4e01d642c9082_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8eaf6ce2f8af425790cb397e4499b14a_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="iaf0f6411562d444f9e80f8a62cc71594_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i969af2be04a041288cd2cfddbec62364_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i411f812e4d114ffb8b1267fa1cb56c6d_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1c6952baf25542b68c9499c21641991f_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i12599e668dbc41358348e5544d2dba07_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i2eb10a316fe84f059ae619a1305077dc_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i7368a505f53e4badbb0e085fcb131b8a_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i78842fece6ba4955bf4a23337f9c5f22_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i16e861eec4c443828199789a528253cf_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i629b6a7bc81546dca94d639d376629f9_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="idafd1bf909ca4919aaaabc6674fb242c_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if665cac9f7d94d4594494bff63142705_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i88009127c2544c78b9aed9223b7b8337_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8fea18f4d9d94ba2b90cc4f81dafacaa_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i07b9844b50d54100a2982651b8823c9a_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i232ddf875322462bbd406ee0ae4f9c85_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i2b3d697a4fad4697830a9e243e1e0747_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib3d70f93807b47b3aff1d8a1e73cb8f5_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="idef7b076ea1546a89cde23fde1560ab0_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i496a22b78b1d457ca678ca6d564331b5_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ie9ccb9aa1cc34b1e9f6f123765de70e6_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4798987e78844d73831f5474a76abebe_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="if5e5e1acad6f430bad7029515d202b51_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i3b00b20de7c94aa1933c4f6eb44fb6f6_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i207b52ef8f4b48de8416ca244f8b522d_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i55ce0b393cce45109fb4fabeeeaa64fd_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="id8278bbfd6e74d48a7d676153d80e78e_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib26f9da69a6044e4a8bd640d1dbfd732_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i5457dfbd70624cab91476a355fa5115b_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i553115651d944c87988eb5dd696715f6_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i2a584f32c5b84a33b71234d8cc85f779_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id8ec118f64784127b948ce57a03251d3_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i2041012c7fe94696ab6a160eae5a0d28_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5fea7ff2b8d04558ad6fc2362b74bf38_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i60a807f1dd544cac8e57c11caf619604_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i01ec1719a93544dd847dd8eabc9f9027_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i06b7e00e28414ef1af6c648b94de249d_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ife8d592b718e4648b32dd579c98199c1_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ice26ad0a6ed346fb8cd1cbe7031efb8c_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i2d26596d2402468f925f727a0ba02ff8_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i5fec763a254e49a38e7ad0d9a0f09012_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8302f031c56743a1a3a21fb700613bdb_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="iff9d00b4dac646eb8e2d975cfd2be240_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia6a7f6a3730144bca2ea36f15ea20490_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i6096f7b9393042f5b2b82bc8fb59bd2e_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9b3780cbf7d543e7b543bfaa92165ed4_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i91e2cc727626439296018d3621df8996_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="idcd8a72bb32b468fa5b37fc14195304f_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i9112184634e44b0cbfd9d823f1219aa3_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i920ec4d1d57649248aa990c4b93fe684_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i453a034a54da477f8370e78e927a3539_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i6a991002f04c401e97d727678badafbf_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i7aee8dd846874e159438cc4a03f7bab0_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i00b9571f2a6b4a2bbc14ea2f3077c57b_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i0518e784a66b49d68047ddf7ee9cc00b_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i31e66b96468f420288f19c564089d8a2_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i47183644d19945a8bb49dd3a27546be6_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0c83e880c458472b8c50b6cf24267d08_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i56502c183aac4db6ac72f64b0b31c8c8_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib67fc9ee208641588e1c086557319199_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i916f3760699b40dd9d58b5336d356442_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iedaf2bda66294ffba5d53d0ef7f61370_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="if4c445f8624f40d6824d709a9744cae5_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i37ccb6eef64a4045a8c29d06c8cf02d8_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i3dbe05ea1dac40b0b66f0aac32a160b5_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ifb72505c1d974357bf35c6715df00b92_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i2fc5d639ff1a4b4e921cb3c51ac5125c_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i6fa923eeef864e7aa46c2f7515d33025_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="id6bf4f3e987046c38170406d258eb94a_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8db06e2cc04c458d912a58a028760c4b_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i1f4582f93ea64baf9c7628c58576a173_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i41e8da5f36f54d4bbdfc91d37ee03c6c_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i5424c438f2644ed794b321513eaa316d_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5deab209e23645b498b422f99964df0d_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ib84b38a234fb454083a8048492807925_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic3b2572faea149698d267bcb7cf881f7_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i605343b19cc64b1482f6408c0434084c_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic5c97cf898604cf4ad7406f9531426d4_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i0ac76396403e46669ddb9bb2a99e7626_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id1c93d444f7d4ab4a13e6d1f8efea458_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i5fa54f45363a4ac999c0b20e1c5f28a7_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i178889716f424850af73d18091ac8fb3_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i19889197e7014b5abe659ff2ab7a326e_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ifc84e135342246ada537c96c79411c73_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ie334cb54a91c4aa489e4470d9dd267d2_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ieff90fbe65b14dccbcde52e76abe2491_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i28c4b7c2d0fe47d6a4a59c5126dfe022_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i2f1a31cc19a448fbbbc2285717ad1b08_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i3f62cbc379cc47b1b559838e47e5e9b9_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia6eed07d82dd4b42871be86888306c52_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i1f839300e00c4a4d859e26c2fa5c6e37_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1873788fac6a46e8be4e456fa927ff6a_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i12ba7c96d6b34b73b2dc889a40179104_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9e0ccc4ef75a4c3cac7174f2de54a9cc_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ie8becabeadf84e98b9d419b68203265b_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i68239219992142d2aa3702fc95b596b7_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ife0ab2f3b60049508c2fc1e1d78d4cb9_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9a330731470745e48d563c9c6d517be1_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i8e7548bbd31e49bab7d5fec3a6b41671_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8ac34ad4788d43b3a301f9c1c62308c9_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i106f48ae57ab4181ac0362aa6cfc6106_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1bb172db98c34f69a96a8e61c2990f49_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="iac83ab04fd454d808f7a0f2ba77b1fb3_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iebe8c5ef936a40769b7f7a23f0b8f324_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i29b333eb2dd34c4e84797c94386443a5_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i894f559ee892432bb4a292bbcc61acdc_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i796f5d7d4c4840a8992ef9c2f85752ff_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i89c02fa080d343cc9ff82372eac2f123_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i80392036102c45ecbc3621717d0b2c74_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1b0d1c1d0a014d889948f7983d615275_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ib7ad75c915974e13baa608e010a4dbfe_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i42ff1e292f27485f8ff84644532adc72_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i144c6515230549dc9ae750420daa70c0_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i12c283c3ebdc43f685bfcfb86adbaec3_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i66f80a64500142458617dbf774e7f46a_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ifce0de714d9b45428f3968fc9988e0c7_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i3367c13477ea4799ac8e90b9e213d261_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8fb626460b96415bb179ccaa4c0ed5b5_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="id11e5789ebb948679c1a5ad0d35ae54c_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iffea672a5b3c47eea9012fe82778494b_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ie993d24b54904ea888b1293ce96956fc_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1c1b37038bc7487ea392d8a7578b3110_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i8c5d285afcf84094bbff26299ad4e109_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i2a8c160f547f4d6ca4252136e13831b0_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ic72c4574496a4c4fb83a4560784b72a4_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9d908ad9d290413a98b31cf4d5ea0d87_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i8298a87ec6094a83a8f67eaeaaed0f98_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i246d9eeb9fc948d0a353e9a5e7db555a_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ic58138fbb27f46fa9ceb6e76659f1262_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i583b1aa9afbf4206bfc48b54ba5bc3fd_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i2fa5dc18ef454b7099777b9a2e9edf1b_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i450c72826782487189f185be011ada8c_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i87186edc0be942c3a224af0c83083a2e_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if86e5be3d1d0462981071e831b1b1941_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i118eb58e43a74473be63948e7e8b110d_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i14fb81ce0da94fd782c69b4cf8735fb2_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i4595e7a6d7c0489b8e9bd4072d2f0958_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ifb6afd2ee42744da955bfb4de57ea068_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i52e5864ae7034aacb7d9ee6a4b6ccc99_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5224eaa3aeab4bb6b58685ece2af0a80_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i7e6e8316702148888c8f276675d24468_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie8fabe771e534cf0acd946d6aff01f6e_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ic749d8f0affe4953bf8a83f1ad6aa6b6_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9f0243ceaf5947389c637d5ed6092fe9_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i184a57e2be914b2593d8414dcd7ebd91_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i60cfac9b2a974827a630d010512f5c77_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i14031fe7bc3f40a795242b575acf51dd_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i3eb67a9b82764e84a6203e5424624500_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="if278a32c9dce4fefa94c62fe1b00772f_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7780cd75cc6246779ff11406eb223052_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i691d2c928a4a4a60bc0a0d1ef168d8c9_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i66aa28c488584714acd26eb645da8e89_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i9360b52072034cfdae74e58d3dea3f33_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id7e3e8b15ac3457193a8e87969a76f91_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ic31063913c464d9f982eb66bf1ed7177_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia42b914656c14beba7b1d52f061668e2_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ia376c7c58c6643b982dd021a28407a4e_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1d6cc5a8d92c432cb5364a4922a91d91_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i81cccc8066a04b4e8587f7022fcef5bb_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id91713fd7da44504bbad7b781cd667f1_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i39b68889f48547fbb59d17264b094ef6_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ibdeb350dde814f6da9360e6b2898ed8b_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i939e8441406e477a9fc9fd99aec89197_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iff6994e434614d1a876eb0d4c2bc823f_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i6a65b49f54754536b37dd908a689ce2f_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie60d62e420664954b1fcb37f6569c27f_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i4a75d9e9a4ab4545b4d6d05ead21ec93_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic37a66f35b5c4a6d99c2c3e0d691685f_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i3f78539697c141f2a5eac40f4a433cd2_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5912aea718a849be9bf7b9153fd78d98_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ia241c89cf4794e2bbee7d74dce0875de_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4b6e382369c74f9ea1f6e2762ea30c35_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ieba41c75d5da400e9fb64a10752e1807_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iad2d34311e684aa1a6203f5714c84491_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i0c2dbbb07733475cb4da59ccd3196294_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i08295db3a10c439ca068a77285361be5_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ia15056130be2407b92273859fdb8febf_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4ee43394ce814ec8b0f42fe52e12760b_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i90d459ed7f3b48f1b2b9174f1965fbd3_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i664cbb9c037f4d99a4376475a351858b_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id97af143662643b3842da08b330a6f6a_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ic7759e2ab5024d0fa40501ce6cc6e6b5_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ibd8d56e959874c8cbac753320da2c5e0_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i68c3a86a25ea429f97b80b17ca08e649_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8cd56ef47b4f4058acf28c65ff513a42_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i6fa4a52ab3bc45caa61ce84e01cf51df_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i485a9a2a0c8f4d779f31ad655745be2f_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i66ee637b96ac4b0cb5d60d3c4d7ff8e9_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib1b1017d106d47a89606d3c777ad71f0_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i0bfe547121e24789b19f5f8208fa6fd4_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0d7f9514d7a44d1ca6005181785ac3ba_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i7d1f8a03726c4067a2929437ae2fe5f3_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i25f9cfc65bb24864b3563c647160d27a_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ia7aaf4b905834c92835e38cca37238c7_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i86237042c73a4330be6316b8b9dd8739_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i368def26f6ea4bfaa9177cfd9b260470_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i63a357e6381c4197a2f2034714a76f9c_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="icd7333903aa847658f94ecffe462a28d_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i38fa03f6ded84c66aa2bd6d34a67b4cc_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ic2a3d236dbe3452793a752eded62785d_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1b2a6b8d156a4c78be2c856e9636bc48_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i03f2bbdd3f2943d8b8a157f236abbaa4_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="icc2283c62b61497f9e264c1563dc631b_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ibd21677efb134c17a84394025e299a84_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ieb78ecc3071f4f89a308782d6a88edfb_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i777e00866382412a98d3a01a40a39f9d_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="idebbda9d775f4719aa69f47ce5be05a3_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i50813470f09748ba803e03a49ac76836_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i19eab095e76442c7a15bf5f8be178453_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i63c6e6e9b6ae4771aea32259886b1dbd_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iad15e1fa199a4cbb875175ac153591d6_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i690c132eaf514ca895f63e12fbbb455b_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i59d819aa14d94e3a8762d8ec158426d0_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i015af99c4a2e448e9c7144c5eb3975aa_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if160394e7e1d40f2b37c20e7236b7b62_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i77a21754634a4942a38523ea36f795bd_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1a08b9538fa74a208fbf96aec8a31dcb_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i2d390e81e3db43408b91740c66c31b04_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5f4babed7b4d42b5a5c2d40a153c2633_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="iafe600a9ab7a44c68df5d9ad63069018_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i66818b9b3aff45fa9b5309ab5d6ebdae_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ifb44530d18d642e683cefa298f2e197a_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i3db704224024476bb17f015b1c0abc3c_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i65804c36217740f0b729d452073739ca_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8af97229f0b54fb9a42e82e133be93e3_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i0e62e22d053f4be19970487099e52b46_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i67cc2a6d5c864c8aa19c1d21575a1fda_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ib53589fb1d174c0883c5a99ce3b7df76_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4fe69a5c4f3340bfac6f40428dfe05f1_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ib89bd6041e30431ea64fca96eaf48c0e_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if1283c6dd19e48b2ab1219dcf3751cff_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i346c10c16c374bf6970c356a17deb3f0_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5e475b85e02746e4b631284e2dfad017_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i0a1ad64f1a3644558ba0bd78d14887f5_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib837c1b7b81c46c79b81103985f70413_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="if2b39b6e0ce043d59ef4f7c826aee38e_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4004c5d0ca6d43168b2cc99025ba0344_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i69dfc54530ab4ceebe84a4e443cc7206_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7879c0d85bbc427bb4a31690ab8da4b8_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i6f7f8554621548c9a359d347cbbbac3f_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i46c22958c0c549558f53ab422062f508_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i03538a98c9f84546a0878f97b68fb052_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9758b02c72df4754b31600d639492fd4_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i16af716d82004476883437376d33e296_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1b848b4c72814939a4ee849afee353c0_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="icdfe043a81224cd7aa4b84062546d3e2_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0ec97248e6e44f398ee8bbac82b179bb_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="id6cbc53d626149a08db3eeb2b61e356a_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9d0754c7fbfc40ebb8439cae628ac5f2_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ic0fd94b5ecb742a2acf56d48a30e9baa_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4e2b16d94b1e4ef99fe58558a8b6b7ec_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i2d422a20e0ae4335846ca1405c432d7b_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib99c3f2e02614e95bd95c334578642f6_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i941f7b5cb0944651ad943556245e42af_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i6e245c440a8b4af9833fa1a0c53fb2f1_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ie6dfa6170bb04384890d25bf750f7285_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i52d965366a5743539f8a0c66e807ebf6_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i957af76e03cf41b2b4137b9fb5b797b5_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0fac8e5af73743b892d0ff019286d402_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ic713079734e24fb0aded04ea2f5ef4f1_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i17cb3783cf374d5589ec58a0de356fe9_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i75c76e0dab5d49728cf41af893706809_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i251fe35eeedb4dfda33118b3264a40b0_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i11aebf9815c5450b8eb28d8737503b25_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie503be36392943c2aa1fc032e197cffe_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i7962ec68b8054973bda571c916266fbc_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i77a23c165c324817adfa8ff05e524d4d_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i96dfc5cff1454f418137861a7c0bd661_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i52be8cd00a544fb9837055c28c31a0bc_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i9a091c8ec3e4450b9c534d593ee3f48f_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9f051d97946b48f98a750ba79b71b129_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i22ea02a9de494a629f2a4d89b43a24fb_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i212cc5dc91cd478984ad00fae62e7737_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i00191b17ba9d4f05a61536365cba8dad_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ibb99fb7943bf4d77bb82160d491f0b87_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i18be951542f44ecb96828af068093472_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4adae2c06c9b4940ac03d2eac7f0f1e1_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i1997e6c1765e4a75b9bad7033aac8b26_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iecc5a7943edf4572be993acdc0b1bd83_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i1bb2fb97435a4fc68bf0fac1ebcf132c_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i122148b592b24cdabf78d0a482cdb38a_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ic6234adc69a847759f0dc2168c7a7ed8_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i2dff7af12b264ddc884a1eb374f6b51e_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i494fe80075ac40acbe0318a3db1a774d_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i490240ac5d354958bca7ade168be4ddd_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i26fb731c7d16411daeea4aeb1d065918_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5a3313d8d5cc43f5a89429b00db0f9ff_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i18341461a0b64ada9ce1d9bf3032cbd6_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i106ec6964b614734a6df2f1c7aec49b6_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i42418c9e338b42f1a79e47c3637bb792_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i87bfc75fd15049b0ad902fc45bddb23e_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i3e89c3ffa20849288d5655da93e8d070_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i3359d80da2904900a689911b61bec8e9_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i93a48db34f67401b89ec28786da34bb4_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1ca482bac6f143ad8311c2f32ac8745a_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i77d5cba624204db7a4fdf3c92b03712c_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1bd7def248f4471292b3bc6fe506f3c2_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i8a49b832a4ce4356beec3af3897dd8ca_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ica4dc3e811fa45c38117526d37a372e4_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="id39f1cfaa5034f7d8963544179ed45f7_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i09830464a4ac485fb8800a57861ec07a_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ifd336d1de1d7402e86a487789816638f_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i868e4a3228b745b69f76acf1ef47fa4e_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ied76a8d7c3a849859381acdd5b40e26b_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib963c3361a9e429ea23e9be78632d5f7_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i9c87a451aba6470f8513849722c6f687_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia5574bb64c5442568419329c1ddf953b_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i890b0d4ac71f441eba6bf1198c410a5b_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i98ce489b2b83414fafb7d08826ccae52_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i84a3df8795414451a2635599c9f326f4_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic40e1fc715504106941039635c311b42_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i4cc28cefdee24db587c2c44627a5d4a3_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id90e5b6cac784a01a3ec9b835573dd8b_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i14af6f66309945bbb345d1e5080fc3ab_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5adee58e8c554a2fa51b9dd0dff78319_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ia8954550cb9744329c0944ee64bf182d_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4dc24dbfe93c42a5bedd17d3f4602b07_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i20171878a2664b1396a4e8dfab867c63_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib792371a81394b76adb8d9160ed815f4_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="if1c483984fa940d4a2263fdde35ae2b6_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i40b2a961cef64c3f81dd66d2cc8d30cc_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ie5e248410521459d8d4e90e3229028f7_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i07d6c5cc14f04a4aaecd3ac4c2a56626_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ic77ca9253fc245e696f14b2344a21c4a_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1f766b8bc30a495cabb27a63cdfa21dc_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i74aa9c650ce94f7f8b6a94ad4ec01ce9_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i50d4546f23234e4a95f876fa114ea771_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i78f6125d4e1f4642a4d765a351286c3c_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i93a0aa8ef0ed416c9429b2b5b88cafd0_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ie2f9faa3f7c645ed95dad829fbe0f3f7_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iadc95fab6c004ee8a52836e72d8e51fb_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i34f633e2629c400f81fb20c99145e112_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id4fd30965b31465e953a69a10b46ae75_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i9d5d0922cabe4f6fa55f3ac6507c79fa_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i9fb264a5db024fa1895bcd3a4069036e_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i37b312259598430096ff868f08b6757a_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i51a85394d9a14ff08bfeb689185d9ee0_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie63bc91b9c82473fa1e0ce9ddfc407bc_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i0e2feb214c2c4da99c1a6b518a224dff_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia2f54909f5e146f3bd1d3b4357419206_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i1dc0ed7f6bc641189e3c6e00c91f73c2_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i43e3289369584ba8afd76314fc686eaa_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="if2f69aa2c55f4826a2d6918db36d8504_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if044c23d97b94f7e9198830e79b71e75_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ice42e5369e6b45f0adf19543436ac0b0_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1d701fb1987245ca88cf01f3640777be_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ic16d2db94474459387159b0687052bee_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib6ef5074333a4f0d83205f62d497b7b9_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="id87ab88275fe48e88b999c9d8843e970_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia28c90140a094ef6b236aa35a8e77056_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i9b2df3c4074c46f3829a9f1fe6d1b3d6_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iab8b7c86635743468dc8ac2476edee79_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ia0d190ecec914687861142e006d00019_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8fcf37770f4b482490a1deeb32ca5fb3_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i9a08d0a4fd414fb0a743ba8926a6de8f_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iaa95b6bbe9ce43f59b2c55eccaef0947_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="if9a33a98d27c46748aef00c3c783085e_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5b79863c6ede4c88a5b5a6aae528d65b_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="if0c8f9eac7f34ffeb651669100cadca2_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i86880b7c7c2c429080f9c83aaaf12cfe_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i6353fe8fafb84e8b9c268c65fd303086_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i6337b707147a48869ac16b7992cb215b_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="id1e1fcd02b464ee2a9ec2881679e5e2b_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i9cf5b5276af745aaae4d731df390a2e3_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i9a407e33714d43e5b6f57eceb1da3644_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i774d073624f5479f99c44707399d81a2_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ie104a5f4ba5646e5ac756ddb0f8fe1e9_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iaa7453bcb1f1499cb56bf4c488b9f6ff_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i548df4a2b991433e95457098102bdc1b_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i12056b6b1c854b9b986a9a3fbc149483_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i543547499d5747568f983b53ce0eb701_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic400b23cafa440aca0f838eec065bd9b_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i237bc393dc5541fe92d8e43c47a8e02f_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i53dd9cb72725412faea6075a5b94f5f7_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="ie745b9ff518641abb53ef1f33093480c_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i76eb46ab7e594c6e955830b051a4634d_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i3925875d2d8b49ed84c2f94483fbddc9_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:EvraAndDoxilMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i8aa76dc85f4d47988a65dc0767f87e60_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i17afbc0e69e34400b507b3fa36f4cca9_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="i8abbc5ec72a249a68e86c66cec320d05_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:VerbSurgicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="idd91294a39994bf7a5d46ad21d5ce73f_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AsrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i1e112538e52040febbef4f9ec3d08be6_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PinnacleAcetabularCupSystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i38e0af4dfc454327a9035d9ecf2f71de_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PelvicMeshesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ib6fd89964b9b478c98b0b7b32284ace4_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RisperdalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="idd11e0e4967746c686c30187b7771685_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i3b95b40b62fa4991958c542357558bc5_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i9f2f6f0d91a04e85af9ca78c9af911bc_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:InvokanaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i5f85d89b6d8146aaa779ff9a82bd22b8_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ieb622359a78248788392bf4fc7788239_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:DePuyASRU.S.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i432d9a09731c43af8b981697f2d30a00_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="ia06bd5801ebb4de3847b03a9ebbf31df_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="i888336974542449dbfef3a3a1d8c4d58_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i0511c88e69e54af3b80ae9e01a00203b_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="i93cea90b33244c4f8bd342dd3f008b23_D20200601-20200628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="ib2961f0a11b248a9b0915353245c62bb_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ief20b90c9cc3400e9758007a2c93489a_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="i43837e43114841208382ec8e806920e4_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="if23041d120f4417a80290be9a7d86354_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="jnj:LegalJurisdictionAxis">jnj:StateLevelJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ic8c468efba6f4c8eb730082ee4eedf85_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="jnj:LegalJurisdictionAxis">jnj:FederalLevelJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ib5c767d6b7254013824d1430cea6166d_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib02d3415bfe94365991511ce5fb09ebf_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i27171efe2b3941548d265f05e276162e_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="i653b6f4b1cbf484b8781c02b3402e666_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="i945c4e1bacda4ec68c3b7c94557f3765_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i5fc8a90a726a4462b931044e9118c5df_D20200120-20200120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:SurgicalMeshProductsMarketingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-20</startDate>
            <endDate>2020-01-20</endDate>
        </period>
    </context>
    <context id="i57db9f0a21bd4a538b012b2e386a50fa_I20150430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ContactLensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-04-30</instant>
        </period>
    </context>
    <context id="i5c79c8166fea4d28acc6e2a5c55371e3_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i41e6c3af78c84e7a96704669c8534fbd_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0bf46255c4954869ba02f4fcf0890318_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id03bd483db33402eafee3a37392a50dd_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i395c16cff1fd472887230111aec654c7_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8b2139d6e4794867beaf8b64054355a3_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9335dfec33444d1fa82036d4e0556288_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iddfd422a68bd4c3fb53443eddc899e5d_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1a40709bfe644a94ba4984bd52754e41_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i30de6283641a414eb591a7e379e8ca06_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="if65f698d763e4aa69ebb37089739db4d_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i155df99154524c01b1d1bc1cda9bd334_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia7b66f9b903d4029a697b4d5bbd09f00_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i86e59d6adba6473da76a65735fc95b35_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i6f1238f4cde44b00a401b4e14983e6af_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i0c74256bce09412bb1c7eb851708c6bb_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i68831153f9a14ae1b239033a0c1a9104_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i965b447464ee4a389bab1a83195f092c_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if6d484844090412aa63423ed27e77165_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie7a5f799f220481ba0964cbf04e6d485_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i69a08f7d7ee644f69fa747b7bb19e88c_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib6911c9fe2fc4680883030bd35fb4405_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="iecd272aa6bf84db3985f9de3d1a4af33_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i5b5a49c0f5b94001a4430dceb7eab418_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ib7cacd129fca46088c70b938e656f2d7_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="rate">
        <measure>utr:Rate</measure>
    </unit>
    <unit id="claimant">
        <measure>jnj:claimant</measure>
    </unit>
    <unit id="patient">
        <measure>jnj:patient</measure>
    </unit>
    <unit id="vote">
        <measure>jnj:vote</measure>
    </unit>
    <unit id="claim">
        <measure>jnj:claim</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83L2ZyYWc6OTA4NzliZDJkYWVkNGZhNWE0NjQ1MTkwZTVmM2E5MzgvdGFibGU6MzIyMTJhNWQ2MGFmNDM2MWE0OTllOTc0ZTg2NzFhZGMvdGFibGVyYW5nZTozMjIxMmE1ZDYwYWY0MzYxYTQ5OWU5NzRlODY3MWFkY180LTEtMS0xLTA_d5a78295-3427-4652-be0f-01b19f896eac">0000200406</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83L2ZyYWc6OTA4NzliZDJkYWVkNGZhNWE0NjQ1MTkwZTVmM2E5MzgvdGFibGU6MzIyMTJhNWQ2MGFmNDM2MWE0OTllOTc0ZTg2NzFhZGMvdGFibGVyYW5nZTozMjIxMmE1ZDYwYWY0MzYxYTQ5OWU5NzRlODY3MWFkY181LTEtMS0xLTA_e53aa148-1b6f-408f-a5a0-d6ac5d9e98c2">--01-02</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83L2ZyYWc6OTA4NzliZDJkYWVkNGZhNWE0NjQ1MTkwZTVmM2E5MzgvdGFibGU6MzIyMTJhNWQ2MGFmNDM2MWE0OTllOTc0ZTg2NzFhZGMvdGFibGVyYW5nZTozMjIxMmE1ZDYwYWY0MzYxYTQ5OWU5NzRlODY3MWFkY185LTEtMS0xLTA_b62da1b9-d5a2-4185-a4ae-76c72d2dbae1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83L2ZyYWc6OTA4NzliZDJkYWVkNGZhNWE0NjQ1MTkwZTVmM2E5MzgvdGFibGU6MzIyMTJhNWQ2MGFmNDM2MWE0OTllOTc0ZTg2NzFhZGMvdGFibGVyYW5nZTozMjIxMmE1ZDYwYWY0MzYxYTQ5OWU5NzRlODY3MWFkY18xMC0xLTEtMS0w_cb2e3e74-fd1d-43b6-9201-48db32632981">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83L2ZyYWc6OTA4NzliZDJkYWVkNGZhNWE0NjQ1MTkwZTVmM2E5MzgvdGFibGU6MzIyMTJhNWQ2MGFmNDM2MWE0OTllOTc0ZTg2NzFhZGMvdGFibGVyYW5nZTozMjIxMmE1ZDYwYWY0MzYxYTQ5OWU5NzRlODY3MWFkY18xMS0xLTEtMS0w_1e2f98ce-fa5e-42d3-a0c6-e7d69438de1d">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8yMDY2_8388def3-1bf5-439e-9025-b9f33bc0988e">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6Y2YwNjBjYmEyMTZhNGFjMjk2YzBlNTllMWExMjg1ZTMvdGFibGVyYW5nZTpjZjA2MGNiYTIxNmE0YWMyOTZjMGU1OWUxYTEyODVlM18xLTAtMS0xLTA_b4436604-cf1d-4d30-9905-2358d8f20591">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8xMjI_6e6d15b5-dd88-469d-b2d8-cc8f4b8c6bed">2021-10-03</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6NDNkY2RjZWI3YjFkNDNkN2E1YmM5ODk4MzYxNGU3ZjQvdGFibGVyYW5nZTo0M2RjZGNlYjdiMWQ0M2Q3YTViYzk4OTgzNjE0ZTdmNF8xLTAtMS0xLTA_c1269977-d38e-49db-ae88-90ec19f2f042">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8yMDYw_2cab69be-df58-42fb-91a5-4307742b7fc4">1-3215</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8yMDY3_82bd2c98-188d-4412-be20-72f809efd3c4">Johnson &amp; Johnson</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6NjQ3OGZkMWQxZjk1NDQyMjlhZWI0NTY1MWNjYTRjYmIvdGFibGVyYW5nZTo2NDc4ZmQxZDFmOTU0NDIyOWFlYjQ1NjUxY2NhNGNiYl8wLTAtMS0xLTA_f8a3b532-1549-448b-b760-2b8f4432323b">NJ</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6NjQ3OGZkMWQxZjk1NDQyMjlhZWI0NTY1MWNjYTRjYmIvdGFibGVyYW5nZTo2NDc4ZmQxZDFmOTU0NDIyOWFlYjQ1NjUxY2NhNGNiYl8wLTItMS0xLTA_d31053ac-e140-4c6c-bdda-1cb554b3864f">22-1024240</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8yMDYx_0b6386c9-7530-4a65-a13a-8daedf225dcb">One Johnson &amp; Johnson Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8yMDYy_d92622a6-0bdd-4c9e-b9c0-8f8207b3fe2f">New Brunswick</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8yMDY4_b6ba88f8-c86e-4792-9dd1-58da88b497ef">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8yMDYz_17cf1f80-39fd-4a9f-b122-b084cb04d2d8">08933</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8yMDU3_7c2c7b96-70cd-4d7e-beba-28eabb048771">732</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8yMDU4_bfd4b35e-7ada-4eb3-a04b-b11849c08e10">524-0400</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8yMDY0_7552a630-e4b5-4b0c-a1e5-ba79941c1bae">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8yMDY1_480cbf76-192e-4bf1-9413-2f641f3faff5">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6MzNjNjQ4OTk3Yzc1NDU3NTkzZTgyZjY4YTFlM2ViNTAvdGFibGVyYW5nZTozM2M2NDg5OTdjNzU0NTc1OTNlODJmNjhhMWUzZWI1MF8wLTEtMS0xLTA_ee3a1b17-1865-4c93-8fe2-5ddd46e8397b">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6MzNjNjQ4OTk3Yzc1NDU3NTkzZTgyZjY4YTFlM2ViNTAvdGFibGVyYW5nZTozM2M2NDg5OTdjNzU0NTc1OTNlODJmNjhhMWUzZWI1MF8xLTQtMS0xLTA_40d49ef2-a1ce-4f6b-8240-d7e1be3f16cc">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6MzNjNjQ4OTk3Yzc1NDU3NTkzZTgyZjY4YTFlM2ViNTAvdGFibGVyYW5nZTozM2M2NDg5OTdjNzU0NTc1OTNlODJmNjhhMWUzZWI1MF8yLTItMS0xLTA_e4c68b08-f1fa-4fca-ab4e-5e3681362f8d">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8yMDU5_f35f4804-8ab7-414f-bbe6-7be2014ed954">false</dei:EntityShellCompany>
    <dei:Security12bTitle
      contextRef="i9a8050abbb6b4fa087129310f939d84d_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV8xLTAtMS0xLTA_a8f6b2c0-9497-40c7-8fae-3c97a2377bee">Common Stock, Par Value $1.00</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i9a8050abbb6b4fa087129310f939d84d_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV8xLTEtMS0xLTA_09ba26c6-584e-477c-95b5-50edac66e83b">JNJ</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i9a8050abbb6b4fa087129310f939d84d_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV8xLTItMS0xLTA_0e2c7378-c5b0-4241-a4b5-3c0b979feaa2">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i5b6adc1e7fc54138970a1ffce6545ea4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV8yLTAtMS0xLTA_f7b6158c-8000-4048-be89-661d48a43786">0.250% Notes Due January 2022</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i5b6adc1e7fc54138970a1ffce6545ea4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV8yLTEtMS0xLTA_69a558a5-68ad-458a-9e1f-0ea074f0bd47">JNJ22</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i5b6adc1e7fc54138970a1ffce6545ea4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV8yLTItMS0xLTA_b48087ae-cfcf-4984-ac11-389bf3393943">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i6d7f3f3cd9e848f386315ec977895ad1_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV8zLTAtMS0xLTA_7268f75b-9179-4feb-b24e-65d554787d8d">0.650% Notes Due May 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i6d7f3f3cd9e848f386315ec977895ad1_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV8zLTEtMS0xLTA_bba7a23f-157a-44b0-af22-e6d381604563">JNJ24C</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i6d7f3f3cd9e848f386315ec977895ad1_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV8zLTItMS0xLTA_bdb5e8db-fad7-4851-9ee4-1141cebdffd7">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ie0d2f13d6fae4fea9e15a651e3245c28_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV80LTAtMS0xLTA_5531e7af-fccc-4965-9c66-d63f9671b803">5.50% Notes Due November 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie0d2f13d6fae4fea9e15a651e3245c28_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV80LTEtMS0xLTA_4e4a8fda-fe7f-445c-bb0d-93631413f27d">JNJ24BP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie0d2f13d6fae4fea9e15a651e3245c28_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV80LTItMS0xLTA_9ac4b12b-7946-40aa-992d-7316f59f8e74">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i579388adbc0145f5a9221b1e7204d902_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV81LTAtMS0xLTA_9f23e25c-5579-42d5-988e-d6d103cf0622">1.150% Notes Due November 2028</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i579388adbc0145f5a9221b1e7204d902_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV81LTEtMS0xLTA_69e2f4bc-a92c-4f0d-946c-b5b55509c13c">JNJ28</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i579388adbc0145f5a9221b1e7204d902_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV81LTItMS0xLTA_e6a154ff-3317-44b8-86aa-2f4dee447125">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ia256641b62ca4d77ac7b64775619302f_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV82LTAtMS0xLTA_755f0840-2149-4d0e-b7fc-84d3e4a96d19">1.650% Notes Due May 2035</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia256641b62ca4d77ac7b64775619302f_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV82LTEtMS0xLTA_b6520cb3-ff29-42f6-a3ae-a1b27ffd56f5">JNJ35</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia256641b62ca4d77ac7b64775619302f_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGFibGU6OTRlYWY0OWQwYzNhNDg1M2FkNGRmZWQ3ODc2M2Q0ODUvdGFibGVyYW5nZTo5NGVhZjQ5ZDBjM2E0ODUzYWQ0ZGZlZDc4NzYzZDQ4NV82LTItMS0xLTA_e44ae50d-dc59-4b86-8690-aebd9a099662">NYSE</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i5cd455ee122743e7b308fecfa89422cf_I20211022"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8xL2ZyYWc6NjJhYjJlZGRjNWRkNDYyMWE4YTU2YzE3NWI5MWNkNzUvdGV4dHJlZ2lvbjo2MmFiMmVkZGM1ZGQ0NjIxYThhNTZjMTc1YjkxY2Q3NV8xOTk2_81705644-13e6-499a-b53e-225abaf603e4"
      unitRef="shares">2632596969</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMy0yLTEtMS0w_b65f02b9-6f96-4648-a184-a2977f8c01ab"
      unitRef="usd">17604000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMy00LTEtMS0w_0644412c-e912-4a8d-ae1e-de65c2e9a999"
      unitRef="usd">13985000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfNC0yLTEtMS0w_def080e2-0b34-4f5e-a308-c86922e54eec"
      unitRef="usd">13397000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfNC00LTEtMS0w_ef67b585-3a62-4d26-9453-14cbff438d97"
      unitRef="usd">11200000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfNS0wLTEtMS0wL3RleHRyZWdpb246ZmU0OTZhNDE2NmQ5NDUxNDg5MjJjNDZlMGUwNzQ2ZmZfODg_7d1291a3-d0dc-4c83-8be4-8a15d796067a"
      unitRef="usd">223000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfNS0wLTEtMS0wL3RleHRyZWdpb246ZmU0OTZhNDE2NmQ5NDUxNDg5MjJjNDZlMGUwNzQ2ZmZfOTg_84eeb180-07b2-4628-8f34-0d6f4c036eab"
      unitRef="usd">293000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfNS0yLTEtMS0w_ad950547-1e58-4e1c-8b7b-4aaf1bc9a8fb"
      unitRef="usd">14911000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfNS00LTEtMS0w_aeb735c8-3a1f-4e46-b12c-da84a6dea415"
      unitRef="usd">13576000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfNi0yLTEtMS0w_a881ce8c-16b8-4eae-8731-ee79bd919e4a"
      unitRef="usd">10387000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfNi00LTEtMS0w_c34abce2-5615-4390-9b67-db3fc18c6ec5"
      unitRef="usd">9344000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfNy0yLTEtMS0w_2e80a9ba-d064-48d8-8612-181c2d6babdb"
      unitRef="usd">3590000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfNy00LTEtMS0w_443629d4-4649-4fc3-a931-7f1aafbcf6dd"
      unitRef="usd">3132000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfOS0yLTEtMS0w_03aad98f-b87c-46b1-8b0e-7805f92405d7"
      unitRef="usd">59889000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfOS00LTEtMS0w_50a01945-ba12-4b4d-a50b-815d726c5fb0"
      unitRef="usd">51237000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTAtMi0xLTEtMA_79c1aeea-8302-40c0-848f-7cb2a783b8c7"
      unitRef="usd">47347000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTAtNC0xLTEtMA_e78c9a9e-8e6b-4f17-9967-33767a4fa796"
      unitRef="usd">46804000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTEtMi0xLTEtMA_00ddddb5-1202-4d56-8d7d-0a601bc2e865"
      unitRef="usd">28869000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTEtNC0xLTEtMA_7ea41c07-28c8-47c8-b715-891c87310602"
      unitRef="usd">28038000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTItMi0xLTEtMA_8c9f16bb-3289-4534-aaae-b4f6dcf2ce4b"
      unitRef="usd">18478000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTItNC0xLTEtMA_c0435183-dd50-4085-aad7-845f7e10d4a7"
      unitRef="usd">18766000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTMtMi0xLTEtMA_4a4e99f1-40a2-4050-8c01-814d9b1f76ca"
      unitRef="usd">47776000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTMtNC0xLTEtMA_e850845c-89f1-4016-8b55-da73d4de16d0"
      unitRef="usd">53402000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTQtMi0xLTEtMA_18fdaa41-e221-418b-9859-8ef3a75e6744"
      unitRef="usd">35569000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTQtNC0xLTEtMA_fe5e5991-debe-4f46-91f7-eeb1a6ebe0d4"
      unitRef="usd">36393000000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTUtMi0xLTEtMA_2903e311-d4b4-437f-b624-27758f7d2946"
      unitRef="usd">10646000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTUtNC0xLTEtMA_3a84667f-85b6-468f-8cde-d7d8d7024564"
      unitRef="usd">8534000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTYtMi0xLTEtMA_963e9ce1-893b-467b-9d75-93ada5902e77"
      unitRef="usd">6870000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTYtNC0xLTEtMA_c02144b1-dc12-440a-85ab-b161ca5a9fca"
      unitRef="usd">6562000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTctMi0xLTEtMA_6d48525c-afc7-404f-9aef-b36528bdaa2d"
      unitRef="usd">179228000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMTctNC0xLTEtMA_f5b795f1-a895-4842-984a-aa9bcbb9ffdb"
      unitRef="usd">174894000000</us-gaap:Assets>
    <us-gaap:ShortTermBorrowings
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjAtMi0xLTEtMA_429f800b-de3a-40ac-965c-d82ed230c449"
      unitRef="usd">3798000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjAtNC0xLTEtMA_f210a9a3-8b47-4aa8-8fb4-5159a7f88101"
      unitRef="usd">2631000000</us-gaap:ShortTermBorrowings>
    <us-gaap:AccountsPayableCurrent
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjEtMi0xLTEtMA_8607b6a6-81a2-4038-b917-dd8216af0a38"
      unitRef="usd">8961000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjEtNC0xLTEtMA_28178036-1ff7-452d-ac02-291c4a9b1d03"
      unitRef="usd">9505000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjItMi0xLTEtMA_b7ba5b35-ccbe-4056-9b57-be93d17c43b1"
      unitRef="usd">13812000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjItNC0xLTEtMA_f78cf197-8964-42ff-81fc-1043691f3523"
      unitRef="usd">13968000000</us-gaap:AccruedLiabilitiesCurrent>
    <jnj:AccruedRebatesReturnsAndPromotions
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjMtMi0xLTEtMA_6119e46b-fa0e-4921-9ed2-6304da90b9c3"
      unitRef="usd">12683000000</jnj:AccruedRebatesReturnsAndPromotions>
    <jnj:AccruedRebatesReturnsAndPromotions
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjMtNC0xLTEtMA_c42baf8d-fcef-4c57-b071-cd12f8ade733"
      unitRef="usd">11513000000</jnj:AccruedRebatesReturnsAndPromotions>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjQtMi0xLTEtMA_e5be1624-806b-4879-9295-e85d306e3c72"
      unitRef="usd">3146000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjQtNC0xLTEtMA_d6421287-5624-432d-88ac-a58c691eee3d"
      unitRef="usd">3484000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjUtMi0xLTEtMA_d96afb0e-e297-45fc-a5aa-535ec781fedd"
      unitRef="usd">2161000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjUtNC0xLTEtMA_d84c1b28-a0f8-46ca-b37d-a94f2e910a82"
      unitRef="usd">1392000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjYtMi0xLTEtMA_58fbfe85-005f-4663-92fb-001a46d3e819"
      unitRef="usd">44561000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjYtNC0xLTEtMA_dd048c85-1330-40c6-89c5-9f183d4f9422"
      unitRef="usd">42493000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjctMi0xLTEtMA_b6b3c7e4-f8b8-4f5e-9b0d-4deafb8b6dd8"
      unitRef="usd">30130000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjctNC0xLTEtMA_5d2a9f09-38a5-464b-84ad-a80c3950958b"
      unitRef="usd">32635000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjgtMi0xLTEtMA_674a8bd9-a44f-471d-b123-3127930db99a"
      unitRef="usd">7147000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjgtNC0xLTEtMA_093044ab-cb8e-48ef-b309-855542f6f6c1"
      unitRef="usd">7214000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjktMi0xLTEtMA_8e44805b-1e21-4e03-8c55-1ec5a4b98fbe"
      unitRef="usd">10171000000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMjktNC0xLTEtMA_bb4a09df-a39b-410b-8bbc-9ecd25a22d46"
      unitRef="usd">10771000000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzAtMi0xLTEtMA_3787fe0b-eeb9-4736-827d-471186088a50"
      unitRef="usd">5770000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzAtNC0xLTEtMA_e48d77e4-d0be-4526-9fdd-b068f725bebd"
      unitRef="usd">6559000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzEtMi0xLTEtMA_7075de69-3706-4207-a5e8-5ef502dd867d"
      unitRef="usd">11177000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzEtNC0xLTEtMA_0a754dc0-2894-45d1-89ec-49e0374f687e"
      unitRef="usd">11944000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzItMi0xLTEtMA_8782625d-fae7-49db-a494-6328cb02194a"
      unitRef="usd">108956000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzItNC0xLTEtMA_440d2439-e917-4351-86b1-836277f10924"
      unitRef="usd">111616000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzMtMi0xLTEtMA_79be4af8-56d8-4862-b747-710ad73373fc"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzMtNC0xLTEtMA_dfca3dd8-9f06-4ea1-bbc5-ce688c3887b2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjcxMzYzMTY5MWQyNzRiZTRhOGU4ZTMwMTFiZTg1MTU0XzI5_5f369d27-6e20-4328-9760-da43845373ab"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjcxMzYzMTY5MWQyNzRiZTRhOGU4ZTMwMTFiZTg1MTU0XzI5_a4f0fa70-35f7-471c-9e41-5ba2de995023"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjcxMzYzMTY5MWQyNzRiZTRhOGU4ZTMwMTFiZTg1MTU0XzU0_350f1595-5860-4c0a-b2b9-220f7c5910a9"
      unitRef="shares">4320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjcxMzYzMTY5MWQyNzRiZTRhOGU4ZTMwMTFiZTg1MTU0XzU0_eccce558-1241-4fbd-b36c-889f30ba7dd6"
      unitRef="shares">4320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjcxMzYzMTY5MWQyNzRiZTRhOGU4ZTMwMTFiZTg1MTU0Xzcy_b83f0045-4c7c-4174-99af-c54016274421"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjcxMzYzMTY5MWQyNzRiZTRhOGU4ZTMwMTFiZTg1MTU0Xzcy_b8763806-09a0-4c51-9eab-8ca253074d64"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzUtMi0xLTEtMA_a443c35e-8c51-4a40-a929-c23e43d7404b"
      unitRef="usd">3120000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzUtNC0xLTEtMA_be2a621d-f630-4471-9fdb-91e6d4be9e9e"
      unitRef="usd">3120000000</us-gaap:CommonStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzYtMi0xLTEtMA_70883d7b-5c7a-4ef7-924e-9e994acaa550"
      unitRef="usd">-15415000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzYtNC0xLTEtMA_f001d1dc-5520-4239-90f2-4dae612b06a6"
      unitRef="usd">-15242000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzctMi0xLTEtMA_1cb2f3e1-0e34-42d8-baeb-3f9bd9366975"
      unitRef="usd">121092000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzctNC0xLTEtMA_340a6eed-81eb-491e-9b2b-346fd15c84a9"
      unitRef="usd">113890000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockShares
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjhjNzA2OTYzMjM4YjQxODg5MGYzNmI5MjVlYTFmYTJjXzUw_c4ce138f-61d3-4fe4-95e3-3ac8ea1f9136"
      unitRef="shares">487358000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjhjNzA2OTYzMjM4YjQxODg5MGYzNmI5MjVlYTFmYTJjXzU3_b4c500fe-1fc7-4667-9622-900d41b69665"
      unitRef="shares">487331000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzgtMi0xLTEtMA_a54597bc-7e7e-40c9-9308-c3b6cbc8ffac"
      unitRef="usd">38525000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzgtNC0xLTEtMA_1f146901-19cc-468e-bb67-adeef6cdd48d"
      unitRef="usd">38490000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzktMi0xLTEtMA_40a32ab3-032d-4809-bfc9-77dcf488db43"
      unitRef="usd">70272000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfMzktNC0xLTEtMA_93956990-4a03-42bd-a93a-135fb92a22b8"
      unitRef="usd">63278000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfNDAtMi0xLTEtMA_45a621c3-bd90-494e-a715-d9131a06b915"
      unitRef="usd">179228000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yMi9mcmFnOjNmYjdhMTU2OTZhZTRlZjFiZTg5YTQxYmRjN2IzMGUyL3RhYmxlOmZlMGMxMDFhZWQ4MjRmNGM4OWI5MzM2MTFmZDM4ZjUyL3RhYmxlcmFuZ2U6ZmUwYzEwMWFlZDgyNGY0Yzg5YjkzMzYxMWZkMzhmNTJfNDAtNC0xLTEtMA_ddfc71cb-f87b-4514-b6fb-d14d980a3381"
      unitRef="usd">174894000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMi0yLTEtMS0w_8b0f6d02-d462-44e0-ae9a-2f4f54dff6ec"
      unitRef="usd">23338000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:SalesRevenueGoodsNetPercentToSales
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMi00LTEtMS0w_3f982dd8-2675-4258-88cf-6034e4abae6a"
      unitRef="number">1.000</jnj:SalesRevenueGoodsNetPercentToSales>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMi02LTEtMS0w_b4fe5c0c-16db-4db4-ade5-78b793384205"
      unitRef="usd">21082000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:SalesRevenueGoodsNetPercentToSales
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMi04LTEtMS0w_4dadb1bb-e99d-4828-b566-08f83b0efc34"
      unitRef="number">1.000</jnj:SalesRevenueGoodsNetPercentToSales>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMy0yLTEtMS0w_aeab66e7-b1af-4b6d-be09-ff4b76aee8af"
      unitRef="usd">7250000000</us-gaap:CostOfGoodsAndServicesSold>
    <jnj:CostOfGoodsSoldPercentToSales
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMy00LTEtMS0w_42d0e64a-ae9c-472d-af7e-8a9c102422e4"
      unitRef="number">0.311</jnj:CostOfGoodsSoldPercentToSales>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMy02LTEtMS0w_662f324c-d5c3-423f-bf2b-dd2db13fa9f0"
      unitRef="usd">6972000000</us-gaap:CostOfGoodsAndServicesSold>
    <jnj:CostOfGoodsSoldPercentToSales
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMy04LTEtMS0w_b770aaa6-fc46-4628-8be3-66363b765bcb"
      unitRef="number">0.331</jnj:CostOfGoodsSoldPercentToSales>
    <us-gaap:GrossProfit
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNC0yLTEtMS0w_5f1bc2c3-de0e-4adb-abe9-645064ab70bf"
      unitRef="usd">16088000000</us-gaap:GrossProfit>
    <jnj:GrossProfitPercentToSales
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNC00LTEtMS0w_f667fdb6-9538-4eff-9706-87e45d0a2b07"
      unitRef="number">0.689</jnj:GrossProfitPercentToSales>
    <us-gaap:GrossProfit
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNC02LTEtMS0w_212a1f8f-8b9b-49c9-97c0-1cd6a7601249"
      unitRef="usd">14110000000</us-gaap:GrossProfit>
    <jnj:GrossProfitPercentToSales
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNC04LTEtMS0w_55ed9be7-2f00-4055-a799-48469e453ca1"
      unitRef="number">0.669</jnj:GrossProfitPercentToSales>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNS0yLTEtMS0w_2bbbf028-2b09-4e5c-ad3e-e666388a9dd3"
      unitRef="usd">6000000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <jnj:SellingGeneralAndAdministrativeExpensePercentToSales
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNS00LTEtMS0w_8d9687fb-b35a-46e5-8097-042c86cf68d7"
      unitRef="number">0.257</jnj:SellingGeneralAndAdministrativeExpensePercentToSales>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNS02LTEtMS0w_293b7290-24a5-42b4-95f5-fae4d1b44925"
      unitRef="usd">5431000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <jnj:SellingGeneralAndAdministrativeExpensePercentToSales
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNS04LTEtMS0w_b29eba2f-d7a4-4a0f-9afa-1d6f3b93902d"
      unitRef="number">0.258</jnj:SellingGeneralAndAdministrativeExpensePercentToSales>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNi0yLTEtMS0w_a5a49e78-ef71-4416-8ac7-c144e6fdf8ef"
      unitRef="usd">3422000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNi00LTEtMS0w_7c2eb117-633e-41ae-a683-8d26d2abe79c"
      unitRef="number">0.147</jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNi02LTEtMS0w_eb042bb1-a9fa-4e40-a26c-ff4cc69ed08d"
      unitRef="usd">2840000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNi04LTEtMS0w_0e208ea5-407d-41b8-83e6-f159eb0210b3"
      unitRef="number">0.135</jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNy0yLTEtMS0w_c93010e1-5afe-4a10-ba2d-150a1122fb29"
      unitRef="usd">900000000</us-gaap:ResearchAndDevelopmentInProcess>
    <jnj:ResearchAndDevelopmentInProcessPercentToSales
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNy00LTEtMS0w_c5256d6a-78e0-48bc-8e79-9f51f6c04c23"
      unitRef="number">0.039</jnj:ResearchAndDevelopmentInProcessPercentToSales>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNy02LTEtMS0w_fb42eedc-dee8-4326-a4ec-8182a5b8d6e8"
      unitRef="usd">138000000</us-gaap:ResearchAndDevelopmentInProcess>
    <jnj:ResearchAndDevelopmentInProcessPercentToSales
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfNy04LTEtMS0w_ee650c32-f697-45be-a5d0-67f2aedd9798"
      unitRef="number">0.006</jnj:ResearchAndDevelopmentInProcessPercentToSales>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfOC0yLTEtMS0w_60159bf6-fb2e-4dcf-8430-57c7086f1596"
      unitRef="usd">13000000</us-gaap:InvestmentIncomeInterest>
    <jnj:InvestmentIncomeInterestPercentToSales
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfOC00LTEtMS0w_b5cf12be-a6a2-4985-8ccc-3598c123d54e"
      unitRef="number">-0.001</jnj:InvestmentIncomeInterestPercentToSales>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfOC02LTEtMS0w_eea9a30c-6bd2-48ac-9226-4d99bf6367c9"
      unitRef="usd">12000000</us-gaap:InvestmentIncomeInterest>
    <jnj:InvestmentIncomeInterestPercentToSales
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfOC04LTEtMS0w_a869adb2-df80-4443-888a-a942edfd5923"
      unitRef="number">-0.001</jnj:InvestmentIncomeInterestPercentToSales>
    <us-gaap:InterestExpense
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfOS0yLTEtMS0w_030c26e1-811d-4669-9e4b-d73c45b052d0"
      unitRef="usd">20000000</us-gaap:InterestExpense>
    <jnj:InterestExpensePercentToSales
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfOS00LTEtMS0w_4b1babef-60a5-46e1-9529-d708fb9fb85f"
      unitRef="number">0.001</jnj:InterestExpensePercentToSales>
    <us-gaap:InterestExpense
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfOS02LTEtMS0w_118bd29c-2149-4885-a92f-835015e9c2c9"
      unitRef="usd">44000000</us-gaap:InterestExpense>
    <jnj:InterestExpensePercentToSales
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfOS04LTEtMS0w_8fafd881-d3b8-4f90-a593-53ee9978f0c0"
      unitRef="number">0.002</jnj:InterestExpensePercentToSales>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTAtMi0xLTEtMA_b59f549a-a844-4306-ab36-6bbedc8ceb0d"
      unitRef="usd">-1850000000</us-gaap:OtherNonoperatingIncomeExpense>
    <jnj:OtherNonOperatingIncomeExpensePercentToSales
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTAtNC0xLTEtMA_029111fc-a017-4065-ae08-6acccde5ed5e"
      unitRef="number">0.079</jnj:OtherNonOperatingIncomeExpensePercentToSales>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTAtNi0xLTEtMA_125b75dc-5fde-4692-8115-edc12c4dd12d"
      unitRef="usd">-1200000000</us-gaap:OtherNonoperatingIncomeExpense>
    <jnj:OtherNonOperatingIncomeExpensePercentToSales
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTAtOC0xLTEtMA_f9377020-1fc1-4f97-ac97-87c69cf4aa2b"
      unitRef="number">0.057</jnj:OtherNonOperatingIncomeExpensePercentToSales>
    <us-gaap:RestructuringCharges
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTEtMi0xLTEtMA_3f1abba1-ddf6-467e-8246-ff4fde864f5f"
      unitRef="usd">60000000</us-gaap:RestructuringCharges>
    <jnj:Restructuringchargepercenttosales
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTEtNC0xLTEtMA_fb938392-0d51-4871-b35c-623ad76be0a4"
      unitRef="number">0.002</jnj:Restructuringchargepercenttosales>
    <us-gaap:RestructuringCharges
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTEtNi0xLTEtMA_04c2fe22-46d9-4aa2-ba0b-4c33f197942d"
      unitRef="usd">68000000</us-gaap:RestructuringCharges>
    <jnj:Restructuringchargepercenttosales
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTEtOC0xLTEtMA_a00bcd5c-d11e-4d35-a628-1d42966a2fe3"
      unitRef="number">0.003</jnj:Restructuringchargepercenttosales>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTItMi0xLTEtMA_493bea1d-14ed-47f4-9abb-806cabbfcf6e"
      unitRef="usd">3849000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTItNC0xLTEtMA_160bfe95-e1c4-4f99-9aea-16d3930a1cbc"
      unitRef="number">0.165</jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTItNi0xLTEtMA_c2b61552-cb66-42f9-aa55-14e95085a333"
      unitRef="usd">4401000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTItOC0xLTEtMA_c057f9c8-961b-4fee-b13a-3f1c94dc0ccc"
      unitRef="number">0.209</jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTMtMi0xLTEtMA_33c1062c-cd5a-45b9-a1e0-5a4d61b6a4f0"
      unitRef="usd">182000000</us-gaap:IncomeTaxExpenseBenefit>
    <jnj:IncomeTaxExpenseBenefitPercentToSales
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTMtNC0xLTEtMA_8674d52b-bcfb-4f51-9389-41cf2608f6a0"
      unitRef="number">0.008</jnj:IncomeTaxExpenseBenefitPercentToSales>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTMtNi0xLTEtMA_b95d6729-8ad2-4757-b168-e8360b74c6d4"
      unitRef="usd">847000000</us-gaap:IncomeTaxExpenseBenefit>
    <jnj:IncomeTaxExpenseBenefitPercentToSales
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTMtOC0xLTEtMA_e5f8628b-2f3c-40e0-b578-67c6f2f96b3f"
      unitRef="number">0.040</jnj:IncomeTaxExpenseBenefitPercentToSales>
    <us-gaap:NetIncomeLoss
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTQtMi0xLTEtMA_0441068f-63f4-4f22-98b8-feeb6ea1647e"
      unitRef="usd">3667000000</us-gaap:NetIncomeLoss>
    <jnj:NetIncomeAttributableToParentPercentToSales
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTQtNC0xLTEtMA_4e8e3009-9bdd-4348-8dea-fb38bf273ff8"
      unitRef="number">0.157</jnj:NetIncomeAttributableToParentPercentToSales>
    <us-gaap:NetIncomeLoss
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTQtNi0xLTEtMA_88c415a1-ffc8-4942-9564-20311587b452"
      unitRef="usd">3554000000</us-gaap:NetIncomeLoss>
    <jnj:NetIncomeAttributableToParentPercentToSales
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTQtOC0xLTEtMA_1f3a71db-7e68-4ba8-955a-51464bb00407"
      unitRef="number">0.169</jnj:NetIncomeAttributableToParentPercentToSales>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTctMi0xLTEtMA_d1d99b7c-9efe-4f2f-89ed-e89061a98ada"
      unitRef="usdPerShare">1.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTctNi0xLTEtMA_6e268f60-3d14-4848-973e-2f6292e4a0db"
      unitRef="usdPerShare">1.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTgtMi0xLTEtMA_72613bfc-0853-46e9-92b4-fe62b0b4771a"
      unitRef="usdPerShare">1.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMTgtNi0xLTEtMA_bcd3ec92-29c6-4e46-b3ca-924bc92e6346"
      unitRef="usdPerShare">1.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMjEtMi0xLTEtMA_c48752e5-8681-4c51-8de1-02700fd8ee10"
      unitRef="shares">2632600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMjEtNi0xLTEtMA_8e2e5de2-0fd8-42b6-b03a-d973496d926d"
      unitRef="shares">2632500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMjItMi0xLTEtMA_23a11692-97fc-49a4-be7d-9d8ffb97a049"
      unitRef="shares">2674900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8yOC9mcmFnOmQ1MDkzNDY3NjllZTRmYjI4NGUzNDkwM2U5MjZiNjA5L3RhYmxlOjZmNTMyYTliZTQzYjRlYzA4Y2JiY2QzZDNmMWE0YTBmL3RhYmxlcmFuZ2U6NmY1MzJhOWJlNDNiNGVjMDhjYmJjZDNkM2YxYTRhMGZfMjItNi0xLTEtMA_bbbce720-4523-4d46-9e86-e15a2a1c2dd1"
      unitRef="shares">2669300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMi0yLTEtMS0w_4ca524dd-9e6e-4617-8870-6e726750358f"
      unitRef="usd">68971000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:SalesRevenueGoodsNetPercentToSales
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMi00LTEtMS0w_6c623414-f3f4-411a-9e22-acacee0b0306"
      unitRef="number">1.000</jnj:SalesRevenueGoodsNetPercentToSales>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMi02LTEtMS0w_aa982844-25fb-43ff-b777-5d40ad0eeb39"
      unitRef="usd">60109000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:SalesRevenueGoodsNetPercentToSales
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMi04LTEtMS0w_b771205d-0f3a-4b12-85dd-0d4f0b84d915"
      unitRef="number">1.000</jnj:SalesRevenueGoodsNetPercentToSales>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMy0yLTEtMS0w_1d3ffecc-790f-4816-b947-0a018fea105c"
      unitRef="usd">21900000000</us-gaap:CostOfGoodsAndServicesSold>
    <jnj:CostOfGoodsSoldPercentToSales
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMy00LTEtMS0w_c1677b87-3ffa-4d03-a742-0a3d9f4ed5ce"
      unitRef="number">0.318</jnj:CostOfGoodsSoldPercentToSales>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMy02LTEtMS0w_66c09688-9b53-4fab-8bb0-6b7c2a4446cf"
      unitRef="usd">20613000000</us-gaap:CostOfGoodsAndServicesSold>
    <jnj:CostOfGoodsSoldPercentToSales
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMy04LTEtMS0w_b62efdef-f9e9-47d5-a768-e38acbc15ffc"
      unitRef="number">0.343</jnj:CostOfGoodsSoldPercentToSales>
    <us-gaap:GrossProfit
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNC0yLTEtMS0w_e1149281-705f-4c31-813d-532f0d36137e"
      unitRef="usd">47071000000</us-gaap:GrossProfit>
    <jnj:GrossProfitPercentToSales
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNC00LTEtMS0w_63178a67-323d-4d7a-8e7c-fd7be6ea201b"
      unitRef="number">0.682</jnj:GrossProfitPercentToSales>
    <us-gaap:GrossProfit
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNC02LTEtMS0w_688f88a6-2a44-4b65-9e45-9ee37bf769cd"
      unitRef="usd">39496000000</us-gaap:GrossProfit>
    <jnj:GrossProfitPercentToSales
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNC04LTEtMS0w_c289f9a1-6756-4672-ae76-9d594aab302b"
      unitRef="number">0.657</jnj:GrossProfitPercentToSales>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNS0yLTEtMS0w_ce3b49bd-d5f8-450d-9777-e1a45bdfaf07"
      unitRef="usd">17505000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <jnj:SellingGeneralAndAdministrativeExpensePercentToSales
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNS00LTEtMS0w_cf946b07-fad5-474c-949b-d274f598b68e"
      unitRef="number">0.254</jnj:SellingGeneralAndAdministrativeExpensePercentToSales>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNS02LTEtMS0w_4a011b9a-9c69-4bad-9490-f3d9110f4266"
      unitRef="usd">15627000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <jnj:SellingGeneralAndAdministrativeExpensePercentToSales
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNS04LTEtMS0w_bf9e2702-faeb-4ef0-82b9-8ddc07c35680"
      unitRef="number">0.260</jnj:SellingGeneralAndAdministrativeExpensePercentToSales>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNi0yLTEtMS0w_28332cff-310a-4700-9f4f-b50ce843c560"
      unitRef="usd">9994000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNi00LTEtMS0w_4d87540e-f111-475f-a229-9614468a10a6"
      unitRef="number">0.145</jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNi02LTEtMS0w_122b2af7-ecbc-40ea-a2db-3b732b87eb81"
      unitRef="usd">8127000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNi04LTEtMS0w_6f7777a0-a121-4d2f-a1d8-a9740c4e60fa"
      unitRef="number">0.135</jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNy0yLTEtMS0w_8cf6ce2a-05dc-4a5c-91ef-c028fd61b80a"
      unitRef="usd">900000000</us-gaap:ResearchAndDevelopmentInProcess>
    <jnj:ResearchAndDevelopmentInProcessPercentToSales
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNy00LTEtMS0w_410446c4-b4b8-438d-9a71-05e68a658554"
      unitRef="number">0.013</jnj:ResearchAndDevelopmentInProcessPercentToSales>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNy02LTEtMS0w_a570f2ec-ba11-4823-a1d9-62f803262fad"
      unitRef="usd">144000000</us-gaap:ResearchAndDevelopmentInProcess>
    <jnj:ResearchAndDevelopmentInProcessPercentToSales
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfNy04LTEtMS0w_043bd764-d52d-485f-ada3-4895138e951a"
      unitRef="number">0.003</jnj:ResearchAndDevelopmentInProcessPercentToSales>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfOC0yLTEtMS0w_b0a912fb-12d3-4e63-a908-abceb7cae19f"
      unitRef="usd">40000000</us-gaap:InvestmentIncomeInterest>
    <jnj:InvestmentIncomeInterestPercentToSales
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfOC00LTEtMS0w_de82a135-f20e-42bc-8255-00451c029731"
      unitRef="number">-0.001</jnj:InvestmentIncomeInterestPercentToSales>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfOC02LTEtMS0w_23525f20-da9a-4219-955c-6a3400e39c1c"
      unitRef="usd">98000000</us-gaap:InvestmentIncomeInterest>
    <jnj:InvestmentIncomeInterestPercentToSales
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfOC04LTEtMS0w_2af5c606-608f-43ea-b8ad-597c337aebae"
      unitRef="number">-0.002</jnj:InvestmentIncomeInterestPercentToSales>
    <us-gaap:InterestExpense
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfOS0yLTEtMS0w_61b366e7-0f4f-4541-a1bf-8601e1ce1e9a"
      unitRef="usd">123000000</us-gaap:InterestExpense>
    <jnj:InterestExpensePercentToSales
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfOS00LTEtMS0w_f61c7add-3f5d-4985-af88-6c3ccfd97683"
      unitRef="number">0.002</jnj:InterestExpensePercentToSales>
    <us-gaap:InterestExpense
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfOS02LTEtMS0w_6005836c-584b-4db4-9a04-c5323678f037"
      unitRef="usd">114000000</us-gaap:InterestExpense>
    <jnj:InterestExpensePercentToSales
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfOS04LTEtMS0w_7cf39c1e-4026-4bb7-839f-f8f4207e397a"
      unitRef="number">0.002</jnj:InterestExpensePercentToSales>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTAtMi0xLTEtMA_b7795b75-c2f0-4cc2-9ea9-0ef4952e293f"
      unitRef="usd">-480000000</us-gaap:OtherNonoperatingIncomeExpense>
    <jnj:OtherNonOperatingIncomeExpensePercentToSales
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTAtNC0xLTEtMA_f192435a-b94e-41b7-aa20-9f2eb8e2735c"
      unitRef="number">0.007</jnj:OtherNonOperatingIncomeExpensePercentToSales>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTAtNi0xLTEtMA_18f04dab-1c58-4831-8129-66259fe6fa41"
      unitRef="usd">-545000000</us-gaap:OtherNonoperatingIncomeExpense>
    <jnj:OtherNonOperatingIncomeExpensePercentToSales
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTAtOC0xLTEtMA_2de1adaa-8799-46a9-973b-a3027da0cee0"
      unitRef="number">0.009</jnj:OtherNonOperatingIncomeExpensePercentToSales>
    <us-gaap:RestructuringCharges
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTEtMi0xLTEtMA_1ba7fd63-1d38-4390-a843-f3fbd6fb2377"
      unitRef="usd">169000000</us-gaap:RestructuringCharges>
    <jnj:Restructuringchargepercenttosales
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTEtNC0xLTEtMA_5da3bd35-ff34-4185-96d2-f87214f93c35"
      unitRef="number">0.002</jnj:Restructuringchargepercenttosales>
    <us-gaap:RestructuringCharges
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTEtNi0xLTEtMA_52e01f7a-3af6-4d01-9268-da6f9d451511"
      unitRef="usd">187000000</us-gaap:RestructuringCharges>
    <jnj:Restructuringchargepercenttosales
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTEtOC0xLTEtMA_6b7e2428-9ed3-4790-a6c3-b2432a6b69e6"
      unitRef="number">0.003</jnj:Restructuringchargepercenttosales>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTItMi0xLTEtMA_e537f297-15f2-444f-a16d-5f8f456a13dd"
      unitRef="usd">17940000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTItNC0xLTEtMA_3cb30b72-486f-4e83-a005-7bbaca16d0fa"
      unitRef="number">0.260</jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTItNi0xLTEtMA_3d35efc9-970f-4009-9aed-f2ff4a49ba90"
      unitRef="usd">14850000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTItOC0xLTEtMA_e7fcc175-42c5-4d31-9687-293072f776b2"
      unitRef="number">0.247</jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTMtMi0xLTEtMA_c5d9e91d-7dc7-4291-8201-62d080cd65ed"
      unitRef="usd">1798000000</us-gaap:IncomeTaxExpenseBenefit>
    <jnj:IncomeTaxExpenseBenefitPercentToSales
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTMtNC0xLTEtMA_f150d9d2-3385-4888-bfd9-d02823e3afe7"
      unitRef="number">0.026</jnj:IncomeTaxExpenseBenefitPercentToSales>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTMtNi0xLTEtMA_6d6a551d-5bab-47b8-b442-41408d2e2a34"
      unitRef="usd">1874000000</us-gaap:IncomeTaxExpenseBenefit>
    <jnj:IncomeTaxExpenseBenefitPercentToSales
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTMtOC0xLTEtMA_67ba8fee-a0cd-4609-a883-a4a3cb925853"
      unitRef="number">0.031</jnj:IncomeTaxExpenseBenefitPercentToSales>
    <us-gaap:NetIncomeLoss
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTQtMi0xLTEtMA_55ec364f-11d3-42b2-a28e-0e271cffe4eb"
      unitRef="usd">16142000000</us-gaap:NetIncomeLoss>
    <jnj:NetIncomeAttributableToParentPercentToSales
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTQtNC0xLTEtMA_7f89d9dd-f271-4f61-88ce-173581466e76"
      unitRef="number">0.234</jnj:NetIncomeAttributableToParentPercentToSales>
    <us-gaap:NetIncomeLoss
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTQtNi0xLTEtMA_e36764a5-8074-41c8-9810-c03e6c79307c"
      unitRef="usd">12976000000</us-gaap:NetIncomeLoss>
    <jnj:NetIncomeAttributableToParentPercentToSales
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTQtOC0xLTEtMA_3786fb7f-832b-445c-b5e4-89e65377a475"
      unitRef="number">0.216</jnj:NetIncomeAttributableToParentPercentToSales>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTctMi0xLTEtMA_216657d1-53a6-4bc9-9445-31155ac1ea80"
      unitRef="usdPerShare">6.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTctNi0xLTEtMA_b37bd908-aebb-4ee9-a427-c0aed7cdc460"
      unitRef="usdPerShare">4.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTgtMi0xLTEtMA_a22639a7-8d44-47c4-8be4-ef9eca5d210b"
      unitRef="usdPerShare">6.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMTgtNi0xLTEtMA_2f892aa7-0da6-44e3-a386-128ff19f6af2"
      unitRef="usdPerShare">4.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMjEtMi0xLTEtMA_cc610af1-5f20-4d64-ac3e-a9f171782afe"
      unitRef="shares">2632200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMjEtNi0xLTEtMA_08086eb0-80f4-4575-b357-8259ab23daea"
      unitRef="shares">2633000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMjItMi0xLTEtMA_7b80a22c-fd5b-47f1-b886-d25cfc8df8c8"
      unitRef="shares">2674600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zMS9mcmFnOjFiZmNlMWM4YTA1MDQzM2JiMTEzZDE5YWYyYjdhZjA0L3RhYmxlOjdlZTg0YzAxNGRmZTQ2ODI5OGNlNTA1MjBkOGU4ZGMyL3RhYmxlcmFuZ2U6N2VlODRjMDE0ZGZlNDY4Mjk4Y2U1MDUyMGQ4ZThkYzJfMjItNi0xLTEtMA_d27ad6cd-3628-426b-9e4f-c0131f1957d7"
      unitRef="shares">2670800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMy0xLTEtMS0w_a869423d-563e-4fce-a12d-c1a26a3af5e6"
      unitRef="usd">3667000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMy0zLTEtMS0w_6a5528b1-0f39-4eec-ba3d-7a1e9183427b"
      unitRef="usd">3554000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMy01LTEtMS0w_23ba5ad9-145f-49d1-9cab-73fce239eaf8"
      unitRef="usd">16142000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMy03LTEtMS0w_943cba37-eaf8-482c-aab5-255c6c289663"
      unitRef="usd">12976000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfNi0xLTEtMS0w_c963402f-8ebf-4917-a193-aa4a8c217e09"
      unitRef="usd">-382000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfNi0zLTEtMS0w_5b94ec24-5c4b-4f8b-bbb6-0451818db4ad"
      unitRef="usd">222000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfNi01LTEtMS0w_2e1917b4-36da-4a72-aa50-3006fb81af57"
      unitRef="usd">-241000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfNi03LTEtMS0w_ef5907ac-7b03-45b2-a505-add00892a2b3"
      unitRef="usd">-741000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfOS0xLTEtMS0w_e33a3f09-e4ca-4503-936e-f67a33a02905"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfOS0zLTEtMS0w_a4d818d6-3541-4a4a-8519-d2f640d0ba2d"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfOS01LTEtMS0w_5f0864dd-efa7-4a44-8b1c-85baf545a5a3"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfOS03LTEtMS0w_e3553299-686f-40a5-8283-cac26e3ba199"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTAtMS0xLTEtMA_8ba87608-9a58-4e0a-9d51-5b6c8438832c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTAtMy0xLTEtMA_5ab2f8d2-9f7b-45f3-b35a-c5dce4b8807f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTAtNS0xLTEtMA_eb5188ea-090c-4c8d-b1e5-3f664b684f16"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTAtNy0xLTEtMA_8d6af8ff-2bb1-4209-bcbc-9e4bb4196ca1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTItMS0xLTEtMA_799e3568-2099-4e26-b9ec-e88ebdf3db92"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTItMy0xLTEtMA_58fc92b8-3cb7-4de8-8101-d0cd28f9c457"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTItNS0xLTEtMA_e2058dd7-2795-49cb-b79a-928bed3a93bc"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTItNy0xLTEtMA_5a9fd80f-4656-4a12-ae1e-3586a3294572"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTUtMS0xLTEtMA_80cf36ea-4574-4527-b0c9-f96097e5dace"
      unitRef="usd">40000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTUtMy0xLTEtMA_b7627018-1d46-44e3-9a81-37135f5ddfe7"
      unitRef="usd">6000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTUtNS0xLTEtMA_78484387-a235-4e6f-93a5-4bc8bc6ec0f7"
      unitRef="usd">122000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTUtNy0xLTEtMA_7c5187d2-b872-4056-8219-c9983066a92f"
      unitRef="usd">17000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTYtMS0xLTEtMA_d7b4fddf-f7df-4e8d-a817-7f220da2b2dd"
      unitRef="usd">-273000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTYtMy0xLTEtMA_bc0a94de-e6eb-43d1-9d71-190dc22f0d80"
      unitRef="usd">-203000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTYtNS0xLTEtMA_ca8549fe-8fae-481e-92a3-2ed1687c37a3"
      unitRef="usd">-822000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTYtNy0xLTEtMA_01564439-d967-4761-b5bf-7c4691c794ae"
      unitRef="usd">-604000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTgtMS0xLTEtMA_cc1d7da6-7276-4286-89f2-f954f177b4b1"
      unitRef="usd">-233000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTgtMy0xLTEtMA_855226b7-85d2-4994-b257-03a4f9f4dbc8"
      unitRef="usd">-197000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTgtNS0xLTEtMA_fdb78aa3-bc71-4cf2-a1cc-0f90cfdff517"
      unitRef="usd">-700000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMTgtNy0xLTEtMA_2371a1f7-2dd2-40a7-987e-f2feffdbc2b9"
      unitRef="usd">-587000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjEtMS0xLTEtMA_e5177b56-ac32-4956-86ca-77ae5a22ad9d"
      unitRef="usd">67000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjEtMy0xLTEtMA_548d244c-bf00-401e-ba19-8ade076895a3"
      unitRef="usd">199000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjEtNS0xLTEtMA_ae4a0369-ec5a-4a23-9360-bc9b97e133cd"
      unitRef="usd">-55000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjEtNy0xLTEtMA_6d57a55a-e40d-4d87-92db-389d87b094c5"
      unitRef="usd">1052000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjItMS0xLTEtMA_e2f5883a-de9c-4b16-a0e0-654aba8c0140"
      unitRef="usd">233000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjItMy0xLTEtMA_08a2daea-6b16-49e0-9ece-72fd9d32ff27"
      unitRef="usd">24000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjItNS0xLTEtMA_b4d2a99d-d5cb-4e74-b14d-21c5838e0274"
      unitRef="usd">576000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjItNy0xLTEtMA_c6f2516d-1361-4e43-98c8-4fa65e12f36c"
      unitRef="usd">-54000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjMtMS0xLTEtMA_b2569bfd-b1ea-41ca-bcf4-c1641db50d2d"
      unitRef="usd">-166000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjMtMy0xLTEtMA_10bfa48c-4eaa-43cd-b6f8-b2e119813d1f"
      unitRef="usd">175000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjMtNS0xLTEtMA_77df5d86-8a46-46d0-bb5a-82049a792301"
      unitRef="usd">-631000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjMtNy0xLTEtMA_4ca12eb6-2f54-4e55-99f1-451d4f1fa33f"
      unitRef="usd">1106000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjUtMS0xLTEtMA_870017da-2157-4bb7-b581-cea3245d5049"
      unitRef="usd">-315000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjUtMy0xLTEtMA_29544c2a-8441-4fb4-898c-77eb2d6abf89"
      unitRef="usd">595000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjUtNS0xLTEtMA_11ab1aec-f8a9-4e79-aa37-77e03f05a746"
      unitRef="usd">-173000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjUtNy0xLTEtMA_a210c0c8-7e73-47e7-ab15-290d66957337"
      unitRef="usd">953000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjctMS0xLTEtMA_c8933df5-6dcb-4910-a908-74391a09aad2"
      unitRef="usd">3352000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjctMy0xLTEtMA_f3ec0366-3cdc-40ee-8ff2-4317a6b042a0"
      unitRef="usd">4149000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjctNS0xLTEtMA_33739a8d-ec52-4f99-8e4d-310f4221b2e0"
      unitRef="usd">15969000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOmY3ODk3YTljY2RlODQ2OWM4MDM2ZTE2ZDQ0ZTBmYmI1L3RhYmxlcmFuZ2U6Zjc4OTdhOWNjZGU4NDY5YzgwMzZlMTZkNDRlMGZiYjVfMjctNy0xLTEtMA_a5588fe9-7581-4919-915f-cd25c8e0eb36"
      unitRef="usd">13929000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOjY5MzhmNGVhZjNlMDRhMGU4YTY0Y2U3Mjg5MDYzYjA1L3RhYmxlcmFuZ2U6NjkzOGY0ZWFmM2UwNGEwZThhNjRjZTcyODkwNjNiMDVfMC0wLTEtMS0wL3RleHRyZWdpb246MWU1ZGY3ZTcwMDJkNDljYWFkNjg4ODJhY2NhZDk5YWJfMTYw_76d8cab1-ee84-4188-adcb-76b96e28b47e"
      unitRef="usd">-86000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOjY5MzhmNGVhZjNlMDRhMGU4YTY0Y2U3Mjg5MDYzYjA1L3RhYmxlcmFuZ2U6NjkzOGY0ZWFmM2UwNGEwZThhNjRjZTcyODkwNjNiMDVfMC0wLTEtMS0wL3RleHRyZWdpb246MWU1ZGY3ZTcwMDJkNDljYWFkNjg4ODJhY2NhZDk5YWJfMTc2_f97cd5ee-50b6-44e9-a750-f75c9380bd38"
      unitRef="usd">139000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOjY5MzhmNGVhZjNlMDRhMGU4YTY0Y2U3Mjg5MDYzYjA1L3RhYmxlcmFuZ2U6NjkzOGY0ZWFmM2UwNGEwZThhNjRjZTcyODkwNjNiMDVfMC0wLTEtMS0wL3RleHRyZWdpb246MWU1ZGY3ZTcwMDJkNDljYWFkNjg4ODJhY2NhZDk5YWJfMjEz_bb149deb-8c56-414e-9535-799d7b8f0092"
      unitRef="usd">-65000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOjY5MzhmNGVhZjNlMDRhMGU4YTY0Y2U3Mjg5MDYzYjA1L3RhYmxlcmFuZ2U6NjkzOGY0ZWFmM2UwNGEwZThhNjRjZTcyODkwNjNiMDVfMC0wLTEtMS0wL3RleHRyZWdpb246MWU1ZGY3ZTcwMDJkNDljYWFkNjg4ODJhY2NhZDk5YWJfMjI5_0ac568f8-b562-4812-9d0e-0c161be98933"
      unitRef="usd">-56000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOjY5MzhmNGVhZjNlMDRhMGU4YTY0Y2U3Mjg5MDYzYjA1L3RhYmxlcmFuZ2U6NjkzOGY0ZWFmM2UwNGEwZThhNjRjZTcyODkwNjNiMDVfMC0wLTEtMS0wL3RleHRyZWdpb246MWU1ZGY3ZTcwMDJkNDljYWFkNjg4ODJhY2NhZDk5YWJfMjY0_1c64bcb7-62a9-4654-9c9f-06399159af09"
      unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOjY5MzhmNGVhZjNlMDRhMGU4YTY0Y2U3Mjg5MDYzYjA1L3RhYmxlcmFuZ2U6NjkzOGY0ZWFmM2UwNGEwZThhNjRjZTcyODkwNjNiMDVfMC0wLTEtMS0wL3RleHRyZWdpb246MWU1ZGY3ZTcwMDJkNDljYWFkNjg4ODJhY2NhZDk5YWJfMjgw_1ae7f63e-aaa7-4f8f-83e0-d5ebd6df49c6"
      unitRef="usd">47000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOjY5MzhmNGVhZjNlMDRhMGU4YTY0Y2U3Mjg5MDYzYjA1L3RhYmxlcmFuZ2U6NjkzOGY0ZWFmM2UwNGEwZThhNjRjZTcyODkwNjNiMDVfMi0wLTEtMS0wL3RleHRyZWdpb246YmQzNjVmYWRhYTNiNGI2NDg4NTg5NjRjNTUzOTgzNjZfMTU2_aed7ce57-b8d4-405d-a0b2-43531c27fdf5"
      unitRef="usd">-315000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOjY5MzhmNGVhZjNlMDRhMGU4YTY0Y2U3Mjg5MDYzYjA1L3RhYmxlcmFuZ2U6NjkzOGY0ZWFmM2UwNGEwZThhNjRjZTcyODkwNjNiMDVfMi0wLTEtMS0wL3RleHRyZWdpb246YmQzNjVmYWRhYTNiNGI2NDg4NTg5NjRjNTUzOTgzNjZfMTcy_dd1c2a0c-c995-4cc1-8e34-dbc1a8f9021c"
      unitRef="usd">-207000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOjY5MzhmNGVhZjNlMDRhMGU4YTY0Y2U3Mjg5MDYzYjA1L3RhYmxlcmFuZ2U6NjkzOGY0ZWFmM2UwNGEwZThhNjRjZTcyODkwNjNiMDVfMi0wLTEtMS0wL3RleHRyZWdpb246YmQzNjVmYWRhYTNiNGI2NDg4NTg5NjRjNTUzOTgzNjZfMjA5_e8c66743-a994-488d-af52-461ba6868ab6"
      unitRef="usd">-197000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOjY5MzhmNGVhZjNlMDRhMGU4YTY0Y2U3Mjg5MDYzYjA1L3RhYmxlcmFuZ2U6NjkzOGY0ZWFmM2UwNGEwZThhNjRjZTcyODkwNjNiMDVfMi0wLTEtMS0wL3RleHRyZWdpb246YmQzNjVmYWRhYTNiNGI2NDg4NTg5NjRjNTUzOTgzNjZfMjI1_e54b3842-815a-4dda-9362-66eb75681c63"
      unitRef="usd">-167000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOjY5MzhmNGVhZjNlMDRhMGU4YTY0Y2U3Mjg5MDYzYjA1L3RhYmxlcmFuZ2U6NjkzOGY0ZWFmM2UwNGEwZThhNjRjZTcyODkwNjNiMDVfMi0wLTEtMS0wL3RleHRyZWdpb246YmQzNjVmYWRhYTNiNGI2NDg4NTg5NjRjNTUzOTgzNjZfMjYw_2e242797-44d2-4497-85db-099e89134f84"
      unitRef="usd">-167000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV8zNC9mcmFnOjA1ZWY4MTQ0ZGYyNzQ3ZDQ5YjYxMzVhMjRjMDk3NGM1L3RhYmxlOjY5MzhmNGVhZjNlMDRhMGU4YTY0Y2U3Mjg5MDYzYjA1L3RhYmxlcmFuZ2U6NjkzOGY0ZWFmM2UwNGEwZThhNjRjZTcyODkwNjNiMDVfMi0wLTEtMS0wL3RleHRyZWdpb246YmQzNjVmYWRhYTNiNGI2NDg4NTg5NjRjNTUzOTgzNjZfMjc2_f47a591a-df87-47cc-9314-684dd01fd2a2"
      unitRef="usd">293000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4f560bf19097496e9d3b17c570ba5487_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfMS0xLTEtMS0w_64facb3f-bb67-4161-88ac-53c0a63eb1b9"
      unitRef="usd">69580000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia36f1ef4e53741a698ce4eb8a63cfcc8_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfMS0zLTEtMS0w_a837f20f-cc12-4092-afc5-e4922bd9aba2"
      unitRef="usd">120154000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3d39696cd8124bebbcee13521011bc43_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfMS01LTEtMS0w_e229901d-89b0-4132-9a6a-d5b8a5a5866e"
      unitRef="usd">-15100000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2fc21784cc544993916b76a2883b5fa7_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfMS03LTEtMS0w_f3d734f1-c8c1-43ea-bb34-6e83677b4379"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2b91cb0100d34fc688b5e3ed019ce080_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfMS05LTEtMS0w_dce0649f-9073-4959-a77d-9b5102f5a678"
      unitRef="usd">-38594000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfMi0xLTEtMS0w_e7bb39d5-510b-4fbf-a457-dc29a315dc98"
      unitRef="usd">3667000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia21d27ed7dc047cc83042ea5ddaf0820_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfMi0zLTEtMS0w_f98bd438-32b7-443b-ba9f-3a4ea9ffd2f5"
      unitRef="usd">3667000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfMy0wLTEtMS0wL3RleHRyZWdpb246MTQ5OWY3NWVkYjg4NDM0ODhlOTIwYWY0YTgwZGExMzlfMjY_216fa420-5898-41db-87a6-ecf9455a15bc"
      unitRef="usdPerShare">1.06</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfMy0xLTEtMS0w_07999132-649c-4066-9b97-73bbfcdbc9b3"
      unitRef="usd">2791000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="ia21d27ed7dc047cc83042ea5ddaf0820_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfMy0zLTEtMS0w_97e52dbe-30f6-4cf6-9a63-ca6bd3d4307d"
      unitRef="usd">2791000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfNC0xLTEtMS0w_6cbf556c-928e-4571-8dbd-e1928861aab8"
      unitRef="usd">522000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ia21d27ed7dc047cc83042ea5ddaf0820_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfNC0zLTEtMS0w_4ee8a0e3-9dc4-4473-80e3-e9f0d2a07d86"
      unitRef="usd">62000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i85720d7d2890498ca2589aaaa3d3c267_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfNC05LTEtMS0w_8c707d9e-0ae8-4f35-9fd8-f9b907e60de4"
      unitRef="usd">460000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfNS0xLTEtMS0w_435a1802-c453-41b2-bced-a6ca872f69b0"
      unitRef="usd">391000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i85720d7d2890498ca2589aaaa3d3c267_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfNS05LTEtMS0w_c7f60112-a431-46a8-b367-0ee691bb2693"
      unitRef="usd">391000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfNy0xLTEtMS0w_c93cf6bf-a296-4627-a2ac-f37dd6048e74"
      unitRef="usd">-315000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7c3f7de455fa4be484a940d40bf7d252_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfNy01LTEtMS0w_c4f8a9d3-f8b8-4dce-a02f-6bc686c97b8c"
      unitRef="usd">-315000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfOC0xLTEtMS0w_bbf2a537-00a2-4013-b019-47681db5f6c3"
      unitRef="usd">70272000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic67ffcf2eac440a4a3acf47e9df62981_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfOC0zLTEtMS0w_2beae7f4-e3a6-437b-85ea-d0ecb344676f"
      unitRef="usd">121092000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idd88e9907aaf4e8cbca11111329e2073_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfOC01LTEtMS0w_093d25d8-1f1d-441b-aaaf-7fcb38ad5f18"
      unitRef="usd">-15415000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icdbe49f46d3548e69bcf28fa1c70f4a0_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfOC03LTEtMS0w_00ceea33-891b-4b31-81fd-876047e589c7"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib15db8a9bfc141e3b662784fb2f12036_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjc3NzBmOWIxMTU4YzQzZjNiNjA5NGU5ZjI5ZmViZjZmL3RhYmxlcmFuZ2U6Nzc3MGY5YjExNThjNDNmM2I2MDk0ZTlmMjlmZWJmNmZfOC05LTEtMS0w_13a67fd5-9527-4daa-9adb-7f53d18bd3d5"
      unitRef="usd">-38525000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfMy0xLTEtMS0w_6edfe319-cfba-4c23-a4f8-94ef44352cb0"
      unitRef="usd">63278000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i97cf81456e3d4ee78c0eb5ef14d6adfd_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfMy0zLTEtMS0w_c6ee0172-8697-43b5-82e5-cd8706560389"
      unitRef="usd">113890000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib616b434ad574d54a671235ee0e19c40_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfMy01LTEtMS0w_1a458b75-b52b-4767-9aa7-ca5aea5883ab"
      unitRef="usd">-15242000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i37e41918fcfb4a96aae4c8ddf736f81f_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfMy03LTEtMS0w_f541587a-10cf-4964-8a0a-95d68889397f"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6567971b97b8486f9c4ca8fcaa0bc916_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfMy05LTEtMS0w_96a6189c-2062-4dda-a80f-017f0166fa91"
      unitRef="usd">-38490000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfNC0xLTEtMS0w_b156afe0-2d20-41dd-a2ae-45488fdd38db"
      unitRef="usd">16142000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie0f5194139614002a34759c09867b19b_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfNC0zLTEtMS0w_c65b870e-4b49-4363-a105-1c42aaf2e0bb"
      unitRef="usd">16142000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfNS0wLTEtMS0wL3RleHRyZWdpb246ODljOGFiMDhiM2Q5NGRlYWJjNDhjODBhMzlmZDNiZGRfMjY_69bcc7fa-5a57-488c-8611-2561fc4d79e4"
      unitRef="usdPerShare">3.13</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfNS0xLTEtMS0w_a4f6afe9-b81a-4fe2-b057-f6e66bc21005"
      unitRef="usd">8241000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="ie0f5194139614002a34759c09867b19b_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfNS0zLTEtMS0w_50e675bf-cd03-4682-8d46-eefc09efb67f"
      unitRef="usd">8241000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfNi0xLTEtMS0w_8791d791-4df7-4daf-9b12-b7d3cfdb8aab"
      unitRef="usd">1726000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ie0f5194139614002a34759c09867b19b_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfNi0zLTEtMS0w_b9e72e4c-972f-4722-a5eb-ec5289a63e9c"
      unitRef="usd">-699000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ic6f044a57fb04694b9504b1cc6b855fc_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfNi05LTEtMS0w_7925f759-932d-4744-ad66-b85c9501be1d"
      unitRef="usd">2425000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfNy0xLTEtMS0w_0c7f882f-1a99-46ba-80c7-af8192caa2b1"
      unitRef="usd">2460000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ic6f044a57fb04694b9504b1cc6b855fc_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfNy05LTEtMS0w_c3d9993a-8202-4cb7-bffd-88fb97125a67"
      unitRef="usd">2460000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfOS0xLTEtMS0w_00d52817-860e-4460-b26f-b5945f62211c"
      unitRef="usd">-173000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i280f2f10a11c4c988142fed0ab0a55c4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfOS01LTEtMS0w_93f416e2-0201-4b63-9b87-1a45b0da63a1"
      unitRef="usd">-173000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfMTAtMS0xLTEtMA_22999106-24fa-46a1-a9cf-7ebd8e7e8631"
      unitRef="usd">70272000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic67ffcf2eac440a4a3acf47e9df62981_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfMTAtMy0xLTEtMA_2e25623a-bfd2-4e80-9c70-9e0902ff81b8"
      unitRef="usd">121092000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idd88e9907aaf4e8cbca11111329e2073_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfMTAtNS0xLTEtMA_a3995078-310d-46e7-9bcc-bfd76e1b0d8d"
      unitRef="usd">-15415000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icdbe49f46d3548e69bcf28fa1c70f4a0_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfMTAtNy0xLTEtMA_f017b967-6ec4-4ad9-829a-86670c5f8413"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib15db8a9bfc141e3b662784fb2f12036_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOmY4N2ZjZmNkZmMzNzQyNjk4NjRhY2FkNTczMmQ3Y2E3L3RhYmxlcmFuZ2U6Zjg3ZmNmY2RmYzM3NDI2OTg2NGFjYWQ1NzMyZDdjYTdfMTAtOS0xLTEtMA_6187ce6f-8f97-458f-87c5-33bf99d85952"
      unitRef="usd">-38525000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie4c978ae9bd844bb8485b20fee0394d2_I20200628"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfMS0xLTEtMS0w_902244cc-2826-4214-b0a1-d0fc97293e00"
      unitRef="usd">62978000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i789e8630040645df9671180079be56c4_I20200628"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfMS0zLTEtMS0w_68b76a00-346d-422e-99bd-b7195504a3ec"
      unitRef="usd">113898000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8c1cb280df774543988ac3e60b3700ff_I20200628"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfMS01LTEtMS0w_cd585c4d-a753-413e-94f2-83ea1f8b630d"
      unitRef="usd">-15533000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5b1b5e269d61463c9d13dc7f3431be66_I20200628"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfMS03LTEtMS0w_fa5ed7f8-4bec-4e10-bf23-d62f26addf8e"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc043974a53d45c09c9c4916e8c5d997_I20200628"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfMS05LTEtMS0w_5e50a5dd-fa26-40be-a37b-ce70a1765704"
      unitRef="usd">-38507000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfMy0xLTEtMS0w_541d1da8-e385-411c-bb2b-4b66075ba55d"
      unitRef="usd">3554000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i151bc89c89104e6fad68b01743dd13fc_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfMy0zLTEtMS0w_d5508aea-5702-46ca-a155-73f9807dc3b7"
      unitRef="usd">3554000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfNC0wLTEtMS0wL3RleHRyZWdpb246NGI0NjVkOTYyOWYzNGNmNTljOTU2OWEwZTc1OGM3MWJfMjY_4a7019a7-c9b5-4ca9-b42a-f04db24bd118"
      unitRef="usdPerShare">1.01</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfNC0xLTEtMS0w_3c0e7e82-e6c3-41a1-babe-6178a5233bdb"
      unitRef="usd">2659000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i151bc89c89104e6fad68b01743dd13fc_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfNC0zLTEtMS0w_a94c7276-f02d-481f-9965-ec454ba13e27"
      unitRef="usd">2659000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfNS0xLTEtMS0w_798332af-8bfa-4650-b956-9e8ab6bfcab1"
      unitRef="usd">559000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i151bc89c89104e6fad68b01743dd13fc_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfNS0zLTEtMS0w_f9151178-df31-4007-8cc8-e197bf57af60"
      unitRef="usd">109000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i14461e2d7ae84af4b6b45899f46e8cdc_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfNS05LTEtMS0w_097adb3e-14a6-4284-92b2-981a3a1d0a72"
      unitRef="usd">450000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfNi0xLTEtMS0w_e9f5fec7-59b4-4a59-b92d-442226422d82"
      unitRef="usd">483000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i14461e2d7ae84af4b6b45899f46e8cdc_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfNi05LTEtMS0w_6d9f24a0-727f-47af-9fc6-84e3e81f8eda"
      unitRef="usd">483000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockholdersEquityOther
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfNy0xLTEtMS0w_8df06292-4327-497b-ab7d-b226265e3d9a"
      unitRef="usd">-71000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i151bc89c89104e6fad68b01743dd13fc_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfNy0zLTEtMS0w_a3ae382d-64de-45da-9fa0-19bc0647e60f"
      unitRef="usd">-71000000</us-gaap:StockholdersEquityOther>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfOC0xLTEtMS0w_6c342df7-e48a-4226-9f83-b399222867c0"
      unitRef="usd">595000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i94a2d6ba6c254c6b92dfd2a37f7901ed_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfOC01LTEtMS0w_c0493513-8cce-43f5-8d0e-34ce0290c279"
      unitRef="usd">595000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4de10452fa98443a826d732ac5ecfcd4_I20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfOS0xLTEtMS0w_68f807df-fe1b-43cd-8a9e-316aacb045c6"
      unitRef="usd">64473000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i21919a743da04e9ebb238e98bd59fa74_I20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfOS0zLTEtMS0w_190ce185-aec8-4f40-8067-6fc27e95bf5a"
      unitRef="usd">114831000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i514541208cb44a09bd41a6c7b123cbb4_I20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfOS01LTEtMS0w_0161b62a-5c85-4b4e-a361-e754cae3ef88"
      unitRef="usd">-14938000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i701c9aa0c90c443fa3b9239555242704_I20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfOS03LTEtMS0w_b2fdeb6e-5369-468e-97a6-6e82efa84bd4"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia4593a0dc4364211ae7edf29da4866d3_I20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjA5YmY3OTFiMjJiNTQ5MTY5MDc0NmU1NmZhN2U2MzJiL3RhYmxlcmFuZ2U6MDliZjc5MWIyMmI1NDkxNjkwNzQ2ZTU2ZmE3ZTYzMmJfOS05LTEtMS0w_be2df13d-e677-4a40-99f3-4cfc33f73139"
      unitRef="usd">-38540000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if49e94e75cf04169b3ef119b2c588a4c_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfMy0xLTEtMS0w_42f952f0-c2f2-4b28-a507-d1ca207e9cb3"
      unitRef="usd">59471000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6004d7a658874bffb0b05f268a6fc6e9_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfMy0zLTEtMS0w_2c8bfbfd-1092-48ee-a26d-d7a3928c1efd"
      unitRef="usd">110659000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5e06dbf4f1b44f998d04005f6056c3d5_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfMy01LTEtMS0w_54029c0d-4af4-4b04-897c-a2e827278b61"
      unitRef="usd">-15891000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0ba2e82215dc4171a568af3512fd9d8f_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfMy03LTEtMS0w_82a78fa1-01cf-4f9f-9c8c-e1c4100b6788"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2a829e70799a4429b48066d6c98beb81_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfMy05LTEtMS0w_f43c7a56-07df-4eb3-8363-544f6a907a8c"
      unitRef="usd">-38417000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfNS0xLTEtMS0w_e2c0d9fa-9700-42fd-a855-d693185bc4a5"
      unitRef="usd">12976000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibd97456bd71e47888787febf8fb403c0_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfNS0zLTEtMS0w_b79d9505-919c-4e22-9043-7024ba1c82a2"
      unitRef="usd">12976000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfNi0wLTEtMS0wL3RleHRyZWdpb246Nzg0NmE3MzBiMjY0NDYxYjg0OGI3OTNiYWQ3NjZkYTdfMjY_7be158d4-49e0-48b2-a771-5c7132d4f6aa"
      unitRef="usdPerShare">2.97</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfNi0xLTEtMS0w_5b818b1c-a446-4a96-82e5-1b9aae661f33"
      unitRef="usd">7823000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="ibd97456bd71e47888787febf8fb403c0_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfNi0zLTEtMS0w_09b9487b-3bbe-4c4d-b3de-1369a0a771d7"
      unitRef="usd">7823000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfNy0xLTEtMS0w_19460ba2-a7f7-4b94-9602-00c305512350"
      unitRef="usd">1866000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ibd97456bd71e47888787febf8fb403c0_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfNy0zLTEtMS0w_67ec3584-9c25-4923-bd69-514b5f2a9adb"
      unitRef="usd">-911000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i25e2937f00db4ffab2f056e05c4b797e_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfNy05LTEtMS0w_eeacf1d0-65b1-45bc-8805-b46aeb38463c"
      unitRef="usd">2777000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfOC0xLTEtMS0w_9f4de8f1-d0b6-4048-a17a-05bcc505905c"
      unitRef="usd">2900000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i25e2937f00db4ffab2f056e05c4b797e_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfOC05LTEtMS0w_45822c47-6177-4910-b91d-cc60d65ef7c2"
      unitRef="usd">2900000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockholdersEquityOther
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfOS0xLTEtMS0w_abcbf78b-604d-47a5-89ad-5349337e5be3"
      unitRef="usd">-70000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ibd97456bd71e47888787febf8fb403c0_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfOS0zLTEtMS0w_43669f1d-1f13-469c-b99d-be19e5f1b859"
      unitRef="usd">-70000000</us-gaap:StockholdersEquityOther>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfMTAtMS0xLTEtMA_13396be0-580e-4be6-af55-41643ff80c00"
      unitRef="usd">953000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i76d47fefae324430be757b4f9833ed5f_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfMTAtNS0xLTEtMA_d9528744-8718-47f1-b1d2-44a3e8b0fbc4"
      unitRef="usd">953000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4de10452fa98443a826d732ac5ecfcd4_I20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfMTEtMS0xLTEtMA_2b0a6578-7d94-4297-a356-587bba8b8c39"
      unitRef="usd">64473000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i21919a743da04e9ebb238e98bd59fa74_I20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfMTEtMy0xLTEtMA_b69c2564-facc-44b6-836d-932c548988ec"
      unitRef="usd">114831000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i514541208cb44a09bd41a6c7b123cbb4_I20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfMTEtNS0xLTEtMA_d22d8025-7894-4d02-a02e-e0bde3864bff"
      unitRef="usd">-14938000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i701c9aa0c90c443fa3b9239555242704_I20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfMTEtNy0xLTEtMA_be5f4d2d-d1c0-4140-b6cb-4fbbae684f75"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia4593a0dc4364211ae7edf29da4866d3_I20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80MC9mcmFnOmY3NWQzZjg4ZWRkNTQyMDhiOTE3NWMzNzE1MDc2ZDM5L3RhYmxlOjI1ZWQzMGIxNTRhOTQ5ZWNhM2QwZTdjMWFjYmMwZjI2L3RhYmxlcmFuZ2U6MjVlZDMwYjE1NGE5NDllY2EzZDBlN2MxYWNiYzBmMjZfMTEtOS0xLTEtMA_36b19684-5753-4090-8215-ab3c4956e4b6"
      unitRef="usd">-38540000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMy0yLTEtMS0w_eafa635c-e650-4c0b-971e-a003ec94aafc"
      unitRef="usd">16142000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMy00LTEtMS0w_cf33be8b-bbc1-4de5-833c-ee54482d8532"
      unitRef="usd">12976000000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNS0yLTEtMS0w_a557d3d9-18dd-487c-8a07-ac21ab80d470"
      unitRef="usd">5547000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNS00LTEtMS0w_4dcbdb38-bb13-404e-99c3-7bd9e7a431f6"
      unitRef="usd">5291000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNi0yLTEtMS0w_a12a409b-1c95-4c17-8d9d-453be2e2151c"
      unitRef="usd">920000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNi00LTEtMS0w_35dac905-7aaa-40fc-ba4a-e5d83326e955"
      unitRef="usd">845000000</us-gaap:ShareBasedCompensation>
    <us-gaap:AssetImpairmentCharges
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfOS0yLTEtMS0w_a67b68a5-632a-4826-ac4f-34c86855d7a3"
      unitRef="usd">964000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfOS00LTEtMS0w_6c58532f-8103-46d1-8c86-89a1a5883dbe"
      unitRef="usd">198000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTAtMi0xLTEtMA_de7393b6-0f73-4351-8d96-b8fe603be8f2"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTAtNC0xLTEtMA_6a3f240c-5700-48f5-80b7-f6cbd9a6dfc7"
      unitRef="usd">-1148000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTEtMi0xLTEtMA_765d30ae-4b2c-427e-af56-2fe177199187"
      unitRef="usd">601000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTEtNC0xLTEtMA_c183909b-adb4-4ca9-9f14-db64b9eff617"
      unitRef="usd">60000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTMtMi0xLTEtMA_a72c26d7-fdf2-4b26-880e-84d7e953d005"
      unitRef="usd">-2564000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTMtNC0xLTEtMA_ed60c0c2-af01-478e-b6cd-d3d7584f4028"
      unitRef="usd">-238000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTQtMi0xLTEtMA_f028efa3-678b-47f3-93b6-0bc77c59a925"
      unitRef="usd">-60000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTQtNC0xLTEtMA_60700fc0-898c-477b-8e6e-70c387af3ef3"
      unitRef="usd">74000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTYtMi0xLTEtMA_ed9bc0c5-e7e1-4471-8b26-be760dfdcdd3"
      unitRef="usd">1818000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTYtNC0xLTEtMA_10e5c930-d1d5-4ca5-9ee4-95ca71804644"
      unitRef="usd">440000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTctMi0xLTEtMA_d5073398-fc10-4e0d-ae18-7f1b87928cad"
      unitRef="usd">1178000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTctNC0xLTEtMA_e12a8d86-f16b-4e3a-8b57-ccb579033bf5"
      unitRef="usd">784000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTgtMi0xLTEtMA_4e6dca32-74c4-44be-9154-346a6fe638b9"
      unitRef="usd">182000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTgtNC0xLTEtMA_44ae2ccd-eca7-49ea-932c-ee4a84466385"
      unitRef="usd">-119000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTktMi0xLTEtMA_542ced2a-c1b7-40cc-818d-0b9aadc2371d"
      unitRef="usd">-2082000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMTktNC0xLTEtMA_31e80d47-6609-42c4-b333-2e992c9edad9"
      unitRef="usd">1983000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjAtMi0xLTEtMA_1139b055-46f4-4edb-9ff7-3fe7608ddd11"
      unitRef="usd">-1938000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjAtNC0xLTEtMA_37bed96f-e4d1-44d0-bd1a-8c76123fccc9"
      unitRef="usd">581000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjItMi0xLTEtMA_33fc4197-83d8-4f99-9c01-24d8da934f9d"
      unitRef="usd">17678000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjItNC0xLTEtMA_f7e9085c-a78c-4fe6-9df4-deca1a9e2305"
      unitRef="usd">15193000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjUtMi0xLTEtMA_8db59ce1-d0a5-4e39-b946-9f10fcde422b"
      unitRef="usd">2237000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjUtNC0xLTEtMA_058bdff1-5500-45a8-bfed-ff9e449adaf0"
      unitRef="usd">2024000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjYtMi0xLTEtMA_d2f95f5b-3381-4471-8c3e-ecf6891b219c"
      unitRef="usd">666000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjYtNC0xLTEtMA_69c9fea2-37fc-4997-8355-f8b722040bd9"
      unitRef="usd">100000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjctMi0xLTEtMA_d83f77ce-d3ee-4cee-8e1e-4db78a225cd7"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjctNC0xLTEtMA_8d521824-a336-428f-a8b8-af53841e3d86"
      unitRef="usd">949000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjgtMi0xLTEtMA_932b854d-364e-4ab8-87b5-6f97070efc99"
      unitRef="usd">18843000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjgtNC0xLTEtMA_48914a65-3583-4a8f-9ddb-3c2dd0ef350c"
      unitRef="usd">16243000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjktMi0xLTEtMA_b33088fc-5de3-47d0-aac9-8e3962e9fd16"
      unitRef="usd">16809000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMjktNC0xLTEtMA_fafd54a1-6951-4d37-960f-71ac32814ed5"
      unitRef="usd">6585000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzAtMi0xLTEtMA_9519c278-1d71-49b3-9aa8-23e4ac475ac6"
      unitRef="usd">696000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzAtNC0xLTEtMA_c251ce6b-6a50-4702-a8f7-fd87efd526a6"
      unitRef="usd">125000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzEtMi0xLTEtMA_be521f81-9f09-4785-855e-7faad351c6f1"
      unitRef="usd">414000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzEtNC0xLTEtMA_bb675a9d-e6a0-451d-b037-29bb1a698dd8"
      unitRef="usd">516000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzMtMi0xLTEtMA_dc4eb4de-ec1e-4abc-a040-fd805ca21f94"
      unitRef="usd">-3323000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzMtNC0xLTEtMA_8c73f928-0340-4caf-8967-7e0fa9b626d7"
      unitRef="usd">-12922000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzYtMi0xLTEtMA_d6a9163c-f14e-4cc5-8b51-74fa6816b1f5"
      unitRef="usd">8241000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzYtNC0xLTEtMA_f0cb2356-7b5b-408b-ba23-dee9acee3367"
      unitRef="usd">7823000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzctMi0xLTEtMA_f50c4cca-07dc-46fb-9555-351160d4b224"
      unitRef="usd">2460000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzctNC0xLTEtMA_28852c71-e378-4989-afb3-5839a82a41f4"
      unitRef="usd">2900000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzgtMi0xLTEtMA_dc7a6b9f-271c-4f74-9fbb-a0143a88f9a4"
      unitRef="usd">1283000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzgtNC0xLTEtMA_7c311bde-de09-4ed1-aede-357320469400"
      unitRef="usd">3335000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzktMi0xLTEtMA_e375e742-37aa-4087-9c57-f1e4cc76e828"
      unitRef="usd">821000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfMzktNC0xLTEtMA_46f13d03-65a9-46ef-a179-70c43bcedd66"
      unitRef="usd">310000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDAtMi0xLTEtMA_087f82e8-eff0-486d-94da-a07d47734097"
      unitRef="usd">3000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDAtNC0xLTEtMA_d647a5e3-dd7f-4960-9907-28233d6fe061"
      unitRef="usd">7431000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDEtMi0xLTEtMA_dc9f0b0e-58d1-4edc-89c2-45f8ae07375f"
      unitRef="usd">1452000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDEtNC0xLTEtMA_6de7ff73-bee0-46ac-b96a-282395746a88"
      unitRef="usd">562000000</us-gaap:RepaymentsOfLongTermDebt>
    <jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDItMi0xLTEtMA_cb06c068-50c3-4fde-9b9d-7f0a398087ed"
      unitRef="usd">808000000</jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits>
    <jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDItNC0xLTEtMA_98d978a0-f18a-4285-8119-0c8644cbd50b"
      unitRef="usd">922000000</jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDMtMi0xLTEtMA_5043c4a3-9090-440f-b197-6a9328499572"
      unitRef="usd">168000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDMtNC0xLTEtMA_0328922a-f94d-4f5d-a75d-4883c1940ef4"
      unitRef="usd">0</jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDQtMi0xLTEtMA_198cd066-2ab3-4391-a6a5-b2fdc5caeee0"
      unitRef="usd">101000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDQtNC0xLTEtMA_5430a358-71b5-4ce0-8cb7-ee9c22688ac9"
      unitRef="usd">-569000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDYtMi0xLTEtMA_2e353d52-38f6-432a-b607-71e7794eb673"
      unitRef="usd">-10611000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDYtNC0xLTEtMA_f6e58d89-357c-44f2-a931-2d85114762cb"
      unitRef="usd">-476000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDgtMi0xLTEtMA_78022442-d799-42eb-a71b-ec8c0b33066e"
      unitRef="usd">-125000000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDgtNC0xLTEtMA_50ab4c59-dea3-4b1d-bcdd-16e2a6386a7c"
      unitRef="usd">-135000000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDktMi0xLTEtMA_7433195e-efc5-4536-9e29-fa1cbe1f8080"
      unitRef="usd">3619000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNDktNC0xLTEtMA_d73c3f22-c5f3-43a9-8316-d9baf3d188e7"
      unitRef="usd">1660000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNTAtMi0xLTEtMA_17bcc36c-fc02-43d6-908b-69a9219141a9"
      unitRef="usd">13985000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if49e94e75cf04169b3ef119b2c588a4c_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNTAtNC0xLTEtMA_974a6b8f-e8bd-40c2-88d0-3ec8056c073b"
      unitRef="usd">17305000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNTEtMi0xLTEtMA_9f511098-8b7d-4018-9001-1edab96f903e"
      unitRef="usd">17604000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4de10452fa98443a826d732ac5ecfcd4_I20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNTEtNC0xLTEtMA_9a0859c7-980a-4ce5-88f4-f228e3c394df"
      unitRef="usd">18965000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNTgtMi0xLTEtMA_c93fffc0-c990-464a-b46c-afeccb77df1d"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNTgtNC0xLTEtMA_1f297408-2181-4c8b-99cf-430a49dc29da"
      unitRef="usd">1173000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNTktMi0xLTEtMA_478aa46a-1812-4c7b-97c4-d6e55cd724cd"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNTktNC0xLTEtMA_fa5dc12c-19ff-4feb-bbd5-120b728dc24a"
      unitRef="usd">224000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNjAtMi0xLTEtMA_eb3ec641-9849-488b-8218-d379202fa9e3"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV80Ni9mcmFnOjk2NGE0YjhkMDU5MTQzZjZiZDhmZTcwM2I1NjU3MTUyL3RhYmxlOmIyNjQxYTRhNDIyYTRjMzU4MWMyMWViN2NmZDc1NGI2L3RhYmxlcmFuZ2U6YjI2NDFhNGE0MjJhNGMzNTgxYzIxZWI3Y2ZkNzU0YjZfNjAtNC0xLTEtMA_4aa9fe54-7dd1-4e75-9667-19a5a9130d60"
      unitRef="usd">949000000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81Mi9mcmFnOjhhZDQ5NGE3MzUwNDRiN2Y5MWJkMGJhYjBjMTczMzI4L3RleHRyZWdpb246OGFkNDk0YTczNTA0NGI3ZjkxYmQwYmFiMGMxNzMzMjhfMjgyMQ_2b4d35d9-8d26-4bb8-90f6-14fbae1f476e">The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson &amp;amp; Johnson and its subsidiaries (the Company) and related notes as contained in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent to which COVID-19 impacts the Company&#x2019;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of October&#160;3, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#x2019;s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets along with the Company&#x2019;s on-going vaccine development and distribution efforts. While there was not a material impact to the Company&#x2019;s consolidated financial statements as of and for the quarter ended October&#160;3, 2021, the Company&#x2019;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#x2019;s consolidated financial statements in future reporting periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021. There were no new material accounting standards issued in the fiscal nine months of 2021 that impacted the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted in the fiscal nine months of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform to current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81Mi9mcmFnOjhhZDQ5NGE3MzUwNDRiN2Y5MWJkMGJhYjBjMTczMzI4L3RleHRyZWdpb246OGFkNDk0YTczNTA0NGI3ZjkxYmQwYmFiMGMxNzMzMjhfMjgyOA_cfd2f705-90c5-40f0-ac25-e679e293b435">&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent to which COVID-19 impacts the Company&#x2019;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of October&#160;3, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#x2019;s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets along with the Company&#x2019;s on-going vaccine development and distribution efforts. While there was not a material impact to the Company&#x2019;s consolidated financial statements as of and for the quarter ended October&#160;3, 2021, the Company&#x2019;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#x2019;s consolidated financial statements in future reporting periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81Mi9mcmFnOjhhZDQ5NGE3MzUwNDRiN2Y5MWJkMGJhYjBjMTczMzI4L3RleHRyZWdpb246OGFkNDk0YTczNTA0NGI3ZjkxYmQwYmFiMGMxNzMzMjhfMjgyOQ_75643b3a-89e4-4335-b6f9-17f3528f4a5c">&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021. There were no new material accounting standards issued in the fiscal nine months of 2021 that impacted the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted in the fiscal nine months of 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81Mi9mcmFnOjhhZDQ5NGE3MzUwNDRiN2Y5MWJkMGJhYjBjMTczMzI4L3RleHRyZWdpb246OGFkNDk0YTczNTA0NGI3ZjkxYmQwYmFiMGMxNzMzMjhfMjgzMA_a01ecbb8-5482-4558-8aae-580f96e5c0a5">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform to current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81NS9mcmFnOmJlYzgwOWIzNmRkYzQzMjM4M2NjNTQwM2ZjZTAwYjRlL3RleHRyZWdpb246YmVjODA5YjM2ZGRjNDMyMzgzY2M1NDAzZmNlMDBiNGVfMzI_5534e2ea-e5ef-4e23-b780-c4455879aee6">INVENTORIES &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.896%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goods in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81NS9mcmFnOmJlYzgwOWIzNmRkYzQzMjM4M2NjNTQwM2ZjZTAwYjRlL3RleHRyZWdpb246YmVjODA5YjM2ZGRjNDMyMzgzY2M1NDAzZmNlMDBiNGVfNDE_d0e02885-76df-47bb-8c93-f15f0b3822b1">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.896%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goods in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81NS9mcmFnOmJlYzgwOWIzNmRkYzQzMjM4M2NjNTQwM2ZjZTAwYjRlL3RhYmxlOjVlZWYxNGUxMWU2OTQ4MzI5Mjk2ZDk0YTU0OGRkMGU0L3RhYmxlcmFuZ2U6NWVlZjE0ZTExZTY5NDgzMjkyOTZkOTRhNTQ4ZGQwZTRfMS0yLTEtMS0w_b09a2c15-7c0d-40ca-84c2-be683d3c586e"
      unitRef="usd">1587000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81NS9mcmFnOmJlYzgwOWIzNmRkYzQzMjM4M2NjNTQwM2ZjZTAwYjRlL3RhYmxlOjVlZWYxNGUxMWU2OTQ4MzI5Mjk2ZDk0YTU0OGRkMGU0L3RhYmxlcmFuZ2U6NWVlZjE0ZTExZTY5NDgzMjkyOTZkOTRhNTQ4ZGQwZTRfMS00LTEtMS0w_f2b14104-8a3a-4856-a8d6-96e1551714bd"
      unitRef="usd">1410000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81NS9mcmFnOmJlYzgwOWIzNmRkYzQzMjM4M2NjNTQwM2ZjZTAwYjRlL3RhYmxlOjVlZWYxNGUxMWU2OTQ4MzI5Mjk2ZDk0YTU0OGRkMGU0L3RhYmxlcmFuZ2U6NWVlZjE0ZTExZTY5NDgzMjkyOTZkOTRhNTQ4ZGQwZTRfMi0yLTEtMS0w_92292c74-8461-4372-a30a-6df41efea8d7"
      unitRef="usd">2164000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81NS9mcmFnOmJlYzgwOWIzNmRkYzQzMjM4M2NjNTQwM2ZjZTAwYjRlL3RhYmxlOjVlZWYxNGUxMWU2OTQ4MzI5Mjk2ZDk0YTU0OGRkMGU0L3RhYmxlcmFuZ2U6NWVlZjE0ZTExZTY5NDgzMjkyOTZkOTRhNTQ4ZGQwZTRfMi00LTEtMS0w_2a870afd-4b56-402b-b3c2-67d5dd6c5400"
      unitRef="usd">2040000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81NS9mcmFnOmJlYzgwOWIzNmRkYzQzMjM4M2NjNTQwM2ZjZTAwYjRlL3RhYmxlOjVlZWYxNGUxMWU2OTQ4MzI5Mjk2ZDk0YTU0OGRkMGU0L3RhYmxlcmFuZ2U6NWVlZjE0ZTExZTY5NDgzMjkyOTZkOTRhNTQ4ZGQwZTRfMy0yLTEtMS0w_b95d9356-6d11-4d52-bcae-9db3a56efbfa"
      unitRef="usd">6636000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81NS9mcmFnOmJlYzgwOWIzNmRkYzQzMjM4M2NjNTQwM2ZjZTAwYjRlL3RhYmxlOjVlZWYxNGUxMWU2OTQ4MzI5Mjk2ZDk0YTU0OGRkMGU0L3RhYmxlcmFuZ2U6NWVlZjE0ZTExZTY5NDgzMjkyOTZkOTRhNTQ4ZGQwZTRfMy00LTEtMS0w_b9700c6d-d70e-496b-9786-efee215c36bc"
      unitRef="usd">5894000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81NS9mcmFnOmJlYzgwOWIzNmRkYzQzMjM4M2NjNTQwM2ZjZTAwYjRlL3RhYmxlOjVlZWYxNGUxMWU2OTQ4MzI5Mjk2ZDk0YTU0OGRkMGU0L3RhYmxlcmFuZ2U6NWVlZjE0ZTExZTY5NDgzMjkyOTZkOTRhNTQ4ZGQwZTRfNC0yLTEtMS0w_901b0067-af4d-450f-9647-f6a3c8d569a0"
      unitRef="usd">10387000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81NS9mcmFnOmJlYzgwOWIzNmRkYzQzMjM4M2NjNTQwM2ZjZTAwYjRlL3RhYmxlOjVlZWYxNGUxMWU2OTQ4MzI5Mjk2ZDk0YTU0OGRkMGU0L3RhYmxlcmFuZ2U6NWVlZjE0ZTExZTY5NDgzMjkyOTZkOTRhNTQ4ZGQwZTRfNC00LTEtMS0w_99966b39-c616-4d61-8668-4f6a59d8cb43"
      unitRef="usd">9344000000</us-gaap:InventoryNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RleHRyZWdpb246NGNiMTdhN2IzYjhhNGJkZWIwNGNhN2ViZTNhYjcyODBfMTM2MA_badba801-7ea0-4edc-b899-2a2dcbe42553">INTANGIBLE ASSETS AND GOODWILL&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2020. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with definite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks &#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,618)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks &#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles &#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,637)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,912)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles&#160;&#x2014; net*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with indefinite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased in-process research and development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets with indefinite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets &#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*The majority is comprised of customer relationships&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In the fiscal third quarter of 2021, the Company recorded a partial IPR&amp;amp;D impairment charge of $0.9&#160;billion primarily related to expected development delays in the general surgery digital robotics platform (Ottava) acquired with the Auris Health acquisition in 2019. The impairment charge was calculated based on revisions to the discounted cash flow valuation model reflecting a delay of first in human procedures of approximately two years from the initial acquisition model assumption of the second half of 2022. The remaining reduction was driven by assets that reached commercialization and are now classified as having definite lives.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill as of October&#160;3, 2021 was allocated by segment of business as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(347)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(817)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable intangible assets included in cost of products sold was $1.1 billion and $1.2&#160;billion for the fiscal third quarters ended October&#160;3, 2021 and September&#160;27, 2020, respectively. The amortization expense of amortizable intangible assets included in cost of products sold was $3.6&#160;billion and $3.4&#160;billion for the fiscal nine months ended October&#160;3, 2021 and September&#160;27, 2020, respectively. Intangible asset write-downs are included in Other (income) expense, net. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,700&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,300&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,600&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RleHRyZWdpb246NGNiMTdhN2IzYjhhNGJkZWIwNGNhN2ViZTNhYjcyODBfMTM3Mg_9abc5fbc-deaf-4ee8-ad08-f9be33d4ad44">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with definite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks &#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,618)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks &#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles &#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,637)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,912)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles&#160;&#x2014; net*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with indefinite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased in-process research and development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets with indefinite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets &#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*The majority is comprised of customer relationships&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In the fiscal third quarter of 2021, the Company recorded a partial IPR&amp;amp;D impairment charge of $0.9&#160;billion primarily related to expected development delays in the general surgery digital robotics platform (Ottava) acquired with the Auris Health acquisition in 2019. The impairment charge was calculated based on revisions to the discounted cash flow valuation model reflecting a delay of first in human procedures of approximately two years from the initial acquisition model assumption of the second half of 2022. The remaining reduction was driven by assets that reached commercialization and are now classified as having definite lives.&lt;/span&gt;&lt;/div&gt;</jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4743699b0eac46a588c10333167e9fae_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfMi0yLTEtMS0w_883dba75-6e36-4816-8ab4-9cf1ee7d4f56"
      unitRef="usd">39176000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i137acfc8e8824efc95e1265512dd13d9_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfMi00LTEtMS0w_abd363b7-8126-40c8-ad3b-be1e98fe618c"
      unitRef="usd">39990000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4743699b0eac46a588c10333167e9fae_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfMy0yLTEtMS0w_1ff4abf7-7402-401f-acb3-e3e4922526d3"
      unitRef="usd">19569000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i137acfc8e8824efc95e1265512dd13d9_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfMy00LTEtMS0w_da3c3af1-932d-4636-b10d-acf3974b6eaa"
      unitRef="usd">17618000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4743699b0eac46a588c10333167e9fae_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfNC0yLTEtMS0w_22120f7b-02d6-40de-9c51-575cfaf5b10d"
      unitRef="usd">19607000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i137acfc8e8824efc95e1265512dd13d9_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfNC00LTEtMS0w_e37bb6db-cf81-4c1a-8b33-6f5e37a91073"
      unitRef="usd">22372000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7121dbd0cc754e319650cfe1e9a6d091_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfNS0yLTEtMS0w_a590b91a-c7d0-48ce-a613-f956d58c0a95"
      unitRef="usd">22950000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i364bae74581b41469b167f1d57b47bec_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfNS00LTEtMS0w_0f3f21d3-a1ea-4125-be9b-f431a0febff0"
      unitRef="usd">22898000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7121dbd0cc754e319650cfe1e9a6d091_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfNi0yLTEtMS0w_ecbc5ffd-4cf8-4061-b500-94dacc84fdb7"
      unitRef="usd">11637000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i364bae74581b41469b167f1d57b47bec_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfNi00LTEtMS0w_cf806e46-4a42-46e0-9fbe-30d5432bc950"
      unitRef="usd">10912000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7121dbd0cc754e319650cfe1e9a6d091_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfNy0yLTEtMS0w_ad20cfc2-1c0e-4f36-9d0e-e1753e5df025"
      unitRef="usd">11313000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i364bae74581b41469b167f1d57b47bec_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfNy00LTEtMS0w_50523b2a-61ae-4a1f-9bc4-877227c78293"
      unitRef="usd">11986000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iba2272c30bea4b1482458fce855c3373_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfOS0yLTEtMS0w_8265ea09-611c-4423-ab4c-3937004c9f50"
      unitRef="usd">7013000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i306786a4d54f459696c4fb7907f30ea4_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfOS00LTEtMS0w_3982111a-00d8-4d09-ac30-47498df895c5"
      unitRef="usd">7195000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="idc12ecbfad9b4436a408325ad670fee4_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfMTAtMi0xLTEtMA_dfbeb821-67c4-4bdc-b77c-7245dfe75103"
      unitRef="usd">9843000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i6550a842150844a782974595356be4c8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfMTAtNC0xLTEtMA_91b867f6-208f-455a-abb7-94b37a9b0654"
      unitRef="usd">11849000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfMTEtMi0xLTEtMA_56997be2-7b83-48f3-96d4-db3ea7063417"
      unitRef="usd">16856000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfMTEtNC0xLTEtMA_87f26ba6-49d6-4ebd-b05f-bb901749a21b"
      unitRef="usd">19044000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfMTItMi0xLTEtMA_802ff4c6-259c-415f-8673-3995ff2baeaf"
      unitRef="usd">47776000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjY0ZjU5NzZhYjZjYjQ3OWM4ZWMxZjI4NjNhZmM5N2YxL3RhYmxlcmFuZ2U6NjRmNTk3NmFiNmNiNDc5YzhlYzFmMjg2M2FmYzk3ZjFfMTItNC0xLTEtMA_7e3b59e2-2ef3-4b99-9f02-051149d9ab2d"
      unitRef="usd">53402000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ie9431acda5084235a9355798c8cc8b2e_D20210705-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RleHRyZWdpb246NGNiMTdhN2IzYjhhNGJkZWIwNGNhN2ViZTNhYjcyODBfMTA5OTUxMTYyODEwNDE_66bcb73a-d579-4fbf-815f-7c264c81ab40"
      unitRef="usd">900000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RleHRyZWdpb246NGNiMTdhN2IzYjhhNGJkZWIwNGNhN2ViZTNhYjcyODBfMTM2OA_489fbdde-26ac-4a46-8418-dea4d62906a5">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill as of October&#160;3, 2021 was allocated by segment of business as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(347)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(817)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i58d78224ae6d43cf95b5735d5bb3dabb_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfMS0yLTEtMS0w_57b9b761-0f4c-4272-b343-81d18c05b928"
      unitRef="usd">10336000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i1a29aa136e144ef7a4209eb7a9897d36_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfMS00LTEtMS0w_6d0f79a0-a447-4cf3-ad5c-d20cdfff55a3"
      unitRef="usd">11009000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0fbb196ddcb14beaa7a23bd9de26d3d9_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfMS02LTEtMS0w_35e2fa39-d5c1-4642-a7aa-7885f268dd9f"
      unitRef="usd">15048000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfMS04LTEtMS0w_ba69f65d-28ec-4dfb-a7ed-f3b6dfc6d779"
      unitRef="usd">36393000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i185910f7181845c8aed38c39fd4b6cab_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfMi0yLTEtMS0w_c681827e-cd2f-4c29-a1ae-db92e42c082a"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i18c6f67375de464e98be9b5c858a0996_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfMi00LTEtMS0w_a4db8fac-887c-4c32-96fe-822f922f6e03"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="if7fc25fc53e54e21948d2ce281e9424a_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfMi02LTEtMS0w_b384113e-508f-4a04-a5dc-745881250630"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfMi04LTEtMS0w_55a16563-b4f3-4d54-a34f-778608387f25"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i185910f7181845c8aed38c39fd4b6cab_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfMy0yLTEtMS0w_2d6f850e-50aa-42c2-b2fb-2ea59e47575e"
      unitRef="usd">7000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i18c6f67375de464e98be9b5c858a0996_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfMy00LTEtMS0w_0fd22655-cd87-40a8-8f92-59b58d34fbb9"
      unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="if7fc25fc53e54e21948d2ce281e9424a_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfMy02LTEtMS0w_806da089-b73d-4e08-a94f-6094eb674596"
      unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfMy04LTEtMS0w_f5461482-6196-491c-b186-e3c3fb18d574"
      unitRef="usd">7000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i185910f7181845c8aed38c39fd4b6cab_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfNC0yLTEtMS0w_6ded8070-3fba-4cee-ac7e-4b3af74da0be"
      unitRef="usd">-347000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i18c6f67375de464e98be9b5c858a0996_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfNC00LTEtMS0w_36920655-659c-4068-8e52-e3c4838c3a10"
      unitRef="usd">-283000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="if7fc25fc53e54e21948d2ce281e9424a_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfNC02LTEtMS0w_0b8a5db3-ff97-4a18-9a2f-1970b612fbf4"
      unitRef="usd">-187000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfNC04LTEtMS0w_1c3f8c24-889d-4816-9b5b-7868aa363c8d"
      unitRef="usd">-817000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="i64662abe386b4a3b9044b4dbcffe47d5_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfNS0yLTEtMS0w_9e323bc4-eaf1-4168-b6e4-7431f574387c"
      unitRef="usd">9982000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ia53808fcfd3f400c939324049330ed77_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfNS00LTEtMS0w_23210948-d572-4713-b264-cf36be1140fd"
      unitRef="usd">10726000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i97512951ea1746ff957df24ca33bf674_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfNS02LTEtMS0w_015a5460-3473-4535-b071-7d9fa47d252c"
      unitRef="usd">14861000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOjU3MDljZTU3YjVkNzRhMDc5NTI5ZjAwMmUzZjk0MzBiL3RhYmxlcmFuZ2U6NTcwOWNlNTdiNWQ3NGEwNzk1MjlmMDAyZTNmOTQzMGJfNS04LTEtMS0w_45739ec8-3431-491e-a83a-ed9c1b7acbff"
      unitRef="usd">35569000000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i69229a2a50d442b795aa18fa30c26be4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RleHRyZWdpb246NGNiMTdhN2IzYjhhNGJkZWIwNGNhN2ViZTNhYjcyODBfNjQx_7505ebb3-4816-4c05-aedb-cf29a884ca54">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="if2f30918b36c48df9f73661bf07e071b_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RleHRyZWdpb246NGNiMTdhN2IzYjhhNGJkZWIwNGNhN2ViZTNhYjcyODBfNzUw_e0cbce91-a617-41ab-b9bf-ff23fe467bfb">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RleHRyZWdpb246NGNiMTdhN2IzYjhhNGJkZWIwNGNhN2ViZTNhYjcyODBfODU2_1e9776ea-6cf0-4d5c-864c-bad97249c960"
      unitRef="usd">1100000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RleHRyZWdpb246NGNiMTdhN2IzYjhhNGJkZWIwNGNhN2ViZTNhYjcyODBfODYz_71bca403-294e-46ca-be33-16bd94a1a901"
      unitRef="usd">1200000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RleHRyZWdpb246NGNiMTdhN2IzYjhhNGJkZWIwNGNhN2ViZTNhYjcyODBfOTk4_36a10177-4e2a-4119-8e71-fc5ca3547672"
      unitRef="usd">3600000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RleHRyZWdpb246NGNiMTdhN2IzYjhhNGJkZWIwNGNhN2ViZTNhYjcyODBfMTAwNQ_de4d0089-1963-41d5-93c9-9353b447ef35"
      unitRef="usd">3400000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RleHRyZWdpb246NGNiMTdhN2IzYjhhNGJkZWIwNGNhN2ViZTNhYjcyODBfMTM2OQ_ebe7ebb5-fdca-4ebd-bc09-238a44597de2">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,700&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,300&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,600&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOmYxZjhmMDIyOTIxYjQ5ODA5ODQ3M2NiOWY4YTUzMDU1L3RhYmxlcmFuZ2U6ZjFmOGYwMjI5MjFiNDk4MDk4NDczY2I5ZjhhNTMwNTVfMi0wLTEtMS0w_70f03c3c-ba33-4c9a-b9f2-a9baa1566493"
      unitRef="usd">4700000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOmYxZjhmMDIyOTIxYjQ5ODA5ODQ3M2NiOWY4YTUzMDU1L3RhYmxlcmFuZ2U6ZjFmOGYwMjI5MjFiNDk4MDk4NDczY2I5ZjhhNTMwNTVfMi0yLTEtMS0w_522aa1aa-af24-4d4e-b1c3-c226897fd00f"
      unitRef="usd">4500000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOmYxZjhmMDIyOTIxYjQ5ODA5ODQ3M2NiOWY4YTUzMDU1L3RhYmxlcmFuZ2U6ZjFmOGYwMjI5MjFiNDk4MDk4NDczY2I5ZjhhNTMwNTVfMi00LTEtMS0w_f79de7b7-d246-4e1b-9c38-836734e4c589"
      unitRef="usd">4500000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOmYxZjhmMDIyOTIxYjQ5ODA5ODQ3M2NiOWY4YTUzMDU1L3RhYmxlcmFuZ2U6ZjFmOGYwMjI5MjFiNDk4MDk4NDczY2I5ZjhhNTMwNTVfMi02LTEtMS0w_b9171d47-38b1-47e5-8c87-62a43a7e8246"
      unitRef="usd">4300000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV81OC9mcmFnOjRjYjE3YTdiM2I4YTRiZGViMDRjYTdlYmUzYWI3MjgwL3RhYmxlOmYxZjhmMDIyOTIxYjQ5ODA5ODQ3M2NiOWY4YTUzMDU1L3RhYmxlcmFuZ2U6ZjFmOGYwMjI5MjFiNDk4MDk4NDczY2I5ZjhhNTMwNTVfMi04LTEtMS0w_978415ed-f28b-4af5-8328-c3ec5913a8bf"
      unitRef="usd">3600000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTIwMDM_81c4997e-f023-4e17-bba2-90499d5b690b">FAIR VALUE MEASUREMENTS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings.  These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of October&#160;3, 2021, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $202 million net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating.  Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of October&#160;3, 2021, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $45.8&#160;billion, $35.1&#160;billion and $10.0&#160;billion, respectively. As of January&#160;3, 2021, the Company had notional amounts outstanding for forward foreign exchange contracts and cross currency interest rate swaps of $37.8 billion and $30.6 billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur.  Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of October&#160;3, 2021, the balance of deferred net gain on derivatives included in accumulated other comprehensive income was $21&#160;million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and &lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;net investment hedge&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to derivatives and hedges for the fiscal third quarters ended in 2021 and 2020, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The effects of fair value, net investment and cash flow hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on fair value hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Hedged items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on net investment hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on cash flow hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forward foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to derivatives and hedges for the fiscal nine months ended in 2021 and 2020, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.493%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.302%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.760%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The effects of fair value, net investment and cash flow hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on fair value hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Hedged items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on net investment hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on cash flow hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forward foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(316)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of  October&#160;3, 2021, and January&#160;3, 2021, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Line item in the Consolidated Balance Sheet in which the hedged item is included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Amount of the Hedged Liability&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of derivatives not designated as hedging instruments for the fiscal third quarters and fiscal nine months in 2021 and 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.277%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.149%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain /(Loss) Recognized in Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal Third Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign Exchange Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of net investment hedges for the fiscal third quarters ended in 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.959%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Accumulated&lt;br/&gt;OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From&lt;br/&gt;Accumulated OCI&lt;br/&gt;Into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross Currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of net investment hedges for the fiscal nine months ended in 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.725%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.758%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.080%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="33" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Accumulated OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From&lt;br/&gt;Accumulated OCI&lt;br/&gt;Into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross Currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values.  The Company has elected to measure equity investments that do not have readily determinable fair &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to equity investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.476%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.464%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in Fair Value Reflected in Net Income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales/ Purchases/Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non Current Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments with readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Recorded in Other Income/Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other includes impact of currency&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For equity investments without readily determinable market values, there was a decrease of $25 million in the fair value reflected in net income as a result of impairments. There was an offsetting increase of  $417 million in the fair value reflected in net income due to changes in observable prices and gains on the disposal of the Grail investment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#x2019;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following three levels of inputs are used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 &#x2014; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 &#x2014; Significant other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 &#x2014; Significant unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant financial assets and liabilities measured at fair value as of October&#160;3, 2021 and January&#160;3, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross to Net Derivative Reconciliation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about changes in liabilities for contingent consideration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;2020 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,481 million, which are classified as Level 1 and contingent consideration of $633 million, classified as Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)     &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Includes cross currency interest rate swaps and interest rate swaps as of October&#160;3, 2021. Includes cross currency interest rate swaps as of January&#160;3, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;           (3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Classified as non-current other assets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Includes $595 million and $594 million, classified as non-current other liabilities as of October&#160;3, 2021 and January&#160;3, 2021, respectively.  Includes $18 million and $39 million classified as current liabilities as of October&#160;3, 2021 and January&#160;3, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;           (6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded a contingent consideration reversal of $1,148 million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense, net. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's cash, cash equivalents and current marketable securities as of October&#160;3, 2021 comprised:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.182%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. sovereign securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Gov't securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other sovereign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Subtotal available for sale debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and current marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the fiscal year ended January&#160;3, 2021 the carrying amount was approximately the same as the estimated fair value.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of the available for sale securities as of October&#160;3, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.279%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Instruments not measured at Fair Value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following financial liabilities are held at carrying amount on the consolidated balance sheet as of October&#160;3, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73% Debentures due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.05% Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.650% Notes due 2024 (750MM Euro 1.1581)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% Notes due 2024 (500 MM GBP 1.3465)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.625% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.55% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90%&#160;Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.150% Notes due 2028 (750MM Euro 1.1581)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.95% Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95% Debentures due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.650% Notes due 2035 (1.5B Euro 1.1581)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.55% Notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40%&#160;Notes due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85% Debentures due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Debentures due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.10% Notes due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.85% Notes due 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70% Notes due 2046&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Notes due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50% Notes due 2048&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% Notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2060&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Non-Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average effective interest rate on non-current debt is 2.98%.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the estimated fair value over the carrying value of debt was $5.4 billion at January 3, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The current debt balance as of October&#160;3, 2021 includes $1.3&#160;billion of commercial paper which has a weighted average interest rate of 0.08% and a weighted average maturity of approximately three months.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CollateralAlreadyPostedAggregateFairValue
      contextRef="i386cee1639274652826fd3eed1982a70_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTY0Nw_70980c3d-c3da-41bb-b7fc-a2a21a69b669"
      unitRef="usd">202000000</us-gaap:CollateralAlreadyPostedAggregateFairValue>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i386cee1639274652826fd3eed1982a70_I20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMjMyMg_0ebe033a-a471-406f-b119-ae918b3c642a"
      unitRef="usd">45800000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i0e0add53586f4fb29f2838afbf423ad7_I20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMjMyNg_f7ddfadb-bc57-4ceb-87f7-1846c07cd5e3"
      unitRef="usd">35100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic9852777165f4b609444e7127f04f202_I20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMjMzMw_3c420163-6be4-4149-a3de-768653822363"
      unitRef="usd">10000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i7c4d270b6af043e9be04d479dec5dd5c_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMjQ4Ng_d33c1d6f-480a-42f9-a888-0c69dcbb3db5"
      unitRef="usd">37800000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ib219ae64b99744eaa1b7b8cc1067daf8_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMjQ5Mw_47d5c8f2-9888-467c-93ac-024582f8baa8"
      unitRef="usd">30600000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfNDYyNA_f5985c67-4fd8-4867-aaeb-e0f3d52ad043"
      unitRef="usd">-21000000</us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax>
    <us-gaap:DescriptionOfReclassificationOfCashFlowHedgeGainLoss
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfNDg4Mg_d3f8a00d-1eb3-434a-8f2b-06c3c438d922">next 12 months</us-gaap:DescriptionOfReclassificationOfCashFlowHedgeGainLoss>
    <us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfNTA0Mw_f1faa43c-bedb-4ffb-8fe4-a3e0f05aca86">P18M</us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTE5NzI_5b45fce2-09c1-402f-bd3c-d0bf22bd769c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to derivatives and hedges for the fiscal third quarters ended in 2021 and 2020, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The effects of fair value, net investment and cash flow hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on fair value hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Hedged items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on net investment hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on cash flow hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forward foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to derivatives and hedges for the fiscal nine months ended in 2021 and 2020, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.493%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.302%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.760%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The effects of fair value, net investment and cash flow hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on fair value hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Hedged items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on net investment hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on cash flow hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forward foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(316)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of net investment hedges for the fiscal third quarters ended in 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.959%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Accumulated&lt;br/&gt;OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From&lt;br/&gt;Accumulated OCI&lt;br/&gt;Into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross Currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of net investment hedges for the fiscal nine months ended in 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.725%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.758%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.080%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="33" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Accumulated OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From&lt;br/&gt;Accumulated OCI&lt;br/&gt;Into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross Currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i9dd7f04c9cf442d09d8944a1200e4e9e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOC0xLTEtMS0w_4a8084a8-256a-4957-8539-8017cdd0ea7e"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i2446fd6831b74f84a1fbc08826466b5a_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOC0yLTEtMS0w_1d12d80e-63d1-4a62-b884-7c7066190835"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i5373c09ac6424f71abea9a4af34fad8d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOC0zLTEtMS0w_075c034e-515b-4ed4-99a7-253c91801567"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ia29eda1bae054029be22f80a32d9bed0_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOC00LTEtMS0w_328644f6-c823-443a-b8db-cc99acc8c95c"
      unitRef="usd">-62000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="id1176d5e87c548cf8e03d248b438c1fd_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOC01LTEtMS0w_0ec60514-8ca6-4714-a883-40f7670280f3"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i46ddf01a2ed04decb15a346373711b4b_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOC02LTEtMS0w_b51c54f9-af66-478e-be91-0946e2437d9c"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="iaf5522e302034e189c307e49dc73197d_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOC03LTEtMS0w_61c84224-87c4-4725-aa10-2f76e1360865"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i58a7e978302f42b1aa90a38f29c5a34b_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOC04LTEtMS0w_255d4723-e581-4c49-afd4-6a3e9c275371"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i77a7f12df0b140499e72c6c5292e080d_D20200629-20200927"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOC05LTEtMS0w_cd2011bf-1573-45bd-93c5-962564e76ccb"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i513a49e58ab74680ba8b509c23674bf0_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOC0xMC0xLTEtMA_c797444e-67d9-4352-9dfb-3d17624eed31"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i9dd7f04c9cf442d09d8944a1200e4e9e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOS0xLTEtMS0w_a3b8fc1f-5d15-4d3d-ab14-9d93888d0437"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i2446fd6831b74f84a1fbc08826466b5a_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOS0yLTEtMS0w_7d8d3b74-2e6e-45b0-adb6-618b4a6f90e9"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i5373c09ac6424f71abea9a4af34fad8d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOS0zLTEtMS0w_7d041443-0f5a-49f7-a88a-f50d4511a7df"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ia29eda1bae054029be22f80a32d9bed0_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOS00LTEtMS0w_84cf890b-c185-4745-8579-7780ef4b4e71"
      unitRef="usd">62000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="id1176d5e87c548cf8e03d248b438c1fd_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOS01LTEtMS0w_7bab8f44-2468-4cb6-9bc5-20b519d1bc9e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i46ddf01a2ed04decb15a346373711b4b_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOS02LTEtMS0w_6573a2ef-4e85-4e4b-beb7-868763133176"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="iaf5522e302034e189c307e49dc73197d_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOS03LTEtMS0w_df8e3b11-117f-4cc8-8f0a-0f3de4eaabf3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i58a7e978302f42b1aa90a38f29c5a34b_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOS04LTEtMS0w_f1e74876-7390-422d-91a7-c030da2d75aa"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i77a7f12df0b140499e72c6c5292e080d_D20200629-20200927"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOS05LTEtMS0w_be31544e-5b5b-42cd-bd8d-0f94c6eb2da8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i513a49e58ab74680ba8b509c23674bf0_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfOS0xMC0xLTEtMA_1237809d-872b-49d9-b716-78d72f17ae4b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i48e5c25b196b4581a673892969bb5051_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTMtMS0xLTEtMA_b52fb450-d113-4ecd-b08e-5f3b04e45f77"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i93e401f2dd5c4ea586defab03d5e9b30_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTMtMi0xLTEtMA_6ccfe44a-e971-4d05-b17c-1c2147b7ad6c"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i4c72adb013a948e8a95c6b4603152001_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTMtMy0xLTEtMA_30eec87b-4a1f-4f9d-ad2d-15c7e62a001d"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i82e5fff9c6bd45ca997965825f96a0d3_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTMtNC0xLTEtMA_45b3740e-14ee-44a9-aa84-5b1d8aaa3208"
      unitRef="usd">34000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i99216cc8b79445dd8a6169989e70f809_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTMtNS0xLTEtMA_60287edd-a2f0-4294-8144-57a3ca4cd1c1"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ibfc2d51c1b3943179426ac0f6638ea2b_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTMtNi0xLTEtMA_8987bae5-569f-4ab4-90b1-4f3d5ce5ff68"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i3b598c35682943d4aa693d58ad7185a7_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTMtNy0xLTEtMA_26a2196e-105d-43a1-8636-32df2a2ce6a4"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="id0ccfa0f2f3043db8ffb4dd5132378b0_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTMtOC0xLTEtMA_495c5288-c5ce-4eca-9d56-fee0ec351024"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i77bd06875cea40cbacd7c9e2c6e60de2_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTMtOS0xLTEtMA_38405ccd-5e3d-42fa-93e3-2bd8e62bdbb4"
      unitRef="usd">39000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ia171152160c9457eaf8a8198b50831df_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTMtMTAtMS0xLTA_2431ee5d-630f-436b-994e-ea92c31dc4ec"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i48e5c25b196b4581a673892969bb5051_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTQtMS0xLTEtMA_9ba11c8d-c6a7-45c8-af13-688a31aae279"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i93e401f2dd5c4ea586defab03d5e9b30_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTQtMi0xLTEtMA_aa1878d8-0a7f-472c-87f7-3b821cba4945"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i4c72adb013a948e8a95c6b4603152001_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTQtMy0xLTEtMA_7b898e52-0dbd-43d1-b7e1-fd64afda6beb"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i82e5fff9c6bd45ca997965825f96a0d3_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTQtNC0xLTEtMA_9f49bff0-72ba-4fed-aa8d-f0ab2cab2947"
      unitRef="usd">34000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i99216cc8b79445dd8a6169989e70f809_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTQtNS0xLTEtMA_283e61b1-555d-43fc-aba4-c764b929d97b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ibfc2d51c1b3943179426ac0f6638ea2b_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTQtNi0xLTEtMA_3f1faf95-d28c-47c5-84cd-261cbc9c5478"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i3b598c35682943d4aa693d58ad7185a7_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTQtNy0xLTEtMA_062a8334-178e-402a-8754-03b500d2cae5"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="id0ccfa0f2f3043db8ffb4dd5132378b0_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTQtOC0xLTEtMA_df790f4a-92ff-4425-baa9-9ba2d9e27737"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i77bd06875cea40cbacd7c9e2c6e60de2_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTQtOS0xLTEtMA_a562552e-8ae5-4056-9e6e-9257ca4c2d9a"
      unitRef="usd">39000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ia171152160c9457eaf8a8198b50831df_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTQtMTAtMS0xLTA_2c6e4da1-0d7d-44e3-8192-ac5e864948a1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i5c22296c638b499dacba432243aabb21_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTgtMS0xLTEtMA_9de2667d-6073-4f4d-833e-1ecfdab8bf8f"
      unitRef="usd">-3000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ief08f28671bd449f85c45b2524dc11fd_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTgtMi0xLTEtMA_3e02083d-481d-475c-873f-d13da4d95b45"
      unitRef="usd">58000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i0490b39cdf9e468d851a818d788fa90a_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTgtMy0xLTEtMA_b7a0c252-e902-4fd3-a5da-3987147e799f"
      unitRef="usd">8000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i767f5c4625154f0a8f7d74c8b8c3a35e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTgtNC0xLTEtMA_9c69421f-adeb-4c61-ad7e-a445c7bf7e29"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i0c775ffd78004ecbaf03812778b4fb63_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTgtNS0xLTEtMA_b9975819-18c2-4076-8b7c-d4ba5c1fd42e"
      unitRef="usd">19000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i15408f87a30b40a48076e15baf08bf94_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTgtNi0xLTEtMA_b5762c6a-42cd-4513-82e7-d0150aef417b"
      unitRef="usd">3000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i7b90f9340101469daec861ce7a7fc255_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTgtNy0xLTEtMA_aacd016c-cf3c-4d4a-906b-dead025f93dd"
      unitRef="usd">-81000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i19054c05c6034f23a0b61aa630e73505_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTgtOC0xLTEtMA_97ed75f6-3182-4f77-889a-e773f3316b70"
      unitRef="usd">-13000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i469f78b5da314cda95613d4aba1df12c_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTgtOS0xLTEtMA_6024be83-7d63-4053-bf5e-021d54640870"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ia3d4899630c6450886e61d01be554303_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMTgtMTAtMS0xLTA_ef2212b8-9fd6-4dd8-a6c1-b44aaa732273"
      unitRef="usd">-8000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i5c22296c638b499dacba432243aabb21_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjItMS0xLTEtMA_5219b3d0-94b6-4365-93e0-3df134ba30b7"
      unitRef="usd">-35000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ief08f28671bd449f85c45b2524dc11fd_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjItMi0xLTEtMA_56f84661-d15e-4cc2-9698-1326dcf2d33d"
      unitRef="usd">-155000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i0490b39cdf9e468d851a818d788fa90a_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjItMy0xLTEtMA_ef0f9130-5985-4c36-a56e-86c356f795e5"
      unitRef="usd">37000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i767f5c4625154f0a8f7d74c8b8c3a35e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjItNC0xLTEtMA_2cd36abb-cdfb-45d3-abee-8ef9ee3b9e3e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i0c775ffd78004ecbaf03812778b4fb63_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjItNS0xLTEtMA_4776691f-3545-49f8-977a-498a44488bf9"
      unitRef="usd">42000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i15408f87a30b40a48076e15baf08bf94_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjItNi0xLTEtMA_789cde46-58f5-41e8-8de6-a79ab2501993"
      unitRef="usd">16000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i7b90f9340101469daec861ce7a7fc255_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjItNy0xLTEtMA_360cf74a-a81f-4905-9681-e2baf2446dab"
      unitRef="usd">156000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i19054c05c6034f23a0b61aa630e73505_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjItOC0xLTEtMA_0c1ccd3d-80a4-4d94-a873-5dd1b99afb9b"
      unitRef="usd">-36000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i469f78b5da314cda95613d4aba1df12c_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjItOS0xLTEtMA_56c929db-3d56-4e5c-afbe-65607fbe31f1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ia3d4899630c6450886e61d01be554303_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjItMTAtMS0xLTA_40159af1-b91f-4bcf-975d-3ac5ed711596"
      unitRef="usd">-41000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ic0786ff8f130406bb2514f5c91f8a2a8_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjUtMS0xLTEtMA_6cb3e5d7-313c-49b6-b563-3ebb0ab4cdd9"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i9d4a0150b247424e98fb6ecbe5b9c39d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjUtMi0xLTEtMA_f8ec77e6-5d44-4272-9e08-7ce520eb56ca"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i078ef827e4f344eab96812a9740e1239_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjUtMy0xLTEtMA_bea723d2-8e7e-431f-b17d-1618b4000c68"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ie49f82a46b424edcab630d17792da6b8_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjUtNC0xLTEtMA_3acb7194-d5dd-4720-a79c-ec8e681068e7"
      unitRef="usd">117000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i204468adffd143848aaaba487ce0a656_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjUtNS0xLTEtMA_f58e24bc-d196-46b5-ba4f-e587b3ca6266"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="id01b13e20bd947928cfc3ced046acd64_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjUtNi0xLTEtMA_bfa72aca-f13e-441a-9f7b-fc9fe38a840b"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i3753d069b34e42ffa037aa3a221eec25_D20200629-20200927"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjUtNy0xLTEtMA_c4e533fb-36d0-4de1-a733-b6d85e41aeaa"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i0a8c3429d9ff41b7b0f85c7d87dad8f8_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjUtOC0xLTEtMA_4f61d884-2a53-4da1-b61f-0057fd052e2c"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="iafc5d51a497748cc9ad72884ab239bfb_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjUtOS0xLTEtMA_d8891fd7-264c-4d66-8a22-305482dc86c9"
      unitRef="usd">84000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="iffc2ba0506404c9d92c54405efa208bf_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjUtMTAtMS0xLTA_fc5528e4-4633-416f-ac19-f0eac2d15952"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ic0786ff8f130406bb2514f5c91f8a2a8_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjctMS0xLTEtMA_7c574b72-613c-40db-a2ae-74c319b70c1c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i9d4a0150b247424e98fb6ecbe5b9c39d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjctMi0xLTEtMA_09e4fd9d-191c-4e1e-905d-74a872d7f190"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i078ef827e4f344eab96812a9740e1239_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjctMy0xLTEtMA_e60fd4ff-f223-4c93-af20-285d073da639"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ie49f82a46b424edcab630d17792da6b8_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjctNC0xLTEtMA_0e11c815-c525-4198-ae5b-347eeebb9cd8"
      unitRef="usd">144000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i204468adffd143848aaaba487ce0a656_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjctNS0xLTEtMA_60b5f9ff-2a40-41c4-9f38-716aa924e5e5"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="id01b13e20bd947928cfc3ced046acd64_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjctNi0xLTEtMA_976233df-d018-4da4-acef-e4bc5169311a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i3753d069b34e42ffa037aa3a221eec25_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjctNy0xLTEtMA_a2733944-c950-48a6-ad13-c763a6b9f739"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i0a8c3429d9ff41b7b0f85c7d87dad8f8_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjctOC0xLTEtMA_63a48950-9ebf-48ac-83d2-1391145bf17d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="iafc5d51a497748cc9ad72884ab239bfb_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjctOS0xLTEtMA_33112ee8-9764-4bcb-b91c-3be520e9ab6d"
      unitRef="usd">65000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="iffc2ba0506404c9d92c54405efa208bf_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmZlYjdkNGNhODQxMTQ3ZGZiZTdlM2E2ODM2NGMzMTBjL3RhYmxlcmFuZ2U6ZmViN2Q0Y2E4NDExNDdkZmJlN2UzYTY4MzY0YzMxMGNfMjctMTAtMS0xLTA_9d48aca6-05d5-4f3d-bafd-170353f3be58"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="id97c9bcc0a104ab4bf86bb77681a798a_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOC0xLTEtMS0w_8516b669-2865-4b54-9919-aed6a4674a85"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i36e6f6c2b8274124a6cd37dfbbe9c6fb_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOC0yLTEtMS0w_c6c29bc8-f127-4ff3-a74b-4ac31fccad51"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="if264742b6d944aba8d0e08c08df83a8e_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOC0zLTEtMS0w_9a146e82-42a5-4e89-b8c7-6a8612270f15"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i5c801cb847184a7894fc5ff4b0c3f468_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOC00LTEtMS0w_5ca81942-e620-4353-91d3-0c97427eaebb"
      unitRef="usd">-56000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i515bd1a2d43148349fd6ab9f0a2255e3_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOC01LTEtMS0w_7eb56207-7db8-4130-b87a-262daf803641"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ia8a28c76f65e4001af98e0f096fb76b2_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOC02LTEtMS0w_dac6241a-0442-4c4b-8a07-64516065fc8a"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i3ade907d675d4c8c99740caca6ebd135_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOC03LTEtMS0w_49c1c8f9-0d1f-4cbf-899c-274669bbd3a8"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i6e9d30cc4cfc488a862a5885738d2f05_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOC04LTEtMS0w_08f058a5-e396-4d92-9b0d-6c39370bb989"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="icb60c19364b242d6917f7472855f3905_D20191230-20200927"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOC05LTEtMS0w_745a7b70-c267-428b-aef4-dd3249c29500"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i2c2b9f86e3934a9b831632fa60e4ba21_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOC0xMC0xLTEtMA_fc15b3d7-f04f-4fe1-8c2b-f9f6310e1e49"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="id97c9bcc0a104ab4bf86bb77681a798a_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOS0xLTEtMS0w_073ca979-f210-4b24-90c7-dc31ba1dd821"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i36e6f6c2b8274124a6cd37dfbbe9c6fb_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOS0yLTEtMS0w_70eeda2d-ce61-48d9-a359-58b3779fe444"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="if264742b6d944aba8d0e08c08df83a8e_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOS0zLTEtMS0w_ad59d84f-6b03-4f0b-91ea-ac98687d4488"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i5c801cb847184a7894fc5ff4b0c3f468_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOS00LTEtMS0w_7a37ce50-5714-42ac-9a1a-b923515b6e98"
      unitRef="usd">56000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i515bd1a2d43148349fd6ab9f0a2255e3_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOS01LTEtMS0w_9fa9c6d9-e393-4ef1-8f49-ddcd53b8bacc"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ia8a28c76f65e4001af98e0f096fb76b2_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOS02LTEtMS0w_94be00f8-620a-4209-94e7-07aab3a5c943"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i3ade907d675d4c8c99740caca6ebd135_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOS03LTEtMS0w_93f95d70-29fb-4757-8ea6-6b6ba98681cc"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i6e9d30cc4cfc488a862a5885738d2f05_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOS04LTEtMS0w_b284e6ac-2a67-4d44-a7f3-e538b62487a0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="icb60c19364b242d6917f7472855f3905_D20191230-20200927"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOS05LTEtMS0w_12e1a0b4-1f35-4ac3-abb2-62efa8c34874"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i2c2b9f86e3934a9b831632fa60e4ba21_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfOS0xMC0xLTEtMA_230bfebd-c571-43ec-a4a1-84a3f30e2229"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="id0141e2177d24be384d24197d458ffe0_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTMtMS0xLTEtMA_3f365533-f1ac-4289-9619-6c7e5c34dc17"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i6256db6dc0054ac18b141ae33e5ad29f_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTMtMi0xLTEtMA_d3c7dbf5-9ddb-4766-b706-0e1bcee9b069"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i8631e8b6ef484669be037922391c299d_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTMtMy0xLTEtMA_2a53b440-bec3-4552-b469-fc1a1dcb5174"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ief5d0c9bb17948d6a1b2d29d6f8c062d_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTMtNC0xLTEtMA_aa8d0950-9e3f-421a-9c19-2ded3ab6f4f9"
      unitRef="usd">115000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ic8470a3d16a94257810c1ec46751fcbd_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTMtNS0xLTEtMA_3feb889b-df4a-42c2-a940-827422c862c5"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i91a4caee55e84fdb8343347b7638a55e_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTMtNi0xLTEtMA_94088f67-e966-4494-ba73-b821dfb6f4bd"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i5e79014ed177468abd91b03922e18af0_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTMtNy0xLTEtMA_58bb2287-6566-4f73-9ecf-09ebf9cf8e1b"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i7b8df8e17a0f46c78ae91bd6ad3784ba_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTMtOC0xLTEtMA_90c7b878-cb34-4245-9328-58f9709e9f9a"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i7b9ff999f4544965b285cfeb8d1a0cb1_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTMtOS0xLTEtMA_e742c30d-985c-4e82-8dc7-167f0c220077"
      unitRef="usd">118000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i6bf2c274ee034f6688bb999de3bbb518_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTMtMTAtMS0xLTA_dc6d25db-c1f2-4ced-a30c-ffd1b9d6173b"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="id0141e2177d24be384d24197d458ffe0_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTQtMS0xLTEtMA_7527370e-a51e-41c6-b2a3-d78fdb7f7a32"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i6256db6dc0054ac18b141ae33e5ad29f_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTQtMi0xLTEtMA_8fe53f45-a9e9-489c-96bf-aca5e89d71b8"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i8631e8b6ef484669be037922391c299d_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTQtMy0xLTEtMA_c745511c-aaaf-4f15-8a1e-a134c1294fb1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ief5d0c9bb17948d6a1b2d29d6f8c062d_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTQtNC0xLTEtMA_6fc8747c-5f84-444a-9c51-8dbbaace6c9c"
      unitRef="usd">115000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ic8470a3d16a94257810c1ec46751fcbd_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTQtNS0xLTEtMA_71bd4a28-7bb9-4112-9dcc-414cb534f2b7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i91a4caee55e84fdb8343347b7638a55e_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTQtNi0xLTEtMA_4c86d36f-a8ae-4064-bb93-01ee7b821a03"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i5e79014ed177468abd91b03922e18af0_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTQtNy0xLTEtMA_64179806-be19-44a4-be12-eb2cdc9daab4"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i7b8df8e17a0f46c78ae91bd6ad3784ba_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTQtOC0xLTEtMA_4242054a-cf22-456f-bb08-7a9f111215f7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i7b9ff999f4544965b285cfeb8d1a0cb1_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTQtOS0xLTEtMA_b6a83967-9c61-4a00-9aff-03e619f1c50d"
      unitRef="usd">118000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i6bf2c274ee034f6688bb999de3bbb518_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTQtMTAtMS0xLTA_b5fb8f8a-bd92-4286-9dfd-2f997907b934"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i8602046a27c64bd4926512027a77764a_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTgtMS0xLTEtMA_5251c55c-e861-4cfd-b5e7-5704584b1396"
      unitRef="usd">25000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i18cce9dd23084ad68d56d277f4166138_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTgtMi0xLTEtMA_e2037964-ba40-4983-99bf-e3b1d628400b"
      unitRef="usd">106000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i25b25621104941d6a59c689bab906bf4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTgtMy0xLTEtMA_d1189ab4-9fdb-4e83-97b0-84b7d0f21b23"
      unitRef="usd">-1000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i1f27a2322ca147eab04beab15bad4715_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTgtNC0xLTEtMA_212cc9b3-a8a9-4905-9f5a-73bc83ad8af6"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i3020bbfcfb1340499dec1be0f710b954_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTgtNS0xLTEtMA_5cf6c21e-75de-49ea-a4a7-3299ba3e8896"
      unitRef="usd">24000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i99def0c623bf49c58f2cce64717f9eae_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTgtNi0xLTEtMA_fa8893e9-dfbe-4a98-9104-d65fb6f9673d"
      unitRef="usd">10000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="iafca8a975c524aedb162430401cc1a92_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTgtNy0xLTEtMA_ce7a49d4-5df2-4110-8e83-602171b13d04"
      unitRef="usd">-316000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="id40428336fe54fb0b1d61580ad3f301d_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTgtOC0xLTEtMA_4a7bd98c-8cb8-4474-8fb4-9bff65121c67"
      unitRef="usd">-121000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i855c33350d7746598cba6771e22ebcc2_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTgtOS0xLTEtMA_d77d395e-1b73-41c0-81ea-1b65d4b3d0da"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i61b00628ead94443b3f921a3a6d612de_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMTgtMTAtMS0xLTA_116adcdf-de9e-4569-9f69-11b78a71f344"
      unitRef="usd">-10000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i8602046a27c64bd4926512027a77764a_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjItMS0xLTEtMA_d27b5a72-1bd5-477a-ac41-01a47f361538"
      unitRef="usd">-41000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i18cce9dd23084ad68d56d277f4166138_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjItMi0xLTEtMA_5d804c91-f26f-47dd-8e43-cecc77e56710"
      unitRef="usd">-398000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i25b25621104941d6a59c689bab906bf4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjItMy0xLTEtMA_db4b82aa-7ae0-4682-b94e-38c9bd769c9e"
      unitRef="usd">80000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i1f27a2322ca147eab04beab15bad4715_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjItNC0xLTEtMA_6cafb1af-15df-442b-af2c-6b1686d31fbf"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i3020bbfcfb1340499dec1be0f710b954_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjItNS0xLTEtMA_f7e3b155-33d4-481e-a9bb-f04d40f9d88e"
      unitRef="usd">67000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i99def0c623bf49c58f2cce64717f9eae_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjItNi0xLTEtMA_a52ec858-bd89-4bfb-aec9-06607ea8e553"
      unitRef="usd">25000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="iafca8a975c524aedb162430401cc1a92_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjItNy0xLTEtMA_20ae629d-b185-4568-b731-dc1a23cbe5be"
      unitRef="usd">330000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="id40428336fe54fb0b1d61580ad3f301d_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjItOC0xLTEtMA_e4e0911a-d88e-4398-808f-5e21d15f10f9"
      unitRef="usd">-156000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i855c33350d7746598cba6771e22ebcc2_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjItOS0xLTEtMA_ddb79b6f-1276-4292-9ae5-c559b29cbd9b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i61b00628ead94443b3f921a3a6d612de_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjItMTAtMS0xLTA_d04da86c-2df2-4c09-8622-98621f387d53"
      unitRef="usd">-55000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i94250734c05f4e5ab67af91d5851ea23_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjUtMS0xLTEtMA_d1a46a2a-cc20-4352-aad4-f69377fe83c4"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ib79aa24edb5c4b0589f5ba2b11f35226_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjUtMi0xLTEtMA_35c5b191-3104-4070-b66b-c396319e97ce"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ia495e7b3f52a4352880c86434b292e22_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjUtMy0xLTEtMA_4d83752d-46d3-40a9-b53d-603188c41886"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i9a3574762e24474f8b845e390fc8124e_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjUtNC0xLTEtMA_89fb34b2-9ae2-4466-9fca-36309fa85b69"
      unitRef="usd">307000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i74ad3f15a27f44939475bb5617afa269_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjUtNS0xLTEtMA_38765d70-aea0-4496-8222-8d3caeaaa90d"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i8aec662a2dab41b5ab3eec8dd912eb2c_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjUtNi0xLTEtMA_a80a8b7d-0fb4-42e5-9438-69f076d20895"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ie697d1e6b84a4b06b358ed0548d7499d_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjUtNy0xLTEtMA_0e81a670-9448-4992-83de-4529f875e38d"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ib1e60dc0c01d47d1955296c160459cb5_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjUtOC0xLTEtMA_f9125486-3f1f-49b2-b766-6f3c29fe0219"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i4a1ff01920b54a71b8bdeb95dd658754_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjUtOS0xLTEtMA_a2fd1c22-d496-48c7-b540-85a03ce7930a"
      unitRef="usd">265000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="id36f5e85786140ebaab64dfb8e6e1c3a_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjUtMTAtMS0xLTA_f2ea970b-7950-4b72-8f05-8c54ca33b333"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i94250734c05f4e5ab67af91d5851ea23_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjctMS0xLTEtMA_2df4426f-7ed1-446e-968a-4cca3e54c350"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ib79aa24edb5c4b0589f5ba2b11f35226_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjctMi0xLTEtMA_9110f826-aa04-4684-ab44-2b0c10d4339d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ia495e7b3f52a4352880c86434b292e22_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjctMy0xLTEtMA_80485153-890a-4bb5-97d5-6ab0886cee4a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i9a3574762e24474f8b845e390fc8124e_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjctNC0xLTEtMA_976065ff-e74e-4f46-bda1-08bd5fd282be"
      unitRef="usd">122000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i74ad3f15a27f44939475bb5617afa269_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjctNS0xLTEtMA_be8c9189-4a6a-4b3d-bfd0-396729d09499"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i8aec662a2dab41b5ab3eec8dd912eb2c_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjctNi0xLTEtMA_92294dfa-eb89-408c-93da-53f98cdef8a6"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ie697d1e6b84a4b06b358ed0548d7499d_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjctNy0xLTEtMA_292c0ac6-9164-44af-b7fb-f1c43cf0a6af"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ib1e60dc0c01d47d1955296c160459cb5_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjctOC0xLTEtMA_d8cc8880-987c-4198-a8e1-60666393ec5d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i4a1ff01920b54a71b8bdeb95dd658754_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjctOS0xLTEtMA_0ad2e3d5-ca97-4433-87cf-8c88a6a737e7"
      unitRef="usd">790000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="id36f5e85786140ebaab64dfb8e6e1c3a_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2JkMzZhYzM5MTQzNmM5NjZhZDkwMjdmNTMxNDM3L3RhYmxlcmFuZ2U6MjdjYmQzNmFjMzkxNDM2Yzk2NmFkOTAyN2Y1MzE0MzdfMjctMTAtMS0xLTA_9f31fc29-65d7-46a5-bc64-41d977e07ffc"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTE5ODA_2bb66144-ae52-4028-900c-d29c4bb0d55c">&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of  October&#160;3, 2021, and January&#160;3, 2021, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Line item in the Consolidated Balance Sheet in which the hedged item is included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Amount of the Hedged Liability&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="iba61370bc5134de1ba733b99d4caa214_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjgxNWZkY2UyMWJhMjRiN2Y5YjdhZjY3MDkxNDJjMGNiL3RhYmxlcmFuZ2U6ODE1ZmRjZTIxYmEyNGI3ZjliN2FmNjcwOTE0MmMwY2JfNC0yLTEtMS0w_b32b3c82-a6bb-4fe1-b296-ae99e2983738"
      unitRef="usd">9851000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i547a7a9339204ab39e0413979ed1a2ab_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjgxNWZkY2UyMWJhMjRiN2Y5YjdhZjY3MDkxNDJjMGNiL3RhYmxlcmFuZ2U6ODE1ZmRjZTIxYmEyNGI3ZjliN2FmNjcwOTE0MmMwY2JfNC00LTEtMS0w_48862646-b87a-4d7b-bc27-fede8beb2087"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="iba61370bc5134de1ba733b99d4caa214_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjgxNWZkY2UyMWJhMjRiN2Y5YjdhZjY3MDkxNDJjMGNiL3RhYmxlcmFuZ2U6ODE1ZmRjZTIxYmEyNGI3ZjliN2FmNjcwOTE0MmMwY2JfNC02LTEtMS0w_8ffd8a66-e5db-445f-9703-f8eb05031dd2"
      unitRef="usd">-73000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i547a7a9339204ab39e0413979ed1a2ab_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjgxNWZkY2UyMWJhMjRiN2Y5YjdhZjY3MDkxNDJjMGNiL3RhYmxlcmFuZ2U6ODE1ZmRjZTIxYmEyNGI3ZjliN2FmNjcwOTE0MmMwY2JfNC04LTEtMS0w_f5222432-bbf0-41e0-8de0-f8b6942207c7"
      unitRef="usd">0</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTE5OTY_083b9f5d-262b-40ca-8dfb-9bd8a97a9462">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of derivatives not designated as hedging instruments for the fiscal third quarters and fiscal nine months in 2021 and 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.277%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.149%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain /(Loss) Recognized in Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal Third Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign Exchange Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i2835247bbd164156ac697a316626d4b8_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjNlYTY1YzkxZGQ1NDQ1Yzg5NWU5Zjk0Y2U4ZjkyZjVhL3RhYmxlcmFuZ2U6M2VhNjVjOTFkZDU0NDVjODk1ZTlmOTRjZThmOTJmNWFfNC00LTEtMS0w_07f7d0be-222e-4a7a-8f48-8026addc2266"
      unitRef="usd">-13000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ief9761af24a4460ea012090015fb22ae_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjNlYTY1YzkxZGQ1NDQ1Yzg5NWU5Zjk0Y2U4ZjkyZjVhL3RhYmxlcmFuZ2U6M2VhNjVjOTFkZDU0NDVjODk1ZTlmOTRjZThmOTJmNWFfNC02LTEtMS0w_3a1b3832-a94c-4c90-a590-b205d33a6d5c"
      unitRef="usd">1000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ia6e0ead4649b4a7a87dc1937b5e8d0ce_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjNlYTY1YzkxZGQ1NDQ1Yzg5NWU5Zjk0Y2U4ZjkyZjVhL3RhYmxlcmFuZ2U6M2VhNjVjOTFkZDU0NDVjODk1ZTlmOTRjZThmOTJmNWFfNC03LTEtMS0w_3981c8d9-d34c-4978-8239-4dd2db14835b"
      unitRef="usd">-50000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i4d4896777472483c91059e670b9b3b89_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjNlYTY1YzkxZGQ1NDQ1Yzg5NWU5Zjk0Y2U4ZjkyZjVhL3RhYmxlcmFuZ2U6M2VhNjVjOTFkZDU0NDVjODk1ZTlmOTRjZThmOTJmNWFfNC05LTEtMS0w_48ff9dd2-54be-42d0-a5b0-b3e70af2717c"
      unitRef="usd">66000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjQ5N2NmYzBiOWI2ZDRjZDJiODBkMjM4YTViZTZiNGUzL3RhYmxlcmFuZ2U6NDk3Y2ZjMGI5YjZkNGNkMmI4MGQyMzhhNWJlNmI0ZTNfMy0yLTEtMS0w_1291393e-1efa-45a9-8af4-37c5278a726a"
      unitRef="usd">115000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjQ5N2NmYzBiOWI2ZDRjZDJiODBkMjM4YTViZTZiNGUzL3RhYmxlcmFuZ2U6NDk3Y2ZjMGI5YjZkNGNkMmI4MGQyMzhhNWJlNmI0ZTNfMy00LTEtMS0w_8d69938c-343a-4c36-80d0-cb479d5c9ed0"
      unitRef="usd">-169000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i086fb509c2da43bdbf100b4f08fd1272_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjQ5N2NmYzBiOWI2ZDRjZDJiODBkMjM4YTViZTZiNGUzL3RhYmxlcmFuZ2U6NDk3Y2ZjMGI5YjZkNGNkMmI4MGQyMzhhNWJlNmI0ZTNfMy04LTEtMS0w_487a23a4-e609-4c2a-8e9d-109417011c07"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i7a83ab881bc04e018d1d2f066bc40669_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjQ5N2NmYzBiOWI2ZDRjZDJiODBkMjM4YTViZTZiNGUzL3RhYmxlcmFuZ2U6NDk3Y2ZjMGI5YjZkNGNkMmI4MGQyMzhhNWJlNmI0ZTNfMy0xMC0xLTEtMA_b1c4b2fc-c11a-441f-8ec1-01b8e81ec1c8"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="ib65942949a8b4ab2858ac418b39805b8_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjQ5N2NmYzBiOWI2ZDRjZDJiODBkMjM4YTViZTZiNGUzL3RhYmxlcmFuZ2U6NDk3Y2ZjMGI5YjZkNGNkMmI4MGQyMzhhNWJlNmI0ZTNfNC0yLTEtMS0w_736524dc-bb09-413a-b8bc-651a64f25fad"
      unitRef="usd">141000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i12239b7d99e147329855a8ae0ec87490_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjQ5N2NmYzBiOWI2ZDRjZDJiODBkMjM4YTViZTZiNGUzL3RhYmxlcmFuZ2U6NDk3Y2ZjMGI5YjZkNGNkMmI4MGQyMzhhNWJlNmI0ZTNfNC00LTEtMS0w_8b24d7b1-d683-43d2-8f1d-ecdcd88781a4"
      unitRef="usd">-234000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ib42b4b45f7a24a98ab6f6f966bf2ff2f_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjQ5N2NmYzBiOWI2ZDRjZDJiODBkMjM4YTViZTZiNGUzL3RhYmxlcmFuZ2U6NDk3Y2ZjMGI5YjZkNGNkMmI4MGQyMzhhNWJlNmI0ZTNfNC04LTEtMS0w_7a79c287-574b-465d-97f6-8ece46c22d35"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i3f3dc535bc03400d84053d66430136d1_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjQ5N2NmYzBiOWI2ZDRjZDJiODBkMjM4YTViZTZiNGUzL3RhYmxlcmFuZ2U6NDk3Y2ZjMGI5YjZkNGNkMmI4MGQyMzhhNWJlNmI0ZTNfNC0xMC0xLTEtMA_2b49839f-e280-4f1b-a2f6-feb34621bf77"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmQ3NjY4YmVkNmVkODRmOTVhN2Y0MDc1YThjODRhYjk1L3RhYmxlcmFuZ2U6ZDc2NjhiZWQ2ZWQ4NGY5NWE3ZjQwNzVhOGM4NGFiOTVfMy0yLTEtMS0w_7bb6c557-20f0-48a1-ba50-50c4354017a3"
      unitRef="usd">279000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmQ3NjY4YmVkNmVkODRmOTVhN2Y0MDc1YThjODRhYjk1L3RhYmxlcmFuZ2U6ZDc2NjhiZWQ2ZWQ4NGY5NWE3ZjQwNzVhOGM4NGFiOTVfMy00LTEtMS0w_fec84799-3a8f-452b-aa53-21fde59fb795"
      unitRef="usd">-217000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i342e3f1749ef42f4a46139b2cb020f4f_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmQ3NjY4YmVkNmVkODRmOTVhN2Y0MDc1YThjODRhYjk1L3RhYmxlcmFuZ2U6ZDc2NjhiZWQ2ZWQ4NGY5NWE3ZjQwNzVhOGM4NGFiOTVfMy04LTEtMS0w_8e383e3e-1b6d-496c-99a1-c341f1ec7f19"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="iba821c9267974930aa7f53fa5bcdb8c5_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmQ3NjY4YmVkNmVkODRmOTVhN2Y0MDc1YThjODRhYjk1L3RhYmxlcmFuZ2U6ZDc2NjhiZWQ2ZWQ4NGY5NWE3ZjQwNzVhOGM4NGFiOTVfMy0xMC0xLTEtMA_940e950b-bfb2-4636-9efc-fe3a86f459d5"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="id49fbada050b40ec920b3e2ec7d1b351_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmQ3NjY4YmVkNmVkODRmOTVhN2Y0MDc1YThjODRhYjk1L3RhYmxlcmFuZ2U6ZDc2NjhiZWQ2ZWQ4NGY5NWE3ZjQwNzVhOGM4NGFiOTVfNC0yLTEtMS0w_376684ac-51eb-4ebb-abb5-4c1b9a917db8"
      unitRef="usd">432000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i864a93092b7f471e9b3af685acca4202_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmQ3NjY4YmVkNmVkODRmOTVhN2Y0MDc1YThjODRhYjk1L3RhYmxlcmFuZ2U6ZDc2NjhiZWQ2ZWQ4NGY5NWE3ZjQwNzVhOGM4NGFiOTVfNC00LTEtMS0w_8efef742-cb73-4b29-88ba-bf54f8ba5ffa"
      unitRef="usd">407000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i52e8eabf585e41898fda5db69bd674df_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmQ3NjY4YmVkNmVkODRmOTVhN2Y0MDc1YThjODRhYjk1L3RhYmxlcmFuZ2U6ZDc2NjhiZWQ2ZWQ4NGY5NWE3ZjQwNzVhOGM4NGFiOTVfNC04LTEtMS0w_760e851d-248d-4ba9-b99b-631e32ed74dc"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i380144a9a9fa42fd8158904a1c5d0700_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmQ3NjY4YmVkNmVkODRmOTVhN2Y0MDc1YThjODRhYjk1L3RhYmxlcmFuZ2U6ZDc2NjhiZWQ2ZWQ4NGY5NWE3ZjQwNzVhOGM4NGFiOTVfNC0xMC0xLTEtMA_a1a10200-3b62-4a9c-a2fd-d5ba193b507a"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTE5NTc_9d48c088-df39-41d9-b23d-c3e31d453523">&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to equity investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.476%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.464%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in Fair Value Reflected in Net Income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales/ Purchases/Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non Current Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments with readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Recorded in Other Income/Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other includes impact of currency&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i2c668ea680234cec82c45cb5e0c7a70c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmUxZWYxNGI3Y2ZmZDQwZTM5YTQ2Y2EyYWU3M2M1YTg3L3RhYmxlcmFuZ2U6ZTFlZjE0YjdjZmZkNDBlMzlhNDZjYTJhZTczYzVhODdfMi0yLTEtMS0w_e6dcf1bb-c190-41ab-9835-fcd6a81382b5"
      unitRef="usd">1481000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:EquityFairValueAdjustment
      contextRef="ie922169de489430ca26a82b6556fdcbc_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmUxZWYxNGI3Y2ZmZDQwZTM5YTQ2Y2EyYWU3M2M1YTg3L3RhYmxlcmFuZ2U6ZTFlZjE0YjdjZmZkNDBlMzlhNDZjYTJhZTczYzVhODdfMi00LTEtMS0w_5d4b6bbd-662c-4cc5-8147-b7bc676c45f7"
      unitRef="usd">-83000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod
      contextRef="ie922169de489430ca26a82b6556fdcbc_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmUxZWYxNGI3Y2ZmZDQwZTM5YTQ2Y2EyYWU3M2M1YTg3L3RhYmxlcmFuZ2U6ZTFlZjE0YjdjZmZkNDBlMzlhNDZjYTJhZTczYzVhODdfMi02LTEtMS0w_45c827e4-d2ab-4d57-976f-2818a4a034f7"
      unitRef="usd">469000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i4eb1c56e86814746bc74797880579d47_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmUxZWYxNGI3Y2ZmZDQwZTM5YTQ2Y2EyYWU3M2M1YTg3L3RhYmxlcmFuZ2U6ZTFlZjE0YjdjZmZkNDBlMzlhNDZjYTJhZTczYzVhODdfMi04LTEtMS0w_980f7d4a-3fc2-4239-8da8-46d53f96c0f4"
      unitRef="usd">1867000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i4eb1c56e86814746bc74797880579d47_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmUxZWYxNGI3Y2ZmZDQwZTM5YTQ2Y2EyYWU3M2M1YTg3L3RhYmxlcmFuZ2U6ZTFlZjE0YjdjZmZkNDBlMzlhNDZjYTJhZTczYzVhODdfMi0xMC0xLTEtMA_de978946-56f5-4564-822b-5ea6e448d445"
      unitRef="usd">1867000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ic9a3a355d8f84cf5bf2f61990c01ad9a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmUxZWYxNGI3Y2ZmZDQwZTM5YTQ2Y2EyYWU3M2M1YTg3L3RhYmxlcmFuZ2U6ZTFlZjE0YjdjZmZkNDBlMzlhNDZjYTJhZTczYzVhODdfNC0yLTEtMS0w_fdd7bd95-6a94-4b2e-92e3-250e57a32cb9"
      unitRef="usd">738000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquityFairValueAdjustment
      contextRef="ied95fcc9c6ec43e28079e110635c1c3e_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmUxZWYxNGI3Y2ZmZDQwZTM5YTQ2Y2EyYWU3M2M1YTg3L3RhYmxlcmFuZ2U6ZTFlZjE0YjdjZmZkNDBlMzlhNDZjYTJhZTczYzVhODdfNC00LTEtMS0w_51ee633b-0d85-43fd-94f1-964389a2840f"
      unitRef="usd">392000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod
      contextRef="ied95fcc9c6ec43e28079e110635c1c3e_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmUxZWYxNGI3Y2ZmZDQwZTM5YTQ2Y2EyYWU3M2M1YTg3L3RhYmxlcmFuZ2U6ZTFlZjE0YjdjZmZkNDBlMzlhNDZjYTJhZTczYzVhODdfNC02LTEtMS0w_b83d4150-25c2-48d8-8521-13a0500993c1"
      unitRef="usd">-545000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i5e894ed981be4116a2355b4062397ba2_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmUxZWYxNGI3Y2ZmZDQwZTM5YTQ2Y2EyYWU3M2M1YTg3L3RhYmxlcmFuZ2U6ZTFlZjE0YjdjZmZkNDBlMzlhNDZjYTJhZTczYzVhODdfNC04LTEtMS0w_c445b77b-7d83-4bf3-82e4-bafc877ddeaa"
      unitRef="usd">585000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5e894ed981be4116a2355b4062397ba2_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmUxZWYxNGI3Y2ZmZDQwZTM5YTQ2Y2EyYWU3M2M1YTg3L3RhYmxlcmFuZ2U6ZTFlZjE0YjdjZmZkNDBlMzlhNDZjYTJhZTczYzVhODdfNC0xMC0xLTEtMA_1057e139-e932-41ba-9eab-148c01f49a9b"
      unitRef="usd">585000000</us-gaap:OtherAssetsNoncurrent>
    <jnj:EquityFairValueAdjustmentImpairmentLoss
      contextRef="ied95fcc9c6ec43e28079e110635c1c3e_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfNjcwNg_564aed71-c387-4c9b-af45-6710d5ad3753"
      unitRef="usd">-25000000</jnj:EquityFairValueAdjustmentImpairmentLoss>
    <us-gaap:EquityFairValueAdjustment
      contextRef="if3dd051494d44e5a963f074248d0e103_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfNjgxMA_0b0145bf-6c7a-47cb-a5f0-200e55643b2b"
      unitRef="usd">417000000</us-gaap:EquityFairValueAdjustment>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTE5NjI_5e4c9c3a-3184-4a0b-a7d7-cb2722f0af50">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant financial assets and liabilities measured at fair value as of October&#160;3, 2021 and January&#160;3, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross to Net Derivative Reconciliation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about changes in liabilities for contingent consideration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;2020 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,481 million, which are classified as Level 1 and contingent consideration of $633 million, classified as Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)     &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Includes cross currency interest rate swaps and interest rate swaps as of October&#160;3, 2021. Includes cross currency interest rate swaps as of January&#160;3, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;           (3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Classified as non-current other assets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Includes $595 million and $594 million, classified as non-current other liabilities as of October&#160;3, 2021 and January&#160;3, 2021, respectively.  Includes $18 million and $39 million classified as current liabilities as of October&#160;3, 2021 and January&#160;3, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;           (6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. &lt;/span&gt;&lt;/div&gt;The Company recorded a contingent consideration reversal of $1,148 million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense, net.</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ia541a8d551c4468c8f6e756afd118e10_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNC0yLTEtMS0w_c498ee71-4eb6-4486-8cde-bfac7a29a5ac"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ia929718f7d4b44af9534961189e19b18_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNC00LTEtMS0w_7cd2a826-d69e-4ae9-935d-d684f8151c1b"
      unitRef="usd">459000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i7c61c290cdfa47aa90f28583b201ca61_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNC02LTEtMS0w_efe413ec-22cc-4545-9be8-7f0086adfea0"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i386cee1639274652826fd3eed1982a70_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNC04LTEtMS0w_5b64a571-f03f-4522-9c22-302f3a7a7a38"
      unitRef="usd">459000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ia918a096df5248d794e6e608f618f2d3_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNC0xMC0xLTEtMA_c637db46-5f62-4832-bf3f-b4a13ba82055"
      unitRef="usd">849000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ibdd29fe7311d4c0f9fccaf4d085f95c5_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNS0yLTEtMS0w_c761f7ba-152f-426c-930d-e779a594b246"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ib8bf2953dcaf482eabe10bcdb5890292_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNS00LTEtMS0w_a9f375ae-cc1b-4384-84dc-744cd041b6b6"
      unitRef="usd">707000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i7cc97e40d3d4405d9a96f873abcd8d6e_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNS02LTEtMS0w_9ac91514-4576-4c94-81e0-43bf157c6aeb"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i31ec175a56664fa0bd90af394bda5a04_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNS04LTEtMS0w_45c7a232-e068-41e3-a552-3765a28d8f71"
      unitRef="usd">707000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i0cf8d2cf87a94bf7a55afbbff98f5daf_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNS0xMC0xLTEtMA_73c8df2a-9c9a-4b4b-8429-3ac2e546017b"
      unitRef="usd">240000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ib6cb46a97d3b4230ae9dcca4c2069fb6_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNy0yLTEtMS0w_2cee88cb-a0a8-46af-8815-8dde7e0931bf"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i7b78f843aa1346368fb728d955f6da33_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNy00LTEtMS0w_c12aec86-e5f5-4bba-9562-26b77fc2ae0f"
      unitRef="usd">1166000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ie9e29ba46f0d4a8bb33c9e8eb07ffda5_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNy02LTEtMS0w_7700403e-e978-4619-9d2f-a7c0ff250ac0"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNy04LTEtMS0w_b147a9b5-be51-45c4-a62a-6a6c9214e371"
      unitRef="usd">1166000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="if00b7b3746e54851b72fa7817a56cc7e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfNy0xMC0xLTEtMA_c6af76dc-415e-46be-8a28-adb01d372ddd"
      unitRef="usd">1089000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ia541a8d551c4468c8f6e756afd118e10_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfOS0yLTEtMS0w_5762332d-a355-4929-923e-4415b53ce9bd"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ia929718f7d4b44af9534961189e19b18_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfOS00LTEtMS0w_595f4115-dbc1-45cd-9371-275aa9d0cb4a"
      unitRef="usd">768000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i7c61c290cdfa47aa90f28583b201ca61_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfOS02LTEtMS0w_2b33f432-7f1d-488d-92a9-ec71d66bb40c"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i386cee1639274652826fd3eed1982a70_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfOS04LTEtMS0w_c8340f8b-cf57-4075-b6c7-9cb2a07ddd9d"
      unitRef="usd">768000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ia918a096df5248d794e6e608f618f2d3_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfOS0xMC0xLTEtMA_2292573f-e9e5-4e67-bfb2-2879e970ab6c"
      unitRef="usd">702000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ibdd29fe7311d4c0f9fccaf4d085f95c5_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTAtMi0xLTEtMA_416fe610-91f7-4d6b-9c72-d9ab8eb896ed"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ib8bf2953dcaf482eabe10bcdb5890292_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTAtNC0xLTEtMA_91b5622a-195f-4492-b3f4-e2092a9cb9f0"
      unitRef="usd">468000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i7cc97e40d3d4405d9a96f873abcd8d6e_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTAtNi0xLTEtMA_583fdc69-ba29-4b91-9b7f-90c67965a4c4"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i31ec175a56664fa0bd90af394bda5a04_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTAtOC0xLTEtMA_584bd24c-c551-40e5-8fa5-bbe78798f3b4"
      unitRef="usd">468000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i0cf8d2cf87a94bf7a55afbbff98f5daf_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTAtMTAtMS0xLTA_9ce1979d-7dbe-4ba9-86a6-2a2f524f7477"
      unitRef="usd">1569000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ib6cb46a97d3b4230ae9dcca4c2069fb6_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTItMi0xLTEtMA_db1673d5-5bc0-4a43-ab8d-a72d968a582d"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i7b78f843aa1346368fb728d955f6da33_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTItNC0xLTEtMA_31cb1686-4bc1-46c5-a43e-e68cc97ed07b"
      unitRef="usd">1236000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ie9e29ba46f0d4a8bb33c9e8eb07ffda5_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTItNi0xLTEtMA_224e3e35-4ba8-4bb0-9d25-30eb27620e15"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTItOC0xLTEtMA_07126f6b-57b0-4764-8039-38b3fe4c298c"
      unitRef="usd">1236000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="if00b7b3746e54851b72fa7817a56cc7e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTItMTAtMS0xLTA_c6cc2dd8-0f3e-400c-acbd-8cb5bcab0cc0"
      unitRef="usd">2271000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="ia541a8d551c4468c8f6e756afd118e10_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTUtMi0xLTEtMA_39b3c0fb-577f-482b-82fd-9fec887c3d0a"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="ia929718f7d4b44af9534961189e19b18_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTUtNC0xLTEtMA_9ca57968-4450-46cc-ab09-1f8321fe5007"
      unitRef="usd">51000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="i7c61c290cdfa47aa90f28583b201ca61_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTUtNi0xLTEtMA_c19dabf3-433a-4a97-8bd7-859406d6b5df"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="i386cee1639274652826fd3eed1982a70_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTUtOC0xLTEtMA_ac8e2452-9955-42ad-bdcd-8290a6af2fc4"
      unitRef="usd">51000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="ia918a096df5248d794e6e608f618f2d3_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTUtMTAtMS0xLTA_f9c5a8d3-45eb-4e92-b01b-1fceb8ca15a1"
      unitRef="usd">49000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="ia541a8d551c4468c8f6e756afd118e10_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTctMi0xLTEtMA_b7d387fb-dc68-4dbf-b2cd-5a85eb268ba8"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="ia929718f7d4b44af9534961189e19b18_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTctNC0xLTEtMA_f8303819-df0a-4ef6-82df-e91c1ce330c8"
      unitRef="usd">48000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i7c61c290cdfa47aa90f28583b201ca61_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTctNi0xLTEtMA_59909c96-25b0-410f-867b-8a06d433c4a9"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i386cee1639274652826fd3eed1982a70_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTctOC0xLTEtMA_03ac9072-3210-4d6a-ba63-81bef9b5783f"
      unitRef="usd">48000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="ia918a096df5248d794e6e608f618f2d3_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTctMTAtMS0xLTA_5e882cdf-7737-4fd6-ae49-8afd3be395b6"
      unitRef="usd">38000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib6cb46a97d3b4230ae9dcca4c2069fb6_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTktMi0xLTEtMA_42f18d14-6178-4751-bbd0-1b6a110ae84f"
      unitRef="usd">1867000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7b78f843aa1346368fb728d955f6da33_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTktNC0xLTEtMA_25560207-8b64-49ce-af5d-ebb578e16bd3"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie9e29ba46f0d4a8bb33c9e8eb07ffda5_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTktNi0xLTEtMA_be9a67ca-211f-488e-806c-ba0df95bcc21"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTktOC0xLTEtMA_573185ef-7669-4a33-ad07-d35559d4548d"
      unitRef="usd">1867000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMTktMTAtMS0xLTA_a8e18dee-0065-47af-83d1-57ef37994a04"
      unitRef="usd">1481000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib6cb46a97d3b4230ae9dcca4c2069fb6_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMjAtMi0xLTEtMA_5511efb8-f641-42f3-81c8-65891ace8db5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7b78f843aa1346368fb728d955f6da33_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMjAtNC0xLTEtMA_e2f971ec-4c9a-480e-96c6-6bd43360649c"
      unitRef="usd">18911000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie9e29ba46f0d4a8bb33c9e8eb07ffda5_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMjAtNi0xLTEtMA_11956ab8-2ab2-4a64-94d8-71a504ab0aed"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMjAtOC0xLTEtMA_d5f87f91-2a59-4f18-9fd7-e1cbeac64843"
      unitRef="usd">18911000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMjAtMTAtMS0xLTA_2e53e11a-086b-4844-8791-2c52ebc9c8e5"
      unitRef="usd">14042000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib6cb46a97d3b4230ae9dcca4c2069fb6_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMjItMi0xLTEtMA_c8e0caad-e99c-443a-9228-79e0713fa8ee"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7b78f843aa1346368fb728d955f6da33_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMjItNC0xLTEtMA_6678ed36-d109-4d1e-a6ee-d01be66e2901"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie9e29ba46f0d4a8bb33c9e8eb07ffda5_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMjItNi0xLTEtMA_3969ad91-ecbf-4f82-b26d-0772a787e00d"
      unitRef="usd">613000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMjItOC0xLTEtMA_60eedf27-834b-4407-9b99-3edb6c7df9ad"
      unitRef="usd">613000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjlhYzA0NjI3M2YxMTQ1NzU4NTVhYjc3OTQ4ZjUwNmVmL3RhYmxlcmFuZ2U6OWFjMDQ2MjczZjExNDU3NTg1NWFiNzc5NDhmNTA2ZWZfMjItMTAtMS0xLTA_ead9e491-e7af-4d6f-81e6-fcd27d3a4992"
      unitRef="usd">633000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2Y2ODcxMWRiOTQ1MzBiMzg0NzdlYThmZDJiMTYxL3RhYmxlcmFuZ2U6MjdjZjY4NzExZGI5NDUzMGIzODQ3N2VhOGZkMmIxNjFfMi0yLTEtMS0w_b3da472c-72b0-4305-aafa-38c6ea843915"
      unitRef="usd">1217000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2Y2ODcxMWRiOTQ1MzBiMzg0NzdlYThmZDJiMTYxL3RhYmxlcmFuZ2U6MjdjZjY4NzExZGI5NDUzMGIzODQ3N2VhOGZkMmIxNjFfMi00LTEtMS0w_ba850650-4780-4535-b783-c8dbcef73b71"
      unitRef="usd">1138000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2Y2ODcxMWRiOTQ1MzBiMzg0NzdlYThmZDJiMTYxL3RhYmxlcmFuZ2U6MjdjZjY4NzExZGI5NDUzMGIzODQ3N2VhOGZkMmIxNjFfMy0yLTEtMS0w_eb4bfd2c-4c6d-46e2-80c1-6eec402d6242"
      unitRef="usd">1058000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2Y2ODcxMWRiOTQ1MzBiMzg0NzdlYThmZDJiMTYxL3RhYmxlcmFuZ2U6MjdjZjY4NzExZGI5NDUzMGIzODQ3N2VhOGZkMmIxNjFfMy00LTEtMS0w_41840343-7733-47c2-a1ba-c86345ad272c"
      unitRef="usd">1107000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssets
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2Y2ODcxMWRiOTQ1MzBiMzg0NzdlYThmZDJiMTYxL3RhYmxlcmFuZ2U6MjdjZjY4NzExZGI5NDUzMGIzODQ3N2VhOGZkMmIxNjFfNC0yLTEtMS0w_d6fb07b4-6e3c-4bcf-a102-66c7bc932828"
      unitRef="usd">159000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2Y2ODcxMWRiOTQ1MzBiMzg0NzdlYThmZDJiMTYxL3RhYmxlcmFuZ2U6MjdjZjY4NzExZGI5NDUzMGIzODQ3N2VhOGZkMmIxNjFfNC00LTEtMS0w_3ffb0f36-b0f9-4e33-bff2-0ef9628bc590"
      unitRef="usd">31000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2Y2ODcxMWRiOTQ1MzBiMzg0NzdlYThmZDJiMTYxL3RhYmxlcmFuZ2U6MjdjZjY4NzExZGI5NDUzMGIzODQ3N2VhOGZkMmIxNjFfNi0yLTEtMS0w_53003557-ae37-46d6-9da5-f16c57f4eb1e"
      unitRef="usd">1284000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2Y2ODcxMWRiOTQ1MzBiMzg0NzdlYThmZDJiMTYxL3RhYmxlcmFuZ2U6MjdjZjY4NzExZGI5NDUzMGIzODQ3N2VhOGZkMmIxNjFfNi00LTEtMS0w_ab5fe651-235b-4dbe-b17d-62b5be0cb12f"
      unitRef="usd">2309000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2Y2ODcxMWRiOTQ1MzBiMzg0NzdlYThmZDJiMTYxL3RhYmxlcmFuZ2U6MjdjZjY4NzExZGI5NDUzMGIzODQ3N2VhOGZkMmIxNjFfNy0yLTEtMS0w_4264d4ab-0212-4d56-b0c7-cfd224b4c271"
      unitRef="usd">1260000000</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2Y2ODcxMWRiOTQ1MzBiMzg0NzdlYThmZDJiMTYxL3RhYmxlcmFuZ2U6MjdjZjY4NzExZGI5NDUzMGIzODQ3N2VhOGZkMmIxNjFfNy00LTEtMS0w_ab6921e5-8f29-4388-b967-5012da07c2ce"
      unitRef="usd">2172000000</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilities
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2Y2ODcxMWRiOTQ1MzBiMzg0NzdlYThmZDJiMTYxL3RhYmxlcmFuZ2U6MjdjZjY4NzExZGI5NDUzMGIzODQ3N2VhOGZkMmIxNjFfOC0yLTEtMS0w_c9ab5edf-72e9-415e-8d27-a8e22fdf6634"
      unitRef="usd">24000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjI3Y2Y2ODcxMWRiOTQ1MzBiMzg0NzdlYThmZDJiMTYxL3RhYmxlcmFuZ2U6MjdjZjY4NzExZGI5NDUzMGIzODQ3N2VhOGZkMmIxNjFfOC00LTEtMS0w_20019dea-e8fa-4d44-bc43-d4c29ccdc2fa"
      unitRef="usd">137000000</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i6223e38b49924566951c6ee22df12ea8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmU3YzBlMzVmNDM4MTQ5M2U5Yzk1OTEzMjkzOGMxM2U1L3RhYmxlcmFuZ2U6ZTdjMGUzNWY0MzgxNDkzZTljOTU5MTMyOTM4YzEzZTVfMy0yLTEtMS0w_01b0cfa3-5ff3-4601-90fd-ee486829c1e3"
      unitRef="usd">633000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="if49e94e75cf04169b3ef119b2c588a4c_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmU3YzBlMzVmNDM4MTQ5M2U5Yzk1OTEzMjkzOGMxM2U1L3RhYmxlcmFuZ2U6ZTdjMGUzNWY0MzgxNDkzZTljOTU5MTMyOTM4YzEzZTVfMy00LTEtMS0w_11a52485-3286-4fdf-aeed-b7bddfa1452d"
      unitRef="usd">1715000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmU3YzBlMzVmNDM4MTQ5M2U5Yzk1OTEzMjkzOGMxM2U1L3RhYmxlcmFuZ2U6ZTdjMGUzNWY0MzgxNDkzZTljOTU5MTMyOTM4YzEzZTVfNC0yLTEtMS0w_858b3f3a-aa71-4be7-b5a8-9d2be351a275"
      unitRef="usd">28000000</jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue>
    <jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmU3YzBlMzVmNDM4MTQ5M2U5Yzk1OTEzMjkzOGMxM2U1L3RhYmxlcmFuZ2U6ZTdjMGUzNWY0MzgxNDkzZTljOTU5MTMyOTM4YzEzZTVfNC00LTEtMS0w_f8a08316-133f-449c-b991-32991b286634"
      unitRef="usd">-1088000000</jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmU3YzBlMzVmNDM4MTQ5M2U5Yzk1OTEzMjkzOGMxM2U1L3RhYmxlcmFuZ2U6ZTdjMGUzNWY0MzgxNDkzZTljOTU5MTMyOTM4YzEzZTVfNS0yLTEtMS0w_b71c7685-af69-413a-9371-5100e90c3526"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmU3YzBlMzVmNDM4MTQ5M2U5Yzk1OTEzMjkzOGMxM2U1L3RhYmxlcmFuZ2U6ZTdjMGUzNWY0MzgxNDkzZTljOTU5MTMyOTM4YzEzZTVfNS00LTEtMS0w_13319de5-ad10-48de-a892-76b71067fd59"
      unitRef="usd">107000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmU3YzBlMzVmNDM4MTQ5M2U5Yzk1OTEzMjkzOGMxM2U1L3RhYmxlcmFuZ2U6ZTdjMGUzNWY0MzgxNDkzZTljOTU5MTMyOTM4YzEzZTVfNi0yLTEtMS0w_51617d4f-88df-46e4-b54e-80dd54b7eb5f"
      unitRef="usd">48000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmU3YzBlMzVmNDM4MTQ5M2U5Yzk1OTEzMjkzOGMxM2U1L3RhYmxlcmFuZ2U6ZTdjMGUzNWY0MzgxNDkzZTljOTU5MTMyOTM4YzEzZTVfNi00LTEtMS0w_c430c348-d325-454c-8fde-ca63aea6eed5"
      unitRef="usd">98000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmU3YzBlMzVmNDM4MTQ5M2U5Yzk1OTEzMjkzOGMxM2U1L3RhYmxlcmFuZ2U6ZTdjMGUzNWY0MzgxNDkzZTljOTU5MTMyOTM4YzEzZTVfNy0yLTEtMS0w_3503bfe2-320f-4000-80a4-8ae20f87b2db"
      unitRef="usd">613000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i4de10452fa98443a826d732ac5ecfcd4_I20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmU3YzBlMzVmNDM4MTQ5M2U5Yzk1OTEzMjkzOGMxM2U1L3RhYmxlcmFuZ2U6ZTdjMGUzNWY0MzgxNDkzZTljOTU5MTMyOTM4YzEzZTVfNy00LTEtMS0w_83e9b8c2-96ba-4e62-87f2-1996c8aa2e85"
      unitRef="usd">636000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ibeca5e8660d14e0e95ab595851e5a044_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfOTA2Mg_7c1b29fa-2120-4e0f-a811-6d78603efc47"
      unitRef="usd">1481000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib78fc1819e4c481fb01505843db10e28_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfOTEzMA_45bbffeb-8812-4618-a43c-f6c8ad9b4b3b"
      unitRef="usd">633000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5820db2145564d76a142f0b76e3fbff3_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfOTQ0OQ_2242db00-8338-44d8-aeac-a05927e10be3"
      unitRef="usd">595000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iaed609fd41ee4cf9a82d74bf5e73e604_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfOTQ2NA_59beabb0-3a8a-4970-84cc-a1464bf11f02"
      unitRef="usd">594000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i831bedde345c419192edc69c0e317205_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfOTU2MQ_5ae8d680-8d7a-4f79-9b7c-23c5d1da92ad"
      unitRef="usd">18000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2b704f7750e54b2c8511c93e87192817_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfOTU3Ng_2ba7b8b1-1fe4-4055-8ec4-f7dfd0f65810"
      unitRef="usd">39000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i771e5eadfd734fc987bf5ecca1178170_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfOTgyOQ_aa50f694-e6e1-4683-af5d-43567fba2f67"
      unitRef="usd">-1148000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTIwMTI_ce807754-e985-447f-b56a-fc99705fbe24">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's cash, cash equivalents and current marketable securities as of October&#160;3, 2021 comprised:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.182%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. sovereign securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Gov't securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other sovereign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Subtotal available for sale debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and current marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i5b7dc91718ce4ea0a9b05b4625568ef0_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMS0xLTEtMS0w_25481151-7d4c-4ee2-a235-e15a6c3f8e84"
      unitRef="usd">2607000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i5b7dc91718ce4ea0a9b05b4625568ef0_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMS0zLTEtMS0w_3b475006-9da4-441c-a0af-1216088e6b0c"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i5b7dc91718ce4ea0a9b05b4625568ef0_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMS01LTEtMS0w_a6fbd57d-41b7-433d-9357-7b5537afceef"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i5b7dc91718ce4ea0a9b05b4625568ef0_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMS03LTEtMS0w_aa7c2fce-d074-4102-87ab-0e20400e73ea"
      unitRef="usd">2607000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5b7dc91718ce4ea0a9b05b4625568ef0_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMS05LTEtMS0w_f44a4252-4741-48cc-a9ae-e6b9a0d2ab5c"
      unitRef="usd">2607000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i5b7dc91718ce4ea0a9b05b4625568ef0_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMS0xMS0xLTEtMA_61de31f9-5170-472c-acb4-bda3d7287be0"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="if293da93cdf44458a788e386d073f1ee_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMy0xLTEtMS0w_172e8f87-2e3e-478b-81f5-493bd0861828"
      unitRef="usd">870000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="if293da93cdf44458a788e386d073f1ee_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMy0zLTEtMS0w_9eb6fa08-f668-4957-8f0d-06a3c16b8bc0"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="if293da93cdf44458a788e386d073f1ee_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMy01LTEtMS0w_1c2445b1-b7d5-4c6e-a2dd-cf2d2e4c799f"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="if293da93cdf44458a788e386d073f1ee_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMy03LTEtMS0w_b382a1c0-21ba-4feb-a0d9-edbe082c6002"
      unitRef="usd">870000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if293da93cdf44458a788e386d073f1ee_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMy05LTEtMS0w_70208ffb-246f-4ed9-860e-8344f4265792"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="if293da93cdf44458a788e386d073f1ee_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMy0xMS0xLTEtMA_4b5f9a10-5f20-4007-8b36-0df165819ef9"
      unitRef="usd">870000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i8dcb1b245fd240b0b488db669a604f22_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNC0xLTEtMS0w_d19aac48-d9f7-42f5-8734-c56d3784496f"
      unitRef="usd">1715000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i8dcb1b245fd240b0b488db669a604f22_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNC0zLTEtMS0w_16ead62c-b0c1-4083-9ae6-5999ffba8d03"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i8dcb1b245fd240b0b488db669a604f22_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNC01LTEtMS0w_489511fb-453c-4344-9263-0af71e68a3eb"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i8dcb1b245fd240b0b488db669a604f22_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNC03LTEtMS0w_9a8dd031-e524-4650-9483-92d4d1ae486f"
      unitRef="usd">1715000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8dcb1b245fd240b0b488db669a604f22_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNC05LTEtMS0w_2478fc64-453a-45cf-9200-d8861e83b85e"
      unitRef="usd">1715000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i8dcb1b245fd240b0b488db669a604f22_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNC0xMS0xLTEtMA_9b2fad63-30e7-4d1b-9c60-6e90fa166d1c"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i9f73056213bc43fc94fc5c10e89df326_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNi0xLTEtMS0w_3ead6dbc-20bc-4e0f-9fba-c8810e47a11c"
      unitRef="usd">3604000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i9f73056213bc43fc94fc5c10e89df326_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNi0zLTEtMS0w_fd8d32b4-36d4-46b7-bc20-62508a0485fb"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i9f73056213bc43fc94fc5c10e89df326_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNi01LTEtMS0w_d42e2a91-149e-4b7b-a352-dd46b3a3891e"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i9f73056213bc43fc94fc5c10e89df326_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNi03LTEtMS0w_cf2e2a9d-6b4c-4eee-ba6c-c4017aae8f40"
      unitRef="usd">3604000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9f73056213bc43fc94fc5c10e89df326_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNi05LTEtMS0w_a275d348-5520-4e26-98c4-b5c716d3a6b2"
      unitRef="usd">274000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i9f73056213bc43fc94fc5c10e89df326_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNi0xMS0xLTEtMA_3e8bf813-3bee-44c4-b89f-15adf0bf4fcf"
      unitRef="usd">3330000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="ia9385ca799d84dce96c2206ee78ac799_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNy0xLTEtMS0w_c1f4603f-765c-40e0-a64e-bfe5ab394d80"
      unitRef="usd">2120000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="ia9385ca799d84dce96c2206ee78ac799_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNy0zLTEtMS0w_fc006675-e1cb-48a3-934d-4ecb78ba6943"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="ia9385ca799d84dce96c2206ee78ac799_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNy01LTEtMS0w_03d14b8c-79bc-4b87-83ed-94072a284d71"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ia9385ca799d84dce96c2206ee78ac799_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNy03LTEtMS0w_0fcddb00-8664-4eed-b91c-b8bbcfa211b7"
      unitRef="usd">2120000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia9385ca799d84dce96c2206ee78ac799_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNy05LTEtMS0w_4f5ed5bc-bfe0-49db-a765-8e2efb0fb412"
      unitRef="usd">2120000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ia9385ca799d84dce96c2206ee78ac799_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfNy0xMS0xLTEtMA_af1cf1ec-6ffd-49b8-9c18-7fbb12577928"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="ic741579d386241e4bbf75342917d529a_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfOC0xLTEtMS0w_0cc6758d-6b96-4e7e-b339-a7d4fb4db419"
      unitRef="usd">1174000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="ic741579d386241e4bbf75342917d529a_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfOC0zLTEtMS0w_9a98bfe1-6349-4393-a866-c4ce294f8975"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="ic741579d386241e4bbf75342917d529a_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfOC01LTEtMS0w_ac7b39aa-255d-492f-b43a-bca508fdee9a"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ic741579d386241e4bbf75342917d529a_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfOC03LTEtMS0w_d7b883ff-1bed-48b0-80f2-4f69b58f518f"
      unitRef="usd">1174000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic741579d386241e4bbf75342917d529a_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfOC05LTEtMS0w_5f9e48b7-1f4c-402b-9be7-2a4dc4629277"
      unitRef="usd">1174000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ic741579d386241e4bbf75342917d529a_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfOC0xMS0xLTEtMA_ca12bbf9-63c1-44fe-90f9-15bda0ea7752"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i009c78145cf74486a461497129412728_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfOS0xLTEtMS0w_f9b1fd3a-02a9-47c8-86a3-2d5499119d18"
      unitRef="usd">12090000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i009c78145cf74486a461497129412728_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfOS0zLTEtMS0w_6cd74cb3-e667-4ee2-bd7e-b66c997bdc51"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i009c78145cf74486a461497129412728_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfOS01LTEtMS0w_4d85c592-367a-4c2a-9a47-c0244b34ec55"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i009c78145cf74486a461497129412728_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfOS03LTEtMS0w_06ae1467-59ca-4b7e-acca-b01e2f507746"
      unitRef="usd">12090000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i009c78145cf74486a461497129412728_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfOS05LTEtMS0w_16d76ac5-33ad-4725-a26d-41440458a91d"
      unitRef="usd">7890000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i009c78145cf74486a461497129412728_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfOS0xMS0xLTEtMA_84903d79-2acc-426a-a1e4-d15935a852b4"
      unitRef="usd">4200000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6fb649af90814478b37ac417cea6456b_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTItMS0xLTEtMA_a8dc87a1-50fa-44aa-9ccb-6d8ee8f71474"
      unitRef="usd">18657000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6fb649af90814478b37ac417cea6456b_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTItMy0xLTEtMA_e2649686-d2d9-4c17-8091-0c18add6e027"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6fb649af90814478b37ac417cea6456b_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTItNS0xLTEtMA_c61c5f77-14eb-4fe9-a6b3-9179980fd109"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6fb649af90814478b37ac417cea6456b_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTItNy0xLTEtMA_4a97af1b-016c-4602-ba07-225c7d64aa03"
      unitRef="usd">18657000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6fb649af90814478b37ac417cea6456b_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTItOS0xLTEtMA_22284493-4317-45c5-ad7c-76186feb8844"
      unitRef="usd">9697000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i6fb649af90814478b37ac417cea6456b_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTItMTEtMS0xLTA_4367d0c8-08a0-4731-88c0-7a209ec04647"
      unitRef="usd">8960000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9178d762f0634d6a894dd86815cf64ec_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTMtMS0xLTEtMA_7c8156f0-0b4c-4173-a7f7-9a05e4bdfaa4"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9178d762f0634d6a894dd86815cf64ec_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTMtMy0xLTEtMA_1de5b3df-b966-4cbc-adda-4d6e4de7c8bd"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9178d762f0634d6a894dd86815cf64ec_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTMtNS0xLTEtMA_57bfcc42-5bbf-4146-86a0-f462fe473dba"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9178d762f0634d6a894dd86815cf64ec_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTMtNy0xLTEtMA_3fe50475-2c2d-4c0d-b30a-247b332f0591"
      unitRef="usd">3000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9178d762f0634d6a894dd86815cf64ec_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTMtOS0xLTEtMA_90e684ed-b60f-448e-af1e-744affe822ae"
      unitRef="usd">2000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i9178d762f0634d6a894dd86815cf64ec_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTMtMTEtMS0xLTA_73ad1551-4c2e-4cb4-bc68-6749a451ffb4"
      unitRef="usd">1000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i9178d762f0634d6a894dd86815cf64ec_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTMtMTEtMS0xLTA_a8465f57-846c-4266-9be6-c241b94fc5e8"
      unitRef="usd">1000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id829f858995a40ed8f879e67456295cc_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTQtMS0xLTEtMA_04594201-c0c6-4295-a7c3-f5eb95fdf65a"
      unitRef="usd">251000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id829f858995a40ed8f879e67456295cc_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTQtMy0xLTEtMA_00c6fa3e-8f50-4312-b3cb-91149ae8babc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id829f858995a40ed8f879e67456295cc_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTQtNS0xLTEtMA_f450138d-fc9a-4573-ac70-6b72a0a14dd4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id829f858995a40ed8f879e67456295cc_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTQtNy0xLTEtMA_617ac279-f485-484a-a7bd-f3221ba0137b"
      unitRef="usd">251000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id829f858995a40ed8f879e67456295cc_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTQtOS0xLTEtMA_40625ad2-b7d8-4cf9-a70d-3e6a83ef6106"
      unitRef="usd">15000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="id829f858995a40ed8f879e67456295cc_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTQtMTEtMS0xLTA_4c227f9f-65ac-4f81-a9bc-0ad563624fa2"
      unitRef="usd">236000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6a81061eccb043c396dcd8d5162f888d_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTUtMS0xLTEtMA_7bb3fff3-1d0a-406c-8791-60ee4f6405d6"
      unitRef="usd">18911000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6a81061eccb043c396dcd8d5162f888d_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTUtMy0xLTEtMA_896511e1-dfb0-46a9-8c08-d2a2e7facb00"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6a81061eccb043c396dcd8d5162f888d_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTUtNS0xLTEtMA_a384813d-0400-4240-9c9d-b776257d4902"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6a81061eccb043c396dcd8d5162f888d_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTUtNy0xLTEtMA_89acd65b-93f8-4b2b-bd24-5ac213d70a0c"
      unitRef="usd">18911000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6a81061eccb043c396dcd8d5162f888d_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTUtOS0xLTEtMA_41a26ebe-3771-43da-9b70-55f65a77243c"
      unitRef="usd">9714000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i6a81061eccb043c396dcd8d5162f888d_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTUtMTEtMS0xLTA_d0560459-a950-4195-b3c0-e103f84b48a1"
      unitRef="usd">9197000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTYtMS0xLTEtMA_5520b84e-e345-4a2e-90fb-0ea83e288879"
      unitRef="usd">31001000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <jnj:CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTYtMy0xLTEtMA_30c994a1-97f7-476d-92d7-8b7d1d72a3e9"
      unitRef="usd">0</jnj:CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain>
    <jnj:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTYtNS0xLTEtMA_8ee94b6d-3385-44c3-ad4f-38c825ed0efd"
      unitRef="usd">0</jnj:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss>
    <jnj:CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTYtNy0xLTEtMA_923ef579-0ea0-4773-9b3b-ad948b0269e3"
      unitRef="usd">31001000000</jnj:CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTYtOS0xLTEtMA_4150bc6a-22dd-49b8-b926-77d2b881f2b3"
      unitRef="usd">17604000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjc5YzI2MDBjYzNhNzQ2NWY5YTI2NmE3YTgxYWIwNWNhL3RhYmxlcmFuZ2U6NzljMjYwMGNjM2E3NDY1ZjlhMjY2YTdhODFhYjA1Y2FfMTYtMTEtMS0xLTA_709fc213-1258-49d4-963d-e6242626a4f2"
      unitRef="usd">13397000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTE5OTM_a7848b96-e8b8-4616-9caf-993961691cc7">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTE5NDM_235e0567-b915-4ebb-9afb-9b745b66fbec">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of the available for sale securities as of October&#160;3, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.279%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjYxOGIyOWE2MDdiODQyYjQ4NGY2MjU3NzRmZjU0OWY0L3RhYmxlcmFuZ2U6NjE4YjI5YTYwN2I4NDJiNDg0ZjYyNTc3NGZmNTQ5ZjRfMS0yLTEtMS0w_8d85f2c5-eb6e-4ee3-bfc4-d7ede98c837b"
      unitRef="usd">18895000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjYxOGIyOWE2MDdiODQyYjQ4NGY2MjU3NzRmZjU0OWY0L3RhYmxlcmFuZ2U6NjE4YjI5YTYwN2I4NDJiNDg0ZjYyNTc3NGZmNTQ5ZjRfMS00LTEtMS0w_eb26c8e5-00ad-4b89-81bd-3d0e8f1986c3"
      unitRef="usd">18895000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjYxOGIyOWE2MDdiODQyYjQ4NGY2MjU3NzRmZjU0OWY0L3RhYmxlcmFuZ2U6NjE4YjI5YTYwN2I4NDJiNDg0ZjYyNTc3NGZmNTQ5ZjRfMi0yLTEtMS0w_690526f4-b983-4257-8a95-c605bfa0bb90"
      unitRef="usd">16000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjYxOGIyOWE2MDdiODQyYjQ4NGY2MjU3NzRmZjU0OWY0L3RhYmxlcmFuZ2U6NjE4YjI5YTYwN2I4NDJiNDg0ZjYyNTc3NGZmNTQ5ZjRfMi00LTEtMS0w_ef464c2f-1bf4-4832-940d-010bfa282b83"
      unitRef="usd">16000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjYxOGIyOWE2MDdiODQyYjQ4NGY2MjU3NzRmZjU0OWY0L3RhYmxlcmFuZ2U6NjE4YjI5YTYwN2I4NDJiNDg0ZjYyNTc3NGZmNTQ5ZjRfMy0yLTEtMS0w_9d4af0ec-55ed-4442-940c-5abec7442d88"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjYxOGIyOWE2MDdiODQyYjQ4NGY2MjU3NzRmZjU0OWY0L3RhYmxlcmFuZ2U6NjE4YjI5YTYwN2I4NDJiNDg0ZjYyNTc3NGZmNTQ5ZjRfMy00LTEtMS0w_fc24cf6a-0ee7-4058-87a9-9c43729ece8d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjYxOGIyOWE2MDdiODQyYjQ4NGY2MjU3NzRmZjU0OWY0L3RhYmxlcmFuZ2U6NjE4YjI5YTYwN2I4NDJiNDg0ZjYyNTc3NGZmNTQ5ZjRfNC0yLTEtMS0w_2c7bd39e-c7c7-4c6b-9461-74b7209089eb"
      unitRef="usd">18911000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOjYxOGIyOWE2MDdiODQyYjQ4NGY2MjU3NzRmZjU0OWY0L3RhYmxlcmFuZ2U6NjE4YjI5YTYwN2I4NDJiNDg0ZjYyNTc3NGZmNTQ5ZjRfNC00LTEtMS0w_2958e0cd-43df-4e00-8aaa-c00a000be686"
      unitRef="usd">18911000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTE5ODE_712d4689-bad8-4d78-b4d4-1320eb4623d1">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Instruments not measured at Fair Value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following financial liabilities are held at carrying amount on the consolidated balance sheet as of October&#160;3, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73% Debentures due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.05% Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.650% Notes due 2024 (750MM Euro 1.1581)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% Notes due 2024 (500 MM GBP 1.3465)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.625% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.55% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90%&#160;Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.150% Notes due 2028 (750MM Euro 1.1581)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.95% Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95% Debentures due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.650% Notes due 2035 (1.5B Euro 1.1581)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.55% Notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40%&#160;Notes due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85% Debentures due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Debentures due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.10% Notes due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.85% Notes due 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70% Notes due 2046&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Notes due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50% Notes due 2048&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% Notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2060&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Non-Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:ShortTermBorrowings
      contextRef="i18389b6ef2374d3c823b640e24fe8d12_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNC0yLTEtMS0w_d3d52174-d099-4d96-8f5c-09705532147d"
      unitRef="usd">3798000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="ic4204d24c6ab4dfa89a1c5d5867933ce_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNC00LTEtMS0w_d05b934f-80bc-49cb-a5c8-f8f839c0cd30"
      unitRef="usd">3808000000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7ac4e3b179864a468bfaa6bba91852e4_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNy0wLTEtMS0wL3RleHRyZWdpb246NzVkN2JlYmE3MGI3NDNhZDk4MGMwZmEzYWQ5MzU2M2RfNA_e8a5adbf-8108-486c-b501-757d258744f7"
      unitRef="number">0.0673</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i65df3ffe517245619ee40a22674cf249_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNy0yLTEtMS0w_98b8d301-f532-423f-b52a-a3fe6973c50a"
      unitRef="usd">250000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6fa344c3c3a14482aa8f313597fd1bed_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNy00LTEtMS0w_2ea36064-55f8-4131-9c71-2ec57a30b190"
      unitRef="usd">285000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i07e445fc6ca14fef87c4fea6ac866c95_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfOC0wLTEtMS0wL3RleHRyZWdpb246ZWMyNWZjODg4OGE4NDlhMDg2ZDAxNDAxMmFhYmRhOTZfNA_c11121d0-ca5f-403e-b0ae-e238776ac8db"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7415834b451d40a98618e973debc442e_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfOC0yLTEtMS0w_8f27bea6-6e3e-46c0-a43b-506b4bceb273"
      unitRef="usd">802000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8c8213533087409db4d429fd040785cc_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfOC00LTEtMS0w_f3aa2a13-5291-405f-ad74-323f6a250f98"
      unitRef="usd">857000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9b6ee0ef21ad4005b66cfbd8d7bd5087_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfOS0wLTEtMS0wL3RleHRyZWdpb246N2Y3NTExYzc2ZGQ1NGIzMTkyNTZmMWRiYTM5MTk0MjNfNA_ea1e265f-54dd-4993-baed-ccd21ad90835"
      unitRef="number">0.0205</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i31b2046662244e3b9cbb92c5aed58fb6_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfOS0yLTEtMS0w_81e28a3e-c32e-481b-baa5-2d571ba84900"
      unitRef="usd">499000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie6b4ff6b5de74a15b368ea59a0de5057_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfOS00LTEtMS0w_a831d801-5a2c-42ce-8e2f-1db296d9a461"
      unitRef="usd">511000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibf70d477076242eeb2b9271915ba71b3_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTAtMC0xLTEtMC90ZXh0cmVnaW9uOmFhOTI1MjYzZjFiMjRhMGRhNWI3ZmJmNzJkMGQ2ODBkXzQ_5b6abab0-30a5-4835-aafe-4b748c7540c3"
      unitRef="number">0.00650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib0bd340801084b60adf4d9a44c9274d5_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTAtMi0xLTEtMA_994d7ca8-6a5a-442c-998b-0e5ed812f85e"
      unitRef="usd">867000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia29178df168d49e381facf07098989fb_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTAtNC0xLTEtMA_03a1b7c6-ef4a-4843-98d2-17f83d12f076"
      unitRef="usd">889000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1e3d2dc107be43c5bd3e61ccb2b7faf4_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjRkMTNkMzU4ZTNkMjQxNmI4Mjc4NGFmYzNiZTExNzZhXzQ_41c48f0c-00fe-45d0-a933-a37b6639fc36"
      unitRef="number">0.0550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i54f00a29b7c94893ba5de79c98a063b2_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTEtMi0xLTEtMA_577b46bd-0311-46dd-8081-8a1d32b2109f"
      unitRef="usd">671000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ica369f9fff05494a954f5c22e4edab8c_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTEtNC0xLTEtMA_9bc87605-02d8-46c4-ab3a-b30b457abc21"
      unitRef="usd">769000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie72e7ef5001e45cfa85cdf6654be4b80_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTItMC0xLTEtMC90ZXh0cmVnaW9uOjg1MGJjNzA0MWI0NzRhZTBhMGNjYjdlMTE3NzNmNGNmXzQ_ee10d818-43e4-4a11-9fe0-7d95ba8f382e"
      unitRef="number">0.02625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i44489d6df8a8422c984028d2e3e54b5b_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTItMi0xLTEtMA_91a54844-8b5c-4310-9be1-79c875a97ccb"
      unitRef="usd">749000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i81fc862d12094763922068d4e9c8537d_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTItNC0xLTEtMA_fc90b5c3-cd30-4384-bffe-cc4a55893377"
      unitRef="usd">794000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4147275174c24eac885cc4fb0886ac54_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTQtMC0xLTEtMC90ZXh0cmVnaW9uOjViODM0N2M4MmZhNjQ5MjQ4YWY5YTNlZDJkMzYyN2JiXzQ_816d0e48-c754-4fdb-9049-803aa8be1bb2"
      unitRef="number">0.0055</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i4a6f8d9f883946d6b9af6c9d0a9be721_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTQtMi0xLTEtMA_ae735e27-3d45-4222-8c40-e719404a6323"
      unitRef="usd">993000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if20ce7e060e548869eb894260b6fc64b_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTQtNC0xLTEtMA_ff27be22-94fd-49ba-997c-e767302d3960"
      unitRef="usd">982000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie83d54bb9a4f4816bf50aec027245c33_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTUtMC0xLTEtMC90ZXh0cmVnaW9uOjc5YjIwM2Q5NGZjNzQ2YzlhMmZmZjFhNDZkYTE5M2MyXzQ_031dac21-ee05-489d-9161-345b678014a9"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2d23525d3b284b7d9852bad7add00e33_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTUtMi0xLTEtMA_b1cdf70c-31a2-4f57-941b-66c93f28e7b9"
      unitRef="usd">1995000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id1546f14269e447faa59f6da1aca49e8_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTUtNC0xLTEtMA_e503b943-f7e5-4734-999d-92631ec71fd9"
      unitRef="usd">2119000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia478ea6acea24aff8eff14df6fecc891_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTYtMC0xLTEtMC90ZXh0cmVnaW9uOjIzNThhZDdiNWE5MzQ0M2U5ODQ1YTAzMDIxYTE5NDEyXzQ_35faedee-d62a-44d9-98d6-edd4bb85a389"
      unitRef="number">0.0295</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie5640ee1ce1d47ad801b0d6eef582304_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTYtMi0xLTEtMA_0211e064-047f-47cc-84bb-f061e972b39f"
      unitRef="usd">989000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6d971262bcb64b6b893eb6fedc3a0beb_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTYtNC0xLTEtMA_559d162a-3363-4716-9a06-e649b7ad7bd2"
      unitRef="usd">1078000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iedc4b4fd0b1b4ad390f5f63e58c47e8d_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTgtMC0xLTEtMC90ZXh0cmVnaW9uOjM0OTkwMTc2M2YzMTRlNTc4NTQ2Y2ZkYTE3MmZmMWE1XzQ_6a602c10-898d-4767-9e41-bea1c487a722"
      unitRef="number">0.0095</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i4e50b1400f70460a988afbc0dafd4823_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTgtMi0xLTEtMA_c064ef52-d44f-46b0-92c5-d08bf492f1ee"
      unitRef="usd">1489000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic6cfc552441e4a8e8b91f3deb98f4c44_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTgtNC0xLTEtMA_4478990e-da0d-4ac5-9e74-f9dac10c9960"
      unitRef="usd">1464000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia99340613822456eb8c3641db778ecd7_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTktMC0xLTEtMC90ZXh0cmVnaW9uOjYwNmQzMDdlYTRlZjRiYzFhZGE2ZDllODM0ZjhjNThiXzQ_cab0b76a-a28a-4823-8ae2-a48fe4878fa9"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iaa8046c340764588878db0a7b77c401f_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTktMi0xLTEtMA_b26917db-b6aa-427e-bf6e-5776e70a72e8"
      unitRef="usd">1495000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9fd60cb1106c4c1499568e9a6eebfb28_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMTktNC0xLTEtMA_13928cba-b58c-4a93-9c19-32118c10ebf2"
      unitRef="usd">1622000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i72bdc25703924ba3b6b0ce4527d18d88_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmQxYmEyYzM0YzY2MzRlYmY5NGM3MWZhNzY3OGEyZTgxXzQ_13c8eb39-a557-407e-88c7-ae0a6373c49a"
      unitRef="number">0.01150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8b28e0d7e40047fabff6dba54a753c51_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjAtMi0xLTEtMA_63de2a0a-33f7-4ffb-92f1-b6e977612de4"
      unitRef="usd">863000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id23573442cd349c181d05b7186a88a8f_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjAtNC0xLTEtMA_c4693e92-90ad-45ae-97bb-8e4d3f4ad384"
      unitRef="usd">932000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i99f7ce7c3c0a4e47bc46cb5013b85204_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOjhmYjBjOGIwMGM5YjQ4MDJhYTRhYmRmM2YyNDFkZmE2XzQ_b4de3976-cee7-44f3-b367-c259e2d1690f"
      unitRef="number">0.0695</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i4fce897c159a440fa82606e78f5a8890_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjEtMi0xLTEtMA_c81c15c6-ac89-40b3-b58b-f20d0ede9403"
      unitRef="usd">297000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9442a0f459844bc8b34a3edfbad734f2_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjEtNC0xLTEtMA_0946e807-82f7-4b89-8807-0833eda654d1"
      unitRef="usd">414000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if9abf297178741228613c2f1cc8f19d2_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOmM0ZmYxOTgxMzE4ZTQyNzA5NGE2NTkxN2E5NThlNzdkXzQ_daa8d0ad-2cfe-4e7b-971c-0a8608f14d14"
      unitRef="number">0.0130</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i34ef244a220d41cd93a8040056b208e7_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjMtMi0xLTEtMA_c57d8698-d35a-4568-8856-e74dbb47f6f8"
      unitRef="usd">1733000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i25ff7c6833044a3ebd91c3ef1f1367c4_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjMtNC0xLTEtMA_90000706-9dec-4772-9bc0-d46ab49bb98a"
      unitRef="usd">1678000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id3fec2057e8c4da08b74b29f4fd4267c_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmJlYzFjNmRmY2IzMjQ1NzJhOWE3NWYyYmY0MTY1ZTI0XzQ_721f413e-75a9-4ff1-92a1-1650d182c5c3"
      unitRef="number">0.0495</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i1f58130f89ed4256a62ba7c75eb638c4_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjQtMi0xLTEtMA_fd8220b3-4d4c-4a39-9a60-582ce3341d4f"
      unitRef="usd">498000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iefeb4b2784e6435384a917a1944c658e_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjQtNC0xLTEtMA_bbe79ae4-3aad-4aa4-b6cd-1e14bf73f10c"
      unitRef="usd">647000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i860c18e3721d4d939bd33a8ea77e4421_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjEwNjgyMmI1OTUzNDQ4YWFiZGM2YjdiYWY0YmNlMDc4XzQ_badc7509-56b8-4e67-9ec3-fc540a29cb2c"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9daefad50e444c3b846ecb91f83159bc_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjUtMi0xLTEtMA_31b2165a-ab61-4f59-9283-0b605c0c8a02"
      unitRef="usd">855000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3c801cc1caeb4c179693dba2260b0563_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjUtNC0xLTEtMA_51811d70-deb5-4a63-8cfc-4fcead3a6fd7"
      unitRef="usd">1059000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0dbba3a61c5540838ca8c89692469565_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjJkZGE3YmQ4MjM5MzRlY2I4ZjE5ZGZlODgyNGMwNTAxXzQ_ac1032f1-c4ac-4659-84d5-00f196ff5dfb"
      unitRef="number">0.01650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i4aecaa1385574720ad3d887864eeb207_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjYtMi0xLTEtMA_7cdc8e80-3e76-44e6-b83e-b6fd86fce9a1"
      unitRef="usd">1723000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3125d97f80b94d60b77182ad35bb48fc_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjYtNC0xLTEtMA_b1207fbb-bc84-4d36-98ab-ef59cd0f0928"
      unitRef="usd">1963000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic7aeccd4baaf4417b5ffcdc8852c71d4_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjU2ZmU5OTJiMDZlYzQzY2E5YzU1ZTNmZDAwODllMGMxXzQ_33829150-a683-4824-ba72-9a1e906a12e2"
      unitRef="number">0.0355</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib143b536bc9b45b4826b98a0ac180c8b_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjctMi0xLTEtMA_fa9d8edc-23da-44c0-8d06-02f455a2a101"
      unitRef="usd">980000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ide702a860cec442280c57a5771658c81_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjctNC0xLTEtMA_ad9f8ffc-b192-42a3-acf5-3c3c153b550b"
      unitRef="usd">1134000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic2ca463645bb4a5b9739b8bc175da1db_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmQ0NGFiNGNhM2VkNDQ0NjA5ODA4ODhiNTYyZWU1NDdkXzQ_77b00c77-94ed-4be8-b7e7-35984450c894"
      unitRef="number">0.0595</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i16f1d7b4085841078f18b613f1fe0a77_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjgtMi0xLTEtMA_2f8e4676-77c7-4694-a398-f9f356ef39f6"
      unitRef="usd">993000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib92d6482e7ea404eae4e1c4468904413_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjgtNC0xLTEtMA_d58cd1cf-c3d4-46ce-87c4-8805fe801639"
      unitRef="usd">1439000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id2a6e34f48ee4c7d80d33f78478eb3f2_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmM1ZDY5YmI1OTVkODQxOWM4NDQ4NWNjNzYwYWVjYjA1XzQ_fb4b95b7-270d-4917-9d94-a3f88261a322"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ibdc7fc7a723e450cb48944879c0781e7_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjktMi0xLTEtMA_af8d6856-6139-4c95-996b-58c9cf8f4217"
      unitRef="usd">1481000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia1a7c9dbc6df42aeb77011ac535edea5_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMjktNC0xLTEtMA_d4d98ffc-af26-4d6c-84d8-17e1b35d3b43"
      unitRef="usd">1721000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i57d6a4f83449492094bb6b200701e064_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjdmN2IxNmRmM2YwYjQxZDhiNDhkZTY5ZGE1ZWFmYTM2XzQ_e1540b0f-e9c1-49b4-96d1-ea462bac2875"
      unitRef="number">0.0340</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic2f2afd2bbca40be9ed9eff967565efe_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzAtMi0xLTEtMA_4e2cf73c-ca21-406f-a0a6-0219ca29e1aa"
      unitRef="usd">992000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia7d62d21ca6949dcbc76d7ab670920b7_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzAtNC0xLTEtMA_b6180b90-36f1-472c-b529-1ff10ceff437"
      unitRef="usd">1122000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ied109c22c97143bf9e2d8950f06aa9cd_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmY4ZGMwMDY3MTU0YTQ4MGU4YjBmMGJlNDk1NThjMzEyXzQ_d0180a1f-0cef-47dd-9b99-a6f423464d48"
      unitRef="number">0.0585</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia107789c130e40adb3ad38987e6fbf7c_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzEtMi0xLTEtMA_0fb9afb8-f3ea-45e1-bfdd-6655a01cbdc7"
      unitRef="usd">696000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6d2f5ac2df314410bab3062026857504_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzEtNC0xLTEtMA_8e1922fb-6c64-4e67-bb02-cb4767244d9f"
      unitRef="usd">1013000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if3b49374b2a540819767fb1780941cbf_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjI0NmM3ODY3MTk0ZDQ5ZTc5ODgzYzA1MzQyMDA0MDI0XzQ_af89d61a-eae2-4dc3-939d-d1c83c08c7ad"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i26dfa36f335f442fb41f8059c4cfe77f_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzItMi0xLTEtMA_e51178e6-a9f5-423e-bee7-a49b4022252d"
      unitRef="usd">540000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i25547702bd0f47088ae87a4e661a13e2_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzItNC0xLTEtMA_5ff03c8c-ac6a-4045-865e-e8b919619e69"
      unitRef="usd">693000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic31cdd75b29340eb9d44466d5ec7ffd8_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmJjZWNjOWFjY2EzZTRlMTM5YjdjNTAyNWE4NTEwODRkXzQ_d1898930-d4ed-4d15-ab14-c90cdafa5129"
      unitRef="number">0.0210</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i50afa95426c645b18294c42ab68e0a75_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzQtMi0xLTEtMA_88c8a206-6470-4d6e-ac10-2aa5368ad7f8"
      unitRef="usd">979000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i0a8f75d047704b5aa0d3db1bc03ed292_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzQtNC0xLTEtMA_0e89db23-c471-42a7-a2a7-e1512b0f8292"
      unitRef="usd">933000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3890ce020cce483fa079c7f7418ac44c_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjE2ODA4MmE2NGYzYjQwMzk4ZjQzOTlkNjVkNTRlMzJjXzQ_cfd41061-607d-49ac-9f6f-38a21ffa5b31"
      unitRef="number">0.0485</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3f17e1a230b249b09dc6346803945e09_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzUtMi0xLTEtMA_d6a5f646-0640-4174-8e21-2957a2d9ba79"
      unitRef="usd">297000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6188505bd2214769b12b8c2e7a1c0463_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzUtNC0xLTEtMA_7aa75d9d-5c99-41a1-9610-ca86b6ade23a"
      unitRef="usd">393000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7fa9c5baa5cc4e97becb950d913da01f_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOmZlZmIxNDNmMGM0ZjQwM2ViMzZhNWQ5YjJjNWJiNzA0XzQ_2cd6da85-32a9-4eea-abeb-01ac938999c4"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie788a463953d40fc97d8f8e0d65f542d_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzYtMi0xLTEtMA_0faaf13c-570d-4338-a920-aadb9cd1ebbe"
      unitRef="usd">496000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i0244efd886bd4bd289f13fdfc63a76b3_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzYtNC0xLTEtMA_1d9562af-49a0-44fe-be85-dac2953c0b4d"
      unitRef="usd">640000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5d3f77d18cb74144b8514b9fd3021780_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmRjZDdmODFmYjBiNzRmOGY5YWQxNDgzYzQzMGZlYzY0XzQ_9e190d82-4af5-49eb-9f5c-a9223c9c750f"
      unitRef="number">0.0370</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iab5c42e4384e4963a7ae278858dc9a3b_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzctMi0xLTEtMA_436452df-d1e3-4c61-bcc9-ae68d78e8b7b"
      unitRef="usd">1975000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5c7ebdcd26aa43d5be5ef11db34b14e8_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzctNC0xLTEtMA_72293323-5986-44a3-88a5-e15bcb1522ed"
      unitRef="usd">2319000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7bb0296c854c4acf871e0335393ec672_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjk5ZDA4MzJmNTI5YzQ4YWE5YTI3NTI4ODVlNTNjNzQ5XzQ_3438fd50-b068-498e-bfbd-bf98d5a3242a"
      unitRef="number">0.0375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i25548ce1ad154cad9b4737a0931325b0_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzgtMi0xLTEtMA_cf8e431e-c00c-45c3-b181-145f397bdc7b"
      unitRef="usd">974000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i4e73ad17867f4918ae13cdb77b42664d_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzgtNC0xLTEtMA_f33a717e-2899-4d58-b5d4-92853c4c236c"
      unitRef="usd">1157000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0ea1027adfa8409fa2240d2e0d15da0b_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjE1MTQ3ODUzMzBhNzQ4ZTViODI5NzQ4YzY4ODliYTc0XzQ_a7dfd161-9aec-4d52-9bc2-f3c6af7289da"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="idd27580aa37f4a75b8b17887161c3adc_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzktMi0xLTEtMA_f6ff9a47-0f88-42b9-89ec-13d4c4477994"
      unitRef="usd">743000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if98b3204979e45fb982f58b3cbb646c0_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfMzktNC0xLTEtMA_33157e99-d675-497e-8ede-aedb522fc1c3"
      unitRef="usd">860000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ida0748410a8c4eab9d417837ec838a91_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjBkZmQ2MmNlOTk4NjQ0ZDk5YjA3YTQ5Y2Y2OWRhM2ZlXzQ_d8949ef7-e234-482c-90ae-880fcd7382fe"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i483018bed3724cac829e9c16115d7f55_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNDAtMi0xLTEtMA_2e057b2c-2d7a-4cfc-91a1-52ee0a732c4a"
      unitRef="usd">986000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i193c04c9acbf4263b63c3eda25c9c4c8_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNDAtNC0xLTEtMA_ad76af18-2b67-47ba-a595-40a2da92eb06"
      unitRef="usd">928000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i15cf4b9be03f47eba85d4614348d2034_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNDEtMC0xLTEtMC90ZXh0cmVnaW9uOjA1ZWI0OWYyYzJmYjRmYzM4MjMzZmE1YzNhZTJiNjBlXzQ_aa36c813-5ec6-47ce-b63b-3862f2206769"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i427dbcfc1b924d82bfa86831fd546f1c_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNDEtMi0xLTEtMA_37213dfb-8667-4f02-a2a2-c0a4181336e1"
      unitRef="usd">1225000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic0be6f6c2cd547e687ae5108ce9ac42a_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNDEtNC0xLTEtMA_93fd5c84-a44b-4477-b5f2-2bbe0ccb15ba"
      unitRef="usd">1150000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7ba0ab6b51254970ba452db5939f0a54_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNDItMi0xLTEtMA_071de91a-8afe-4d1a-82a1-d8355d064410"
      unitRef="usd">5000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="idedd08cef78740fc9f67f0cf86fb8ba7_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNDItNC0xLTEtMA_950fe79e-53f1-4b4e-aec4-33957caf6852"
      unitRef="usd">6000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i18389b6ef2374d3c823b640e24fe8d12_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNDMtMi0xLTEtMA_268446ec-ed35-4db8-a663-cc64a30612a3"
      unitRef="usd">30130000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic4204d24c6ab4dfa89a1c5d5867933ce_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RhYmxlOmNkZjQ5OWUwY2RmODQ5NmJhNzQzNTFjY2ZlY2U3OTBjL3RhYmxlcmFuZ2U6Y2RmNDk5ZTBjZGY4NDk2YmE3NDM1MWNjZmVjZTc5MGNfNDMtNC0xLTEtMA_54d529e8-7c36-4448-9c25-f1f218b0d685"
      unitRef="usd">33571000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTE0OTg_150ee395-16d1-4335-adcf-8e10f2871287"
      unitRef="number">0.0298</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <jnj:ExcessOfFairValueOverCarryingValueOfDebt
      contextRef="i6e38f2e44f714a3d8fd4adc7b4276d3d_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTE1Nzg_8c79059e-6110-4500-be26-900db18b690c"
      unitRef="usd">5400000000</jnj:ExcessOfFairValueOverCarryingValueOfDebt>
    <us-gaap:ShortTermBorrowings
      contextRef="ia1e15dae48b34058996995a2834d63fe_I20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTE2NDU_7b1ef5f0-01a1-41b8-82c9-34291d5123b7"
      unitRef="usd">1300000000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="ia1e15dae48b34058996995a2834d63fe_I20211003"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTE3MTQ_f112bc26-0ec9-4ab3-abcc-d2ce9a69a2eb"
      unitRef="number">0.0008</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentTerm
      contextRef="i0ac5b17e0fad468a80e8667a23da5ace_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV82NC9mcmFnOmI0YzY4MzJhNDI1NDQ3M2ZiNDZjOGM4MTU1ODg3ZDg0L3RleHRyZWdpb246YjRjNjgzMmE0MjU0NDczZmI0NmM4YzgxNTU4ODdkODRfMTE3NjY_bbd3914a-27c8-4908-900e-0be63d1335cd">P3M</us-gaap:DebtInstrumentTerm>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfNDEzNQ_dfc927df-4dd9-4c06-ba10-ea4476e3d935">INCOME TAXES&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The worldwide effective income tax rates for the fiscal nine months of 2021 and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;2020 were 10.0% an&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;d 12.6%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In the second fiscal quarter of 2021, the Company reorganized the ownership structure of certain wholly-owned international subsidiaries. As part of this reorganization, the Company increased the tax basis of certain assets to fair value in accordance with applicable local regulations.  Accordingly, the Company recorded a local deferred tax benefit of approximately $2.3&#160;billion, which was partially offset by a related increase in the U.S. GILTI deferred tax liability of approximately $1.7&#160;billion. The net impact of this restructuring was approximately $0.6&#160;billion net benefit or 3.4% decrease to the 2021 year-to-date effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In 2019, Switzerland enacted the Federal Act on Tax Reform and AHV Financing (TRAF), which became effective on January 1, 2020. More information on the provisions of TRAF can be found in the Company&#x2019;s Annual Report on Form 10-K for the year ended January 3, 2021. During the first fiscal quarter of 2020, the final canton where the Company maintains significant operations enacted TRAF legislation and, accordingly, the Company recorded a deferred tax benefit of approximately $0.3&#160;billion for the remeasurement of existing deferred tax liabilities offset by a related $0.2&#160;billion increase in U.S. GILTI deferred taxes. During the second fiscal quarter of 2020, the Company received rulings from the Swiss Federal and cantonal tax authorities in the remaining jurisdictions where it has significant operations. These rulings resulted in the Company increasing the tax basis of certain assets to fair value. As a result, the Company recorded additional deferred tax benefits in the second fiscal quarter of 2020 to recognize this step-up.  The total benefit recorded related to Swiss Tax reform in the fiscal nine months of 2020 was approximately $0.4&#160;billion, or 2.7% net benefit to the Company&#x2019;s year-to-date  effective tax rate, inclusive of the impact of U.S. GILTI deferred taxes. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Additionally the following items impacted the Company&#x2019;s effective tax rate as compared to the same period in the prior fiscal year:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt"&gt;as a result of the recent filing of the 2020 U.S. tax return, as well as the impact of non-recurring favorable tax items, the Company recorded a 1.0% net benefit to the effective tax rate for the fiscal nine months of 2021.   &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt"&gt;in the third quarter of 2021 the Company accrued additional legal expenses, $1.4&#160;billion for the Talc related litigation at an effective tax rate of 23.5% and $0.8&#160;billion for the Risperdal settlement at an effective tax rate of 16.4% (See note 11 to the Consolidated Financial Statements for more details).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt"&gt;in the third quarter of 2021 the Company recorded a partial IPR&amp;amp;D charge of $0.9&#160;billion for the Ottava intangible asset (acquired with the Auris Health acquisition in 2019) at an effective rate of 22.4% (See Notes 3 and 9 to the Consolidated Financial Statements for more details). &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt"&gt;in the fiscal nine months of 2020, the Company reduced a contingent consideration liability related to the 2019 Auris Health acquisition that benefited the fiscal nine months of 2020 tax rate by approximately 1.0% (see Note 4 to the Consolidated Financial Statements for more details). &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt"&gt;the Company had lower income in higher tax jurisdictions relative to lower tax jurisdictions as compared to the same period in the prior year. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company also generated additional tax benefits from stock-based compensation that were either exercised or vested during the first three fiscal quarters of 2021 and 2020.  Additionally the company has reversed unrecognized tax benefit liabilities in 2021 as a result of the completion of tax examinations in certain international jurisdictions. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As of October&#160;3, 2021, the Company had approximately $3.3 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. In other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;major jurisdictions where the Company conducts business, the years that remain open to tax audit or are under appeal go back to the year 2008. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfMTE0_7afa043e-1392-4f8e-9fb6-ee9b339a0204"
      unitRef="number">0.100</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfMTIx_3929c349-98ed-451b-8929-d725794e14dc"
      unitRef="number">0.126</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <jnj:DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfNTA3_cb60f183-a45d-40c9-bb6c-e74dd760dbf1"
      unitRef="usd">2300000000</jnj:DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization>
    <jnj:IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfNjE4_058447bc-ef4d-4d9a-b2e4-36c642139ad6"
      unitRef="usd">1700000000</jnj:IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfNjc3_5405c713-f0e3-4f53-be53-549d8ab4b658"
      unitRef="usd">600000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfNjk1_afdd6e53-71d0-4e89-a0a3-9e51537db1c0"
      unitRef="number">-0.034</jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent>
    <jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset
      contextRef="ic6211b8d8ccd49788ecbb637deed070a_D20191230-20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfMTIzMg_68db4da8-9947-4898-bc07-f3a3a1c9ad97"
      unitRef="usd">300000000</jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset>
    <jnj:IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI
      contextRef="ic6211b8d8ccd49788ecbb637deed070a_D20191230-20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfMTMxNA_04eef3fa-a94b-4610-8d96-d4cccf939440"
      unitRef="usd">200000000</jnj:IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI>
    <jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfMTg4MQ_e288d848-957f-4e98-830b-6b9dd0ed9913"
      unitRef="usd">400000000</jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset>
    <jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfMTg4OA_f19ed240-bcd1-4e8f-b5b9-1dcd86d3ea8a"
      unitRef="number">0.027</jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfNDk0NzgwMjMzMTgzMQ_19f8128e-4380-4bb1-a6c9-8c9cfcfe43b7"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <jnj:EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount
      contextRef="ice0924be1a6f4deb9320312504bf1648_D20210705-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfNDk0NzgwMjMzMTgzNw_7b4d866f-f999-4f4d-b192-2cc89600a3dd"
      unitRef="usd">1400000000</jnj:EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount>
    <jnj:EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent
      contextRef="ice0924be1a6f4deb9320312504bf1648_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfNDk0NzgwMjMzMTg1MQ_ee888547-03c1-48da-a852-4265fb4d46a5"
      unitRef="rate">0.235</jnj:EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent>
    <jnj:EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount
      contextRef="i0b4d8090e5a94aa6a43b8958bfdeabf1_D20210705-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfNDk0NzgwMjMzMTg1OA_26d3af91-d458-449f-8a12-feadf1d026d9"
      unitRef="usd">800000000</jnj:EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount>
    <jnj:EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent
      contextRef="i0b4d8090e5a94aa6a43b8958bfdeabf1_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfNDk0NzgwMjMzMTg3Mg_1f195ddf-d5fb-40c7-925a-3816590e970a"
      unitRef="rate">0.164</jnj:EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i9861446e76324a08b1c77c4fa0b1b5a3_D20210705-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfNDk0NzgwMjMzMTg3OQ_c61165a8-14fd-4331-a62b-eb989326819d"
      unitRef="usd">900000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i9861446e76324a08b1c77c4fa0b1b5a3_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfNDk0NzgwMjMzMTg5Mw_c8f44334-cd3c-4dc9-ad6c-4adb69a5a425"
      unitRef="number">0.224</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent
      contextRef="ie6bf26a76e934a0abbe42eb60a86e6f4_D20191230-20200927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfNDk0NzgwMjMzMTkxNw_9407eb64-1670-408c-bc91-4e63c0c50117"
      unitRef="number">0.010</jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i524495c8e7d941efbc4c7057a7d882bf_I20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83MC9mcmFnOjM3M2Q4NmQ0N2IwMjQ1NjliMmUyZDI1ODkwNGUxNTIzL3RleHRyZWdpb246MzczZDg2ZDQ3YjAyNDU2OWIyZTJkMjU4OTA0ZTE1MjNfMzI4OQ_f8ac4238-1111-4b61-aaf5-eb9e9ee02d00"
      unitRef="usd">3300000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RleHRyZWdpb246MmFiZDM4NWI2NzAxNGE5MGI5NDlhNTA1NjZkZjMxOTNfODkw_46b8584b-802f-49f5-93c2-cfcbed5a2362">PENSIONS AND OTHER BENEFIT PLANS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of Net Periodic Benefit Cost&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net periodic benefit costs for the Company&#x2019;s defined benefit retirement plans and other benefit plans include the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal Third Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(617)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company Contributions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the fiscal nine months ended October&#160;3, 2021, the Company contributed $71 million and $232 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RleHRyZWdpb246MmFiZDM4NWI2NzAxNGE5MGI5NDlhNTA1NjZkZjMxOTNfODg3_c4b7600c-30db-4e85-9617-32587a03070e">Net periodic benefit costs for the Company&#x2019;s defined benefit retirement plans and other benefit plans include the following components:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal Third Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(617)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i1a7e0b9b6e694546bcf63ba4da67114c_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMy0yLTEtMS0w_ed55ef0f-aeca-434a-a8c7-a2c155d0be67"
      unitRef="usd">339000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i6d181abffa774cef94773798ffcbc773_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMy00LTEtMS0w_e32133a2-ad57-4d77-98cc-e0978f55fc1d"
      unitRef="usd">330000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="iae538c397d5b4172843ae849a0fa8309_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMy02LTEtMS0w_2f509452-fe43-4452-98ac-d667476d49f3"
      unitRef="usd">78000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i0db0747f8e0e4cf9ad8b2c2022602317_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMy04LTEtMS0w_92a6b74f-a5eb-4988-b15f-e10a00b15460"
      unitRef="usd">72000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i8f89fe3ec42c4ee6b74d0ae62c74a640_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMy0xMC0xLTEtMA_25df1661-3318-46cc-837c-3f8ef6e95b71"
      unitRef="usd">1019000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ie8ad9c18d6ef430fa4f2b3d36ff46598_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMy0xMi0xLTEtMA_91ab5520-3397-48bb-aabf-8dd64c7c9e4e"
      unitRef="usd">979000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="icb909ef9c68340daae79d3dce5aa8dc4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMy0xNC0xLTEtMA_5df48f68-6d48-46e5-bddb-a452d67a7b60"
      unitRef="usd">232000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="iaf1dec1c43ca4835b67df10da682c97a_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMy0xNi0xLTEtMA_63ec0edc-cfd2-41e1-b5d4-30a4f58de642"
      unitRef="usd">216000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i1a7e0b9b6e694546bcf63ba4da67114c_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNC0yLTEtMS0w_40076091-46cc-429d-a272-aa0dbfbbae0f"
      unitRef="usd">192000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i6d181abffa774cef94773798ffcbc773_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNC00LTEtMS0w_56056fa2-4583-4133-a0c5-7a1cc8883f82"
      unitRef="usd">238000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="iae538c397d5b4172843ae849a0fa8309_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNC02LTEtMS0w_750d27d6-4292-4775-8a60-a328a89cc1f1"
      unitRef="usd">20000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i0db0747f8e0e4cf9ad8b2c2022602317_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNC04LTEtMS0w_cfbd8840-867c-4fde-9206-2da5e7c0afd5"
      unitRef="usd">33000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i8f89fe3ec42c4ee6b74d0ae62c74a640_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNC0xMC0xLTEtMA_bc623b8d-292f-4903-af62-d8be43af0d0c"
      unitRef="usd">578000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ie8ad9c18d6ef430fa4f2b3d36ff46598_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNC0xMi0xLTEtMA_4f2263e3-4919-4c1c-9308-0205bfbeea44"
      unitRef="usd">715000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="icb909ef9c68340daae79d3dce5aa8dc4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNC0xNC0xLTEtMA_a48fb0f9-baff-4c86-b53d-0c69fe1adb11"
      unitRef="usd">61000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="iaf1dec1c43ca4835b67df10da682c97a_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNC0xNi0xLTEtMA_12ccdda3-cdd5-42cc-b1d8-baf69bfd0f48"
      unitRef="usd">99000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i1a7e0b9b6e694546bcf63ba4da67114c_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNS0yLTEtMS0w_921d233c-a00a-4fb6-9d5e-6aed1c80e7a3"
      unitRef="usd">661000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i6d181abffa774cef94773798ffcbc773_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNS00LTEtMS0w_f3475b35-f5bb-4ac4-bc87-515a03e46bfa"
      unitRef="usd">617000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="iae538c397d5b4172843ae849a0fa8309_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNS02LTEtMS0w_aff2bce0-afb3-49ad-9019-3cba2b7bab0a"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i0db0747f8e0e4cf9ad8b2c2022602317_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNS04LTEtMS0w_64322ca5-ef98-4096-895e-30c65f762fe5"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i8f89fe3ec42c4ee6b74d0ae62c74a640_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNS0xMC0xLTEtMA_0cf74e07-a56d-4120-9597-fe6e5c251ad3"
      unitRef="usd">1988000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ie8ad9c18d6ef430fa4f2b3d36ff46598_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNS0xMi0xLTEtMA_6cfdadb9-4d44-4f96-b2f2-d6e849fa3d12"
      unitRef="usd">1839000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="icb909ef9c68340daae79d3dce5aa8dc4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNS0xNC0xLTEtMA_451dc268-9c99-418e-baf5-2975c370b4a2"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="iaf1dec1c43ca4835b67df10da682c97a_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNS0xNi0xLTEtMA_b4a32a29-40d0-405d-a5ca-c2c5b27f1d67"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i1a7e0b9b6e694546bcf63ba4da67114c_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNi0yLTEtMS0w_7acce750-2772-4026-8204-b47390edae2c"
      unitRef="usd">-46000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i6d181abffa774cef94773798ffcbc773_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNi00LTEtMS0w_fb853693-7bcb-4aac-a827-4f9d74c14dab"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="iae538c397d5b4172843ae849a0fa8309_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNi02LTEtMS0w_01c7c513-95aa-49be-a1ed-52f5b1823668"
      unitRef="usd">-8000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i0db0747f8e0e4cf9ad8b2c2022602317_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNi04LTEtMS0w_5f564800-b185-46bb-9600-3216feb5b27b"
      unitRef="usd">-7000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i8f89fe3ec42c4ee6b74d0ae62c74a640_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNi0xMC0xLTEtMA_42665e3a-b946-4ab5-bec2-0526d7fe28ba"
      unitRef="usd">-136000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ie8ad9c18d6ef430fa4f2b3d36ff46598_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNi0xMi0xLTEtMA_a2ff0b3d-8756-47e1-a551-93a2b809edf9"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="icb909ef9c68340daae79d3dce5aa8dc4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNi0xNC0xLTEtMA_4b147291-b6e7-436a-b34a-86967cda4e4b"
      unitRef="usd">-23000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="iaf1dec1c43ca4835b67df10da682c97a_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfNi0xNi0xLTEtMA_e9e6dc20-b32d-4058-a5cc-db0030a9b1bf"
      unitRef="usd">-23000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i1a7e0b9b6e694546bcf63ba4da67114c_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOC0yLTEtMS0w_bb3898a2-a7f8-450c-89d4-fbd21d65b61c"
      unitRef="usd">-314000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i6d181abffa774cef94773798ffcbc773_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOC00LTEtMS0w_2efd301b-30d5-45e1-8f5d-49f6b3f6d6bb"
      unitRef="usd">-224000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="iae538c397d5b4172843ae849a0fa8309_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOC02LTEtMS0w_dc501326-e3ef-495f-b4f6-48420d38151b"
      unitRef="usd">-38000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i0db0747f8e0e4cf9ad8b2c2022602317_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOC04LTEtMS0w_10a2dbd1-fb04-4eb0-901f-df608257696a"
      unitRef="usd">-36000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i8f89fe3ec42c4ee6b74d0ae62c74a640_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOC0xMC0xLTEtMA_ed74d85f-ea20-407f-ae09-8cc91cdeca72"
      unitRef="usd">-944000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ie8ad9c18d6ef430fa4f2b3d36ff46598_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOC0xMi0xLTEtMA_974bf7b8-8a71-47f5-8a65-c5841907df9e"
      unitRef="usd">-669000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="icb909ef9c68340daae79d3dce5aa8dc4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOC0xNC0xLTEtMA_c1f9fb54-573e-4a75-a902-b5238a92064d"
      unitRef="usd">-113000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="iaf1dec1c43ca4835b67df10da682c97a_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOC0xNi0xLTEtMA_6eb15ef7-fd6c-4c1f-ad2f-7e8d36241674"
      unitRef="usd">-107000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i1a7e0b9b6e694546bcf63ba4da67114c_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOS0yLTEtMS0w_f32275fe-97a5-44e1-899b-ba9387622d15"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i6d181abffa774cef94773798ffcbc773_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOS00LTEtMS0w_d0708f19-dfb6-497f-bd1a-1b876d6720e2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="iae538c397d5b4172843ae849a0fa8309_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOS02LTEtMS0w_6f90a824-d633-4f52-88aa-10aacd5f98dd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i0db0747f8e0e4cf9ad8b2c2022602317_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOS04LTEtMS0w_d23a7e49-f400-445f-8de2-f1c6a7590255"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i8f89fe3ec42c4ee6b74d0ae62c74a640_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOS0xMC0xLTEtMA_1a519542-5bd5-4018-b66f-88bdc1a85180"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="ie8ad9c18d6ef430fa4f2b3d36ff46598_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOS0xMi0xLTEtMA_91077076-3041-4e68-954a-bfbefbfbca2b"
      unitRef="usd">-19000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="icb909ef9c68340daae79d3dce5aa8dc4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOS0xNC0xLTEtMA_856e81e8-4131-44d4-a473-cc1bf96010b7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="iaf1dec1c43ca4835b67df10da682c97a_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfOS0xNi0xLTEtMA_ae21c848-159a-449c-b42c-9cc9be623b27"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i1a7e0b9b6e694546bcf63ba4da67114c_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMTAtMi0xLTEtMA_fbd6f015-e035-4c04-838e-4455cc467345"
      unitRef="usd">138000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i6d181abffa774cef94773798ffcbc773_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMTAtNC0xLTEtMA_42218c88-0623-4883-a9d7-381cad7c1517"
      unitRef="usd">175000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="iae538c397d5b4172843ae849a0fa8309_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMTAtNi0xLTEtMA_bf2293c1-189a-4a73-ab04-c5ae4dca3935"
      unitRef="usd">127000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i0db0747f8e0e4cf9ad8b2c2022602317_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMTAtOC0xLTEtMA_b31a0130-ee1b-424e-8a1d-f582baf6499e"
      unitRef="usd">132000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i8f89fe3ec42c4ee6b74d0ae62c74a640_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMTAtMTAtMS0xLTA_81a51b17-2643-4556-ab74-ec922e67a401"
      unitRef="usd">418000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ie8ad9c18d6ef430fa4f2b3d36ff46598_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMTAtMTItMS0xLTA_f635229e-8382-46da-86ec-4ab6279f4f7a"
      unitRef="usd">544000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="icb909ef9c68340daae79d3dce5aa8dc4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMTAtMTQtMS0xLTA_bd505ad8-2e2a-4ccb-a852-ea744d6ae370"
      unitRef="usd">378000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="iaf1dec1c43ca4835b67df10da682c97a_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RhYmxlOjU3YjA1ZjZlZGU4ZjRjNzE5M2I3MWRjMDNjNjExNjdiL3RhYmxlcmFuZ2U6NTdiMDVmNmVkZThmNGM3MTkzYjcxZGMwM2M2MTE2N2JfMTAtMTYtMS0xLTA_c2aab837-11fa-4618-af58-2c1b69d03731"
      unitRef="usd">394000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:PensionContributions
      contextRef="ieeff0339058f4ac9808b5eba4dc8ff41_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RleHRyZWdpb246MmFiZDM4NWI2NzAxNGE5MGI5NDlhNTA1NjZkZjMxOTNfNjIz_4c33e0c2-1ae7-4ab2-a2e9-77894f49e401"
      unitRef="usd">71000000</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="i87dfc4ba292d4afcaa274be4bf5a6019_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83My9mcmFnOjJhYmQzODViNjcwMTRhOTBiOTQ5YTUwNTY2ZGYzMTkzL3RleHRyZWdpb246MmFiZDM4NWI2NzAxNGE5MGI5NDlhNTA1NjZkZjMxOTNfNjMw_acfdd0fc-5384-4be9-b28a-e1ffd5f62cbf"
      unitRef="usd">232000000</us-gaap:PensionContributions>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RleHRyZWdpb246YTQxOGZlYzY2M2M4NDc1Yjk5OWRmZmM3MWU1NzQ1MTFfOTI3_5462b371-97da-4522-a757-38f88526995d">ACCUMULATED OTHER COMPREHENSIVE INCOME&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other comprehensive income (loss) consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.306%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Employee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Accumulated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;On&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;On Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Comprehensive&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&amp;amp; Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts in accumulated other comprehensive income are presented net of the related tax impact.  Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries.  For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details on reclassifications out of Accumulated Other Comprehensive Income:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain/(Loss) On Derivatives &amp;amp; Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RleHRyZWdpb246YTQxOGZlYzY2M2M4NDc1Yjk5OWRmZmM3MWU1NzQ1MTFfOTI5_de98f8c2-511c-4d83-b838-a0f556c2ca2a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other comprehensive income (loss) consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.306%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Employee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Accumulated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;On&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;On Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Comprehensive&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&amp;amp; Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6c9b670acb814f2e8e8cae1d3b139677_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNC0yLTEtMS0w_12078408-f937-4d89-8765-013d7ae4b660"
      unitRef="usd">-8938000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i49a74fa2fdfe4f89beaadf820f5ac713_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNC00LTEtMS0w_735a18a3-412a-483d-a25d-a170f9382ad1"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i40bb249c8086466faca49b2fa9bc2a92_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNC02LTEtMS0w_b12c13c2-0444-400c-8ffa-fc42b9272d38"
      unitRef="usd">-6957000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i90665923dd1c4a2fa6d99222fb60dc98_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNC04LTEtMS0w_e25a9d07-c662-4148-a87d-aedc6c9f9db8"
      unitRef="usd">652000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib616b434ad574d54a671235ee0e19c40_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNC0xMC0xLTEtMA_e6bff0f0-a773-4b00-b93e-68f1f88be8c9"
      unitRef="usd">-15242000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="idfb362df49f946cc91574b4a35909613_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNS0yLTEtMS0w_2006916f-75cd-4849-9701-31cb858bb7d6"
      unitRef="usd">-241000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i32fd6f9a0ed9441682053b3f396c5491_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNS00LTEtMS0w_614f4ceb-362d-4412-9a7b-fca31a8cf922"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ifd186072d3fc4864a3c6f62ea4a983ec_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNS02LTEtMS0w_ad583850-0e38-4bdf-a1c6-cf10faeced32"
      unitRef="usd">700000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1585241dd83540d68d0d4bb0179b4c35_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNS04LTEtMS0w_f07cd0fb-329c-44ac-bba7-ba0e2d333d8a"
      unitRef="usd">-631000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i280f2f10a11c4c988142fed0ab0a55c4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNS0xMC0xLTEtMA_f4cb785a-4d62-4129-8876-08a6df35e47c"
      unitRef="usd">-173000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iae5d5570b0974f90b2b495ca2a503dae_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNy0yLTEtMS0w_973271a0-7adb-48d0-95a2-635d4df9db01"
      unitRef="usd">-9179000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9d619304e810451eaf68e4fe20b97b9e_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNy00LTEtMS0w_3552de3b-9e8f-40f5-9f8c-4ec5b464f4dc"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idc89c7db9aca490ebbcb9ac5ff66d285_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNy02LTEtMS0w_bc823686-d9b3-42f9-aabb-9468cc952bc8"
      unitRef="usd">-6257000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id1ed865a3a524e718fe97e4283367b0d_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNy04LTEtMS0w_fac21684-14ec-4e71-a995-5a91c3dd89d1"
      unitRef="usd">21000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idd88e9907aaf4e8cbca11111329e2073_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83Ni9mcmFnOmE0MThmZWM2NjNjODQ3NWI5OTlkZmZjNzFlNTc0NTExL3RhYmxlOmFiNjNkMzg4NTRlOTQ2MzVhMTI5Nzc2YjcyNGZmYjUyL3RhYmxlcmFuZ2U6YWI2M2QzODg1NGU5NDYzNWExMjk3NzZiNzI0ZmZiNTJfNy0xMC0xLTEtMA_4fd5ab69-5ee6-498d-94a9-b923e1bb6fa6"
      unitRef="usd">-15415000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RleHRyZWdpb246ZmUzOGYyNDM5YjIxNDgyNzljNjcxNjJlODAwYzZmMmVfMTQ5MQ_1caeaad4-ee29-4244-a49d-5a8d8d32fb5a">EARNINGS PER SHARE&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of basic net earnings per share to diluted net earnings per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Third Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Shares in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net earnings per share &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,633.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential shares exercisable under stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: shares which could be repurchased under treasury stock method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,674.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,669.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,674.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,670.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The diluted net earnings per share calculation for the fiscal third quarter ended October&#160;3, 2021 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company&#x2019;s stock. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The diluted net earnings per share calculation for the fiscal third quarter ended September&#160;27, 2020 excluded 20&#160;million shares related to stock options, as the exercise price of these options was greater than their average market value. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The diluted net earnings per share calculation for the fiscal nine months ended October&#160;3, 2021 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company's stock.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The diluted net earnings per share calculation for the fiscal nine months ended September&#160;27, 2020 excluded 17&#160;million shares related to stock options, as the exercise price of these options was greater than their average market value.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RleHRyZWdpb246ZmUzOGYyNDM5YjIxNDgyNzljNjcxNjJlODAwYzZmMmVfMTQ5NA_212a9b99-fc31-476c-bd15-e9d9100579a2">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of basic net earnings per share to diluted net earnings per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Third Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Shares in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net earnings per share &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,633.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential shares exercisable under stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: shares which could be repurchased under treasury stock method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,674.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,669.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,674.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,670.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfMi0yLTEtMS0w_69d94152-4963-4ba3-a140-3d10a66e1147"
      unitRef="usdPerShare">1.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfMi00LTEtMS0w_7a56abdb-a583-4ca5-8a0a-6c7fbb391d85"
      unitRef="usdPerShare">1.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfMi02LTEtMS0w_5d955522-b950-48ff-a8cb-d95e8c173f06"
      unitRef="usdPerShare">6.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfMi04LTEtMS0w_9c4b7207-ce9c-4fb7-8fff-14664ed2fe5a"
      unitRef="usdPerShare">4.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfMy0yLTEtMS0w_88d79de9-2b00-418d-be5f-aa2833596334"
      unitRef="shares">2632600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfMy00LTEtMS0w_1d0d2994-1648-4192-bac4-fc51152c30ee"
      unitRef="shares">2632500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfMy02LTEtMS0w_2eb64105-3e4c-4f32-9ca0-cce55a808c53"
      unitRef="shares">2632200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfMy04LTEtMS0w_b7a65e19-2b86-4b6c-9fc0-fca22aea9850"
      unitRef="shares">2633000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfNC0yLTEtMS0w_bdaf8586-3db7-4c16-b919-ece11b52e4f0"
      unitRef="shares">138300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfNC00LTEtMS0w_a460b375-8e92-4345-8eed-639b0d745224"
      unitRef="shares">115700000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfNC02LTEtMS0w_45431f98-fce2-425f-be31-06296d177269"
      unitRef="shares">139100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfNC04LTEtMS0w_3ea612fa-077c-4a28-a531-80a8bc4edfd8"
      unitRef="shares">120200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfNS0yLTEtMS0w_07b33048-3eb5-49b3-8df6-15e50e5d1b23"
      unitRef="shares">96000000.0</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfNS00LTEtMS0w_41cb7a10-51c1-4c74-8c6a-93f6b40aa5ed"
      unitRef="shares">78900000</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfNS02LTEtMS0w_1b7cd632-8011-4c4a-9bdc-cc9b5c2ee57c"
      unitRef="shares">96700000</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfNS04LTEtMS0w_6bb9c60f-ee61-4867-9485-cf1f881798f3"
      unitRef="shares">82400000</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfNy0yLTEtMS0w_d8cf4b5c-f360-4947-b215-8e1dfd7a0397"
      unitRef="shares">2674900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfNy00LTEtMS0w_2c9465ca-9f27-44bb-9a96-ca99005ccdcf"
      unitRef="shares">2669300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfNy02LTEtMS0w_f1950867-7f69-4f83-bd4c-3c21f0bbb86d"
      unitRef="shares">2674600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfNy04LTEtMS0w_7a462450-ba9c-44c9-a681-7d0e4d595851"
      unitRef="shares">2670800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfOC0yLTEtMS0w_62b6259e-03cb-4fe1-981b-80a2e640e257"
      unitRef="usdPerShare">1.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfOC00LTEtMS0w_c3a8f62a-9253-470b-91a9-cbda1a6724a1"
      unitRef="usdPerShare">1.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfOC02LTEtMS0w_2373aabb-03e5-44d0-ad65-e0fb46626a79"
      unitRef="usdPerShare">6.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RhYmxlOmM1NmI0NjQ0OGJjZDRkZDdiZmFmOWJhN2Y0ZmQ3YTdhL3RhYmxlcmFuZ2U6YzU2YjQ2NDQ4YmNkNGRkN2JmYWY5YmE3ZjRmZDdhN2FfOC04LTEtMS0w_4101123a-9eec-42e1-abff-3e5091e8c82c"
      unitRef="usdPerShare">4.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RleHRyZWdpb246ZmUzOGYyNDM5YjIxNDgyNzljNjcxNjJlODAwYzZmMmVfNTM3_ee8ddb68-cbfa-4fb5-8567-fa87a3fc4fc6"
      unitRef="shares">20000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV83OS9mcmFnOmZlMzhmMjQzOWIyMTQ4Mjc5YzY3MTYyZTgwMGM2ZjJlL3RleHRyZWdpb246ZmUzOGYyNDM5YjIxNDgyNzljNjcxNjJlODAwYzZmMmVfMTE4OA_fab25cd1-a16b-43a1-8b8b-14ecebcc167c"
      unitRef="shares">17000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMjU5MQ_2b026b53-941e-41a5-b68e-b1a4d72db870">SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SALES BY SEGMENT OF BUSINESS &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Third Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 27,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 27,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skin Health/Beauty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oral Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Baby Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Women's Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Wound Care/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:168pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Exports&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SIMPONI / SIMPONI ARIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;STELARA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TREMFYA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER IMMUNOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Infectious Diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;COVID-19 VACCINE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EDURANT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / rilpivirine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;PREZISTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / PREZCOBIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; /&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;                                    &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;            REZOLSTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / SYMTUZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER INFECTIOUS DISEASES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONCERTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / methylphenidate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / XEPLION&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / INVEGA   TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / TREVICTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;RISPERDAL CONSTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER NEUROSCIENCE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;DARZALEX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ERLEADA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;* &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;* &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; / &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;abiraterone acetate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER ONCOLOGY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pulmonary Hypertension&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;UPTRAVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER PULMONARY HYPERTENSION&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cardiovascular / Metabolism / Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;PROCRIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / EPREX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;MEDICAL DEVICES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interventional Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Orthopaedics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;HIPS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;KNEES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TRAUMA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SPINE, SPORTS &amp;amp; OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Surgery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ADVANCED&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;GENERAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONTACT LENSES / OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SURGICAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL MEDICAL DEVICES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;WORLDWIDE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*Percentage greater than 100% or not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inclusive of VELCADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which was previously disclosed separately&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Third Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 27,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 27,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer Health &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.7)%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Devices&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment earnings before provision for taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Expense not allocated to segments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide income before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.5)%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*Percentage greater than 100% or not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Consumer Health&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Includes intangible amortization expense of $0.1 billion in both the fiscal third quarter of 2021 and 2020 and $0.3&#160;billion in both the fiscal nine months of 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Includes litigation expense of $1.4&#160;billion and $0.5&#160;billion in the fiscal third quarter of 2021 and 2020, respectively. Includes litigation expense of  $1.5&#160;billion and $1.2&#160;billion in the fiscal nine months of 2021 and 2020, respectively. Litigation expense in both periods is primarily related to talc.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Includes a restructuring related charge of $0.1&#160;billion in both the fiscal nine months of 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Pharmaceutical&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes divestiture gains of $0.6&#160;billion in the fiscal nine months of 2021 related to two brands outside the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes intangible amortization expense of $0.8&#160;billion in both the fiscal third quarter of 2021 and 2020. Includes intangible amortization expense of $2.5&#160;billion and $2.4&#160;billion in the fiscal nine months of 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes net litigation expense of $0.8&#160;billion and $1.0&#160;billion in the fiscal third quarter of 2021 and 2020, respectively. Includes net litigation expense of  $0.7&#160;billion and $1.0&#160;billion in the fiscal nine months of 2021 and 2020, respectively. Litigation expense in 2021 is primarily related to Risperdal. Litigation expense in 2020 is related to the opioid settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes a gain on securities of $0.1&#160;billion in the fiscal third quarter of 2021 and $0.2&#160;billion in both the fiscal nine months of 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes a restructuring related charge of $0.1&#160;billion in both the fiscal nine months of 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In fiscal 2020 and 2021, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $1.2&#160;billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Devices &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes a contingent consideration reversal of $0.2&#160;billion in the fiscal third quarter of 2020 and $1.1&#160;billion in the fiscal nine months of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes a restructuring related charge of $0.1 billion in both the fiscal third quarter of 2021 and 2020, respectively. Includes a restructuring related charge of $0.2&#160;billion in both the fiscal nine months of 2021 and 2020, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes intangible amortization expense of $0.3&#160;billion and $0.2&#160;billion in the fiscal third quarter of 2021 and 2020, respectively. Includes intangible amortization expense of $0.8&#160;billion and $0.7&#160;billion in the fiscal nine months of 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes a gain on securities of $0.1&#160;billion in the fiscal nine months of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Includes an in-process research and development expense of $0.9&#160;billion related to the general surgery offering in digital robotics (Ottava) acquired with the Auris Health acquisition in 2019 in both the fiscal third quarter and fiscal nine months of 2021. See Note 3 to the Consolidated Financial Statements for more details.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Amounts not allocated to segments include interest income/expense and general corporate income/expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SALES BY GEOGRAPHIC AREA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.279%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.486%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.889%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.486%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.889%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.486%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.339%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.486%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Third Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Western Hemisphere, excluding U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia-Pacific, Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <jnj:SalesBySegmentOfBusinessTableTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMjU4MA_7493cca7-b8ae-47ec-8a50-b6d6d33b5dc6">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SALES BY SEGMENT OF BUSINESS &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Third Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 27,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 27,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skin Health/Beauty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oral Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Baby Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Women's Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Wound Care/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:168pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Exports&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SIMPONI / SIMPONI ARIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;STELARA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TREMFYA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER IMMUNOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Infectious Diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;COVID-19 VACCINE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EDURANT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / rilpivirine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;PREZISTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / PREZCOBIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; /&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;                                    &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;            REZOLSTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / SYMTUZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER INFECTIOUS DISEASES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONCERTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / methylphenidate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / XEPLION&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / INVEGA   TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / TREVICTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;RISPERDAL CONSTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER NEUROSCIENCE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;DARZALEX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ERLEADA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;* &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;* &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; / &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;abiraterone acetate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER ONCOLOGY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pulmonary Hypertension&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;UPTRAVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER PULMONARY HYPERTENSION&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cardiovascular / Metabolism / Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;PROCRIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / EPREX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;MEDICAL DEVICES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interventional Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Orthopaedics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;HIPS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;KNEES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TRAUMA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SPINE, SPORTS &amp;amp; OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Surgery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ADVANCED&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;GENERAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONTACT LENSES / OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SURGICAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL MEDICAL DEVICES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;WORLDWIDE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*Percentage greater than 100% or not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inclusive of VELCADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which was previously disclosed separately&lt;/span&gt;&lt;/div&gt;</jnj:SalesBySegmentOfBusinessTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5932fe6bc8874865bd9bae6cd5c4e149_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNS0yLTEtMS0w_7ff5a007-42fb-4ed0-98f3-d2737fe48bf4"
      unitRef="usd">686000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9863b76d1752421eab7f10a27e21c3a6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNS00LTEtMS0w_f9b245f6-fba0-476b-894c-205da08a06aa"
      unitRef="usd">601000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5932fe6bc8874865bd9bae6cd5c4e149_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNS02LTEtMS0w_d3deaad5-99a3-4fa0-a159-3bf9b9138853"
      unitRef="number">0.140</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8648858c71084557978cd6faeca2cacd_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNS04LTEtMS0w_6fe72279-3c8e-472f-9a30-491268678f7d"
      unitRef="usd">1960000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38fb4207f4f44740a27e0c6df6aeb726_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNS0xMC0xLTEtMA_1e7a607f-1150-432d-b2c3-ee87a1c75f72"
      unitRef="usd">1917000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8648858c71084557978cd6faeca2cacd_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNS0xMi0xLTEtMA_b8293154-260d-4875-a257-3a3be26b906b"
      unitRef="number">0.022</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1c9f29f75fe43e4847364d3f7c39cab_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNi0yLTEtMS0w_673dcf62-f6d4-4e55-b218-b15dab3f3008"
      unitRef="usd">686000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7a63d17adab4e81bbe6f8151842a30c_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNi00LTEtMS0w_3ebe878d-5a5a-4167-b128-34bc4d82cf94"
      unitRef="usd">541000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib1c9f29f75fe43e4847364d3f7c39cab_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNi02LTEtMS0w_7f982590-8cd8-4970-82f8-878db6092aae"
      unitRef="number">0.269</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib646ba6c37f94afe9e3d21b88039c182_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNi04LTEtMS0w_08506df7-590f-41d0-a46f-3340a1900d12"
      unitRef="usd">1894000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f7b6f883fcb4fa4a9afe5cf3bdb0815_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNi0xMC0xLTEtMA_e45e0c76-a277-4024-b7da-9b8a4ce64709"
      unitRef="usd">1722000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib646ba6c37f94afe9e3d21b88039c182_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNi0xMi0xLTEtMA_7f455a7c-51b3-4403-9d51-cd2a910668cc"
      unitRef="number">0.100</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d28ecdc380c4101b6135c161dfad020_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNy0yLTEtMS0w_db9cf39f-492d-42e1-8f67-e78a166cd4a0"
      unitRef="usd">1372000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d474e7ed1044d528c7b1ffac5e15cea_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNy00LTEtMS0w_e6be5c79-1146-4afe-ab83-46b25c8bbb3f"
      unitRef="usd">1142000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6d28ecdc380c4101b6135c161dfad020_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNy02LTEtMS0w_58f489f1-2bec-4059-96ef-859b24300b87"
      unitRef="number">0.201</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie547a8c88fa940efb218427e0eabd0c6_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNy04LTEtMS0w_0bc7e374-586a-4dc4-b01e-0a130ac7d5d6"
      unitRef="usd">3854000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ddac223612a4d06a37f3fd6878493ca_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNy0xMC0xLTEtMA_34294058-cabc-4c07-a0bf-3ded0accf57c"
      unitRef="usd">3639000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie547a8c88fa940efb218427e0eabd0c6_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNy0xMi0xLTEtMA_93df5949-1846-49f0-b645-c98cb14d8c91"
      unitRef="number">0.059</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5975dabe875348b9b232e9e29d323eed_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOS0yLTEtMS0w_9cfa9a23-eb5f-494b-a30e-953492bead64"
      unitRef="usd">569000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i40ce11cf1c234e67b7e6b1a8988ba942_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOS00LTEtMS0w_e2992824-0fab-4794-b2e0-447805124e9f"
      unitRef="usd">572000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5975dabe875348b9b232e9e29d323eed_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOS02LTEtMS0w_06640b79-0364-44b7-8fa7-7f5526440d95"
      unitRef="number">-0.005</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0847920abf9d4769baf2ea560468bf0d_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOS04LTEtMS0w_a271b6da-78c8-40a4-81d3-b4609b5d41b2"
      unitRef="usd">1862000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifaf4498d8f5049aa8af464f01fcd4088_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOS0xMC0xLTEtMA_2a9cbc13-9702-45d4-b768-fff31d9c3f1c"
      unitRef="usd">1767000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0847920abf9d4769baf2ea560468bf0d_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOS0xMi0xLTEtMA_cc9cf64d-25f0-404e-b120-ecdbcc948d8b"
      unitRef="number">0.054</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37f5a592ff13494aada072e3bba0cea0_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAtMi0xLTEtMA_1fc44e50-cb14-4544-af7f-7f8396c91842"
      unitRef="usd">555000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd69d35e5a314c3f80c3949f37cc664f_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAtNC0xLTEtMA_dea74251-208f-41dc-aade-08ad65dbea87"
      unitRef="usd">577000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i37f5a592ff13494aada072e3bba0cea0_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAtNi0xLTEtMA_1a00d5dd-f326-4d1d-884c-dc93652620e5"
      unitRef="number">-0.038</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04f3d42910f54dbdbe61282d28955d56_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAtOC0xLTEtMA_b93a09a8-a6dd-4c8d-8f66-4e16cbb17f55"
      unitRef="usd">1595000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iddf4ba62d5ce4571a62ee75dcd2a8e3c_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAtMTAtMS0xLTA_796d33e3-7ddc-4737-b925-16053aa87daf"
      unitRef="usd">1506000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i04f3d42910f54dbdbe61282d28955d56_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAtMTItMS0xLTA_d885b162-3bab-4fa8-b7a6-2c0e00024716"
      unitRef="number">0.059</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2674760a7034ccdac2446519a5166a9_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEtMi0xLTEtMA_6ce49ed4-087b-4b19-8ca4-0153caecc87a"
      unitRef="usd">1124000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7da3b551671f44d192917a4c6f2efa57_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEtNC0xLTEtMA_371780e4-c77f-41a5-b2f3-f3832c6782ab"
      unitRef="usd">1149000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie2674760a7034ccdac2446519a5166a9_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEtNi0xLTEtMA_96c7fa10-c5b4-49d9-bf3b-1ab9fe6f55bb"
      unitRef="number">-0.022</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9f77528e7ac40108b66c8931a2c701e_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEtOC0xLTEtMA_9b8db0f7-f3b7-4e8d-9329-2bf71cc886d2"
      unitRef="usd">3457000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff3b6e1b8fdd425390328188812a6eb0_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEtMTAtMS0xLTA_e2403b8c-775d-48eb-83c9-40018599ad0f"
      unitRef="usd">3273000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id9f77528e7ac40108b66c8931a2c701e_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEtMTItMS0xLTA_e288000f-9a15-494f-abdd-98ecb679800d"
      unitRef="number">0.056</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic833af6372324ca3b5bfa4fcad54732c_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMtMi0xLTEtMA_6a4e6b1c-f57d-4ec9-99ed-4a14ace79c25"
      unitRef="usd">150000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i525fc27ed821404fb38182e25fa87eb5_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMtNC0xLTEtMA_6de390c4-dd42-478e-a06f-d0978af73996"
      unitRef="usd">164000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic833af6372324ca3b5bfa4fcad54732c_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMtNi0xLTEtMA_297250ab-0f90-41c1-b5a6-267372b1bf8e"
      unitRef="number">-0.084</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i55f1d4591fc84cfc8c2e037ca49db283_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMtOC0xLTEtMA_ce98aa63-1208-490a-98a6-51a7f9a44cdb"
      unitRef="usd">478000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibee17d8505bb4fe98b2e9fa97001fe0a_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMtMTAtMS0xLTA_ec2ad1cf-01d3-41e3-88c3-f55c068d3ef8"
      unitRef="usd">510000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i55f1d4591fc84cfc8c2e037ca49db283_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMtMTItMS0xLTA_40c2cff8-6ca2-4e38-9875-a9b3ff55e513"
      unitRef="number">-0.062</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8085b27842a47b581f106618510e63b_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQtMi0xLTEtMA_59993a86-ce74-40d4-9e92-7b020346c41d"
      unitRef="usd">248000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i050772dc13db458dae8ef05843e7c1e4_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQtNC0xLTEtMA_a86331b9-28de-41f5-b047-6099cedfc628"
      unitRef="usd">248000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic8085b27842a47b581f106618510e63b_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQtNi0xLTEtMA_b7639d4c-0276-4eb7-a7c4-fe1751aeffe7"
      unitRef="number">0.001</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie892e3f1014a404389b2b3050897a15c_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQtOC0xLTEtMA_1cc77646-5df4-4e11-847a-d43d72d1d634"
      unitRef="usd">762000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03fd89880da847f0a48e5cd794cb0e76_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQtMTAtMS0xLTA_7b853a9a-afd6-4f07-a95e-e57a24205827"
      unitRef="usd">694000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie892e3f1014a404389b2b3050897a15c_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQtMTItMS0xLTA_cfdd7fc1-8e2f-4dd7-af19-399573c61287"
      unitRef="number">0.099</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice21827a874a4c00b01f16ab3cf18368_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUtMi0xLTEtMA_e39dcbe2-a558-4acb-b266-2b5a9ff491c0"
      unitRef="usd">398000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iddf1dd064873494095b906942f5d38ed_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUtNC0xLTEtMA_eafcfbd0-98ce-4123-a7e9-e3be17b4356f"
      unitRef="usd">412000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ice21827a874a4c00b01f16ab3cf18368_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUtNi0xLTEtMA_ad9587d0-62f3-476a-b177-ec772f116bb6"
      unitRef="number">-0.033</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29ed38871138472c98810a5cd7f1dd95_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUtOC0xLTEtMA_38421dcf-9db7-4c47-a2fc-d9c21e5d58c7"
      unitRef="usd">1240000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf97184ab0f344fa943bfc3649c4080c_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUtMTAtMS0xLTA_1c732af2-1433-4edf-aedd-ea0c582337e9"
      unitRef="usd">1204000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i29ed38871138472c98810a5cd7f1dd95_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUtMTItMS0xLTA_486eb18a-905d-4753-8aae-31bf7329804a"
      unitRef="number">0.030</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba082d308e2e40fab4c4792324108b13_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTctMi0xLTEtMA_f2acd523-7f49-4fb6-91ac-3210047c2201"
      unitRef="usd">95000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i62d3c4191ff94bc2b0b06fd86e9ebbc2_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTctNC0xLTEtMA_9f1e7210-1a1b-4d92-926c-d453f3614249"
      unitRef="usd">91000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iba082d308e2e40fab4c4792324108b13_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTctNi0xLTEtMA_8e2e0618-657f-4f0d-9510-6e586392b50d"
      unitRef="number">0.052</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e4744bfcdba4605b67ce9cf20e5ed37_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTctOC0xLTEtMA_0266849c-e0f9-4c88-ab8c-a007e18e48a7"
      unitRef="usd">288000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a9371cd71e74f32b3d3425e7fa3120f_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTctMTAtMS0xLTA_0a9e5e29-d105-4ed9-a8e2-387ab5be19d2"
      unitRef="usd">279000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2e4744bfcdba4605b67ce9cf20e5ed37_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTctMTItMS0xLTA_a439968f-472c-47ea-94c5-53144eda17d5"
      unitRef="number">0.033</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c26ef7358064431907c0c0b8e35ca05_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTgtMi0xLTEtMA_ddf72218-8c69-4160-a7c9-be0a4094692d"
      unitRef="usd">296000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9015829b0dd4cc083d55eb4725146ad_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTgtNC0xLTEtMA_4b86c444-f90e-4cb8-a3bc-8276e5828fab"
      unitRef="usd">302000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9c26ef7358064431907c0c0b8e35ca05_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTgtNi0xLTEtMA_06fe83d8-2bf2-46d1-9796-4e575c013970"
      unitRef="number">-0.020</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i046a4a03db32475eb292807b6b65dc2a_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTgtOC0xLTEtMA_92f60a6d-5a63-4611-9f43-4cbe54b1065a"
      unitRef="usd">879000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i987662a6928046d9a653a39c7642a99a_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTgtMTAtMS0xLTA_f11e48e7-2a74-416b-90ff-46a3234c45df"
      unitRef="usd">831000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i046a4a03db32475eb292807b6b65dc2a_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTgtMTItMS0xLTA_6dee8d95-27e8-4a37-b2e7-aade2991a24a"
      unitRef="number">0.058</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf3567b227cf43b7b727c573098b1019_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTktMi0xLTEtMA_6be083f7-fb0c-4173-b6ca-b6734d3b4c55"
      unitRef="usd">391000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7fe2032b4fab44759101707824a42b5f_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTktNC0xLTEtMA_0c1cd166-4870-4570-af77-019e1d9613b0"
      unitRef="usd">393000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idf3567b227cf43b7b727c573098b1019_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTktNi0xLTEtMA_a7a725d3-f199-435d-b4c8-20a6334544c6"
      unitRef="number">-0.003</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if08e07c77ca240b6ac145790e6d91e27_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTktOC0xLTEtMA_436b23fc-f34a-4805-90a5-ba91de8a5d71"
      unitRef="usd">1167000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7237727cb89c4b3ca79fd4c8ab24fae8_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTktMTAtMS0xLTA_5434078c-746d-47ca-bd9b-e4ccde411fc1"
      unitRef="usd">1110000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if08e07c77ca240b6ac145790e6d91e27_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTktMTItMS0xLTA_18213182-4b2f-485b-9db8-39dc32c8c49f"
      unitRef="number">0.052</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i776cc9f3f12444e19c75d71e9f1306ab_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEtMi0xLTEtMA_9e08ebc8-97fb-458a-bcdb-cdb32eb904ac"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i42c653266dbc4cbfb3ad7de36334d59d_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEtNC0xLTEtMA_5cf53178-ae7f-4bee-a9e6-0fc75ff69cf8"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i776cc9f3f12444e19c75d71e9f1306ab_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEtNi0xLTEtMA_391b987f-fa3d-45ce-890f-905ce3aeef6b"
      unitRef="number">0.201</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf9f5672587c42ef82b704011560ab84_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEtOC0xLTEtMA_dccb320c-73ca-46b6-8535-620c9ff9ce04"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4cc4e2c56fe94f0ebb2696dfb6777df9_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEtMTAtMS0xLTA_8c49d092-3380-4ec0-b52d-ccc8ac9e4ec5"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icf9f5672587c42ef82b704011560ab84_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEtMTItMS0xLTA_0660395b-cebe-493e-84e9-44fc4250275f"
      unitRef="number">-0.057</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1864c3f454d54b6099348e1437264d1e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjItMi0xLTEtMA_e08e094b-9cc6-444e-bb9b-82eac690e864"
      unitRef="usd">229000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0001607d8afa4b969777538d3b0090ac_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjItNC0xLTEtMA_aa0057fc-a6aa-414c-9d25-cf82783a7160"
      unitRef="usd">227000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1864c3f454d54b6099348e1437264d1e_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjItNi0xLTEtMA_f7a310bc-e045-4158-8925-0b9ffd7cb861"
      unitRef="number">0.005</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe9e6fb867164bcab52ce074dbf7118b_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjItOC0xLTEtMA_b0948981-8f5c-4662-a6ba-3c6054a225b5"
      unitRef="usd">675000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f00d71bd5644d7386d54e5e7ba6f9aa_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjItMTAtMS0xLTA_d24b937f-e794-4c12-9111-cd28d565f5b2"
      unitRef="usd">654000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibe9e6fb867164bcab52ce074dbf7118b_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjItMTItMS0xLTA_8ffc0ae4-9879-43a0-b152-584f0813517c"
      unitRef="number">0.031</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f6ca30128844134ad0de910cf66a408_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMtMi0xLTEtMA_d0940cfe-af75-4937-abbf-e7059b0f92a7"
      unitRef="usd">232000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f8cb7b296594fc5add46b54007f21d3_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMtNC0xLTEtMA_8436edbf-655d-47a6-8165-05f40e110c62"
      unitRef="usd">230000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0f6ca30128844134ad0de910cf66a408_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMtNi0xLTEtMA_c87e85da-ccf9-4f7a-bee0-2e3fc0f80563"
      unitRef="number">0.008</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i988a335b32c84bc3982666bf61d8fd38_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMtOC0xLTEtMA_da334a04-92aa-4f23-8925-2e3556525140"
      unitRef="usd">684000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0f9db2930c7434cb55c268ec21f1fe3_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMtMTAtMS0xLTA_673e313f-200b-4350-a8b4-88d1b11a9588"
      unitRef="usd">664000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i988a335b32c84bc3982666bf61d8fd38_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMtMTItMS0xLTA_ae6b34f6-3261-4e3d-8b09-e5ace3f2c2c3"
      unitRef="number">0.030</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic97d6e50fa564ecfa01edcf954ca9b30_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjUtMi0xLTEtMA_6e72d6ed-0ec1-45c0-a2b3-0f2c5f6ef331"
      unitRef="usd">122000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ccb194a8c094e919fdb8681e73ce223_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjUtNC0xLTEtMA_84dfacdc-404a-4820-9582-5eddb03c7d6d"
      unitRef="usd">125000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic97d6e50fa564ecfa01edcf954ca9b30_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjUtNi0xLTEtMA_0d0041dc-6f31-4ffb-a6a3-66f26ef26bb2"
      unitRef="number">-0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf724d7bf6384a4d99527cb12064aaf7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjUtOC0xLTEtMA_ffd61357-f392-431b-86b4-34e766f4106e"
      unitRef="usd">390000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id60c33805d624a1e863dd18b29ce66d8_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjUtMTAtMS0xLTA_4ca038ee-ceb0-44fd-9bf6-69b301e31c9a"
      unitRef="usd">370000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icf724d7bf6384a4d99527cb12064aaf7_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjUtMTItMS0xLTA_9b9a22b4-5f9d-40d7-8fcc-992674f734e2"
      unitRef="number">0.053</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa415248ab90441fa1cc6656b8dcf614_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjYtMi0xLTEtMA_0e7ada08-e165-4c58-825a-8721a7804a68"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib69f132a3f0b40c581d2942e7d57a5b9_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjYtNC0xLTEtMA_3463a8af-d549-40a4-9811-e063a7c33c6d"
      unitRef="usd">64000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifa415248ab90441fa1cc6656b8dcf614_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjYtNi0xLTEtMA_cc47d7a3-84cc-4a02-a59a-a53898d7e41c"
      unitRef="number">-0.052</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic01e2ce9f12a469dba08795b5a902ed6_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjYtOC0xLTEtMA_88290da3-0591-437a-8a94-a067174f2604"
      unitRef="usd">186000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie95cdb275193469989a402b370c02342_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjYtMTAtMS0xLTA_fea54be5-5a9d-4af3-8792-3acbc04dcd22"
      unitRef="usd">175000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic01e2ce9f12a469dba08795b5a902ed6_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjYtMTItMS0xLTA_4c676dd7-34f6-4770-ba81-045eb63d2862"
      unitRef="number">0.058</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98adf17c3209468a982a0f7200c745a1_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjctMi0xLTEtMA_b1a020c6-5fe5-49bb-a40a-f671c7cdf4d7"
      unitRef="usd">182000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idca691679ad64cf583644d8594234216_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjctNC0xLTEtMA_c22f7174-9b6e-4200-a586-ada7f740bb2f"
      unitRef="usd">189000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i98adf17c3209468a982a0f7200c745a1_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjctNi0xLTEtMA_584c6e87-51b1-4637-9f2a-9b6a059c062e"
      unitRef="number">-0.035</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb215856dcc24e3f9d3079bf180a51ff_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjctOC0xLTEtMA_9d2453f8-e649-4418-bdda-8d319ce90c70"
      unitRef="usd">575000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3add39942c4242daa496b88f14058185_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjctMTAtMS0xLTA_1bfc3e3a-25d0-4ced-b87a-00801a5a942b"
      unitRef="usd">545000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifb215856dcc24e3f9d3079bf180a51ff_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjctMTItMS0xLTA_ec20072b-e720-4422-afb1-cf29ed6a655c"
      unitRef="number">0.054</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a5b1e45c95842418dbd6dcbe4bce0b6_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjktMi0xLTEtMA_2fe0905e-b3dc-4780-a868-b2c5e6f188f7"
      unitRef="usd">1625000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91bd273779f6455f9fb27bde5dca4f93_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjktNC0xLTEtMA_5aeea039-4a6d-49cb-9c52-ebca9f9a9b90"
      unitRef="usd">1556000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8a5b1e45c95842418dbd6dcbe4bce0b6_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjktNi0xLTEtMA_33bc6cd5-1c91-4d69-bbe8-9e49bc228647"
      unitRef="number">0.045</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e2b0381a81c41c495cc13d352d5aeae_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjktOC0xLTEtMA_0e423c45-fc65-43a6-a86d-3d6b929e6839"
      unitRef="usd">4987000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i932f9d2df6c34e58b2f54f1f4929c220_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjktMTAtMS0xLTA_5385fefc-846f-493c-90a7-e84c8a827fb9"
      unitRef="usd">4853000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2e2b0381a81c41c495cc13d352d5aeae_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjktMTItMS0xLTA_57758fdf-1e7c-414a-8b33-dadac13029f0"
      unitRef="number">0.028</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38d436a7587f45a1ab95abb5b18a129f_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzAtMi0xLTEtMA_ed64bd25-1308-4d85-9892-d40305bc59ff"
      unitRef="usd">2075000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9a74be9ea184900b90a441048493bc4_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzAtNC0xLTEtMA_7e5a2baa-d8a7-4abb-9e7c-4ad56638ba11"
      unitRef="usd">1958000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i38d436a7587f45a1ab95abb5b18a129f_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzAtNi0xLTEtMA_aff8132c-6123-40a8-9ed5-242a7ab2981a"
      unitRef="number">0.059</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0250c72ff9ac405c928f736053a9f5ff_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzAtOC0xLTEtMA_c3c7ef82-82e1-4e90-a6fd-d78e05a8d838"
      unitRef="usd">5991000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c4878d8e6ac4393a3e73e04f398611b_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzAtMTAtMS0xLTA_32ebf200-ce54-4066-9391-4c1596776737"
      unitRef="usd">5582000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0250c72ff9ac405c928f736053a9f5ff_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzAtMTItMS0xLTA_55340bed-d32b-47c1-ac8a-0ce09cfc8646"
      unitRef="number">0.073</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27ba7c90a4c1434586cbf514f3e51927_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzEtMi0xLTEtMA_fcc2b2e0-4db6-4242-ae07-69a05b750a76"
      unitRef="usd">3700000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8aa1fb345ea8443c9e0bc1aa8418aaec_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzEtNC0xLTEtMA_bde06e30-1acc-4f8f-86a6-a0c3da6b6b75"
      unitRef="usd">3514000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i27ba7c90a4c1434586cbf514f3e51927_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzEtNi0xLTEtMA_418d18c7-3dbe-42f4-b069-223961cfeeae"
      unitRef="number">0.053</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i185910f7181845c8aed38c39fd4b6cab_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzEtOC0xLTEtMA_27d4d38e-519e-4ce4-a633-993c2787cf4f"
      unitRef="usd">10978000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa93431137654cfa8d08a279d01cc337_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzEtMTAtMS0xLTA_54143d48-fb85-468f-b0c5-67e51f51f52e"
      unitRef="usd">10435000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i185910f7181845c8aed38c39fd4b6cab_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzEtMTItMS0xLTA_bb7936ae-6bdd-4ab3-99f3-966a94ce681b"
      unitRef="number">0.052</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2860d64b06e045eb890021c7710f0aad_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzYtMi0xLTEtMA_f7002cd7-20f3-4491-85c1-a34ff1d95f3b"
      unitRef="usd">2771000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59be6ed5442a4a678a48fc617f1eb13e_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzYtNC0xLTEtMA_ec0aa9da-8920-41a5-aa69-bd208810135e"
      unitRef="usd">2558000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2860d64b06e045eb890021c7710f0aad_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzYtNi0xLTEtMA_626eb13a-fc07-483f-a079-05216c9986fe"
      unitRef="number">0.083</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c17375fbded4a6ba40cab9f3d8326d7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzYtOC0xLTEtMA_87c21356-d3ac-410a-bce6-c10224dabd84"
      unitRef="usd">7932000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45b42eb8b685491a806080af8dc02aac_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzYtMTAtMS0xLTA_d39ecda7-69c7-469c-946f-23b8c5091e1f"
      unitRef="usd">7330000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8c17375fbded4a6ba40cab9f3d8326d7_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzYtMTItMS0xLTA_6625d976-2b1e-4b32-ba5b-9d7616a6869d"
      unitRef="number">0.082</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieab9cec340d34cec86ad2425fd1846fd_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzctMi0xLTEtMA_24b2fbb1-fbc5-404f-a998-b9daf7ab82f6"
      unitRef="usd">1480000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0cca5cafe25a4fe0a525fbc02d000afb_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzctNC0xLTEtMA_cc0ad683-a6cc-4bf1-9352-f1a241644b12"
      unitRef="usd">1230000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ieab9cec340d34cec86ad2425fd1846fd_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzctNi0xLTEtMA_1ad66855-fcb2-4987-8a3e-2214689a6fb5"
      unitRef="number">0.203</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic00d19a36bdf402ea98bd292be45894b_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzctOC0xLTEtMA_a0344658-1162-4476-b466-6608f5d22a81"
      unitRef="usd">4464000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87a41a88262640b3b2d8b6e97dba1464_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzctMTAtMS0xLTA_aa5b3b70-ec38-47e3-8782-2c911b29b2db"
      unitRef="usd">3619000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic00d19a36bdf402ea98bd292be45894b_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzctMTItMS0xLTA_1f4e5f9a-4635-43e8-a0d3-05364b521bc7"
      unitRef="number">0.233</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia281107d882e4be6a4d88169207e2a36_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzgtMi0xLTEtMA_3c1c7fce-6050-4a0e-800b-faf13e289533"
      unitRef="usd">4250000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd6a9a9e55274bffada72f2726569f6e_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzgtNC0xLTEtMA_e7d28df0-71b5-47ec-82a2-be29ae9acc0f"
      unitRef="usd">3789000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia281107d882e4be6a4d88169207e2a36_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzgtNi0xLTEtMA_0de0598f-b9d6-4ec0-bdac-2719ad33ad5b"
      unitRef="number">0.122</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77effd52b2654ae686fe2393749c515d_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzgtOC0xLTEtMA_2fa5af8e-02f5-4612-87cf-da41d3c05c8c"
      unitRef="usd">12395000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia37c81e1cad0453994f3e00b01af754d_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzgtMTAtMS0xLTA_0de3ba95-d84c-4942-bbbe-d4079708a11e"
      unitRef="usd">10950000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i77effd52b2654ae686fe2393749c515d_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMzgtMTItMS0xLTA_d1183ca2-0553-411a-b8dc-fa88f4a61678"
      unitRef="number">0.132</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41ab0a4211f24f9391eae4b6c0bce606_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDAtMi0xLTEtMA_ecc7d3d0-3534-4665-b4e3-2e2860efc34d"
      unitRef="usd">480000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c1c64eccdd14e999154f3c36cce6b77_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDAtNC0xLTEtMA_fb1e3046-4f18-4fd1-acfd-03bf0e072920"
      unitRef="usd">634000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i41ab0a4211f24f9391eae4b6c0bce606_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDAtNi0xLTEtMA_21ee8329-2674-4cad-9005-1cdd8f99106c"
      unitRef="number">-0.243</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i909f193a74e24bfd8a95144ed8637f1a_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDAtOC0xLTEtMA_61fe636a-2445-46ae-878b-2802da900475"
      unitRef="usd">1508000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id049e506122f4113a401765a69fb9f08_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDAtMTAtMS0xLTA_acb825cd-ec29-4934-8244-96f6074c3316"
      unitRef="usd">1852000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i909f193a74e24bfd8a95144ed8637f1a_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDAtMTItMS0xLTA_0cef0fbc-a467-4dfd-8307-490055fdb14e"
      unitRef="number">-0.186</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0dab22a716c64564ba838f1dd48d7f2d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDEtMi0xLTEtMA_0f73dcbc-74bd-410c-bb6f-458d0ebc6200"
      unitRef="usd">47000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iacbd09691dfd48849fa8a06109049218_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDEtNC0xLTEtMA_82b7b2fd-24fb-4628-8514-f694405e0a75"
      unitRef="usd">78000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0dab22a716c64564ba838f1dd48d7f2d_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDEtNi0xLTEtMA_1d90ca31-8142-40b5-b3c1-52801b600fba"
      unitRef="number">-0.402</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0bef40f936c45448366cedf462d82d6_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDEtOC0xLTEtMA_4aa96fd0-0b57-4173-8d6d-d67702895220"
      unitRef="usd">197000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifda8dae70c484419b819b08a661b39d5_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDEtMTAtMS0xLTA_67c3082e-e593-44cd-8472-d4fd108720e0"
      unitRef="usd">321000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib0bef40f936c45448366cedf462d82d6_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDEtMTItMS0xLTA_9c61bd7e-6551-4124-8af6-442985c119cf"
      unitRef="number">-0.387</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c3e9d721cf949aba7bed39328685faf_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDItMi0xLTEtMA_cab5af70-d38f-4d66-949e-de2edaa67c4a"
      unitRef="usd">234000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic218b0d17bf9480fb2a4af23655e9de2_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDItNC0xLTEtMA_d73aa5b3-ee0f-4d6e-9839-df3fb0699c0c"
      unitRef="usd">209000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7c3e9d721cf949aba7bed39328685faf_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDItNi0xLTEtMA_f25afeca-ab40-43bb-b96a-2a11064b66e4"
      unitRef="number">0.122</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i742b390271ec444ebf304d883a7aaf85_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDItOC0xLTEtMA_2cd7ecec-01c6-4b15-a8f7-50c9bbad9c01"
      unitRef="usd">721000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0637885c2824f0e9c6471d6d38dc762_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDItMTAtMS0xLTA_ae5cc4e4-1366-4381-be02-890754fa62c4"
      unitRef="usd">673000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i742b390271ec444ebf304d883a7aaf85_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDItMTItMS0xLTA_51238462-f661-4e69-a43e-7ddf58316d88"
      unitRef="number">0.071</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i020a9535952b4c63a401a40815ddf115_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDMtMi0xLTEtMA_05bade86-80fd-4a65-8d51-7c3b25e25a8f"
      unitRef="usd">761000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85aea8ddbc744caa8e21718122998c19_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDMtNC0xLTEtMA_649338ab-1467-4688-ba54-a31aefced8a4"
      unitRef="usd">921000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i020a9535952b4c63a401a40815ddf115_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDMtNi0xLTEtMA_141109d5-0660-4d13-a8e3-87c6dddd8d5d"
      unitRef="number">-0.174</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i49c1d50e36104bbd9d2fff5426a37ba7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDMtOC0xLTEtMA_4f573bac-803f-4758-8ea2-ed81763d2876"
      unitRef="usd">2426000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide16825e0c5042f89d58332d23f6ae0a_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDMtMTAtMS0xLTA_1a478a3a-6cf9-4606-b937-1677c473ab39"
      unitRef="usd">2846000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i49c1d50e36104bbd9d2fff5426a37ba7_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDMtMTItMS0xLTA_b95d386a-fd4a-417c-afa8-2bf3078583c9"
      unitRef="number">-0.148</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i65144a7d9e2a4b1db67b59d28e3d74cc_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDUtMi0xLTEtMA_d9a527ac-ba4d-429d-b384-c70a67b203be"
      unitRef="usd">295000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6d3a01a24804bc9af0ecb6a9b2c67fb_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDUtNC0xLTEtMA_2329b3c6-1fb9-4abd-b868-fa66d8870483"
      unitRef="usd">312000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i65144a7d9e2a4b1db67b59d28e3d74cc_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDUtNi0xLTEtMA_49f24549-d24b-4db9-bf1e-15f47a29c345"
      unitRef="number">-0.053</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50211f0c1289483e8e0e6d1eed3c67e3_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDUtOC0xLTEtMA_c2de9304-56b3-4eb6-9ee6-1c64254846fa"
      unitRef="usd">840000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i655717f0369640c4b9a157a17bb82e9d_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDUtMTAtMS0xLTA_369880c2-6cc7-4c6b-a165-fb3f2034c710"
      unitRef="usd">840000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i50211f0c1289483e8e0e6d1eed3c67e3_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDUtMTItMS0xLTA_e96c8d21-2635-4b7e-b3b3-8b2c9bf8136d"
      unitRef="number">0.000</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf386660945d4d5d9e6b8634ef6532a1_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDYtMi0xLTEtMA_51a743e2-c0ef-4e0f-b7f7-a42b1095719c"
      unitRef="usd">276000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb6d6e4976ac495b99e5329deaf58bfc_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDYtNC0xLTEtMA_89ee4db3-da9b-4d0a-8cec-663980ec123f"
      unitRef="usd">280000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibf386660945d4d5d9e6b8634ef6532a1_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDYtNi0xLTEtMA_8aa313c4-6677-442c-97dd-6ba16a3a420c"
      unitRef="number">-0.011</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7c46e72eb484be486c63c78eb02e206_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDYtOC0xLTEtMA_3622c6b7-b06f-4c0f-b433-c137908642e2"
      unitRef="usd">877000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i40bfe120527540219fcb38f6a07a75c7_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDYtMTAtMS0xLTA_9b573304-3bea-4e97-9139-a74d4d6255f2"
      unitRef="usd">827000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib7c46e72eb484be486c63c78eb02e206_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDYtMTItMS0xLTA_0cd753c0-c2c8-4e8f-bd22-092568ad29cc"
      unitRef="number">0.061</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3510e548888f4e1fa6f52d81f4ab6cf3_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDctMi0xLTEtMA_ea3f3899-85f7-41e6-aa02-7cfe2e6a2708"
      unitRef="usd">571000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56965738078b457fae12de6ffa955475_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDctNC0xLTEtMA_a4b8f3c4-446b-4e5a-bdb2-be05c5e12e94"
      unitRef="usd">592000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3510e548888f4e1fa6f52d81f4ab6cf3_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDctNi0xLTEtMA_79a33435-f093-470f-8983-50c304dc9e76"
      unitRef="number">-0.033</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72a6f6ec594242669dac6cfa2e2c7076_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDctOC0xLTEtMA_b4075aa7-775f-4b2b-98ff-1a79b5ea8154"
      unitRef="usd">1717000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i90f1a8b28bba41749b15a878c6c18fad_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDctMTAtMS0xLTA_6d4614b9-3e38-4b2d-b585-4b431e8f3068"
      unitRef="usd">1667000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i72a6f6ec594242669dac6cfa2e2c7076_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDctMTItMS0xLTA_16e69256-befd-400a-b6b0-9411946ac2fc"
      unitRef="number">0.030</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91266aa05dd2425d985bfd9033fb1fb3_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDktMi0xLTEtMA_fb6598b5-72f1-47cf-9527-cfa62d2de53f"
      unitRef="usd">1569000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15626b644ab14a8fb91a1555191c8648_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDktNC0xLTEtMA_b54f3753-e8b8-472e-a15c-9e1eeb860f24"
      unitRef="usd">1313000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i91266aa05dd2425d985bfd9033fb1fb3_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDktNi0xLTEtMA_372dd3b6-306e-4e19-bfb6-9c637837d0b5"
      unitRef="number">0.195</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibae5bbcea9f94ad5b94969117f4e506e_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDktOC0xLTEtMA_aaf85462-0441-4952-9a8e-fd3680de76a2"
      unitRef="usd">4396000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iadc37e4e06744f8fb3399608c7e6ab66_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDktMTAtMS0xLTA_fa8b9b2f-3ea7-47fb-86a1-1a6346b9430d"
      unitRef="usd">3668000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibae5bbcea9f94ad5b94969117f4e506e_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNDktMTItMS0xLTA_5ddef944-b170-472a-9dd0-5eec01c2020a"
      unitRef="number">0.199</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibad7ff907c4d46428f779f4bdb8db2ce_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTAtMi0xLTEtMA_bc4ceab1-399d-44ab-81e1-e68a21343330"
      unitRef="usd">809000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if38f3c37921e44cda1b5db6443989c29_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTAtNC0xLTEtMA_a4d59305-6dad-4eda-b633-6083f421dccf"
      unitRef="usd">634000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibad7ff907c4d46428f779f4bdb8db2ce_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTAtNi0xLTEtMA_43e6122a-3173-4d9e-9b73-bc0201c7d412"
      unitRef="number">0.277</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73f09c17c23a42ac9ebe11023c84580f_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTAtOC0xLTEtMA_ae169f9d-1f30-4d6d-bd36-f04b2220b6bc"
      unitRef="usd">2404000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc3bf48554b44e80be08a060489581ca_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTAtMTAtMS0xLTA_aebca971-3fb6-4a7e-bdca-5dd657c28ade"
      unitRef="usd">1795000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i73f09c17c23a42ac9ebe11023c84580f_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTAtMTItMS0xLTA_1d85d522-8fd1-460e-9543-ba0b6a0d4691"
      unitRef="number">0.339</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i744f7d39a15a411bbf361d82d82dfe4e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTEtMi0xLTEtMA_8fe4f2b7-9829-497b-bee4-071bd110421a"
      unitRef="usd">2378000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7d413bd46d24d6abe8b625214ada14c_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTEtNC0xLTEtMA_f3b2c99b-28bc-4b9e-99b3-27d5bcec5cfe"
      unitRef="usd">1947000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i744f7d39a15a411bbf361d82d82dfe4e_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTEtNi0xLTEtMA_77b6c9f3-1243-4774-b8a3-243615570e3c"
      unitRef="number">0.222</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifcfdef25565c4ba58a2615e2ab0fc2ab_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTEtOC0xLTEtMA_54cbb2ab-86f8-4a3c-8c28-c58c3cf60175"
      unitRef="usd">6800000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iadc0a4943c0e4c70a773401d645f1312_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTEtMTAtMS0xLTA_b7b07f7a-0000-4627-b2e1-73eb9403c1d9"
      unitRef="usd">5463000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifcfdef25565c4ba58a2615e2ab0fc2ab_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTEtMTItMS0xLTA_3ce67ed7-79e2-4387-b478-a39920ba3214"
      unitRef="number">0.245</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i784ee54441974c4eb54e9257b0e31430_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTMtMi0xLTEtMA_95f8ec32-846a-4c8c-b0f1-92d924d453c3"
      unitRef="usd">376000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3480e995cfa436c961a9a4d13e49bd9_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTMtNC0xLTEtMA_92d3d5d7-bbeb-4ad3-8b68-8056a1169180"
      unitRef="usd">222000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i784ee54441974c4eb54e9257b0e31430_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTMtNi0xLTEtMA_2dcb739f-818f-4af8-a9be-3891b4bc0fb9"
      unitRef="number">0.697</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie13682ac60d24dee80fa0761d2ecfc64_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTMtOC0xLTEtMA_1ff12cac-1cd2-421c-b80f-64e9a9c2167b"
      unitRef="usd">975000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f1311d4010d4f319357cbf0e5b86b3d_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTMtMTAtMS0xLTA_3f8bb297-5194-4b62-a3d6-10693ff4e7e9"
      unitRef="usd">650000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie13682ac60d24dee80fa0761d2ecfc64_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTMtMTItMS0xLTA_6ff320b3-2713-44a2-b077-cfbd422ba0cb"
      unitRef="number">0.501</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf40956a9c1347769a071ff6bfafc142_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTQtMi0xLTEtMA_fbe964b7-0a32-4dbe-85c1-a05dc58e4102"
      unitRef="usd">161000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4658279dda2e4f0fa81448f27d0b4f77_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTQtNC0xLTEtMA_e65f82f9-75c9-499d-b180-c74983e2b225"
      unitRef="usd">105000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icf40956a9c1347769a071ff6bfafc142_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTQtNi0xLTEtMA_a261c713-faf7-4225-b697-4db3e92fc618"
      unitRef="number">0.525</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i199ccf31df6140dcb89e1686bb513228_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTQtOC0xLTEtMA_af523b1f-6f82-489e-b95e-806d89fc68d1"
      unitRef="usd">459000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d8b2515e72b4a779aaf43dfbe387804_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTQtMTAtMS0xLTA_0137847b-f69b-44ac-8a19-40efec31aab1"
      unitRef="usd">316000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i199ccf31df6140dcb89e1686bb513228_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTQtMTItMS0xLTA_35add58c-bc9b-41f2-956a-cb8da3fa4b17"
      unitRef="number">0.454</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa84aee89c7944bf90b3125200ecd80e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTUtMi0xLTEtMA_9a13e59d-28d2-474a-a542-6ff0a25fb580"
      unitRef="usd">537000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie349729608994bf887fda0639a138ad3_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTUtNC0xLTEtMA_316dcdff-f566-4459-8c06-2757c96e6b5c"
      unitRef="usd">327000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iaa84aee89c7944bf90b3125200ecd80e_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTUtNi0xLTEtMA_8d686e09-24e3-4a49-8eef-ab29c0327bb5"
      unitRef="number">0.641</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2f2c2e83225451d902cf2623ede1f1c_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTUtOC0xLTEtMA_a45476bc-fde5-401c-a838-e9157a97c196"
      unitRef="usd">1434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29cff2e6865142d9a4661c3fcb511df1_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTUtMTAtMS0xLTA_e8e3ae42-2535-4f11-a6a8-5c435d2e71c1"
      unitRef="usd">965000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie2f2c2e83225451d902cf2623ede1f1c_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTUtMTItMS0xLTA_11e2453d-3ca1-4031-94d2-1618ff333a7b"
      unitRef="number">0.485</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b35562d3e004031ba416de20b26cf73_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTctMi0xLTEtMA_e7bf01e7-3dc1-4503-9ef6-b0c3c90efd16"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba4873f02ec94b1199e6f56536d6dfe1_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTctNC0xLTEtMA_605fe772-9f9e-48d2-8f86-bb03940d341b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i319fc8a3857049aa8eee5c1b14cce0dc_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTctOC0xLTEtMA_ac5ff573-cd1b-4e68-92c0-f62f7dae4ad6"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56710d10c9af4516b82e08bcd605ff90_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTctMTAtMS0xLTA_45bc4177-116a-49cb-8f5e-26609caa17c7"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b95a95d0ab74b0593bd0223e4b8ad13_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTgtMi0xLTEtMA_3632d12c-9c49-4b53-b2ee-9bef2c5f3b5c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8c876f733014aa39f0d8214e223f585_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTgtNC0xLTEtMA_de4a0c4d-4cbd-44d6-9b05-5b3d2ef00606"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifaa2dae0ae2f4573be92b240376298b0_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTgtOC0xLTEtMA_32ead7a2-0339-4bbc-adf9-4b9ac19dab6f"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b04f604d38f430783a61651065a0a13_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTgtMTAtMS0xLTA_82bec315-8f30-41dc-9425-1cc03779a4ee"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifaa2dae0ae2f4573be92b240376298b0_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTgtMTItMS0xLTA_a7e581b8-4472-4271-aa97-9954a8b8f5f6"
      unitRef="number">-0.686</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide71f27d89ff4ecba07e81f6917e063e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTktMi0xLTEtMA_75bdad11-df91-45c3-9a73-88a23d375ea6"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5df2445aa9db4bcba1f2c495dfcf06c7_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTktNC0xLTEtMA_f7c9bc55-f48e-4237-8b00-cbef01a63646"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ide71f27d89ff4ecba07e81f6917e063e_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTktNi0xLTEtMA_ec06e01e-592a-4236-9ae0-8e41e7c647a4"
      unitRef="number">-0.264</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c2ea56b89e848afb39b9ca75576f81a_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTktOC0xLTEtMA_1fb5037c-dbd4-461e-97a5-99698997e8fb"
      unitRef="usd">18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7d0cd308a8142d6a92cd40abc7d9327_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTktMTAtMS0xLTA_a50f5174-f204-4f65-bed1-961fbc8d4b42"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3c2ea56b89e848afb39b9ca75576f81a_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNTktMTItMS0xLTA_de931f48-e85a-439b-9eb3-1ba456ac13fc"
      unitRef="number">0.916</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id029b233fbaa480b812c80c34fbb60f5_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjItMi0xLTEtMA_b4786c11-c4c2-478f-9dd7-0d8c513d26b5"
      unitRef="usd">679000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c03fd29ef754d63b27fc58525b944c6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjItNC0xLTEtMA_9663e83e-1ae4-40c6-9ebf-46331c31458f"
      unitRef="usd">413000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id029b233fbaa480b812c80c34fbb60f5_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjItNi0xLTEtMA_4af3a79e-b275-4d65-a482-a624ea03a058"
      unitRef="number">0.643</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ad4fad0fa5b4730bebb0dfc08f8b7f8_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjItOC0xLTEtMA_380cb61e-dd2d-4a6a-8a3e-83adcf03138f"
      unitRef="usd">1635000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b2360aa64bf40069c6622e4971e8616_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjItMTAtMS0xLTA_bf0da281-17f4-42b0-8817-5b41b126325b"
      unitRef="usd">1265000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9ad4fad0fa5b4730bebb0dfc08f8b7f8_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjItMTItMS0xLTA_403c006b-ba62-4032-8b6f-387a87070115"
      unitRef="number">0.292</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb258923b1f94a218e7cf9e72e1a4e29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjMtMi0xLTEtMA_817a2412-7acb-4234-9d01-a5747c7dae5c"
      unitRef="usd">709000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc0f0b78e2774313ad18d0495403fcce_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjMtNC0xLTEtMA_f5cae74d-085e-46e8-9e4f-6f1977df32e4"
      unitRef="usd">451000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idb258923b1f94a218e7cf9e72e1a4e29_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjMtNi0xLTEtMA_e419660a-c80c-47fa-9fa7-9fdbb23ecfef"
      unitRef="number">0.572</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie38211ff6f4549ca99cf9a47fdc50a68_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjMtOC0xLTEtMA_cb320dce-a7b3-47d6-948d-ce205d5e4057"
      unitRef="usd">1788000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc3c076d95ff48c485eb3d0187e68b87_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjMtMTAtMS0xLTA_2fa7fd01-4d42-4e0f-b309-77b95aa16a76"
      unitRef="usd">1397000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie38211ff6f4549ca99cf9a47fdc50a68_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjMtMTItMS0xLTA_13a79502-2099-4f01-af86-c86c527e086a"
      unitRef="number">0.280</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e8c4072e9244960b877a66a60def445_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjQtMi0xLTEtMA_68d84b6c-a4c0-476b-81a6-4fe61175bd4f"
      unitRef="usd">1389000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24d94e00bd754768a1c1b598eb47950d_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjQtNC0xLTEtMA_fd5dbb9a-b074-4997-a3d7-6825b8ddfb2a"
      unitRef="usd">864000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9e8c4072e9244960b877a66a60def445_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjQtNi0xLTEtMA_f93d6b76-a5f3-4d9f-a6bc-1f6abd431631"
      unitRef="number">0.606</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i48712a124534471ea2804e884605a06f_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjQtOC0xLTEtMA_dd9cbfc1-e2b7-4691-a7e0-1d32ab0a1f32"
      unitRef="usd">3424000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3ded785627e4686af72f0b8d2f046fe_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjQtMTAtMS0xLTA_f9ca5a67-f1b6-4462-9aa2-ac208e886c79"
      unitRef="usd">2662000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i48712a124534471ea2804e884605a06f_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjQtMTItMS0xLTA_edbaed02-d432-4696-8811-d58afc8eae4f"
      unitRef="number">0.286</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0cd8c26245b493ea80fd420a16b98d9_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjYtMi0xLTEtMA_be83d511-9d06-4ec2-8745-d74046a860ba"
      unitRef="usd">270000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic49e6c0c298b45d384afc6010a6b7762_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjYtNC0xLTEtMA_6851954d-a4b4-4f7c-acc4-ab560716a1e6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96b42a988d6c44c5ab94f2e2bc145a16_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjYtOC0xLTEtMA_22a0b9e4-be62-40d5-b8e8-201abdd2444e"
      unitRef="usd">421000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d2c74c6b3434964b75d4a41dae81179_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjYtMTAtMS0xLTA_a57ec3bf-3781-4ed3-9081-37a80d443dd1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0693b3d163314be799135d4bc4076c22_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjctMi0xLTEtMA_d60d6b8d-5d7c-4ae6-945c-2b8569dc309a"
      unitRef="usd">233000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief37e3faf17c4c568270eae6b145b3cd_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjctNC0xLTEtMA_3594f52d-58a9-4bff-a397-396623c3f698"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6cbad562537b416c87c3c047d42d646a_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjctOC0xLTEtMA_b6e25172-c876-4f2d-b5c3-d43f6d30873b"
      unitRef="usd">346000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5edcc1f3bb72432eb95672f9fe6b9d10_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjctMTAtMS0xLTA_da49d1f4-5079-4052-b3da-e572e83923ac"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06145f78f1d34def882f37c971b1b1d9_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjgtMi0xLTEtMA_582d2dd1-7ea3-492d-92e0-d43036c49bbf"
      unitRef="usd">502000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7ec43159f654583ba1e536a80658f9f_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjgtNC0xLTEtMA_7ffe2e3a-da96-4f86-81a8-33caa3b51d21"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f8c3daec6804be1859d4f0afafc33f0_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjgtOC0xLTEtMA_6268e30d-7e96-4480-8408-74b749142a24"
      unitRef="usd">766000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i867a837018b24f99a9a411f45c919e92_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNjgtMTAtMS0xLTA_43344555-da05-483f-800e-fd5d6e6095f3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb6e3d84fcc04f4ca22b4170593731ed_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzAtMi0xLTEtMA_95a708e4-4517-4bee-854f-0212d8590fe1"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0de05d9759a54853ac7066c47b8847e0_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzAtNC0xLTEtMA_72a5c425-d600-4a8b-af42-ca7def9ad1ca"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idb6e3d84fcc04f4ca22b4170593731ed_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzAtNi0xLTEtMA_3ce0d976-3e1e-4717-b5f5-bc6431846659"
      unitRef="number">0.084</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic83f61d0cfea4373978c400de01b8b78_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzAtOC0xLTEtMA_5cab1d0b-7d99-4d17-955a-4ba5bff027a3"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if43c23fa8a1c41859b4371ea5c634e3d_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzAtMTAtMS0xLTA_512e6e40-e777-411b-9d84-d9a910186b06"
      unitRef="usd">33000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic83f61d0cfea4373978c400de01b8b78_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzAtMTItMS0xLTA_ed41bd57-e107-4873-ad25-4d0ad36772d9"
      unitRef="number">-0.048</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1bd97635393475dad752c246c239a5d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzEtMi0xLTEtMA_d21e1622-b8a4-4e7a-b7c3-1ebeda74b285"
      unitRef="usd">247000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc468b2507d144f2a14b7c6ac31458ab_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzEtNC0xLTEtMA_c2e58dc5-64a7-4ac4-873b-60864c4ee24e"
      unitRef="usd">226000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib1bd97635393475dad752c246c239a5d_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzEtNi0xLTEtMA_7007d810-c347-46df-aea4-aea5bd67cb9a"
      unitRef="number">0.097</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica34b4218d3541b09c3da6d94f2cb5e6_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzEtOC0xLTEtMA_831af114-84b1-495a-acd8-2c7b1228fc7d"
      unitRef="usd">733000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i992584c4bfc6471d9deb7b1eb40513be_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzEtMTAtMS0xLTA_38645ab2-e699-4ed0-947d-7c15a7c9e6ee"
      unitRef="usd">684000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ica34b4218d3541b09c3da6d94f2cb5e6_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzEtMTItMS0xLTA_6cc4fc19-abec-4de0-86fb-c1732d0ddfcb"
      unitRef="number">0.072</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d7969d1f8aa4dda8ea8586ae9c4137b_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzItMi0xLTEtMA_1d523dd9-8e56-4fa9-8b08-bfb7193c82a5"
      unitRef="usd">259000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3eb3f22e2a6640ce84be77248010d037_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzItNC0xLTEtMA_240a508e-66ad-4e5b-822c-d84220b73bda"
      unitRef="usd">236000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0d7969d1f8aa4dda8ea8586ae9c4137b_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzItNi0xLTEtMA_fb7a35b1-c976-4ce0-96bb-d1b30b4e14df"
      unitRef="number">0.096</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1aea64ee5d24421ab72f13729dedbd07_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzItOC0xLTEtMA_f1125ad1-71d2-480a-9b87-fd624e2de294"
      unitRef="usd">764000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id867ff6ff03b414389070eb180dfb49b_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzItMTAtMS0xLTA_e5de7ce0-a60e-4cfa-b06c-1c87fc113ffe"
      unitRef="usd">716000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1aea64ee5d24421ab72f13729dedbd07_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzItMTItMS0xLTA_1060ec33-9d29-4913-8388-24b302a14eec"
      unitRef="number">0.067</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6506a7038e6c4b3fa851ccb2c53be423_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzQtMi0xLTEtMA_cb4741a0-7e32-414e-a76e-81ae67a67be8"
      unitRef="usd">380000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide35fefcff44453d8d65564e21d05eb2_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzQtNC0xLTEtMA_8c353290-515c-4920-8d34-df5b00c1458d"
      unitRef="usd">379000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6506a7038e6c4b3fa851ccb2c53be423_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzQtNi0xLTEtMA_5f7b9cc6-f5f8-4653-9e3c-df3d0b2231af"
      unitRef="number">0.004</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id44eb4835c3848728a14a8c3f6cdc458_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzQtOC0xLTEtMA_f2b5f16e-fb80-4f77-981f-7193c93d4586"
      unitRef="usd">1128000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81052cefe0fd4a0b8c431e3080dd0f2e_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzQtMTAtMS0xLTA_925dc45d-2333-4396-ba24-c9b0cc9f1cc3"
      unitRef="usd">1154000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id44eb4835c3848728a14a8c3f6cdc458_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzQtMTItMS0xLTA_7d12130e-2838-4542-8601-194973ed5e74"
      unitRef="number">-0.022</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94d8014e61a64d64883ac98c61c9fc14_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzUtMi0xLTEtMA_a2511edd-fdec-4739-9c09-12f8acf558bf"
      unitRef="usd">137000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3c431fe980745c0b7193b78927935bd_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzUtNC0xLTEtMA_50a1d236-c113-4b76-aabe-9adff2bdac3b"
      unitRef="usd">147000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i94d8014e61a64d64883ac98c61c9fc14_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzUtNi0xLTEtMA_b51135fc-08c5-43c6-90c2-1dbc685c3f10"
      unitRef="number">-0.071</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8525a44d8d614f5cb1fbc085ac7ad72a_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzUtOC0xLTEtMA_c53fa218-ff68-4539-93ab-6bad5eed9a5c"
      unitRef="usd">440000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a2a1d85a1814d26a7c59cb5406c544e_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzUtMTAtMS0xLTA_bbca902f-5497-443a-a464-e43d11f3a85c"
      unitRef="usd">461000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8525a44d8d614f5cb1fbc085ac7ad72a_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzUtMTItMS0xLTA_ad2bb687-01ca-4a44-ad42-30e351291754"
      unitRef="number">-0.046</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia499ee071d3a4a3d9c98fc4f9f4361e1_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzYtMi0xLTEtMA_59a9b0a0-7997-4a66-a7dd-612e5845fdd4"
      unitRef="usd">517000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i540e20523e4d4912bdc772d9ad3994cb_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzYtNC0xLTEtMA_8685ce80-5c36-44bd-86c4-1e52aff2310a"
      unitRef="usd">526000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia499ee071d3a4a3d9c98fc4f9f4361e1_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzYtNi0xLTEtMA_e936f8ac-2b4f-4425-9412-1d96124bd6d8"
      unitRef="number">-0.017</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73c1c368ad7148d183d9d0514e949c26_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzYtOC0xLTEtMA_be4ca1f4-8c36-49b8-a2b9-c9e153370e68"
      unitRef="usd">1568000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24eecfd1ba81496297deca71fae20acc_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzYtMTAtMS0xLTA_63f20671-e1b3-4c40-83b9-8ca14edbb64b"
      unitRef="usd">1615000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i73c1c368ad7148d183d9d0514e949c26_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfNzYtMTItMS0xLTA_cfe0dcfd-a9f2-4a86-ab2e-4a1ea9602e87"
      unitRef="number">-0.029</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie28012ef976642138e574f32ea5efcf8_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODAtMi0xLTEtMA_98257513-5d8c-42e3-b0af-b4f955990453"
      unitRef="usd">18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic76c81a4858d4b609fe0712808499995_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODAtNC0xLTEtMA_275ea0a4-4573-47dd-95e1-85a40b75b598"
      unitRef="usd">24000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie28012ef976642138e574f32ea5efcf8_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODAtNi0xLTEtMA_55f0139e-54b6-4e9b-ac52-58a8f9931070"
      unitRef="number">-0.260</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b9be986d0744a89a11e10191af92b0e_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODAtOC0xLTEtMA_80c181ca-292b-46f3-ab88-cf32d8733d92"
      unitRef="usd">55000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f066a7522d44e21adceaa01bcb1f033_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODAtMTAtMS0xLTA_0f201c15-cf96-4651-a729-077bf954ba2d"
      unitRef="usd">79000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5b9be986d0744a89a11e10191af92b0e_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODAtMTItMS0xLTA_8e74933c-7830-481d-a310-08d34aa32b03"
      unitRef="number">-0.296</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i882e0bdc376e4cedb6907617bd05c7c5_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODEtMi0xLTEtMA_00c628b2-e8c8-4517-a075-3003bd37e776"
      unitRef="usd">93000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e2cfa64c77f4036aad98fade9ef0701_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODEtNC0xLTEtMA_0c101f5b-1612-43fa-a137-dc7777676d69"
      unitRef="usd">78000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i882e0bdc376e4cedb6907617bd05c7c5_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODEtNi0xLTEtMA_749a9d05-438a-41cf-9878-4366ba756dfb"
      unitRef="number">0.183</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1fdc084f5464520a7448be49c5db0ac_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODEtOC0xLTEtMA_9ecbb8d5-9ea2-4301-adb6-2138b80213f6"
      unitRef="usd">270000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0244f8cf8aa940419de1c1d28d1e142b_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODEtMTAtMS0xLTA_0f71a3f6-966f-4c6e-b2d5-1b4a29edef74"
      unitRef="usd">252000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id1fdc084f5464520a7448be49c5db0ac_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODEtMTItMS0xLTA_4b083ab5-0534-4e54-a2bf-91dcdddc24d2"
      unitRef="number">0.069</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98f0dbf3d46c438aa1e111583f3997d4_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODItMi0xLTEtMA_980f7970-7e2c-4fdc-b698-6c741260a027"
      unitRef="usd">110000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ef97d90cd6c439db72bf9c70f28da42_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODItNC0xLTEtMA_749b32dc-4fa4-439d-8a2c-ef817959732d"
      unitRef="usd">102000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i98f0dbf3d46c438aa1e111583f3997d4_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODItNi0xLTEtMA_61a90730-d366-4a56-aed0-2d78dbb403b5"
      unitRef="number">0.078</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61f0183768bc4e7b9bc935793c8ef1ba_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODItOC0xLTEtMA_a9b641c0-50d6-4730-8766-91bb8955fbaa"
      unitRef="usd">325000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10eb1b72e5a84ad7ac1da3701bb76c90_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODItMTAtMS0xLTA_2a6d23d0-83e3-4b59-9eac-eb2cfc5a205d"
      unitRef="usd">331000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i61f0183768bc4e7b9bc935793c8ef1ba_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODItMTItMS0xLTA_785cb477-9743-4f19-9116-0b743ed4c648"
      unitRef="number">-0.018</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0374102facf24dc5823fc308260ee163_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODUtMi0xLTEtMA_b05850ed-2a11-427f-9725-0fb61c985233"
      unitRef="usd">835000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23ec342a5f954896b84f92b9d5abcbf9_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODUtNC0xLTEtMA_e9976ba2-153e-4874-85fc-388f55d7c6ae"
      unitRef="usd">759000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0374102facf24dc5823fc308260ee163_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODUtNi0xLTEtMA_a2829052-100c-428e-902b-f690d80f70b7"
      unitRef="number">0.102</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b66ffdc877e4f1e89900a1d433731ee_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODUtOC0xLTEtMA_183b7227-1355-4066-bbae-791f00f07e39"
      unitRef="usd">2448000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i562f5f706f934d47812f786fbf3d7b58_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODUtMTAtMS0xLTA_d14358b8-0c3c-4ca0-bd29-f2edc294a493"
      unitRef="usd">2285000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7b66ffdc877e4f1e89900a1d433731ee_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODUtMTItMS0xLTA_6fc8ad47-6f17-40e6-bc11-d55ea18016a5"
      unitRef="number">0.072</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if306bf45e84e4e3892e099cf48267fe1_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODYtMi0xLTEtMA_a077c27f-f675-444a-a232-57c8b6508efb"
      unitRef="usd">854000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d13ded3c3b947ca960fe5a1e8612116_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODYtNC0xLTEtMA_9c47c6a9-e61b-4c21-bcf4-ea0e3dac2909"
      unitRef="usd">846000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if306bf45e84e4e3892e099cf48267fe1_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODYtNi0xLTEtMA_294e5d4a-359f-4529-8d11-82062926099b"
      unitRef="number">0.008</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ebeaa1f49bf4e0baa2712e4c5bf91de_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODYtOC0xLTEtMA_0eda0912-049d-42b3-bd13-c71f24d7e5d4"
      unitRef="usd">2770000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5bdc076fc45d46928fdee43fba7031c4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODYtMTAtMS0xLTA_1fbdd423-f6e8-48b2-adac-8c845c6f7b53"
      unitRef="usd">2565000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0ebeaa1f49bf4e0baa2712e4c5bf91de_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODYtMTItMS0xLTA_2e8fd715-0565-4bcb-b4bd-3128c847ae07"
      unitRef="number">0.080</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea17f40f7b2248da9dcf9bbeb1298aae_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODctMi0xLTEtMA_5718de35-580e-4eb6-bd51-b4cf9df47aa9"
      unitRef="usd">1689000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibaf3b58ecba448c98c4fbea9e5a1bebb_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODctNC0xLTEtMA_5b1ed83a-4a1e-49c3-8501-61fb4403a92d"
      unitRef="usd">1605000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iea17f40f7b2248da9dcf9bbeb1298aae_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODctNi0xLTEtMA_95932337-4d0b-42bc-8b14-00fbe6d9302c"
      unitRef="number">0.053</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5884a5e7ed954d8aa9eddb0b6e4da9da_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODctOC0xLTEtMA_53313fb7-9e87-4fe0-b086-c43f14d3dbf8"
      unitRef="usd">5218000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50df7cd55cd6495a81565d60de245388_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODctMTAtMS0xLTA_1de8e3b0-efa3-4fa7-ad36-c00257a1ea3e"
      unitRef="usd">4850000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5884a5e7ed954d8aa9eddb0b6e4da9da_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODctMTItMS0xLTA_aa810cc1-8d93-4158-9b20-ee04cef54798"
      unitRef="number">0.076</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic189fd1fc7df4bdcb5e752b731b041bb_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODktMi0xLTEtMA_d88bc998-36d1-4037-8873-4b7232f043e1"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia84578dea56b42ee89fdffe82f1f0218_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODktNC0xLTEtMA_a2c14447-88bb-4570-b99b-2052f1aac1b0"
      unitRef="usd">43000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic189fd1fc7df4bdcb5e752b731b041bb_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODktNi0xLTEtMA_c8bb4adb-39df-4102-aeee-ff9508592e60"
      unitRef="number">-0.195</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d9afbd7f944468489ecd62be054ea29_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODktOC0xLTEtMA_c13c1ee0-d7ae-4a57-8196-cca3c8b2c858"
      unitRef="usd">117000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c352bec2ed24d399d4198a694dc76c6_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODktMTAtMS0xLTA_084ecc8c-344c-4aad-84dc-ca09ad755827"
      unitRef="usd">150000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6d9afbd7f944468489ecd62be054ea29_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfODktMTItMS0xLTA_ec0666b8-6bd2-4737-ae42-83f064f7e023"
      unitRef="number">-0.221</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4827a6e9fcb14cf5a2e458c318845354_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTAtMi0xLTEtMA_a45613c1-bb28-43cd-900e-05407e63037b"
      unitRef="usd">122000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c05ffbc94dd44c8877b9c05314ad378_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTAtNC0xLTEtMA_81ec815a-e155-41cf-b1a2-83ed1f0cc3cb"
      unitRef="usd">107000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4827a6e9fcb14cf5a2e458c318845354_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTAtNi0xLTEtMA_7201ffc7-29ef-4294-b5f0-45ab3534bbad"
      unitRef="number">0.142</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c1d26f41ed64110ba7168ddec63bb54_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTAtOC0xLTEtMA_5a34b9c5-4433-4db5-8637-d53b5ca79611"
      unitRef="usd">372000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1967287f9578497e995a11c707bf2f53_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTAtMTAtMS0xLTA_9ab5342f-1595-4fc0-b8c9-fa54116adadd"
      unitRef="usd">319000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8c1d26f41ed64110ba7168ddec63bb54_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTAtMTItMS0xLTA_3851d01c-caa0-43c0-b1c3-16007b912e2c"
      unitRef="number">0.164</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide1e53eb0492409cb4653d655cefdab7_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTEtMi0xLTEtMA_5d422ac3-e4e2-45d9-a66e-dea63ae14454"
      unitRef="usd">157000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iddca17b69fda4b1cb462915c216a46d8_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTEtNC0xLTEtMA_056ec031-538d-4b3b-ba86-bf0a9d012402"
      unitRef="usd">149000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ide1e53eb0492409cb4653d655cefdab7_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTEtNi0xLTEtMA_bc8842c3-f0a0-482a-9db2-8800ed52c186"
      unitRef="number">0.045</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib42c8f3666d34ae7aa8627db6a446790_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTEtOC0xLTEtMA_335b05c0-eaa1-4009-9aa7-78f316d390bd"
      unitRef="usd">489000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3d0a4693f564cb8bc9e73e16b7952c1_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTEtMTAtMS0xLTA_b87eb771-30b4-4b83-9594-757ee34f249a"
      unitRef="usd">469000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib42c8f3666d34ae7aa8627db6a446790_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTEtMTItMS0xLTA_aefbffc1-73e9-4294-9ea8-317176cd9ee9"
      unitRef="number">0.041</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5284a31246ef4a8c838a1e4123f9f505_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTMtMi0xLTEtMA_e313c0b9-07aa-4f52-a5e2-713c34d426ef"
      unitRef="usd">648000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5e9cffd91ca411a853422a72582bb93_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTMtNC0xLTEtMA_142979c0-0ce9-47ad-9805-8b43df3612d0"
      unitRef="usd">585000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5284a31246ef4a8c838a1e4123f9f505_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTMtNi0xLTEtMA_20501cfd-46c9-4d68-9ec2-f15267aebd46"
      unitRef="number">0.110</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice59f9c85be54b839acb8e82d6d4f087_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTMtOC0xLTEtMA_e4fcca02-2b9f-4d91-a12a-b2dec696520d"
      unitRef="usd">1882000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5854490403eb4af9a2d3b60108890558_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTMtMTAtMS0xLTA_e33f9c25-39b2-48ec-81ae-1a2a9aced8b5"
      unitRef="usd">1704000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ice59f9c85be54b839acb8e82d6d4f087_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTMtMTItMS0xLTA_02cf334c-2c39-4df1-b19e-b50844fcbeb6"
      unitRef="number">0.104</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idbeee4aeea57426e992c6d70c15e7c2b_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTQtMi0xLTEtMA_8c7a34e5-7afe-4d44-8b8c-c83b3a84d71f"
      unitRef="usd">355000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd2c49b4b2204484a5dc99464f909943_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTQtNC0xLTEtMA_0c922e80-133c-4628-bbc5-9888d1614650"
      unitRef="usd">341000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idbeee4aeea57426e992c6d70c15e7c2b_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTQtNi0xLTEtMA_e2628839-c14d-4283-9826-1753910fee8e"
      unitRef="number">0.043</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic558f7b084d04003a7b5d749f85db400_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTQtOC0xLTEtMA_689307a4-4549-47a0-8ce3-c8f5d54cd63d"
      unitRef="usd">1111000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i622659a4109b4f55941ea9eab234897d_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTQtMTAtMS0xLTA_536f7c3c-5481-44ae-bf11-f6224ad54000"
      unitRef="usd">983000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic558f7b084d04003a7b5d749f85db400_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTQtMTItMS0xLTA_c7893193-3df1-4341-a052-edc01a235be7"
      unitRef="number">0.130</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd9e4baa754142e2874a7b15ef2af88e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTUtMi0xLTEtMA_2f97215c-3cff-4003-ba28-32de9081225e"
      unitRef="usd">1004000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i76cf0ef8cb30429197a1518d631d35d8_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTUtNC0xLTEtMA_969af61d-6ba7-4f9b-8a91-79510355fd1b"
      unitRef="usd">926000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifd9e4baa754142e2874a7b15ef2af88e_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTUtNi0xLTEtMA_31ed58ac-ecd6-47f7-8764-473535822b63"
      unitRef="number">0.085</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie84450c6d85a401fbd2cf8cf38737ead_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTUtOC0xLTEtMA_874b2f76-ab2d-41ed-af89-ccbc06696e51"
      unitRef="usd">2994000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1bea109b1b7492ea05f6750a7a1228f_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTUtMTAtMS0xLTA_bb3dbc1d-103c-4a2a-99eb-851d4d6b2a69"
      unitRef="usd">2688000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie84450c6d85a401fbd2cf8cf38737ead_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTUtMTItMS0xLTA_c6677fc9-e911-470e-aef7-a12f3be0edc7"
      unitRef="number">0.114</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i600831f07e1a4339b1e94d5e21d66372_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTctMi0xLTEtMA_de899b0d-d97c-4f62-8761-9b22501dec3f"
      unitRef="usd">71000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2af09556bc84fd1ba481c7e0406146e_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTctNC0xLTEtMA_ac45fe5e-4d54-4c07-a5fb-105b2e37fd1b"
      unitRef="usd">70000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i600831f07e1a4339b1e94d5e21d66372_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTctNi0xLTEtMA_71373980-0255-4748-8dbf-302862fee458"
      unitRef="number">0.013</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1af77281c754257a1fa2e2fc2ed937c_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTctOC0xLTEtMA_93223348-099d-4043-a930-51ff1a3a2bd2"
      unitRef="usd">210000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06dfeb7913f3474fb76e8bafad008be1_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTctMTAtMS0xLTA_a552172f-61ef-4cd0-8781-e6e8e4d3212d"
      unitRef="usd">220000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if1af77281c754257a1fa2e2fc2ed937c_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTctMTItMS0xLTA_4a76b9ca-533b-4aec-ab63-e307f1b039c9"
      unitRef="number">-0.047</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1290f60dba7e446e8d8b08ad7c42874c_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTgtMi0xLTEtMA_d7b4f086-9f41-4782-a296-d2d4a784d140"
      unitRef="usd">69000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d862660b5a04a089a8bdc443ee48fbd_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTgtNC0xLTEtMA_5486bdb2-450c-45c8-8798-13471c28335e"
      unitRef="usd">81000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1290f60dba7e446e8d8b08ad7c42874c_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTgtNi0xLTEtMA_0478d370-cc90-4e95-b8d5-5100305a362f"
      unitRef="number">-0.167</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia53773f630fc465eb5108bfbd89f5f47_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTgtOC0xLTEtMA_237411df-3db3-464e-b7f0-a8936c3608b9"
      unitRef="usd">242000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45ee541218b04971b53ff4e5d19ad204_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTgtMTAtMS0xLTA_89ce7b7d-1369-40f2-b042-32723f1ce72d"
      unitRef="usd">254000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia53773f630fc465eb5108bfbd89f5f47_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTgtMTItMS0xLTA_2a0d58f5-e2f6-4fdb-9c08-63e6a0ac34a2"
      unitRef="number">-0.051</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8360a75d208433d90de437993ea4a59_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTktMi0xLTEtMA_7f7746f6-31c5-4ed7-8afc-76242bfeede0"
      unitRef="usd">140000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6d0af4fc35f41b78b153cac7769eca7_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTktNC0xLTEtMA_ff530ae0-35c0-4889-98ca-6235f993bee9"
      unitRef="usd">152000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if8360a75d208433d90de437993ea4a59_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTktNi0xLTEtMA_d3f19904-9d16-4e1b-94a1-66df984ed727"
      unitRef="number">-0.084</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1242a55b9a0485193c8b3dfc6ebdc75_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTktOC0xLTEtMA_c80ca9ea-21c0-4f7c-a3c9-a50114112351"
      unitRef="usd">452000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i951a06fcbe4640689f8e364e8afdbcd2_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTktMTAtMS0xLTA_5f27baf2-dd37-4083-a36b-2d3803ed6545"
      unitRef="usd">475000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic1242a55b9a0485193c8b3dfc6ebdc75_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfOTktMTItMS0xLTA_9b228754-4227-450c-a2bd-7efe78e07bc2"
      unitRef="number">-0.049</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98c68fd3171e4813b03d948e6c1538d5_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAxLTItMS0xLTA_9c612543-9f7b-48ac-81e1-619b59c31ec9"
      unitRef="usd">81000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fed2345a1ee4c23bd04c0f52f574fb5_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAxLTQtMS0xLTA_e535599c-89e1-470f-bfcd-d84577e51fd4"
      unitRef="usd">60000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i98c68fd3171e4813b03d948e6c1538d5_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAxLTYtMS0xLTA_10d06ad5-d3b7-48bb-9a2b-bbd350f61d80"
      unitRef="number">0.347</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i024835e205554573a9c3504cb27a8c5a_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAxLTgtMS0xLTA_97b9827e-ae73-4233-a84a-6b4c6b52f1c5"
      unitRef="usd">239000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c485d85051e4317842b009e214d3fe0_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAxLTEwLTEtMS0w_1e0d69d4-60e6-4b1f-9d4c-283f480426eb"
      unitRef="usd">210000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i024835e205554573a9c3504cb27a8c5a_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAxLTEyLTEtMS0w_6789184d-af67-442d-8b2b-68fffc814526"
      unitRef="number">0.139</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2039f6815f94c8eb39335bdd8780f31_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAyLTItMS0xLTA_3796ef33-58d4-4fb9-a0d6-55af97ea23e1"
      unitRef="usd">307000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f82ffb3600448bdb45ded460d8052af_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAyLTQtMS0xLTA_137257d0-c337-4d56-a01c-7ac5dc5366cc"
      unitRef="usd">317000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie2039f6815f94c8eb39335bdd8780f31_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAyLTYtMS0xLTA_a1b1c1ec-75f5-49dd-af79-4b292f99a5da"
      unitRef="number">-0.029</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0bdfd9d747b14c3fb94da3568d458766_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAyLTgtMS0xLTA_33ca9c88-1f17-41b7-a15d-2b6e9f110767"
      unitRef="usd">1045000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b106a80587443fa9b0d89c8d306ddd9_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAyLTEwLTEtMS0w_0b189d63-7568-4df4-8e34-a3c816be88fc"
      unitRef="usd">1008000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0bdfd9d747b14c3fb94da3568d458766_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAyLTEyLTEtMS0w_da289306-ad58-4541-a26d-e75f06272cd7"
      unitRef="number">0.037</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1fad4ca7557147fe95699ddfe8a3615d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAzLTItMS0xLTA_7be94a19-4341-47cd-9188-289fd09f420d"
      unitRef="usd">388000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8c8e0238b104ea08be4e264097dc22e_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAzLTQtMS0xLTA_57be8a46-f5a5-472e-a27d-2e0e059db09b"
      unitRef="usd">377000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1fad4ca7557147fe95699ddfe8a3615d_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAzLTYtMS0xLTA_fb5842bc-4d93-4832-9c81-30c06404e85e"
      unitRef="number">0.031</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4a4e436169b42529a9d0389c604a63f_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAzLTgtMS0xLTA_3ca3927f-83f2-4329-9bea-a5646bf0bb42"
      unitRef="usd">1284000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6cddbb6a917e47509f085811d392a493_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAzLTEwLTEtMS0w_07363a90-0326-4319-9f49-08347f87e96b"
      unitRef="usd">1218000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib4a4e436169b42529a9d0389c604a63f_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTAzLTEyLTEtMS0w_a1322d64-7ccd-4110-929e-10029cd44b2b"
      unitRef="number">0.055</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i49e72c9dd590489aa2ee17a974f38a86_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA2LTItMS0xLTA_7a76b98e-7f4b-459e-98f1-b7074bf1fcfb"
      unitRef="usd">1525000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id58b0cb1491f4c01a2650b1b46fbefa7_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA2LTQtMS0xLTA_e56d305e-7541-4c4c-bbbe-62d617bc6960"
      unitRef="usd">1267000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i49e72c9dd590489aa2ee17a974f38a86_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA2LTYtMS0xLTA_76c2268d-1047-4a23-8432-e80f1bc0d6d8"
      unitRef="number">0.203</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b81c853b79c40f5a5e333ea61fb2b15_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA2LTgtMS0xLTA_92c28a59-6104-4ba4-a553-2f39ac7a1659"
      unitRef="usd">4364000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i053a5c0a067448d38267b4d4d0371d39_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA2LTEwLTEtMS0w_c1e29cc3-b304-4d7d-bdee-34183e4cc18b"
      unitRef="usd">3623000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8b81c853b79c40f5a5e333ea61fb2b15_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA2LTEyLTEtMS0w_6a6f2008-ffe2-47bf-9589-41498d84cd5f"
      unitRef="number">0.204</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7230aa1f363542928871b474a14f1f8e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA3LTItMS0xLTA_696c3570-4b65-4630-a341-2343862506b1"
      unitRef="usd">2140000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic09e7e58a12a4405a99ed854054ef46f_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA3LTQtMS0xLTA_8465ff14-76de-45ab-896a-75857e569858"
      unitRef="usd">1862000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7230aa1f363542928871b474a14f1f8e_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA3LTYtMS0xLTA_1ac48f3f-479a-4584-bc5c-9d86ec4e391c"
      unitRef="number">0.149</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic88a9f1b52334567a7c5d218c774bdf4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA3LTgtMS0xLTA_aa5c8006-3040-4305-ae8d-32a11f2bd2a7"
      unitRef="usd">6406000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ea1dce9275644229c0975d44045301f_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA3LTEwLTEtMS0w_40eb69af-ebc0-452c-b732-91df9c941bee"
      unitRef="usd">5310000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic88a9f1b52334567a7c5d218c774bdf4_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA3LTEyLTEtMS0w_1b6ad49c-03fd-4161-9c20-61d8f028293c"
      unitRef="number">0.206</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia50d35187ab3428390ef63a28a7e6961_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA4LTItMS0xLTA_f7c6600b-1d0c-4fa3-be80-0ddd00b600f8"
      unitRef="usd">3665000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25bc2d1842ab4478b3d89958785ab19e_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA4LTQtMS0xLTA_ab88dc35-4f70-40f6-a72d-60887b00be7a"
      unitRef="usd">3129000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia50d35187ab3428390ef63a28a7e6961_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA4LTYtMS0xLTA_4ff5139c-9214-4599-8f77-94569e1997e0"
      unitRef="number">0.171</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8d3a81114da408489e4e01d642c9082_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA4LTgtMS0xLTA_7ac6bfae-b3ed-4bbc-8dd3-475d0bfe64dd"
      unitRef="usd">10770000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8eaf6ce2f8af425790cb397e4499b14a_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA4LTEwLTEtMS0w_14e28a27-6fec-499a-8e6e-a3660694c48f"
      unitRef="usd">8933000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id8d3a81114da408489e4e01d642c9082_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTA4LTEyLTEtMS0w_9609f486-6755-4e63-9aa2-0855c47cd44a"
      unitRef="number">0.206</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf0f6411562d444f9e80f8a62cc71594_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEwLTItMS0xLTA_c44f4558-5d6e-4b55-bf5f-f0c8387a1f3a"
      unitRef="usd">841000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i969af2be04a041288cd2cfddbec62364_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEwLTQtMS0xLTA_ca8fe376-c04d-4162-988b-ec7e8573482a"
      unitRef="usd">585000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iaf0f6411562d444f9e80f8a62cc71594_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEwLTYtMS0xLTA_7b17c6c4-e918-4033-8c41-f28e3da2ff99"
      unitRef="number">0.437</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i411f812e4d114ffb8b1267fa1cb56c6d_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEwLTgtMS0xLTA_ae598ac8-0be7-4988-903c-d7af3d110d88"
      unitRef="usd">2302000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c6952baf25542b68c9499c21641991f_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEwLTEwLTEtMS0w_5396bc4c-3d37-4fe0-a91e-c55bac3297d8"
      unitRef="usd">1540000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i411f812e4d114ffb8b1267fa1cb56c6d_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEwLTEyLTEtMS0w_79013339-7b37-4940-882c-2199999fedb8"
      unitRef="number">0.495</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12599e668dbc41358348e5544d2dba07_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTExLTItMS0xLTA_a5c672f0-b437-4a61-896a-31ce7fa75a0b"
      unitRef="usd">739000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2eb10a316fe84f059ae619a1305077dc_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTExLTQtMS0xLTA_c6922b08-aec8-44d5-ae3c-da9f5ba3ff90"
      unitRef="usd">514000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i12599e668dbc41358348e5544d2dba07_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTExLTYtMS0xLTA_efd5e4f1-67f4-4208-a599-34d62f7f1928"
      unitRef="number">0.437</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7368a505f53e4badbb0e085fcb131b8a_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTExLTgtMS0xLTA_ef68ee7f-4940-4ef1-8383-01f7ab54f149"
      unitRef="usd">2076000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78842fece6ba4955bf4a23337f9c5f22_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTExLTEwLTEtMS0w_8f2886ab-bcb2-4132-af13-bf397cb76d48"
      unitRef="usd">1397000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7368a505f53e4badbb0e085fcb131b8a_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTExLTEyLTEtMS0w_25f31129-e923-46fe-ba1e-c112ea69834c"
      unitRef="number">0.486</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16e861eec4c443828199789a528253cf_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEyLTItMS0xLTA_3e2a5576-98de-47a2-ab4d-7c2333a4884a"
      unitRef="usd">1580000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i629b6a7bc81546dca94d639d376629f9_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEyLTQtMS0xLTA_1e563e5b-30d5-4f6f-8ab9-c42ac2b528d4"
      unitRef="usd">1099000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i16e861eec4c443828199789a528253cf_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEyLTYtMS0xLTA_c5d9668e-fb7c-462e-9638-33328fc62665"
      unitRef="number">0.437</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idafd1bf909ca4919aaaabc6674fb242c_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEyLTgtMS0xLTA_27c44467-0c0c-420a-98d1-c70540f7ec87"
      unitRef="usd">4378000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if665cac9f7d94d4594494bff63142705_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEyLTEwLTEtMS0w_7a1c2a26-c215-41b6-b87f-b34c3d7a1c6a"
      unitRef="usd">2937000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idafd1bf909ca4919aaaabc6674fb242c_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTEyLTEyLTEtMS0w_d7b4e0de-ae40-4b21-a909-eb63f39f447f"
      unitRef="number">0.491</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88009127c2544c78b9aed9223b7b8337_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE0LTItMS0xLTA_5d6a6283-0d3f-47bd-b72f-b63fe04151f5"
      unitRef="usd">214000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fea18f4d9d94ba2b90cc4f81dafacaa_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE0LTQtMS0xLTA_add0c88f-deee-458f-b4f3-2a84ac9467fe"
      unitRef="usd">152000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i88009127c2544c78b9aed9223b7b8337_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE0LTYtMS0xLTA_e565ad3f-f536-4854-bdd6-22a28056ab9a"
      unitRef="number">0.405</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07b9844b50d54100a2982651b8823c9a_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE0LTgtMS0xLTA_3db90aea-bf24-4191-86c2-bbc27f9c7346"
      unitRef="usd">578000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i232ddf875322462bbd406ee0ae4f9c85_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE0LTEwLTEtMS0w_5c2e8173-e5c9-4caf-96fd-d6103a3c5b91"
      unitRef="usd">407000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i07b9844b50d54100a2982651b8823c9a_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE0LTEyLTEtMS0w_d6d5a083-cdcf-4274-94c7-db6b47a5e018"
      unitRef="number">0.418</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b3d697a4fad4697830a9e243e1e0747_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE1LTItMS0xLTA_0f2eaaca-c701-448b-81f8-6c777b15e1eb"
      unitRef="usd">130000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3d70f93807b47b3aff1d8a1e73cb8f5_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE1LTQtMS0xLTA_ded8317b-3ead-4096-a91a-40330c228693"
      unitRef="usd">55000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idef7b076ea1546a89cde23fde1560ab0_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE1LTgtMS0xLTA_b206081a-5d8c-42e1-889b-6f251ebd5e5d"
      unitRef="usd">329000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i496a22b78b1d457ca678ca6d564331b5_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE1LTEwLTEtMS0w_3ea1b8de-005d-46f4-ab88-018394429b2e"
      unitRef="usd">112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9ccb9aa1cc34b1e9f6f123765de70e6_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE2LTItMS0xLTA_bb532773-9d52-4f2f-ab4f-1260cb30b77c"
      unitRef="usd">344000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4798987e78844d73831f5474a76abebe_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE2LTQtMS0xLTA_bdb9eb27-696c-495e-8c5e-f20749e39f03"
      unitRef="usd">206000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie9ccb9aa1cc34b1e9f6f123765de70e6_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE2LTYtMS0xLTA_55b6d07b-1db2-4d64-907f-2ff06460d18e"
      unitRef="number">0.667</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5e5e1acad6f430bad7029515d202b51_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE2LTgtMS0xLTA_bc03aacd-ea44-4324-b746-55ffd951add3"
      unitRef="usd">907000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b00b20de7c94aa1933c4f6eb44fb6f6_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE2LTEwLTEtMS0w_524ca655-4f4a-4940-a35f-bd925ea34f1f"
      unitRef="usd">519000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if5e5e1acad6f430bad7029515d202b51_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE2LTEyLTEtMS0w_173b0160-12af-484f-adbc-57bedc22beee"
      unitRef="number">0.747</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i207b52ef8f4b48de8416ca244f8b522d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE4LTItMS0xLTA_66a780df-6b9a-4d53-8410-ef58318682a4"
      unitRef="usd">413000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i55ce0b393cce45109fb4fabeeeaa64fd_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE4LTQtMS0xLTA_3cef158a-290d-49bd-82ac-a27c3546ab50"
      unitRef="usd">450000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i207b52ef8f4b48de8416ca244f8b522d_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE4LTYtMS0xLTA_c71e557a-ce9a-471b-a195-af36bf43ac2d"
      unitRef="number">-0.083</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8278bbfd6e74d48a7d676153d80e78e_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE4LTgtMS0xLTA_5590b108-3020-45e7-8448-925154c5b26a"
      unitRef="usd">1311000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib26f9da69a6044e4a8bd640d1dbfd732_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE4LTEwLTEtMS0w_f1ee9bcd-6f45-4dae-8bf7-3c1199604e07"
      unitRef="usd">1329000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id8278bbfd6e74d48a7d676153d80e78e_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE4LTEyLTEtMS0w_6b21e89e-4284-454c-a613-ecbbc5f57bf7"
      unitRef="number">-0.013</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5457dfbd70624cab91476a355fa5115b_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE5LTItMS0xLTA_44c4b8e8-91c6-4f23-b4d5-de25d1ff0ebb"
      unitRef="usd">654000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i553115651d944c87988eb5dd696715f6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE5LTQtMS0xLTA_20aece40-204a-4a03-b92b-182508ad3793"
      unitRef="usd">581000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5457dfbd70624cab91476a355fa5115b_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE5LTYtMS0xLTA_888f7851-8ad7-4630-a952-6cdfabfc68f6"
      unitRef="number">0.126</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a584f32c5b84a33b71234d8cc85f779_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE5LTgtMS0xLTA_5bed2498-0c5d-4ce3-b07b-a15b7a2a6d29"
      unitRef="usd">1996000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8ec118f64784127b948ce57a03251d3_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE5LTEwLTEtMS0w_166d748a-26e4-401c-aef3-649ad911d460"
      unitRef="usd">1682000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2a584f32c5b84a33b71234d8cc85f779_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTE5LTEyLTEtMS0w_e8f40cca-92da-462a-a87f-10c94e560b3b"
      unitRef="number">0.187</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2041012c7fe94696ab6a160eae5a0d28_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIwLTItMS0xLTA_10b15d5b-b724-459b-bde5-22254a77ce8e"
      unitRef="usd">1066000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fea7ff2b8d04558ad6fc2362b74bf38_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIwLTQtMS0xLTA_d1ed26da-9474-4df9-80b4-38ada280ecd8"
      unitRef="usd">1031000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2041012c7fe94696ab6a160eae5a0d28_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIwLTYtMS0xLTA_4e084fa0-2a99-43c3-a4b0-675af0a51be3"
      unitRef="number">0.035</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60a807f1dd544cac8e57c11caf619604_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIwLTgtMS0xLTA_e80525c7-42c9-4f0b-90eb-8274095c2502"
      unitRef="usd">3307000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01ec1719a93544dd847dd8eabc9f9027_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIwLTEwLTEtMS0w_d0969191-bac5-4045-99d8-6522423ad847"
      unitRef="usd">3011000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i60a807f1dd544cac8e57c11caf619604_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIwLTEyLTEtMS0w_6c42e18e-4e30-45a8-b460-fd65efe1faed"
      unitRef="number">0.099</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06b7e00e28414ef1af6c648b94de249d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIyLTItMS0xLTA_87c3c3fd-2f57-4fc8-b950-1b30e633d280"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife8d592b718e4648b32dd579c98199c1_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIyLTQtMS0xLTA_41cf3e63-4649-403e-a809-9a8f7863d552"
      unitRef="usd">58000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i06b7e00e28414ef1af6c648b94de249d_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIyLTYtMS0xLTA_3231bf12-f127-4f5d-8fe9-2fda984e3be7"
      unitRef="number">-0.570</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice26ad0a6ed346fb8cd1cbe7031efb8c_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIyLTgtMS0xLTA_ed840f34-a0f9-4ae5-afb5-bce7f0dff5ed"
      unitRef="usd">96000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d26596d2402468f925f727a0ba02ff8_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIyLTEwLTEtMS0w_00a30e0b-d6ee-417a-8798-10425300bc76"
      unitRef="usd">284000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ice26ad0a6ed346fb8cd1cbe7031efb8c_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIyLTEyLTEtMS0w_caf7ddab-7729-4a84-a5f9-43de157bff42"
      unitRef="number">-0.662</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fec763a254e49a38e7ad0d9a0f09012_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIzLTItMS0xLTA_027ad494-12b8-4d98-835b-9d219f28f631"
      unitRef="usd">523000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8302f031c56743a1a3a21fb700613bdb_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIzLTQtMS0xLTA_727bbb37-4fac-47ab-9f6b-83806ad2529f"
      unitRef="usd">532000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5fec763a254e49a38e7ad0d9a0f09012_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIzLTYtMS0xLTA_1ad86790-8a62-4be4-bba2-52668638a5ad"
      unitRef="number">-0.018</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff9d00b4dac646eb8e2d975cfd2be240_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIzLTgtMS0xLTA_2c6cae64-eb11-4542-8a99-049a9c4ce042"
      unitRef="usd">1653000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia6a7f6a3730144bca2ea36f15ea20490_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIzLTEwLTEtMS0w_2336fe24-bca9-4f95-bfe7-c6f321233977"
      unitRef="usd">1564000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iff9d00b4dac646eb8e2d975cfd2be240_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTIzLTEyLTEtMS0w_ecf5d1e9-dd42-4887-a3e7-3536b38edf83"
      unitRef="number">0.057</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6096f7b9393042f5b2b82bc8fb59bd2e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI0LTItMS0xLTA_d84e5658-aba6-4254-a223-81e44bd34b21"
      unitRef="usd">548000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b3780cbf7d543e7b543bfaa92165ed4_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI0LTQtMS0xLTA_0fdfc95d-452e-423c-bbcd-51a0bfdf3f6e"
      unitRef="usd">590000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6096f7b9393042f5b2b82bc8fb59bd2e_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI0LTYtMS0xLTA_fd176f3c-947a-43b7-8782-01256b0dd6e5"
      unitRef="number">-0.072</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91e2cc727626439296018d3621df8996_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI0LTgtMS0xLTA_a8be63e9-f64b-485a-b228-fefbc4d484ca"
      unitRef="usd">1749000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idcd8a72bb32b468fa5b37fc14195304f_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI0LTEwLTEtMS0w_8d3e7fa4-0b02-43fe-866d-b4ac0068e844"
      unitRef="usd">1848000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i91e2cc727626439296018d3621df8996_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI0LTEyLTEtMS0w_badc9722-7b45-4640-8363-fc3cb77d137a"
      unitRef="number">-0.054</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9112184634e44b0cbfd9d823f1219aa3_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI3LTItMS0xLTA_6f1ca681-8a7d-4a8e-be6d-d6eccdd742e5"
      unitRef="usd">32000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i920ec4d1d57649248aa990c4b93fe684_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI3LTQtMS0xLTA_d0882a6d-8826-4fc1-ac22-82b336ab3017"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9112184634e44b0cbfd9d823f1219aa3_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI3LTYtMS0xLTA_7f475e66-60ca-4c8a-ba5d-cca361c506dc"
      unitRef="number">0.496</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i453a034a54da477f8370e78e927a3539_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI3LTgtMS0xLTA_180563f9-3f10-441e-9536-e462fa8874f1"
      unitRef="usd">76000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a991002f04c401e97d727678badafbf_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI3LTEwLTEtMS0w_8f6b8038-d538-4edc-9aca-d91da396c73f"
      unitRef="usd">63000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i453a034a54da477f8370e78e927a3539_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI3LTEyLTEtMS0w_16679dc1-5853-408c-9179-4fdce67f37f9"
      unitRef="number">0.210</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7aee8dd846874e159438cc4a03f7bab0_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI4LTItMS0xLTA_d56c9166-e16d-42a2-b15d-5ecea4b3ebea"
      unitRef="usd">94000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00b9571f2a6b4a2bbc14ea2f3077c57b_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI4LTQtMS0xLTA_9007a835-451e-4359-a881-37e909ac7e75"
      unitRef="usd">181000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7aee8dd846874e159438cc4a03f7bab0_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI4LTYtMS0xLTA_7b9ccd2a-f32e-48bd-b861-f2086d5f6f7b"
      unitRef="number">-0.480</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0518e784a66b49d68047ddf7ee9cc00b_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI4LTgtMS0xLTA_04b5b3fc-e7a2-4b6c-8336-b440af928dae"
      unitRef="usd">352000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31e66b96468f420288f19c564089d8a2_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI4LTEwLTEtMS0w_af6019d6-1e1c-4c44-8e85-56a6de56faa4"
      unitRef="usd">556000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0518e784a66b49d68047ddf7ee9cc00b_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI4LTEyLTEtMS0w_5aae8033-7e08-44b2-ade2-d51a59640519"
      unitRef="number">-0.366</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47183644d19945a8bb49dd3a27546be6_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI5LTItMS0xLTA_e1fb0e42-305b-4ae9-9033-98dfe276831f"
      unitRef="usd">126000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c83e880c458472b8c50b6cf24267d08_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI5LTQtMS0xLTA_c1b78f21-8097-4bd1-aac0-9c65968ee076"
      unitRef="usd">203000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i47183644d19945a8bb49dd3a27546be6_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI5LTYtMS0xLTA_d3288c4b-3b35-4441-8bf5-c648d0c41dff"
      unitRef="number">-0.376</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56502c183aac4db6ac72f64b0b31c8c8_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI5LTgtMS0xLTA_70f789f5-c409-400b-bc1f-5127836dc9b8"
      unitRef="usd">428000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib67fc9ee208641588e1c086557319199_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI5LTEwLTEtMS0w_d37a1bf1-cde4-4ee9-bc4b-d1db5331bbbe"
      unitRef="usd">619000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i56502c183aac4db6ac72f64b0b31c8c8_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTI5LTEyLTEtMS0w_895030af-d840-440e-b4ad-0c8f62c0ce40"
      unitRef="number">-0.307</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i916f3760699b40dd9d58b5336d356442_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMyLTItMS0xLTA_d5e53a7e-d8c5-449c-89cf-637933933b87"
      unitRef="usd">610000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iedaf2bda66294ffba5d53d0ef7f61370_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMyLTQtMS0xLTA_2469d059-3e3e-4fce-9469-2561c9e2bb00"
      unitRef="usd">510000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i916f3760699b40dd9d58b5336d356442_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMyLTYtMS0xLTA_f01b17ac-7607-484c-a76c-b9bc9a68dfb9"
      unitRef="number">0.197</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4c445f8624f40d6824d709a9744cae5_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMyLTgtMS0xLTA_9aa78ea3-82b5-4cb6-bac4-f9700794fc4b"
      unitRef="usd">1778000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37ccb6eef64a4045a8c29d06c8cf02d8_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMyLTEwLTEtMS0w_3cc5bccc-f32e-4172-8c85-0d0d94c9c0f5"
      unitRef="usd">1541000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if4c445f8624f40d6824d709a9744cae5_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMyLTEyLTEtMS0w_59b07ac1-4a2c-4bee-b1d8-2633f41546fe"
      unitRef="number">0.154</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3dbe05ea1dac40b0b66f0aac32a160b5_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMzLTItMS0xLTA_36fecf4c-b34f-479e-9ab3-b528110d8bcc"
      unitRef="usd">258000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb72505c1d974357bf35c6715df00b92_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMzLTQtMS0xLTA_67ed9017-743c-48bc-a00a-cfe20d6f8d53"
      unitRef="usd">239000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3dbe05ea1dac40b0b66f0aac32a160b5_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMzLTYtMS0xLTA_24af325c-ec95-44fc-ab72-2f78b6f0a128"
      unitRef="number">0.079</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2fc5d639ff1a4b4e921cb3c51ac5125c_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMzLTgtMS0xLTA_4b213a32-1d25-4e58-a79b-c03ad8ec6056"
      unitRef="usd">821000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6fa923eeef864e7aa46c2f7515d33025_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMzLTEwLTEtMS0w_3a2ff895-bce4-43bf-885a-06905af29f0d"
      unitRef="usd">742000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2fc5d639ff1a4b4e921cb3c51ac5125c_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTMzLTEyLTEtMS0w_e9dd1afc-ac23-4c01-bb22-80e68e803426"
      unitRef="number">0.107</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6bf4f3e987046c38170406d258eb94a_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM0LTItMS0xLTA_5176d864-05e8-4a4f-9d99-7eed565a56ff"
      unitRef="usd">868000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8db06e2cc04c458d912a58a028760c4b_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM0LTQtMS0xLTA_5c565432-5028-47ff-a0e2-4d47a68a48bb"
      unitRef="usd">749000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id6bf4f3e987046c38170406d258eb94a_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM0LTYtMS0xLTA_6c8fe6a4-53bb-4244-a195-7f9079da38ab"
      unitRef="number">0.159</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f4582f93ea64baf9c7628c58576a173_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM0LTgtMS0xLTA_1d5daa07-d70e-4efb-9bf1-4f038c0007bf"
      unitRef="usd">2599000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41e8da5f36f54d4bbdfc91d37ee03c6c_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM0LTEwLTEtMS0w_5edeed9b-de2d-4cf3-ad65-1a68153250ab"
      unitRef="usd">2283000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1f4582f93ea64baf9c7628c58576a173_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM0LTEyLTEtMS0w_e2153880-256a-44b6-99df-8df2cc36070f"
      unitRef="number">0.139</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5424c438f2644ed794b321513eaa316d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM2LTItMS0xLTA_c51fe7e8-d79a-4e21-964a-a95adbbbcb2d"
      unitRef="usd">299000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5deab209e23645b498b422f99964df0d_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM2LTQtMS0xLTA_e65f1abb-3ba0-4e57-a117-2867d7b1ab34"
      unitRef="usd">244000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5424c438f2644ed794b321513eaa316d_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM2LTYtMS0xLTA_d59d7015-8053-490c-9454-26c6dc718d4c"
      unitRef="number">0.228</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib84b38a234fb454083a8048492807925_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM2LTgtMS0xLTA_9a368867-1a02-4929-b439-22fe3e879436"
      unitRef="usd">861000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3b2572faea149698d267bcb7cf881f7_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM2LTEwLTEtMS0w_af7c1e4d-6dd6-4787-a6a2-eb9e7d187f1f"
      unitRef="usd">729000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib84b38a234fb454083a8048492807925_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM2LTEyLTEtMS0w_4dcdf6a2-4356-4d2a-9bda-2feae183d8c8"
      unitRef="number">0.182</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i605343b19cc64b1482f6408c0434084c_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM3LTItMS0xLTA_78ff2fd1-060e-4b43-b78b-b2fdc7025ab8"
      unitRef="usd">159000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5c97cf898604cf4ad7406f9531426d4_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM3LTQtMS0xLTA_3c79b684-5584-4fd4-a137-e22f98cd6013"
      unitRef="usd">148000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i605343b19cc64b1482f6408c0434084c_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM3LTYtMS0xLTA_e20d1106-553b-4504-9092-3ec196c22589"
      unitRef="number">0.074</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ac76396403e46669ddb9bb2a99e7626_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM3LTgtMS0xLTA_0e111a2a-ca72-4be7-962a-07a471e56478"
      unitRef="usd">510000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1c93d444f7d4ab4a13e6d1f8efea458_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM3LTEwLTEtMS0w_59d10c4e-3824-4507-9b14-5f42f522be1c"
      unitRef="usd">458000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0ac76396403e46669ddb9bb2a99e7626_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM3LTEyLTEtMS0w_e416f2ff-139d-4989-80ae-d9b3ca42168a"
      unitRef="number">0.113</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fa54f45363a4ac999c0b20e1c5f28a7_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM4LTItMS0xLTA_54efebd1-6876-4d1d-a2be-226a8954b493"
      unitRef="usd">458000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i178889716f424850af73d18091ac8fb3_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM4LTQtMS0xLTA_8b35acfb-1ced-4e64-becd-5aba198e9169"
      unitRef="usd">392000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5fa54f45363a4ac999c0b20e1c5f28a7_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM4LTYtMS0xLTA_c10f0bf1-bfdd-4a47-8f3c-177140e72786"
      unitRef="number">0.170</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i19889197e7014b5abe659ff2ab7a326e_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM4LTgtMS0xLTA_fce8e8f5-0ff2-4028-b1f5-32eb94cfc2e6"
      unitRef="usd">1371000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc84e135342246ada537c96c79411c73_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM4LTEwLTEtMS0w_b72af1b8-d808-44c1-b69c-a21b5615c80b"
      unitRef="usd">1187000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i19889197e7014b5abe659ff2ab7a326e_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTM4LTEyLTEtMS0w_07c3c7ed-f465-41ba-a903-2d46af68e242"
      unitRef="number">0.155</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie334cb54a91c4aa489e4470d9dd267d2_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQwLTItMS0xLTA_523d5fc8-b35f-4e87-9ef6-a748bee8f53e"
      unitRef="usd">265000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieff90fbe65b14dccbcde52e76abe2491_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQwLTQtMS0xLTA_4c884fd8-b51c-4694-840d-7d06349434e2"
      unitRef="usd">226000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie334cb54a91c4aa489e4470d9dd267d2_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQwLTYtMS0xLTA_6693d807-43a5-4c3b-b6c2-dbbdac056b30"
      unitRef="number">0.173</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28c4b7c2d0fe47d6a4a59c5126dfe022_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQwLTgtMS0xLTA_ffb265fd-b081-446e-96ee-146756102cf8"
      unitRef="usd">792000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f1a31cc19a448fbbbc2285717ad1b08_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQwLTEwLTEtMS0w_35610cda-0e92-4567-be02-ca45d046c5e1"
      unitRef="usd">692000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i28c4b7c2d0fe47d6a4a59c5126dfe022_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQwLTEyLTEtMS0w_92aa6c29-df07-4da1-9485-3b21483fc5d0"
      unitRef="number">0.146</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f62cbc379cc47b1b559838e47e5e9b9_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQxLTItMS0xLTA_d9dd003a-f356-4af2-9b18-2e392bd39552"
      unitRef="usd">44000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia6eed07d82dd4b42871be86888306c52_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQxLTQtMS0xLTA_1938d8ea-d853-403b-ac15-72e9c204ca73"
      unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3f62cbc379cc47b1b559838e47e5e9b9_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQxLTYtMS0xLTA_a41c5c19-6df7-4676-9211-474b10b6971b"
      unitRef="number">0.304</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f839300e00c4a4d859e26c2fa5c6e37_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQxLTgtMS0xLTA_03bef81f-6e7e-489e-83b7-88d93be731c9"
      unitRef="usd">135000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1873788fac6a46e8be4e456fa927ff6a_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQxLTEwLTEtMS0w_b8f903ca-8693-4da2-b425-404b7c6a5938"
      unitRef="usd">100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1f839300e00c4a4d859e26c2fa5c6e37_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQxLTEyLTEtMS0w_8c697849-9d9d-4c91-a81b-56eb6db841b2"
      unitRef="number">0.346</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12ba7c96d6b34b73b2dc889a40179104_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQyLTItMS0xLTA_2b68b6dd-b3e5-4189-b7d2-6f768dde5dc8"
      unitRef="usd">309000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e0ccc4ef75a4c3cac7174f2de54a9cc_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQyLTQtMS0xLTA_6afd1200-9b3f-4ec6-a2de-64c5c8b36573"
      unitRef="usd">260000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i12ba7c96d6b34b73b2dc889a40179104_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQyLTYtMS0xLTA_a57de3bf-0552-43f6-9739-9b0aae593b10"
      unitRef="number">0.190</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8becabeadf84e98b9d419b68203265b_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQyLTgtMS0xLTA_d7d9ee82-d5a7-4ba0-b32f-7d8c1333ae1c"
      unitRef="usd">927000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68239219992142d2aa3702fc95b596b7_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQyLTEwLTEtMS0w_5690b66c-ca89-460b-b938-6cb72a17c640"
      unitRef="usd">792000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie8becabeadf84e98b9d419b68203265b_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQyLTEyLTEtMS0w_2a74e4d3-4ed2-499f-aa2b-bc2918bc8702"
      unitRef="number">0.171</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife0ab2f3b60049508c2fc1e1d78d4cb9_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ0LTItMS0xLTA_816bf68d-aace-48b7-b685-2d3373da0e98"
      unitRef="usd">47000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a330731470745e48d563c9c6d517be1_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ0LTQtMS0xLTA_aba2d3f8-386c-47dd-aab8-d27071346552"
      unitRef="usd">40000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ife0ab2f3b60049508c2fc1e1d78d4cb9_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ0LTYtMS0xLTA_f566dc1e-2526-4c67-ae74-552e7363b2a6"
      unitRef="number">0.144</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e7548bbd31e49bab7d5fec3a6b41671_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ0LTgtMS0xLTA_5b30bd88-7b45-4b48-91a9-4dce922d58f5"
      unitRef="usd">125000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ac34ad4788d43b3a301f9c1c62308c9_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ0LTEwLTEtMS0w_22ad4ee5-0a6a-481f-ae55-b853543d7e5f"
      unitRef="usd">121000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8e7548bbd31e49bab7d5fec3a6b41671_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ0LTEyLTEtMS0w_3ded6865-4498-4b77-9743-56c3b9160f2c"
      unitRef="number">0.028</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i106f48ae57ab4181ac0362aa6cfc6106_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ1LTItMS0xLTA_8fc4c238-0a06-490e-a9e8-fe4fbfede981"
      unitRef="usd">54000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1bb172db98c34f69a96a8e61c2990f49_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ1LTQtMS0xLTA_4947e5de-1683-4397-b6f8-8f46c37146a4"
      unitRef="usd">57000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i106f48ae57ab4181ac0362aa6cfc6106_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ1LTYtMS0xLTA_f09a6efc-aaa8-4b51-8fe0-0d423a686520"
      unitRef="number">-0.044</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac83ab04fd454d808f7a0f2ba77b1fb3_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ1LTgtMS0xLTA_c30896c4-bebb-4edc-8ad6-199430975eea"
      unitRef="usd">176000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iebe8c5ef936a40769b7f7a23f0b8f324_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ1LTEwLTEtMS0w_bd6cfa0d-0adc-4ff7-baa7-3b42a0a3b9bd"
      unitRef="usd">183000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iac83ab04fd454d808f7a0f2ba77b1fb3_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ1LTEyLTEtMS0w_c6b97191-c3fb-4410-8239-6fa1c0b8b783"
      unitRef="number">-0.037</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29b333eb2dd34c4e84797c94386443a5_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ2LTItMS0xLTA_a57512be-b348-4457-be54-e4b406ba3eb7"
      unitRef="usd">101000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i894f559ee892432bb4a292bbcc61acdc_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ2LTQtMS0xLTA_110a20f8-247d-467a-879d-b2ff60ab948c"
      unitRef="usd">97000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i29b333eb2dd34c4e84797c94386443a5_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ2LTYtMS0xLTA_25b04d3d-42c9-4a01-82a1-08bb61b389f0"
      unitRef="number">0.034</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i796f5d7d4c4840a8992ef9c2f85752ff_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ2LTgtMS0xLTA_1a1e65d2-135e-48fa-b52c-9ec297ded4e1"
      unitRef="usd">301000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89c02fa080d343cc9ff82372eac2f123_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ2LTEwLTEtMS0w_efdf162e-6428-40e6-a8e4-43ec36a6a6bd"
      unitRef="usd">304000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i796f5d7d4c4840a8992ef9c2f85752ff_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ2LTEyLTEtMS0w_fabe36a4-82a4-4d6f-88e9-9f4ba86ceef4"
      unitRef="number">-0.011</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80392036102c45ecbc3621717d0b2c74_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ5LTItMS0xLTA_d6f4d38b-8647-47b7-a090-c34b21ab0138"
      unitRef="usd">800000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b0d1c1d0a014d889948f7983d615275_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ5LTQtMS0xLTA_3acf9f2b-1263-4ee3-9631-7c7858911db9"
      unitRef="usd">931000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i80392036102c45ecbc3621717d0b2c74_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ5LTYtMS0xLTA_d79d2ca4-4389-4998-b1d0-c6a83dd33fce"
      unitRef="number">-0.140</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7ad75c915974e13baa608e010a4dbfe_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ5LTgtMS0xLTA_9ae1a971-935b-41dc-abda-f8eea6793a77"
      unitRef="usd">2379000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i42ff1e292f27485f8ff84644532adc72_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ5LTEwLTEtMS0w_61fbc5c8-ea2b-46a3-be84-8e7ca6a5d6ef"
      unitRef="usd">2574000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib7ad75c915974e13baa608e010a4dbfe_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTQ5LTEyLTEtMS0w_3b866884-19c3-4279-9559-a89887fb5d5f"
      unitRef="number">-0.076</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i144c6515230549dc9ae750420daa70c0_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUwLTItMS0xLTA_a64fa6a5-c0a3-4259-958f-c56b60b1d2c0"
      unitRef="usd">333000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12c283c3ebdc43f685bfcfb86adbaec3_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUwLTQtMS0xLTA_1a1c159b-7305-49e1-a0ff-1fc53156a938"
      unitRef="usd">351000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i144c6515230549dc9ae750420daa70c0_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUwLTYtMS0xLTA_b7d701b6-a6c4-41ed-a2f3-37028d8094e2"
      unitRef="number">-0.051</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66f80a64500142458617dbf774e7f46a_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUwLTgtMS0xLTA_bd2ac8a2-c68c-4c2d-85bb-1e27a4c91f81"
      unitRef="usd">1007000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifce0de714d9b45428f3968fc9988e0c7_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUwLTEwLTEtMS0w_af2c11e3-4861-4660-830d-fc219fcfc304"
      unitRef="usd">1052000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i66f80a64500142458617dbf774e7f46a_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUwLTEyLTEtMS0w_e5577df1-6b93-47c7-b495-74a8f19fa079"
      unitRef="number">-0.042</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3367c13477ea4799ac8e90b9e213d261_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUxLTItMS0xLTA_3a016432-dc8b-4c3c-82cf-5f5dde833506"
      unitRef="usd">1133000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fb626460b96415bb179ccaa4c0ed5b5_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUxLTQtMS0xLTA_0ed83a38-bce0-4925-8371-d3dc39f89517"
      unitRef="usd">1281000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3367c13477ea4799ac8e90b9e213d261_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUxLTYtMS0xLTA_220e89b5-f58e-49f8-b898-f45352ee9465"
      unitRef="number">-0.115</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id11e5789ebb948679c1a5ad0d35ae54c_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUxLTgtMS0xLTA_0dd8074d-d9b6-4f9d-b8c9-e70442e4f5f1"
      unitRef="usd">3386000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iffea672a5b3c47eea9012fe82778494b_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUxLTEwLTEtMS0w_63b4c78a-2ce1-40e6-88b1-638a9a7cc179"
      unitRef="usd">3625000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id11e5789ebb948679c1a5ad0d35ae54c_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUxLTEyLTEtMS0w_bfdad2ea-24c5-4517-bb3b-e06147b8428b"
      unitRef="number">-0.066</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie993d24b54904ea888b1293ce96956fc_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUzLTItMS0xLTA_5e7dd8d6-f0eb-414a-8ee1-62f847e6a093"
      unitRef="usd">636000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c1b37038bc7487ea392d8a7578b3110_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUzLTQtMS0xLTA_d23be0b1-0899-46bb-a05c-295bc117bfde"
      unitRef="usd">630000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie993d24b54904ea888b1293ce96956fc_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUzLTYtMS0xLTA_76b26533-2b1b-47c6-bc93-ac134fb8b54f"
      unitRef="number">0.008</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c5d285afcf84094bbff26299ad4e109_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUzLTgtMS0xLTA_a3655c6d-55c0-4d04-9418-6dd6ed07d207"
      unitRef="usd">1794000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a8c160f547f4d6ca4252136e13831b0_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUzLTEwLTEtMS0w_2710cc67-b09f-44e8-a859-0997555edea6"
      unitRef="usd">1716000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8c5d285afcf84094bbff26299ad4e109_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTUzLTEyLTEtMS0w_0b294cb4-94ef-4085-8a4a-bcebb16d9925"
      unitRef="number">0.045</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic72c4574496a4c4fb83a4560784b72a4_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU0LTItMS0xLTA_47de444f-bffc-4344-ac09-ebf7a78dd8e1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d908ad9d290413a98b31cf4d5ea0d87_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU0LTQtMS0xLTA_b3477f33-322e-447e-b7d4-13eaba6682fc"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic72c4574496a4c4fb83a4560784b72a4_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU0LTYtMS0xLTA_d33de107-a260-464d-b989-0b0a85e0cd06"
      unitRef="number">0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8298a87ec6094a83a8f67eaeaaed0f98_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU0LTgtMS0xLTA_6a74fbb7-098b-48ab-9677-8fe3034e3262"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i246d9eeb9fc948d0a353e9a5e7db555a_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU0LTEwLTEtMS0w_91801474-2443-4764-a83e-b34473a25a59"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8298a87ec6094a83a8f67eaeaaed0f98_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU0LTEyLTEtMS0w_7fc5350e-dc0b-4557-8460-258d836a2673"
      unitRef="number">0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic58138fbb27f46fa9ceb6e76659f1262_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU1LTItMS0xLTA_6c15dd1c-4944-43fe-a7cf-4411c6d44bcd"
      unitRef="usd">636000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i583b1aa9afbf4206bfc48b54ba5bc3fd_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU1LTQtMS0xLTA_20034c9c-a8d8-4b56-819c-9a1b7c202da9"
      unitRef="usd">630000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic58138fbb27f46fa9ceb6e76659f1262_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU1LTYtMS0xLTA_4c60f441-f104-4b27-bffb-9d3d0a34ab44"
      unitRef="number">0.008</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2fa5dc18ef454b7099777b9a2e9edf1b_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU1LTgtMS0xLTA_4a2c9491-7bbb-4907-b527-ab12dcd59206"
      unitRef="usd">1794000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i450c72826782487189f185be011ada8c_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU1LTEwLTEtMS0w_fc29c14f-0052-44ba-93c0-a5cdf9317448"
      unitRef="usd">1716000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2fa5dc18ef454b7099777b9a2e9edf1b_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU1LTEyLTEtMS0w_51ca6c46-cdd0-4832-a19d-e6006a802b16"
      unitRef="number">0.045</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87186edc0be942c3a224af0c83083a2e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU3LTItMS0xLTA_d5ddb654-69fd-4bfd-a533-a534c8a1b2b7"
      unitRef="usd">66000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if86e5be3d1d0462981071e831b1b1941_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU3LTQtMS0xLTA_d2cddcda-8a46-4bb6-8428-dd3de6f6d95f"
      unitRef="usd">156000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i87186edc0be942c3a224af0c83083a2e_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU3LTYtMS0xLTA_e7529cd3-a9f6-4d7a-8316-d2255dcc13ec"
      unitRef="number">-0.574</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i118eb58e43a74473be63948e7e8b110d_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU3LTgtMS0xLTA_37f57455-04c0-413c-affa-a2ffb3310668"
      unitRef="usd">249000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14fb81ce0da94fd782c69b4cf8735fb2_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU3LTEwLTEtMS0w_75ffc1d1-0bc9-4ab4-bc3e-dfae97ac664f"
      unitRef="usd">405000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i118eb58e43a74473be63948e7e8b110d_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU3LTEyLTEtMS0w_fbce01bf-779b-4562-8348-186f824cef20"
      unitRef="number">-0.384</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4595e7a6d7c0489b8e9bd4072d2f0958_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU4LTItMS0xLTA_2efb1c23-ab42-4ed8-8111-2443dc02cbb3"
      unitRef="usd">67000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb6afd2ee42744da955bfb4de57ea068_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU4LTQtMS0xLTA_e98eeb6d-e4cd-4b08-9806-3964caeb9a25"
      unitRef="usd">68000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4595e7a6d7c0489b8e9bd4072d2f0958_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU4LTYtMS0xLTA_28207726-204b-4313-9840-5ef2fa32a466"
      unitRef="number">-0.010</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52e5864ae7034aacb7d9ee6a4b6ccc99_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU4LTgtMS0xLTA_de2b254a-04af-4fe9-a457-7f2488659d40"
      unitRef="usd">194000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5224eaa3aeab4bb6b58685ece2af0a80_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU4LTEwLTEtMS0w_d62dfc1c-d89c-4dee-83e4-87484602328e"
      unitRef="usd">173000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i52e5864ae7034aacb7d9ee6a4b6ccc99_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU4LTEyLTEtMS0w_fed18271-3607-4fc5-bcae-1a9a74927d27"
      unitRef="number">0.119</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e6e8316702148888c8f276675d24468_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU5LTItMS0xLTA_9e1c1ee7-ce5c-49c7-8e06-5bbcc4fe7545"
      unitRef="usd">133000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8fabe771e534cf0acd946d6aff01f6e_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU5LTQtMS0xLTA_9d106ab0-8b1a-4f03-9667-f3e313b318dc"
      unitRef="usd">224000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7e6e8316702148888c8f276675d24468_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU5LTYtMS0xLTA_6505e8f7-7070-410c-8fea-5340bfafa124"
      unitRef="number">-0.403</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic749d8f0affe4953bf8a83f1ad6aa6b6_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU5LTgtMS0xLTA_be51082b-1a6c-476c-bc96-ed7ad4f54f6a"
      unitRef="usd">443000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f0243ceaf5947389c637d5ed6092fe9_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU5LTEwLTEtMS0w_a98aa5fd-fa52-4c10-ab61-30f7be76cd27"
      unitRef="usd">578000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic749d8f0affe4953bf8a83f1ad6aa6b6_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTU5LTEyLTEtMS0w_610d7349-6741-457e-af18-ae64fcd5e318"
      unitRef="number">-0.234</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i184a57e2be914b2593d8414dcd7ebd91_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYxLTItMS0xLTA_ae6d753c-2a83-4313-bddd-9d86457b49e2"
      unitRef="usd">47000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60cfac9b2a974827a630d010512f5c77_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYxLTQtMS0xLTA_b0007534-b86a-45f2-9c6e-e3e124b9d135"
      unitRef="usd">69000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i184a57e2be914b2593d8414dcd7ebd91_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYxLTYtMS0xLTA_8b980028-a3d9-472e-89cc-f009b0e6a591"
      unitRef="number">-0.309</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14031fe7bc3f40a795242b575acf51dd_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYxLTgtMS0xLTA_097bc589-8f3d-46fd-8442-b2ea5823bc95"
      unitRef="usd">168000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3eb67a9b82764e84a6203e5424624500_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYxLTEwLTEtMS0w_789e84b7-9528-4df3-befa-36b6126fbddc"
      unitRef="usd">215000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i14031fe7bc3f40a795242b575acf51dd_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYxLTEyLTEtMS0w_7fcb0226-682b-489c-87c1-5d85247764d8"
      unitRef="number">-0.217</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if278a32c9dce4fefa94c62fe1b00772f_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYyLTItMS0xLTA_3cabebac-bda0-496d-b782-a0ee6d682651"
      unitRef="usd">65000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7780cd75cc6246779ff11406eb223052_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYyLTQtMS0xLTA_9a6d56f2-2ee1-4296-b6a9-721ad425824e"
      unitRef="usd">63000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if278a32c9dce4fefa94c62fe1b00772f_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYyLTYtMS0xLTA_c3e24079-e40e-403a-b855-c426cb1e171d"
      unitRef="number">0.031</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i691d2c928a4a4a60bc0a0d1ef168d8c9_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYyLTgtMS0xLTA_d674b6cd-c6a3-427f-8447-293bd80403ac"
      unitRef="usd">198000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66aa28c488584714acd26eb645da8e89_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYyLTEwLTEtMS0w_629ce88e-06c8-4a71-afdc-d3ce273cd5ce"
      unitRef="usd">208000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i691d2c928a4a4a60bc0a0d1ef168d8c9_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYyLTEyLTEtMS0w_5bc979d5-74c0-456f-ae4e-9921a59a6633"
      unitRef="number">-0.047</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9360b52072034cfdae74e58d3dea3f33_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYzLTItMS0xLTA_89dc31da-d068-4be5-914f-e02ce816fc58"
      unitRef="usd">112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7e3e8b15ac3457193a8e87969a76f91_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYzLTQtMS0xLTA_fa129810-e751-45a4-ad20-42319f2697e4"
      unitRef="usd">132000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9360b52072034cfdae74e58d3dea3f33_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYzLTYtMS0xLTA_42d7402e-4432-4f38-aa1d-0caa62304b28"
      unitRef="number">-0.146</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic31063913c464d9f982eb66bf1ed7177_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYzLTgtMS0xLTA_da1aaf60-94f8-448d-9bd4-dcd6eb112257"
      unitRef="usd">366000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia42b914656c14beba7b1d52f061668e2_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYzLTEwLTEtMS0w_4d23900a-c865-4690-9e85-a5239b2a5f99"
      unitRef="usd">423000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic31063913c464d9f982eb66bf1ed7177_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTYzLTEyLTEtMS0w_48054bb1-003e-46c9-a0fa-a12e3cc12f0f"
      unitRef="number">-0.134</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia376c7c58c6643b982dd021a28407a4e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY1LTItMS0xLTA_59a914c7-7025-4a8b-974c-3f63039914e4"
      unitRef="usd">51000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d6cc5a8d92c432cb5364a4922a91d91_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY1LTQtMS0xLTA_f81324f3-5bf4-4a03-af2f-40878bd7b499"
      unitRef="usd">75000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia376c7c58c6643b982dd021a28407a4e_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY1LTYtMS0xLTA_2321fbc6-3e2f-45a4-8329-e11a97f799bf"
      unitRef="number">-0.326</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81cccc8066a04b4e8587f7022fcef5bb_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY1LTgtMS0xLTA_eec73753-cd24-4c32-af4c-0b7b5cc164c4"
      unitRef="usd">168000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id91713fd7da44504bbad7b781cd667f1_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY1LTEwLTEtMS0w_153d8faf-2dc7-4bf4-bee7-cc4630226c26"
      unitRef="usd">238000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i81cccc8066a04b4e8587f7022fcef5bb_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY1LTEyLTEtMS0w_dff31b73-1618-47d9-8e29-7bca7dc7c5ba"
      unitRef="number">-0.293</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39b68889f48547fbb59d17264b094ef6_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY2LTItMS0xLTA_c11a0af1-4a15-4115-bc58-d36ff0d54b9a"
      unitRef="usd">200000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibdeb350dde814f6da9360e6b2898ed8b_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY2LTQtMS0xLTA_ecd22cca-0918-4ea5-91b7-4dbb8577c548"
      unitRef="usd">219000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i39b68889f48547fbb59d17264b094ef6_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY2LTYtMS0xLTA_2b7d0870-d125-486f-a8c5-b3abc5f9d2d4"
      unitRef="number">-0.087</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i939e8441406e477a9fc9fd99aec89197_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY2LTgtMS0xLTA_2a01183b-9f2a-4aec-a6be-60cb30e8d95d"
      unitRef="usd">615000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff6994e434614d1a876eb0d4c2bc823f_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY2LTEwLTEtMS0w_2a22ca48-6043-480e-97e5-b4db3e836a8c"
      unitRef="usd">670000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i939e8441406e477a9fc9fd99aec89197_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY2LTEyLTEtMS0w_546d4c22-2774-45cc-8837-fadce0015370"
      unitRef="number">-0.083</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a65b49f54754536b37dd908a689ce2f_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY3LTItMS0xLTA_83ddb338-0618-4b85-8955-2e4495c90c0f"
      unitRef="usd">251000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie60d62e420664954b1fcb37f6569c27f_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY3LTQtMS0xLTA_952ddca6-99a1-4b76-9087-dc0bbc27b28f"
      unitRef="usd">294000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6a65b49f54754536b37dd908a689ce2f_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY3LTYtMS0xLTA_01802e31-1d75-48f3-aed5-05f85573f0fb"
      unitRef="number">-0.148</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a75d9e9a4ab4545b4d6d05ead21ec93_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY3LTgtMS0xLTA_ed66ebd1-caf5-4b63-9320-97a4db0ecdb0"
      unitRef="usd">783000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic37a66f35b5c4a6d99c2c3e0d691685f_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY3LTEwLTEtMS0w_e51374a9-c2ed-453d-a504-ab7068a0f2e8"
      unitRef="usd">908000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4a75d9e9a4ab4545b4d6d05ead21ec93_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTY3LTEyLTEtMS0w_720775ef-022e-4b4c-b55c-cf4b1a6e1864"
      unitRef="number">-0.138</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f78539697c141f2a5eac40f4a433cd2_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcwLTItMS0xLTA_8e321039-b8b7-475f-9b43-31da57ce7124"
      unitRef="usd">7221000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5912aea718a849be9bf7b9153fd78d98_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcwLTQtMS0xLTA_436266da-3c14-4de8-afe9-6223d18316e0"
      unitRef="usd">6438000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3f78539697c141f2a5eac40f4a433cd2_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcwLTYtMS0xLTA_00fe2f9c-4c59-4964-b0a9-3b972edebff7"
      unitRef="number">0.122</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia241c89cf4794e2bbee7d74dce0875de_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcwLTgtMS0xLTA_f640dad5-3c69-4e48-a262-7b8463de97ce"
      unitRef="usd">20536000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b6e382369c74f9ea1f6e2762ea30c35_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcwLTEwLTEtMS0w_c015b21f-c01b-48d7-8c3f-7c4a82f88ca2"
      unitRef="usd">18619000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia241c89cf4794e2bbee7d74dce0875de_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcwLTEyLTEtMS0w_dd8d72be-c726-4cb3-ba16-f1c8123451a6"
      unitRef="number">0.103</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieba41c75d5da400e9fb64a10752e1807_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcxLTItMS0xLTA_1469a5a3-5df9-4640-b41a-69e51a4db2fe"
      unitRef="usd">5773000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad2d34311e684aa1a6203f5714c84491_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcxLTQtMS0xLTA_abe27a2b-0667-4df6-9cdb-ae131861e039"
      unitRef="usd">4980000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ieba41c75d5da400e9fb64a10752e1807_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcxLTYtMS0xLTA_cc14183c-869c-458d-bce2-f6833c7025d0"
      unitRef="number">0.159</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c2dbbb07733475cb4da59ccd3196294_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcxLTgtMS0xLTA_85f52aa2-c134-4f77-801b-7b674b82cce1"
      unitRef="usd">17256000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08295db3a10c439ca068a77285361be5_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcxLTEwLTEtMS0w_5b91b497-76be-4ac1-bb91-a8cd4b1a110a"
      unitRef="usd">14685000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0c2dbbb07733475cb4da59ccd3196294_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcxLTEyLTEtMS0w_f47dc6ae-7796-4289-beb1-fd69eea591b1"
      unitRef="number">0.175</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia15056130be2407b92273859fdb8febf_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcyLTItMS0xLTA_e5616de6-0720-4931-b7bc-3111ba653622"
      unitRef="usd">12994000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ee43394ce814ec8b0f42fe52e12760b_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcyLTQtMS0xLTA_e8f79fa2-5d6b-4a3b-b121-8895463490e4"
      unitRef="usd">11418000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia15056130be2407b92273859fdb8febf_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcyLTYtMS0xLTA_df2ae2a9-c341-41f1-9b4a-8c2d8d5074eb"
      unitRef="number">0.138</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18c6f67375de464e98be9b5c858a0996_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcyLTgtMS0xLTA_a808b3f1-6fd0-4439-8406-a4bb3f7fc513"
      unitRef="usd">37792000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i90d459ed7f3b48f1b2b9174f1965fbd3_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcyLTEwLTEtMS0w_e374f548-45fa-491c-ba39-4c8d3500259a"
      unitRef="usd">33304000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i18c6f67375de464e98be9b5c858a0996_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTcyLTEyLTEtMS0w_c10c43e8-2940-4b0d-91c7-e35745e1c99d"
      unitRef="number">0.135</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i664cbb9c037f4d99a4376475a351858b_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTgzLTItMS0xLTA_7961f5d7-c8e4-4086-ae3f-1db84acbf7a0"
      unitRef="usd">444000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id97af143662643b3842da08b330a6f6a_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTgzLTQtMS0xLTA_b5b02965-4041-49e7-a699-7b5e81545164"
      unitRef="usd">399000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i664cbb9c037f4d99a4376475a351858b_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTgzLTYtMS0xLTA_89c9f661-a1d2-4ff1-96d4-f5c73e2336a2"
      unitRef="number">0.111</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7759e2ab5024d0fa40501ce6cc6e6b5_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTgzLTgtMS0xLTA_b7bae1b2-15e3-4a9a-ad52-f89a4d585aa5"
      unitRef="usd">1353000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd8d56e959874c8cbac753320da2c5e0_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTgzLTEwLTEtMS0w_b7f6ab5c-7e32-4d57-9b56-6f5147aad5e6"
      unitRef="usd">1019000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic7759e2ab5024d0fa40501ce6cc6e6b5_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTgzLTEyLTEtMS0w_d9c76426-a28a-4163-b5a9-4286ad8c3cf1"
      unitRef="number">0.327</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68c3a86a25ea429f97b80b17ca08e649_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg0LTItMS0xLTA_bfb327fb-fb11-4a68-8a96-f6b668c200bc"
      unitRef="usd">513000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8cd56ef47b4f4058acf28c65ff513a42_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg0LTQtMS0xLTA_05efc0f6-5862-4a0f-bef2-1ff461ff1b32"
      unitRef="usd">437000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i68c3a86a25ea429f97b80b17ca08e649_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg0LTYtMS0xLTA_1d6715a2-2141-4eb2-8d41-d3d8e73b9922"
      unitRef="number">0.177</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6fa4a52ab3bc45caa61ce84e01cf51df_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg0LTgtMS0xLTA_5f641e36-3bcd-4ad6-8db6-ecf39f916b19"
      unitRef="usd">1599000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i485a9a2a0c8f4d779f31ad655745be2f_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg0LTEwLTEtMS0w_1fc8330f-d190-423d-ac02-ce80fb264ec2"
      unitRef="usd">1134000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6fa4a52ab3bc45caa61ce84e01cf51df_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg0LTEyLTEtMS0w_ed1205bd-dc2f-461a-a00e-7fcaee92cb18"
      unitRef="number">0.411</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66ee637b96ac4b0cb5d60d3c4d7ff8e9_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg1LTItMS0xLTA_8ce9e94a-8fa7-40dd-a5eb-31dde09e65e5"
      unitRef="usd">957000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1b1017d106d47a89606d3c777ad71f0_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg1LTQtMS0xLTA_6fbda353-842b-4eaf-9514-2512affd7dec"
      unitRef="usd">836000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i66ee637b96ac4b0cb5d60d3c4d7ff8e9_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg1LTYtMS0xLTA_1f3eb85f-9d84-4f59-ba41-df07e1965153"
      unitRef="number">0.145</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0bfe547121e24789b19f5f8208fa6fd4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg1LTgtMS0xLTA_c6924ce2-cc24-47af-a3eb-fd440c138d3a"
      unitRef="usd">2952000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d7f9514d7a44d1ca6005181785ac3ba_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg1LTEwLTEtMS0w_21f6d13d-bc71-4c04-963a-79e3c40aaa47"
      unitRef="usd">2153000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0bfe547121e24789b19f5f8208fa6fd4_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg1LTEyLTEtMS0w_fb091499-bafe-474a-97fb-39d91b3bbb2c"
      unitRef="number">0.371</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d1f8a03726c4067a2929437ae2fe5f3_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg3LTItMS0xLTA_19cb30bb-50f4-4a39-a938-eea77d359e43"
      unitRef="usd">1249000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25f9cfc65bb24864b3563c647160d27a_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg3LTQtMS0xLTA_96c7e913-89b9-4167-8bd0-28acd55c16dc"
      unitRef="usd">1308000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7d1f8a03726c4067a2929437ae2fe5f3_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg3LTYtMS0xLTA_374d6bdb-524e-4650-a93d-a2f8aebd94a4"
      unitRef="number">-0.045</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7aaf4b905834c92835e38cca37238c7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg3LTgtMS0xLTA_b3370273-6065-4402-9d86-8e5484fafaff"
      unitRef="usd">3821000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86237042c73a4330be6316b8b9dd8739_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg3LTEwLTEtMS0w_60c1cfab-dd99-4d76-822c-cb8288c9b6c1"
      unitRef="usd">3427000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia7aaf4b905834c92835e38cca37238c7_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg3LTEyLTEtMS0w_52114389-d0b5-4558-87b2-1196ec1f1a8c"
      unitRef="number">0.115</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i368def26f6ea4bfaa9177cfd9b260470_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg4LTItMS0xLTA_4c7e44e2-e022-46ff-b858-25dfc2219517"
      unitRef="usd">843000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63a357e6381c4197a2f2034714a76f9c_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg4LTQtMS0xLTA_38f0d2cf-37d5-4c37-b141-a57027fc334a"
      unitRef="usd">774000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i368def26f6ea4bfaa9177cfd9b260470_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg4LTYtMS0xLTA_bc2d613b-7c85-4bd6-b87d-3aac1e9868df"
      unitRef="number">0.088</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd7333903aa847658f94ecffe462a28d_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg4LTgtMS0xLTA_4826de02-8f35-4621-ba5a-c50e427e461f"
      unitRef="usd">2611000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38fa03f6ded84c66aa2bd6d34a67b4cc_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg4LTEwLTEtMS0w_0e2dd0d8-2907-4f9d-b059-22262adfe62c"
      unitRef="usd">2145000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icd7333903aa847658f94ecffe462a28d_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg4LTEyLTEtMS0w_8ba2954a-0488-458a-b951-d2567aa63952"
      unitRef="number">0.217</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2a3d236dbe3452793a752eded62785d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg5LTItMS0xLTA_63193ac6-b840-4e70-abc2-a06ae38e048f"
      unitRef="usd">2093000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b2a6b8d156a4c78be2c856e9636bc48_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg5LTQtMS0xLTA_22e229d1-94af-4819-a9e6-6dcc9fe50c22"
      unitRef="usd">2083000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic2a3d236dbe3452793a752eded62785d_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg5LTYtMS0xLTA_bbe41cad-2ef5-4e80-b5bf-0e314e685b1a"
      unitRef="number">0.005</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03f2bbdd3f2943d8b8a157f236abbaa4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg5LTgtMS0xLTA_731cf98b-ca67-48ba-9a62-dd7bc880fb00"
      unitRef="usd">6433000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc2283c62b61497f9e264c1563dc631b_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg5LTEwLTEtMS0w_efe1f5d6-1f0a-4967-b873-fd6931dbd6e3"
      unitRef="usd">5572000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i03f2bbdd3f2943d8b8a157f236abbaa4_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTg5LTEyLTEtMS0w_dab180f8-e245-4920-89d7-2df45e089325"
      unitRef="number">0.154</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd21677efb134c17a84394025e299a84_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkxLTItMS0xLTA_6bb09eec-b5b2-4c71-b1eb-b1b0ea8fa617"
      unitRef="usd">210000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb78ecc3071f4f89a308782d6a88edfb_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkxLTQtMS0xLTA_9c12e381-4b40-4956-85a8-d65cfaf2de7b"
      unitRef="usd">221000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibd21677efb134c17a84394025e299a84_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkxLTYtMS0xLTA_2569d3c9-bb89-4722-9e05-b14f3e4a1428"
      unitRef="number">-0.053</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i777e00866382412a98d3a01a40a39f9d_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkxLTgtMS0xLTA_26892bc6-bb55-4c00-a66a-c3464cde5c8c"
      unitRef="usd">654000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idebbda9d775f4719aa69f47ce5be05a3_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkxLTEwLTEtMS0w_bb392f78-0c91-4eb9-bb09-02f5a5872739"
      unitRef="usd">564000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i777e00866382412a98d3a01a40a39f9d_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkxLTEyLTEtMS0w_3ac3a1b2-a89b-4d12-aa5f-68619ee72b73"
      unitRef="number">0.159</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50813470f09748ba803e03a49ac76836_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkyLTItMS0xLTA_27c37586-5f03-4cda-b3e6-ac81e321f223"
      unitRef="usd">146000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i19eab095e76442c7a15bf5f8be178453_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkyLTQtMS0xLTA_ebc393da-c55b-4c2a-8ca1-a10eaff75203"
      unitRef="usd">124000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i50813470f09748ba803e03a49ac76836_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkyLTYtMS0xLTA_efbb4ab0-5e63-4dc7-804e-24afc4d37589"
      unitRef="number">0.188</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63c6e6e9b6ae4771aea32259886b1dbd_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkyLTgtMS0xLTA_96fb5015-8dd6-4d90-acc7-74e468eac8c8"
      unitRef="usd">451000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad15e1fa199a4cbb875175ac153591d6_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkyLTEwLTEtMS0w_1f962f9a-fb34-4c7a-95b0-a6cfb2f81a90"
      unitRef="usd">344000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i63c6e6e9b6ae4771aea32259886b1dbd_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkyLTEyLTEtMS0w_0f7f048f-9345-4406-a780-ac97fcf6f2e8"
      unitRef="number">0.313</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i690c132eaf514ca895f63e12fbbb455b_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkzLTItMS0xLTA_36c887fa-31f8-42d3-b780-246f36b5f29c"
      unitRef="usd">356000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59d819aa14d94e3a8762d8ec158426d0_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkzLTQtMS0xLTA_a030efee-2db3-4251-802d-692b3860ebe9"
      unitRef="usd">345000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i690c132eaf514ca895f63e12fbbb455b_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkzLTYtMS0xLTA_83925221-9770-4658-af38-946f7632e6de"
      unitRef="number">0.033</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i015af99c4a2e448e9c7144c5eb3975aa_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkzLTgtMS0xLTA_99b9ed07-e980-49fc-97c7-a498fec174fa"
      unitRef="usd">1105000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if160394e7e1d40f2b37c20e7236b7b62_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkzLTEwLTEtMS0w_b5a28e1b-7053-4354-b959-fbd3f4db22d3"
      unitRef="usd">908000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i015af99c4a2e448e9c7144c5eb3975aa_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTkzLTEyLTEtMS0w_bfa2448f-d424-4db0-81a9-e16ebacf111b"
      unitRef="number">0.218</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77a21754634a4942a38523ea36f795bd_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk1LTItMS0xLTA_fc718506-5209-439d-9f0a-f4f5fcad7905"
      unitRef="usd">184000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a08b9538fa74a208fbf96aec8a31dcb_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk1LTQtMS0xLTA_1b198b1a-7aee-4ca7-8c6b-4e286c8d397a"
      unitRef="usd">205000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i77a21754634a4942a38523ea36f795bd_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk1LTYtMS0xLTA_602327fe-812c-43b7-969b-c171728ef986"
      unitRef="number">-0.098</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d390e81e3db43408b91740c66c31b04_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk1LTgtMS0xLTA_0173ae33-fd04-4921-aa25-00d6b34c68a8"
      unitRef="usd">579000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f4babed7b4d42b5a5c2d40a153c2633_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk1LTEwLTEtMS0w_8ae6dc7f-41b4-4789-ac0c-87172708058e"
      unitRef="usd">527000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2d390e81e3db43408b91740c66c31b04_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk1LTEyLTEtMS0w_1fc9dcaf-6f60-4b55-9d7d-93a82920eaf8"
      unitRef="number">0.100</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iafe600a9ab7a44c68df5d9ad63069018_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk2LTItMS0xLTA_37d4315f-2e21-4800-9484-0f1285994338"
      unitRef="usd">131000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66818b9b3aff45fa9b5309ab5d6ebdae_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk2LTQtMS0xLTA_7fd27d8c-1cb8-47f0-8044-f357390a0379"
      unitRef="usd">102000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iafe600a9ab7a44c68df5d9ad63069018_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk2LTYtMS0xLTA_20f98350-029f-4c99-b8f3-9d4b66240790"
      unitRef="number">0.281</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb44530d18d642e683cefa298f2e197a_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk2LTgtMS0xLTA_49462df8-7e27-4171-9818-5e490c45dfcc"
      unitRef="usd">403000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3db704224024476bb17f015b1c0abc3c_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk2LTEwLTEtMS0w_9f03d7bb-613e-4b52-a486-e5c07301c00d"
      unitRef="usd">298000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifb44530d18d642e683cefa298f2e197a_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk2LTEyLTEtMS0w_dcf5a716-a7ef-4a77-ae61-c426bd9300c5"
      unitRef="number">0.354</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i65804c36217740f0b729d452073739ca_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk3LTItMS0xLTA_4aa2c31a-cabe-4a75-b090-c8c32f43978e"
      unitRef="usd">316000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8af97229f0b54fb9a42e82e133be93e3_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk3LTQtMS0xLTA_ab30b258-156d-44c4-85cc-2e9bbba97fbe"
      unitRef="usd">308000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i65804c36217740f0b729d452073739ca_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk3LTYtMS0xLTA_927eff0c-eb19-4098-8478-8591519be0a1"
      unitRef="number">0.028</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e62e22d053f4be19970487099e52b46_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk3LTgtMS0xLTA_35c55aaf-d5e3-4fc0-8f24-00f38d2a4ea4"
      unitRef="usd">983000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67cc2a6d5c864c8aa19c1d21575a1fda_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk3LTEwLTEtMS0w_dce4c8b1-ffdf-4eff-a58e-3c59179d36c8"
      unitRef="usd">825000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0e62e22d053f4be19970487099e52b46_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk3LTEyLTEtMS0w_18a790ce-81f6-4283-820d-6468e929ba28"
      unitRef="number">0.192</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib53589fb1d174c0883c5a99ce3b7df76_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk5LTItMS0xLTA_e6b30827-6af4-47ce-b79f-b7206e3dd4d9"
      unitRef="usd">455000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4fe69a5c4f3340bfac6f40428dfe05f1_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk5LTQtMS0xLTA_6813ca25-5f88-4b8a-8298-eb2fd717670f"
      unitRef="usd">433000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib53589fb1d174c0883c5a99ce3b7df76_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk5LTYtMS0xLTA_0234c540-e865-4680-add7-4fd223197ec6"
      unitRef="number">0.053</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib89bd6041e30431ea64fca96eaf48c0e_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk5LTgtMS0xLTA_e3d096ea-dbee-48bc-ac2f-9b2e35998d14"
      unitRef="usd">1352000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1283c6dd19e48b2ab1219dcf3751cff_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk5LTEwLTEtMS0w_a27b729b-5e0b-4d3b-93f1-ea740f865c2a"
      unitRef="usd">1194000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib89bd6041e30431ea64fca96eaf48c0e_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMTk5LTEyLTEtMS0w_8d4817d6-8dfd-49dc-b613-3e65a8195d9a"
      unitRef="number">0.133</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i346c10c16c374bf6970c356a17deb3f0_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAwLTItMS0xLTA_82371058-166e-43d0-b851-5b27b3d65686"
      unitRef="usd">260000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e475b85e02746e4b631284e2dfad017_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAwLTQtMS0xLTA_12a7775d-1d52-43b4-a551-cfa3ccfb81a5"
      unitRef="usd">253000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i346c10c16c374bf6970c356a17deb3f0_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAwLTYtMS0xLTA_ed359eb8-262d-404b-818e-2786f21231a7"
      unitRef="number">0.024</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a1ad64f1a3644558ba0bd78d14887f5_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAwLTgtMS0xLTA_fb6d4de0-3bd4-4de2-a775-af17a9966cac"
      unitRef="usd">805000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib837c1b7b81c46c79b81103985f70413_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAwLTEwLTEtMS0w_afbc498f-eac5-4473-9bf1-42b36a5e289a"
      unitRef="usd">698000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0a1ad64f1a3644558ba0bd78d14887f5_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAwLTEyLTEtMS0w_cf925332-4527-4e12-a44e-5c57dced7456"
      unitRef="number">0.152</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2b39b6e0ce043d59ef4f7c826aee38e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAxLTItMS0xLTA_0a01f949-c286-41a0-9673-da58787ac013"
      unitRef="usd">715000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4004c5d0ca6d43168b2cc99025ba0344_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAxLTQtMS0xLTA_7fd9f807-8cf6-429f-a806-992aeb9dae6b"
      unitRef="usd">685000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if2b39b6e0ce043d59ef4f7c826aee38e_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAxLTYtMS0xLTA_f987d8dd-a3d9-4cfb-b09a-98b1fcf45b55"
      unitRef="number">0.042</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69dfc54530ab4ceebe84a4e443cc7206_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAxLTgtMS0xLTA_594e5d80-469f-4da0-9127-c80098f66e0d"
      unitRef="usd">2157000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7879c0d85bbc427bb4a31690ab8da4b8_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAxLTEwLTEtMS0w_216791b8-d105-42e9-b9ef-ef383a07ce7c"
      unitRef="usd">1892000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i69dfc54530ab4ceebe84a4e443cc7206_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAxLTEyLTEtMS0w_9a43efdb-a77c-4fa5-87d3-902f6206b57b"
      unitRef="number">0.140</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f7f8554621548c9a359d347cbbbac3f_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAzLTItMS0xLTA_21cd5368-90cf-44cf-945f-3c84e6e9ef66"
      unitRef="usd">400000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46c22958c0c549558f53ab422062f508_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAzLTQtMS0xLTA_2bee8c3f-9bcd-4584-a7ca-51b8b0d4429b"
      unitRef="usd">449000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6f7f8554621548c9a359d347cbbbac3f_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAzLTYtMS0xLTA_4ba1c2cb-ee49-4279-ac7f-1fbad5ec2780"
      unitRef="number">-0.111</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03538a98c9f84546a0878f97b68fb052_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAzLTgtMS0xLTA_3c251591-0c19-4a3d-9517-77d3a4e7177d"
      unitRef="usd">1236000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9758b02c72df4754b31600d639492fd4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAzLTEwLTEtMS0w_13056172-356b-4fd4-be5c-b93de5963287"
      unitRef="usd">1142000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i03538a98c9f84546a0878f97b68fb052_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjAzLTEyLTEtMS0w_56d93176-a1d4-470e-b196-3a5f0cd0901c"
      unitRef="number">0.082</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16af716d82004476883437376d33e296_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA0LTItMS0xLTA_589d1dcb-dbb5-4c40-bdfc-a5a35c7bdbc8"
      unitRef="usd">306000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b848b4c72814939a4ee849afee353c0_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA0LTQtMS0xLTA_9711d754-815e-44ce-8935-f79874431dce"
      unitRef="usd">295000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i16af716d82004476883437376d33e296_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA0LTYtMS0xLTA_90c2b3b7-16ca-4883-b6d1-0db1fc09c931"
      unitRef="number">0.035</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icdfe043a81224cd7aa4b84062546d3e2_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA0LTgtMS0xLTA_841464bd-3e2b-4114-8279-7bfa8bdbbed3"
      unitRef="usd">952000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ec97248e6e44f398ee8bbac82b179bb_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA0LTEwLTEtMS0w_d73a05a8-ace3-406e-a200-b15c5ad8da9a"
      unitRef="usd">805000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icdfe043a81224cd7aa4b84062546d3e2_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA0LTEyLTEtMS0w_f55cc049-b73d-420b-82be-b4992d343eb4"
      unitRef="number">0.182</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6cbc53d626149a08db3eeb2b61e356a_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA1LTItMS0xLTA_9b41affc-4f4b-4026-b3b1-493cede8cfa6"
      unitRef="usd">705000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d0754c7fbfc40ebb8439cae628ac5f2_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA1LTQtMS0xLTA_43252311-952f-4ee3-bf1f-923fd606f873"
      unitRef="usd">745000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id6cbc53d626149a08db3eeb2b61e356a_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA1LTYtMS0xLTA_a8476fc1-ece3-47a1-9d26-7b0386bddd28"
      unitRef="number">-0.053</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic0fd94b5ecb742a2acf56d48a30e9baa_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA1LTgtMS0xLTA_3cbfc987-dadf-40c9-a1ce-84f46c41e340"
      unitRef="usd">2187000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e2b16d94b1e4ef99fe58558a8b6b7ec_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA1LTEwLTEtMS0w_d2969cc1-affd-4ca7-b8e6-131c27e1b9ae"
      unitRef="usd">1947000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic0fd94b5ecb742a2acf56d48a30e9baa_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA1LTEyLTEtMS0w_8071ab2b-f83b-40cd-90a4-499a82390005"
      unitRef="number">0.123</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d422a20e0ae4335846ca1405c432d7b_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA3LTItMS0xLTA_e0c323f2-6636-47a6-bb4e-9c9b007c39cb"
      unitRef="usd">948000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib99c3f2e02614e95bd95c334578642f6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA3LTQtMS0xLTA_20a15c9e-9428-454c-bc3f-770b520d1096"
      unitRef="usd">913000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2d422a20e0ae4335846ca1405c432d7b_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA3LTYtMS0xLTA_31197b0b-5159-4702-bb63-5a1c66c9fd50"
      unitRef="number">0.039</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i941f7b5cb0944651ad943556245e42af_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA3LTgtMS0xLTA_e9f13d5e-36d8-4a27-85ab-7d11a069b562"
      unitRef="usd">2881000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e245c440a8b4af9833fa1a0c53fb2f1_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA3LTEwLTEtMS0w_9fa58d01-7037-4138-872c-bd0b1cf07f19"
      unitRef="usd">2247000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i941f7b5cb0944651ad943556245e42af_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA3LTEyLTEtMS0w_b6aeda1a-5147-4cf6-8c3f-71f0c4b24420"
      unitRef="number">0.282</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6dfa6170bb04384890d25bf750f7285_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA4LTItMS0xLTA_55776a2f-0f65-41c3-a397-b5ba92fd2900"
      unitRef="usd">1457000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52d965366a5743539f8a0c66e807ebf6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA4LTQtMS0xLTA_7c9153f8-532b-42ce-971e-c027574c2830"
      unitRef="usd">1239000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie6dfa6170bb04384890d25bf750f7285_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA4LTYtMS0xLTA_2e841b29-af4b-48dc-b75c-7cc625c234c7"
      unitRef="number">0.176</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i957af76e03cf41b2b4137b9fb5b797b5_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA4LTgtMS0xLTA_ec05ea85-5a94-4e2d-a216-60d8cd08e94c"
      unitRef="usd">4418000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0fac8e5af73743b892d0ff019286d402_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA4LTEwLTEtMS0w_2f4a1e8c-b2f8-4929-9a8f-8f5392ad886c"
      unitRef="usd">3556000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i957af76e03cf41b2b4137b9fb5b797b5_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA4LTEyLTEtMS0w_428e4df2-bd00-4eea-b53b-fefa0e96355c"
      unitRef="number">0.242</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic713079734e24fb0aded04ea2f5ef4f1_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA5LTItMS0xLTA_125013f7-3cac-4127-8dad-d86ba27bbafb"
      unitRef="usd">2405000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17cb3783cf374d5589ec58a0de356fe9_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA5LTQtMS0xLTA_c71689c5-2b2d-45a9-a762-afc9a1fe6d38"
      unitRef="usd">2152000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic713079734e24fb0aded04ea2f5ef4f1_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA5LTYtMS0xLTA_22f42349-a6f2-4806-8fc0-a311a7fad9be"
      unitRef="number">0.118</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75c76e0dab5d49728cf41af893706809_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA5LTgtMS0xLTA_1344e6cd-a7e2-4c4a-9995-3204ce799388"
      unitRef="usd">7299000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i251fe35eeedb4dfda33118b3264a40b0_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA5LTEwLTEtMS0w_b701275b-0e2d-4516-a0d5-64c33947d473"
      unitRef="usd">5803000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i75c76e0dab5d49728cf41af893706809_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjA5LTEyLTEtMS0w_01accaca-aa0a-436a-af29-47bbca5be250"
      unitRef="number">0.258</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11aebf9815c5450b8eb28d8737503b25_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjExLTItMS0xLTA_7a83494d-03aa-40c7-8521-6819f22ad593"
      unitRef="usd">440000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie503be36392943c2aa1fc032e197cffe_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjExLTQtMS0xLTA_c98b8b7b-f4b0-4036-b58e-371147f4fe0d"
      unitRef="usd">421000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i11aebf9815c5450b8eb28d8737503b25_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjExLTYtMS0xLTA_7b78bc69-75f8-49b2-b5e2-ebf93878dc99"
      unitRef="number">0.046</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7962ec68b8054973bda571c916266fbc_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjExLTgtMS0xLTA_29ddb666-f56a-473f-a747-26530af8cef9"
      unitRef="usd">1304000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77a23c165c324817adfa8ff05e524d4d_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjExLTEwLTEtMS0w_9d8da738-096d-4ad7-b0fc-097a8dc0ff46"
      unitRef="usd">1079000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7962ec68b8054973bda571c916266fbc_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjExLTEyLTEtMS0w_0a26a477-ed42-41af-baee-6a535a4a67ee"
      unitRef="number">0.209</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96dfc5cff1454f418137861a7c0bd661_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEyLTItMS0xLTA_ebff7189-9bcb-4736-9104-753aa1bd350a"
      unitRef="usd">705000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52be8cd00a544fb9837055c28c31a0bc_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEyLTQtMS0xLTA_bb32e726-3721-4a72-9187-43e30d87cb98"
      unitRef="usd">579000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i96dfc5cff1454f418137861a7c0bd661_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEyLTYtMS0xLTA_65e0dbcf-87cf-492d-8c0b-e4e3fbe46e6d"
      unitRef="number">0.218</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a091c8ec3e4450b9c534d593ee3f48f_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEyLTgtMS0xLTA_d779c250-548f-467f-b986-3222ef81aaa1"
      unitRef="usd">2126000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f051d97946b48f98a750ba79b71b129_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEyLTEwLTEtMS0w_63260545-0245-41b8-8282-4d4d41101f43"
      unitRef="usd">1644000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9a091c8ec3e4450b9c534d593ee3f48f_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEyLTEyLTEtMS0w_c44b70fc-b825-42ac-b5c8-df7e8f9d0aa3"
      unitRef="number">0.293</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22ea02a9de494a629f2a4d89b43a24fb_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEzLTItMS0xLTA_468e3338-74bb-471a-a912-f6a3778746f4"
      unitRef="usd">1144000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i212cc5dc91cd478984ad00fae62e7737_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEzLTQtMS0xLTA_816dcc67-1a60-4cf4-be1b-7c6a8beb50c7"
      unitRef="usd">1000000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i22ea02a9de494a629f2a4d89b43a24fb_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEzLTYtMS0xLTA_0d533d0c-16d2-44b0-93f1-3503158bbe73"
      unitRef="number">0.146</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00191b17ba9d4f05a61536365cba8dad_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEzLTgtMS0xLTA_45109f9e-4df6-430d-af96-4bda7b167ec6"
      unitRef="usd">3430000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb99fb7943bf4d77bb82160d491f0b87_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEzLTEwLTEtMS0w_30e4919c-6f0d-442d-a99b-1f6b01f711b1"
      unitRef="usd">2723000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i00191b17ba9d4f05a61536365cba8dad_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjEzLTEyLTEtMS0w_666ce9ff-ec62-4e33-bfac-fc54a5c76ea0"
      unitRef="number">0.260</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18be951542f44ecb96828af068093472_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE1LTItMS0xLTA_d18a705b-08ec-4531-9f84-75640262ddcb"
      unitRef="usd">508000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4adae2c06c9b4940ac03d2eac7f0f1e1_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE1LTQtMS0xLTA_0af6f9df-5a76-4c2d-9672-f71fa3061154"
      unitRef="usd">492000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i18be951542f44ecb96828af068093472_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE1LTYtMS0xLTA_0f0c8453-76c1-4e2f-b7b1-f0c4fc471faa"
      unitRef="number">0.033</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1997e6c1765e4a75b9bad7033aac8b26_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE1LTgtMS0xLTA_16fc6003-86a2-4550-8c9a-f1a83f5c5ff0"
      unitRef="usd">1577000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iecc5a7943edf4572be993acdc0b1bd83_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE1LTEwLTEtMS0w_642fcdcb-4c53-4d6f-adc5-12329ad402ef"
      unitRef="usd">1168000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1997e6c1765e4a75b9bad7033aac8b26_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE1LTEyLTEtMS0w_8f8c6c6c-4f25-44bf-8b06-3b948d2a9b30"
      unitRef="number">0.350</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1bb2fb97435a4fc68bf0fac1ebcf132c_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE2LTItMS0xLTA_c375aaa1-d4ca-4582-98ee-0c617fd12d2a"
      unitRef="usd">752000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i122148b592b24cdabf78d0a482cdb38a_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE2LTQtMS0xLTA_05d4d4c1-2277-4a6d-91f4-2845e29930ad"
      unitRef="usd">660000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1bb2fb97435a4fc68bf0fac1ebcf132c_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE2LTYtMS0xLTA_553c2780-2352-461f-a2f8-791efc802b2e"
      unitRef="number">0.139</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6234adc69a847759f0dc2168c7a7ed8_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE2LTgtMS0xLTA_70f295db-94f1-4432-933a-adcfb289a530"
      unitRef="usd">2292000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2dff7af12b264ddc884a1eb374f6b51e_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE2LTEwLTEtMS0w_db87bf7d-991e-4d03-a5a7-873e43032be8"
      unitRef="usd">1912000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic6234adc69a847759f0dc2168c7a7ed8_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE2LTEyLTEtMS0w_75ba6a3e-5623-4d69-91b9-39ba788b5792"
      unitRef="number">0.199</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i494fe80075ac40acbe0318a3db1a774d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE3LTItMS0xLTA_e9b8d946-348b-4e6d-bfb7-b8061633b19b"
      unitRef="usd">1261000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i490240ac5d354958bca7ade168be4ddd_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE3LTQtMS0xLTA_a6a01bef-d635-4c12-979b-a67c7d34dad8"
      unitRef="usd">1152000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i494fe80075ac40acbe0318a3db1a774d_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE3LTYtMS0xLTA_c0caed3b-ad58-45d8-9b1d-b28fb9d2746a"
      unitRef="number">0.094</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26fb731c7d16411daeea4aeb1d065918_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE3LTgtMS0xLTA_39bd5bc6-bebe-4da2-88a6-cc37842bb957"
      unitRef="usd">3869000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a3313d8d5cc43f5a89429b00db0f9ff_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE3LTEwLTEtMS0w_d15eb728-176e-40fe-9573-a6ff07db826f"
      unitRef="usd">3080000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i26fb731c7d16411daeea4aeb1d065918_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE3LTEyLTEtMS0w_fc119544-4bb6-4e5e-b980-5338ee67de71"
      unitRef="number">0.256</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18341461a0b64ada9ce1d9bf3032cbd6_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE5LTItMS0xLTA_31035172-265b-4bfd-820a-d4134fccabdf"
      unitRef="usd">475000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i106ec6964b614734a6df2f1c7aec49b6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE5LTQtMS0xLTA_4195b15c-9280-4139-92b7-b69d45328938"
      unitRef="usd">473000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i18341461a0b64ada9ce1d9bf3032cbd6_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE5LTYtMS0xLTA_729baa2d-61a0-49c7-a2d7-15053e10e14a"
      unitRef="number">0.006</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i42418c9e338b42f1a79e47c3637bb792_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE5LTgtMS0xLTA_915932e1-df52-462a-8a44-daf1af452915"
      unitRef="usd">1414000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87bfc75fd15049b0ad902fc45bddb23e_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE5LTEwLTEtMS0w_c8dd79d7-7da4-4af6-bd8b-b662bd8d93b8"
      unitRef="usd">1160000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i42418c9e338b42f1a79e47c3637bb792_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjE5LTEyLTEtMS0w_2de080d6-4812-425d-965c-846081af918b"
      unitRef="number">0.219</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e89c3ffa20849288d5655da93e8d070_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIwLTItMS0xLTA_aac58cf2-8ccd-4ff1-8051-608178e30ffc"
      unitRef="usd">714000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3359d80da2904900a689911b61bec8e9_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIwLTQtMS0xLTA_78bcffd7-ef1f-4f2f-a4bd-a96f7a67fab3"
      unitRef="usd">608000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3e89c3ffa20849288d5655da93e8d070_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIwLTYtMS0xLTA_3a6a73af-7cf2-4112-be16-87a9dab959d7"
      unitRef="number">0.174</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93a48db34f67401b89ec28786da34bb4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIwLTgtMS0xLTA_72243b87-350f-49c7-933c-6517bad2f1e4"
      unitRef="usd">2103000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ca482bac6f143ad8311c2f32ac8745a_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIwLTEwLTEtMS0w_b54487d4-6c8e-4755-8d73-6b0f4503e27e"
      unitRef="usd">1683000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i93a48db34f67401b89ec28786da34bb4_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIwLTEyLTEtMS0w_2ad45e92-29a6-4f0a-8718-a87c6fa97f1c"
      unitRef="number">0.250</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77d5cba624204db7a4fdf3c92b03712c_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIxLTItMS0xLTA_0aaeab29-aed2-4d56-9114-66e7455afec9"
      unitRef="usd">1189000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1bd7def248f4471292b3bc6fe506f3c2_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIxLTQtMS0xLTA_eaaf5cfb-0ae2-4d66-af25-b9f997d9f9a4"
      unitRef="usd">1081000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i77d5cba624204db7a4fdf3c92b03712c_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIxLTYtMS0xLTA_6d1b24be-5cba-49f5-bff4-22878fc11a69"
      unitRef="number">0.101</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a49b832a4ce4356beec3af3897dd8ca_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIxLTgtMS0xLTA_2a8c7885-b7a7-4fe9-89d9-b556f2747728"
      unitRef="usd">3517000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica4dc3e811fa45c38117526d37a372e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIxLTEwLTEtMS0w_26f43eb6-7ecc-4740-8604-2b5fa2a3d226"
      unitRef="usd">2843000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8a49b832a4ce4356beec3af3897dd8ca_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIxLTEyLTEtMS0w_93eaa9d6-e158-4d8d-9081-9068ce280bdd"
      unitRef="number">0.237</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id39f1cfaa5034f7d8963544179ed45f7_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIzLTItMS0xLTA_8665d40f-94f6-4a56-89b0-8d367a6366ff"
      unitRef="usd">359000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09830464a4ac485fb8800a57861ec07a_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIzLTQtMS0xLTA_8b3a65aa-9245-4413-a783-19cdbfedd083"
      unitRef="usd">375000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id39f1cfaa5034f7d8963544179ed45f7_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIzLTYtMS0xLTA_87efd90b-fec6-4f25-af74-d8f4c1667b54"
      unitRef="number">-0.043</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd336d1de1d7402e86a487789816638f_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIzLTgtMS0xLTA_b4a84481-73e6-4c34-83b8-8c23bb816b0e"
      unitRef="usd">1082000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i868e4a3228b745b69f76acf1ef47fa4e_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIzLTEwLTEtMS0w_42e5f0e1-cb40-4be4-aeba-05814f2b0230"
      unitRef="usd">924000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifd336d1de1d7402e86a487789816638f_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjIzLTEyLTEtMS0w_90c3073f-dfe2-4f27-a76a-f6db969a2bba"
      unitRef="number">0.170</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied76a8d7c3a849859381acdd5b40e26b_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI0LTItMS0xLTA_6f642c3a-6047-496f-9cf6-d6002b2626d5"
      unitRef="usd">522000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib963c3361a9e429ea23e9be78632d5f7_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI0LTQtMS0xLTA_52c8256c-d223-4578-ae31-5340ad6c243b"
      unitRef="usd">455000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ied76a8d7c3a849859381acdd5b40e26b_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI0LTYtMS0xLTA_2135de2c-51d5-490d-afa7-0998c9953061"
      unitRef="number">0.149</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c87a451aba6470f8513849722c6f687_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI0LTgtMS0xLTA_3c5e7ab2-0882-4fac-a1fe-a5dd8c99def8"
      unitRef="usd">1525000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5574bb64c5442568419329c1ddf953b_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI0LTEwLTEtMS0w_83333a8d-2b8a-4246-bbfd-d5767a48a375"
      unitRef="usd">1274000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9c87a451aba6470f8513849722c6f687_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI0LTEyLTEtMS0w_52fc006e-90b0-42a6-8d4f-cb6873e3bb07"
      unitRef="number">0.198</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i890b0d4ac71f441eba6bf1198c410a5b_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI1LTItMS0xLTA_a6a6b833-55d6-45b7-b4a3-fd1125334826"
      unitRef="usd">882000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98ce489b2b83414fafb7d08826ccae52_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI1LTQtMS0xLTA_09d0c4cf-d569-471b-8112-16e754de450c"
      unitRef="usd">830000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i890b0d4ac71f441eba6bf1198c410a5b_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI1LTYtMS0xLTA_eac355df-2d51-4094-ab45-33acfe7f80b0"
      unitRef="number">0.062</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84a3df8795414451a2635599c9f326f4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI1LTgtMS0xLTA_dafe5ef5-805b-4249-b777-4368cb805b5f"
      unitRef="usd">2607000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic40e1fc715504106941039635c311b42_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI1LTEwLTEtMS0w_44759593-c15f-498e-891a-308bc3f62a1c"
      unitRef="usd">2198000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i84a3df8795414451a2635599c9f326f4_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI1LTEyLTEtMS0w_081de124-4764-4c70-947e-b17986f8c7c1"
      unitRef="number">0.186</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4cc28cefdee24db587c2c44627a5d4a3_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI4LTItMS0xLTA_86fd987a-49a8-4c3b-93b2-dfad3009da68"
      unitRef="usd">117000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id90e5b6cac784a01a3ec9b835573dd8b_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI4LTQtMS0xLTA_16a67423-b030-4a54-8022-7b0880bce7a2"
      unitRef="usd">98000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4cc28cefdee24db587c2c44627a5d4a3_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI4LTYtMS0xLTA_b04d3e3e-c8d1-4829-b083-637224131765"
      unitRef="number">0.196</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14af6f66309945bbb345d1e5080fc3ab_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI4LTgtMS0xLTA_e15e0518-c3e9-4576-8523-6740e38e1d29"
      unitRef="usd">333000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5adee58e8c554a2fa51b9dd0dff78319_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI4LTEwLTEtMS0w_3c4b9793-346d-4fd5-8f1a-849c87874449"
      unitRef="usd">236000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i14af6f66309945bbb345d1e5080fc3ab_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI4LTEyLTEtMS0w_a121650b-11a7-4463-88c4-fd458ffaf486"
      unitRef="number">0.411</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8954550cb9744329c0944ee64bf182d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI5LTItMS0xLTA_b3f60e7c-7bae-41c8-b588-19a6d2bd55fa"
      unitRef="usd">191000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4dc24dbfe93c42a5bedd17d3f4602b07_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI5LTQtMS0xLTA_4256d693-ec14-4796-adbb-fe9c1f93f062"
      unitRef="usd">153000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia8954550cb9744329c0944ee64bf182d_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI5LTYtMS0xLTA_eb8a33de-3510-47eb-b3d4-d69cb9fa4035"
      unitRef="number">0.247</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20171878a2664b1396a4e8dfab867c63_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI5LTgtMS0xLTA_7624b053-a48d-4753-89eb-ea99a9b90c3e"
      unitRef="usd">577000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib792371a81394b76adb8d9160ed815f4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI5LTEwLTEtMS0w_a5d04be0-7b17-4500-8f48-5b957010d317"
      unitRef="usd">409000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i20171878a2664b1396a4e8dfab867c63_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjI5LTEyLTEtMS0w_5d1e35d9-ce76-4176-93d2-ea37a34bd090"
      unitRef="number">0.411</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1c483984fa940d4a2263fdde35ae2b6_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMwLTItMS0xLTA_6d7d2bf5-73ed-44b2-ba16-c7aec8664cb5"
      unitRef="usd">308000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i40b2a961cef64c3f81dd66d2cc8d30cc_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMwLTQtMS0xLTA_652530b4-4182-46df-9c19-c8a2f534b006"
      unitRef="usd">251000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if1c483984fa940d4a2263fdde35ae2b6_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMwLTYtMS0xLTA_253e7827-0887-4654-90c8-e4f84346b54e"
      unitRef="number">0.227</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5e248410521459d8d4e90e3229028f7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMwLTgtMS0xLTA_f044d67e-d4e7-4865-9ccc-3f9996307680"
      unitRef="usd">910000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07d6c5cc14f04a4aaecd3ac4c2a56626_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMwLTEwLTEtMS0w_be7fa04e-4748-447d-9ba7-3f8efebdef49"
      unitRef="usd">645000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie5e248410521459d8d4e90e3229028f7_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMwLTEyLTEtMS0w_8abe84de-77db-49b1-ae4e-bb17a139d4b0"
      unitRef="number">0.411</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic77ca9253fc245e696f14b2344a21c4a_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMzLTItMS0xLTA_16d371e5-6a6f-40f8-b014-73be50950bf9"
      unitRef="usd">3117000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f766b8bc30a495cabb27a63cdfa21dc_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMzLTQtMS0xLTA_275e5351-a894-4619-a3c7-97070dc02b8c"
      unitRef="usd">3092000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic77ca9253fc245e696f14b2344a21c4a_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMzLTYtMS0xLTA_991746c3-66a3-4c00-ab38-93ce5494b03a"
      unitRef="number">0.008</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74aa9c650ce94f7f8b6a94ad4ec01ce9_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMzLTgtMS0xLTA_b5e6e25f-a9d5-4f11-961c-f844a30b31dc"
      unitRef="usd">9470000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50d4546f23234e4a95f876fa114ea771_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMzLTEwLTEtMS0w_20e97382-04ad-4687-ae72-5c68dde94347"
      unitRef="usd">7852000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i74aa9c650ce94f7f8b6a94ad4ec01ce9_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjMzLTEyLTEtMS0w_2c72aabd-9fd8-4922-ab3f-7fa3eaa50a42"
      unitRef="number">0.206</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78f6125d4e1f4642a4d765a351286c3c_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM0LTItMS0xLTA_b1c95978-16e1-4961-9466-b7f7a59d1301"
      unitRef="usd">3527000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93a0aa8ef0ed416c9429b2b5b88cafd0_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM0LTQtMS0xLTA_35badb99-bda5-4e38-81a8-ec5d48aa0e1a"
      unitRef="usd">3058000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i78f6125d4e1f4642a4d765a351286c3c_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM0LTYtMS0xLTA_a5f415ff-7973-4b83-a231-d322d44fcdea"
      unitRef="number">0.154</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2f9faa3f7c645ed95dad829fbe0f3f7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM0LTgtMS0xLTA_36f5cb88-b873-458e-a928-0866769c2f18"
      unitRef="usd">10731000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iadc95fab6c004ee8a52836e72d8e51fb_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM0LTEwLTEtMS0w_1b15d766-a30a-40f6-8f38-b7814d4d9828"
      unitRef="usd">8518000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie2f9faa3f7c645ed95dad829fbe0f3f7_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM0LTEyLTEtMS0w_0160595d-9ac3-471f-9846-67d5b68c12c5"
      unitRef="number">0.260</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34f633e2629c400f81fb20c99145e112_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM1LTItMS0xLTA_416ebb07-5d44-447d-84b0-e306acaa6c08"
      unitRef="usd">6644000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4fd30965b31465e953a69a10b46ae75_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM1LTQtMS0xLTA_57afae84-d074-4626-b395-f2e244f28830"
      unitRef="usd">6150000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i34f633e2629c400f81fb20c99145e112_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM1LTYtMS0xLTA_dbd0f7e6-62f7-4a78-baed-af41fe06c5d2"
      unitRef="number">0.080</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7fc25fc53e54e21948d2ce281e9424a_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM1LTgtMS0xLTA_ca4c53dd-aefc-497a-9e07-3b73560a96c2"
      unitRef="usd">20201000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d5d0922cabe4f6fa55f3ac6507c79fa_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM1LTEwLTEtMS0w_a778cd3e-8f36-4ed6-90c2-1090a7077e79"
      unitRef="usd">16370000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if7fc25fc53e54e21948d2ce281e9424a_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM1LTEyLTEtMS0w_2e618a6e-2a51-490c-a88c-4830d0d9676f"
      unitRef="number">0.234</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9fb264a5db024fa1895bcd3a4069036e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM4LTItMS0xLTA_563062ce-ae74-4d65-9541-32a6105e43c3"
      unitRef="usd">11963000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37b312259598430096ff868f08b6757a_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM4LTQtMS0xLTA_76f7902e-fd19-4ffe-aec0-d353ce1e71a3"
      unitRef="usd">11086000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9fb264a5db024fa1895bcd3a4069036e_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM4LTYtMS0xLTA_fc3ef7bb-f459-4c39-93f5-e8a2bd88796d"
      unitRef="number">0.079</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51a85394d9a14ff08bfeb689185d9ee0_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM4LTgtMS0xLTA_3cad3635-0320-4043-8292-b7f2c2d12926"
      unitRef="usd">34993000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie63bc91b9c82473fa1e0ce9ddfc407bc_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM4LTEwLTEtMS0w_92c83f7d-14ac-44b6-9cae-a122d717d75b"
      unitRef="usd">31324000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i51a85394d9a14ff08bfeb689185d9ee0_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM4LTEyLTEtMS0w_aacb872a-0732-4915-bb71-80b88135a547"
      unitRef="number">0.117</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e2feb214c2c4da99c1a6b518a224dff_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM5LTItMS0xLTA_89309b00-6aaa-4a43-94a0-d53e4c197d21"
      unitRef="usd">11375000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2f54909f5e146f3bd1d3b4357419206_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM5LTQtMS0xLTA_3225f9d5-834a-4576-bd52-d6232ff7be56"
      unitRef="usd">9996000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0e2feb214c2c4da99c1a6b518a224dff_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM5LTYtMS0xLTA_7ac1b276-dbcb-41b7-a550-daeace2f8ffc"
      unitRef="number">0.138</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1dc0ed7f6bc641189e3c6e00c91f73c2_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM5LTgtMS0xLTA_041df218-765b-4517-afa6-5f68a180a989"
      unitRef="usd">33978000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43e3289369584ba8afd76314fc686eaa_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM5LTEwLTEtMS0w_d42567d7-ec4c-49a4-9b6f-0d2c901b2622"
      unitRef="usd">28785000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1dc0ed7f6bc641189e3c6e00c91f73c2_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjM5LTEyLTEtMS0w_89fea4b8-1c2d-4553-ada5-58f04c83b6dc"
      unitRef="number">0.180</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjQwLTItMS0xLTA_9783ddab-ced5-4689-bc27-63758937a62b"
      unitRef="usd">23338000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjQwLTQtMS0xLTA_0c90a699-8425-4812-9baf-72df90f4eb37"
      unitRef="usd">21082000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjQwLTYtMS0xLTA_215cb318-bcc6-4f0d-aaac-f400b6cf3306"
      unitRef="number">0.107</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjQwLTgtMS0xLTA_2418a1ff-aacf-469e-b42e-864301c0a6c9"
      unitRef="usd">68971000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjQwLTEwLTEtMS0w_20da4197-4fd6-48b5-90c3-49d6bc836ec6"
      unitRef="usd">60109000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjg0ZmE2YTg4MDhlZTQyZWQ5MzcwZmJiNWI2OGE4NTkwL3RhYmxlcmFuZ2U6ODRmYTZhODgwOGVlNDJlZDkzNzBmYmI1YjY4YTg1OTBfMjQwLTEyLTEtMS0w_37156fe8-34a3-4d90-b872-4f8af091b049"
      unitRef="number">0.147</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMjYwNg_562a78e8-5e46-4949-9c71-babefac4f8a8">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Third Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 27,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 27,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer Health &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.7)%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Devices&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment earnings before provision for taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Expense not allocated to segments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide income before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.5)%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*Percentage greater than 100% or not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Consumer Health&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Includes intangible amortization expense of $0.1 billion in both the fiscal third quarter of 2021 and 2020 and $0.3&#160;billion in both the fiscal nine months of 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Includes litigation expense of $1.4&#160;billion and $0.5&#160;billion in the fiscal third quarter of 2021 and 2020, respectively. Includes litigation expense of  $1.5&#160;billion and $1.2&#160;billion in the fiscal nine months of 2021 and 2020, respectively. Litigation expense in both periods is primarily related to talc.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Includes a restructuring related charge of $0.1&#160;billion in both the fiscal nine months of 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Pharmaceutical&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes divestiture gains of $0.6&#160;billion in the fiscal nine months of 2021 related to two brands outside the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes intangible amortization expense of $0.8&#160;billion in both the fiscal third quarter of 2021 and 2020. Includes intangible amortization expense of $2.5&#160;billion and $2.4&#160;billion in the fiscal nine months of 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes net litigation expense of $0.8&#160;billion and $1.0&#160;billion in the fiscal third quarter of 2021 and 2020, respectively. Includes net litigation expense of  $0.7&#160;billion and $1.0&#160;billion in the fiscal nine months of 2021 and 2020, respectively. Litigation expense in 2021 is primarily related to Risperdal. Litigation expense in 2020 is related to the opioid settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes a gain on securities of $0.1&#160;billion in the fiscal third quarter of 2021 and $0.2&#160;billion in both the fiscal nine months of 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes a restructuring related charge of $0.1&#160;billion in both the fiscal nine months of 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In fiscal 2020 and 2021, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $1.2&#160;billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Devices &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes a contingent consideration reversal of $0.2&#160;billion in the fiscal third quarter of 2020 and $1.1&#160;billion in the fiscal nine months of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes a restructuring related charge of $0.1 billion in both the fiscal third quarter of 2021 and 2020, respectively. Includes a restructuring related charge of $0.2&#160;billion in both the fiscal nine months of 2021 and 2020, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes intangible amortization expense of $0.3&#160;billion and $0.2&#160;billion in the fiscal third quarter of 2021 and 2020, respectively. Includes intangible amortization expense of $0.8&#160;billion and $0.7&#160;billion in the fiscal nine months of 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes a gain on securities of $0.1&#160;billion in the fiscal nine months of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Includes an in-process research and development expense of $0.9&#160;billion related to the general surgery offering in digital robotics (Ottava) acquired with the Auris Health acquisition in 2019 in both the fiscal third quarter and fiscal nine months of 2021. See Note 3 to the Consolidated Financial Statements for more details.&lt;/span&gt;&lt;/div&gt;(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMjYwNg_d877e0b9-880a-4135-94f5-c556f4627b23">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Third Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 27,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 27,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer Health &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.7)%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Devices&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment earnings before provision for taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Expense not allocated to segments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide income before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.5)%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*Percentage greater than 100% or not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Consumer Health&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Includes intangible amortization expense of $0.1 billion in both the fiscal third quarter of 2021 and 2020 and $0.3&#160;billion in both the fiscal nine months of 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Includes litigation expense of $1.4&#160;billion and $0.5&#160;billion in the fiscal third quarter of 2021 and 2020, respectively. Includes litigation expense of  $1.5&#160;billion and $1.2&#160;billion in the fiscal nine months of 2021 and 2020, respectively. Litigation expense in both periods is primarily related to talc.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Includes a restructuring related charge of $0.1&#160;billion in both the fiscal nine months of 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Pharmaceutical&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes divestiture gains of $0.6&#160;billion in the fiscal nine months of 2021 related to two brands outside the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes intangible amortization expense of $0.8&#160;billion in both the fiscal third quarter of 2021 and 2020. Includes intangible amortization expense of $2.5&#160;billion and $2.4&#160;billion in the fiscal nine months of 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes net litigation expense of $0.8&#160;billion and $1.0&#160;billion in the fiscal third quarter of 2021 and 2020, respectively. Includes net litigation expense of  $0.7&#160;billion and $1.0&#160;billion in the fiscal nine months of 2021 and 2020, respectively. Litigation expense in 2021 is primarily related to Risperdal. Litigation expense in 2020 is related to the opioid settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes a gain on securities of $0.1&#160;billion in the fiscal third quarter of 2021 and $0.2&#160;billion in both the fiscal nine months of 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes a restructuring related charge of $0.1&#160;billion in both the fiscal nine months of 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In fiscal 2020 and 2021, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $1.2&#160;billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Devices &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes a contingent consideration reversal of $0.2&#160;billion in the fiscal third quarter of 2020 and $1.1&#160;billion in the fiscal nine months of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes a restructuring related charge of $0.1 billion in both the fiscal third quarter of 2021 and 2020, respectively. Includes a restructuring related charge of $0.2&#160;billion in both the fiscal nine months of 2021 and 2020, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes intangible amortization expense of $0.3&#160;billion and $0.2&#160;billion in the fiscal third quarter of 2021 and 2020, respectively. Includes intangible amortization expense of $0.8&#160;billion and $0.7&#160;billion in the fiscal nine months of 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes a gain on securities of $0.1&#160;billion in the fiscal nine months of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Includes an in-process research and development expense of $0.9&#160;billion related to the general surgery offering in digital robotics (Ottava) acquired with the Auris Health acquisition in 2019 in both the fiscal third quarter and fiscal nine months of 2021. See Note 3 to the Consolidated Financial Statements for more details.&lt;/span&gt;&lt;/div&gt;(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="if2f69aa2c55f4826a2d6918db36d8504_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfMi0yLTEtMS0w_5167df69-fc8d-403e-b4a4-9019181730fd"
      unitRef="usd">-636000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if044c23d97b94f7e9198830e79b71e75_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfMi00LTEtMS0w_25e98338-57fa-40b2-a2a3-f8c9f65d1820"
      unitRef="usd">191000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ice42e5369e6b45f0adf19543436ac0b0_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfMi04LTEtMS0w_4aa5c3bb-6783-4997-8858-20485fcaab91"
      unitRef="usd">956000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1d701fb1987245ca88cf01f3640777be_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfMi0xMC0xLTEtMA_c4ef35a8-6765-437a-8234-d6e442506c07"
      unitRef="usd">993000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="ice42e5369e6b45f0adf19543436ac0b0_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfMi0xMi0xLTEtMA_fc0cd038-8867-48e2-838d-8e7024f6b832"
      unitRef="number">-0.037</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic16d2db94474459387159b0687052bee_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfMy0yLTEtMS0w_399db545-d66a-4745-a643-3f12c0739573"
      unitRef="usd">4259000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib6ef5074333a4f0d83205f62d497b7b9_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfMy00LTEtMS0w_d4ab62eb-b706-45f3-b561-7fb4762ae308"
      unitRef="usd">3439000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="ic16d2db94474459387159b0687052bee_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfMy02LTEtMS0w_b0d9fdbd-1e34-43f3-9c7f-590e44180e11"
      unitRef="number">0.238</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id87ab88275fe48e88b999c9d8843e970_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfMy04LTEtMS0w_e5d75b8a-b72a-4843-9bca-689ffba2858d"
      unitRef="usd">13838000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia28c90140a094ef6b236aa35a8e77056_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfMy0xMC0xLTEtMA_c4e03f35-8d8a-4a24-9a47-5b58eaad1af1"
      unitRef="usd">11787000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="id87ab88275fe48e88b999c9d8843e970_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfMy0xMi0xLTEtMA_ba2bcdb2-d020-40f6-89f3-251c4b4495ee"
      unitRef="number">0.174</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9b2df3c4074c46f3829a9f1fe6d1b3d6_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNC0yLTEtMS0w_9dc6c8e4-ff9a-40a8-b0c9-b10c9a9fce43"
      unitRef="usd">423000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iab8b7c86635743468dc8ac2476edee79_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNC00LTEtMS0w_c332b43e-9797-4ded-b283-300d6571cf01"
      unitRef="usd">1010000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="i9b2df3c4074c46f3829a9f1fe6d1b3d6_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNC02LTEtMS0w_20f5154f-ff62-413d-96af-0a1443e345ce"
      unitRef="number">-0.581</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia0d190ecec914687861142e006d00019_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNC04LTEtMS0w_fa08462c-02c5-40fc-a2ba-e4f6c87a0db6"
      unitRef="usd">3798000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8fcf37770f4b482490a1deeb32ca5fb3_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNC0xMC0xLTEtMA_8e9d9465-0bee-4f41-bb50-807cfc300bf1"
      unitRef="usd">2681000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="ia0d190ecec914687861142e006d00019_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNC0xMi0xLTEtMA_0156f062-382c-4309-8771-80085b6a5a6f"
      unitRef="number">0.417</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9a08d0a4fd414fb0a743ba8926a6de8f_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNS0yLTEtMS0w_e98a9f11-6462-48a1-8808-122540b1a0d0"
      unitRef="usd">4046000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iaa95b6bbe9ce43f59b2c55eccaef0947_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNS00LTEtMS0w_28c1f0bb-be01-414b-955c-88b0ee1789fd"
      unitRef="usd">4640000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="i9a08d0a4fd414fb0a743ba8926a6de8f_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNS02LTEtMS0w_81417c0a-637a-4951-9c67-849bfdf9b531"
      unitRef="number">-0.128</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if9a33a98d27c46748aef00c3c783085e_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNS04LTEtMS0w_c5b3584d-5999-4785-90d4-a4c2ac7d66d0"
      unitRef="usd">18592000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5b79863c6ede4c88a5b5a6aae528d65b_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNS0xMC0xLTEtMA_b79fb667-28f5-4334-b444-864c0d92bab6"
      unitRef="usd">15461000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="if9a33a98d27c46748aef00c3c783085e_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNS0xMi0xLTEtMA_6306a1da-b47c-435a-b4af-face20c754af"
      unitRef="number">0.203</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if0c8f9eac7f34ffeb651669100cadca2_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNi0yLTEtMS0w_5211771e-b2b5-4d9c-b680-e82c15674ccd"
      unitRef="usd">197000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i86880b7c7c2c429080f9c83aaaf12cfe_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNi00LTEtMS0w_fc4129aa-df2f-4ae0-bc57-9b05fcbbce4e"
      unitRef="usd">239000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6353fe8fafb84e8b9c268c65fd303086_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNi04LTEtMS0w_e58cf316-883d-46d0-a8cd-5763d065473e"
      unitRef="usd">652000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6337b707147a48869ac16b7992cb215b_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNi0xMC0xLTEtMA_0a65c73c-dc65-4d63-89f3-e76c321d2480"
      unitRef="usd">611000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNy0yLTEtMS0w_ab0c487e-827b-4f48-8609-248406ce8b7f"
      unitRef="usd">3849000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNy00LTEtMS0w_d5304ca6-ed21-4094-9c12-c9cfdf6e6ef9"
      unitRef="usd">4401000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNy02LTEtMS0w_2c7c70eb-face-4ed4-a51a-98c96ee177c4"
      unitRef="number">-0.125</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNy04LTEtMS0w_3e284871-4a4c-459a-826a-776f16e2a012"
      unitRef="usd">17940000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNy0xMC0xLTEtMA_33b44bfe-4629-4c1e-a788-85a67955ee8e"
      unitRef="usd">14850000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOjMwZmI4NTM0MjUxYzRjZTlhZTIzOWRhYjkyODYzYjViL3RhYmxlcmFuZ2U6MzBmYjg1MzQyNTFjNGNlOWFlMjM5ZGFiOTI4NjNiNWJfNy0xMi0xLTEtMA_fdaf4ebc-1b1d-40c6-bc58-9aefbc551266"
      unitRef="number">0.208</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:AdjustmentForAmortization
      contextRef="if2f69aa2c55f4826a2d6918db36d8504_D20210705-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMzcw_8aa97004-945c-433a-be08-95921542f084"
      unitRef="usd">100000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="if044c23d97b94f7e9198830e79b71e75_D20200629-20200927"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMzcw_e6202d57-8367-4e97-a5b1-2171384d8907"
      unitRef="usd">100000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="ice42e5369e6b45f0adf19543436ac0b0_D20210104-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDA5_8d54d0fc-cd79-44fa-bafc-2e7ffaee3316"
      unitRef="usd">300000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i1d701fb1987245ca88cf01f3640777be_D20191230-20200927"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDA5_a58d69a6-d28f-4d8e-87d2-f3f73d1b8ba2"
      unitRef="usd">300000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:LitigationSettlementExpense
      contextRef="i27ba7c90a4c1434586cbf514f3e51927_D20210705-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDky_3b5ff64f-bef8-417f-8a47-3ef6cc2d152c"
      unitRef="usd">1400000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i8aa1fb345ea8443c9e0bc1aa8418aaec_D20200629-20200927"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk5_18dcdf45-6d9c-4429-97b4-e5a4a9ba42da"
      unitRef="usd">500000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i185910f7181845c8aed38c39fd4b6cab_D20210104-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMyOTY1Mw_ecbc2314-8a4f-41b9-a2c0-1906c1046f6e"
      unitRef="usd">1500000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="iaa93431137654cfa8d08a279d01cc337_D20191230-20200927"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMyOTY2OQ_822a1471-f8bd-45c3-8056-c60af5b44767"
      unitRef="usd">1200000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:RestructuringCharges
      contextRef="i185910f7181845c8aed38c39fd4b6cab_D20210104-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMyOTgzNg_885371c8-0343-4eb4-9062-579d4487a2c5"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="iaa93431137654cfa8d08a279d01cc337_D20191230-20200927"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMyOTgzNg_98f2fe6e-7f64-4698-9ee3-440113dfb9b6"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="id87ab88275fe48e88b999c9d8843e970_D20210104-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNjcy_0f8c1073-2689-4f3d-b29d-6b37f83d32b2"
      unitRef="usd">600000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:AdjustmentForAmortization
      contextRef="ic16d2db94474459387159b0687052bee_D20210705-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfOTQ3_6cca26d1-e121-4291-8ef2-76916b080734"
      unitRef="usd">800000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="ib6ef5074333a4f0d83205f62d497b7b9_D20200629-20200927"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfOTQ3_f779657e-00c1-4d40-b18d-9851220ac58b"
      unitRef="usd">800000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="id87ab88275fe48e88b999c9d8843e970_D20210104-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMTAyNw_3ff04262-5870-42fa-af9e-eac19629ccc0"
      unitRef="usd">2500000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="ia28c90140a094ef6b236aa35a8e77056_D20191230-20200927"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMTAzNA_4d6118fe-442a-437f-a930-95de1f4ad945"
      unitRef="usd">2400000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:LitigationSettlementExpense
      contextRef="ia15056130be2407b92273859fdb8febf_D20210705-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMzMDM3MQ_3de3b240-bfb7-4315-adea-599934bebcbf"
      unitRef="usd">800000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i4ee43394ce814ec8b0f42fe52e12760b_D20200629-20200927"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMzMDM4NQ_795a8a09-8500-434d-8e0f-eb2faed7d409"
      unitRef="usd">1000000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i18c6f67375de464e98be9b5c858a0996_D20210104-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMzMDQwOQ_25443727-16f6-4ad3-8d78-f30ea1ed3c4c"
      unitRef="usd">700000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i90d459ed7f3b48f1b2b9174f1965fbd3_D20191230-20200927"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMzMDQyMw_a41e7c1a-667b-4ac6-b918-f658a734c9a0"
      unitRef="usd">1000000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="ic16d2db94474459387159b0687052bee_D20210705-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMTA5OTUxMTYzNTk5NA_e8b53ce5-23a2-4b0c-8db3-e5d9cdda5c9e"
      unitRef="usd">100000000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="id87ab88275fe48e88b999c9d8843e970_D20210104-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMTA5OTUxMTYzNjAyMQ_797685df-f246-40ae-b41f-715ad562701b"
      unitRef="usd">200000000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="ia28c90140a094ef6b236aa35a8e77056_D20191230-20200927"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMTA5OTUxMTYzNjAyMQ_b9e8c56b-4749-476f-ba63-4b8620d669f7"
      unitRef="usd">200000000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:RestructuringCharges
      contextRef="i18c6f67375de464e98be9b5c858a0996_D20210104-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMzMDc4Mw_0eda3042-c918-457b-93dd-06816dbf896a"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i90d459ed7f3b48f1b2b9174f1965fbd3_D20191230-20200927"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMzMDc4Mw_ecdf2d00-1484-44d8-ade0-7c5e26624148"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <jnj:AmountPrepaidAndDueToManufacturers
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMTU2Mw_cc4902a2-d527-43ff-9e79-03488689ddf3"
      unitRef="usd">1200000000</jnj:AmountPrepaidAndDueToManufacturers>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="id1e1fcd02b464ee2a9ec2881679e5e2b_D20200629-20200927"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMzMjYzOA_0b1f1953-5ee3-4d81-a725-bac30d18f6df"
      unitRef="usd">-200000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i9cf5b5276af745aaae4d731df390a2e3_D20191230-20200927"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMzMjY2NQ_2a72a9a4-489f-461b-b6fa-94ff81bb4ec8"
      unitRef="usd">-1100000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:RestructuringCharges
      contextRef="i34f633e2629c400f81fb20c99145e112_D20210705-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMjEzMw_669a160e-4e97-4eaf-bf60-4ba5d7b28058"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="id4fd30965b31465e953a69a10b46ae75_D20200629-20200927"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMjEzMw_934b65c2-c506-48a4-a2ec-49e6ddc23c5e"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="if7fc25fc53e54e21948d2ce281e9424a_D20210104-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMzMTc0NQ_8afb4474-a472-47cd-b79c-b94834834992"
      unitRef="usd">200000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i9d5d0922cabe4f6fa55f3ac6507c79fa_D20191230-20200927"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMzMTc0NQ_9432e32b-c578-440c-86d5-4e725c286787"
      unitRef="usd">200000000</us-gaap:RestructuringCharges>
    <us-gaap:AdjustmentForAmortization
      contextRef="i9b2df3c4074c46f3829a9f1fe6d1b3d6_D20210705-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMjIyOQ_9f3799f8-dfee-4668-a5f4-85895728a633"
      unitRef="usd">300000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="iab8b7c86635743468dc8ac2476edee79_D20200629-20200927"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMjIzNg_eef3d56d-8d8e-458f-80c1-8681a0ce854a"
      unitRef="usd">200000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="ia0d190ecec914687861142e006d00019_D20210104-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMjI1NA_99f1f611-ae56-4e20-9b41-02324008c6e3"
      unitRef="usd">800000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i8fcf37770f4b482490a1deeb32ca5fb3_D20191230-20200927"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMzMTIyNw_919366c8-ebfe-43dd-98ba-26ecec07e2f5"
      unitRef="usd">700000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="ia0d190ecec914687861142e006d00019_D20210104-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMjM2NQ_79169c2f-82f1-4b31-abd3-1bbb6df4ee50"
      unitRef="usd">100000000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="i9b2df3c4074c46f3829a9f1fe6d1b3d6_D20210705-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMjM2NQ_adb712a1-eb67-4812-b488-cf11cc361b3c"
      unitRef="usd">100000000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9b2df3c4074c46f3829a9f1fe6d1b3d6_D20210705-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMzMTQ5OQ_1b1a08e9-8770-4ea3-a13b-d5097afd67ba"
      unitRef="usd">900000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia0d190ecec914687861142e006d00019_D20210104-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfNDk0NzgwMjMzMTQ5OQ_3e811849-9fa7-48b0-ba2b-555f501bec3b"
      unitRef="usd">900000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RleHRyZWdpb246NTFkZjVmOGM4N2JlNGY1ZmE5ZmE0MjFiYzRlNGY3OTJfMjU5OQ_ffbc0475-8bda-441f-b695-61ea7e61948e">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SALES BY GEOGRAPHIC AREA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.279%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.486%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.889%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.486%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.889%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.486%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.339%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.486%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Third Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Western Hemisphere, excluding U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia-Pacific, Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9fb264a5db024fa1895bcd3a4069036e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfMi0yLTEtMS0w_2a6b1cb1-7a59-4bba-a750-c08341907b8a"
      unitRef="usd">11963000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37b312259598430096ff868f08b6757a_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfMi00LTEtMS0w_d9830a00-3023-4608-8274-050a18978d28"
      unitRef="usd">11086000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="i9fb264a5db024fa1895bcd3a4069036e_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfMi02LTEtMS0w_177753bd-f780-4bab-8f67-553ccb77a592"
      unitRef="number">0.079</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51a85394d9a14ff08bfeb689185d9ee0_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfMi04LTEtMS0w_643620e5-b6b5-42c4-98c8-efd63b47b59b"
      unitRef="usd">34993000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie63bc91b9c82473fa1e0ce9ddfc407bc_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfMi0xMC0xLTEtMA_055b90e9-8353-41e3-aa4f-9e53e3999611"
      unitRef="usd">31324000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="i51a85394d9a14ff08bfeb689185d9ee0_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfMi0xMi0xLTEtMA_df52b0ec-3d79-4ed7-9340-60d569879938"
      unitRef="number">0.117</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a407e33714d43e5b6f57eceb1da3644_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfMy0yLTEtMS0w_afb5fa8f-150c-4cf4-b63b-e8f12876c25c"
      unitRef="usd">5587000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i774d073624f5479f99c44707399d81a2_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfMy00LTEtMS0w_fbdec8e4-fc7b-4404-9dac-a3be6ce1e6cb"
      unitRef="usd">4819000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="i9a407e33714d43e5b6f57eceb1da3644_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfMy02LTEtMS0w_4472e8ab-5016-491a-a03b-a954a236a8ee"
      unitRef="number">0.159</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie104a5f4ba5646e5ac756ddb0f8fe1e9_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfMy04LTEtMS0w_4401b4f0-a815-4a08-a33b-aba98040b7b0"
      unitRef="usd">16669000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa7453bcb1f1499cb56bf4c488b9f6ff_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfMy0xMC0xLTEtMA_602c3c01-6d8f-4db1-82a3-a2ea6e048f50"
      unitRef="usd">13709000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="ie104a5f4ba5646e5ac756ddb0f8fe1e9_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfMy0xMi0xLTEtMA_a328d646-030a-4b5d-83a6-054cf233a04a"
      unitRef="number">0.216</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i548df4a2b991433e95457098102bdc1b_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNC0yLTEtMS0w_2cfdaba2-d7a2-44ed-9a83-8b3d3773c62d"
      unitRef="usd">1500000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12056b6b1c854b9b986a9a3fbc149483_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNC00LTEtMS0w_647cfd86-ca40-442c-89f7-38af5ee0773e"
      unitRef="usd">1296000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="i548df4a2b991433e95457098102bdc1b_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNC02LTEtMS0w_63caeadf-1088-4944-b7fb-58eabb2167ac"
      unitRef="number">0.157</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i543547499d5747568f983b53ce0eb701_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNC04LTEtMS0w_097d1eca-d75c-46ce-8a77-304da4767f27"
      unitRef="usd">4291000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic400b23cafa440aca0f838eec065bd9b_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNC0xMC0xLTEtMA_a955eaeb-0d76-4d13-8a88-da8aa2a01b8f"
      unitRef="usd">3931000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="i543547499d5747568f983b53ce0eb701_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNC0xMi0xLTEtMA_ad085dfb-f352-4cfa-b083-b00191991f08"
      unitRef="number">0.092</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i237bc393dc5541fe92d8e43c47a8e02f_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNS0yLTEtMS0w_026c49ef-61a5-452d-8ee0-f99153500e5e"
      unitRef="usd">4288000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53dd9cb72725412faea6075a5b94f5f7_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNS00LTEtMS0w_555e501d-3dd5-463e-9ccc-3dcb8eb81d57"
      unitRef="usd">3881000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="i237bc393dc5541fe92d8e43c47a8e02f_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNS02LTEtMS0w_fa98b49e-4fd0-4813-8870-424ebb3081b3"
      unitRef="number">0.105</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie745b9ff518641abb53ef1f33093480c_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNS04LTEtMS0w_bb2c5caf-d185-47e7-a7fc-f36c2744a7f0"
      unitRef="usd">13018000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i76eb46ab7e594c6e955830b051a4634d_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNS0xMC0xLTEtMA_602046e4-cf13-47a0-a041-fe11d5f5fe27"
      unitRef="usd">11145000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="ie745b9ff518641abb53ef1f33093480c_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNS0xMi0xLTEtMA_8516ce8d-781a-4dd1-ad5f-c8e93104cdcc"
      unitRef="number">0.168</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNi0yLTEtMS0w_1c4de039-b10c-476d-a434-4171310cc408"
      unitRef="usd">23338000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie226ca01ae74401da5cfcfff06dcbbc6_D20200629-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNi00LTEtMS0w_87f494e7-572c-4ae1-8e06-7b93d9bf44b3"
      unitRef="usd">21082000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNi02LTEtMS0w_d1438ed8-7b7a-4a38-8fa4-52a888ad442c"
      unitRef="number">0.107</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNi04LTEtMS0w_d4606205-5b8b-463c-88ce-d8b39a82c209"
      unitRef="usd">68971000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38f84fda1a874165b14bd76eb9b0b8e4_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNi0xMC0xLTEtMA_df10bd64-8cc7-4254-aad4-640d34c94d82"
      unitRef="usd">60109000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84Mi9mcmFnOjUxZGY1ZjhjODdiZTRmNWZhOWZhNDIxYmM0ZTRmNzkyL3RhYmxlOmI1MmYwMGU1ZjNkMzQ4MmFiNDZkMmM1ODU2M2JiMTJlL3RhYmxlcmFuZ2U6YjUyZjAwZTVmM2QzNDgyYWI0NmQyYzU4NTYzYmIxMmVfNi0xMi0xLTEtMA_02300e81-8b87-4cbf-8c80-e0eed2b28f2c"
      unitRef="number">0.147</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84NS9mcmFnOjhlYjExMjRjMTFjNTQyY2M4Nzk4M2EzMTkwYWNmYmY4L3RleHRyZWdpb246OGViMTEyNGMxMWM1NDJjYzg3OTgzYTMxOTBhY2ZiZjhfMTUxMg_55d543df-2f70-4e15-a409-051c1d34828a">ACQUISITIONS AND DIVESTITURESDuring the first fiscal quarter of 2021, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.6&#160;billion. During the fiscal first quarter of 2020, the Company completed the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc., for a purchase price of $0.8 billion. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;amp;D, for $0.8 billion. XBiotech may be eligible to receive additional payments upon the receipt of certain commercialization authorizations. The transaction was accounted for as a business combination and included in the Pharmaceutical segment. Additionally, the Company completed the acquisition of all outstanding shares in Verb Surgical Inc., a company with world-class robotics and data science capabilities, including those shares previously held by Verily. The transaction was accounted for as a business combination and included in the Medical Devices segment. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;amp;D, for $0.4 billion, goodwill for $0.2 billion, other assets of $0.2 billion and liabilities assumed of $0.3 billion. The fair value of the Company's previously held equity investment in Verb Surgical Inc. was $0.4 billion.</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i3925875d2d8b49ed84c2f94483fbddc9_D20210104-20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84NS9mcmFnOjhlYjExMjRjMTFjNTQyY2M4Nzk4M2EzMTkwYWNmYmY4L3RleHRyZWdpb246OGViMTEyNGMxMWM1NDJjYzg3OTgzYTMxOTBhY2ZiZjhfMjky_040a0d52-80d8-453e-b7d8-b8c8cd1ee036"
      unitRef="usd">600000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i8aa76dc85f4d47988a65dc0767f87e60_D20191230-20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84NS9mcmFnOjhlYjExMjRjMTFjNTQyY2M4Nzk4M2EzMTkwYWNmYmY4L3RleHRyZWdpb246OGViMTEyNGMxMWM1NDJjYzg3OTgzYTMxOTBhY2ZiZjhfNTU1_8a77291e-1568-4322-8c8f-c5586f0efbb0"
      unitRef="usd">800000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i17afbc0e69e34400b507b3fa36f4cca9_I20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84NS9mcmFnOjhlYjExMjRjMTFjNTQyY2M4Nzk4M2EzMTkwYWNmYmY4L3RleHRyZWdpb246OGViMTEyNGMxMWM1NDJjYzg3OTgzYTMxOTBhY2ZiZjhfNjc2_9b2e3f00-6519-4388-ab72-9d80bab9141e"
      unitRef="usd">800000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i8abbc5ec72a249a68e86c66cec320d05_I20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84NS9mcmFnOjhlYjExMjRjMTFjNTQyY2M4Nzk4M2EzMTkwYWNmYmY4L3RleHRyZWdpb246OGViMTEyNGMxMWM1NDJjYzg3OTgzYTMxOTBhY2ZiZjhfMTM0Mg_d8d17753-ac81-412f-b85a-fdfd05528eb8"
      unitRef="usd">400000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="i8abbc5ec72a249a68e86c66cec320d05_I20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84NS9mcmFnOjhlYjExMjRjMTFjNTQyY2M4Nzk4M2EzMTkwYWNmYmY4L3RleHRyZWdpb246OGViMTEyNGMxMWM1NDJjYzg3OTgzYTMxOTBhY2ZiZjhfMTM1OQ_f2cce31c-97f6-42dc-a195-aca6f2c13fda"
      unitRef="usd">200000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="i8abbc5ec72a249a68e86c66cec320d05_I20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84NS9mcmFnOjhlYjExMjRjMTFjNTQyY2M4Nzk4M2EzMTkwYWNmYmY4L3RleHRyZWdpb246OGViMTEyNGMxMWM1NDJjYzg3OTgzYTMxOTBhY2ZiZjhfMTM3OQ_d6bad0f3-4e08-4383-8000-38f4db3df7e4"
      unitRef="usd">200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="i8abbc5ec72a249a68e86c66cec320d05_I20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84NS9mcmFnOjhlYjExMjRjMTFjNTQyY2M4Nzk4M2EzMTkwYWNmYmY4L3RleHRyZWdpb246OGViMTEyNGMxMWM1NDJjYzg3OTgzYTMxOTBhY2ZiZjhfMTQwOQ_e6245d40-cf39-4100-bb0e-799399ea9432"
      unitRef="usd">300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="i8abbc5ec72a249a68e86c66cec320d05_I20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84NS9mcmFnOjhlYjExMjRjMTFjNTQyY2M4Nzk4M2EzMTkwYWNmYmY4L3RleHRyZWdpb246OGViMTEyNGMxMWM1NDJjYzg3OTgzYTMxOTBhY2ZiZjhfMTUwNQ_214ac227-b26f-42c4-ae81-280cd137660e"
      unitRef="usd">400000000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfOTEzMDM_7e82caf8-1906-4743-a065-ed2f7cc34b02">LEGAL PROCEEDINGS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; supplier indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. Due to the ongoing impacts of the COVID-19 pandemic, certain trials have been rescheduled or delayed.  The Company continues to monitor its legal proceedings as the situation evolves and in person trials resume.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of October&#160;3, 2021, the Company has determined that &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;PRODUCT LIABILITY&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The most significant of these cases include: the DePuy ASR&#x2122; XL Acetabular System and DePuy ASR&#x2122; Hip Resurfacing System; the PINNACLE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Acetabular Cup System; pelvic meshes; RISPERDAL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;; XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;; body powders containing talc, primarily JOHNSONS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Baby Powder; INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;; and ETHICON PHYSIOMESH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Flexible Composite Mesh. As of October&#160;3, 2021, in the United States there were approximately 300 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR&#x2122; XL Acetabular System and DePuy ASR&#x2122; Hip Resurfacing System; 5,400 with respect to the PINNACLE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Acetabular Cup System; 10,700 with respect to pelvic meshes; 9,000 with respect to RISPERDAL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;; 6,600 with respect to XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;; 38,200 with respect to body powders containing talc; 100 with respect to INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 4,700 with respect to ETHICON PHYSIOMESH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Flexible Composite Mesh.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; XL Acetabular System and DePuy ASR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Hip Resurfacing System used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson &amp;amp; Johnson. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip System plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 31, 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 31, 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle &lt;/span&gt;&lt;span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the class actions filed in that country&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company continues to receive information with &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and DePuy ASR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Hip-related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson &amp;amp; Johnson (collectively, DePuy) relating to the PINNACLE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation also has been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Acetabular Cup System and the related settlement program.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp;amp; Johnson arising out of Ethicon's pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved a majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company's accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon's pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands and class actions in Israel, Australia and Canada. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court issued a decision and entered damages awards to the three Lead Applicants. The Company appealed the decision to the intermediate appellate court, the Full Court. The appeal was heard in February 2021 and, in March 2021, the Full Court entered a judgment dismissing the appeal. An application for special leave to the High Court of Australia was filed in April 2021, and in July 2021, the High Court agreed to hear oral argument on the application, which is scheduled to occur in November 2021. With respect to class members other than the Lead Applicants, the Federal Court will conduct an individual case assessment process that will require proof of use and causally related loss, although the form of that process has not yet been decided. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021, which is subject to court approval. The Company has established accruals with respect to product liability litigation associated with Ethicon's pelvic mesh products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Flexible Composite Mesh, claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp;amp; Johnson alleging personal injury arising out of the use of this hernia mesh device.&#160;Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., one multi-plaintiff lawsuit pending in Oklahoma state court and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement was entered into in September 2021. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. The costs associated with this proposed settlement are reflected in the Company&#x2019;s accruals. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;Claims have also been filed against Ethicon and Johnson &amp;amp; Johnson alleging personal injuries arising from the PROCEED&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt; Mesh and PROCEED&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt; Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the US, and in jurisdictions outside the US. Discovery is underway in the MCL proceedings. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Ethicon and Johnson &amp;amp; Johnson also have been subject to claims for personal injuries arising from the PROLENE&#x2122; Polypropylene Hernia System (PHS). In January 2020, New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Flexible Composite Mesh, PROCEED&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Mesh and PROCEED&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Ventral Patch, and PROLENE&#x2122; Polypropylene Hernia System products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson &amp;amp; Johnson arising out of the use of RISPERDAL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0&#160;billion of punitive damages related to one plaintiff, which the trial judge reduced to $6.8&#160;million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company's accruals.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Claims for personal injury arising out of the use of XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson &amp;amp; Johnson; and JPI&#x2019;s collaboration partner for XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, Bayer AG and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases have been filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and Johnson  &amp;amp; Johnson announced an agreement in principle to settle the XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A significant number of personal injury claims alleging that talc causes cancer were made against Johnson &amp;amp; Johnson Consumer Inc. and Johnson &amp;amp; Johnson arising out of the use of body powders containing talc, primarily JOHNSON&#x2019;S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Baby Powder. The number of these personal injury lawsuits, filed in state and federal courts in the United States as well as outside of the United States, continued to increase through, and including, October 2021. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7&#160;billion in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Ingham v. Johnson &amp;amp; Johnson, et al., &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;No. ED 207476 (Mo. App.), reducing the overall award to $2.1&#160;billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Ingham &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;decision by the United States Supreme Court was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $2.5&#160;billion. The facts and circumstances, including the terms of the award, were unique to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Ingham&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; decision and not representative of other claims brought against the Company.  The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company&#x2019;s confidence in the safety of its talc products, in certain circumstances the Company has and may settle cases. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2021, Johnson &amp;amp; Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring).  As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor), (b) Royalty A&amp;amp;M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor's direct parent, Johnson &amp;amp; Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI's assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers&#x2019; compensation statute or act (the Talc-Related Liabilities).  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2021, notwithstanding the Company&#x2019;s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Filing). As a result of the LTL Bankruptcy Filing, the Court entered a temporary restraining order staying all litigation against LTL and Old JJCI.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Further hearings on whether a permanent restraining order staying all litigation against those entities, as well other entities, such as Johnson &amp;amp; Johnson, its affiliates, and certain other third parties, are scheduled in November 2021.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; The Company has agreed to provide funding to LTL for the payment of amounts the Bankruptcy Court determines are owed by LTL through the establishment of a $2&#160;billion trust in furtherance of this purpose. The Company has established a reserve for approximately $2&#160;billion in connection with the aforementioned trust, resulting in an incremental $1.4&#160;billion litigation charge. Subsequent to the fiscal third quarter, the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Company has de-consolidated LTL as a result of the bankruptcy filing.  The impact of the de-consolidation is not material to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2019, the Company&#x2019;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary chapter 11 petition under chapter 11 of title 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#x2019;s potential liability for personal injury from exposure to talcum powder sold by Imerys (Talc Claims). In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. During the bankruptcy, the Company proposed to resolve Imerys's (and the Company&#x2019;s) obligations arising out of Talc Claims involving the Company&#x2019;s products by agreeing to assume the defense of litigation of all such Talc Claims, waiving the Company&#x2019;s indemnification claims against Imerys, and lifting the automatic stay to enable the Talc Claims to proceed outside the bankruptcy forum with the Company agreeing to settle or pay any judgment against Imerys. Imerys rejected that proposal. In May 2020, Imerys, its parent Imerys S.A., the Tort Claimants&#x2019; Committee (TCC), and the Future Claimants&#x2019; Representative (FCR) (collectively, the Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related thereto. The Plan Proponents have since filed numerous amendments to the Plan and Disclosure Statement. A hearing on the Plan Proponent&#x2019;s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement, allowing Imerys to proceed with soliciting votes on the Plan. In March 2021, the Company voted to reject the Plan and opted out of the consensual releases in the Plan. In April 2021, the Plan Proponents announced the Plan had received the requisite number of accepting votes to confirm the Plan.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2021, the Bankruptcy Court issued a ruling deeming almost 16,000 votes in favor of the Plan as withdrawn, based upon evidence that no due diligence had been done by the plaintiff&#x2019;s counsel to ascertain whether the votes were cast on behalf of individuals who used the Company&#x2019;s products.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Bankruptcy Court also ruled that more than 1,500 votes cast by another firm should count as rejecting instead of accepting. In October 2021, Imerys filed a notice on the docket cancelling the confirmation hearing on its Plan that was scheduled to begin in November 2021. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In July 2021, Imerys commenced an adversary proceeding against the Company in the Imerys Bankruptcy (the Imerys adversary proceeding).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Imerys adversary proceeding sought, among other things, certain declarations with respect to the indemnification obligations allegedly owed by the Company to Imerys.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The TCC and FCR simultaneously filed a motion for temporary restraining order and preliminary injunction seeking to enjoin the Company from undergoing a corporate restructuring that would separate the Company&#x2019;s talc liabilities from its other assets.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The bankruptcy court denied the motion.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company thereafter filed a motion to dismiss the adversary proceeding.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Bankruptcy Court has not yet decided the motion to dismiss. In October 2021, the Company filed a Notice of  Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the LTL Bankruptcy Filing should apply to the Imerys adversary proceeding&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2020, Cyprus Mines Corporation and its parent (together, Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company and Imerys in the Imerys Bankruptcy seeking a declaration of indemnity rights under certain contractual agreements (the Cyprus adversary proceeding). The Company denies such indemnification is owed, and filed a motion to dismiss the adversary complaint. In February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan. The Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against Talc Claims asserted against it. Cyprus has not yet sought approval of its Disclosure Statement and Plan. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the LTL Bankruptcy Filing should apply to the Cyprus adversary proceeding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2021, several of the Company&#x2019;s insurers involved in coverage litigation in New Jersey State Court (the Coverage Action) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action. In March 2021, the Company filed a limited response and reservation of rights with respect to the motion. The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. In October 2021, LTL filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the LTL Bankruptcy Filing should apply to the Coverage Action.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2018, a securities class action lawsuit was filed against Johnson &amp;amp; Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson &amp;amp; Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON'S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Baby Powder, and that purchasers of Johnson &amp;amp; Johnson&#x2019;s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, Defendants answered the complaint. In April 2021 briefing on Plaintiffs&#x2019; motion for class certification was completed. Discovery is ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2019, a shareholder filed a complaint initiating a summary proceeding in New Jersey state court for a books and records inspection. In August 2019, Johnson &amp;amp; Johnson responded to the books and records complaint and filed a cross motion to dismiss. In September 2019, Plaintiff replied and the Court heard oral argument. The Court has not yet ruled in the books and records action. In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson &amp;amp; Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#x2019;S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Baby Powder, and that Johnson &amp;amp; Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;In re Johnson &amp;amp; Johnson Talc Stockholder Derivative Litigation&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2020, a report was delivered to the Company&#x2019;s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues and demanding that suit be brought against certain Directors. Four of the shareholders who sent demands are plaintiffs in th&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;e &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;In re Johnson &amp;amp; Johnson Talc Stockholder Derivative Litigation&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel&#x2019;s report. In October 2020, the shareholders filed a consolidated complaint, and in January 2021, Johnson &amp;amp; Johnson moved to dismiss the consolidated complaint. In March 2021, Plaintiffs filed a motion for discovery. The Court temporarily terminated Johnson &amp;amp; Johnson&#x2019;s motion to dismiss pending a decision on Plaintiff&#x2019;s motion for discovery. In October 2021, the Court requested supplemental briefing on Plaintiff&#x2019;s motion for discovery. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson &amp;amp; Johnson Savings Plan against Johnson &amp;amp; Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson &amp;amp; Johnson stock as a Johnson &amp;amp; Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#x2019;S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants&#x2019; motion but granted leave to amend. In June 2020, Plaintiffs filed an amended complaint, and in July 2020, Defendants moved to dismiss the amended complaint. As of October 2020, briefing on Defendants&#x2019; motion was complete. In February 2021, the Court granted Defendants&#x2019; motion, and granted Plaintiffs leave to amend. In April 2021, Plaintiffs informed the Court that they did not intend to file an amended complaint, and the Court dismissed the case with prejudice. In May 2021, Plaintiffs filed a notice of appeal with the Third Circuit. In July 2021, Plaintiffs filed their opening brief in the Third Circuit and in September 2021, Defendants filed their response brief. In October 2021, Plaintiffs filed their reply brief. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California&#x2019;s Consumer Legal Remedies Act (CLRA) relating to JOHNSON&#x2019;S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Baby Powder. In that lawsuit, the plaintiffs allege that Johnson &amp;amp; Johnson violated the CLRA by failing to provide required Proposition 65 warnings.  In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company&#x2019;s favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. In October 2021, a Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit.   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In addition, the Company has received preliminary inquiries and subpoenas to produce documents regarding talc matters from Senator Murray, a member of the Senate Committee on Health, Education, Labor and Pensions, the Department of Justice and the U.S. Congressional Subcommittee on Economic and Consumer Policy. The Company produced documents as required in response and will continue to cooperate with government inquiries.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Claims for personal injury have been made against a number of Johnson &amp;amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp;amp; Johnson, arising out of the use of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. In December 2016, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company's accruals.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Claims for personal injury have been made against a number of Johnson &amp;amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp;amp; Johnson, arising out of the use of ELMIRON&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, a prescription medication  indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases also have been filed in various state courts. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with ELMIRON&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;INTELLECTUAL PROPERTY&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain subsidiaries of Johnson &amp;amp; Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company&#x2019;s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. Significant matters are described below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medical Devices&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2016, Dr. Ford Albritton sued Acclarent, Inc. (Acclarent) in United States District Court for the Northern District of Texas alleging that Acclarent&#x2019;s RELIEVA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Spin and RELIEVEA SpinPlus&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; products infringe U.S. Patent No. 9,011,412.  Dr. Albritton also alleges breach of contract, fraud and that he is the true owner of Acclarent&#x2019;s U.S. Patent No. 8,414,473. Trial began in October 2021, and shortly thereafter, the parties reached an agreement to settle the case. Plaintiff's motion to dismiss with prejudice was filed in October 2021. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2017, Board of Regents, The University of Texas System and TissueGen, Inc. (collectively, UT) filed a lawsuit in the United States District Court for the Western District of Texas against Ethicon, Inc. and Ethicon US, LLC (collectively, Ethicon) alleging the manufacture and sale of VICRYL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Plus Antibacterial Sutures, MONOCRYL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Plus Antibacterial Sutures, PDS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Plus Antibacterial Sutures, STRATAFIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; PDS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Antibacterial Sutures and STRATAFIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; MONOCRYL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Plus Antibacterial Sutures infringe plaintiffs&#x2019; United States Patent Nos. 6,596,296 (&#x2019;296) and 7,033,603 (&#x2019;603) directed to implantable polymer drug releasing biodegradable fibers containing a therapeutic agent. UT is seeking damages and an injunction. In December 2018, Ethicon filed petitions with the United States Patent and Trademark Office (USPTO), seeking Inter Partes Review (IPR) of both asserted patents. In June 2020, the USPTO denied institution of the &#x2019;296 patent IPR and granted institution of the &#x2019;603 patent IPR. UT dismissed the &#x2019;603 patent from the suit and no longer accuses PDS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Plus Antibacterial Sutures or STRATAFIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; PDS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Plus Antibacterial Sutures of infringement. In August 2021, the parties entered into a settlement agreement, and the case was dismissed. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (collectively, Intuitive) filed a patent infringement suit against Auris Health, Inc. (Auris) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos. 6,246,200 (&#x2019;200); 6,491,701 (&#x2019;701); 6,522,906 (&#x2019;906); 6,800,056 (&#x2019;056); 8,142,447 (&#x2019;447); 8,620,473 (&#x2019;473); 8,801,601 (&#x2019;601); and 9,452,276 (&#x2019;276) based on Auris&#x2019; Monarch&#x2122; Platform. Auris filed IPR Petitions with the U.S. Patent and Trademark Office (USPTO) regarding the &#x2019;200, &#x2019;056, &#x2019;601 &#x2019;701, &#x2019;447, &#x2019;276 and &#x2019;906 patents. Intuitive subsequently dropped the &#x2019;200, &#x2019;473 and &#x2019;701 patents from the suit. In December 2019, the USPTO instituted review of the &#x2019;601 patent and denied review of the &#x2019;056 patent. In February and March 2020, the USPTO instituted review of the &#x2019;200, &#x2019;447, &#x2019;701 and &#x2019;906 patents and denied review of the &#x2019;276 patent. In December 2020, the USPTO declared all of the challenged claims in the &#x2019;601 patent to be invalid. Intuitive has appealed that decision. In March 2021, the USPTO ruled that the challenged claims of the &#x2019;447 and &#x2019;906 patents are not invalid. Auris has appealed that decision. Trial is scheduled to begin in January 2023. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2019, RSB Spine LLC (RSB Spine) filed a patent infringement suit against DePuy Synthes, Inc. in United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of United States Patent Nos. 6,984,234 and 9,713,537 by one or more of the following products:  ZERO-P-VA&#x2122; Spacer, ZERO-P&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Spacer, ZERO-P NATURAL&#x2122; Plate, SYNFIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; LR Spacer and SYNFIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Evolution System. RSB Spine seeks monetary damages and injunctive relief. In November 2019, the suit was consolidated for pre-trial purposes with other patent infringement suits brought by RSB Spine in the United States District Court for the District of Delaware against Life Spine, &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Inc., Medacta USA, Inc., and Precision Spine, Inc. A stay that had been entered pending Inter Partes Review at the U.S. Patent &amp;amp; Trademark Office has been lifted, and trial is scheduled to begin in December 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In March 2020, Osteoplastics, LLC filed a patent infringement suit against DePuy Synthes, Inc., DePuy Synthes Products, Inc., Medical Device Business Services, Inc., and Synthes, Inc. (collectively, DePuy Synthes) in the United States District Court for the District of Delaware. In the suit, Osteoplastics alleges willful infringement of U.S. Patent Nos. 8,781,557; 9,929,920; 9,330,206; 9,626,756; 9,672,617; 9,672,302; and 9,275,191 based on the PROPLAN CMF&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Virtual Surgical Planning Services and the TruMatch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; CMF Personalize Solutions. In April 2020, Osteoplastics filed an amended complaint to substitute U.S. Patent No. 9,292,920 for U.S. Patent No. 9,929,920.  Osteoplastics seeks monetary damages and injunctive relief. In June 2020, DePuy Synthes filed a motion to dismiss the complaint. In October 2020, the Court dismissed Medical Device Business Services, Inc. from the case but otherwise denied the motion. In June 2021, Osteoplastics admitted that the PROPLAN CMF&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Virtual Surgical Planning Services do not infringe any asserted patents. Trial is scheduled for October 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Pharmaceutical&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes lawsuits the Company's subsidiaries have brought against generic companies that have filed ANDAs with the FDA or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson &amp;amp; Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement and invalidity of the applicable patents. In the event the Company's subsidiaries are not successful in an action, or the automatic statutory stay of the ANDAs expires before the United States District Court rulings are obtained, the generic companies involved would have the ability, upon approval of the FDA, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company's subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. The Inter Partes Review (IPR) process with the USPTO, created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits, to challenge the applicable patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Beginning in January 2019, Janssen Inc. and Janssen Oncology Inc. (collectively, Janssen) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations in Canada against Apotex Inc. (Apotex), Pharmascience Inc. (Pharmascience) and Dr. Reddy's Laboratories Ltd. and Dr. Reddy's Laboratories, Inc. (collectively, DRL) in response to those parties&#x2019; filing of Abbreviated New Drug Submissions (ANDS) seeking approval to market generic versions of ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; before the expiration of the Canadian Patent No. 2,661,422 (&#x2019;422). The trial in these actions concluded in November 2020, and the Court issued a decision holding the &#x2019;422 patent invalid in January 2021. In February 2021, Janssen appealed the decision.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each of these Canadian actions, Janssen is seeking an order enjoining the defendants from marketing their generic versions of ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before the expiration of the &#x2019;422 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March 2021, Janssen Pharmaceuticals, Inc. (JPI) and Bayer Pharma AG and Bayer AG (collectively, Bayer) filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Lupin Limited and Lupin Pharmaceuticals, Inc. which filed an ANDA seeking approval to market a generic version of XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before expiration of U.S. Patent No. 10,828,310 (&#x2019;310). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In April 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Accord Healthcare Inc., Accord Healthcare Limited, and Intas Pharmaceuticals Limited which filed an ANDA seeking approval to market a generic version of XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; before expiration of the &#x2019;310 patent. In July 2021, the parties entered into a confidential settlement agreement, and the action was dismissed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Dr. Reddy&#x2019;s Laboratories, Inc. and Dr. Reddy&#x2019;s Laboratories, Ltd. which filed an ANDA seeking approval to market a generic version of XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before expiration of the &#x2019;310 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals U.S.A., Inc. (collectively, Taro) which filed an ANDA seeking approval to market a generic version of XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before expiration of the &#x2019;310 patent. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. which filed an ANDA seeking approval to market a generic version of XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before expiration of the &#x2019;310 patent. In August 2021, the court entered a joint stipulation dismissing Teva Pharmaceutical Industries Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the Northern District of West Virginia against Mylan Pharmaceuticals Inc. and Mylan Inc. which filed an ANDA seeking approval to market a generic version of XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before expiration of the &#x2019;310 patent. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In each of these lawsuits, JPI and Bayer are seeking an order enjoining defendants from marketing their generic version of XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; before the expiration of the &#x2019;310 patent. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;/INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;/INVOKAMET XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Beginning in July 2017, Janssen Pharmaceuticals, Inc., Janssen Research &amp;amp; Development, LLC, Cilag GmbH International and Janssen Pharmaceutica NV (collectively, Janssen) and Mitsubishi Tanabe Pharma Corporation (MTPC) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against a number of generic companies that filed ANDAs seeking approval to market generic versions of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; and/or INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; XR before expiration of MTPC&#x2019;s United States Patent Nos. 7,943,582 (&#x2019;582) and/or 8,513,202 (&#x2019;202) relating to INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; and/or INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; XR. Janssen is the exclusive licensee of the asserted patents. Named defendants include MSN Laboratories Private Ltd. and MSN Pharmaceuticals, Inc. (MSN); Zydus Pharmaceuticals (USA) Inc. (Zydus). These cases were consolidated into one action (Polymorph Main Action).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2017, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Zydus which filed ANDAs seeking approval to market generic versions of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;and INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;before expiration of MTPC&#x2019;s United States Patent No. 7,943,788 (&#x2019;788), 8,222,219 (&#x2019;219) and/or 8,785,403 (&#x2019;403) relating to INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;and INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (Compounds Main Action). Janssen is the exclusive licensee of the asserted patents. Trial concluded in October 2020. The Court issued a decision holding that the patents are not invalid and would be infringed by Zydus&#x2019; generic products. Zydus has appealed the decision. In July 2021, Janssen and Zydus entered into a confidential settlement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2019, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against MSN, which filed an ANDA seeking approval to market a generic version of INVOKAMET XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before expiration of the &#x2019;582 patent and &#x2019;202 patent relating to INVOKAMET XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. In October 2019, Janssen and MTPC initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against MSN, which filed ANDAs seeking approval to market generic versions of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; and INVOKAMET XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before expiration of the &#x2019;788 patent. In July 2021, Janssen and MSN entered into a confidential settlement and the lawsuits were dismissed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2019, Janssen and MTPC initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Dr. Reddy&#x2019;s Laboratories, Inc. and Dr. Reddy&#x2019;s Laboratories Ltd (DRL), who filed an ANDA seeking approval to market a generic version of INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; before expiration of the &#x2019;788 patent. In January 2021, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Macleods), which filed an ANDA seeking approval to market a generic version of INVOKAMET XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; before expiration of the &#x2019;582 patent and &#x2019;202 patent relating to INVOKAMET XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. In February 2021, Janssen filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Macleods), which filed an ANDA seeking approval to market a generic version of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; before expiration of United States Patent No. 10,617,668 (&#x2019;668)  relating to INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. In September 2021, Janssen and MTPC dismissed the lawsuit against Macleods relating to the &#x2019;668 patent. These lawsuits have not been consolidated with the Polymorph Main Action or Compound Main Action.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"&gt;In each of these U.S. lawsuits, Janssen and MTPC are seeking an order enjoining the defendant from marketing their generic versions of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:102%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"&gt;, INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:102%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"&gt; and/or, INVOKAMET XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:102%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"&gt;before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2020, Janssen Inc., Janssen Pharmaceutica NV and MTPC initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#x2019;s filing of an ANDS seeking approval to market a generic version of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the Canadian Patent Nos. 2,799,204, 2,534,024 and 2,671,357. Janssen Inc., Janssen Pharmaceutica NV and MTPC are seeking an &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;order enjoining Sandoz from marketing its generic version of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the relevant patents. The trial is scheduled to begin in August 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2020, Janssen Inc. (Janssen) and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#x2019;s filing of an ANDS seeking approval to market a generic version of OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10 mg,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;before the expiration of Canadian Patent No. 2,659,770 (&#x2019;770). Trial is scheduled to begin in January 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in Canada in response to Apotex&#x2019;s filing of an ANDS seeking approval to market a generic version of OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10 mg,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;before the expiration of the &#x2019;770 patent. Trial is scheduled to begin in February 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against JAMP Pharma Corporation (JAMP) in Canada in response to JAMP&#x2019;s filing of an ANDS seeking approval to market a generic version of OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10 mg before the expiration of the &#x2019;770 patent and Canadian Patent No. 2,621,273 (&#x2019;273). Trial is scheduled to begin in April 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each of these Canadian actions, Janssen and Actelion are seeking an order enjoining the defendants from marketing their generic versions of OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. (Teva), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; before the expiration of United States Patent No. 9,439,906 (&#x2019;906).  Trial concluded in October 2020. In October 2021, the court issued a decision in Janssen's favor.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2019, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited (Mylan), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the &#x2019;906 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, Janssen initiated a patent infringement lawsuit in the United States District Courts for the Districts of New Jersey and Delaware against Pharmascience Inc., Mallinckrodt PLC and Specgx LLC (collectively, Pharmascience), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before the expiration of the &#x2019;906 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In each of these U.S. lawsuits, Janssen is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2018, Janssen Inc. and Janssen Pharmaceutica NV (collectively, Janssen Canada) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Teva Canada Limited (Teva Canada) in response to Teva's filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before the expiration of Canadian Patent Nos. 2,309,629 (&#x2019;629) and 2,655,335 (&#x2019;335). Janssen subsequently discontinued the portion of the lawsuit relating to the &#x2019;629 patent. In May 2020, the Canadian Federal Court issued a Public Judgment and Reasons declaring that Teva Canada&#x2019;s generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, if approved, would infringe certain claims of the &#x2019;335 patent and that the claims of the &#x2019;335 patent are not invalid for obviousness. Teva Canada appealed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2020, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience Inc. in response to Pharmascience Inc.'s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the &#x2019;335 patent. A summary trial on the issue of infringement is scheduled for November 2021. The trial is scheduled to begin in July 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2021, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in response to Apotex's filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the &#x2019;335 patent. A summary trial on the issue of infringement is scheduled for December 2021. The trial is scheduled to begin in September 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each of these Canadian lawsuits, Janssen Canada is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp;amp; Development, LCC (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., and Mylan Institutional LLC (collectively, Mylan). Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (546 mg) before expiration of United States Patent No. 10,143,693 (&#x2019;693) relating to INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(546 mg). Janssen is seeking an order enjoining Mylan from marketing a generic version of INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; before the expiration of the &#x2019;693 patent. Trial is scheduled to begin in October 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(819 mg) before expiration of the &#x2019;693 patent. Janssen is seeking an order enjoining Mylan from marketing a generic version of INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (819 mg) before the expiration of the &#x2019;693 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (273 mg and 410 mg) before expiration of the &#x2019;693 patent. Janssen is seeking an order enjoining Mylan from marketing a generic version of INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (273 mg and 410 mg) before the expiration of the &#x2019;693 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Beginning in January 2018, Pharmacyclics LLC (Pharmacyclics) and Janssen Biotech, Inc. (JBI) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies that filed ANDAs seeking approval to market generic versions of IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; 140 mg capsules before expiration of Pharmacyclics&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;United States Patent Nos. 8,008,309, 7,514,444, 8,697,711, 8,735,403, 8,957,079, 9,181,257, 8,754,091, 8,497,277, 8,925,015, 8,476,284, 8,754,090, 8,999,999, 9,125,889, 9,801,881, 9,801,883, 9,814,721, 9,795,604, 9,296,753, 9,540,382, 9,713,617 and/or 9,725,455 relating to IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. JBI is the exclusive licensee of the asserted patents. The named defendants include the following generic companies: Sandoz Inc. and Lek Pharmaceuticals d.d. (collectively, Sandoz).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In January 2019 and February 2019, Pharmacyclics and JBI amended their complaint against Sandoz to allege infringement of United States Patent Nos. 10,125,140 and 10,106,548. In August 2019, Pharmacyclics and JBI amended their complaint against Sandoz to further allege infringement of U.S. Patent Nos. 10,294,231 and 10,294,232.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen Pine Brook LLC and Natco Pharma Ltd. (collectively, Alvogen), which filed an ANDA seeking approval to market generic versions of IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; tablets, asserting infringement of United States Patent Nos. 7,514,444, 8,003,309, 8,476,284, 8,497,277, 8,697,711, 8,753,403, 8,754,090, 8,754,091, 8,952,015, 8,957,079, 9,181,257, 9,296,753,  9,655,857, 9,725,455, 10,010,507, 10,106,548, and 10,125,140. In June 2019, Pharmacyclics and JBI amended their complaint against Alvogen to further allege infringement of United States Patent No. 10,213,386. Pharmacyclics and JBI are seeking an order enjoining the defendants from marketing generic versions of IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Trial in the foregoing actions against Sandoz and Alvogen took place in October 2020. In May 2021, JBI, Pharmacyclics and Sandoz entered into a confidential settlement agreement. In August 2021, the District Court issued a decision in favor of Pharmacyclics and Janssen finding the asserted claims against Alvogen to be infringed and not invalid. Alvogen has appealed that decision.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In September 2021, Pharmacyclics and Janssen Inc. (Janssen Canada) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Natco Pharma (Canada) Inc. (Natco) in response to Natco&#x2019;s filing of two ANDSs seeking approval to market generic versions of IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;capsules before the expiration of Canadian Patent Nos. 2,663,116; 2,928,721; 2,800,913; 3,007,787; 3,007,788, 2,875,986; and 3,022,256. The trial is scheduled to begin in July 2023. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Pharmacyclics and Janssen are seeking an order enjoining Natco from marketing its generic versions of IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;UPTRAVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In April 2020, Actelion Pharmaceuticals Ltd (Actelion) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Zydus Pharmaceuticals (USA), &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Inc. and Zydus Worldwide DMCC (collectively, Zydus),  who filed an ANDA seeking approval to market a generic version of UPTRAVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;before expiration of Nippon Shinyaku&#x2019;s United States Patent Nos. 7,205,302 (&#x2019;302); 8,791,122 (&#x2019;122); and 9,284,280 (&#x2019;280) relating to UPTRAVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. In January 2021, the court entered a joint stipulation dismissing the claims against Zydus related to the &#x2019;122 and &#x2019;280 patents.  Actelion is the exclusive licensee of the &#x2019;302 patent. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Actelion and Nippon Shinyaku are seeking an order enjoining Zydus from marketing a generic version of UPTRAVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;before the expiration of the &#x2019;302 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;GOVERNMENT PROCEEDINGS&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Like other companies in the pharmaceutical, consumer health and medical devices industries, Johnson &amp;amp; Johnson and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Average Wholesale Price (AWP) Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson and several of its pharmaceutical subsidiaries (the J&amp;amp;J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&amp;amp;J AWP Defendants were ultimately dismissed. The J&amp;amp;J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. The case brought by Illinois was settled after trial. In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), Johnson &amp;amp; Johnson and ALZA Corporation. All other cases have been resolved.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Opioid Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Beginning in 2014 and continuing to the present, Johnson &amp;amp; Johnson and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in approximately 3,300 lawsuits related to the marketing of opioids, including DURAGESIC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, NUCYNTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; and NUCYNTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; ER. The suits also raise allegations related to previously owned active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children suffering from Neonatal Abstinence Syndrome; hospitals; and health insurers/payors. To date, complaints against pharmaceutical manufacturers, including Johnson &amp;amp; Johnson and JPI, have been filed by the state Attorneys General in Arkansas, Florida, Idaho, Illinois, Kentucky, Louisiana, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, South Dakota, Texas, Washington and West Virginia. Complaints against the manufacturers also have been filed in state or federal court by city, county and local government agencies in the following states: Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, West Virginia and Wisconsin. The Government of Puerto Rico filed suit in Superior Court of San Juan. There are approximately 390 cases pending in various state&#160;courts. There are over 2,900 federal cases coordinated in a federal Multi-District Litigation (MDL) pending in the U.S. District Court for the Northern District of Ohio.&#160;In addition, the Province of British Columbia filed suit against Johnson &amp;amp; Johnson and its Canadian affiliate Janssen Inc., and many other industry members, in Canada, and is seeking to have that action certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada. Additional proposed class actions have been filed in Canada against Johnson &amp;amp; Johnson and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. In October 2019, an anti-trust complaint was filed by private plaintiffs in federal court in Tennessee and is pending transfer to the MDL. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions.&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The trial in the matter filed by the Oklahoma Attorney General resulted in a judgment against Johnson &amp;amp; Johnson and JPI in the amount of $465&#160;million. Johnson &amp;amp; Johnson and JPI have appealed the judgment. The Company believes that it has strong grounds to overturn this judgment. In October 2019 Johnson &amp;amp; Johnson and JPI announced a settlement of the first case set for trial in the MDL with two counties in Ohio. In April 2021, three California counties and the City of Oakland commenced a trial in California state court against Johnson &amp;amp; Johnson and JPI, and other affiliates, as well as three other pharmaceutical manufacturers. The trial concluded in October 2021 and the parties are awaiting a ruling.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2019, Johnson &amp;amp; Johnson received a grand jury subpoena from the United States Attorney&#x2019;s Office for the Eastern District of New York for documents related to the Company&#x2019;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#x2019; and distributors&#x2019; monitoring programs and reporting under the Controlled Substances Act. In September 2019, Johnson &amp;amp; Johnson received subpoenas from the New York State Department of Financial Services (NYDFS) as part of an industry-wide inquiry into the effect of opioid prescriptions on New York health insurance premiums.&#160;In September 2020, the Company learned that NYDFS filed a statement of charges related to this investigation. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2021, the Company and JPI announced a settlement agreement with the State of New York and its participating subdivisions, including Nassau County and Suffolk County, resolving their opioid-related claims against the Company on terms consistent with the Company&#x2019;s previously announced agreement in principle to contribute up to $5&#160;billion to all-in settlement of opioid-related claims by states, cities, counties, and tribal governments. The settlement provides New York and its participating subdivisions with up to $263&#160;million to address opioid-related issues, reimburses attorney fees and costs, and removes the Company and Janssen from a multi-defendant trial of opioid-related claims that commenced in Suffolk County in June 2021. In exchange, the Company and JPI receive releases from the claims asserted by New York and the participating parties, including   NYDFS.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2021, the Company and JPI announced a settlement agreement with the State of Texas and its participating subdivisions, including Dallas County, Bexar County, and Tarrant County, resolving their opioid-related claims against the Company on terms consistent with the Company&#x2019;s previously announced agreement to contribute up to $5&#160;billion to all-in settlement of opioid-related claims by states, cities, counties, and tribal governments. The settlement provides Texas and its participating subdivisions with up to $297&#160;million to address opioid-related issues and reimburse attorney fees and costs, and removes the Company and Janssen from multi-defendant bellwether trials of opioid-related claims scheduled to commence in Texas state courts in early 2022. In exchange, the Company and JPI will receive releases from the claims asserted by Texas and the participating subdivisions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Johnson &amp;amp; Johnson, JPI and other pharmaceutical companies have also received subpoenas or requests for information related to opioids marketing practices from the following state Attorneys General: Alaska, Indiana, Montana, New Hampshire, South Carolina, Tennessee, Texas and Washington. In September 2017, Johnson &amp;amp; Johnson and JPI were contacted by the Texas and Colorado Attorney General&#x2019;s Offices on behalf of approximately 38 states regarding a multi-state Attorney General investigation. In October 2019, the Company announced a proposed agreement in principle that would include the Company paying $4&#160;billion as settlement of these matters. In October 2020, the Company agreed to contribute up to an additional $1&#160;billion to an all-in settlement amount that would resolve opioid lawsuits filed and future claims by states, cities, counties and tribal governments, for a total of $5&#160;billion which has been accrued, subject to various conditions and an agreement being finalized. This agreement in principle is not an admission of liability or wrong-doing. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims have been finalized and up to 25% of the all-in settlement is expected to be paid within the next 12 months, depending upon the level of participation by the states and their subdivisions. The terms provide a period of time for states to elect to participate in the agreement and, thereafter, a period for the subdivisions of the participating states to opt-in. The opt-in period expires in January 2022.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company retains the right to opt-out of the agreement if, in its sole discretion, there is insufficient participation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From June 2017 through December 2019, the Company&#x2019;s Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and i&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;n April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Board unanimously adopted the recommendations of the independent counsel&#x2019;s report.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2019, one of the shareholders who sent a demand filed a derivative complaint against Johnson &amp;amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that Johnson &amp;amp; Johnson has suffered damages as a result of those alleged breaches. In May 2020, the shareholder filed an amended complaint challenging the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Board&#x2019;s rejection of his demand. In August 2020, Johnson &amp;amp; Johnson moved to dismiss the amended complaint. In February 2021, the Court held oral argument on Johnson &amp;amp; Johnson's motion. In August 2020, another shareholder who sent a demand filed a separate derivative complaint in the same court making similar allegations. In October 2020, the Court granted defendants&#x2019; request to reassign the second-filed case to the division where the first-filed case is pending. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In December 2019, two additional shareholders who sent demands filed two separate derivative complaints making similar allegations against Johnson &amp;amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the United States District for the District of New Jersey. In April 2020, the two federal cases were consolidated into a single action captioned&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt; In re Johnson &amp;amp; Johnson Opioid Stockholder Derivative Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. In July 2020, the shareholders filed a consolidated complaint. In September 2020, Johnson &amp;amp; Johnson moved to dismiss the consolidated complaint, and in December 2020, the shareholders opposed Johnson &amp;amp; Johnson&#x2019;s motion. Johnson &amp;amp; Johnson filed its reply in February 2021. In July 2020, an additional shareholder who sent a demand filed a derivative complaint in the same federal court making similar allegations against the same defendants named in the consolidated action. In January 2021, pursuant to an order in the consolidated action, the third case was consolidated into the consolidated action. In February 2021, the Court granted the shareholders motion to voluntarily dismiss the consolidated action without prejudice, and the shareholders&#x2019; counsel then filed a notice of association in the first-filed derivative action pending in the Superior Court of New Jersey. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson &amp;amp; Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney's Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ASR&#x2122; XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; case filed pursuant to the False Claims Act against the companies concerning the hip devices. In February 2016, the District Court granted the companies&#x2019; motion to dismiss with prejudice, unsealed the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; complaint, and denied the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; relators&#x2019; request for leave to file a further amended complaint. The &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the District Court&#x2019;s dismissal in part, reversed in part, and affirmed the decision to deny the relators&#x2019; request to file a third amended complaint. The relators&#x2019; remaining claims are now pending before the District Court, and the District Court has not yet closed the fact discovery time period. In March 2021, DePuy filed its motion to strike and dismiss the relators&#x2019; second amended complaint; the District Court denied DePuy&#x2019;s motion to strike and dismiss on July 6, 2021.  DePuy filed a motion for reconsideration of the District Court&#x2019;s July 6, 2021 ruling.  On August 18, 2021, the District Court stated that it was reviewing DePuy&#x2019;s motion for reconsideration, and on September 16, 2021, in connection with the District Court&#x2019;s review of the motion for reconsideration, the District Court ordered the parties to file additional submissions by September 30, 2021, which are now under review by the District Court.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2012, Johnson &amp;amp; Johnson was contacted by the California Attorney General's office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by Johnson &amp;amp; Johnson's subsidiary, Ethicon, Inc. (Ethicon). In May 2016, California and Washington filed civil complaints against Johnson &amp;amp; Johnson, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states:  Kentucky, Mississippi, West Virginia and Oregon. In April 2019, Johnson &amp;amp; Johnson and Ethicon settled the Washington case. The California case started trial in July 2019 and concluded in September 2019. The trial date for the Kentucky case was scheduled for September 2019 but has been adjourned and no new trial date has been scheduled. In October 2019, Johnson &amp;amp; Johnson and Ethicon settled the multi-state investigation with 41 other states and the District of Columbia. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $344&#160;million. In April 2020, the Court in California denied the Company's motion for a new trial. In August 2020, the Court entered judgment with respect to the penalties of $344&#160;million, but denied the Attorney General&#x2019;s request for injunctive relief. The Company is appealing the penalty judgment. In April 2020, the Company settled the West Virginia case. In October 2020, the Company settled with the Attorney General of Oregon.  In November 2020, the Company settled with the Attorney General of Mississippi. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against Johnson &amp;amp; Johnson and Johnson &amp;amp; Johnson Consumer Companies, Inc. (now known as Johnson &amp;amp; Johnson Consumer Inc.) (JJCI).&#160;The complaint alleges that defendants violated the Mississippi Consumer Protection Act by &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;failing to disclose alleged health risks associated with female consumers' use of talc contained in JOHNSON'S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Baby Powder and JOHNSON'S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. The Mississippi Supreme Court granted Johnson &amp;amp; Johnson and JJCI's request to file an interlocutory appeal of the denial of the motion for summary judgment in late 2019. Johnson &amp;amp; Johnson and JJCI moved for summary judgment on the grounds that the State's claim was barred by preemption. In April 2021, the Mississippi Supreme Court dismissed the Company&#x2019;s interlocutory appeal and remanded the case back to the Hinds County Chancery Court. Discovery is now proceeding in that court. In August 2021, Johnson &amp;amp; Johnson and JJCI filed a Petition for Writ of Certiorari in the US Supreme Court. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The State of New Mexico filed an Amended Complaint in March 2020. The Company moved to dismiss certain of the claims in the Amended Complaint, which was granted. The Company then filed a motion for partial judgment on the pleadings in December 2020, which was denied. The Company made its first document production in February 2021 and discovery is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Forty-two states have commenced a joint investigation into the Company&#x2019;s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington. The Company has entered into a tolling agreement with thirty-three States, which is set to expire in November 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2016, Janssen Pharmaceuticals, Inc. (JPI) received a Civil Investigative Demand from the United States Attorney&#x2019;s Office for the Southern District of New York related to JPI&#x2019;s contractual relationships with pharmacy benefit managers over the period from January 1, 2006 to the present with regard to certain of JPI's pharmaceutical products. The demand was issued in connection with an investigation under the False Claims Act. The Company has provided documents in response to the demand. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2016, Johnson &amp;amp; Johnson and Janssen Products LP were served with a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; and INTELENCE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, and anti-kickback violations in connection with the promotion of these products.&#160;The complaint was filed under seal in December 2012.&#160;The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators.&#160;Summary judgment and Daubert motions are currently pending with the Court. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or SIMPONI ARIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April and September 2017, Johnson &amp;amp; Johnson received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, OLYSIO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, STELARA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;and ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;.&#160;The subpoenas also seek documents relating to&#160;Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies. The Company has provided documents in response to the subpoenas. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2017, Johnson &amp;amp; Johnson received a subpoena from the United States Attorney's Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc.(DePuy) spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these hospitals. Johnson &amp;amp; Johnson and DePuy have produced documents in response to the subpoena and are fully cooperating with the government&#x2019;s investigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2018 the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp;amp; Johnson do Brasil Ind&#xfa;stria e Com&#xe9;rcio de Produtos para Sa&#xfa;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson &amp;amp; Johnson to cooperate with these inquiries by producing the requested information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;GENERAL LITIGATION&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In March 2018, a purported class action was filed in the Circuit Court Third Judicial District Madison County, Illinois against Johnson &amp;amp; Johnson Consumer, Inc. (JJCI), alleging violations of state consumer fraud statutes based on nondisclosure of &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;alleged health risks associated with talc contained in JOHNSON'S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Baby Powder. The complaint seeks damages but does not allege personal injury. In August 2021, the Court granted JJCI&#x2019;s motion to dismiss the complaint.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March and April 2015, over 30 putative class action complaints were filed by contact lens patients in a number of courts around the United States against Johnson &amp;amp; Johnson Vision Care, Inc. (JJVCI) and other contact lens manufacturers, distributors, and retailers, alleging vertical and horizontal conspiracies to fix the retail prices of contact lenses. The complaints allege that the manufacturers reached agreements with each other and certain distributors and retailers concerning the prices at which some contact lenses could be sold to consumers. The plaintiffs are seeking damages and injunctive relief. All of the class action cases were transferred to the United States District Court for the Middle District of Florida in June 2015. The plaintiffs filed a consolidated class action complaint in November 2015. Discovery and pre-trial motion practice are complete. Trial is scheduled to begin in March 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in September 2017, multiple purported class actions were filed on behalf of indirect purchasers of REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; against Johnson &amp;amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) alleging that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The cases were consolidated for pre-trial purposes as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; In re REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Antitrust Litigation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in United States District Court for the Eastern District of Pennsylvania. The consolidated complaint seeks damages and injunctive relief.  Discovery is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, Walgreen Co. and Kroger Co., filed an antitrust complaint against Johnson &amp;amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in the United States District Court for the Eastern District of Pennsylvania.  The complaint alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  The complaint seeks damages and injunctive relief. In March 2019, summary judgment was granted in favor of Janssen. In February 2020, the United States Court of Appeals for the Third Circuit reversed the District Court&#x2019;s decision. Discovery is ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to Johnson &amp;amp; Johnson in connection with its investigation of whether Janssen&#x2019;s REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp;amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act.  The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2021, plaintiffs appealed the District Court&#x2019;s decision to the United States Court of Appeals for the District of Columbia Circuit.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia.&#160;The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;.&#160; TRACLEER&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; is subject to a Risk Evaluation and Mitigation Strategy required by the Food and Drug Administration, which imposes restrictions on distribution of the product.&#160; In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland.&#160; In October 2019, the Court granted Actelion&#x2019;s motion to dismiss the amended complaint. In April 2021, the United States Court of Appeals for the Fourth Circuit reversed and remanded. Discovery is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research &amp;amp; Development, LLC, and Johnson &amp;amp; Johnson (collectively, Janssen) were served with a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; complaint filed on behalf of the United States, 28 states, and the District of Columbia.&#160;The complaint, which was filed in December 2017 in United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; to the government in connection with direct government sales and government-funded drug reimbursement programs.&#160;At this time, the federal and state governments have declined to intervene. The case has been transferred to United States District Court for the District of New Jersey. In September 2019, Janssen moved to dismiss the complaint. In February 2021, the judge has set a renewed schedule for the Company's motion to dismiss, with briefs to be fully submitted by early July 2021. In April 2021, Janssen renewed its motion to dismiss pursuant to Court order.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In April 2019, Blue Cross &amp;amp; Blue Shield of Louisiana and HMO Louisiana, Inc. filed a class action complaint against Janssen Biotech, Inc, Janssen Oncology, Inc, Janssen Research &amp;amp; Development, LLC (collectively, Janssen) and BTG International Limited in the United States District Court for the Eastern District of Virginia on behalf of indirect purchasers of ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. Several additional complaints were filed thereafter in Virginia and New Jersey. The indirect purchaser complaints generally allege that the defendants violated the antitrust and consumer protections laws of several states and the Sherman Act by &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;pursuing patent litigation relating to ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; in order to delay generic entry and seek damages. The Virginia cases have been transferred to the United States District Court for the District of New Jersey and consolidated with the New Jersey case. A consolidated amended complaint was filed in February 2021. In April 2021, Janssen moved to dismiss the Indirect Purchaser Action. Discovery in the Indirect Purchaser Action is ongoing. In May 2020, a class action complaint was filed against Janssen Biotech Inc., Janssen Oncology, Inc., Janssen Research &amp;amp; Development LLC and BTG International Limited in the United States District Court for the District of New Jersey, on behalf of direct purchasers of ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. The direct purchaser complaint alleges that defendants violated the Sherman Act by pursuing patent litigation relating to ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; in order to delay generic entry, and seek damages and injunctive relief. In April 2021, Janssen moved to compel arbitration of the Direct Purchaser Action. In October 2021, the Court granted Janssen&#x2019;s motion and compelled arbitration of the Direct Purchaser Action.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2019, a class action antitrust complaint was filed against Janssen R&amp;amp;D Ireland (Janssen) and Johnson &amp;amp; Johnson in the United States District Court for the Northern District of California. The complaint alleges that Janssen violated federal and state antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the development and marketing of combination antiretroviral therapies (cART) to treat HIV. The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers Squibb and Japan Tobacco. In March 2020, the Court granted in part and denied in part defendants&#x2019; motions to dismiss.  Plaintiffs filed an amended complaint in April 2020. Defendants moved to dismiss the amended complaint.  In July 2020, the Court granted in part and denied in part the renewed motion to dismiss. Discovery is ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California. The complaint alleges that certain of BWI&#x2019;s&#160;business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In January 2020, BWI filed a motion to dismiss the complaint. In August 2020, the Court granted in part and denied in part BWI&#x2019;s motion to dismiss. Discovery is ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, Johnson &amp;amp; Johnson received a demand for indemnification from Pfizer Inc., pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson &amp;amp; Johnson, Inc. received a demand for indemnification from Sanofi Consumer Health, Inc., pursuant to the 2016 Asset Purchase Agreement between J&amp;amp;J, Inc. and Sanofi. In January 2020, Johnson &amp;amp; Johnson received a demand for indemnification from Boehringer Ingelheim Pharmaceuticals, Inc., pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim.  The notices seek indemnification for legal claims related to over-the-counter ZANTAC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ranitidine) products. Plaintiffs in the underlying actions allege that ZANTAC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against Johnson &amp;amp; Johnson, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#x2019;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2020, Ethicon moved to dismiss certain causes of action in the complaint. Discovery is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Beginning in May 2021, multiple &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;putative &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;class actions were filed in state and federal courts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(California, Florida, New York, and New Jersey)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; against various Johnson &amp;amp; Johnson entities alleging violations of state consumer fraud statutes based on nondisclosure of alleged benzene contamination of certain Neutrogena and Aveeno sunscreen products &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;and the affirmative promotion of those products as &#x201c;safe&#x201d;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;; and, in at least one case, alleging a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;strict liability manufacturing defect and failure to warn &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;claims, asserting that the named plaintiffs&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; suffered unspecified injuries as a result of alleged exposure to benzene.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; The Judicial Panel on Multi-District Litigation has consolidated all pending actions, except one product liability matter, in the United States District Court-Southern District of Florida-Fort Lauderdale Division. In October 2021, the Company reached an agreement in principle for the settlement of a nationwide class, encompassing the claims of the consolidated actions, subject to approval by the Florida federal Court.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson or its subsidiaries are also parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="idd91294a39994bf7a5d46ad21d5ce73f_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNDYxNA_a9179e42-ff5e-493b-ae8c-beabb8491a67"
      unitRef="claimant">300</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i1e112538e52040febbef4f9ec3d08be6_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNDc3OA_492ac407-fe45-4409-a8f0-8de3ec42f368"
      unitRef="claimant">5400</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i38e0af4dfc454327a9035d9ecf2f71de_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNDgzNA_1846fc7e-8e26-4105-834b-c332189743f3"
      unitRef="claimant">10700</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="ib6fd89964b9b478c98b0b7b32284ace4_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNDg2OA_8f760924-3ae6-4687-8c50-c50911ba5012"
      unitRef="claimant">9000</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="idd11e0e4967746c686c30187b7771685_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNDg5OQ_3f72cee1-e469-4c99-b3ad-d9883ea5c73e"
      unitRef="claimant">6600</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i3b95b40b62fa4991958c542357558bc5_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNDkyOA_43196601-aaa2-4299-8276-ece3e448f123"
      unitRef="claimant">38200</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i9f2f6f0d91a04e85af9ca78c9af911bc_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNDk3Nw_e7768e34-bf63-4a0d-99e9-043461e160f3"
      unitRef="claimant">100</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i5f85d89b6d8146aaa779ff9a82bd22b8_I20211003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNTAxMg_f16ac735-b7ec-4b5f-b903-eeb9221927b6"
      unitRef="claimant">4700</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:Numberofpatientsinsettlement
      contextRef="ieb622359a78248788392bf4fc7788239_I20211003"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNjQwMg_6cb3d2e7-ec66-43e6-9cd8-e8cd841b3fd7"
      unitRef="patient">10000</jnj:Numberofpatientsinsettlement>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i432d9a09731c43af8b981697f2d30a00_I20210531"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTIwOTA_14aa2093-c484-420e-83a3-8477bc93f524"
      unitRef="claimant">3600</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="ia06bd5801ebb4de3847b03a9ebbf31df_D20191001-20191031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTQ1NTU_3a3a237f-f2d0-457c-83a1-bec5879e115b"
      unitRef="usd">8000000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i888336974542449dbfef3a3a1d8c4d58_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTQ2Mzc_f464269e-1751-4acd-bfb1-8fbce9db7d9e"
      unitRef="usd">6800000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i0511c88e69e54af3b80ae9e01a00203b_D20180701-20180731"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTA5OTUxMTY0NzY2MjM_fbeab3b0-f975-45a9-89b5-945361c27190"
      unitRef="usd">4700000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i93cea90b33244c4f8bd342dd3f008b23_D20200601-20200628"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTA5OTUxMTY0NzY2Mzc_b6c1e9a2-db3e-4dc6-8cff-bfcdef085be6"
      unitRef="usd">2100000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="ib2961f0a11b248a9b0915353245c62bb_D20210601-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTA5OTUxMTY0NzY2NTE_2b77f713-aa67-459a-92f0-0bb2c84b05ce"
      unitRef="usd">2500000000</us-gaap:PaymentsForLegalSettlements>
    <jnj:LossContingencyReserveEstablishedWithinTrust
      contextRef="ief20b90c9cc3400e9758007a2c93489a_D20211001-20211031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTA5OTUxMTY0NzY2NjU_740b0225-2896-4734-906b-47b6b3119083"
      unitRef="usd">2000000000</jnj:LossContingencyReserveEstablishedWithinTrust>
    <jnj:LossContingencyReserveEstablishedWithinTrust
      contextRef="ief20b90c9cc3400e9758007a2c93489a_D20211001-20211031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTA5OTUxMTY0NzY2Nzc_3f2d81ce-e4cb-45ab-9e00-6f935b4ae0e9"
      unitRef="usd">2000000000</jnj:LossContingencyReserveEstablishedWithinTrust>
    <us-gaap:LitigationSettlementExpense
      contextRef="ief20b90c9cc3400e9758007a2c93489a_D20211001-20211031"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTA5OTUxMTY0NzY2ODk_44cb1d23-77fd-42db-b886-a5f4d3b857ed"
      unitRef="usd">1400000000</us-gaap:LitigationSettlementExpense>
    <jnj:LossContingencyNumberOfVotesInFavor
      contextRef="ief20b90c9cc3400e9758007a2c93489a_D20211001-20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTA5OTUxMTY0NzY3MDM_a15ae4e6-fc38-4d22-a08a-bff0d973c639"
      unitRef="vote">16000</jnj:LossContingencyNumberOfVotesInFavor>
    <jnj:LossContingencyNumberOfVotesRejected
      contextRef="ief20b90c9cc3400e9758007a2c93489a_D20211001-20211031"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTA5OTUxMTY0NzY3MTE_1f98014b-0fe3-4790-9f8d-37a60b8cf8a7"
      unitRef="vote">1500</jnj:LossContingencyNumberOfVotesRejected>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i43837e43114841208382ec8e806920e4_I20211003"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNTc3MDQ_e48de382-174f-4dbe-b55e-6476b82488c9"
      unitRef="claimant">3300</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="if23041d120f4417a80290be9a7d86354_I20211003"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTA5OTUxMTY0NzY3MTg_51b4d854-2370-4afe-adc2-785ffc28400b"
      unitRef="claimant">390</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="ic8c468efba6f4c8eb730082ee4eedf85_I20211003"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTA5OTUxMTY0NzY3MjM_cc2cafee-c06c-49fc-83a5-dcd272c9178f"
      unitRef="claimant">2900</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="ib5c767d6b7254013824d1430cea6166d_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNjA1MTk_ac16ca4e-dec6-4764-8656-ce8d5a5783e5"
      unitRef="usd">465000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="ib02d3415bfe94365991511ce5fb09ebf_D20210601-20210630"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNjIxOTE_37d639e9-d741-44e8-adf2-a17eaeba3bab"
      unitRef="usd">5000000000</us-gaap:LossContingencyDamagesAwardedValue>
    <jnj:LossContingencyDamagesAwardedAdditionalReimbursementValue
      contextRef="ib02d3415bfe94365991511ce5fb09ebf_D20210601-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNjIzNzI_2f8a6f44-bb3a-42df-8278-c0092cdbaa29"
      unitRef="usd">263000000</jnj:LossContingencyDamagesAwardedAdditionalReimbursementValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i27171efe2b3941548d265f05e276162e_D20211001-20211031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTA5OTUxMTY0NzY3MzA_fbf70238-93e7-472c-95cc-9a429b45c0d4"
      unitRef="usd">5000000000</us-gaap:LossContingencyDamagesAwardedValue>
    <jnj:LossContingencyDamagesAwardedAdditionalReimbursementValue
      contextRef="i27171efe2b3941548d265f05e276162e_D20211001-20211031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMTA5OTUxMTY0NzY3NDI_11441c9a-2d65-4f60-8f02-1156d1bf69e7"
      unitRef="usd">297000000</jnj:LossContingencyDamagesAwardedAdditionalReimbursementValue>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i653b6f4b1cbf484b8781c02b3402e666_I20191031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNjMzMjU_c0594418-1c2f-4f58-afff-03fcce12786b"
      unitRef="usd">4000000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <jnj:LossContingencyEstimateOfAdditionalPossibleLoss
      contextRef="i945c4e1bacda4ec68c3b7c94557f3765_I20201031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNjM0MzA_e7060f67-2ce5-4c83-8437-ae69d945d753"
      unitRef="usd">1000000000</jnj:LossContingencyEstimateOfAdditionalPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i945c4e1bacda4ec68c3b7c94557f3765_I20201031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNjM1OTA_cc0a2b42-beda-4f49-b2cd-c3462428b18b"
      unitRef="usd">5000000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i5fc8a90a726a4462b931044e9118c5df_D20200120-20200120"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNzA1Njc_cb339ae6-46ed-4b07-b5dd-2140a8063fc8"
      unitRef="usd">344000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i5fc8a90a726a4462b931044e9118c5df_D20200120-20200120"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfNzA3MzE_0f1a7436-657a-4076-a550-f0683b7d639b"
      unitRef="usd">344000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i57db9f0a21bd4a538b012b2e386a50fa_I20150430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV84OC9mcmFnOjQ1ZTk2NmI0ZTQxZDQ0YTRhYTY2YjIzMjg3YmNlZDcyL3RleHRyZWdpb246NDVlOTY2YjRlNDFkNDRhNGFhNjZiMjMyODdiY2VkNzJfMjE5OTAyMzQ1NDU0OA_7ee1c3d4-7082-4a64-a419-57984ee47511"
      unitRef="claim">30</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfMjU2Ng_b6bc33a3-bdba-4079-8fb6-f1ca1f39025d">RESTRUCTURING&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fiscal second quarter of 2018 the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions will include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. In the fiscal third quarter of 2021, the Company recorded a pre-tax charge of $121 million, which is included on the following lines of the Consolidated Statement of Earnings, $60 million in restructuring, $18 million in cost of products sold and $43 million in other (income) expense, net. In the fiscal nine months of 2021, the Company recorded a pre-tax charge of $333&#160;million, which is included on the following lines of the Consolidated Statement of Earnings, $169&#160;million in restructuring, $65&#160;million in cost of products sold and $99&#160;million in other (income) expense, net. Total project costs of approximately $1.6 billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In total, the Company expects the Global Supply Chain actions to generate approximately $0.6 billion to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by 2022. The Company expects to record pre-tax restructuring charges of approximately $1.9 billion to $2.3 billion, over the 4 to 5 year period of this activity. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization.&#160; &#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal third quarter of 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Write-offs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year activity:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Charges  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(287)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Settled non cash &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, October 3, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash outlays for severance are expected to be substantially paid out over the next 18 months in accordance with the Company's plans and local laws. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="i5c79c8166fea4d28acc6e2a5c55371e3_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfNjYw_b2d03409-ebf8-482b-ae2f-5564aaa9091f"
      unitRef="usd">121000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i41e6c3af78c84e7a96704669c8534fbd_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfNzQ4_67f3b9e9-1baa-4298-9e2f-724574993bf1"
      unitRef="usd">60000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i0bf46255c4954869ba02f4fcf0890318_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfNzY5_6e11038c-bb7a-44e3-8e2e-08c0e7992ca9"
      unitRef="usd">18000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="id03bd483db33402eafee3a37392a50dd_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfODAx_9880bf7e-1d77-488e-88fe-48a44a36cafb"
      unitRef="usd">43000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i395c16cff1fd472887230111aec654c7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfODk2_7c73f290-a2a6-43e5-870f-991693d989fe"
      unitRef="usd">333000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i8b2139d6e4794867beaf8b64054355a3_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfOTg0_cc3cbde9-6742-4638-bc36-8b7c6f56e0a1"
      unitRef="usd">169000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i9335dfec33444d1fa82036d4e0556288_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfMTAwNQ_7d7e4c21-b0d1-427e-af64-dbf4c73285cc"
      unitRef="usd">65000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="iddfd422a68bd4c3fb53443eddc899e5d_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfMTAzNw_791b70ff-88a7-42e8-83d2-4d0176456d8c"
      unitRef="usd">99000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i1a40709bfe644a94ba4984bd52754e41_I20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfMTExMA_0eeafee8-efac-4e3f-a410-9f7249607459"
      unitRef="usd">1600000000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <jnj:RestructuringandRelatedCostExpectedFutureSavings
      contextRef="i30de6283641a414eb591a7e379e8ca06_I20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfMTMzOA_8b7d8b2b-d848-460f-ad93-1516b61a9159"
      unitRef="usd">600000000</jnj:RestructuringandRelatedCostExpectedFutureSavings>
    <jnj:RestructuringandRelatedCostExpectedFutureSavings
      contextRef="if65f698d763e4aa69ebb37089739db4d_I20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfMTM0NA_723c0036-6747-4381-8bdc-35bb5bdb01c5"
      unitRef="usd">800000000</jnj:RestructuringandRelatedCostExpectedFutureSavings>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i30de6283641a414eb591a7e379e8ca06_I20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfMTUwMQ_4e9c11ca-5e77-4da0-b1a6-34023de22ca9"
      unitRef="usd">1900000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="if65f698d763e4aa69ebb37089739db4d_I20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfMTUwNw_fb4cf7cb-73ed-4db6-b201-e4aed46fe7f2"
      unitRef="usd">2300000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <jnj:RestructuringandRelatedCostDurationofRestructuringPlan
      contextRef="i155df99154524c01b1d1bc1cda9bd334_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfMTUyMA_b799468b-b982-4eaf-8ff7-11290b29df4e">P4Y</jnj:RestructuringandRelatedCostDurationofRestructuringPlan>
    <jnj:RestructuringandRelatedCostDurationofRestructuringPlan
      contextRef="ia7b66f9b903d4029a697b4d5bbd09f00_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfMTUyNg_eda58e3e-0a3d-4e6b-888e-89c57fd1e9b7">P5Y</jnj:RestructuringandRelatedCostDurationofRestructuringPlan>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfMjU2NQ_60a367c0-6255-4fdc-b011-fa6ed92af8ff">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal third quarter of 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Write-offs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year activity:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Charges  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(287)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Settled non cash &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, October 3, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash outlays for severance are expected to be substantially paid out over the next 18 months in accordance with the Company's plans and local laws. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i86e59d6adba6473da76a65735fc95b35_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfMS0xLTEtMS0w_fe06398c-5786-4123-b82e-c7c85081121e"
      unitRef="usd">135000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i6f1238f4cde44b00a401b4e14983e6af_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfMS0yLTEtMS0w_4eee205d-2aba-4673-af76-6dcdd7c501c1"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i0c74256bce09412bb1c7eb851708c6bb_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfMS0zLTEtMS0w_f905c8a8-b5fd-4476-b9ec-083c9c251ef7"
      unitRef="usd">9000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i68831153f9a14ae1b239033a0c1a9104_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfMS01LTEtMS0w_2b99304e-195f-461c-9a0b-62ff2694187a"
      unitRef="usd">144000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i965b447464ee4a389bab1a83195f092c_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfNC0xLTEtMS0w_3ec4194f-5c61-4814-a8bd-fbc076d910aa"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="if6d484844090412aa63423ed27e77165_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfNC0yLTEtMS0w_2555bb05-af60-412a-8d1e-f4053baa2517"
      unitRef="usd">38000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ie7a5f799f220481ba0964cbf04e6d485_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfNC0zLTEtMS0w_0b66dfe3-626e-46ec-8908-09ea383d47bc"
      unitRef="usd">295000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i69a08f7d7ee644f69fa747b7bb19e88c_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfNC01LTEtMS0w_d6d7883a-2ea4-4866-9c67-24190610dabe"
      unitRef="usd">333000000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="i965b447464ee4a389bab1a83195f092c_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfNS0xLTEtMS0w_1bd4f87e-f3ee-4924-9df8-2a62185fe322"
      unitRef="usd">17000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="if6d484844090412aa63423ed27e77165_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfNS0yLTEtMS0w_5af0a468-bdb5-44d7-a033-8d886f5bf1dd"
      unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="ie7a5f799f220481ba0964cbf04e6d485_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfNS0zLTEtMS0w_6aee315a-f92c-403f-9c1f-e18302989057"
      unitRef="usd">270000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i69a08f7d7ee644f69fa747b7bb19e88c_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfNS01LTEtMS0w_a5c9b44e-afcc-4ced-bcad-968e0f1d060b"
      unitRef="usd">287000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i965b447464ee4a389bab1a83195f092c_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfNi0xLTEtMS0w_97f22e06-7f98-4394-860d-7169afdb6560"
      unitRef="usd">0</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="if6d484844090412aa63423ed27e77165_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfNi0yLTEtMS0w_467dddf1-ecd3-48a3-857e-9c4d681ab6b2"
      unitRef="usd">38000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="ie7a5f799f220481ba0964cbf04e6d485_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfNi0zLTEtMS0w_624e8637-8ae2-48b3-80c9-b3d932c3c56c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i69a08f7d7ee644f69fa747b7bb19e88c_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfNi01LTEtMS0w_029a3c0a-adcf-48c9-884e-421c52c2aaba"
      unitRef="usd">38000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserve
      contextRef="ib6911c9fe2fc4680883030bd35fb4405_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfOS0xLTEtMS0w_b5d27858-1084-4e9a-b947-d2ff8aaa9149"
      unitRef="usd">118000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="iecd272aa6bf84db3985f9de3d1a4af33_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfOS0yLTEtMS0w_6fa63665-8326-4ddc-a2bb-327d87171568"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i5b5a49c0f5b94001a4430dceb7eab418_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfOS0zLTEtMS0w_058d7752-086f-4d65-bec9-0cb46d4bca73"
      unitRef="usd">34000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ib7cacd129fca46088c70b938e656f2d7_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RhYmxlOjQ3N2YwNzFlZWQ2MjRkNDVhNTEwNTRkYTE1MGJjZmI2L3RhYmxlcmFuZ2U6NDc3ZjA3MWVlZDYyNGQ0NWE1MTA1NGRhMTUwYmNmYjZfOS01LTEtMS0w_6395c3ca-4b01-4bec-9259-bf4fedb9fa1c"
      unitRef="usd">152000000</us-gaap:RestructuringReserve>
    <jnj:RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid
      contextRef="i69a08f7d7ee644f69fa747b7bb19e88c_D20210104-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOmY0MTBlZTZlMDNjODQ1NmY4NmE5ZmVlOTk3ZjA4ZTY1L3NlYzpmNDEwZWU2ZTAzYzg0NTZmODZhOWZlZTk5N2YwOGU2NV85MS9mcmFnOmZhMjk2NjVhZDc1ODQxYmU5YTRlODI4ZjQ3OGUxMzUzL3RleHRyZWdpb246ZmEyOTY2NWFkNzU4NDFiZTlhNGU4MjhmNDc4ZTEzNTNfMTg5Mw_314c90a7-c14c-4393-bbd1-0f44d77e7c97">P18M</jnj:RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139721079512920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 22, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct.  03,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-3215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Johnson & Johnson<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-1024240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Johnson & Johnson Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Brunswick<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">524-0400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,632,596,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000200406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--01-02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, Par Value $1.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A0.250NotesDue2022Member', window );">0.250% Notes Due January 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.250% Notes Due January 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes Due May 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.650% Notes Due May 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ24C<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes Due November 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">5.50% Notes Due November 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ24BP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes Due November 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.150% Notes Due November 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes Due May 2035</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.650% Notes Due May 2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A0.250NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A0.250NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139721079098760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 17,604<span></span>
</td>
<td class="nump">$ 13,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">13,397<span></span>
</td>
<td class="nump">11,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, trade, less allowances for doubtful accounts and credit losses $223 (2020, $293)</a></td>
<td class="nump">14,911<span></span>
</td>
<td class="nump">13,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories (Note 2)</a></td>
<td class="nump">10,387<span></span>
</td>
<td class="nump">9,344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">3,590<span></span>
</td>
<td class="nump">3,132<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">59,889<span></span>
</td>
<td class="nump">51,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment at cost</a></td>
<td class="nump">47,347<span></span>
</td>
<td class="nump">46,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(28,869)<span></span>
</td>
<td class="num">(28,038)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">18,478<span></span>
</td>
<td class="nump">18,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net (Note 3)</a></td>
<td class="nump">47,776<span></span>
</td>
<td class="nump">53,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (Note 3)</a></td>
<td class="nump">35,569<span></span>
</td>
<td class="nump">36,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred taxes on income (Note 5)</a></td>
<td class="nump">10,646<span></span>
</td>
<td class="nump">8,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">6,870<span></span>
</td>
<td class="nump">6,562<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">179,228<span></span>
</td>
<td class="nump">174,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Loans and notes payable</a></td>
<td class="nump">3,798<span></span>
</td>
<td class="nump">2,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,961<span></span>
</td>
<td class="nump">9,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">13,812<span></span>
</td>
<td class="nump">13,968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_AccruedRebatesReturnsAndPromotions', window );">Accrued rebates, returns and promotions</a></td>
<td class="nump">12,683<span></span>
</td>
<td class="nump">11,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee related obligations</a></td>
<td class="nump">3,146<span></span>
</td>
<td class="nump">3,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued taxes on income (Note 5)</a></td>
<td class="nump">2,161<span></span>
</td>
<td class="nump">1,392<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">44,561<span></span>
</td>
<td class="nump">42,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt (Note 4)</a></td>
<td class="nump">30,130<span></span>
</td>
<td class="nump">32,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred taxes on income (Note 5)</a></td>
<td class="nump">7,147<span></span>
</td>
<td class="nump">7,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent', window );">Employee related obligations (Note 6)</a></td>
<td class="nump">10,171<span></span>
</td>
<td class="nump">10,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Long-term taxes payable (Note 5)</a></td>
<td class="nump">5,770<span></span>
</td>
<td class="nump">6,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">11,177<span></span>
</td>
<td class="nump">11,944<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">108,956<span></span>
</td>
<td class="nump">111,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock &#8212; par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)</a></td>
<td class="nump">3,120<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss) (Note 7)</a></td>
<td class="num">(15,415)<span></span>
</td>
<td class="num">(15,242)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">121,092<span></span>
</td>
<td class="nump">113,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Less: common stock held in treasury, at cost (487,358,000 and 487,331,000 shares)</a></td>
<td class="nump">38,525<span></span>
</td>
<td class="nump">38,490<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">70,272<span></span>
</td>
<td class="nump">63,278<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 179,228<span></span>
</td>
<td class="nump">$ 174,894<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_AccruedRebatesReturnsAndPromotions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_AccruedRebatesReturnsAndPromotions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720994212712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowances for doubtful accounts</a></td>
<td class="nump">$ 223<span></span>
</td>
<td class="nump">$ 293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (per share)</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">4,320,000,000<span></span>
</td>
<td class="nump">4,320,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">3,119,843,000<span></span>
</td>
<td class="nump">3,119,843,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares (in shares)</a></td>
<td class="nump">487,358,000<span></span>
</td>
<td class="nump">487,331,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139721082211944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Earnings - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 23,338<span></span>
</td>
<td class="nump">$ 21,082<span></span>
</td>
<td class="nump">$ 68,971<span></span>
</td>
<td class="nump">$ 60,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SalesRevenueGoodsNetPercentToSales', window );">Sales to customers percent to sales</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">$ 7,250<span></span>
</td>
<td class="nump">$ 6,972<span></span>
</td>
<td class="nump">$ 21,900<span></span>
</td>
<td class="nump">$ 20,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_CostOfGoodsSoldPercentToSales', window );">Cost of products sold percent to sales</a></td>
<td class="nump">31.10%<span></span>
</td>
<td class="nump">33.10%<span></span>
</td>
<td class="nump">31.80%<span></span>
</td>
<td class="nump">34.30%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">$ 16,088<span></span>
</td>
<td class="nump">$ 14,110<span></span>
</td>
<td class="nump">$ 47,071<span></span>
</td>
<td class="nump">$ 39,496<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_GrossProfitPercentToSales', window );">Gross Profit Percent To Sales</a></td>
<td class="nump">68.90%<span></span>
</td>
<td class="nump">66.90%<span></span>
</td>
<td class="nump">68.20%<span></span>
</td>
<td class="nump">65.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, marketing and administrative expenses</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 5,431<span></span>
</td>
<td class="nump">$ 17,505<span></span>
</td>
<td class="nump">$ 15,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SellingGeneralAndAdministrativeExpensePercentToSales', window );">Selling marketing and administrative expenses percent to sales</a></td>
<td class="nump">25.70%<span></span>
</td>
<td class="nump">25.80%<span></span>
</td>
<td class="nump">25.40%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">$ 3,422<span></span>
</td>
<td class="nump">$ 2,840<span></span>
</td>
<td class="nump">$ 9,994<span></span>
</td>
<td class="nump">$ 8,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales', window );">Research and development expense percent to sales</a></td>
<td class="nump">14.70%<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
<td class="nump">14.50%<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ResearchAndDevelopmentInProcessPercentToSales', window );">In-process research and development percent to sales</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">$ (13)<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
<td class="num">$ (40)<span></span>
</td>
<td class="num">$ (98)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_InvestmentIncomeInterestPercentToSales', window );">Interest income percent to sales</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net of portion capitalized</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">$ 114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_InterestExpensePercentToSales', window );">Interest expense, net of portion capitalized percent to sales</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="nump">$ 1,850<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 480<span></span>
</td>
<td class="nump">$ 545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_OtherNonOperatingIncomeExpensePercentToSales', window );">Other (income) expense, net percent to sales</a></td>
<td class="nump">7.90%<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring (Note 12)</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
<td class="nump">$ 187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_Restructuringchargepercenttosales', window );">Restructuring charge percent to sales</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">$ 3,849<span></span>
</td>
<td class="nump">$ 4,401<span></span>
</td>
<td class="nump">$ 17,940<span></span>
</td>
<td class="nump">$ 14,850<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales', window );">Earnings before provision for taxes on income percent to sales</a></td>
<td class="nump">16.50%<span></span>
</td>
<td class="nump">20.90%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">24.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for taxes on income (Note 5)</a></td>
<td class="nump">$ 182<span></span>
</td>
<td class="nump">$ 847<span></span>
</td>
<td class="nump">$ 1,798<span></span>
</td>
<td class="nump">$ 1,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_IncomeTaxExpenseBenefitPercentToSales', window );">Provision for taxes on income percent to sales</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 3,667<span></span>
</td>
<td class="nump">$ 3,554<span></span>
</td>
<td class="nump">$ 16,142<span></span>
</td>
<td class="nump">$ 12,976<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_NetIncomeAttributableToParentPercentToSales', window );">Net earnings percent to sales</a></td>
<td class="nump">15.70%<span></span>
</td>
<td class="nump">16.90%<span></span>
</td>
<td class="nump">23.40%<span></span>
</td>
<td class="nump">21.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET EARNINGS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (per share)</a></td>
<td class="nump">$ 1.39<span></span>
</td>
<td class="nump">$ 1.35<span></span>
</td>
<td class="nump">$ 6.13<span></span>
</td>
<td class="nump">$ 4.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (per share)</a></td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="nump">$ 6.04<span></span>
</td>
<td class="nump">$ 4.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>AVG. SHARES OUTSTANDING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (shares)</a></td>
<td class="nump">2,632.6<span></span>
</td>
<td class="nump">2,632.5<span></span>
</td>
<td class="nump">2,632.2<span></span>
</td>
<td class="nump">2,633.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (shares)</a></td>
<td class="nump">2,674.9<span></span>
</td>
<td class="nump">2,669.3<span></span>
</td>
<td class="nump">2,674.6<span></span>
</td>
<td class="nump">2,670.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CostOfGoodsSoldPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of goods sold percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CostOfGoodsSoldPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_GrossProfitPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross profit percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_GrossProfitPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income loss from continuing operations before income taxes minority interest and income loss from equity method investments percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_IncomeTaxExpenseBenefitPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax expense benefit percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_IncomeTaxExpenseBenefitPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_InterestExpensePercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest expense percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_InterestExpensePercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_InvestmentIncomeInterestPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment income interest percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_InvestmentIncomeInterestPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_NetIncomeAttributableToParentPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Income Attributable to Parent Percent to Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_NetIncomeAttributableToParentPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherNonOperatingIncomeExpensePercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other non operating income expense percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherNonOperatingIncomeExpensePercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense excluding acquired in process cost percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ResearchAndDevelopmentInProcessPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>research and development in process percent to sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ResearchAndDevelopmentInProcessPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_Restructuringchargepercenttosales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring charge percent to sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_Restructuringchargepercenttosales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SalesRevenueGoodsNetPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales revenue goods net percentage to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SalesRevenueGoodsNetPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SellingGeneralAndAdministrativeExpensePercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selling general and administrative expense percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SellingGeneralAndAdministrativeExpensePercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139721082609560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 3,667<span></span>
</td>
<td class="nump">$ 3,554<span></span>
</td>
<td class="nump">$ 16,142<span></span>
</td>
<td class="nump">$ 12,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax', window );">Foreign currency translation</a></td>
<td class="num">(382)<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="num">(241)<span></span>
</td>
<td class="num">(741)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) arising during period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassifications to earnings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net change</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Employee benefit plans:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax', window );">Prior service cost amortization during period</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(122)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax', window );">Gain (loss) amortization during period</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="nump">822<span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net change</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Derivatives &amp; hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Unrealized gain (loss) arising during period</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="nump">1,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Reclassifications to earnings</a></td>
<td class="num">(233)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="num">(576)<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net change</a></td>
<td class="num">(166)<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="num">(631)<span></span>
</td>
<td class="nump">1,106<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(315)<span></span>
</td>
<td class="nump">595<span></span>
</td>
<td class="num">(173)<span></span>
</td>
<td class="nump">953<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 3,352<span></span>
</td>
<td class="nump">$ 4,149<span></span>
</td>
<td class="nump">$ 15,969<span></span>
</td>
<td class="nump">$ 13,929<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30304-110892<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720992930168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign Currency Translation</a></td>
<td class="num">$ (86)<span></span>
</td>
<td class="nump">$ 139<span></span>
</td>
<td class="num">$ (315)<span></span>
</td>
<td class="num">$ (207)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax', window );">Employee Benefit Plans</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax', window );">Derivatives &amp; Hedges</a></td>
<td class="num">$ (43)<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="num">$ (167)<span></span>
</td>
<td class="nump">$ 293<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139721079224488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Common Stock Issued Amount</div></th>
<th class="th"><div>Treasury Stock Amount</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 29, 2019</a></td>
<td class="nump">$ 59,471<span></span>
</td>
<td class="nump">$ 110,659<span></span>
</td>
<td class="num">$ (15,891)<span></span>
</td>
<td class="nump">$ 3,120<span></span>
</td>
<td class="num">$ (38,417)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">12,976<span></span>
</td>
<td class="nump">12,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(7,823)<span></span>
</td>
<td class="num">(7,823)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Employee compensation and stock option plans</a></td>
<td class="nump">1,866<span></span>
</td>
<td class="num">(911)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(2,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,900)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(70)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Sep. 27, 2020</a></td>
<td class="nump">64,473<span></span>
</td>
<td class="nump">114,831<span></span>
</td>
<td class="num">(14,938)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(38,540)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Jun. 28, 2020</a></td>
<td class="nump">62,978<span></span>
</td>
<td class="nump">113,898<span></span>
</td>
<td class="num">(15,533)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(38,507)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">3,554<span></span>
</td>
<td class="nump">3,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(2,659)<span></span>
</td>
<td class="num">(2,659)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Employee compensation and stock option plans</a></td>
<td class="nump">559<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(483)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(483)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(71)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Sep. 27, 2020</a></td>
<td class="nump">64,473<span></span>
</td>
<td class="nump">114,831<span></span>
</td>
<td class="num">(14,938)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(38,540)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Jan. 03, 2021</a></td>
<td class="nump">63,278<span></span>
</td>
<td class="nump">113,890<span></span>
</td>
<td class="num">(15,242)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(38,490)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">16,142<span></span>
</td>
<td class="nump">16,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(8,241)<span></span>
</td>
<td class="num">(8,241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Employee compensation and stock option plans</a></td>
<td class="nump">1,726<span></span>
</td>
<td class="num">(699)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(2,460)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,460)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Oct. 03, 2021</a></td>
<td class="nump">70,272<span></span>
</td>
<td class="nump">121,092<span></span>
</td>
<td class="num">(15,415)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(38,525)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Jul. 04, 2021</a></td>
<td class="nump">69,580<span></span>
</td>
<td class="nump">120,154<span></span>
</td>
<td class="num">(15,100)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(38,594)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">3,667<span></span>
</td>
<td class="nump">3,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(2,791)<span></span>
</td>
<td class="num">(2,791)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Employee compensation and stock option plans</a></td>
<td class="nump">522<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(391)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(315)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(315)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Oct. 03, 2021</a></td>
<td class="nump">$ 70,272<span></span>
</td>
<td class="nump">$ 121,092<span></span>
</td>
<td class="num">$ (15,415)<span></span>
</td>
<td class="nump">$ 3,120<span></span>
</td>
<td class="num">$ (38,525)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720991721864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Cash dividends paid (in dollars per share)</a></td>
<td class="nump">$ 1.06<span></span>
</td>
<td class="nump">$ 1.01<span></span>
</td>
<td class="nump">$ 3.13<span></span>
</td>
<td class="nump">$ 2.97<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139721078819784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 3,667<span></span>
</td>
<td class="nump">$ 3,554<span></span>
</td>
<td class="nump">$ 16,142<span></span>
</td>
<td class="nump">$ 12,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net earnings to cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization of property and intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,547<span></span>
</td>
<td class="nump">5,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">920<span></span>
</td>
<td class="nump">845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset write-downs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">964<span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reversal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Net gain on sale of assets/businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(601)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,564)<span></span>
</td>
<td class="num">(238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Credit losses and accounts receivable allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities, net of effects from acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,818)<span></span>
</td>
<td class="num">(440)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,178)<span></span>
</td>
<td class="num">(784)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase/(Decrease) in accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="num">(119)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Decrease/(Increase) in other current and non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,082<span></span>
</td>
<td class="num">(1,983)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">(Decrease)/Increase in other current and non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,938)<span></span>
</td>
<td class="nump">581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH FLOWS FROM OPERATING ACTIVITIES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,678<span></span>
</td>
<td class="nump">15,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,237)<span></span>
</td>
<td class="num">(2,024)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from the disposal of assets/businesses, net (Note 10)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash acquired (Note 10)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(949)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,843)<span></span>
</td>
<td class="num">(16,243)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Sales of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,809<span></span>
</td>
<td class="nump">6,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities', window );">Credit support agreements activity, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">696<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other (primarily licenses and milestones)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(414)<span></span>
</td>
<td class="num">(516)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH USED BY INVESTING ACTIVITIES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,323)<span></span>
</td>
<td class="num">(12,922)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfOrdinaryDividends', window );">Dividends to shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,241)<span></span>
</td>
<td class="num">(7,823)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,460)<span></span>
</td>
<td class="num">(2,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,283<span></span>
</td>
<td class="nump">3,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of short-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(821)<span></span>
</td>
<td class="num">(310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">7,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,452)<span></span>
</td>
<td class="num">(562)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits', window );">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">808<span></span>
</td>
<td class="nump">922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities', window );">Credit support agreements activity, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="num">(569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH USED BY FINANCING ACTIVITIES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,611)<span></span>
</td>
<td class="num">(476)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(125)<span></span>
</td>
<td class="num">(135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,619<span></span>
</td>
<td class="nump">1,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash equivalents, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,985<span></span>
</td>
<td class="nump">17,305<span></span>
</td>
<td class="nump">$ 17,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, END OF PERIOD</a></td>
<td class="nump">$ 17,604<span></span>
</td>
<td class="nump">$ 18,965<span></span>
</td>
<td class="nump">17,604<span></span>
</td>
<td class="nump">18,965<span></span>
</td>
<td class="nump">$ 13,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1', window );">Fair value of assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Fair value of liabilities assumed and noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(224)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Net cash paid for acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfOrdinaryDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfOrdinaryDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720991642856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson &amp; Johnson and its subsidiaries (the Company) and related notes as contained in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.</span></div><div><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of October&#160;3, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets along with the Company&#8217;s on-going vaccine development and distribution efforts. While there was not a material impact to the Company&#8217;s consolidated financial statements as of and for the quarter ended October&#160;3, 2021, the Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021. There were no new material accounting standards issued in the fiscal nine months of 2021 that impacted the Company.</span></div><div style="margin-top:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the fiscal nine months of 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current year presentation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=SL108384541-122693<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=d3e31137-122693<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720991474936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">INVENTORIES <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"><tr><td style="width:1.0%"/><td style="width:51.896%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.310%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goods in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720991640296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text">INTANGIBLE ASSETS AND GOODWILL<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2020. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"/><td style="width:61.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with definite lives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; gross</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,176&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,990&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,569)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,618)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,607&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,372&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles &#8212; gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,637)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,912)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; net*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased in-process research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,843&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,849&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets &#8212; net</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,776&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,402&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*The majority is comprised of customer relationships</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In the fiscal third quarter of 2021, the Company recorded a partial IPR&amp;D impairment charge of $0.9&#160;billion primarily related to expected development delays in the general surgery digital robotics platform (Ottava) acquired with the Auris Health acquisition in 2019. The impairment charge was calculated based on revisions to the discounted cash flow valuation model reflecting a delay of first in human procedures of approximately two years from the initial acquisition model assumption of the second half of 2022. The remaining reduction was driven by assets that reached commercialization and are now classified as having definite lives.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill as of October&#160;3, 2021 was allocated by segment of business as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:39.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.660%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to divestitures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(347)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(283)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(817)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at October 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable intangible assets included in cost of products sold was $1.1 billion and $1.2&#160;billion for the fiscal third quarters ended October&#160;3, 2021 and September&#160;27, 2020, respectively. The amortization expense of amortizable intangible assets included in cost of products sold was $3.6&#160;billion and $3.4&#160;billion for the fiscal nine months ended October&#160;3, 2021 and September&#160;27, 2020, respectively. Intangible asset write-downs are included in Other (income) expense, net. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"><tr><td style="width:1.0%"/><td style="width:18.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.910%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,700</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,500</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,500</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,300</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,600</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720993125800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings.  These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of October&#160;3, 2021, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $202 million net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating.  Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of October&#160;3, 2021, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $45.8&#160;billion, $35.1&#160;billion and $10.0&#160;billion, respectively. As of January&#160;3, 2021, the Company had notional amounts outstanding for forward foreign exchange contracts and cross currency interest rate swaps of $37.8 billion and $30.6 billion, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur.  Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October&#160;3, 2021, the balance of deferred net gain on derivatives included in accumulated other comprehensive income was $21&#160;million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net investment hedge</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal third quarters ended in 2021 and 2020, net of tax:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.102%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 27, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal nine months ended in 2021 and 2020, net of tax:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.493%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.302%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.760%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 27, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(316)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of  October&#160;3, 2021, and January&#160;3, 2021, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges </span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Line item in the Consolidated Balance Sheet in which the hedged item is included</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount of the Hedged Liability<br/></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of derivatives not designated as hedging instruments for the fiscal third quarters and fiscal nine months in 2021 and 2020: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.010%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.277%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain /(Loss) Recognized in Income on Derivative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of net investment hedges for the fiscal third quarters ended in 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.814%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.959%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated<br/>OCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 27, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of net investment hedges for the fiscal nine months ended in 2021 and 2020:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:24.725%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.758%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.265%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="33" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated OCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 27, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values.  The Company has elected to measure equity investments that do not have readily determinable fair </span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:25.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.365%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.464%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.667%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales/ Purchases/Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(545)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded in Other Income/Expense</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other includes impact of currency</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity investments without readily determinable market values, there was a decrease of $25 million in the fair value reflected in net income as a result of impairments. There was an offsetting increase of  $417 million in the fair value reflected in net income due to changes in observable prices and gains on the disposal of the Grail investment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#8217;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following three levels of inputs are used to measure fair value:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8212; Quoted prices in active markets for identical assets and liabilities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8212; Significant other observable inputs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8212; Significant unobservable inputs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of October&#160;3, 2021 and January&#160;3, 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:48.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.904%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.318%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,058)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,260)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in liabilities for contingent consideration is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.807%"><tr><td style="width:1.0%"/><td style="width:41.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.606%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 27, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,088)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">2020 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,481 million, which are classified as Level 1 and contingent consideration of $633 million, classified as Level 3.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes cross currency interest rate swaps and interest rate swaps as of October&#160;3, 2021. Includes cross currency interest rate swaps as of January&#160;3, 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classified as non-current other assets. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes $595 million and $594 million, classified as non-current other liabilities as of October&#160;3, 2021 and January&#160;3, 2021, respectively.  Includes $18 million and $39 million classified as current liabilities as of October&#160;3, 2021 and January&#160;3, 2021, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a contingent consideration reversal of $1,148 million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense, net. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cash, cash equivalents and current marketable securities as of October&#160;3, 2021 comprised:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"/><td style="width:22.208%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.727%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.153%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.153%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.153%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.727%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.454%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.153%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.182%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Gain</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. sovereign securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. reverse repurchase agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other sovereign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal available for sale debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the fiscal year ended January&#160;3, 2021 the carrying amount was approximately the same as the estimated fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the available for sale securities as of October&#160;3, 2021 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.415%"><tr><td style="width:1.0%"/><td style="width:43.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.279%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.031%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Instruments not measured at Fair Value:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial liabilities are held at carrying amount on the consolidated balance sheet as of October&#160;3, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.838%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.259%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73% Debentures due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Notes due 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.05% Notes due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.650% Notes due 2024 (750MM Euro 1.1581)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% Notes due 2024 (500 MM GBP 1.3465)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.625% Notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.55% Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90%&#160;Notes due 2028</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.150% Notes due 2028 (750MM Euro 1.1581)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.95% Notes due 2029</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% Notes due 2030</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95% Debentures due 2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.375% Notes due 2033</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.650% Notes due 2035 (1.5B Euro 1.1581)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.55% Notes due 2036</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95% Notes due 2037</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% Notes due 2037</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40%&#160;Notes due 2038</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85% Debentures due 2038</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Debentures due 2040</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10% Notes due 2040</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.85% Notes due 2041</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Notes due 2043</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70% Notes due 2046</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Notes due 2047</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50% Notes due 2048</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% Notes due 2050</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2060</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-Current Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average effective interest rate on non-current debt is 2.98%.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the estimated fair value over the carrying value of debt was $5.4 billion at January 3, 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The current debt balance as of October&#160;3, 2021 includes $1.3&#160;billion of commercial paper which has a weighted average interest rate of 0.08% and a weighted average maturity of approximately three months.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720993142712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">INCOME TAXES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The worldwide effective income tax rates for the fiscal nine months of 2021 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2020 were 10.0% an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">d 12.6%, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In the second fiscal quarter of 2021, the Company reorganized the ownership structure of certain wholly-owned international subsidiaries. As part of this reorganization, the Company increased the tax basis of certain assets to fair value in accordance with applicable local regulations.  Accordingly, the Company recorded a local deferred tax benefit of approximately $2.3&#160;billion, which was partially offset by a related increase in the U.S. GILTI deferred tax liability of approximately $1.7&#160;billion. The net impact of this restructuring was approximately $0.6&#160;billion net benefit or 3.4% decrease to the 2021 year-to-date effective tax rate.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In 2019, Switzerland enacted the Federal Act on Tax Reform and AHV Financing (TRAF), which became effective on January 1, 2020. More information on the provisions of TRAF can be found in the Company&#8217;s Annual Report on Form 10-K for the year ended January 3, 2021. During the first fiscal quarter of 2020, the final canton where the Company maintains significant operations enacted TRAF legislation and, accordingly, the Company recorded a deferred tax benefit of approximately $0.3&#160;billion for the remeasurement of existing deferred tax liabilities offset by a related $0.2&#160;billion increase in U.S. GILTI deferred taxes. During the second fiscal quarter of 2020, the Company received rulings from the Swiss Federal and cantonal tax authorities in the remaining jurisdictions where it has significant operations. These rulings resulted in the Company increasing the tax basis of certain assets to fair value. As a result, the Company recorded additional deferred tax benefits in the second fiscal quarter of 2020 to recognize this step-up.  The total benefit recorded related to Swiss Tax reform in the fiscal nine months of 2020 was approximately $0.4&#160;billion, or 2.7% net benefit to the Company&#8217;s year-to-date  effective tax rate, inclusive of the impact of U.S. GILTI deferred taxes. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Additionally the following items impacted the Company&#8217;s effective tax rate as compared to the same period in the prior fiscal year:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">as a result of the recent filing of the 2020 U.S. tax return, as well as the impact of non-recurring favorable tax items, the Company recorded a 1.0% net benefit to the effective tax rate for the fiscal nine months of 2021.   </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">in the third quarter of 2021 the Company accrued additional legal expenses, $1.4&#160;billion for the Talc related litigation at an effective tax rate of 23.5% and $0.8&#160;billion for the Risperdal settlement at an effective tax rate of 16.4% (See note 11 to the Consolidated Financial Statements for more details).</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">in the third quarter of 2021 the Company recorded a partial IPR&amp;D charge of $0.9&#160;billion for the Ottava intangible asset (acquired with the Auris Health acquisition in 2019) at an effective rate of 22.4% (See Notes 3 and 9 to the Consolidated Financial Statements for more details). </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">in the fiscal nine months of 2020, the Company reduced a contingent consideration liability related to the 2019 Auris Health acquisition that benefited the fiscal nine months of 2020 tax rate by approximately 1.0% (see Note 4 to the Consolidated Financial Statements for more details). </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">the Company had lower income in higher tax jurisdictions relative to lower tax jurisdictions as compared to the same period in the prior year. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company also generated additional tax benefits from stock-based compensation that were either exercised or vested during the first three fiscal quarters of 2021 and 2020.  Additionally the company has reversed unrecognized tax benefit liabilities in 2021 as a result of the completion of tax examinations in certain international jurisdictions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of October&#160;3, 2021, the Company had approximately $3.3 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. In other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">major jurisdictions where the Company conducts business, the years that remain open to tax audit or are under appeal go back to the year 2008. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720993167848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pensions and Other Benefit Plans</a></td>
<td class="text">PENSIONS AND OTHER BENEFIT PLANS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of Net Periodic Benefit Cost</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans include the following components:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.338%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(661)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,988)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,839)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost/(credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments and settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company Contributions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal nine months ended October&#160;3, 2021, the Company contributed $71 million and $232 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139721088624552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Income</a></td>
<td class="text">ACCUMULATED OTHER COMPREHENSIVE INCOME<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) consist of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:34.774%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.719%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.306%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.991%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Accumulated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Comprehensive</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,938)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,242)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(631)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,257)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,415)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in accumulated other comprehensive income are presented net of the related tax impact.  Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries.  For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details on reclassifications out of Accumulated Other Comprehensive Income:</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Derivatives &amp; Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139721161862200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">EARNINGS PER SHARE<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"/><td style="width:53.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.304%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.308%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Shares in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings per share </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,633.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: shares which could be repurchased under treasury stock method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,674.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,669.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,674.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,670.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The diluted net earnings per share calculation for the fiscal third quarter ended October&#160;3, 2021 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company&#8217;s stock. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The diluted net earnings per share calculation for the fiscal third quarter ended September&#160;27, 2020 excluded 20&#160;million shares related to stock options, as the exercise price of these options was greater than their average market value. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The diluted net earnings per share calculation for the fiscal nine months ended October&#160;3, 2021 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company's stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The diluted net earnings per share calculation for the fiscal nine months ended September&#160;27, 2020 excluded 17&#160;million shares related to stock options, as the exercise price of these options was greater than their average market value.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720993122456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments of Business and Geographic Areas</a></td>
<td class="text">SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY SEGMENT OF BUSINESS </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent Change</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consumer Health</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:168pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Exports</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER IMMUNOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">COVID-19 VACCINE</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">EDURANT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / rilpivirine</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / PREZCOBIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> /</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">                                    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">            REZOLSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / SYMTUZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER INFECTIOUS DISEASES</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONCERTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / methylphenidate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / XEPLION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / INVEGA   TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / TREVICTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;RISPERDAL CONSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER NEUROSCIENCE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> / </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">abiraterone acetate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER ONCOLOGY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER PULMONARY HYPERTENSION</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MEDICAL DEVICES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">HIPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">KNEES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TRAUMA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ADVANCED</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONTACT LENSES / OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SURGICAL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL MEDICAL DEVICES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WORLDWIDE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,082&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inclusive of VELCADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT  </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:36.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27,<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27,<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.7</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before provision for taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.8)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.5)%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.8%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consumer Health</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Includes intangible amortization expense of $0.1 billion in both the fiscal third quarter of 2021 and 2020 and $0.3&#160;billion in both the fiscal nine months of 2021 and 2020. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Includes litigation expense of $1.4&#160;billion and $0.5&#160;billion in the fiscal third quarter of 2021 and 2020, respectively. Includes litigation expense of  $1.5&#160;billion and $1.2&#160;billion in the fiscal nine months of 2021 and 2020, respectively. Litigation expense in both periods is primarily related to talc.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Includes a restructuring related charge of $0.1&#160;billion in both the fiscal nine months of 2021 and 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pharmaceutical</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes divestiture gains of $0.6&#160;billion in the fiscal nine months of 2021 related to two brands outside the U.S.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes intangible amortization expense of $0.8&#160;billion in both the fiscal third quarter of 2021 and 2020. Includes intangible amortization expense of $2.5&#160;billion and $2.4&#160;billion in the fiscal nine months of 2021 and 2020, respectively.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes net litigation expense of $0.8&#160;billion and $1.0&#160;billion in the fiscal third quarter of 2021 and 2020, respectively. Includes net litigation expense of  $0.7&#160;billion and $1.0&#160;billion in the fiscal nine months of 2021 and 2020, respectively. Litigation expense in 2021 is primarily related to Risperdal. Litigation expense in 2020 is related to the opioid settlement.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes a gain on securities of $0.1&#160;billion in the fiscal third quarter of 2021 and $0.2&#160;billion in both the fiscal nine months of 2021 and 2020, respectively. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes a restructuring related charge of $0.1&#160;billion in both the fiscal nine months of 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In fiscal 2020 and 2021, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $1.2&#160;billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Devices </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes a contingent consideration reversal of $0.2&#160;billion in the fiscal third quarter of 2020 and $1.1&#160;billion in the fiscal nine months of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes a restructuring related charge of $0.1 billion in both the fiscal third quarter of 2021 and 2020, respectively. Includes a restructuring related charge of $0.2&#160;billion in both the fiscal nine months of 2021 and 2020, respectively.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes intangible amortization expense of $0.3&#160;billion and $0.2&#160;billion in the fiscal third quarter of 2021 and 2020, respectively. Includes intangible amortization expense of $0.8&#160;billion and $0.7&#160;billion in the fiscal nine months of 2021 and 2020, respectively. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes a gain on securities of $0.1&#160;billion in the fiscal nine months of 2021.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Includes an in-process research and development expense of $0.9&#160;billion related to the general surgery offering in digital robotics (Ottava) acquired with the Auris Health acquisition in 2019 in both the fiscal third quarter and fiscal nine months of 2021. See Note 3 to the Consolidated Financial Statements for more details.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amounts not allocated to segments include interest income/expense and general corporate income/expense. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY GEOGRAPHIC AREA</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.279%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.486%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.889%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.486%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.889%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.486%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.751%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.339%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.486%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,587&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,819&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,669&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,709&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere, excluding U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific, Africa</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,288&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,881&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,018&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720993074392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Acquisitions and Divestitures</a></td>
<td class="text">ACQUISITIONS AND DIVESTITURESDuring the first fiscal quarter of 2021, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.6&#160;billion. During the fiscal first quarter of 2020, the Company completed the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc., for a purchase price of $0.8 billion. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;D, for $0.8 billion. XBiotech may be eligible to receive additional payments upon the receipt of certain commercialization authorizations. The transaction was accounted for as a business combination and included in the Pharmaceutical segment. Additionally, the Company completed the acquisition of all outstanding shares in Verb Surgical Inc., a company with world-class robotics and data science capabilities, including those shares previously held by Verily. The transaction was accounted for as a business combination and included in the Medical Devices segment. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;D, for $0.4 billion, goodwill for $0.2 billion, other assets of $0.2 billion and liabilities assumed of $0.3 billion. The fair value of the Company's previously held equity investment in Verb Surgical Inc. was $0.4 billion.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures.  This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720993099752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Proceedings</a></td>
<td class="text">LEGAL PROCEEDINGS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; supplier indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. Due to the ongoing impacts of the COVID-19 pandemic, certain trials have been rescheduled or delayed.  The Company continues to monitor its legal proceedings as the situation evolves and in person trials resume.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of October&#160;3, 2021, the Company has determined that </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">PRODUCT LIABILITY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant of these cases include: the DePuy ASR&#8482; XL Acetabular System and DePuy ASR&#8482; Hip Resurfacing System; the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acetabular Cup System; pelvic meshes; RISPERDAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; body powders containing talc, primarily JOHNSONS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Baby Powder; INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; and ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Flexible Composite Mesh. As of October&#160;3, 2021, in the United States there were approximately 300 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR&#8482; XL Acetabular System and DePuy ASR&#8482; Hip Resurfacing System; 5,400 with respect to the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acetabular Cup System; 10,700 with respect to pelvic meshes; 9,000 with respect to RISPERDAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; 6,600 with respect to XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; 38,200 with respect to body powders containing talc; 100 with respect to INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 4,700 with respect to ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Flexible Composite Mesh.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> XL Acetabular System and DePuy ASR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hip Resurfacing System used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson &amp; Johnson. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip System plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 31, 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 31, 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle </span><span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the class actions filed in that country</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company continues to receive information with </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and DePuy ASR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hip-related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson &amp; Johnson (collectively, DePuy) relating to the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation also has been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acetabular Cup System and the related settlement program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp; Johnson arising out of Ethicon's pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved a majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company's accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon's pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands and class actions in Israel, Australia and Canada. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court issued a decision and entered damages awards to the three Lead Applicants. The Company appealed the decision to the intermediate appellate court, the Full Court. The appeal was heard in February 2021 and, in March 2021, the Full Court entered a judgment dismissing the appeal. An application for special leave to the High Court of Australia was filed in April 2021, and in July 2021, the High Court agreed to hear oral argument on the application, which is scheduled to occur in November 2021. With respect to class members other than the Lead Applicants, the Federal Court will conduct an individual case assessment process that will require proof of use and causally related loss, although the form of that process has not yet been decided. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021, which is subject to court approval. The Company has established accruals with respect to product liability litigation associated with Ethicon's pelvic mesh products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Flexible Composite Mesh, claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp; Johnson alleging personal injury arising out of the use of this hernia mesh device.&#160;Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., one multi-plaintiff lawsuit pending in Oklahoma state court and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement was entered into in September 2021. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. The costs associated with this proposed settlement are reflected in the Company&#8217;s accruals. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Claims have also been filed against Ethicon and Johnson &amp; Johnson alleging personal injuries arising from the PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> Mesh and PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the US, and in jurisdictions outside the US. Discovery is underway in the MCL proceedings. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ethicon and Johnson &amp; Johnson also have been subject to claims for personal injuries arising from the PROLENE&#8482; Polypropylene Hernia System (PHS). In January 2020, New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Flexible Composite Mesh, PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Mesh and PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Ventral Patch, and PROLENE&#8482; Polypropylene Hernia System products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson arising out of the use of RISPERDAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0&#160;billion of punitive damages related to one plaintiff, which the trial judge reduced to $6.8&#160;million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company's accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury arising out of the use of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson &amp; Johnson; and JPI&#8217;s collaboration partner for XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Bayer AG and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases have been filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and Johnson  &amp; Johnson announced an agreement in principle to settle the XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> related product liability litigation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A significant number of personal injury claims alleging that talc causes cancer were made against Johnson &amp; Johnson Consumer Inc. and Johnson &amp; Johnson arising out of the use of body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Baby Powder. The number of these personal injury lawsuits, filed in state and federal courts in the United States as well as outside of the United States, continued to increase through, and including, October 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7&#160;billion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ingham v. Johnson &amp; Johnson, et al., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No. ED 207476 (Mo. App.), reducing the overall award to $2.1&#160;billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ingham </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">decision by the United States Supreme Court was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $2.5&#160;billion. The facts and circumstances, including the terms of the award, were unique to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ingham</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> decision and not representative of other claims brought against the Company.  The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company&#8217;s confidence in the safety of its talc products, in certain circumstances the Company has and may settle cases. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, Johnson &amp; Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring).  As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor), (b) Royalty A&amp;M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor's direct parent, Johnson &amp; Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI's assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers&#8217; compensation statute or act (the Talc-Related Liabilities).  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, notwithstanding the Company&#8217;s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Filing). As a result of the LTL Bankruptcy Filing, the Court entered a temporary restraining order staying all litigation against LTL and Old JJCI.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further hearings on whether a permanent restraining order staying all litigation against those entities, as well other entities, such as Johnson &amp; Johnson, its affiliates, and certain other third parties, are scheduled in November 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The Company has agreed to provide funding to LTL for the payment of amounts the Bankruptcy Court determines are owed by LTL through the establishment of a $2&#160;billion trust in furtherance of this purpose. The Company has established a reserve for approximately $2&#160;billion in connection with the aforementioned trust, resulting in an incremental $1.4&#160;billion litigation charge. Subsequent to the fiscal third quarter, the </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Company has de-consolidated LTL as a result of the bankruptcy filing.  The impact of the de-consolidation is not material to the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2019, the Company&#8217;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary chapter 11 petition under chapter 11 of title 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#8217;s potential liability for personal injury from exposure to talcum powder sold by Imerys (Talc Claims). In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. During the bankruptcy, the Company proposed to resolve Imerys's (and the Company&#8217;s) obligations arising out of Talc Claims involving the Company&#8217;s products by agreeing to assume the defense of litigation of all such Talc Claims, waiving the Company&#8217;s indemnification claims against Imerys, and lifting the automatic stay to enable the Talc Claims to proceed outside the bankruptcy forum with the Company agreeing to settle or pay any judgment against Imerys. Imerys rejected that proposal. In May 2020, Imerys, its parent Imerys S.A., the Tort Claimants&#8217; Committee (TCC), and the Future Claimants&#8217; Representative (FCR) (collectively, the Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related thereto. The Plan Proponents have since filed numerous amendments to the Plan and Disclosure Statement. A hearing on the Plan Proponent&#8217;s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement, allowing Imerys to proceed with soliciting votes on the Plan. In March 2021, the Company voted to reject the Plan and opted out of the consensual releases in the Plan. In April 2021, the Plan Proponents announced the Plan had received the requisite number of accepting votes to confirm the Plan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, the Bankruptcy Court issued a ruling deeming almost 16,000 votes in favor of the Plan as withdrawn, based upon evidence that no due diligence had been done by the plaintiff&#8217;s counsel to ascertain whether the votes were cast on behalf of individuals who used the Company&#8217;s products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Bankruptcy Court also ruled that more than 1,500 votes cast by another firm should count as rejecting instead of accepting. In October 2021, Imerys filed a notice on the docket cancelling the confirmation hearing on its Plan that was scheduled to begin in November 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In July 2021, Imerys commenced an adversary proceeding against the Company in the Imerys Bankruptcy (the Imerys adversary proceeding).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Imerys adversary proceeding sought, among other things, certain declarations with respect to the indemnification obligations allegedly owed by the Company to Imerys.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The TCC and FCR simultaneously filed a motion for temporary restraining order and preliminary injunction seeking to enjoin the Company from undergoing a corporate restructuring that would separate the Company&#8217;s talc liabilities from its other assets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The bankruptcy court denied the motion.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company thereafter filed a motion to dismiss the adversary proceeding.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Bankruptcy Court has not yet decided the motion to dismiss. In October 2021, the Company filed a Notice of  Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the LTL Bankruptcy Filing should apply to the Imerys adversary proceeding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2020, Cyprus Mines Corporation and its parent (together, Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company and Imerys in the Imerys Bankruptcy seeking a declaration of indemnity rights under certain contractual agreements (the Cyprus adversary proceeding). The Company denies such indemnification is owed, and filed a motion to dismiss the adversary complaint. In February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan. The Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against Talc Claims asserted against it. Cyprus has not yet sought approval of its Disclosure Statement and Plan. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the LTL Bankruptcy Filing should apply to the Cyprus adversary proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2021, several of the Company&#8217;s insurers involved in coverage litigation in New Jersey State Court (the Coverage Action) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action. In March 2021, the Company filed a limited response and reservation of rights with respect to the motion. The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. In October 2021, LTL filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the LTL Bankruptcy Filing should apply to the Coverage Action.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2018, a securities class action lawsuit was filed against Johnson &amp; Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson &amp; Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON'S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Baby Powder, and that purchasers of Johnson &amp; Johnson&#8217;s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, Defendants answered the complaint. In April 2021 briefing on Plaintiffs&#8217; motion for class certification was completed. Discovery is ongoing. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2019, a shareholder filed a complaint initiating a summary proceeding in New Jersey state court for a books and records inspection. In August 2019, Johnson &amp; Johnson responded to the books and records complaint and filed a cross motion to dismiss. In September 2019, Plaintiff replied and the Court heard oral argument. The Court has not yet ruled in the books and records action. In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson &amp; Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Baby Powder, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">In re Johnson &amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2020, a report was delivered to the Company&#8217;s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues and demanding that suit be brought against certain Directors. Four of the shareholders who sent demands are plaintiffs in th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">In re Johnson &amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel&#8217;s report. In October 2020, the shareholders filed a consolidated complaint, and in January 2021, Johnson &amp; Johnson moved to dismiss the consolidated complaint. In March 2021, Plaintiffs filed a motion for discovery. The Court temporarily terminated Johnson &amp; Johnson&#8217;s motion to dismiss pending a decision on Plaintiff&#8217;s motion for discovery. In October 2021, the Court requested supplemental briefing on Plaintiff&#8217;s motion for discovery. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson &amp; Johnson Savings Plan against Johnson &amp; Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson &amp; Johnson stock as a Johnson &amp; Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants&#8217; motion but granted leave to amend. In June 2020, Plaintiffs filed an amended complaint, and in July 2020, Defendants moved to dismiss the amended complaint. As of October 2020, briefing on Defendants&#8217; motion was complete. In February 2021, the Court granted Defendants&#8217; motion, and granted Plaintiffs leave to amend. In April 2021, Plaintiffs informed the Court that they did not intend to file an amended complaint, and the Court dismissed the case with prejudice. In May 2021, Plaintiffs filed a notice of appeal with the Third Circuit. In July 2021, Plaintiffs filed their opening brief in the Third Circuit and in September 2021, Defendants filed their response brief. In October 2021, Plaintiffs filed their reply brief. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California&#8217;s Consumer Legal Remedies Act (CLRA) relating to JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Baby Powder. In that lawsuit, the plaintiffs allege that Johnson &amp; Johnson violated the CLRA by failing to provide required Proposition 65 warnings.  In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company&#8217;s favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. In October 2021, a Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the Company has received preliminary inquiries and subpoenas to produce documents regarding talc matters from Senator Murray, a member of the Senate Committee on Health, Education, Labor and Pensions, the Department of Justice and the U.S. Congressional Subcommittee on Economic and Consumer Policy. The Company produced documents as required in response and will continue to cooperate with government inquiries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. In December 2016, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company's accruals.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, a prescription medication  indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases also have been filed in various state courts. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> related product liability litigation.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">INTELLECTUAL PROPERTY</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain subsidiaries of Johnson &amp; Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company&#8217;s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. Significant matters are described below.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medical Devices</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2016, Dr. Ford Albritton sued Acclarent, Inc. (Acclarent) in United States District Court for the Northern District of Texas alleging that Acclarent&#8217;s RELIEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Spin and RELIEVEA SpinPlus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> products infringe U.S. Patent No. 9,011,412.  Dr. Albritton also alleges breach of contract, fraud and that he is the true owner of Acclarent&#8217;s U.S. Patent No. 8,414,473. Trial began in October 2021, and shortly thereafter, the parties reached an agreement to settle the case. Plaintiff's motion to dismiss with prejudice was filed in October 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2017, Board of Regents, The University of Texas System and TissueGen, Inc. (collectively, UT) filed a lawsuit in the United States District Court for the Western District of Texas against Ethicon, Inc. and Ethicon US, LLC (collectively, Ethicon) alleging the manufacture and sale of VICRYL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Plus Antibacterial Sutures, MONOCRYL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Plus Antibacterial Sutures, PDS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Plus Antibacterial Sutures, STRATAFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> PDS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Antibacterial Sutures and STRATAFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> MONOCRYL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Plus Antibacterial Sutures infringe plaintiffs&#8217; United States Patent Nos. 6,596,296 (&#8217;296) and 7,033,603 (&#8217;603) directed to implantable polymer drug releasing biodegradable fibers containing a therapeutic agent. UT is seeking damages and an injunction. In December 2018, Ethicon filed petitions with the United States Patent and Trademark Office (USPTO), seeking Inter Partes Review (IPR) of both asserted patents. In June 2020, the USPTO denied institution of the &#8217;296 patent IPR and granted institution of the &#8217;603 patent IPR. UT dismissed the &#8217;603 patent from the suit and no longer accuses PDS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Plus Antibacterial Sutures or STRATAFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> PDS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Plus Antibacterial Sutures of infringement. In August 2021, the parties entered into a settlement agreement, and the case was dismissed. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (collectively, Intuitive) filed a patent infringement suit against Auris Health, Inc. (Auris) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos. 6,246,200 (&#8217;200); 6,491,701 (&#8217;701); 6,522,906 (&#8217;906); 6,800,056 (&#8217;056); 8,142,447 (&#8217;447); 8,620,473 (&#8217;473); 8,801,601 (&#8217;601); and 9,452,276 (&#8217;276) based on Auris&#8217; Monarch&#8482; Platform. Auris filed IPR Petitions with the U.S. Patent and Trademark Office (USPTO) regarding the &#8217;200, &#8217;056, &#8217;601 &#8217;701, &#8217;447, &#8217;276 and &#8217;906 patents. Intuitive subsequently dropped the &#8217;200, &#8217;473 and &#8217;701 patents from the suit. In December 2019, the USPTO instituted review of the &#8217;601 patent and denied review of the &#8217;056 patent. In February and March 2020, the USPTO instituted review of the &#8217;200, &#8217;447, &#8217;701 and &#8217;906 patents and denied review of the &#8217;276 patent. In December 2020, the USPTO declared all of the challenged claims in the &#8217;601 patent to be invalid. Intuitive has appealed that decision. In March 2021, the USPTO ruled that the challenged claims of the &#8217;447 and &#8217;906 patents are not invalid. Auris has appealed that decision. Trial is scheduled to begin in January 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2019, RSB Spine LLC (RSB Spine) filed a patent infringement suit against DePuy Synthes, Inc. in United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of United States Patent Nos. 6,984,234 and 9,713,537 by one or more of the following products:  ZERO-P-VA&#8482; Spacer, ZERO-P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Spacer, ZERO-P NATURAL&#8482; Plate, SYNFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> LR Spacer and SYNFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Evolution System. RSB Spine seeks monetary damages and injunctive relief. In November 2019, the suit was consolidated for pre-trial purposes with other patent infringement suits brought by RSB Spine in the United States District Court for the District of Delaware against Life Spine, </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inc., Medacta USA, Inc., and Precision Spine, Inc. A stay that had been entered pending Inter Partes Review at the U.S. Patent &amp; Trademark Office has been lifted, and trial is scheduled to begin in December 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2020, Osteoplastics, LLC filed a patent infringement suit against DePuy Synthes, Inc., DePuy Synthes Products, Inc., Medical Device Business Services, Inc., and Synthes, Inc. (collectively, DePuy Synthes) in the United States District Court for the District of Delaware. In the suit, Osteoplastics alleges willful infringement of U.S. Patent Nos. 8,781,557; 9,929,920; 9,330,206; 9,626,756; 9,672,617; 9,672,302; and 9,275,191 based on the PROPLAN CMF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Virtual Surgical Planning Services and the TruMatch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> CMF Personalize Solutions. In April 2020, Osteoplastics filed an amended complaint to substitute U.S. Patent No. 9,292,920 for U.S. Patent No. 9,929,920.  Osteoplastics seeks monetary damages and injunctive relief. In June 2020, DePuy Synthes filed a motion to dismiss the complaint. In October 2020, the Court dismissed Medical Device Business Services, Inc. from the case but otherwise denied the motion. In June 2021, Osteoplastics admitted that the PROPLAN CMF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Virtual Surgical Planning Services do not infringe any asserted patents. Trial is scheduled for October 2022.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pharmaceutical</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes lawsuits the Company's subsidiaries have brought against generic companies that have filed ANDAs with the FDA or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson &amp; Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement and invalidity of the applicable patents. In the event the Company's subsidiaries are not successful in an action, or the automatic statutory stay of the ANDAs expires before the United States District Court rulings are obtained, the generic companies involved would have the ability, upon approval of the FDA, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company's subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. The Inter Partes Review (IPR) process with the USPTO, created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits, to challenge the applicable patents.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in January 2019, Janssen Inc. and Janssen Oncology Inc. (collectively, Janssen) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations in Canada against Apotex Inc. (Apotex), Pharmascience Inc. (Pharmascience) and Dr. Reddy's Laboratories Ltd. and Dr. Reddy's Laboratories, Inc. (collectively, DRL) in response to those parties&#8217; filing of Abbreviated New Drug Submissions (ANDS) seeking approval to market generic versions of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before the expiration of the Canadian Patent No. 2,661,422 (&#8217;422). The trial in these actions concluded in November 2020, and the Court issued a decision holding the &#8217;422 patent invalid in January 2021. In February 2021, Janssen appealed the decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian actions, Janssen is seeking an order enjoining the defendants from marketing their generic versions of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the &#8217;422 patent.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2021, Janssen Pharmaceuticals, Inc. (JPI) and Bayer Pharma AG and Bayer AG (collectively, Bayer) filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Lupin Limited and Lupin Pharmaceuticals, Inc. which filed an ANDA seeking approval to market a generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of U.S. Patent No. 10,828,310 (&#8217;310). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Accord Healthcare Inc., Accord Healthcare Limited, and Intas Pharmaceuticals Limited which filed an ANDA seeking approval to market a generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before expiration of the &#8217;310 patent. In July 2021, the parties entered into a confidential settlement agreement, and the action was dismissed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Dr. Reddy&#8217;s Laboratories, Inc. and Dr. Reddy&#8217;s Laboratories, Ltd. which filed an ANDA seeking approval to market a generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;310 patent.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals U.S.A., Inc. (collectively, Taro) which filed an ANDA seeking approval to market a generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;310 patent. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. which filed an ANDA seeking approval to market a generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;310 patent. In August 2021, the court entered a joint stipulation dismissing Teva Pharmaceutical Industries Ltd.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the Northern District of West Virginia against Mylan Pharmaceuticals Inc. and Mylan Inc. which filed an ANDA seeking approval to market a generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;310 patent. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In each of these lawsuits, JPI and Bayer are seeking an order enjoining defendants from marketing their generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before the expiration of the &#8217;310 patent. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning in July 2017, Janssen Pharmaceuticals, Inc., Janssen Research &amp; Development, LLC, Cilag GmbH International and Janssen Pharmaceutica NV (collectively, Janssen) and Mitsubishi Tanabe Pharma Corporation (MTPC) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against a number of generic companies that filed ANDAs seeking approval to market generic versions of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and/or INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> XR before expiration of MTPC&#8217;s United States Patent Nos. 7,943,582 (&#8217;582) and/or 8,513,202 (&#8217;202) relating to INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and/or INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> XR. Janssen is the exclusive licensee of the asserted patents. Named defendants include MSN Laboratories Private Ltd. and MSN Pharmaceuticals, Inc. (MSN); Zydus Pharmaceuticals (USA) Inc. (Zydus). These cases were consolidated into one action (Polymorph Main Action).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2017, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Zydus which filed ANDAs seeking approval to market generic versions of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">before expiration of MTPC&#8217;s United States Patent No. 7,943,788 (&#8217;788), 8,222,219 (&#8217;219) and/or 8,785,403 (&#8217;403) relating to INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (Compounds Main Action). Janssen is the exclusive licensee of the asserted patents. Trial concluded in October 2020. The Court issued a decision holding that the patents are not invalid and would be infringed by Zydus&#8217; generic products. Zydus has appealed the decision. In July 2021, Janssen and Zydus entered into a confidential settlement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2019, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against MSN, which filed an ANDA seeking approval to market a generic version of INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;582 patent and &#8217;202 patent relating to INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. In October 2019, Janssen and MTPC initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against MSN, which filed ANDAs seeking approval to market generic versions of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;788 patent. In July 2021, Janssen and MSN entered into a confidential settlement and the lawsuits were dismissed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2019, Janssen and MTPC initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Dr. Reddy&#8217;s Laboratories, Inc. and Dr. Reddy&#8217;s Laboratories Ltd (DRL), who filed an ANDA seeking approval to market a generic version of INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before expiration of the &#8217;788 patent. In January 2021, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Macleods), which filed an ANDA seeking approval to market a generic version of INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before expiration of the &#8217;582 patent and &#8217;202 patent relating to INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. In February 2021, Janssen filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Macleods), which filed an ANDA seeking approval to market a generic version of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before expiration of United States Patent No. 10,617,668 (&#8217;668)  relating to INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. In September 2021, Janssen and MTPC dismissed the lawsuit against Macleods relating to the &#8217;668 patent. These lawsuits have not been consolidated with the Polymorph Main Action or Compound Main Action.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">In each of these U.S. lawsuits, Janssen and MTPC are seeking an order enjoining the defendant from marketing their generic versions of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:102%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">, INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:102%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"> and/or, INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:102%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, Janssen Inc., Janssen Pharmaceutica NV and MTPC initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the Canadian Patent Nos. 2,799,204, 2,534,024 and 2,671,357. Janssen Inc., Janssen Pharmaceutica NV and MTPC are seeking an </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">order enjoining Sandoz from marketing its generic version of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the relevant patents. The trial is scheduled to begin in August 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2020, Janssen Inc. (Janssen) and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before the expiration of Canadian Patent No. 2,659,770 (&#8217;770). Trial is scheduled to begin in January 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in Canada in response to Apotex&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of the &#8217;770 patent. Trial is scheduled to begin in February 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against JAMP Pharma Corporation (JAMP) in Canada in response to JAMP&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10 mg before the expiration of the &#8217;770 patent and Canadian Patent No. 2,621,273 (&#8217;273). Trial is scheduled to begin in April 2022.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian actions, Janssen and Actelion are seeking an order enjoining the defendants from marketing their generic versions of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. (Teva), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before the expiration of United States Patent No. 9,439,906 (&#8217;906).  Trial concluded in October 2020. In October 2021, the court issued a decision in Janssen's favor.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited (Mylan), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, Janssen initiated a patent infringement lawsuit in the United States District Courts for the Districts of New Jersey and Delaware against Pharmascience Inc., Mallinckrodt PLC and Specgx LLC (collectively, Pharmascience), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In each of these U.S. lawsuits, Janssen is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, Janssen Inc. and Janssen Pharmaceutica NV (collectively, Janssen Canada) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Teva Canada Limited (Teva Canada) in response to Teva's filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of Canadian Patent Nos. 2,309,629 (&#8217;629) and 2,655,335 (&#8217;335). Janssen subsequently discontinued the portion of the lawsuit relating to the &#8217;629 patent. In May 2020, the Canadian Federal Court issued a Public Judgment and Reasons declaring that Teva Canada&#8217;s generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if approved, would infringe certain claims of the &#8217;335 patent and that the claims of the &#8217;335 patent are not invalid for obviousness. Teva Canada appealed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience Inc. in response to Pharmascience Inc.'s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement is scheduled for November 2021. The trial is scheduled to begin in July 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in response to Apotex's filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement is scheduled for December 2021. The trial is scheduled to begin in September 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian lawsuits, Janssen Canada is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp; Development, LCC (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., and Mylan Institutional LLC (collectively, Mylan). Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (546 mg) before expiration of United States Patent No. 10,143,693 (&#8217;693) relating to INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(546 mg). Janssen is seeking an order enjoining Mylan from marketing a generic version of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before the expiration of the &#8217;693 patent. Trial is scheduled to begin in October 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(819 mg) before expiration of the &#8217;693 patent. Janssen is seeking an order enjoining Mylan from marketing a generic version of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (819 mg) before the expiration of the &#8217;693 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (273 mg and 410 mg) before expiration of the &#8217;693 patent. Janssen is seeking an order enjoining Mylan from marketing a generic version of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (273 mg and 410 mg) before the expiration of the &#8217;693 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in January 2018, Pharmacyclics LLC (Pharmacyclics) and Janssen Biotech, Inc. (JBI) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies that filed ANDAs seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> 140 mg capsules before expiration of Pharmacyclics&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">United States Patent Nos. 8,008,309, 7,514,444, 8,697,711, 8,735,403, 8,957,079, 9,181,257, 8,754,091, 8,497,277, 8,925,015, 8,476,284, 8,754,090, 8,999,999, 9,125,889, 9,801,881, 9,801,883, 9,814,721, 9,795,604, 9,296,753, 9,540,382, 9,713,617 and/or 9,725,455 relating to IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. JBI is the exclusive licensee of the asserted patents. The named defendants include the following generic companies: Sandoz Inc. and Lek Pharmaceuticals d.d. (collectively, Sandoz).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2019 and February 2019, Pharmacyclics and JBI amended their complaint against Sandoz to allege infringement of United States Patent Nos. 10,125,140 and 10,106,548. In August 2019, Pharmacyclics and JBI amended their complaint against Sandoz to further allege infringement of U.S. Patent Nos. 10,294,231 and 10,294,232.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen Pine Brook LLC and Natco Pharma Ltd. (collectively, Alvogen), which filed an ANDA seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, asserting infringement of United States Patent Nos. 7,514,444, 8,003,309, 8,476,284, 8,497,277, 8,697,711, 8,753,403, 8,754,090, 8,754,091, 8,952,015, 8,957,079, 9,181,257, 9,296,753,  9,655,857, 9,725,455, 10,010,507, 10,106,548, and 10,125,140. In June 2019, Pharmacyclics and JBI amended their complaint against Alvogen to further allege infringement of United States Patent No. 10,213,386. Pharmacyclics and JBI are seeking an order enjoining the defendants from marketing generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Trial in the foregoing actions against Sandoz and Alvogen took place in October 2020. In May 2021, JBI, Pharmacyclics and Sandoz entered into a confidential settlement agreement. In August 2021, the District Court issued a decision in favor of Pharmacyclics and Janssen finding the asserted claims against Alvogen to be infringed and not invalid. Alvogen has appealed that decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2021, Pharmacyclics and Janssen Inc. (Janssen Canada) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Natco Pharma (Canada) Inc. (Natco) in response to Natco&#8217;s filing of two ANDSs seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">capsules before the expiration of Canadian Patent Nos. 2,663,116; 2,928,721; 2,800,913; 3,007,787; 3,007,788, 2,875,986; and 3,022,256. The trial is scheduled to begin in July 2023. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pharmacyclics and Janssen are seeking an order enjoining Natco from marketing its generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2020, Actelion Pharmaceuticals Ltd (Actelion) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Zydus Pharmaceuticals (USA), </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inc. and Zydus Worldwide DMCC (collectively, Zydus),  who filed an ANDA seeking approval to market a generic version of UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">before expiration of Nippon Shinyaku&#8217;s United States Patent Nos. 7,205,302 (&#8217;302); 8,791,122 (&#8217;122); and 9,284,280 (&#8217;280) relating to UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. In January 2021, the court entered a joint stipulation dismissing the claims against Zydus related to the &#8217;122 and &#8217;280 patents.  Actelion is the exclusive licensee of the &#8217;302 patent. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Actelion and Nippon Shinyaku are seeking an order enjoining Zydus from marketing a generic version of UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before the expiration of the &#8217;302 patent.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GOVERNMENT PROCEEDINGS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like other companies in the pharmaceutical, consumer health and medical devices industries, Johnson &amp; Johnson and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Average Wholesale Price (AWP) Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and several of its pharmaceutical subsidiaries (the J&amp;J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&amp;J AWP Defendants were ultimately dismissed. The J&amp;J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. The case brought by Illinois was settled after trial. In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), Johnson &amp; Johnson and ALZA Corporation. All other cases have been resolved.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Opioid Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in 2014 and continuing to the present, Johnson &amp; Johnson and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in approximately 3,300 lawsuits related to the marketing of opioids, including DURAGESIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, NUCYNTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and NUCYNTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> ER. The suits also raise allegations related to previously owned active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children suffering from Neonatal Abstinence Syndrome; hospitals; and health insurers/payors. To date, complaints against pharmaceutical manufacturers, including Johnson &amp; Johnson and JPI, have been filed by the state Attorneys General in Arkansas, Florida, Idaho, Illinois, Kentucky, Louisiana, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, South Dakota, Texas, Washington and West Virginia. Complaints against the manufacturers also have been filed in state or federal court by city, county and local government agencies in the following states: Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, West Virginia and Wisconsin. The Government of Puerto Rico filed suit in Superior Court of San Juan. There are approximately 390 cases pending in various state&#160;courts. There are over 2,900 federal cases coordinated in a federal Multi-District Litigation (MDL) pending in the U.S. District Court for the Northern District of Ohio.&#160;In addition, the Province of British Columbia filed suit against Johnson &amp; Johnson and its Canadian affiliate Janssen Inc., and many other industry members, in Canada, and is seeking to have that action certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada. Additional proposed class actions have been filed in Canada against Johnson &amp; Johnson and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. In October 2019, an anti-trust complaint was filed by private plaintiffs in federal court in Tennessee and is pending transfer to the MDL. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The trial in the matter filed by the Oklahoma Attorney General resulted in a judgment against Johnson &amp; Johnson and JPI in the amount of $465&#160;million. Johnson &amp; Johnson and JPI have appealed the judgment. The Company believes that it has strong grounds to overturn this judgment. In October 2019 Johnson &amp; Johnson and JPI announced a settlement of the first case set for trial in the MDL with two counties in Ohio. In April 2021, three California counties and the City of Oakland commenced a trial in California state court against Johnson &amp; Johnson and JPI, and other affiliates, as well as three other pharmaceutical manufacturers. The trial concluded in October 2021 and the parties are awaiting a ruling.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Johnson &amp; Johnson received a grand jury subpoena from the United States Attorney&#8217;s Office for the Eastern District of New York for documents related to the Company&#8217;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#8217; and distributors&#8217; monitoring programs and reporting under the Controlled Substances Act. In September 2019, Johnson &amp; Johnson received subpoenas from the New York State Department of Financial Services (NYDFS) as part of an industry-wide inquiry into the effect of opioid prescriptions on New York health insurance premiums.&#160;In September 2020, the Company learned that NYDFS filed a statement of charges related to this investigation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2021, the Company and JPI announced a settlement agreement with the State of New York and its participating subdivisions, including Nassau County and Suffolk County, resolving their opioid-related claims against the Company on terms consistent with the Company&#8217;s previously announced agreement in principle to contribute up to $5&#160;billion to all-in settlement of opioid-related claims by states, cities, counties, and tribal governments. The settlement provides New York and its participating subdivisions with up to $263&#160;million to address opioid-related issues, reimburses attorney fees and costs, and removes the Company and Janssen from a multi-defendant trial of opioid-related claims that commenced in Suffolk County in June 2021. In exchange, the Company and JPI receive releases from the claims asserted by New York and the participating parties, including   NYDFS.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, the Company and JPI announced a settlement agreement with the State of Texas and its participating subdivisions, including Dallas County, Bexar County, and Tarrant County, resolving their opioid-related claims against the Company on terms consistent with the Company&#8217;s previously announced agreement to contribute up to $5&#160;billion to all-in settlement of opioid-related claims by states, cities, counties, and tribal governments. The settlement provides Texas and its participating subdivisions with up to $297&#160;million to address opioid-related issues and reimburse attorney fees and costs, and removes the Company and Janssen from multi-defendant bellwether trials of opioid-related claims scheduled to commence in Texas state courts in early 2022. In exchange, the Company and JPI will receive releases from the claims asserted by Texas and the participating subdivisions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Johnson &amp; Johnson, JPI and other pharmaceutical companies have also received subpoenas or requests for information related to opioids marketing practices from the following state Attorneys General: Alaska, Indiana, Montana, New Hampshire, South Carolina, Tennessee, Texas and Washington. In September 2017, Johnson &amp; Johnson and JPI were contacted by the Texas and Colorado Attorney General&#8217;s Offices on behalf of approximately 38 states regarding a multi-state Attorney General investigation. In October 2019, the Company announced a proposed agreement in principle that would include the Company paying $4&#160;billion as settlement of these matters. In October 2020, the Company agreed to contribute up to an additional $1&#160;billion to an all-in settlement amount that would resolve opioid lawsuits filed and future claims by states, cities, counties and tribal governments, for a total of $5&#160;billion which has been accrued, subject to various conditions and an agreement being finalized. This agreement in principle is not an admission of liability or wrong-doing. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims have been finalized and up to 25% of the all-in settlement is expected to be paid within the next 12 months, depending upon the level of participation by the states and their subdivisions. The terms provide a period of time for states to elect to participate in the agreement and, thereafter, a period for the subdivisions of the participating states to opt-in. The opt-in period expires in January 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company retains the right to opt-out of the agreement if, in its sole discretion, there is insufficient participation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From June 2017 through December 2019, the Company&#8217;s Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Board unanimously adopted the recommendations of the independent counsel&#8217;s report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2019, one of the shareholders who sent a demand filed a derivative complaint against Johnson &amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. In May 2020, the shareholder filed an amended complaint challenging the </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Board&#8217;s rejection of his demand. In August 2020, Johnson &amp; Johnson moved to dismiss the amended complaint. In February 2021, the Court held oral argument on Johnson &amp; Johnson's motion. In August 2020, another shareholder who sent a demand filed a separate derivative complaint in the same court making similar allegations. In October 2020, the Court granted defendants&#8217; request to reassign the second-filed case to the division where the first-filed case is pending. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2019, two additional shareholders who sent demands filed two separate derivative complaints making similar allegations against Johnson &amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the United States District for the District of New Jersey. In April 2020, the two federal cases were consolidated into a single action captioned</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> In re Johnson &amp; Johnson Opioid Stockholder Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. In July 2020, the shareholders filed a consolidated complaint. In September 2020, Johnson &amp; Johnson moved to dismiss the consolidated complaint, and in December 2020, the shareholders opposed Johnson &amp; Johnson&#8217;s motion. Johnson &amp; Johnson filed its reply in February 2021. In July 2020, an additional shareholder who sent a demand filed a derivative complaint in the same federal court making similar allegations against the same defendants named in the consolidated action. In January 2021, pursuant to an order in the consolidated action, the third case was consolidated into the consolidated action. In February 2021, the Court granted the shareholders motion to voluntarily dismiss the consolidated action without prejudice, and the shareholders&#8217; counsel then filed a notice of association in the first-filed derivative action pending in the Superior Court of New Jersey. </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson &amp; Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney's Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ASR&#8482; XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> case filed pursuant to the False Claims Act against the companies concerning the hip devices. In February 2016, the District Court granted the companies&#8217; motion to dismiss with prejudice, unsealed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint, and denied the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> relators&#8217; request for leave to file a further amended complaint. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the District Court&#8217;s dismissal in part, reversed in part, and affirmed the decision to deny the relators&#8217; request to file a third amended complaint. The relators&#8217; remaining claims are now pending before the District Court, and the District Court has not yet closed the fact discovery time period. In March 2021, DePuy filed its motion to strike and dismiss the relators&#8217; second amended complaint; the District Court denied DePuy&#8217;s motion to strike and dismiss on July 6, 2021.  DePuy filed a motion for reconsideration of the District Court&#8217;s July 6, 2021 ruling.  On August 18, 2021, the District Court stated that it was reviewing DePuy&#8217;s motion for reconsideration, and on September 16, 2021, in connection with the District Court&#8217;s review of the motion for reconsideration, the District Court ordered the parties to file additional submissions by September 30, 2021, which are now under review by the District Court.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2012, Johnson &amp; Johnson was contacted by the California Attorney General's office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by Johnson &amp; Johnson's subsidiary, Ethicon, Inc. (Ethicon). In May 2016, California and Washington filed civil complaints against Johnson &amp; Johnson, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states:  Kentucky, Mississippi, West Virginia and Oregon. In April 2019, Johnson &amp; Johnson and Ethicon settled the Washington case. The California case started trial in July 2019 and concluded in September 2019. The trial date for the Kentucky case was scheduled for September 2019 but has been adjourned and no new trial date has been scheduled. In October 2019, Johnson &amp; Johnson and Ethicon settled the multi-state investigation with 41 other states and the District of Columbia. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $344&#160;million. In April 2020, the Court in California denied the Company's motion for a new trial. In August 2020, the Court entered judgment with respect to the penalties of $344&#160;million, but denied the Attorney General&#8217;s request for injunctive relief. The Company is appealing the penalty judgment. In April 2020, the Company settled the West Virginia case. In October 2020, the Company settled with the Attorney General of Oregon.  In November 2020, the Company settled with the Attorney General of Mississippi. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Companies, Inc. (now known as Johnson &amp; Johnson Consumer Inc.) (JJCI).&#160;The complaint alleges that defendants violated the Mississippi Consumer Protection Act by </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">failing to disclose alleged health risks associated with female consumers' use of talc contained in JOHNSON'S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Baby Powder and JOHNSON'S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. The Mississippi Supreme Court granted Johnson &amp; Johnson and JJCI's request to file an interlocutory appeal of the denial of the motion for summary judgment in late 2019. Johnson &amp; Johnson and JJCI moved for summary judgment on the grounds that the State's claim was barred by preemption. In April 2021, the Mississippi Supreme Court dismissed the Company&#8217;s interlocutory appeal and remanded the case back to the Hinds County Chancery Court. Discovery is now proceeding in that court. In August 2021, Johnson &amp; Johnson and JJCI filed a Petition for Writ of Certiorari in the US Supreme Court. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The State of New Mexico filed an Amended Complaint in March 2020. The Company moved to dismiss certain of the claims in the Amended Complaint, which was granted. The Company then filed a motion for partial judgment on the pleadings in December 2020, which was denied. The Company made its first document production in February 2021 and discovery is ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Forty-two states have commenced a joint investigation into the Company&#8217;s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington. The Company has entered into a tolling agreement with thirty-three States, which is set to expire in November 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, Janssen Pharmaceuticals, Inc. (JPI) received a Civil Investigative Demand from the United States Attorney&#8217;s Office for the Southern District of New York related to JPI&#8217;s contractual relationships with pharmacy benefit managers over the period from January 1, 2006 to the present with regard to certain of JPI's pharmaceutical products. The demand was issued in connection with an investigation under the False Claims Act. The Company has provided documents in response to the demand. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2016, Johnson &amp; Johnson and Janssen Products LP were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and INTELENCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, and anti-kickback violations in connection with the promotion of these products.&#160;The complaint was filed under seal in December 2012.&#160;The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators.&#160;Summary judgment and Daubert motions are currently pending with the Court. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April and September 2017, Johnson &amp; Johnson received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, OLYSIO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, SIMPONI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.&#160;The subpoenas also seek documents relating to&#160;Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies. The Company has provided documents in response to the subpoenas. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, Johnson &amp; Johnson received a subpoena from the United States Attorney's Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc.(DePuy) spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these hospitals. Johnson &amp; Johnson and DePuy have produced documents in response to the subpoena and are fully cooperating with the government&#8217;s investigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2018 the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp; Johnson do Brasil Ind&#250;stria e Com&#233;rcio de Produtos para Sa&#250;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson &amp; Johnson to cooperate with these inquiries by producing the requested information.</span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GENERAL LITIGATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2018, a purported class action was filed in the Circuit Court Third Judicial District Madison County, Illinois against Johnson &amp; Johnson Consumer, Inc. (JJCI), alleging violations of state consumer fraud statutes based on nondisclosure of </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">alleged health risks associated with talc contained in JOHNSON'S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Baby Powder. The complaint seeks damages but does not allege personal injury. In August 2021, the Court granted JJCI&#8217;s motion to dismiss the complaint.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March and April 2015, over 30 putative class action complaints were filed by contact lens patients in a number of courts around the United States against Johnson &amp; Johnson Vision Care, Inc. (JJVCI) and other contact lens manufacturers, distributors, and retailers, alleging vertical and horizontal conspiracies to fix the retail prices of contact lenses. The complaints allege that the manufacturers reached agreements with each other and certain distributors and retailers concerning the prices at which some contact lenses could be sold to consumers. The plaintiffs are seeking damages and injunctive relief. All of the class action cases were transferred to the United States District Court for the Middle District of Florida in June 2015. The plaintiffs filed a consolidated class action complaint in November 2015. Discovery and pre-trial motion practice are complete. Trial is scheduled to begin in March 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in September 2017, multiple purported class actions were filed on behalf of indirect purchasers of REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) alleging that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The cases were consolidated for pre-trial purposes as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Antitrust Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in United States District Court for the Eastern District of Pennsylvania. The consolidated complaint seeks damages and injunctive relief.  Discovery is ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, Walgreen Co. and Kroger Co., filed an antitrust complaint against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in the United States District Court for the Eastern District of Pennsylvania.  The complaint alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The complaint seeks damages and injunctive relief. In March 2019, summary judgment was granted in favor of Janssen. In February 2020, the United States Court of Appeals for the Third Circuit reversed the District Court&#8217;s decision. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to Johnson &amp; Johnson in connection with its investigation of whether Janssen&#8217;s REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act.  The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2021, plaintiffs appealed the District Court&#8217;s decision to the United States Court of Appeals for the District of Columbia Circuit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia.&#160;The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.&#160; TRACLEER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> is subject to a Risk Evaluation and Mitigation Strategy required by the Food and Drug Administration, which imposes restrictions on distribution of the product.&#160; In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland.&#160; In October 2019, the Court granted Actelion&#8217;s motion to dismiss the amended complaint. In April 2021, the United States Court of Appeals for the Fourth Circuit reversed and remanded. Discovery is ongoing.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research &amp; Development, LLC, and Johnson &amp; Johnson (collectively, Janssen) were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint filed on behalf of the United States, 28 states, and the District of Columbia.&#160;The complaint, which was filed in December 2017 in United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> to the government in connection with direct government sales and government-funded drug reimbursement programs.&#160;At this time, the federal and state governments have declined to intervene. The case has been transferred to United States District Court for the District of New Jersey. In September 2019, Janssen moved to dismiss the complaint. In February 2021, the judge has set a renewed schedule for the Company's motion to dismiss, with briefs to be fully submitted by early July 2021. In April 2021, Janssen renewed its motion to dismiss pursuant to Court order.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2019, Blue Cross &amp; Blue Shield of Louisiana and HMO Louisiana, Inc. filed a class action complaint against Janssen Biotech, Inc, Janssen Oncology, Inc, Janssen Research &amp; Development, LLC (collectively, Janssen) and BTG International Limited in the United States District Court for the Eastern District of Virginia on behalf of indirect purchasers of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Several additional complaints were filed thereafter in Virginia and New Jersey. The indirect purchaser complaints generally allege that the defendants violated the antitrust and consumer protections laws of several states and the Sherman Act by </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">pursuing patent litigation relating to ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in order to delay generic entry and seek damages. The Virginia cases have been transferred to the United States District Court for the District of New Jersey and consolidated with the New Jersey case. A consolidated amended complaint was filed in February 2021. In April 2021, Janssen moved to dismiss the Indirect Purchaser Action. Discovery in the Indirect Purchaser Action is ongoing. In May 2020, a class action complaint was filed against Janssen Biotech Inc., Janssen Oncology, Inc., Janssen Research &amp; Development LLC and BTG International Limited in the United States District Court for the District of New Jersey, on behalf of direct purchasers of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The direct purchaser complaint alleges that defendants violated the Sherman Act by pursuing patent litigation relating to ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in order to delay generic entry, and seek damages and injunctive relief. In April 2021, Janssen moved to compel arbitration of the Direct Purchaser Action. In October 2021, the Court granted Janssen&#8217;s motion and compelled arbitration of the Direct Purchaser Action.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2019, a class action antitrust complaint was filed against Janssen R&amp;D Ireland (Janssen) and Johnson &amp; Johnson in the United States District Court for the Northern District of California. The complaint alleges that Janssen violated federal and state antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the development and marketing of combination antiretroviral therapies (cART) to treat HIV. The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers Squibb and Japan Tobacco. In March 2020, the Court granted in part and denied in part defendants&#8217; motions to dismiss.  Plaintiffs filed an amended complaint in April 2020. Defendants moved to dismiss the amended complaint.  In July 2020, the Court granted in part and denied in part the renewed motion to dismiss. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California. The complaint alleges that certain of BWI&#8217;s&#160;business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In January 2020, BWI filed a motion to dismiss the complaint. In August 2020, the Court granted in part and denied in part BWI&#8217;s motion to dismiss. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, Johnson &amp; Johnson received a demand for indemnification from Pfizer Inc., pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson &amp; Johnson, Inc. received a demand for indemnification from Sanofi Consumer Health, Inc., pursuant to the 2016 Asset Purchase Agreement between J&amp;J, Inc. and Sanofi. In January 2020, Johnson &amp; Johnson received a demand for indemnification from Boehringer Ingelheim Pharmaceuticals, Inc., pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim.  The notices seek indemnification for legal claims related to over-the-counter ZANTAC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ranitidine) products. Plaintiffs in the underlying actions allege that ZANTAC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against Johnson &amp; Johnson, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#8217;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2020, Ethicon moved to dismiss certain causes of action in the complaint. Discovery is ongoing.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning in May 2021, multiple </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">putative </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">class actions were filed in state and federal courts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(California, Florida, New York, and New Jersey)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> against various Johnson &amp; Johnson entities alleging violations of state consumer fraud statutes based on nondisclosure of alleged benzene contamination of certain Neutrogena and Aveeno sunscreen products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and the affirmative promotion of those products as &#8220;safe&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">; and, in at least one case, alleging a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strict liability manufacturing defect and failure to warn </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">claims, asserting that the named plaintiffs</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> suffered unspecified injuries as a result of alleged exposure to benzene.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Judicial Panel on Multi-District Litigation has consolidated all pending actions, except one product liability matter, in the United States District Court-Southern District of Florida-Fort Lauderdale Division. In October 2021, the Company reached an agreement in principle for the settlement of a nationwide class, encompassing the claims of the consolidated actions, subject to approval by the Florida federal Court.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson or its subsidiaries are also parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720993048584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text">RESTRUCTURING<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal second quarter of 2018 the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions will include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. In the fiscal third quarter of 2021, the Company recorded a pre-tax charge of $121 million, which is included on the following lines of the Consolidated Statement of Earnings, $60 million in restructuring, $18 million in cost of products sold and $43 million in other (income) expense, net. In the fiscal nine months of 2021, the Company recorded a pre-tax charge of $333&#160;million, which is included on the following lines of the Consolidated Statement of Earnings, $169&#160;million in restructuring, $65&#160;million in cost of products sold and $99&#160;million in other (income) expense, net. Total project costs of approximately $1.6 billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company expects the Global Supply Chain actions to generate approximately $0.6 billion to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by 2022. The Company expects to record pre-tax restructuring charges of approximately $1.9 billion to $2.3 billion, over the 4 to 5 year period of this activity. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization.&#160; &#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal third quarter of 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:33.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.881%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.972%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Write-offs</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January 3, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Charges  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(270)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(287)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Settled non cash </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, October 3, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash outlays for severance are expected to be substantially paid out over the next 18 months in accordance with the Company's plans and local laws. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720994469608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of October&#160;3, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets along with the Company&#8217;s on-going vaccine development and distribution efforts. While there was not a material impact to the Company&#8217;s consolidated financial statements as of and for the quarter ended October&#160;3, 2021, the Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New and Recently Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021. There were no new material accounting standards issued in the fiscal nine months of 2021 that impacted the Company.</span></div><div style="margin-top:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the fiscal nine months of 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current year presentation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy</a></td>
<td class="text">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720993182392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"><tr><td style="width:1.0%"/><td style="width:51.896%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.310%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goods in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720994392984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"/><td style="width:61.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with definite lives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; gross</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,176&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,990&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,569)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,618)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,607&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,372&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles &#8212; gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,637)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,912)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; net*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased in-process research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,843&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,849&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets &#8212; net</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,776&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,402&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*The majority is comprised of customer relationships</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In the fiscal third quarter of 2021, the Company recorded a partial IPR&amp;D impairment charge of $0.9&#160;billion primarily related to expected development delays in the general surgery digital robotics platform (Ottava) acquired with the Auris Health acquisition in 2019. The impairment charge was calculated based on revisions to the discounted cash flow valuation model reflecting a delay of first in human procedures of approximately two years from the initial acquisition model assumption of the second half of 2022. The remaining reduction was driven by assets that reached commercialization and are now classified as having definite lives.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Goodwill</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill as of October&#160;3, 2021 was allocated by segment of business as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:39.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.660%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to divestitures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(347)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(283)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(817)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at October 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Intangible Asset Amortization Expense</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"><tr><td style="width:1.0%"/><td style="width:18.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.910%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,700</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,500</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,500</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,300</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,600</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720994054600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of Derivative Activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal third quarters ended in 2021 and 2020, net of tax:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.102%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 27, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal nine months ended in 2021 and 2020, net of tax:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.493%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.302%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.760%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 27, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(316)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of net investment hedges for the fiscal third quarters ended in 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.814%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.959%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated<br/>OCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 27, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of net investment hedges for the fiscal nine months ended in 2021 and 2020:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:24.725%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.758%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.265%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="33" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated OCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 27, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Derivative Financial Instruments and Classification on Consolidated Balance Sheet</a></td>
<td class="text"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of  October&#160;3, 2021, and January&#160;3, 2021, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges </span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Line item in the Consolidated Balance Sheet in which the hedged item is included</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount of the Hedged Liability<br/></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Effect of Derivatives not Designated as Hedging Instruments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of derivatives not designated as hedging instruments for the fiscal third quarters and fiscal nine months in 2021 and 2020: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.010%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.277%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain /(Loss) Recognized in Income on Derivative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Activity Related to Equity Investments</a></td>
<td class="text"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:25.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.365%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.464%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.667%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales/ Purchases/Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(545)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded in Other Income/Expense</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other includes impact of currency</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Financial Assets and Liabilities at Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of October&#160;3, 2021 and January&#160;3, 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:48.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.904%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.318%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,058)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,260)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in liabilities for contingent consideration is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.807%"><tr><td style="width:1.0%"/><td style="width:41.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.606%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 27, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,088)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">2020 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,481 million, which are classified as Level 1 and contingent consideration of $633 million, classified as Level 3.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes cross currency interest rate swaps and interest rate swaps as of October&#160;3, 2021. Includes cross currency interest rate swaps as of January&#160;3, 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classified as non-current other assets. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes $595 million and $594 million, classified as non-current other liabilities as of October&#160;3, 2021 and January&#160;3, 2021, respectively.  Includes $18 million and $39 million classified as current liabilities as of October&#160;3, 2021 and January&#160;3, 2021, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. </span></div>The Company recorded a contingent consideration reversal of $1,148 million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense, net.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Marketable Securities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cash, cash equivalents and current marketable securities as of October&#160;3, 2021 comprised:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"/><td style="width:22.208%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.727%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.153%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.153%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.153%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.727%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.454%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.153%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.182%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Gain</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. sovereign securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. reverse repurchase agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other sovereign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal available for sale debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Available for Sale Securities Maturities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the available for sale securities as of October&#160;3, 2021 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.415%"><tr><td style="width:1.0%"/><td style="width:43.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.279%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.031%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Financial Liabilities not Measured at Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Instruments not measured at Fair Value:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial liabilities are held at carrying amount on the consolidated balance sheet as of October&#160;3, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.838%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.259%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73% Debentures due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Notes due 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.05% Notes due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.650% Notes due 2024 (750MM Euro 1.1581)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% Notes due 2024 (500 MM GBP 1.3465)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.625% Notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.55% Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90%&#160;Notes due 2028</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.150% Notes due 2028 (750MM Euro 1.1581)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.95% Notes due 2029</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% Notes due 2030</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95% Debentures due 2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.375% Notes due 2033</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.650% Notes due 2035 (1.5B Euro 1.1581)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.55% Notes due 2036</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95% Notes due 2037</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% Notes due 2037</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40%&#160;Notes due 2038</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85% Debentures due 2038</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Debentures due 2040</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10% Notes due 2040</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.85% Notes due 2041</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Notes due 2043</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70% Notes due 2046</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Notes due 2047</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50% Notes due 2048</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% Notes due 2050</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2060</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-Current Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720991436744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Components of Net Periodic Benefit Cost</a></td>
<td class="text">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans include the following components:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.338%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(661)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,988)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,839)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost/(credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments and settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720993073272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Components of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) consist of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:34.774%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.719%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.306%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.991%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Accumulated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Comprehensive</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,938)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,242)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(631)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,257)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,415)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139721079650632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"/><td style="width:53.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.304%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.308%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Shares in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings per share </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,633.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: shares which could be repurchased under treasury stock method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,674.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,669.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,674.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,670.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720994393832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SalesBySegmentOfBusinessTableTextBlock', window );">Sales By Segment Of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY SEGMENT OF BUSINESS </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent Change</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consumer Health</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:168pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Exports</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER IMMUNOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">COVID-19 VACCINE</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">EDURANT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / rilpivirine</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / PREZCOBIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> /</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">                                    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">            REZOLSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / SYMTUZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER INFECTIOUS DISEASES</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONCERTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / methylphenidate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / XEPLION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / INVEGA   TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / TREVICTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;RISPERDAL CONSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER NEUROSCIENCE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> / </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">abiraterone acetate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER ONCOLOGY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER PULMONARY HYPERTENSION</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MEDICAL DEVICES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">HIPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">KNEES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TRAUMA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ADVANCED</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONTACT LENSES / OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SURGICAL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL MEDICAL DEVICES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WORLDWIDE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,082&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inclusive of VELCADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Operating Profit by Segment of Business</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT  </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:36.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27,<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27,<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.7</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before provision for taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.8)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.5)%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.8%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consumer Health</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Includes intangible amortization expense of $0.1 billion in both the fiscal third quarter of 2021 and 2020 and $0.3&#160;billion in both the fiscal nine months of 2021 and 2020. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Includes litigation expense of $1.4&#160;billion and $0.5&#160;billion in the fiscal third quarter of 2021 and 2020, respectively. Includes litigation expense of  $1.5&#160;billion and $1.2&#160;billion in the fiscal nine months of 2021 and 2020, respectively. Litigation expense in both periods is primarily related to talc.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Includes a restructuring related charge of $0.1&#160;billion in both the fiscal nine months of 2021 and 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pharmaceutical</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes divestiture gains of $0.6&#160;billion in the fiscal nine months of 2021 related to two brands outside the U.S.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes intangible amortization expense of $0.8&#160;billion in both the fiscal third quarter of 2021 and 2020. Includes intangible amortization expense of $2.5&#160;billion and $2.4&#160;billion in the fiscal nine months of 2021 and 2020, respectively.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes net litigation expense of $0.8&#160;billion and $1.0&#160;billion in the fiscal third quarter of 2021 and 2020, respectively. Includes net litigation expense of  $0.7&#160;billion and $1.0&#160;billion in the fiscal nine months of 2021 and 2020, respectively. Litigation expense in 2021 is primarily related to Risperdal. Litigation expense in 2020 is related to the opioid settlement.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes a gain on securities of $0.1&#160;billion in the fiscal third quarter of 2021 and $0.2&#160;billion in both the fiscal nine months of 2021 and 2020, respectively. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes a restructuring related charge of $0.1&#160;billion in both the fiscal nine months of 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In fiscal 2020 and 2021, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $1.2&#160;billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Devices </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes a contingent consideration reversal of $0.2&#160;billion in the fiscal third quarter of 2020 and $1.1&#160;billion in the fiscal nine months of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes a restructuring related charge of $0.1 billion in both the fiscal third quarter of 2021 and 2020, respectively. Includes a restructuring related charge of $0.2&#160;billion in both the fiscal nine months of 2021 and 2020, respectively.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes intangible amortization expense of $0.3&#160;billion and $0.2&#160;billion in the fiscal third quarter of 2021 and 2020, respectively. Includes intangible amortization expense of $0.8&#160;billion and $0.7&#160;billion in the fiscal nine months of 2021 and 2020, respectively. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes a gain on securities of $0.1&#160;billion in the fiscal nine months of 2021.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Includes an in-process research and development expense of $0.9&#160;billion related to the general surgery offering in digital robotics (Ottava) acquired with the Auris Health acquisition in 2019 in both the fiscal third quarter and fiscal nine months of 2021. See Note 3 to the Consolidated Financial Statements for more details.</span></div>(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.<span></span>
</td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT  </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:36.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27,<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27,<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.7</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before provision for taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.8)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.5)%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.8%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consumer Health</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Includes intangible amortization expense of $0.1 billion in both the fiscal third quarter of 2021 and 2020 and $0.3&#160;billion in both the fiscal nine months of 2021 and 2020. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Includes litigation expense of $1.4&#160;billion and $0.5&#160;billion in the fiscal third quarter of 2021 and 2020, respectively. Includes litigation expense of  $1.5&#160;billion and $1.2&#160;billion in the fiscal nine months of 2021 and 2020, respectively. Litigation expense in both periods is primarily related to talc.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Includes a restructuring related charge of $0.1&#160;billion in both the fiscal nine months of 2021 and 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pharmaceutical</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes divestiture gains of $0.6&#160;billion in the fiscal nine months of 2021 related to two brands outside the U.S.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes intangible amortization expense of $0.8&#160;billion in both the fiscal third quarter of 2021 and 2020. Includes intangible amortization expense of $2.5&#160;billion and $2.4&#160;billion in the fiscal nine months of 2021 and 2020, respectively.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes net litigation expense of $0.8&#160;billion and $1.0&#160;billion in the fiscal third quarter of 2021 and 2020, respectively. Includes net litigation expense of  $0.7&#160;billion and $1.0&#160;billion in the fiscal nine months of 2021 and 2020, respectively. Litigation expense in 2021 is primarily related to Risperdal. Litigation expense in 2020 is related to the opioid settlement.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes a gain on securities of $0.1&#160;billion in the fiscal third quarter of 2021 and $0.2&#160;billion in both the fiscal nine months of 2021 and 2020, respectively. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes a restructuring related charge of $0.1&#160;billion in both the fiscal nine months of 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In fiscal 2020 and 2021, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $1.2&#160;billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Devices </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes a contingent consideration reversal of $0.2&#160;billion in the fiscal third quarter of 2020 and $1.1&#160;billion in the fiscal nine months of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes a restructuring related charge of $0.1 billion in both the fiscal third quarter of 2021 and 2020, respectively. Includes a restructuring related charge of $0.2&#160;billion in both the fiscal nine months of 2021 and 2020, respectively.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes intangible amortization expense of $0.3&#160;billion and $0.2&#160;billion in the fiscal third quarter of 2021 and 2020, respectively. Includes intangible amortization expense of $0.8&#160;billion and $0.7&#160;billion in the fiscal nine months of 2021 and 2020, respectively. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes a gain on securities of $0.1&#160;billion in the fiscal nine months of 2021.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Includes an in-process research and development expense of $0.9&#160;billion related to the general surgery offering in digital robotics (Ottava) acquired with the Auris Health acquisition in 2019 in both the fiscal third quarter and fiscal nine months of 2021. See Note 3 to the Consolidated Financial Statements for more details.</span></div>(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY GEOGRAPHIC AREA</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.279%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.486%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.889%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.486%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.889%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.486%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.751%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.339%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.486%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 27, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,587&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,819&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,669&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,709&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere, excluding U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific, Africa</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,288&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,881&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,018&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SalesBySegmentOfBusinessTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales by segment of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SalesBySegmentOfBusinessTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720993077144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal third quarter of 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:33.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.881%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.972%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Write-offs</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January 3, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Charges  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(270)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(287)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Settled non cash </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, October 3, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash outlays for severance are expected to be substantially paid out over the next 18 months in accordance with the Company's plans and local laws. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720991692856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials and supplies</a></td>
<td class="nump">$ 1,587<span></span>
</td>
<td class="nump">$ 1,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Goods in process</a></td>
<td class="nump">2,164<span></span>
</td>
<td class="nump">2,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">6,636<span></span>
</td>
<td class="nump">5,894<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 10,387<span></span>
</td>
<td class="nump">$ 9,344<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139721079054104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-Lived Intangible Assets</a></td>
<td class="nump">$ 16,856<span></span>
</td>
<td class="nump">$ 19,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets - net</a></td>
<td class="nump">47,776<span></span>
</td>
<td class="nump">53,402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-Lived Intangible Assets</a></td>
<td class="nump">7,013<span></span>
</td>
<td class="nump">7,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember', window );">Purchased In-Process Research And Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-Lived Intangible Assets</a></td>
<td class="nump">9,843<span></span>
</td>
<td class="nump">11,849<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember', window );">Patents And Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets with definite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">39,176<span></span>
</td>
<td class="nump">39,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="num">(19,569)<span></span>
</td>
<td class="num">(17,618)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">19,607<span></span>
</td>
<td class="nump">22,372<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Customer relationships and other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets with definite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">22,950<span></span>
</td>
<td class="nump">22,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="num">(11,637)<span></span>
</td>
<td class="num">(10,912)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">11,313<span></span>
</td>
<td class="nump">$ 11,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development | Auris Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139721079326264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Goodwill By Segment (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Oct. 03, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill Beginning of Period</a></td>
<td class="nump">$ 36,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill, related to divestitures</a></td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/Other</a></td>
<td class="num">(817)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill End of Period</a></td>
<td class="nump">35,569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill Beginning of Period</a></td>
<td class="nump">10,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill, related to divestitures</a></td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/Other</a></td>
<td class="num">(347)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill End of Period</a></td>
<td class="nump">9,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill Beginning of Period</a></td>
<td class="nump">11,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill, related to divestitures</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/Other</a></td>
<td class="num">(283)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill End of Period</a></td>
<td class="nump">10,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill Beginning of Period</a></td>
<td class="nump">15,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill, related to divestitures</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/Other</a></td>
<td class="num">(187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill End of Period</a></td>
<td class="nump">$ 14,861<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139721082496296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Narrative (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of amortizable intangible assets</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember', window );">Patents And Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Assets, Weighted-Average Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Customer relationships and other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Assets, Weighted-Average Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720994420120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Oct. 03, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2021</a></td>
<td class="nump">$ 4,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">4,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">4,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">4,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">$ 3,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139721079383352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax', window );">Accumulated other comprehensive income on derivatives, after tax</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss', window );">Reclassification of foreign exchange contracts into earnings, period</a></td>
<td class="text">next 12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge', window );">Maximum length of time for hedge exposure</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate on non-current debt</a></td>
<td class="nump">2.98%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ExcessOfFairValueOverCarryingValueOfDebt', window );">Excess of the estimated fair value over the carrying value of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="nump">$ 3,798<span></span>
</td>
<td class="nump">2,631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="nump">0.08%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral already posted, aggregate fair value</a></td>
<td class="nump">$ 202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">45,800<span></span>
</td>
<td class="nump">37,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">35,100<span></span>
</td>
<td class="nump">$ 30,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Changes in Fair Value Reflected in Net Income</a></td>
<td class="nump">417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember', window );">Equity Investments without readily determinable value | Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityFairValueAdjustmentImpairmentLoss', window );">Equity, fair value adjustment, impairment loss</a></td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Changes in Fair Value Reflected in Net Income</a></td>
<td class="nump">$ 392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityFairValueAdjustmentImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity, Fair Value Adjustment, Impairment Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityFairValueAdjustmentImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ExcessOfFairValueOverCarryingValueOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of fair value over carrying value of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ExcessOfFairValueOverCarryingValueOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAlreadyPostedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAlreadyPostedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the transactions or other events that will result in the reclassification into earnings of gains or losses reported in accumulated other comprehensive income. May include the time period over which gains or losses will be reclassified to earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720997469384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Derivative Activity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross currency interest rate swaps | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Cross currency interest rate swaps | Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Cross currency interest rate swaps | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Cross currency interest rate swaps | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Cross currency interest rate swaps | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Interest Rate Swap | Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Interest Rate Swap | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Interest Rate Swap | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Interest Rate Swap | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Interest Rate Swap | Interest (income)/Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="num">(62)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">62<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Net Investment Hedging [Member] | Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Net Investment Hedging [Member] | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Net Investment Hedging [Member] | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Net Investment Hedging [Member] | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Net Investment Hedging [Member] | Interest (income)/Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="num">(35)<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="num">(155)<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="num">(398)<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">58<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="num">(316)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">37<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="num">(156)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">8<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(121)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">42<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">19<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Interest (income)/Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 307<span></span>
</td>
<td class="nump">$ 265<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061172-113977<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80845-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720994044936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Derivatives, Balance Sheet Location (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Carrying Amount of the Hedged Liability</a></td>
<td class="nump">$ 1,284<span></span>
</td>
<td class="nump">$ 2,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember', window );">Long-term Debt | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Carrying Amount of the Hedged Liability</a></td>
<td class="nump">9,851<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability</a></td>
<td class="num">$ (73)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720991753464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Forward foreign exchange contracts | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain/(Loss) Recognized In Income on Derivative</a></td>
<td class="num">$ (13)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">$ (50)<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720994048792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Gain/(Loss) Recognized In Accumulated OCI</a></td>
<td class="nump">$ 115<span></span>
</td>
<td class="num">$ (169)<span></span>
</td>
<td class="nump">$ 279<span></span>
</td>
<td class="num">$ (217)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other Income Expense Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross Currency Interest Rate Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Gain/(Loss) Recognized In Accumulated OCI</a></td>
<td class="nump">141<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="nump">432<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross Currency Interest Rate Contract | Other Income Expense Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80845-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139721082450712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Activity Related to Equity Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Non Current Other Assets</a></td>
<td class="nump">$ 6,870<span></span>
</td>
<td class="nump">$ 6,562<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Changes in Fair Value Reflected in Net Income</a></td>
<td class="nump">417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities | Equity Investments with readily determinable value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Carrying value, beginning of period</a></td>
<td class="nump">1,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Changes in Fair Value Reflected in Net Income</a></td>
<td class="num">(83)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod', window );">Sales/ Purchases/Other</a></td>
<td class="nump">469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Carrying value, end of period</a></td>
<td class="nump">1,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Non Current Other Assets</a></td>
<td class="nump">1,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities | Equity Investments without readily determinable value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Carrying value, beginning of period</a></td>
<td class="nump">738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Changes in Fair Value Reflected in Net Income</a></td>
<td class="nump">392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod', window );">Sales/ Purchases/Other</a></td>
<td class="num">(545)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Carrying value, end of period</a></td>
<td class="nump">585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Non Current Other Assets</a></td>
<td class="nump">$ 585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityInvestmentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Investment [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityInvestmentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139721079600712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">$ 1,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">1,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Available-for-sale Securities, Equity Securities</a></td>
<td class="nump">1,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">18,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total Gross Assets</a></td>
<td class="nump">1,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossLiability', window );">Credit Support Agreement (CSA)</a></td>
<td class="num">(1,058)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,107)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Total Net Asset</a></td>
<td class="nump">159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total Gross Liabilities</a></td>
<td class="nump">1,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossAsset', window );">Credit Support Agreement (CSA)</a></td>
<td class="num">(1,260)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,172)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total Net Liabilities</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">633<span></span>
</td>
<td class="nump">$ 1,715<span></span>
</td>
<td class="nump">1,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue', window );">Changes in estimated fair value (6)</a></td>
<td class="nump">28<span></span>
</td>
<td class="num">(1,088)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">613<span></span>
</td>
<td class="nump">636<span></span>
</td>
<td class="nump">633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reversal</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (1,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets and liabilities Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Available-for-sale Securities, Equity Securities</a></td>
<td class="nump">1,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">1,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">1,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Available-for-sale Securities, Equity Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">18,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Available-for-sale Securities, Equity Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">633<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract | Quoted prices in active markets for identical assets and liabilities Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract | Significant other observable inputs Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract | Significant unobservable inputs Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts | Quoted prices in active markets for identical assets and liabilities Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts | Significant other observable inputs Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts | Significant unobservable inputs Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember', window );">Auris Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reversal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,148)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities | Auris Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentDetailAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentDetailAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueGrossAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueGrossAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all foreign currency derivative assets not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all foreign currency derivative liabilities not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720994263688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">$ 18,911<span></span>
</td>
<td class="nump">$ 14,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">17,604<span></span>
</td>
<td class="nump">13,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">13,397<span></span>
</td>
<td class="nump">$ 11,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Total cash, cash equivalents and current marketable securities, Carrying Amount</a></td>
<td class="nump">31,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain', window );">Total cash, cash equivalents and current marketable securities, Unrecognized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss', window );">Total cash, cash equivalents and current marketable securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue', window );">Total cash, cash equivalents and current marketable securities, Estimated Fair Value</a></td>
<td class="nump">31,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">12,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity Securities, Unrecognized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">12,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">7,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">2,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity Securities, Unrecognized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">2,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">2,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Non-U.S. sovereign securities(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity Securities, Unrecognized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | U.S. reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">1,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity Securities, Unrecognized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">1,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">1,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Corporate debt securities(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">3,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity Securities, Unrecognized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">3,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">3,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">2,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity Securities, Unrecognized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">2,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">2,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Time deposits(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">1,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity Securities, Unrecognized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">1,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">1,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale Securities - Carrying Amount</a></td>
<td class="nump">18,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Unrecognized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">18,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">9,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">9,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | Non-U.S. sovereign securities(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale Securities - Carrying Amount</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Unrecognized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | Corporate debt securities(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale Securities - Carrying Amount</a></td>
<td class="nump">251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Unrecognized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | U.S. Gov't securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale Securities - Carrying Amount</a></td>
<td class="nump">18,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Unrecognized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">18,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">9,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">$ 8,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, and Short-term Investments, Estimated Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, and Short-term Investments, Accumulated Gross Unrealized Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesClassifiedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_SovereignDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_SovereignDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139721079249016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Oct. 03, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Cost Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due within one year</a></td>
<td class="nump">$ 18,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost', window );">Due after five years through ten years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total debt securities</a></td>
<td class="nump">18,911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due within one year</a></td>
<td class="nump">18,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Due after five years through ten years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total debt securities</a></td>
<td class="nump">$ 18,911<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720997823256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="nump">$ 3,798<span></span>
</td>
<td class="nump">$ 2,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">30,130<span></span>
</td>
<td class="nump">$ 32,635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="nump">3,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">30,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="nump">3,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 33,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member', window );">6.73% Debentures due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">6.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member', window );">6.73% Debentures due 2023 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member', window );">6.73% Debentures due 2023 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member', window );">3.375% Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member', window );">3.375% Notes due 2023 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member', window );">3.375% Notes due 2023 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.05Notesdue2023Member', window );">2.05% Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.05Notesdue2023Member', window );">2.05% Notes due 2023 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.05Notesdue2023Member', window );">2.05% Notes due 2023 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes due 2024 (750MM Euro 1.1581)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes due 2024 (750MM Euro 1.1581) | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes due 2024 (750MM Euro 1.1581) | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes due 2024 (500 MM GBP 1.3465)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes due 2024 (500 MM GBP 1.3465) | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes due 2024 (500 MM GBP 1.3465) | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member', window );">2.625% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member', window );">2.625% Notes due 2025 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member', window );">2.625% Notes due 2025 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member', window );">0.55% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member', window );">0.55% Notes due 2025 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member', window );">0.55% Notes due 2025 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member', window );">2.45% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member', window );">2.45% Notes due 2026 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member', window );">2.45% Notes due 2026 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 2,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member', window );">2.95% Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member', window );">2.95% Notes due 2027 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member', window );">2.95% Notes due 2027 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member', window );">0.95% Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member', window );">0.95% Notes due 2027 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member', window );">0.95% Notes due 2027 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member', window );">2.90%&#160;Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member', window );">2.90%&#160;Notes due 2028 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member', window );">2.90%&#160;Notes due 2028 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes due 2028 (750MM Euro 1.1581)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes due 2028 (750MM Euro 1.1581) | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes due 2028 (750MM Euro 1.1581) | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member', window );">6.95% Notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">6.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member', window );">6.95% Notes due 2029 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member', window );">6.95% Notes due 2029 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member', window );">1.30% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member', window );">1.30% Notes due 2030 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member', window );">1.30% Notes due 2030 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member', window );">4.95% Debentures due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member', window );">4.95% Debentures due 2033 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member', window );">4.95% Debentures due 2033 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member', window );">4.375% Notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member', window );">4.375% Notes due 2033 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member', window );">4.375% Notes due 2033 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes due 2035 (1.5B Euro 1.1581)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes due 2035 (1.5B Euro 1.1581) | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes due 2035 (1.5B Euro 1.1581) | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member', window );">3.55% Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member', window );">3.55% Notes due 2036 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member', window );">3.55% Notes due 2036 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member', window );">5.95% Notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member', window );">5.95% Notes due 2037 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member', window );">5.95% Notes due 2037 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member', window );">3.625% Notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member', window );">3.625% Notes due 2037 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member', window );">3.625% Notes due 2037 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member', window );">3.40%&#160;Notes due 2038</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member', window );">3.40%&#160;Notes due 2038 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member', window );">3.40%&#160;Notes due 2038 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member', window );">5.85% Debentures due 2038</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member', window );">5.85% Debentures due 2038 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member', window );">5.85% Debentures due 2038 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member', window );">4.50% Debentures due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member', window );">4.50% Debentures due 2040 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member', window );">4.50% Debentures due 2040 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member', window );">2.10% Notes due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member', window );">2.10% Notes due 2040 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member', window );">2.10% Notes due 2040 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member', window );">4.85% Notes due 2041</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member', window );">4.85% Notes due 2041 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member', window );">4.85% Notes due 2041 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member', window );">4.50% Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member', window );">4.50% Notes due 2043 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member', window );">4.50% Notes due 2043 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member', window );">3.70% Notes due 2046</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member', window );">3.70% Notes due 2046 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member', window );">3.70% Notes due 2046 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 2,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member', window );">3.75% Notes due 2047</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member', window );">3.75% Notes due 2047 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member', window );">3.75% Notes due 2047 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member', window );">3.50% Notes due 2048</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member', window );">3.50% Notes due 2048 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member', window );">3.50% Notes due 2048 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member', window );">2.25% Notes due 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member', window );">2.25% Notes due 2050 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member', window );">2.25% Notes due 2050 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member', window );">2.45% Notes due 2060</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member', window );">2.45% Notes due 2060 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member', window );">2.45% Notes due 2060 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_NotesDuePeriodFifteenMember', window );">Other | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_NotesDuePeriodFifteenMember', window );">Other | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.05Notesdue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.05Notesdue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_NotesDuePeriodFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_NotesDuePeriodFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139721079265400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_IncomeTaxTextualsAbstract', window );"><strong>Income Tax (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Worldwide effective income tax rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">12.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization', window );">Deferred tax benefits related to tax basis increase of certain assets due to reorganization</a></td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax benefit, net</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent', window );">Increase (decrease) in effective income tax rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI', window );">Increase in U.S. GILTI deferred tax liability</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset', window );">Deferred tax benefit related to TRAF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent', window );">Deferred tax benefit related to TRAF, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">Effective income tax rate, prior year income taxes, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_IncomeTaxTextualsAbstract', window );"><strong>Income Tax (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses', window );">Effective income tax rate, impairment losses, amount</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses', window );">Effective income tax rate, impairment losses, percent</a></td>
<td class="nump">22.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_BabyPowderMember', window );">Baby Powder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_IncomeTaxTextualsAbstract', window );"><strong>Income Tax (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount', window );">Effective income tax rate, accrued legal expenses, amount</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent', window );">Effective income tax rate, accrued legal expenses, percent</a></td>
<td class="nump">23.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_RisperdalMember', window );">Risperdal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_IncomeTaxTextualsAbstract', window );"><strong>Income Tax (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount', window );">Effective income tax rate, accrued legal expenses, amount</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent', window );">Effective income tax rate, accrued legal expenses, percent</a></td>
<td class="nump">16.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember', window );">Auris Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_IncomeTaxTextualsAbstract', window );"><strong>Income Tax (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent', window );">Increase (decrease) in effective income tax rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Basis Increase of Certain Assets due to Reorganization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Accrued Legal Expenses, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Accrued Legal Expenses, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_IncomeTaxTextualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Textuals Abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_IncomeTaxTextualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deferred Tax Liabilities, Global Intangible Low-Taxed Income (GILTI)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_BabyPowderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_BabyPowderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_RisperdalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_RisperdalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139721082477944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Retirement Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Components of net periodic benefit cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 339<span></span>
</td>
<td class="nump">$ 330<span></span>
</td>
<td class="nump">$ 1,019<span></span>
</td>
<td class="nump">$ 979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="nump">578<span></span>
</td>
<td class="nump">715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(661)<span></span>
</td>
<td class="num">(617)<span></span>
</td>
<td class="num">(1,988)<span></span>
</td>
<td class="num">(1,839)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost/(credit)</a></td>
<td class="num">(46)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(136)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial losses</a></td>
<td class="nump">314<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="nump">944<span></span>
</td>
<td class="nump">669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1', window );">Curtailments and settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="nump">418<span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Components of net periodic benefit cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost/(credit)</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial losses</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1', window );">Curtailments and settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
<td class="nump">$ 378<span></span>
</td>
<td class="nump">$ 394<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720993398056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Oct. 03, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contribution to pension plans</a></td>
<td class="nump">$ 71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International retirement plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contribution to pension plans</a></td>
<td class="nump">$ 232<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720994759592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="nump">$ 69,580<span></span>
</td>
<td class="nump">$ 62,978<span></span>
</td>
<td class="nump">$ 63,278<span></span>
</td>
<td class="nump">$ 59,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="num">(315)<span></span>
</td>
<td class="nump">595<span></span>
</td>
<td class="num">(173)<span></span>
</td>
<td class="nump">953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="nump">70,272<span></span>
</td>
<td class="nump">64,473<span></span>
</td>
<td class="nump">70,272<span></span>
</td>
<td class="nump">64,473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Accumulated Foreign Currency Adjustment Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,938)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(9,179)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,179)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Accumulated Net Investment Gain (Loss) Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Accumulated Defined Benefit Plans Adjustment Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,957)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(6,257)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,257)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(631)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(15,100)<span></span>
</td>
<td class="num">(15,533)<span></span>
</td>
<td class="num">(15,242)<span></span>
</td>
<td class="num">(15,891)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="num">(315)<span></span>
</td>
<td class="nump">595<span></span>
</td>
<td class="num">(173)<span></span>
</td>
<td class="nump">953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">$ (15,415)<span></span>
</td>
<td class="num">$ (14,938)<span></span>
</td>
<td class="num">$ (15,415)<span></span>
</td>
<td class="num">$ (14,938)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139721082353112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Details) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Reconciliation of basic net earnings per share to diluted net earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net earnings per share</a></td>
<td class="nump">$ 1.39<span></span>
</td>
<td class="nump">$ 1.35<span></span>
</td>
<td class="nump">$ 6.13<span></span>
</td>
<td class="nump">$ 4.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Average shares outstanding &#8212; basic</a></td>
<td class="nump">2,632.6<span></span>
</td>
<td class="nump">2,632.5<span></span>
</td>
<td class="nump">2,632.2<span></span>
</td>
<td class="nump">2,633.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Potential shares exercisable under stock option plans</a></td>
<td class="nump">138.3<span></span>
</td>
<td class="nump">115.7<span></span>
</td>
<td class="nump">139.1<span></span>
</td>
<td class="nump">120.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod', window );">Less: shares which could be repurchased under treasury stock method</a></td>
<td class="num">(96.0)<span></span>
</td>
<td class="num">(78.9)<span></span>
</td>
<td class="num">(96.7)<span></span>
</td>
<td class="num">(82.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Average shares outstanding &#8212; diluted</a></td>
<td class="nump">2,674.9<span></span>
</td>
<td class="nump">2,669.3<span></span>
</td>
<td class="nump">2,674.6<span></span>
</td>
<td class="nump">2,670.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net earnings per share</a></td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="nump">$ 6.04<span></span>
</td>
<td class="nump">$ 4.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720981999800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 23,338<span></span>
</td>
<td class="nump">$ 21,082<span></span>
</td>
<td class="nump">$ 68,971<span></span>
</td>
<td class="nump">$ 60,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">10.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 11,963<span></span>
</td>
<td class="nump">11,086<span></span>
</td>
<td class="nump">$ 34,993<span></span>
</td>
<td class="nump">31,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 11,375<span></span>
</td>
<td class="nump">9,996<span></span>
</td>
<td class="nump">$ 33,978<span></span>
</td>
<td class="nump">28,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">13.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="nump">3,514<span></span>
</td>
<td class="nump">$ 10,978<span></span>
</td>
<td class="nump">10,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,625<span></span>
</td>
<td class="nump">1,556<span></span>
</td>
<td class="nump">$ 4,987<span></span>
</td>
<td class="nump">4,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,075<span></span>
</td>
<td class="nump">1,958<span></span>
</td>
<td class="nump">$ 5,991<span></span>
</td>
<td class="nump">5,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,372<span></span>
</td>
<td class="nump">1,142<span></span>
</td>
<td class="nump">$ 3,854<span></span>
</td>
<td class="nump">3,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">20.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | OTC | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 686<span></span>
</td>
<td class="nump">601<span></span>
</td>
<td class="nump">$ 1,960<span></span>
</td>
<td class="nump">1,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | OTC | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 686<span></span>
</td>
<td class="nump">541<span></span>
</td>
<td class="nump">$ 1,894<span></span>
</td>
<td class="nump">1,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">26.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Skin Health/Beauty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,124<span></span>
</td>
<td class="nump">1,149<span></span>
</td>
<td class="nump">$ 3,457<span></span>
</td>
<td class="nump">3,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(2.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Skin Health/Beauty | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 569<span></span>
</td>
<td class="nump">572<span></span>
</td>
<td class="nump">$ 1,862<span></span>
</td>
<td class="nump">1,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Skin Health/Beauty | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 555<span></span>
</td>
<td class="nump">577<span></span>
</td>
<td class="nump">$ 1,595<span></span>
</td>
<td class="nump">1,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Oral Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 398<span></span>
</td>
<td class="nump">412<span></span>
</td>
<td class="nump">$ 1,240<span></span>
</td>
<td class="nump">1,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Oral Care | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="nump">$ 478<span></span>
</td>
<td class="nump">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(8.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Oral Care | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 248<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="nump">$ 762<span></span>
</td>
<td class="nump">694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Baby Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 391<span></span>
</td>
<td class="nump">393<span></span>
</td>
<td class="nump">$ 1,167<span></span>
</td>
<td class="nump">1,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Baby Care | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 95<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="nump">$ 288<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Baby Care | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 296<span></span>
</td>
<td class="nump">302<span></span>
</td>
<td class="nump">$ 879<span></span>
</td>
<td class="nump">831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Women's Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="nump">$ 684<span></span>
</td>
<td class="nump">664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Women's Health | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">20.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Women's Health | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 229<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="nump">$ 675<span></span>
</td>
<td class="nump">654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Wound Care/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 182<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
<td class="nump">545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Wound Care/Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">$ 390<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(2.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Wound Care/Other | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">$ 186<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(5.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 12,994<span></span>
</td>
<td class="nump">11,418<span></span>
</td>
<td class="nump">$ 37,792<span></span>
</td>
<td class="nump">33,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">13.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 7,221<span></span>
</td>
<td class="nump">6,438<span></span>
</td>
<td class="nump">$ 20,536<span></span>
</td>
<td class="nump">18,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">12.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 5,773<span></span>
</td>
<td class="nump">4,980<span></span>
</td>
<td class="nump">$ 17,256<span></span>
</td>
<td class="nump">14,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">15.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 4,250<span></span>
</td>
<td class="nump">3,789<span></span>
</td>
<td class="nump">$ 12,395<span></span>
</td>
<td class="nump">10,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">12.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,771<span></span>
</td>
<td class="nump">2,558<span></span>
</td>
<td class="nump">$ 7,932<span></span>
</td>
<td class="nump">7,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">8.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,480<span></span>
</td>
<td class="nump">1,230<span></span>
</td>
<td class="nump">$ 4,464<span></span>
</td>
<td class="nump">3,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">20.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | REMICADE&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 761<span></span>
</td>
<td class="nump">921<span></span>
</td>
<td class="nump">$ 2,426<span></span>
</td>
<td class="nump">2,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(17.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | REMICADE&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 480<span></span>
</td>
<td class="nump">634<span></span>
</td>
<td class="nump">$ 1,508<span></span>
</td>
<td class="nump">1,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(24.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | REMICADE&#174; | U.S. Exports</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(40.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | REMICADE&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 234<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="nump">$ 721<span></span>
</td>
<td class="nump">673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">12.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 571<span></span>
</td>
<td class="nump">592<span></span>
</td>
<td class="nump">$ 1,717<span></span>
</td>
<td class="nump">1,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 295<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="nump">$ 840<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(5.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 276<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="nump">$ 877<span></span>
</td>
<td class="nump">827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | STELARA&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,378<span></span>
</td>
<td class="nump">1,947<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="nump">5,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">22.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | STELARA&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,569<span></span>
</td>
<td class="nump">1,313<span></span>
</td>
<td class="nump">$ 4,396<span></span>
</td>
<td class="nump">3,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">19.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | STELARA&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 809<span></span>
</td>
<td class="nump">634<span></span>
</td>
<td class="nump">$ 2,404<span></span>
</td>
<td class="nump">1,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">27.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | TREMFYA&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 537<span></span>
</td>
<td class="nump">327<span></span>
</td>
<td class="nump">$ 1,434<span></span>
</td>
<td class="nump">965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">64.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | TREMFYA&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 376<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="nump">$ 975<span></span>
</td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">69.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | TREMFYA&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 161<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="nump">$ 459<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">52.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(26.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,389<span></span>
</td>
<td class="nump">864<span></span>
</td>
<td class="nump">$ 3,424<span></span>
</td>
<td class="nump">2,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">60.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 679<span></span>
</td>
<td class="nump">413<span></span>
</td>
<td class="nump">$ 1,635<span></span>
</td>
<td class="nump">1,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">64.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 709<span></span>
</td>
<td class="nump">451<span></span>
</td>
<td class="nump">$ 1,788<span></span>
</td>
<td class="nump">1,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">57.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 502<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 766<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | COVID-19 | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">421<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | COVID-19 | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">346<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | EDURANT&#174; / rilpivirine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 259<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="nump">$ 764<span></span>
</td>
<td class="nump">716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">9.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | EDURANT&#174; / rilpivirine | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">8.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | EDURANT&#174; / rilpivirine | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 247<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="nump">$ 733<span></span>
</td>
<td class="nump">684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">9.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | PREZISTA&#174; / PREZCOBIX&#174; / REZOLSTA&#174; / SYMTUZA&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 517<span></span>
</td>
<td class="nump">526<span></span>
</td>
<td class="nump">$ 1,568<span></span>
</td>
<td class="nump">1,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | PREZISTA&#174; / PREZCOBIX&#174; / REZOLSTA&#174; / SYMTUZA&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 380<span></span>
</td>
<td class="nump">379<span></span>
</td>
<td class="nump">$ 1,128<span></span>
</td>
<td class="nump">1,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | PREZISTA&#174; / PREZCOBIX&#174; / REZOLSTA&#174; / SYMTUZA&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 137<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="nump">$ 440<span></span>
</td>
<td class="nump">461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(7.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 110<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(26.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">$ 270<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">18.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,689<span></span>
</td>
<td class="nump">1,605<span></span>
</td>
<td class="nump">$ 5,218<span></span>
</td>
<td class="nump">4,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 835<span></span>
</td>
<td class="nump">759<span></span>
</td>
<td class="nump">$ 2,448<span></span>
</td>
<td class="nump">2,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">10.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 854<span></span>
</td>
<td class="nump">846<span></span>
</td>
<td class="nump">$ 2,770<span></span>
</td>
<td class="nump">2,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | CONCERTA&#174; / methylphenidate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 157<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="nump">$ 489<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | CONCERTA&#174; / methylphenidate | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(19.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | CONCERTA&#174; / methylphenidate | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">$ 372<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">14.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA&#174; / XEPLION&#174; / INVEGA TRINZA&#174; / TREVICTA&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,004<span></span>
</td>
<td class="nump">926<span></span>
</td>
<td class="nump">$ 2,994<span></span>
</td>
<td class="nump">2,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA&#174; / XEPLION&#174; / INVEGA TRINZA&#174; / TREVICTA&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 648<span></span>
</td>
<td class="nump">585<span></span>
</td>
<td class="nump">$ 1,882<span></span>
</td>
<td class="nump">1,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA&#174; / XEPLION&#174; / INVEGA TRINZA&#174; / TREVICTA&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 355<span></span>
</td>
<td class="nump">341<span></span>
</td>
<td class="nump">$ 1,111<span></span>
</td>
<td class="nump">983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 140<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="nump">$ 452<span></span>
</td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(8.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">$ 242<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(16.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 388<span></span>
</td>
<td class="nump">377<span></span>
</td>
<td class="nump">$ 1,284<span></span>
</td>
<td class="nump">1,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">$ 239<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">34.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 307<span></span>
</td>
<td class="nump">317<span></span>
</td>
<td class="nump">$ 1,045<span></span>
</td>
<td class="nump">1,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(2.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3,665<span></span>
</td>
<td class="nump">3,129<span></span>
</td>
<td class="nump">$ 10,770<span></span>
</td>
<td class="nump">8,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">17.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,525<span></span>
</td>
<td class="nump">1,267<span></span>
</td>
<td class="nump">$ 4,364<span></span>
</td>
<td class="nump">3,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">20.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,140<span></span>
</td>
<td class="nump">1,862<span></span>
</td>
<td class="nump">$ 6,406<span></span>
</td>
<td class="nump">5,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">14.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | DARZALEX&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,580<span></span>
</td>
<td class="nump">1,099<span></span>
</td>
<td class="nump">$ 4,378<span></span>
</td>
<td class="nump">2,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">43.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | DARZALEX&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 841<span></span>
</td>
<td class="nump">585<span></span>
</td>
<td class="nump">$ 2,302<span></span>
</td>
<td class="nump">1,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">43.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | DARZALEX&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 739<span></span>
</td>
<td class="nump">514<span></span>
</td>
<td class="nump">$ 2,076<span></span>
</td>
<td class="nump">1,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">43.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | ERLEADA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 344<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="nump">$ 907<span></span>
</td>
<td class="nump">519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">66.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | ERLEADA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 214<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="nump">$ 578<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">40.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | ERLEADA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">$ 329<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | IMBRUVICA&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,066<span></span>
</td>
<td class="nump">1,031<span></span>
</td>
<td class="nump">$ 3,307<span></span>
</td>
<td class="nump">3,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | IMBRUVICA&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 413<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">$ 1,311<span></span>
</td>
<td class="nump">1,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(8.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | IMBRUVICA&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 654<span></span>
</td>
<td class="nump">581<span></span>
</td>
<td class="nump">$ 1,996<span></span>
</td>
<td class="nump">1,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">12.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | ZYTIGA&#174; / abiraterone acetate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 548<span></span>
</td>
<td class="nump">590<span></span>
</td>
<td class="nump">$ 1,749<span></span>
</td>
<td class="nump">1,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(7.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | ZYTIGA&#174; / abiraterone acetate | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
<td class="nump">284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(57.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | ZYTIGA&#174; / abiraterone acetate | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 523<span></span>
</td>
<td class="nump">532<span></span>
</td>
<td class="nump">$ 1,653<span></span>
</td>
<td class="nump">1,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | OTHER ONCOLOGY(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 126<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="nump">$ 428<span></span>
</td>
<td class="nump">619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(37.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | OTHER ONCOLOGY(1) | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">49.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | OTHER ONCOLOGY(1) | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="nump">$ 352<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(48.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 868<span></span>
</td>
<td class="nump">749<span></span>
</td>
<td class="nump">$ 2,599<span></span>
</td>
<td class="nump">2,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">15.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 610<span></span>
</td>
<td class="nump">510<span></span>
</td>
<td class="nump">$ 1,778<span></span>
</td>
<td class="nump">1,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">19.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 258<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="nump">$ 821<span></span>
</td>
<td class="nump">742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 458<span></span>
</td>
<td class="nump">392<span></span>
</td>
<td class="nump">$ 1,371<span></span>
</td>
<td class="nump">1,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 299<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="nump">$ 861<span></span>
</td>
<td class="nump">729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">22.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 159<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="nump">$ 510<span></span>
</td>
<td class="nump">458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 309<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="nump">$ 927<span></span>
</td>
<td class="nump">792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 265<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="nump">$ 792<span></span>
</td>
<td class="nump">692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">17.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">30.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 101<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">$ 301<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">14.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | Other | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(4.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,133<span></span>
</td>
<td class="nump">1,281<span></span>
</td>
<td class="nump">$ 3,386<span></span>
</td>
<td class="nump">3,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(11.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">931<span></span>
</td>
<td class="nump">$ 2,379<span></span>
</td>
<td class="nump">2,574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(14.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 333<span></span>
</td>
<td class="nump">351<span></span>
</td>
<td class="nump">$ 1,007<span></span>
</td>
<td class="nump">1,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(5.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 636<span></span>
</td>
<td class="nump">630<span></span>
</td>
<td class="nump">$ 1,794<span></span>
</td>
<td class="nump">1,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 636<span></span>
</td>
<td class="nump">630<span></span>
</td>
<td class="nump">$ 1,794<span></span>
</td>
<td class="nump">1,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA&#174; / INVOKAMET&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 133<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="nump">$ 443<span></span>
</td>
<td class="nump">578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(40.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA&#174; / INVOKAMET&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="nump">$ 249<span></span>
</td>
<td class="nump">405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(57.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA&#174; / INVOKAMET&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">$ 194<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT&#174; / EPREX&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 112<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="nump">$ 366<span></span>
</td>
<td class="nump">423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(14.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT&#174; / EPREX&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(30.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT&#174; / EPREX&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 251<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="nump">$ 783<span></span>
</td>
<td class="nump">908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(14.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(32.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="nump">$ 615<span></span>
</td>
<td class="nump">670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(8.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 6,644<span></span>
</td>
<td class="nump">6,150<span></span>
</td>
<td class="nump">$ 20,201<span></span>
</td>
<td class="nump">16,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3,117<span></span>
</td>
<td class="nump">3,092<span></span>
</td>
<td class="nump">$ 9,470<span></span>
</td>
<td class="nump">7,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3,527<span></span>
</td>
<td class="nump">3,058<span></span>
</td>
<td class="nump">$ 10,731<span></span>
</td>
<td class="nump">8,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">15.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Interventional Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 957<span></span>
</td>
<td class="nump">836<span></span>
</td>
<td class="nump">$ 2,952<span></span>
</td>
<td class="nump">2,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">14.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Interventional Solutions | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 444<span></span>
</td>
<td class="nump">399<span></span>
</td>
<td class="nump">$ 1,353<span></span>
</td>
<td class="nump">1,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">11.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Interventional Solutions | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 513<span></span>
</td>
<td class="nump">437<span></span>
</td>
<td class="nump">$ 1,599<span></span>
</td>
<td class="nump">1,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">17.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,093<span></span>
</td>
<td class="nump">2,083<span></span>
</td>
<td class="nump">$ 6,433<span></span>
</td>
<td class="nump">5,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,249<span></span>
</td>
<td class="nump">1,308<span></span>
</td>
<td class="nump">$ 3,821<span></span>
</td>
<td class="nump">3,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(4.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 843<span></span>
</td>
<td class="nump">774<span></span>
</td>
<td class="nump">$ 2,611<span></span>
</td>
<td class="nump">2,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">8.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | HIPS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 356<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="nump">$ 1,105<span></span>
</td>
<td class="nump">908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | HIPS | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 210<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="nump">$ 654<span></span>
</td>
<td class="nump">564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(5.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | HIPS | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 146<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="nump">$ 451<span></span>
</td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">18.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | KNEES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 316<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="nump">$ 983<span></span>
</td>
<td class="nump">825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | KNEES | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 184<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="nump">$ 579<span></span>
</td>
<td class="nump">527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(9.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | KNEES | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 131<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">$ 403<span></span>
</td>
<td class="nump">298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">28.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | TRAUMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 715<span></span>
</td>
<td class="nump">685<span></span>
</td>
<td class="nump">$ 2,157<span></span>
</td>
<td class="nump">1,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | TRAUMA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 455<span></span>
</td>
<td class="nump">433<span></span>
</td>
<td class="nump">$ 1,352<span></span>
</td>
<td class="nump">1,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | TRAUMA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 260<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="nump">$ 805<span></span>
</td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | SPINE, SPORTS &amp; OTHER</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 705<span></span>
</td>
<td class="nump">745<span></span>
</td>
<td class="nump">$ 2,187<span></span>
</td>
<td class="nump">1,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(5.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | SPINE, SPORTS &amp; OTHER | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">449<span></span>
</td>
<td class="nump">$ 1,236<span></span>
</td>
<td class="nump">1,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(11.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | SPINE, SPORTS &amp; OTHER | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 306<span></span>
</td>
<td class="nump">295<span></span>
</td>
<td class="nump">$ 952<span></span>
</td>
<td class="nump">805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,405<span></span>
</td>
<td class="nump">2,152<span></span>
</td>
<td class="nump">$ 7,299<span></span>
</td>
<td class="nump">5,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">11.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Surgery | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 948<span></span>
</td>
<td class="nump">913<span></span>
</td>
<td class="nump">$ 2,881<span></span>
</td>
<td class="nump">2,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Surgery | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,457<span></span>
</td>
<td class="nump">1,239<span></span>
</td>
<td class="nump">$ 4,418<span></span>
</td>
<td class="nump">3,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">17.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Surgery | ADVANCED</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,144<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">$ 3,430<span></span>
</td>
<td class="nump">2,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">14.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Surgery | ADVANCED | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 440<span></span>
</td>
<td class="nump">421<span></span>
</td>
<td class="nump">$ 1,304<span></span>
</td>
<td class="nump">1,079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Surgery | ADVANCED | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 705<span></span>
</td>
<td class="nump">579<span></span>
</td>
<td class="nump">$ 2,126<span></span>
</td>
<td class="nump">1,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">21.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Surgery | GENERAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,261<span></span>
</td>
<td class="nump">1,152<span></span>
</td>
<td class="nump">$ 3,869<span></span>
</td>
<td class="nump">3,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">9.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Surgery | GENERAL | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 508<span></span>
</td>
<td class="nump">492<span></span>
</td>
<td class="nump">$ 1,577<span></span>
</td>
<td class="nump">1,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Surgery | GENERAL | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 752<span></span>
</td>
<td class="nump">660<span></span>
</td>
<td class="nump">$ 2,292<span></span>
</td>
<td class="nump">1,912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">13.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,189<span></span>
</td>
<td class="nump">1,081<span></span>
</td>
<td class="nump">$ 3,517<span></span>
</td>
<td class="nump">2,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">10.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Vision | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 475<span></span>
</td>
<td class="nump">473<span></span>
</td>
<td class="nump">$ 1,414<span></span>
</td>
<td class="nump">1,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Vision | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 714<span></span>
</td>
<td class="nump">608<span></span>
</td>
<td class="nump">$ 2,103<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">17.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 882<span></span>
</td>
<td class="nump">830<span></span>
</td>
<td class="nump">$ 2,607<span></span>
</td>
<td class="nump">2,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 359<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="nump">$ 1,082<span></span>
</td>
<td class="nump">924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(4.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 522<span></span>
</td>
<td class="nump">455<span></span>
</td>
<td class="nump">$ 1,525<span></span>
</td>
<td class="nump">1,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">14.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Vision | SURGICAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 308<span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="nump">$ 910<span></span>
</td>
<td class="nump">645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">22.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Vision | SURGICAL | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="nump">$ 333<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">19.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Vision | SURGICAL | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 191<span></span>
</td>
<td class="nump">$ 153<span></span>
</td>
<td class="nump">$ 577<span></span>
</td>
<td class="nump">$ 409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">24.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageChangeInSalesBySegmentOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage change in sales by segment of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageChangeInSalesBySegmentOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OTCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OTCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_BeautyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_BeautyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OralCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OralCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_BabyCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_BabyCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_WomensHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_WomensHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_ImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_ImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RemicadeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RemicadeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_StelaraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_StelaraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TremfyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TremfyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_COVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_COVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_DARZALEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_DARZALEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ERLEADAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ERLEADAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_IMBRUVICAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_IMBRUVICAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ZYTIGAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ZYTIGAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OPSUMITMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OPSUMITMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_UPTRAVIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_UPTRAVIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_XareltoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_XareltoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PROCRITEPREXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PROCRITEPREXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_HIPSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_HIPSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_KNEESMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_KNEESMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TRAUMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TRAUMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SPINEOTHERMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SPINEOTHERMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_SurgeryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_SurgeryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ADVANCEDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ADVANCEDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_GENERALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_GENERALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_VisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_VisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SURGICALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SURGICALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139721083699544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="num">(12.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Worldwide income before tax</a></td>
<td class="nump">$ 3,849<span></span>
</td>
<td class="nump">$ 4,401<span></span>
</td>
<td class="nump">$ 17,940<span></span>
</td>
<td class="nump">$ 14,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_AmountPrepaidAndDueToManufacturers', window );">Amount prepaid and due to manufacturers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Reversal of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 4,046<span></span>
</td>
<td class="nump">4,640<span></span>
</td>
<td class="nump">$ 18,592<span></span>
</td>
<td class="nump">15,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="num">(12.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="num">$ (636)<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="nump">$ 956<span></span>
</td>
<td class="nump">993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | PHARMACEUTICAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 4,259<span></span>
</td>
<td class="nump">3,439<span></span>
</td>
<td class="nump">$ 13,838<span></span>
</td>
<td class="nump">11,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="nump">23.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain (loss) on disposition of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLoss', window );">Unrealized gain (loss) on securities</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 423<span></span>
</td>
<td class="nump">1,010<span></span>
</td>
<td class="nump">$ 3,798<span></span>
</td>
<td class="nump">2,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="num">(58.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLoss', window );">Unrealized gain (loss) on securities</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">In-process research and development expense</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="nump">$ 652<span></span>
</td>
<td class="nump">611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember', window );">Auris Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Reversal of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember', window );">Other Income | Auris Health | Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Reversal of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_AmountPrepaidAndDueToManufacturers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount Prepaid and Due to Manufacturers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_AmountPrepaidAndDueToManufacturers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageChangeInOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage change in operating income loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageChangeInOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720994266136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 23,338<span></span>
</td>
<td class="nump">$ 21,082<span></span>
</td>
<td class="nump">$ 68,971<span></span>
</td>
<td class="nump">$ 60,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="nump">10.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 11,963<span></span>
</td>
<td class="nump">11,086<span></span>
</td>
<td class="nump">$ 34,993<span></span>
</td>
<td class="nump">31,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="nump">7.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 5,587<span></span>
</td>
<td class="nump">4,819<span></span>
</td>
<td class="nump">$ 16,669<span></span>
</td>
<td class="nump">13,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="nump">15.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember', window );">Western Hemisphere, excluding U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">1,296<span></span>
</td>
<td class="nump">$ 4,291<span></span>
</td>
<td class="nump">3,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="nump">15.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember', window );">Asia-Pacific, Africa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 4,288<span></span>
</td>
<td class="nump">$ 3,881<span></span>
</td>
<td class="nump">$ 13,018<span></span>
</td>
<td class="nump">$ 11,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="nump">10.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageChangeInSalesByGeographicArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage change in sales by geographic area.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageChangeInSalesByGeographicArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentsGeographicalAreasAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentsGeographicalAreasAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720994291080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (Note 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,569<span></span>
</td>
<td class="nump">$ 36,393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember', window );">bermekimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business acquisition cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_VerbSurgicalInc.Member', window );">Verb Surgical Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (Note 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Fair value of previously held equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_EvraAndDoxilMember', window );">Evra and Doxil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain (loss) on disposition of assets</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments accounted under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117311354&amp;loc=d3e32014-111567<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_VerbSurgicalInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_VerbSurgicalInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_EvraAndDoxilMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_EvraAndDoxilMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139721087379944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 20, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($) </div>
<div>vote</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 28, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 03, 2021 </div>
<div>USD ($) </div>
<div>claimant </div>
<div>patient</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>claimant</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2015 </div>
<div>claim</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_AsrMember', window );">ASR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember', window );">Pinnacle Acetabular Cup System</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PelvicMeshesMember', window );">Pelvic Meshes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_RisperdalMember', window );">Risperdal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_XareltoMember', window );">XARELTO&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_TalcMember', window );">Talc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_InvokanaMember', window );">Invokana</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PhysiomeshMember', window );">Physiomesh</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OpioidMember', window );">Opioid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_ContactLensesMember', window );">Contact Lenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending claims | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation | Opioid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue', window );">Damages awarded, including settlement for related issues, reimbursement for legal fees, and removal from related claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation | Opioid | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue', window );">Damages awarded, including settlement for related issues, reimbursement for legal fees, and removal from related claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember', window );">Judicial Ruling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 8,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss contingency, estimate of possible loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LossContingencyEstimateOfAdditionalPossibleLoss', window );">Loss contingency, estimate of additional possible loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation | Physiomesh</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation | Opioid | State Level Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation | Opioid | Federal Level Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member', window );">DePuy ASR U.S. | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_Numberofpatientsinsettlement', window );">Number of patients in settlement | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_BabyPowderMember', window );">Baby Powder | Talc | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LossContingencyReserveEstablishedWithinTrust', window );">Reserve established</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LossContingencyNumberOfVotesInFavor', window );">Number of votes in favor | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LossContingencyNumberOfVotesRejected', window );">Number of votes rejected | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_BabyPowderMember', window );">Baby Powder | Judicial Ruling | Damages from Product Defects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Litigation contingency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember', window );">Oklahoma Attorney General vs. Johnson &amp; Johnson and JPI | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_SurgicalMeshProductsMarketingMember', window );">Surgical Mesh Products Marketing | Judicial Ruling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded</a></td>
<td class="nump">$ 344.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LegalProceedingTextualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Legal Proceeding Textuals Abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LegalProceedingTextualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Damages Awarded, Additional Reimbursement, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyEstimateOfAdditionalPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Estimate of Additional Possible Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyEstimateOfAdditionalPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyNumberOfVotesInFavor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number of Votes in Favor</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyNumberOfVotesInFavor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyNumberOfVotesRejected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number of Votes Rejected</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyNumberOfVotesRejected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyReserveEstablishedWithinTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Reserve Established within Trust</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyReserveEstablishedWithinTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_Numberofpatientsinsettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of patients in settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_Numberofpatientsinsettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProductLiabilityContingencyNumberOfClaimant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product liability contingency number of claimant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProductLiabilityContingencyNumberOfClaimant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121555522&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_AsrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_AsrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PelvicMeshesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PelvicMeshesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RisperdalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RisperdalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_XareltoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_XareltoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TalcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TalcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_InvokanaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_InvokanaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PhysiomeshMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PhysiomeshMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OpioidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OpioidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ContactLensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ContactLensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LegalJurisdictionAxis=jnj_StateLevelJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LegalJurisdictionAxis=jnj_StateLevelJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LegalJurisdictionAxis=jnj_FederalLevelJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LegalJurisdictionAxis=jnj_FederalLevelJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_BabyPowderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_BabyPowderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_DamagesFromProductDefectsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_DamagesFromProductDefectsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_SurgicalMeshProductsMarketingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_SurgicalMeshProductsMarketingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720998393256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
<td class="nump">$ 187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring charges recorded to date</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_RestructuringandRelatedCostExpectedFutureSavings', window );">Cost savings expected</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring estimated cost</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_RestructuringandRelatedCostExpectedFutureSavings', window );">Cost savings expected</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring estimated cost</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Supply Chain | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_RestructuringandRelatedCostDurationofRestructuringPlan', window );">Period for activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Supply Chain | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_RestructuringandRelatedCostDurationofRestructuringPlan', window );">Period for activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_RestructuringandRelatedCostDurationofRestructuringPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Duration of Restructuring Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_RestructuringandRelatedCostDurationofRestructuringPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_RestructuringandRelatedCostExpectedFutureSavings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Expected Future Savings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_RestructuringandRelatedCostExpectedFutureSavings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139720999391640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Schedule of Restructuring Reserve (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
<td class="nump">$ 187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments for Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(287)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Restructuring Reserve, Settled without Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid', window );">Period of cash outlays for severance expected to be paid out</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Employee Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments for Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Restructuring Reserve, Settled without Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Asset Write-off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments for Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Restructuring Reserve, Settled without Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Other Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments for Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(270)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Restructuring Reserve, Settled without Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring And Related Cost, Expected Period Of Cash Outlays For Severance Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveSettledWithoutCash2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the reserve for full or partial settlement through consideration other than cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveSettledWithoutCash2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=jnj_AssetWriteoffMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=jnj_AssetWriteoffMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>82
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MF55O9X+'0ID#8/]$PG@N-\P)5H^Z'/T/4$L#!!0    ( *. 75.6&0^[% <
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M3QMTUHU9$8\__XS^1YV\2.8A+MDR3_],-GQ[,?-G:,,>XT/*[_.7CZQ-J+[
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M?7?%;'OZ6Y2Q9EZ3%_62X3K>)SQ.D__ 5:!K/#;+9-21 -MMRWH"##RALIX
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M>#J=.!U%J>6YX1"VT6%SZ@:ADFVKPVS*K"'H&LEE!P[U.]B@2'97)-M8I+]
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MPG,<7]U\.HI2)["51;S187/JA':@J*4.0]02R64'KC,RL]3JFP;K[:;RYZ&
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MBFZE)=-H)BC0'OST-/[J!![;V+L$)/L$C).3A-\*$Z(H_8"2*(E[SC,Y#5]
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M;0 F*Q1<K91'@S*>T"ID4<@!+8+XM*E1("09KL?)RY)^6W*-^M'"4%JH@LC
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M>_YL('QZ6YJ^1+?B-Y1S%Z.K^&.I)&J #N#WA<-(:;Z0@>Z5]=D?4$L#!!0
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M,^RW0%>35/5A5>&GE[6R- OY[8Z&3]2.@<XWBGRO/YR"PS@[^1M02P,$%
M  @ I(!=4QRO2M@3!   +PD  !D   !X;"]W;W)K<VAE971S+W-H965T,38N
M>&ULK5;?<^(V$/Y7=MS.#<Q0# 8"Y( 9(+2A<P0F)->'3A^$O8!ZLL1)<@C_
M?5>R(="2M ]] 6FU^^G;GW)OK_0WLT6T\)H*:?K!UMK=;1B:>(LI,U6U0TDG
M:Z539FFK-Z'9:62)-TI%&-5J-V'*N P&/2];Z$%/959PB0L-)DM3I@\C%&K?
M#^K!4?#(-UOK!.&@MV,;7*)]WBTT[<(32L)3E(8K"1K7_6!8OQTUG;Y7^,IQ
M;\[6X#Q9*?7-;:9)/Z@Y0B@PM@Z!T=\+CE$(!T0TOA>8P>E*9WB^/J+_['TG
M7U;,X%B)WWABM_V@$T"":Y8)^ZCV]UCXTW)XL1+&_\(^UVUT X@S8U5:&!.#
ME,O\G[T6<3@SZ-3>,8@*@\CSSB_R+.^898.>5GO03IO0W,*[ZJV)')<N*4NK
MZ923G1T,XSA+,\$L)C"W6]0P5BFE=^OB_H(PE;%*L1=:NLM9A'&!.\IQHW=P
MNS!3TFX-3&2"R:5]2!Q/1*,CT5'T(> \ME6H-2H0U:+Z!WB-D^,-C]=X!V_R
M/>/V +\/5\9JJHT_/L!LGC";'K/YOP?S7W#'X^?9\Y?AT^0.YD_WDT<8SV>+
MQ\G]Y&$Y_3J!Z0/M)_XR)5%: VH-RA.(+PAP3P!*0AE3IC.2&NN421?62E"+
M<KFY!2IX*F<)OU!7AZ4O7GN2[H0Z(%X(GY1E L[]'F=:HXP/,)<P0HEK;MWR
M#C5_8:X#S=70E.[H=J8-4809%X(ZUL%K)@WANOY=8IQI;CD!+ 2)X1-+=Y_A
M'I,-B::%9SFM7YG,:,1 42[P(Y0ZE6ZC4X8ZE&XJW5:[##>M"$KU5B5J1F5X
MH/$7;YG<$$34K)?II SM6HVT&W[7;I2!2E"MB/D9:K=2;W?+\.F'3E2//COL
MR&'3H8-NUEME&*8J<RGA;@2]Q>F#]#"-0%)#F21%B:<,:<QM+7L%GNZ8:XEC
MJN)CW.U9S+@!J2RPY$^:)&1(0_QX"6%0V/9$@NZU!;0!JV"'-.U<&9$JI<NF
M6-#GQ$=+CTQ)-]G*\(0S31GQ-.B:A!>'"5K&!=6AO.ZBH3IR'HTIS4KPQ+NU
MM/27'NOW6NM4J8Y.P!ICP8SA:QY[3B3,?*C^6QO>7A3R_*+ ?KH"3A%"&O^)
M"U&.6LJ=*0.^TAMIL.)R57UKE&/YY^5Z#=-EFD!$1C/21=CEFL+/5<)C6!7F
ML3*$NB3 !V41;GP6_QGKZM_].6^YBUZYQH2<0J8E=7_.BC24+EBY1!GF"C..
M72T#,UZ6T6C7XD V>=$Q_]">46V^1_7:K W/'K$4]<8_U0;\C?E[=I*>O@:&
M^2/XIIY_2LR8WG!R2N":3&O5=BL G3_/^<:JG7\25\K2 ^N76_JB0>T4Z'RM
MB'ZQ<1><OI$&?P%02P,$%     @ I(!=4VDD,S7% P  N H  !D   !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&ULS599;^,V$/XK [5H-T"@TV?6-N!DLP?0
MI*[=XZ'H RV-+2(4J26I./GW'5*RZVT3-T!:M"_B-?-QOIGA:"8[I>],B6CA
MH1+23(/2VOHBBDQ>8L5,J&J4=+)1NF*6EGH;F5HC*[Q2):(TC@=1Q;@,9A._
MM]"SB6JLX!(7&DQ354P_7J)0NVF0!/N-)=^6UFU$LTG-MKA"^U.]T+2*#B@%
MKU :KB1HW$R#>7)QV7/R7N!GCCMS- ?'9*W4G5M\*J9![ Q"@;EU"(R&>[Q"
M(1P0F?&YPPP.5SK%X_D>_;WG3ES6S."5$K_PPI;38!1 @1O6"+M4NX_8\>D[
MO%P)X[^P:V6S.("\,595G3)94''9CNRA\\.1PN@YA;132+W=[47>RG?,LME$
MJQUH)TUH;N*I>FTRCDL7E)75=,I)S\ZNF99<;@TL4,.J9!HGD25<=QKE'<9E
MBY$^@S&&&R5M:>!:%EA\J1^1/0>CTKU1E^E)P.]S&T*<G4,:I\D)O.Q ,O-X
MV8M)PJ_SM;&:<N*W$_B] W[/X_=>Y<2_P9@O;S_=?EC!XGH)JX_SY37\6")L
ME*!W0^# #3!Z!KF2.1><^9Q6&Y>2/ =)SQ?W5M1DA?$LK8*"B\9B\8S$!;SG
M)F>"[N*Z@!\:IBV=^4#NCV[)TB\B#&\\1P-<P@T7@BPQ9T!!4VO2[<(&*ZPM
M5FXG'?JM^"4BEZ?H? U)F(W=IP^#,,F@%XXSF-^CIOK1RAB@RF,LDX7SV3=?
MC=(D?=LY*3T?9&DXZ,9^-Z9^S,(8%LJBM)PH=U#X@#KGAJT%0D/,R0ZK\CM0
MM?=^+9@TD&2C,(,DZ8=#FH_#!)(T)M3OT)B+/=*NY'D)N6I$ 6ND,-:-SDNJ
M)D4';*FBFD8_=C=4:$M%CAX/PO@,W@Q'X?C,KX8TC-*P=_82VOO8$\$AN<J-
M@S$9VZZ](X9Q.()W)W.D=?O0?3)R>]PCMX\&/CM/)Q=0]N2-:%.5_A]@74*W
M265]OGWN\@U]6OTY/;C,1>,.F#B$1"/AT19E]G$LS#DPX_&[F"'4FN?H7HC3
M[J1@1U*" D.B3'IYUKF1?DEWQ.*>B<9KN;,K5=5,/GIW#M^:]L;P7V#^Q$/
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MNP).]*]JBP?9V>"?& IFQ5&#7K1W5"_!_PA'#508X3_MB0F/NWH&<AL7(V(
MQ5=A: _YKMC 17G*HW%]!R!:)1,U7L!SA+!(XBH34;[=\X9:T10!E:\!/XV]
MNZ?5,5:*$ZH8F GXO1\(7B['E_VS/0>PVSNA)W )0N7C2+Z3Q!%>XP"*P/([
MAW?<B*.3(!9P!4Y"0SD!MHX@<DOU3N3B*$Z@?3F,=IT$ ,(?WP2B_HLW_<EY
M_V1P=3D\@73#Y7*S*A;%;>,!GA-%<# (%JL8"T1. KU&CH%F8TSO"J8=/Q9
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M,^"Y3F#H,]+5T.Y>CRA Y#/2PG%M[-)8 ^;4/G)10$<..N%6J)E&P0I20FG
M5AQZO&%:8I# ^//!J8AT2NH(\B\[?LA6S9;38K'AVZ;.]!EC$F9?X3Q&DHT+
M::'-:%=:9EB6*I$$;499^I?/U-[N-"2(&#'/[5LZ&9#Z:ZQL)#"5]5VQ3K-Y
M/JNV9,J3W&4L",1'&>A9H$:4;-?E8N R0FR(I50(M19^%3"319T^@XMB!J\P
MH'3_8!E6#.S32IYY,[R8;AD+R:MN&BU"#D+?FF0G'Z!"D:XL]V;139IBN@G!
MP((&XAA+NN&/A(]'_O/OT>"Q'B._ 6X3HBI P MXVOWFCC9:ZBW4Z,C;2+<>
M',9T&QKL<5!]#.!D^#$#.CL%2#Y7Y_W&U@')H;'M/8=9'=(E IN]9FW(RH\=
M16@90H;84@>=&CJB]Y!N]JQY(^FK>[8G/[T8C@8._HPGEU/USW2Y_J7ML3[\
MT&=76VL;P5F,VZ[[?@HV(('2"(,)B27*(YFZ)0LN1="X-9]GLZ_TE^"'1DTW
MY6U6-M0]039/-$,/4TP<$SS2,7BR22G'(OO0K"Y]\3PCS5?/[[84' 9>*H(=
M"I@!GIRPX1K38FS\]D_?]E&XG&X=SY5FBB_\4[P7-#PAO]_%'$]'? B"L(,G
M7)7D)>G@C@J495S7L@DX$-NK3L2B!'6_>CT8#2;;<,5FJ,_@(7#@#0DVW 5:
MNQ",V 0(F]H*ZJ*9G83Q.=FY8^&%PGXP/B$=0,&3D"W'A!,D>IL_<D!6=WY$
MU^1Y?"U]$N).[VM LV<5TP@L3;4K/;%8%-NM9+5T!UPR>WO[AET3MET-N\H1
M2]C+_LFE.@,3@B<>M5%IV"RT):=4$"[*@82^'NTI)/ \<2>IY1Z*080D**3=
MXF=Q'L,&H3A)Z%(6YCMVG]7T:O+Z,7NP"Y%(7S44@D.7D,"Z@\F$)%GZI)'<
M1?+9_>L&8(D$3&*,X0E"6PC?D#$V>>VF"'MZAQ+ 5C N&4GB^,B-D73+I>C<
M\4J'X0K#@]@&4U:IB%0Q-!Y;M+68CL U=-AE83\'B='C[;O0X;T3L@OU;CPY
M.WTW/!ULM>$D(?D)K! *]3=(DPCGAC4=D^!>>M+DW@@1MIB3[&CD'H87.U$L
M,:,MTS/LZQC#P"R6EI+B![FYB%GL*P!G)/]R^<?FYF1ZFZG;,F.)I^J[=$52
M_H,J2K4J:K7,TE6^NKW9+*3<&JYFBTV5?\AXV_?MX*Q]?^+C73Z[4Q_32JW+
M[ ,;P(M[-<^KV:*HLKFJLG7*.A(7!_W):#AZ/57'@U?CR8 L[.U06#P^JLO^
M;]V;NO^O;N3NW,"B4IZ!=!OR-.#X1WQ*$$II5RDJ?E 7=VFY1.$,CD)9#\'F
M>?LGD5@F=X;(?)R8%(NM[LC&A'/2"8P_A2YG6875G@M9))?A;<&8:<: *PEA
M0'3PB9_M7?\L+6FW2EUG-T69P23%!QNH\%'5Z5]8T7=<GPD@]'F;Q9/:'%AG
M).2-"VW;0&=95?W,&THH=C/!1+I8%#-8<J[J F9MG@,X].T=)F:6D,%5M_TW
M7\V*9;:5!OM#3S@SR3VRC);]@^=RWSM"EF.TEP8H1(B_#:J[EF*QXH6_6 C/
M,R*C3E>W^?4B4^F2CTC\M[B=RIJC N'/&'"O+7R(I.L""Z'&4S<6=[5 \L\&
MDIC 9S?D*0B\<>7-,^KP,TNL"-VEA>[N KU]H1=YG=_NR\FFYG:39M>@O>L7
MR^RH,JO6F3Q-M+CO?<'&07=CC;3P],:?.^GNMF?[NVUUM\[*O)C#?(PS^3(M
M<T24,EML 5FGB]D3BDNY0UUN9O6FY,,PVQDS>.?M%QG[\Y:B6^]X^IX,<YRN
MJG-( !BG^:IJM@V_0F/MDWXLU'4)$?#MIJ[H9IPLR>8;T1Y_.]I[7[>7MPL<
MKP7A;P?.WKE76?TI[+:/VV#7_;]UFL]N'GWIYO][QY$IGW*828X%RGFZ^,QL
ME[/;T(-TQ3HO<N;UNEYDS %/>AUQKK!>E<W@>'6>54_YVA>I^IG;C2U?XZ!_
MBY/O&Q_V$;*=]9 H.-Z1]4Z*Y3I=W:N,7! BP)T*R%<A\%GMS; )G^-3RW2U
MN4FW(J=ER:?,;#IFFO^0SF84"LE_OK'/B7[,16BJ&'2LOO_46D5YBVQJ_;;J
M@7MEP$)G V$43<C92BRKWVPDP%6;]=KB J=$\D<JGN5\FZ[368Z=/R$A=;$N
M:G9W0#3N%:1;53=9F3*<E'P,M1+>L0'9;$W+;QY7!E9)",KLSTT.!?94?UEL
M1.84@.6^T*5E55CI.E/S; '#4-?<?:N2C>Q?7"_H$Q;W&"MK6!> 2KY$?319
MNH:L?\'[A !WLB0?.2NS&S[)*\86C8)"RT:-&]I'*PNVEQW[1Z45/*]R%#18
M;C!QD:=8T7K8P^#NU=G,JJ'9H[':ORJ>HBH6<C-YKJ[31<J[W?:QZ<U:@@&\
M5]2,HV0I-)^"AC5.WY_/<UNO+.Z[ +Y#+= !\2PK:\:#K=GG&=RA6 MCG155
MC3W3?2@+JFX+&&@E([>NN8-1$N1=TOR$F]-BV,)NN6+6+&W$0]&2E14F6U__
M%(UY*CZYVQ#^J:"V'QO<W7!:YTM!SLV#EEK:P1++?($ 5:QXB*HJX$N<W/AS
MIOH WL-SA.D,R*_$*M\EU'UC.ORBC;]?B/\R"F1VB?37 .$+E/"U1*R1(OH>
MY.@;TO,3^SVU,*?]A) WXV/AD +U**,&!&O[?/?,R<.6.ZX!9\WX6'#5-#V+
M&^0# HA.DM_F=(^R %;8?S\<UW7Z(7UNG:#\$A^Q)$<G?P]U'N!SBIAFF1HA
M>2FSE?VD'5I?Y2N$5F;!*6^C/V;J):OB>0:W7S"2H93>IJQ/%]RY538!E=&O
MFAK[:*M4RKK5W*PHUP6[+SN#>H^/T.\\7/]]NBX"SVYG16+A$_V7OQO:/%)_
MM<JI&-%GQ?;!7I>-384G.FT_J,&F+-:9/#HLCQOKYFZ[#IV03XGR^6%I48?J
M'?2+] /L+,&6D5@S!^"E_@G#[?,SKCS^RU9=(,^5>'SVV^%=8-ZWZ%=Y^M,%
M&,I-/G-4_Z9$IN(@/J$C37O-HEWS00SI!/'VCPX1"2X+ ORKFGM/_<#CJ/4[
M&I"Q6_FU$',_<&9_4O-P]>$'27W[.YS'X?;73.>(URQ?%]D-ID*0X,!2L^V'
MNEC+KW+@376QE+=W68I4RP'X_J: DS0?N,'#S[1>_@]02P,$%     @ I(!=
M4R?5FKU\!   D@H  !D   !X;"]W;W)K<VAE971S+W-H965T,3DN>&ULQ59A
M;]LV$/TK!V_H-L"Q'3O-LM8QX,0IY@]ILCC)!@S[0$EGBRA%*B05Q_WU>Z1D
MQ=Z:% ,*[(,MD3R^>_?N>.)X;>PGES-[>BJ4=J>=W/OR7;_OTIP+X7JF9(V5
MI;&%\!C:5=^5ED46-Q6J/QP,CON%D+HS&<>Y:SL9F\HKJ?G:DJN*0MC-&2NS
M/NT<=K83-W*5^S#1GXQ+L>(%^[ORVF+4;U$R6;!VTFBRO#SM3 _?G1T%^VAP
M+WGM=MXI1)(8\RD,YMEI9Q (L>+4!P2!QR.?LU(!"#0>&LQ.ZS)LW'W?HG^(
ML2.61#@^-^IWF?G\M'/2H8R7HE+^QJQ_Y2:>MP$O-<K%?UK7MJ-1A]+*>5,T
MF\&@D+I^BJ=&AYT-)X,7-@R;#</(NW846<Z$%Y.Q-6NRP1IHX26&&G>#G-0A
M*0MOL2JQST^FZ4,EG0P*.1(ZHQE$<E[ZRK(;]SU<!,-^VL"=U7##%^!^H4NC
M?>[H0F><[>_O@UK+;[CE=S9\%? J]3T:C+HT' P/7\$;M?&.(M[H!;RSRF'&
M.3HW12*UJ /_<YHX;U$A?[WBXJAU<11=''TK2;\"=_[;W7PQOYU??5S0]..,
M9O/[B\7M_/;NYF(QJZS4*_(YTU):Y_'O4J'HH1+6LR6SC,)U26IR7 HK/!,B
MU4[$4^&Z<2_$*(7>4!:9<D9^;2B!6>8()]G)C*/=76_10X'Z''!A?)T+G(R4
M*R^#5\<KG%<D['8'TW)J5EI^!JH@-(X#+YYHA7815RS*))"[ IRE'Z5.3<$_
M$3^AZSCNDF;?#5&(LK3F2>(8LMK0]X/>\9OO#H\'[Q.I%.+HT9X248-:D'TE
M!OOQPEFI. :,6?&<N.A2*;+A4#OR)AI('1.YBE4##V&[J9#AA&W!G\ NZ=(Z
MEVE.N7!4H#-(X*-+A/YAE%E%F:3.\&SD%\J =M"44K8^Z,(@93;,CI;6%/3'
MF32>@3G7::]+:,1!R,JF\,%05*8<Z$*3$VKE"!E8"FGI4:@JKO\SPC48(D0#
M)H@?,&C*$MHB5FWT@2B,]?*S2%2(VPN]DN%5.,<>M)_MY]<W;T11O@^_64UO
MGTK+OQ ;*$6L9(T%3R@!1LV1R#+9B%J*32@B1U5IZBJ+1J4/06PE@O(%VU0*
M!8IU>Z]\;FPS<K4 .X5>AYNF2%<(-XJ("4JV_2!][@?QT*(25=44YVNE/FV9
MJ\U_+*YPLB!L%NK6 1X)A[-[M@DM*EO72IUS$<$":"P4?.A4=I J)(.L20PH
MU9TFPR> 7"I9HR9240HD 2[9=9MXZB-B4#>-0QS(1VDJAT3FK%#)FT  >?WV
M"EYR%D.:P6,*UWO=XO^LU:-MK79I94RVQF"[-'Q>,K%#U9C->6M78[Q*MG('
MLZH U=IN]+5SV93,#__.!T,$OVDZ3Y#KRR42%=H-I?>E#UE_YYZ X[.*MZ&0
M.*2TOC*TL^V%:UK?,Y[-Z]O:I8!W?-\4+[%UT/OY;:=NEMN!-V6\=: Z<8>)
MKSDNC6R# =:7!DVA&00'[35T\C=02P,$%     @ I(!=4_\GCD]))P  B(8
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M+\X__O,[4?"@3UV6G41:Z0DZOXHK0(H.&NU>!/P_P1>4F'9>0)@2HK+6GY,
MO3F! 0 &VVWH@( <-?Q&F5R1 5XU0$T0403:Q\GO"Y/KEB:"?4<(JI 0(C3'
M78";##UH4@(G;#/8>B-V7+!ON[1[G@$\I,OM1V19$S/;W7/=9MRP"R1,()0$
M?A$^!J569 (UPV1JRK198LNIKOIL#^ "%LN 1F5M<GW;S614-D,$+(R(.'11
M SSY[8D)WDC(%;16X=KQEJ-F3)$$@QO<):H,$3B8P*8<(V>#RRL(HZM@F 7
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M0TZ78MQ:@SU-@(\  &-\#40)1,.Q'MC@Y/:RD.P6AJ2I&+$6\#6 ;ZY2PG"
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MXI0#E>HPF:$M0CUA!B$55-"7BED>_3TO+5!"Y]>P98W#<&T:+.AHVB&(..Y
M NQ$(VQM,_WD-HRE!/,C-RBIMW*W>R3L+I1XV!J%W/UK\&[M&C5(@5R#+P+
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M9P!LI5N8L9+,O?YBJEJ8!6;.\:(+=('HV#/S0XYE_9+LJX/DXN,%,DGP[\B
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MIGW-3(5"MH%509<*?PM-IG+BIX*-ALM$ C1S?HTOOV R&Q%)WSO#-?QKAG>
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M%QR^*IP+%W<I&,(6XDXMC2I4)DT0EUEF&Q.468H;JU6FR(M?NZ??SJ8!JEG
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MQ2ZKK0O)/P-NZ%V5(DUY8MT:L7Y$O?$@Z^$\NXZAAL4BM\TB%(WN-"569([
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M#DI3$EG>N:K'*TWZ^NC3JS$U'"EC[/7<>JC6W3Z<IG[X:7([82*_YPJ<Z/@
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M)1^7/)KQ@@:@?YYCL=478M#\PNS5/P%02P,$%     @ I(!=4[Q6B:&2 P
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M1-75VZY[VU;!&RX:B\4C$@^EX"0#5\-S4[,<EP$5J4%]B\'JND38*4$%2/#
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M)Z, =-NKVXU5M>^/6V6IV_IE2=\;:B= ]SM%Z>PVSD#_8:[^ %!+ P04
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MX- E)+#N8#(B298^:2!WD5QV_[H!6"(!DQAC>(30YL,W9$R=O'931'UZBQ+
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M&=" Q@F70>!R">VM?9*X(*1*=9E<Y44"M.0?ZQB*EZJ*_\**KF6[S$V^RSM
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MH#R:.=W*#)F%T4@_H5:@D?/_KH ZWGEG0]_MMM*@G1/!D5Y"K<JC:95_Y0I
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M\1REX4J"QFDON&Q<##JNWA<\<5R9C3$X)Q.EGMWD-NL%D1.$ E/K&!C=ECA
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M63H,_7!.ORO4KH#6ITK9]<2=B/4/L/\+4$L#!!0    ( *2 75/MB/7GZ (
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M<WAA?+S;#J.8I&YX<03*$H774,EEIM'M=K,IE497#THVXH+>S&^OWCKE(+*
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MA6WAHP02BD_@8<)&H@1@71)FW0$IH3<G$^!D$N;DH2/=SMI]$('&23AG'R2
M[5S<@XL"U],PU[\X@&DH"S\$ 4Q-PTS]DN"E-L':QX N(U_50H&$:9B$?RVT
M5*:B1I^->Z$:M#)U0.B\'GB4CO6(H/.,8+2'!#:?<E_Q38%1Z:B/":B=$U/F
M*0PI4#$-I\1NET#_HI$J1@H,3OE('@:T3(>EY8"']69D"HQ,PXP\M'_U)N<$
MR#D)D[/7NX8I0A(@Z"0>QWD2(-LD3+;#.4]BY[U=>FH5PV&$J6\#@=:38<],
M3CWJM)/G+H?M9N+(L!/FJ:82D(LD+!>]?/%UF6_2>7*<C.2'P/!)F.$'],/>
MIR$)L'HR;%Y^RL%Z)^<)J$ 25H$/I7H2:EDKGC3XD/RZ:)Y/U*E>XT-5:)^
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M>;S;/[@2TM&7] ,@ 5="[+[$,J':VS_X4&[[O\,<BH5II8"#('Y?P1P?NNT
M+NL7' :Q>PQWJ4P/%=$]A$DJ< _$[A_L1G1^9EJ\A\62X!A(^(2^G@#HB9WT
MG;P]T9$=<J,N -O$SFUG3TYT^/I&'TV!O]3.7]M*^5XKQA80 R8I>0R,T48(
M3G\NQK;]-_5-&0X-^@:\TMYX=:08U?EJ6@7 5CH66TT4H\YLI<!6VINM'2A&
M=;Y:# F(I>P)(48!IM0>9G>"&-4C9HLN *34#E)GB%'GN)<"0:F=H':"_9FE
M>^?[9_NHR*YE+N-%VA#Q&7EN^_<-$/7P8]#- YQZO:-.-[IM^V\:@H<&4W@
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M&AGPR?K'HTXT8WH:@!"3+V- 6=:;LHXT8\Z)5P:,96,QUD@S9\:&P-AP2/;
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M- 9M#]!^IA3N'#L@_'P?_P-02P,$%     @ I(!=4\!A7ZDY#P  (H0  !D
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MU8Z:VTI]DR"N >KYGJEJW0_T L-7SN)?4$L#!!0    ( *2 75/VFG^ISR\
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M3; $O4LUQUDC76/%?2_O5_B:M&K/GA/BOF I0!F8 @B: F3!*8#"0: X?=)
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M/I<E\N?VJ7U<=+3V*5K@*8IGBAA@\A6+X#>  7"8[T]#T+MD+;LQ$ENKVT+
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M,6G+5DPZ<\)D":;O=I\P<OR\@ 1*A.:B1(0MIT9Q$J@0*H,*(8$*H2RH$%(
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M4_LEU%$.IFA!'=W7IXE!#8D25R?0&,Y 8SS#NN."R?NKK8'*/<+!K$3\G O
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M]?%)_U^;_SL]NSA?_,?JXZ?_^7*;]N@W($)4&;0$"[0$9T%+L *$J$-_=:P
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MSBN0!5>'[^ U+7 09NJ:V":2)_:97A ;?&YB@R6H8.EV4S53)VN%;,6TYB9
M3Y:<&KZ]@#;X,M &+Z -/@NTP2N8A3JT4^<5RH*/FI(T+82HF%X3VVPR4^NE
M0#;XW,@&2Q#J5!)DC41KF^D%L<'/)C8\F;,[/;DXZBX6/_4GYYM_.33+Z[R
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MF,<_?EBOWJUO'Q[8_/NO-S?WN[\\?,#O-[?_?)S.=_\?4$L#!!0    ( *2
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M@+Z_XER]7A0=-!]H1O\!4$L#!!0    ( *2 75,F]9KED ,  "X,   9
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MTRO+YK0<:+$ONJ^-T-C+%:\)-O0@S0+\OA5X;JN!$:C_(BS^ U!+ P04
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M)+P%(:%!)/P@1L(F +NX7ONFS.A4VQM(0CLE:[5?LH3%N]B6O($9'-V@V,A
M#;G65#(/DNRU-YEUC:]:MY&SPDX5,G7*G!&JQFA B*X!H1XP_36CWT:^CKTU
MU!;6C9JQGI&J!FN0B*Y"XI*\GND-9""(;@%!9""([!"\O#>:@!LVZVT7JL9H
M,(CL&+RZ-WJ-*!!NQGI&JAJL(2GJ6X-=TH#Y) (>W3/?NBM!AI9H<(NF,.Q#
M/[!#;*WTL+GWKQ=Z?HF0UR*$ZD*+,T+5; V.D7US65LQ_4!?S7YL6(QOL<'$
MAJO8SM4G*A@/P)J+_'")J;>V+^XS5KK@C1)A:V9LX(GM\#Q?[K,XQ4??YK?
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MP-.((Y@"T( A4=2<@P?G4=B=4^'VEY7I;U!+ P04    " "D@%U3EXJ[',
M   3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!
M5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]I
MSI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z
M3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=
MQ_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( *2
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M^UM87]YPV2P,"YO]B]*J#F\Q5KV4U[[L@WJG>7OXBNGP!=:;[U!+ P04
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( *. 75/#S_H7[P   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( *. 75.97)PC$ 8  )PG   3
M      "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ HX!=
M4R)4#2QK!@  ]B(  !@              ("!#@@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( *. 75.6&0^[% <  )D<   8
M      " @:\.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M" "C@%U3/34M$+<"  "V!P  &               @('Y%0  >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L! A0#%     @ I(!=4W;83P6%!P  ^"<  !@
M             ("!YA@  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4
M Q0    ( *2 75/8<*H>R00  (P3   8              " @:$@  !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " "D@%U3O#F0CO "  "2
M"   &               @(&@)0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L! A0#%     @ I(!=4U6@B.OX!0  ;QT  !@              ("!QB@
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( *2 75,#I#]V
MB@(  +<&   8              " @?0N  !X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"% ,4    " "D@%U3&HE>S>X(  !H)0  &
M@(&T,0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ I(!=
M4_\[;B)3!@  O@\  !D              ("!V#H  'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"% ,4    " "D@%U3 "Y4 VL"   /!0  &0
M        @(%B00  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0
M   ( *2 75/"IB)%_@8  "H1   9              " @01$  !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ I(!=4XLA.?@6&   [E8
M !D              ("!.4L  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"% ,4    " "D@%U3_48WDX4(  "^%@  &0              @(&&8P
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( *2 75,%L2O!
MM 0  -H*   9              " @4)L  !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L! A0#%     @ I(!=4QRO2M@3!   +PD  !D
M ("!+7$  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " "D
M@%U3:20S-<4#  "X"@  &0              @(%W=0  >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( *2 75/=AX4+,A4  +(U   9
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M970R,BYX;6Q02P$"% ,4    " "D@%U3E>S 0W "   7!0  &0
M    @(%DR   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (
M *2 75,5J!XKP 4  (8-   9              " @0O+  !X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L! A0#%     @ I(!=4YFW+BD<#@  ;38  !D
M             ("! M$  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M% ,4    " "D@%U3O%:)H9(#  #Q!P  &0              @(%5WP  >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( *2 75.)I)'0V@(
M  H&   9              " @1[C  !X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L! A0#%     @ I(!=4ZL<N((O P  / <  !D              ("!
M+^8  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " "D@%U3
MAT7F(M(5  " 2   &0              @(&5Z0  >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+ 0(4 Q0    ( *2 75.KZT26? ,  #0'   9
M      " @9[_  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%
M  @ I(!=4T ,M_!H @  .@8  !D              ("!40,! 'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " "D@%U31$%'YQ0$   /$
M&0              @('P!0$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M 0(4 Q0    ( *2 75.M&6[FV0,  'H0   9              " @3L* 0!X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ I(!=4T09O9 /
M P  ZPD  !D              ("!2PX! 'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6Q02P$"% ,4    " "D@%U3?##N8CL"  "U!0  &0
M@(&1$0$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( *2
M75.[6G/4"P4  /L2   9              " @0,4 0!X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL4$L! A0#%     @ I(!=4^GUCB73"0  >%0  !D
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M=#0Q+GAM;%!+ 0(4 Q0    ( *2 75/P-T2E?@@   \Y   9
M  " @? P 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @
MI(!=4Q)+QY1""   S#X  !D              ("!I3D! 'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6Q02P$"% ,4    " "D@%U3'1U04Y0"  #K!P  &0
M            @($>0@$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4
M Q0    ( *2 75/ 85^I.0\  "*$   9              " @>E$ 0!X;"]W
M;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ I(!=4R3*FOV>!
MH1,  !D              ("!650! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX
M;6Q02P$"% ,4    " "D@%U3 G4,<IP$   "%   &0              @($N
M60$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( *2 75,\
M<!&X8@(  !4&   9              " @0%> 0!X;"]W;W)K<VAE971S+W-H
M965T-#@N>&UL4$L! A0#%     @ I(!=4YZ#K&7%!   +A<  !D
M     ("!FF ! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *2 75,F]9KED ,  "X,   9              "
M@96E 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ I(!=
M4X,$V(62!P  $RH  !D              ("!7*D! 'AL+W=O<FMS:&5E=',O
M<VAE970U-2YX;6Q02P$"% ,4    " "D@%U3D4IZBF@$  #B%0  &0
M        @($EL0$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0
M   ( *2 75.Y'5VAH00  * 5   9              " @<2U 0!X;"]W;W)K
M<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ I(!=4PY@E6T: P  9A$
M  T              ( !G+H! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "D
M@%U3EXJ[',     3 @  "P              @ 'AO0$ 7W)E;',O+G)E;'-0
M2P$"% ,4    " "D@%U3VAPK#FD$   %)@  #P              @ '*O@$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ I(!=4_,@BWGI 0  $B(  !H
M             ( !8,,! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ I(!=4[)H2=C5 0  OR$  !,              ( !@<4! %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&     $$ 00"^$0  A\<!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1063</ContextCount>
  <ElementCount>391</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>184</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Earnings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEarnings</Role>
      <ShortName>Consolidated Statements of Earnings</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Consolidated Statements of Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1008009 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2124105 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2126106 - Disclosure - Pensions and Other Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlans</Role>
      <ShortName>Pensions and Other Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2130107 - Disclosure - Accumulated Other Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome</Role>
      <ShortName>Accumulated Other Comprehensive Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2133108 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2136109 - Disclosure - Segments of Business and Geographic Areas</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas</Role>
      <ShortName>Segments of Business and Geographic Areas</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2141110 - Disclosure - Acquisitions and Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AcquisitionsandDivestitures</Role>
      <ShortName>Acquisitions and Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2144111 - Disclosure - Legal Proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/LegalProceedings</Role>
      <ShortName>Legal Proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2146112 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.jnj.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Inventories</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2307302 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/IntangibleAssetsandGoodwill</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/FairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2327304 - Disclosure - Pensions and Other Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansTables</Role>
      <ShortName>Pensions and Other Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/PensionsandOtherBenefitPlans</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2331305 - Disclosure - Accumulated Other Comprehensive Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2334306 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/EarningsPerShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2337307 - Disclosure - Segments of Business and Geographic Areas (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables</Role>
      <ShortName>Segments of Business and Geographic Areas (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2347308 - Disclosure - Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/RestructuringTables</Role>
      <ShortName>Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Restructuring</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/InventoriesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/IntangibleAssetsandGoodwillTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Intangible Assets and Goodwill - Goodwill By Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Goodwill By Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Fair Value Measurements - Summary of Derivative Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Derivative Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Fair Value Measurements - Derivatives, Balance Sheet Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails</Role>
      <ShortName>Fair Value Measurements - Derivatives, Balance Sheet Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2420412 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2421413 - Disclosure - Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails</Role>
      <ShortName>Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2422414 - Disclosure - Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2423415 - Disclosure - Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2425416 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/IncomeTaxes</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2428417 - Disclosure - Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2429418 - Disclosure - Pensions and Other Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails</Role>
      <ShortName>Pensions and Other Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/PensionsandOtherBenefitPlansTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2432419 - Disclosure - Accumulated Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2435420 - Disclosure - Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/EarningsPerShareTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2439422 - Disclosure - Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2440423 - Disclosure - Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2442424 - Disclosure - Acquisitions and Divestitures - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails</Role>
      <ShortName>Acquisitions and Divestitures - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2445426 - Disclosure - Legal Proceedings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/LegalProceedingsDetails</Role>
      <ShortName>Legal Proceedings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/LegalProceedings</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2448427 - Disclosure - Restructuring - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/RestructuringNarrativeDetails</Role>
      <ShortName>Restructuring - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="jnj-20211003.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2449428 - Disclosure - Restructuring - Schedule of Restructuring Reserve (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails</Role>
      <ShortName>Restructuring - Schedule of Restructuring Reserve (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="jnj-20211003.htm">jnj-20211003.htm</File>
    <File>a20213q2021ex322cfocertifi.htm</File>
    <File>a20213qex311ceocertificati.htm</File>
    <File>a20213qex312cfocertificati.htm</File>
    <File>a20213qex321ceocertificati.htm</File>
    <File>jnj-20211003.xsd</File>
    <File>jnj-20211003_cal.xml</File>
    <File>jnj-20211003_def.xml</File>
    <File>jnj-20211003_lab.xml</File>
    <File>jnj-20211003_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>jnj-20211003_g1.jpg</File>
    <File>jnj-20211003_g10.jpg</File>
    <File>jnj-20211003_g11.jpg</File>
    <File>jnj-20211003_g12.jpg</File>
    <File>jnj-20211003_g13.jpg</File>
    <File>jnj-20211003_g2.jpg</File>
    <File>jnj-20211003_g3.jpg</File>
    <File>jnj-20211003_g4.jpg</File>
    <File>jnj-20211003_g5.jpg</File>
    <File>jnj-20211003_g6.jpg</File>
    <File>jnj-20211003_g7.jpg</File>
    <File>jnj-20211003_g8.jpg</File>
    <File>jnj-20211003_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>87
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "jnj-20211003.htm": {
   "axisCustom": 1,
   "axisStandard": 33,
   "contextCount": 1063,
   "dts": {
    "calculationLink": {
     "local": [
      "jnj-20211003_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "jnj-20211003_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "jnj-20211003.htm"
     ]
    },
    "labelLink": {
     "local": [
      "jnj-20211003_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "jnj-20211003_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "jnj-20211003.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 664,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 50,
   "keyStandard": 341,
   "memberCustom": 114,
   "memberStandard": 61,
   "nsprefix": "jnj",
   "nsuri": "http://www.jnj.com/20211003",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.jnj.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Inventories",
     "role": "http://www.jnj.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Intangible Assets and Goodwill",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwill",
     "shortName": "Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Fair Value Measurements",
     "role": "http://www.jnj.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124105 - Disclosure - Income Taxes",
     "role": "http://www.jnj.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126106 - Disclosure - Pensions and Other Benefit Plans",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlans",
     "shortName": "Pensions and Other Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130107 - Disclosure - Accumulated Other Comprehensive Income",
     "role": "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome",
     "shortName": "Accumulated Other Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133108 - Disclosure - Earnings Per Share",
     "role": "http://www.jnj.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136109 - Disclosure - Segments of Business and Geographic Areas",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas",
     "shortName": "Segments of Business and Geographic Areas",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141110 - Disclosure - Acquisitions and Divestitures",
     "role": "http://www.jnj.com/role/AcquisitionsandDivestitures",
     "shortName": "Acquisitions and Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i524495c8e7d941efbc4c7057a7d882bf_I20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.jnj.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i524495c8e7d941efbc4c7057a7d882bf_I20211003",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144111 - Disclosure - Legal Proceedings",
     "role": "http://www.jnj.com/role/LegalProceedings",
     "shortName": "Legal Proceedings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146112 - Disclosure - Restructuring",
     "role": "http://www.jnj.com/role/Restructuring",
     "shortName": "Restructuring",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Inventories (Tables)",
     "role": "http://www.jnj.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307302 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327304 - Disclosure - Pensions and Other Benefit Plans (Tables)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables",
     "shortName": "Pensions and Other Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331305 - Disclosure - Accumulated Other Comprehensive Income (Tables)",
     "role": "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables",
     "shortName": "Accumulated Other Comprehensive Income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334306 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://www.jnj.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:SalesBySegmentOfBusinessTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337307 - Disclosure - Segments of Business and Geographic Areas (Tables)",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables",
     "shortName": "Segments of Business and Geographic Areas (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:SalesBySegmentOfBusinessTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i524495c8e7d941efbc4c7057a7d882bf_I20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i524495c8e7d941efbc4c7057a7d882bf_I20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2347308 - Disclosure - Restructuring (Tables)",
     "role": "http://www.jnj.com/role/RestructuringTables",
     "shortName": "Restructuring (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i524495c8e7d941efbc4c7057a7d882bf_I20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405401 - Disclosure - Inventories (Details)",
     "role": "http://www.jnj.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i524495c8e7d941efbc4c7057a7d882bf_I20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i524495c8e7d941efbc4c7057a7d882bf_I20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408402 - Disclosure - Intangible Assets and Goodwill (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
     "shortName": "Intangible Assets and Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i524495c8e7d941efbc4c7057a7d882bf_I20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i6223e38b49924566951c6ee22df12ea8_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Intangible Assets and Goodwill - Goodwill By Segment (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
     "shortName": "Intangible Assets and Goodwill - Goodwill By Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
     "shortName": "Intangible Assets and Goodwill - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i524495c8e7d941efbc4c7057a7d882bf_I20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails",
     "shortName": "Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i524495c8e7d941efbc4c7057a7d882bf_I20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i524495c8e7d941efbc4c7057a7d882bf_I20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i524495c8e7d941efbc4c7057a7d882bf_I20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i086fb509c2da43bdbf100b4f08fd1272_D20210705-20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Fair Value Measurements - Summary of Derivative Activity (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
     "shortName": "Fair Value Measurements - Summary of Derivative Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "id0141e2177d24be384d24197d458ffe0_D20210104-20211003",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i524495c8e7d941efbc4c7057a7d882bf_I20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Fair Value Measurements - Derivatives, Balance Sheet Location (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
     "shortName": "Fair Value Measurements - Derivatives, Balance Sheet Location (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "iba61370bc5134de1ba733b99d4caa214_I20211003",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i2835247bbd164156ac697a316626d4b8_D20210705-20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
     "shortName": "Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i2835247bbd164156ac697a316626d4b8_D20210705-20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Earnings",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
     "shortName": "Consolidated Statements of Earnings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003",
      "decimals": "3",
      "lang": "en-US",
      "name": "jnj:SalesRevenueGoodsNetPercentToSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
     "shortName": "Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i524495c8e7d941efbc4c7057a7d882bf_I20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419411 - Disclosure - Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails",
     "shortName": "Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i2c668ea680234cec82c45cb5e0c7a70c_I20210103",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i524495c8e7d941efbc4c7057a7d882bf_I20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420412 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i524495c8e7d941efbc4c7057a7d882bf_I20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i524495c8e7d941efbc4c7057a7d882bf_I20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421413 - Disclosure - Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails",
     "shortName": "Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i524495c8e7d941efbc4c7057a7d882bf_I20211003",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i524495c8e7d941efbc4c7057a7d882bf_I20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422414 - Disclosure - Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails",
     "shortName": "Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i524495c8e7d941efbc4c7057a7d882bf_I20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i524495c8e7d941efbc4c7057a7d882bf_I20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423415 - Disclosure - Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails",
     "shortName": "Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i18389b6ef2374d3c823b640e24fe8d12_I20211003",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425416 - Disclosure - Income Taxes (Details)",
     "role": "http://www.jnj.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i1a7e0b9b6e694546bcf63ba4da67114c_D20210705-20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428417 - Disclosure - Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
     "shortName": "Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i1a7e0b9b6e694546bcf63ba4da67114c_D20210705-20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "ieeff0339058f4ac9808b5eba4dc8ff41_D20210104-20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionContributions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429418 - Disclosure - Pensions and Other Benefit Plans (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails",
     "shortName": "Pensions and Other Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "ieeff0339058f4ac9808b5eba4dc8ff41_D20210104-20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionContributions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i4f560bf19097496e9d3b17c570ba5487_I20210704",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432419 - Disclosure - Accumulated Other Comprehensive Income (Details)",
     "role": "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
     "shortName": "Accumulated Other Comprehensive Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i6c9b670acb814f2e8e8cae1d3b139677_I20210103",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Comprehensive Income",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435420 - Disclosure - Earnings Per Share (Details)",
     "role": "http://www.jnj.com/role/EarningsPerShareDetails",
     "shortName": "Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
     "shortName": "Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003",
      "decimals": "3",
      "lang": "en-US",
      "name": "jnj:PercentageChangeInSalesBySegmentOfBusiness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "jnj:PercentageChangeInOperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439422 - Disclosure - Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
     "shortName": "Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "jnj:PercentageChangeInOperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440423 - Disclosure - Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
     "shortName": "Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003",
      "decimals": "3",
      "lang": "en-US",
      "name": "jnj:PercentageChangeInSalesByGeographicArea",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i524495c8e7d941efbc4c7057a7d882bf_I20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442424 - Disclosure - Acquisitions and Divestitures - Narrative (Details)",
     "role": "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
     "shortName": "Acquisitions and Divestitures - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i8aa76dc85f4d47988a65dc0767f87e60_D20191230-20200329",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "idd91294a39994bf7a5d46ad21d5ce73f_I20211003",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "jnj:ProductLiabilityContingencyNumberOfClaimant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claimant",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445426 - Disclosure - Legal Proceedings (Details)",
     "role": "http://www.jnj.com/role/LegalProceedingsDetails",
     "shortName": "Legal Proceedings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "idd91294a39994bf7a5d46ad21d5ce73f_I20211003",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "jnj:ProductLiabilityContingencyNumberOfClaimant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claimant",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448427 - Disclosure - Restructuring - Narrative (Details)",
     "role": "http://www.jnj.com/role/RestructuringNarrativeDetails",
     "shortName": "Restructuring - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i5c79c8166fea4d28acc6e2a5c55371e3_D20210705-20211003",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449428 - Disclosure - Restructuring - Schedule of Restructuring Reserve (Details)",
     "role": "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails",
     "shortName": "Restructuring - Schedule of Restructuring Reserve (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i68831153f9a14ae1b239033a0c1a9104_I20210103",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical",
     "shortName": "Consolidated Statements of Comprehensive Income (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "if49e94e75cf04169b3ef119b2c588a4c_I20191229",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Equity",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
     "shortName": "Consolidated Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i6004d7a658874bffb0b05f268a6fc6e9_I20191229",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Consolidated Statements of Equity (Parenthetical)",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical",
     "shortName": "Consolidated Statements of Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "ic5071d6c996f48fc95ef504bf678f0df_D20210705-20211003",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1008009 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20211003.htm",
      "contextRef": "i9cc95a1f66114023bedf8203854e55b4_D20210104-20211003",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 184,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States",
        "verboseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "jnj_A0.250NotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.250% Notes Due 2022 [Member]",
        "label": "0.250% Notes Due 2022 [Member]",
        "verboseLabel": "0.250% Notes Due January 2022"
       }
      }
     },
     "localname": "A0.250NotesDue2022Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A0.650NotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.650% Notes Due 2024 [Member]",
        "label": "0.650% Notes Due 2024 [Member]",
        "terseLabel": "0.650% Notes due 2024 (750MM Euro 1.1581)",
        "verboseLabel": "0.650% Notes Due May 2024"
       }
      }
     },
     "localname": "A0.650NotesDue2024Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/Cover",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A0550NotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.550 Notes due 2025",
        "label": "0.550 Notes due 2025 [Member]",
        "terseLabel": "0.55% Notes due 2025"
       }
      }
     },
     "localname": "A0550NotesDue2025Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A095NotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.95% Notes due 2027",
        "label": "0.95% Notes due 2027 [Member]",
        "terseLabel": "0.95% Notes due 2027"
       }
      }
     },
     "localname": "A095NotesDue2027Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1.150NotesDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.150% Notes Due 2028 [Member]",
        "label": "1.150% Notes Due 2028 [Member]",
        "terseLabel": "1.150% Notes due 2028 (750MM Euro 1.1581)",
        "verboseLabel": "1.150% Notes Due November 2028"
       }
      }
     },
     "localname": "A1.150NotesDue2028Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/Cover",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1.650NotesDue2035Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.650% Notes Due 2035 [Member]",
        "label": "1.650% Notes Due 2035 [Member]",
        "terseLabel": "1.650% Notes due 2035 (1.5B Euro 1.1581)",
        "verboseLabel": "1.650% Notes Due May 2035"
       }
      }
     },
     "localname": "A1.650NotesDue2035Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/Cover",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1300NotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.300% Notes due 2030",
        "label": "1.300% Notes due 2030 [Member]",
        "terseLabel": "1.30% Notes due 2030"
       }
      }
     },
     "localname": "A1300NotesDue2030Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.05Notesdue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.05% Notes due 2023 [Member]",
        "label": "2.05% Notes due 2023 [Member]",
        "terseLabel": "2.05% Notes due 2023"
       }
      }
     },
     "localname": "A2.05Notesdue2023Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.45Notesdue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.45% Notes due 2026 [Member]",
        "label": "2.45% Notes due 2026 [Member]",
        "terseLabel": "2.45% Notes due 2026"
       }
      }
     },
     "localname": "A2.45Notesdue2026Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.625Notesdue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.625 Notes due 2025 [Member]",
        "label": "2.625 Notes due 2025 [Member]",
        "terseLabel": "2.625% Notes due 2025"
       }
      }
     },
     "localname": "A2.625Notesdue2025Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.900Notesdue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.900% Notes due 2028 [Member]",
        "label": "2.900% Notes due 2028 [Member]",
        "terseLabel": "2.90%\u00a0Notes due 2028"
       }
      }
     },
     "localname": "A2.900Notesdue2028Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.95Notesdue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.95% Notes due 2027 [Member]",
        "label": "2.95% Notes due 2027 [Member]",
        "terseLabel": "2.95% Notes due 2027"
       }
      }
     },
     "localname": "A2.95Notesdue2027Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A210NotesDue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.10% Notes due 2040",
        "label": "2.10% Notes due 2040 [Member]",
        "terseLabel": "2.10% Notes due 2040"
       }
      }
     },
     "localname": "A210NotesDue2040Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2250NotesDue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.250% Notes due 2050",
        "label": "2.250% Notes due 2050 [Member]",
        "terseLabel": "2.25% Notes due 2050"
       }
      }
     },
     "localname": "A2250NotesDue2050Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2450NotesDue2060Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.450% Notes due 2060",
        "label": "2.450% Notes due 2060 [Member]",
        "terseLabel": "2.45% Notes due 2060"
       }
      }
     },
     "localname": "A2450NotesDue2060Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.375Notesdue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.375% Notes due 2023 [Member]",
        "label": "3.375% Notes due 2023 [Member]",
        "terseLabel": "3.375% Notes due 2023"
       }
      }
     },
     "localname": "A3.375Notesdue2023Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.400Notesdue2038Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.400% Notes due 2038 [Member]",
        "label": "3.400% Notes due 2038 [Member]",
        "terseLabel": "3.40%\u00a0Notes due 2038"
       }
      }
     },
     "localname": "A3.400Notesdue2038Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.500Notesdue2048Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.500% Notes due 2048 [Member]",
        "label": "3.500% Notes due 2048 [Member]",
        "terseLabel": "3.50% Notes due 2048"
       }
      }
     },
     "localname": "A3.500Notesdue2048Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.55Notesdue2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.55% Notes due 2036 [Member]",
        "label": "3.55% Notes due 2036 [Member]",
        "terseLabel": "3.55% Notes due 2036"
       }
      }
     },
     "localname": "A3.55Notesdue2036Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.625Notesdue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.625% Notes due 2037 [Member]",
        "label": "3.625% Notes due 2037 [Member]",
        "terseLabel": "3.625% Notes due 2037"
       }
      }
     },
     "localname": "A3.625Notesdue2037Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.70Notesdue2046Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.70% Notes due 2046 [Member]",
        "label": "3.70% Notes due 2046 [Member]",
        "terseLabel": "3.70% Notes due 2046"
       }
      }
     },
     "localname": "A3.70Notesdue2046Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.75Notesdue2047Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.75% Notes due 2047 [Member]",
        "label": "3.75% Notes due 2047 [Member]",
        "terseLabel": "3.75% Notes due 2047"
       }
      }
     },
     "localname": "A3.75Notesdue2047Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.375Notesdue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.375% Notes due 2033 [Member]",
        "label": "4.375% Notes due 2033 [Member]",
        "terseLabel": "4.375% Notes due 2033"
       }
      }
     },
     "localname": "A4.375Notesdue2033Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.50Debenturesdue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.50% Debentures due 2040 [Member]",
        "label": "4.50% Debentures due 2040 [Member]",
        "terseLabel": "4.50% Debentures due 2040"
       }
      }
     },
     "localname": "A4.50Debenturesdue2040Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.50Notesdue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.50% Notes due 2043 [Member]",
        "label": "4.50% Notes due 2043 [Member]",
        "terseLabel": "4.50% Notes due 2043"
       }
      }
     },
     "localname": "A4.50Notesdue2043Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.85Notesdue2041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.85% Notes due 2041 [Member]",
        "label": "4.85% Notes due 2041 [Member]",
        "terseLabel": "4.85% Notes due 2041"
       }
      }
     },
     "localname": "A4.85Notesdue2041Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.95Debenturesdue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.95% Debentures due 2033 [Member]",
        "label": "4.95% Debentures due 2033 [Member]",
        "terseLabel": "4.95% Debentures due 2033"
       }
      }
     },
     "localname": "A4.95Debenturesdue2033Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.50NotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.50% Notes Due 2024 [Member]",
        "label": "5.50% Notes Due 2024 [Member]",
        "terseLabel": "5.50% Notes due 2024 (500 MM GBP 1.3465)",
        "verboseLabel": "5.50% Notes Due November 2024"
       }
      }
     },
     "localname": "A5.50NotesDue2024Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/Cover",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.85Debenturesdue2038Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.85% Debentures due 2038 [Member]",
        "label": "5.85% Debentures due 2038 [Member]",
        "terseLabel": "5.85% Debentures due 2038"
       }
      }
     },
     "localname": "A5.85Debenturesdue2038Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.95Notesdue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.95% Notes due 2037 [Member]",
        "label": "5.95% Notes due 2037 [Member]",
        "terseLabel": "5.95% Notes due 2037"
       }
      }
     },
     "localname": "A5.95Notesdue2037Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A6.73Debenturesdue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.73% Debentures due 2023 [Member]",
        "label": "6.73% Debentures due 2023 [Member]",
        "terseLabel": "6.73% Debentures due 2023"
       }
      }
     },
     "localname": "A6.73Debenturesdue2023Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A6.95Notesdue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.95% Notes due 2029 [Member]",
        "label": "6.95% Notes due 2029 [Member]",
        "terseLabel": "6.95% Notes due 2029"
       }
      }
     },
     "localname": "A6.95Notesdue2029Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ADVANCEDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ADVANCED [Member]",
        "label": "ADVANCED [Member]",
        "terseLabel": "ADVANCED"
       }
      }
     },
     "localname": "ADVANCEDMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AccruedRebatesReturnsAndPromotions": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.",
        "label": "Accrued Rebates Returns And Promotions",
        "verboseLabel": "Accrued rebates, returns and promotions"
       }
      }
     },
     "localname": "AccruedRebatesReturnsAndPromotions",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_AmountPrepaidAndDueToManufacturers": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount Prepaid and Due to Manufacturers",
        "label": "Amount Prepaid and Due to Manufacturers",
        "terseLabel": "Amount prepaid and due to manufacturers"
       }
      }
     },
     "localname": "AmountPrepaidAndDueToManufacturers",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_AsiaPacificAfricaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asia-Pacific, Africa [Member]",
        "label": "Asia-Pacific, Africa [Member]",
        "terseLabel": "Asia-Pacific, Africa"
       }
      }
     },
     "localname": "AsiaPacificAfricaMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AsrMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASR.",
        "label": "ASR [Member]",
        "terseLabel": "ASR"
       }
      }
     },
     "localname": "AsrMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AssetWriteoffMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Write-off [Member]",
        "label": "Asset Write-off [Member]",
        "terseLabel": "Asset Write-off"
       }
      }
     },
     "localname": "AssetWriteoffMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AurisHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auris Health",
        "label": "Auris Health [Member]",
        "terseLabel": "Auris Health"
       }
      }
     },
     "localname": "AurisHealthMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BabyCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baby Care [Member]",
        "label": "Baby Care [Member]",
        "terseLabel": "Baby Care"
       }
      }
     },
     "localname": "BabyCareMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BabyPowderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baby Powder [Member]",
        "label": "Baby Powder [Member]",
        "terseLabel": "Baby Powder"
       }
      }
     },
     "localname": "BabyPowderMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BeautyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beauty [Member]",
        "label": "Beauty [Member]",
        "terseLabel": "Skin Health/Beauty"
       }
      }
     },
     "localname": "BeautyMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BermekimabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "bermekimab [Member]",
        "label": "bermekimab [Member]",
        "terseLabel": "bermekimab"
       }
      }
     },
     "localname": "BermekimabMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CONCERTAMethylphenidateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CONCERTA/Methylphenidate [Member]",
        "label": "CONCERTA/Methylphenidate [Member]",
        "terseLabel": "CONCERTA\u00ae / methylphenidate"
       }
      }
     },
     "localname": "CONCERTAMethylphenidateMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CONTACTLENSESOTHERMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CONTACT LENSES/OTHER [Member]",
        "label": "CONTACT LENSES/OTHER [Member]",
        "terseLabel": "CONTACT LENSES / OTHER"
       }
      }
     },
     "localname": "CONTACTLENSESOTHERMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_COVID19Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19",
        "label": "COVID-19 [Member]",
        "terseLabel": "COVID-19"
       }
      }
     },
     "localname": "COVID19Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CardiovascularMetabolismOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardiovascular/Metabolism/Other [Member]",
        "label": "Cardiovascular/Metabolism/Other [Member]",
        "terseLabel": "Cardiovascular / Metabolism / Other"
       }
      }
     },
     "localname": "CardiovascularMetabolismOtherMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss",
        "label": "Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss",
        "negatedTerseLabel": "Total cash, cash equivalents and current marketable securities, Unrecognized Loss"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, and Short-term Investments, Estimated Fair Value",
        "label": "Cash, Cash Equivalents, And Short-Term Investments, Estimated Fair Value",
        "terseLabel": "Total cash, cash equivalents and current marketable securities, Estimated Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, and Short-term Investments, Accumulated Gross Unrealized Gain",
        "label": "Cash, Cash Equivalents, and Short-term Investments, Accumulated Gross Unrealized Gain",
        "terseLabel": "Total cash, cash equivalents and current marketable securities, Unrecognized Gain"
       }
      }
     },
     "localname": "CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ConsumerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumer.",
        "label": "Consumer [Member]",
        "terseLabel": "Consumer Health"
       }
      }
     },
     "localname": "ConsumerMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ContactLensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contact Lenses",
        "label": "Contact Lenses [Member]",
        "terseLabel": "Contact Lenses"
       }
      }
     },
     "localname": "ContactLensesMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CostOfGoodsSoldPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "jnj_GrossProfitPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of goods sold percent to sales.",
        "label": "Cost Of Goods Sold Percent To Sales",
        "terseLabel": "Cost of products sold percent to sales"
       }
      }
     },
     "localname": "CostOfGoodsSoldPercentToSales",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_DARZALEXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DARZALEX [Member]",
        "label": "DARZALEX [Member]",
        "terseLabel": "DARZALEX\u00ae"
       }
      }
     },
     "localname": "DARZALEXMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_DePuyASRU.S.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DePuy ASR U.S. [Member]",
        "label": "DePuy ASR U.S. [Member]",
        "terseLabel": "DePuy ASR U.S."
       }
      }
     },
     "localname": "DePuyASRU.S.Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Tax Basis Increase of Certain Assets due to Reorganization",
        "label": "Deferred Tax Assets, Tax Basis Increase of Certain Assets due to Reorganization",
        "terseLabel": "Deferred tax benefits related to tax basis increase of certain assets due to reorganization"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EDURANTrilpivirineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EDURANT/rilpivirine [Member]",
        "label": "EDURANT/rilpivirine [Member]",
        "terseLabel": "EDURANT\u00ae / rilpivirine"
       }
      }
     },
     "localname": "EDURANTrilpivirineMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ERLEADAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ERLEADA",
        "label": "ERLEADA [Member]",
        "terseLabel": "ERLEADA"
       }
      }
     },
     "localname": "ERLEADAMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Accrued Legal Expenses, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Accrued Legal Expenses, Amount",
        "terseLabel": "Effective income tax rate, accrued legal expenses, amount"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesAmount",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Accrued Legal Expenses, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Accrued Legal Expenses, Percent",
        "terseLabel": "Effective income tax rate, accrued legal expenses, percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAccruedLegalExpensesPercent",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent",
        "label": "Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent",
        "terseLabel": "Increase (decrease) in effective income tax rate, percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_EquityFairValueAdjustmentImpairmentLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity, Fair Value Adjustment, Impairment Loss",
        "label": "Equity, Fair Value Adjustment, Impairment Loss",
        "terseLabel": "Equity, fair value adjustment, impairment loss"
       }
      }
     },
     "localname": "EquityFairValueAdjustmentImpairmentLoss",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EquityInvestmentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investment [Roll Forward]",
        "label": "Equity Investment [Roll Forward]",
        "terseLabel": "Equity Investment [Roll Forward]"
       }
      }
     },
     "localname": "EquityInvestmentRollForward",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period",
        "label": "Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period",
        "terseLabel": "Sales/ Purchases/Other"
       }
      }
     },
     "localname": "EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EquityInvestmentswithReadilyDeterminableValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments with Readily Determinable Value [Member]",
        "label": "Equity Investments with Readily Determinable Value [Member]",
        "terseLabel": "Equity Investments with readily determinable value"
       }
      }
     },
     "localname": "EquityInvestmentswithReadilyDeterminableValueMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EquityInvestmentswithoutReadilyDeterminableValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments without Readily Determinable Value [Member]",
        "label": "Equity Investments without Readily Determinable Value [Member]",
        "terseLabel": "Equity Investments without readily determinable value"
       }
      }
     },
     "localname": "EquityInvestmentswithoutReadilyDeterminableValueMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EvraAndDoxilMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evra and Doxil",
        "label": "Evra and Doxil [Member]",
        "terseLabel": "Evra and Doxil"
       }
      }
     },
     "localname": "EvraAndDoxilMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ExcessOfFairValueOverCarryingValueOfDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of fair value over carrying value of debt.",
        "label": "Excess Of Fair Value Over Carrying Value Of Debt",
        "terseLabel": "Excess of the estimated fair value over the carrying value of debt"
       }
      }
     },
     "localname": "ExcessOfFairValueOverCarryingValueOfDebt",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value",
        "terseLabel": "Changes in estimated fair value (6)"
       }
      }
     },
     "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset",
        "label": "Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset",
        "terseLabel": "Deferred tax benefit related to TRAF"
       }
      }
     },
     "localname": "FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset, Percent",
        "label": "Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset, Percent",
        "terseLabel": "Deferred tax benefit related to TRAF, percent"
       }
      }
     },
     "localname": "FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_FederalLevelJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Level Jurisdiction",
        "label": "Federal Level Jurisdiction [Member]",
        "terseLabel": "Federal Level Jurisdiction"
       }
      }
     },
     "localname": "FederalLevelJurisdictionMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_GENERALMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GENERAL [Member]",
        "label": "GENERAL [Member]",
        "terseLabel": "GENERAL"
       }
      }
     },
     "localname": "GENERALMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_GrossProfitPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 8.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross profit percent to sales.",
        "label": "Gross Profit Percent To Sales",
        "totalLabel": "Gross Profit Percent To Sales"
       }
      }
     },
     "localname": "GrossProfitPercentToSales",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_HIPSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIPS [Member]",
        "label": "HIPS [Member]",
        "terseLabel": "HIPS"
       }
      }
     },
     "localname": "HIPSMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_IMBRUVICAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IMBRUVICA [Member]",
        "label": "IMBRUVICA [Member]",
        "terseLabel": "IMBRUVICA\u00ae"
       }
      }
     },
     "localname": "IMBRUVICAMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]",
        "label": "INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]",
        "terseLabel": "INVEGA SUSTENNA\u00ae / XEPLION\u00ae / INVEGA TRINZA\u00ae / TREVICTA\u00ae"
       }
      }
     },
     "localname": "INVEGASUSTENNAXEPLIONTRINZATREVICTAMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_INVOKANAINVOKAMETMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "INVOKANA/INVOKAMET [Member]",
        "label": "INVOKANA/INVOKAMET [Member]",
        "terseLabel": "INVOKANA\u00ae / INVOKAMET\u00ae"
       }
      }
     },
     "localname": "INVOKANAINVOKAMETMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunology [Member]",
        "label": "Immunology [Member]",
        "terseLabel": "Immunology"
       }
      }
     },
     "localname": "ImmunologyMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "jnj_NetIncomeAttributableToParentPercentToSales",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income loss from continuing operations before income taxes minority interest and income loss from equity method investments percent to sales.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Percent To Sales",
        "totalLabel": "Earnings before provision for taxes on income percent to sales"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_IncomeTaxExpenseBenefitPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "jnj_NetIncomeAttributableToParentPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax expense benefit percent to sales.",
        "label": "Income Tax Expense Benefit Percent To Sales",
        "terseLabel": "Provision for taxes on income percent to sales"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitPercentToSales",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_IncomeTaxTextualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Textuals Abstract.",
        "label": "Income Tax (Textuals) [Abstract]",
        "verboseLabel": "Income Tax (Textuals)"
       }
      }
     },
     "localname": "IncomeTaxTextualsAbstract",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Deferred Tax Liabilities, Global Intangible Low-Taxed Income (GILTI)",
        "label": "Increase (Decrease) in Deferred Tax Liabilities, Global Intangible Low-Taxed Income (GILTI)",
        "terseLabel": "Increase in U.S. GILTI deferred tax liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_InfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infectious Diseases [Member]",
        "label": "Infectious Diseases [Member]",
        "terseLabel": "Infectious Diseases"
       }
      }
     },
     "localname": "InfectiousDiseasesMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InterestExpensePercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 6.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expense percent to sales.",
        "label": "Interest Expense Percent To Sales",
        "terseLabel": "Interest expense, net of portion capitalized percent to sales"
       }
      }
     },
     "localname": "InterestExpensePercentToSales",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_InterestIncomeExpenseNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Income Expense Net Member.",
        "label": "Interest Income Expense Net Member",
        "verboseLabel": "Interest (income)/Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNetMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InterventionalSolutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interventional Solutions [Member]",
        "label": "Interventional Solutions [Member]",
        "verboseLabel": "Interventional Solutions"
       }
      }
     },
     "localname": "InterventionalSolutionsMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InvestmentIncomeInterestPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment income interest percent to sales.",
        "label": "Investment Income Interest Percent To Sales",
        "terseLabel": "Interest income percent to sales"
       }
      }
     },
     "localname": "InvestmentIncomeInterestPercentToSales",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_InvokanaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Invokana [Member]",
        "label": "Invokana [Member]",
        "terseLabel": "Invokana"
       }
      }
     },
     "localname": "InvokanaMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_KNEESMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "KNEES [Member]",
        "label": "KNEES [Member]",
        "terseLabel": "KNEES"
       }
      }
     },
     "localname": "KNEESMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_LegalJurisdictionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Jurisdiction",
        "label": "Legal Jurisdiction [Axis]",
        "terseLabel": "Legal Jurisdiction [Axis]"
       }
      }
     },
     "localname": "LegalJurisdictionAxis",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_LegalJurisdictionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Jurisdiction [Domain]",
        "label": "Legal Jurisdiction [Domain]",
        "terseLabel": "Legal Jurisdiction [Domain]"
       }
      }
     },
     "localname": "LegalJurisdictionDomain",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_LegalProceedingTextualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Proceeding Textuals Abstract.",
        "label": "Legal Proceeding (Textuals) [Abstract]",
        "terseLabel": "Legal Proceeding (Textuals)"
       }
      }
     },
     "localname": "LegalProceedingTextualsAbstract",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_LitigationSettlementByCompaniesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement by companies.",
        "label": "Litigation Settlement By Companies [Axis]",
        "terseLabel": "Litigation Settlement By Companies"
       }
      }
     },
     "localname": "LitigationSettlementByCompaniesAxis",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_LitigationSettlementByCompaniesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement by companies.",
        "label": "Litigation Settlement By Companies [Domain]",
        "terseLabel": "Litigation Settlement By Companies"
       }
      }
     },
     "localname": "LitigationSettlementByCompaniesDomain",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Damages Awarded, Additional Reimbursement, Value",
        "label": "Loss Contingency, Damages Awarded, Additional Reimbursement, Value",
        "terseLabel": "Damages awarded, including settlement for related issues, reimbursement for legal fees, and removal from related claims"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedAdditionalReimbursementValue",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_LossContingencyEstimateOfAdditionalPossibleLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Estimate of Additional Possible Loss",
        "label": "Loss Contingency, Estimate of Additional Possible Loss",
        "terseLabel": "Loss contingency, estimate of additional possible loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfAdditionalPossibleLoss",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_LossContingencyNumberOfVotesInFavor": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number of Votes in Favor",
        "label": "Loss Contingency, Number of Votes in Favor",
        "terseLabel": "Number of votes in favor"
       }
      }
     },
     "localname": "LossContingencyNumberOfVotesInFavor",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_LossContingencyNumberOfVotesRejected": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number of Votes Rejected",
        "label": "Loss Contingency, Number of Votes Rejected",
        "terseLabel": "Number of votes rejected"
       }
      }
     },
     "localname": "LossContingencyNumberOfVotesRejected",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_LossContingencyReserveEstablishedWithinTrust": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Reserve Established within Trust",
        "label": "Loss Contingency, Reserve Established within Trust",
        "terseLabel": "Reserve established"
       }
      }
     },
     "localname": "LossContingencyReserveEstablishedWithinTrust",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_MedicalDevicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Devices [Member]",
        "label": "Medical Devices [Member]",
        "terseLabel": "MEDICAL DEVICES",
        "verboseLabel": "Medical Devices"
       }
      }
     },
     "localname": "MedicalDevicesMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_NetIncomeAttributableToParentPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Income Attributable to Parent Percent to Sales",
        "label": "Net Income Attributable to Parent Percent to Sales",
        "totalLabel": "Net earnings percent to sales"
       }
      }
     },
     "localname": "NetIncomeAttributableToParentPercentToSales",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_NeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neuroscience [Member]",
        "label": "Neuroscience [Member]",
        "terseLabel": "Neuroscience"
       }
      }
     },
     "localname": "NeuroscienceMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_NotesDuePeriodFifteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes due period fifteen.",
        "label": "Notes Due Period Fifteen Member",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "NotesDuePeriodFifteenMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_Numberofpatientsinsettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of patients in settlement",
        "label": "Number of patients in settlement",
        "terseLabel": "Number of patients in settlement"
       }
      }
     },
     "localname": "Numberofpatientsinsettlement",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_OPSUMITMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OPSUMIT [Member]",
        "label": "OPSUMIT [Member]",
        "terseLabel": "OPSUMIT\u00ae"
       }
      }
     },
     "localname": "OPSUMITMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OTCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OTC [Member]",
        "label": "OTC [Member]",
        "terseLabel": "OTC"
       }
      }
     },
     "localname": "OTCMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OTHERNEUROSCIENCEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OTHER NEUROSCIENCE [Member]",
        "label": "OTHER NEUROSCIENCE [Member]",
        "terseLabel": "OTHER NEUROSCIENCE"
       }
      }
     },
     "localname": "OTHERNEUROSCIENCEMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]",
        "label": "Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]",
        "terseLabel": "Oklahoma Attorney General vs. Johnson &amp; Johnson and JPI"
       }
      }
     },
     "localname": "OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oncology [Member]",
        "label": "Oncology [Member]",
        "terseLabel": "Oncology"
       }
      }
     },
     "localname": "OncologyMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OpioidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid",
        "label": "opioid [Member]",
        "terseLabel": "Opioid"
       }
      }
     },
     "localname": "OpioidMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OralCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oral Care [Member]",
        "label": "Oral Care [Member]",
        "terseLabel": "Oral Care"
       }
      }
     },
     "localname": "OralCareMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OrthopaedicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orthopaedics [Member]",
        "label": "Orthopaedics [Member]",
        "terseLabel": "Orthopaedics"
       }
      }
     },
     "localname": "OrthopaedicsMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax",
        "label": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax",
        "negatedTerseLabel": "Prior service cost amortization during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax",
        "label": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax",
        "negatedTerseLabel": "Gain (loss) amortization during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_OtherImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Immunology [Member]",
        "label": "Other Immunology [Member]",
        "terseLabel": "OTHER IMMUNOLOGY"
       }
      }
     },
     "localname": "OtherImmunologyMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherIncomeExpenseNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Income Expense Net [Member]",
        "label": "Other Income Expense Net [Member]",
        "terseLabel": "Other (income) expense",
        "verboseLabel": "Other Income Expense Net"
       }
      }
     },
     "localname": "OtherIncomeExpenseNetMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherInfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Infectious Diseases [Member]",
        "label": "Other Infectious Diseases [Member]",
        "terseLabel": "OTHER INFECTIOUS DISEASES"
       }
      }
     },
     "localname": "OtherInfectiousDiseasesMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other [Member]",
        "label": "Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherNonOperatingIncomeExpensePercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other non operating income expense percent to sales.",
        "label": "Other Non Operating Income Expense Percent To Sales",
        "terseLabel": "Other (income) expense, net percent to sales"
       }
      }
     },
     "localname": "OtherNonOperatingIncomeExpensePercentToSales",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_OtherOncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Oncology [Member]",
        "label": "Other Oncology [Member]",
        "terseLabel": "OTHER ONCOLOGY(1)"
       }
      }
     },
     "localname": "OtherOncologyMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]",
        "label": "PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]",
        "terseLabel": "PREZISTA\u00ae / PREZCOBIX\u00ae / REZOLSTA\u00ae / SYMTUZA\u00ae"
       }
      }
     },
     "localname": "PREZISTAPREZCOBIXREZOLSTASYMTUZAMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PROCRITEPREXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PROCRIT/EPREX [Member]",
        "label": "PROCRIT/EPREX [Member]",
        "terseLabel": "PROCRIT\u00ae / EPREX\u00ae"
       }
      }
     },
     "localname": "PROCRITEPREXMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PatentsAndTrademarksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patents And Trademarks [Member]",
        "label": "Patents And Trademarks [Member]",
        "terseLabel": "Patents And Trademarks"
       }
      }
     },
     "localname": "PatentsAndTrademarksMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PelvicMeshesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pelvic meshes.",
        "label": "Pelvic Meshes [Member]",
        "terseLabel": "Pelvic Meshes"
       }
      }
     },
     "localname": "PelvicMeshesMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PercentageChangeInOperatingIncomeLoss": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage change in operating income loss.",
        "label": "Percentage Change in Operating Income Loss",
        "terseLabel": "Percentage Change in Operating Income Loss"
       }
      }
     },
     "localname": "PercentageChangeInOperatingIncomeLoss",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PercentageChangeInSalesByGeographicArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage change in sales by geographic area.",
        "label": "Percentage Change In Sales By Geographic Area",
        "terseLabel": "Percentage Change In Sales By Geographic Area"
       }
      }
     },
     "localname": "PercentageChangeInSalesByGeographicArea",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PercentageChangeInSalesBySegmentOfBusiness": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage change in sales by segment of business.",
        "label": "Percentage Change In Sales By Segment Of Business",
        "terseLabel": "Percent Change (as a percent)"
       }
      }
     },
     "localname": "PercentageChangeInSalesBySegmentOfBusiness",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical.",
        "label": "Pharmaceutical [Member]",
        "terseLabel": "PHARMACEUTICAL"
       }
      }
     },
     "localname": "PharmaceuticalMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PhysiomeshMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physiomesh [Member]",
        "label": "Physiomesh [Member]",
        "terseLabel": "Physiomesh"
       }
      }
     },
     "localname": "PhysiomeshMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PinnacleAcetabularCupSystemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pinnacle Acetabular cup system.",
        "label": "Pinnacle Acetabular Cup System [Member]",
        "terseLabel": "Pinnacle Acetabular Cup System"
       }
      }
     },
     "localname": "PinnacleAcetabularCupSystemMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From The Exercise Of Stock Options And Excess Tax Benefits",
        "label": "Proceeds From The Exercise Of Stock Options And Excess Tax Benefits",
        "verboseLabel": "Proceeds from the exercise of stock options/employee withholding tax on stock awards, net"
       }
      }
     },
     "localname": "ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities",
        "label": "Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities",
        "terseLabel": "Credit support agreements activity, net"
       }
      }
     },
     "localname": "ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities",
        "label": "Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities",
        "terseLabel": "Credit support agreements activity, net"
       }
      }
     },
     "localname": "ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ProductLiabilityContingencyNumberOfClaimant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product liability contingency number of claimant.",
        "label": "Product Liability Contingency Number Of Claimant",
        "terseLabel": "Product liability contingency, number of claimants"
       }
      }
     },
     "localname": "ProductLiabilityContingencyNumberOfClaimant",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_PulmonaryHypertensionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pulmonary Hypertension [Member]",
        "label": "Pulmonary Hypertension [Member]",
        "terseLabel": "Pulmonary Hypertension"
       }
      }
     },
     "localname": "PulmonaryHypertensionMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PurchasedInProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased In-Process Research And Development [Member]",
        "label": "Purchased In-Process Research And Development [Member]",
        "terseLabel": "Purchased In-Process Research And Development"
       }
      }
     },
     "localname": "PurchasedInProcessResearchAndDevelopmentMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_RISPERDALCONSTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RISPERDAL CONSTA [Member]",
        "label": "RISPERDAL CONSTA [Member]",
        "terseLabel": "RISPERDAL CONSTA\u00ae"
       }
      }
     },
     "localname": "RISPERDALCONSTAMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_RemicadeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remicade [Member]",
        "label": "Remicade [Member]",
        "terseLabel": "REMICADE\u00ae"
       }
      }
     },
     "localname": "RemicadeMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense excluding acquired in process cost percent to sales.",
        "label": "Research And Development Expense Excluding Acquired In Process Cost Percent To Sales",
        "terseLabel": "Research and development expense percent to sales"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_ResearchAndDevelopmentInProcessPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "research and development in process percent to sales",
        "label": "Research and development in process percent to sales",
        "terseLabel": "In-process research and development percent to sales"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcessPercentToSales",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring And Related Cost, Expected Period Of Cash Outlays For Severance Paid",
        "label": "Restructuring And Related Cost, Expected Period Of Cash Outlays For Severance Paid",
        "terseLabel": "Period of cash outlays for severance expected to be paid out"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "jnj_RestructuringandRelatedCostDurationofRestructuringPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and Related Cost, Duration of Restructuring Plan",
        "label": "Restructuring and Related Cost, Duration of Restructuring Plan",
        "terseLabel": "Period for activity"
       }
      }
     },
     "localname": "RestructuringandRelatedCostDurationofRestructuringPlan",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "jnj_RestructuringandRelatedCostExpectedFutureSavings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and Related Cost, Expected Future Savings",
        "label": "Restructuring and Related Cost, Expected Future Savings",
        "terseLabel": "Cost savings expected"
       }
      }
     },
     "localname": "RestructuringandRelatedCostExpectedFutureSavings",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_Restructuringchargepercenttosales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring charge percent to sales",
        "label": "Restructuring charge percent to sales",
        "terseLabel": "Restructuring charge percent to sales"
       }
      }
     },
     "localname": "Restructuringchargepercenttosales",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_RisperdalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risperdal.",
        "label": "Risperdal [Member]",
        "terseLabel": "Risperdal"
       }
      }
     },
     "localname": "RisperdalMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SPINEOTHERMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SPINE &amp; OTHER [Member]",
        "label": "SPINE &amp; OTHER [Member]",
        "terseLabel": "SPINE, SPORTS &amp; OTHER"
       }
      }
     },
     "localname": "SPINEOTHERMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SURGICALMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SURGICAL [Member]",
        "label": "SURGICAL [Member]",
        "terseLabel": "SURGICAL"
       }
      }
     },
     "localname": "SURGICALMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SalesBySegmentOfBusinessTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales by segment of business.",
        "label": "Sales By Segment Of Business [Table Text Block]",
        "terseLabel": "Sales By Segment Of Business"
       }
      }
     },
     "localname": "SalesBySegmentOfBusinessTableTextBlock",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_SalesRevenueGoodsNetPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "jnj_GrossProfitPercentToSales",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales revenue goods net percentage to sales.",
        "label": "Sales Revenue Goods Net Percent To Sales",
        "terseLabel": "Sales to customers percent to sales"
       }
      }
     },
     "localname": "SalesRevenueGoodsNetPercentToSales",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]",
        "label": "Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]",
        "label": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]",
        "terseLabel": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_SellingGeneralAndAdministrativeExpensePercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 7.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selling general and administrative expense percent to sales.",
        "label": "Selling General And Administrative Expense Percent To Sales",
        "terseLabel": "Selling marketing and administrative expenses percent to sales"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensePercentToSales",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.",
        "label": "Shares Which Could Be Repurchased Under Treasury Stock Method",
        "negatedTerseLabel": "Less: shares which could be repurchased under treasury stock method"
       }
      }
     },
     "localname": "SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "jnj_SimponiSimponiAriaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Simponi/Simponi Aria [Member]",
        "label": "Simponi/Simponi Aria [Member]",
        "terseLabel": "SIMPONI / SIMPONI ARIA\u00ae"
       }
      }
     },
     "localname": "SimponiSimponiAriaMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_StateLevelJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "State Level Jurisdiction",
        "label": "State Level Jurisdiction [Member]",
        "terseLabel": "State Level Jurisdiction"
       }
      }
     },
     "localname": "StateLevelJurisdictionMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_StelaraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stelara [Member]",
        "label": "Stelara [Member]",
        "terseLabel": "STELARA\u00ae"
       }
      }
     },
     "localname": "StelaraMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SupplyChainMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply Chain",
        "label": "Supply Chain [Member]",
        "terseLabel": "Supply Chain"
       }
      }
     },
     "localname": "SupplyChainMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SurgeryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgery [Member]",
        "label": "Surgery [Member]",
        "terseLabel": "Surgery"
       }
      }
     },
     "localname": "SurgeryMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SurgicalMeshProductsMarketingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgical Mesh Products Marketing",
        "label": "Surgical Mesh Products Marketing [Member]",
        "terseLabel": "Surgical Mesh Products Marketing"
       }
      }
     },
     "localname": "SurgicalMeshProductsMarketingMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TRAUMAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TRAUMA [Member]",
        "label": "TRAUMA [Member]",
        "terseLabel": "TRAUMA"
       }
      }
     },
     "localname": "TRAUMAMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TalcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Talc [Member]",
        "label": "Talc [Member]",
        "terseLabel": "Talc"
       }
      }
     },
     "localname": "TalcMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TremfyaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tremfaya",
        "label": "Tremfya [Member]",
        "terseLabel": "TREMFYA\u00ae"
       }
      }
     },
     "localname": "TremfyaMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_UNITEDSTATESExportsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UNITED STATES Exports [Member]",
        "label": "UNITED STATES Exports [Member]",
        "terseLabel": "U.S. Exports"
       }
      }
     },
     "localname": "UNITEDSTATESExportsMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_UPTRAVIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UPTRAVI [Member]",
        "label": "UPTRAVI [Member]",
        "terseLabel": "UPTRAVI\u00ae"
       }
      }
     },
     "localname": "UPTRAVIMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_VerbSurgicalInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Verb Surgical Inc. [Member]",
        "label": "Verb Surgical Inc. [Member]",
        "terseLabel": "Verb Surgical Inc."
       }
      }
     },
     "localname": "VerbSurgicalInc.Member",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_VisionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vision[Member]",
        "label": "Vision [Member]",
        "terseLabel": "Vision"
       }
      }
     },
     "localname": "VisionMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WesternHemisphereExcludingUSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Western Hemisphere, excluding U.S. [Member]",
        "label": "Western Hemisphere, excluding U.S. [Member]",
        "terseLabel": "Western Hemisphere, excluding U.S."
       }
      }
     },
     "localname": "WesternHemisphereExcludingUSMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WomensHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Women's Health [Member]",
        "label": "Women's Health [Member]",
        "terseLabel": "Women's Health"
       }
      }
     },
     "localname": "WomensHealthMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WoundCareandOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wound Care and Other [Member]",
        "label": "Wound Care and Other [Member]",
        "terseLabel": "Wound Care/Other"
       }
      }
     },
     "localname": "WoundCareandOtherMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_XareltoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xarelto [Member]",
        "label": "Xarelto [Member]",
        "terseLabel": "XARELTO\u00ae"
       }
      }
     },
     "localname": "XareltoMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ZYTIGAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZYTIGA [Member]",
        "label": "ZYTIGA [Member]",
        "terseLabel": "ZYTIGA\u00ae / abiraterone acetate"
       }
      }
     },
     "localname": "ZYTIGAMember",
     "nsuri": "http://www.jnj.com/20211003",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r183",
      "r196",
      "r197",
      "r198",
      "r199",
      "r201",
      "r203",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r183",
      "r196",
      "r197",
      "r198",
      "r199",
      "r201",
      "r203",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case Type"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r408",
      "r413",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r553",
      "r604",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r408",
      "r413",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r553",
      "r604",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r210",
      "r316",
      "r317",
      "r554",
      "r603",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r210",
      "r316",
      "r317",
      "r554",
      "r603",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r349",
      "r408",
      "r413",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r553",
      "r604",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r349",
      "r408",
      "r413",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r553",
      "r604",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r211",
      "r212",
      "r316",
      "r318",
      "r606",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r211",
      "r212",
      "r316",
      "r318",
      "r606",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r6",
      "r24",
      "r216",
      "r217"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, trade, less allowances for doubtful accounts and credit losses $223 (2020, $293)"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r18",
      "r565",
      "r589"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "verboseLabel": "Accrued taxes on income (Note 5)"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r20",
      "r565",
      "r589"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Long-term taxes payable (Note 5)"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r70",
      "r76",
      "r79",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r41",
      "r274"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r76",
      "r86",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r67",
      "r68",
      "r69",
      "r76",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Accumulated Net Investment Gain (Loss) Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r73",
      "r75",
      "r76",
      "r591",
      "r612",
      "r615"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive income (loss) (Note 7)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r72",
      "r76",
      "r79",
      "r130",
      "r131",
      "r132",
      "r467",
      "r608",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income",
        "verboseLabel": "AOCI Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r64",
      "r76",
      "r79",
      "r467",
      "r532",
      "r533",
      "r534",
      "r535",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Accumulated Foreign Currency Adjustment Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r117",
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net earnings to cash flows from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r28",
      "r218",
      "r246"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "verboseLabel": "Allowances for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r117",
      "r259",
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization expense of amortizable intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax",
        "negatedTerseLabel": "Accumulated other comprehensive income on derivatives, after tax"
       }
      }
     },
     "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r117",
      "r272"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset write-downs"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r127",
      "r191",
      "r198",
      "r205",
      "r242",
      "r464",
      "r468",
      "r525",
      "r563",
      "r588"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r56",
      "r127",
      "r242",
      "r464",
      "r468",
      "r525"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r222"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Available-for-sale Securities, Unrecognized Gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r223"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Available-for-sale Securities, Unrecognized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r220",
      "r248"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Available-for-sale Securities - Carrying Amount"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "auth_ref": [
      "r227"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r224",
      "r227",
      "r584"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r226"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r224",
      "r226",
      "r583"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Cost Basis"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r224",
      "r228",
      "r585"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "totalLabel": "Total debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "auth_ref": [
      "r224",
      "r228",
      "r581"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost",
        "totalLabel": "Total debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r225"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r224",
      "r225",
      "r582"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r219",
      "r221",
      "r248",
      "r568"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Available-for-sale Securities",
        "verboseLabel": "Available-for-sale Securities - Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesMember": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale Securities [Member]",
        "terseLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r480",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]",
        "terseLabel": "Time deposits(1)"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r404",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r404",
      "r409",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r454",
      "r455",
      "r457"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Business acquisition cost"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r116",
      "r459"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "negatedTerseLabel": "Reversal of contingent consideration",
        "terseLabel": "Contingent consideration reversal"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r453",
      "r456",
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "terseLabel": "Liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "verboseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r38",
      "r119"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and Cash Equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r120",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents, Policy"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Total cash, cash equivalents and current marketable securities, Carrying Amount"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r113",
      "r119",
      "r124"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF PERIOD",
        "periodStartLabel": "Cash and Cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r113",
      "r529"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r126",
      "r127",
      "r152",
      "r156",
      "r157",
      "r159",
      "r161",
      "r169",
      "r170",
      "r171",
      "r242",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollateralAlreadyPostedAggregateFairValue": {
     "auth_ref": [
      "r503"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.",
        "label": "Collateral Already Posted, Aggregate Fair Value",
        "terseLabel": "Collateral already posted, aggregate fair value"
       }
      }
     },
     "localname": "CollateralAlreadyPostedAggregateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r52",
      "r295",
      "r571",
      "r595"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Cash dividends paid (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r130",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock Issued Amount",
        "verboseLabel": "Common Stock, Par Value $1.00"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value per share (per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock \u2014 par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r82",
      "r84",
      "r85",
      "r92",
      "r575",
      "r599"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r91",
      "r101",
      "r574",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "verboseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r350",
      "r398",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities(1)"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r199",
      "r201",
      "r207",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate, Non-Segment"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r97",
      "r554"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CrossCurrencyInterestRateContractMember": {
     "auth_ref": [
      "r350",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.",
        "label": "Cross Currency Interest Rate Contract [Member]",
        "terseLabel": "Cross Currency Interest Rate Contract",
        "verboseLabel": "Cross currency interest rate swaps"
       }
      }
     },
     "localname": "CrossCurrencyInterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DamagesFromProductDefectsMember": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk of loss arises with respect to product defects and recalls, or improperly performed services which actually or allegedly resulted in damages suffered by the injured party, excluding major product liability matters.",
        "label": "Damages from Product Defects [Member]",
        "terseLabel": "Damages from Product Defects"
       }
      }
     },
     "localname": "DamagesFromProductDefectsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r16",
      "r18",
      "r19",
      "r564",
      "r566",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale and Held-to-maturity [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale and Held-to-maturity [Abstract]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Schedule of Available for Sale Securities Maturities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Weighted average interest rate"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r422",
      "r423"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "verboseLabel": "Deferred taxes on income (Note 5)"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r117",
      "r128",
      "r432",
      "r440",
      "r441",
      "r442"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "verboseLabel": "Deferred tax provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r422",
      "r423"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred taxes on income (Note 5)"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r429"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "terseLabel": "Deferred tax benefit, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r326",
      "r365",
      "r392",
      "r398",
      "r399"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedLabel": "Recognized actuarial losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r326",
      "r366",
      "r393",
      "r398",
      "r399"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "verboseLabel": "Amortization of prior service cost/(credit)"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r326",
      "r364",
      "r391",
      "r398",
      "r399"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r326",
      "r331",
      "r363",
      "r390",
      "r398",
      "r399"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "verboseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r361",
      "r388",
      "r398",
      "r399"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]",
        "verboseLabel": "Components of net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1": {
     "auth_ref": [
      "r327",
      "r368",
      "r395"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment",
        "negatedLabel": "Curtailments and settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r329",
      "r362",
      "r389",
      "r398",
      "r399"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "verboseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r117",
      "r186"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization of property and intangibles"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueGrossLiability": {
     "auth_ref": [
      "r58",
      "r62",
      "r484"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeAssets",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Asset, Fair Value, Gross Liability",
        "negatedTerseLabel": "Credit Support Agreement (CSA)"
       }
      }
     },
     "localname": "DerivativeAssetFairValueGrossLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r59",
      "r60",
      "r522"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "totalLabel": "Total Net Asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": {
     "auth_ref": [
      "r490",
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.",
        "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings",
        "terseLabel": "Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing"
       }
      }
     },
     "localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r57",
      "r61",
      "r484",
      "r552"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Total Gross Assets"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r57",
      "r61",
      "r484",
      "r552"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Total Gross Liabilities",
        "verboseLabel": "Carrying Amount of the Hedged Liability"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r482"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Gain/(Loss) Recognized In Income on Derivative"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentDetailAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument Detail [Abstract]",
        "verboseLabel": "Financial assets and liabilities at fair value"
       }
      }
     },
     "localname": "DerivativeInstrumentDetailAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r481",
      "r485",
      "r492",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r478",
      "r481",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r478",
      "r481",
      "r492",
      "r499",
      "r500",
      "r506",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.",
        "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred",
        "terseLabel": "Amount of gain or (loss) reclassified from AOCI into income"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.",
        "label": "Derivative Instruments in Hedges, Assets, at Fair Value",
        "verboseLabel": "Derivatives designated as hedging instruments : Assets"
       }
      }
     },
     "localname": "DerivativeInstrumentsInHedgesAssetsAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.",
        "label": "Derivative Instruments in Hedges, Liabilities, at Fair Value",
        "verboseLabel": "Derivatives designated as hedging instruments : Liabilities"
       }
      }
     },
     "localname": "DerivativeInstrumentsInHedgesLiabilitiesAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r59",
      "r60",
      "r522"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "totalLabel": "Total Net Liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueGrossAsset": {
     "auth_ref": [
      "r58",
      "r62",
      "r484"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Liability, Fair Value, Gross Asset",
        "negatedTerseLabel": "Credit Support Agreement (CSA)"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueGrossAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r471",
      "r473",
      "r474",
      "r478",
      "r479",
      "r488",
      "r492",
      "r504",
      "r505",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the transactions or other events that will result in the reclassification into earnings of gains or losses reported in accumulated other comprehensive income. May include the time period over which gains or losses will be reclassified to earnings.",
        "label": "Description of Reclassification of Cash Flow Hedge Gain (Loss)",
        "verboseLabel": "Reclassification of foreign exchange contracts into earnings, period"
       }
      }
     },
     "localname": "DescriptionOfReclassificationOfCashFlowHedgeGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r404",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedTerseLabel": "Cash dividends paid"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]",
        "verboseLabel": "NET EARNINGS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r93",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r150",
      "r152",
      "r159",
      "r160",
      "r161",
      "r165",
      "r166",
      "r576",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (per share)",
        "verboseLabel": "Basic net earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r93",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r152",
      "r159",
      "r160",
      "r161",
      "r165",
      "r166",
      "r576",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (per share)",
        "verboseLabel": "Diluted net earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "verboseLabel": "Reconciliation of basic net earnings per share to diluted net earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r529"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "verboseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Worldwide effective income tax rate (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": {
     "auth_ref": [
      "r425",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent",
        "terseLabel": "Effective income tax rate, impairment losses, percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": {
     "auth_ref": [
      "r425",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.",
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent",
        "terseLabel": "Effective income tax rate, prior year income taxes, percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Accrued compensation and employee related obligations"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r570",
      "r596"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Employee-related Liabilities",
        "verboseLabel": "Employee related obligations (Note 6)"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee Severance"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r136",
      "r144",
      "r146",
      "r168",
      "r243",
      "r311",
      "r312",
      "r415",
      "r416",
      "r417",
      "r433",
      "r434",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r538",
      "r608",
      "r609",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.",
        "label": "Equity, Fair Value Adjustment",
        "terseLabel": "Changes in Fair Value Reflected in Net Income"
       }
      }
     },
     "localname": "EquityFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investments accounted under the equity method.",
        "label": "Equity Method Investments, Fair Value Disclosure",
        "terseLabel": "Fair value of previously held equity investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r520"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Available-for-sale Securities, Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r12",
      "r17",
      "r239",
      "r587",
      "r629",
      "r630",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "periodEndLabel": "Carrying value, end of period",
        "periodStartLabel": "Carrying value, beginning of period"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r513",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r513",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r513",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "verboseLabel": "Financial Liabilities not Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r350",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r398",
      "r514",
      "r543",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "verboseLabel": "Fair Value, Hierarchy"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r513",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r350",
      "r352",
      "r357",
      "r398",
      "r514",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted prices in active markets for identical assets and liabilities Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r350",
      "r352",
      "r357",
      "r398",
      "r514",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant other observable inputs Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r350",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r398",
      "r514",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant unobservable inputs Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r516"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r516"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r515"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r350",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r398",
      "r543",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "verboseLabel": "Fair Value, Measurements, Fair Value Hierarchy"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r480",
      "r488",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Financial Liabilities"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Finite-Lived Intangible Assets, Weighted-Average Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Less accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Intangible Asset Amortization Expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r260",
      "r262",
      "r265",
      "r269",
      "r555",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r265",
      "r559"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Finite-Lived Intangible Assets, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r260",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r265",
      "r555"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Finite-Lived Intangible Assets, Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "verboseLabel": "Intangible assets with definite lives:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue": {
     "auth_ref": [
      "r486"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all foreign currency derivative assets not designated as hedging instruments.",
        "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value",
        "verboseLabel": "Derivatives not designated as hedging instruments : Assets"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": {
     "auth_ref": [
      "r486"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all foreign currency derivative liabilities not designated as hedging instruments.",
        "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value",
        "verboseLabel": "Derivatives not designated as hedging instruments : Liabilities"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r350",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "verboseLabel": "Forward foreign exchange contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r403",
      "r407",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "verboseLabel": "International retirement plans"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "terseLabel": "Gain (loss) on disposition of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "negatedTerseLabel": "Net gain on sale of assets/businesses"
       }
      }
     },
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r251",
      "r252",
      "r562"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill End of Period",
        "periodStartLabel": "Goodwill Beginning of Period",
        "terseLabel": "Goodwill (Note 3)"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill, related to acquisitions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r255"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Currency translation/Other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "negatedTerseLabel": "Goodwill, related to divestitures"
       }
      }
     },
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r96",
      "r127",
      "r191",
      "r197",
      "r201",
      "r204",
      "r207",
      "r242",
      "r525"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r501"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.",
        "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r478",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HeldToMaturitySecurities": {
     "auth_ref": [
      "r219",
      "r229",
      "r568"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity",
        "totalLabel": "Held-to-maturity Securities - Carrying Amount"
       }
      }
     },
     "localname": "HeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": {
     "auth_ref": [
      "r231",
      "r234"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain",
        "terseLabel": "Held-to-maturity Securities, Unrecognized Gain"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": {
     "auth_ref": [
      "r232",
      "r235"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss",
        "negatedLabel": "Held-to-maturity Securities, Unrecognized Loss"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesClassifiedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-maturity [Abstract]",
        "terseLabel": "Debt Securities, Held-to-maturity [Abstract]"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesClassifiedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "auth_ref": [
      "r230",
      "r233",
      "r568"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity, Fair Value",
        "terseLabel": "Held-to-maturity Securities - Estimated Fair Value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldtomaturitySecuritiesMember": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in debt securities classified as held-to-maturity.",
        "label": "Held-to-maturity Securities [Member]",
        "terseLabel": "Held-to-maturity Securities"
       }
      }
     },
     "localname": "HeldtomaturitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r117",
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r89",
      "r191",
      "r197",
      "r201",
      "r204",
      "r207",
      "r560",
      "r572",
      "r579",
      "r601"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Earnings before provision for taxes on income",
        "verboseLabel": "Worldwide income before tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r404",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]",
        "verboseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]",
        "verboseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r426",
      "r428",
      "r430",
      "r438",
      "r444",
      "r446",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r128",
      "r145",
      "r146",
      "r189",
      "r424",
      "r439",
      "r445",
      "r602"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for taxes on income (Note 5)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses": {
     "auth_ref": [
      "r425"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount",
        "terseLabel": "Effective income tax rate, impairment losses, amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Increase/(Decrease) in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Increase in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Increase in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in assets and liabilities, net of effects from acquisitions and divestitures:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Decrease/(Increase) in other current and non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "(Decrease)/Increase in other current and non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r161"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Potential shares exercisable under stock option plans"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r261",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets with indefinite lives:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r261",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InformationByCategoryOfDebtSecurityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity.",
        "label": "Debt Security Category [Axis]",
        "terseLabel": "Debt Security Category [Axis]"
       }
      }
     },
     "localname": "InformationByCategoryOfDebtSecurityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r258",
      "r263"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Total intangible assets - net",
        "verboseLabel": "Intangible assets, net (Note 3)"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets and Goodwill"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r87",
      "r185",
      "r540",
      "r541",
      "r577"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense, net of portion capitalized"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r350",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest Rate Contract"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r29",
      "r249"
     ],
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r55"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories",
        "verboseLabel": "Inventories (Note 2)"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "auth_ref": [
      "r31",
      "r32",
      "r249"
     ],
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "verboseLabel": "Raw materials and supplies"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r30",
      "r249"
     ],
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "verboseLabel": "Goods in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r99",
      "r184"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedTerseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_JudicialRulingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation outcome that occurs as a result of judicial intervention, supervision, or approval.",
        "label": "Judicial Ruling [Member]",
        "terseLabel": "Judicial Ruling"
       }
      }
     },
     "localname": "JudicialRulingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "Legal Proceedings"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r45",
      "r127",
      "r199",
      "r242",
      "r465",
      "r468",
      "r469",
      "r525"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r27",
      "r127",
      "r242",
      "r525",
      "r567",
      "r593"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r48",
      "r127",
      "r242",
      "r465",
      "r468",
      "r469",
      "r525"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation expense",
        "verboseLabel": "Litigation charge"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.",
        "label": "Long-term Debt [Member]",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "LongTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Non-Current Debt",
        "verboseLabel": "Long-term debt (Note 4)"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Excluding Current Maturities [Abstract]",
        "terseLabel": "Non-Current Debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of long-term debt outstanding calculated at point in time.",
        "label": "Long-term Debt, Weighted Average Interest Rate, at Point in Time",
        "terseLabel": "Weighted average interest rate on non-current debt"
       }
      }
     },
     "localname": "LongtermDebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r300",
      "r301",
      "r302",
      "r305",
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r300",
      "r301",
      "r302",
      "r305",
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "verboseLabel": "Product Liability Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "auth_ref": [
      "r295",
      "r298",
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Damages awarded"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r295",
      "r298",
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Litigation contingency"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r299",
      "r304",
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss contingency, estimate of possible loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r300",
      "r301",
      "r302",
      "r305",
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of pending claims"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r7",
      "r46"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "periodEndLabel": "Carrying value, end of period",
        "periodStartLabel": "Carrying value, beginning of period"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Realized Gain (Loss)",
        "terseLabel": "Unrealized gain (loss) on securities"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.",
        "label": "Maximum Length of Time, Foreign Currency Cash Flow Hedge",
        "terseLabel": "Maximum length of time for hedge exposure"
       }
      }
     },
     "localname": "MaximumLengthOfTimeForeignCurrencyCashFlowHedge",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "auth_ref": [
      "r3",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures.  This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "verboseLabel": "Acquisitions and Divestitures"
       }
      }
     },
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "NET CASH USED BY FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "NET CASH USED BY INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r113",
      "r115",
      "r118"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "NET CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r80",
      "r83",
      "r90",
      "r118",
      "r127",
      "r135",
      "r139",
      "r140",
      "r141",
      "r142",
      "r145",
      "r146",
      "r158",
      "r191",
      "r197",
      "r201",
      "r204",
      "r207",
      "r242",
      "r525",
      "r573",
      "r597"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net earnings",
        "terseLabel": "Net earnings",
        "totalLabel": "Net earnings"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging [Member]"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r133",
      "r134",
      "r137",
      "r138",
      "r147",
      "r148",
      "r149",
      "r244",
      "r245",
      "r319",
      "r320",
      "r321",
      "r322",
      "r418",
      "r435",
      "r436",
      "r437",
      "r556",
      "r557",
      "r558",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New and Recently Adopted Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "verboseLabel": "International"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": {
     "auth_ref": [
      "r121",
      "r122",
      "r123"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.",
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)",
        "totalLabel": "Net cash paid for acquisitions"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]",
        "verboseLabel": "Acquisitions"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1": {
     "auth_ref": [
      "r121",
      "r122",
      "r123"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Assets Acquired",
        "verboseLabel": "Fair value of assets acquired"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": {
     "auth_ref": [
      "r121",
      "r122",
      "r123"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed",
        "negatedLabel": "Fair value of liabilities assumed and noncontrolling interests"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r191",
      "r197",
      "r201",
      "r204",
      "r207"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "verboseLabel": "Total Segment Operating Income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r199",
      "r201",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Non Current Other Assets",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Securities:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]",
        "terseLabel": "Employee benefit plans:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent [Abstract]",
        "terseLabel": "Derivatives &amp; hedges:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r63",
      "r73",
      "r526",
      "r527",
      "r530"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r67",
      "r68",
      "r73"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r65",
      "r73"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax",
        "terseLabel": "Derivatives &amp; Hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "auth_ref": [
      "r65",
      "r73"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "terseLabel": "Unrealized gain (loss) arising during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r73",
      "r77"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "negatedTerseLabel": "Reclassifications to earnings"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax": {
     "auth_ref": [
      "r66",
      "r73",
      "r489",
      "r508"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax",
        "verboseLabel": "Amount of gain or (loss) recognized in AOCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": {
     "auth_ref": [
      "r66",
      "r73",
      "r489",
      "r494",
      "r508"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax",
        "terseLabel": "Gain/(Loss) Recognized In Accumulated OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r63",
      "r74",
      "r528",
      "r537"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r81",
      "r84",
      "r86",
      "r91",
      "r311",
      "r531",
      "r536",
      "r538",
      "r574",
      "r598"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Net change",
        "totalLabel": "Other comprehensive income (loss)",
        "verboseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r71",
      "r73"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedTotalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": {
     "auth_ref": [
      "r71",
      "r74",
      "r463"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax",
        "negatedTerseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r73",
      "r77",
      "r78",
      "r238"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedTerseLabel": "Reclassifications to earnings"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r67",
      "r73"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized holding gain (loss) arising during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeMember": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other revenue.",
        "label": "Other Income [Member]",
        "terseLabel": "Other Income"
       }
      }
     },
     "localname": "OtherIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "verboseLabel": "Customer relationships and other intangible assets"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableAxis": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Group of items that represent other investments not readily marketable, including description of investment, fair value, and value as measured by quoted value method.",
        "label": "Other Investment Not Readily Marketable [Axis]",
        "terseLabel": "Other Investment Not Readily Marketable [Axis]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Investment Not Readily Marketable [Line Items]",
        "terseLabel": "Other Investment Not Readily Marketable [Line Items]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableNameDomain": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the investment category or actual investment title.",
        "label": "Other Investment Not Readily Marketable, Name [Domain]",
        "terseLabel": "Other Investment Not Readily Marketable, Name [Domain]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableTable": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the information about other investments not readily marketable, including, but not limited to, description of investment, fair value and value as measured by quoted price.",
        "label": "Other Investment Not Readily Marketable [Table]",
        "terseLabel": "Other Investment Not Readily Marketable [Table]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedTerseLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r324",
      "r325",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r376",
      "r379",
      "r383",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "verboseLabel": "Other Benefit Plans"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Other Restructuring"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income.",
        "label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]",
        "terseLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r103",
      "r106",
      "r129"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other (primarily licenses and milestones)"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r112",
      "r280"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedTerseLabel": "Payments for Restructuring"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfOrdinaryDividends": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.",
        "label": "Payments of Ordinary Dividends",
        "negatedLabel": "Dividends to shareholders"
       }
      }
     },
     "localname": "PaymentsOfOrdinaryDividends",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisitions, net of cash acquired (Note 10)"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r349",
      "r351",
      "r357",
      "r375",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r398",
      "r400",
      "r401",
      "r402",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Pensions and Other Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionContributions": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.",
        "label": "Payment for Pension Benefits",
        "terseLabel": "Contribution to pension plans"
       }
      }
     },
     "localname": "PensionContributions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r323",
      "r325",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r376",
      "r379",
      "r383",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r402",
      "r403",
      "r409",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "verboseLabel": "Retirement Plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r8",
      "r36",
      "r37"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassification"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from long-term debt, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r108",
      "r111",
      "r129"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "verboseLabel": "Sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "verboseLabel": "Proceeds from the disposal of assets/businesses, net (Note 10)"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "verboseLabel": "Proceeds from short-term debt"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r40",
      "r273"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r14",
      "r275",
      "r594"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r94",
      "r247"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "verboseLabel": "Credit losses and accounts receivable allowances"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedLabel": "Repayment of short-term debt"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r420",
      "r642"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "In-process research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r420"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Restructuring"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "auth_ref": [
      "r279",
      "r282",
      "r289",
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs incurred to date for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "terseLabel": "Restructuring charges recorded to date"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r279",
      "r282",
      "r289",
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Restructuring estimated cost"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r117",
      "r278",
      "r285",
      "r291"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring (Note 12)",
        "verboseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesMember": {
     "auth_ref": [
      "r281",
      "r285",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included.",
        "label": "Restructuring Charges [Member]",
        "terseLabel": "Restructuring Charges"
       }
      }
     },
     "localname": "RestructuringChargesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r280",
      "r287"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Reserve balance ending",
        "periodStartLabel": "Reserve balance beginning"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserveSettledWithoutCash2": {
     "auth_ref": [
      "r278",
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash.",
        "label": "Restructuring Reserve, Settled without Cash",
        "negatedTerseLabel": "Restructuring Reserve, Settled without Cash"
       }
      }
     },
     "localname": "RestructuringReserveSettledWithoutCash2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r25",
      "r312",
      "r419",
      "r592",
      "r611",
      "r615"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r136",
      "r144",
      "r146",
      "r243",
      "r415",
      "r416",
      "r417",
      "r433",
      "r434",
      "r608",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r376",
      "r379",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r403",
      "r407",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r376",
      "r379",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r403",
      "r407",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r376",
      "r379",
      "r383",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r376",
      "r379",
      "r383",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r182",
      "r183",
      "r196",
      "r202",
      "r203",
      "r210",
      "r211",
      "r214",
      "r315",
      "r316",
      "r554"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Sales",
        "terseLabel": "Sales to customers",
        "verboseLabel": "Sales to customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "verboseLabel": "Sales to customers"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r76",
      "r536",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "verboseLabel": "Components of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Equity Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r382",
      "r383",
      "r386",
      "r387",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r481",
      "r492",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of Derivative Activity"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Financial Assets and Liabilities at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of Derivative Financial Instruments and Classification on Consolidated Balance Sheet"
       }
      }
     },
     "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r260",
      "r264",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r10",
      "r33",
      "r34",
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Summary of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "verboseLabel": "Components of Net Periodic Benefit Cost"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r491",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.",
        "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]",
        "terseLabel": "Schedule of Effect of Derivatives not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r283",
      "r284",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r280",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Restructuring Reserve"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "auth_ref": [
      "r95",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r88",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r191",
      "r194",
      "r200",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r191",
      "r194",
      "r200",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "verboseLabel": "Operating Profit by Segment of Business"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of securities that an institution sells and agrees to repurchase at a specified date for a specified price, net of any reductions or offsets.",
        "label": "Securities Loaned or Sold under Agreements to Repurchase [Member]",
        "terseLabel": "U.S. reverse repurchase agreements"
       }
      }
     },
     "localname": "SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r179",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r196",
      "r197",
      "r198",
      "r199",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r207",
      "r214",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]",
        "verboseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r191",
      "r195",
      "r201",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r213",
      "r214",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "verboseLabel": "Segments of Business and Geographic Areas"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingInformationRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information, Revenue for Reportable Segment [Abstract]",
        "verboseLabel": "Sales by segment of business"
       }
      }
     },
     "localname": "SegmentReportingInformationRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentsGeographicalAreasAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments, Geographical Areas [Abstract]",
        "verboseLabel": "Sales by geographic area"
       }
      }
     },
     "localname": "SegmentsGeographicalAreasAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, marketing and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r15",
      "r564",
      "r590"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-term Debt",
        "terseLabel": "Current Debt",
        "verboseLabel": "Loans and notes payable"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SovereignDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by foreign government (not within the country of domicile of the entity).",
        "label": "Sovereign Debt Securities [Member]",
        "terseLabel": "Non-U.S. sovereign securities(1)"
       }
      }
     },
     "localname": "SovereignDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r1",
      "r179",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r196",
      "r197",
      "r198",
      "r199",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r207",
      "r214",
      "r256",
      "r277",
      "r282",
      "r293",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]",
        "verboseLabel": "Statement, Business Segments"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r126",
      "r127",
      "r152",
      "r156",
      "r157",
      "r159",
      "r161",
      "r169",
      "r170",
      "r171",
      "r242",
      "r311",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r54",
      "r130",
      "r131",
      "r132",
      "r136",
      "r144",
      "r146",
      "r168",
      "r243",
      "r311",
      "r312",
      "r415",
      "r416",
      "r417",
      "r433",
      "r434",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r538",
      "r608",
      "r609",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r168",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "auth_ref": [
      "r22",
      "r23",
      "r311",
      "r312",
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "terseLabel": "Employee compensation and stock option plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity:",
        "verboseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r127",
      "r130",
      "r131",
      "r132",
      "r136",
      "r144",
      "r242",
      "r243",
      "r312",
      "r415",
      "r416",
      "r417",
      "r433",
      "r434",
      "r461",
      "r462",
      "r470",
      "r525",
      "r531",
      "r532",
      "r538",
      "r609",
      "r610"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r539",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r539",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r539",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r53",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock Amount"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r53",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "verboseLabel": "Treasury stock, shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r53",
      "r313",
      "r314"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "verboseLabel": "Less: common stock held in treasury, at cost (487,358,000 and 487,331,000 shares)"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r311",
      "r312",
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r350",
      "r580",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. Gov't securities"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r421",
      "r427"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r151",
      "r161"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (shares)",
        "totalLabel": "Average shares outstanding \u2014 diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "AVG. SHARES OUTSTANDING"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r150",
      "r161"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (shares)",
        "verboseLabel": "Average shares outstanding \u2014 basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8475-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL6284393-111563"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=117311354&loc=d3e32014-111567"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(c))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=116646759&loc=d3e14981-108350"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=SL108413299-114919"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=SL108413299-114919"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2919-114920"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4587-114921"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998890-113959"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(6)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109999712-113959"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624186-113959"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624258-113959"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061172-113977"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80845-113994"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30304-110892"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30755-110894"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "820",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=35710923&loc=d3e45360-110995"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.13(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=121551529&loc=d3e60009-112784"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r643": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r644": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r645": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r646": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r647": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r648": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724391-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>88
<FILENAME>0000200406-21-000070-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000200406-21-000070-xbrl.zip
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MJG^+\_L47O_M\XKPTW/;/F[?.[E_@0)[0DU_?8QT7_2-.]YY[?2MC>_%GJ^
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M(?-J5K*835O/D*-XK0<#V779HZN#1C6,$&I#K66#,I2W#H,T;)'CTN2 VL%
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M!C\3!MRU6(D,U!J@*K&UA @L*9/TF=I]K!YW9?_O9'_OFH1#"1668RV-DA:
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MO^V#;8\V)\LK+K_+)%5?3BG%2N: !#DHISJ,B]12:C<5G6@47&DTR:@(+F,
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M'AQ_''!L[<+'-YFEA+06Z[EW+[&E(7 BN4/@E(;<T9Y@@HFT:\^$-YPPG3.
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M5MU[P91G.&IBRC0_)5>J+0T&:A*5H=WKD/+9AY!WT\Q!? (U/UL5_:1$&8P
M@6Y!H@!;IM!+K]D+*C2?87?I+]N^9X#<G@H0\#*P@!!Z"U"7^GGD+AJ,N\'(
M\_L/R(19?DZJ:-6NI218>@\Q.@K%ONRS(.R@<$B"8$^2_)P\8:(\@(L9T[('
MTP4U5X@F;4A\M;F+;RF$EX9=G 42QI'==<#2*A1$;&@2N U(%$+L^P_)A%E^
M5K)0MQI4!AVJ@D8@6OHG$P_K)UUF:"!V99#LZ<BR+TQI24Q3:2%3 N$\G%]0
MAY*:132<F2GQG?C**LXLP8LC0#W8<J9L6.9;I?=JP@6XE:QE@GFT"3/]K&19
M%G):!DAJ&6@Y'LI"D1:Q\K"!.($LN#)(UDS_>DU O:DWS1H8')KHD)-20LR"
M)<TP&?R:?A2OS*31)(A 5T=J&LNR-RITQE1#]8:]C."E"0I=)TSTDW*%1HKG
MT*$0 HBB9.#LUI=5^PQ]@IT65X7(FN9?7Y5%0S F:K%A@Y@2UI@U]:B*/9+-
M3)28PTMZ((=)$,G@/0%P2L$@JE%>IG)"*%520)]@,FW"-#\I5U+I0Z55S#G
MDN#%*&KV'GO,M>G,(NUW(K*F^=?[OMQ=4RC-4<$XH#201!VZ01I,F9@H,/3
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M\U9F'IR\-.L@7),5=2@MCA_=6S&UQ.A9YY>7*S/GU)F>:AL./' +&527.6Z
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M_IO\_6_7_C]X#J(?F]U, %E6&I+#R+SL494RJM?^=>2PVS'$6S$I+;7RQ:4
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MD2P/Z!-E@N0V JRQW!H?[K];_6]VI'_3Z6QZ;S8[50I40[6DKM9GP\:\X@2
M8X,WJ W@26+8L' FN"WWEDVPPOOL+J>'V;'!6U0@B,"HC"0W4$0OL#'GY-+
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MP18A:0RNP_U'K _#XF",2U,-S&&OK0Z+5L.T-7J&SL/B1ZP/P\<QV8AJHF.
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M?N@IR=-58];(=D6CO(9.*<:<@"P$H^B0Y[O+\A;>5.C%CN%- 0B[[9U](M(
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M7!7JA0X+QA-WH,C],6'=AW+@AY_*?.B+$!:$%Y#-&.'"6(\4P\08;#-O),<
MGJTP9L%XX4?ZH0I"G+FZ51!7* @I*<:<!J4QTQX;0@'74(TLU@H@S((QQ3.@
MB!+<,)95!T S3:4RVF -5%(\($46X92*UI[/!2 ,PC$)_S&D$"A\K05EA'I'
M,A_;>O)%Y:1?!04\/0?Y3/.0*14(04QBHY$2S)J F(^\M; <],MAAZ=G):$T
MDB%SF8_[)4&HH#.6F0Q@J/)2+JQ9^]7H:(3"V*K@28BUT CP(Z+(.,H#P!8T
MQR70+2HY#UGO*U+O+6"*B"],D,P9JB0/RGGJL([MY.B"\<2O@B\>IG6SX9HI
MBT(\(!$AX !&D;/>9%X;AN>X=7.+%!Z,*4QFM768J& U$V S;(:,HM(++@)Q
MV8(QQ:)1Y(_\VXO2#XI1"0.LWQYZ[:KQN/SKJW_#/XW+R# "@.81M9(!;>+)
MX<%[I;* (K4^Q[+,Z6\&P],ND**7]]-#GQ\<#E\PLI+QX^'+D]P-#U\ 1?^_
MI>K25_\>'.O^JW^;\@^X0?VZOL_%N^GR &XX+(Y?4+A3G$*JN_E!_X6%9?+E
M4GVO\>6VZ!;EB_]"U?]>!IAS&G0O[YZ^^)]=H.,@Z?B39+OHZ?[_+ ]T?Y""
M).>AOG"0?_<O,(.G5&]/ZCED<)]NWO?C.6$29_&QL[&[OI;L[*[NKN\D9^<P
M_Z/?67_]<7MC=P.&OMI92];_[_5?JYVWZ\GKK<W-C9V=C:W._,R(7&M&G_3@
M$&1Q6/27D[65URL)09RIZ\RB>L##3T->:QIOMK8WDW^#1/:+?F?4@YO8I!'<
M;1]B/-!:Q34.0F#,$*$F=AHBB$K./.?FTC2(I*^CBG0^?[%6V%%4-;$+P%*3
M_$C_.35KQ==W9/OK'MT<N:/UK_MOU=%6;P]M[O[9W=_=[VZN=8ZVUC[@3F^/
M=7KK?+_W3W=K]PO=/UIE^[M[^!WM=/>^'_<Z:^LG^Y\^DOW=U>][WP]09W>_
MM[6V?[CU:1_N\X5WR-[)UMN/I/./_/:.[)_N?;*B<_3WX=[1W]W]M]M'G4_;
M7SIK>Z>;G];9WNY'LO=]G78^;?#-3YTOG>\?O[JW_S#W%UQ+NE_-44$V>V_R
MS=X_7_;?;N+]MQ]0YVCCV][NX2$\]VASU^*]HR_?]L@'"L\[W5S;(Y\EE=+Y
M0%-L D\953Y5B/#4* "FQB(EI5]Z!6KU0Z47IU1X=2T9!UT'C#/4INO'WYJB
M!-6: @-U]?' OQB_>.GRP7%7GX+:KMB@^M'+YEZF& Z+7KS=2W VAM&@--Q9
M,6K]=:-5E5J1G$;%.@0-/G3C!S<Z=Z72N7\,W<7OLA6DU)7?HA5\Y7<_NBM?
MP8K?^UTE6P$;?JW;_E&M0[T6L-J1:O^[!%+0_.!8NUB3_X(<?TOP6='O^G!A
MP>NUOF]U(,YI W9>&U2F\E__A05Z.6&\9N+MG!9@3D_+A*MEKKO)QWYN"^>3
MS9VKC!*ZUO3NW1Z%HNSI(?P:)@UH':97=(WN=HNA*;Y=9JX^C'0)1KE[NNV/
MBW*XD);K36[>?A1[<)_.T9]'>[WUT\W=_</.VS='FT=?X/H_NYW=;A=^_VWS
MZ #O[VXVO_D'GL7[^[O'1S!FLOFVD^_M;GR#N:"]3YNG6]'2O?V(MSY]!,NW
M?KJU]D]W$\,8=U>'FSLH_OULP.D6 BA@ W8I<Q2E2L6R2LJEDP&0DL*1B>/I
M#2_/V[W[EU0PE \.$A].]]3P\/R<>KES77_OTSHOGQ= 8S6MB70DM7@D[T?E
M8 2N8#(LDAU?]3>LIXYI4I0)YK^YWY,B),-#'[\'+W:8PW#6O]G#F!^7K-IA
M_!HKRBXJM3\JI'()#GIX#/W3Y:@P-&B7:F;_F2Q+[0DGON^\NW]T/:/-7C@]
M]&D/;GD8E5CJ]&EZZG69^OYE:NU]-:[U.OR^D$KMUG <E-S&9^&%P]SPU#DI
M4R:42PUQ,K56!F9B&I)W2Z^V[+"(<1BZG,1%OQ4P%S_P\2X+0]S\+H_-Y44Y
MQPY)AK+;.2087^T>W-XA84H^A$."U/4&VSHD[9R>?$ZM0W*?#LEN"<//([!:
M>(^DL];YLD>VC_8_;="]HS=?XOL.6<=[O4V^M?:%;7[?^]9Y^Q'&]^&<1U*@
MS?B[MS#>(Y=O?OH [S_0O=U_\KWO7]C6[L'WSM$ZVM]UO<Z;LQZ)Q40HE66I
MH]*G\;BX5'N   IYB^.INXB1QB-AK4=R*X_D8=3/-3V2J7@\A$L2X=H8Y ^G
M3VI0?BB+7GWKN_\[+&[@_\S KFR.@.+KHM?+!W'_,@DYP,#^J-K5?,!-AO5J
M^_(-/*Q3/6LAE>.=-AI./A.KC5 &7,# P;4AP:0*Z[CE@+*,$9,%RY9>X902
MS&_ET3S1MM4%-48>Q""?9Z9M?Y /HJP/._#-K\=0]'-UV+E5,L52NI0Q3%+C
M"4HS$B12/C@:&:HYI2#YE^X=OTR:=]?GK\?769?STV_KWS0H_,@%4>N7$^HG
M>I ,CKV-^1LNR?M)/APD8")BH.?W.7:(;[E#Q^0*I_16ONN/O^.4W+M'7 WV
M>CM_#^2,7"1Y0Z9XD^:F:;S#"[)"^,QG9<5[S8=S8+@?Q\L9Q KLX[+X&N7L
M;(2RUKJQ<4\)\&W2Q=J_+D;]87GZ&KRXA53"C<MS](%NO=W_ B[+M_VC+[BS
M]N%T\ZA[""X0/',/P_5'>[O;1WN]C?,N#^FL6;;?@]^MO>EM[7Y$G;6-TZU/
M;\ %@OD=?02EW3GLQ$V:KCR9=7F"U-2 V*68,P7Z6YK49 *EQ,C &"7PGUEZ
M%5GG;U\._.F57D^=)C7G88IK.O(+[_X\4GSBO&#NZF\;31ICW7%K@8'V8XOD
MQD0D'<6(4VU3#Y1(F14V-<[I%%O#.3-4"A:67A$064088>B'@8C;F[0Y9.#?
M*F4?'?,B9C4G1S,GI0$@JSSP?-8X5)>6![J??Z_>_WX#F49Q09:>D?C_MK&R
MO;*SDC05(V6U7&?E->D4*[]?([9PK1VJ>4'M#Z[V5ITK_6#0_'D' \ +J?+N
MY I^^XR, -UD59IQ"GI+"YYJ3'4JG895)80["U!BJ^^32]W!Y'U7?]>+YQ0^
M%GN]AI=;Y6YQTO_UF.OTLU-$Q%:H*0);"$91^=0HBU(9US,S-);ZU3CUSW+4
M'YSD]LMY5EI^T!R+Z[DN#2TK.[95OH<KP5XMIL]R)X*RST88+8%ZJ97"IRQ3
M)%7.X92#NI#2,)7Y\"/'X^$CQ0VMWA= U>Y^?KRPWN6=*/7],\YLP$&BE*H
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M,*A+!/1@_(LN/&8P3(ZK9KZVJIAS\-&U>FS.5S'\5C_9LL.B\N7)<O3G\>1
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M&3^-)=W-'E!#A;K^O[IK_'W,Z8K0>%(_.$LG;6+38;@SB+&>Y&=,AUJYYO"
M&41Z>7O=E61W9I_1%;X>?#6M2A_$T8]/<!@=NZHXLG]Z]2)-S96)X-CYBQWN
MIRT@ .[H,89JTJ]G\1DLUYE^T57*R33U:2&<^1L<#",>_F"8Q]9'NY7J!]*^
MCO:I/[PB]O T@WL/+FBMF#:JWON8O$S>;'16.Z\W5M\E&YTW6]N;J_%HFAL>
M3G1-<JNE)U^!Z=FB^)(5F!ZW<V^G[5QO:0A9NL&S'GO1_M[ZJ[.SU1F?^=&\
M6^VL)3L?_]S96-M8W=Y8O_F2/?8T7F_!N-]MK &-UY(_5]\!T=>3G;_6UV]!
M[L<>^V\?^U6!5LP37(OYKV45?-K,N]T*#:Y_BWT_DYVJFTZT>>_!V-3OUO10
M__XS8!?/+.-C5'=NOO4>Z<1<E& HTRH']WC@7XQ?O(S'773UZ8N\7XV^^M'+
ML[ Q/N#<D8G5\^JO&P6NY(J0+.KPYJ3.YL&->E^IU/OXS,8SWPFUPK"\\FNT
M@F_Y'6=7/_1'O_S18#%=P80LRF )T.1ZM[WF&:N/=DYGS<6/<S*M_)DH5]AD
M"\"O >EL?(.'.<QW(5:B<94N78E+^0CS>9OHS]5W-=/5G9U9*W,-03':?CFH
M"F[39I#6>A_"RQ],?.[.8'[=G)FCP=L<#EY<@]5_.NUKR,"S6+IKG_3=KMBM
M#_R^..U0_6^AIOU:#^J6W#:^B%')K[H[>Y#BC>A^;@'.\\Y-%@XEB[!\_WU^
MF6XTQ=FI59UGYFIN_\Z_O>@7_3=ETY(QQM:WXPG;HX%;J@/HW^H/<DX84]Q*
MGSG%L _&,ILAGNG,24E,^+P1+33<%I@G'@K0T]W!_RZE8BFI@U=PBV_#%_U1
M+W5%=;IWO&(IZ>N>CX]+#[0^?A%9=;7OXI_U*9^N#E_'KF&PIO_H[L@#<\+R
MP:_@WI7S[.@_IV:M^/J.;'_=HYLC=[3^=?^M.MKJ[:'-W3^[^[O[W<VUSM'6
MV@?<Z>VQ3F^=[_?^Z6[M?J'[1ZML?W</OZ.=[M[WXUYG;?UD_]-'LK^[^GWO
M^P'J[.[WMM;V#[<^[<-]OO .V3O9>ON1=/Z1IYNYZMG>F_[6$=SUR!UN[GXD
M6[O[A_N[V]W]HS?Y_NX!W]O]\&VOMWW4(1O?-]]^/'U'MP_W>M^Z6ST8T]O-
M;YMK;P[W/WU@FT?;O<[;3;;U:8-O?M\DF[MO>OMKFVS_:/H;>-9HGWP4^[V/
M)WO?UT\V/[WI[J\=G';>[B$8*]\[^O)]\_O>M\U/^U\VOQ_V.KM_A\U3=/IN
M=WVXN8-./AO! R)&I2(HD3+!9*JQ9*DF*LN"M AKL_0*9\L"L7__<98WKK W
M-U24R0V%XCY5T^0>Y&;Z_5(UM="R+ BAGDK#E"*,"Z$XML)[0ES Q&M9RS+"
MK2S/FRRCB2PCP1C#Q*9>89(R+5VJ/?9 #<$M\4HKI4"6Z;*2?(YD^5=P:NJZ
MQ3HF-FEK\Z! _4<:[9(%?'X:[5'0R92NTVY%C0/;ZK$;Z+'.ZQE,XGQ $GF2
M(D-9R@+WJ:9(IE8*18CGS'M;Z3&JLKOJL<MUR8-BDE:"YPF3M!)\;Q(\12(^
MB,QPR5.J!2 11T2J&*<I9M:$P*AT*@,)QLL$H3F2X,<._3S%CG8=6JZ;\0VJ
MH_\ AP/W+]<EM,M)MSI&.9Y+61_-%+.07#$RPS#JCGO]-?7<,5]GV!PMF?SW
MH]CFL\*[.A[FFZ)<:\8XGMOV9&JM.-]"G$&,Q^(,]^GZO[9/]S^Y8T-8O ^*
MXX4YDT[O ^^L??S663O@FT=_'W76XO@^GG2^?R#[O?VPM7;P.7.8**QIZI"S
M*;.2IM)XEDJ-N<N40"+32Z] V5]0!<EOP =H^4:\=7NKT?+6@O'6[L%G"6#0
M8(E2E!FP-(+(5 9 C<B)P"RBPL?X%5$7>>M<>D,;5EI8)^RB5';\L!7,6PGF
MU O33G'$699BSV7*/+:@M3.3,JT#-E9I&6)DF"TKC.<HFM2*\")Z8:T(WY\(
M3]TP[4U&0?N"&X8#B# 3J8GQ8:<ET\)YS3"O BD\$W,DPK]"0#B62/2'1=7,
M[+=.,?0)^;V-!R\\%!F3]1345ZNW;J*W\EGH(26V7MH4"Q.AA_:IS"A.O<^4
M<0HKS\!AQ&B9RC8 _(Q%]E&@1RNRMQ?9*=2PE&EC/4FYP#QE5*%4&9&ESM!@
ML02R68 ::IFR.Z>1+'# ]RGD[7WICW7NSK;*K*I$'R+9K_6;'A5O-,1=KVF[
MVG=;D;"K5>ITZS[=0J?-YL81+Y%61J<."98RZ60J!28I!G1"G##:.+/T"KPG
M=>=-K#8 ,K^"_"@HI!7D>Q?D*3AAC JB'(OYK2IEP=)4*_ GLH"U!L4<A'-1
MD#$E<R3(/P$GX]I)&*S_L>S/WY7W%.&IEC6K*_GG&8+M%E6GX3.%36VP9^'!
M5ZN=;ZN=MV8WFA#5VBD94B,S"RK:X%0:Y--,(A[ Y"+NLJ577"U+J>;(=VQE
M=A%Q5BNS=Y#9*:+B2".L&$^-CJ4&AKE4<V12&3-ZB+ \& 0RBY<)G:<([:\1
M[XF=-(>GR]799/4A'+'"LSX'KVH7-ABVH9^%1Q]C.K^/5 :'<7U,X[=E,1BT
MJNTF552[J\/-''VKU-OJYTQ9K+W7J:0(E!NR*)4,\$EF#=&9I$9: "0L6Z;L
MSLJM#?S,KQ@_4N"G%>-[%./.ZXD8^TQ:I95/I1<F90%GJ5(B2RG-1*99T)D2
M(,9B6<Y5:?.OD/WRS@\&+V(QP:@WJIOQ.G]<^MC4%A:_#8W<>$%_FS=TLCJE
M[=H,:>%UU\<7H.E6>P4LX/?J\RNU8*L ;Z0 UV=Q#$(._F=XBDG$,8Z+5+K,
MI4@+A(TE7@J^](K(92DN!E8N9*.U,95%%/;'RMYMA?TIA'T&[60QF]>B+"72
MRI1E\(_),$^EPC8FSR&!2"7LB,KY$/9?/ABS'(^*:R,QSS<2TV84WE2E;<SB
M%W#? A;&I)1(E3).6:JU]JEA03@;B/4L5B#)999=5&EM'.;9"/'3QF%:(;ZY
M$,_@$HL8Y5C2U#F.4H8D!R%V62H9#YG'R#&=54*<B;8&Z;%KD(:Z?U"=OE+G
MI%2 I"E'HFTYTN(CDRF%ZWUOT&7KWYJ#J=X6A3O)N]U6N=U(N6W.(A2FF5<
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MLT&0C^+Q[1P6Y7#7E[T_B[(L3F 56SAY(SAY=*;;%2,J2(0,+#?5L9#!IDJ
M-^@D\8Y09(&DL3ERIMHBR];YNYOSUXKNW45WUA,$@FBEXW&Z+(L',\;#3PU+
M.>9*9T%*H-?2*[(LZ#R=T/@K^"V3 [;O@J+:P-4\P8XQ2=_7%&U;"-]&?9WI
M3R4%RHS0(I6XJIZD,C4*9ZD#Z(&%#DA3&9..E+BS^FK#SO,KO8]ZP&PKO7>2
MWAGP023.)*(BQ2$ ^.#$I=HBDA*%+=/*8 <$>Z66.>)S)+V_0B0'>+T<>3<;
M-&TS!Y\#_HA4?3<E:JO$;J/$SK28,IG1W%">6AOKL1 7J3(\2XU7U.',,FIP
M=4*VQ/.4@=1*\()BD%:"[T6"9V,@F;0!JRR5*A[22$( =R+8%"-&A<*!<D(K
M"59BGN*7OT@0I,(AI3=ZZ ?+\&(X*IM-IN.RZ!61".U):(N+38[Z1V.MMET3
M>;LF\6K?O9\0N%5O-U)O9SI,"1Q/NQ<&^ @!0%$$I\H[D@J*F-,*&66C>B/+
M0MZY8+P-DLRO&#\H0&G%^$'$>+;0@1&C@W1IL#ZDS$87 V4XM0Z3(+7S&8UB
MC)<YGB<Q_I6B);;HQ;.7JP[U=9_NWG&W./4>8$M]1DEA8+3Z]IBE]<;F ;.,
MO;'UAKS;-75;K^R.^NY,8RK/C<>Q!X1$\>PEF:E4$<53+[FC2'AJ,U*=N'WW
MCA!M6&5^!?E1PBJM(-^W(,\ %R<8P41F*8_2S"AQJ93:III+*Q3VWE,7!9G)
M]@RUI\$M;;NJ9PM1&A)/6MVT&NUV&NU,MRJGA [Q?'E/5-RW#E&9:9URRKW-
M) [>N9@TA]NLD^<LP(^YX],*\)T%>!:22&:Q(3+5*,B4":M30S.7:L4"\0HC
M+<&WP,M4/<,VW8O5-,)>+-]K(R<+#TM:#^N.ZNQ, RLN@PE>\A0A'D"="9HJ
M$@R\Q9H)1[W$:ND58\O\[H"DC97,K^@^"B!I1??.HCN+1!QBTH+H8DKCV696
MI%)9GJJ )74L*$8 B3"RS-INWH]>S=P_2(>^[(&LF/&99JP-BCP#] &4C26$
M:T#7M@O?+=78F0901AAJ,\_2( TX5('[5!GD4N:\#D8:X9Q<>D71,J9W[J'9
MAD3F5WP?!X&TXGL?XCN#0K@C6@6D4BHU!P>"F50R[5(MD:6*(\6E ?&-9<!M
M)<YS.%.D=:GF"8]<.)!@QL=J3R6XJ68[.)/\FC$MC5.I9BRD+,,N-9C0E&*2
M*8J<44HOO<J6,<OFR+UJQ7@1<4DKQO<KQC, !8&L,J9-:HWT*9-5;UG *Y)S
MSD@005@<Q9C@-H?D<85P_0<IK@U&$6W,9/$QRD]3Y%;[KG7&;JGKOISI:>(9
MDXB;%/MX(JM'-)66<WAKN69&R6!\=18:SMKTDF<LUO.1^=J*]5W$>@;"&,,T
M4BZDFBJ3,HQ,*HVQJ?+6$:Z!K,T1A]E<B?6O$&.9[O3409:FXUH;8GD^\.5B
M&EVKU6ZGU;Z?:?U*,YD%#[K,>Z-2EE&12I*Y&&G!4B I-4=+KS@HM?;LM&<L
MPT^4"MO*\*UE> :9>"9=%C=O'8H=C#@1J0K.I08)&3+"C3>N.D*-JSF2X5\A
MN%*?W'K7U-?6XYHG)%+1=#8RW.JPV^FP,XU@,Y1QYX5*:89$R@C*4LV]3+D/
M'!'GI,A<U1T!9W?>Z&F#)O,KPH]WB&LKPO<APK-[/#KCS%F4$JD8P! 7#V3V
M-F7*(YJQ(&3F*Q%6;.[/)'ON53D/7(W3GN[3GNYS+Q4*K3Z^D3X^T]A69I((
MPATPC<] "SN3:@::65 BK0$R*:9CP%HN*]ZV8&DQU;V5%;5">T.AG0%1C"%'
M&%6IC\=@,,H!1 D#_U!!LBQ@!"2,( HO"SQ/0OLK1'->%[U>/NSY>*A/[ [W
M&GX!8_=]"TS?;#9A_+#),K>XQ\-8]V^#_$4_[_[OTK <^?/*8&:E5OONS#JU
M*N$:*N%,_]=,&<]TD"D73J9,"I*:C&5IAI%V&:49#3:RRCE=L(#\=Q-#U?+?
M@_+?;(EKL)HZ8#T58FC.:YP:8WEJO9#24BDS0Z[DOU\A_6#G4)?^L.@Z7P[&
M1W;[_XSRX>GM#JJ^+K"]VS+.'Z2]PT'5[9+=_J#J.R*QZC3ZIX)C17QJ8;\D
ME=R1E\FQ+I.ONCORR7__R/"\]V4EM?<2WMCHO+G, !7]G3BT][K<*G>&,3OO
MGSBPZ:,;+PFU)ND:)NGC<'-LDEXKM/]_A\CV_NGK3VJT=62_P?7?-W?W^.:G
M#Z>=[]LPYNU#F!^LR>8)C"'. <.\T/]]W^"?>:!".9*EPA,4&UJ":<L$2IUF
M5#(.@$J;'^.6*]CG=HYVRSZ+Q3Z:!11TAE+*XZEW&8XYH RGW&CBO%(<5<?-
MK*"+&5,7/DB.?9D,(CV3W_1H>%B4H !=<B7O59<.[H_M;A#@F>')B@$'JY/Q
MMKSX)+SX$7VF' 7,%4^Y! 7&+-*I(4:EA*"061X[X:D?J+)+V>D.1K!EI\5F
M)V\!#'(N4TQ H;%@7&JHL*F4*E!D@ .<6'K%EBE!RP#NXO]?0\?57/8RR0>#
MT8V5VRUWG.C=F'&C&FK+B$_"B/;TLY$T(,0XJ+3,I@QG+%5*A]1RAK @&6,$
MWU2OW7(;I.6D!>>D3%")1(J4CA:2Q].SM$FEU813E#$G6'4,!5;+DM$;J;1I
MJ+]R@N\SX'KG++"YBY)=/X/BLBG.=QAFWC(H9K10Y32V.[(W53_3[1?-&+64
M^UC$"YA(,Y1J151JP9HPZC*&F*D4"&D[H[5)%'=+HFCE]HYR.UNOZXD6!+LT
MB-B9E64X5L685&$O'#->P7_S)[>_PG[9JK6CWJCI-E)5R,2#]TI_Z/N#_*N?
M-$CK%H/![TU>1=86\=Y\H7][%%PR@'G"JYN6 HY9H$K&?SW+ '6!X#N@?L</
MM\*N_M;JP1OIP;VSE352 DPQ*;>93ID/60H6S(,7I!335FL>*WPQ7V;X8F_(
M"U+7)H NHG#?'KRTPCU_PCT#<@)"V&%G4\[C5B:A*E4HD)0Y[04F!@DM*N$F
M[.)).$\BW+]"HNBV'VKXT"5>EWT8=%OVN_@AE3%-UQN2SBBY-1]RF[>U@S?3
M8V?ZSV-K2* >I\A3!GK,R=1H;U(:E'&*@L7*..@Q@I?17!WIU<KR(H996EF^
M=UF>P224(0TD<ZG$(,%,X7B6! %99B(X#'J:Q9P$C.FR5+]RZ.7)$B??^<'@
M18RY3-,G#WW7)7D_&99>#T;EZ7*BAW#%8)A<[68\W7;];C/*F6W6=H/U1@)[
M\(,-UL.CSO=5&//>]\VC3;9W].';UMH!WWR[][W3@W$<_=/=@W'L[?Y]]'_?
M/YY\!@)[3&5(!78T9<&S5'%/4ZJ!"S0."M.8,R*S9<KEI=NK53'5'.[EMVPV
M-VQ&/QMF.4+!ISC8+)Z1F*4*N #<7>08-D()P1LVH_AR-KO[IOVO'7&:-Y?L
MC'RV^V6W$L^9?6[.N,J,33.?^7B2H4H513*UU AKK Q!VZ575"YS<N<SA-I@
M\?R*[J-X8*WHWEET9SPN'# 3"N$4*VO!-DJ?&@,&4CMPCH1UCDE7B2Z[N\,U
M?Z'@Q>J\-+BR6+0-$B\\(JG464/<]8JH&WW;'<5E?5^4<8BKPV&9F]$P]B??
M+6+C.1AD671A;@<;,%P J&WPZ6:J\,SA&PQI2K2A*:+$I4PBE9H 4";+G U,
M2F<877J5H662M7'D9RSNCX)B6G%_$G&?03Z**BZ40BG3B*:,&)=J176**0]&
M$4V(D4NO! 5QEW,D[K]ZS\DJXC>+A/[G+ABH;4;9-J-\C&:4JWUW4>.WVOL&
MVKNS=N;P$<9CAK:EJ7%1A2OF4YUAGCJ%*=9(&(7CKG^FE@FYL_IN8T[S*\F/
MW:&RE>3[D.39'F$NV Q;DP:9F91QS%(C@DD=9DY)\,FHQ%&2V;)4<W?"ZQ\5
M/!]O",$_XT?/W,OZB-8?7Y)(U6#,^R1600R281&[3@Z*;NZJ\HDW>5_W;0[H
MJFH14W6\.[N_-3.=YIZ,U(CQN!CD<?E?5">_YE_]RY/<#0_'TCOSPWK-7J#I
M3[2!,8R&5_]D7I8.G]OMF_DWCK:2\\ P\EYX1*T$[1.DT"IXKU06D/2"?R9R
M:?RCPW(\@V-]X%-3>OTEU0$F^$)W3_3I8.F/,^O0R_OIN74_OV1/LS"[U0EY
M1:BZF *%+ENG.:3GWUM_=7:V.LF_=._X93)^M]I92W8^_KFSL;:QNKVQOG.E
M",S+-%YOP;C?;:RM[J[#R'?AS^9Z9W<GV7J3K*]N=S8Z;^=_#K]][.N1RT$-
MO4S6BFY7EX.&+'6N1,PGVLR[W>HDZ?5OUH..?N_+^MMDM0<J?7A^-WY6<G3Y
M_[/WK3UM)=G:?\7BG7/4(['HNE^2$1(=2)K6P22!= 1?HKH&$V,SMNF$_/JW
M:MM@ATL"V(9M4ZT9(+;W=NVJ>IYUK;4^)_ ,NJ<O>*4V52P]IJ1>DMQ9(K3-
M:3^\N/CCI6_U3]OF_$6K4XVXNNCEZ%XC'LL@O"(5JCD=OCW"I]9K#/,,T9&=
M/OKB$7K7*O1>$57#]SA;DXK<^C9:PP]\CU/^H"M_-EB])AYXU\<?JTK\6>9U
M/O,J[G377_BM:G%&0\VVUNBOC3=\E^<?,G6=9N!U*YL[C?VC5L\WWIV97AI?
M8ZOC@[]/.=%[5%Q]P$<78B)WW:!KT]S1U?_8WN_KV5*=Q;Y:T-E($CX/JIJ*
M9*WL)8OZ+L>?EG4Z]I+6$T[R]B#R<G^@9SPAO]P?S^& 8/74V9AW9_TTBM"[
M:!^AY](]HA236M((B.-(8B^<UB(R%9VNVF4R&X54$?GX:;/RFTK$829'(/\)
MG;/PNM<]R4Z#/+Z/K<'1J]$>3B;>,/:]T>^']#]?I[/=NZ]&/M63=WAG\\OW
MYN8!;1ZWT^?>GQP<;[/FFP_IM2]?=\@'OG-\V&H>;_!+G^KQX4ES?^?\8+_=
M.MQ_]_W@^'WZ_@UV0/YJ'9!WWP\WFR<['[?0P?X?)U=]JND9\,[WO]*8_FHW
M-YNMYIN_CW<VCXX/3OXZ3M=]V2$'WP[VWQ_MO#F,.RUT7OE3]]#73\JB*#PB
MX)D@P%A 8((V0"*+G/D817 KZX2N4EJGR'9)9)D*X@F!25>8+<KI!8Z/.\<O
M*LDS O*;;M?G*@PCD;S?K=Z\A"R0@MF[8!9=8I9&K7*O8B!"<F"$*U#*11"(
MLL",-4%4'??06DW./3[%WO^?HN$4#>?.&DX@1#B#L F2,82]X2ZZ&",2WEGK
M1,5]" FBH?I#$UDTG#JS);ED2\MBX XYP,);8-ZR?&"!@U16ZJ35,()XTG#P
M*E(E57>Y-9PI45XTG/EBEEUBEGGC+;86@M8YO9XHL%P(0"HJ:E&(CK*BX4SG
MSUK BIZO<J6(;FR<]KK^S WZC7ZW[>>1RUM2YI[&]9,7>#=6=)ISYT+OGY8+
M_;VTRD7_N0^7GD]X>$PP5H@@P6(3@5GAP0:D(49FI3 A*!-7UN4JX74ZM%F
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M*O.Y7*ET"+#SPDB!,&&YRCQ;39Q:H+LLT)V[(5]D[*R@.C;B.0]>VR"!1(2
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M'GT )C3)7G<.22)CXICWF%1"F4Q_%*[@NBZXGKN3H CE><)W=RR4HZ92IM6
M))AQ]AI(,"[]4-()[2(SAMB5]1F4[BUA_OM6"!STSMS@K)>[#?S6[ Y" Y-K
M617%TUDSC\&U,X'C57QU9'J?)^BJ*!MW8:NM20\ C=A8:S!X'W.;T]Q7G#"1
M:P(E[4,)%G.T4)3 _M* ]#$.W8\AZBJ(G@[5BT&W7]2+AP!VPN:/5E-%DTV
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ML.G,:6N0!OH]E&X BQ4EOUC:<HKP 50V>;Y?8$N%"!)0SK-GG&$PV$90 N&
M7<!!YZ0>4B?O9(%GO0/L5\!9U(ZIL#JVZ:/ 3J:-"#1R#TPK#B8J!<)1YZ+7
M4BAZL]I1L+J@6'T4N[Z(TBG@.5'<#R&NJ'# %;/ O&6@3>)+QRFA0JJ(:"Z5
M@TN-C:6!Y]R#]$64SA*K8PM>NIC=:P&2KB. 62M!41TAJL@(DH%J:>HF2I]K
M4'YW<!1ZC=^&(?E__V#,EP!]S:WV*][)"YVC6M)FM],]#;FL2.?ST%%95) '
M="/9WQCLM-"WBMHV<E=4S:WDX$A$P)PCH(/1@$)DFI- -,T!>U63GJ@%N M@
MSU^@=?=&M!:=9#KP-E]=@C=B31CE)C?:3*H)3EJ),237P" A:8Y$TMQR$]6J
MY' !;_T,_")U'P6X8ZF+DW'/O+& '5? 5-4[AV@0@G =@XB&X95USNIT,K8
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M,N,]MYK$+H'>FL@9-]S0F_!^=[=.@7I]!?H,W+D%X'4$^(3GEG).B=8@E(C
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M=5J"&HN$UR=WPY9E*LM4EJDL4UV5E)E;2T5)F;V2,C:0G(P"84S ,(J!":/
M4B$A5V_7V%HB-*V1DO(+V^BBIG(:9_@YQ,LGY__)YQ QWKV]7^5O[6Z__^_5
M1B<,LI$[,-^>6<CXD6W;!S0Z:H;!;JQ1\YC%D!^3Z;=.4Q=%/B%+M$CR@\CT
MEW$0J?1>(*:"9#?WN;R[_"C.\850R\LRU9A?I:-1^L XCX;9P!0SFB'/D$TO
M$TX*O]:)7\=EU1R+RFA/(2JK@'D7P" 205@G5!*7TBI7^'7!@%OXM2S3\XL$
M_J+N_:CO4H.6TO?/JO0])XQI[I*AX#7#(5K'7%)#I)%>*6+CL)C;E(>V2@VW
M1U=C=B?3BJV-Q' J 2&3*U)C"A9A#4P*A;WE43BZLB[1*I'7,Q-+V<@2FI@!
MT3@A8W21!.,80X89:EQD,F@?!=$*%Z)96*(9IS\3&TR0D4&@1@"CTH+BP8!'
MP5G*F) BYM+W>!7IPC2%:>93H-8GU25HC:0QD07EK#,X_T>)#@1)>CO5E *U
MB\(Y8Q\-TM03[A7@B#TPABV8M/ @8Z(<93R/6%6E[]E4;IJ"^!KK%MX&IB,3
MGG*F@M V*1HJ&IQ,F<@,*KK%PN)\7/H>H;25#:6@=((XLQ2#PM&#D@(E/9(K
M[60I?5]X9IZ:A<7<6V6TC0XS'*@5@DC%HB4Q;3LJBF:Q^(PSSL["R8B1T7/0
MG$A@WAC0QMND67#JL<K5<?BP]#VIB691$K06Z)/58OU>8?>B0F#Z<7'%M>;!
M(WI<K]KT_EA8\ Z7/:+4(YE57[<RZS2:Z8W&3OKT4;^QU?'!7P0:AE+Q:K1A
MCI-0S?,E"+N]1*H9@&USV@\O+OYX>;%.K4[U2-5%+T],[W.K T.HO>"GUT!8
M?=_P[9>CIO9ZC8NJ<_T(C:,O'KZ+U]"M#>^I6L-(WOHV6L.WOO>SVZHUI?B#
M[OKS;Y1(/>NQ8KRF"%F0P>HU1!=IK'>#P4CH77Q@1$.TTF%O9N,']'0O'WV$
MCSY ??G%)0\8T0U&RU"(/([5HN]DM.QW!Z9]:T+S\C__^S PZ45?Z0%;OVJ$
MM/SSL>'<V<E9VPQ&4U*E!59__9 ;6+TR3!!\QI,U+!W;J,SKX8Q4=1X:&R?)
M+!L\XXFY..Q53<IX>FZ8EV>5&_67Z9R9WGG)C7IFN5&"$!JHLDQKPK@0FF,G
M0B#$1TR"4:-&E[B$%6;DY,OC(-F%U_QR>)(_\^Z\>?R%-8_3^^1UNH?[OG/R
MCAZ0+7K5R9>^AZ;K3@[(^Y.#[SNTN;E-=O<_D^:;U\<''],S?M\Y/]STQP?[
M_L<*]B+X&"C6X*(UP!RA8%A4H%F(C%%.7*X3(>@JD:K$%4I<81Y$HZ6+"B>*
M"=2S$*1R*%@>(F9>&!]](9J%)9IQ;E06'0A+ DIH"8Q:#HH$#LXKB007B"J]
MLHXQ756Z1# +T\PI@BFPL(PRX[EDGC,C)":4IZT9L'8,W4XU)8*Y*)PSSHW"
MAG%E)0?+B<WIWA*T,1*<X288KA0UMLJ-(NQZ.F;)C:HMXN\!>"H#PQJKF/1;
M9K0P)C"GO(^2BJ1TQ*);+"S.Q[E1D3/,E32 D8O M&"@##*@N1=**4VUC"4W
MJO#,/#6+I,)*+;'-AZ*9$C%I$\XDVC$&6:>Q*)K%XC/..#<J"1*!E79 D"#
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M8V.=.I1K&A((PN4@L<%@C0T@L%2&$TJMM[FQBN#3-'@NL9L:0_AQ#?4"X=E
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M(UHXSZT NY.N&B47J)Y2B9V_9_"Z8!07$@!+(@<;1"NM4G1))\<Q\[B =V'
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MA!^.(!8(/R"$IUV)V#KNA0%CVS+$7:Y\Z$- 1$9J)=/2*@\0OB;33\F7_$
MW.[Y0<S9DCOWS4U*',="GG3+ZNR22GL7AZ-!QX]B&*N\V0^FKOP+!J,?)G-F
M,S:_X=_=DRR@:?W9Z-2B+>?2EC/IA11GC!@144Q>("Z81"92 _.5>!=)TEC7
MF=$DN;KU4L*\GHUZ>-R#_D4]++1ZF$X:H)AGB5+D1<HA%M8@S8A$P3B;6"!:
MQUP"<%5>DZ2]Q(8]:*S[A$>]NL2C5BL7]SN]7CZAUT_5<0V7XOAY2.TI*661
M:<>-H5Q(:03Q,D9*0R(T6OUY>TRNGHQ3%1TXCP[<G<F#1)3SGDF/DL<4=&
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MW^/3SPX;2ST!:NEQG>/;(LT]12Y*S0+S0M?5'5?!@BDGD9_O09='*==1(/V
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ME/8R\9.[[J(\;SMI'O?I4S.*XCZ]!^4T'5X1?8YTSRFMP'I"'$N"G, 8&1X
M,)JGX-3*.B&KDEUU6]SD/BT>BX='XE.3@H+$>T'B!4T _&$9N43<<HJXC #"
MY")B. C.J// \NM$ H9<=6,\)!*+!V/6@]%0LJD]CO]7O!C/V8M1G+-S:K7I
MF L;* C+4T1\SE"5F$0FP%^1*,&B" E34?,+1M@"&3\%Q,_,AU% /#>(+ZB)
MP((R1RV2Q *(+4G(.,^15HI2Y96FAM4@-GJ1$D8^(P_&#8?%+AUK_ZGC8O=S
MH'#A1NBG#W^]G/Z_!.*^>QYU5$CX0Z[?SH*FIY[E@JK<$:XI+.7)1RV$9TRQ
M>\I(.%_:BK*BS[&B[TQO+6HJ1;38P(I./.*<,F0=]X@9IC#FWJ3L;%"KN+#R
MYXQJAJ72TO(@>.+"2",]3TX9K!+# /1[2EI84/V0J+[@Z<QHT,'$(HR#1CP
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MIDNWITF2QC0E[L$$%,8C3D"-@DG($#-&I$2=C3:MK'.UJDJ>P(5#X",QFX+
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MXLRS"3V<$&4N)A5GQ)VO"#??:JY=(=S<=<S%6;@U>9+_= _RJE27-LTO3\]
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MKXOL[?V:OU_G>$2H@BM1%*:3T R22@PIWB,+Z)5SKNKE+F\G]&H#=*=9ZJ/
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MKQ@6R9ET.G&K$AJUO"*!AN05(2 VQ/8,L7/$0S+.(CJA6=2R2M%YQY""+Z;
MYIP#16');3P1\,TKU@VM*TX\;"CN&XKG3PH-NGCRNV2V.:$X O-%.6:%0?1D
MQ3O1]>9W>XWD>R,<-B3W#<G#N;.[C50J%4:SP57J!S",N; ,(6IAO!)B>45Y
M#<EW@^1;D2$;DM<!R;-<&*55R@.PZ#7Y9(>&81**16L4I5&^V)8+]Q[)]T;+
M;$CN&9+GZ)B$5W 5Q#Z'4I$<F:M5MD)Y(4"'(FQJ2.XYDI=.QVR([1MB9_FP
MHC!9YES/0#%0Y2=#%:*,3(5.VL)C,(18<_FPP ;67H#UWFB8#<0] _$\_=*G
MZFLI;N9DN1D4E5C DIBP7&E5*IB7)V>Q1"A?+2=KFIQL:^-1M='AX._'&/8S
M_9F&?YU5 FZ?')!QC9._5\L_/#S!26E@=]D$LV'T]R=G^.U^W][LZ9L7;!W(
M3:LI*'A_-![68?UAE/<[3_J/#\-TO'L:$,Q]<&)!?^"SCV 8'^V?'%__D3FC
M''/5\;W_N$;6>Q+B?'?,_]P]\P+O\6UF@:*%=PQK</ #[G_ 3^.-OY][IH/A
M(;O0AQ<?_V$><J>BN+*P?ZQQVN'Q58]\1]/K@HF8Q%%!2X/>290E@C8E>.E+
M(E-4SYB6"2<!)7TFIZ<U"D2Z.* N@$E!-@)EML&4'#$KSXO<N.9[4/-(L2?G
M,EI0Q@5=!"H93)#1!"4O?H_)7)JB-1H;H5A$L ZX412LHHZ6/^@8[F8*B_?W
MCSZ0J1YT=GDP' ]P,#XY.,#1ISJ\% \/:@#UU_#XTZ!#;4Z#XR,*KD^#8?K
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MW#<DSW)AB,XD92CY=9@9< .,(*T8%SG;2AU#OCPMUX;D%6>--23W#<FS7-@
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M)>,4 Y4D<T4DEF.*R3GK!,+&$ZE@X26H!\3IK8.C@V%*^WD%UXW6VW3=)+H
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M4=.G[!0][3].)>*Z9SIZ3V#KK,GW\X-'7SN;4*<9T/DN(^=^] 7!RMUAW.T
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MYW-NX&[@;@&ENP;W.*"44&3A'0>.+@,&$\!+)2 E KKTTCJ>&[@;N.^6=[>
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M[3.M3(<2A%J"7R>!?7'P[A>8'H?PEO:('HS90F5:+S)]1E[U7QO0KPOTH^]
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MD-Y\]K=!^H3/7IE08D0!*H12$_EU+9!G4) V/9-]D<+T6M\UI#]&I#>W_&Q
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M<[+/T-Z=K%2(0ICB"FCE(V"Q'+P+$9A/2DLML'A!&E7J#H%TUG4*:>.OSLT
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M*8%EEH/U/$D1!&>NS"UHTR5/3H/GM.M%O=2N."(M3*%#[PBO*@J1,2<?;,L
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MLHU?FT5"K"X\F8#,*HN<&5NX#9K+PDMFWESBG&TJ\"Y0.*:OHMB,VF@P)AI
M[1"\=!:**U+I7*0KFNBKZY+_IL%SVM:E$TF339E-]L@P^XR9$Y'5UC%$WO(-
M.H3="?J:R+9(/!:(,B%A-V:P)F)MR*!*MHQK.9K]C;)+PQ.;]_7\HB[A=998
MT.:,T23+4NW0:.M0X2 O:GG2Z.L,P7?)%(?M/E];'*KA*%_V/Y_H'KZN?.AC
MS9L=T'4&Q\,OPP__V1QN/A_-*"L!@U/!@#!U_HKC1&332/46:X7F7HJ1]U6+
M.^6OS;]S5069HBFQCHZ3N5H7 <F^0&M<)"[+6\^"3F%T3&Y]L4G7)@5D:CC
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MCRC#^'.O3*K@>WIE]XPN%_/U6&IDCS<^[D:J0?'G,PE")6#G8+XTPPY)9T+
M,1A#6%8C5XU^.0LYW=I->ZBLPUUW_M5[9UD"-E=W$S$Q4(Z!MN1J^J@3<L(9
M1((/6@86K;8YZ'@YPO/?Y_STL8MVD?V?\]9FN&MO1K60@]H9&=683$)$UQBD
MY^#(K9[I?-"9M9+MM=MU3278J]@9C)]T[-5=7+G+:Y4K2GU^57^DRVM[D?TY
ML'2MWIDY.X0?^J<*/:__VYN=:V!R,<XUU&N7EX'*WYXNC_K;^7)VOBSR6MB)
MH3\5UTQRNMDMS>3B])>UX:S%M]Z\.#SJ@Y*$=W^/[7;^[WE!SV55<)VC?LVR
MDOVGUZ]S2/G-M:A<Z6\N8CG!^;#87UD<MT$,SUX37W'BM[GV#3=/]K[GKH:@
M@4_ !A.3-*$Z(LXT1MPY@JST!FEO?/(I\G%Y\:Q*@QD:>(;>^'GE#/#'RRJU
M:(D[:HFQ(@:"W@\7T]_G@&R][Q^=]P[:<0^^QA^'L3O(U9.W\N0CT"3N(K$R
M\0!4B@&V":US;$1R_7 )MIL ?W7T</_.#[0^?I[53N^H^WI9]T7T-[_O*L>!
M9\F$DLD#W'*:S1%#$?5>&XFQ92%D]/^$@9]A?,NV_9G#E\,I>^,(YA#<[%G*
MX;IC!?VZOO\A98P]A!2]>NY^08Y(]N2BUF#&%<+, X_7P2*K!46<2I% QKBT
M G@\6Y[5#C<'8&ZC:' 66FQP%-9P:Z4%&Z6-T"Z%:$$.BJ)9, '9S'U$ K/)
M$!2XT(ASDY"VA*(4;4@D8/B[R:[^57W.+RJ:3ZT!^!TA5U[%X; ]"E@_E):Y
MIX 5+?,(0L0:>[LD$2-"2"B 4LDE2@H9*BQBFD@!VV44S@U%Y<QT[B^?8SY!
M M) R"1>T!WTVJU0FZMQL 9$JFZSGB5J5/;=R2G)$(>VU1[\ZW*&MQ#5QR:J
M4Q[GN*2LVOCKT__8SN%O:Y7?M_V]&N*WL2%&2Y(;&RG)*+=8.^*5\CQ9[(@3
MECV,#;ETIN4\[IN]G'4^@IL%=WL,_ UXY%8_"]^_>X-!7)CSKT^._\V/NUX2
M +K5B/ 4<N^-[*M2AX ':F""4A,3LA$Q-S0BF\.A_<?F2MYQJF^48*E^L?X_
M1ZT<YZK+:O-+5W/:I_HCVG:NL\U_'IWQSV&O'"K^UR7C<[=3L_>4RSO%2&XE
MAJ_=#HG&]UVO$P?IX\@'EH?G>H-LD/"=#4X:*RRGF>W2J^W0: ($JZFON8\U
M*G&3AS9'5^<B+X9! 3*U31J=>-O+#!2^';3"./4[5;D\E0,=!6B)N5JE#/?M
M65QM')Z_)D%Z1G)S"<:LL]HWU#Q1ND2E53(:QG/O:A<YC4YBJV4$;_LV*;%2
ML'AO1?/M1_/[KN%8P19P1*3"0'BU1\Z;G"B3S&,O,"%7!F=_&8SU3,6+@ED(
M!3.M/?9MJ-J][T!XQR=-0?OLP_MSHRP ]/DJD]/60WD?1V^Z_)K;9.=R6NYY
M)#&WIL/5[4&O BT;1P?XIZ+6YTI9ZBJ?P;#GOR%7'ZO*RP*4QDYT:WT4-K;J
MD_WQ1^Z(DE\'"_-/'.1+AXM5GZ->"N?+8LZ?^QT5KU:7DJ[^;+_S-OX#;\N-
M"KIG=33G2S6G"^MJ8IFO?CGIER_:CL-Q5Y=\@?@#5K\[KB.%=YX6#)T_I'9.
M8IZ' *Q>V<;HO#7.>%KPPQM?IG8]'TX;"^RK=? :)QL<G+JD\PP?!DX=_(.X
MD^#4V22R4Q=-C)@&7)?H7ZYAK:9:&TTCI]8 5V%L5(]W)C>YW@T\GT'E<O>0
MW,C0U@5P;;C.)'E>8ZJ;VR'TCK*>/>H.\T'/4>G@J"%)>X3Q4?U@&-?4@3SN
M]?-%<^U>-:)=^6XO /%K]C+')VI/E?>7;DW^:ML\3L!O?/I<?\88_KF$$#ZF
M_K0SES9_?E;O.<</-[NWG[DFK6\4R.;D7NMWU4KN[ WP0C;]+KE<;71'_4]N
M:4G?V7;+]5M7(9_<"/DS6RG,2^UT[ $LZ*Q:S^%UPO/F[$#!8&1I1G6CN1JT
M6V_LJ71D8P.F&J04G(6LN, +J/9Z56X5<2H!];D$(-KZO,2ZV&Z!(1GDJE/8
MTD-PS^O01?UY4^+7L?FU4\)RUH6S"WJO&GZ/[7_.G GP'>"M61XN%+\.,C<Y
MOPZ]HV'V<4Z-T3E!7:[^ 'X"'W3AC/,@1UZK455);W26 ZZ0[9H=@&ER[=I%
M:M4O.&WH<_H!\-.XMB5?:M2/)QW59[/SXQ[:XQ%W';&D+-(]6-=3"UB_9-R0
M\49=>^Y^8.>F_7[8Y7X_3]+21\ZKI<]?0+]RFJ,;ZL%3?_4&0]"KK=$Q@U,[
MN(#M?HY/#>*?^]N=CR>;:W^WF@?^>V/KT_[FUN^MS3RW?NO+]^;6-MWYL)V=
MMLL&L?.^M;/6X,VO&[1YLOJC^6%=-#YLB.9:>[^YM0J&=>?;SD'CQ^96,V7#
MNLNETT)SAS2F"7$#EM P3Y%/'E9>6,HDO=CLAS!%/:7*!V\Y2\10PYS.E?A<
M:B7$Q68_?ZTW/V]L-C]7J\VU:G/KC_5/U>_KS?7W&UO57_]>;3YX Z"?W]_Y
MYTE<)IYXM"1*[K!P@6@'JI'(I)*T_BF[B&:5UNO6"@<T4C,.J[]J#PM@,Y9D
MT'J#X=/39SK5X?^Q@/W9[\=PU(Z;"19B_/CYZ0=UK]77B^,]MNNY4Q)CCQ@.
M+E<V XXE48A1H97%#"L<+\I]'H_")8L>8\D94Y:39&70ADC!J'07<9RE[_!4
M^DY]2)_7_XP/7JSK#?":W+UD<DKC5 ]7AVW;'5':D8T]?<GH]^.FL1<JB?T9
M&MY>KS2N[=W\*ELNF])R^6J+<3,+</;\MK\'2S#L';ZM VVSK_E3=*W\;SUQ
M8B)<?2#GN65;VQX.XMO3;WX+K0%@XOAMJUL_<?VFW\;W,);(O 47)ES4@C?Z
M\V1WEO%HA\;SP\:?//[S<OVG"W,W1G^C?)DQ?>6?\3*YX]\$N_I#KWOG=3>K
ME@45S^9>I;KK_91UG?^]:LH>X5XIN]M5GV)=R[T^DA[0_$97_<G\QY^.%KO%
M2RFY]-H9<\9&M&8^@\;,C>:,O1\E3K;J0J^/XT*O]5QT<H,1DB]]59HYI]\8
MA>$NK\D-I>M)!V'J&SWN[&EB=]EP\SSW^]/$U?HKNU2O>"GJ,.!9O.2UKT81
MC!L+QLM1A[^L97>R7R=9&J,\YN!?#['S-UJ->>[\S=9CG.(_;;WUBE?B<SP<
MQCI33-6H*]HK7HPB%D4LBE@4L2AB\:!B\1,>=>7$DH4@6#><;OXY]O]I^5@G
MQ&X@"3]]YHLB<INUFCD0?N%6[+]N/.M[UB.^F%GWQ*J(G7$R2L,%E\XGR9SE
MP4I%"/<_.QLH9[3MSDG7L5N3O9JQ;.9<^:*,M[]KFGPTWO[@2Z[W)#L'<-T/
M7_A.'FMWLBX:=(,UOGXZR/?;/%C_T3P(K8OC[9M;H=58^[O3[/S];6=KO]/\
MT&#YVML'_L?.A\;W!H7_Y6&8],_4.,;']6C[S_C[;@Q"Q(03LM%;Q!G/30>\
M0I9Z(D3(X_!4'FY_U7' ^TC[72?;/Y#NF00_;Z>S9^JA9PU6&8@FUJ5DE>(^
M)L.58LKHE+SS\&T-5HPE-;,[/!:P/B98\02LC!+&+$4V"(5X4 H9[3V*V"B=
MA$B>A S6RT>9"EA?#%AM%$Q[9E00CA-%-6<V:FXL3E8S;(IE?4JPTC.PTB0P
M4)_<GH4SQ/-W1EN/@I2**QFX26QI15W5K*5@]05@%0>'8;.3CCARGXP-VE$/
ML*024T94,:Q/B55^AE5#K72* PL6T2%NM$:.B(0BP19C^)9+#%B]JA5[P>H+
MP*I.VJ3(HN?4\QBS/ 1LHZ1><2LY_DEGU8S5VTVA*D!^*"#_:+S#/VHPK^Y2
M$1*1DB#&B$9< CW63'G$0 DG&8UPBBRMD#>8%)?V!:,Y:AN,)SKD@F4&U)@G
MZEA@,B4NA=$_&UI0+._C K9U!EA#K!."8@"LR?-WG$/6NH1T"))[Y4WD<6G%
MJ +7%PQ7[PPV,1DO->,X6!N5"2SX**S5P?^LK7F!Z^/"M3FQKV!>N4Y2(_!@
MLWV- KD07)YX2X-45KE,E2DK7/D%P]4F N CGC-ON6;"206L"W K-?5&71HX
M5JSK?.$ZL:[U6:T8//(I4,1)),B)P!'#P(B$#E%R"G E5PUT?0JXWCJQ[GV,
MSRRQOI&+'>)@>/?,^H6'OI.RFK%P+T]9S2$5?;J;15O=4EL!L9CDHF&GE<2Y
M-5_VVCDU 5FJ*+@#.+CDG(TXY4._]Z86L_7%HU*+@M;%R447M-X=K9-DM)!8
MR&2!5 C-@%DPABSV BE+O-=:LZ0SLV#W3G 5M"XN6N>0C"YHO3M:)]EH)7"@
M*LAL5@&R2@FDK<3(,JJM-MZ31 "M]ZX<*6!=7+#.(1M=P'IWL$[2T3ZYH#7'
M2$L%1#B%B S%$M%@150>VQ1$KO,J8'VY8'V ='0!Z^.!=3KE[+RDS.F P+3F
M=H,8F'"2%(%ZC<"'$@[8+ZV(^Y=Z%;PN+E[GD' N>+T/7B<Q<=@9*ED$I]40
M@[@G'AF&-8)M$2ZY&"WG2RN*7)ZS6/#Z8O ZAXQSP>L]\#J5<K9<)X>30<XF
ML*]>2^0$"PA["12)V. (^*Z2%+B^7+C.(>-<X'H?N$[,*Z'>AV 9@J\"@?OB
MD2-!9_1*XU+ B>NE%7/O>JX'A.MK.,J=AQ+Z/&5@-(ZC KSEKL2C<8TWZ9=4
MZF4N=!]:K!STZ?Y^JK=WLYM_MUKO;5%FMU%FGZ<RTH:20!GSR&)L$4].(A-$
M1-+&0+S&45D&S&,&];C4AJK4N3U'W,XA&UUP^U"XG>2F$^-*."90$LXA;CU'
MSFN%!!$6LPCZ-]GL,:B"VY>)VSGDI0MN'PJWDRPU^/?4^8B132Z'YVQ !MPZ
MQ+RSU"EG'0;<%FO[0E$[AP1U0>U#H7:2KI:<4>JM0,"/-.+82*0-L&2&O11)
M29IB'N5>4/LR4?O4!Z<+I!\*TM-);>R3XA$K9(4,B!.*D1%&H11E%)X*8@/+
MYZB-OIS6+L!^$<!^@)1V ?:" 'OJ1)A/P09G$ ^<(Y[ 6CN:*()=!@<I618(
MS<#6,WK^%6"_"&#/(?==L/M@V)W*A'-!@J=2(^,- )CHF+-J E&CA&<*.VX!
MNY?K5@IN7P1NYY $+[A].-Q.;"[@DE%+ ;(X8/@B M!J;Y&G7CBJ8%MSE]T%
MP>UK.'Z]VNG!S9R,)IOV4G78;_7ZU6"JV_FOO_A^#*WA3>;)E+J>)\V,#^"!
MX;N?*[?I7=],?^4]GVHS\:[>[Z+F;J/F6E/)<F5!8I4 VZ,4!25')=(4**3C
MBAD<@XW4+ZWPRYTF;J[E2H7>XE;H/4"J?#I:D%H_8D GL=\KN'X*7$\ETYT6
M3!J&E/,YF6X]LIJJ'#H(L-,$5+7+HRDU)?2W!2KJ*PA?P*QZL=5/B.E)HAT3
MK[P@#!EA+>+&160)Z%M!DW!$4R:E7EJY3V2_ 'F!@?P B?8"Y"<$\B3W+I*0
M7&., +4"@?ODD)'P(Z-$INAR= &,\WWJW J0%QC(#Y![+T!^0B!/9]PYE5)$
M9I$S7 +/=@*YZ"G"@LJ@4J3:Y>(W5ASH9P3FQ3I!7B#\&!">Q/DM30G#GB&M
M!$!818*L$ 099JG3V,20S*SZU>(D+S:*YYQ<+R;Y*?$\G6]WA"MJ"'(R*L29
M!..<1V1J::3RP?+(7>YQ6"SRR\3R R3<"Y:?%,L3VQQ-E,%3\)09#3D'KW,.
MWJ/@0 -C:QQQ:7&P_),D?&@-#MOV.-]GO![^Y97EE8OQRM?09.%3]+V]+KPA
M5* ]CFR_9=M5NS<8Q-)A8=&;_-_14G^PK>[@W_46%_-\"_.\.=WZWSFFC<Z3
MK572B OLD3:!H^0")4$"\2)^:841OD!C2@J&%Z^"I&!XWAB>U(G0F +#Q"&&
M<]\G$0G220#5-DDZEF20+CO+M&#X!6/XZ4I$"H;OC.%)74CP A-&)8HLYE;&
M(B''DT1<<XH#TT00P/#]9WH4""\NA)^N.*1 ^,X0GE2$$&QI<($ =\8<\>AP
M[J&24$@2:RJ4--("A!=IX%^!\.(-#R@0GC>$IVM!8H =TV!]HZ7YP)A*R$9L
MD/;>$ \[915=6C&\<.D7C.('* @I*)X_BJ=&VRONDG(:::L( DI5#]T2R O-
MB<$J)!-S^] RVOX%H_CIZD$*BN^.XJDB$$^224YP)!2+B%LED#68(B<HTS8/
MYN)A:860>X_C*BA>7!0_725(0?$]4#S5]B@Z(F)2* 7I\] ?8-2!)J2B!D9%
M.9&* XKQY:,23X?BU]")X=U1?VA;[4[L#@>5[<+"QN&P'>N?2^N%!4^9W_7
M]J1,HAF'6<%E_;9V%+=ZGR>[O]H-T\)!BO:[C?:;'F.0&*5*I(C 4 G$><[,
M&>.0LX9I)2D-1)03W*\ \D_8HZ% ?@Z0GR3C ^AMG8A!(0\MX48EY *QB#@
M?)"*XD@+Y%\!Y!\@(5\@O\"0G^3N93+8:LI1D(PAG@1%6EN /+;6!Y&,#J%
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M$E8",2@[_H@[WOB^:WT* 2>/!-,<P<H;Y*BV*)*4@DB2^M%@J,M![;,M'_;
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M\U[=E7H,*I1#W6^9K"W;4SSK5$/ :K-;3=K95&C&PX.813O(,MR[;E[0Y2E
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MFSXQKW50)D3PYG)?:4YT0"X*("HV'ZP21C+&EU;H&\GHLBP]Y%XTP._I^Q>
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MQEM7LC2+IEU;T\VP%0L^28J2#!SE@\QYBIA&CHA@'4L,8_T@69K2K7-Q(9R
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MCT&74CV@2\U14T]C08YX\0GN#?E9(']Z1M1EMGS[X%>C][&OG!ERT\(!//5
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M.\"X%;HG^^M5A&#:WXGJC"\$+&AS""(Q]L90D^2G9[K04+_1O5-T+XBCSD^
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MG^'-130)K<6&>;K2!"V(3U=ZQD1C5$G$D)^>$UZH1_YP]B<=+TF_5;]N-X$
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MUDAKB#C6&&!.02O$L-9DC@@"BO6E5G D&[W'":Y5_-LUT+?T7HQC0TY2S)%
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M$0^]EBY<D 0FQ2R[U>)A*+Y<A;W.'._DS\W8/=-V\U1JKA2Z)@D4$8-42F&
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M&PBH:_>0]$ =U_R>27#*,8R6N8^>AO7V]*ROCS37LS7:#JO1]N^__.RC__4
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MZI 8GY59AT\O>;3@45(@RCUH[CTDRH5SBE"'/#V7W0;UT!2/9)AJ36I$,I9
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MZF&B#>]1X'W3 DLO/'TO;Y@ZJ9N7QJ-7M.R4<DF[/'E(C$_E27:,WD1"<>)
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M9('4:9"S39L\M$'#IV<YBF3!!OB##^8OK7A\4=U$9M-1=315ZU4TZ1XE.B;
MI\0]6$Q)L@<=8-.C[C48>0\4J^?8I6EI3\]TO=C_IOBX%(]!.FTM9J2$+9DP
M=8\-*W@5R&,G[@])\5GB'FPZTX8RN<4\[7#L0;E/.SS=Z=PET[3*$V/>,?&]
M8?SJR?RK#/+VIC\"QF<*8$CKU(4 S!BPU!I$,L\GJ]4>8RJ9XW*GK\G;;P6P
MK0!VD/?V-2*E1L511T$N6#)YYM8TBI%H[7MAQQ'/MOPG"F"Y35<D2X@O-4F7
M$D3+O%L=44O56->4).QV^T>FN%-L-.\X1*)YU]'3F&$F#RJD%7CLK/TA*3[;
MV%&@M6H4ID>9)L4\/XO"H=7H/N^@@RR*]=U1YTWQL2E^K=+P=?9XQQFWI_B4
MM8])(O2<0FJ\LO8C!^NMA%B&E,)YQ.$O"F#O]OGM?OO#$OP*.XS&I6E70W.<
M_#HV:K%T:Y!ZU;S3]H<D^*S?OA%U;RE4&Y-@IQPT0PS*ALUCK_/#TS/+E@YZ
M8(IK9B,:N7BI:-1T^M U]^EB:R(I.VU_3(K/TO:]I,QH&BKT%J8?U8*5>>B:
M<R2Q.*#+T[->O[AC8WQL=_I*@[S=Z8^ \=FJ;8C,I8\08<GJ.M;@I=10!WHR
MZDGH11?[*/[T'_+V?_RW_OC@EA= CZ+ALZ^QK_%#N<9=%]+^7/2.+QK$7_WL
M5Y_][2<__YO/?O%WG_WX\[__U4]^_-G??J\ELWMY^UY5A]SOV+V^8_L:=W"-
M/8CX7]8-_&%W:;UF_G"PE*RD7!.F 3:CO(IQH&'.M<%[=#*,+[_^9_MV7NNW
MWWXZP\G0OGP1E%W?L5,ZMXX%Z[_]29M#S_/F90TN:YB)RPCJF,-:?E:X=DXP
M0T%^ [ WHS\PY$436#=.8H+J77VP:RI+'46:RGLT.FS(#P;YJ0L",P%1LY#G
M$1ZP=0DVN@8"R"U)3M3CTS.]P>N%4C;D1X'\\O#B=<8\[W3MK>@]ZWZ(H\/0
M&K 6#:B$P:-IR*X,O74?@Y^>$[R]>HWAAO<H\%Z0[P9,5;0.9,4.OG2N&N/J
MLQ<NK;]'"\2VT =C_-0?,0ACLU:FA:;)>,=IH8$@L M2;GV>UWUIA+PI^>HE
M:9ORXU*.3CT+9-+*.+1;&M2!";KE6'-YCQ:)3?G!*#_KGZ@Q%8<TPOS$ TKC
M(#6/P!5-8(A4@VG*Y0UM'9''P?RR /AU]GQ[XK?C]TRHL$UDP7NH##3]<<_!
M+5$8\U;.0QE+,IK\Q@L#CQ^/WKLNUAY$K?"'W1SVFHDIMWFNS0.L-)L7ZSJ<
MT%+D CU)Y%TMN+,#\+?GU8*$I%8LA]+&#%-FT!(<DP72/H\^; YCABGE#?-N
MY'Y@R*U!RYA3ZB1H-HT>Q#P*)ZR"^%Y;B#;D!X/\5"TPGQ&G@8=(M/0-!P6M
MS8/UE)-0ZC&O-<]O5*Y69]F0'P7RBS'*E<9\QR@WH_=4+:BKL".Y!J%5,BC2
M@M<.89#D7-?JP!9GB%+>7IU@V/ >!=YW+72LT-P]3D<L(Y?JV*QHK2TGG689
M=[7@_A@_50NDC )F$&K*&' P!UD)179B=('YB*?).+^!<G6U8%-^8,H%M#3/
MTR17S%IM#>$Q@Y1,R?NN%MPAY6?5@N*:')4#+X53M)J"S[]:BL5M#6K-8]N6
M[,$;DKTO]&$PO^B)7VG/MR=^.WY/U8*!W"I9#\Q* 4$T>/<41B/M?=Z_Y"]F
M^NV1Z-TC!==J).XJZ/NF$5.)A5*.W@$CNP)PEJ*CN8SN[Z.1N-V7(QU_OSNO
M%?1Y:ZEU"I$A!M0\O1?V&G)*R8VFBPJKUP'>Z/7J:[O7X;B48^^8LV)=FX]Z
M%8\#8?250@2F^#Z;CS;E!Z/\;"V2#-9A$$HCGS%*]N )4A#1@I118U]2$ND-
MICU;\#"47^YHNLZ<[QCE9OB>J@5M@'58@DX94\ TTAK_LR SWI16(F/W_T )
M9L-[I_"^:Z*35!K$>?4=(F%761. I4H1BZJTJP7WQ_BI6F 2Q?,DFT:;CCAF
M#8*1@J'/O^912\I/SYG?L.X)H@>F7&/#HKWQR(XRDH-K8AQ)J0QO>5<+[H_R
M<VW&/.]E00E8ALUX.]7@-EG'*BV7&*&L-<,YO\EQQ]L/@_E%3_Q*>[X]\=OQ
M>ZH6U)<B;I< BM-,>VQA,LRAY\)8>JJJ[<45/])JPY=JP5]]:_[K_OSRLM9S
M^,6__.M+K_W%OVE?_.;YO\\/?R;FB/"6RT3AJR^_^6)]YZ=?]U_/'_E-_]&_
M?=&^_:<_8G#V@]^]D$_CZ4?,O_GRU__Z[7_\(V>_VWJF)S<WIQG6:X+R[_?J
MY>TX__A/_RYS^=5D+OC7W?Y/L#%?[*?VZW^SWWWS]%=_\CO]\Q?_$O[L/?SS
M7__C_)*_6@_%)U^.3Y;YG^_VI5_Y_/>PK_]Q_BK??OG5I]_I>O[9H_/=B9(\
M]>:TYG  .9I9+25:']45YU]^=Q#.G^GML^6GB/46Z\"5=9B&L$JO&KNQ09T.
M3FS_T;]CT#6)9,!<,!71X2:Y*";G"6+_\W_'YV$+W@1;G[ V])*AN]?LI$ZD
M2Z?TY?WX]X?WZ]:_7D#^VK[ZIG_ZQT]^U+[XYJM?V^\^_>)?7M[1EQ_ZT1_>
MFS\\\>L6_QF4+P_V=U\^W?VW\;LGX _%O#_\RW_X\MN7+_W94?'=US*^E?(?
M?SF^3?_%KZ'(?^DG_V\O5M^62'?R6M=<6(8[>;'R5DNYF]=*K/NU?O#7RF\3
MO]_KN>L9P_<3A/V[S_]Z:<!^\M>?_\-/?OSY+[=.Y[[&OL;WHUOZ1R=HQCC]
M__[/[N]\]._<C\K^SOVH[._<C\K^SOVH[.\\\G?N1V5_YWY4]G?N1V5_YQ$?
ME3L;WKJ<AWT1<_M-_Y?OU-P^^>4J^<Y/O_E>9[7V-?8U'OD:=UV_^;B+I/88
M^WOVGQ)A==<:,P]LJH:9";E8+DF*^'N,>^X6T]NVJ/WC[\\G.EDIC=(X5.D8
M, H%ZWF$U%S0J@^V^/2,>'5[Z1:C."[%3=E&PDP$A-FS(#1; P8Y&@VR]QCG
MW!3?GN+3Q*87CZ!4)L!KY$L[!R/5P%ZZI((EK>7?6;<^W,-0?+%)_$ISG'>3
M^*W8/8UKBE8=1"E8:A!PK'%-:AA&J9P[Y$PO^R/2VZN7-6YXCP+ONR:X,A?M
M8%XB8(O#,):8:J=:J9.7/:YY?XR?QC6=W7IR"*GT'-#4@K4"8<@\HEN18E8F
MXV]RV1KK#PRYK_E[ZEI4>$TNS+>!2\X0FT$M/>YIS?N#_&Q:TWG&2EYJX)ZG
M)6^%@WJA0*,D9)O$][5)YDV\?A'4IOPHE%_TPZ^TYML/OQV^9XN@M,Y@"2@8
MB 5,E(,7TR7R2-:DYCK2#*+A+1^(WL>J#GZ<15![#/U]L_T3 ILP0.F&H$/9
M)7KB:E$ZH>YL__'.N'B>[??A&7AX&)[2C$-(@IA2&.0T;^YT.;T^/9=TI%5W
MF^(/3+'4%80,9,<Q_1*Q.D JE3'=U#RYWMG^0U)\RO;'TD>-@T(1FG&&Q1&\
M#PAI#*3Y(4W(GYXQ7^VG;(J/0O'E;/]UYGA'&3=C]Y3M3XTX%8, :57JND.0
M-C]KN4GG[*HO"LI\?9"QX3T*O!<<Z6%H!<RS5RS5C%+M@CVF.HUP&SO;?W^,
MG[+]91"FGBG,N]NF?6XT&7<*O8X\3^E$GG3E <OU]?@-^7$A1RFF!A:K#&S,
M.G*:ST)9TE_>8>QL__U!?I;M3Z-*SM/W;DEC0,@M6(T0YD$>AP-AK\N2OTEY
M2S,^#.67_?#KK/GVPV^'[RG;WUN"6+R%5F&$&3=;L!A[X%&M=X7J2680_0':
M;CZT-.,/NJ7_VD5.NXKYWIW]O5-F5[**'JN71K'E.CV9,:3O7/\!3[ATGNN7
MVK7KVOLPC /&-OV3TCWDU%J/VJGT\O2LY4C5S$WQA^XX2CX=#VXI4D,V49J?
MY,K,UCB-N'/]AZ3XE.NGX<URR4$0/&"W$;2DZ4B6!#9&XWFSGIXE[YW0#T/Q
M?]#9?Y4YWC'&S=@]R_6/W%W*)+;)6NE>-+BM7/^(W->&CE3RVO5\J%VQ&]X/
MO=#=1R_("5('9%%/.LH0B-,OH]'^LS7/.PUX0,9/N?Y*"E@[A%IA,L[3/MND
M/LP;B[&F+"W;TS.\T7+U'J8-^8$AGV9X^66-#;&E:A1C29)8BM7LMG/]]P?Y
M6:X?TJ"6<@M>.06L\ZQ6RA98^W3!ULH*Y$5YVO,[CT/Y13_\2FN^_?#;X7O*
M]0^/FE"7^SWZ--)H05<7;-:FR;.[0UW;$@\U8OM8G?V7=;]^]O6W__3E5];;
M%W5K?>UK[&MLK:^M]74,[^?=&(=;&F(Q,]#T>8D-%!0S6X?I$XW\'A7!'>,<
MR4G*Y^7"I-5S= \E#@RXMLR:9@F]&W/+13NN9.4;P#V\_,"00QE:1Z4R?6(4
M0L^%<J49\5!LP.\C!;8A/QCDIVJB4N6N*8<9N.H:<>8@WF( L=I*J8E:?=$A
MB;(AOS/(_^)UB8PKK?FZ#_-7GL3OC,:M.#Y5%C-C(V_36 /V@%3B,M8M&,Q[
MVKTI&CX]7RHL_N4&^*@ O\)*&YL-=(U%,E8%R:5GJ=4FSO/_>=<4[X_N,[6P
MG#D"YT!Q27IBA-5!0$%Z0<%A\[_Q])S?"!PI7[DA_]!S^@3S.4"HG WSC,TZ
MY40NKJT)9]TUQ?N#_*RF2+&F.LQ#:SI]\<83<( :J@N(5'6J2V[H#<+NT'T8
MRB^ZXE=:\UU3O!V^IYIBF3<"LVAHT:>1+D6"\%+X3$J]II%,ZHML[Y&:^QZK
MIKC5P@YTLKWKOV22U@?0H&[HPTP3<QU-'2@BQSU!=+PS#L]+ EBY(W8(/0($
MI#&"RSSGH+11 9*6Q$_/@ELM[($IIFRY\ P])%5,R@8#8D9.:$Q#ZYX@.B3%
MIYQ_EA$;U!$RM^FHU,S!E_:0E95D&#5GM*=GYJU2\# 47XPRKC3'.\JX&;NG
M/+]7:)2R!ZXRV?5&TP)S"]FLIJXR;^F8%OCMU=6ZS>Y1V+VP&J1QSEGCO.F"
M3$6&8J]C="0PD+:3_?>'^"G9CP+4IH,=9.2).$$*;L5"+;$C3 ><TEBC!92.
M)$2R(?_0P;(,BWG,1Z$)5B(SF*=]F[X9L6.M.]E_?Y"?)?MCA]9BF[&S1@XX
MM 6/989, /,0;Z/3FD" -PFO3A=NRH]"^>75(-=9\^V&WP[?4[)?W$ +6H@H
M$K"(!=>20H-";$99"TQ\TZ%4>_=,P!8+NU6( I8;9&K>,Q9@S<8%^G1F"%A*
MVZ,!=W;\E?,Z .4T;VA=N0>, 3O'8%XA6"3K6?H\%%]"E*A[^OF!(4\.1BXM
M%3*L+-ZAREIG2)F\HNS1@/N#_%0F .@ VE)0M!%0TIK_Z12HU:JCEUC78H()
MN6S('P;RRQ'*=<9\1R@WH_>L4. =4[46H(\R3;3$X,5'B#TG["3%DST]QT,U
M(VUV/[0(41[@WMK\/\7<Q,52X3%1-G>SK31VAXB?"@6<4QTJ'JH13P/M%M0(
M0FOL5=;.@1B?GND-YFV@'QCR.OTPR97 *:'RT Z$=?KDN=49J/DN%-P?Y&>%
M@CYZ&J512"-:0)VHNW .HY'FU+Q1ST_/Y4WAK2?X,)1?5AJ[SIIO-_QV^)[M
M$#=/TQ1+Z(#3#U>(0;1Q@#:P]"B:H3P]I_+VZFZ[.YX*:%_\Y@,#J!^@6/#'
M=_[F+^R[]VV2^^77+W,)G\YWNG^]ONOI^6]^\O-?_OLC\?*^'4IV:E]C7^,>
MKK%+H5L>[7M?M=(@$7,?GO(,R-@$LV*$TD%U_F&/.QW.>?L_O_V3,J=[U-[K
MRIQ"P*7T[*G[_."QV]+W7>-.\Q8>R'7;%']@BKNS]%ISY#1PB%J.P@*-3*2W
MX7O<Z9 4GTF<U00]2PKHJUE!"P4I)J%1J<,&M,X^*=[2*7='\2L%SJZTQUO@
M[/84G^J94$A;KAK<10,R0- ^[Y0G'+FC)01Y>BYOWRUU;(&SPP+\&JWA"6Z,
M0I0%,('IVJ,3DV&TK$/?9^9IF^'; WRJ5@*)@J^>02]KZCC&8$06:D;"VGJI
M2QZ%RI'RH)OB#TQQZ^[-M#&7@9S4C'1^4GOQ>9A;?H]:Y:;X]A2?E2/=L\)@
M";'J=*F[+XL<-408Q8HP<-9IAVEC_# 87U8+OLX>[V+D[> ]%2.SU6S)(9BH
M!VQI?F9E!!)*VCN#<WXI1AY)T7]+E&V)LILY*"5*RLAQ1.7542<Q]Y@-U2J3
M9-HY^^.=<;\[S]D#U\Q%*)01\PPSF@7/G8)523U#&@ O*Y:O7H^^IZJ/2_$T
M9C:=TM*9<,DE6RJ^EC)Z3RQ8\L[9'Y+B4\Z^>\V:VQ(]*=-1J6!!JJ5@*78;
M@PO$13%LB;*'H?ABE'&E.=Y1QLW8/67J^W#'>?R&TFE:X%8Y2,0> &U4;,LZ
MZV1W:Y0]$+R75$(K=>KJ9!V9DW7+ $5%R%?7^L[7'Q+C?SS;##:\Q%2"M$83
M8XW3AYXL,W8DZ=.?KO+TC&6+D#TPQ=92Z6E84C6L[L(E<;&:2BZ:&NU\_2$I
M/LO7IZ$$0RT,S[AZV"QH\55[J\-A2#*-3\\9MR?],!A?]*2OM,?;D[X=O*=\
M?1P\EI9.T(PO>[\H&,LRQ,JC#AK0IPW.Z4+7RU89VRIC#W:N70@R--:4H=LH
M":N)ED&Y)Y@1J&,IOK/UQSOA?G^>K<]417A8R&E(0&@Y^#K@ &ED\C) ZSS@
MRM79^MU-<%R*BS99K4!I!IG8LPD3-.DSR! $:G%GZP])\2E;;S''/GH/T#Q/
MBDL*$J$%4O L%+MW73'&UAIZ&(HOQQC7F>,=8]R,W5.V7K)" 4A!F>-:'"[!
M1I:@TP(SS9M)K4]VKX\P-KM'8?>"3E@J-E0K&G1$Z5HY(=;2/2L7LZT3=G^(
MGV7RU;6WR*&KK &X42?LE8.ARIAN%N.PI^?T)L5MH!\8\C'O9)X.-O?4,([I
MFG&%V!EFH,5.L'/YA^3XO/>^&$A/'J8'-?WL7' M'= PO.6!S6'&ST_/&J\N
MK&^,CX+Q92&PZ\SU]K-O!^\IE^_# %<NOR%@F+3&L(IOH2?J\U$>*25_V1AR
M)'H?3PB,'T4(['_\]///MQ+8OL:^QE8"VTI@1_+9+HD7&"0N2!EGT(U@60KD
M;ID&:_'WV8:T0Z\;>V_IO$XYIH<M)5(H$'5&7MJ"+CGF@:.,:HTU+A57V5//
M#TQQLB@SWEZ+67F&7E&&#R7K52RG5K<2V#$I/M4IDR<53Q;8>@]8C8-4\H =
MA*JT&3W;#,%V&O3N*'ZE$MB5]G@K@=V>XE/%DB)DX-&#)*C3%CL')?50$R<&
MZ4.%GI[U0AYE*X$=%N!7F&&8YW3L:YJ[.69<-CDQQDI4<_+X/DN-MAF^/<"G
M>F1,G*WGM<)DWB-42,$,2HBQD6>L)+:D_/A((B2;X@_=]#?0S7MCQX;@Q4J%
MAM%2R14H;R6P8U)\5HT4Z]0JCX#))\8L&JS&&F2988X2B_2),5R] 7UC?!2,
M+SK35]KC78V\';R_.QL+K-JJC4"#8L ER:F-6]!L @I+96/:X!3?'DG;?BN!
M;26PVXT^CTXQFIJSX7)*VRA-K5&.I#')SMD?[XR#/YDMXH8YE1&@SP@#)<:@
M*!CB2"!%%7->1US> @8/3#&1I.F0>+8QL Q3+SE.IDNC[LWZSMD?DN)3SIY'
M VY20ZHN,\H8<:D)81BY\/0[+69>:D+QZN6GF^*C4'PQRKC2'.\HXV;LGNWL
MB$,EEQ@BZ A858/+R#/20"<"C+RT1T#>;A/\,/!>F#MPQ&ET6Y)&")TDUSX,
M5 ;TI/P^PT7;!-\>XU.^'A4)VI# '3A@XA1T>E6A=-18L;11Z],SQB.)D&R*
M/S#%N3E'A'EH R*3>YJN6"J>:C2ON>Y\_2$I/LO7ZXBYL7N@E/M*^4$P% J]
MU,@YSAL9V[3&NF4Y'P;CBY[TE?9X>]*W@_>4KV]U%..T]+_Z=*6-.5BG%"H"
M>=,<8RU+*.?MD73\=FO]5@*[59ZO2,2:"1(SQA&=84:9!:9EXZS5=K;^>"=<
M/L_6HQG4G"Q4\[X.N!(\:@Q5:H:!67EU$^2TE< >F&*QH0PP/54O.%QM^B<R
MO9*<O6ON>V_',2D^4P+S'!V*A%2H!<2*04JM ;JZNRD/7Q1OA8+'H?BR$MAU
MYGC'&#=C]Y2MGX?I?#9C#=V3!HPJ09#GAZ*I)/4>+3T]PZ'T"3:['UH)K!-T
M@!9+'N@]J7)$X:C:"SC23M8?DN)3LCZ76HK9"*WT''#4&&0 AAA'E@:&W?#I
M667K^3TPQ<2U@E$K50BKF"6MJ4$J7"R-9CM9?TB*SY+UK?9YXSR%,=H(.!_9
M8$5ZR'5:8]:VA+.?G@7VJ.K#8'Q9ZNLZ>[P=Z=O!>]9<+\8:ZYI0'100) >!
MV *MQ5D*Z@:K\U3?7MVT=L?-]5OJZ[VEOG[UB\_^_N\^VUI?^QK[&EOK:VM]
M'<AI>S?V\I*+Z/#4$F.-(M-E-]7:LW,;_)^M+-ZQUT=PW\IY);*3YRC @6RL
MN>;IQSGKF!\@4L^M8=.U^'2'7@],,8Y.:J7BR!FC#ZLT,$Y7OHT>RTB[$GE(
MBD^52)*4ZU(5*4,DH(O-&$PE=(?1.#%Q')/BO/.@#T/QQ03*E>9X)U!NQNZI
M$ADA8RT80Q<J 6EM/&V- XX&D)-RK_3T7/9.HL=A]X(?+>J-(J:>(^;4C7!4
M4^K3*Y,:^]Y)='^(G\J4TX^.ZUZ&YDN*4[P&JS"".O1<5*4E7#N)<CE2CG1#
M_L%W$L$TR-1:TCX? C!/D+35D;FD.L9[%"HWY >#_*R*:<"K\\M#Z=$#MNQ!
M\TBAV^H*F\:]PG>;QW0+9S\,Y9?=\.NL^7;#;X?OJ8XI#25QHR!MM(#S7 Y.
M*8?<J9@D70(,2T'G4([X%@G;(F&WFXI&JBG61#4S^B#E6',AF]1TSR/N9/_1
MSKC__=F_G2?[!3*GN 86B&8<,J.2X%)2*#Y=E]RHT!(3![I:!G$/11^7XM*1
MR[SM/0(C=73*,R[!#FU8BXEWLO^0%)\M]@!CYM)":@762@ ,5B;%=5BN=;@D
M*Y/BLA5*'H;BBU'&E>9X1QDW8_>4[.\M%^TN 0AFD!'1@R3I 5AH0(*<C-?8
MT9&$#3:['WKLR)(UPI$L$V(IXA:]\<H"B_ H>^SHD!2?\OG#J6'K,61O:[MQ
MAS!-<@DV$ILJ4;7Z]"S7K];:%!^78I?,-3E/?ZM.2\PZ/TDQJY3!$=/>Z7%,
MBL\3]L,KJHS0K9: R#FHCQ00/).5#K(R?K0UPAX'X\MC1]?9X^U(WP[>4[J^
M#ITA;IX!<%DZG3TM@3_LH=3"K?;&6.CI.97KQXZV1MC6"#O(>_N:9H-IQ-2I
MQ]HCYC:CSH&#JP!9[UGZ3M8?[X3[[7FR/EI,0U%#!:& R6)0FBY*LR(L;#6F
M_/3,:7?F/S#%\P)82XO5:.UW(7&H535"F3Y*1MS)^D-2_"<;/71(7+NW7Z:C
M=0232$$5K+LVZ^0SQI!-\<-0?%F'^#ISO&.,F[%[2M8/%6[26K#<-& =OE0Z
M+:AX&G5@\5*>GO%0P@:;W0^M+J1MU+(TQ,UQ_L+>!0T[8JYUS4CNSOS[0_R4
MR2^*O32) 6DM[6G+R4[ H<KTI630/+#7FH WJ>S%O@\,^8RGM,8FQ;TBL#O:
M=+9U(B_-T&5WYM\?Y&>)?DC$FEQ"2]._0N@:?#I@H8\LV2+7SG5UYHMN4_XP
ME%^6ZKW.FF\W_';XGE+]:IC[:+Z*[#7@L!*F8YZ#1A@T;YH7GC%TPA_T^N[O
M7V'LOY+N/Z3"V"]__I.??O[FDU_^_&>_^-4O/_EO]L]?_>B3G_WJ;S[_Q18=
MV]?8U]BB8UMT[$!^W(64S. AI2!!*BA5+1=M&;FNK1LUCUW:/)Y']_OSTB:D
MVDHFF1Y<'6MQR@B*981<!3OU&9H1K1VK1_+G-L4?NK1)%4"+U#@#,BU%1LDS
M*(/IT,,H479I\Y 4GTJ;X+W+/&Z#>FT!B^ ,T*J%DEP\-D30&98AZJ;XSBC^
MBU<F5:ZSQ^L^S%]Y(KVS*[>B^%3D1+=4H7KH'34@L :K/$(:;JWT"BSQZ3FE
MM^D=C/]R$WQ4@E\SC91+%M/)[1"<$%L4EJ'L),-C@5W@O#^\SS8D52BI: JQ
MKCUGEEO0DC@PMVS8.<U/5ND#\MXU^L"0*Y?IDT%E: .YH.=Y:V.CK*@P&NX"
MY_U!?E;@3#D62@PA%_*E'(K!>ZG!-;=>E#((OTB/X2YP/@SEEV>9KK/FN\!Y
M.WQ/!<Y"37-B"I;6/#'''CPIA6QEQ-JBQK3FB0_5:+B5Q[;RV,W<ET0V.%&3
MZ9H@,HEDS)R96LX==*\9.> 1%\\S_D6TI58]-/<2L&(,WD8-5BR7RMY\;7C,
M\>H@9(]:'YAB%Q3'&81(0LTZX\\NJ#9ZGUY+C3OC?TB*3QE_Y93:C!Z#I-)7
MW:X'T5S"8!5&S)/P_O0,NG5/'H;BBT'&E>9X!QDW8_>4Y]=8P;-S2%0MX+QE
MP:FE$-L:9HI:9P0R+?#;S>[#L/NN!:YKH1=FDP2 M;&MX0:<%K?@9+>_3ZY_
M6^#;4WQ*YPLF)/06YLWR@"E-6[Q*=NS#9'K1WEM^>M;K]XALBH]+<>Q5&5 Z
M=<215:8;O2KM IY8W;?RV"$I/LO7-\X6BTFPVG.8!W /-F]4\%1JL2;-EO+8
M%A!\((PO.M)7VN/M2-\.WE.V?I12:T0-SKD%A.C3!GL/CJK09B34?6WS^@#I
M^JT\MI7'#O+>OL(]:52]EMP(**%:E.:Y=P>GU)<^^4[6'^^$2^?)>G5,-L8:
MM<099$2@X-E30,VUMRYU&#T]\_7>R>XE."[%VB(7K#Q\5(S=IU^2M5HG$*ME
MP$[6'Y+B4[(>,Q3(*04M, +V&6CX2",HY-$HTA!>^H&X*;XWBE_9GG^E/=[M
M^;>G^)2V-T&F45/H+YD"MLESFP:9/68A;ZV!7-X.OKOS#POP:S+V<31%+[TZ
M(QA8'84:BN78U<UV=_[]T7W>G3^]*Q4.S=JTT;%JL+2JZM/SIKKVQV)\D1^3
M+3_VP)!C!T^T.$\=^U =O4@I8N+DW.ONSK\_R,^S_:"D==KP&52W@-4XN'0*
M*:<*W).K]=6=K[@I?QC*+^?[K[/F.]]_.WS/%H-'3C;#I3 DKW18;4&C84!5
M$\@Z'[ R\86]&/Q[8X\OLO?+?_WZ'_O7O_M>6^_W-?8U'OD:NRZX];J^[_ &
M&L)T=F*/UC'G(C.VM82Q5,S0V'=!\'@N4#XO"/98,^0!@2C32D)2<,<>M*K'
MR#5K]:=GQ:L7)>[PY;@4NVJ=ST"/JXS0M7C34G/&PD((@W9!\) 4G^EU14NE
MZL0600(6K,&7?!=S] *QI:@T*4Y'"F,VQ1\^"7&E.=Y)B)NQ>RH#YI24/7I8
M8CY+(0"F!:8<BJ5*5'6T$M?TSM;:>QAV+[3D8!KLI7I41"K)FF(NA0!+1["Q
M:X'WA_BI%MAUI-Q*#YG:-,\&'*28!VXI623U>:-7+5#D726^#?G#0$Y]XEP1
MHXFC#96<A\T'H)8\'$;:M<#[@_RL%JC#BK28 L?, 5.6( S3$V_14QV11])%
M.>Q:X.-0?M$-O]*:;S?\=OB>:H%.UML\CJ<?CKQ6@E)XD<#F-&)%!T18#3M;
MJNM8.?XMU74S_Z53&T:)HWO$+"@:&Q0?7.)@D/(>R?[MOQSI ,0_T?$JS&0P
M0AQ4IOM2<["L'+RX+2%9T+C4PM_@]?M2]^CR<2$OT)1*)K+"TVG).F1&*$1=
M(G=_KUK AOQ@D)\*!5PUS6A30LE+9 1J#\JIAQJ!Y_VN(#E^IQE^=;IQ0WX4
MR"_&*%<:\QVCW(S>4ZD NF#R>?+:R_2NM!J<2PU<*T&ID+$N+7!^N[4V'P;>
M"[6"PC:8>LQUK,?!,65V'=-18V4ONU9P?XR?U0IJ+-VDA&** 3NT8) H4&Q2
M6Y2N6)^>\0VFJUMR-N3'A3P.J]++!#U/-]Q%H<4Q8E(0:AAAUPKN#_*S6@$,
MM-1EVF^8SCCJM.EJ,L+:E*A@380FY?E-*=N4/PSEEVL%UUGS[8??#M]3K0!!
M.K8!J[87EP"'!2_9P^C#8E?*I4Q\ ;=.V*%J!5LG[%;2!IQRG,=7GOXK#H_6
M>HO8#4;I [_K=-B5@CLZ_LIYI2!!B2D/#KE:#9A6.U.S%IJ0&["[#5^-#KAE
MQ!X9\L35,\OT6V:(TDH1[;6(Q;:DAT;772FX/\A/E8)YA)-HG0>TPUH!;AJ,
M"8*-JI9&IY;E1;_D>D'R#?E1(+^L;'"=,=\1RLWH/:L4P$#(.)FE&:6@1 HR
M:@R64S(>UM3[R^KO/=?W,/"^:Z&YU)59:.:EH3+(2C'8$,T<2:+N2L'],7ZJ
M%*2,V*FV:9<[K,5[%E2UA P1:V?5+--"\QO0/3KTP)!#F=Y8+KWWYMA&LSS/
M>/$,A(;1XZX4W!_D9Y4"YS@#[.(A]A<_/%&8(58)A#5G16ZXM'[+&XE[N/=A
M*+_HAU]IS;<??CM\3Y6"F*Q6JQ;,H@7,-#\;L.9\W:L5[["F>Z$<RA&_]51!
M^^(W'QA _0#5@C^^\S=_8=^];Y/<+[]^F6OX=+[3_>OU74_/G_WU/WSVTQ]_
M_M?__EB\O'>'TIW:U]C7N(=K['KHUD?[WFLDR;H/E;7\#TMTZ0[2A#.7F!W>
M9V1JQU^W=> ^_^UYK9--,BJV$+/94HA=T@V0 DG2 6"MZ R_$..!W+=-\8<>
M?%RP]DQ903%7,%M[M3/TI%S'Z%L?[9 4GQ4S55R</0ST."G.%+Q(#YE30AXX
M9E@]*88MO_(P%%],H5QICG<*Y6;LGDJ9["Q>20.7EU9IA\ENA[!N9!:65E4G
MN]?//&UVC\+NA4JF$O1*\Q2/!96S-RN<JB8"HN%U5S+O#_%3)1.T-2>B, I-
M)YOS",;( :CD:$-J'[JFDG/$#?D#0\X&N28J-0-*8FO#9(Q8>@%LV'8E\_X@
M/]=':]*,LX2HU ):X^!QU/G'&62W&L= 6I1'WOT*#T/YY4KF==9\N^&WP_>L
MDFE ALRA-X2P*L_!K?= 5G(Q-.+>GYXA'DJH>.NC;7VTVPDS4!NUU#$2%AR8
M)&462L8U>B-ZGZFG[:+<^(S[W9\L0_$Q.(D&]>HK#J&@RPAQR6;)6R[1GI[Y
M^K&F/9-]7(H+>%]*&]$*XG"5/&]XJ2 U)XM_<$YVLO]H%)^2_>X9.@.%S)!F
MG,$P*18.F'N.3;C.>_KT7*Z/,C;%1Z'XLK+"=>9X1QDW8_>4[*?28_,ZPL1T
M+%V4%F3>KM"QY^$=J5.;0<8'F%O:\!X%W@N.M$5-57K-'5>93FO)N#HM^GP*
M4/8VE#MD_)3M;\Q:H<10YJT,2#S"M,C37 - 'Y)L^MHOD\6PM8\>&?(12VK*
MBN3S05 QGJ@;JW/R!+JS_?<'^5FVGS)0+%A"!%QRXBY!0""L0@[.(SL-S"O;
M3WAU36]3?A3*+_OAUUGS[8??#M]3MK\B.J_JG M,?,'F9Z5*:(/[/*Q;-)OX
M@KZ]>NIP*YQMA;.#O+>OF;J&;A%,6T=%(] !ADW4,=M22=D*9W=V_/W^O!"
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M1A&B8CVML<:0M0='&]MAJ[<NO3'8G>-#=,S*C&)QK1PHE:D4 BI\#J2S0?5
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MYC*N,#6U5$L*DU0%7*5@9P?YE8_\R3Z7J@$K *.:T6TBJ[]BI6.PZ]XA;/U
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MX;&)'<6KBV)+K'DM%DS6 NE*5L60L\RU>C0J]#; *XGBF7Q!DR &'XPPX+*
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MFU>\Y\/# 7/89ZRURJ .V^KRM\-1'OSO*8V:.F/X-YP.Z#"W;^3DF\L(A%1
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M>SKQC6$Y<Z9S846HF12A!^5L5!!SB]^$*",6Z*&:-8/X;*@F5R5C=B P)2]
M6Q#$/$@XD-E "I!1,\CEIKIL<Y\.\M4%^?PNEHNI\F[*+ 6ZTZ@/;Y&4!97
MB S=%"N#&*4HLI2LH\8Z,6:@&S/O=+7__H3B?N%_\_#O[?.5V3UEW3),9S\W
M5 P/3VFR5/^<_-G91=I\\[<7G/R>OYR=VPJ*E]T5:1*"=;5UM*BEA."KQ.+L
M$[0;,V]:^FKHMAJ[#_;N#93\/_\/:J5_&/SSG6>_ F'PKB;?*:.G932^G?[W
M=#@>ML4<WS[,=X?CXZ,W/_+W:?]H?#HJXSW^Y!_WC])?7UD.[#XZEP//]A\_
MO_=RY_G#YSM[/SW?W6,\ZAU@W,..OO=Z9^^O%X__X$_FSV9,[Y=_/7SUYQ_Y
M.&IP#W[^G;%^[]7NSSLO=_[84;MW__V</]<\V'OZ^O'>SLL'>S\^>ZS_'+*,
MJ3M[O[W<>?K$VFS!Y"IT;7F%15E!((.05B7%BA@UTIFXYH-9\NW&I6JQ 65U
MK>@/9+$QR\"<#$QR3N9L-P:%I>LQ[\C)Z+1L;-^^\^MO]Q_=W[O_8/?1X/;N
MW<'=^[_?>[1W?^^WA_<>?0B$]X_YF[,Z@?OP,+-TOZ5PHDT_ 8ZEGW-EW^B]
M61"_@>AGU^O=];49"73 (C-!,CYZ %6RY3WQ*K6)(7=/1ZTEV,FS,JC#T?B$
MOS9]-OC?4QJ=E-'@J+:I]VIS,.0E*,<THI,R8$I[.#Z3P^/-R7OO'!WP(KT:
M\'JUUF-Y</+B:!#YS_)X<'1Z,A[F,OF[UGIL\(+),%^N_?R?9\2T.I73B;CE
M3WAZP+NR-=B;N>:HI*.GA[QV>4"#XU$1)_1R\)3X"NV54>;?\_</^'*CP3^&
MAXDY]G>#\O*X'([+YN"PG&RVIZ#CX]'12U;T)V7_U>"_+F,\!&W1VZSS)(,V
M(R1= P":&G-.[S<?E"#A'>,!+V4\_,P/]LO1>/S@<$;,/*C-5C@9J[=L(WQK
M0N;Y7Z^>\-*2S%8+E!D%6%-$]/Q=9-*0LBJLNMS&MOQH5\$XW-_GG[8&<W3D
M?-BO@4RX),8GZ#Z#^KL8E^\BF6%TO%\F4.;?TE0#3L"TOS^8,*7QX.1H\@?#
MPP;\X=/)C?$GM+<W_C5@DGY0_N*3'C<'+Y@S/QL\H_'@X'3_9,C79YPT9/ "
M/IT( );*_.\;P4+[1WS;35H,$A.RAOC"-W7TJO":5K:N!__WQ^'12>%KWC],
M6YL-9DU$G(X2?T9A63%,I=WN9=".1-[EA+9"!A\0R=F<9.LN@;XX^;ZKP.BP
M -I_/!WS-H_'O.IQ>#AY\#O\["PN1Y,?]IJDK64T*OG;Q?[NWF_J2>OTH8,J
M0EG'V#=:-U.ABF0MNBI+C:VYMIR3'S9X"_NF52H-1X._:?]T<C+>/]LO^&SR
MX3[B,\@GGP_0 8T8R.V4\R4%'1RQ8?"ZL6\^JB=L%@[;MS01SILS?W__/P__
M#QT<_W#W[%!>Y@ J3S4F65PH!EJK"RM]-)6,JY 2A2?WK^?</7RK9N\W9C2L
MP_:89WIG0H#Y##+Y_85_/=SGU2IC?HVI5K[_=B'._GBBB??89O[YZ"B_X+7_
M=@_N\Z2?A*B+J5(*9U7@@XLH*'HM0D89*0;%TOIS!_>MG#N@5RQ1!X7-TLG)
MXW/))*@PZQHTR_:-\#VF5XU&C0>GQT=G/&OR1VSO\I$_%Z4LH9DGIR&;N*_/
MU F=GCP[&KWY:7P&EQFJ=P:.E%BL-W!,A"W_8A#?G*5VQ?/#-&#FQPAICLXS
M>O8ILG?[[9WOO[JD$FK<DD_?I*WMF"_/BH$_[/<RBH-'I_\_>U_>W+:1[?M5
M4'Y+K"I0@XU8XGJI8B0Y4:ZV2+)G[']<#: AP28)#D!*5C[].^=T-]  02U>
M0M'AK3LS,@D"C>ZS+[]3"ITB= .CF^%-2:'<%N4X'21C8%VC+,#!SY.*%IVR
M.0-ZS?D4= ?X'C6UF_)]A"HM0+_(!X))>I,7BPK8_IJ/0>/=X0) "GS['3SF
M*;W2/CPQ@4>W[.5G+]E"%L?)D">!PQPO8G[(0Q\<EX0GKF.EUG KV39&LAU?
M'EO@\Z=A:@?!T!VP)+0'V)\-MOB0#;(T@_,<.MC&B[)M>9JLDFVF<27W\GF2
MT_:D+X_MTS\_9$Z2<-=.!E&0^0//29,!LZ,A'#SSX3O;S5*&)[U<+-:<=$$N
MNA I3S?+-TQV["W :)_.-<'Q3R8A%T@H]6.66ID[\+B%%CR"9H/#/'!#<+5B
M-\T"[MU/0J03Q\U6(RWA7O]3B$G[XA],3'_> C%QW_&&J6<-DLP%J]H&.@('
MD ]P$'(4<1:!AXC$Y#[9'92VYT_+AAV'$YK?R5 'VEW]MB:96L^.' ]H\<<<
M3%>P:]0;5*_A_=_BZS>)C'\P:;VY/?GS@V-[+'&<8! [?@:J+O$&#'.43F@E
MJ>T&OF_Q^XV:W>7XHO&T .-C,W+A<\G(V<;?E)([XE=L?,SF<\S+3=,]VN0K
M\-;RYY.!.]U3A/NG#=\Y)Y-#Z_WEGY_?[_]IO;L\OWYW^<YY]_'PK^./5^Z[
MR<GX_7YRUR7<DWU<!UYW/C[9?_WI9/_\^N2WU]<G']_GQQ^/[S"S_\YY^^GD
MKS\R.(&_CO>//P0\=!*6A0,[LL!("SPPS"U_.."IDP5)XGJQY2REB)P,MAGH
MS T=+W!9G'+'"NTD#!,XH-3IIN".#GX;'1EGYZ=[!P?[AR>_/9QV6TWH_?'L
M!Q?4?@%XWS0&XK$=-_("'C.7<\:Y%87.D,=Q\&*-O/%'<3VMX,7(8S;4O]"*
M45$84#HY6,/5(J[R- <7&ZV:DN+IQ?A&>/XW\#&H(6/,;JL%7DTW&+-\4ADE
ML$-),8E96:2+9%[;1W>OT)'GXS%/Y@L,"N$,^1(_;B(_K^#!L]DX![,<\Z&3
M*:('-N$'8;!/!+.] D_MAI=35!L4J=<"_O!E<_T8.10?EW".*ZM K;(YO%5>
M<1&VG\,>4^( _U>&-@I\"U9BS&=15DH;@W)6P9%=8W_!5;JAF%X5^-(YZ.I$
M>!.DNT_?'NX#]1MPUO ZB(2H-GI>POM6QC6[X4;,.28/J^2:IXLQVH\E*-8Q
MN^/IKM'*/2I2HSS'I  =#I?B$2R_)*MH"54^E]3,Z00K&<@Q8//Q\.4ZX.G
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MJ3"]2A4K@QD#"QK(<SX?<SKJ5XIFY7,4\20E\,E &NDD[2CI5];/FZ;_$D)
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MUI)W+/&S;"QR-4O8/,K;HF-46V1V@CI"4X-0R5/"<NUPMG@0XCT([D=0$ER
M F&@23.BH4G]1$#AX$6$O78_#S<GTP"$:<"TC\VI-&AK.C"6Q OH3;*0U4-(
M:&,">I#(M]K.P \/JY(A>%(=/J3+1"AO*>,2B9N^ENPM:)X2#NK'!"V&Y**0
MM?3VL#E!'PD(M*Z<:;0WS:8<"Y:7+#._+CDWCCB(C!%"[B9,T<P5G^)2QKT_
M2SE&=DT@W>D"P2@6)>+'E%)8 F4.)JS\Q.<T5J.J-$I$ B9TN6DJ4'[O9 ZB
MF!0:9%5]QKD6?_TV0EL72_5T0=SN>H<QDU IQ$,EJ&KD$ (XNW?_.M@K9$?*
M0'!]ZWI (2*6@>M(.5*X<CRN+6%)$HNQI >)^"?,4A1GUQR6TDDO.;9 ]\F7
MA6]SIT;Z-M0DLZ]*!(O'@-5)AO!8X2\CRR)EH=0=<^0_^2*_@[+O(UM<9ZV]
M1K,R'\L522O_C\7X3ENC=AL*:@L4,'A/.$8TQLNK!:U68FAI2ZM!<4#.U C*
M\.,B21:(\J6SFV/O&O_NL(G@WPE=4M6PATP\IW/ ?<RJP#[)8F9372Z2_FDX
M00"F51(5DGXG(5KP&P0!RY#2I1A:5,2$-5IH4=$,2D29N1)6-YH8@FU8<V\%
MG7C'YT)$(N6ER@%8$E9"+(F.9,)?E)%(_ [Y1%@0$A83IYSIABC]&P>;SVH_
M56A6/6O<=FND=,S;^10]B4($K$BC.=I%_%$=F* 2;)^^04I]5.QPR0A[BHO3
MKXUJ-*Y-L,-?%^-Q<8M,SH#UP/T%W>-K<5@IMO%UTQ)$'=5$/9^*.WB'373P
M:.M75=R9RNSXOLX1VED2I[#UA([71.!L"N@^1QU3@C&OVUV[ N#@[XE#/=TS
MZ8U&_<;AB>B3C.2SR#:\:S]I#Y[4"5(5J)M)>0 -_(&QE3L]5J6 >X'4A+(9
MS<<4O,,U324>F)"'JE*J=:^6<:TTJ88PJ5PF*AC9.S(U8-:^\BCM&5_GR&'5
MDA*ZA.ZFQ9UP/42IQ?@.AS< #X$8:=GEFE5((,-[N^>[QJ]@JYARZB7&W21R
MK:H!4F^AO\3IIS&[!L9;VO*E-VX-<U]*X#=Z1#**!!MFJ8(XK;=#JTE2-A+\
MNP :13M-()7JJNSKT#L\UTDC9D6!:R>>R[(PCD+;CX+,25V+69:H?[&&KOUE
M]2_;$O6'RV&.+P]O3R]''VR/,<>*W$'BA=[ <RP^"%WF#D(O".(D<K.AX[WX
MQ>WO-SR[O@.KGIA L/M+0K F/=NB$,]T+4NCLITNTVKL;K"YL.D0_Y)$%ZLP
MO*Q97EI1'NM0+-SO@L_FNLD[&B/0(TM1-TEWC,(G>$-R'7,%[-B%U&X *8$5
M[S#C)U<M\K"$Q*TY;WTKE(;GZL0P"I.B:H<X[PM2T&2GX)4>JGCF%ICE-I'0
M3EI1AJ/:ZOWIZES@S0J%+F;:8%1>3$5:E\T&;[V)-AL=%AEH= S;3?SR37P+
MK(RVX1F;@T&A6Y0-DK$6E5'!,,WFNEC,2I (*V/'X,46XSR5.70-\+/7["*C
M<THB%H,2'9L-GL6I(E8&74:=F'PW(*R'')453-$M/:>I3+*+.O#1#E:W#)B+
M7;3&Y P$FH8!=[UE=9DD+ER3T,]>[I'[\QB95A5ZQE)S]5<Y2*ODW='!R8&"
MN#IK&:J_"^J3V;679[]?[!#Q_0$VJXR@6>9JTD.L^+D@O4>1CP"QGZ9C.9JC
ME=5IH+V5 J181*]J0+1DBDD]2&)M\_<1)8OWCWS\!]<SNM:VGG%U/>.#]8F=
M>L;8<EGH<7_H6X$7^TD<IVG*?-]Q,B<:VO::-L$>=H;)?:?8X?.)H0TW$X*3
M#FIE#&W-]MG7;NHZ]_39&+D;O8DM(]=4V_E80V1CD@C#+RKF >NJJN##LVM6
M3EC"%W2,#U?+K@Y.KQT:;9.)5=6PR*%@*$K!QZ!2B!33J;R>:"A2[2K+5R77
M^5_%[+KD4^J&2L"*PV@O9=F-2?X9?LAG>56D?#G($^>S HO;#C'!*/PV<H7*
M,J]'HG5_PX!0JLFN<50'?.O^UQXOK&L.G_'IM+H;WS!:[1Z< [R56#E&V')X
M&+@0N\8I&=9U40L&O!NW4:LF69G8T L[-J2,>*E(:9%@WCA;8+)93'VA^H#F
MA[I;'2_F,A?1'$-==-H[T:TILF'J2@KQ"\QL\OKQ(?][90A]4:6=Z#FS_#@=
MAI;-X]A+N1MZ =J8$?PS<^TTP['M=H13NP?BCW88?1 ]*HY>3W@OJDJ+G^^+
M<I 15H/P]"T;+W@=0H_^<2%T6/_EFP\N<YGC!MD@<U)KX V#!$/H]B#FR3 $
MOP"$3_SBEW!W.8 N4HK +V,91>[.HJJ%%59T3+4\C4I3"5F%3( 5+1@U!BX4
MUS^%IL(P=%T_"KRAYWA>E,89S_"U[#1,/" VI"D'Y\ C3>$?'9H:?B^:\O]Y
M-.4<_Y5\R#S?<_R(#^Q@: \\EJ2#.(OM09C%"8?S"=((82!WPQ4T-9$TE;=#
M/!3S:>='VNVUG>R?EI- I/82Q!F-8JM+WU4BL05XH&4326_DE1JB)8. VA S
M+(03$#1X.XP'PA=I4Z_9']YY(*?2C+EJE80^LO1SPVW1U<;CFN% -]UTE+5X
M:%X4#.=!3^?FEUG^+_\X.]QYU6_\B]$E<$&=Z,/6.1;+:9)4E##%@"@<_?9
MO^) ?V5WB SR6]\D2Y:!E9H+6?/\.L\.*"'>KETY*A; ]F",=RO75^5NVKUG
M-"&Y3](>HU;HF,%4+MDDGS1U0?><8&GCO"B[[W=VG8^!1\:S:_1%="]%Z06<
M.5Y@;;=JKY6Y'OP.C 9C! ;#&&O7&Z>&T)Z:4LH&,ZF=5:E?6RM$UQ-OP&\M
M?WQIV&D-I*87=[9T8@-!@=NX9<TOCRFMUORO5M99B$J0SQQ]<ZV*5B55M9^
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M-9TB]8O19WBD0B"+)ZA2KE:*31W"3Q3*YE)NR\!\58PY(7]4,W@J53W757G
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M$8(3%LW@AC?TEB-L3,HKA0%&0XG1_D,3C*0U2)D^0L: 3SVJG9XMV >WL@%
M$>DGD99<Q>?/7Z.^?W=Y^-L6@.\+=FY5YO=O'S2'(;.I%'_M42(*O*G!:I(?
MG$YQ=5=WO1$@>=&.&H*IU,-$-<OO"01;8KX+,=/2\!6/"\]0>5GH6!DO&VQ7
M0L?-L6E]![O-%@K.O(8_::J-4(I_5F5&](\=4\)054G.L>]=?-GZ3)008_/B
M.4]3E)>$58KF"C+WT3S=O?>*%4&Q\Z.=%J1HC0 MJ])4I8X$*5YEC5XL8O1!
M:V/T8J<VC6K-N&PCZ5)XO?RZT7$3S>I95DU$?4"8>F3#,7W?-CW':>JZ'&='
M*"T9OIY*M:NT+6@.,A6I-U3+LM%XO=8D"(7AW(Q/PM%2G?(K?'8=+2:[LCM4
MJ@^967&Y5M_"F_*69QY+)]D*[Z1:C,7^UL<C-[IY2:U>GR&T&0HE/OU8R&DY
MUZVY061<">Z2WX)=^?S8;*/5XKULMD37FQU;>?'+?T;G!T>7IYM.*>N'\]#K
M .\'G7SYQ]FA4/._LCOT'.@J8_2;]AG\HZ/"Z?/["]R^I$_]_AJ%!2)8'.43
MNA&N3GS2_U["MZRC].ASW&<=L*[@PB6LF1PW&A]#"JZVT.IF.VS+#)W0=.VF
MR!S^WMF<.E!MWA7PD<8R?RMGC!(<"B^;"1+\1J2GES^7W&.J3@=6==FG9K ?
M@8%^  -[I=9'IM$JT;7A9/?T]X!%G>6IC.?=W^PC,3;;[3[/G2]K]7>W?JZL
MG>(:G:?'-6YYSRLN)#?[1V#''TZ?];/C%G3_*ZHKA]OJRM75E0]62W:J*^W(
MR;* 6YX]##Q_&#%GZ%M)ZB%6O\?]8)V@^VV=M48Y?<G*HF,%@6Q.%_@3/<C9
M<YT 7!OM]L<Y\0<[6\&].8+[V;L=SXMO^ U;Y@=5)2U89OF2)=;:\L?F\$<?
MD@"!]==^!C,P6#R'M\AG,A^EW <\T$<0Q)8''P&7BX".QML<P[9YD^4[OANS
MI7A8PXWBZVUT;,.8[KDSA-.78FHJ.]K<00C\JS-,3\PN/0<R_ %B3/=FES:(
M%$6V<SL&\XOW[E]B\XX/+K>[]S6[9_SG?-,W\)FR.*G/=I&6,,00>OO>3&?S
M]3DH*,J/BJ+G_68T&'46FL9>/F97QF^3^'=13CDEN0@6D5[UU7J(<?)V9>$7
MF5Z@"A=Q7EWGQB6;LIBK/.M>4<YD*X'Q\OCR;$\E5>\Q'U?,$'W20*[>288K
MRMKUBO8G%EBM6QAOLI%H&FN7QIN\?6H:TG83OV83_W/>[ZN@J&JF3JS$Z0G,
MR'/-8=@4_<'?.^IH0G-HNR8XT1K$G+,CIFS)!I>M -D*D*T V>!-_,_YKEY=
M*EQ-,:",&^,\P=%N=:/;<D/I21>(3'6/'5^<M(O1S\K\!H>'UOD:O&)%S1M\
MM?/*>'^7+I;K7UZ^N1CMR.OHBAW5R":FN]'HU!:L#]56(.R8+)EX>88@VF#8
M71O'.$9O1!_O//O(IM.*;.H&-6TG2/SOFF#H,4[%">G!RLVT0C>Y-YPJQ=8N
M C=Y![_8@%+V4Q"&#=AN&.Z88#DYCF,Z=M183G:DV55!.#0]#?/?0\S_9V57
M;?*!_A LL=; \TML72L6T[1JJ\BO,14$]D2K9TA'+U$SMA]J%Y*0(BL0;T7?
M,C5E$T"OT'_48D_*2K6N*374-,,+7=9!RN5M^%X]J:BI7O'3QY5R/GLKHYT_
MU1LKUV5E@#5H?I.,Z'.(_VZTL_!06A0#"1J:>!,T4)\NJ[CM:7SI:?2 2"]Q
M:M/4O#YNW4R78(,)PVC9/UON^CZR#HW^_OZ.%A=>G#RZQT,V=M19)(ID;$YO
MAPQ//#^)](T:/3!R9;Q$< 24;\6WLD6V_LF7%\8\FCDU#(%G8,^R9,R+="FT
M:6JQT?8E6MGN2_75S@]D$__(I+AY-O$&G\9] "%;+M_<<.+SX_"5(6';0AAN
MT_>;F##\O6/\4.'=M?/X!9_-:[BA/IW>'LBJ^'N).?5#T80VGIZR'RY;!=,"
MZQ$CC@3RWTHTULA]O0E&1*]4857]\^=NV%N]!>0$%:%5D7?W_X%"\A94T>.1
MBM;--]9F\@T=X3,H-]GD[9/)._-9V&A?NY'K2L]96K[UD:BISUPZJGQ)&XA?
MQZ)<4?>,)<F]49$:?O([H4\J'7@!3R_^4DB4PNP4G^UH")4='$AQ01T?:1 @
MA65ZL7F6Z0\0HWPLR&.%*(]!%)F.Y9GPY]#U3,L1,QH=TP]LTQT&NT\FWHZJ
MW\XGNQ]!P]\B:*Q&T'@0$:.#H!%:ML_\V+="Q_>8"Y?YW&=)-(QM)TJ29)T(
M&EV;5PK<CK&+/L56+OZ-<K$?E_V!"6U-6_VSG\]&#'AZ=O'F^'#CVP2?Z19W
M<,PZ!I_QLM5;!EX^O!L*N'^LD;=F:OQ:6;:V8D8D,]LR)E?FYFW=6C=MI0)8
M@7P^C,P@:$!.X>^=WF%9NDK0DHJ;H1-Z!=;:)53?Z(/5HDE<\..(IJ]5E.OB
M,B*H]8JF+]^ZM6[:8S ]4!;5Z8?[I9">['SV8J@+SO2<Y- ?H^.SWJY__.(>
MB81?_SCR:/--I4>!YC0,1H2WPBIP;-,)FB8=^/MAJZ"&''=VC<W XWG\])$6
MCSXEP?>$620;KH^?[S"234NL*+"H@]]&QL6;B\N#D\W'C'JF6UUW%C?SU,('
M O\/#"UY<,;:WU:&]0 *ZDO\_ML563T'8MWDVI[5(FQEO55D>FYD1I9?ZVGX
M&_3TP_V&[:QM"RYUN0%1./Q(QC^!-F,W1?G<!:@RMNO0M5Z/OX[&(((W;5?4
MRUDF+^F['XP-?]@$2L-F7S;6;&UV[CY/5,W@=^*%:HD9JBXW8)])%ZI[>="G
M:1RS,;Q$\JDL4KC@:(]^>3'CR=5G1,'KZMCV7- ?BI-^7)M\XSA)Z91'U8(^
M85AEUS]\SN3XXPKVS7016S%0W7%9&@3]2$A0&>C;64L8DOP5&6FLS2/MPZ7)
MS/C=3]^H$N\YL->/*>U7%..Y5F3Z3H,2!'_OJ'*\X=!TW6$S>-$=:O@KU2*N
M^'\7<*OQ'?8ZU%51 ARE*'6^5@;,JF8'6(#6+-GD"%M5A*\Y4#M040>AY6P1
MCX&._EBD5W47\SEG%=(T.$]C5M:P+1H5UP'S+1U^#SHTC3R3?(_#) 4>CK)I
MC006CNTG"4JQJ@LG#R2G1<9KO)T'+^[@\* =7,0W>;&H0 )BD94FV!3"SG-7
M,,K<Z<PV;^N)M:B)98^AJQ>6K_B1M,2/:X0ML=:N 9[;8C)! T=4*1;"$249
MC#]K>:NMS!1RH4Z\]J.*'55Z=G/RR;W]_6MDSU5%+<NE+%NF_$<RI1:*>B13
MMCI>NYRY'6+ZI!:,8-N"L;H%X\&6BDX+1N*Y5NQ98<18X@66&[$HL5,WLMQA
MQOW86^<FK"YN6 Y7*77Q8T:M-MF=^1&C5H(J+L\/3]YO/$T\TXU690TMS6D]
M>@Q1-UIHMF*)]PXIVEM*SZRS!&)UXM6\9R2EV9I)6<WS^4).6>K)/HG\[:Z\
M_-%9IQ40#^OGC(VNH7@Y]'QC<K7S=. :VW--/VHJ'N'O)5CRS3^<M6*3J\/9
M?62:3'+4XPV-S3Z;YUE\I ?+@3T>69JO%1<Y&S*;LS,_>MW50C^.0MGH/I^7
MH1VM5B@KF..'%&\;[45UC_&Q<FY#)%>[EG,KNK8TCS2/#3R3*_)E/.H/^O&E
MF!=\U9%ZX>:>Z0\ETHY_/7_S]G!OXQG_F6XRV?SM4=6M_A<9%+E+QGE2B:!'
MZZ.=5CSHU[R8\^1:M97\\>OA=YT4O51"_)WG1']G6GQ89-WK6#YCD24\2]NC
MUM2$S2IP$ZM^%=2B+BFSOL^JG<>M>JV!DM5#BT/3LD(JG3,"<VA[IN=Y.'+/
MCP(SL&W\,W!IOA[^&0T#TPK@VLBT0]MTX)]XP= SK8BN]>!G3D"?1L[0M.PA
M?1KXIA-ZS;4671!%]!^\&5P;AO1G:-GPI]W\Z=*?L++ H4^#:&CZB+D7F4[D
MPPWI@J%GF6[HT 6VBZC1:D @? !W]X;#=O!MRX1?AQL-0OF+!M?!I]-5<V[Q
M)UDQ'A>W>$I+DO=GA<!4%R,?\4]+\?9T-UUJFI0H3;O_7 G0[DB-:/?T4N^H
MJZ-)'\,9PUE-4U$*FY=T%F-0DO,N*!9.XX$=O^)MW;PZ1EZ)(#FP)LIS?!K^
MT_*!DT,JG6VUVGWMVC+0_=>@T%>M$9LN.DMS(L]T7%LM3?SSV5=Q->!$F$^[
M;_.^YPB')8MJ-+XIKC /"&LU?BV+XA,9@;B6$S9/5(6E&.?085[YVZ?W8:W#
M^/JQ(P!SK(/!.@\AV(6I_UAV;]D7%A@49'6TK /-?- -$%#QT@#1S ?-ZHB&
MCC(U^BP4S5" O[$7(!0?2\/ 1/ZVX#]#*S U,6368DE(*3F;#"CX:X228H5'
M2*5[LHL.&#ENZ.^N6L37 (K\D'SS?'&J-JWFANP)F:Z;2INMY%<%T5K2"YE)
M8#<UW8/P!YY(>"^*@.R8P:CSKX=]/"9O^=A!@%<E%[."C6Y"KJ6T5LU*AB42
M0,&23]D*6&3Y-%5\5=N\LLNCA^];TY3Q/EJSQVY]86=\,ILW\Y.?.X4,>XJ%
M[%Z!V0?UVM,S6->:5]^YV+QEC;Q4"Q'+H^^62L_ITQ[0LOEM007HFQ@?NJ_V
M_#&NZ5J1R[J!H4<W$/J^:]JV_PK^C)P0XPWX9VA99F2[KPP7C!:P2<*@^3-$
MY/\P&)I1"#]#@H9O' ?,#O])S2'N[G?:L8==4ZK77^=QK18*#Q@Q@E4?1H#_
M49CJ^79T;)H%0S;9F[/+\]';PTVU9Y_Y%JN@4PWA"#Y;#7?8#=G1,&#UK4@%
MG>0ST+#&Q74^O6.?%J"W=^6PQY>=K]92!OS^+ETL3:,T7KZY&.V8VZ$M#W0,
MA=N.H=4=0P]V '4ZAN*APZ(PM'CJ!-[08U'F##D(B&'H9D/+#]<UM$7POXS3
M"W;Y=U&.4S@>X*[CY:I^N@:XYQO, U^S:-_HFNK>;&I'Y-;>SGW!/L<:FJ[E
M-)@;EK/S"N-VD6W:3O,Y_+TC;.>(PH!.V,P.@+_;-?,;?K+K3=DM-7<W&(TJ
MFL(,M*[GL+9\)GUC-?U5Q3<Z80W!VK07PKG1BH3PF/4YW:'5) (U@/*'LH@-
M =6E9,_=^D&;N4%W[K%G'O!MQ*X^I@ANW1RQR1CGCVI3;ZCN:417FRBL!&]_
M( TV6IG\"'<)/?3O;H<%?<X'F8,I3R0V_\\43A-'\]OIVX/SD^.#DTOC[/QT
M[^!@__#DMXOULQ595D?Y)Y ,E#=I:K*D:3]K&>0F391>3.#*:\[&\VOBQ F&
M!<&&2/D-R!G\*;#:'#OY3../XGI: 0F(/D3U+_R5POE!,()Y19!1>9HS:@ D
M7E[$'\&600$(^PKB"P5960<8C?C.F#+1\V?"C@%!T6W'!2[EJ@ NF<IX-9\F
MVANU-2S^1+WZ8DJ+Q@M%7A0^OS.*&8?SY+O&Q0(^TA: T62:LHUW!2[,*2RB
M/3F?WG 0^U<J((JKR^M_BW#6I ")7P$?YQGL(;I6]15&7!8+."5X4Y$WZ]P/
MCB)=)/@N>$'?&^,VCL'MPDOXN+@%A45@#R!>JARM:8J!)V4.1C^"$<-97\D]
MP>.8,Q'\SRCD*XM_DOP&W,\9AQ_,\1GP4<HF#'^7$)!3R:O%6#:?K]X,^%GS
MIM],#JS%_[J/[T?P_K WQK^OBS&O&&SY68EQ\Y>C?Y_M&$?U#CP32;":6RM^
M0_AJDEO;8J'-O"^1'_Z@6_QAP'L:^W5>%)P1-BY \=(L^BD*D@*TLF# SCUK
M460:M[Q4-4ZL:I<Y@0K'=^7$>WK=:B,1,@D-EP@(7"#$8GQ#VA^3Q)(>:R2Q
M68DI#E&^W1@*<',EKSK+!/\)N1#X8X("1%AL6<D6&)N6,&7T?K=YQ64VCSQ9
MR;[ F0E;5-S$&^"3:"_F8-5<5<J>5#)99+73\1TP&8+H"8<NGV;"5+R?V%0<
M)BT75W KF9K#(IV[HJSO76_$G0&+PG\6L&RX 6TJO'"RD+X#.HXYVE@ESR?Q
MHJQD: A;S:5P$WGZ/,N4\(5;)6"NU/5I>/^2DP5<5>(,8?]O\.1 ZE924& .
M<E[7"<^8Q&]CT[LNE.!L48(0JVH[M_VN**3AD7 YO(\0J8)*-#'5?M:$@6M-
M62]\Z(S=B819_U:V;K]K'./Z:F0/>FW3 %EU71-DG=JM%Z(^*?D$L?&(E'3J
ME:R 2K@8YRF=.BYF5O*!2(S #H!TYY(U)B")\T&J(F^:;OG2R-TQ'!1+KA>8
M$$;.O,;U .UTG9C5,D"\ BYL @\5^)#H#?%4$,V*7[%Q5>![WC *9-#KX:9J
M6E(@0A83X*-;89U@BIE/I]7=^ 8XB.T:I\1=>&M!A]<,C I2XJ"V0"P(BL0;
M2C=.N!&P$4T&7"RS^^Q#Q,,N0+G>LDI>#-R)<3:1LB)GL8E[FAA97<S)N!?D
M+P]?4M%B)NBH):10=7.1%U?[O <+*D#SF$T)YVD)3*LJ_F6BE>AN6MSV-P3L
MW&>GC8[>C_214YA.'RN;:<4F_K@*_726%R *GI/F7NX4<2Q;C$V7@4T-5!4X
MJ"(4D-4'_L#PE#_.#MMJ_"'MW9"'4.'(NAAV_*P$ (9MI\7T=2DY8 %"Z9QG
ML'DH4X#[1806#H4^S3TW= /NN;;MA1X<6.B&#D]"'EI^Y%C<^W"(P1C;LMP7
M5. Q@=7_OQ?6"Q1H\$BXP^?YSV!\#-*"CADO>$&+^W\O/DX__GPF5/I1SN(<
M1.;='NTB&M5W)]3%<IKMU2NKX&TYW9V"S:G[]B[>+VZ.G/.;=^[Q(OUX<//^
MM^CCZ>2==7SYZ_C]Y?OQ\?[)Q]/]/^V3R3OO9'(P?#]Y.SZ]_.2^_SCRWE^^
MLX_<D_&[OV:3D_V#V_?_?N.\OQS]]>ZO*^OD\OWD=/_]]>F_W\-]/@U/G'>W
MI[^]<4[>AM[I7C1))J^GIQ__M.$[YV1R:+V__//S^_T_K7>7Y]?O+M\Y[SX>
M_G7\\<I]-SD9O]]/[H[<\S'__?SN_;_36>QX_LD^K@.O.Q^?[+_^=+)_?GWR
MV^OKDX_O\^./QW>G^VG^SGG[Z>2O/[*3R\0]WO_S _?"E,/^#^S RP9>&O-!
M/!SR@>\%?APZ7A@FT8M?L#+1HKR-=LZ_-/9:)]C5LKL*XCB@(V$SX*?[;\Y'
MOQU<'.YMHY9/EQ2F<?)F[]W)Y1:$XTM:I2CRN-V_+]Z_@W-A/@F^)Z.N9.09
M:7:.)@[0XD.49E 3Q>T432I*;W75#4B%$LQTM."KQ6PVSD$CZ4ZI:5RR:H(V
M(%A5XT^@O4"D&&?S.YD"IV,%=3])"E,WF5J.+1FNH.$Y152$GL593A3'81^+
M$G2%\CRZEI%(OX&=N#I2!4[310Y[SLI&,-(-:)?:=ZF]I,;#(D>SO()W_(O)
MR8B-Q(P7<RJ)'$O,?BEHZ]:@GS%HEX,_MT ?HKDIVJ/\FHTS\H"O\W%:$KQ[
MEG%"3J<HSPD'EW8./QS%%4AM0G2^N)NF\!U_98 #.<OAVTJDI&3<$(S710F6
M\+]FY'[")A8&^C-F4]_=.!.=PX9S7&1 !W0#_2WOL6G.#LV^T\!-$"<R INS
MG/*[RO@-4P*B%'=4?@)B9_"0U\ ?X' !<:3L&FE$FONF\3]P=(OD$U)2L<@K
MH#"XZAC3._#_LUDN_@'.!/QU NX+W@2YZ7=89'6=E]QLN07X]S'_G",AXM_O
MBO*3:9Q>Y_#OTT]C>/@$;G!1+& 3]]FG8@[_NN2?<8W_9A6&#>;RG?\-=&J\
MS=&D1M=G;WE?A:[5-E.06G>?ZF@*N$$M=Q1W,,F1B2AX>O>X &S3CT9WK7X&
MCF0QP]<:E?E?Q93^4!N_!T(,[#9X!1,S_U-,;R>+N78BOW$@>_SZH3.!E^;X
M/R7B(2"Z7-N7_=9G!O($SFB/E>"JX_.[9WB*)=Y3L^6AFL;Y=9%RX[ 22Q3G
MW-RC>^Y31*_GO":!-W,&/ITZ=)TDS#8]" JAR0Q5/A4R[+?FS-!Q7H :*8SS
M/%'% ZKDYV(Q ^X'8A!A KCV@F'E)1/WP8  _N>K;/S,<2W/3L&ZSSS/#EAH
M.9$5\X@%:>B[P]4V_M:,?XH9?WPY&IY>OOE\?/G..OD+WO3RZL/0CKTT''H#
MQPVL@<<R/F!IX@R"<)AEB1."9H_!I(]Z#'JA]52, DCE!C0G1GB)T\'\\*U7
M(@RK4PJ2W9,)) D3SP]Y%C,_\\#YBP-P,< /Y![G:18.MT[@&JCGX_&')'$2
M(!D^2"P_&7A1E@Q"EPT':9(Z@9-$=A!F+WYQS*C/(:RU"]%14A0E$!*;JWB?
M^OJ8PIIU6+()QA@OC_>/=G0"I" G]J*NB&V2D :IUPIRHJ3>%=1Z",]-4[*U
M133^#,/>4]'Z\"M8?'D%\KD8 TF 4-7D9#VX?:5-@O9=,\TZPSX'5+)Z X<I
MTQ 82:8HBTRMWAD3Z@(AZT<V=\@<8=,<,9>:G"+9DJLPB9%GN4BD8)7$C"1Z
M*P#9LOED<$>\=,[&_YKS$MZZH&"S&,'"ZW/1;-EF7;O&2&Z@R)9@>#IM/7'9
M3F[&V3^\C4_<KUA8*:V7G/%B-N94)D=)#QER,%Y2;)T2$60/?ER@'[!C&A.0
M3DD^8V.1*Z#6[[P4S2[T0C%\5'5FN&*#(YXTR)'!O,2NJ::5$8/&]QGWV#35
MLKS@@UK[JX-79#\O84LR##P+*Q]X@L1MU2089'\D(P'-A=LB(_B:\R7V00O'
MS(A3$]ZRNC.0K'"KE-Q.+&HR07AG3+9J\KEDGID8Q30%>PR;A;12 LJ6&>#F
MC97C O*8S\C/8Y1:@_?3'BT>J!(.\-T"3J;"W TP\'43HA<NU)4PY\$&0<;0
M,M<RH8W'.A5.)1%/,>5S+.B"?<@Y#KU(M_7'#]4?1]OZX]7UQP_6$W?JC],@
M\QTO<RV6A5Y@A3'W61R"2DT\:SCTLG76'Z,K"%Z]BG+(&07S=JY7K\03Q8]Z
M!<%8650RX=WNG 9M,16R!%C\HQK;AMI?SZ;6\9%6R8E4]_E$<9"H"2BO>,/5
M+?9O%=ZH*I9:L*'(PCX($ SR.Y19%5D(X*^*[DESN5+&-/A_87%$+B7'XJA6
MG1%*/U$ =$\@+LN^=R#NN==[4DMTT^\WE<&*.2946^$;Y5#7$9PZ@"/(0AF/
M-3$]PJ0X.U1/%%4=>.3_>Z6'LJC2CG,2#Y/ #U(_#IRA9]ENZ'BI[;E6PIEO
M^W[Z81^=$\NVP,GJ\5(&_J/<E$4UN&)L]O-1456:>[(OB'5TR\J4IV_9>,%K
M#\7_AWDH)Q]']O'EIP\LL?V$>1RWT!]X@>\-0G_H#Q(>ID,V#$*7#U_\XOG#
M)9]$N % W&/*?=]/-")<VW28-R),6"1[E!6]PVJ\',2AK#(!;P%K"<%.17EX
M50+%@?&)]A>:5(L2*1',N^96';/R@46QZ13NF% MNM;'+T5X1G8K53/ E\(O
MTED.C$>1YL7N:PKSR5 >.4F&WI!&]>]8SM/$[)I?*%]A3P;)3]FGL4A13R9<
MKJY^L'8#$7D41N^C.-?49&WM51' BG'+QV/\7['*WKQU*QRJ=QP#?\N2I3;&
M@EV_V8R5<U5UR6Y9+BO,RP7VKS_W!DX%,-#"B.K?YQ*,\_R&#NRJQ)<'M^@.
MU>"L .4J4@++M45*.M>=+J=P-@FO'?$#5LV[?KB*I=)%:9$LA&O9R19+IJIO
M3 X6IFE$1?^L +=#42#XGT!J<+CBGZ(R*EXH8P%-"N7T4-57G4@!YU 6""H>
MIJ(0U/R"5V-! &0<8%T02\G]U(I>!;!&B\#DFMMK*9K/P6PA7UN4V\%N2X='
ME/_AQP*R0:QK"@)DC(+G0I@D6(L]2H2\T($C'G&TZC2KYCCKPZ #-?8YOJZ2
M)*_S*:/X #RH%%7@+T_>[;^^V$%^JS=F6COD ^I:RZ=@*0'QT,Y0TT"6<7'V
M\ABP7B4I\YFL&IXVR] 32?BN>.DD7TRJ)G+3':VC']^8LW*JZAUIJ35^5Z6/
M851%T2VBRZOVT3[_]AF%6">PEE2KDMJ,!U1%#?DB-0'\4A"!SJ,JI$5B$(,C
M1)] 2)A7K+H)R1/,O6 3<ITWNEAD63'^)#\R92V9[)'*2TD0 W4./?6&ZFUP
MUB$O)U0A7V'YN[[PKK30$LS:V]<OC 6_)8:^,$ T+\C,(R[EQF*&'SS)++2<
MU/7L89SQR'/]81390]M.^#"+K8C'F30+?<L>B#]<JV461M_++(S^<6;AX>?3
MRX,/+MCH;L2C01IX]L#S>#A@:>8,F!UPQF/FQBQ^\<LJHS 61J%$:AR@;]PR
MK_HI5M4 H#=)X4.S-I*$Z8+TU2T,H'!6<W-9>UT]A?L$"_S]1/LX7P93+O<2
M;!-$/M?KS?_I[LWA7R=_'7YPLA#38-X@CETV\)PT&X1.$ X2RXJ<)(T9<Z(7
MOSB^>[][0Y2<IB!YJR[Q4H5[93;%_ECW+OWMC$MS"J,CDHA%!7NUK&44OA>:
M%76!>CVR4@ZK7<4[HE^I]A@H%ZUK#8$ )%4<V3W\,RAPH*=^?2?M'8);H913
M;>TH]:*@QX!K6[Q6&_PUKTGS7U=RAC L-L7V;X\H^4;V 14F/-$XV =Q"C]2
MEL"O<(NR_A?>ZI*5)9++\[(5OM8\< ([L($5G-B-0.!Z8>KXP\P:<B?P;=_A
M0M+:EI2TMN7:6_/@;\EK_S7ZD,598#EN.(A<'@R\P$D&T3"!_V*>$\7>,+%2
M[UF;"H]EQ"^U$[Z6>K=VPM]'T"?[AQ]LV_/L)&(#)_6' R_SK4&86<X U(&?
MVG'F1SP FR$*OM)FD.: /(MO8#5T;8:8C\>W7+1-HOE0K6:H%F:@LB-$+OTS
MJ_18(X4X.2L%FJ#S"%OB%O;C:09%PY'+UH3.D<_>?G!6M0Z;TFI('V@2TNJ<
M>T)0!?:8_A=(2;9>YE,A*'**6'6J%:J^<H7F&#K%I\MEOU2-6GW"<M)I*@M'
MX>7ICTX):+<XLUN.*6HLZPK,Y3A<<&\;%M*4[/:<,]GG3^_0W'P/#Y>EQ5+N
MJQ-E[11RMTLSW5!J&00W8*5H+Y1<UMXDK32Z%?Q:*G-I\T=C,];E/ZL"+&C?
MWU).5Y]@H6XU8W>XN*=H)7_HQN 9Q7829U[HQ6$0VHD%.LJS'.[[/I8)VM$7
M*J,5IM1!)7I;3[,S";2 %_QCK:F3C\=PKS<?$FL8@<H)!W;B9*!PAN& 95DV
ML-PL2;@-_JH?O_C%>\""JKMKM216I3+#W9*K;M"7R"[M-=194^@'!/X4$HO
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MOMVK%7M%$D[KH*U%-PZ<X02')> ,$4YL48HN\>7PP^5V<^_9W#;$@1YT:.N
MVKP:T?7-X P!EK67E\DBG[?43& N7T!M_.5$/JXM>FJWHLGO8&*:X:R,DA.,
M3-I\0C40^LVPFJ52THE/[V0NHY^&&LH1-O<*NEG^^82)&72J!A@S5F#(**M4
M&YK6?KG&2.[(6XR/8SG&'9_#38M*O@WVE5/*&"N'[D3A@,C1R[!XF5Q+2U]H
M_L;;:H0T/N@35RWIM57??2L1=UK>@U=]ZY4BBQ[:<017/+*0) 'Z1KA]K14S
M]>.,:H.I=P==-GT6S HZT>^JL!D,X[0V1^W0U)RASGM0-41:FRKH;V%+$*>"
MXMZWZUF@J0#H&D_=]M5#,3PD46ZEVW3?RXB'JS>^[Y$]+T/N)6]C5]0DKOG4
MBU@6_%#E6K-HUU*+%@5)BJP%)(%<FBR :3]Z4W)^6E&SLRJ0(GWN=H6VAE_2
MK9W^J9+AO2^LMJX/6\^K50MP/@F^A%?7S4@JI 0$MY1POXNRN+H#TH(-%%?7
MPX)@V:O"YS4".OA@!R#W$J0FX3_)?^YH.3<D9.WEVP7PDGG%!+D>F.\5+03R
M,70S]?>;"],X.MIKRCD:]$"Y000_* $&84/FDJ-PBQ=SKF&M:PNAZ*>4,+V&
MLCS>901K#7&Z!2.]C+DL4)];X=C5>!SZ*ZN90K@ ;4]1^TIP(0UUA^!\YHPZ
M36I4':5C(S4;I@&T:<.#Z+@W&,:I];9ZRR;<U'34X#7MVQ#J?%.FF'X$WI_*
MNKQI84R!3[5GU!?6M^QI+'C:-NE<U68B$JR>K2#96N5Y+1]50;MVHW6MK$T;
ML8C:GI9P1)2E86*!H@I&9>P&=DUR=-TRJT.>D\4B.MN61B]^%439,$M"%EDL
M<'SF>;X31ZYM>1Z/;#M,AJEHZ[= \%D#]<<6HNR[U ;_-;)//B8?DMAU(\;]
M@>?S=.#%5C"(AVDZ<&S/8J'ENW!@+WYQO54-$C5$64^BIX],-3=25F#]U+):
M6,.@R\G3YJ9JSG4-KT>L5?)J)DM4R;QHQH5NJ713J=0]_NO@@Y79+/!<?^ /
M S;X_^Q]:7>;2-;P7^'DZ9XG/4<B[$ORO'V.8RO=FO$VEI.9SI<^!106"0(-
M(#ON7__>J@*$)&0+V1;(JIG3CBVQ5-W]WKJ+)IE&'^FZU/<EPU(=VD[%V8!*
M>U0W5$AP;0%;U8&OM.IEW7D7N^H%A6-:!+(8V=TO=LY;Y0UV]X)^75#;3,4^
M6%A4W%P:["M&'&EYEZM^83&=;*MG5:R,SA_=TU2:>?.I(I1<V<+J%N<'G94#
MNN,Q:?0%"K@,+%R7L8)_D%@B,2:JVOOW@!S[%UTBJB_<H)5@[3?'A4UY/!]P
M5W,T\<C-]*A">/N/?QP/?\G;E=5GVE%/LW*HR,S<G$JK^RD??3FW=4G %RS6
M]@F 1H]\%(3YT0,)4835[+V\EUL2I-_3\G2O8 $?3Q";ETMWF/XO:=).C284
MNLSWRI.OA7]<_'X^NCC_W]&+A,E>^VRNCPBHY3*^(^X[Y0 .S2= <S2.[U@/
M_ORWMZCPS)>'B"F_Y!VR\??TD7[T3.-5.7\T(XT/E\_M'Y!K('3^-UT-:D;L
MI"V,7=*"\CY7I>4D95#5\[\J9B+PY(0LK]JKFXBHW)%\>!UY&DKM<_+"JK(=
M;E$N0-TDV  -IE(?U$%)@O/)"1A/IMF*&2RO:IQ%L)4SB&OK3FH!D_>K0)%7
MC8.35/W"ZJUJGR7=1>>1Y&%:6EIWQUJ3XGF: NUT12]=,+[E!WL&$)@6JO,R
M'[U P?OO)&#^+.&8.$%)4*:3C19AL6Q.U&8^;Y02<9!IT3)/BUZ?%OUHFO-2
M6K3L.$B5D:8K2-=L3T$N,)MB.))MZ:JEMYH671L/6FB+RD;"+>3L+8<CJ<PH
M@Y@K)5'E')3P/@_XYN$SX 9V;D-LH-E$F#*M749^G?LB;0W$6H+SJ<]%UII#
M4K%8SIJ/YS,KR[O+EC3T-I9SY:+$#:(8'..%5FTH=4"+Q'DYW /;!QF6'Q4=
M5TWZ\DQ*6O3E5O(3B^398KXF.TK+9=C*HXLS":(><I6X^/R%S+**.J,'(2#=
ME]70-,2(;#BM282<OXHYM$L[0:31,6T'0/R4HHUU-4=G.<FQ. F;*X@XNHGW
MH8LXL7P^Q4EVWZ=9UBRN2FNSJWW>V5"0FN;8=<IWX:!C/<F+X$,*M#,S.?;L
MK<1_B1TQ+0].RS9,!$/KVP.*X%S>XH5]Y-%=EK<UG&_AEF13L33S8O;)O&/Y
MO -2I7?1(IF0E;&]D S&\DX 2CD4<WF@9#[S<;G+T/)3BPA=GLF=Q2'UPU::
M-@84;;0U_BAO3\$HF\X4HY8BJ_0F]%J-7\A=)\LB %$(&W)*M<&4^VIQ\7I\
M;]OPGG:/6MOQOE)%!TLIGT';UI#N\30K,3_Q&@?3(J>*;88,F(BP'Y#<Y0A,
M#9*;?9NWB2\Z - B[%Q_R>0@5S+*:"W3%D4DEYQ2TI8Y<PD,2P(+?*F;UYP3
MK\=%03.5BCG+U!QM4Z>C*@7F[>R74]=JN87T2JAR2Q#1R#/ 9%X&DY<G=9Q$
MYPW:P^(<]?&1=Y>%PCZ]9&>7*<F4S,,F/%7R@4RZQS,ERT&$6Z6VSO/)J]8=
M,8W\?H@<3+DE-SN(10/*\O?AEY*%>L+EU>#K<,2'S&^%9L(CP_/KP>G@_'C
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M%@1K#N=8[*IL,1=5!JH3APO8Q:465!$3)B,)0ERT#4<"4QIW@9<7+L)&(UH
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M8K);BW$ #W:M7Y,=]8(9=:.\V_'%(K&1#F_)+?YX?WT_A>\(61YT0MV__C2
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MB%<"=QY%>N.^.GL<_7I^>]1^!G/T\FKP=3BZ?IG:#UVTGF:0RFU9I)N!]IU
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MV\C3O8XS% J78Y1,D(MG=%W""(4X?8EZ[<?N<^+$PTF?0>2]"GCSXID38J$
M1'X!"9X1K*9Q&'CEEX_2=^>@_U-3G^ 9 =05QE]3GF/V3'N?^LL^.X):]LHY
MJW)6W9!5U9XJ:9Q5>0#MQ>84[%,MT?-$[]H ],^\14]SXI3%?1JRPHGSD(A3
MV:L)#:^%-FG8X%V&P)0HDC;:2"E2R,K^+ESBQ,51AFZP<)-@E.%$R,:P$+)R
M(4Z$*,Z$"481@-R?A8NY)NTM^^_'@%X41,(T"6"1]Q@E IH M62I,$:W6' P
MCH0$NR%*T\ /L"=D,;!SY,?)A/XZ2Q+8-KMSFN"4P""KMJ%[H1UND!"D/&7
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MX02RGD 4B^<7<0)9GU\DR[Q>MM/X4?A$\ [C1SK4]%Z>'TA__N?H:G!Z?7&
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MYIJTM^R_'P-Z41 )TR2 1=YCE AH M22I<(8W6+!P3@2$NR&*$T#/\">D,7
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MS[]RTMR&-*^O!E^&Q_NK?UJE36+NKRC^"!X^A6V08V^P#9*,11VF)#249E3
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M'3-G@+UUG[VQ&P!^:(%\_-.5ZWH/''$GVN?/%^>X6<?2M2/\]W%-BUP?A"'
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MBS@.!_X@G,X-AHP* S2J#!8EI4#HJ<OL87)GF]>#^5A)YZ.1>S:1ZR)L;C4
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MBL_2Y^1$X(H$ J(\;F+*>FPUPCM8IL(?$\2!B8HP!W[9-Q2UK A'&?Y*XFH
MX3^9R_X3 6W2N<](Z0%A8989HR3 Z[9\/U!EE'U.FC[",9@V)U0C:$632#B&
M=@8@(#+\*5I@ PT%+9[.1I8<$(<5<@__%L2Y<LGN&) 94$TR!5I,7I0DMKWQ
M3HD@G.L<P:#C@T"U2!&1I*+.D%"V)>%+>=%HS*TLJN<->7&C-_+-"=Q3RIH'
M<APFZ-7(_G-T1.AH0)X (HI^\C5>I>='Z61^CD"B->I&FP/O._ $H.YW@.G
MFVA'W_7?]6-MS!Q>K49R=1!-DDC"@\?S:%."RX H_">6&LMQ\Y<1;DF 7\.M
M :Y'E_IW_;@FQOU0[:C</8QA$8VB3_7W'WR\"_U@O.<DCD?!O<6VQ=T^_ +C
M\0V\)Q)17+/*2_#J-6WL/6(2DE[.9U3J;'*'D6LOCCZ-'HZAP+@XG<SX;%4V
M;R&$BP=HGYN.KMVDBO&:=?G,4!RVQL\E@S Q(,Y"DF>7+MB<,^J*BURDK2/X
MA@F?'6LB04]7?2=U8+S__KMV3X_&^YU[,5MK9W&A^-']^=FQ3MU_=*UC8L\
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M_,PQ0(5?O7OX5T]\ R-^_2^7G\Z^<*?@\N+J^E,EO +DI;1U9F$4E1<42"4
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M N[W.'.R&I#Y>E.4TJRYBZY*"I7FN9_*D> B]"F&J8N1Y 4([DE0+*7$ LN
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M;TCL'O5677D1H<)+OGX-"[\2#' GV;)@;'FX.$@V&S!?J4*8GF:8C$'28L_
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MQJ^T.M6#51&F.#*U6XW,?G2>)<XP"D7'#>@<Z"'PD L]7D(-\9R U0)9)H%
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MH%@$KEV.VNX"L[2ZL1!>NR0WN^_Q21[S+@37+4?O^6'T0A- 60*9!M/.]^;
M(-LL#:O7 QKEHM<&L.L]L(V:[8XY]/J8_N[Z!/,W!N/3,(JST9_6GM[A=\-N
M5#(0'Y\LHQ0IMN:I>5@8,8)3P,\ST%R([Z,/J1TQMUQQ-9 "ZHF^)#=8(8QL
MR;K1#HSN'FVV=T*D=-&Q"%RW'+QT07'A+@]4-_\/D"SA=[0$4TF)8@9.-^?C
M8:_?5:C/R,+IYGR[21:&U-*#DQKZ?RH0_W9-9?2L!5R"#[_\'U!+ P04
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MABI+9#;H @J'R)27 O]'0&X23FZ%;DBQV.,9<BL155TQU:;!K[[[$_I\RCO
M^7@M8K1.X<Q$3;K 4>1@+ G)981&L\A!9<Z;),KOP32D4*T>/VHIH:83-5LB
M1=]"!*0K L/@X (1DYI2A:+)4+Y()DA02%:3:#'8B,LUH<5]H(84J]7C134U
M5"/&Z^DG?/:L^UJ"1<.%0N^-D1"I(I(J2:R@CJ@<F9,)O](FCM,ZB"&%6?44
M_^AAKJ;H-QU\]./TXY>/,)T#+EZ]_W9=0JJ#4<+B@F58))(;3;Q$=)IZ(P5(
M=.>:>!);8!M24%6/%K654I$MLX_0+;Z^F?@^"5"\G(^ERJ?PEZNH0!OTYV.F
M)?%,B:4>2 !KG-4@G&B2WKL/5#.!?^YF\WF):)A6Z,I1E=&5XT5:%SGA"D34
M$D.HU"2_?3^L(3G7U1AS>XY4TTQ-=^JJ<.%C!W'<#Q'^>P+]^$_3B[.RP_F_
M_>MWBC 2P42%. FW&I>"*''-=SA.@DL/'AR ;#*5:@FPH_O>=KNY&06/HNX6
M6\\7:TJF8*D)@6BA<4W)#'T1I001%&>,TRXI)X^Q5_N(<L]3'/>R+_;#K.MF
MGTM5T2B9*, '5+!%)TNB%2!!Z$ H!$5-##:U<6,W8!F2A=Z3![>JR?<<^>JQ
M[1O_M414%[+AE/)&1T62CQA.\5+PP7TD6C/.-=5"F2;.[&8X0\IS5"9"A?&O
MO5FT0<(0(.<4,C%03A7*$(D/4A.!OC4WDNG(<\.=HL=5J1QA-[H2(RIH86]2
M_&OZKPLH;R'@ZCU_"XME-RTG%7"-/IN5D9F/A+;*>8IAE?:ECB8X$CRB"^ R
MLUDF;FZDOVX=@-SN24-*;532>(,A/EP5PHCBKZ!9(DES1V2BN%PE&0E-V<8
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MAT-E4Q5E5KPD<FT;Z66_C30?):$ERS&2)("3$M82KZDFC(IDN8C!\B95M9O
M#&(+>>B<VEN+]2X1WFI#8!1DCP[!.(B(35'BA4DD9RTC-8P";V*XMH,WB$WG
MH7.N@:9K6K7[RBM&P4:,[<O1#EON14S)D'(-#Z[G,69P'*QJ<GK_ 5R#V+X>
M.N]JZK9FSXCU_?619H)%C"^(2S01F;4CEI?]+,XH=\;[')LT#KF!8Q#[UD,G
MU#ZZJWO0'(6;;2Q7'26#T@1T"Z,5:$7Q%PE&HA7UE 7! \UMNFC?#VL(N]M#
M9U=%Q1[Z8/N&6^VO0]GKC/NF3V]TW/U!02J=?.]UO>%AA97EQJ.?)K//_X3T
M 7[VXVEY\45&AKV%./'S^3B/HU_UQ"X'D@WCW 8*Q.5".AQ.$CP#DJURTM!$
ME6IRD*RF$%6LXBY8;L$HV,IHAJ!MDKXD]_J[@Y(DOC0QURKYS)WG230).*I)
M,*AL\-&(OM&Z'IP@=5?]7>"?KV%W"N%2DBJ7\U"IE/S*4L@IN27)R"R#X<*U
MZ;A968XA):6?+M4K<N4@A']37NB'JG_7F]E\T<%BW/6K^$6!PL1/YR_2OY;G
M&=3?8'&2BS#1Y%*:$\MIP%*IX#@)0G@B0*F@(Z7)QT,3?P]Y]CZQ> >D6V2X
M?'(A_HN3EZ]7H/V#H)%;B/:":_C/65Z_R:-_H6B&1LDU]91$)]"N)L.(C5$3
M#+)TXE8GU,X6I1?#DFI(/1J&,*5N';P<C*9VXE^]$\/WZ^-AZ4KM83>>=:N&
M-&6[^F4':;RX)>B+;CS'J/)5G_I_ _A#Z5+V4CC-+$CBN(GGER,&RAC1@H+7
M&O_(K<\C#T*BI^(8#&W>#9AW!W$M7GSRXTFI9OL)1?/K=\MN4("&K%/FD7AA
MR]7>@1.GF"1@F64Y61UHDT;?M01H.9!W&_"?5@9\!? D7T&\'%D)2FHC-;$4
MPRL9I2<6R4 T<)XIE2+$)OO*S21Z,D%YLPFP2Y1R./(T-RJ_3SOPD_'_0OKG
M;-(WHEXY(B?3M:'=:"+/I6&TY!N,)S1JAM$7AH-6^$2B4"%:R,!$DQW(5@(]
ME97YZ!/AH,PYR.)ZY;GDR'0 34QFEDBC#7%EX'1B5$9O)7 XM'D_Q**X<QJ(
M1LM9+OTDK=+E &RYR\LYPE&#)E+KG&_2+KY=:G^X(?"CV+EW[JV6]H?G'2N(
M+DNTB4QY0R3#>-IYH0@W)LB8N="R22%]&^]XN M5<]XVTWISSB)@U,[T_-J@
M^/5]AX&KCQ<SK'QWKM$'$N'GL]%EFDUVH@2G&&ZG'$B03I,<C(K &(6;+;;:
M\KFF<$,JQSX:UX_&EL%OFB21I50XJ8W,N! %DXGWN!J9D U+3D7AFK08/\BF
MR9$KQ8]JV@]%BHI]\&_)<0DHX% D#XY$KRD" DX\Q\E'1;94>VZ!-W&6[\%T
MD&A*,F\4+JN$R[)Q 6") _S6*",92"]SFYOF=X^FCNO\U^+.+A/L44IJ=$=
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M^-\OW[_][O4TG9_A9/'=JQF&!>;O?A\O3K[[SXSS?WU79M.S[_YS.OO7^$L
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M%HC/(%CPV0B3.@IA!M2.+E3[3LD:@NU-BM-;Z@T" +<PK:/T6X!JF9[5B>K
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M(J_1K6\6=8K*) F,*0<J< 4^<P?U,%9!"R55D[Y2FR$=,H>S+W5W#-E!Y-[
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MX47?(+6P"U;]Z0S7Y4O; &Q9C_$@PL-480S"YQ8ZTI^,@VB-X8$,)Y9!%V9
M!>,@%F. ,\E\,$H'+8Y(6QZHMCB,LNS"P=#SYLYGX_G?,9PN3M;M.#*W9$_'
M5:NRF#5X.H$A62FB%LAXVJJ&]_:#]Y\*.+#@IT-);< $P/EL,7I+*_NT=)A>
MA3DNU=5IGY.*$I89'TH6#L$;#C9&*T.R/FYUBT!/O_9!TZ]N?\S=KS\FJV
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M0YQ/$!Q,S\ /!_\-:8G\4E&AH^2,&%D:?)21S5XZ_)%K:;*,.:ZV,:JC*UW
MO4&-J<Y)Q4N?)<8/B.K+8LWG,)L-%['ND]^_P6@*N/80!6>&Z$5-6&DR:54&
M(K0 (=!95J')*.PG,+U!+:G%0.4VGW@$SD>SSQ/XY@?I:)3>S>%B_-&/YMG'
MV7P"D^EED*%$20$W.EYZ;"='?"[31"G73@K%).M2D_+\F]X0ZPU$6[$GZ'+Y
MR^C5\?AK0+.Y+/O:U/Z"0L%_F@[2C;E]-)D4;W$1*5LZCM?K.\T;_LB'@0^#
MX6#V@UTZX[3CI<C#,#2MG-/E$LVC!/$_"55=*-=BA]G3^MZ0WKYFS:C8:76Y
MS#/T!R?S\C4B3$0_^0+32Z; \9+ZXVAD"$R5+O56$!EIB$X+80UOH:WKP+Q!
MU>HM\XIM7.]A GS@5=FEX3L,Q]_N'\\T:9ZMH20SL$0JB:L%Q0E#G0605JO5
M3O/5%&(SJK>I&958J-DFME?RF./&JUCFR^:RO:G2LDM0$@5$:4W,$IIHS@Y8
M*^J3'PY?4(M:\[0NWOTO119I]K_C<#R%]&__BAL<W/U+/ 7A]]G)M<W_;_]Z
M,_JQ3I#\-G/I0_D#A:^2M83[I:#1:A)2Z8J=471.14H@!8MK,<RJ)D?8$Y@.
M*N=S&W58&[GN3TNS:Y5'T)9ISQW ;9$!6DMW7B(CM#J7W72D!Q%[UQ:38J0<
M$F%9EJ(MD8C5S)<17#;@7Z"2?B-:LB%O]&659!OY-U".FR[$!>$RD\YG$V)R
M1$M: IQ"$&_D8H1&4$;JA(9\DS2-523[-XPK,K6:G=%+S!5S,U;C D?QO^:#
MZ[N1A:(SZ4&$) F-I>\TV$7" "!*J9S(H.UJ05#=",\*GC^*L5&#C@97W.M@
ME7^< "PS/#L ;&EL/(OP90R.*GQVT)'^9#0X4YX'&C0%)8"1;#P"Q0.46(GD
M2L=HEL$D&YL8'2^D+<\8'B^C+-MP4'D^[M%\,G@XEE(Z2B55FOCH<.],PA7[
M"H]:57(Y9%20NM2A/GKP_FV(RH(?UY):11NBY/R7>X#QL$PUP 4N8CT+E:4@
MQ**K?:20B:0^$$?16DK)"88&#_Y7=/BP.U6=K8?PUBV&2L*OF/BT'M&-LG?!
M5+L<=1.8_5>CUB#J2=Y[2+ER)>I&;(JSD!WZ.-EQ=)TYS<1&;XA.*CO)?>D,
M<YC,/U&'NB_BMQ%NB^C!,N5\67QS.^'$E^%%C#"J\&#SQA'O@B+4\6!=D#RL
M=DRJ7.KQ$,]^R^'JD+6IO*.'I!N$$8['$SSE_ P^E72H!;(;8%X*L,9% @$/
M4*D86BFAV"::<U"EG<UJ1\<Z*K 1T1M0@CK2;K /W(;,EM;O4DL7NYY+%BU=
M"&BFTD7P5)!@465#L+)D"X"236)*3Z)ZZW9B?6H:9$'?8+GY-+J :1E+>H#F
M9>)&%=E:U8/>HFZQ;SP %5P*U.->F'(IW$#%QJU1E9"XU(QQCG\UJ>C: ^_/
M1(#V1?LV$JX<\RD'XOSK;4MC2KF47"3"LU1$,N=)2 S7I!F:Q4Z9R+ITNGCX
MU!=+I=I%O.,JLJE=MGOE\0B*,)^5+@ZW4Q4R\\$K(J)&/(!V1=!1$D\%>!T5
MS[E+,\UUSSY4QGK+J?+7]1'2HNT&+/K?W>!Q02M;"N&D5:7CF2B!0IF(YHA4
M*)V5[-*O>]VS#Y6WWG)Z%=U%EC;D.)_!=QC-H8CKY/<93$9^>#R?SL:XF90_
M]V$\^O)A\!W2==5;^/&@+59Y5-LV) V MN]7TEJZ*XU-A#/,E]:$PCITW&RP
M0C.(5F;-192B4V.3!IC[)F(O8"RJOA_A.'J$X\-MQJB%J*G"_1,]X53Z<GEB
MI1&$*LN4,%D%:))^LBO@2B;P]!$/1V$ZF_@XNTQ!9>5I(-2(DFWB$_J!7!(:
M4J*6XB]#RSXQFY'M_Q#8BU9M,*$K,=0@"'<CE66#A0+IKX/9U5(P)[_'X3P-
M1E^*4/"O=.%_O_1>4>I5)HD"+>,=.1Z@.I.LJ.=*(&K3\C/;!NN+V1JU&']4
M'=&6KLJFY>-&,^=^"-.??CP\@BZ]TDQ9[X@3(1,I?>EJ72I_0I310'#.=)DA
MWO%U;T4I6DFX03+87>1RRVWX.HC)!)KJ3'H"N13.4_2.G(+2<$&X"(ZBF]OD
M3J@?['U5T[S,R;8_1E^ZV.;IYL#4<1HS#\0988A441"/BR!*2B,Y"*I=M3OJ
M5]Q,O;T6=.JKO@T;>^NGW074'[*O^E9L=6JLO8NH]Z<'G$HJN">,.8Y'+R@2
M> ("QOMLM.(J=[FD>(W\[]17O0']6TBX35]U3C,702424HYH;9<,RV1<Z?&C
MO0TV";:F@_,;Z:N^E?@?]U7?1G:5<U)/YI/QMV5]#63GT 2B).%;R\2D8BQ[
M2Z3AEB.B$#H5LG3Z3N^_^)!I["7$RF[G7V%:#)"_P-?!]-L53.#6+_YU.<W1
M^:Q8$F4*ED),%M%9JSEA%E*4W &-7>X0GW_3(7/:0)85?<M%7OMTX#_[.,CH
MYN8)+G>I?!%R"$R3(%.9=>L-L51KDFWF5@8J>>H24-CP^$/GM(;4-B:!U[K,
MNE<$42X?WJ'O,)T-2L^LZ2<_*0F-WV'W&ZAMGM[OVFCG=:S<];@,GGHNN,Q1
MVLQ"9)XKX,%H/!TCO=SF1=6+M.Z""B88F42FJ#H&E<AS3FRFJ)1>,!N94B$W
M:3OQ%*C&?5FS1X,%EX4[7FDF+'TBOG0&#5PX+C3+>MTLG;?7E[6:7FS9CW4;
M^3>LAW[8)^VNU=G%Q(^F&2832.R2<Q=PRP8T:DM7=7"!^& -,92!I<(KR9I^
M'EU OB'-:<9-P]K7>UC/((Z_C$H3V?<);0 \L4O<[%KO;TH#2U?)93.] 4SQ
MU^9?\;>/9G[T97#[FQ=-!"ZN_.B7\3C]<S <7G)F?08M2 Q"HWVN&/%6E828
M3"FXJ)QLTB!XKZM\VYK\2K2CP7W1'8[(<\HI$IM2PK<S* W?(G':,!>H5J";
MW#6_007:2:8-FMS75.3C.>[<H]D]+;Y$7>4NQDPX*\U1T DB+CF+!&<+W#$M
M8],N)&V6]8;T\!7QWZ LI<'J[OW"92H-H2V@ FJC\-NE@5C/#)'428Y.NF.J
MR7[8=EG_H]TM^&\P0N $T<Y^?(39U1B-B!)@6.2U_.P'D]_\< [HGI4;^?D$
M+L$;&7E"?$GB*2,BP^\P6**%0ZQ)1LF:[,/=(;XAK6O$2\4Y X\S!M8(8_K3
MCWL_7><(4!JUD=P1W,X#D4$R%$O61 4A2F=P&DSC]KG=@.XKVZ>9#C5EYJ5S
M>):+7&G3]Y,?^E&$\RN &6[!1RDMUN>'=Q\,KOPZZ.2'OTS&\V]3?,3U!4CY
M/==#R2#=S22[[OFH)$CM@"26%[4A^)%9$4G4B?'$M8709-C!?I;W\ME&+33T
MZ=:;KT%3&L2<M@+\R7]=-J+J KMEO?6.N%]%"^%7H4KCE].#5Z3&V@1AA%/$
MT.!Q@[ (GW-)K//&,6<@MZF/>57JNUUOX[>DO=O07SE'Y>3[Q)<9%^/?!\L:
M8!&8MLXFXD+IV1C11@\E4=]0I1QC:+9#EYK;QT_>OZ.S%T+&U:2YQR;)7M!L
MLXU$.26(U#P3YWTBT7.IDK*2K6:FO/$FR7LPY6IP\2(=DKL _)\.R;OQN773
MVUW(>)$.R<YP83131,N<K].JK0!#\">OF>%2MKW9/8P.R6V591L.*EL6/\'D
M*_QC\-6'FY,P"@>+0Y SBY:52"6MP22BN#,"? +.N\SN7'WNJPB?]A'[N)+,
M*O?1^0TFX7P^^5(2/=%R^M,2$0?/7+G(4J5"U%))0DB1&"6853FHZ+M8A^N?
M_I:XK""_C5]DK>36#_#%#S]/QA&@V,4]6JEL>E*_I-5.^%825$.QK"5S0(.2
MBADK:69)<1,II*#MY::']IQJ/2Z7;3<S1N, [M6W<L$8CUD25@Q_R2*0 $H1
M?#^SI=&YB%U*,[<^"#=#ZK,OK(CO L4_]\.[$O+(J)&>9L*+;LORY:#[PX@V
M'L!RI4TT'3:(9UZS_YVB$L'WMXB:HJS=16TR3O-X>^?[XV[E/S[-BZ!.\_'0
MXTDUFETJH)D"0YLEEWQ%B>Z04Y$3%H4/EFJ;?*?F:MU?N3_VJ],T;B_CRH;<
M-99Q_N9G@W*;.QA-;Z?&7^+.JG+,@1AC%I,@+ DB,Z*TQ\\@LAR<[,#]4^]X
M&V17DV*#",##K>W'.__5?X'IT3\]/C\M+NXOI0V08DEKMRH1:3(G7ME *+="
M"*81<I.$G^>A';YZ-**A8L[D8N5/H;L+OY_!X&N83Z8+Q;X&;5-)Z@! <92I
M<R9YXDOG<$:=E$&I2#OM$3L#.'P-V9_\&Z0BK@=^/IY_N;H!R#-E>+YE8G+I
M!92Y)S;;TBU6IA"< M4FM^999(>O.6U(:)#2]]G_N,X5&T\6<CB_/1VGESDG
MEYU@A,>42X$I)TYR1G!_*)V# I5Q33.#_OKQ!*:WHQFU!%\Q26_-=G<&4YA\
MAY/IS(?A8'H%J32<&XPN)O/I[-*@_>0$)$*5#+C#E2H"ZBT1EG.K<HZB4^.V
M;=YY^ K05,J/M<'T/D=0OE\65[5W*GKR^S= 0QKM(I%4@$R$X&A H]U<FBE;
M8C4HJ2W0D)K<-3R!Z? 5I+;@'^N$K;A#+%WFW\8SF+X?_>R_CR>7WGN:DN;E
M?E83Z9,BH30U%,X;0'T-43\7V>SXJL.GNX5,'U/N6E%^!O\)<0;I,EJAF/>!
M>&]=\9%P[4XK/+18]AD7C_9N3\Z7[WK[I.\DU34!J-Z)+"L@\8@:?/4S.,V?
M\1=*"6GY#9=6&8LP,[&RM)+T&?'R[$GDT1I><C?VXDFL1W?XVM*.C#4JTRMH
MN1'AG:?\ &L6V65=&M]&AN=8,@J]'YX)>D"26XN6K]PA1O'<:P]?(UK+>HU>
MU YW?H91$<<BU#Z]WOPN*=>"!IZ(=LD0&?&T\R(*HF*,(EIME&U2-?8\M,-7
MF48TK-&4WC7BC^[\KI, E5-:,A.)T#F5H=6&!,HDH=[PI(SC$)H,AEP/9U\5
M7Y4O0"O*^*6KNDI[M#LGZ=A/89':A1L9V. -\4JCH2PE$%>*P9-QSGE%?>1=
MLOH[]6]\_/J72JFMP>>XFEPK-]5]B.8"_\1RFE,'3+5[*V\"L__6RGU)VLAW
M3PGOB_TDT-35V: W9!!;*DU&O?3$T;+Y:72/7;5.K?ME_8F&ROL@?1O!5DY[
M> >?YS^.SL]^_=/Y,G</+1U&4S1$E3XUDCM!G,+EQ0QHRE+-<1?KX"0\?O)^
M.WG6D?:XFJ@JIRZ=#:9X7*7;F8:R-",5$4\>1Q&*L)Z$:!G)AAN#OZ:38!U8
M6WGL@5/61TBU$\5]^/%Y_,]T.SQ496FL1:>">H=87&3$&\:)9=98&6VBOLMG
MMOK< V>LEY@J]SL^_<?07^%RCF;X>T;PXQ<8P<0/?SO_T[^/KT93E.DHW?NG
MS^]O('/'C!0\$+THKO0VDQ(M)HEGJVSVPJU.QEO+[(ZO/W %V(?0*^<,+?/?
M/\+TZB;;<?K13_X!Q3M8CISEG$)"']]G(8G,#GU'[2A!5?8FL#)"LLO=;8=7
M'3C_M879(M7G[J9PYF?SZXKJ+(317N,^%3(0J:0E5C!/HJ1&4\^B3&UB\FO
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M,*5EF5!$V20)?N*&>.<M+H"C-C F)>^20ET'S1NRN5^(HA9%%EO<W25M.2T
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M'4P0):'3MGNB:+HC7<X9;=Z2A*2&S?)<M]))W88Q38VZO^7L6!QQ0E>"R;\
MIBD8WIJD/MR+&#267K&<-%@.%Q5)R$XPVIQ4Z!XNE4SU9Q?H&5PIX!RZK5+.
M+CCR6!2#)CY!"0)1C$,@< 10&DSALF%ZQTWC.^@@)_?^OP>^-D07*'3FG"P=
MF%;N?5WJYC'G(NYYCZ,H_,=/-K\VECV@9+D'N8WP)@93<%KQ*SQS?<9C5<#
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MQ3N$RT!Q_KM_P(R<0H:O/E)QZ%U@RFA7I 76;>@-&CV]'I1VVD7E92A<Y[4
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MVX1FG&F>I%:LGJF6I5-=L6R?KJE04G;5\^/I&0?YMZ>X%0+$W1UHO&S!0NJ
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M<W)P3=W-\8MS;0<$_3I*)WRF(G2O5$@(T7R7M7)4 U+/W]XG4,31OYH-87X
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MZE]I2"Q^EYVVW^I\$#(WG[;8TS8?L;23CN6@1,;+R!_-B9D:_;@/JN_=!SU
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ME<T(56WW*!/N@"S?;CC.(S;Y+481&ZNT'558AS0GN3';L9^; =DINB\P^.Y
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MQBI0,2F&T4:X-"8W)?U]H5DMJ]3*9[3RZLPMFN&+]JY3 ZV(.?;=1D TCNH
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M";NE2K=PU*4LMP2T;>MXJ$^&5.@W%X\G[3E'<M-[3*PU1L8!>: (]16Y<R"
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M\93TG+<#L1N0,+5D_GV?[;9)PL N]58FG&^I%4[#"PR&R9JJ58F$JHVB-]Z
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MK>U8U+KL=<RH3A9O:*B:U[70T- R/KD+U?S5;S_POP( Y !_YO3?5I*?T X
MCW[-AKMF;MK4;WN[^YK.!:$-_EXL,#+G<# >1XME'09OW06SSW>H9^X$^D7_
M&+//O.6)^QZONQ6B]J#N37';S@% \0F5AW,7,5?$IF/]5GFPG\E<$,;@Z6)R
M@E#TSHW;'S*W">/+"+9EC)20'9\UL;,MGH.O+O*'7'#'FG *P; C$TWP1VS-
M]]0#0'I8B$^>Y>0O6XEFV8<G/N$_[P[H'+W7$1-?4YC]\EY,]2L1I&$$@_\*
M38#-AZZ!=QJUVRT:*?SXB1,&49N7,\]2"6C!@G9CUW&W+W/Q.<8'@/EO,QO:
MT*7M[OO;;#RRR3(#[I_'S1["R1L;,8WHJ+(?<SP?J%,Y.@< .:CR"Y3AS>XR
MUY\.5W7U-3T^MFPA?/W$= <DMJ15\M[^>"62_Z<+0Z<FU([:]H<M1./"=U^4
MA@+)D,Y9NX^:I)_&LO'1MIXJ/T(4"[;7\;1;TU<O0Y5TMD#\ H?=DR_9$5?9
M? :T8?(FYR%FW;N1S9N/?S' B8C+[/SPP'!JTS0NO6G0X:*#?UO^KQ.1L._<
M@6'O'4PWH$_6?, 1(R8*0@QS6"=2" 9B#P#%X!SI0-SN@O'0W2-H9IT/'J=%
M(T57C ')MHCG,8WN!M*A%<U:K:I#CE'%-]ODBCA>Q7\S14&)#F9HT=UW$VB6
MA'/-P<-"<<9C)@J@D2C$F)L3IMDZJN14_(:@@Q<7_-T=F0[^3 #=G0QA'C=8
M!'>IN9,5Z=N[+7^^TLYP4JMS>M29]QBZ)X<2;,_>2I->#O['_<93%M:,-S L
M4>54K+%]C);"XJX\*XDC,[[N68Y@CP9!6AKHY12>),$:ZFJ70YRJV^JQ:4HW
M"E%1C1I36VI^^X&WWHSKDW?>PS5'L01O<P#4',V9<"6LVBKRO24!\O4);%(!
MF 9)!XOK J5M%UY3L7Z2I[<]9<81M<$LU/:"U]*[M!M;"O88W57PL0/ W7EY
MZ$W6>ZP\>QRF0<>]LO8BXP#T%/QO3.H"]>K'X&-!ZWY3Q]4ZQT6(>%;FR6KO
MPC1H_2?2SAGQ0UN/U[091V"C\_5SS\J@(I,'@%#M!5S*W.% 1\IFFET*=V4#
M(BXBV+OZI_7]U=CPH+K#JO:FH]*+ZB1QPEP%X_C9]2M2'S^16:CV"-^%<'%+
M%$0-DQYJ"(I2&N?8VD56J6N(8(&L,^F):,NB= Z'EJ(@'F6)AFV[D71Y&I "
MSC ^21]>0'<+R78787+;W71]VD;;E=6?[PJXK'LU8^H)SS'&=\W%^=*.:GHL
MW6][X^W)0XUD\\73RLGS:]VTS=WK(_"@8:$^"B1;!I.!AJH$X 2J<@Q%B^:+
M=VM=Q!BWLXJC M\4Z'PV]XD%/3O%0VRRY^E_$,L4&UOD1F9RF.0 (#8#&_64
M>\(>DO&8R,(CA98A=*OC";*,,\7@Z:HUGZO6N4K[M F8PP$@>YYJ4QL^+;78
MVY.7#I1DJ[IYT#DFTUD,?OP F<KQ$(*&4JW1S4W/1WOCY1D>K8:=FTLALG=>
M]0++PWY7<HR,H]?^FTTB>NJRGD$A#$WV&)!JST"*"EE2EC93#947(+QT18;D
MQH12JJFNK1E+RS$A[ICI@AXF+WC@B:=Y@1&2.+S+1Y^G%N_6CX*#X.F0)O]'
MOV);Z!I>''MUHF(>L67D%;I?-[1_^*<%,:6_7>QSE+)'@ Y^+O>^BFP%.H[\
M>R4IM(L#X+&L4N,+L'%@?<<F'IE4*L*>F?I.XW[T.08X+;E+S-2_NXY=N#:6
M:"G;\- /6UK6UC"3$%*K69']IO#9)6709G!50L@89E#N1"7$4F_@+;E6K]Q!
M7:W6<]A6O0C7ATQ$4K]MTI5[6;)@MN<#C0. DO,5*D?$C'%&/D,=[@8+T@O=
M62\-L]3 !$EG_4(XWJL<\UP\LMS *YSOHOUU &@7/=NJLI-9JAFA]E>8<(ZL
M;G@:G/F>.8I,@5[XJZP(Y;8RO_#8CI'VIQ>( ZSI3[I$8KLJ&^X-SI@39S4T
MSY,@NQ Z^O6/HMX<IJ+7*XX"Q&6U&^BRTNI:1+1=YKI 4II6P1''9ZS%_ =S
MKWT52N^*_ZV>":#AA&##\S+M%\@BZ:TL=*^0&E8M;G?DL[&.'5_HF$[@0K.F
M"T@F<L; J)U'ZRDB-M 'X:?^=E7FY@26#S99!.G.@F3-<;'*#;55"^.XK+]
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MK)N09?+TM"X!%O =TC$7<W]RCA[W#ON !7CKSV%DL)]*$D$60!WP+3/3Q7S
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M ]@F"$CYP+=5")"L3_J06]*)8"".!"51W4'((H+BD/5DH>S&SR7WET-P5UG
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M15%) A<ULP22:N"GL TUE 6$&#192=@&71T899>:DRIR/[%/Q6HN6N6(7/V
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M0QDBU@'3+J4(^M".T_G)RGGQ"$VZ^Z"$(>@_:;C8&M8Q?.*CIE91ENR5VH"
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MJ?L[,]]/.%=[FXE?EOOH=)ZZ(TS+H%<[42*B]O91X9]^6 Q]#-9!AYL..Z#
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MRD^6O.XNHZDV7Q".+\U>LA(*:?:\\WJD,_J8EM'.Q/3&>\3W;W)R8"KB1[B
MFOA!"UR4I#PTI'DM+D?'4M71;LPCY1',YS"F8>7)SF_<G?CV==@H'S]3*QQ4
M?/_PBTY9Y;#;^OQKIJE]S-+;+8:,A;:)ADZD>@AKPC/E<5#-O$IW6:S^H8OT
M,^G%N4%*W$\'/<_& B&KF>TSC$N.G8C;,S7(3C*HCUR<88LTI-CP<8R8 DU1
M))IQ(,V$%9@<>>&,U+[^;QGWN$0C5[F='[*ES;\<?G\(,#6]@1B"'H;,9B;#
M?12#!'7SVB?+RS-E\(/5 X_F(%.,Z#S>? BWK>S43XNFX8/#UY/GI7QJ-]-T
M K=:1'HHGY=/87L2VNR$Z2;P3IUA9M*)\'>(X3&643L@A]L[)C!DF:PY2++>
M&=84.C\U[:P[U12[QQ^8[([>TY:>2LW\/L!1.<,P;$/5$1>C9TGC;%8.-[7%
MDBE,#2WM"L+9(M.L70E!ER43FQ4>^LM%E9>^?>IY/F[J-F5Q@J[*WY@*0#<6
M318C790B]YFN&*:%_)7K$YNLLSF[2*+<<+.(9KP(Y:;[L'%%Q2)]MK8V3BM5
M1U3.[9F'/3\ [ 8V?]H ])^D_H,8?D6 )CV<QS6L6SR@FF )9:2VDDEW_I37
ME<2!"5GH'6=F8Z\! .UX!H_F0G_+.4DP@#6;A-SOL_UXP&0/1-0CS<S_C_G_
M80W*0!*)?08_2J[7RR2$F8S[=V/$M1G12?9C'<BD(7#YX*?POH\GIA)'(\4]
M:YH2Y+>;[^ZOTL/_&J2<N=&#"L$= 2]326FMFT9L5,#NT%/[3$[4KY@4'&!*
M+N5$?_LJH]U<E:^:[-0MFF&O(U-,N8/[P;+AQJ,">,!GP[9TQBS+@Y'QFCJP
M>>G>8P9W)K.NPK-[O#BG+^OQS:,MA;N5'^2>3S^>W>?T.V,_Z@%I\F8[IE:1
M(V4(B0]2D9,FW5(_3>=:=X[I,*]S\ (O&^N&MR^:5.K>/#E,3:4Y*:M[?(MT
M."]R/BX1.(JR)5.8 6,0'!)MVVQ4.!C0J>QA8)LXT_#PR)HJUSRM3??A:$%4
MO=>M#.LGPP:)UF&-F9^\IF?J41SI 4B4"K?73<R$S SR151\4T_ZFJ2QKJMN
M.*0#)HJ'"-Y]?-<V-)R@MD-X9T_SV>WTM <4KPC&&&L3-\=&#NIMP%1A$B$%
MI^N,^I5NEVTX51I9>GXOO=J[D7^1^="9%IVJ^V:;BNGS'5_B?/*!W[V0Z!1S
M!A)ELZ\2V@QMQ/!#!+5:8I+*6D/[@%C0Y?F&4SM?UC392(V]"*75W\^CB_6'
M;,N58F;5/539ZKODS9GAEIN8#P@2VN8@OK%6DS[6QM;29S^W4>;"\2>F15OV
ML0X=C&U6=QEPR_P=U/P:7X#O(S#"UCDR+BP'<":$;<O1Y.9] C-=6A2])0HU
MF9*LTO#BOLWN)[8TW?]X*$E0Y]+2K4TO2O/74)/-D*@?6PK>T4.RMBW<YWCI
M^K(76&]W2(UID57N&S112,S=[+;=^*%ZSB4)Z77]\/O[PR[P,R>AS2K--3"5
MNOF <$XIM/))MDML>!+SB];NK18V.\FG7PC;U=U[&;MCW_P ![DMZ%+3S&+O
M,R6?=Q;3)IE]/:HW+_0@?556R*#16#MBO)1U%)XHB1R YN<HY0X?&3(+9)C_
M2*M3M^LTG9FJ6^?HYF6:?RB)C33*<4'=>9D;\Z6ZLVJS]%'$-'FR !+]QD;"
MZKO8R)[$&7!?M"IUT*YK=?\*5M']5L&I;_"4O3<1$$\3\CKZ_E)O=L;.5T=&
M-/F97A!"FNF5&!D^V< Z^[&6+#7N.ST^)^L[-6%[E:2SH[_,)\9T[\U[7BO%
M$VC)JJH'*FLH<!^8"08BXOA1JU;S,QN.\M?':$C0$@6)S,XB1+'A[1K;N7>\
MCF:V5[UM\F-C9WWC60XYO5,ZZU*G>G1[:4KW#K^8]GY2'"LEJ)')]B&T;8%I
M$FJRJ:=#)9 >P2C ,/L;;EZ4+$TZ/=*J!Z:XCQ\Z.K0C[:BMV9*\W1>7UL )
M2ZO31X6[X&IZG CJ]K1E@H;", 7<C>.O NN"*,L9WM'MHN;DA&/S6555HT;T
MQ5]W/UVL%(O_/'7Y'/7.KF[+1D?,#J\"0EL-IH[(D1-O0]4+=PZ .I;TM9)3
M\]?([1BAUZS,%R'NQB-0BD2TA9ND%?U&56-MOM7;P!NYH67(]\[RQ[G:S&6.
M3!%K.YA)G4DL5&,JWN2XHZA'@L9R"1+F/I@4[Z_7B$F>/Q;;IL69,:R*^?H[
M3Q3OQ7=+G+YXMJZ.O0_VD]6?NC'^ #OK 5Y^!,:C97 NIZ>MF=,UL\8.RYU[
MVT[T75[^-$VH[=2VJ]\IWJW]QH _8C_R-ID1M$T8$LMB>YU>JW[5 VW^^@Q%
MF?'S<F$T<-3*V.?G\5L_T7^Q0]1WT>3&&BR'C=S:U/ [7P:ICR>+/7^4C08V
MH9VYE[C9! H\U1',9R\:?:PG?!Q-B:J@FLC-3#J%E\WOQ#DQ)2<P7=KA 8WQ
M\]"),"&&6DSRY]-*9VZ887L@$3+<@CXRE^G^EO0Z&F&<<*2 IOOM3>.G-?W(
MV)^AYLK=NXS[;T=45'18?,3TI=RZ%7:I)Q_@W(,A4O_;;$+;.*&Z,YEZ=QJ'
MVA+W=L]89? Z?1ME605$0@@/D$ CI>QT54BGI5QM'A >N"22X>-&O6]4I8'E
M 9D_MROR@]6Q8_.EW0.@5AY'-IJ5QBU^S"6UFN)DQNHR4RSR$^J6'M(&0.]"
MW8;&X>\-.?T-%N5"3U*"JW9_21%[\OC;?I(M]SF!0D16$^GW ZC'F+/4M?ZE
M*HH+N-PB3:/O\FMY.?I+M5B_U[S^<;B!KV%8NM*WM^?MSTL<E^(#^]G!(*:;
M!\@2*"L\(%$%U?[V?.ZZ;4Y'=-.7W$<\H.CSY%Q_9-0Y[:6R>MV8A>\&:Z<E
MPR?W9X*WV=0D;0B%L^(!3Z-(XP/C>9#H)-L >C<C8^W&)%/SXL-)K9K8S\^8
MX9TF"B%CWMT-94\2Q&6GIMXNJ^UW5))VK+:V1_:N;-^-5B>TR9$I!609<G F
M&$I6X<B.+=L85%9M+D.D"W>A9;HB!?MV2RO=NI9:?"CU>9J,0?<S"T'Q+@"/
MQMF&DAFXL'P[?ZY%IP9AWM9[F4!I)#(<PE5@>E,7WHD&]:,Y,C6TD6_D[IF$
MC7HBHI,';/J,>9W[Q(0V='&)'E[[+NM>=E1U_N??YQ+^*EHD[# +WW""0=<_
MJ)0_0S_- QIL2A@N&$(:^D7E<]PELKRU<U[:E:KDNY53![6ZM39MD7)32A9I
M7U0-B: 1.3(-+%>PE%D IW.M&UH=B^G![TN=1BABB]X09=;296:/UR5^4-U-
M#_!QN9M"._'H\*9;Y0H!!GU. &, M.B!Q$29,(C<!<?C B$-4ZN1$XSSHPZH
M3F,CO)CR)?$^"&DSB_H(74[R#9,'[M2S=YX!M;HWE"=:]6"T_0"+[L1KP4'I
MA@WW'CR31;^*3/=V72*]O*PF61J<^YY._^%[@.RE,;(1P#:'^LB;"/YP==YK
MN?B;;<&QK&*4WC)3NF\VI?&F6="H:]HQVR%(-^MS;I#Z_<_93N9Y[ OX=SQ
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M9='DAKQV'A#B<V_X_*$^D3']AATY*E*DE01' _P#>-- N ]8PRE3B:P=H%?
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M9F<Q;02-"W@Q\)3>)QYP/F0Y.?]J<P6=M+W2V+@"A7>IW5%SXO 6_Y7?V22
M^1W%.$3\'$U%TR-A>WQ -JR)+/?)&D8:FS2;E"R<5EG1NLV%YE(R>M&_9MCF
MD,QI3I?V[^F+A\5<U5I]RO8_PC_!$BE(NA=\GRDW&6^ T^<VVF@$$46T02*5
MOP@,ITX_K.BH1%-?';=.>38]8Z\6=-G*-\:$A25'JT7-6]:\9:-L4)0"3(T)
M1R&6I<R-@_80V@SJ9C[+&)]UO6*,#Q?!H>$]GNAAR^PV@9MR3=]C!72MKY52
MQV2GM')QXZ3EG><?'JG,,,Z%<^Z3N\/9V^IG-L)27_& "1.:1@4;GNU[*]\H
M3M?*#M%)% UJ0J=J)E-.=464] ?',3_IY.9F(["*+TE1<#!X$RA$F(1&<V2)
ME+%.= (/J-=;7%>\5<'QJIQ<N+:/P?1+6&S.%8Q[E*UZ4F?E';#[[-1?4L42
MOQL2((%Y8H,E1WV0-I!1B*P-(0G@^UM5AJECD5>5X];\2\PNG4Q$KHR$A?VX
M@IKKWA][CI^5G:K_:-._EM;]<"W@$-ZKHBZ@V7JKA)\_RQ<V_@Z9>(28%8/'
M(V:6__8]0P[?WWF@]6]6^K\3\G:XGS_!,&!^.I'$^@:K5/3G:#?^S@4>4&MY
M@V.!5_"]X-]AH]CXD;2]=4PA[WG_L\ZP\S);59RV!IQ.2_ %3J3WK,FD C</
MASK53D:-GHTSD1 )&QH9?W(R*KU-^89NQ ,9/NV793__)8_9T;KUI\UNIN.-
M-1,$SI*YB%<<)6E*G\0F_+K;:J%\IO5XW+C;5]'F,]??5GK<U_'8V:#,UL6_
M10H2S@XDRG!V@CN+_?S=1BK-,V6Q-T\TL8^4T8R]J0U?YBW7!?@O1QA>Z;\!
M\'EXR!^_EO#WCA?^MY]G_,?EOQ3^%PJ?4F8&0F((QBY*9%X728;C/M3B5(P-
MI%3<BM:P8%[_\-=-5UFGH-!H^8<UOPN6PDY9-0+I4M1O]KHN3W_R@+.(2;(M
MMXZSR^;EG\[424B\%A]4GU]1&,?<99?X'B8YSLVK-OT$1([9LT'R7>J=E]D6
M_-< 9LV-V-?__,'._S<$%P=75!C*W[7 ?R2RT-]YP."@U]C:BC!'<18Z.LX^
M0!A'%?  1_O]R&YYN7_W0ZC(/#+#@Z!$:-.[FCEQ98:J1^_Y\SCB*,?J,9J6
M;M)=:,DM_/5:;=[">[HD-#PL-QMC_O#6^B6?%L_1#ZQT@Y[MG^X:U(2'_\'L
M(?@Q<@V!WLSVQ%T ZQBJK%=-8 DWCTJ6^.QTME6P:=#(VB1(M[M*QZ)^X6J*
MT8JSN]/6>^N!YS2EY+16;'8R21RY7:PP>*)XSF48HIXS 74^W&?*=K2:VVA\
MJD,KSR-5+YHIC(07#<W6K6J[I"E&'LP0N-$N_@BK<I3RX>T^(DL5[&"'<,Z
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M]O<^MJ=T'!Z.YP&$MJ<S*W<')I:A:=2OW_O@OWA1$!R54!ZP[3"WD@?09WD
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MA#/+HO.[[$(O,\B=&"F\GN_$6X^*7Y):0TY&=!<)><NF9W6' W\TU+8J::H
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M)#N737U/'[ #!EBG438C*-7Y%*VC$14KLDK'OLP]23+V58B]*;'#XV%,$,(
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M5O1?\:]+LU^G2;CZ]M@@J>DBFM:B@T,91(C=Y./K)V7\,$1SLWV <">"[HX
MU%93V,9SK1JV8P8SUA2[<0-K+;-C5090C9.-:RU_9,Z<O_0QNB2QA]GK N&H
M_!=S4N44;COAB5&FU9AF/91TCYE-Q\3@#-1%2"%FA\<\:ED./ \\],1A E6"
M/>:121OE?UA<H>U:U #@#-J"(2>UQ9ZEB;J0*A^QL<?LZ[Q;1"'Y8&)%U]L
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M>UJ#8\R&436[JE3;E]HNW^L-F"B 1OWO7H[UD0%U<N_0)/XL:+99&(]]EQ!
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MB/G8XJP,^A8.RE[#3_]Q*OM>I7?O1,Q^1Z6H_DNI:JH2&J==^&P3D#8XR."
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M.WF<GOCM9[Y*E^GJJ(U_=9%P)_JU<*1G[H'%T*]&EH?S!1G[=6IR\@GL2$@
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M2^)S2V8*M]U\>D4=U'@DI(:CY3W<7G_9EQ_E#:"X(EMGY %31$@.<OX OI4
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M'J/G I9WO';9TB+BJ5/T^8!6AH6#:+37[/&\/ZI>TW@3I2XZXC*]JQ6B_V@
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M+VC.:<Q\W=W>6>QZ27'XCEF>='LFKZQ@2;SJ__]'0/_?VW^RU!Z/@&Q6'Z<
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M8<AUAP>F5>_-2(5%8ES +".-(Z@)"E")&84IFUHPK=!H(-@HO<.-FJQ5_-$
M*L;:,QERK"GI=4:6(NI!^A5][T^G"XZ,C.]<<'=((^S47J?N7(?2LP/S8C%P
MNE!N?"T,*E";\:6)3GN?@[IE,EQSYY$+D2(=5ZQ55KI;>/_)CR*86)?PVOB.
MX[[4V75EXO*1I[45 9/-LE-=!3\\/&QNJ(D7WHB/KHH]-K)N'SH T???.>%9
M<@ .N=)T&8@-.W9.+?PP>F];0Y);G$=#LQ6A07)P\?4[I6"UT+N3G6FU&0AR
MQQX\H/ZM%/(9P(."?2 V/9$[TWB^.1@Y]L5Y\=AH3N:RR>UI@(\#6V>BP?]1
MO0C ;G ;T@^2<^@FNQ/[U8B"9QT 8S^UBEJ[QB3]W@Q$-*QCE^:JMA!L.SJ!
M@S$'PRVXLDL_'+96J7@6$\_A![,%M E+X8!K.\+F98$4/OX3EN4, P,]=G:)
M$X<!%[,G!,$YU'F(,_)J&X*/*&'"-SEWB+A?1CW;D-^_H2S8-F0VZ;]?^/_A
M"^%00#>/]LMTB'_*]*B0D@\0N/-.]?_YSHIKSVM*VJPBY2"?<CR/X_D!E)5V
MM5."=>B Q WVKU\V3>6&;3]7;BVB+U-]T>\3C'\NO3G8;[MIN.F9??O[<KE7
MTD\V?<1KPO0<G=3+4?_X2&2RY GQHN?]BY4^V5(176M'':1;/ G=T-_[YL6V
M(75(AVW(F/_JL]JEG*W#&L6=E]BO".3R0FYV;,?%HDBK?I+0KSL8.ZQ=[G?Y
MQM77Q1<>J$V?3UJQ64J%;&%268O;D.3T3B'L:"M0 H:&9A+%BG7:E^[!R1CL
MAP$&(%86A+ 5B@G'L515W5C2SQ#XSLY#=0L >H^X/%IF&U)R@V'%$0DF],0@
M+)_5OD<"R4/D%K8B+A5!#PKF2&'[+)$\A*^?T. #<1XH>A%T5%-;U6;<K[5M
MO+$].DKG\P^=TD0>RT=;(3?YWMT9U@QH"PW4?&Z(YVJW=I=J.P(]XGU%KNB:
MS\%#I9GQ=Y>1!7B&>%XW:LL()H4E3\ZR-/ZA@!FLY+SKDN[?U4#\38&S?%\_
M2O\>^H<:N+\IP+5E8(&YN0WYFQXEG'U' >UMB.4"%<=2F,4F0# 9CL@_"?^[
M=)I-[#^W(>27,$&"/R&#HP#L+68),T0?AU/M;*Z1.]LF+D52KI1^NU2B=H,8
M U_\K]OGJ@4A(+D8*]&I'8GH(4$Y,)9Z7G^;3Z$)D.%7LC*O0?=I,T8&3+X1
MWDSD]W#)-PG+IU7GCLK'0=31F)\]M3\M0F'RG4(L#?83CMP*.,\8(X#/CH%(
M:%J]S%M='+A!O: C=CA<+5RXIG)EQ5SU4'U6EQC7[UZF%V<.UE1+<V:,VX+9
MS0G;C4 ;,1"]A7OH:V=78(VPOB!MC]XIA?7$,.1]JZ"@Z_DI#79GEC/A 4X7
M[LM<>/WIW%==0)U3PE@EXP81XIA!@K@!(GW^,/U72T+CNK@_7!48J@&P3I,_
M+YM.O;#C^3A?$#D2CM(D5GDTG/9UD15\YWU>D[8-J4>M63 U,#T<WG;@!O,
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M9VWN,W8WNZR4]E$^$BDQ0KP^!UNCPE?QP@1_)!$$6AOW<!NW@%6FP3)<WH/
M/1>99,OP2T2''Z@KO_@XNMTCX-I@0?G,VQQUXKW9FSS$-XTO_<1CHIW_O2VH
M+.YHWY<Y9U=A(^%1^H=?U&M^2=B1*Y$#>G].-/&6/5TFOL?#[U5-G[P5$"II
M$1H4*I9]W#%17OZ"V-N3>^*ZBZ!OL+,HCL "4YXSN;F)?>''DN3;P-(+XN<-
M&*9&6$7.H<BKJO"[9&W#X]D>#VF\&PUV5Y>&Q*J;ZE,D#F0-+5J^'?QE2TGJ
MQ?*AE8 @RGH\$JJ?,/X3*N0?D6^9="EIW_Q[HG2B7/>)B&(-EB;2?KR1O6]
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M6892J E/QG3,TK><5#:\. 9Q%"[!N@X$,XVQW8/XQEM)F"-!V5\WMR&2'$4
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M(V+!H.WR^ *](W^NJC?\%N4Q7Z'(@?"62_OU+CY.<=<P_.;K_]#GF,&6;T6
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M:6730IP1/F)Y*L XHW;?^1X_G>)=.U_&[9T9<YB3;IQR$OJM.U,$>-6$^K0
MZ4?#HO%L/[#AN(DNDWB*6P+KC$"Y_L+8*:F0< KC>Q2!=>F]S<_=6WLV1<SO
M-E\I3:SQT-R"+EPZ[>J4?=%:W6&O09\@Y6W#?I4\@%#?FP]D)8VJ*3UK3+B;
M?+U]O\#/E\E.+X".'?F>HM49"IK/U[H$\E\Z6JAK\Y^AWC%%86=M_OHL*NPN
MH@:(!SPVP'416'8_>$!WM^/ \I^CY2"Z55;F_YNSKT\K\20_<B2I5)XCY\**
M@Q!/%FKA/B5R[#W&07EK?ZIN#'R^S8DA]S!-7L"VJON\E(Z!GY^Z;5UWLMMW
M ?: A +;!A;SHX B'#TD9SH'8($08=HH 1^P6:6CT:!*/E''\Z=:_Y7D-3ZA
M_ODYYMS.J2'9<F019>X3C ]YI)3E 1'9QKA^#,.&(!/RL^T6F,@Y12C%M)!$
M9YTW>%^Y^/7J@\?^+U/7% K=K(Z+;34R.>V2M:>YZ?L7;B%(2295D.^#E&\H
M/K!A>YT89\=[Z"ESFW:';U%0^+[F6Y>>/4B=/)OFD+G/(#O0_X=%E(>_0J)3
M9=J[^X(GA2<GZ7O8"AR]'@QE@'"74*FQ$LMQS \S?\.\X0*!]E5,TZZRKJ55
M?=-C^RYY>3[823W%+*1KV9GFJ#\UH K/C$7_.D:S)/EU0@:3];<&YO!,KSF2
M4I@#8_Q8W'B+450YRW@DWSW%K3K9N)6F],HMEH1K.7%NT.B]I-DE: 7)D @!
MNO>4<Q11FS\LB\RUCV/,EIPM8MHUX?;ZZ'<HA%VGII16ED6Q%J=WF;>Q<H?D
MS*L39>4G4<K57\]8]-P*;B$-[H-%\30$?0SP3>@W=HV82,6T"+-=(4%B%]1:
M<!L)+>DGT[ ]6S,=,[5].US:MXAH)6\]9>WAY92;F";YHAYS *00,W= A]BF
M< >Y%-6"'7*K,<V"NU3XJM.LH5?,",K7LFDWL*C)]^J"]*R5X*WRQ;T+3U.M
MXQ04SJ5<. ,_ !LZC=(X.BA(-2T"X_W,O4>KYK>JM"A_G>41O<6K?HIKWY3R
M:4F[VY4)NR:$?4.]K31D\(_!*[J0&LB1JV8E(2HXRA'D_N[)33)#3PT@OANX
MO<B/@Z*2Y)PK2O./F/B13K]/MNYO-="1#[/OT$DV^;Q]^[T45C1'ELQ"N,Z]
M6-P0FG&4$(TI$6[B 8-S8V%VH0'[:)O%K)BLAZQ;RD8!+F!X\&W3UQTZ$5X=
M_!_C1MJ>.#A\$VA$$EHFEG&T4P9L.('\3$"7D.CGF NL42CZQ>4QL73C!0G(
MU_IBVO'2'K] $9/R6*?")/(7]Y^94'72CT+WO6\M8W#;X9$@;,4 1SF:AAV*
M8*5!@32[&+00DHW3(TG1N(W>F0J/7$J_ZC]QKXSS.\RV.]D>=,HF]J/>ZXX-
M<9N?[W$GOR0PS%'WL2H8+RRTC=B$'NID)4,[7T%J+6/KNC-L^N9TE\,-6,;)
MFBG]WI=ZYXLWM#H,+#R^=L-@7! .1ESF,")Y*IEQ&C4X HN9"G/D4+!() ,W
M0O/,H(DUA-*(0L4%0F5,FYWYY7452=N2Q!]^V^5I[3'6?:RYA$]1'ECQA[9X
MWF5?#9/@YF*\L4-M-+MZ;(SK)FYF9YRN_L(=VW&_';XA2[?E22D6&5>W:= 2
M1CH$"H7O[SX R-\ =R*K#V(&'U$Q]%I&-:N(8=EVP;^Y-P1[@A&4J#,FWQUF
M>3//^;(\7J70;_YJ8FGVM_#?6^G*NUKY>^62#2\FY"T)L?=QL-RZNJV0O#/W
M.<8''#H9PF^UA-5M) L$H.6FUUJ+@O<;C_V8M4^;Z^_^"%E1*\])J6'WY 8%
M'XWXB8(E!A$7\$& ')'D";R)FZU''K9C;1XXY1]C)OH&*U*<.(X7_Q9?W:%/
MPI;L47R^F&Y7\<(QS$+0__UCNC@?4O&N ^&!.B,&?DZ!;37$L6"J9!>&G*8L
M#-68OYB^.2K/5M[K1+8+%!0J_9ZM)/M;Q'?)^<&.M_LQC,-$ 2@8%G.CV@V3
M656(%/'0C2::;KQNLR+V?G'YE%E7IO@]&Y?VCU,SJW"G5BOY8I)?4EBD<<D7
MEZ%?:EN -(CT]VP1"#O>6<\#1A98Q^L8\Q%,NQ.]:N5]CUJJMKWP-=G= @I]
M+BRX%*[SX4N:3UG,QX=HG9=:WLCX#-*;8/I7!$3,>S$^^*%*Q/=+VN)PNT-N
MTL2U QF^K68B?0$-LI\_-@0*!JW]'NQXTMI],'VP)D-QS_>.,E+'0TE+6*+M
ME]AA0=PW&$H*#R@CSBVP#T(C]DRS%XQ'#8["!YGK2F_TCK;GD*>K[CSHMSZ?
MFM:>_,6V<.*-=<J^<AF4SB_ YP'>\?@A35C$D'T1UQMD%!"<AA/$LR\W?ODM
MK#K^B5Y&=)1AF['SR3BK*1%B,8F2!#(LR _(#!L[2".MU4^L144 5 CS@UJ>
MVVWF ??#=A8XY9?9>UWW]W#?53QY;S3=H"KSW*6?_"C]%)//<1=_=D);Y#D;
MI5DMD#!;&>Y!O\GCR(BQO+^&2;_D7.IQ'NYLKAC3ZEK6VGC@BF=I4M 0V6;'
MB2B'%!&\V_ -RIWUPJE@0QVB*Q12:^>@W^+;%B M/!U/0VV "L9WY8P_L[/I
M-E.KC-FE^K7&Q"^@P+<LO=7IF]C-'V2I[W>_/Z%9Q6U:C#:&Q1N9\%-&-BN4
M6X3;[GMV82<AJJAL\]EYK2\*M,JR_FV!@BNJZXF(5]X[!'\$&>=0D(9=$YB
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MA ?@14(P5.Z/[,(++UW(Z&%'58]$87*J]68/\YG.K0^6I]&(_2FO,-)(U;G
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M?'[UZ ,7:L9O2,J4HK4*TA_X2\N*8\N"V+*\D^\X-H^VF[ZPC0\V5GGW1UF
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M3J:U]_W1!*C4UFC9YOA_ %!+ P04    " "D@%U3T >\OO2$  "PE0  $P
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M+#YV9:N<.RN(7=!Z,(!SA-; JNU"5@40+'VM;2<JLQIO]R[;'/PD\2@D5H>
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MN@SDI,YV/Q@K"*PV?]9]4(SJL=]&&7 Z<;3+\)@'?WYU(63P+(<*ULD1/=;
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M*;8G(U_X7X[SC*%6[LU#9*,7\B\NJ%O'#U_\<F)C$F%N:VS:@TN#"^9PH&<
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MK4K*D1]5&2!TC*1EU=<451:>_6-'A&W^9![VHRG+)H^1 I-.*V>=+6IRR-H
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MXC0OX.#=.;IKUFK)N*']3C3S%8:8JGUSGFDKMAB7)I4H278@&AR)"%J<?Q;
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MMUY% 06_^TC7Z:>6O&N7]6P2.NSZ<KXCHQS_((_\G6PJ-K@KGQ\'^ML4MB#
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M5RL_*+S%6>4N8<>:R5H&2>R</Q'0:/+=@VL6/K*%!6M*]!MKN]?I#PV4$7Q
M/5&H*Q4 +\EU#-AT9!5>98#RUP,_0,ZS))+JY]/U);C.;GIEH-=0>/=VWRB(
M"%5%)8RN"&<W(PFF:ZDXETT5_A*C]#5().BJ+B9UVG2 :TRH8LO$D]UHOXK0
M0>P)#0C;PD4ER;32LV/J5+*18OO#'HK1SYX]KSU$=/=UE'"ZWF!V 63%YC5X
M?DO%W'R,R@LAVE]L^S[6NW[N!]WFX4 (?6.W.82WYT!A'9:()!IC9[&+_6ES
M'<37\'IHQ#M/2>XFH::O?UY$-D#VUEL]2"J1>I:+ W86[-V28I@1WSSMK+[;
MU? SAK^3#H%CT..JU*5S WE#X6C.>,KG&PNEGJWN/_>3++)=!2Y>J)%C,K'G
M2K#A%O"W@TGZT5K<D7',PP%D-U]7HP2X/=4X,;E)?:=3B $2-S,*?6?3 2->
M56&GI>'VDJBAWQF@T]QNHU!CZ>)IO(<P+Y7C'HTMI \60^J6GB7)WJE+5@S]
MF4VUASQ9O X9!]SB@[_WPH(]0CF8C!PF$_+B'X#!3M0F$F%6GD++S+]WO7SD
ML@@' Q0B";%;KX&^S)H?M@T8,%:XLR4.:T86OZ<./+'I<3J/[<R"H>9J=7[=
MO_ FD]*@M3JZ]5Q<Z6FN( ##^_)][I]8&9G:=F^XI0J9=BP_X'W^!\-#U2*B
MHGH'/(ICBQTSA>2"6=9U>;]RSJ/9A3J5*N[IA?I2,4._#<(Y.DH-O*^VFN\B
ME_?>A/(!2!P#=+1;<I!7\V>"_MA7H0/>W\G%2UGT4.1B 9)HR7T<V68!\>"=
M-J%S^N1Y,KT6H0S^H&/QF&@9ABH]<R2'I]A'?V!V-N.$4$NM@3-,M4GN->G1
M56W8KSB,&F:Q&G84Z80!SJYN^I-NJ/#!M2P:@$BB,YXM.B*S\^B) "3/O:'2
MN\;]GQ)$WF<L[/3?+>R_;J8;U).^WUOK:9.=8Q(8HG1.O>3RE:S/)J.8JOK-
M$ ;HV 8^.38(QM:JOY')[#O]U%JC<1%QU-Q /L11A6.NQL;K&>W-9"C"R^.4
MEVY,YFI\L,[FU$>Q;<SB'8P ]2PS_"0O((Z3]@@"2^@8'?=(=:[5'W*DULIZ
M7I?,5OZX ]/\.&%\?=@%V8X7E5W",V6O;ICMH@"-GG9D+?OF=](H^0/34</A
M%+Q^3T*K&%68%%F7@TOT5?91JCV2\0LJ4.GFJ]"?*)5A_[C_]*OGW_KIL,6F
M;":;#<<UWQ5\*MNL'=/PZ),>EYOI00+XVX1;]!H#1!4\V0$[@6:2CAR(,#6(
MV$..)0UUM-QNPW A#-'3"W#1@YD)KR^;?_8?Y2?9+K#GJL\?&?'Y&=G[C0'2
MFI_=MJ&*4"HV0N7^IGEXTJ5(RE4!)9Y"6.'=[UN^Z I1CPI9KV"^P=\_JZMD
M4LUDLBA0.F>+XDT&J$V) ?*X>.;5.0:H/9STHD_\R5/[2H@=$$X_MI!Z$;*8
M4K^>Q &-G_GVF'<>XEJI#7G)3GK/.PR=E5OZ"?N,V4PC:9'3,P9UTQ95#JW/
M_-%,7?7IK*M+M1 W 6.?,NG42YN=+5RB22?X.')Q!A;+)+IW($)>_O.A/R[0
M?V@NG*H&&N\JMW@\T=#7_&[-U19[/_)TUIV[)S)D>2[=Y%'8#<+;$(8IS%#9
MYH)Q!\\4DP_1DNFGYC<,='X@6,I_!0G6/[]35W7/X?LQ\H\^7YD7BC]HI8*J
M<Y*7NR>L(6D0'@VV$>:0#D#CZ)SCSL$6UAU+WG96OW.>1%W$-SOXFKU][^*M
M^NUD:J$+"/Z>=P$,R&X1+#Z%SC"["45&(&N%8B-@LY)*1(=/!SN7A4UG+1.$
ME:?Y'W]\)/4Z<O.H1-F"UPHO((7=W,$SS0)&YW @0A:1G=RJ7A)!YD0](;MN
MU)-(U^HOS:GFTSYSDLEB]X2G ETT_M#^VV;-_[>+-6_Q&%9 K>>YQW"S'TY"
MS;;:>V74JC()KY:+48PS6;-[:G7E2<3K_,W)!^Y'[\0GI(_^]C,X07MGP(HP
M&%56AT9C.=4M#O>N$"H^5/_8S!@4?)MNA7+1O<-WPH0%,+++7L2$R5XT578F
MFX?3_!U<!<9I!<E/G@2XS/Z>I0Y"-^=:C(QNQ9E_-M_6[@:$<$?60DIX"YF>
MM?-V/@!>_$6G=>TP0"TZ#)"1P-2P%:TXN9XD IE^QC3UJ"3/61SX!>&+CT21
M=',]#_+2I7(O7D[ R[RM\H>/E'3!)ZZFG6Y/FD $Z6X61GQVO_HY_+J22AC'
M<QGF>]]_^H^Y4<0\A1D!VF0Q]QF@&;35! *VA G3M(/$(0PU"K.P"=13QF\_
M>H+=<\^^NF=^O.O'&5G#5857F*>EG'U_$OD/]5#E::C6HU0.X''H"80@8)L/
MO]UQW<U]1 ]R/R-%+Y4!*D]OKN2Z1K.[8E[ULTIO,LL>V:8,6<P5A)U$X@)L
MZ3VYK/'=,"\O-&#^8/A$ $3_=9DY.8\ROVS&5N\29NRU\.L]C]:2UN8>T88<
M2_1'Z '+Q"4+THUP&5>YX=HW_1/5I=W6IK&S\OLF/+S7OM)RD0^0TVID<RTO
MBFKHT((P43QHT^X V][H.6WXN%-^@=03X=8N/V?\^+U;BW$<: <2!JE";992
M-(&=+@;H)/TP]3"Q)X)Z>6F# :H#.FR&U3NC?&[Y#%(*G681210;3MOIJE0+
M9T\L$:HRE7P/:&: )&J1T]GMF9)RF?>2[1M:TJ"T_H-/7G7ZU\R]]_D<Y2GU
M%B)O@[71KO]S4.O_;_^;=JZNJ@3ILB9DATY;"<F:7M[><PX<EQ,AC#2H # &
M:/<L\N??+$"OBF9-=H'X^*<%3YM'J-,]L3VX\T^NU7S"IB%3]47C=E#__L=[
M)F.0VIIX!YOOV_11[]3]X.KZ)^$)>QO&<BQQ[48Z59]#/>C7ST]1SZC>4'<-
M;,ZB#KO%R5<85OZ#>10&F?[X+LUF)>(F!^),FCGH):MG#6Z?O66E)&9TZOZB
M.-_1]4-2+V3_W_>N>8\:^9Z\=^]:J>A9]R!O-I94,WTVD$Y<-'1,42/XJ(;#
MN0.Q,OL2:WNO[&>&/8K>AVRL18X5'K\L?MRC,;2\R'-#;<TNI^5'?0-<3G-'
M8?])7H?QE-PQ7C:H= OH[G]^&G6(U$,5AS)AA7MB0#([DSJ"0XHI<G<:JBDF
M5$6)7-]TZ3,TS/3JH\!5$>VAVXYDDXZ+6+X;?GVEP29<%X.'$]'!B%LVTYMP
MD2U^EWMJG$_ZRX(U=$LHG],)7M0+Z?7VJ _\-LM8ZE4F<K%V9H#>,F%GRSB9
M =H\3;F'[/"F#S'_EH#@F(/?KD9.O+4R1%&AV!.:$!DLR.QEHW>K'Q;T+0)6
M]00ZYR 1!Q,&T;*Z)=@L7IM@!6.+/R$\>IF) "S&+YDK$W]QW;9W+BTI;C+H
M]:WUQMP^(WZ;/K#U_XH(EHX+TVMU3]9%$^=NVK>)F>GMF/YC.Z2;'@@DDS;"
M%,5;KP"?$!\)0GJGOZ&Z$SY#[EA%H<MYZ;"C/T] _\->V'.U==4%"^LV.OJY
M93Y*\Z\2%NRZ=&I>L;/F!; K-!PV]GLG_I>%?1A0U_S1TM59)NY7^I\$Z?6_
M!)EM_^9?!2FN^NHRZ^/+I27_1Y64=;LAV_+K&#(WBAE0:N&RP0Q0K)*R!B_/
MNJ!@RE9&\%GG6-4C*_*71/1X+)Z!J>=@,9 _*@S0SSD8U2'$X'),GG'"N%D1
MVCIE>^YR=*=U.?L-'CO]-&3*H$T+H$LWDE"@MU4B?]6BF6 KTIS$3H]DPK?L
M> 8H'GV/.%_4C<+-<G$UD,W97EOVOF7W8@4E)/%*)3! )Z[4"I_SASHF7GA,
M!Y\PKIDWU5X;UYCL_SM5W ^^\X^D 3F2>R>4P@P?WCY(IZUXS8T08A,.]362
M-#X4KB(4D!FK,3MPW;9#8U/N;)"OU^&JI+.'+NOE.K$57-'/QF/;DZ=UR=)C
M 0P0(%\ .(ZV"X)Y6X6\*H'<H0Y13_NVDKMJTPLU40OZ*2TC.1>=$TDM$5U<
M]Y7':44,D-. ,QY* .-49IW)<*#,=Q$2'WKBQR,]_3-EI0_E[HQ0#=]#Y7/^
ME%\9=P\S272W5+]EI.[+'X%Z)U%;M82=]NJ&U*RVH86HHK3*OWB\-7%)A0,+
M#]TS)AJG:[[U.B;DM__DAEUP?'06SOC8HT 9=TB3V_XOE@1(?687[##B'F!$
M7%TJ_CH@9EP+;'R8+WY9JZ32]62N(J>\XX%OFME8D-V9(<UYEVE_WC=ZWQR.
MP:>V5I!'((OE* F#TX#<8G(W5CST^W.>\$58/$K0MU72X9XMU3!U[_;([IW6
M,8+2:A)V\T2/?EZ(KG.3.7]3D8QA+8O9&I8'PH0$<6X;B[0A@A!IUIA4B#VL
M5,'[TE>1*JWT.BLJ?R9XK=+3+L;KN[69=&W&?>?X/IL,0_FS$8G:O.S(MC-T
M9;@AV1W0H.AV46R P$# B/2=+JU<@^4JAA&L?:[1J7??&*,I+\ WW^K-;Z5?
MW3_$6LG^C*A YQ0JH0\C)?4,B<&XY"@J6!\;H1>$AOMVAPJ/Z<%DT3%4@XS#
M!*4 W7C!.MW-+=<P%O&J*BZ)GXK'RE=D$$,O((MEDM*D^LT-(@LY'$7V_UP3
MOP3K-C, K^O8 ?/+/H>=@DMGRN>>A+PT6D_[T,0O-9>L87R#HR(*"<CYQNCY
M4"SA7.1LH(MTLD,G T.<['X^B,9A!7X9\(3HPII'T,ZM<=Q'R%N$6XH3CTW@
M+W+"!S2KG*1HN+2!9JV_M9X!"@[)0M4%- KI4Y*2R6VHHW1]2"?DT#2FPTR2
MM!C<8DSZI,&!J;G4X!IR&6_F9(^0R@A(>7L%I(:'4 4ZR!%$]G98(DKB)RV9
M>A$213^$<$&R ]/20/KIII9*TS]U7@/Z/.\$;</6#9P-U2Z]=+:RE7%[D(.-
M@2Q^,#@+<)&0>%3'T"S[XH=,7 CD*XSM)U!4M.YXDG1[?=OQ8>7<D(_&)U*?
ME[=4JZW4=1D?18M5-KZ<INR<?YQ_F0N4+C$!>STYF98K2_M8PW6'EA=ZI@^_
M%A  N.KF</7'0V,)UA""$QF59A'-)YC,]E/VZ#FA<N#O;/<PAO8!^1 JB+@#
M3)+BS9N)F$0&R+T/'1DJ1<Q-6]SW>71=2(C;7Y8JA$;*QUU62$UY W[(R75!
M+.:(*Y;*?YO\FHB-:S9Y#\\FGQ[_65T)6)7 .TQ)_)9>&797@S(,$3.RN\N_
MD_EF!TDYQ/YXJ5[+L?S[@G^2IU3(:;0\C.=6Q &D!QH/ 3T%LP+N7?0CQ+V8
M9J$SV4N:8[]_=]$R9Y0??(F8Z:Q;N"U<)_!,K_.UX/:T+3L'L8!\AO;EZ=;+
MUE/ :8HALNU2#0,DWHX0>H9#LZ][$$<WE6/UCLS!UOLDZ $*$3'I5B;UR?[J
M23)/$L&U]&]@%L1ER@5Z'XP7Z<[+!ZR/=DY*'B(^RL9-[6XHG:A9;HGJG=%]
M6*1)\(-D;*:<]3:]_, 4]!ADH 9<#EAD^DD4T9%WQMYQ))35TVY^EJI"U",.
MX'PX%VR]5]YY7L%;*_ZR_'"B6R1:99D;^]1&B<*'\  ,*<H(1UHKQ#/$&<<V
MF,;SDF1C'#5J:"$IKR$8G B&WO4^X3PGO;/UB#^2-7%G2UIF<@)UE %Z@(F%
M<",7WZ-.,D ^ ]"EC/A2#RQ?LT;!PVJX 2^KN:]&A,[]!HIN^=J8#)^:V%NN
M%396-I"R*F(""L@$5BWY:)%SB.AN](SRI-4PQD/?<=(Z1T]M\?O3,NPQ[,RL
M_64/_9:.=:'#SB?M[/M9C+^DJ+TJ]@'Y_MTB< GB40850!@1C?,HK'",0S-Q
MLN,UR29L5X5G;:;\0R9>(>UB?0AW1:V/S@_[A>Z5BZKYEV6;:O(.)>97J##=
M;WP^?1+,AO0:FH;V&/ 1 RM"Q:D2#D:[Z&->X=8C 3$:^FJW76[*1 ::^QJ@
M5"O[$F*F!'R^Y?#&(1=1L+J>'N2T7 ^D&DVP9(#8>.(=)YH-<44__C#E98\;
M\3A^672(=<B_Q#;^.QNUFI8CE2Z 2_Z> 1\WR1HP_WNHQS3MO2_"GU2 EXM%
M>F*YQ!B@1.21/U@V+\'GL/8O2IM/F^+E:X5/?ZF-6??&SQF5]%HT?1MTL7+2
M>;]MRIY%'X34@ D7<+XGZ>W8:JV7-6"N>;A0-[+Z]/AN20"W9[!7]EMO]19!
M096Z":NSXL]?ND07HG.VCALI=81V8&K!G>"I;)Q!8ZX$+9<*\2-6,$#DGR3W
M, VE*^"38KH$Q?70\PV5M1F#[;HV<>8/93+8'H]>I01%)'-^8H#,X;YTCAZ2
M25OCT.8 ?HL[="3KJMWD)HUX\'>S5.)<*R@HO/.YPWQ=#DOSXQQ#32T%VEL6
MA>JY,PX[8L>4GOP]3.5,J/)<Z)!H\M=,VB<]'=DQB(<TZ>D&"^XI8#84(^2@
M$Y1&0_>&Y"$P6J$(#&Y^YR;[[-AMIY.*\O4\Y:<L6U(TPX)?<6A+3D/L OX]
M\Z8.41\S0*GC2[P4T0!>VME4S =.JA90RASPYPQ06 *0AD?&ZAGETP<7 G+H
M+<_\/;2HLC-7]E/T?O=.>54:7V9G9=F 50.Z6:YOW>2$2>DX,[,K<]L)ONX*
MLV_+IJCFW8AB]8'S4[)A>3H5RD$_$XJ\2F:HI3.K/;N4OX<5GF* 7B/7L&3U
M=>3!!:^=9+IX&U,[%!B@ J;,^WJ,F<"GEW:#V9/KH4,8(8R;[Q2]#^?;S03
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MU3!*M:EHJ:V(+5I0-/?RE7G5)@W5JVY.X?Y84N:CGC!]HD?N'4*9:<S&"&_
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M(X]N4XXPI&:#FUR6\,#.+0N5 4Z_;:C7>:6;+V^%7[Z7G\,M^X.ON/AN -T
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MREL9P;;,[*4@E$82B.YW?(*^_7*1""E9<2HHQ46GZ=]^C.S+*$X]];;WW\4
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M^?7'W?3=I*/'I??1WW/WH$,EWG/ZLW)'5Q["]&&W^ #]6:HYHP$=6(R>;AN
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M4Z=CI?&84V]L94HVLF/?>T$%AA5UU1C2<\9RM$(Q8ZZGI_]$LACDU8G[P_R
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M*_?E^J6W/]Y5G]DM+@4!7%3Y<5\Q*@T,1^,=4"0IG@X82;X@O9B4UTX'\'W
M6_:@F;R3(R_C9%^U!MF;*F1<]XL0!:J=O6)\.?G)81%,]7,FUVNFDK_!C%H#
MPA06Z#20.%!U&L];^7 ,$Z(\(KFIM? DTOB^-H[X[T7=T1'>FNZ\71,N%^^1
MK?ZJ5Y>'HR%3;NLNDZ4['7#B$T/I?(3XTMB=R&+K,&&%)UT3D2&E]GU^&##/
MF^D;OAF$K@#_:SO9CW7QAZF/11;C3_7O%B)^($@:F31.1;(-A9.4A(&39(<V
M]S%B.7A:,?[W.IQ5]]8C&YW:D3.C[J@8J;[G+749$]/NR<XRJ?=_W')(%TJ
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MZ5-%W0-0K0I7'F?GH87"">[W=5%S6Y;CZXM?&1BV(-GV7RJ*7M)&@ U"[73
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M7H).4*0FH%R-+6_Z3M9Y<\.GOGC4O?*[</F98/9XN[#E9<Y#S_X=U']4] V
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M]4=GC;TX9;#&5NKU*>_6BL6YBJ%,F-?05"@=@-VK@0RT98_\67ED/N3?Y*T
M_38-(C:GTDHZ]P=];^'GTM6;RDWKV5AG6;FEX2VB1U7M1P!3C"CUK+OMG=3W
M?PN)3X/E:-.@K[<JY]=AI%OZ;&:E>F4M0UB7:X97).TP>@(_ ;^A=UC[;0NI
MGL\U43R)"$O6W+%%AXMIB-<M^N]F0J+0"[KN[8TO]#C>_/D$OS([ZJ2+:_[2
MVK+GE--9($<X5XP;]'#RO1>(O/[\)0NO##"$_RD3J<!4)N-6U/WQVI>V!F/+
MPR&#ZA$Z W9<8>H-M]\L)/5:NS]@D_XU_I26]K&T)_<>3<S;KP*F.AXB:]4,
M%]A''G"<_U#QOZCCW>>9ZB5:D(K(IKY,NE=<B1*B(J'H]8/T]./.9?F+F<".
M;RH: JQJ?:F]F)T?"E7"9<FG4C?I 'MDG\^1Q!LNE%BN2U%\Q]W@=_7F1\-A
M 89C\U!1B@JAH1LM-$T"MHGR-QS%C496O>_HR5\(U97BVNE-ZTJFRE$S46X!
MK+0?<R(J'HK&70W#3&7KY_1C$9DGP^^W4QQ?%$3;?B2QD[4I:M3\UHNZ6A@+
MY8.=LGQCZT:F+P'B8:$;1>_.=*3=S+ , P\Z!N($Y1)G.AYL<ZD<FD&#-EJ,
ME_:KP:/OV+$38O$C/:Z*NN:'/9)6VTH[AXI*?S%CR7/M?W<+ M:<OW>.5!MW
M6$[K6*I RLW5[;L"-VLG*_@5NR KB.E[=(![<W!MJ18B!N4%^ETT;[Q!!ZA.
M%Q1]E' UN&;F.^WH7F2]_U;+R_+FUF'08^')-47I#R;Q6J=4OG;*<\7HR6]!
M7--VD:)U,M1BX$+F#$490I/_3M*_@#^0PD6,9Q"M407R,()B,0FD TQY;;MJ
MV:M,D@MK@Z?$^X$[Z^4Z<EN?5[6,G)6\\7*-2&'@UC-^F?US2!,2B@%A!]0/
M-('6AN:P^-ZDVK$^H686]\>HS:O&;TYJ;W*Q5D+WTR$)G78X*R*ROXA\970K
MIX-2ATHGL<"PO7P+%D-3$?:^FW=;D22*^9!Y>(&8H6F(;[#[8V)8_<YUA9LV
M)L77*EYHQ_"<&0LYN/#I2UJ,=XG'_U<(.AEWPF+0 C0E-"=//.W86)TKRG<P
MP/_&93AQ\9$4K.V-C36!_U)MOOVH5?)L?89SY8I?0B?NLK7UQ5-!F5,R,] D
MGZ#]8BR(%5+>F[N@+X+W3$"HF9-C$RL5'GB+'[T[^2Q,+GH.V4!29BRX>.R+
MI*+K?,.+C#E]X95I/O]79-T-=40A1^5&![*.]! ?C,UIK^0C,V-+8BOV/K-)
M^G:\S7;1Z9-V7]#?N"6_>_(, 2PS<+?DF?-<2<A'H:$PAJPNUU^A6B9$R@P%
MJY<M\?R^N['/X! -H6#B;C/-)K**K %K5W:IST!WHVJMU_H[>8#Q"N?Z8U=U
M^\,/3'Z"9G23R3PW?NT%<'NK'_$DU.;YBLG?[PJ=R'Y5$=A5]-[Z-@!H5F<(
MY80'*@5VO4GS?5GZI#YYY/(>N+PERHY,,^@4T>#"?LMFR<^;L[0S'Z<E]STQ
M8: JWO+]_]YCTO\\M,")<&;:Z4B[9YT$(>Q<5EF5TP<<;HS]UU.%\@1P>QS$
M. V%R0(?#]DYD&0FV-1@5QVVNC8:7BD/@WUI0;9CJK8MV8'JL,RI!X0K,4[*
M$$;84R)0>%A5L5#)GU\(C5X6R/I:%%[6&RJW3 >D,/[\&B96F^.M"YRWY%D_
MS;5I5^!@ET<[9IU#!P 1VI-TP(.AZ=[."K0WZ7I(4,J(A3YQ#J/1R'XVX(?M
MFJ( L9'!<3[%U-T?+5T7A-/,1B@\"3T0O8XW"4]52BW[3-48;/4<'<"WHV-%
M?8?RDI"!;P)C)!43>>;U)9ODZ8"HX]V>&AW %+9N(!:6&,UZ7((W,I8.B+3=
M$!#8N-[SHETY@EUH]1S*"#**-U<.^--CH:Q9<E2TPS&$@??X&5!:>)Y#Y?)1
M+2>C'_?NF:&'46Z@Z3#GLX^@+*14W3VR_[L)])&.'Q3!H(0]D<.(6>R#;X[P
M19=5B%R6(>U 2&/E TK?==>W$XBW $X7@=UHHWA:5I&\Z]+8?N*,U[X4SR5:
MUIHS.X,VF.COP7&@'J:&-)7)&Z--(%-W71BZF7PK^9 2D/S.*<7B6N G5)/
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M4#EDE6KQL[WG,')"=A^ZO=9!XEVAG-GF-?DX>TF:(M^7#00 MX6V9X5W9@]
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M8(3Z^@))4I/0:V?7Q(DHTSH_!P>&9%#WKE%2GF 5%P0D"2,X/57,VS*]:)"
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M((]NSA7K;/XEOQ/-*@P>17(XP?<9:HZEXTF79P4 #-$PX5V $59@3\_W5EG
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M#66")K:ZT8=I:B0)#&N?+N'^W)64&8LW.)$[&FELGSIZQCOC=%"PYDR$<DX
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M@L*)19$.<DL 9KML0#W,;-9_?AS^MW]/G=Y LJ/^59TF6Y!L=2KEW+E+'DY
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M7VL3]?5!>+G! 1.E%T]!\SF;_O%HGH;76VC)]B%!P61X+ L$((=&JU!Z,'-
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MG%G>MG9'^"B)79YVC[NO]BV2QS :6GCGKP"7FS7VKG?/AX@>"TNR+QTCF_U
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ME#X6Z(KP 19HWBMY[S:QS<*Z@B3UG=_,E+W.&-]A5$'F/F2Q?Q5/>D)VH"*
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M0_/!AW*&2"=I$M[85^OM Q%$7.Q6.E:X&RQ<(),5SWB=M>X?\LC+=V3 3RG
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M%:G] 7;[5RRY#KVLY]V+R8-?AVUFH99:(=*H,*NY=9+"P@2>U4) 2)EJ<DK
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MG_LB&D3ZH('%()3=N&$,429 VQ>,HD%Y<8P)W&",4S56:0FS+LN#.CX=/NU
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M\FHUB>_A@:X[ ;%M[V]_T<#9UV1[J88/96PIOR[/^W85IO#TD6L/CXF[E]R
M18/^M.*-U[UYY[=>QRNA?R-'QBL]W_''O/%TX8]I)5F#!:3=P# ^L(#"UJU<
M7O L.X;1 &:S<UL:()/FE(GF;2[_FC G%]:N;0_+ M 99>9WD%%O-]R,!3R&
MT>)80 VGB#6L&)(9)6)]BE-4E,'(S'(]7OS*N</?ST_8_);>%U%9(X[*HWH
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MY_V-<G0];/T.C.@=0:DYB9AHMX%LIOKNN:W$@!%3[Q*'8H?4>,VKAKH1LL
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MF 2#,+F97PSVP*3IH53T\Q"3<VG3JL\;L.LGB)D$///''J[]/<HR8IJ[%D,
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M,QJ(&<0Z*X]0+XU.$;).M.F>;P^[N@QW\7#L-K+_RQ<S_^4%S2X0I.31*3?
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MG4.^;A%S3VW^C2S]7TF"K)'_!5!+ P04    " "D@%U3Z\:$GM1%   Y8@
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MYV9*+FK9>X]YF.H56V[L-NGGK'2V8VVM[,:QH8;/4>:I_'&1$O+H/CE*:08
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M"EGH [\$'4 59>K%B#/KK5C ]C$7JW>UO&"Y&\2P@)N%&(9012&B4R-NNFN
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M_ .E&W0E>?O'\Z[$6>T?I?)(^2\CMZ\9<<Q]7EHJ1XXD,GD>T>1][)OKM$@
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MIW;D6KG%XX0VU>@&F6O#'Z[.6UI(B$@)SAG/NRC477,M%A^!]W4]2%87T-
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M8NJWRRA\>S$SUG ZAG8/; -X7:C>_]EA[^\)]"S]=R.LM=WO8HR;>V%(_K[
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M"*A5=R#R<3M5;GNEYL&+1*RL2D-B]_<_ )@?C=NTT[K_V4< U*]WPO>.,5Y
M_WUQO87.3X-KZQBZGL(8H5EU#770:GZM+?:_YH=+F-_,!JB3OYUPU\SY6<",
M@R$=4@B]2?K.U$_"MX*+Y1=97I_>./OW;OKXW;SUL_IW YEC&&;&#^PJ$AB5
MIBGS+?XI# B"TC/RX%CWJNO[S7]3 :W*6[J)%P$]TJM:UIRLG^KQHZAD2SY4
M8@'.7PEE*U^[U+T[9E<(-;,M/KA+9*L(V8C:D_D^#R5OKYKYGV]P<>A7E%"D
MM.C)'XE^>M;SZZR,!+\"2!ZI\J)+(32E'PB2&5;01[F!P*'**SY^>G!P[).
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M[5;36-''I=9TK/,(5GFUMO@NZR:-??LV9@TW?OSX0?R%?:+)UC?DLP(2FC(
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ME><YBN=VWDVH=GV-\Q<S7JPMKG;,U4Y[J6CXKM!30;W#8\PX)\VK,K^RW->
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MY_+QL1O=/Q7\QA3&/#*^KO4Z)!R;\MR=()U_*.E9X/Y]W <C2__3[T:")+$
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ML[)GH\;/:,(J?KHRP-[*:Z%)[H#LAX5[S7^ZM9#-3D?:..IJHDV4216\[;9
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MF9<7505;NL!=U.O -2S^]G_+W;^RW''\H_%[=MD[,$!X[\E(/@;*=Q T<>E
M"W69$8LG ZP+=#3( *>08 NFT2%7823F0)HA9_\SX+]-\,?MD0WM/^:?63DY
M=/N7*@!&FT*%D'09"<IL"$@Q_3RE0?R%F$GB?X#-.ZOT)UMJ_&FSB-$3R])G
MPG^B+:^P(6/$6?Q>D-.*7O[[+:9I,-?]T9AA;>09, V^C@+9[B^<Z%HY?!C1
M<E/I'0NSZKFZ(8G^;!*[#M\Z#U+C^@>;G_[IQMCOOOK(=V%YL(QU[CF:)O:!
M#1GR)0$;K+-P&@-](!P/)L05 _1$QD^,,R@C-9#VXW_YC3>.%3;D3Z:LFZ2!
M12NYYPPHM0N(U.0F#*^CY#-2!]$FFV6;] 3\5&[S71Q3$2PJ\#/(B7^Z&?>[
MK[9KKV\L.K$A"A8P.O\E]&(%%1D&UF,-.@J6:D  HVL3"J.8K9H4@V("'^E>
M_[_L]OTS=(XMOM_,^94"8\3=A3$CR&S(FG-_'EJ+!,/ '#:Q/8/HC="[&NU@
M?6L>!$^0OXY-])\LZ4:E@Q6\?2X;/:@&PES!\>+& 5N6Z2(LES'$8+805JQ)
M)QU8*6#%Q64;W/Q[M+\?*K_YZ934%IVF"J85)2@S2AU&<P;J3X(S2S+QT,]8
M!)C[&1@LH+B9V_\F)YYQB5G^SW#_AD_$#HNRS#SCT(M@R'?7__S=E9F<39V;
M>^S!HL(:Q7QG&(.3>4"IH#<537KEQ#-O,I!_@\/!F*_PWAHQT-*-I@1,+'KG
M,M.]1ZO=\<[6 Z ]_C!:Q[TQR?(R&J1FQ"EL.9JA!?[JTM@0IAX;TGCT9]6@
M04,-S&-H:Q,;%M)!/@5])^: 977@RS.:,,,QQ!9\,RPF@Y4\?_?:-WVF ?):
MRU[HDRM-.TQNGMQV[U=K_-?QKVF1H1JL<?3*"2\X30#-W.W;L# .^R,9HA/X
MT9]/QJRAG\&P'VI8Y_5-"D #6H$NO:;T_6](XN"25"B15RFVM(O4 QBBL.37
M@#?S=Q\V7Z=]O7"HV[L_\<Z'Q^A93>;//?+W.]^%VK:@I*F=T8NU<**0#\&Z
M1ULZ*.L+K?]45X?TCNVPGC?'>9-/28'%!/+7(?Y;J*T(_<9<X7*@&R:P")BI
MSBH*&\(RZ62(,+H6+EH;H=11PW\/]8^&^&^\-/#W6$3=)\XP$@O1D6R(O\D,
M2A[=7HH!P%S5'U .SO !9?!7)"1(DKDO,Q-1\@RK(;HA4K^O0LB=#K5<"8()
MUF30]04^9_7QSNS?8:$K.!'/(.!FM]6CV9 8/]9W* 4L+90?A$'H&NAXVSL?
MXR_348O,0L^%:>880;<"$BK)$$U@\<U-/D,(Z[;"XK,.4Y6B)OM2>+O7U$2M
M?4U+]IE*V*4O1*Y4CJJ&?N]72'[N,((7,8">IJJ<B3G]@>KV,;?HQ /)JPM-
M6W&53[^9?S#^SO'-KROC ZF:7YD3"R1/'$?M][*:?11*</TA)7M& %<)H.B+
MJ\<>5NUVJGS>.AGM-ED'%='?A9YD\LM*6U"_OR=N)%A%3.-NFS8'GGM?.2D@
M(MS.W!TB_L/ZE S8PF%X%MR._7C9?1LJY^,FFP4BIM=W-VZF*/A]S/9KDI:Y
M&4;"Q,F)4#42UY2U\ *AK-6FD%WS.R^9AKO[I^@GRWL0]P'\DQ%WD_K^"B@
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MP]7+'/!+/@??F.5WRJ4&"DJ:"PAXE^P]TB;SY-=S I)6-\]'VYA(QSAGQD.
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M/<<9+00/M@97 =7RJWA&P4H=6K"2K%[4(2"*I!''AD@9[-W?!CIPO)N6%VI
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M3 NE1*(LW7K>U;\LS=EJHE5]IX^ES^Y12:>66-6X[HY\$YF^65R9P*KWA G
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MY&NV!=APF@\"V]A3OA]B]O/_*!B#<L'AWJ;EA:-:O^"(XV_8GVC^?/7UIKY
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MMV0:VY$QHY\QT/X!N;I>K9.TZMGU$ZC&8)P$K"="-U)B+R,1?E2R+QM\.A*
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M#P+:R-.])U[6<_\H%D/2P.'.)F6$HSKODL/Q%^SS^5RKT19EWJG("6*72*0
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M=HS9_@=.O7!_2;)5LKK3.XN;>Y*)MR1/F-Y]),NG0O"=V\]A[.'(IQ'T0N9
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M2!C&B/M!Y+N,NX/6 MXCQ-Q(84N'@8O^[AL#LVWBV,B.S"=&I8 W*H#?1KF
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M" 4R%3#0ZP&(!.:0(D2@#)&@L5(I)59MPKO%3(U2]AOC]CXM.X&J'9E<CM7
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M.7K+PO;#@"N;FWJSAURMI-!+NJIX5ZMYO5[KS:(LCN.,1Y#'E$*4Z849382
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MN]$=_*_1<ZA!JE'V'&I',;;GD,?(740:SY<K^Z&H8YC+7A649H7!!08F2P7
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MQ[>=4>U4>-NY2^/LA6T1J'7.UIW^N7IKY?O'/6%"Y;"P[SA&TMH+R-H+F<A
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MXS^_63]^_V3YZV(R7[A,ALTUUDC))&5&Y-1:R$):"]GUH$ 9 U2F1&C&[)<
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M.@_'.H"_SQ::3R?_XQR_'WJY<M;=KWPR<\6HU^?W&*(4%P:D$CHGC16 8V.
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MTF8RFZST)VN&JH_V>9@]3,2T:OJX?/OR&__O^>*=JYY0[NCGG#*>9A2DN>8
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M \&,*9HJ;OQ+K!\-/S9CPTE8IK:5,@84&S\&KGW;_S(X>G[5]Y&(J;]^#$E
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MH1YW$U"GC2>XM_$"RT69S&,W Y6;Y!?^E&<+97[V])AXSY";13D*X-.P\'9
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MYP*M?00XMB7>R&?33P&O4\Q7:EZFK11+<'=S^LD]=*37E+03PQ1 CTP>M?C
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M1"L$;=4D=M\X73&)5L%?U))HO](_B.]B463%\ZF49HKS^C_6XD.S&/$HQ2*
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M1PKQ&'*24HC3D$/*#6LIS5D28&E+R?@=">P<Y]@LJ=K5W<@**F%KO]6S[Y'
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M7?ZOAIAVI>_6[\VBWG/9OO6[/0&?S4__]6_-;\P_G.7JO_[M_P-02P,$%
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M8-* 8/6+*@H&C%_*_7\\>.F%8 ZC_O5\/5U/<?4AQ!E.&.?H:46 =R(1"]:
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M%F2$7=FE^VI?7/49JG6];CN'WOAK=Q?7YU)$+[XKHFV.NXC)B,2KIQY &>W
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MKG.Q%+,CR2;%)L%$'V=@1VOR$63L)=:#X?!Y,^"78J'E>E!07-XJR*_.EW5
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ML)$%-NYU\#2!O03X!R+A460-J)8NSH8V@UGR-0-WFA7=&G5U_W1L@CR8I(L
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ME$R;9G'_V\R@:<"YIZ9'A=\U*^^GMW]&V[*V*K52<@Y^]=P]V-H$BRE@4<M
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M2I['% (39-VS(F=$6:O!98K<=50\%J0_3&VZ<#=C:2355?MB\\D*OV$Q,((
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M"Y&S6OR),=+.4_33MH@\JK$<6ZE^F[$<V^AA!)AZ9M9#T10,FR2!,>5 !:[
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M"7QW4S5;AHM#G(NW^\&CU(XY!&DLA4 V1 B.6Y 2,QH,5LC&5X;/$SB6\/3
MY^-N"AK5&7G#PGU3?'WR%S3": 8D0 Y*:N)*RP0Y"W)VK8G&-(E5NY$WEDBU
M'>AZ4\X8S\@[MTKGPMOLDU606;84/Y&+2>%V EM$U,B=L*JQ[W^'FK%$F^UQ
MM:WH1W!D;JI7K[.&/DUG<8'S[S6Y<U5@_A'3;)J(S:O*N8\UN5.GKKT(B\FM
MJWF5L-9!NX04XI!X'2CE$GC#R7D@>5*0HX/S;:=4],E-)_RZX\/O\*H??)9H
M;62X20S_ZB"&^U)XN6HW\&;Z>K&<?*TF_F[AB<U"J *\.))(2H6$H0B[/BH;
M2\Q</=@,&SM+MJ:S$\S]\<!\=+H=@9^ZZY9_8L=_N)RG+V%!IQXYZ+ID2;L^
MQ$R!HB$Y(#GM4IALG9%,MAFYVXJA;H5S['AVPZ@0\-?;":>X7%Y</?8[CU:4
M[*0"&YD$Q6. 8&J#D61E,3H$']MVQ>B=I6Z[X0@+F4>"@O&$DVU\0E$,JUTN
M(29.IZ3-&J(4B:2B66T9S0J.:D?L'P[P([R\&E[W(QE'V_T&^60^KZ[A:L>O
MO<2K,;SOR\\NG?DY,H7.*4/PK17I+DAPOM OQBDKM)?1-LE"'XB_;AOE""_=
MQHB/8YG%^S(LOM3_U1JU[^&B_E&8YDW#UWN>QKO]!S>9Q[LG_P>9R%M?Q&@>
M@7/):6LD#UZ;"$ZXZ*SDPK497]=R(N]I^H+Y\@)IVY'P3Z;Y@0ZN7EVJX',4
M2@(KIE:IT2_1QEJC$95209HBFZ3-.U$WDOY,^R+FH3'M7S,CB"[?3,ML_O7Z
M[>]UG_D?]:;SIBCRQZIM@2C11*\$1*,5*&DRT,&3P:6@R<CGF+ )X#K2-RSD
M&B#C40/B_M4T O2M1A>>D;MQAE^_S>9A_N/-UV^T?^L!])+(F2QK,PU<N?&?
MIY-_8WXS?1WF4_)&%NNA"+AX7V[')2S6S5)SX-Y9#9A#[5V52 :R%+#.%>O)
M<8JQ29JO&4=#SZ-H@+]-<RP'!\,(=L7O>)&71/ER)=='4SIJ5_RH,8#TMG+C
M67T>+  ]5Y)6(WO2Q.MYGJQA\3D2[#SJU].;(D< RYLG%&0*%O>>4*R[R*0H
MF0@!D.M<>U(&")*SVB.. E6#GK49"/4SPH:MX1XG-'M5Y@C N6'HE@Q:\\ 3
M'3ZVU $BHC[/Y>!,RF@$XP*;S)/:<49>,P >PCO=2_BC@\_&>5M>ZFJ022S>
M(2@;\6HR3:G^CE8^>-/DV#W"<7=;*7_[<7?;:&($V*K;[9IR7E!8= ;<*OU0
MHB69D(U5@C-NLB<?N<FS@%L2QH25_97[<,K%;I(> 49.9]]Q]2;__FO4]8RA
MPKEBF4$IJ_TD(\02),BB2M!,6:>;-!IYEJIA#[7&2.I/'V, UPW];V=ABOG]
M_'1VD3]-24,GG^=XE>X_FWW$;]<U,FL!ZFPU[1;(\<J_5!!*9(#1&2>3,[DT
ML58[TCOLR[G6@#R #D< U9>S>8V1EKAQWVE!_D30$83SIE:J>' J9$C1U='=
M,K<Z/I^C:M@G=JU/U-[T,0)P_3&;XH^K"\Q?+Z=YS8517FG%ZA/^0I$NJM5S
M&@E9:L]+QI1XD[=.F\D9]D%=8SCUH($1X.A%F/[S;/*5]L2WV6*R7',10D@R
MV9HL*;I.@I001- @,3,O3&#1Z!8XVDS.L&_D&N.H!PV, $>?3L_FJX*+'R?3
M_%OU.*=58M?,,&M,-+63,L\4MP3+(<B<@?9$4-YZ.L6;F*5GJ1KVA5QC5/6G
MCQ& :W.N[^U-69GP(5NF&*2LZ^NGVF@AR0#>,Y9KVX_4IM?^3^@:UHEOGRKM
M4RTC0%F]X3J;_?'HANOE15@L)F6"^:;TQEJ5M$[$3U@UUC(<7*3]PTLPT06C
M'6^2CN].XK"YL5Z1L>$BLH&:1@S <V0R%Y,*L#JU2DE'DDI6DKDF03DKL/!T
M2+@-/4VD#0 ZXFPK;8S@K?E3?)RD=/GU\J*^9/DTG=]<V/X^N\B3Z><Z_.><
M!29\\74*O% UEB$?5#H2GW)UE#<RIIOT-=^=Y&$3N0,CLV>-CM@B/L]IK4$X
M5\PSC5F##=Y=!5$.G0?A7(F6VZ)8L\JBW4@>UET<-7:WUNB^;_N:HO?V(;LF
M1RA*+8%3/'_]U@13!&L9:FN2+J7)),6?4C9L(GA@+.ZFGQ&8RZ<; ]_*B_G
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MZ39PN<X"V]JGD*+\@KQVOG">''I+6[5$'046'=L,E-Z"QI& KS> S ZCK1$
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MAJYS'QF6>]?G7\=F!Q%)K-X 8LVJ<$EBU=&#9@&S5;J0TWCD-KM92FQT.!\
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M7N@)@O:^'WNP[FW7O]L;E>)XB;6=#:]^ 3D#!HA1^H6\5ET8SUHVN7;O0-O
M[]/[0,FC>Z^>-3+*.ZXN&WOGZ_DM%C^$@6IXC?\D $.A<]%K1V<E9Z"*T!",
M#< -)W^>963\*,S4*MX.)+X7/ZZ7?G\CZ0?WOL[EY M:2(HG"K QU]ZD%-%H
MQ( B8Q3Y)\#I_FDCM3O;J/U>2J-_$8^AD/:F@N"AP-Y,RVS^=:6O&ZYOV?0E
M1UX4@R1K[^0Z<BEZJR &X4N,+D7=9,#ZCO0.W):Z3RP>4G.CB#MO&?V(WW%Z
MB8L:E;RFTV$^#1<O+Q?+V5?:#R?3_'8V_?R6XIA\-=7VQ8_;4R9<W)XSM[)0
M,6-1/(!7.M=VJO052@U))%&0Y2AUFR.@&4O#7FLT!OJ@^C_2L/6I8VOWBJD^
M/O40/N56G+=V-E52@1R"!*Q>H"EM#/A<&!0*<V1Q2@C1Y+U4LYAXN]-G]2A;
M1D1NK*W-7^GD$4@RP"*)9,>R%\&A:-*U;0=:1^J[;H.B/?V%K34V F=VO<-/
MTO]<3A:3FV%5=,CX$$J=Q"?I] FU?6<P'JS$$F5AUL8FR9DGZ!G+3+E&.)CU
MKY218JM^.4>\;H=B1/8J6'W=)2Q)3MY.=H"9::6MY\8U*;;]*67#XJT7_7?
MU.[*& &Z;KIXKCE;.S@K44GEHG >P4M-HF)T 'AI$1 +YR4:;A^F;7KNIKN)
MJK%,>CJ,%>M/0>.(J:^HO]XLJ)(C4AF88"-)1TEP15NP%)A9R:5@I0V^[E(Q
MDC:Z^^MW\UW%#J(>N*3NY6RZN*3(>MV'2R:7D GPA5.L[,ERQQ(0C-;1:A50
ME@?'V\;<\?U51^%G[Z*:62]R&EC#'[X$LI0)+Y<U07)-?U!>.O2:-BOM6.7H
M#%U-Q=.^Q.(,2S;R#GK>M/8HLK![:GMOF0VL\S\P5\)?X?=)PL4-_5(03P8L
MUCQ8K)5.F7D@T=B4BDSLH>NZ4>>;UAY%0G)/G>\MLS%XF)=Q<>](RYP.Y1#!
MQTP>D:M-X96MW8TU+]*YH&63ROT'= P,CT-[D7LH85P86N^H&*Q1R@"+-<Q"
M52B(J\)(C'%70HJN3=.SAY0,[$CLH]>G,;*#D <^7=Y\_7HYG5W,/O]86\F"
MBGNF(+K:9@,%[9:D' COE4;,Y"B5#B?+PW5'H^Y=5#3K25Y#ZWI:,)'(+^MD
M90R+FY.Q".N(>0&<&4\6LABHWT/1.A<E$2UC773^Q/H#>Y']Z;X/^0V,@7=X
M.9\MT@2G:=VO.8J<;&8!<G;U?"P6@A:2_").<;(S.5O70?N/5Q[85>A-[WO*
M;&"-OY^FN_9*2QE"R@HR2UC;*$GP/GA SGG.A0N=NU24W5]UV*=Q_6EZ#UD-
MG1FXO/@ZFX;YC]_I+\^75V/)K]FP408=G044]8A2A1-.=:C/8FHO=HI]_,]*
M"'[R$<,^/>M/_WU)<>A$8)CGR>Q[6*3+BS#_ Y<ASBXFBZ^K%H_7["CGG%$F
M@)"UHQ"%0>"=4H $>HU))U=$!U!T^*AA'XSU!XZ^I3JX-TCK?">YD"+"Q>FL
MOBB:3=<N3<K))T'QLC>I$-J] $?>#?#HO0W22W)Z.[F$SWQ()V#8\0.C/TD.
M>M6T.@#GRR^S;Z&FS];T"Z')NDD&6:&L 7$"AX)#$LJSH%2(MDMZ^?'*G=3O
MQJ_^/64V=!^&R_EGG*\]'DPN!^$0# 8ZVHRWX%1&8%)(K8((0JH.RKZW:"<]
M^_'K>7=)#:SBOTWNN#%&H+/<T>'D1;WM(@Z"XQXBZLR-%C;P+K'^W36[Y7;8
M^#6\LZ &5/!BOCS_,)_ER[1\/S^E<VB2<)72=,HKPX($FUPB@#(//B#Y(]:)
MD)C43G49'$[KW\GRTG</,[Q/$3!P3'B@BX)>Q#\.^-2"_&L.UAM)"N>L50@Z
M6 J 4](0;=&0Z@X*2:L<N]29;(.AQU0,DSKN1[&/4;*GE(=.)IV]O#:/SF',
MS!40N-HQN3:CQ02)*U$DB2%TJBZY67!P+>^KF-F^4AI8M2\P7"[7WDTTJK"8
M!02?6&WLQ.FK2-\R@KCAFA76)65T=\UA;@':*'AG60V]?>?AXB7)ZR:_&;(.
M3@++6.\ZN868#0>NT).GA,[$3GOXWJK#9/T;;>3=Y37T;@[QQQW*BY?9:V^
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M9-CZ$.'@5\#O7WY\<_;ZP\>;A(%T6'R=OANU+:!(-A!YK ECKTL1Y(&@Z0"
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MH(-J> 1(7J?Z'B7E;I(9.>JB XO K*S-XP))T0D%+.;,'*,?8\N',4]3-FR
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M#%4E=[@!RTUACC%: ^6J2WGVP8^W[4,Y])WAR>P;F_QWAR+;P"U(23R4!R\
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M[Z^0['V'4$NS!6>)4.BZ2\H]Q@O6DYRH=H$&Z5R7N29//MP6;6<1Y7PHOHY
M!]X=S/5R,DO+Y47ZMDFZVYPJFFA6OC"#ADPDQH_$&2X)* \R1*N>E)0,Y,2^
M1%7;68WG,MG#"68,*-O2OCMLWG-E\5@1F8$1*9DD5D5+O$[ H_3.QRKS&Q]0
MT=CQ&TZZ3R;&]F5U8Q/U>XIE2/O/:=,3>S^QE'-9ZD-)2AY*)CDEECE#&(W!
M 5"61.Q@I0Y]NS$ ^HMI/B#/FN8D'KP)^(S^X;:#27!FTYZ ,X,\X<HC3XP@
MVFLFDHTNTBK-Y@Y2TW9TY[ELSNF"&(&M>;*)?7]'P9 EJ30]1C]/TC+*QH5
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M9FEC871I+FAT;5!+ 0(4 Q0    ( *2 75.).>NXJ <  *DD   >
M      "  1<.  !A,C R,3-Q97@S,3)C9F]C97)T:69I8V%T:2YH=&U02P$"
M% ,4    " "D@%U35/&LY04&  #7)P  '@              @ '[%0  83(P
M,C$S<65X,S(Q8V5O8V5R=&EF:6-A=&DN:'1M4$L! A0#%     @ I(!=4\C>
M4U4J200 L% _ !               ( !/!P  &IN:BTR,#(Q,3 P,RYH=&U0
M2P$"% ,4    " "D@%U38(LS#(88  #G!P$ $               @ &4900
M:FYJ+3(P,C$Q,# S+GAS9%!+ 0(4 Q0    ( *2 75.=DHYE^"0  $EO 0 4
M              "  4A^! !J;FHM,C R,3$P,#-?8V%L+GAM;%!+ 0(4 Q0
M   ( *2 75,%0,4?IX4  )F1!0 4              "  7*C! !J;FHM,C R
M,3$P,#-?9&5F+GAM;%!+ 0(4 Q0    ( *2 75/!:_=A#ID  ,*K   3
M          "  4LI!0!J;FHM,C R,3$P,#-?9S$N:G!G4$L! A0#%     @
MI(!=4S',U0EM.@  #$\  !0              ( !BL(% &IN:BTR,#(Q,3 P
M,U]G,3 N:G!G4$L! A0#%     @ I(!=4Y]$LHU-7@   ',  !0
M     ( !*?T% &IN:BTR,#(Q,3 P,U]G,3$N:G!G4$L! A0#%     @ I(!=
M4_S.J>P]<   #X<  !0              ( !J%L& &IN:BTR,#(Q,3 P,U]G
M,3(N:G!G4$L! A0#%     @ I(!=4R-ITH416P  )W,  !0
M ( !%\P& &IN:BTR,#(Q,3 P,U]G,3,N:G!G4$L! A0#%     @ I(!=4] '
MO+[TA   L)4  !,              ( !6B<' &IN:BTR,#(Q,3 P,U]G,BYJ
M<&=02P$"% ,4    " "D@%U3MN*[2XB0  #\H@  $P              @ %_
MK < :FYJ+3(P,C$Q,# S7V<S+FIP9U!+ 0(4 Q0    ( *2 75,;PL<,CGL
M $J,   3              "  3@]" !J;FHM,C R,3$P,#-?9S0N:G!G4$L!
M A0#%     @ I(!=4PZ-F@'91@  :6$  !,              ( !][@( &IN
M:BTR,#(Q,3 P,U]G-2YJ<&=02P$"% ,4    " "D@%U3WILBP:H\  "45
M$P              @ $!  D :FYJ+3(P,C$Q,# S7V<V+FIP9U!+ 0(4 Q0
M   ( *2 75/KQH2>U$4  #EB   3              "  =P\"0!J;FHM,C R
M,3$P,#-?9S<N:G!G4$L! A0#%     @ I(!=4U$)7WVW.P  1E<  !,
M         ( !X8() &IN:BTR,#(Q,3 P,U]G."YJ<&=02P$"% ,4    " "D
M@%U3DNS;Q(!!   55   $P              @ ')O@D :FYJ+3(P,C$Q,# S
M7V<Y+FIP9U!+ 0(4 Q0    ( *2 75-*K4$"(#\! /KA#  4
M  "  7H "@!J;FHM,C R,3$P,#-?;&%B+GAM;%!+ 0(4 Q0    ( *2 75,1
M>$R2^+8  '<7"  4              "  <P_"P!J;FHM,C R,3$P,#-?<')E
:+GAM;%!+!08     %P 7  4&  #V]@L    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
